<SEC-DOCUMENT>0000950170-25-029149.txt : 20250227
<SEC-HEADER>0000950170-25-029149.hdr.sgml : 20250227
<ACCEPTANCE-DATETIME>20250227163925
ACCESSION NUMBER:		0000950170-25-029149
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		89
CONFORMED PERIOD OF REPORT:	20241231
FILED AS OF DATE:		20250227
DATE AS OF CHANGE:		20250227

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Xenon Pharmaceuticals Inc.
		CENTRAL INDEX KEY:			0001582313
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				980661854
		STATE OF INCORPORATION:			A1
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36687
		FILM NUMBER:		25679892

	BUSINESS ADDRESS:	
		STREET 1:		200 - 3650 GILMORE WAY
		CITY:			BURNABY
		STATE:			A1
		ZIP:			V5G 48W
		BUSINESS PHONE:		(604) 484-3300

	MAIL ADDRESS:	
		STREET 1:		200 - 3650 GILMORE WAY
		CITY:			BURNABY
		STATE:			A1
		ZIP:			V5G 48W
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>xene-20241231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-02-27T16:25:52.9491+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xene="http://www.xenon-pharma.com/20241231" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16">
 <head>
  <title>10-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_ee040fe6-5ff9-4b8b-b421-2951ce6d6d91" name="dei:DocumentFiscalPeriodFocus" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2">FY</ix:nonNumeric><ix:nonNumeric id="F_50016ee7-5920-4be7-8a65-1501db419c63" name="dei:EntityCentralIndexKey" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2">0001582313</ix:nonNumeric><ix:nonNumeric id="F_0359f0fc-03f6-4a5e-8245-5e7df891b1e1" name="dei:AmendmentFlag" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2">false</ix:nonNumeric><ix:nonFraction id="F_39c5f094-0153-4965-ad86-c59ffc0f4633" name="us-gaap:CommonStockNoParValue" contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f" unitRef="U_UnitedStatesOfAmericaDollarsShare" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_26650381-9407-4b93-8775-249a9131e1c0" name="us-gaap:CommonStockNoParValue" contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35" unitRef="U_UnitedStatesOfAmericaDollarsShare" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_1d3d9cda-8981-47f6-bb6f-8de466ce6eb3" name="us-gaap:CommonStockSharesAuthorizedUnlimited" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2">Unlimited</ix:nonNumeric><ix:nonNumeric id="F_00c5c9bd-d79a-4de3-b0a2-1106d3ce3eca" name="us-gaap:CommonStockSharesAuthorizedUnlimited" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b">Unlimited</ix:nonNumeric><ix:nonFraction id="F_a8ea127d-d3e2-44fe-898c-1a5dafe7f461" name="us-gaap:CommitmentsAndContingencies" contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_c639d4bb-46d7-4e69-bffd-36f05365c504" name="us-gaap:CommitmentsAndContingencies" contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_47b3f612-5e00-48af-b88b-1d3d02b7448e" name="us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f">http://fasb.org/us-gaap/2024#LeaseholdImprovementsMember</ix:nonNumeric><ix:nonFraction id="F_a0537c61-71b0-4915-978f-b5bbcfc84362" name="xene:LesseeNumberOfOperatingLeases" contextRef="C_f76418ce-447a-47fa-abce-3e02aca037d2" unitRef="U_Lease" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction><ix:nonNumeric id="F_d1be6160-6c62-483e-bb44-87d26b17b9bb" name="us-gaap:TaxCreditCarryforwardExpirationDate" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2">2045-12-31</ix:nonNumeric><ix:nonNumeric id="F_1acbb9ae-6eb8-45fa-9c42-da9b98b84dfc" name="us-gaap:OpenTaxYear" contextRef="C_5cf39887-6843-4791-adcb-c66041161085">2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023</ix:nonNumeric><ix:nonFraction id="F_a4a2478d-a313-4066-8e4d-8e8806c474dd" name="us-gaap:NumberOfReportableSegments" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" unitRef="U_Segment" decimals="0" format="ixt-sec:numwordsen">One</ix:nonFraction><ix:nonNumeric id="F_d1e546bf-38de-44e9-b552-f72e3c4a430a" name="us-gaap:SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2">http://fasb.org/srt/2024#ChiefExecutiveOfficerMember</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="xene-20241231.xsd"/></ix:references><ix:resources><xbrli:context id="C_809415c5-c3f1-437a-ba07-2d600eeb3db7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_855c2687-033c-4d5b-9d65-93762e253c78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_870ddace-7d98-45a8-a1ed-2e57f3f089eb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_878cde20-56e4-4ebb-9add-30ed0cd3a427"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_884f4d71-a8e8-44ee-82ca-8ef780dfaa13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_88dd1245-4241-4674-abff-66b46ec29d01"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8a94fa8c-ce7f-4a9e-a9e7-bc7ebbe394c7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">xene:XEN496Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8af453ba-33f4-44f7-9e63-cd2ff108e084"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8cda2242-cdda-436c-b1a1-5d38d90e788c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">xene:RegulatoryMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xene:AssetPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xene:FirstOrderPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8f08380d-a06a-4f90-aa7a-aeae88ce9ee1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">xene:Pre-ClinicalDiscoveryAndOtherProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8f26e8bc-db97-43e5-8f12-99b79372a387"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8f915973-7e56-4b21-9f25-8542155d2101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8fa80a4b-d219-444e-a4d3-dce7bd9ccd8b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_91296a7e-80ef-40a4-84c1-540e6b53ed31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">xene:UnderwrittenPublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xene:JefferiesLLCAndStifelNicolausCompanyIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_959e7299-f8b2-49e1-8078-5dac2b5e2683"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_95fad8c0-4f7c-4bda-85cb-111b56b2cfba"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xene:NeurocrineBiosciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9887e0d2-0944-45f8-8ebe-b8362c753b06"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9a4e5db1-ae6b-4123-9a4b-819384e01155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9a7e217e-4eb8-4d7c-b2ca-de82b025bdab"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">xene:GuaranteedInvestmentCertificatesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9dc51c40-1728-4dc4-81a5-109cda1ab80c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9e565a8f-9b0e-4173-a3a3-09356a71706a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9eb01a35-61ba-4b6e-af95-b573e9492a46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:InvestmentCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9ee56ce4-a340-480e-9aec-44adf7965a2c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9fcee154-e6d6-49cc-9847-f1ad966fc19f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xene:Series1PreferredSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9fde0c8e-4519-4f2d-bac4-a130605b9e35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a3786e8d-3a38-4f5f-915c-ad289a237b50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a4e5a889-56d8-4a0f-bc5c-ed4272cae01a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a52ed6c9-11b1-42c8-b685-959088b4d45d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a581601f-604c-40e0-a538-b4058e27858a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a9775569-4b1a-42fc-b962-e5d75b4877a4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_aae837d9-73f6-4e0d-b04b-74e170785875"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">xene:AzetukalnerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ab08f408-103c-4988-a8d5-e291b741e1ed"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xene:AssetPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xene:FirstOrderPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ae6f53cc-56cf-4ba7-a7f9-cfdd12d99cbe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">xene:ExchangeAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">xene:BVFPartnersLPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-03-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_aec75604-252f-46ec-a913-19116503fa3a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xene:TwoThousandNineteenInducementEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b0bfec10-59dd-4234-9f58-271c37fde21d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">xene:SalesBasedMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xene:NeurocrineBiosciencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xene:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b156f885-8692-4ecf-bf11-f2e6c2c97795"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b17712b6-e1df-4014-af5c-fd1016d8f5cd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b273b0da-ce99-4209-9b93-ffb50f246430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b54bd813-bcee-4527-8ce0-2c924fa24d1d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b676a389-6e42-455f-9fad-4ecafdc8c411"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b6853865-a835-4d1f-bb65-e80788e06f13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">xene:BurnabyBritishColumbiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b73046f7-b8e0-4dca-8c99-1daba94d7875"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xene:TwoThousandFourteenAmendedAndRestatedStockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bc5911cd-b1ff-4b0f-a581-4c001670e9a5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-02-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c0de2a82-98b0-4310-ad4c-fc4a77de4ddf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c36523e7-e5b9-4c2d-b6c3-bb9552e83dbd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c6f61c40-d49e-48b0-81c2-ceb75830debe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c9472f62-0148-495c-b52e-860ba1e4f49e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ccebda2c-e532-4b8e-ac5b-a03dd5ef7b48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">xene:NeedhamMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cdaa9dc0-7dd9-4606-9431-1abf2c692823"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">xene:CashAndMoneyMarketFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ce952f40-3105-427e-bbaa-fffd07f2063c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">xene:FirstRenewalOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">xene:BurnabyBritishColumbiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d2815981-23d1-4abc-9bb7-2d642884bbe6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d9195ae5-00f1-40d7-86d7-25551a0a0739"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d9305b94-dbef-4162-bdc8-5136220dcc47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dcfeb94e-b8c0-4a04-9c3a-f7a9d496157a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dd36de89-61c3-47d3-b597-7a827f1ad7ff"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">xene:ResearchEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_de04a46d-af61-488e-a31d-4bcee768b536"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">xene:CashAndMoneyMarketFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e03fe75c-2f66-4f62-8b71-f0cb7b6dd2c7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xene:NeurocrineBiosciencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xene:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e0854642-1362-4d48-aab9-14c1634c7adf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xene:TwoThousandFourteenAmendedAndRestatedStockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e1049099-ba3b-4285-9482-cc2e1b4be2e0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e41e64f7-0a7c-4d69-9147-98202c4d2812"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xene:JefferiesLLCAndStifelNicolausCompanyIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">xene:AtMarketEquityOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e51a83d7-051a-440a-9383-caa0acb0c6a7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e5737a61-1f16-4af6-ac8a-b3e0f4d46fae"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xene:JefferiesLLCAndStifelNicolausCompanyIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">xene:AtMarketEquityOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-09-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e9b5b17b-a190-4b8c-8268-dec97ce1d7a0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">xene:UnderwrittenPublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xene:JefferiesLLCStifelNicolausCompanyIncorporatedJPMorganSecuritiesLLCAndSVBSecuritiesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ea541069-c8a0-41f5-a186-def6edd37f4a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ebe1e93e-63c9-48fd-b7f8-764857c13f18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ecdb23a3-e394-4b57-b4f0-5e84d7ca4b27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f2b24689-5075-4df6-a2da-72c8837936dc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f7541451-edb6-4acb-8f0a-790bab15be88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f75f1b7d-970c-44d9-af0e-c5a826dcce23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">xene:CashAndMoneyMarketFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f76418ce-447a-47fa-abce-3e02aca037d2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">xene:BurnabyBritishColumbiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f8c4b477-a573-4a64-a72d-9223363b6d20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f90eb819-58f1-4a64-8683-5de3a214bcb5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xene:JefferiesLLCStifelNicolausCompanyIncorporatedJPMorganSecuritiesLLCAndSVBSecuritiesLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f91f0158-e869-4802-841d-82a3345ebc02"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">xene:UnderwrittenPublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xene:JefferiesLLCStifelNicolausCompanyIncorporatedJPMorganSecuritiesLLCAndSVBSecuritiesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f956e4c2-abe5-46ae-8429-402134a46f35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fa095704-4846-4a02-9bc0-f78ed31e8f79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fb8162b3-a597-4e6d-b07d-93335801c609"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">xene:AzetukalnerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fc078d20-42fa-4250-b769-ef250cdd40e5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0031901f-461f-45c7-b720-6eb40956e950"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_01045051-1058-4f3f-b914-02cf2190b1d1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">xene:ResearchEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_01a82667-15d7-4024-a57e-2657379f179f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0451fb9b-54f6-4a4b-8ade-92b89ad35f70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xene:AssetPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xene:FirstOrderPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0514d61f-b883-40b3-87d9-7e278b3a6820"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xene:JefferiesLLCStifelNicolausCompanyIncorporatedJPMorganSecuritiesLLCBofASecuritiesIncAndRBCCapitalMarketsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-01</xbrli:startDate><xbrli:endDate>2023-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0592fb80-0d71-435e-a735-fefde780f550"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xene:TwoThousandFourteenAmendedAndRestatedStockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0a8f0fd9-0cf5-45b3-8b78-096409d7c4d6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">xene:UnderwrittenPublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xene:JefferiesLLCStifelNicolausCompanyIncorporatedJPMorganSecuritiesLLCBofASecuritiesIncAndRBCCapitalMarketsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0cc08d87-8298-44c1-a950-93f5421805de"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xene:NeurocrineBiosciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0cd8e1e9-eb16-4592-8338-e8cd60e3e9b2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0dedc115-eabd-4f39-a7bf-4c55dd4adc43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">xene:GuaranteedInvestmentCertificatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0e65ad73-e8f3-456e-8770-603f8bf6e43d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0ee5ccd7-b9d5-48bc-900e-21a7360e15ff"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0f230ef8-cad8-4ce7-bee0-026b0567d14a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">xene:BurnabyBritishColumbiaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">xene:SecondRenewalOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_13ef935b-4e96-4f11-925b-9ffc59e4e262"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_144eba44-d44f-40ad-8b2c-6acd462b2319"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">xene:Pre-ClinicalDiscoveryAndOtherProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1687d09a-5433-43c2-90f1-f650513a2fa1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xene:JefferiesLLCAndStifelNicolausCompanyIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">xene:AtMarketEquityOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_16c2e333-259f-4e18-b025-1a7840b2cf5d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xene:NeurocrineBiosciencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xene:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1747e417-b850-4047-ad97-74e446f3c37c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_18ce0587-947d-4000-ad21-226659cdded6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">xene:GuaranteedInvestmentCertificatesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_196d5f56-7bc1-4e8e-86d8-d5f88f81bbfa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1a3df49e-e657-4eb0-a563-0c1b8605f4aa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1aa8c882-c640-42ab-9434-c87e60af198d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1c604906-e061-40ec-b25c-b0b029e35f62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1c8819fe-6ad0-42fe-bce0-e8f35f30bcb8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1e9a793b-d120-4f40-8894-7ddb1de35191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_22406e30-26c0-4443-96a7-32b9fcae62e4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2298e5e3-65b4-4e1c-93f1-f5027b90c559"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">xene:GuaranteedInvestmentCertificatesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_279f5f99-a2c7-4a1f-b98a-9e98fe07b653"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">xene:UnderwrittenPublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xene:JefferiesLLCStifelNicolausCompanyIncorporatedJPMorganSecuritiesLLCBofASecuritiesIncAndRBCCapitalMarketsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-01</xbrli:startDate><xbrli:endDate>2023-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_27ad495b-a0bb-495a-8e89-83c9f5fe8b65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_283501b6-a859-4835-8637-5667f1ffb39b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">xene:Pre-ClinicalDiscoveryAndOtherProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_286fc5c3-6fd1-4b6d-bd7e-b335add2e3e5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_28f99d5a-d64c-4e7b-8a46-afb927c32234"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_295d7ebf-ecb2-4863-8055-c5d32414b32f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">xene:UnderwrittenPublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xene:JefferiesLLCStifelNicolausCompanyIncorporatedJPMorganSecuritiesLLCBofASecuritiesIncAndRBCCapitalMarketsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_30871dbf-c703-4cc7-943f-7794f870694c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_31a54459-014b-4693-8a7e-9d5cd1d9fedb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_31d21974-f2b1-4354-9468-ccf01410882d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">xene:XEN496Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_32311f37-d351-4094-8188-e5c4e217f4c9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xene:Series1PreferredSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">xene:ExchangeAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">xene:BVFPartnersLPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-03-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_33309322-16ac-4275-af41-8afa3963db9f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_38463dbb-8c79-451f-b24c-b502ace3c611"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xene:PaciraBiosciencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3a167406-79b6-4756-b860-23ced3e7666d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3c658b98-b12a-46a6-99c1-797a10c45fb8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3c7df611-38a7-4085-9e60-23c55dba93c2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xene:JefferiesLLCAndStifelNicolausCompanyIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">xene:AtMarketEquityOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3cd561ce-d56f-4072-b50b-523fee0cd886"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3e2186d8-8a70-4a7a-821a-ef78292cca8c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xene:NeurocrineBiosciencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xene:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-02-01</xbrli:startDate><xbrli:endDate>2025-02-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_40c485fd-1ab2-4c3b-9ab4-26de3dc49364"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">xene:ProvincialTaxCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_44cf67e5-b119-4290-96d0-c01203738404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4936f148-6a25-41e1-bce8-c9880d5a5e27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">xene:UnderwrittenPublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xene:JefferiesLLCAndStifelNicolausCompanyIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_494ce105-0b9f-4d43-a7ae-9d4280f4ce87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xene:NeurocrineBiosciencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xene:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4984049b-32ea-46b9-98fa-440cbfdf680d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">xene:TermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4b115a6a-6683-4a17-b413-9e8bb98b7a0b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4b92f893-c873-482f-8d2a-12d3073fc31f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4d6ff41e-1e70-42b9-bd5c-6e5b839ec13f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4dbe77ca-9a85-4dcf-8f71-e478f9594e17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">xene:AzetukalnerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4e096b75-1c3e-4f4b-a2d5-46dab7c31772"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_50bacaa3-fec8-476a-a9ec-7fcc62c9f5b7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_53032a5e-ec82-4a52-98b9-c114209ab7e7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">xene:GuaranteedInvestmentCertificatesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_577a2a65-5c5b-4519-baed-db30c894bf0f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_580473ec-137a-44c3-af0d-b97a202a4a2e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xene:JefferiesLLCAndStifelNicolausCompanyIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">xene:AtMarketEquityOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5a1c869a-3031-45a1-b8b8-07258801ac33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">xene:TermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5a4cf558-ec87-4536-9f7e-a17702358f73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5cf39887-6843-4791-adcb-c66041161085"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">xene:CanadaAndUnitedStatesRevenueAgencyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5edde648-d952-4a12-a2fc-5d27c42f48db"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">xene:GuaranteedInvestmentCertificatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_620b04e6-7aa7-4a6e-b3fe-1655d998a981"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xene:NeurocrineBiosciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_63ad59ce-e171-4295-bb49-279aaf68cd61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_664789f3-25f8-4a48-9938-65726d2fa13a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">xene:ProvincialTaxCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_678bf7e6-b4a8-4a8d-a08d-fd80c5153186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6c905a81-8dbd-4c7f-94d4-609f8be01e6a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6cf3e3b1-576f-40f1-acd3-00e00c79c90c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6f467048-a278-4893-a073-167e3300ed14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:InvestmentCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_71cbb8cb-9965-4745-9068-1c329cd37142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xene:Series1PreferredSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_75650c11-6320-415c-9740-299a3731566d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_779d7deb-a421-4227-83c3-8ac2dfc35f90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7a64b01e-5173-4d9f-837a-bbb2c4168382"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">xene:NeedhamMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7ab2ed07-5dfe-432a-be61-bebc4c8597c5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7bc29ce6-ec8e-46b1-9da8-77d97bcac7c2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7c1e5b7a-577b-4134-b465-b0ccd0cdbae9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">xene:RegulatoryMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xene:NeurocrineBiosciencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xene:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7e416cfe-b299-48b2-a9f3-089ca9635d44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xene:NeurocrineBiosciencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xene:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7e56dc4c-bf82-4de2-abd8-51bda8f0b0a0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7f8727e8-25d3-49ce-a4eb-f560f9d67b08"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001582313</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">xene:CashAndMoneyMarketFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_Lease"><xbrli:measure>xene:Lease</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_Segment"><xbrli:measure>xene:Segment</xbrli:measure></xbrli:unit><xbrli:unit id="U_UnitedStatesOfAmericaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_Option"><xbrli:measure>xene:Option</xbrli:measure></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit></ix:resources></ix:header></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.3in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">p</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:13pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UNITED STATES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:13pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:13pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Washington, D.C. 20549</span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:13pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FORM </span><span style="font-size:13pt;font-family:Times New Roman;"><ix:nonNumeric id="F_74c10fcc-5185-4106-8536-c14609b50866" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:13pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10-K</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:13pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Mark One)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_03bf3640-9f1d-4ffa-bb95-a7bc5f8d5eb1" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the fiscal year ended </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_74e1769b-2de2-43bc-bc7f-15a96c7a7d25" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cd636dd0-d655-4d3f-a4af-a07b889030b8" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f219e2a4-faf9-472c-ae3f-f1c57fa08fc1" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="dei:DocumentFiscalYearFocus"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024</span></ix:nonNumeric></span></ix:nonNumeric></span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">OR</span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_2d000b7e-2fdc-4452-9b5c-fc7c5f912115" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM                      TO</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">                     </span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commission File Number </span><span style="font-size:8.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8670ace6-2fd2-426d-abd3-90e67b768e47" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">001-36687</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:17.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7e5042d8-196c-46b3-828c-6d89ec5841cc" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:17.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">XENON PHARMACEUTICALS INC.</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Exact Name of Registrant as Specified in its Charter)</span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50%;box-sizing:content-box;"/>
    <td style="width:50%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_e1f5bd45-2079-47f5-aaa4-78aa7f51a5ed" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="dei:EntityAddressCountry" format="ixt-sec:countrynameen"><ix:nonNumeric id="F_97661067-8b59-46b2-9af9-ebe811cd7f20" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:edgarprovcountryen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Canada</span></ix:nonNumeric></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_a2f4b0da-bce2-4f5d-847d-25c254a2f1a7" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">98-0661854</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(State or other jurisdiction of</span></p><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">incorporation or organization)</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(I.R.S. Employer<br/>Identification No.)</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span><ix:nonNumeric id="F_17c7a2c1-2772-49ee-8814-7eca1b6ab380" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">200-3650 Gilmore Way</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span><ix:nonNumeric id="F_5e0df37e-6b2c-4157-b7e3-520f417cad57" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Burnaby</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_2a6d07f8-f81b-44b3-87e3-7763fe6842cf" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">British Columbia</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_87c7665e-81a3-4ca5-8aff-26b74c83997c" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">V5G 4W8</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Address of principal executive offices)</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:4.5pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registrant&#8217;s telephone number, including area code: (</span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e314dadd-0c14-4f8c-b1bf-3a59bd851778" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">604</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0e876845-2f49-4d21-80c5-ec35f796dff2" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">484-3300</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:38%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:15%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:45%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Title of each class</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Trading</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Symbol(s)</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_95416a47-40d4-4ada-ab79-8caf4cefe5ea" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common Shares, without par value</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_83b09a56-6899-4ebd-864c-6ea382337f93" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">XENE</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_33d88abe-c966-4e07-91a5-f18189789294" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">The Nasdaq Stock Market LLC</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(The Nasdaq Global Market)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities registered pursuant to Section 12(g) of the Act: </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. </span><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3ca7fa25-674c-495c-81f3-bb7d3e351a50" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="dei:EntityWellKnownSeasonedIssuer"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. </span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2d4b2c6a-24d8-4def-85aa-dae5d9ea37fc" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="dei:EntityVoluntaryFilers"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. </span><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bed2fda5-e147-43ee-9dc4-744834f9e5e1" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="dei:EntityCurrentReportingStatus"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files). </span><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8bea4781-37e6-4650-907d-cc7e64909a46" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="dei:EntityInteractiveDataCurrent"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:18.88%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:55.86%;box-sizing:content-box;"/>
    <td style="width:1.06%;box-sizing:content-box;"/>
    <td style="width:20.16%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:2.04%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10.8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:7.5pt;"><ix:nonNumeric id="F_9307ed67-2525-454e-b194-f9cf431e0fa0" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Large accelerated filer</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accelerated filer</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></p></td>
   </tr>
   <tr style="height:3.6pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-accelerated filer</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Smaller reporting company</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:7.5pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_ce6b4e56-9bc1-4f4b-bc9d-b9ada0738468" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Wingdings',serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Wingdings',serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Emerging growth company</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:7.5pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_acf2b768-839c-45c0-a0a4-3a986b71bdc8" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Wingdings',serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  </span><span style="font-size:7.5pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_550af773-d0b9-469a-a376-3cd5b5b19e4f" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements</span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  </span><span style="font-size:7.5pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_a88f4685-3073-444a-a240-9ff526ccdd29" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). </span><span style="font-size:7.5pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_7e8881be-741d-4f8e-b7a8-25e142099168" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="dei:DocumentFinStmtRestatementRecoveryAnalysisFlag" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). </span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:7.5pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_9ac0cabd-b1b9-4c1e-a76f-5d0afd5dfb9d" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="dei:EntityShellCompany" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The aggregate market value of the voting and non-voting common equity held by non-affiliates of the Registrant, based on the closing price of the common shares on The Nasdaq Global Market on June 30, 2024, was approximately $</span><span style="font-size:7.5pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6e2f0da3-86ca-4e86-93d2-c54ba5ae626a" contextRef="C_f8c4b477-a573-4a64-a72d-9223363b6d20" name="dei:EntityPublicFloat" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2,946.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. Common shares held by each executive officer and director and by each other person who may be deemed to be an affiliate of the Registrant, have been excluded from this computation.  This determination of affiliate status is not necessarily a conclusive determination for other purposes.</span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The number of common shares of the Registrant outstanding as of </span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">February 24, 2025 was </span><span style="font-size:7.5pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fa70130d-93be-49b6-9798-b48076e7bae5" contextRef="C_bc5911cd-b1ff-4b0f-a581-4c001670e9a5" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">76,542,811</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE</span></p>
  <div style="font-size:8.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2a97915a-bd1d-4dc6-b239-d45a6dee0ead" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="dei:DocumentsIncorporatedByReferenceTextBlock" escape="true"><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Portions of the Registrant&#8217;s Definitive Proxy Statement relating to the 2024 Annual Meeting of Shareholders, which will be filed with the Securities and Exchange Commission subsequent to the date hereof, are incorporated by reference into Part III of this Report. Such Proxy Statement will be filed with the Securities and Exchange Commission not later than 120 days following the end of the Registrant&#8217;s fiscal year ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:12.26%;box-sizing:content-box;"/>
    <td style="width:16.66%;box-sizing:content-box;"/>
    <td style="width:12.2%;box-sizing:content-box;"/>
    <td style="width:20%;box-sizing:content-box;"/>
    <td style="width:13.34%;box-sizing:content-box;"/>
    <td style="width:25.54%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:8pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Auditor Firm Id:</span></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;"><ix:nonNumeric id="F_919e3f4b-d556-4860-b9ed-0c8731417db5" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="dei:AuditorFirmId"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:8pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Auditor Name:</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;"><ix:nonNumeric id="F_33485b29-5e99-4fbd-a1fa-62a77acc7429" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="dei:AuditorName"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">KPMG LLP</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:8pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Auditor Location:</span></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;"><ix:nonNumeric id="F_b825c2a0-2c70-4cc5-bfaf-12fd5afd5e1a" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="dei:AuditorLocation"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vancouver, BC, Canada</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="border-top:2.25pt double;padding-top:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.3in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">XENON PHARMACEUTICALS INC.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FORM 10-K</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the Fiscal Year Ended December 31, 2024</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:8%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:82%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:8%;box-sizing:content-box;"/>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Page</span></p></td>
   </tr>
   <tr style="height:13.7pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="3" style="padding-top:0in;text-indent:12.25pt;vertical-align:bottom;padding-bottom:0in;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_i"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">PART I</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.027777777777777776in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
   </tr>
   <tr style="height:13.7pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:12.25pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1_business"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Business</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.027777777777777776in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1A.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:12.25pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1a_riskfactors"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Risk Factors</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.027777777777777776in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1B.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:12.25pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#unresolved_staff_comments"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Unresolved Staff Comments</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.027777777777777776in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">66</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1C.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:12.25pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1c_cybersecurity"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Cybersecurity</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.027777777777777776in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">67</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 2.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:12.25pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_2_properties"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Properties</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.027777777777777776in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">68</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 3.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:12.25pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_3"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Legal Proceedings</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.027777777777777776in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">68</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 4.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:12.25pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_4"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Mine Safety Disclosures</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.027777777777777776in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">68</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.027777777777777776in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="3" style="padding-top:0in;text-indent:12.25pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_ii"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">PART II</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.027777777777777776in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">69</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 5.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:12.25pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_5"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Market for Registrant&#8217;s Common Equity, Related Shareholder Matters and Issuer Purchases of Equity Securities</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.027777777777777776in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">69</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 6.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:12.25pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#reserved"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">[Reserved]</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.027777777777777776in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">70</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 7.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:12.25pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_7_managements_discussion_analysis_f"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.027777777777777776in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">71</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 7A.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:12.25pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_7a_quantitative_qualitative_disclos"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.027777777777777776in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 8.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:12.25pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_8"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Financial Statements and Supplementary Data</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.027777777777777776in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">81</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 9.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:12.25pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9_changes_in_disagreements_with_acc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.027777777777777776in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">103</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 9A.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:12.25pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9a"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Controls and Procedures</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.027777777777777776in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">103</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 9B.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:12.25pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9b"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Other Information</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.027777777777777776in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">104</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 9C.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:12.25pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#disclosure_regard_foreign_juris"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.027777777777777776in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">104</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.027777777777777776in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="3" style="padding-top:0in;text-indent:12.25pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_iii"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">PART III</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.027777777777777776in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">105</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 10.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:12.25pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_10"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Directors, Executive Officers and Corporate Governance</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.027777777777777776in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">105</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 11.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:12.25pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#executive_compensation"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Executive Compensation</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.027777777777777776in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">105</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 12.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:12.25pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_12"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Security Ownership of Certain Beneficial Owners and Management and Related Shareholder Matters</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.027777777777777776in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">105</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 13.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:12.25pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_13"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.027777777777777776in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">105</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 14.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:12.25pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_14"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Principal Accountant Fees and Services</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.027777777777777776in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">105</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.027777777777777776in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="3" style="padding-top:0in;text-indent:12.25pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_iv"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">PART IV</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.027777777777777776in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">106</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 15.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:12.25pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_15"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Exhibits, Financial Statement Schedules</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.027777777777777776in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">106</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 16.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:12.25pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#form_10k_summary"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form 10-K Summary</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.027777777777777776in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">108</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.027777777777777776in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="3" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#power_of_attorney"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Signatures</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.027777777777777776in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">109</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">i</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_i"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PAR</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">T I</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Forward-Looking Statements</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain statements contained in this Annual Report on Form 10-K may constitute forward-looking statements under applicable law. The words or phrases &#8220;would be,&#8221; &#8220;will allow,&#8221; &#8220;intends to,&#8221; &#8220;may,&#8221; &#8220;believe,&#8221; &#8220;plan,&#8221; &#8220;will likely result,&#8221; &#8220;are expected to,&#8221; &#8220;will continue,&#8221; &#8220;is anticipated,&#8221; &#8220;estimate,&#8221; &#8220;project,&#8221; or similar expressions, or the negative of such words or phrases, are intended to identify &#8220;forward-looking statements.&#8221; You should read these statements carefully because they discuss future expectations, contain projections of future results of operations or financial condition, or state other &#8220;forward-looking&#8221; information. These statements relate to our future plans, objectives, expectations, intentions and financial performance and the assumptions that underlie these statements. These forward-looking statements include, but are not limited to:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to identify additional products or product candidates either from our internal research efforts or through acquiring or in-licensing other product candidates or technologies; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the initiation, timing, cost, progress and success of our research and development programs, pre-clinical studies and clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to advance product candidates into, and successfully complete, clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to recruit sufficient numbers of patients for our current and future clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to obtain funding for our operations in sufficient amounts or on terms acceptable to us, including funding necessary to complete further development, approval and, if approved, commercialization of our product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to independently develop and commercialize product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">developments relating to our competitors and our industry, including the success of competing therapies that are or become available; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our pre-commercial, commercialization, marketing and manufacturing capabilities and strategy; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to obtain and maintain intellectual property protection for our product candidates and the duration of such protection;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the therapeutic benefits, effectiveness and safety of our product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing of, and our and our collaborators&#8217; ability to obtain and maintain, regulatory approvals for our product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the accuracy of our estimates of the size and characteristics of the markets that may be addressed by our products and product candidates and our ability to serve those markets, either alone or in partnership with others;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the rate and degree of market acceptance and clinical utility of any future products;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the pricing and reimbursement of our product candidates, if approved;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our expectations regarding federal, state and foreign regulatory requirements;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to establish and maintain collaborations;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our expectations regarding market risk, including interest rate changes and foreign currency fluctuations;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to engage and retain the employees required to grow our business;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our future financial performance; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the direct and indirect impact of pandemics, epidemics and other public health emergencies on our business and operations, including supply chain, manufacturing, research and development costs, clinical trial conduct, clinical trial data and employees.</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements. Factors that might cause such a difference include, but are not limited to, those discussed in this report in Part I, Item 1A &#8212; &#8220;Risk Factors,&#8221; and elsewhere in this Annual Report on Form 10-K. Forward-looking statements are based on our management&#8217;s beliefs and assumptions and on information currently available to our management. These statements, like all statements in this report, speak only as of their date, and we undertake no obligation to update or revise these statements in light of future developments. In this Annual Report on Form 10-K, &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us,&#8221; &#8220;Xenon,&#8221; and &#8220;the Company&#8221; refer to Xenon Pharmaceuticals Inc. and its subsidiary. Unless otherwise noted, all dollar amounts in this report are expressed in United States dollars.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Annual Report on Form 10-K, and although we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted a thorough inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely upon these statements.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Annual Report on Form 10-K includes our trademarks and registered trademarks, including the Xenon logo and other trademarks or service marks of Xenon. Other trademarks, trade names or service marks appearing in this Annual Report on Form 10-K belong to their respective holders.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risk Factors Summary</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our business is subject to numerous risks and uncertainties, including those highlighted in the section of this report captioned &#8220;Risk Factors.&#8221; The following is a summary of the principal risks we face:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have incurred significant losses since our inception and anticipate that we will continue to incur significant losses for the foreseeable future.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will need to raise additional funding, which may not be available on acceptable terms, if at all. Failure to obtain capital when needed may force us to delay, limit or terminate our product discovery and development programs or commercialization efforts or other operations.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our business substantially depends upon the successful development of azetukalner. If we are unable to obtain regulatory approval for, and successfully commercialize, azetukalner, our business may be materially harmed.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clinical trials may fail to demonstrate adequately the safety and efficacy of our, or our collaborators&#8217;, product candidates at any stage of clinical development. Terminating the development of any of our, or our collaborators&#8217;, product candidates could materially harm our business and the market price of our common shares.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We, or our collaborators, may find it difficult to enroll patients in our clinical trials which could delay or prevent the successful completion of clinical trials of our product candidates.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We, or our collaborators, may incur unexpected costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our, or our collaborators&#8217;, product candidates.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The regulatory approval processes of the FDA, EMA and regulators in other foreign jurisdictions are lengthy, time-consuming and inherently unpredictable. If we, or our collaborators, are unable to obtain regulatory approval for our product candidates in a timely manner, or at all, our business may be substantially harmed.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unable to establish our own sales, marketing and distribution capabilities or enter into agreements for these purposes, we may not be successful in independently commercializing any future products.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our prospects for successful development and commercialization of our partnered products and product candidates are dependent upon the research, development and marketing efforts of our collaborators.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our reliance on third parties to manufacture our product candidates may increase the risk that we will not have sufficient quantities of our product candidates, raw materials, APIs or drug products when needed or at an acceptable cost.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We rely on third parties to conduct our pre-clinical studies and clinical trials. If these third parties do not successfully carry out their contractual duties, including to comply with applicable laws and regulations or meet expected deadlines, our business could be substantially harmed.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We could be unsuccessful in obtaining or maintaining adequate patent protection for one or more of our products, product candidates or future products.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may not be able to protect our intellectual property rights throughout the world.</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our business and operations could suffer in the event of an actual or perceived information security incident such as a cybersecurity breach, system failure or other compromise of our systems and/or information, including information held by a third-party contractor or vendor.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The market price of our common shares may be volatile, and purchasers of our common shares could incur substantial losses.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Future sales and issuances of our common shares or securities convertible into or exchangeable for common shares would cause our shareholders to incur dilution and could cause the market price of our common shares to fall.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Risk Factors are not guarantees that no such conditions exist as of the date of this report and should not be interpreted as an affirmative statement that such risks or conditions have not materialized, in whole or in part.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1_business"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1. Business</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. We are advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. In addition to our proprietary product candidates, we also have partnered programs with academic and industry collaborators, including Neurocrine Biosciences, Inc., or Neurocrine Biosciences.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Strategy</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our goal is to build a fully-integrated and profitable biopharmaceutical company that discovers, develops, and commercializes innovative therapeutics to treat a range of neurological and psychiatric disorders.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Key components of our strategy include:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Leveraging our discovery capabilities &#8211; which were founded upon our understanding of the genetics of channelopathies combined with proprietary biology and medicinal chemistry assets and know-how &#8211; to identify product candidates for development;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Advancing selected proprietary product candidates through clinical development;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Selectively establishing collaborations that allow us to potentially expand our internal capabilities and/or address broader commercial opportunities than may be possible independently;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Identifying opportunities to further expand our pipeline though indication expansion, acquisition, or in-licensing of external product candidates; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commercializing product candidates alone or in collaboration with others.</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Pipeline</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img255015816_0.jpg" alt="img255015816_0.jpg" style="width:720px;height:330px;"/></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Product Candidates</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Azetukalner</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for the treatment of multiple indications that include epilepsy, including focal onset seizures, or FOS, and primary generalized tonic-clonic seizures, or PGTCS, as well as neuropsychiatric disorders including major depressive disorder, or MDD, and bipolar depression, or BPD.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Epilepsy Programs</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Focal Onset Seizures</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Phase 3 azetukalner clinical studies in FOS (X-TOLE2 and X-TOLE3) continue to advance, with the first topline data readout anticipated in the second half of 2025. Designed closely after the Phase 2b X-TOLE clinical trial, the Phase 3 X-TOLE clinical trials are multicenter, randomized, double-blind, placebo-controlled studies evaluating the clinical efficacy, safety, and tolerability of 15 mg or 25 mg of azetukalner administered orally with food as adjunctive treatment in approximately 360 patients with FOS per study. The primary efficacy endpoint is the median percent change, or MPC, in monthly seizure frequency from baseline through the 12-week double-blind period, or DBP, of azetukalner compared to placebo. Upon completion of the DBP in the Phase 3 FOS epilepsy studies, eligible patients may enter an OLE study for up to three years.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Primary Generalized Tonic-Clonic Seizures</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Phase 3 X-ACKT clinical study continues to enroll patients and is intended to support potential regulatory submissions in an additional epilepsy indication of PGTCS. X-ACKT is a multicenter, randomized, double-blind, placebo-controlled study evaluating the clinical efficacy, safety, and tolerability of 25 mg of azetukalner administered with food as adjunctive treatment in approximately 160 patients with PGTCS. The primary efficacy endpoint is the MPC in monthly PGTCS frequency from baseline through the 12-week DBP of azetukalner compared to placebo. Upon completion of the DBP in the X-ACKT study, eligible patients may enter an open-label extension, or OLE, study for up to three years.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Summary of Azetukalner Clinical Results in Epilepsy</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Phase 1: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Phase 1 studies conducted in healthy subjects suggested that azetukalner was generally well tolerated in the doses examined, and its pharmacokinetic profile supported a once-daily dosing schedule with food and without the need for titration, which has been utilized in all Phase 2 and Phase 3 trials. In addition, data from a Phase 1b transcranial magnetic stimulation, or TMS, study &#8211; which was designed to assess azetukalner&#8217;s ability and potency to modulate cortical excitability &#8211; demonstrated activity in the target CNS tissue and helped inform dose selection for our Phase 2b clinical trial.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Phase 2b X-TOLE Clinical Trial: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2021, we announced topline results from the Phase 2b X-TOLE clinical trial, which was designed as a randomized, double-blind, placebo-controlled, multicenter study to evaluate the clinical efficacy, safety, and tolerability of 10 mg, 20 mg, or 25 mg of azetukalner administered as once-daily adjunctive treatment with food in adult patients with focal epilepsy. The study included a total of 325 randomized and treated subjects in the safety population and 323 subjects in the modified intent-to-treat population for the efficacy analyses. Subjects had an average age of 40.8 &#177; 13.3 years, and 8.9%, 40.6%, or 50.5% of the subjects were on and continued taking one, two, or three stable background ASMs throughout the study, respectively, and failed a median of 6 previous ASMs prior to study entry. The median baseline seizure frequency across the study groups was approximately 13.5 seizures per month. Of the 285 subjects who completed the double-blind period, 96.5% entered the OLE to evaluate the long-term safety, tolerability, and effectiveness of azetukalner.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Summary of X-TOLE Efficacy Results in the DBP</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The X-TOLE trial met its primary efficacy endpoint with azetukalner demonstrating a statistically significant and dose-dependent reduction from baseline in monthly (defined as 28 days) focal seizure frequency when compared to placebo (monotonic dose response; p&lt;0.001). Primary and secondary measures in the topline data set included a pairwise comparison of each active dose to placebo and a responder analysis with the proportion of patients who achieved a 50% or greater reduction in monthly focal seizure frequency from baseline. Azetukalner demonstrated a statistically significant reduction from baseline in monthly focal seizure frequency in pairwise comparisons to placebo for all three azetukalner doses. The median percent reduction in monthly focal seizure frequency was 52.8% in the azetukalner 25 mg group, 46.4% in the azetukalner 20 mg group, and 33.2% in the azetukalner 10 mg group compared to 18.2% in the placebo group. Statistical significance was achieved for all dose groups compared to placebo with 2-sided p-values of p&lt;0.001 for 25 mg vs. placebo, p&lt;0.001 for 20 mg vs. placebo, and p=0.035 for 10 mg vs. placebo. A prespecified secondary endpoint of the study was a responder analysis, which compared the proportion of study subjects treated with azetukalner who achieved a &#8805;50% reduction in monthly focal seizures versus placebo. The percentage of subjects who achieved a &#8805;50% reduction in monthly focal seizures was 54.5% in the azetukalner 25 mg group, 43.1% in the azetukalner 20 mg group, and 28.3% in the azetukalner 10 mg group compared to 14.9% in the placebo group. Statistical significance was achieved for all dose groups compared to placebo with 2-sided p-values of p&lt;0.001 for 25 mg vs. placebo, p&lt;0.001 for 20 mg vs. placebo, and p=0.037 for 10 mg vs placebo. In addition to the topline data, further sub-analyses were presented in December 2021. These sub-analyses include the proportion of patients with at least a 75% reduction in monthly focal seizure frequency from baseline along with the proportion of patients who achieved 100% reduction in monthly seizure frequency from baseline. Efficacy results are summarized in the following table; all p-values are 2-sided comparing the active dose to placebo for the prespecified primary and secondary seizure reduction endpoints:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <table style="margin-left:6%;border-spacing:0;table-layout:auto;width:89.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:37.74%;box-sizing:content-box;"/>
    <td style="width:17.24%;box-sizing:content-box;"/>
    <td style="width:17.24%;box-sizing:content-box;"/>
    <td style="width:17.24%;box-sizing:content-box;"/>
    <td style="width:10.54%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:25.9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="border-top:0.5pt solid;padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid;padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Azetukalner 25 mg</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(n=112)</span></p></td>
    <td style="border-top:0.5pt solid;padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Azetukalner 20 mg</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(n=51)</span></p></td>
    <td style="border-top:0.5pt solid;padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Azetukalner 10 mg</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(n=46)</span></p></td>
    <td style="border-top:0.5pt solid;padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Placebo</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(n=114)</span></p></td>
   </tr>
   <tr style="height:34.55pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Median reduction from baseline in monthly focal seizure frequency</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">52.8%</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(p&lt;0.001)</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46.4%</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(p&lt;0.001)</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33.2%</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(p=0.035)</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18.2%</span></p></td>
   </tr>
   <tr style="height:34.55pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Patients with </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">at least a 50%</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;reduction in monthly focal seizure frequency from baseline</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">54.5%</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(p&lt;0.001)</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43.1%</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(p&lt;0.001)</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28.3%</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(p=0.037)</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.9%</span></p></td>
   </tr>
   <tr style="height:34.55pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Patients with </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">at least a 75%</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;reduction in monthly focal seizure frequency from baseline</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29.5%</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29.4%</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.7%</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.1%</span></p></td>
   </tr>
   <tr style="height:34.55pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Patients with </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">100% </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">reduction in monthly focal seizure frequency from baseline</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.3%</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.8%</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.2%</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.8%</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additional sub-analyses were performed in patients with different baseline characteristics given that X-TOLE included a difficult-to-treat patient population as defined by the number of prior failed ASMs, concomitant ASMs on study, and baseline seizure burden. The table below outlines a sub-group analyses of median percent reduction in seizures within the 25 mg dose group, showing that there was a significant increase in seizure reduction in patients with less disease severity at baseline:</span></p>
  <table style="margin-left:5.731%;border-spacing:0;table-layout:auto;width:89.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:33.32%;box-sizing:content-box;"/>
    <td style="width:33.34%;box-sizing:content-box;"/>
    <td style="width:33.34%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="border-top:0.5pt solid #000000;padding-top:0in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Azetukalner 25 mg <br/>Median reduction from baseline in monthly focal seizures frequency</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Placebo</span></p></td>
   </tr>
   <tr style="height:14.4pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Overall in X-TOLE</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;52.8% (n=112)</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;18.2% (n=114)</span></p></td>
   </tr>
   <tr style="height:14.4pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prior failed ASMs &gt; 6</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43.2% (n=45)</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.2% (n=47)</span></p></td>
   </tr>
   <tr style="height:14.4pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prior failed ASMs </span><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">&lt;</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;6</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">58.3% (n=67)</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20.5% (n=67)</span></p></td>
   </tr>
   <tr style="height:14.4pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Concomitant ASMs = 3</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">51.3% (n=54)</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20.4% (n=56)</span></p></td>
   </tr>
   <tr style="height:14.4pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Concomitant ASMs </span><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">&lt;</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;2</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">59.7% (n=58)</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.4% (n=58)</span></p></td>
   </tr>
   <tr style="height:14.4pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Baseline seizures &gt; 8.5 per month</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50.8% (n=83)</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18.2% (n=84)</span></p></td>
   </tr>
   <tr style="height:14.4pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Baseline seizures </span><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">&lt;</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;8.5 per month</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">70.6% (n=29)</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18.8% (n=30)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, an analysis of seizure reduction across seizure subtypes showed a median percent reduction in monthly focal seizure frequency of 86.9% (n=23) in &#8216;type 4&#8217; focal seizures that lead to generalized tonic-clonic seizures in the 25 mg dose group. A time-to-event analysis analyzing the time to reach the baseline monthly focal seizure count during the double-blind period showed a marked dose-dependent decrease in the rate of seizure recurrence when comparing azetukalner to placebo.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These marked reductions in seizures were associated with statistically significant improvements in overall status, as assessed by physicians using the Clinical Global Impression of Change, or CGI-C, and by subject self-reporting using the Patient Global Impression of Change, or PGI-C, scales in the azetukalner 25 mg group, which are shown in the table below:</span></p>
  <table style="margin-left:5.667%;border-spacing:0;table-layout:auto;width:82.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:42.2%;box-sizing:content-box;"/>
    <td style="width:28.9%;box-sizing:content-box;"/>
    <td style="width:28.9%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="border-top:0.5pt solid;padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid;padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Azetukalner 25 mg</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(n=112)</span></p></td>
    <td style="border-top:0.5pt solid;padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Placebo</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(n=114)</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">CGI-C (Portion of patients much improved or very much improved)</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46.4%</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(p&lt;0.001)</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22.8%</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">PGI-C (Portion of patients much improved or very much improved)</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42.9%</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(p=0.001)</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.9%</span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The azetukalner 25 mg group was statistically significant in CGI-C and PGI-C, and the azetukalner 20 mg group was statistically significant in PGI-C, while the azetukalner 20 mg group in CGI-C and the azetukalner 10 mg group for both CGI-C and PGI-C showed numerical improvements over placebo but were not statistically significant.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Summary of X-TOLE Safety Results in the DBP</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Azetukalner was generally well tolerated in the DBP with AEs generally consistent with other ASMs. The incidence of treatment-emergent adverse events, or TEAEs, was higher in the treatment groups as compared to the placebo group, with 62.3% of patients in the placebo group, 67.4% of patients in the azetukalner 10 mg group, 68.6% of patients in the azetukalner 20 mg group, and 85.1% of patients in the azetukalner 25 mg group experiencing at least one TEAE. The TEAEs that were greater than or equal to 5% in all treatment arms were attributed to nervous system disorders; psychiatric disorders; general disorders; gastrointestinal disorders; eye disorders; and infections &#8211; with the majority related to the central nervous system, mild or moderate in severity, and occurring early in the treatment period. Across all azetukalner dose groups (n=211), the most common TEAEs were dizziness (n=52, 24.6%), somnolence (n=33, 15.6%), fatigue (n=23, 10.9%), and headache (n=21, 10.0%). The breakdown of subjects with dizziness across dose groups including placebo is as follows: 8 subjects (7.0%) in the placebo group, 3 subjects (6.5%) in the 10 mg group, 13 subjects (25.5%) in the 20 mg group, and 36 subjects (31.6%) in the 25 mg group. The incidence of treatment-emergent serious adverse events, or SAEs, was similar in all four arms of the study with 2.6% of patients in the placebo group, 4.3% of patients in the azetukalner 10 mg group, 3.9% of patients in the azetukalner 20 mg group, and 2.6% of patients in the azetukalner 25 mg group experiencing at least one treatment-emergent SAE. There were 3.5% of subjects in the placebo group, 2.2% of subjects in the azetukalner 10 mg group, 13.7% of subjects in the azetukalner 20 mg group, and 15.8% of subjects in the azetukalner 25 mg group that had an AE leading to treatment discontinuation. Two TEAEs of urinary retention were reported in the active treatment groups, one of which required a dose reduction, and both subjects remained on drug with no other changes or intervention. There was no evidence of urinary retention based upon mean differences across treatment groups in the total or individual items of the American Urological Association Symptom Index. There was no cardiovascular signal of concern based on vital signs from resting or orthostatic tests; there were no safety signals of concern from physical or neurologic exams; and there were no signals of concern from ECGs, safety labs or urinalysis. Weight changes were modest with mean (SD) changes of 0.2 kg (2.4) in the placebo group, 0.6 kg (2.3) in the 10 mg group, 1.6 kg (2.2) in the 20 mg group and 1.9 kg (2.9) in the 25 mg group.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Additional Post Hoc Sub-Analyses of X-TOLE Data and Interim Open Label Extension (OLE) Data:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additional sub-analyses of the X-TOLE data suggest that the rapid onset of efficacy for azetukalner was associated with starting at an effective, therapeutic dose. There was a statistically significant reduction in median seizure frequency within one week for all doses compared with placebo. Rapid onset of efficacy of azetukalner was seen at week 1, with a dose-dependent reduction from baseline in median weekly seizure frequency of 39.1% (p&lt;0.01, n=46), 41.5% (p=0.04, n=50) and 55.4% (p&lt;0.001, n=110) in the 10 mg, 20 mg, and 25 mg groups, respectively, compared to placebo (20.2%, n=114).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The most recent interim data from the ongoing 7-year X-TOLE OLE, in which participants received open&#8209;label azetukalner at a dose of 20 mg once daily with food, were presented in December 2024. For ongoing OLE patients, monthly MPC reductions in FOS frequency ranged from 61% to 82% during month 1 to OLE study month 24 and were maintained at 85% at OLE study month 36. Patients who were receiving 1 to 2 anti-seizure medications, or ASMs, at baseline experienced higher monthly MPC reductions in FOS frequency from baseline at OLE study month 36 (100% seizure reduction, n=67), compared to those receiving 3 ASMs (80.6% seizure reduction, n=80). For those participants who were treated for &gt;36 months in the OLE, 32.7% (48/147) achieved seizure freedom for a period of at least 12 months. Azetukalner continues to be generally well&#8209;tolerated in the OLE, with AEs generally consistent with prior results in the double-blind period and other ASMs; no new safety signals were identified. A total of 182 participants were treated in the OLE for &#8805;12 months, 165 participants were treated for &#8805;24 months, and 143 participants were treated for &#8805;36 months at the time of the analysis cutoff (October 7, 2024). Retention rates with azetukalner at 12, 24, and 36 months into the OLE study period were 66%, 60%, and 52%, respectively.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">About Epilepsy and Seizure Types</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Epilepsy is a chronic neurologic disorder, the hallmark of which is recurrent, unprovoked and unpredictable seizures. Individuals are diagnosed with epilepsy if they have two unprovoked seizures (or one unprovoked seizure with the likelihood of recurrent seizures) that were not caused by a known and reversible medical condition. Seizures are generally described in two major groups: focal onset seizures, or FOS, and generalized onset seizures. FOS are the most common type of seizure experienced by people with epilepsy. FOS are localized within the brain and can either stay localized or spread to the entire brain, which is typically categorized as a secondarily generalized seizure. FOS account for approximately 60% of seizures in the U.S., which results in a total FOS patient population of approximately 1.8 million patients. Generalized onset seizures affect both sides of the brain or groups of cells on both sides of the brain at the same time. This term includes primary generalized tonic-clonic seizures, or PGTCS, absence seizures, and atonic seizures. Generalized onset seizures account for approximately 30% of seizures in the U.S., or approximately 0.9 million patients, of which the majority experience PGTCS. The remaining 10% of seizures in the U.S. are characterized as unknown onset seizures, which occurs when the beginning of the seizure is unknown. As more information is learned, unknown onset seizures may later be diagnosed as focal onset or generalized onset seizures.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Numerous ASMs are available for the treatment of seizures in the U.S., although there are fewer indicated for PGTCS. The treatment of an individual patient with FOS or PGTCS is currently focused on reduction of seizure frequency, with seizure freedom as the ultimate goal. Early treatment typically begins with monotherapy followed by increasing use of polypharmacy to manage patients with residual seizure burden. Despite the availability of multiple treatment options, up to 50% of patients are considered inadequately managed with initial lines of therapy warranting additional treatment options. For poorly managed patients, physicians increasingly turn to complementary mechanisms used as adjunctive therapy to control seizures. We believe there is a need for new, more effective and tolerable treatments for FOS and PGTCS that have rapid onset of action, unique mechanisms of action important in polypharmacy, and are easy to take (for example, once-daily and no dose titration). Based on our market research, we believe azetukalner could offer a compelling value proposition to address FOS and PGTCS, if approved.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Neuropsychiatric Programs</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We continue to explore the applicability of azetukalner in neuropsychiatric disorders based on establishing a strong scientific rationale, availability of preclinical and clinical data, and a determination of unmet medical needs. A Phase 3 program evaluating azetukalner in major depressive disorder, or MDD, is underway, and we recently announced plans for a Phase 3 program in bipolar depression, or BPD, with initiation of the first of two azetukalner clinical studies in bipolar I and bipolar II depression expected by mid-year.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Major Depressive Disorder</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Phase 3 MDD program includes three multicenter, randomized, double-blind, placebo-controlled clinical trials to evaluate the clinical efficacy, safety, and tolerability of 20 mg of azetukalner administered orally with food over the 6-week DBP as monotherapy treatment in approximately 450 patients with moderate-to-severe MDD per study. The primary efficacy endpoint is the change from baseline in the HAM-D17 score at week 6 in patients who received azetukalner compared to placebo. Upon completion of the DBP, eligible patients may enter an OLE study for up to 12 months. X-NOVA2, the first of three planned Phase 3 clinical trials evaluating azetukalner in patients with MDD, is currently enrolling patients, and X-NOVA3 is expected to initiate mid-year.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, patient enrollment in the investigator-sponsored Phase 2 proof-of-concept study of azetukalner in MDD led by Icahn School of Medicine at Mount Sinai is complete, and topline results are anticipated in the first half of 2025.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Summary of Azetukalner Clinical Results in MDD</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Phase 2 Proof-of-Concept X-NOVA Clinical Trial: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2023, we reported topline results from the randomized, double-blind, placebo-controlled, Phase 2 proof-of-concept X-NOVA clinical trial, which evaluated the clinical efficacy, safety, and tolerability of 10 mg and 20 mg of azetukalner taken once daily with food in 168 patients with moderate to severe MDD. The primary objective was to assess the efficacy of azetukalner compared to placebo on improvement of depressive symptoms in subjects diagnosed with moderate to severe MDD, using the Montgomery-&#197;sberg Depression Rating Scale, or MADRS, score change through week 6.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Summary of X-NOVA Efficacy Data in the DBP: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The primary endpoint of the study was a change in MADRS at week 6. The mean reduction was 13.90 in the placebo group, 15.61 in the azetukalner 10 mg group and 16.94 in the azetukalner 20 mg group. A clear dose response and a clinically meaningful, but not statistically significant, 3.04 difference between placebo and the azetukalner 20 mg group (p=0.135) was observed. A significantly different change was achieved on the following additional endpoints in the study:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pre-specified endpoint of the Hamilton Depression Rating Scale, or HAM-D17, at week 6 with a mean reduction of 10.18 in the placebo group and 13.26 in the azetukalner 20 mg group (p=0.042);</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Key secondary endpoint of a change in the Snaith-Hamilton Pleasure Scale, or SHAPS, measuring anhedonia at week 6 with a reduction of 5.30 in the placebo group and 7.77 in the azetukalner 20 mg group (p=0.046);</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">MADRS at week 1 with a mean reduction of 4.88 in the placebo group and 7.54 in the azetukalner 20 mg group (p=0.047) demonstrating early onset of efficacy; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At least minimally improved symptoms of depression as assessed by physicians using the Clinical Global Impression of Improvement, or CGI-I, (p=0.004) in the azetukalner 20 mg group compared to placebo.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Summary of X-NOVA Safety and Tolerability Data in the DBP:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Azetukalner was generally well tolerated with similar rates of adverse events reported across all treatment arms. The most commonly reported TEAEs in the azetukalner 20 mg group included dizziness (17.9%), somnolence (10.7%), headache (8.9%) and disturbance in attention (8.9%), as compared to the placebo group which reported dizziness (7.3%), somnolence (1.8%), headache (12.7%) and disturbance in attention (0%). Rates of discontinuation were similar across all treatment arms and rates of discontinuation due to TEAEs were low with three patients in the azetukalner 20 mg group (5.4%), as compared to two patients in the placebo group (3.6%). No serious adverse events, or SAEs, were reported in the two azetukalner treatment groups and there were two patients (3.6%) in the placebo group who experienced a treatment-emergent SAE. Azetukalner was not associated with notable weight gain, and patients did not report notable sexual dysfunction.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Investigator-Led Phase 2 Proof-of-Concept Study of Azetukalner in MDD</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are also collaborating with the Icahn School of Medicine at Mount Sinai to support an ongoing investigator-sponsored Phase 2 proof-of-concept, randomized, parallel-arm, placebo-controlled multi-site study of azetukalner for the treatment of MDD in approximately 60 subjects. The primary objective of the study is to investigate the effect of azetukalner on the brain reward circuit as measured by the change in bilateral ventral striatum activity as assessed by functional MRI, or fMRI. The secondary objectives are to test the effect of azetukalner compared to placebo on clinical measures of depression and anhedonia using the MADRS and SHAPS, respectively.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">About Major Depressive Disorder (MDD)</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">MDD is a common, chronic neurological disorder characterized by low mood, inability to feel pleasure, feelings of guilt and worthlessness, low energy, and other emotional and physical symptoms that last for two weeks or more, and which impairs social, occupational, educational, or other important functioning. MDD is highly prevalent and difficult to treat. According to the National Institutes of Health, an estimated 7.8% of U.S. adults (21.0 million) experience MDD each year, and of them approximately two-thirds had severe impairment associated with their depression. Results of the Sequenced Treatment Alternatives to Relieve Depression, or STAR*D trial, funded by the National Institute of Mental Health, indicate that nearly two-thirds of diagnosed and treated patients do not experience adequate treatment response with first-line therapy, and that the majority of these initial failures also fail second-line treatment, highlighting the need for new anti-depressant medications with novel mechanisms of action.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Intellectual Property Related to Azetukalner</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have a comprehensive strategy in place to protect and expand the intellectual property portfolio that covers azetukalner. Importantly, two U.S. patents were issued in 2021 with claims covering: (1) distinct crystalline forms of azetukalner drug substance and related pharmaceutical compositions, along with methods for their preparation and use; and (2) various methods of orally administering azetukalner with or close to a meal. These U.S. patents are expected to expire in 2040 and 2039, respectively, absent any extensions of patent term. For a more detailed description of our intellectual property portfolio covering our pipeline of product candidates, see &#8220;&#8212;Intellectual Property&#8221; below.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Early-Stage Pipeline: Next Generation Ion Channel Modulators</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We continue to expand our portfolio by leveraging our extensive ion channel expertise to discover and develop potassium and sodium channel therapeutics, with the goal of filing multiple investigational new drug applications, or INDs, or equivalent, in 2025. IND-enabling work is underway with multiple Kv7 development candidates, which we believe may have utility in a broad range of therapeutic indications including seizures, pain, and neuropsychiatric disorders, such as MDD and BPD. In addition, IND-enabling work is underway with a lead Nav1.7 development candidate. Nav1.7 is an important pain-related target, based on strong human genetic validation, that may represent a new class of medicines without the limitations of opioids. We also expect a lead candidate within our Nav1.1 program will enter IND-enabling studies in 2025 as pre-clinical data suggests that targeting Nav1.1 could potentially address the underlying cause and symptoms of Dravet Syndrome.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Partnered Program with Neurocrine Biosciences</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2019, we entered into a license and collaboration agreement with Neurocrine Biosciences to develop treatments for epilepsy. The agreement also included a multi-year research collaboration to discover, identify and develop additional novel Nav1.6 and Nav1.2/1.6 inhibitors, which was completed in June 2022. As part of this ongoing collaboration, NBI-921355, a Nav1.2/1.6 sodium channel inhibitor, has progressed into a Phase 1 first-in-human study as a potential treatment for certain types of epilepsy, triggering an anticipated $7.5 million milestone payment to Xenon. For a more detailed description of the terms of this agreement with Neurocrine Biosciences, see &#8220;&#8212;Collaborations, Commercial and License Agreements&#8221; below.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Collaborations, Commercial and License Agreements</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">License and Collaboration Agreement with Neurocrine Biosciences, Inc.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2019, as amended in January 2021 and February 2022, we entered into a license and collaboration agreement, or the Collaboration Agreement, with Neurocrine Biosciences to establish a collaboration under which the parties will identify, research and develop sodium channel inhibitors, including XEN901, renamed as NBI-921352, and certain pre-clinical candidates, or DTCs, and research compounds which Neurocrine Biosciences will have the exclusive right to further develop and commercialize under the terms and conditions set forth in the Collaboration Agreement.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Neurocrine Biosciences has an exclusive, royalty-bearing, sublicensable license to certain of our intellectual property rights for the research, development and commercialization of these compounds on a worldwide basis for the treatment, cure, diagnosis, prediction or prevention of any human disease or disorder, state, condition and/or malady, subject to certain exceptions set forth in the Collaboration Agreement. We also granted to Neurocrine Biosciences a non-exclusive, non-royalty-bearing, sublicensable license to certain of our intellectual property rights for the screening of compounds for identification as a Select Nav Inhibitor (as defined below) and for the research of certain compounds otherwise expressly excluded from the Collaboration Agreement, or the Excluded Compounds.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the term of the Collaboration Agreement, other than the Excluded Compounds and otherwise in accordance with the terms of the Collaboration Agreement, neither we nor any of our respective affiliates are permitted to directly or indirectly research, develop, manufacture or commercialize a compound that, as its primary mechanism of action, binds to and inhibits voltage-gated sodium channels Nav1.2 and Nav1.6, such compound referred to as a Select Nav Inhibitor.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each party is solely responsible for all costs such party incurs to conduct its activities under the development and research plans, provided that, with respect to NBI-921352 development and research activities, Neurocrine Biosciences reimburses us for certain full-time employees and out-of-pocket expenses incurred by us, and with respect to certain development activities related to certain DTCs, Neurocrine Biosciences may make agreed-upon reimbursements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Except for the activities set forth in the development plans, Neurocrine Biosciences is solely responsible, at its sole cost and expense, for all development and manufacturing of the compounds and any pharmaceutical product that contains a compound, subject to the Co-Funding Option (as defined below). We will have the right to elect to co-fund the development of one product in the first indication that meets or exceeds a specified prevalence threshold, or a Major Indication, under such development plan and to receive a mid-single digit percentage increase in royalties owed on the net sales as calculated pursuant to the terms of the Collaboration Agreement, or Net Sales, of such products in the U.S., or the Co-Funding Option. If we exercise the Co-Funding Option, the parties will share equally all reasonable and documented costs and expenses that Neurocrine Biosciences incurs in connection with the development of such product in the applicable indication, except costs and expenses that are solely related to the development of such product for regulatory approval outside the U.S. We have not exercised this option as of February 27, 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Neurocrine Biosciences paid us an upfront payment of $50.0 million, which included a $30.0 million payment in cash. For the remainder of the upfront payment, concurrently with the entry into the Collaboration Agreement, the parties entered into the Share Purchase Agreement (as defined below) pursuant to which we issued and sold common shares to Neurocrine Biosciences for an aggregate purchase price of $20.0 million.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In January 2022, we received an aggregate milestone payment of $15.0 million in the form of a $6.75 million payment in cash and a $8.25 million equity investment, based on the U.S. Food and Drug Administration's, or FDA&#8217;s, acceptance of a protocol amendment to expand the study population of a clinical trial in pediatric patients with SCN8A-DEE. In February 2025, NBI-921355, a Nav1.2 and Nav1.6 sodium channel inhibitor in development for the potential treatment for certain types of epilepsy, has progressed into a Phase 1 clinical study in healthy adult participants, triggering an anticipated $7.5 million milestone payment to us.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Collaboration Agreement also provides for potential aggregate development and regulatory milestone payments from Neurocrine Biosciences to us of up to $325.0 million for a NBI-921352 product and up to $247.5 million for each other Compound up to a maximum of three other Compounds. Sales-based milestones of up to $150.0 million for each Compound will be paid from Neurocrine Biosciences to us upon the achievement of certain Net Sales targets, up to a maximum of four Compounds.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Neurocrine Biosciences&#8217; obligations to pay royalties with respect to a product and country will expire upon the latest of: (i) the expiration of the last to expire valid claim in (a) the parties&#8217; joint patent rights filed during the Research Term or a specified period of time thereafter or (b) our patent rights as specified in the Collaboration Agreement, in each case that cover such product; (ii) ten years from the first commercial sale of the product in such country; and (iii) the expiration of regulatory exclusivity for such product in such country, or the Royalty Term. Royalty payments are subject to reduction in specified circumstances, including expiration of patent rights or if average Net Sales decrease by a certain percentage after the introduction of a generic product. Unless earlier terminated, the term of the Collaboration Agreement will continue on a product-by-product and country-by-country basis until the expiration of the Royalty Term for such product in such country.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Neurocrine Biosciences may terminate the Collaboration Agreement in its entirety or on a product-by-product or country-by-country basis, for any or no reason, by providing at least 90 days&#8217; written notice, provided that such unilateral termination will not be effective (i) with respect to a NBI-921352 product until Neurocrine Biosciences has used its commercially reasonable efforts to complete one Phase 2 clinical trial for a NBI-921352 product; (ii) with respect to a DTC product until Neurocrine Biosciences has used its commercially reasonable efforts to complete one Phase 1 clinical trial for a DTC product; and (iii) with respect to the Collaboration Agreement in its entirety until Neurocrine Biosciences has used its commercially reasonable efforts to complete both of these clinical trials. Either party may terminate the Collaboration Agreement in the event of a material breach in whole or in part, subject to specified conditions. If Neurocrine Biosciences is entitled to terminate the Collaboration Agreement due to our uncured material breach, in lieu of termination, Neurocrine Biosciences may elect to reduce all subsequent payments owing from Neurocrine Biosciences to us by half.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upon the termination of the Collaboration Agreement for any reason, all licenses and other rights granted to Neurocrine Biosciences by us shall terminate, provided that if termination is solely with respect to one or more products or countries, then such termination will apply only to the terminated products or countries. Upon termination in certain cases, Neurocrine Biosciences has agreed to grant us licenses to certain Neurocrine Biosciences intellectual property that is reasonably necessary, and that was actually used by Neurocrine Biosciences for the development, manufacturing or commercialization of the terminated products, to research, develop and commercialize the terminated products in the terminated countries. Such license will be royalty-free with respect to any terminated product for which a Phase 2 clinical trial was not completed prior to the effective date of termination, and otherwise will be royalty-bearing ranging from a low-single digit percentage to a high-single digit percentage depending on the stage of development of the applicable product at the effective date of termination.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Share Purchase Agreements</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In January 2022, pursuant to the Collaboration Agreement, we entered into a Share Purchase Agreement, or SPA, with Neurocrine Biosciences pursuant to which we issued and sold 258,986 of our common shares to Neurocrine Biosciences in private placements for aggregate purchase price of $8.25 million ($31.855 per share). The purchase price represented a 15% premium to our 30-day volume-weighted average price immediately prior to the public announcements.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Asset Purchase Agreement with 1st Order Pharmaceuticals, Inc.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In April 2017, we entered into an asset purchase agreement with 1st Order Pharmaceuticals, Inc., or 1st Order, pursuant to which we acquired all rights with respect to azetukalner (previously known as 1OP2198 and XEN1101). 1st Order previously acquired 1OP2198 from Valeant Pharmaceuticals Luxembourg S.a.r.l., an indirect subsidiary of Bausch Health Companies Inc., together with Valeant Pharmaceuticals Ireland Limited, Bausch Health, and assumed certain obligations, including potential milestone and royalty payments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2018, we signed an agreement with Bausch Health to buy out all future milestone payments and royalties owed to Bausch Health with respect to azetukalner, including up to $39.6 million in potential clinical development, regulatory and sales-based milestones and a mid-to-high single digit percentage royalty on commercial sales in exchange for a one-time payment of $6.0 million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In August 2020, we entered into an amendment to the asset purchase agreement to amend certain definitions in the agreement and to modify the payment schedule for certain milestones. Through December 31, 2024, we have paid $2.0 million based on progress against these milestones. We remain responsible for future potential payments of up to $6.0 million in regulatory milestones. There are no royalty obligations to 1st Order.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intellectual Property</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As part of our business strategy, we strive to protect the proprietary technologies that we believe are important to our business, including pursuing and maintaining patent protection intended to cover our product candidates and their methods of use and processes for their manufacture, as well as other inventions that are important to our business. We plan to continue to expand our intellectual property estate by filing patent applications directed to compositions, methods of use, treatment and patient selection, formulations and manufacturing processes created or identified from our ongoing development of our product candidates and future products. We also rely on trade secrets, internal know-how, technological innovations and agreements with third parties to develop, maintain and protect our competitive position. Our ability to be competitive will depend on the success of this strategy.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, we owned, co-owned or licensed 21 U.S. issued patents, 78 issued patents in foreign jurisdictions (exclusive of European patent national validations), and over 355 pending patent applications.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With regard to azetukalner, as of December 31, 2024, we owned 7 U.S. issued patents, 33 issued patents in foreign jurisdictions (exclusive of European patent national validations) and over 175 pending patent applications. The issued patents, along with any patents issuing from these applications, are expected to expire between 2028 and 2045 (absent any extensions of term).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With regard to our selective inhibitors of Nav1.6 and/or Nav1.2, as of December 31, 2024, we owned 10 U.S. issued patents, 43 issued patents in foreign jurisdictions (exclusive of European patent national validations), and over 90 pending patent applications. The issued patents, along with any patents issuing from these applications, are expected to expire between 2037 and 2044 (absent any extensions of term). Pursuant to our collaboration with Neurocrine Biosciences, Neurocrine Biosciences controls the prosecution, maintenance and other matters relating to the patent portfolio for the selective Nav1.6 inhibitors and dual Nav1.2/1.6 inhibitors subject thereto, although we have a right to comment.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> With regard to our development programs, including targets related to Kv7 (exclusive of azetukalner), Nav1.1 and Nav1.7, as of December 31, 2024, we owned 4 U.S. issued patents and over 80 pending U.S. and foreign patent applications. The issued patents, along with any patents issuing from these applications, are expected to expire between 2036 and 2045 (absent any extensions of term).</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Competition</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The biotechnology and pharmaceutical industries are highly competitive and are characterized by rapidly advancing technologies and a strong emphasis on proprietary products. While we believe that our technology, development experience, scientific knowledge and drug discovery approach provide us with certain advantages, we face potential competition in our discovery and product candidate development efforts from many different approaches and sources, including pharmaceutical and biotechnology companies, academic institutions and governmental agencies and public and private research institutions. Any product candidates or products that we, or our collaborators, successfully develop and commercialize will compete with existing products and new products that may become available in the future.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many of the companies against which we are competing or against which we may compete in the future have significantly greater financial resources and expertise in research and development, manufacturing, pre-clinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we, or our collaborators, do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaboration arrangements with large and established companies.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our commercial opportunities could be reduced or eliminated if our competitors develop and commercialize products or therapies that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we may develop. Our competitors also may obtain FDA, European Medicines Agency, or EMA, or other foreign regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. In addition, our ability to compete may be affected in many cases by insurers or other third-party payers.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Aside from the product marketplace, our competitors also compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites, recruiting patients for clinical trials, and by acquiring technologies complementary to, or necessary for, our programs.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The key competitive factors affecting the success of all of our product candidates, if approved, are likely to be their efficacy, safety, convenience, price, the effectiveness of alternative products, the level of competition and the availability of coverage, and adequate reimbursement from government and other third-party payers. Our product candidates that are in clinical development may compete with various therapies and drugs, both in the marketplace and currently under development.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If one or more of our proprietary or partnered product candidates is approved for the treatment of epilepsy, we anticipate that they could potentially compete with other anti-seizure medications, or ASMs, or one another. Commonly prescribed ASMs include brivaracetam, carbamazepine, cenobamate, clobazam, eslicarbazepine acetate, ethosuximide, gabapentin, lacosamide, lamotrigine, levetiracetam, oxcarbazepine, perampanel, phenytoin, topiramate, and valproate. There are other ASMs in development that could potentially compete with our products, including product candidates in development from AbbVie Inc., Biohaven Ltd., Neurona Therapeutics Inc., NeuShen Therapeutics, Inc., Praxis Precision Medicines, Inc., QurAlis Corporation, Rapport Therapeutics, Inc., SK Life Science Inc., Supernus Pharmaceuticals, Inc. and Zhimeng Biopharma, Inc. If one or more of our proprietary product candidates were approved for the treatment of MDD, we anticipate that they could potentially compete with other anti-depressant medications, or ADs. Patients with MDD are typically treated with a variety of ADs, which include selective serotonin reuptake inhibitors, or SSRIs, benzodiazepines, serotonin / norepinephrine reuptake inhibitors, or SNRIs, norepinephrine and dopamine reuptake inhibitors, or NDRIs, N-methyl-D-aspartate, or NMDA, receptor agonists and atypical antipsychotics. Currently prescribed antidepressants include benzodiazepines, brexpiprazole, bupropion, bupropion/dextromethorphan, cariprazine, citalopram, duloxetine, escitalopram, esketamine, fluoxetine, ketamine, sertraline, trazodone, tricyclic agents, venlafaxine, vilazodone and vortioxetine. We are aware of several companies developing product candidates for the treatment of MDD including AbbVie Inc., Alto Neuroscience, Inc., Axsome Therapeutics, Inc., Biohaven Ltd., Intra-Cellular Therapies, Inc., Johnson &amp; Johnson Innovative Medicine, Neumora Therapeutics, Inc., and Neurocrine Biosciences, Inc. If one or more of our proprietary product candidates were approved for the treatment of depressive episodes associated with bipolar I or II disorder (bipolar depression), we anticipate that they could potentially compete with other generic antipsychotic and atypical antipsychotic medications. Patients with bipolar depression are typically treated with a variety of atypical antipsychotics as well as mood stabilizers and sometimes in combination with antidepressants. We are aware of several companies developing product candidates for the treatment of bipolar depression including Alto Neuroscience, Inc, Neumora Therapeutics, Inc. and NRx Pharmaceuticals, Inc.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Government Regulation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are developing small-molecule product candidates, which are regulated as drugs by the FDA and equivalent regulatory authorities outside the U.S. Within the FDA, the Center for Drug Evaluation and Research, or CDER, regulates drugs. Drugs are subject to regulation under the Federal Food, Drug, and Cosmetic Act, or FD&amp;C Act, and other federal, provincial, state, local and foreign statutes and regulations. The FD&amp;C Act and corresponding regulations govern, among other things, the testing, manufacturing, safety, efficacy, labeling, packaging, storage, record keeping, distribution, import, export, reporting, advertising and other promotional practices involving drugs. The extensive regulatory requirements to which drugs are subject under the FD&amp;C Act and other applicable statutes, regulations, and guidance are subject to change and often are revised or reinterpreted by the FDA and other regulatory authorities in ways that may have a significant impact on our business. FDA approval of an IND, must be obtained before clinical testing of drugs is initiated, and each clinical study protocol for such product candidates is reviewed by the FDA and an institutional review board, or IRB, prior to initiation in the U.S. FDA approval also must be obtained before marketing of drugs in the U.S. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, provincial, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources, and we may not be able to obtain the required regulatory approvals. Failure to comply with the applicable U.S. regulatory requirements at any time during the product development process, approval process or after approval may subject an applicant and/or sponsor to a variety of administrative or judicial sanctions. These sanctions could include, among other actions, FDA&#8217;s refusal to approve pending applications, withdrawal of an approval, imposition of a clinical hold, issuance of warning or untitled letters and other types of enforcement-related letters, product recalls, product seizures, relabeling or repackaging, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement of profits, or civil or criminal investigations and penalties brought by FDA and the Department of Justice or other governmental entities.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">U.S. Drug Development Process</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The process required by the FDA before a drug product may be marketed in the U.S. generally involves the following:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">completion of nonclinical laboratory tests and animal studies according to good laboratory practices, or GLPs, and applicable requirements for the humane use of laboratory animals and other applicable regulations;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">submission to the FDA of an application for an IND, which must become effective before human clinical studies may begin;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">performance of adequate and well-controlled human clinical studies according to the FDA&#8217;s regulations commonly referred to as good clinical practices, or GCPs, and any additional requirements for the protection of human research subjects and their health information, to establish the safety and efficacy of the proposed product for its intended use;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">submission to the FDA of an NDA for drug products for marketing approval that includes substantial evidence of safety and efficacy, which is usually based on large-scale Phase 3 clinical studies;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">satisfactory completion of an FDA pre-approval inspection of the manufacturing facility or facilities where the product is produced to assess compliance with good manufacturing practices, or GMP, to assure that the facilities, methods and controls are adequate to consistently manufacture the product pursuant to regulatory requirements;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">potential FDA inspection of the nonclinical and clinical study sites that generated the data in support of the NDA; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">payment of applicable user fees and FDA review and approval of the NDA.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The data required to support an NDA is generated in two distinct development stages: pre-clinical and clinical. For new chemical entities, the pre-clinical development stage generally involves synthesizing the active component, developing the formulation and determining the manufacturing process, evaluating purity and stability, as well as carrying out non-human toxicology, pharmacology and drug metabolism studies in the laboratory, which support subsequent clinical testing. The conduct of the pre-clinical tests must comply with federal regulations, including GLPs and the U.S. Department of Agriculture&#8217;s Animal Welfare Act. The sponsor must submit the results of the pre-clinical tests, together with manufacturing information, analytical data, any available clinical data or literature and a proposed clinical protocol, to the FDA as part of the IND. An IND is a request for authorization from the FDA to administer an investigational drug product to humans. The central focus of an IND submission is on the general investigational plan and the protocol(s) for human trials. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA raises concerns or questions regarding the proposed clinical trials and places the IND on clinical hold within that 30-day time period. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns or questions before the clinical trial can begin. Some long-term pre-clinical testing, such as animal tests of reproductive AEs and carcinogenicity, may continue after the IND is submitted. The FDA may also impose clinical holds on a drug candidate at any time before or during clinical trials due to safety concerns or non-compliance. Accordingly, submission of an IND does not guarantee the FDA will allow clinical trials to begin, or that, once begun, issues will not arise that could cause the trial to be suspended or terminated.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the FDA accepts the IND, the drug can then be studied in human clinical trials to determine if the drug is safe and effective. The clinical stage of development involves the administration of the drug product to human subjects, including patients, under the supervision of qualified investigators in accordance with GCPs, which establish standards for conducting, recording data from, and reporting the results of clinical trials, and also include the requirement that all research subjects provide their informed consent in writing for their participation in any clinical trial.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Human clinical studies are typically conducted in three sequential phases that may overlap or be combined:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Phase 1. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The drug is initially introduced into healthy human subjects and tested for safety. In the case of some products for severe or life-threatening diseases, especially when the product may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients that have the condition or disease being studied.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Phase 2. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The drug is evaluated in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine a dose range and dosing schedule.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Phase 3. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clinical studies are undertaken to further evaluate dosing and dosing schedule, clinical efficacy, and safety in an expanded patient population at geographically dispersed clinical study sites. These clinical studies are intended to establish the overall risk/benefit ratio of the product and provide an adequate basis for product labeling.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Post-approval clinical studies, sometimes referred to as Phase 4 clinical studies, may be conducted after initial marketing approval. These clinical studies are used to gain additional experience from the treatment of patients in the intended therapeutic indication, particularly for long-term safety follow-up. In certain instances, the FDA may mandate the performance of Phase 4 clinical trials as a condition of approval of an NDA. During all phases of clinical development, regulatory agencies require extensive monitoring and auditing of all clinical activities, clinical data and clinical study investigators.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Concurrent with clinical studies, companies usually complete additional animal studies and must also develop additional information about the physical characteristics of the drug as well as finalize a process for manufacturing the product in commercial quantities in accordance with GMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other requirements, the sponsor must develop methods for ensuring the quality, identity, strength and purity of the final drug. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the drug does not undergo unacceptable deterioration over its labeled shelf life.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, due to disasters and public health emergencies, we may be required to develop and implement additional clinical trial policies and procedures designed to help protect subjects. For example, the FDA has issued guidance on conducting clinical trials during major disruptions due to disasters and public health emergencies, which describes a number of considerations for sponsors of clinical trials impacted by these events, to ensure the safety of trial participants, maintaining GCP compliance, and minimizing risks to trial integrity. We may be required to make further adjustments to our clinical trials or business operations based on current or future guidance and regulatory requirements as a result of major disruptions due to disasters and public health emergencies.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">U.S. Review and Approval Processes</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">After the completion of clinical studies of a drug, FDA approval of an NDA must be obtained before commercial marketing of the drug can begin. The NDA must include results of product development, laboratory and animal studies, human studies, information on the manufacture and composition of the product, proposed labeling and other relevant information. In addition, under the Pediatric Research Equity Act, or PREA, an NDA or supplement to an NDA must contain data to assess the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may grant deferrals for submission of data or full or partial waivers. Unless otherwise required by regulation, PREA does not apply to any drug for an indication for which orphan designation has been granted. The testing and approval processes require substantial time and effort, and there can be no assurance that the FDA will accept the NDA for filing and, even if filed, that any approval will be granted on a timely basis, if at all.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Prescription Drug User Fee Act, or PDUFA, as amended, each NDA must be accompanied by a substantial user fee. PDUFA also imposes an annual product fee for drugs and an annual establishment fee on facilities used to manufacture prescription drugs. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a small business. Additionally, no user fees are assessed on NDAs for products designated as orphan drugs, unless the product also includes a non-orphan indication.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Within 60 days following submission of the application, the FDA reviews the NDA to determine if it is substantially complete before the agency accepts it for filing. The FDA may refuse to file any marketing application that it deems incomplete or not properly reviewable at the time of submission and may request additional information, including additional clinical data. In this event, the NDA must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review of the NDA. The FDA reviews the application to determine, among other things, whether the proposed product is safe and effective for its intended use, and whether the product is being manufactured in accordance with GMPs. The FDA may refer applications for novel products or products that present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. During the product approval process, the FDA also will determine whether a Risk Evaluation and Mitigation Strategy, or REMS, is necessary to assure the safe use of the product. If the FDA concludes a REMS is needed, the sponsor of the NDA must submit a proposed REMS; the FDA will not approve the application without a REMS, if required.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notwithstanding the submission of relevant data and information, the FDA may ultimately decide that the NDA does not satisfy its regulatory criteria for approval and deny approval. Data obtained from clinical studies are not always conclusive and the FDA may interpret data differently than we interpret the same data. If the agency decides not to approve the marketing application, the FDA will issue a complete response letter, which typically describes all of the specific deficiencies in the application identified by the FDA. The deficiencies identified may be minor (e.g., requiring labeling changes) or major(e.g., requiring additional clinical studies). Additionally, the complete response letter may include recommended actions that the applicant might take to place the application in a condition for approval. If a complete response letter is issued, the applicant may either resubmit the NDA, addressing all of the deficiencies identified in the letter, or withdraw the application.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If a product receives regulatory approval, the approval will be limited to the specific diseases and dosages studied in clinical trials, and the indications for use may otherwise be limited, which could restrict the commercial value of the product. Further, the FDA may require that certain contraindications, warnings or precautions be included in the product labeling. The FDA may impose restrictions and conditions on product distribution, prescribing or dispensing pursuant to a REMS request, or otherwise limit the scope of any approval. Drug approvals may be withdrawn for non-compliance with regulatory standards or if problems occur following initial marketing.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">One of the performance goals agreed to by the FDA under the PDUFA is to complete its review of 90% of standard new molecular entity, or NME, NDAs within ten months from the filing date and 90% of priority NME NDAs within six months from the filing date, whereupon a review decision is to be made. The FDA does not always meet its PDUFA goal dates, and its review goals are subject to change from time to time. The review process and the PDUFA goal date may be extended by three months if, within the last three months before the PDUFA goal date, the FDA requests (or the application sponsor otherwise provides) a substantial amount of new data or new information not previously submitted to, or reviewed by, the FDA (e.g., a major new clinical safety or efficacy study report, a proposed REMS), or a new analysis or major reanalysis of studies previously submitted to the pending application.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Post-Approval Requirements</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rigorous and extensive FDA regulation of drug continues after approval, particularly with respect to GMP. We will rely, and expect to continue to rely, on third parties for the production of clinical and commercial quantities of any products that we may commercialize. Manufacturers of our products will be required to comply with applicable requirements in the GMP regulations, including quality control and quality assurance and maintenance of records and documentation. Other post-approval requirements applicable to drug manufacturers, include reporting of GMP deviations that may affect the safety, efficacy or quality of a distributed product, record-keeping requirements, reporting of adverse effects, reporting updated safety and efficacy information, and complying with electronic record and signature requirements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also must comply with the FDA&#8217;s advertising and promotion requirements, such as those related to direct-to-consumer advertising, the prohibition on promoting products for uses or in patient populations that are not described in or are otherwise inconsistent with the product&#8217;s approved labeling (known as &#8220;off-label use&#8221;), and industry-sponsored scientific and educational activities. Discovery of previously unknown problems or the failure to comply with the applicable regulatory requirements may result in restrictions on the marketing of a product or withdrawal of the product from the market as well as possible civil or criminal sanctions. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval, may subject an applicant or manufacturer to administrative or judicial civil or criminal sanctions and adverse publicity. FDA sanctions could include refusal to approve pending applications, withdrawal of an approval, clinical hold, warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, mandated corrective advertising or communications with doctors, debarment, restitution, disgorgement of profits, or civil or criminal penalties. An agency or judicial enforcement action could have a material adverse effect on us.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with GMPs and other laws. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain GMP compliance. Discovery of problems with a product after approval may result in restrictions on a product, manufacturer or holder of an approved NDA, including withdrawal of the product from the market. In addition, changes to the manufacturing process or facility generally require prior FDA approval before being implemented and other types of changes to the approved product, such as adding new indications and additional labeling claims, are also subject to further FDA review and approval.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fast Track Designation, Priority Review, Breakthrough Therapy Designation and Accelerated Approval</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA has various programs, including fast track designation, priority review, breakthrough therapy designation and accelerated approval, which are intended to expedite or simplify the process for the development and FDA review of drugs. Even if a drug qualifies for one or more of these programs, the FDA may later decide that the drug no longer meets the conditions for qualification. Generally, drugs that are eligible for these programs are those for serious or life-threatening conditions, those with the potential to address unmet medical needs and those that offer meaningful benefits over existing treatments. While these pathways can reduce the time it takes for the FDA to review an NDA, they do not guarantee that a product will receive FDA approval.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To be eligible for a fast track designation, the FDA must determine, based on the request of a sponsor, that a drug is intended to treat a serious or life threatening disease or condition for which there is no effective treatment and demonstrates the potential to address an unmet medical need for the disease or condition. Under the fast track program, the sponsor of a drug candidate may request the FDA to designate the product for a specific indication as a fast track product concurrent with or after the filing of the IND for the drug candidate. The FDA must make a fast track designation determination within 60 days after receipt of the sponsor&#8217;s request. In addition to other benefits, such as the ability to use surrogate endpoints and have greater interactions with the FDA, the FDA may initiate review of sections of a fast track product&#8217;s NDA before the application is complete. This rolling review is available if the applicant provides, and the FDA approves, a schedule for the submission of the remaining information and the applicant pays applicable user fees. However, the FDA&#8217;s time period goal for reviewing a fast track application does not begin until the last section of the NDA is submitted. A fast track drug also may be eligible for accelerated approval and priority review. In addition, the fast track designation may be withdrawn by the FDA if it believes that the designation is no longer supported by data emerging in the clinical trial process.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA may give a priority review designation to drugs that offer major advances in treatment, or provide a treatment where no adequate therapy exists. A priority review means that the goal for the FDA to review an application is six months, rather than the standard review of ten months under current PDUFA guidelines. These six- and ten-month review periods are measured from the &#8220;filing&#8221; date rather than the receipt date for NDAs for new molecular entities, which typically adds approximately two months to the timeline for review and decision from the date of submission. Most products that are eligible for fast track designation are also likely to be considered appropriate to receive a priority review.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the provisions of the new Food and Drug Administration Safety and Innovation Act, or FDASIA, enacted by Congress in 2012, a sponsor can request designation of a drug candidate as a &#8220;breakthrough therapy,&#8221; typically by the end of the drug&#8217;s Phase II trials. A breakthrough therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. Drugs designated as breakthrough therapies are also eligible for accelerated approval. For breakthrough therapies, the FDA may take certain actions, such as intensive and early guidance on the drug development program, that are intended to expedite the development and review of an application for approval.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FDASIA also codified and expanded on FDA&#8217;s accelerated approval regulations, under which FDA may approve a drug for a serious or life threatening illness that provides meaningful therapeutic benefit over existing treatments based on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on an intermediate clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit. A surrogate endpoint is a marker that does not itself measure clinical benefit but is believed to predict clinical benefit. This determination takes into account the severity, rarity or prevalence of the disease or condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require a sponsor of a drug receiving accelerated approval to perform Phase IV or post marketing studies to verify and describe the predicted effect on irreversible morbidity or mortality or other clinical endpoint, and the drug may be subject to accelerated withdrawal procedures. All promotional materials for drug candidates approved under accelerated regulations are subject to prior review by the FDA.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for the FDA review or approval will not be shortened. Furthermore, fast track designation, priority review, accelerated approval and breakthrough therapy designation, do not change the standards for approval and may not ultimately expedite the development or approval process.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Controlled Substance Regulation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The United States Controlled Substances Act, or CSA, establishes registration, security, recordkeeping, reporting, storage, distribution and other requirements administered by the Drug Enforcement Administration, or DEA. The DEA is concerned with the control of handlers of controlled substances, and with the equipment and raw materials used in their manufacture and packaging, in order to prevent loss and diversion into illicit channels of commerce. The DEA regulates controlled substances as Schedule I, II, III, IV or V substances. Schedule I substances by definition have a high potential for abuse, have no established medicinal use, and may not be marketed or sold in the U.S. A pharmaceutical product may be listed as Schedule II, III, IV or V, with Schedule II substances considered to present the highest risk of abuse and Schedule V substances the lowest relative risk of abuse among such substances. Annual registration is required for any facility that manufactures, distributes, dispenses, imports or exports any controlled substance. The registration is specific to the particular location, activity and controlled substance schedule. For example, separate registrations are needed for import and manufacturing, and each registration will specify which schedules of controlled substances are authorized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The DEA typically inspects a facility to review its security measures prior to issuing a registration. Security requirements vary by controlled substance schedule, with the most stringent requirements applying to Schedule I and Schedule II substances. Required security measures include background checks on employees and physical control of inventory through measures such as cages, surveillance cameras and inventory reconciliations. Records must be maintained for the handling of all controlled substances, and periodic reports made to the DEA. Reports must also be made for thefts or losses of any controlled substance, and to obtain authorization to destroy any controlled substance. In addition, special authorization and notification requirements apply to imports and exports.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The DEA conducts periodic inspections of certain registered establishments that handle controlled substances. Failure to maintain compliance with applicable requirements, particularly as manifested in loss or diversion, can result in enforcement action that could have a material adverse effect on our business, results of operations and financial condition. The DEA may seek civil penalties, refuse to renew necessary registrations, or initiate proceedings to restrict, suspend or revoke those registrations. In certain circumstances, violations could result in criminal proceedings. Individual states also regulate controlled substances, and we and our contract manufacturers will be subject to state regulation on distribution of these products, including licensing, recordkeeping and security.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Controlled substances are also regulated pursuant to several international drug control treaties. These treaties are enforced by the United National Commission on Narcotic Drugs. The U.S. is a signatory to these treaties and thus must conform its laws and regulations to the international requirements, which generally include licensing, recordkeeping and reporting requirements. Any change in the international treaties regarding classification of these products could affect regulation of these substances in the U.S. and in other countries. Further, marketing approval and controlled substance classification procedures vary among countries, can involve additional testing and administrative review periods and may be otherwise complicated if our product candidates contain ingredients already classified as controlled substances in the countries where we develop them, which could make such product candidates subject to applicable controlled substances laws prior to commercialization. Foreign regulation of controlled substances can differ significantly from U.S. DEA and state regulations. The time required to obtain marketing approval and controlled substance classification in other countries may differ from and be longer than that required to obtain FDA approval and DEA classification in the U.S.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">17</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">U.S. Patent Term Extension and Marketing Exclusivity</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depending upon the timing, duration and specifics of the FDA approval of the use of our product candidates, some of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch-Waxman Act. The Hatch-Waxman Act permits a patent term extension of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. Patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the product&#8217;s approval date. Only one patent applicable to an approved product is eligible for extension and the application for the patent term extension must be submitted within 60 days of receipt of FDA approval. The U.S. Patent and Trademark Office, in consultation with the FDA, reviews and approves the application for any patent term extension.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Hatch-Waxman Act, a drug product containing a new chemical entity as its active ingredient is entitled to five years of market exclusivity. A drug product is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is defined as the molecule or ion responsible for the activity of the drug substance, excluding those appended portions of the molecule that cause the drug to be an ester, salt, or other noncovalent derivative. During this exclusivity period, the FDA may not approve an abbreviated new drug application, or ANDA, or a 505(b)(2) NDA submitted by another company that contains the previously approved active moiety. However, an ANDA or 505(b)(2) NDA may be submitted after four years if it contains a certification of patent invalidity or non-infringement.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A drug product whose active ingredient was previously FDA-approved, and for which the sponsor is required to generate new clinical investigations such as to support new indications, dosages, strengths or dosage forms, is entitled to three years of market exclusivity. This three-year exclusivity covers only the conditions of use associated with the new clinical investigations and, as a general matter, does not prohibit the FDA from approving ANDAs or 505(b)(2) NDAs for generic versions of the original unmodified drug product, although the approval of such an application may not be effective until, at the earliest, after the full five years of market exclusivity has expired.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A drug product can also obtain pediatric market exclusivity in the U.S. and, if granted, adds six months to existing marketing exclusivities and any Orange Book-listed patent term(s). This six-month exclusivity, which runs from the end of other exclusivity periods and/or patent term(s), may be granted based on the timely, voluntary, and as-agreed upon completion of a pediatric study in accordance with an FDA-issued &#8220;Written Request&#8221; for such a study, even if the data do not show that the drug product was effective in the pediatric population studied.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Additional Regulation</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Manufacturing, sales, promotion and other activities following drug approval are also subject to regulation by numerous regulatory authorities in addition to the FDA, including, in the United States, the Centers for Medicare &amp; Medicaid Services, other divisions of the Department of Health and Human Services, the Drug Enforcement Administration for controlled substances, the Consumer Product Safety Commission, the Federal Trade Commission, the Occupational Safety &amp; Health Administration, the Environmental Protection Agency and state and local governments. In the United States, the activities of pharmaceutical manufacturers are subject to federal and state laws designed to prevent &#8220;fraud and abuse&#8221; in the healthcare industry. The laws generally limit financial interactions between manufacturers and healthcare providers or other participants in the healthcare industry and/or require disclosure to the government and public of such interactions. Many of these laws and regulations contain ambiguous requirements or require administrative guidance for implementation. Pharmaceutical manufacturers are also required to provide discounts or rebates under government healthcare programs or to certain government and private purchasers in order to obtain coverage under federal healthcare programs such as Medicaid. Participation in such programs may require tracking and reporting of certain drug prices. Manufacturers are subject to fines and other penalties if such prices are not reported accurately. The handling of any controlled substances must comply with the U.S. Controlled Substances Act and Controlled Substances Import and Export Act. Drugs must meet applicable child-resistant packaging requirements under the U.S. Poison Prevention Packaging Act. Manufacturing, sales, promotion and other activities are also potentially subject to federal and state consumer protection and unfair competition laws.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The failure to comply with regulatory requirements subjects manufacturers to possible legal or regulatory action. Depending on the circumstances, failure to meet applicable regulatory requirements can result in criminal prosecution, fines or other penalties, injunctions, recall or seizure of drugs, total or partial suspension of production, denial or withdrawal of product approvals, exclusion from participation in government healthcare programs or refusal to allow a firm to enter into supply contracts, including government contracts. In addition, even if a firm complies with FDA and other requirements, new information regarding the safety or efficacy of a product could lead the FDA to modify or withdraw product approval. Prohibitions or restrictions on sales or withdrawal of future products marketed by us could materially affect our business in an adverse way.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Changes in regulations, statutes or the interpretation of existing regulations could impact our business in the future by requiring, for example: (i) changes to our manufacturing arrangements; (ii) additions or modifications to product labeling; (iii) the recall or discontinuation of our products; or (iv) additional record-keeping requirements. If any such changes were to be imposed, they could adversely affect the operation of our business.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Global Anti-Corruption Laws</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The U.S. Foreign Corrupt Practices Act and the Canadian Corruption of Foreign Public Officials Act, the U.S. Travel Act, the OECD Anti-Bribery Convention, Title 18 United States Code section 201, and any other applicable domestic or foreign anti-corruption or anti-bribery laws to which we are subject prohibit corporations and individuals from engaging in certain activities to obtain or retain business or to influence a person working in an official capacity. It is illegal to pay, offer to pay or authorize the payment of anything of value to any foreign government official, government staff member, political party or political candidate in an attempt to obtain or retain business or to otherwise influence a person working in an official capacity. We may also be held liable for the acts of our third-party agents under the U.S. Foreign Corrupt Practices Act, Canadian Corruption of Foreign Public Officials Act, and other applicable anti-corruption and anti-bribery laws. Noncompliance with these laws could subject us to investigations, sanctions, settlements, prosecution, other enforcement actions, disgorgement of profits, significant fines, damages, other civil and criminal penalties or injunctions, suspension or debarment from contracting with certain persons, the loss of export privileges, whistleblower complaints, reputational harm, adverse media coverage and other collateral consequences. Any investigations, actions or sanctions or other previously mentioned harm could have a material negative effect on our business, operating results and financial condition.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Government Regulation Outside of the U.S.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to regulations in the U.S., we will be subject to a variety of regulations in other jurisdictions governing, among other things, research, development, testing, manufacture, quality control, controlled substances, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of drugs, and reimbursement requirements. Generally, before a new drug can be marketed, considerable data demonstrating its quality, safety and efficacy must be obtained, organized into a format specific for each regulatory authority, submitted for review and approved by the regulatory authority. Whether or not we obtain FDA approval for a product candidate, we must obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical studies or marketing of the product candidate in those countries. Certain countries outside of the U.S. have a similar process that requires the submission of a clinical study application much like the IND prior to the commencement of human clinical studies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The requirements and processes governing the conduct of clinical studies, product licensing, coverage, pricing and reimbursement vary from country to country. In all cases, the clinical studies are conducted in accordance with GCP and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki. The Clinical Trials Regulation EU No 536/2014, or the CTR, which replaced the Clinical Trials Directive, entered into application on January 31, 2022, harmonizes the procedures for the submission, assessment and monitoring of clinical drug trials in the EU, thus simplifying the current rules for clinical trial authorization and standards of performance. The CTR requires a clinical trial sponsor to obtain approval from the national competent authority (NCA) of each European Union member state in which the clinical trial is to be conducted. Furthermore, the sponsor can only start a clinical trial at a specific study site after the local research ethics committee, or REC, has issued a favorable opinion. Subject to the transition arrangement referenced below, a sponsor submits a single application for a clinical trial authorization, or CTA, through a centralized EU clinical trials portal called the Clinical Trials Information System, or CTIS. One NCA (the reporting EU member state selected by the sponsor) takes the lead in validating and evaluating the application, as well as consulting and coordinating with the other concerned member states in which the clinical trial is to be conducted. If an application is rejected, it may be amended and resubmitted through CTIS. A concerned member state may in limited circumstances declare an &#8220;opt-out&#8221; from an approval and prevent the clinical trial from being conducted in that member state. The CTR foresees a three-year transition period. As of January 31, 2023, all new CTA applications had to be submitted via CTIS and be made pursuant to the CTR. From and after January 31, 2025, all clinical trials (including those approved under the Clinical Trial Directive (now replaced by the CTR)) need to comply with the CTR and be recorded in CTIS.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the UK, clinical trials of medicinal products for human use are primarily governed by the Medicines for Human Use (Clinical Trials) Regulations 2004 (as amended). Similar to the EU, before a clinical trial can be initiated in the UK, a CTA must be obtained from the Medicines and Healthcare products Regulatory Agency, or MHRA, as well as a positive opinion from a REC.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">19</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To obtain regulatory approval of an investigational drug under EU regulatory systems, we must submit a marketing authorization application, or MAA. There are two types of marketing authorizations:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The centralized MA is issued by the European Commission through the centralized procedure, based on the opinion of the Committee for Medicinal Products for Human Use, or the CHMP, of the EMA, and is valid throughout the entire territory of the EEA. The centralized procedure is mandatory for certain types of products, such as biotechnology medicinal products, orphan medicinal products, advanced-therapy medicinal products (gene-therapy, somatic cell-therapy or tissue-engineered medicines) and medicinal products containing a new active substance indicated for the treatment of human immunodeficiency virus, acquired immunodeficiency syndrome, cancer, neurodegenerative disorders, diabetes, auto-immune and other immune dysfunctions and viral diseases. The centralized procedure is optional for products containing a new active substance not yet authorized in the EEA, or for products that constitute a significant therapeutic, scientific or technical innovation or which are in the interest of public health in the EU. Under the centralized procedure, the maximum timeframe for the evaluation of a MA application by the EMA is 210 days, excluding clock stops, when additional written or oral information is to be provided by the applicant in response to questions asked by the CHMP. Clock stops may extend the timeframe of evaluation of a MA application considerably beyond 210 days. Where the CHMP gives a positive opinion, the EMA provides the opinion together with supporting documentation to the European Commission, who makes the final decision to grant a MA, which is ordinarily issued within 67 days of receipt of the EMA&#8217;s recommendation. Accelerated assessment might be granted by the CHMP in exceptional cases, when a medicinal product is expected to be of a major public health interest, particularly from the point of view of therapeutic innovation. The timeframe for the evaluation of a MA application under the accelerated assessment procedure is 150 days, excluding clock stops, but it is possible that the CHMP may revert to the standard time limit for the centralized procedure if it determines that the application is no longer appropriate to conduct an accelerated assessment.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">National MAs, which are issued by the NCAs of the EEA member states and only cover their respective territory, are available for products not falling within the mandatory scope of the centralized procedure. Where a product has already been authorized for marketing in a member state of the EEA, this national MA can be progressively recognized in other EEA member states through the mutual recognition procedure. If the product has not received a national MA in any EEA member state at the time of application, it can be approved simultaneously in various EEA member states through the decentralized procedure. Under the decentralized procedure, an identical dossier is submitted to the NCAs of each of the EEA member states in which the MA is sought, one of which is selected by the applicant as the Reference Member State (the RMS). The competent authority of the RMS prepares a draft assessment report, a draft summary of the product characteristics (SmPC), and a draft of the labeling and package leaflet, which are sent to the other EEA member states, referred to as the Concerned Member States, for their approval. If the Concerned Member States raise no objections, based on a potential serious risk to public health, to the assessment, SmPC, labeling, or packaging proposed by the RMS, the product is subsequently granted a national MA in all EEA member states to which an application was submitted</span><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In relation to the UK, until the end of 2024, under the Northern Ireland Protocol which is contained in the Agreement on the withdrawal of the United Kingdom of Great Britain and Northern Ireland from the European Union and the European Atomic Energy Community, centralized MAs continue to provide a valid basis for commercializing medicinal products in Northern Ireland. However, centralized MAs no longer provide a valid basis for the commercialization of medicinal products in Great Britain. Pursuant to the Windsor Framework (which is a political declaration by the European Commission and the UK Government to correct the post-Brexit restrictions of movements of goods including medicines), from January 1, 2025, all new medicinal products for the UK market will be authorized by the MHRA which will grant on behalf of the UK Licensing Authority a single UK-wide MA for all medicinal products intended for sale in the UK, enabling medicinal products to be sold in a single pack and under a single authorization throughout the UK, including Northern Ireland, but the UK packaging must carry a clearly legible &#8216;UK only&#8217; to be allowed onto the UK market.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since leaving the EU, the MHRA has introduced changes to national licensing procedures, including procedures to prioritize access to new medicines that will benefit patients, an accelerated assessment procedure, and new routes of evaluation for novel products and biotechnological products. There is no wholesale recognition of EU pharmaceutical legislation between the jurisdictions, and EU MAs do not automatically provide a valid basis for the commercialization of medicinal products in Great Britain, From January 1, 2024, companies are able to request the MHRA to recognize MAs granted by acceptable Reference Regulators in foreign jurisdictions (including the EU) under a new International Recognition Procedure, or IRP. IRP allows the MHRA to take into account the expertise and decision-making of trusted regulatory authorities to conduct targeted assessments of IRP applications while retaining the authority to reject applications if the evidence provided is considered insufficiently robust.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The application used to file the NDA in the U.S. is similar to that required in the EU, with the exception of, among other things, country-specific document requirements. Reimbursement approval for the drug by regulatory authorities is also required before a drug may be commercialized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">20</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The EU also provides opportunities for data and market exclusivity. For example, in the EU, upon receiving marketing authorization, innovative medicinal products (including both small molecules and biological medicinal products) approved on the basis of a complete independent data package consisting of quality, preclinical testing results, and clinical trial data receive eight years of data exclusivity upon grant of an MA, and an additional two years of marketing exclusivity. If granted, data exclusivity prevents generic or biosimilar applicants from cross-referencing the innovator&#8217;s preclinical and clinical trial data contained in the dossier of the reference medicinal product when applying for a generic or biosimilar MA until the data exclusivity period has expired. Even if a generic and a biosimilar product is approved, it can be marketed only until the expiration of the full ten-year exclusivity period. The overall ten-year period can be extended to a maximum of 11 years if, during the first eight years of those ten years, the MA holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are determined to bring a significant clinical benefit in comparison with currently approved therapies. The UK domestic law follows the same formula of regulatory data and marketing exclusivity. However, there is no guarantee that a product will be considered by the EU&#8217;s regulatory authorities to be a new chemical entity or new active substance, and products may not qualify for data exclusivity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Products receiving orphan designation in the EU can receive ten years of market exclusivity, provided that the orphan designation is maintained at the time of grant of the marketing authorization. During the ten-year orphan market exclusivity period, no application for a similar medicinal product for the same indication may be accepted by any regulatory authority in the EU for approval. An orphan product can also obtain an additional two years of market exclusivity in the EU for completing pediatric studies in compliance with an agreed Pediatric Investigation Plan even though the data do not lead to approval of a pediatric indication. No extension to any supplementary protection certificate can be granted on the basis of pediatric studies for orphan indications.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The criteria for designating an &#8220;orphan medicinal product&#8221; in the EU are similar in principle but not identical to those in the U.S. Under Article 3 of Regulation (EC) 141/2000, a medicinal product may be designated as orphan if (1) it is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition; (2) either (a) such condition affects no more than five in 10,000 persons in the EU when the application is made, or (b) the product, without the benefits derived from orphan status, would not generate sufficient return in the EU to justify investment; and (3) there exists no satisfactory method of diagnosis, prevention or treatment of such condition authorized for marketing in the EU, or if such a method exists, the product will be of significant benefit to those affected by the condition, as defined in Regulation (EC) 847/2000. The criteria for orphan designation must be re-assessed and confirmed at the time when a marketing authorization is granted in order to benefit from a period of 10 years orphan market exclusivity. The MHRA conducts an equivalent assessment, against the criteria specific to the UK. In the EEA, orphan drug designation must be requested before submitting an application for MA. The EMA&#8217;s Committee for Orphan Medicinal Products (COMP) is required to re-assess the granted orphan designation at the time of MA grant to ensure that it continues to meet the criteria for the designation to be maintained. Otherwise, the orphan designation can be revoked. In contrast, the MHRA does not grant orphan designations during the development of the medicinal product. Instead, the MHRA will decide whether the criteria are satisfied at the point of grant of an MA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the EEA and the UK, orphan medicinal products are eligible for financial incentives such as reduction of fees or fee waivers and are, upon grant of a marketing authorization, entitled to ten years of market exclusivity for the approved therapeutic indication. The applicant will receive a fee reduction for the marketing authorization application if the orphan drug designation has been granted, but not if the designation is still pending at the time the marketing authorization is submitted. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The 10-year market exclusivity may be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan designation, for example, if the product is sufficiently profitable not to justify maintenance of market exclusivity. Additionally, marketing authorization may be granted to a similar medicinal product for the same therapeutic indication at any time if:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the second applicant can establish that its product, although similar, is safer, more effective or otherwise clinically superior;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the applicant consents to a second orphan medicinal product application; or</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the applicant cannot supply enough orphan medicinal product.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A &#8220;similar medicinal product&#8221; is defined as a medicinal product containing a similar active substance or substances as contained in an authorized orphan medicinal product, and which is intended for the same therapeutic indication.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">21</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the EEA, companies developing a new medicinal product must agree upon a pediatric investigation plan, or PIP, with the EMA&#8217;s Pediatric Committee, or PDCO, and must conduct pediatric clinical trials in accordance with that PIP, unless a waiver applies. The PIP sets out the timing and measures proposed to generate data to support a pediatric indication of the drug for which MA is being sought. The PDCO can grant a deferral of the obligation to implement some or all of the measures of the PIP until there are sufficient data to demonstrate the efficacy and safety of the product in adults. Further, the obligation to provide pediatric clinical trial data can be waived by the PDCO when this data is not needed or appropriate because the product is likely to be ineffective or unsafe in children, the disease or condition for which the product is intended occurs only in adult populations, or when the product does not represent a significant therapeutic benefit over existing treatments for pediatric patients. Products that are granted a MA with the results of the pediatric clinical trials conducted in accordance with the PIP (even where such results are negative) are eligible for six months&#8217; supplementary protection certificate extension (if any is in effect at the time of approval). In the case of orphan medicinal products, a two-year extension of the orphan market exclusivity may be available. This pediatric reward is subject to specific conditions and is not automatically available when data in compliance with the PIP are developed and submitted. According to local law requirements, the UK MHRA adopts a similar approach to the EEA to facilitate the development of medicinal products for the pediatric population.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For other countries outside of the EU, such as Canada and countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct of clinical studies, product and establishment licensing, coverage, data protection, pricing and reimbursement vary from country to country. In all cases, again, the clinical studies are conducted in accordance with GCP and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, inability to import or export, seizure of products, operating restrictions and criminal prosecution.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pharmaceutical Coverage, Pricing and Reimbursement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Significant uncertainty exists as to the coverage and reimbursement status of any product candidates for which we obtain regulatory approval. In the U.S. and markets in other countries, sales of any products for which we receive regulatory approval for commercial sale will depend, in part, on the availability of coverage and adequate reimbursement from third-party payers. Third-party payers include government programs such as Medicare or Medicaid, and private payers such as private health insurance and managed care plans, and other organizations. These third-party payers may deny or limit coverage or reimbursement for a product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Within the U.S., coverage and reimbursement for drug products can differ significantly from payer to payer. One third-party payer&#8217;s decision to cover a particular drug product or service does not ensure that other payers will also provide coverage for the product or will provide coverage at an adequate reimbursement rate. Third-party payers may attempt to control costs by limiting coverage (e.g., to specific drug products on an approved list, or formulary, which might not include all of the FDA-approved drug products for a particular indication), by controlling utilization (e.g., requiring pre-approval or prior authorization for new or innovative drug therapies before they will provide coverage for specific patients) and by limiting the amount of reimbursement for drugs.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The cost of pharmaceuticals continues to generate substantial governmental and third-party payer interest. We expect that the pharmaceutical industry will experience pricing pressures due to the trend toward managed healthcare, the increasing influence of managed care organizations and additional legislative proposals. Third-party payers are increasingly challenging the price and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy. We may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of our products, in addition to the costs required to obtain the FDA approvals. Our product candidates may not be considered medically necessary or cost-effective. A payer&#8217;s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While we cannot predict what cost-containment measures will be adopted or otherwise implemented in the future, new measures or any announcement of proposed measures could have a material adverse effect on our ability to obtain adequate prices for our product candidates and to operate profitably.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In international markets, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. There can be no assurance that our products will be considered medically reasonable and necessary for a specific indication, that our products will be considered cost-effective by third-party payers, that coverage or an adequate level of reimbursement will be available or that the third-party payers&#8217; reimbursement policies will not adversely affect our ability to sell our products profitably.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">22</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, in many foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing and reimbursement vary widely from country to country. For example, the EU provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products. Historically, products launched in the EU do not follow price structures of the U.S. and generally prices tend to be significantly lower.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Healthcare Reform</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the U.S. and foreign jurisdictions, there have been a number of legislative and regulatory changes to the healthcare system that could affect our future results of operations. In particular, there have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs generally and drug costs specifically.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the U.S., for example, the Patient Protection and Affordable Care Act, as amended, or PPACA, is a sweeping law enacted in March of 2010 that expanded healthcare coverage through Medicaid expansion and the implementation of the individual mandate for health insurance coverage and which included changes to the coverage and reimbursement of drug products under government healthcare programs. Beyond the PPACA, there are ongoing and widespread healthcare reform efforts, a number of which have focused on regulation of prices or payment for drug products. For example, federal legislation eliminated a statutory cap on Medicaid drug rebate program rebates effective January 1, 2024. As another example, the Inflation Reduction Act (IRA) of 2022 includes a number of changes intended to address rising prescription drug prices in Medicare Parts B and D. These changes, which have varying implementation dates, include caps on Medicare Part D out-of-pocket costs, Medicare Part B and Part D drug inflation rebates and a new Medicare Part D manufacturer discount drug program (replacing the PPACA Medicare Part D coverage gap discount program), and a drug price negotiation program for certain high-spend Medicare Part B and D drugs. The IRA is likely to have a significant impact on the pharmaceutical industry as implementation proceeds. As another example, in 2022, subsequent to the enactment of the IRA, the Biden administration announced its commitment to expanding certain IRA reforms. There have been significant and wide-ranging reforms to federal policy and the federal government under the new Trump administration. Drug pricing and payment reform was a focus of the prior Trump administration, and that focus is likely to continue under the new Trump administration. Other potential healthcare reform efforts under the Trump administration may affect access to healthcare coverage or the funding of healthcare benefits. There is significant uncertainty regarding the nature or impact of any such reform implemented by the Trump administration through executive action or by Congress. These changes or other changes could affect the market conditions for our products. We expect continued scrutiny on drug pricing and government price reporting from Congress, agencies, and other bodies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. For example, on January 5, 2024, the FDA approved Florida&#8217;s Section 804 Importation Program, or SIP, proposal to import certain drugs from Canada for specific state healthcare programs. It is unclear how this program will be implemented, including which drugs will be chosen, and whether it will be subject to legal challenges in the United States or Canada. Other states have also submitted SIP proposals that are pending review by the FDA. Any such approved importation plans, when implemented, may result in lower drug prices for products covered by those programs. Additionally, a number of states have enacted state drug price transparency and reporting laws that could substantially increase our compliance burdens and expose us to greater liability under such state laws if and when we have marketed products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Healthcare reform efforts have been and may continue to be subject to scrutiny and legal challenge. For example, with respect to the PPACA, tax reform legislation was enacted that eliminated the tax penalty established for individuals who do not maintain mandated health insurance coverage beginning in 2019 and, in 2021, the U.S. Supreme Court dismissed the latest judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the PPACA. As another example, revisions to regulations under the federal anti-kickback statute would remove protection for traditional Medicare Part D discounts offered by pharmaceutical manufacturers to pharmacy benefit managers and health plans. Pursuant to court order, the removal was delayed and recent legislation imposed a moratorium on implementation of the rule until January 2032. As another example, the IRA drug price negotiation program has been challenged in litigation filed by various pharmaceutical manufacturers and industry groups.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect that healthcare reform measures that have been or in the future may be adopted, may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved product, and could seriously harm any future revenue generation. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payers. Complying with any new legislation and regulatory changes could be time-intensive and expensive, resulting in a material adverse effect on our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">23</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. We cannot be sure whether additional legislative changes will be enacted, or whether FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the regulatory approvals, if any, of our product candidates may be. In addition, increased scrutiny by Congress of the FDA&#8217;s approval process may significantly delay or prevent regulatory approval, as well as subject us to more stringent product labeling and post-marketing testing and other requirements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, different pricing and reimbursement schemes exist in other countries. In the European Community, governments influence the price of pharmaceutical products through their pricing and reimbursement rules and control of national healthcare systems that fund a large part of the cost of those products to consumers. Some jurisdictions operate positive and negative list systems under which products may be marketed only once a reimbursement price has been agreed upon. Some of these countries may require, as a condition of obtaining reimbursement or pricing approval, the completion of clinical trials that compare the cost-effectiveness of a particular product to other then-available therapies. Other member states allow companies to fix their own prices for medicines, but monitor and control company profits. The downward pressure on healthcare costs in general, particularly prescription drugs, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross-border imports from low-priced markets exert a commercial pressure on pricing within a country.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On May 1, 2021, the EU and UK trade and cooperation agreement, or TCA, entered into application. The TCA includes specific provisions concerning pharmaceuticals, which include the mutual recognition of the outcomes of GMP inspections. Applicants and MA holders may submit GMP certificates issued by the MHRA for sites located outside the EU/EEA as supporting information for EU regulatory submissions. However, the TCA does not foresee wholesale mutual recognition of UK and EU pharmaceutical regulations. The regulatory regime in Great Britain currently broadly aligns with EU regulations. However, it is possible that these regimes may diverge in the future, given proposed legislative changes such as the European Commission&#8217;s proposals for the entire overhaul of the pharmaceutical regulatory regime.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other Healthcare Laws and Compliance Requirements</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the United States, pharmaceutical manufacturers are subject to numerous other federal, state and local laws designed to, for example, prevent fraud and abuse; promote transparency in interactions with others in the healthcare industry; regulate pricing of drugs and protect the privacy of individual information. These laws, some of which may apply only if a pharmaceutical manufacturer has an approved product, are enforced by various federal and state enforcement authorities, including but not limited to, the U.S. Department of Justice, and individual U.S. Attorney offices within the Department of Justice, the U.S. Department of Health and Human Services, or HHS, HHS&#8217; various divisions, including but not limited to, the Centers for Medicare &amp; Medicaid Services, or CMS, and the Office of Inspector General, and state boards of pharmacy.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may be subject to various federal and state laws pertaining to healthcare &#8220;fraud and abuse,&#8221; including anti kickback laws, and false claims laws, for activities related to sales of any products reimbursable by third party payers such as federal healthcare programs (including Medicare and Medicaid) or, in some cases, commercial health plans. Anti-kickback laws generally prohibit a pharmaceutical manufacturer from soliciting, offering, receiving, or paying anything of value to generate business, including the purchase, prescription or use of a particular drug. False claims laws generally prohibit anyone from knowingly and willingly presenting, or causing to be presented, any claims for payment for reimbursed drugs or services to third-party payers that are false or fraudulent. Although the specific provisions of these laws vary, their scope is generally broad and there may not be regulations, guidance or court decisions that apply the laws to particular industry practices. There is therefore a possibility that our practices might be challenged under such laws.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Laws and regulations have also been enacted by the federal government and various states to regulate the sales and marketing practices of pharmaceutical manufacturers with marketed products. The laws and regulations generally limit financial interactions between manufacturers and healthcare providers; require manufacturers to adopt certain compliance standards; require disclosure to the government and public of financial interactions; require disclosure of marketing expenditures or pricing information, regulate drug pricing and/or require the registration of pharmaceutical sales representatives. Many of these laws and regulations contain ambiguous requirements or require administrative guidance for implementation. Given the lack of clarity in laws and their implementation, any future activities (if we obtain approval and/or reimbursement from federal healthcare programs for our product candidates) could be subject to challenge.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Federal laws, including the Medicaid Drug Rebate Program, require pharmaceutical manufacturers to report certain calculated product prices to the government or provide certain discounts or rebates to government authorities or private entities, often as a condition of reimbursement under government healthcare programs. These laws are complex and the failure to calculate reported prices correctly or provide appropriate prices and rebates can expose a manufacturer to penalties and other sanctions.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The distribution of drugs and biological products is subject to additional requirements and regulations, including extensive record-keeping, licensing, storage and security requirements intended to prevent the unauthorized sale of pharmaceutical products.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">24</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Federal and state consumer protection and unfair competition laws and regulations broadly regulate marketplace activities and that potentially harm consumers and could apply to the activities of pharmaceutical manufacturers.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may be subject to data privacy and security laws in the various jurisdictions in which we operate, obtain or store personally identifiable information. Numerous U.S. federal and state laws govern the collection, use, disclosure and storage of personal information. Various foreign countries also have, or are developing, laws governing the collection, use, disclosure and storage of personal information. Globally, there has been an increasing focus on privacy and data protection issues that may affect our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Efforts to ensure that our activities comply with applicable healthcare laws and regulations will involve substantial costs. Given the breadth of the laws and regulations, limited guidance for certain laws and regulations and evolving government interpretations of the laws and regulations, governmental authorities may possibly conclude that our business practices may not comply with such laws. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, exclusion from government funded healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations. Further, defending against any such actions can be costly, time-consuming and may require significant personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the extent that any of our products are sold in a foreign country or if we contract with vendors or independent contractors outside of the U.S., we may be subject to similar foreign laws and regulations, which may include, for instance, applicable post-approval requirements, including safety surveillance, anti-corruption/anti-bribery laws, anti-kickback laws, healthcare fraud and abuse laws, and implementation of corporate compliance programs and reporting of payments or transfers of value to healthcare professionals. While we are not aware of any current issues, we are unable to predict whether we will be subject to actions under applicable healthcare laws, or the impact of such actions on our business. However, the costs of defending such actions or claims, as well as any sanctions imposed, could result in a material adverse effect on our business or financial condition.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Environmental Matters</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our operations require the use of hazardous materials (including biological materials) which subject us to a variety of federal, provincial and local environmental and safety laws and regulations. Some of the regulations under the current regulatory structure provide for strict liability, holding a party potentially liable without regard to fault or negligence. We could be held liable for damages and fines as a result of our, or someone else&#8217;s, business operations should contamination of the environment or individual exposure to hazardous substances occur. We believe that we are in material compliance with applicable environmental laws and that continued compliance therewith will not have a material adverse effect on our business. We cannot predict, however, how changes in laws or development of new regulations will affect our business operations or the cost of compliance.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Human Capital</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our board of directors and management recognize that creating long-term enterprise value is advanced by considering the interests and concerns of many stakeholders, including those of our employees. As of December 31, 2024, we had 327 employees, including 316 full-time and part-time permanent employees, of which 181 are located in Canada and 135 are located in the U.S. Of our employees, 239 were primarily engaged in research and development, 98 of whom hold a Ph.D. or M.D. (or equivalent) degree, and 88 were engaged in general and administrative or commercial activities. None of our employees are represented by a labor union. We have not experienced any work stoppages and we consider our relations with our employees to be good.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">   </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As competition for qualified personnel in the biotechnology and pharmaceutical field is intense, attracting and retaining qualified employees at all levels is critical to our business. We continuously strive to ensure that employee morale remains strong, and conduct employee engagement surveys to identify areas of focus and monitor employee turnover rates. For the last several years, our company turnover rate has been lower than the industry market average.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have established comprehensive and competitive compensation and benefits programs to attract and retain highly qualified personnel and to incentivize and reward strong performance. In addition to providing our employees with competitive salaries, we believe that employees should share in the potential financial gains resulting from the advancement of our programs by way of annual bonuses to permanent employees based on the achievement of corporate and/or personal objectives. To align the interests of our employees with those of our shareholders, we award stock options to all permanent employees, both upon initial hiring and annually thereafter. Our leave programs include paid vacation, personal, sick, disability and other paid and unpaid leaves. Our health and wellness programs include medical, dental, vision care, retirement savings, employee assistance programs, flexible work schedules and other benefits.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">   </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a biopharmaceutical company with highly educated employees, we believe that our employees must stay current with advances in our industry and continue to grow in their careers. We support our employees' further development through a variety of internal training and external professional development opportunities, including conference attendance and tuition reimbursement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">25</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We recruit the best-qualified employees regardless of sex, gender, ethnicity, race, religion, or other protected traits, and it is our policy to comply with all applicable laws related to discrimination in the workplace. We are committed to diversity, equity, inclusion and accessibility at all levels of our company.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Manufacturing</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently rely, and expect to continue to rely, on third-party contract manufacturers, or CMOs, to manufacture (or produce sufficient quantities of materials required for the manufacture of) our product candidates for pre-clinical testing and clinical trials, and we intend to do so for the commercial manufacture of our products. Similarly, we may rely on collaborators to manufacture, either directly or through CMOs, product candidates licensed to them. Accordingly, we have not internally developed any manufacturing facilities or hired related personnel.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To date, we have obtained materials for our product candidates from multiple third-party manufacturers and suppliers. We believe that all of the materials required for the manufacture of our product candidates can be obtained from more than one source. However, the manufacturing processes for each of our product candidates vary and sourcing adequate supplies may be made more difficult depending on the type of product candidate involved. Our product candidates generally can be manufactured in reliable and reproducible synthetic processes from readily available starting materials, excipients and packaging components.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Corporate Information</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We were incorporated in the Province of British Columbia on November 5, 1996 under the predecessor to the Business Corporations Act (British Columbia) under the name &#8220;Xenon Bioresearch Inc.&#8221; We continued from British Columbia to the federal jurisdiction pursuant to Section 187 of the Canada Business Corporations Act, or the CBCA, on May 17, 2000 and concurrently changed our name to &#8220;Xenon Genetics Inc.&#8221; We registered as an extra-provincial company in British Columbia on July 10, 2000 and changed our name to &#8220;Xenon Pharmaceuticals Inc.&#8221; on August 24, 2004. We had one wholly-owned subsidiary as of December 31, 2024, Xenon Pharmaceuticals USA Inc., which was incorporated in Delaware on December 2, 2016. Our principal executive offices are located at 3650 Gilmore Way, Burnaby, British Columbia, Canada V5G 4W8, and our telephone number is (604) 484-3300. We are a reporting issuer in British Columbia, Alberta and Ontario, but our shares are not listed on any recognized Canadian stock exchange. Our common shares trade on the Nasdaq Global Market under the symbol &#8220;XENE.&#8221;</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Where You Can Find Additional Information</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We make available free of charge through our investor relations website, http://investor.xenon-pharma.com, our annual reports, quarterly reports, current reports, proxy statements and all amendments to those reports as soon as reasonably practicable after such material is electronically filed or furnished with the U.S. Securities and Exchange Commission, or SEC. These reports may also be obtained without charge by contacting Investor Relations, Xenon Pharmaceuticals Inc., 3650 Gilmore Way, Burnaby, British Columbia, Canada V5G 4W8, e-mail: investors@xenon-pharma.com. Our website and the information contained therein or incorporated therein are not intended to be incorporated into this Annual Report on Form 10-K. The SEC maintains a website that contains reports, proxy and information statements, and other information regarding reports that we file or furnish electronically with them at www.sec.gov. Additional information related to Xenon is also available on SEDAR+ at www.sedarplus.ca.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">26</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1a_riskfactors"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1A. Risk Factors</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">You should carefully consider the following risk factors, in addition to the other information contained in this report, including the section of this report captioned &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and our financial statements and related notes. If any of the events described in the following risk factors and the risks described elsewhere in this report occurs, our business, operating results and financial condition could be seriously harmed. This report on Form 10-K also contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in the forward-looking statements as a result of factors that are described below and elsewhere in this report. Our risk factors are not guarantees that no such conditions exist as of the date of this report and should not be interpreted as an affirmative statement that such risks or conditions have not materialized, in whole or in part.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Financial Condition and Capital Requirements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:2.267%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have incurred significant losses since our inception and anticipate that we will continue to incur significant losses for the foreseeable future.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investment in biopharmaceutical product development is highly speculative because it entails substantial capital expenditures and significant risk that a product candidate may fail to demonstrate adequate efficacy or an acceptable safety profile, gain regulatory approval and become commercially viable. We have no products approved for commercial sale and have not generated any revenue from product sales to date, and we will continue to incur significant research and development and other expenses related to our clinical development and ongoing operations. As a result, we are not profitable and have incurred losses in each period since our inception. Since our inception, we have devoted substantially all of our financial resources and efforts to research and development, including pre-clinical studies, manufacturing of investigational drug and our clinical trials. Our financial condition and operating results, including net losses, may fluctuate significantly from quarter to quarter and year to year. Accordingly, you should not rely upon the results of any quarterly or annual periods as indications of future operating performance. We do not expect to have sustained profitability for the foreseeable future. We had net losses of $234.3 million, $182.4 million and $125.4 million for the years ended December 31, 2024, 2023 and 2022, respectively, and an accumulated deficit of $899.5 million as of December 31, 2024, which were driven by expenses incurred in connection with our research and development programs and from general and administrative costs associated with our operations. We expect to continue to incur significant losses for the foreseeable future, and we expect these losses to increase as we continue our research and development of, and seek regulatory approvals for our product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect to incur significant expenses and increasing operating losses for the foreseeable future as we:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">seek marketing authorization for and prepare for the potential commercial launch of azetukalner;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">invest to further develop azetukalner for our current and future indications;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">advance additional product candidates into pre-clinical and clinical development; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">seek regulatory and marketing approvals for any of our product candidates that successfully complete clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">require the manufacture of larger quantities of our product candidates for clinical development and potential commercialization;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">hire additional commercial, clinical, scientific, management and administrative personnel;  </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">acquire or in-license other assets and technologies; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">maintain, protect and expand our intellectual property portfolio; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">create additional infrastructure to support our operations and any future commercialization efforts. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our expenses could increase beyond expectations for a variety of reasons, including if we are required by the U.S. Food and Drug Administration, or FDA, the European Medicines Agency, or EMA, or other regulatory authorities to perform clinical and other studies including post-approval commitments in addition to those that we currently anticipate, or if there are any delays in establishing appropriate manufacturing arrangements to support our clinical trials, the development of any of our product candidates or commercialization. Our prior losses, combined with expected future losses, have had and will continue to have an adverse effect on our shareholders&#8217; equity and working capital.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">27</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:2.267%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We do not generate any revenue from product sales and may never become profitable</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our ability to generate revenue and achieve profitability depends on our ability, alone or with collaborators, to successfully complete the development of, and obtain the regulatory approvals necessary to commercialize, our product candidates.  Successful commercialization will require achievement of many key milestones, including demonstrating safety and efficacy in clinical trials, obtaining regulatory, including marketing, approval for these product candidates, manufacturing, marketing and selling those products for which we, or any of our existing or future collaborators, may obtain regulatory approval, satisfying any post-marketing requirements and obtaining reimbursement for our products from private insurance or government payers. Because of the uncertainties and risks associated with these activities, we are unable to accurately and precisely predict the timing and amount of revenues, the extent of any further losses or if or when we might achieve profitability. We and our existing or future collaborators may never succeed in these activities and, even if we do, we may never generate revenues that are large enough for us to achieve profitability. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Additionally, our expenses could increase if we are required by the FDA, EMA or other regulatory authorities to perform clinical trials in addition to those currently expected, or if there are any delays in completing our clinical trials or the development of any of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If any of our product candidates fail in clinical trials or do not gain regulatory approval, or if any of our future products, if any, once approved, fail to achieve market acceptance or adequate market share, we may never become profitable. If we are unable to generate sufficient revenue to become profitable and remain so, our financial condition and operating results will be negatively impacted, and the market price of our common shares might be adversely impacted.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:2.267%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We will need to raise additional funding, which may not be available on acceptable terms, if at all. Failure to obtain capital when needed may force us to delay, limit or terminate our product discovery and development programs or commercialization efforts or other operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since our inception, we have dedicated most of our resources to the discovery and development of our pre-clinical and clinical product candidates.  We expect to continue to spend substantial amounts of resources to continue the pre-clinical and clinical development of our current and future programs. If we are able to gain marketing approval for product candidates that we develop, we will require significant additional amounts of capital in order to launch and commercialize such product candidates to the extent that such launch and commercialization are not the responsibility of a collaborator. In addition, other unanticipated costs may arise in the course of our development efforts. Because the design and outcome of our planned and anticipated clinical trials is highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the development and commercialization of any product candidate we develop.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our future capital requirements depend on many factors, including but not limited to:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the scope, progress, results and costs of researching and developing our current product candidates, as well as additional product candidates we may develop and pursue in the future; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing of, and the costs involved in, obtaining marketing approvals for our product candidates and any additional product candidates we may develop and pursue in the future;  </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the number of future product candidates that we may pursue and their development requirements; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">if approved, the costs of commercialization activities for any product candidate that receives regulatory approval to the extent such costs are not the responsibility of an existing or future collaborator, including the costs and timing of establishing product sales, marketing, distribution and manufacturing capabilities; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">subject to the receipt of regulatory approval, revenue, if any, received from commercial sales of our product candidates and any additional product candidates we may develop and pursue in the future; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">whether our existing collaborations generate substantial milestone payments and, ultimately, royalties on future approved products for us;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to maintain existing collaborations and to establish new collaborations, licensing or other arrangements and the financial terms of such arrangements; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs associated with any transactions to acquire or in-license other product candidates and technologies;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our headcount growth and associated costs as we expand our research and development efforts and initiate pre-commercial and commercial activities; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patents, including litigation costs and the outcome of such litigation; and </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">28</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the ongoing costs of operating as a public company. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on our research and development plans and our timing expectations related to the progress of our programs, we expect that our existing cash and cash equivalents and marketable securities as of the date of this report, will enable us to fund our operating expenses and capital expenditure requirements for at least the next 12 months.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our operating plan may change as a result of many factors currently unknown to us, and we may need to seek additional funds sooner than planned. Raising funds in the future may present additional challenges and future financing may not be available in sufficient amounts or on terms acceptable to us, if at all. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, reduce or terminate our product development programs or plans for commercialization.</span></p>
  <p style="text-indent:2.267%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may allocate our limited resources to pursue a particular product candidate or indication and fail to capitalize on other product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because we have limited financial and management resources, we focus on a limited number of research programs and product candidates. As a result, we may forgo or delay pursuit of opportunities with other product candidates or for our current product candidates in other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial drugs or profitable market opportunities. Our spend on current and future research and development programs and product candidates for specific indications may not yield any commercially viable drugs. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:2.267%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Raising additional capital may cause dilution to our existing shareholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect our expenses to increase in connection with our planned operations. Unless and until we can generate a substantial amount of revenue from any approved product candidates, we expect to finance our future cash needs through public or private equity offerings, debt financings, royalty-based financing, collaborations, licensing arrangements or other sources, or any combination of the foregoing. In addition, we may seek additional capital due to favorable market conditions or strategic considerations, even if we believe that we have sufficient funds for our current or future operating plans.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The terms of any financing arrangements we enter into may adversely affect the holdings or the rights of our shareholders and the issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price of our common shares to decline. The sale of additional equity or convertible securities also would dilute all of our shareholders.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Historically, we have also financed our operations through the incurrence of debt. Any future incurrence of indebtedness would result in increased fixed payment obligations and, potentially, the imposition of restrictive covenants. Such covenants could include limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We could also be required to seek funds through collaborations or marketing, distribution or licensing arrangements, or royalty-based financings with third parties, and we may have to relinquish valuable rights to our technologies, future revenue streams or product candidates, or grant licenses on terms that may not be favorable to us. If we are unable to raise additional capital when needed, we may be required to delay, reduce or terminate our product discovery and development programs, commercialization efforts, or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. In addition, any additional fundraising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize our product candidates.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">29</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:2.267%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are subject to risks associated with currency fluctuations which could impact our results of operations</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A portion of our cash and cash equivalents and marketable securities are denominated in Canadian dollars, and we incur significant expenses in Canadian dollars in connection with our operations in Canada. We do not currently engage in foreign currency hedging arrangements for our Canadian dollar expenditures, and, consequently, foreign currency fluctuations, including as a result of trade relations between Canada and the United States, may adversely affect our earnings; however, in the future, we may engage in exchange rate hedging activities in an effort to mitigate the impact of exchange rate fluctuations. Any hedging technique we implement may fail to be effective. If our hedging activities are not effective, changes in currency exchange rates may have a more significant impact on the market price of our common shares.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Business and Industry</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:2.267%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We and our collaborators face substantial competition in the markets for our product candidates, which may result in others discovering, developing or commercializing products before us or doing so more successfully than we, or our collaborators, do.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products. We face potential competition in drug discovery and product development from many different approaches and sources, including major pharmaceutical, specialty pharmaceutical and biotechnology companies, academic institutions, governmental agencies, as well as public and private research institutions. Any product candidates that we, or our collaborators, successfully develop and commercialize will compete with existing products and any new products that may become available in the future.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The key competitive factors affecting the success of all of our product candidates, if approved, are likely to be their efficacy, safety and/or tolerability, convenience and ease of administration, price, the potential advantages of alternative products, the level of generic competition, and the availability of coverage and adequate reimbursement from government and other third-party payers.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many of the companies against which we are competing or against which we may compete in the future have significantly greater financial resources and expertise in research and development, manufacturing, pre-clinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we, or our collaborators, do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaboration arrangements with large and established companies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our commercial opportunities could be reduced or eliminated if our competitors develop and commercialize products or therapies that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we may develop. Our competitors also may obtain FDA, EMA or other foreign regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. In addition, our ability to compete may be affected by decisions made by insurers or other third-party payers.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If one or more of our proprietary or partnered products were approved for the treatment of epilepsy, we anticipate that they could potentially compete with other anti-seizure medications, or ASMs, or one another. If one or more of our proprietary products were approved for the treatment of major depressive disorder, or MDD, we anticipate that they could potentially compete with other anti-depressant medications, or ADs. In addition, we plan to develop one or more proprietary products for the treatment of bipolar disorder, or BPD, and if any such products were approved for treatment of BPD, we anticipate that they could potentially compete with other anticonvulsant and antipsychotic medications.</span></p>
  <p style="text-indent:2.267%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have no marketed proprietary products and have not yet completed clinical development beyond Phase 2 clinical trials, which makes it difficult to assess our ability to develop our future product candidates and commercialize any resulting products independently.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a company, we have no previous experience in completing a Phase 3 clinical trial and related regulatory requirements including a New Drug Application, or NDA, or equivalent submission, or the commercialization of products. We have not yet demonstrated our ability to independently and repeatedly conduct clinical development after Phase 2, obtain regulatory approval, manufacture drug substance or drug product on a registrational and commercial scale or arrange for a third-party to do so on our behalf, and commercialize therapeutic products. We will need to develop such abilities if we are to execute on our business strategy to develop and independently commercialize product candidates. To execute on our business plan for the development of independent programs, we will need to successfully:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reach agreement with multiple regulatory agencies on clinical and pre-clinical studies required for registration; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">execute our clinical development and manufacturing plans for later-stage product candidates; </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">30</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtain required regulatory approvals in each jurisdiction in which we will seek to commercialize products; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">build and maintain appropriate pre-commercialization capabilities as well as commercial sales, distribution and marketing capabilities; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">build and implement effective market access strategy and gain market acceptance for our future products, if any; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">manage our spending as costs and expenses increase due to clinical trials, regulatory approvals and commercialization activities. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unsuccessful in accomplishing these objectives, we will not be able to develop and commercialize any future product candidates independently and could fail to realize the potential advantages of doing so.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:2.267%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are not successful in discovering, developing and commercializing additional product candidates, our ability to expand our business and achieve our strategic objectives may be impaired.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have built a product development pipeline by identifying product candidates either from our internal research efforts or through acquiring or in-licensing other product candidates or technologies. Both our internal discovery efforts and our assessment of potential acquisition or in-licensing opportunities require substantial technical, financial and human resources, regardless of whether we identify any viable product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unable to identify additional product candidates suitable for clinical development and commercialization either from our internal research efforts or through acquiring or in-licensing other product candidates or technologies, we may not be able to obtain product revenue in future periods, which likely would result in significant harm to our financial position and adversely impact the market price of our common shares.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:2.267%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we fail to attract and retain our executive officers and key personnel, we may be unable to successfully develop our product candidates, perform our obligations under our collaboration agreements, conduct our clinical trials and commercialize our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our success depends in part on our continued ability to attract, retain and motivate highly qualified management, clinical and scientific personnel. Our industry has experienced a high rate of turnover of management personnel in recent years. Replacing executive officers or other key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to develop, gain regulatory approval of and commercialize products successfully.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are highly dependent upon our executive officers, including Mr. Ian Mortimer, our President and Chief Executive Officer. The loss of services of one or more of our executive officers could materially delay or even prevent the successful development of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we will need to hire additional personnel as we expand our clinical development activities and develop commercial capabilities, including a sales infrastructure to support our independent commercialization efforts. We may not be able to attract and retain personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for individuals with similar skill sets. The inability to recruit or loss of the services of any executive or key employee may impede the progress of our research, development and commercialization objectives.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:2.267%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our employees, collaborators and other personnel may engage in misconduct or other improper activities, including non-compliance with legal and regulatory standards and requirements, which could cause significant liability for us and harm our reputation.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are exposed to the risk of fraud or other misconduct by our employees, collaborators, vendors, investigational site staff, consultants, commercial partners and other personnel. Misconduct by those parties could include intentional, reckless and/or negligent conduct or disclosure of unauthorized activities to us that violates:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the regulations of the FDA, EMA and other foreign regulators, including those laws requiring the reporting of true, complete and accurate information to such authorities; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">manufacturing standards; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">insider trading laws;  </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">data privacy, data protection and security; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">federal and state healthcare fraud and abuse laws and regulations in the U.S. and abroad; and  </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">31</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">laws that require the reporting of financial information or data accurately.  </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. Additionally, we are subject to applicable foreign, federal and state data privacy and security laws. For additional information, see &#8220;Risk Factors &#8212; We are subject to evolving global laws and regulations relating to privacy, data protection and information security, which may require us to incur substantial compliance costs, and any failure or perceived failure by us to comply with such laws and regulations may harm our business and operations.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Various laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Any misconduct could also involve the improper use or misrepresentation of information obtained in the course of clinical trials or creating fraudulent data in our pre-clinical studies or clinical trials, which could result in regulatory sanctions and cause serious harm to our reputation. We have adopted a code of conduct applicable to all of our employees, officers, directors, agents and representatives, including consultants, but it is not always possible to identify and deter misconduct, and the precautions we take to detect and prevent misconduct may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or claims, demands, or lawsuits stemming from an actual or alleged failure to comply with these laws and regulations. Additionally, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves, achieving a favorable settlement or otherwise asserting our rights, those actions could have a significant impact on our business, including the imposition of civil, criminal and administrative penalties, damages, monetary fines, disgorgement, integrity oversight and reporting obligations, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations. Additionally, defending against any such actions can be costly, time-consuming and may require significant financial and personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:2.267%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may encounter difficulties in managing our growth, including headcount, and expanding our operations successfully.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our business strategy involves continued development and, where development is successful, commercialization of select product candidates. In order to execute on this strategy, we will need to build out a regulatory, sales, manufacturing, supply chain and marketing infrastructure and expand our development capabilities or contract with third parties to provide these capabilities and infrastructure for us. To achieve this, we will need to identify, hire and integrate personnel, compensate our employees on adequate terms in an increasingly competitive, inflationary market and continue to implement and improve our managerial, operational and financial systems. As our operations expand, we expect that we will need to manage additional relationships with various strategic collaborators, suppliers and other third parties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Future growth will impose significant added responsibilities on members of management including the need to identify, recruit, maintain, motivate and integrate additional employees. Also, our management may need to divert a disproportionate amount of its attention away from our day-to-day activities and devote a substantial amount of time to managing these growth activities. We may not be able to effectively manage the expansion of our operations, which may result in weaknesses in our business, give rise to operational errors, loss of business opportunities, loss of employees and reduced productivity amongst remaining employees. Our expected growth could require significant capital expenditures and may divert financial resources from other projects, such as the development of existing and additional product candidates. If we are unable to effectively manage our growth, our expenses may increase more than expected, our ability to generate and grow revenue could be reduced, and we may not be able to implement our business strategy. Our future financial performance and our ability to commercialize product candidates and compete effectively will depend, in part, on our ability to effectively manage any future growth.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:2.267%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are subject to evolving global laws and regulations relating to privacy, data protection and information security, which may require us to incur substantial compliance costs, and any failure or perceived failure by us to comply with such laws and regulations may harm our business and operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the ordinary course of business, we process personal data and other sensitive information, including our proprietary and confidential business data, trade secrets, intellectual property, data about trial participants collected in connection with clinical trials, and other sensitive data. Our data processing activities subject us to numerous data privacy and security obligations, such as various laws, regulations, guidance, industry standards, external and internal privacy and security policies, contracts, and other obligations that govern the processing of personal data by us and on our behalf.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">32</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the U.S., federal, state, and local governments have enacted numerous data privacy and security laws, including data breach notification laws, personal data privacy laws, and consumer protection laws. For example, the U.S. federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, imposes specific requirements relating to the privacy, security, and transmission of individually identifiable health information that apply to most U.S. healthcare providers with which we interact, such as our U.S. clinical trial sites. At the state level, the California Consumer Privacy Act of 2018, or CCPA, as amended and supplemented by the California Privacy Rights Act, imposes obligations on businesses to which it applies. The CCPA allows for statutory fines for noncompliance. Although the CCPA exempts some data processed in the context of clinical trials, the CCPA, to the extent applicable to our business and operations, may increase compliance costs and potential liability with respect to other personal information we maintain about California residents. Other states have also enacted data privacy laws.  In addition, Washington state enacted the My Health, My Data Act, a health-focused consumer privacy law, which took effect in March 2024.  This law imposes obligations related to the collection and sharing of certain health-related information that is not subject to HIPAA and that does not fall within certain other exceptions in the law.  Other states have enacted, or are in the process of enacting, similar health-focused consumer privacy laws. Additional data privacy and security laws have been proposed and enacted at the federal, state, and local levels in recent years, which could further complicate compliance efforts. For example, in June 2024, the Protecting Americans&#8217; Data from Foreign Adversaries Act of 2024 took effect.  This law prohibits data brokers from making available certain personally identifiable sensitive data of U.S. individuals to &#8220;foreign adversary&#8221; countries, such as the People&#8217;s Republic of China, or the PRC, and entities controlled by such countries. Additionally, in January 2025, the U.S. Department of Justice published a final rule implementing President Biden&#8217;s Executive Order 14117, &#8220;Preventing Access to Americans&#8217; Bulk Sensitive Personal Data and United States Government-Related Data by Countries of Concern.&#8221; This final rule prohibits certain data brokerage transactions and transactions involving certain bulk human &#8216;omic data, including human genomic data and biospecimens from which such data can be derived, with restricted persons and jurisdictions, such as the PRC.  The final rule also places restrictions on certain vendor, employment and investment agreements with such jurisdictions. Most provisions of the final rule are scheduled to take effect in April 2025.  These restrictions may affect our ability to engage in collaborations or license agreements with entities in restricted countries or with a nexus to such countries going forward.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Outside the U.S., the European Union&#8217;s General Data Protection Regulation, or EU GDPR, and the United Kingdom&#8217;s GDPR, or UK GDPR, impose strict requirements for processing the personal data of individuals. For example, under the EU GDPR, government regulators may impose temporary or definitive bans on data processing, as well as fines of up to 20 million euros or 4% of annual global revenue, whichever is greater. Further, individuals may initiate litigation related to our processing of their personal data.  Certain foreign jurisdictions have enacted data localization laws and cross-border personal data transfer laws, which could make it more difficult to transfer information across jurisdictions, such as transferring or receiving personal data that originates in the European Union, or EU. Additional jurisdictions have enacted and continue to enact and modify their data privacy laws, which increases the complexity of the data privacy landscape.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although we endeavor to comply with all applicable data privacy and security obligations, these obligations are quickly changing in an increasingly stringent fashion, creating some uncertainty as to how to comply, and potentially requiring us to modify our policies and practices, which may be costly and may divert the attention of management and technical personnel. Further, we may at times fail, or be perceived to have failed, to have complied and could face significant consequences. These consequences may include, but are not limited to, government enforcement actions, investigations and other proceedings; additional reporting requirements and/or oversight; bans on processing personal data; orders to destroy or not use personal data; and imprisonment of company officials. Any of these events could have a material adverse effect on our reputation, business, or financial condition, including but not limited to: interruptions or stoppages in our business operations, including our clinical trials; inability to process personal data or to operate in certain jurisdictions; limited ability to develop or commercialize our products; expenditure of time and resources to defend any claim or inquiry; adverse publicity; or revision or restructuring of our operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">    </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">33</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:2.267%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our business and operations could suffer in the event of an actual or perceived information security incident such as a cybersecurity breach, system failure, or other compromise of our systems and/or information, including information held by a third-party contractor or vendor.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We rely on both internal information technology systems and networks, and those of third-party vendors and contractors, to acquire, transmit, store and otherwise process information in connection with our business activities. Our ability to effectively manage our business depends on the security, reliability and adequacy of our and our third-party contractors&#8217; and vendors&#8217; technology systems. Any incident, whether hostile or inadvertent, that adversely impacts the confidentiality, integrity or availability of our systems and/or data, including phishing, business email compromise, social engineering, ransomware or other malware, or any security breach, security incident or other destruction, loss, or unauthorized use or other processing of data maintained or otherwise processed by us or on our behalf could result in a loss of intellectual property or misappropriation of trade secrets, disruptions to our business and operations, subject us to increased costs and require us to expend time and resources to address the matter, may subject us to claims, demands, and proceedings by private parties, regulatory investigations and other proceedings, and fines, penalties, and other liability and have a material adverse effect on our business. In addition, the loss, alteration or other damage to or other unavailability of pre-clinical data or clinical trial data from completed or ongoing clinical trials for our product candidates could result in delays in our development and regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Any cyber-attack, security breach or incident, or other destruction, loss or unauthorized processing of data maintained or otherwise processed by us or on our behalf, or the perception any such matter has occurred, could result in actual or alleged violations of applicable U.S. and international privacy, data protection, information security and other laws and regulations, harm our reputation and subject us to litigation and governmental investigations and proceedings by federal, state and local regulatory entities in the U.S. and by international regulatory entities, resulting in exposure to material civil and/or criminal proceedings and liability. In addition, we may incur significant additional expense to implement further measures relating to privacy, data protection and information security, whether in response to an actual or perceived security breach or incident or otherwise.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To date, we have not experienced any material impact to our business, financial position or operations resulting from cyberattacks or other information security incidents; however, because of frequently changing attack techniques, along with the increased volume and sophistication of such attacks, our business, financial position or operations could be adversely impacted in the future. Moreover, the increasingly distributed nature of computing, including prevalent use of mobile devices to access confidential information and widespread use of cloud-based applications hosted in remote data centers, increases the risk of security breaches and incidents. These risks may be heightened due to the increasing number of our and our third-party vendors&#8217; and contractors&#8217; personnel working remotely. As cyber threats continue to evolve, we may be required to expend significant additional resources to continue to modify or enhance our protective measures or to investigate and remediate information security vulnerabilities, threats and incidents. While we have implemented layered security measures, our computer systems and the external systems and services used by our third-party contract manufacturers, or CMOs, and contract research organizations, or CROs, and their vendors and contractors remain potentially vulnerable to these events and there can be no assurance that we will be successful in preventing cyber-attacks or successfully mitigating their effects. Our liability insurance may not be sufficient in type or amount to cover us against claims related to security breaches, cyberattacks and other related breaches.</span></p>
  <p style="text-indent:2.267%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">A variety of risks associated with international operations could materially harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We must dedicate additional resources to comply with numerous laws and regulations in each jurisdiction in which we operate and plan to operate outside the U.S., including those countries outside the U.S. in which we are conducting clinical trials. As we engage in significant cross-border and international activities, we will be subject to risks related to international operations, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">different regulatory requirements for conducting clinical trials, registering and maintaining approval of, manufacturing and advertising drugs in foreign countries; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reduced protection for intellectual property rights in certain countries; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in tariffs, trade barriers and regulatory requirements including as a result of trade relations between Canada and the United States; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">economic weakness, including inflation, political instability or open conflict in particular foreign economies and markets; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">differing and multiple payer reimbursement regimes, government payers or patient self-pay systems; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations of doing business in another country; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">workforce uncertainty in countries where labor unrest is more common than in North America; </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">34</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">potential or actual violations of domestic and international anti-corruption laws, such as the U.S. Foreign Corrupt Practices Act and the U.K. Bribery Act, or of U.S. and international import, export and re-export control and sanctions laws and regulations, the likelihood of which may increase with an increase of operations in foreign jurisdictions, directly or indirectly through third parties (whose corrupt or other illegal conduct may subject us to liability), which may involve interactions with government agencies or government-affiliated hospitals, universities and other organizations, such as conducting clinical trials, selling our products, and obtaining necessary permits, licenses, patent registrations, and other regulatory approvals; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">tighter restrictions on privacy and data protection, and more burdensome obligations associated with the collection, use and retention of data, including clinical data and genetic material, may apply in jurisdictions outside of North America; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">business interruptions resulting from geopolitical actions, including war, civil and political unrest and terrorism, or natural disasters including earthquakes, typhoons, floods and fires; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">supply and other disruptions resulting from the impact of public health pandemics or epidemics on our strategic partners, third-party manufacturers, suppliers and other third parties upon which we rely; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">business interruptions resulting from increased government scrutiny on the use of certain foreign biotechnology service providers due to national security concerns, including the potential for legislation that restricts or prohibits the use of such third-party service providers.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unable to successfully manage these risks associated with cross-border and international activities, our business could be materially harmed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:2.267%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">U.S. holders of our common shares may suffer adverse tax consequences if we are characterized as a passive foreign investment company.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">U.S. investors should be aware that based on our gross income and gross assets, we were a passive foreign investment company, or PFIC, for the taxable year ended December 31, 2024 and we may be a PFIC in 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Generally, for any taxable year in which 75% or more of our gross income is passive income, or at least 50% of the quarterly average percentage of our assets (as determined under applicable Treasury Regulations) are held for the production of, or produce, passive income, we would be characterized as a PFIC, for U.S. federal income tax purposes. For PFIC testing purposes, a range of factors can affect the determination, including the market price of our common shares and how we spend or otherwise hold our cash. Thus, our status as a PFIC is a fact-intensive determination made on an annual basis and the applicable law is subject to varying interpretation. In addition, a company&#8217;s PFIC status can be made only after the end of each taxable year. Accordingly, we cannot provide any assurance regarding our PFIC status for the current taxable year or future taxable years.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are a PFIC for any year in which a U.S. investor hold our shares, such U.S. holders of our common shares may suffer adverse tax consequences including in years after we cease to be classified as a PFIC. Gains realized by such U.S. holders on the sale of our common shares would be taxed as ordinary income, rather than as capital gain, and the preferential tax rate applicable to dividends received on our common shares would be lost. Interest charges would also be added to taxes on gains and dividends realized by all U.S. holders. U.S. holders should consult their own tax advisors with respect to their particular circumstances.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A U.S. holder may avoid these adverse tax consequences by timely making a qualified electing fund election. For each year that we would meet the PFIC gross income or asset test, an electing U.S. holder would be required to include in gross income its pro rata share of our net ordinary income and net capital gains, if any. A U.S. holder may make a qualified electing fund election only if we commit to provide U.S. holders with their pro rata share of our net ordinary income and net capital gains. We will provide, upon request, our U.S. holders with the information that is necessary in order for them to make a qualified electing fund election and to report their pro rata shares of ordinary earnings and net capital gains for each year we believe we were a PFIC. U.S. holders should consult their own tax advisors with respect to making this election and the related reporting requirements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A U.S. holder may also mitigate the adverse tax consequences by timely making a mark-to-market election. Generally, for each year that we meet the PFIC gross income or asset test, an electing U.S. holder would include in gross income the increase in the value of its common shares during each of its taxable years and deduct from gross income the decrease in the value of such shares during each of its taxable years. A mark-to-market election may be made and maintained only if our common shares are regularly traded on a qualified exchange, including the Nasdaq Global Market, or Nasdaq. Whether our common shares are regularly traded on a qualified exchange is an annual determination based on facts that, in part, are beyond our control. Accordingly, a U.S. holder might not be eligible to make a mark-to-market election to mitigate the adverse tax consequences if we are characterized as a PFIC. U.S. holders should consult their own tax advisors with respect to the possibility of making this election.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">35</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, if we are or become a PFIC (or our PFIC status is uncertain), it may deter certain U.S. investors from purchasing our common shares, which could have an adverse impact on the market price of our common shares.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:2.267%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have significant Canadian federal net operating loss carryforwards which are limited in life, Canadian federal investment tax credit carryforwards and provincial investment tax credit carryforwards which could expire unused and be unavailable to offset future income tax liabilities. The rules dealing with Canadian and U.S. federal, provincial, state, and local income taxation are constantly under review by persons involved in the legislative process and by the Canada Revenue Agency, Internal Revenue Service and the U.S. Treasury Department. Changes to tax laws, or changes in interpretations of existing laws (which changes may have retroactive application), including with respect to net operating losses and tax credits, could adversely affect us or holders of our common shares. In recent years, many such changes have been made and changes are likely to continue to occur in the future. Future changes in tax laws could have a material adverse effect on our business, cash flow, financial condition or results of operations.</span></p>
  <p style="text-indent:2.267%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may become subject to income tax in jurisdictions in which we are organized or operate, which would reduce our future earnings</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There is a risk that we may become subject to income tax in jurisdictions outside of Canada and the U.S., if under the laws of any such jurisdiction, we are considered to be carrying on a trade or business there or earn income that is considered to be sourced there and we do not qualify for an exemption. In jurisdictions where we do not believe we are subject to tax, we can provide no certainty that tax authorities in those jurisdictions will not subject one or more tax years to examination. Tax examinations are often complex as tax authorities may disagree with the treatment of items reported by us, the result of which could have a material adverse effect on our operating results and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:2.267%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Acquisitions or other strategic transactions could disrupt our business, cause dilution to our shareholders and otherwise harm our business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We actively evaluate various strategic transactions on an ongoing basis, including the acquisition of other businesses, products or technologies as well as pursuing strategic alliances, licensing transactions or investments in complementary businesses. Any of these transactions could be material to our financial condition and operating results and expose us to many risks, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">disruption in our relationships with collaborators or suppliers as a result of such a transaction; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">unanticipated liabilities related to acquired companies; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">difficulties integrating acquired personnel, technologies and operations into our existing business; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">retention of key employees; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">diversion of management time and focus from operating our business to pursuing strategic transactions and managing any such strategic alliances, joint ventures or acquisition integration challenges; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">dilution to our shareholders if we issue equity in connection with such transactions; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">increases in our expenses and reductions in our cash available for operations and other uses; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">possible write-offs or impairment charges relating to acquired businesses. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Foreign acquisitions involve unique risks in addition to those mentioned above, including those related to integration of operations across different cultures and languages, currency risks and the particular economic, political and regulatory risks associated with specific countries.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Also, the anticipated benefit of any strategic alliance or acquisition may not materialize. Future acquisitions or dispositions could result in potentially dilutive issuances of our equity securities, the incurrence of debt, contingent liabilities or amortization expenses or write-offs of goodwill, any of which could harm our financial condition. We cannot predict the number, timing or size of future acquisitions, or the effect that any such transactions might have on our operating results.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">36</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:2.267%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our current and future operations in the U.S. and elsewhere will be subject, directly or indirectly, to applicable federal and state fraud and abuse, government pricing and transparency, health information privacy and security, and other healthcare laws and regulations, non-compliance with which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm, administrative burdens, and diminished profits and future earnings.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Healthcare providers and third-party payers in the U.S. and elsewhere play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Our arrangements with healthcare providers, third-party payers, patients and other parties within the healthcare industry may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell, and distribute any products for which we obtain marketing approval. Restrictions under applicable healthcare and data privacy laws and regulations include the following, some of which will apply only if and when we have a marketed product:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of, any good or service for which payment may be made under federal and state healthcare programs such as Medicare and Medicaid; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">federal civil and criminal false claims laws, including the federal False Claims Act, which can be enforced through civil whistleblower, or qui tam actions, as well as civil monetary penalty laws can impose criminal and civil penalties, assessment, and exclusion from participation for various forms of fraud and abuse involving the federal healthcare programs, such as Medicare and Medicaid;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, as amended, which imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program and also establishes requirements related to the privacy, security, and transmission of individually identifiable health information which apply to many healthcare providers, physicians, and third-party payers with whom we interact; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the FDCA, which, among other things, strictly regulates drug product and medical device marketing, prohibits manufacturers from marketing such products for off-label use and regulates the distribution of samples; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">federal laws that require pharmaceutical manufacturers to report certain calculated product prices to the government or provide certain discounts or rebates to government authorities or private entities, often as a condition of reimbursement under governmental healthcare programs; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the so-called federal "sunshine law" or Open Payments which requires manufacturers of drugs, devices, biologics, and medical supplies to report to the Centers for Medicare &amp; Medicaid Services information related to payments and other transfers of value to teaching hospitals, physicians, and other healthcare practitioners, as well as ownership and investment interests held by physicians and their immediate family members; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">federal and state consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payers, including private insurers; state and foreign laws that limit financial interactions between manufacturers and healthcare providers; require manufacturers to adopt certain compliance standards; require disclosure to the government and public of financial interactions; require disclosure of marketing expenditures or pricing information, regulate drug pricing and/or require the registration of pharmaceutical sales representatives; and state and foreign laws governing the collection, export, privacy, use, protection and security of biological materials and health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Efforts to ensure that our activities comply with applicable healthcare laws and regulations will involve substantial costs. Given the breadth of the laws and regulations, limited guidance for certain laws and regulations and evolving government interpretations of the laws and regulations, governmental authorities may possibly conclude that our business practices may not comply with such laws. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, exclusion from government funded healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations. Further, defending against any such actions can be costly, time-consuming and may require significant personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">37</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:2.267%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our research and development activities involve the controlled use of potentially harmful biological materials as well as hazardous materials, chemicals, and various radioactive compounds typically employed in molecular and cellular biology. For example, we routinely use cells in culture and we employ small amounts of radioisotopes. We cannot completely eliminate the risk of accidental contamination or injury from the use, storage, handling, or disposal of these materials through our maintenance of up-to-date licensing and training programs. In the event of contamination or injury, we could be held liable for damages that result, and any liability could exceed our resources. We currently carry insurance covering certain claims arising from our use of these materials. However, if we are unable to maintain our insurance coverage at a reasonable cost and with adequate coverage, our insurance may not cover any liability that may arise. We are subject to Canadian federal, provincial, and local laws and regulations and may be subject to U.S. and/or foreign, laws and regulations governing the use, storage, handling, and disposal of these materials and specified waste products. Complying with regulations regarding the use of these materials could be costly, and if we fail to comply with these regulations, it could have a material adverse effect on our operations and profitability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:2.267%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We or the third parties upon whom we depend may be adversely affected by earthquakes or other natural disasters and our business continuity and disaster recovery plans may not adequately protect us from serious disaster.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our headquarters are located in Burnaby, British Columbia, Canada. We are vulnerable to natural disasters such as earthquakes that could disrupt our operations. If a natural disaster, power outage, fire or other event occurred that prevented us from using all or a significant portion of our headquarters, that damaged critical infrastructure, such as the manufacturing facilities of our CMOs, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time. Although we carry insurance for earthquakes and other natural disasters, we may not carry sufficient business interruption insurance to compensate us for all losses that may occur. The disaster recovery and business continuity plans we have in place may not be adequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of a natural disaster or earthquake, which could have a material adverse effect on our business. In addition, we may lose samples or other valuable data. The occurrence of any of the foregoing could have a material adverse effect on our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to the Discovery, Development and Commercialization of Our Product Candidates</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:2.267%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our business substantially depends upon the successful development of azetukalner. If we are unable to obtain regulatory approval for, and successfully commercialize, azetukalner, our business may be materially harmed</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently have no products approved for commercial sale and are investing significant efforts and financial resources in the development of our clinical-stage product candidate, azetukalner for the treatment of epilepsy, MDD, BPD and potentially other neurological disorders. Our future business success depends on the continued development and ultimate regulatory approval of azetukalner. We will need to successfully enroll and complete our azetukalner Phase 3 clinical trials and any other future Phase 3 clinical trials. The future regulatory and commercial success of azetukalner is subject to a number of risks, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">successful patient enrollment in clinical trials and ultimate completion of clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">safety and efficacy data from our clinical programs that support acceptable risk-benefit profiles of azetukalner in the intended patient populations; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">receipt and maintenance of marketing approvals from applicable regulatory authorities; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">completing any post-marketing studies required by applicable regulatory authorities; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtaining and maintaining patent and trade secret protection and regulatory exclusivity for azetukalner; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">making arrangements with third-party manufacturers for both clinical and commercial supplies of azetukalner; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establishing sales, marketing and distribution capabilities and commercial launch of azetukalner, if and when approved, whether alone or in collaboration with others; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">successful commercial launch of azetukalner, if and when approved; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">acceptance of azetukalner, if and when approved, by patients, the medical community and third-party payers; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtaining and maintaining acceptable pricing, third-party insurance coverage and adequate reimbursement; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">maintaining a continued acceptable safety profile of azetukalner following approval; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">effectively competing with other therapies; </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">38</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">enforcing and defending intellectual property rights and claims; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">raising sufficient funds to support regulatory approval and commercialization activities. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many of these risks are beyond our control, including the risks related to clinical development, the regulatory submission and approval process, potential threats to our intellectual property rights and the manufacturing, marketing and sales efforts of any future collaborator. If we or any collaborator are unable to develop, receive regulatory approval for, or successfully commercialize azetukalner for our initial or potential additional indications, or if we experience delays as a result of any of these risks or otherwise, our business could be materially harmed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, of the large number of drugs in development in the pharmaceutical industry, only a small percentage result in the submission of an NDA to the FDA and even fewer are approved for commercialization. Furthermore, even if we do receive regulatory approval for azetukalner for any indication, any such approval may be subject to limitations on the indications or uses or patient populations for which we may market azetukalner. Accordingly, even if we are able to obtain the requisite financing to continue to fund our development programs, we cannot ensure that we will successfully develop or commercialize azetukalner for any indication.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:2.267%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our approach to drug discovery is unproven, and we do not know whether we will be able to develop any products of commercial value.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our approach to drug discovery may not reproducibly or cost-effectively result in the discovery of product candidates and development of commercially viable products that safely and effectively treat human disease.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our drug discovery efforts may initially show promise in identifying additional product candidates yet fail to yield viable product candidates for clinical development or commercialization. Such failure may occur for many reasons, including that any product candidate may, on further study, be shown to have serious or unexpected side effects or other characteristics that indicate it is unlikely to be safe or otherwise does not meet applicable regulatory criteria and/or not be capable of being produced in commercial quantities at an acceptable cost, or at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If our discovery activities fail to identify novel targets for drug discovery, or such targets prove to be unsuitable for treating human disease, or if we are unable to develop product candidates with specificity and selectivity for such targets, we will fail to develop viable products. If we fail to develop and commercialize viable products, we will not achieve commercial success.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:2.267%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Results of pre-clinical studies and/or earlier clinical trials may not be predictive of the results of later-stage clinical trials and the results of our clinical trials may not satisfy regulatory requirements and we may experience delays or unexpected difficulties in obtaining regulatory approval.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The results of pre-clinical studies, either generated by us, by our CROs or by other third parties from which we have in-licensed or acquired a product candidate, may not be predictive of results in clinical testing. Moreover, pre-clinical results can often be difficult to compare across different studies for a variety of reasons, including differences in experimental protocols and techniques, personnel, equipment and other factors, which may make the pre-clinical results less reliable and predictive of clinical trial results. In addition, published clinical data or case reports from third parties or early clinical trial data of our product candidates may not be predictive of the results of later-stage clinical trials. Interpretation of results from early, usually smaller, studies that suggest a clinically meaningful response in some patients, requires caution. Results from later stages of clinical trials enrolling more patients may fail to show the desired safety and efficacy results or otherwise fail to be consistent with the results of earlier trials of the same product candidate. Later clinical trial results may not replicate earlier clinical trials for a variety of reasons, including differences in trial design, different trial endpoints (or lack of trial endpoints in exploratory studies), patient population, number of patients, patient selection criteria, trial duration, drug dosage and formulation and lack of statistical power in the earlier studies. These uncertainties are enhanced where the diseases or disorders under study lack established clinical endpoints, validated measures of efficacy, as is often the case with disorders for which no drugs have been developed previously and where the product candidates target novel mechanisms.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">39</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, our product candidates may not be approved even if they achieve their primary endpoints in our Phase 3 clinical trials. The FDA, EMA or foreign regulatory authorities may disagree with our trial design and our interpretation of data from pre-clinical studies and clinical trials or require additional data. In addition, any of these regulatory authorities may change its requirements or recommendations for the approval of a product candidate at any time in the future, even after reviewing and providing comments or advice on a protocol for a pivotal clinical trial that, if successful, would potentially form the basis for an application for approval by the FDA, EMA or another foreign regulatory authority. For example, the FDA may refuse to accept our planned NDA for substantive review or may conclude after review of our data that our application is insufficient to obtain regulatory approval. If the FDA does not approve our planned NDA, it may require that we conduct additional clinical, nonclinical or manufacturing studies before it will reconsider our application. Depending on the extent of these or any other studies required by the FDA or another regulatory authority, approval of an NDA or equivalent filing may be significantly delayed or we may be unable to obtain approval of an NDA or equivalent filing because such studies may require us to expend more resources than we have available. Furthermore, applicable regulatory authorities may also approve our product candidates for a narrower indication or population than we request or may grant approval contingent on the performance of costly post-marketing commitments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:2.267%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interim, initial, &#8220;top-line&#8221; and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available, and are subject to audit and verification procedures that could result in material changes in the final data.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, we may publicly disclose preliminary or top-line data from our pre-clinical studies and clinical trials, which are based on preliminary analyses of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular pre-clinical study or clinical trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the top-line or preliminary results that we report may differ from future results of the same studies or trials, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Top-line data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, top-line data should be viewed with caution until the final data are available.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and could have a material adverse effect on the success of our business. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is material or otherwise appropriate information to include in our disclosure. If the interim, topline or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could harm our business, results of operations, prospects or financial condition. Further, disclosure of interim, top-line or preliminary data by us or by our competitors could result in volatility in the price of our common shares.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:2.267%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Clinical trials may fail to demonstrate adequately the safety and efficacy of our, or our collaborators&#8217;, product candidates at any stage of clinical development. Terminating the development of any of our, or our collaborators&#8217;, product candidates could materially harm our business and the market price of our common shares.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our and our collaborators&#8217; clinical product candidates, which include azetukalner and NBI-921355 (being developed by our collaborator Neurocrine Biosciences), along with product candidates we expect to enter clinical development, which include our pre-clinical compounds, are in varying stages of development and will require substantial clinical development, testing and regulatory approval prior to commercialization.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Before obtaining regulatory approvals for the commercial sale of our product candidates, we, or our collaborators, must demonstrate through lengthy, complex and expensive pre-clinical testing and clinical trials that each product candidate is both safe and effective for use in each target indication. Failure can occur at any time during the clinical trial process. Clinical trials often fail to demonstrate safety and efficacy of the product candidate studied for the target indication. Most product candidates that commence clinical trials are never approved as products. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier trials. In addition to the safety and efficacy trials of any product candidate, clinical trial failures may result from a multitude of factors including flaws in trial design, dose selection, statistical analysis plan, placebo effect, patient enrollment criteria, patient compliance and trial execution. Data obtained from trials and studies are susceptible to varying interpretations, and regulators may not interpret our data as favorably as we do, which may delay, limit or prevent regulatory approval. Failure of a clinical trial due to any of these reasons could materially harm our business and the market price of our common shares.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">40</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the case of some of our and our collaborators&#8217; product candidates, we and our collaborators are seeking to develop treatments for certain diseases or disorders for which there is relatively limited clinical experience, and clinical trials may use novel endpoints and measurement methodologies or subjective patient feedback, which adds a layer of complexity to these clinical trials and may delay regulatory approval. Negative or inconclusive results from our, or our collaborators&#8217;, clinical trials could lead to a decision or requirement to conduct additional pre-clinical testing or clinical trials or result in a decision to terminate the continued development of a product candidate. For example, in October 2021, we released topline data from our Phase 2b X-TOLE clinical trial of azetukalner in adult patients with focal epilepsy. In addition, in November 2023, we released topline data from our Phase 2 X-NOVA clinical trial of azetukalner in patients with MDD. There can be no assurance that our ongoing azetukalner Phase 3 clinical trials or any other future Phase 3 clinical trials will demonstrate adequate efficacy and safety results and that we will be able to obtain regulatory approval of azetukalner. Any of the foregoing outcomes would materially and adversely impact our business, product candidate pipeline and future prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If our, or our collaborators&#8217;, product candidates are not shown to be both safe and effective in clinical trials, such product candidates will be unable to obtain regulatory approval or be successfully commercialized. In addition, our, or our collaborators&#8217;, failure to demonstrate positive results in clinical trials in any indication for which we, or our collaborators, are developing clinical product candidates could adversely affect development efforts in other indications. In such case, we would need to develop other compounds and conduct associated pre-clinical testing and clinical trials, as well as potentially seek additional financing, all of which would have a material adverse effect on our business, growth prospects, operating results, financial condition and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:2.267%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We, or our collaborators, may find it difficult to enroll patients in our clinical trials which could delay or prevent the successful completion of clinical trials of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We, or our collaborators, may not be able to identify, recruit and enroll a sufficient number of patients, or those with required or desired characteristics to achieve diversity in a study, to complete clinical trials in a timely manner, or at all. Patient enrollment for clinical trials is affected by factors including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">severity of the disease or disorder under investigation; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">design of the study protocol;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">size of the patient population and geographic dispersion; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">identification of patients; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">eligibility criteria for the study in question; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">perceived risks and benefits of the product candidate under study; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to recruit clinical trial investigators with the appropriate competencies, staff and experience; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">proximity and availability of clinical trial sites for prospective patients; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">availability of competing therapies and clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">efforts to facilitate timely enrollment in clinical trials; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">patient referral practices of physicians. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our and our collaborators' clinical trials will compete with other clinical trials for product candidates that are in the same therapeutic areas as our product candidates, and this competition will reduce the number and types of patients available to us, because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors. Since the number of qualified clinical investigators is limited, we expect to conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of patients who are available for our clinical trials at such clinical trial sites.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our and our collaborators' inability to enroll a sufficient number of patients for our clinical trials would result in significant delays or might require us to abandon one or more clinical trials altogether. Delays in patient enrollment may result in increased costs, affect the timing or outcome of the planned clinical trials, affect product candidate development and approval process and jeopardize our ability to seek and obtain the regulatory approval required to commence product sales and generate revenue, any of which could cause the value of our company to decline and limit our ability to obtain additional financing if needed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">41</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our success also depends on the collective performance, contributions, and expertise of the personnel who manage our clinical trial sites. There is significant competition for qualified personnel, particularly those with higher educational degrees, in the biopharmaceutical and related services industries. Increased personnel turnover and labor shortages facing the biopharmaceutical services industry could have a negative impact on the third parties we rely on to execute our clinical trials. While we seek to choose trial sites with adequate staffing support, we cannot be certain that personnel turnover or the broader labor market dynamics in this industry will not negatively impact our trial sites. If our sites are negatively impacted by these factors, our ability to enroll our clinical trials in a timely fashion may be hindered and might negatively affect our business, development timelines, and financial condition.</span></p>
  <p style="text-indent:2.267%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We, or our collaborators, may incur unexpected costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our, or our collaborators&#8217;, product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To obtain the requisite regulatory approvals to commercialize any of our product candidates, we, or our collaborators, must demonstrate through extensive pre-clinical studies and clinical trials that our, or our collaborators&#8217;, product candidates are safe and effective in humans. We, or our collaborators, may experience delays in completing our, or our collaborators&#8217;, clinical trials or pre-clinical studies, and initiating or completing additional clinical trials or pre-clinical studies, including as a result of regulators not allowing or delay in allowing clinical trials to proceed under an IND, or not approving or delaying approval for any clinical trial application or similar approval we need to initiate a clinical trial. We, or our collaborators, may also experience numerous unforeseen events during our clinical trials that could delay or prevent our, or our collaborators&#8217;, ability to complete development for a product candidate, or receive marketing approval or commercialize the product candidates we, or our collaborators, develop, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delay or failure in obtaining the necessary approvals from regulators or institutional review boards, or IRBs, in order to commence a clinical trial at a prospective trial site, or their suspension or termination of a clinical trial once commenced; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">inability to reach agreement with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites, or the breach of such agreements; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may experience challenges or delays in recruiting principal investigators or study sites to lead our clinical trials;  </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">side effects or adverse events in study participants presenting an unacceptable safety risk; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure of third-party contractors, such as CROs, or investigators to comply with regulatory requirements, including good clinical practices, or GCPs; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">difficulty in having patients complete a trial, adhere to the trial protocol, or return for post-treatment follow-up; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the number of subjects or patients required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may be insufficient or slower than we anticipate, and the number of clinical trials being conducted at any given time may be high and result in fewer available patients for any given clinical trial, or patients may drop out of these clinical trials at a higher rate than we anticipate;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clinical sites deviating from trial protocol or dropping out of a trial;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may have to amend clinical trial protocols submitted to regulatory authorities or conduct additional studies to reflect changes in regulatory requirements or guidance, which it may be required to resubmit to an IRB and regulatory authorities for re-examination; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">challenges or delays with accessing certain species of animals to complete our pre-clinical studies;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">problems with investigational medicinal product storage, stability and distribution; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our inability to manufacture, or obtain from third parties, adequate supply of drug substance or drug product sufficient to complete our pre-clinical studies and clinical trials, including supply chain issues resulting from any events affecting raw material supply or manufacturing capabilities abroad; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a requirement to undertake and complete additional pre-clinical studies to generate data required to initiate clinical development or to support the continued clinical development of a product candidate or submission of an NDA or equivalent; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">unforeseen disruptions, caused by man-made or natural disasters, public health pandemics or epidemics, civil unrest or military conflict, or other business interruptions;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">governmental or regulatory delays; and</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">42</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes to the policies, regulations and guidelines of the FDA, EMA or other foreign regulators regarding development, approval, and marketing of biopharmaceutical products, including but not limited to, in the U.S., as a result of policies implemented by the new presidential administration that may, for example, render our clinical data insufficient for approval or restrict us from marketing our product candidates in the manner in which we anticipate.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These risks and uncertainties could impact any of our, or our collaborators&#8217;, clinical programs and any of the clinical, regulatory or operational events described above could change our, or our collaborators&#8217;, planned clinical and regulatory activities. Challenges in enrolling and retaining patients in our clinical trials, including in our azetukalner Phase 3 clinical trials, whether as a result of pandemics, geopolitical events, or for any other reasons, may further delay the trials or cause them to be discontinued.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The results of any Phase 3 or other pivotal clinical trials may not be adequate to support marketing approval. These clinical trials are lengthy and usually involve many hundreds to thousands of patients. Clinical trials can also be lengthy due to the challenge of identifying patients. Even if patients are successfully identified, they may fail screening criteria, including baseline seizure burden for epilepsy clinical trials, and, as a result, not be enrolled in the trial. Any challenges associated with identifying, screening and/or enrolling patients in our trials may extend the time needed to complete our clinical trials or require additional sites to be initiated in order to achieve target enrollment numbers and to complete our clinical trials, which may increase the cost of our operations and/or delay the timing of our regulatory approval. In addition, if the FDA, EMA or another foreign regulator disagrees with our, or our collaborators&#8217;, choice of the key testing criterion, or primary endpoint, or if the results for the primary endpoint are not robust or significant relative to the control group of patients not receiving the experimental therapy, or our statistical analysis is inconclusive, such regulator may refuse to approve our product candidate in the region in which it has jurisdiction. The FDA, EMA or other foreign regulators also may require additional clinical trials as a condition for approving any of these product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We, or our collaborators, could also encounter delays if a clinical trial is suspended or terminated by us, by our collaborators, by the IRBs of the institutions in which such trial is being conducted, by any Data Safety Monitoring Board for such trial, or by the FDA, EMA or other foreign regulatory authorities. Such authorities may impose such a suspension or termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA, EMA or other foreign regulatory authorities resulting in the imposition of a clinical hold, product candidate manufacturing problems, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. In addition, delays can occur due to safety concerns arising from trials or other clinical data regarding another company&#8217;s product candidate in the same compound class as one of ours.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, changes in applicable regulatory requirements and guidance may occur and we may need to amend clinical trial protocols to reflect these changes or to include additional objectives that could yield important scientific information critical to our overall development strategy. The protocol amendment process often requires review and approval by several review bodies, including regulatory agencies and scientific, regulatory and ethics boards and IRBs which may affect timely completion of a clinical trial. Further, these protocol amendments may not be accepted by the review bodies in the form submitted, or at all, which may impact costs, timing or successful completion of a clinical trial.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we, or our collaborators, experience delays in the completion of, or termination of, any clinical trial of one of our product candidates, the commercial prospects of the product candidate may be harmed, the period during which we may have the exclusive right to commercialize our products under patent protection could be shortened, and our, or our collaborators&#8217;, ability to commence product sales and generate product revenue from the product will be delayed. In addition, any delays in completing our clinical trials will increase our costs and slow down our product candidate development and approval process and may ultimately lead to the termination of a clinical trial and development of a product candidate. Any of these occurrences may harm our business, financial condition and prospects significantly. In addition, many of the factors that cause or lead to a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our, or our collaborators&#8217;, product candidates.</span></p>
  <p style="text-indent:2.267%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following regulatory approval, if obtained.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Undesirable side effects caused by any of our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA, EMA or comparable foreign regulatory authorities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Results of our clinical trials could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics. For example, while adverse events in our X-TOLE and X-NOVA clinical trials were generally mild or moderate in severity, there can be no guarantee that we will observe a similar tolerability profile of azetukalner in our ongoing Phase 3 clinical trials or in other future clinical trials. Many compounds that initially showed promise in clinical or earlier-stage testing are later found to cause undesirable or unexpected side effects that prevented further development of the compound.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">43</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If unacceptable side effects arise in the development of our product candidates, we, the FDA, EMA or comparable foreign regulatory authorities, the IRBs, or independent ethics committees at the institutions in which our trials are conducted, could suspend, limit or terminate our clinical trials, or the independent safety monitoring committee could recommend that we suspend, limit or terminate our trials, or the FDA, EMA or comparable foreign regulatory authorities could order us to cease clinical trials or deny approval of our product candidates for any or all targeted indications. Treatment-emergent side effects that are deemed to be drug-related could delay recruitment of clinical trial subjects or cause subjects that enroll in our clinical trials to discontinue participation in our clinical trials. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff. We may need to train medical personnel using our product candidates to understand the side effect profiles for our clinical trials and upon any commercialization of any of our product candidates. Inadequate training in recognizing or managing the potential side effects of our product candidates could result in harm to patients that are administered our product candidates. Any of these occurrences may adversely affect our business, financial condition and prospects significantly.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, clinical trials of our product candidates are conducted in carefully defined sets of patients who have agreed to enter into clinical trials. Consequently, it is possible that our clinical trials may indicate an apparent positive effect of a product candidate that is greater than the actual positive effect, if any, or alternatively fail to identify undesirable side effects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="text-indent:2.267%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Changes in methods of product candidate manufacturing or formulation may result in additional costs or delay.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As product candidates are developed through pre-clinical to late-stage clinical trials towards approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods and formulations, are altered along the way in an effort to optimize products, processes and results and/or to target different populations. Such changes may also result in inventions that result in additional patent protection. Any of these changes could cause our product candidates to perform differently and not provide the same drug exposure profile in children and/or cause side effects different to those observed with the same formulation in adults or with other formulations. Unexpected changes in the performance of a new formulation may affect the results of planned clinical trials or other future clinical trials conducted with the altered materials. This could delay completion of clinical trials, require the conduct of additional bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs and/or delay or jeopardize approval of our product candidates and/or jeopardize our, or our collaborators&#8217;, ability to commence product sales and generate revenue.</span></p>
  <p style="text-indent:2.267%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The regulatory approval processes of the FDA, EMA and regulators in other foreign jurisdictions are lengthy, time-consuming and inherently unpredictable. If we, or our collaborators, are unable to obtain regulatory approval for our product candidates in a timely manner, or at all, our business may be substantially harmed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The regulatory approval process is expensive, and the time required to obtain approval from the FDA, EMA or other foreign regulatory authorities in other jurisdictions to sell any product is uncertain and may take years. Whether regulatory approval will be granted is unpredictable and depends upon numerous factors, including the substantial discretion of the regulatory authorities. Approval policies, regulations, or the type and amount of pre-clinical and clinical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions. Moreover, pre-clinical and clinical data are often susceptible to varying interpretations and analyses, and even if the pre-clinical studies show promising results and clinical trials are successfully completed, we cannot guarantee that the FDA, EMA or other foreign regulatory authorities in other jurisdictions will interpret the results as we do, and more trials, manufacturing-related studies or non-clinical studies could be required before we submit our product candidates for approval. Many companies that have believed their product candidates performed satisfactorily in pre-clinical studies and clinical trials have nonetheless failed to obtain marketing approval of their products. To the extent that the results of our studies and trials are not satisfactory to the FDA, EMA or other foreign regulatory authorities in other jurisdictions for support of a marketing application, approval of our product candidates may be significantly delayed, or we may be required to expend significant additional resources, which may not be available to us, to conduct additional trials in support of potential approval of our product candidates. It is also possible that none of our existing product candidates or any of our future product candidates will ever obtain regulatory approval, even if we expend substantial time and resources seeking such approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our product candidates could fail to receive regulatory approval for many reasons, including the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the FDA, EMA or other foreign regulatory authorities may disagree with the design or implementation of our, or our collaborators&#8217;, clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we, or our collaborators, may be unable to demonstrate to the satisfaction of the FDA, EMA or foreign other regulatory authorities that a product candidate is safe and effective for its proposed indication; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the results of clinical trials may not meet the level of statistical significance required by the FDA, EMA or other foreign regulatory authorities for approval; </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">44</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we, or our collaborators, may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the FDA, EMA or other foreign regulatory authorities may disagree with our, or our collaborators&#8217;, interpretation of data from pre-clinical studies or clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the data collected from clinical trials of our product candidates may not be sufficient to support the submission of an NDA, or other submission or to obtain regulatory approval in the U.S. or elsewhere; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the FDA, EMA or other foreign regulatory authorities may fail to approve the manufacturing processes, controls or facilities of third-party manufacturers with which we, or our collaborators, contract for clinical and commercial supplies; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the pre-approval inspections of Xenon, manufacturing, clinical sites, pre-clinical or clinical service providers, conducted by regulatory authorities may identify errors or omissions that may result in the product candidate not being approved; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the approval policies or regulations of the FDA, EMA or other foreign regulatory authorities may significantly change in a manner rendering our, or our collaborators&#8217;, clinical data insufficient for approval. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if we, or our collaborators, obtain approval for a particular product, regulatory authorities may grant approval contingent on the performance of costly post-approval commitments including clinical trials, or may approve a product with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the FDA, EMA or other foreign regulatory authorities&#8217; policies with respect to clinical trials may change and additional government regulations may be enacted. For instance, the regulatory landscape related to clinical trials in the EU recently evolved. The EU Clinical Trials Regulation, or CTR, which was adopted in April 2014 and repealed the EU Clinical Trials Directive, became applicable on January 31, 2022. The implementation of the CTR also includes the implementation of the Clinical Trials Information System, or CTIS, a new clinical trial portal and database that will be maintained by the EMA in collaboration with the European Commission and the EU Member States. The objectives of the CTR include consistent rules for conducting trials throughout the EU, consistent data standards and adverse events listing, and consistent information on the authorization status. Information on the conduct and results of each clinical trial carried out in the EU will be made publicly available. The CTR authorizes EU Member States to regulate certain aspects of clinical trials at the national level. To the extent an EU Member State where we plan to conduct any of our clinical trials is slow to adopt CTIS or implements other regulatory changes at the national level, or technical issues are encountered with the CTIS system and/or process, our clinical trial may be delayed in such EU Member State, and our costs may be increased. The main legislation that applies to clinical trials in the United Kingdom, or UK, is the UK Medicines for Human Use (Clinical Trials) Regulations 2004, which transposes the EU Clinical Trials Directive into domestic law. The UK has implemented the Integrated Research Application System, which allows a single application to be reviewed by both the Medicines and Healthcare products Regulatory Agency and a research ethics committee at the same time. Requirements and obligations that relate to the conduct of clinical trials in the UK remain largely aligned with the EU position. A statutory instrument to amend the Medicines for Human Use (Clinical Trials) Regulations 2004 was laid before parliament on December 12, 2024, and will come into force in early 2026 after a 12-month implementation period to address the research sector&#8217;s need for a more efficient, streamlined and adaptable regulatory framework for clinical trials. Complying with changes in regulatory requirements in different jurisdictions can result in additional costs, delay our clinical development plans, or expose us to greater liability if we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies governing clinical trials, our development plans, including our azetukalner Phase 3 clinical trials, may be impacted.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, because there may be approved treatments for some of the diseases or disorders for which we may seek approval, in order to receive regulatory approval, we may need to demonstrate in clinical trials that the product candidates we develop to treat those diseases or disorders are not only safe and effective, but may need to be compared to existing products, which may make it more difficult for our product candidates to receive regulatory approval or adequate reimbursement.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">45</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:2.267%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Even if we obtain and maintain approval for our product candidates from one jurisdiction, we may never obtain approval for our product candidates in other jurisdictions, which would limit our market opportunities and adversely affect our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sales of our approved products, if any, will be subject to the regulatory requirements governing marketing approval in the countries in which we obtain regulatory approval, and we plan to seek, ourselves or with collaborators, regulatory approval to commercialize our product candidates in North America, the EU and in additional foreign countries. Clinical trials conducted in one country may not be accepted by regulatory authorities in other countries and regulatory approval in one country does not ensure approval in any other country, while a failure or delay in obtaining regulatory approval in one country may have a negative effect on the regulatory approval process in others. For example, approval in the U.S. by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one foreign regulatory authority does not ensure approval by the FDA, EMA or regulatory authorities in other countries. Approval procedures vary among jurisdictions and can be lengthy and expensive, and involve requirements and administrative review periods different from, and potentially greater than, those in the U.S., including additional pre-clinical studies or clinical trials. Even if our product candidates are approved, regulatory approval for any product may be withdrawn by the regulatory authorities in a particular jurisdiction. We do not have experience in obtaining regulatory approval in international markets. If we, or our collaborators, fail to comply with regulatory requirements or to obtain and maintain required approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:2.267%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If product liability lawsuits are brought against us, we may incur substantial liabilities in excess of our limited product liability insurance coverage and may be required to limit commercialization of our current and any future products.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We face an inherent risk of product liability as a result of the clinical testing of our product candidates, and we will face an even greater risk if we commercialize any product candidates. For example, we may be sued if any of our product candidates, including any that are developed in combination with other therapies, allegedly causes injury or is found to be otherwise unsuitable during product testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability and a breach of warranties. Claims could also be asserted under state or provincial consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our product candidates. Even successful defense would require significant financial and management resources. There is also risk that third parties we have agreed to indemnify could incur liability. Regardless of the merits or eventual outcome, liability claims may result in:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">decreased demand for our product candidates or any resulting products; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">injury to our reputation; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">withdrawal of clinical trial participants; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">costs to defend the related litigation; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a diversion of management&#8217;s time and our resources; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">substantial monetary awards to trial participants or patients; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">product recalls, withdrawals or labeling, marketing or promotional restrictions; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">loss of revenue; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the inability to commercialize our product candidates; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a decline in the market price of our common shares. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently carry product liability insurance with amounts of coverage that we believe are appropriate relative to our current clinical programs; however, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. If and when we obtain marketing approval for product candidates, we intend to expand our insurance coverage to include the sale of commercial products; however, we may then be unable to obtain product liability insurance on commercially reasonable terms or in adequate amounts. On occasion, large judgments have been awarded in class action lawsuits based on drugs or medical treatments that had unanticipated adverse effects. A successful product liability claim or series of claims brought against us could cause the market price of our common shares to decline and, if judgments exceed our insurance coverage, could adversely affect our future results of operations and business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">46</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Patients with certain of the diseases, or disorders, targeted by our product candidates are often already in severe and advanced stages of disease and have both known and unknown significant pre-existing and potentially life-threatening conditions. During the course of treatment, patients have in the past and may in the future suffer adverse events, including death, for reasons that may be related to our product candidates. Such events could subject us to costly litigation, require us to pay substantial amounts of money to injured patients, delay, negatively impact or end our opportunity to receive or maintain regulatory approval to market those product candidates, or require us to suspend or abandon our commercialization efforts. Even in a circumstance in which we do not believe that an adverse event is related to our products, the investigation into the circumstance may be time-consuming or inconclusive. These investigations may interrupt our sales efforts, delay our regulatory approval process in other countries, or impact and limit the type of regulatory approvals our product candidates receive or maintain. As a result of these factors, a product liability claim, even if successfully defended, could have a material adverse effect on our business, financial condition or results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:2.267%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are unable to establish our own sales, marketing and distribution capabilities or enter into agreements for these purposes, we may not be successful in independently commercializing any future products.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not have a sales or marketing infrastructure and, as a company, have no sales, marketing or distribution experience. Our strategy involves building our own commercial infrastructure to selectively commercialize future products in certain commercial markets which will be expensive and time consuming. For certain products, including azetukalner, and/or specific commercial markets, we evaluate commercial partners from time to time. In some cases, we may seek to retain the right to participate in the future development and commercialization of such products if we believe such involvement would advance our business. We cannot be certain that we will be successful in consummating any such commercial partnerships or, if consummated, whether such partnerships will be successful.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To develop internal sales, distribution and marketing capabilities in the U.S., we will have to invest significant amounts of financial and management resources, some of which will need to be committed prior to any confirmation that any of our product candidates will be approved. We have no prior experience as a company in the marketing, sale and distribution of biopharmaceutical products and there are significant risks involved in building and managing a commercial organization. For any future products for which we decide to perform sales, marketing and distribution functions ourselves, we could face a number of additional risks, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the maintenance of existing or the establishment of new supply arrangements with third-party logistics providers and secondary packagers; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the maintenance of existing or the establishment of new scaled production arrangements with third-party manufacturers to obtain finished products that are appropriately packaged for sale; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a continued acceptable safety profile following any marketing approval; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to recruit and retain adequate numbers of qualified sales and marketing personnel or develop alternative sales channels; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the ability of our products to secure acceptance from physicians, healthcare providers, patients, third-party payers and the medical community including identifying an adequate number of physicians and patients; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">unforeseen costs and expenses associated with creating and maintaining an independent sales and marketing organization; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to compete with other therapies. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Where and when appropriate, we may elect to utilize contract sales forces, distribution partners or collaborators that have sales, marketing and distribution capabilities to assist in the commercialization of or to independently commercialize our product candidates. If we enter into arrangements with third parties to perform sales, marketing and distribution services for a product, the resulting revenue or the profitability from this revenue to us is likely to be lower than if we had sold, marketed and distributed that product ourselves. In addition, we may not be successful in entering into arrangements with third parties to sell, market, and distribute our product candidates or may be unable to do so on terms that are favorable to us. We likely will have little control over such third parties, and any of these third parties may fail to devote the necessary resources and attention to sell, market, and distribute our current or any future products effectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">47</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:2.267%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Even if we receive regulatory approval to commercialize any of our product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and delays.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any of our product candidates for which we, or any existing or future collaborators, obtain regulatory approval, as well as the manufacturing processes, post-approval studies, labeling, advertising and promotional activities for such product, among other things, will be subject to ongoing requirements of and review by the FDA and other regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, registration and listing requirements, requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents, requirements regarding the distribution of samples to physicians and recordkeeping. We and our contract manufacturers will also be subject to user fees and periodic inspection by the FDA and other regulatory authorities to monitor compliance with these requirements and the terms of any product approval we may obtain. In addition, our product candidates may receive schedule classifications under the Controlled Substances Act of 1970 (or scheduling classifications under similar legislation outside of the U.S.) which will result in additional complexity and may result in delays and restrictions with respect to manufacturing, supply chain, licensing, import/export and distribution.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if a product is approved, the FDA or another applicable regulatory authority, as the case may be, may limit the indications for which the product may be marketed, require extensive precautions and warnings on the product labeling or require expensive and time-consuming post-approval commitments including clinical trials or onerous risk management activities, including Risk Evaluation and Mitigation Strategies, or REMS, in the U.S. as conditions of approval to help ensure that the benefits of the drug outweigh the potential risks. REMS can include medication guides, communication plans for healthcare professionals, and elements to assure safe use, or ETASU. ETASU can include, but are not limited to, special training or certification for prescribing or dispensing, dispensing only under certain circumstances, special monitoring, and the use of patient registries. The requirement for a REMS can materially affect the potential market and profitability of the drug.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For any approved product, we, or our collaborators, will need to ensure continued compliance with extensive regulations and requirements regarding the manufacturing processes, labeling, packaging, serialization, distribution, adverse event reporting, storage, advertising, promotion and recordkeeping for the product. These requirements include submissions of safety and other post-approval information and reports, as well as continued compliance with current good manufacturing practices, or cGMP, good distribution practices, or GDP, and current good clinical practices, or cGCP, for any clinical trials that we, or our collaborators, are required to conduct post-approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Post-approval discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or other problems with our product or with third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, amongst other things, restrictions on the labeling or marketing, withdrawals, consent decrees, clinical holds, post-approval requirements or restrictions, recalls, fines, warning letters, injunctions, penalties, exclusions from federal healthcare programs, seizures and/or detentions, among other consequences and adverse actions. Occurrence of any of the foregoing could have a material and adverse effect on our business and results of operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, prescription drugs may be promoted only for the approved indications in accordance with the approved label. The FDA, EMA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label use may be subject to significant liability. However, physicians may, in their independent medical judgment, prescribe legally available products for off-label uses. The FDA does not regulate the behavior of physicians in their choice of treatments but the FDA, EMA and other foreign regulators do restrict manufacturers' communications on the subject of off-label use of their products. The EU and other foreign jurisdictions also prohibit direct-to-consumer advertising for prescription-only medicines.</span></p>
  <p style="text-indent:2.267%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">To the extent we develop and commercialize product candidates that contain or are considered controlled substances, any failure by us or our CROs, CMOs and other contractors to comply with controlled substance laws and regulations, may adversely affect the results of our business operations and our financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may in the future develop product candidates that are considered controlled substances in multiple jurisdictions, such as the U.S., Canada, and the EU, which will expose us to additional controlled substance regulatory requirements in each applicable jurisdiction where we engage in regulated activities, including storage, manufacture, research, clinical trials, import, and export, among other activities. For example, obtaining and maintaining the necessary registrations may result in delay of the importation, manufacturing or distribution of our controlled substance product candidates and may extend our anticipated timelines for clinical trials we run.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Controlled substances or scheduled substances are regulated by the DEA under the CSA. The DEA regulates compounds as Schedule I, II, III, IV or V substances. Pharmaceutical products approved for use in the U.S. may be listed as Schedule II, III, IV or V, with Schedule II substances considered to present the highest potential for abuse or dependence and Schedule V substances the lowest relative risk of abuse among such substances.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">48</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Scheduling determinations by the DEA are dependent on FDA approval of a substance or a specific formulation of a substance. This scheduling determination will be dependent on FDA approval and the FDA&#8217;s recommendation as to the appropriate schedule, which may introduce a delay into the approval and any potential rescheduling process. There can be no assurance that the DEA will make a favorable scheduling decision. Substances that are Schedule II, III, IV or V controlled substances at the federal level may also require scheduling determinations under state laws and regulations, as well as similar foreign controlled substances regulations, if applicable. If approved by the FDA, a number of post-approval activities involving controlled substances will be subject to regulation by the DEA, including DEA regulations relating to registration and inspection of facilities, manufacturing, storage, distribution and physician prescription procedures, among others. Furthermore, failure of our contractors, such as our CROs and CMOs, to maintain compliance with the CSA during development and/or commercialization, as applicable, can result in a material adverse effect on our business, financial condition and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Individual U.S. states and countries outside of the U.S. have also established controlled substance laws and regulations. Those laws and regulations, including state-controlled substances laws that often but not necessarily mirror federal law, may separately schedule our product candidates. Complying with different controlled substances requirements across different jurisdictions can increase the cost of our operations and expose us to additional liabilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="text-indent:2.267%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Even if we obtain marketing approval for our product candidates, the presence of a controlled substance in the product candidate may lead to adverse publicity or public perception regarding our current or future product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If our product candidates that are subject to controlled substances regulation are approved for commercial sale, adverse publicity or public perception of controlled substances in general or other controlled substances could negatively impact market acceptance or consumer perception of our product candidates. We may face limited adoption if clinicians or patients are unwilling to try a novel treatment that contains a controlled substance. Any adverse publicity associated with illness or other adverse effects resulting from patients&#8217; use or misuse of our or similar therapies distributed by other companies could have a material adverse impact on our business, prospects, financial condition and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Future adverse events and research in controlled substances that are present in the product candidates could also result in greater governmental regulation, stricter labeling requirements and potential regulatory delays in the testing or approvals of our product candidates. Any increased scrutiny could delay or increase the costs of obtaining regulatory approval for our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:2.267%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Any product candidates for which we obtain approval may become subject to unfavorable third-party coverage and reimbursement practices, as well as pricing regulations, which may adversely affect demand for such products as well as our ability to obtain an appropriate return from the sale of the products.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our, or our collaborators&#8217;, ability to commercialize any products successfully will depend, in part, on the extent to which coverage and reimbursement for these products and related treatments will be available from government healthcare programs, such as Medicare and Medicaid, and private third-party payers, such as private health insurers, managed care plans, and other organizations. Government authorities and private third-party payers decide which drugs they will pay for and establish reimbursement levels. A primary trend in the U.S. healthcare industry is cost containment. Government authorities and third-party payers have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. We cannot be sure that coverage and reimbursement will be available for any product that we, or our collaborators, commercialize and, if reimbursement is available, the level of reimbursement. In addition, coverage and reimbursement may impact the demand for, or the price of, any product candidate for which we or a collaborator obtains marketing approval. If coverage and reimbursement are not available or are limited, we, or our collaborators, may not be able to successfully commercialize any product candidate for which marketing approval is obtained.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There is significant uncertainty related to third-party payer coverage and reimbursement of newly approved products. Within the U.S., coverage and reimbursement varies from one third party payer to another. One third-party payer&#8217;s determination to provide coverage for a product candidate does not assure that other payers will also provide coverage for the product candidate. As a result, the coverage determination process is often time-consuming and costly. Factors payers consider in determining reimbursement are based on whether the product is: (i) a covered benefit under its health plan; (ii) safe, effective and medically necessary; (iii) appropriate for the specific patient; (iv) cost-effective; and (v) neither experimental nor investigational. We may be required to provide scientific and clinical support for the use of our products to each third-party payer separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As federal and state governments implement additional healthcare cost containment measures, including measures to lower prescription drug pricing, we cannot be sure that our products, if approved, will be covered by private or public payers, and if covered, that the reimbursement will be adequate or competitive with other marketed products. Actions by federal and state governments and health plans may put additional downward pressure on pharmaceutical pricing and healthcare costs, which could negatively impact coverage and reimbursement for our products if approved, our revenue, and our ability to compete with other marketed products and to recoup the costs of our research and development.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">49</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or demanded by private payers and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the U.S. In order to obtain and maintain acceptable reimbursement levels and access for patients at copay levels that are reasonable and customary, we may have to offer discounts or rebates from list prices or to implement other unfavorable pricing modifications. We cannot be sure that reimbursement will be available for any product candidate that we commercialize and, if reimbursement is available, the level of reimbursement.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Outside the U.S., the commercialization of therapeutics is generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost containment initiatives in Europe, Canada and other countries has and will continue to put pressure on the pricing and usage of therapeutics such as our product candidates. In many countries, particularly the countries of the EU, medical product prices are subject to varying price control mechanisms as part of national health systems. In these countries, pricing negotiations with governmental authorities can take considerable time after a product receives marketing approval. To obtain reimbursement or pricing approval in some countries, we, or our collaborators, may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidate to other available therapies. In general, product prices under such systems are substantially lower than in the U.S. Other countries allow companies to fix their own prices for products but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we, or our collaborators, are able to charge for our product candidates. Accordingly, in markets outside the U.S., the reimbursement for our products may be reduced compared with the U.S. and may be insufficient to generate commercially reasonable revenue and profits.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Some of our or our collaborators' target patient populations may be in orphan or niche indications, such as SCN8A-DEE. In order for therapies that are designed to treat smaller patient populations to be commercially viable, the pricing, coverage and reimbursement for such therapies needs to be higher, on a relative basis, to account for the lack of volume. Accordingly, we or our collaborators may need to implement pricing, coverage and reimbursement strategies for any approved product that accounts for the smaller potential market size. If we or our collaborators are unable to establish or sustain coverage and adequate reimbursement for our or our collaborators&#8217; current and any future products from third-party payers or the government, the adoption of those products and sales revenue will be adversely affected, which, in turn, could adversely affect the ability to market or sell those products.</span></p>
  <p style="text-indent:2.267%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Healthcare and other reforms may increase the difficulty and cost for us to commercialize any products that we, or our collaborators, develop and affect the prices we may obtain.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The U.S. and some foreign jurisdictions are considering or have enacted a number of legislative and regulatory proposals to change the healthcare system in ways that could affect our ability to sell any of our products profitably, once such products are approved for sale. Among policy makers and payers in the U.S. and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. In the U.S., the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For example, in 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, collectively, the PPACA, was enacted and includes measures that have significantly changed the way healthcare is financed by both governmental and private insurers. Beyond the ACA, there are ongoing and widespread healthcare reform efforts, a number of which have focused on regulation of prices or payment for drug products. Drug pricing and payment reform was a focus of the first Trump administration and the Biden administration. For example, federal legislation eliminated a statutory cap on Medicaid drug rebate program rebates effective January 1, 2024. As another example, the Inflation Reduction Act (IRA) of 2022 includes a number of changes intended to address rising prescription drug prices in Medicare Parts B and D. These changes, which have varying implementation dates, include caps on Medicare Part D out-of-pocket costs, Medicare Part B and Part D drug price inflation rebates, a new Medicare Part D manufacturer discount drug program (replacing the PPACA Medicare Part D coverage gap discount program) and a drug price negotiation program for certain high-spend Medicare Part B and D drugs. The IRA is likely to have a significant impact on the pharmaceutical industry as implementation proceeds. As another example, in 2022, subsequent to the enactment of the IRA, the Biden administration announced its commitment to expanding certain IRA reforms. Drug pricing and payment reform was a focus of the prior Trump administration and that focus is likely to continue under the new Trump administration. Other potential healthcare reform efforts under the Trump administration may affect access to healthcare coverage or the funding of health care benefits. There is significant uncertainty regarding the nature or impact of any such reform implemented by the Trump administration through executive action or by Congress. Further, a number of states have enacted state drug price transparency and reporting laws that could substantially increase our compliance burdens and expose us to greater liability under such state laws if and when we have marketed products. These and other health reform measures that are implemented may have a material adverse effect on our operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, a number of states have enacted state drug price transparency and reporting laws that could substantially increase our compliance burdens and expose us to greater liability under such state laws if and when we have marketed products. These and other health reform measures that are implemented may have a material adverse effect on our operations.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">50</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Healthcare reform efforts have been and may continue to be subject to scrutiny and legal challenge. For example, with respect to the PPACA, tax reform legislation was enacted that eliminated the tax penalty established for individuals who do not maintain mandated health insurance coverage beginning in 2019 and, in 2021, the U.S. Supreme Court dismissed the latest judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the PPACA. As another example, revisions to regulations under the federal anti-kickback statute would remove protection for traditional Medicare Part D discounts offered by pharmaceutical manufacturers to pharmacy benefit managers and health plans. Pursuant to court order, the removal was delayed and recent legislation imposed a moratorium on implementation of the rule until January 2032. As another example, the IRA drug price negotiation program has been challenged in litigation filed by various pharmaceutical manufacturers and industry groups.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are unable to predict the future course of federal or state healthcare or other reform legislation in the U.S. Any further changes in the law or regulatory framework could reduce our ability to generate revenue in the future or increase our costs, either of which could have a material and adverse effect on our business, financial condition and results of operations. The continuing efforts of the government and other third-party payers to contain or reduce costs of healthcare and/or impose price controls may adversely affect the demand for our product candidates, if approved, and our ability to achieve or maintain profitability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the EU, similar political, economic and regulatory developments may affect our, or our collaborators&#8217;, ability to profitably commercialize our current or any future products. In addition to continuing pressure on prices and cost containment measures, legislative developments at the EU or member state level may result in significant additional requirements or obstacles that may increase our operating costs. The EU is undergoing a revision of its general pharmaceutical legislation to consolidate various legal instruments and achieve key policy objectives such as improving patient access to medicines, enhancing supply chain security, promoting innovation, ensuring environmental sustainability, and addressing antimicrobial resistance. The legislative proposal was considered by the European Parliament in April 2024 for a position to be adopted. The legislative process will take considerable time to complete as the proposal will require agreement by the European Parliament and the European Council. In international markets, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. Our future products, if any, might not be considered medically reasonable and necessary for a specific indication or cost-effective by third-party payers. An adequate level of reimbursement might not be available for such products and third-party payers&#8217; reimbursement policies might adversely affect our, or our collaborators&#8217;, ability to sell any future products profitably.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. We cannot be sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our product candidates, if any, may be. In addition, increased scrutiny by the U.S. Congress of the FDA&#8217;s approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-approval testing and other requirements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, other broader legislative changes have been adopted that could have an adverse effect upon, and could prevent, our products&#8217; commercial success. For example, the Budget Control Act of 2011, as amended, resulted in the imposition of reductions in Medicare (but not Medicaid) payments to providers in 2013 and remains in effect through 2032 unless additional Congressional action is taken. Any significant spending reductions affecting Medicare, Medicaid or other publicly funded or subsidized health programs that may be implemented and/or any significant taxes or fees that may be imposed on us could have an adverse impact on our results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, the U.S. Supreme Court&#8217;s June 2024 decision in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Loper Bright Enterprises v. Raimondo </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">overturned the longstanding </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Chevron </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">doctrine, under which courts were required to give deference to regulatory agencies&#8217; reasonable interpretations of ambiguous federal statutes. The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Loper </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">decision could result in additional legal challenges to regulations and guidance issued by federal agencies, including the FDA, on which we rely. Any such legal challenges, if successful, could have a material impact on our business. Additionally, the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Loper</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> decision may result in increased regulatory uncertainty, inconsistent judicial interpretations, and other impacts to the agency rulemaking process, any of which could adversely impact our business and operations. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, our business could be materially harmed.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the U.S. or in other jurisdictions. If we, or our collaborators, are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we, or our collaborators, are not able to maintain regulatory compliance, our product candidates may lose any marketing approval that may have been obtained and we may not achieve or sustain profitability, which would adversely affect our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">51</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:2.267%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Disruptions at the FDA and other government agencies caused by funding shortages could prevent our product candidates from being developed, approved, or commercialized in a timely manner, or at all, which could negatively impact our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The ability of the FDA and foreign regulatory authorities to review or approve new product candidates can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory, and policy changes, the FDA&#8217;s or foreign regulatory authorities&#8217; ability to hire and retain key personnel and accept the payment of user fees, and other events that may otherwise affect the FDA&#8217;s or foreign regulatory authorities&#8217; ability to perform routine functions. Average review times at the FDA and foreign regulatory authorities have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. For example, over the last several years, the U.S. federal government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities. If a prolonged government shutdown occurs, preventing the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, the Trump Administration has enacted several executive actions that could impose significant burdens on, or otherwise materially delay, the FDA&#8217;s ability to engage in routine regulatory and oversight activities. It is difficult to predict how these executive actions and executive actions that may be taken under the current Trump Administration may affect the FDA&#8217;s ability to exercise its regulatory authority. If these executive actions impose constraints on the FDA&#8217;s ability to engage in oversight and implementation activities in the normal course, our business may be negatively impacted.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Dependence on Third Parties</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:2.267%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our prospects for successful development and commercialization of our partnered products and product candidates are dependent upon the research, development and marketing efforts of our collaborators.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have no control over the resources, time and effort that our collaborators may devote to our programs and limited access to information regarding or resulting from such programs. We are dependent on our collaborators, including Neurocrine Biosciences, to fund and conduct the research and any clinical development of product candidates under our agreements with each of them, and for the successful regulatory approval, marketing and commercialization of one or more of such products or product candidates. Such success will be subject to significant uncertainty.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our ability to recognize revenue from successful collaborations may be impaired by multiple factors including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a collaborator may shift its priorities and resources away from our programs due to a change in business strategies, or a merger, acquisition, sale or downsizing of its company or business unit; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a collaborator may cease development in therapeutic areas which are the subject of our strategic alliances; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a collaborator may change the success criteria for a particular program or product candidate thereby delaying or ceasing development of such program or candidate; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a significant delay in initiation of certain development activities by a collaborator will also delay payment of milestones tied to such activities, thereby impacting our ability to fund our own activities; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a collaborator could develop a product that competes, either directly or indirectly, with our current or future products, if any; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a collaborator with commercialization obligations may not commit sufficient financial or human resources to the marketing, distribution or sale of a product; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a collaborator with manufacturing responsibilities may encounter regulatory, resource or quality issues and be unable to meet demand requirements; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a collaborator may exercise its rights under the agreement to terminate our collaboration; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a dispute may arise between us and a collaborator concerning the research or development of a product candidate, commercialization of a product or payment of royalties or milestone payments, any of which could result in a delay in milestones, royalty payments or termination of a program and possibly resulting in costly litigation or arbitration which may divert management attention and resources; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a collaborator may not adequately protect the intellectual property rights associated with a product or product candidate; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a collaborator may use our proprietary information or intellectual property in such a way as to invite litigation from a third-party; and </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">52</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">disruptions caused by man-made or natural disasters or public health pandemics or epidemics or other business interruptions. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If our collaborators do not perform in the manner we expect or fulfill their responsibilities in a timely manner, or at all, the clinical development, regulatory approval and commercialization efforts could be delayed, terminated or be commercially unsuccessful. Conflicts between us and our collaborators may arise. In the event of termination of one or more of our collaboration agreements, it may become necessary for us to assume the responsibility of any terminated product or product candidates at our own expense or seek new collaborators. In that event, we could be required to limit the size and scope of one or more of our independent programs or increase our expenditures and seek additional funding which may not be available on acceptable terms or at all, and our business could be materially and adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:2.267%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not be successful in establishing new collaborations or maintaining our existing alliances, which could adversely affect our ability to develop product candidates and commercialize products.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the ordinary course, we engage with other biotechnology and pharmaceutical companies to discuss potential in-licensing, out-licensing, alliances and other strategic transactions. The advancement of our product candidates and development programs and the potential commercialization of our current and future product candidates will require substantial additional cash to fund expenses. Additionally, there are certain jurisdictions where a collaborator may be able to realize the market potential of our product candidates better than us. For these or other reasons, we may decide to collaborate with additional pharmaceutical and biotechnology companies with respect to development and potential commercialization.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We face significant competition in seeking appropriate collaborators and the negotiation process is time-consuming and complex. Moreover, we may not be successful in our efforts to establish other collaborations or other alternative arrangements for any current or future product candidates because our research and development pipeline may be insufficient, our current or future product candidates may be deemed to be at too early of a stage of development for collaboration effort and/or third parties may view our product candidates as lacking the requisite potential to demonstrate safety and efficacy. Even if we are successful in our efforts to establish collaborations, the terms that we agree upon may not be favorable to us and we may not be able to maintain such collaborations if, for example, development or approval of a product candidate is delayed or sales of an approved product are disappointing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If any of our existing collaboration agreements are terminated, or if we determine that entering into other product collaborations is in our best interest but we either fail to enter into, delay in entering into or fail to maintain such collaborations:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the development of certain of our current or future product candidates may be terminated or delayed; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our cash expenditures related to development or commercialization of any such product candidates would increase significantly and we may need to seek additional financing sooner than expected; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may be required to hire additional employees or otherwise develop expertise, such as clinical, regulatory, sales and marketing expertise, some of which we do not currently have; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may delay commercialization or reduce the scope of any sales or marketing activities; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we will bear all of the risk related to the development or commercialization of any such product candidates; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the competitiveness of any product that is commercialized could be reduced. </span></div></div>
  <p style="text-indent:2.267%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our reliance on third parties to manufacture our product candidates may increase the risk that we will not have sufficient quantities of our raw materials, APIs or drug products when needed or at an acceptable cost.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> We do not own or operate manufacturing or testing facilities for the production of clinical or commercial quantities of our product candidates, and we lack the resources and the capabilities to do so. As a result, we currently rely on third parties for the manufacture and supply of the active pharmaceutical ingredients, or APIs, in our product candidates and the final drug product formulation for all of our product candidates that are being used in our clinical trials and pre-clinical studies as well as packaging, labelling and distribution of clinical trial supplies. Our current strategy is to outsource all manufacturing of our product candidates to third parties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">53</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we rely on our collaborators, either directly or through CMOs, to manufacture product candidates licensed to them or to work with CMOs to produce sufficient quantities of materials required for the manufacture of our product candidates for pre-clinical testing and clinical trials and intend to do so for the commercial manufacture of our products. If we, or our collaborators, are unable to arrange for such third-party manufacturing sources, or fail to do so on commercially reasonable terms, we, or our collaborators, may not be able to successfully produce sufficient supply of a product candidate or we, or our collaborators, may be delayed in doing so. Such failure or substantial delay could delay our clinical trials and materially harm our business. The manufacture of biopharmaceutical products is complex and requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls. The process of manufacturing our product candidates is susceptible to product loss due to contamination, equipment failure or improper installation or operation of equipment, vendor or operator error, contamination and inconsistency in yields, variability in product characteristics and difficulties in scaling the production process. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects and other supply disruptions. If microbial, viral or other contaminations are discovered in our product candidates or in the third-party manufacturing facilities in which our product candidates are made, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination. Any adverse developments affecting manufacturing operations for our product candidates, if any are approved, may result in shipment delays, inventory shortages, lot failures, product withdrawals or recalls, or other interruptions in the supply of our products. We may also have to take inventory write-offs and incur other charges and expenses for products that fail to meet specifications, undertake costly remediation efforts or seek more costly manufacturing alternatives.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Reliance on third-party manufacturers entails risks to which we would not be subject if we manufactured product candidates ourselves, including reliance on these third parties for regulatory compliance and quality control and assurance, volume production, the possibility of breach of the manufacturing agreement by the third-party because of factors beyond our control (including a failure to synthesize and manufacture our product candidates in accordance with our product specifications), the impact of industry consolidation, including business combinations involving such third parties, and the possibility of termination or nonrenewal of the agreement by the third-party at a time that is costly or damaging to us. Although we believe that there are several potential alternative manufacturers who could manufacture our product candidates, we may incur added costs and delays in identifying and qualifying any such replacement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">   </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we typically order raw materials, APIs and drug product and services on a purchase order basis and do not enter into long-term dedicated capacity or minimum supply arrangements with any commercial manufacturer. There is no assurance that we will be able to timely secure needed supply arrangements on satisfactory terms, or at all. Our failure to secure these arrangements as needed could have a material adverse effect on our ability to complete the development of our product candidates or, to commercialize them, if approved. We may be unable to conclude agreements for commercial supply with third-party manufacturers or may be unable to do so on acceptable terms. There may be difficulties in scaling up to commercial quantities and formulation of our product candidates, and the costs of manufacturing could be prohibitive.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, the FDA, EMA and other foreign regulatory authorities require that our product candidates be manufactured according to cGMP and similar foreign standards. Pharmaceutical manufacturers and their subcontractors are required to register their facilities and/or products manufactured at the time of submission of the marketing application and then annually thereafter with the FDA, EMA and other foreign regulatory agencies. They are also subject to pre-approval inspections and periodic unannounced inspections by the FDA, EMA and other foreign regulatory agencies. Any subsequent discovery of problems with a product, or a manufacturing or laboratory facility used by us or our collaborators, may result in restrictions on the product or on the manufacturing or laboratory facility, including product recall, suspension of manufacturing, importation bans, product seizure or a voluntary withdrawal of the drug from the market. Any failure by our, or our collaborators&#8217;, third-party manufacturers to comply with cGMP or any failure to deliver sufficient quantities of product candidates in a timely manner, could lead to a delay in, or failure to obtain, regulatory approval of any of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to third-party manufacturers, we rely on other third parties to store, test, monitor, label, package and transport bulk drug substance and drug product. If we are unable to arrange for such third-party sources, or fail to do so on commercially reasonable terms, we may not be able to successfully supply sufficient product candidate or we may be delayed in doing so. Such failure or substantial delay could materially harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">54</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:2.267%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If any third-party manufacturer of our product candidates is unable to increase the scale of its production of our product candidates, and/or increase the product yield of its manufacturing, then our costs and time to manufacture the product may increase and commercialization may be delayed.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In order to produce sufficient quantities to meet the demand for clinical trials and, if approved, subsequent commercialization of our product candidates, our third-party manufacturers will be required to increase their production and optimize their manufacturing processes while maintaining the quality of the product. The transition to larger scale production could prove difficult. In addition, if our third-party manufacturers are not able to optimize their manufacturing processes to increase the product yield for our product candidates, or if they are unable to produce increased amounts of our product candidates while maintaining the quality of the product, then we may not be able to meet the requirements for registration and validation and the demands of clinical trials or market demands, which could delay regulatory approvals and decrease our ability to generate profits and have a material adverse impact on our business and results of operation.</span></p>
  <p style="text-indent:2.267%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We rely on third parties to conduct our pre-clinical studies and clinical trials. If these third parties do not successfully carry out their contractual duties, including to comply with applicable laws and regulations or meet expected deadlines, our business could be substantially harmed.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We rely on entities outside of our control, which may include academic institutions, CROs, hospitals, clinics and other third-party collaborators, to monitor, support, conduct and/or oversee pre-clinical and clinical studies of our current and future product candidates. As a result, we have less control over the timing and cost of these studies and the ability to recruit trial subjects than if we conducted these trials with our own personnel. For example, an investigator-sponsored Phase 2 proof-of-concept clinical trial examining azetukalner in MDD and anhedonia is being conducted in partnership with academic collaborators at the Icahn School of Medicine at Mount Sinai.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unable to maintain or enter into agreements with these third parties on acceptable terms, or if any such engagement is terminated prematurely, we may be unable to enroll patients on a timely basis or otherwise conduct our trials in the manner we anticipate. In addition, there is no guarantee that these third parties will devote adequate time and resources to our studies or perform as required by our contract or in accordance with regulatory requirements, including maintenance of clinical trial information regarding our product candidates. If these third parties fail to meet expected deadlines, fail to transfer to us any regulatory information in a timely manner, fail to adhere to protocols or fail to act in accordance with regulatory requirements or our agreements with them, or if they otherwise perform in a substandard manner or in a way that compromises the quality or accuracy of their activities or the data they obtain, then clinical trials of our future product candidates may be extended or delayed with additional costs incurred, or our data may be rejected by the FDA, EMA or other foreign regulatory agencies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ultimately, we are responsible for ensuring that each of our clinical trials is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards, and our reliance on third parties does not relieve us of our regulatory responsibilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We, our CROs and CMOs are required to comply with current good laboratory practices, or cGLP, cGCP and cGMP regulations and guidelines enforced by the FDA, the competent authorities of the member states of the European Economic Area and comparable foreign regulatory authorities for products in clinical development. Regulatory authorities enforce these regulations through periodic inspections of clinical trial sponsors, principal investigators, clinical trial sites, manufacturing facilities, nonclinical testing facilities and other contractors. If we or any of our CROs or CMOs fail to comply with these applicable regulations, the clinical data generated in our non-clinical studies and clinical trials may be deemed unreliable and our submission of marketing applications may be delayed or the FDA, EMA or another foreign regulatory authority may require us to perform additional clinical trials before approving our marketing applications. Upon inspection, the FDA, EMA or another foreign regulatory authority could determine that any of our clinical trials fail or have failed to comply with applicable cGCP regulations. In addition, our clinical trials must be conducted with product produced under the cGMP regulations enforced by the FDA, EMA and other foreign regulatory authorities, and our clinical trials may require a large number of test subjects. Our failure to comply with cGLP, cGCP and cGMP regulations may require us to repeat clinical trials or manufacture additional batches of drug, which would delay the regulatory approval process and increase our costs. Moreover, our business may be implicated if any of our CROs or CMOs violates federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws, or if this is asserted or reported to have occurred.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If any of our clinical trial sites terminates for any reason, we may experience the loss of follow-up information on patients enrolled in our ongoing clinical trials unless we are able to transfer the care of those patients to another qualified clinical trial site. Further, if our relationship with any of our CROs or CMOs is terminated, we may be unable to enter into arrangements with alternative CROs or CMOs on commercially reasonable terms, or at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our use of foreign CROs and CMOs in some jurisdictions, such as China, may be or may become subject to U.S. legislation, sanctions, trade restrictions and other regulatory requirements which may increase the cost of, and cause delays for, our pre-clinical product candidates.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">55</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Switching or adding CROs, CMOs or other suppliers can involve substantial cost and require extensive management time and focus. In addition, there is a natural transition period when a new CRO, CMO or supplier commences work. As a result, delays may occur, which can materially impact our ability to meet our desired clinical development timelines. If we are required to seek alternative supply arrangements, the resulting delays and potential inability to find a suitable replacement could materially and adversely impact our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Intellectual Property</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:2.267%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We could be unsuccessful in obtaining or maintaining adequate patent protection for one or more of our product candidates or future products.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our commercial success will depend, in part, on our ability to obtain and maintain patent, trademark and trade secret protection of our product candidates and future products, their respective components, formulations, methods used to manufacture them and methods of treatment, as well as successfully defending against third-party challenges. We evaluate our global patent portfolio in the ordinary course of business to enhance patent protection in areas of our strategic focus and in key markets for our product candidates and future products and may abandon existing patents or patent applications related to terminated development programs, areas, or markets of low strategic importance. Patents might not issue with respect to our patent applications that are currently pending, and issued patents might later be found to be invalid or unenforceable, be interpreted in a manner that does not adequately protect our product candidates or any future products, or fail to otherwise provide us with any competitive advantage. The patent position of biotechnology and pharmaceutical companies is generally highly uncertain because it involves complex legal and factual considerations that may be impacted by changes in the law. In addition, the standards applied by the U.S. Patent and Trademark Office, or USPTO, and foreign patent offices in issuing patents are not always applied uniformly or predictably, and also may be subject to changing law. Consequently, patents may not issue from our pending patent applications, or we may end up with patent claims of different scope in different jurisdictions. As such, we do not know the degree of future protection that we will have on our future products and proprietary technology, if any, and a failure to obtain adequate intellectual property protection with respect to our product candidates and future products, as well as other proprietary technology could have a material adverse impact on our business and ability to achieve profitability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or patent applications will be due to be paid to the USPTO and various governmental patent offices outside of the U.S. in several stages over the lifetime of the patents and/or applications. The USPTO and foreign governmental patent offices require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application and maintenance process. We employ reputable law firms and other professionals to help us comply with respect to the patents and patent applications that we own or co-own, and we rely upon collaborators to effect compliance with respect to the patents and patent applications that we out-license.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">56</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:2.267%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our intellectual property rights will not necessarily provide us with competitive advantages.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business, or may not permit us to maintain our competitive advantage. The following examples are by way of illustration only:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">others may be able to make compounds that are similar to our product candidates or future products but that are not covered by the claims of the patents that we own, co-own or may in-license;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">others may independently develop similar or alternative technologies without infringing our intellectual property rights; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">patents that we own, co-own or may in-license may not provide us with any competitive advantages, or may be held invalid or unenforceable as a result of legal challenges by our competitors; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may obtain patents for certain compounds many years before we obtain marketing approval for products containing such compounds, and because patents have a limited life, the term(s) may begin to run out prior to the commercial sale of the related product, thereby limiting the commercial value of our patents; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we might not have been the first to make or file upon the inventions covered by the patents or pending patent applications;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">it is possible that our pending patent applications will not issue as patents;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we cannot predict the scope of protection of any patent issuing from our patent applications, including whether the patent applications that we own will result in patents with claims directed to our product candidates or future products or uses thereof in the United States or in foreign countries;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may fail to develop additional proprietary technologies that are patentable and/or may fail to adequately protect such technologies;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the laws of certain foreign countries may not protect our intellectual property rights to the same extent as the laws of the U.S., or we may fail to apply for or obtain adequate intellectual property protection in all the jurisdictions in which we operate; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the patents of others may have an adverse effect on our business, for example by preventing us from commercializing our future products.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any of the aforementioned threats to our competitive advantage could have a material adverse effect on our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:2.267%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not be able to protect our intellectual property rights throughout the world.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Filing, prosecuting, enforcing and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the U.S. can be less extensive than those in the U.S. In addition, the laws of some foreign countries may not protect intellectual property rights to the same extent as the laws in the U.S. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the U.S., or from offering to sell, selling, using, making or importing products made using our inventions in and into the U.S. or other jurisdictions. Competitors may use our inventions in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the U.S. These products may compete with our future products, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many companies have encountered significant problems in protecting, enforcing and defending intellectual property rights in certain foreign countries. The legal systems of some countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property rights, particularly those relating to biotechnology and pharmaceutical products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">57</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Proceedings to enforce our patent rights in foreign countries could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing as patents and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from our intellectual property</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:2.267%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may be involved in lawsuits to enforce our patents or the patents of our licensors, which could be expensive, time consuming and unsuccessful, and those patents could be found invalid or unenforceable if challenged</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any of our intellectual property rights could be challenged or invalidated despite measures we or our licensors take to obtain patent and other intellectual property protection with respect to our product candidates and proprietary technology.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Competitors may infringe our patents or the patents of our licensors. To stop infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that a patent in suit is not valid or is not enforceable. In such cases, third parties may be able to use our technology without paying licensing fees or royalties. Even if the validity of our patents is upheld, a court may refuse to stop the other party from using the technology at issue on the ground that the other party&#8217;s activities are not covered by our patents or that the legal requirements for imposing injunctive relief are not met. In addition, third parties may affirmatively challenge our rights to, or the scope or validity of, our patents. An adverse result in any litigation or post-grant proceeding could put additional patents at risk of being invalidated, held unenforceable or interpreted narrowly, and could put any of our patent applications at risk of not yielding an issued patent. Any efforts to enforce our intellectual property rights are likely to be costly and may divert the efforts of our scientific and management personnel.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For example, if we were to initiate legal proceedings against a third-party to enforce a patent covering one of our product candidates or future products, the defendant could defend or counterclaim that our patent is invalid and/or unenforceable. In patent litigation in the U.S. and in some foreign countries, defendant defenses and counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, for example, lack of novelty, obviousness, patent ineligibility, loss of priority claims, lack of written description, or lack of enablement. Grounds for an assertion of unenforceability could be an allegation that someone connected with prosecution of the patent withheld material information from the USPTO or an applicable foreign counterpart where such a duty to disclose exists, or made a misleading statement, during prosecution. For example, administrative proceedings such as derivation proceedings, entitlement proceedings, ex parte reexamination, inter partes review, post-grant review, or opposition proceedings, provoked by third parties or initiated by the USPTO or any foreign patent authority may be used to challenge inventorship, ownership, claim scope, or validity of our patents or a patent of our licensor. An unfavorable outcome in any of these proceedings could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms, if any license is offered at all. Litigation or administrative proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. Certain foreign countries may provide for compulsory licensing of our patent rights that would preclude us from enforcing our patents against a third party.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With respect to challenges to the validity of our patents or the patents of our licensors, for example, there might be prior art of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on a product candidate or future product. As another example, a litigant or the USPTO itself could challenge our patents on this basis even if we believe that we have conducted our patent prosecution in accordance with the duty of candor and in good faith. The outcome following such challenges is unpredictable. Even if a challenger does not prevail, our patent claims may be construed in a manner that would limit our ability to enforce such claims against the challenger and others. The cost of defending such a challenge, particularly in a foreign country, and any resulting loss of patent protection could have a material adverse impact on one or more of our product candidates and our business.</span></p>
  <p style="text-indent:2.267%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Patent protection and patent prosecution for some of our product candidates and future products is dependent on, and the ability to assert patents and defend them against claims of invalidity is maintained by, third parties.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There have been and may be times in the future when certain patents that relate to our product candidates or any future products are controlled by our collaborators, including licensees, sublicensees or licensors. Although we may, under such arrangements, have rights to consult with our collaborators on actions taken as well as back-up rights of prosecution and enforcement, we have in the past and may in the future relinquish rights to prosecute and maintain patents and patent applications within our portfolio as well as the ability to assert such patents against infringers. For example, currently the rights relating to the patent portfolio for certain selective Nav1.6 inhibitors and dual Nav1.2/1.6 inhibitors are exclusively licensed to Neurocrine Biosciences, and Neurocrine Biosciences has the first right to bring and control any action in connection with product infringement.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">58</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If any current or future collaborator with rights to file, prosecute, enforce and/or defend patents related to our product candidates or future products fails to appropriately prosecute and maintain patent protection for patents covering any of our product candidates, or if patents covering any of our product candidates or future products are asserted against infringers or defended against claims of invalidity or unenforceability in a manner which adversely affects such coverage, our ability to develop and commercialize any such product candidates or future products may be adversely affected and we may not be able to prevent competitors from making, using, importing, offering for sale, and/or selling competing products.</span></p>
  <p style="text-indent:2.267%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Claims that our product candidates or the sale, offer for sale, importation, manufacture, or use of our future products infringe the patent or other intellectual property rights of third parties could result in costly litigation, could require substantial time and money to resolve, even if litigation is avoided, and could prevent or delay us from developing or commercializing our product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our commercial success depends, in part, upon our ability to develop product candidates and commercialize our future products, without infringing the intellectual property rights or other proprietary rights of others. Third parties might allege that we, or our collaborators, are infringing, misappropriating, or otherwise violating their intellectual property rights. Such third parties might resort to litigation against us or other parties we have agreed to indemnify, which litigation could be based on either existing intellectual property or intellectual property that arises in the future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It is possible that relevant patents or patent applications held by third parties will cover our product candidates at the time of launch and we may also fail to identify relevant patents or patent applications held by third parties that might be asserted to cover our product candidates. For example, U.S. applications filed before November 29, 2000, and certain applications filed after that date that were not filed outside the U.S. remain confidential until patents issue. Other patent applications in the U.S. and several other jurisdictions are published approximately 18 months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. Furthermore, publication of discoveries in the scientific or patent literature often lags behind actual discoveries. Therefore, we cannot be certain that we, or our collaborators, were the first to invent, or the first to file patent applications on our product candidates or for their uses, or that our product candidates will not infringe patents that are currently issued or that will be issued in the future. Additionally, pending patent applications and patents which have been published can, subject to certain limitations, be later amended in a manner that could cover our current or future products, if any, or their use.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The coverage of patents is subject to interpretation by the courts, and the interpretation is not always uniform. If we were sued for patent infringement, we would need to demonstrate that our product candidates, our future products, or methods of use either do not infringe the patent claims of the relevant patent or that the patent claims are invalid or unenforceable, and we may not be able to do this. Proving invalidity may be difficult. Even if we are successful in these proceedings, we may incur substantial costs and the time and attention of our management and scientific personnel could be diverted in pursuing these proceedings, which could have a material adverse effect on our business and operations. Furthermore, we may not have sufficient resources to bring these actions to a successful conclusion.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may choose to challenge the enforceability or validity of claims of a third party&#8217;s patent by requesting an administrative proceeding, for example, derivation proceedings, entitlement proceedings, ex parte reexamination, inter partes review, post-grant review, or opposition proceedings, before the USPTO or similar proceedings before any foreign patent authority. These administrative proceedings are expensive and may consume our time or other resources. The costs of these administrative proceedings could be substantial and may consume our time or other resources. If we fail to obtain a favorable result in the USPTO or any foreign patent office, we may be exposed to litigation by a third party alleging that the patent may be infringed by our product candidates or future products.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Defending against claims of patent infringement or other violations of intellectual property rights could be costly and time consuming, regardless of the outcome. Thus, even if we were to ultimately prevail, or to settle at an early stage, such litigation or threatened litigation could burden us with substantial unanticipated costs. In addition, litigation or threatened litigation could result in significant demands on the time and attention of our management team, distracting them from the pursuit of other company business. Claims that the selling, using, making, offering to sell, or importing, of our product candidates or future products infringe, misappropriate or otherwise violate third-party intellectual property rights could therefore have a material adverse impact on our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Third parties may be able to sustain the costs of complex intellectual property litigation or proceedings more effectively than we can. In addition, the uncertainties associated with litigation could have a material adverse effect on our ability to raise the funds necessary to conduct our clinical trials, continue our internal research programs, in-license needed technology, or enter into strategic collaborations that would help us bring our product candidates to market.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">59</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:2.267%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Unfavorable outcomes in intellectual property litigation could limit our research and development activities and/or our ability to commercialize certain products.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any future intellectual property litigation other administrative proceedings will result in additional expense and distraction of our personnel. There is inevitable uncertainty in intellectual property litigation, and we could lose, even if the case against us is weak or flawed. An unfavorable outcome in such litigation or proceedings may expose us or any future strategic collaborators to loss of our proprietary position, expose us to significant liabilities, or require us to seek licenses that may not be available on commercially acceptable terms, if at all, each of which could have a material adverse effect on our business. If we are found to infringe a third-party&#8217;s intellectual property rights, we could be forced, including by court order, to cease developing, manufacturing or commercializing the infringing product candidate or future product. Alternatively, we may be required to obtain a license from such third-party in order to use the infringing technology and continue developing, manufacturing or marketing the infringing product candidate or future product.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For example, if third parties successfully assert their intellectual property rights against us, we might be barred from using certain aspects of our technology or barred from developing and commercializing certain future products. Alternatively, we may be required to pay substantial damage awards to the plaintiff, including up to treble damages and attorneys&#8217; fees if we are found to have willfully infringed a patent. As another alternative, we may be required to obtain a license from the intellectual property owner to continue our research and development programs or to market any resulting product. It is also possible that we may be required to modify or redesign our product candidates or future products, if any, in order to avoid infringing or otherwise violating third-party intellectual property rights. This may not be technically or commercially feasible, may render those products less competitive, or may delay or prevent the entry of those products to the market. Any of the foregoing could limit our research and development activities, our ability to commercialize one or more product candidates, or both.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we choose or are required to seek a license from a third-party, we may be required to pay license fees or royalties or both, which could be substantial. These licenses may not be available on acceptable terms, or at all. Even if we or any future collaborators were able to obtain a license, the rights may be nonexclusive, which could result in our competitors gaining access to the same intellectual property. Ultimately, we could be prevented from commercializing a product, or be forced, by court order or otherwise, to cease some or all aspects of our business operations as a result of actual or threatened litigation. Further, we could be found liable for significant monetary damages as a result of claims of intellectual property infringement. In the future, we may receive offers to license and demands to license from third parties claiming that we are infringing their intellectual property or owe license fees and, even if such claims are without merit, we could fail to successfully avoid or settle such claims.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If Neurocrine Biosciences or other collaborators license or otherwise acquire rights to intellectual property controlled by a third party in various circumstances, for example, where a product could not be developed or commercialized in a country without the third-party intellectual property rights or, where it is decided that it would be useful to acquire such third-party rights to develop or commercialize the product, they are eligible under our collaboration agreements to decrease payments payable to us on a product-by-product basis and, in certain cases, on a country-by-country basis. Any of the foregoing events could harm our business significantly.</span></p>
  <p style="text-indent:2.267%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we breach any agreement under which we license the use, development and commercialization rights to our product candidates or technology from third parties, we could lose license rights that are important to our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under existing or future license and other agreements, we are or may become subject to various obligations, including diligence obligations such as development and commercialization obligations, as well as potential milestone payments and other obligations. If we fail to comply with any of these obligations or otherwise breach our license agreements, our licensing partners may have the right to terminate the applicable license in whole or in part or convert an exclusive license to a non-exclusive license. Generally, the loss of any such license, or any license exclusivity thereunder, could materially harm our business, prospects, financial condition and results of operations.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">60</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:2.267%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are unable to prevent unauthorized disclosure of trade secrets and other proprietary information, our competitive position could be harmed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to patents, we rely on trade secrets, technical know-how and proprietary information concerning our discovery platform, business strategy and product candidates, which can be difficult to protect, in order to maintain our competitive position. In the course of our research and development activities and our business activities, we often rely on confidentiality agreements to protect our proprietary information. Such confidentiality agreements are used, for example, when we talk to vendors of laboratory, manufacturing, pre-clinical development or clinical development goods or services or potential strategic collaborators. In addition, each of our employees and consultants is required to sign a confidentiality agreement and invention assignment agreement upon joining our company. Our employees, consultants, contractors, business partners or outside scientific collaborators might intentionally or inadvertently disclose our trade secret information in breach of these confidentiality agreements or our trade secrets may otherwise be misappropriated. Our collaborators might also have rights to publish data and we might fail to apply for patent protection prior to such publication. It is possible that a competitor will make use of such information, and that our competitive position will be compromised. In addition, to the extent that our employees, consultants or contractors use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions. Enforcing a claim that a third-party illegally obtained and is using any of our trade secrets is expensive and time consuming, and the outcome is unpredictable. In addition, courts outside the U.S. sometimes are less willing than U.S. courts to protect trade secrets. Moreover, our competitors may independently develop equivalent knowledge, methods and know-how. If we cannot maintain the confidentiality of our proprietary technology and other confidential information, then our ability to protect our trade secret information would be jeopardized, which would adversely affect our competitive position.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we, or our licensors, may be subject to claims that former employees, collaborators or other third parties have an interest in our owned or in-licensed patents, trade secrets, or other intellectual property as an inventor or co-inventor. For example, we, or our licensors, may have inventorship disputes arise from conflicting obligations of employees, consultants or others who are involved in developing our product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship or our, or our licensors&#8217;, ownership of our owned or in-licensed patents, trade secrets or other intellectual property. If we, or our licensors, fail in defending against any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property that is important to our product candidates. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></p>
  <p style="text-indent:2.267%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Changes in U.S. patent law, or laws in other countries, could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our patents, thereby impairing our ability to protect our product candidates and future products.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our success is heavily dependent on intellectual property, particularly patents. The patent positions of pharmaceutical and biopharmaceutical companies can be highly uncertain and involve complex legal and factual questions for which important legal principles remain unresolved. No consistent policy regarding the breadth of claims allowed in patents in these fields has emerged to date in the U.S. or other countries. In addition, Congress or other foreign legislative bodies may pass patent reform legislation that is unfavorable to us. For example, there have been recent changes regarding how patent laws are interpreted, and both the USPTO and Congress have recently made significant changes to the patent system. There have been U.S. Supreme Court decisions that now show a trend of the Supreme Court which is distinctly negative on some patents. The trend of these decisions along with resulting changes in patentability requirements being implemented by the USPTO could make it increasingly difficult for us to obtain, maintain and/or enforce patents on our products. We cannot accurately predict future changes in the interpretation of patent laws or changes to patent laws which might be enacted into law. Those changes may materially affect our patents, our ability to obtain patents, the costs to prosecute our patent applications and enforce our patents and/or the patents and applications of our collaborators. The patent situation in these fields outside the U.S. also has uncertainties. Changes in either the patent laws or in interpretations of patent laws in the U.S. and other countries may diminish the value of our intellectual property or narrow the scope of our patent protection. Accordingly, we cannot predict the breadth of claims that may be allowed or enforced in the patents we own or to which we have a license or third-party patents. As an example, European patent applications have the option, upon issuance of a patent, of becoming a Unitary Patent, which is subject to the jurisdiction of the Unitary Patent Court, or UPC. The option of a Unitary Patent and the creation of the UPC are significant changes in European patent practice. As the UPC is a new court system, there is little precedent for the court, increasing the uncertainty of any litigation in the UPC.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">61</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:2.267%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Intellectual property litigation and administrative proceedings may lead to unfavorable publicity that harms our reputation and causes the market price of our common shares to decline.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the course of any intellectual property litigation or administrative proceeding, there could be public announcements of the initiation of the litigation or proceeding as well as results of hearings, rulings on motions, and other interim rulings in the litigation or proceeding. If securities analysts or investors regard these announcements as negative, the perceived value of our existing products, programs or intellectual property could be diminished. Accordingly, the market price of our common shares may decline. Such announcements could also harm our reputation or the market for our future products, which could have a material adverse effect on our business.</span></p>
  <p style="text-indent:2.267%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we do not obtain protection under the Hatch-Waxman Act in the U.S. and similar foreign legislation by extending the patent terms for patents covering our product candidates, our business may be materially harmed.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depending upon the timing, duration and specifics of FDA marketing approval of our product candidates, if any, one or more U.S. patents may be eligible for limited patent term extension under the Hatch-Waxman Act. However, we may not be granted an extension if, for example, we fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than five years.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unable to obtain patent term extension or the duration of any such extension is less than we request, the period during which we will have the right to exclusively market our product may be shortened and our competitors may obtain approval of competing products following our patent expiration, and our revenue could be reduced, possibly materially.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If any of our products are approved by the FDA, listing patents in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) is mandatory, and the decision to list or not list a given patent in the Orange Book could give rise to allegations of antitrust liability, from the Federal Trade Commission or private parties. In addition, we may be required by court order to delist patents from the Orange Book that are found to be improperly listed, which could impact our ability to take advantage of the benefits of the Hatch-Waxman Act, including the 30-month stay of generic approval.</span></p>
  <p style="text-indent:2.267%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If our trademarks are not adequately protected, we may not be able to build name recognition in our markets of interest, which could adversely affect our business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our current and future trademarks, including our corporate name, Xenon, has not been trademarked in each market where we operate and plan to operate. Our trademark applications for our corporate name or the name of our products may not be allowed for registration, and our registered trademarks may not be maintained or enforced. During trademark registration proceedings, we may receive rejections, which we may be unable to overcome in our responses. Third parties may also attempt to register trademarks utilizing the Xenon name on their products, and we may not be successful in preventing such usage. In addition, in the USPTO and in comparable patent offices in many foreign countries, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Our trademarks may not survive such proceedings. If we do not secure registrations for our trademarks, we may encounter more difficulty in enforcing them against third parties than we otherwise would.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, any name we have proposed to use with our product candidates in the United States, regardless of whether we have registered it or applied to register it as a trademark, must be approved by the FDA. Similar requirements exist in Europe and other foreign countries. If the FDA (or an equivalent administrative body in a foreign country) objects to any of our proposed product names, we may need to identify a suitable substitute name, for example, that would qualify under applicable trademark laws, not infringe the existing rights of third parties, and be acceptable to the FDA. This may require additional expense.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, there could be potential trademark infringement claims brought by owners of other registered trademarks that incorporate variations of or allegedly cause confusion with our registered or unregistered trademarks. If we assert trademark infringement claims, a court may determine that the marks we have asserted are invalid or unenforceable, or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of such trademarks. If we are unable to establish name recognition based on our trademarks, we may not be able to compete effectively, and our business may be adversely affected.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">62</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Ownership of Our Common Shares</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:2.267%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The market price of our common shares may be volatile, and purchasers of our common shares could incur substantial losses.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our common shares are listed on Nasdaq under the trading symbol &#8220;XENE.&#8221; The market price of our common shares has fluctuated in the past and is likely to be volatile in the future. As a result of this volatility, investors may experience losses on their investment in our common shares. The market price for our common shares may be influenced by many factors, including the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">announcements by us or our competitors of new products, product candidates or new uses for existing products, significant contracts, commercial relationships or capital commitments and the timing of these introductions or announcements; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">actions by any of our collaborators regarding our product candidates they are developing, including announcements regarding clinical or regulatory decisions or developments of our collaboration; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">unanticipated serious safety concerns related to the use of any of our products and product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">negative or inconclusive results from clinical trials of our product candidates, leading to a decision or requirement to conduct additional pre-clinical testing or clinical trials or resulting in a decision to terminate the continued development of a product candidate; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays of clinical trials of our product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure to obtain or delays in obtaining or maintaining product approvals or clearances from regulatory authorities; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adverse regulatory or reimbursement announcements; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">announcements by us or our competitors of significant acquisitions, strategic collaborations, licenses, joint ventures or capital commitments; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the results of our efforts to discover or develop additional product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our dependence on third parties, including our collaborators, CROs, clinical trial sponsors and clinical investigators; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory or legal developments in Canada, the U.S. or other countries; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">developments or disputes concerning patent applications, issued patents or other proprietary rights; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the recruitment or departure of key personnel; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the level of expenses related to any of our product candidates or clinical development programs; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">actual or anticipated quarterly variations in our financial results or those of our competitors; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sales of common shares by us, our insiders or our shareholders in the future, as well as the overall trading volume of our common shares; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in the structure of healthcare payment systems; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">commencement of, or our involvement in, litigation; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the impact of pandemics, epidemics or other public health crises on our business and the macroeconomic environment; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">general economic, industry and market conditions; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">market conditions in the pharmaceutical and biotechnology sectors and other factors that may be unrelated to our operating performance or the operating performance of our competitors, including changes in market valuations of similar companies; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the other factors described in this &#8220;Risk Factors&#8221; section. </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">63</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the stock market in general, and Nasdaq and the biopharmaceutical industry in particular, have from time to time experienced volatility that often has been unrelated to the operating performance of the underlying companies. Fluctuating inflation and interest rates, for example, can result in significant volatility. These broad market and industry fluctuations may adversely affect the market price of our common shares, regardless of our operating performance. In several recent situations where the market price of a stock has been volatile, holders of that stock have instituted securities class action litigation against the company that issued the stock. If any of our shareholders were to bring a lawsuit against us, the defense and disposition of the lawsuit could be costly and divert the time and attention of our management and harm our operating results.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:2.267%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Future sales and issuances of our common shares or securities convertible into or exchangeable for common shares would cause our shareholders to incur dilution and could cause the market price of our common shares to fall.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The market price of our common shares could decline as a result of sales of a large number of our common shares or the perception that these sales could occur. These sales, or the possibility that these sales may occur, also might make it more difficult for us to sell equity securities in the future at a time and at a price that we deem appropriate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to our equity incentive plans, our compensation committee (or a subset or delegate thereof) is authorized to grant equity-based incentive awards to our employees, directors and consultants. Future stock option grants and issuances of common shares under our share-based compensation plans will result in dilution to all shareholders and may have an adverse effect on the market price of our common shares.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, in the future, we may issue additional common shares, preferred shares, or other equity or debt securities convertible into common shares in connection with a financing, collaboration agreement, acquisition, litigation settlement, employee arrangements or otherwise. We may also issue additional common shares upon the exercise of pre-funded warrants that we have issued from time to time. Any such issuance, including any issuances pursuant to our &#8220;at-the-market&#8221; equity offering program under our sales agreement with Jefferies and Stifel, could result in substantial dilution to our existing shareholders and could cause the market price of our common shares to decline.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:2.267%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are governed by the corporate and securities laws of Canada which in some cases have a different effect on shareholders than the corporate laws of Delaware and U.S. securities laws.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are governed by the Canada Business Corporations Act, or CBCA, and other relevant laws, which may affect the rights of shareholders differently than those of a company governed by the laws of a U.S. jurisdiction, and may, together with our articles and by-laws, have the effect of delaying, deferring or discouraging another party from acquiring control of our company by means of a tender offer, a proxy contest or otherwise, or may affect the price an acquiring party would be willing to offer in such an instance. The material differences between the CBCA and Delaware General Corporation Law, or DGCL, that may have the greatest such effect include, but are not limited to, the following: (i) for material corporate transactions (such as mergers and amalgamations, other extraordinary corporate transactions or amendments to our articles) the CBCA generally requires a two-thirds majority vote by shareholders, whereas DGCL generally only requires a majority vote; and (ii) under the CBCA, holders of 5% or more of our shares that carry the right to vote at a meeting of shareholders can requisition a special meeting of shareholders, whereas such right does not exist under the DGCL. In addition, our board of directors is responsible for appointing the members of our management team and certain provisions of the CBCA and our articles and by-laws may frustrate or prevent any attempts by our shareholders to replace or remove our current management by making it more difficult for shareholders to replace members of our board of directors. Certain of these provisions include the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">shareholders cannot amend our articles unless such amendment is approved by shareholders holding at least two-thirds of the shares entitled to vote on such approval; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">shareholders must give advance notice to nominate directors or to submit proposals for consideration at shareholders&#8217; meetings; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">applicable Canadian corporate and securities laws generally require, subject to certain exceptions, a tender offer (also known as a take-over bid) to remain open for a minimum of 105 days and that more than 50% of the outstanding securities not owned by the offeror be tendered before the offeror may take up the securities. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any provision in our articles, by-laws, under the CBCA or under any applicable Canadian securities law that has the effect of delaying or deterring a change in control could limit the opportunity for our shareholders to receive a premium for their common shares, and could also affect the price that some investors are willing to pay for our common shares, thereby depressing the market price of our common shares.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">64</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:2.267%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">U.S. civil liabilities may not be enforceable against us, our directors, or our officers.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are governed by the CBCA and our principal place of business is in British Columbia, Canada. Many of our directors and officers reside outside of the U.S., and all or a substantial portion of their assets as well as all or a substantial portion of our assets are located outside the U.S. As a result, it may be difficult for investors to effect service of process within the U.S. upon us and certain of our directors and officers or to enforce judgments obtained against us or such persons, in U.S. courts, in any action, including actions predicated upon the civil liability provisions of U.S. federal securities laws or any other laws of the U.S. Additionally, rights predicated solely upon civil liability provisions of U.S. federal securities laws or any other laws of the U.S. may not be enforceable in original actions, or actions to enforce judgments obtained in U.S. courts, brought in Canadian courts, including courts in the Province of British Columbia.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:2.267%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are at risk of securities class action litigation.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us because biotechnology companies have experienced significant share price volatility in recent years. If we face such litigation, it could result in substantial costs and a diversion of management&#8217;s attention and resources, which could harm our business. In addition, an increase in litigation against biotechnology companies may make it more difficult and more expensive for us to obtain director and officer liability insurance, and we may be required to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:2.267%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our management has broad discretion over the use of our cash and we may not use our cash effectively, which could adversely affect our results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management has broad discretion in the application of our cash resources. Shareholders may not agree with our decisions, and our use of our cash resources may not improve our results of operation or enhance the value of our common shares. Our failure to apply these funds effectively could have a material adverse effect on our business, delay the development of our product candidates and cause the market price of our common shares to decline. In addition, pending their use, they may be placed in investments that do not produce significant income or that may lose value.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:2.267%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We do not anticipate paying any cash dividends on our common shares in the foreseeable future.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not currently intend to pay any cash dividends on our common shares in the foreseeable future. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business. As a result, capital appreciation, if any, of our common shares may be investors&#8217; sole source of gain for the foreseeable future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:2.267%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Reports published by analysts, including projections in those reports that differ from our actual results, could adversely affect the price and trading volume of our common shares.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The trading market for our common shares depends in part on the research and reports that industry or securities analysts publish about us or our business. If one or more of the analysts who cover us issues an adverse opinion about our company, our common share price would likely decline. If one or more of these analysts ceases research coverage of us or fails to regularly publish reports on us, we could lose visibility in the financial markets, which in turn could cause the price of our common shares or trading volume to decline.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:2.267%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">There is no public market for our outstanding pre-funded warrants.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There is no public trading market for our outstanding pre-funded warrants, and we do not expect a market to develop. In addition, we do not intend to list the outstanding pre-funded warrants on Nasdaq or any other national securities exchange or nationally recognized trading system. Without an active trading market, the liquidity of the outstanding pre-funded warrants will be limited.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">65</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General Risk Factors</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:2.267%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Unstable market and economic conditions may have serious adverse consequences on our business and financial condition</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Global credit and financial markets have at times experienced extreme disruptions characterized by increased market volatility, increased rates of inflation, declines in consumer confidence, declines in economic growth, increases in unemployment rates, and uncertainty about economic stability. The current conflicts between Ukraine and Russia and in the Middle East, as well as recent failures in the global banking sector, have created volatility in the capital markets and are expected to have further global economic consequences. Limited liquidity, defaults, non-performance and other adverse developments affecting financial institutions or parties with which we do business, or perceptions regarding these or similar risks, have in the past and may in the future lead to market-wide liquidity problems. For example, in March 2023, Silicon Valley Bank was closed and placed into receivership and, subsequently, additional financial institutions have been placed into receivership. There is no guarantee that the U.S. government or governments in other jurisdictions will intervene to provide access to uninsured funds in the future in the event of the failure of other financial institutions, or that the U.S. government or governments in other jurisdictions would do so in a timely fashion. If another such disruption in credit and financial markets and deterioration of confidence in economic conditions occurs, our business may be adversely affected. If the equity and credit markets were to deteriorate significantly in the future, including as a result of a pandemic, political unrest or war, or further instability of the global banking sector, it may make any necessary equity or debt financing more difficult to complete, more costly, and more dilutive. Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our growth strategy, financial performance and the market price of our common shares and could require us to delay or abandon development or commercialization plans. In addition, there is a risk that one or more of our current collaborators, service providers, manufacturers and other partners would not survive or be able to meet their commitments to us under such circumstances, which could directly affect our ability to attain our operating goals on schedule and on budget.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:2.267%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have incurred, and expect to continue to incur, significant costs as a result of laws, regulations and investor-driven standards relating to corporate governance and other matters</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Laws and regulations affecting public companies, including provisions of the Dodd-Frank Wall Street Reform and Consumer Protection Act, Sarbanes-Oxley Act of 2002, the CBCA, applicable Canadian securities laws, and rules adopted or proposed by the SEC, Nasdaq, Corporations Canada and applicable Canadian securities regulators have resulted in, and will continue to result in, significant compliance costs to us as we evaluate the implications of these rules and respond to their requirements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compliance with the various reporting and other requirements applicable to public companies also requires considerable time and attention of management.  In the future, if we are not able to issue an evaluation of our internal control over financial reporting, as required, or we or our independent registered public accounting firm determine that our internal control over financial reporting is not effective, this shortcoming could have an adverse effect on our business and financial results and the price of our common shares could be negatively affected. New rules could make it more difficult or more costly for us to obtain certain types of insurance, including director and officer liability insurance, and we may be forced to accept reduced policy limits and coverage or incur substantially higher costs to obtain the coverage that is the same or similar to our current coverage. The impact of these events could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors and board committees, and as our executive officers. We cannot predict or estimate the total amount of the costs we may incur or the timing of such costs to comply with these rules and regulations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the SEC and applicable Canadian securities regulators regularly pursue various rulemaking efforts, including recently with respect to environmental, social and governance, or ESG, matters. In March 2024, the SEC adopted climate-related disclosure rules but subsequently issued an order implementing a stay of its final rules. A variety of organizations also measure the performance of companies on such ESG topics, and the results of these assessments are widely publicized. Investment in funds that specialize in companies that perform well in such assessments are increasingly popular, and major institutional investors have publicly emphasized the importance of such ESG measures to their investment decisions. If additional rules regarding ESG matters are formally adopted or if investors continue to increase their focus on ESG matters, we could incur substantially higher costs in our efforts to comply and cannot be certain that our efforts will be viewed as adequate by regulators or by such investors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="unresolved_staff_comments"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1B. </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unresolved Staff Comments</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">66</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:nonNumeric id="F_cc934457-1a83-43cf-9428-e626356b09b5" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1c_cybersecurity"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1C. Cybers</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ecurity</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We rely on both internal information technology systems and networks, and those of third-party vendors and contractors, to acquire, transmit, store and otherwise process information in connection with our business activities. Our ability to effectively manage our business depends on the security, reliability and adequacy of our and our third-party contractors&#8217; and vendors&#8217; technology systems. As such, we have implemented an information security program designed to identify, assess, and manage risks from cybersecurity threats.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We perform risk assessments relating to cybersecurity and technology risks at least annually. Our cybersecurity risk management program has been developed based on industry standards, including those published by the National Institute of Standards and Technology (&#8220;NIST&#8221;). Highlights of the program include:</span></p><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Corporate policies and procedures that guide our use of information systems, confidentiality and security strategy;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Identifying critical assets and high-risk threats, and implementing technical prevention and detection controls and response and recovery practices;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6c9306dd-c4bb-4323-899d-270f3db50624" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A third-party risk management process to assist in making risk-informed technology product and services decisions on third parties</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> who provide, manage, store or have access to material data or information, including the completion of security questionnaires and independent assessments of controls, audits and/or contract terms;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ea5608ee-c75f-4ebb-bb69-847f12eb41f6" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Defined data loss </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">prevention standards in place to detect and prevent data loss, including requiring third-party service providers with access to personal, confidential or proprietary information to implement and maintain comprehensive cybersecurity practices consistent with applicable legal standards and industry best practices</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Security awareness training for employees to identify cybersecurity concerns and take appropriate actions; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Evaluating our program&#8217;s effectiveness by performing regular internal and third-party assessments of our controls, including external penetration testing and consultation on security enhancements.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks identified through our cybersecurity program are assessed to determine the potential impact and likelihood of occurrence and mitigation plans are developed and implemented accordingly.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6c2076fd-9b1a-4971-87bc-5e26dfc9d77e" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Audit Committee of our Board of Directors bears the primary responsibility for oversight of cybersecurity risks. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f7174961-8f59-4616-bd1e-dc23e4e32335" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" escape="true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Audit Committee is composed of board members with diverse expertise, including risk management, technology and finance, equipping them to oversee cybersecurity risks effectively.</span></ix:nonNumeric></span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_eff38539-a678-47f4-ba43-88d88d782e7b" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" escape="true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ab575f10-394b-4e64-8f77-0da4c2e6307a" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="cyd:CybersecurityRiskRoleOfManagementTextBlock" escape="true" continuedAt="F_ab575f10-394b-4e64-8f77-0da4c2e6307a_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Management&#8217;s oversight is performed through an IT Strategy Committee, a subset of executive management including our Chief Financial Officer, or CFO, and Chief Legal Officer, and relevant functional expertise, including our Senior Vice President, Information Systems, or SVP, IS. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5f668af9-9a08-483a-835b-9bb496ea8c87" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our SVP, IS, is the primary member of the IT Steering Committee charged with responsibility for assessing, monitoring and managing our cybersecurity risks</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></ix:nonNumeric></span></ix:nonNumeric></span><span style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_ab575f10-394b-4e64-8f77-0da4c2e6307a_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2bda5c05-cbe8-4815-9e1a-7005413013d8" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" escape="true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With over 20 years of experience in information technology strategy and operations, his background includes extensive experience as an IT executive at various companies.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cdc90510-c29d-4ceb-9f36-d4128908d53e" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" escape="true"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_faeafed5-4a62-4fb3-b543-44dc06d346fb" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At least annually, the SVP, IS, and the CFO provide a comprehensive report to the Audit Committee regarding cybersecurity risk assessments, planned enhancements to our cyber security program</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and incident reports and remediation, if any</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></ix:continuation></span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The SVP, IS, oversees processes for the regular monitoring of our information systems, including potential vulnerabilities. In the event of a cybersecurity incident, the IT organization and designated members of executive management follow an established Cybersecurity Incident Response Plan. This plan includes immediate actions to contain the threat, mitigate the impact and assess materiality, and requires retrospective review and identification of corrective actions to reduce future risk.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the fiscal year ended December 31, 2024, we </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8b3a7573-839f-4af8-8188-283332f373e4" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">did not experience any material impact</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to our business, financial position or operations resulting from previously identified cyberattacks or other information security incidents, but we cannot provide assurance that they will not be materially affected in the future by such risks or any future material breaches. For a discussion of these risks, see &#8220;Item 1A&#8212;Risk Factors&#8212;Risk Related to Our Business and Industry&#8212;Our business and operations could suffer in the event of an actual or perceived information security incident such as a cybersecurity breach, system failure, or other compromise of our systems and/or information, including information held by a third-party contractor or vendor.&#8221;</span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">67</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_2_properties"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 2. P</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">roperties</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our headquarters are located in Burnaby, British Columbia, where we currently occupy approximately 53,023 square feet of office and laboratory space. The term of the lease expires in June 2032. We currently pay an aggregate of approximately $138,154 per month in base rent, property tax, common area maintenance fees and management fees, and the landlord holds a security deposit equal to approximately $62,561.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also occupy approximately 17,057 square feet of office space in Needham, Massachusetts. The term of the lease expires in November 2027. We currently pay an aggregate of approximately $69,234 per month in base rent, operating expense and insurance, and the landlord holds a security deposit equal to approximately $187,627.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe that our existing facilities are adequate to meet our business requirements for the near-term and that additional space will be available on commercially reasonable terms, if required.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_3"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 3</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Legal Proceedings</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, we may become involved in legal proceedings or be subject to claims arising in the ordinary course of our business. We are not presently a party to any legal proceedings that, in the opinion of our management, would reasonably be expected to have a material adverse effect on our business, financial condition, operating results or cash flows if determined adversely to us. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_4"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 4</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Mine Safety Disclosures</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="part_ii">&#160;</p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">68</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART II</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_5"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 5</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Market for Registrant&#8217;s Common Equity, Related Shareholder Matters and Issuer Purchases of Equity Securities</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Market Information</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our common shares have been traded on the Nasdaq Global Market since November 5, 2014 under the symbol &#8220;XENE.&#8221; On February 24, 2025, the last reported sale price of our common shares was $38.37 per share.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Holders</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of February 24, 2025, there were approximately 72 holders of record of our common shares. The actual number of shareholders is greater than this number of record holders and includes shareholders who are beneficial owners but whose common shares are held in street name by brokers and other nominees.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dividends</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have never declared or paid any cash dividends on our common shares or any other securities. We currently anticipate that we will retain all available funds and any future earnings, if any, in the foreseeable future for use in the operation of our business and do not currently anticipate paying cash dividends in the foreseeable future. Payment of future cash dividends, if any, will be at the discretion of the board of directors, subject to applicable law and will depend on various factors, including our financial condition, operating results, current and anticipated cash needs, the requirements of current or then-existing debt instruments and other factors the board of directors deems relevant.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Canadian withholding tax at a rate of 25% (subject to reduction under the provisions of any applicable income tax treaty or convention to which Canada is a signatory) will be payable on the gross amount of a dividend on our common shares paid or credited, or deemed to be paid or credited, to a holder of our common shares who, for purposes of the Income Tax Act (Canada), is not (and is not deemed to be) resident in Canada, or a Non-Resident of Canada Holder. The Canadian withholding tax will be deducted directly by us or our paying agent from the amount of the dividend otherwise payable and remitted to the Receiver General for Canada. The rate of withholding tax applicable to a dividend paid on our common shares to a Non-Resident of Canada Holder who is a resident of the U.S. for purposes of the Canada-U.S. Tax Convention (1980), or the Convention, is the beneficial owner of the dividend and qualifies for the full benefits of the Convention will generally be reduced to 15% or, if such a Non-Resident of Canada Holder is a company beneficially owning at least 10% of our voting shares, to 5%. Not all persons who are residents of the U.S. for purposes of the Convention will qualify for the benefits of the Convention. In some circumstances, persons deriving amounts through fiscally transparent entities (including limited liability companies) may not be entitled to benefits under the Convention. The Multilateral Convention to Implement Tax Treaty Related Measures to Prevent Base Erosion and Profit Shifting, of which Canada is a signatory, affects many of Canada's tax treaties (but not the Convention), including the ability to claim benefits thereunder. Non-Resident of Canada Holders should consult their own tax advisors to determine their entitlement to relief under an applicable income tax treaty or convention.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">69</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities Authorized for Issuance Under Equity Compensation Plans</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by this item is incorporated by reference to our Proxy Statement for the 2025 Annual Meeting of Shareholders to be filed with the SEC within 120 days after the end of the fiscal year ended December 31, 2024.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock Performance Graph</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">This performance graph shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, or incorporated by reference into any filing of Xenon Pharmaceuticals Inc. under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following graph shows a comparison of the total cumulative returns of an investment of $100 in cash from December 31, 2019 through December 31, 2024 in (i) our common shares, (ii) the Nasdaq Biotechnology Index, and (iii) the Nasdaq Composite Index. The comparisons in the graph are required by the SEC and are not intended to forecast or be indicative of the possible future performance of our common stock. The graph assumes that all dividends have been reinvested (to date, we have not declared any dividends).</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img255015816_1.jpg" alt="img255015816_1.jpg" style="width:720px;height:275px;"/></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Issuer Repurchases of Equity Securities</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_6"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ite</span><span id="reserved"></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">m 6. [Reserved]</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">70</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_7_managements_discussion_analysis_f"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 7. Management&#8217;s Discussion and Analysis of</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Financial Condition and Results of Operations</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">You should read the following discussion and analysis together with our consolidated financial statements and notes included elsewhere in this Annual Report. The following discussion contains forward-looking statements that involve risks and uncertainties. Our actual results could differ from those expressed or implied in any forward-looking statements as a result of various factors, including those set forth under the caption Part I, Item 1A &#8212; &#8220;Risk Factors.&#8221; Throughout this discussion, unless the context specifies or implies otherwise, the terms &#8220;Xenon,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to Xenon Pharmaceuticals Inc. and its subsidiary.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Overview</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics. We are advancing an ion channel product portfolio to address areas of high unmet medical need, including epilepsy and depression.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Azetukalner Clinical Development</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for the treatment of multiple indications that include epilepsy, including focal onset seizures, or FOS, and primary generalized tonic-clonic seizures, or PGTCS, as well as neuropsychiatric disorders including major depressive disorder, or MDD and bipolar depression, or BPD</span><span style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Epilepsy Programs</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Phase 3 X-TOLE2/3 azetukalner clinical studies in FOS continue to advance, with the first topline data readout anticipated in the second half of 2025.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Phase 3 X-ACKT clinical study continues to enroll patients and is intended to support potential regulatory submissions in an additional epilepsy indication of PGTCS.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Building upon more than 700+ patient-years of data to date from the ongoing X-TOLE open-label extension, or OLE, study, we continue to generate long-term scientific evidence supporting azetukalner&#8217;s compelling efficacy and safety profile, with approximately one in three patients on drug for at least 36 months achieving seizure freedom for a period of one year or longer.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Neuropsychiatric Program</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">X-NOVA2, the first of three planned Phase 3 clinical trials evaluating azetukalner in patients with MDD is currently enrolling patients, and X-NOVA3 is expected to initiate mid-year.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We recently announced plans for a Phase 3 BPD program with initiation of the first of two azetukalner clinical studies in bipolar I and bipolar II depression expected by mid-year. Initiation of this program is based on a strong scientific rationale </span><span style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8211; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">supported by promising clinical data with azetukalner and the Kv7 mechanism in MDD and preclinical research examining the genetic links between BPD and Kv7 and evidence of Kv7 downregulation in BPD &#8211;  as well as a large unmet medical need. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Patient enrollment in the investigator-sponsored Phase 2 proof-of-concept study of azetukalner in MDD led by Icahn School of Medicine at Mount Sinai is complete, and topline results are anticipated in the first half of 2025.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Early-Stage Pipeline: Next Generation Ion Channel Modulators</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We continue to expand our portfolio by leveraging our extensive expertise to discover and develop potassium and sodium channel therapeutics, with the goal of filing multiple INDs, or equivalent, in 2025.</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IND-enabling work is underway with multiple Kv7 development candidates. Kv7 may have utility in a broad range of therapeutic indications including seizures, pain, and neuropsychiatric disorders, such as MDD and BPD.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IND-enabling work is underway with a lead Nav1.7 development candidate. Nav1.7 is an important pain-related target, based on strong human genetic validation, that may represent a new class of medicines without the limitations of opioids.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect a lead candidate within our Nav1.1 program will enter IND-enabling studies in 2025. Pre-clinical data suggests that targeting Nav1.1 could potentially address the underlying cause and symptoms of Dravet Syndrome</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">71</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Partnered Program</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As part of our ongoing collaboration with Neurocrine Biosciences to develop treatments for epilepsy, NBI-921355, a Nav1.2 and Nav1.6 sodium channel inhibitor in development for the potential treatment for certain types of epilepsy, has progressed into a Phase 1 clinical study in healthy adult participants, triggering an anticipated $7.5 million milestone payment to Xenon.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have funded our operations primarily through the sale of equity securities, funding received from our licensees and collaborators, and debt financing. We did not recognize any revenue in the years ended December 31, 2024 and 2023, as compared to revenue from collaboration agreements of $9.4 million for the year ended December 31, 2022. To date, we have not had any products approved for sale and have not generated any revenue from product sales. We do not expect to generate revenue from product sales unless and until we successfully complete development and obtain regulatory approval for a product candidate, which we expect will take a number of years, if ever, and the outcome of which is subject to significant uncertainty.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will continue to require additional capital to develop our product candidates and fund operations for the foreseeable future. We have incurred net losses in each year since inception and expect to continue to incur net losses for the foreseeable future. Our net losses were $234.3 million, $182.4 million, and $125.4 million for the years ended December 31, 2024, 2023, and 2022, respectively. As of December 31, 2024, we had an accumulated deficit of $899.5 million. Substantially all of our net losses have resulted from costs incurred in connection with our research and development programs and from general and administrative costs associated with our operations. We anticipate that our operating expenses will increase substantially, particularly as we:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">prepare for the potential commercial launch of azetukalner;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">invest significantly to further develop azetukalner for our current and future indications;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">advance additional product candidates into pre-clinical and clinical development; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">seek regulatory and marketing approvals for any of our product candidates that successfully complete clinical trials;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">require the manufacture of larger quantities of our product candidates for clinical development and potential commercialization; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">hire additional commercial, clinical, scientific, management and administrative personnel; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">acquire or in-license other assets and technologies;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">maintain, protect and expand our intellectual property portfolio; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">create additional infrastructure to support our operations and any future commercialization efforts.</span></div></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial Operations Overview</span></p>
  <p style="margin-left:2.267%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To date, our revenue has been primarily derived from collaboration and licensing agreements and we have not generated any revenue from product sales. If our development efforts for our product candidates are successful and result in regulatory approval, we may generate revenue in the future from product sales. We cannot predict if, when, or to what extent we will generate revenue from the commercialization and sale of our product candidates. We may never succeed in obtaining regulatory approval for any of our product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may also generate revenue in the future from payments as a result of license or collaboration agreements for any of our product candidates or intellectual property, such as our license and collaboration agreement with Neurocrine Biosciences, or the Neurocrine Collaboration, described in &#8220;Business &#8212; Collaborations, Commercial and License Agreements&#8221; and &#8220;Note 10&#8221; of the consolidated financial statements included elsewhere in this Annual Report on Form 10-K. We cannot provide assurance as to the timing of future milestone or royalty payments under the Neurocrine Collaboration, or that we will receive any of these payments at all.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">72</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table is a summary of revenue recognized for the years ended December 31, 2024, 2023 and 2022 (in thousands):</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:56.449%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.518%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.518%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.518%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="8" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Recognition of the transaction price</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">372</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development services</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,938</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Milestone payments</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,124</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Total revenue</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,434</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the terms of the Neurocrine Collaboration, we received an upfront cash payment of $30.0 million and a $20.0 million equity investment in our common shares in December 2019. The overall transaction price of the arrangement was measured and allocated to certain performance obligations and revenue was recognized as those performance obligations were completed. In January 2022, based on the U.S. Food and Drug Administration&#8217;s (&#8220;FDA&#8221;) approval to expand the SCN8A-DEE study population to include subjects aged between 2 and 11 years, we received an aggregate milestone payment of $15.0 million in the form of $6.75 million cash and $8.25 million equity investment in our common shares. The equity investment was measured at fair value on the date of issuance and the resulting premium with the cash payment, was recognized as revenue. Research and development services were recognized as revenue at fair market value as the services were rendered. The research collaboration was completed in June 2022.</span></p>
  <p style="margin-left:2.267%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Operating Expenses</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes our operating expenses for the years ended December 31, 2024, 2023 and 2022 (in thousands):</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:57.089%;box-sizing:content-box;"/>
    <td style="width:1.28%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.598%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.28%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.598%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.28%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.598%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.28%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">210,394</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">167,512</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">105,767</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">68,904</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46,542</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32,810</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">279,298</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">214,054</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">138,577</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="margin-left:2.267%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Expenses</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expenses represent costs incurred to conduct development of our proprietary product candidates and our drug discovery efforts, including any acquired or in-licensed product candidates or technology, and costs to support any partnered product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expenses consist of costs incurred in performing research and development activities, including:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">personnel-related expenses, consisting of salaries, benefits and stock-based compensation for employees engaged in scientific research and development;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">third-party expenses incurred in connection with the pre-clinical and clinical development of our product candidates, including under agreements with CROs;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">third-party expenses relating to formulation, process development and manufacture of drug substance and drug product for use in our pre-clinical testing, clinical trials and potential commercial supply;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">third-party acquisition, license and collaboration fees;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">laboratory consumables; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">certain indirect costs incurred in support of overall research and development activities, including facilities, depreciation and information technology costs.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Project-specific expenses reflect costs directly attributable to our clinical development candidates for which we have incurred significant expenses. All remaining research and development expenses are reflected in pre-clinical, discovery and other program expenses. At any given time, we have several active early-stage research and drug discovery programs. Our personnel and infrastructure are typically deployed over multiple projects and are not directly linked to any individual internal early-stage research or drug discovery program. Therefore, we do not maintain financial information for our internal early-stage research and internal drug discovery programs on a project-specific basis.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">73</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expense all research and development costs as incurred. Payments we make for research and development services prior to the services being rendered are recorded as prepaid assets in our consolidated balance sheets and are expensed as the services are provided. Costs for certain development activities are recognized based on an evaluation of the progress to completion of specific tasks using information and data provided to us by our vendors and third-party service providers.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect that our research and development expenses will increase substantially in the future as we continue to invest in research and development activities related to developing our product candidates, including investments in manufacturing, as our programs advance into later stages of development and we continue to conduct clinical trials, advance our internal drug discovery programs into pre-clinical development and continue our early-stage research. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size, scope and duration of later-stage clinical trials.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clinical development timelines, likelihood of regulatory approval, and commercialization and associated costs are uncertain, difficult to estimate, and can vary significantly. The process of conducting the necessary clinical research to obtain regulatory approval is costly and time-consuming, and the successful development of our product candidates is highly uncertain. As a result, we cannot accurately estimate or know the nature, timing and costs that will be necessary to complete the pre-clinical and clinical development for any of our product candidates or when and to what extent we may generate revenue from the commercialization and sale of any of our product candidates or achieve profitability.</span></p>
  <p style="margin-left:2.267%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">General and Administrative Expenses</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General and administrative expenses consist primarily of personnel-related expenses, consisting of salaries, benefits and stock-based compensation for our employees engaged in executive, finance, legal, business development, commercial and administrative functions, insurance costs, professional fees for auditing, tax and legal services, costs related to maintenance and filing of intellectual property, costs incurred as we prepare for commercialization, and allocated facility-related and information technology costs not otherwise included in research and development expenses.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect that general and administrative expenses will increase in the future as we expand our operating activities to support our continued research activities and development of our product candidates, and as we prepare for commercialization. We will also continue to incur increased accounting, audit, legal, regulatory, compliance and director and officer insurance costs as well as investor and public relations expenses associated with operating as a public company.</span></p>
  <p style="margin-left:2.267%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Income (Expense)</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interest income. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interest income consists of income earned on our cash and investment balances. We anticipate that our interest income will continue to fluctuate depending on our cash and investment balances and interest rates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Unrealized fair value gain (loss) on trading securities. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Trading securities are recorded at fair value. Unrealized fair value gain (loss) on trading securities is related to changes in market pricing on the investments classified as trading securities during the period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Foreign exchange gain (loss).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Net foreign exchange gain (loss) consists of gains and losses from the impact of foreign exchange fluctuations on our monetary assets and liabilities that are denominated in currencies other than the U.S. dollar (principally the Canadian dollar). We will continue to incur substantial expenses in Canadian dollars and will remain subject to risks associated with foreign currency fluctuations.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Critical Accounting Policies and Significant Judgments and Estimates</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management&#8217;s discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which have been prepared in conformity with generally accepted accounting principles in the United States, or GAAP. The preparation of our consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the revenue and expenses incurred during the reported periods. We base estimates on our historical experience, known trends and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The items in our financial statements requiring significant estimates and judgments are as follows:	</span></p>
  <p style="margin-left:2.267%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue recognition:</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue recognition is a critical accounting estimate due to the magnitude and nature of the revenues we receive.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our primary sources of revenue are derived from non-refundable upfront payments, funding for research and development services, milestone payments, and royalties under license and collaboration agreements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">74</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In contracts where we have more than one performance obligation to provide our customer with goods or services, each performance obligation is evaluated to determine whether it is distinct. The consideration under the contract is then allocated between the distinct performance obligations based on their respective relative standalone selling prices. The estimated standalone selling price of each deliverable reflects our best estimate of what the selling price would be if the deliverable was regularly sold on a standalone basis and is determined by reference to market rates for the good or service when sold to others or by using an adjusted market assessment approach if selling price on a standalone basis is not available.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The consideration allocated to each distinct performance obligation is recognized as revenue when control is transferred to our customer for the related goods or services. We generally recognize revenue from non-refundable upfront payments over the estimated term of the performance obligation or period in which the underlying benefit is transferred to our customer. If non-refundable license fees have value to the customer on a standalone basis, separate from the undelivered performance obligations, they are recognized upon delivery. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. Consideration in exchange for research and development services performed by us on behalf of the licensee is recognized upon performance of such activities at rates consistent with prevailing market rates. Consideration associated with at-risk substantive performance milestones, including sales-based milestones, is recognized as revenue using the most likely amount method when it is probable that a significant reversal of the cumulative revenue recognized will not occur. At the end of each subsequent reporting period, we re-evaluate the probability of achievement of such milestones, and if necessary, adjust the estimate of the overall transaction price. Sales-based royalties received in connection with licenses of intellectual property are subject to a specific exception in the revenue standards, whereby the consideration is not included in the transaction price and recognized in revenue until the customer&#8217;s subsequent sales or usages occur.</span></p>
  <p style="margin-left:2.267%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and development costs:</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development costs is a critical accounting policy due to the magnitude of the costs and the requirement to estimate the proportionate performance of vendors to calculate third-party accrued and prepaid research and development expenses.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We accrue for estimated costs of research and development activities conducted by third-party service providers, which include the conduct of pre-clinical studies and clinical trials, and manufacturing activities. Third-party service providers generally provide estimates of proportionate performance to allow us to determine an appropriate accrual. When determining the adequacy of an accrual, we analyze progress based on the level of services performed, progress of the studies, including the phase or completion of events, and contracted costs. Payments made to third parties under these arrangements in advance of the receipt of the related services are recorded as prepaid expenses until the services are rendered. Our historical prepaid and accrual estimates have not been materially different from the actual costs.</span></p>
  <p style="margin-left:2.267%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock-based compensation:</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-based compensation is a critical accounting estimate due to the magnitude of and the many assumptions that are required to calculate stock-based compensation expense.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We grant stock options to employees, consultants, directors and officers pursuant to our equity incentive plans. Compensation expense is recorded using the fair value method. We calculate the fair value of stock options using the Black-Scholes option-pricing model which requires that certain assumptions, including the expected life of the option and expected volatility of the stock, be estimated at the time that the options are granted. The expected volatility is based on the historical volatility of our common shares calculated based on a period of time commensurate with the expected term assumption. The expected term of our stock options has been determined utilizing our available historical data and we recognize forfeitures as they occur. We amortize the fair value of stock options using the straight-line method over the vesting period of the options.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also grant performance share unit awards (&#8220;PSUs&#8221;) to certain employees and officers pursuant to our equity incentive plans. The grant date fair value of PSUs is determined based on the closing market price of our common shares. Compensation expense is recognized if the performance condition is considered probable of achievement using our best estimates and is amortized on a straight-line basis over the requisite service period of each separately vesting tranche of the award. Forfeitures are accounted for in the period they occur.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Changes in any of these assumptions may materially affect the fair value of awards granted and the amount of stock-based compensation expense recognized.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">75</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Results of Operations</span></p>
  <p style="margin-left:2.267%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Comparison of Years Ended December 31, 2024, 2023 and 2022</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the results of our operations for the years ended December 31, 2024, 2023 and 2022 together with changes in those items (in thousands):</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:37.3%;box-sizing:content-box;"/>
    <td style="width:1.2%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:7.74%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.2%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:7.74%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.2%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:7.74%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.2%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.34%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.34%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Ended</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">31,</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change<br/>2024 vs. 2023</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change<br/>2023 vs. 2022</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Increase/(Decrease)</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Increase/(Decrease)</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,434</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(9,434</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development expenses</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">210,394</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">167,512</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">105,767</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42,882</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">61,745</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative expenses</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">68,904</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46,542</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32,810</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,362</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,732</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other:</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest income</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41,943</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,620</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,713</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,323</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,907</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unrealized fair value gain (loss) on trading securities</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,550</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(2,934</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(3,550</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,484</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign exchange gain (loss)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(1,064</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">199</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(1,891</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(1,263</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,090</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss before income taxes</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(238,419</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(182,685</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(125,255</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(55,734</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(57,430</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="margin-left:2.267%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We did not recognize any revenue in the years ended December 31, 2024 and 2023, as compared to revenue of $9.4 million for 2022. Revenue recognized in 2022 was related to the Neurocrine Collaboration, including $0.4 million of the overall transaction price, $1.9 million in research and development services, and a $7.1 million milestone.</span></p>
  <p style="margin-left:2.267%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Expenses</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes research and development expenses for the years ended December 31, 2024, 2023 and 2022 together with changes in those items (in thousands):</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:37.3%;box-sizing:content-box;"/>
    <td style="width:1.2%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:7.74%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.2%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:7.74%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.2%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:7.74%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.2%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.34%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.34%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Ended</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">31,</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change<br/>2024 vs. 2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change<br/>2023 vs. 2022</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Increase/(Decrease)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Increase/(Decrease)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Direct external costs:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Azetukalner</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">106,806</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">89,303</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37,367</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,503</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">51,936</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">XEN496</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,152</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,765</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(5,152</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(9,613</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Pre-clinical and discovery programs</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,546</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,552</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,711</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,994</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,841</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Indirect costs:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Personnel-related (including stock-based <br/>compensation)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">70,810</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">47,945</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,650</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,865</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,295</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other unallocated expenses</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,232</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,560</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,274</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,672</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,286</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development expenses</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">210,394</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">167,512</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">105,767</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42,882</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">61,745</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expenses increased by $42.9 million for the year ended December 31, 2024 as compared to 2023. Direct external costs related to azetukalner increased by $17.5 million primarily due to our ongoing Phase 3 epilepsy clinical trials and the initiation of our first Phase 3 MDD clinical trial, manufacturing activities to support current and future clinical trials as well as our potential NDA submission, partially offset by a decrease in costs for our Phase 2 MDD clinical trial which completed in late 2023. The decrease in direct external costs related to XEN496 of $5.2 million is due to our decision in May 2023 to no longer pursue the clinical development of XEN496. Pre-clinical and discovery program costs increased by $6.0 million due to the advancement of multiple potential drug candidates targeting Kv7, Nav1.7 and Nav1.1. Personnel-related costs increased by $22.9 million driven by an increase in headcount to support late-stage development and an increase in stock-based compensation expense due to an increase in the number of options granted at a higher fair value.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">76</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expenses increased by $61.7 million for the year ended December 31, 2023 as compared to 2022. Direct external costs related to azetukalner increased by $51.9 million primarily due to ongoing site initiation and patient enrollment in our Phase 3 epilepsy clinical trials, increase in manufacturing activities to support current and future clinical trials and a potential NDA submission, as well as the completion of our Phase 2 MDD clinical trial. The decrease in direct external costs related to XEN496 of $9.6 million is due to our decision in May 2023 to no longer pursue the clinical development of XEN496. Personnel-related costs increased by $14.3 million driven by an increase in headcount to support late-stage development and an increase in stock-based compensation expense due to an increase in the number of options granted at a higher fair value.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:2.267%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">General and Administrative Expenses</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes general and administrative expenses for the years ended December 31, 2024, 2023 and 2022 together with changes in those items (in thousands):</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:37.3%;box-sizing:content-box;"/>
    <td style="width:1.2%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:7.74%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.2%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:7.74%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.2%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:7.74%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.2%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.34%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.34%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Ended</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">31,</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change<br/>2024 vs. 2023</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change<br/>2023 vs. 2022</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Increase/(Decrease)</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Increase/(Decrease)</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Personnel-related (including stock-based <br/>compensation)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">48,247</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32,166</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,814</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,081</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,352</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Professional and consulting fees</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,127</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,760</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,189</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,367</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,571</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,530</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,616</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,807</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">914</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">809</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative expenses</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">68,904</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46,542</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32,810</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,362</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,732</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General and administrative expenses increased by $22.4 million for the year ended December 31, 2024 as compared to 2023. Personnel-related costs increased by $16.1 million primarily due to higher headcount to support our expanding research and development activities and future potential commercialization as well as an increase in stock-based compensation expense due to an increase in the number of options granted at a higher fair value. Professional and consulting fees increased by $5.4 million primarily associated with legal services in support of our ongoing business operations and pre-commercial activities.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General and administrative expenses increased by $13.7 million for the year ended December 31, 2023 as compared to 2022. Personnel-related costs increased by $9.4 million primarily due to higher headcount to support our expanding research and development activities as well as an increase in stock-based compensation expense due to an increase in the number of options granted at a higher fair value. Professional and consulting fees increased by $3.6 million primarily associated with legal services in support of our ongoing business operations and market research activities.</span></p>
  <p style="margin-left:2.267%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Income</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes our other income for the years ended December 31, 2024, 2023 and 2022 together with changes in those items (in thousands):</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:37.3%;box-sizing:content-box;"/>
    <td style="width:1.2%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:7.74%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.2%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:7.74%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.2%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:7.74%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.2%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.34%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.34%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Ended</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">31,</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change<br/>2024 vs. 2023</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change<br/>2023 vs. 2022</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Increase/(Decrease)</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Increase/(Decrease)</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest income</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41,943</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,620</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,713</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,323</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,907</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unrealized fair value gain (loss) on trading securities</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,550</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(2,934</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(3,550</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,484</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign exchange gain (loss)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(1,064</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">199</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(1,891</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(1,263</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,090</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40,879</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31,369</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,888</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,510</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,481</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other income increased by $9.5 million for the year ended December 31, 2024 as compared to 2023. Interest income increased by $14.3 million driven by a higher average balance of marketable securities and higher average market yields on investments. The unrealized fair value gain on trading securities decreased by $3.6 million due to the fact that we did not hold any marketable securities classified as trading in 2024.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other income increased by $27.5 million for the year ended December 31, 2023 as compared to 2022. Interest income increased by $18.9 million driven by a higher balance of marketable securities and an increase in market yields on investments. The unrealized fair value gain on trading securities increased by $6.5 million due to changes in market yields on trading securities, partially offset by a lower balance of trading securities.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">77</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Liquidity and Capital Resources</span></p>
  <p style="margin-left:2.267%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Sources of Liquidity</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To date, we have financed our operations primarily through the sale of equity securities, funding received from collaboration and license agreements, and debt financing. Since our initial public offering through December 31, 2024, we have raised aggregate net cash proceeds of more than $1.4 billion primarily from the issuance of equity securities. As of December 31, 2024, we had cash and cash equivalents and marketable securities of $754.4 million</span><span style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Except for any obligations of our collaborators to make milestone payments under our agreements with them, we do not have any committed external sources of capital. Until such time as we can generate substantial product revenue, if ever, we expect to finance our cash needs through a combination of collaboration agreements and equity or debt financings.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We entered into an &#8220;at-the-market&#8221; equity offering sales agreement in August 2020, amended as of March 2022, with Jefferies LLC and Stifel, Nicolaus &amp; Company, Incorporated, or the ATM Program, and a new prospectus supplement was filed with the SEC on August 9, 2024, pursuant to which we refreshed the ATM Program and may sell common shares having gross proceeds of up to $350.0 million, from time to time. As of December 31, 2024, an aggregate of 310,000 common shares have been sold for proceeds of $12.1 million, net of commissions and transaction expenses.</span></p>
  <p style="margin-left:2.267%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Funding Requirements</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have incurred significant operating losses since inception. As of December 31, 2024, we had an accumulated deficit of $899.5 million. We expect to continue to incur significant expenses in excess of our revenue and expect to incur operating losses over the next several years. Our net losses may fluctuate significantly from quarter to quarter and year to year. We expect to incur significant expenses and increasing operating losses for the foreseeable future as we prepare for the potential commercial launch of azetukalner; invest significantly to further develop azetukalner for our current and future indications; advance additional product candidates into pre-clinical and clinical development; seek regulatory and marketing approvals for any of our product candidates that successfully complete clinical studies; manufacture larger quantities of our product candidates of clinical development and potential commercialization; hire additional commercial, clinical, scientific, management and administrative personnel; acquire or in-license other product candidates and technologies; make milestone or other payments under our in-license or other agreements, including, without limitation, payments to 1st Order Pharmaceuticals, Inc and other third parties; maintain, protect and expand our intellectual property portfolio; establish a sales, marketing, distribution and other commercial infrastructure to commercialize any products for which we may obtain marketing approval; create additional infrastructure and incur additional costs to support our operations and our product development and planned future commercialization efforts; and experience any delays or encounter issues with any of the above.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our future capital requirements are difficult to forecast and will depend on many factors, including:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the scope, progress, results and costs of researching and developing our current product candidates, as well as other additional product candidates we may develop and pursue in the future;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing of, and the costs involved in, obtaining marketing approvals for our product candidates and any other additional product candidates we may develop and pursue in the future; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the number of future product candidates that we may pursue and their development requirements;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">if approved, the costs of commercialization activities for any product candidate that receives regulatory approval to the extent such costs are not the responsibility of an existing or future collaborator, including the costs and timing of establishing product sales, marketing, distribution and manufacturing capabilities;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">subject to the receipt of regulatory approval, revenue, if any, received from commercial sales of our product candidates and any other additional product candidates we may develop and pursue in the future;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">whether our existing collaborations generate substantial milestone payments and, ultimately, royalties on future approved products for us;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to maintain existing collaborations and to establish new collaborations, licensing or other arrangements and the financial terms of such agreements;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our headcount growth and associated costs as we expand our research and development and initiate pre-commercial and commercial activities;</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">78</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patents, including litigation costs and the outcome of such litigation; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the ongoing costs of operating as a public company.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on our research and development plans and our timing expectations related to the progress of our programs, we expect that our existing cash and cash equivalents and marketable securities as of the date of this report will enable us to fund our operating expenses and capital expenditure requirements for at least the next 12 months. However, our estimates and assumptions may prove to be wrong, and we cannot guarantee that our existing capital resources will be sufficient to conduct and complete all of our anticipated research and development efforts and future commercialization efforts. Additionally, the process of testing drug candidates in clinical trials is costly, and the timing of progress in these trials remains uncertain. Further, inflation may affect our use of capital resources by increasing our cost of labor and research and development expenses. Our long-term funding requirements will consist of operational, capital, and manufacturing expenditures, including those contractual commitments described below. Because of the inherent risks and uncertainties associated with the development and commercialization of our product candidates, we are unable to estimate the amounts of capital outflows and operating expenditures associated with our long-term anticipated pre-clinical studies and clinical trials.</span></p>
  <p style="margin-left:2.267%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Contractual Commitments</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In April 2017, we acquired azetukalner from 1st Order Pharmaceuticals, Inc., or 1st Order, pursuant to an asset purchase agreement. In August 2020, we and 1st Order amended the asset purchase agreement to amend certain definitions in the agreement and to modify the payment schedule for certain milestones. Through December 31, 2024, we have paid $2.0 million based on progress against these milestones. Future potential payments to 1st Order include up to $6.0 million in regulatory milestones. There are no royalty obligations to 1st Order.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have operating leases for research laboratories and office space in Burnaby, British Columbia and office space in Needham, Massachusetts. The terms of the leases expire in June 2032 and November 2027, respectively. Amounts related to future lease payments for operating lease obligations as of December 31, 2024 totaled $10.2 million, with $1.7 million expected to be paid within the next 12 months.</span></p>
  <p style="margin-left:2.267%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash Flows</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table shows a summary of our cash flows for the years ended December 31, 2024, 2023 and 2022 (in thousands):</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:53.361%;box-sizing:content-box;"/>
    <td style="width:1.381%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:11.705%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.381%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:11.705%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.381%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:11.705%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.381%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash used in operating activities</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(181,389</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(151,112</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(101,028</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash provided by (used in) investing activities</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">165,000</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(111,385</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(293,405</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,130</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">353,522</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">278,471</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="margin-left:11.2%;text-indent:-3.096%;padding-left:2.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amounts have been reclassified as described in Note 2 of our consolidated financial statements.</span></p>
  <p style="margin-left:2.267%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Operating Activities</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the year ended December 31, 2024, net cash used in operating activities totaled $181.4 million, compared to $151.1 million in 2023. The increase was primarily related to higher research and development and general and administrative expenses, as well as changes in operating assets and liabilities, partially offset by higher interest income.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">   </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the year ended December 31, 2023, net cash used in operating activities totaled $151.1 million, compared to $101.0 million in 2022. The increase was primarily related to higher research and development and general and administrative expenses, and a decrease in revenue recognized, partially offset by higher interest income and changes in operating assets and liabilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">     </span></p>
  <p style="margin-left:2.267%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Investing Activities</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the year ended December 31, 2024, net cash provided by investing activities totaled $165.0 million, compared to net cash used of $111.4 million in 2023. The change was driven primarily by an increase in the redemption of marketable securities, net of purchases. In addition, there was a decrease in the purchases of property, plant and equipment.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the year ended December 31, 2023, net cash used in investing activities totaled $111.4 million, compared to $293.4 million in 2022. The change was driven primarily by an increase in the redemption of marketable securities, net of purchases. This was partially offset by an increase in the purchases of property, plant and equipment.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">79</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="margin-left:2.267%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Financing Activities</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the year ended December 31, 2024, net cash provided by financing activities totaled $12.1 million, compared to $353.5 million in 2023. The decrease was primarily related to net proceeds from the issuance of common shares of $12.1 million in 2024 as compared to net proceeds of $353.5 million in 2023 from the issuance of common shares and pre-funded warrants.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the year ended December 31, 2023, net cash provided by financing activities totaled $353.5 million, compared to $278.5 million in 2022. The increase was primarily related to net proceeds of $353.5 million in 2023 as compared to net proceeds of $277.8 million in 2022 from the issuance of common shares and pre-funded warrants.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Related Party Transactions</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For a description of our related party transactions, see &#8220;Certain Relationships and Related Transactions, and Director Independence.&#8221;</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Outstanding Share Data</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of February 24, 2025, we had 76,542,811 common shares issued and outstanding, outstanding pre-funded warrants to purchase an additional 2,173,081 common shares, outstanding stock options to purchase an additional 10,364,025 common shares, outstanding performance share units convertible into 194,000 common shares and an outstanding warrant to purchase an additional 40,000 common shares.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_7a_quantitative_qualitative_disclos"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 7A. Quantitative and Qualitat</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ive Disclosures About Market Risk</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are exposed to various market risks, including changes in currency exchange rates and interest rates. Market risk is the potential loss arising from adverse changes in market rates and prices.</span></p>
  <p style="margin-left:2.267%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Foreign currency risk</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, we had U.S. dollar denominated cash and cash equivalents and marketable securities of $685.7 million and Canadian dollar denominated cash and cash equivalents and marketable securities of CAD$98.7 million.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are subject to foreign currency exchange rate risk in part, as a result of entering into transactions denominated in currencies other than U.S. dollars, particularly those denominated in Canadian dollars. We also hold Canadian dollar denominated cash and cash equivalents, accounts receivable and accounts payable.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Changes in foreign currency exchange rates can create significant foreign exchange gains or losses to us. We do not currently hedge our exposure and thus assume the risk of future gains or losses on the amounts of Canadian dollars held. While we have experienced increased foreign exchange fluctuations in recent periods, we do not believe that an immediate 10% increase or decrease in the relative value of the U.S. dollar to the Canadian dollar would have a material effect on our operating results.</span></p>
  <p style="margin-left:2.267%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interest rate sensitivity</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, we had cash and cash equivalents and marketable securities of $754.4 million. Our interest rate sensitivity is primarily attributable to our cash and cash equivalents and marketable securities. A 100 basis point, or 1%, unfavorable change in interest rates would have resulted in approximately a $4.0 million decrease in the fair value of our marketable securities as of December 31, 2024. We do not enter into investments for speculative purposes and have not used any derivative financial instruments to manage interest rate exposure.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">80</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_8"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 8. Financial Statements and Supplementary Data</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">XENON PHARMACEUTICALS INC.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Index to Consolidated Financial Statements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Year ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:93.72%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:5.28%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Index</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:right;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:right;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:12.25pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#audit_report"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Reports of Independent Registered Public Accounting Firm</span></a><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">82</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:right;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:12.25pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#balance_sheets"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Balance Sheets as of December 31, 2024 and 2023</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:right;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#statements_of_operations"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2024, 2023 and 2022</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85</span></p></td>
   </tr>
   <tr style="height:4.3pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:right;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:12.25pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#shares_and_shareholder_equity"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Statements of Shareholders&#8217; Equity for the years ended December 31, 2024, 2023 and 2022</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">86</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:right;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:12.25pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_cash_flows"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Statements of Cash Flows for the years ended December 31,</span></a><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;"> </span><a href="#shares_and_shareholder_equity"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">2024, 2023 and 2022</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">87</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:right;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:12.25pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#notes_to_financial_statements"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Notes to Consolidated Financial Statements</span></a><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">88</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">81</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="audit_report"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Report of Independent Registered Public Accounting Firm</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the Shareholders and Board of Directors<br/>Xenon Pharmaceuticals Inc.:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ca0385dc-63d2-40fc-9ea3-2a230c4deaeb" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="dei:AuditorOpinionTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Opinion on the Consolidated Financial Statements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have audited the accompanying consolidated balance sheets of Xenon Pharmaceuticals Inc. (the Company) as of December 31, 2024 and 2023, the related consolidated statements of operations and comprehensive loss, shareholders&#8217; equity, and cash flows for each of the years in the three-year period ended December 31, 2024 and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the years in the three-year period ended December 31, 2024, in conformity with U.S. generally accepted accounting principles.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company&#8217;s internal control over financial reporting as of December 31, 2024, based on criteria established in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Internal Control &#8211; Integrated Framework (2013)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> issued by the Committee of Sponsoring Organizations of the Treadway Commission, and our report dated February 27, 2025 expressed an unqualified opinion on the effectiveness of the Company&#8217;s internal control over financial reporting.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Basis for Opinion</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Critical Audit Matters</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Critical audit matters are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. We determined that there are no critical audit matters.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/s/ KPMG LLP</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Chartered Professional Accountants</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have served as the Company&#8217;s auditor since 1999.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Vancouver, Canada</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">February 27, 2025</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">82</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Report of Independent Registered Public Accounting Firm</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the Shareholders and Board of Directors<br/>Xenon Pharmaceuticals Inc.:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Opinion on Internal Control Over Financial Reporting</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have audited Xenon Pharmaceuticals Inc.&#8217;s (the Company) internal control over financial reporting as of December 31, 2024, based on criteria established in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Internal Control &#8211; Integrated Framework (2013)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> issued by the Committee of Sponsoring Organizations of the Treadway Commission. In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2024, based on criteria established in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Internal Control &#8211; Integrated Framework</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">(2013)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> issued by the Committee of Sponsoring Organizations of the Treadway Commission.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2024 and 2023, the related consolidated statements of operations and comprehensive loss, shareholders&#8217; equity, and cash flows for each of the years in the three-year period ended December 31, 2024, and the related notes (collectively, the consolidated financial statements), and our report dated February 27, 2025 expressed an unqualified opinion on those consolidated financial statements.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Basis for Opinion</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management&#8217;s Annual Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Definition and Limitations of Internal Control Over Financial Reporting</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/s/ KPMG LLP</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Chartered Professional Accountants</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Vancouver, Canada</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">February 27, 2025</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">83</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">XENON PHARMACEUTICALS INC.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="balance_sheets"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consolidated Balance Sheets</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Expressed in thousands of U.S. dollars except share amounts)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.313%;box-sizing:content-box;"/>
    <td style="width:1.48%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.623000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.48%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.623000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.48%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Assets</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current assets:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6dc39787-7119-4c1b-8849-b2511c38b97d" contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">142,712</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2eeceed8-6ac3-4f4c-a59e-9a050aabb107" contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">148,643</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities (note 5)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_acd9d3a0-222d-4d0d-ae84-25d00c5ac69a" contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f" name="us-gaap:MarketableSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">484,193</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5c848739-67f8-4716-a1ae-1038bcfffd2f" contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35" name="us-gaap:MarketableSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">489,439</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts receivable</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_13d86e32-9138-42d4-94f3-cef415f1e138" contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f" name="us-gaap:AccountsReceivableNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,469</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4850a452-bf2e-4dea-844a-7ef7549eaadf" contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35" name="us-gaap:AccountsReceivableNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">874</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9a15be7a-bfba-45b2-ba25-52336e6fa9b4" contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,890</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f6e1fb00-cc45-43d8-9bae-b5261e70f4c9" contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,006</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7d554c63-57b9-45bc-b32d-b6bd78b54edd" contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">635,264</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6057e138-69aa-4d28-8b69-5a9a793b0a3b" contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">644,962</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities, long-term (note 5)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7715a948-882b-4e3b-8e22-9f7c2128638e" contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f" name="us-gaap:MarketableSecuritiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">127,496</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cac65d7d-f527-4d9f-9c56-945f974a56b4" contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35" name="us-gaap:MarketableSecuritiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">292,792</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease right-of-use asset, net (note 7)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2a3f25d2-1604-43d5-927d-8036c4c699fa" contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,939</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b5a9fd1b-c0c4-439d-a15e-5396e3c2baed" contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,193</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property, plant and equipment, net (note 6)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fad3bebc-47f1-4978-a771-a91aa792cdca" contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,278</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_da28435d-1cfa-4731-b463-7eec094fdb8d" contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,653</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax assets (note 13)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9909017d-a6a9-4796-a382-2831e9f0721e" contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f" name="us-gaap:DeferredIncomeTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,666</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_472e70d0-959d-4b08-9d23-8934d3ae1fda" contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35" name="us-gaap:DeferredIncomeTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">802</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid expenses, long-term</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b611f19c-8d7f-4125-87bc-483311402689" contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f" name="us-gaap:PrepaidExpenseNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,496</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_501d86e1-d1ea-467c-8fdb-d00b47881337" contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35" name="us-gaap:PrepaidExpenseNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,396</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total assets</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d07904b0-a91d-4fdc-9edf-2dc84fa1334e" contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">798,139</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1547721e-f5a6-40e2-9542-9927e2a4f3b3" contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">964,798</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Liabilities and shareholders&#8217; equity</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current liabilities:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts payable and accrued liabilities (note 8)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b13924f3-670e-4b60-9a09-0e0620f619be" contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">34,221</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2595d4cb-9e26-49df-929c-75d9ad58b5c9" contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,974</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liability (note 7)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e98f47d9-2136-41e3-92ec-6c5e2f91312f" contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,369</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5f80e307-1937-4716-a562-f7facfeb9e04" contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,299</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_10961cbe-8588-48fc-941d-d88ca42c41ba" contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,590</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_73c988fd-fa80-4796-922c-541681a0ac61" contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,273</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liability, long-term (note 7)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_69675a05-1880-42f0-bc7c-28f2d56e376b" contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,646</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2612ac4a-6943-43fb-abd7-0af76fee12cb" contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,604</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total liabilities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2f066d07-9eb7-4f32-96f4-5539b105968c" contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43,236</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9a3f768d-3450-4800-bdd3-cfe662b26bdc" contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">36,877</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shareholders&#8217; equity:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common shares, </span><span><span style="-sec-ix-hidden:F_39c5f094-0153-4965-ad86-c59ffc0f4633;"><span style="-sec-ix-hidden:F_26650381-9407-4b93-8775-249a9131e1c0;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">without</span></span></span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;par value; </span><span><span style="-sec-ix-hidden:F_1d3d9cda-8981-47f6-bb6f-8de466ce6eb3;"><span style="-sec-ix-hidden:F_00c5c9bd-d79a-4de3-b0a2-1106d3ce3eca;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">unlimited</span></span></span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares authorized; issued and<br/>&#160;&#160;&#160;outstanding: </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_385dd1e2-fbba-4c8d-8780-59529df01316" contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_55558247-ace0-4409-a269-b246de2be885" contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">76,416,086</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;(December 31, 2023 - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b696a4ac-c742-4b5a-880d-0b59c201ffaf" contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_52d162be-b94e-4876-a874-ea391dacfe35" contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">75,370,977</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">) (note 9)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a1a545e7-ae7b-46b1-bc7c-6cb3d00a5f9f" contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,456,836</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fae97182-1420-46d5-9da3-fa5f1b08ef6e" contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,436,374</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additional paid-in capital</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c396720c-9803-44a7-9054-c8f1908b54a9" contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">199,149</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0288a900-9516-4361-b55e-25c5ceb73436" contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">156,764</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accumulated deficit</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_486287c4-ea82-4928-9f66-89cd8cd6d2be" contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">899,470</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_274ddab6-698d-484c-8ae1-8317d59f47d3" contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">665,140</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accumulated other comprehensive loss</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_867527ff-8595-43d5-8d1e-eef739a2c324" contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,612</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_484e5f92-8b80-447b-b6dd-f99ee7462376" contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">77</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total shareholders' equity</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_48d7464d-bebf-40d7-ac43-619a11fddf38" contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">754,903</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_92f91707-55d0-4f96-a3c3-8fc5596e7373" contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">927,921</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total liabilities and shareholders&#8217; equity</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_835ea991-7ed5-44cb-9336-8104afba589a" contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">798,139</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b3bb91d3-875c-4df2-9e31-c48f68a7f50f" contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">964,798</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">   </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_a8ea127d-d3e2-44fe-898c-1a5dafe7f461;"><span style="-sec-ix-hidden:F_c639d4bb-46d7-4e69-bffd-36f05365c504;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commitments and contingencies (note 12)</span></span></span></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Subsequent event (note 10)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">84</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">XENON PHARMACEUTICALS INC.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="statements_of_operations"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consolidated Statements of Operations and Comprehensive Loss</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Expressed in thousands of U.S. dollars except share and per share amounts)</span></p>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;text-align:left;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:57.089%;box-sizing:content-box;"/>
    <td style="width:1.28%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.598%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.28%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.598%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.28%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.598%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.28%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue (note 10)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_447fc576-8309-411e-bc94-bc8bbf27fd11" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,434</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e5c8384a-c78a-4a2e-bc5d-547c5b8cad53" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">210,394</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7a38c236-f556-415f-9e46-5528b3e39735" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">167,512</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_85bcf776-c4dd-4235-9e76-e46ab8ac6e43" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">105,767</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_46438c6a-9e87-49e0-8929-e5c58d99686b" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">68,904</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_40115b69-e8b6-4f5f-b72e-a775b4be7c7c" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">46,542</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_da2e7173-36b6-47b0-ad26-2ff006bceafe" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,810</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c209dec3-166d-4257-a830-32adf9ecf15a" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">279,298</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_75a2e4a7-a01d-4d54-9f77-7c96c7eaa230" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">214,054</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f695f82f-d796-44e1-a7b0-d597843469d5" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">138,577</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_78b07f53-1579-4777-bbc8-c559555cb56c" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">279,298</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_93c3d00b-f953-448d-83e7-77634fb74ebd" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">214,054</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b1273147-6de5-43cf-a696-1f98d61a1abb" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">129,143</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income (expense):</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest income</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_62280b6a-692f-4d51-aba9-f77e2988b43b" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41,943</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8fe97750-3a79-48e6-aed0-db7f6400c766" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,620</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1fd4a085-544c-4e49-8bb7-f703ac2d4a2d" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,713</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unrealized fair value gain (loss) on trading securities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b1268a37-8104-44c9-8f6c-2ca1b74f669b" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="us-gaap:DebtSecuritiesTradingUnrealizedGainLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,550</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_da4a3182-fdec-4ef2-b85f-cef4ef8c6651" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="us-gaap:DebtSecuritiesTradingUnrealizedGainLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,934</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign exchange gain (loss)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_279fa379-edeb-438f-adc1-7c9bed1e61f4" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,064</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cfbd39e6-51d3-4a9d-b7ef-6fb4c6ae96ee" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">199</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c80b2901-cfad-48b3-b155-7d890e247e37" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,891</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9c58b7d1-fafe-4cb3-ad5c-6a4213187cb5" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">40,879</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_66839f2a-d7f3-4b3d-a6d7-9960d976d8b4" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31,369</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e30b69d4-e1a3-4c2b-80ef-2587d16627c5" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,888</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss before income taxes</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_52fc254e-982c-4f33-b015-87b866eb88f6" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">238,419</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b6f70fe5-f9c9-4768-b162-2fbe2a9340b4" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">182,685</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_28c85c2d-b1e2-45a4-9864-b43d4358a3a5" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">125,255</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Income tax recovery (expense) (note 13)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eb45b234-0131-4d1a-a9eb-f548c0b228ef" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">4,089</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1e138eed-5ee7-498c-a491-7507fa01e9e1" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">292</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6d7819fc-e6bb-42e0-bb56-385f910ffc90" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">118</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bc79b445-3b03-4399-aa35-58fa3b665726" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">234,330</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_72a498d1-eca6-48f2-a851-b2da900c44ef" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">182,393</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4631a160-7e6f-44e6-b9f8-71e4f979ade2" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">125,373</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss attributable to preferred shareholders</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b4e6f264-4f4f-49a5-beca-0e18dde4c948" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="xene:NetIncomeLossAvailableToPreferredStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">437</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss attributable to common shareholders</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5149dd99-68e3-475c-8e8c-417aad9e2cdc" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">234,330</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_19d9d7ed-c593-478b-a9cd-b764823a5349" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">182,393</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_64368606-c249-4e8c-a802-aff11e4649c0" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">124,936</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other comprehensive income (loss):</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unrealized gain (loss) on available-for-sale securities (note 5)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_26bb6b0b-606d-4376-a702-b274bfca57de" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,535</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1b432161-bcaf-4c5b-be5f-fdad3e2b5351" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,923</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a73f2f29-75a1-4079-8fe5-8738296373e5" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,010</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Comprehensive loss</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6b2bedad-0e88-4d40-870f-b0e946109ece" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">235,865</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3b4b66e6-85c0-4002-8de9-d082c8279c4c" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">179,470</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_88c7167e-391c-4bb5-8fe8-29a9af457af3" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">127,383</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per common share (note 11):</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Basic and diluted</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_50950cc1-f474-439d-8a87-8ccaaef085a0" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_b99f121c-5216-412b-b3e9-6541c3345ddf" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">3.01</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_08153874-c4d7-4f03-9e1b-b0bf7f632bf6" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_45a793b9-8030-4fab-b6b0-e30d0de4997a" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">2.73</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0dd87bab-b074-4242-a8e9-fe14c68875d2" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_358ef9c6-eae6-43e5-81d3-d38ccd8b3a0c" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">2.06</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average common shares outstanding (note 11):</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Basic and diluted</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_32b7928e-0220-4b0e-9957-ba5371524862" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_2a7a383d-32ee-4f8f-a468-2cecc1004c4f" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">77,894,643</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_de236e4e-8ead-4f06-84de-0f78fe95b0ef" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_8a8a6e1e-f940-4034-abcb-38a7312382ef" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">66,889,005</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_88133d6e-d7fe-4125-8ca9-27294dcdb1cb" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_06672432-87a1-41cf-9ce1-45319b57b381" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">60,542,142</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">85</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">XENON pharmaceuticals INC</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="shares_and_shareholder_equity"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consolidated Statements of Shareholders&#8217; Equity</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Expressed in thousands of U.S. dollars except share amounts)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:23.88%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:6.62%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.44%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:5.460000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:6.46%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:6%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:6%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:6%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:8.96%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:6.18%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="border-top:0.5pt solid #000000;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Convertible<br/>preferred shares</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;border-right:0.5pt solid #000000;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="border-top:0.5pt solid #000000;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Common shares</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="border-top:0.5pt solid #000000;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Additional<br/>paid-in<br/>capital</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="border-top:0.5pt solid #000000;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated<br/>deficit</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="border-top:0.5pt solid #000000;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated other <br/>comprehensive<br/>loss</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="border-top:0.5pt solid #000000;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total<br/>shareholders'<br/>equity</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid #000000;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance as of December 31, 2021</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d8aa7f8d-1a7e-4649-bc01-ad3546d75285" contextRef="C_c36523e7-e5b9-4c2d-b6c3-bb9552e83dbd" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,016,000</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0389c95b-9053-4a53-ab15-36026fbc56d8" contextRef="C_c36523e7-e5b9-4c2d-b6c3-bb9552e83dbd" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,732</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a1c10987-d136-49e9-89aa-4b13a412531f" contextRef="C_0cd8e1e9-eb16-4592-8338-e8cd60e3e9b2" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">51,634,752</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f5415eab-6f29-43b8-9237-fd6eedd0682f" contextRef="C_0cd8e1e9-eb16-4592-8338-e8cd60e3e9b2" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">783,170</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d222a03d-1d2f-4afd-82ca-91039bc3f86a" contextRef="C_286fc5c3-6fd1-4b6d-bd7e-b335add2e3e5" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">117,495</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_71bd3815-9f16-4cd7-a027-d1533faa05d6" contextRef="C_8fa80a4b-d219-444e-a4d3-dce7bd9ccd8b" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">357,374</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e99f6e07-b014-4f6a-bb72-b07c91935d0a" contextRef="C_8f26e8bc-db97-43e5-8f12-99b79372a387" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-">990</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a9123e52-2ef9-407f-9281-17ef3888293b" contextRef="C_7bc29ce6-ec8e-46b1-9da8-77d97bcac7c2" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">550,033</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss for the year</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c1aab079-c492-4b5b-bb14-aa9984f25fba" contextRef="C_d2815981-23d1-4abc-9bb7-2d642884bbe6" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">125,373</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fe47ff74-51f6-43c2-bf2a-d82ba3527c80" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">125,373</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common shares and pre-funded <br/>&#160;&#160;warrants, net (note 9a and note 9e)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_144d5004-b099-45a0-9028-04ff810c7d50" contextRef="C_6cf3e3b1-576f-40f1-acd3-00e00c79c90c" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">9,357,348</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_865b0f4b-0f51-4675-8001-9c990f00f103" contextRef="C_6cf3e3b1-576f-40f1-acd3-00e00c79c90c" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">268,379</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ed991982-9fba-4db1-bdcf-f504ebd4a97f" contextRef="C_9dc51c40-1728-4dc4-81a5-109cda1ab80c" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,387</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7bde4560-4c9f-4ff7-a8fd-0243e0ceaa56" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">277,766</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Conversion of preferred shares (note 9d)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3f11fb99-4527-4f24-842c-0350ca7ab545" contextRef="C_9887e0d2-0944-45f8-8ebe-b8362c753b06" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" unitRef="U_shares" decimals="INF" sign="-" format="ixt:num-dot-decimal">1,016,000</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9159e801-48b9-4400-8bb3-f78bc1336ec0" contextRef="C_9887e0d2-0944-45f8-8ebe-b8362c753b06" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">7,732</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4e3a9af1-8806-429f-a489-6e27d6af4a50" contextRef="C_6cf3e3b1-576f-40f1-acd3-00e00c79c90c" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,016,000</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0252277c-3612-42fd-9054-933e2fad4f15" contextRef="C_6cf3e3b1-576f-40f1-acd3-00e00c79c90c" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,732</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation expense (note 9c)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_294d37ce-a3ac-4c90-a307-d56509671652" contextRef="C_9dc51c40-1728-4dc4-81a5-109cda1ab80c" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,376</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bffa6b73-2cb4-4adc-af54-31a510e23031" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,376</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercise of stock options</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fe9e7f7e-8184-4a99-aebf-490ebb3645b2" contextRef="C_6cf3e3b1-576f-40f1-acd3-00e00c79c90c" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">579,601</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_85cb7d2a-553b-4878-9cd8-d16fa015b599" contextRef="C_6cf3e3b1-576f-40f1-acd3-00e00c79c90c" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,855</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5e078531-a325-4177-be4f-4ad61ed8d3bb" contextRef="C_9dc51c40-1728-4dc4-81a5-109cda1ab80c" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">5,150</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2dd5c129-3c4e-4a92-bb5c-b06a53ee0d75" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">705</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other comprehensive loss</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1d7afd8a-1310-4f67-8535-2cc6096aa834" contextRef="C_809415c5-c3f1-437a-ba07-2d600eeb3db7" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,010</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f2bfc3d8-8605-4025-babf-e93f261f156f" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,010</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance as of December 31, 2022</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e2b903a9-7e87-434b-bed5-c59a67503a98" contextRef="C_3c658b98-b12a-46a6-99c1-797a10c45fb8" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">62,587,701</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ca1b9283-04bb-4fff-9afa-168d5b230e92" contextRef="C_3c658b98-b12a-46a6-99c1-797a10c45fb8" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,065,136</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c9d3bce3-5f14-4771-97d9-f6b16fd717be" contextRef="C_a9775569-4b1a-42fc-b962-e5d75b4877a4" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">142,108</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aa7f04a2-94da-4d34-8d83-13cda5adb3f6" contextRef="C_44cf67e5-b119-4290-96d0-c01203738404" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">482,747</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ce6d890e-0539-48d4-b5ec-779afd6b91ba" contextRef="C_13ef935b-4e96-4f11-925b-9ffc59e4e262" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3,000</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_30fa6019-eb62-4628-8d97-4ceab60c6615" contextRef="C_959e7299-f8b2-49e1-8078-5dac2b5e2683" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">721,497</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss for the year</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_46400233-3975-4337-9106-ec1613aa5467" contextRef="C_4d6ff41e-1e70-42b9-bd5c-6e5b839ec13f" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">182,393</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d76fc319-87fc-443f-bd6a-616f0f555684" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">182,393</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common shares and pre-funded <br/>&#160;&#160;warrants, net (note 9a and note 9e)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fc153deb-431d-4fc1-b3b5-af8a2ce9fada" contextRef="C_b676a389-6e42-455f-9fad-4ecafdc8c411" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">10,701,842</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5f61eb2a-5e59-4349-bede-03b0f6069e48" contextRef="C_b676a389-6e42-455f-9fad-4ecafdc8c411" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">330,010</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b78cb211-7f1f-4f17-89ed-cf3ebc750a8f" contextRef="C_3a167406-79b6-4756-b860-23ced3e7666d" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,477</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3281de95-3365-4d72-b955-b2c66059539e" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">353,487</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Conversion of pre-funded warrants (note 9e)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f7ce2daf-cdd2-404b-aa29-b9764bc6fffa" contextRef="C_b676a389-6e42-455f-9fad-4ecafdc8c411" name="xene:StockIssuedDuringPeriodSharesConversionOfPreFundedWarrant" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,700,000</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_33b3cb41-e41e-470c-9a37-4b6baa284c60" contextRef="C_b676a389-6e42-455f-9fad-4ecafdc8c411" name="xene:StockIssuedDuringPeriodValueConversionOfPreFundedWarrant" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,913</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fc2a4f14-c610-458d-bb10-f72cd0e4a10c" contextRef="C_3a167406-79b6-4756-b860-23ced3e7666d" name="xene:StockIssuedDuringPeriodValueConversionOfPreFundedWarrant" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">35,913</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation expense (note 9c)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4528a618-75aa-4279-94f6-14966a1e8d9b" contextRef="C_3a167406-79b6-4756-b860-23ced3e7666d" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,372</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f1d5e415-7c3b-417f-a682-1e816b979f02" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,372</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercise of stock options</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_39a578fc-7313-43ea-8d1d-ec592ea406f1" contextRef="C_b676a389-6e42-455f-9fad-4ecafdc8c411" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">381,434</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5a7780ed-87b8-402d-b96e-77f2a7852448" contextRef="C_b676a389-6e42-455f-9fad-4ecafdc8c411" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,315</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_38512282-4f68-471f-ab8e-3195a3a8ffb6" contextRef="C_3a167406-79b6-4756-b860-23ced3e7666d" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">5,280</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cfa4ef8a-acf0-4d79-9b08-4bdc5043fbab" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other comprehensive income</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_394d9e85-2acf-48e3-858f-e02cebc31aa0" contextRef="C_196d5f56-7bc1-4e8e-86d8-d5f88f81bbfa" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,923</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_621815bb-fd4b-4904-ba46-68c2a2094f44" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,923</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance as of December 31, 2023</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aa5a87dc-398f-4a20-b67d-90b1982f6656" contextRef="C_c6f61c40-d49e-48b0-81c2-ceb75830debe" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">75,370,977</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_908f3a51-2dea-4524-865c-7269aed4e0b7" contextRef="C_c6f61c40-d49e-48b0-81c2-ceb75830debe" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,436,374</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0cab1014-f9c4-4635-99f1-54a42b91bf3b" contextRef="C_f2b24689-5075-4df6-a2da-72c8837936dc" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">156,764</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_61e41cd3-66b3-4f13-920f-973aa7c35e87" contextRef="C_1747e417-b850-4047-ad97-74e446f3c37c" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">665,140</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_202f1d2f-618d-4c36-95f3-590cb0de5dff" contextRef="C_fc078d20-42fa-4250-b769-ef250cdd40e5" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">77</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_094e2625-b20d-4123-84de-d608972c6fef" contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">927,921</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss for the year</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c087d726-8cc1-4ae1-9acf-eec729ffdf39" contextRef="C_870ddace-7d98-45a8-a1ed-2e57f3f089eb" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">234,330</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c55fed37-7aa9-4ca1-9dd5-e08c72d4bee2" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">234,330</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common shares, net (note 9a)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ef8a891d-4a22-423e-be1d-83da98a7006c" contextRef="C_a3786e8d-3a38-4f5f-915c-ad289a237b50" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">310,000</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ee317498-55da-4959-93df-4c043ccf6c5d" contextRef="C_a3786e8d-3a38-4f5f-915c-ad289a237b50" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,083</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_36092e08-3cae-421b-9457-0b2cba7dbba0" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,083</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation expense (note 9c)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f992802e-6296-43c7-9d29-fac3e7aa9d91" contextRef="C_d9305b94-dbef-4162-bdc8-5136220dcc47" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">50,717</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dfd099a2-3b85-4d94-8375-abace29fbfa0" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">50,717</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercise of stock options</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3b951ef8-9665-4ff8-b90a-143ba9d75398" contextRef="C_a3786e8d-3a38-4f5f-915c-ad289a237b50" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">735,109</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2f4ba682-2848-4b1a-9310-c8ffbde371fc" contextRef="C_a3786e8d-3a38-4f5f-915c-ad289a237b50" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,379</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_674737da-e559-4a0b-a892-9ea241992b40" contextRef="C_d9305b94-dbef-4162-bdc8-5136220dcc47" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">8,332</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_06407877-7b3c-4686-b06e-34d7b22079f3" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">47</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other comprehensive loss</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8661b83f-bf8c-45ba-88d1-dad29c962a66" contextRef="C_884f4d71-a8e8-44ee-82ca-8ef780dfaa13" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,535</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eb22dc9a-99e1-48ee-9faa-4a701689bc37" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,535</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance as of December 31, 2024</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8d69a115-fc74-4df1-a849-b06cbc90629d" contextRef="C_1a3df49e-e657-4eb0-a563-0c1b8605f4aa" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">76,416,086</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8302afa2-d470-44a7-af08-956a5a7ad3bc" contextRef="C_1a3df49e-e657-4eb0-a563-0c1b8605f4aa" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,456,836</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_17a9b201-d547-431c-927c-7321434aec3e" contextRef="C_4b115a6a-6683-4a17-b413-9e8bb98b7a0b" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">199,149</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a6656241-11b5-4c57-b4a5-2f504a4bc03b" contextRef="C_1e9a793b-d120-4f40-8894-7ddb1de35191" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">899,470</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2cce1c7f-19f9-4140-8d79-4e2f536dd661" contextRef="C_7ab2ed07-5dfe-432a-be61-bebc4c8597c5" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,612</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4e78c5ca-67ad-405f-b838-20638f64a459" contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">754,903</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">86</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">XENON PHARMACEUTICALS INC.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="consolidated_statements_cash_flows"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consolidated Statem</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ents of Cash Flows</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Expressed in thousands of U.S. dollars)</span></p>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;text-align:left;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:57.089%;box-sizing:content-box;"/>
    <td style="width:1.28%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.598%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.28%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.598%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.28%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.598%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.28%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Operating activities:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e40e84b4-6681-4df5-929e-d4e0532a3c56" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">234,330</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4a6d56e2-412d-49a3-aa27-70918f161a68" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">182,393</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_453a8117-ab6f-40d7-8bd2-23ebd73f6c03" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">125,373</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:10pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adjustments to reconcile net loss to net cash used in operating activities:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest receivable and accretion of discounts on marketable securities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d83ea07a-39ae-4621-b9f3-1303fd6437ed" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="xene:InterestReceivableAndAccretionOfDiscountsOnMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">816</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ddb8ab76-2150-45e0-b698-aa57af5070e3" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="xene:InterestReceivableAndAccretionOfDiscountsOnMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,785</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_66f77084-e2be-4710-a0c4-e902a06c23ac" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="xene:InterestReceivableAndAccretionOfDiscountsOnMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,598</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciation of property, plant and equipment</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_94141482-b19a-43eb-bf64-763fab10bb1e" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,560</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_866686ca-e387-44e5-bd20-e488a8ce6887" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,061</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4f8dcad2-c816-4446-a183-515d4d460383" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,405</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-cash operating lease expense</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_48ab69c6-4d2e-4761-b7e9-47e6bf68da3f" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,254</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_47bfa0f2-60cb-47df-ba07-caa3d3853075" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,213</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_467745a6-8d55-4ba8-939d-a62fbeb7dc75" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">819</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred income tax recovery</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7288b4ea-523b-4271-8385-60235e0a980d" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">8,864</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_301af402-34d9-4774-a882-bd1e4b3d3987" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">292</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_83330ba2-c12b-42fd-9a3b-a7eaf6c4d9a3" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">44</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ce6bdf12-ff53-4966-ad74-14c0074a0f62" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">50,717</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ac449ca6-904a-4080-a4ef-61c8e673ce69" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,372</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d23d30ec-9a8d-4ec9-8648-50e798e7071e" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,376</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unrealized foreign exchange (gain) loss</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_639635c8-0ac8-4431-bd18-03cec099e2e8" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">745</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_11c381fb-5325-4da7-a15e-dfacc761e063" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">640</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a9bb7456-5417-4ba5-b438-9b8de388443a" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,729</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unrealized fair value (gain) loss on trading securities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_09e1d623-6e84-4658-821b-8297afee3fae" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="us-gaap:DebtSecuritiesTradingUnrealizedGainLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,550</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_185b8f53-830d-4e8d-967e-5a0606840f5e" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="us-gaap:DebtSecuritiesTradingUnrealizedGainLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,934</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:10pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Changes in operating assets and liabilities:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts receivable</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e3220857-4754-403d-8339-3b411cee0c67" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:IncreaseDecreaseInAccountsReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">614</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a51391e5-a6e9-49d0-8c74-94c6eda71eb4" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="us-gaap:IncreaseDecreaseInAccountsReceivable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">130</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dff3f36b-b5d4-4e20-9460-735c32c30294" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="us-gaap:IncreaseDecreaseInAccountsReceivable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,757</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_18c2fe85-e07b-4040-962a-b615dae2852e" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">984</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4ff1905b-24f0-4769-a6e0-9d618d780be3" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,574</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4cf4bc99-bbd0-4230-b733-615d89c6babf" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,495</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts payable and accrued liabilities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ad428d46-feee-448f-9a39-f290fd6658a4" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,531</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_375fcfdb-312a-4408-9f32-fb8022029b35" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,931</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a7d10099-a45d-4cfd-a578-802d26c6e5c1" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,062</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liability</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2d67988f-b07d-48e1-8d0f-d4d5976d6669" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,220</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_30247b71-2b4b-46a7-bd67-544fd6652939" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">267</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b4923755-cdb8-4fc7-9503-5ee34d2d6cd0" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">600</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash used in operating activities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_efd9307f-a3ac-4582-b3b0-28f494750a14" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">181,389</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1ba5df0a-bc2b-413d-bf6b-c2736cbe6ddc" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">151,112</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ee805c93-a8da-4408-aaae-9ce209b1e85a" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">101,028</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Investing activities:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchases of property, plant and equipment</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_72be9a5f-bfaa-4007-8c59-02d2287ce9d4" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,075</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2b75c44c-0b38-4e02-94b1-632668585a3d" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,617</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0b6595c5-9bbc-4ba9-923c-b07efaafc402" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,894</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchase of marketable securities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_86c7ef54-87b5-4255-9b93-b856589d7369" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:PaymentsToAcquireMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">532,268</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bc0238aa-1ff1-472b-b6fc-b8d61dddea91" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="us-gaap:PaymentsToAcquireMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">793,907</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5edbd239-b506-41f6-a678-98511c3176ef" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="us-gaap:PaymentsToAcquireMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">551,137</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from marketable securities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b9a73644-02df-42d6-9102-be668b1221eb" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">700,343</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_59e0729a-e04a-4468-81c7-03b2d3c7b67a" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">688,139</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e7a64e96-d080-41bd-aa98-318506a187e6" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">260,626</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash provided by (used in) investing activities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6599f4b4-9334-4a65-a562-a8875ef7eb90" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">165,000</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1e2b6583-565b-4bbf-922c-4cf671ac7ad5" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">111,385</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2be2ab21-4a54-45f2-b091-d8203c39ed18" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">293,405</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financing activities:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from public offerings, net</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_954f2858-3870-4edf-b9ba-43e5168373db" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,083</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8133d723-44a2-40b3-8ea7-69767b8ce1f0" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">353,487</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cafc83a8-bb3c-468b-a9c0-b2cf3b2a8c4e" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">277,766</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from exercise of stock options</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_257803d3-b705-489f-ab03-c615e530c570" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">47</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4ffde8b0-0451-4df5-8932-7c90979dae48" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bdff1d77-f378-4f90-9923-a40076318f1d" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">705</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_53345580-9e6f-426a-bf8e-f5bcef31f147" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,130</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8a4c0835-7376-4774-973d-c758b2a94dde" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">353,522</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_031d1f1d-3a20-45d3-87ad-b751bb52478d" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">278,471</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Effect of exchange rate changes on cash and cash equivalents</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0e82ab7e-6aa6-447c-a3a8-64c6790fcb8b" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,672</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b176baad-ca75-4d1e-9301-ceecc9e0a9e6" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">376</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9649d0f2-ed00-49c3-bae6-aacbd60385c9" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,484</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Increase (decrease) in cash and cash equivalents</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f4379bb2-4d49-4d2d-b524-a01d41bd53d5" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">5,931</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8ca89132-5030-46ff-9bac-5cee5c2ea9e3" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">91,401</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_768bd748-cad1-4b49-9501-9e8504420bad" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">118,446</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents, beginning of year</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8c8b2226-a3f2-4582-b94b-0a877aec5f12" contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">148,643</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5b4f2d10-8d03-4304-80ec-fd08258a787d" contextRef="C_959e7299-f8b2-49e1-8078-5dac2b5e2683" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">57,242</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_44b9adbf-4d80-43c8-8237-0c29623c2233" contextRef="C_7bc29ce6-ec8e-46b1-9da8-77d97bcac7c2" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">175,688</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents, end of year</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_de392aa8-ac3f-46cd-8fdd-cc7a3052fe34" contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">142,712</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1c4bc058-1456-4dcf-b374-7a0f349d6be8" contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">148,643</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f2475e74-5672-4add-a7a9-d4c636090f69" contextRef="C_959e7299-f8b2-49e1-8078-5dac2b5e2683" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">57,242</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Supplemental disclosures:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash paid for operating lease</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2d5f0ca1-9aa8-4812-9e69-ceaabbba57cc" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,672</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5b7e2872-11ce-44cf-91b7-644890bc18fe" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,624</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3faecadf-0540-4269-9ffb-0c719c0375ef" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">919</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash received for lease incentives</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_409c220b-adb9-4d50-a0b2-c59e4ddbfe7b" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="xene:CashReceivedForLeaseIncentives" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,489</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Supplemental disclosures of non-cash transactions:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Fair value of stock options exercised on a cashless basis</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ecba1115-f0c6-45bf-86c9-6d237b3a43fb" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="xene:FairValueOfStockOptionsExercisedOnCashlessBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,305</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c63746f7-07b6-4f00-a3dd-bddc84508d3d" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="xene:FairValueOfStockOptionsExercisedOnCashlessBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,250</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7df17ace-2832-4763-b053-7e593c29d34e" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="xene:FairValueOfStockOptionsExercisedOnCashlessBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,491</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Fair value of pre-funded warrants exercised</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e1dcc252-47db-42f6-b405-616575b38869" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="xene:FairValueOfPreFundedWarrantsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,913</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchases of property, plant and equipment included in <br/>&#160;&#160;&#160;accounts payable and accrued liabilities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1ee14c35-0b74-48fb-ba08-f18d53a073d4" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="xene:PurchasesOfPropertyPlantAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">391</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Right-of-use asset obtained in exchange for new operating <br/>&#160;&#160;&#160;lease liability</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d5896ef3-35e0-4bf2-987b-546d98b5f56f" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,019</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">87</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">XENON PHARMACEUTICALS INC.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="notes_to_financial_statements"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notes to Consolidated Financial Statements</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Expressed in thousands of U.S. dollars except share and per share amounts)</span></p>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d08a4738-8de9-4baf-8cd4-f6fde5267b8c" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" escape="true"><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nature of the business:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></div></div><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Xenon Pharmaceuticals Inc. (the &#8220;Company&#8221;), incorporated in 1996 under the predecessor to the Business Corporations Act (British Columbia) and continued federally in 2000 under the Canada Business Corporations Act, is a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing ion channel therapeutics for patients in need.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has incurred significant operating losses since inception. As of December 31, 2024, the Company had an accumulated deficit of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b058bb96-cc64-4ded-b96f-6e4e8a509f40" contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">899,470</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and a net loss of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9dc9a77b-c6e7-42eb-a0cf-90aee2767fa5" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">234,330</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for the year ended December 31, 2024. Management expects to continue to incur significant expenses in excess of revenue and to incur operating losses for the foreseeable future. To date, the Company has financed its operations primarily through the sale of equity securities, funding received from collaboration and license agreements, and debt financings.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Until such time as the Company can generate substantial product revenue, if ever, management expects to finance the Company&#8217;s cash needs through a combination of collaboration agreements, equity and debt financings. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The continuation of research and development activities and the future commercialization of its products are dependent on the Company&#8217;s ability to successfully raise additional funds when needed. It is not possible to predict either the outcome of future research and development programs or the Company&#8217;s ability to continue to fund these programs in the future.</span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_574be053-639d-4e8f-8935-1ee0635a9d11" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:BasisOfAccounting" escape="true"><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basis of presentation:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></div></div><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These consolidated financial statements are presented in U.S. dollars and have been prepared in accordance with generally accepted accounting principles in the United States ("GAAP").</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has one wholly-owned subsidiary as of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, Xenon Pharmaceuticals USA Inc., which was incorporated in Delaware on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0ddfc50f-30f4-4f66-8085-88c8399645e3" contextRef="C_b273b0da-ce99-4209-9b93-ffb50f246430" name="dei:EntityIncorporationDateOfIncorporation" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 2, 2016</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All intercompany transactions and balances have been eliminated on consolidation. Certain information has been reclassified to conform with the financial presentation adopted for the current year.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Correction of prior period error</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2024, the Company identified a presentation error related to the accretion of discounts on marketable securities, which was incorrectly presented within proceeds from marketable securities as part of net cash provided by (used in) investing activities in the consolidated statements of cash flows. As a result, a correction was made to the prior periods to reclassify the amount of accretion of discounts on marketable securities within net cash used in operating activities, resulting in an increase in net cash used in operating activities and a corresponding decrease in net cash used in investing activities for the years ended December 31, 2023 and 2022 of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c33c4fa4-8946-42f0-ad00-dc235f02f888" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="us-gaap:PriorPeriodReclassificationAdjustment" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">5,785</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c7c44499-b706-4a46-b48f-d1921e93680c" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="us-gaap:PriorPeriodReclassificationAdjustment" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,598</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively, from the previously reported amounts. The Company evaluated the materiality of the presentation error, both quantitatively and qualitatively, and concluded it was not material to the consolidated financial statements for any prior period. These presentation changes had no effect on the previously reported consolidated balance sheets, consolidated statements of operations and comprehensive loss, or consolidated statements of shareholders&#8217; equity.</span></p></ix:nonNumeric></div>
  <div><ix:nonNumeric id="F_846cbfe8-ebdc-46be-ab72-849c1ab163fe" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:SignificantAccountingPoliciesTextBlock" escape="true" continuedAt="F_846cbfe8-ebdc-46be-ab72-849c1ab163fe_1"><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Significant accounting policies:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_98dce005-8f8c-4c64-b13a-5474ea23b780" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:UseOfEstimates" escape="true"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Use of estimates: </span></div></div><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant areas of estimates include, but are not limited to, revenue recognition including estimated timing of completion of performance obligations and the determination of stock-based compensation. These estimates and assumptions take into account historical and forward-looking factors that the Company believes are reasonable. Estimates and assumptions are reviewed quarterly. All revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">88</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_846cbfe8-ebdc-46be-ab72-849c1ab163fe_1" continuedAt="F_846cbfe8-ebdc-46be-ab72-849c1ab163fe_2"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ecf100e2-7193-4969-8e77-b971815534d5" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" escape="true"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash and cash equivalents: </span></div></div><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash equivalents are highly liquid investments that are readily convertible into cash with terms to maturity of three months or less when acquired. Cash equivalents are recorded at cost plus accrued interest, which approximates the fair value.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7e615fd3-3e3f-46ae-8e6f-48616e48e3ad" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:MarketableSecuritiesPolicy" escape="true"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(c)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Marketable securities: </span></div></div><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Marketable securities are debt securities with original maturities exceeding three months and accrue interest based on a fixed interest rate for the term. Effective July 1, 2022, the Company classifies its marketable securities as either trading securities or available-for-sale securities. Marketable securities are carried at fair value.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fair value gains and losses for marketable securities classified as trading securities are recorded through the consolidated statement of operations. These securities are classified as current assets as the Company has the intent and ability to convert these securities into cash without penalty within the next 12 months.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unrealized fair value gains and losses for marketable securities classified as available-for-sale are recorded through other comprehensive income (loss) in shareholders' equity. When the fair value of an available-for-sale security falls below the amortized cost basis, it is evaluated to determine if any of the decline in value is attributable to credit loss. Decreases in fair value attributable to credit loss are recorded directly to the consolidated statement of operations with a corresponding allowance for credit losses, limited to the amount that the fair value is less than the amortized cost basis. If the credit quality subsequently improves the allowance is reversed up to a maximum of the previously recorded credit losses. When the Company intends to sell an impaired available-for-sale security, or if it is more likely than not that the Company will be required to sell the security prior to recovering the amortized cost basis, the entire fair value adjustment will immediately be recognized in the consolidated statement of operations with no corresponding allowance for credit losses. Realized gains and losses and credit losses, if any, on available-for-sale securities are included in interest income, based on the specific identification method. Available-for-sale securities are also adjusted for amortization of premiums and accretion of discounts to maturity, with such amortization and accretion included within interest income. Available-for-sale securities with a remaining maturity date greater than one year are classified as non-current assets.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_734a97ce-c5d4-4fa5-b394-7b9368f8d1c6" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:LegalCostsPolicyTextBlock" escape="true"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(d)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intellectual property:</span></div></div><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The costs incurred in establishing and maintaining patents for intellectual property developed internally are expensed in the period incurred.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_03e4637c-1767-4d30-8df1-6527f61d5c6a" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(e)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property, plant and equipment: </span></div></div><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property, plant and equipment are stated at cost less accumulated depreciation and/or accumulated impairment losses, if any. Repairs and maintenance costs, which do not improve or extend the life of the respective asset, are expensed in the period incurred. Upon retirement or sale, the cost of the disposed asset and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is recognized as a component of income or loss for the period.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b6a3be30-8b06-40cb-9f66-6c500e2c1624" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="xene:ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" escape="true"><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property, plant and equipment are amortized over their estimated useful lives using the straight-line method based on the following rates:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:49.12%;box-sizing:content-box;"/>
          <td style="width:1.78%;box-sizing:content-box;"/>
          <td style="width:49.1%;box-sizing:content-box;"/>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Asset</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Rate</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research equipment</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_5b9f790a-11bf-47a4-8b6b-0d8b12c700c4" contextRef="C_01045051-1058-4f3f-b914-02cf2190b1d1" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Office furniture and equipment</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_e882a652-287d-4b6e-a262-5a439063ba03" contextRef="C_9e565a8f-9b0e-4173-a3a3-09356a71706a" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer equipment</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_55edf1a0-44de-4cb6-be88-8787b272dce4" contextRef="C_31a54459-014b-4693-8a7e-9d5cd1d9fedb" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_47b3f612-5e00-48af-b88b-1d3d02b7448e;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Over the lesser of lease term or<br/>   estimated useful life</span></span></span></p></td>
         </tr>
        </table></ix:nonNumeric></div></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div><ix:nonNumeric id="F_0e7997c7-8d93-4cb1-8e4b-580f7890f6aa" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" escape="true" continuedAt="F_0e7997c7-8d93-4cb1-8e4b-580f7890f6aa_1"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(f)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Impairment of long-lived assets: </span></div></div></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_0e7997c7-8d93-4cb1-8e4b-580f7890f6aa_1"><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company monitors its long-lived assets for indicators of impairment. If such indicators are present, the Company assesses the recoverability of affected assets by determining whether the carrying value of such assets is less than the sum of the undiscounted future cash flows of the assets. If such assets are found not to be recoverable, the Company measures the amount of such impairment by comparing the carrying value of the assets to the fair value of the assets, with the fair value generally determined based on the present value of the expected future cash flows associated with the assets. The Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ce964814-00f1-4e91-86c5-21d6315a6231" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t recognize any impairment charges through </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></ix:continuation></div><p style="margin-left:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">89</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_846cbfe8-ebdc-46be-ab72-849c1ab163fe_2" continuedAt="F_846cbfe8-ebdc-46be-ab72-849c1ab163fe_3"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d20dad3e-6481-4d96-878f-caa139b68dbb" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:LesseeLeasesPolicyTextBlock" escape="true"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(g)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Leases:</span></div></div><p style="margin-left:9.2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company determines if an arrangement contains a lease at the inception of a contract. The lease classification is determined at lease commencement, which is the date the underlying asset is available for use by the Company. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Leases classified as operating leases are recorded as lease liabilities based on the present value of minimum lease payments over the lease term, discounted using the lessor&#8217;s rate implicit in the lease or the Company&#8217;s incremental borrowing rate, if the lessor&#8217;s implicit rate is not readily determinable. The lease term includes all periods covered by renewal and termination options where the Company is reasonably certain to exercise the renewal options or not to exercise the termination options. Corresponding right-of-use assets are recognized consisting of the lease liabilities, initial direct costs and any lease incentive payments. Lease liabilities are drawn down as lease payments are made and right-of-use assets are depreciated over the term of the lease. Operating lease expenses are recognized on a straight-line basis over the term of the lease, consisting of interest accrued on the lease liability and depreciation of the right-of-use asset, adjusted for changes in index-based variable lease payments in the period of change. Lease payments on short-term operating leases with lease terms twelve months or less are expensed on a straight-line basis over the lease term. The Company has elected to not separate non-lease elements embedded in its lease agreements.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_38a412cb-fdb7-4ae7-a3a2-cf2baead9a41" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:ConcentrationRiskCreditRisk" escape="true"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(h)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Concentration of credit risk: </span></div></div><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents and marketable securities. The Company's investments are limited to investment-grade securities with strong credit ratings with the objective to preserve capital and maintain liquidity. Cash and cash equivalents were held at major financial institutions in Canada and the United States which may at times be in excess of federally insured limits. The Company does not believe that it is subject to credit risk beyond the standard credit risk associated with commercial banking relationships.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4142c5d0-78b3-4218-820a-3a405b81c821" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" escape="true"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(i)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial instruments and fair value: </span></div></div><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company measures certain financial instruments and other items at fair value.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To determine the fair value, the Company uses the fair value hierarchy for inputs used to measure fair value of financial assets and liabilities. This hierarchy prioritizes the inputs to valuation techniques used to measure fair value into three levels: Level 1 (highest priority), Level 2, and Level 3 (lowest priority).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Level 1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> - Unadjusted quoted prices in active markets for identical instruments.</span></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Level 2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates, yield curves, etc.), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs). </span></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Level 3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> - Inputs are unobservable and reflect the Company&#8217;s assumptions as to what market participants would use in pricing the asset or liability. The Company develops these inputs based on the best information available. </span></div></div><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. Changes in the observability of valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy. The carrying amount of accounts receivable, accounts payable and accrued liabilities approximates fair value due to the nature and short-term of those instruments. The Company&#8217;s cash and cash equivalents and marketable securities are measured at fair value on a recurring basis and the level of fair value hierarchy utilized is described in note 4.</span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_0d2dc80f-7197-4c62-a692-232c6c1ac643" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:RevenueRecognitionPolicyTextBlock" escape="true" continuedAt="F_0d2dc80f-7197-4c62-a692-232c6c1ac643_1"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(j)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue recognition: </span></div></div><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognizes the amount of revenue to which it expects to be entitled, for the transfer of promised goods or  services to customers under a five-step model: (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when or as a performance obligation is satisfied. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer.</span></p><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Collaboration agreements may require the Company to deliver various rights and/or services, including intellectual property rights or licenses and research and development services. Under such collaboration agreements, the Company is generally eligible to receive non-refundable upfront payments, funding for research and development services, milestone payments, and royalties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">90</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_846cbfe8-ebdc-46be-ab72-849c1ab163fe_3" continuedAt="F_846cbfe8-ebdc-46be-ab72-849c1ab163fe_4"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_0d2dc80f-7197-4c62-a692-232c6c1ac643_1"><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In contracts where the Company has more than one performance obligation to provide its customer with goods or services, each performance obligation is evaluated to determine whether it is distinct based on whether (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available and (ii) the good or service is separately identifiable from other promises in the contract. The consideration under the contract is then allocated between the distinct performance obligations based on their respective relative standalone selling prices. The estimated standalone selling price of each deliverable reflects the Company&#8217;s best estimate of what the selling price would be if the deliverable was regularly sold on a standalone basis and is determined by reference to market rates for the good or service when sold to others or by using an adjusted market assessment approach if selling price on a standalone basis is not available.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The consideration allocated to each distinct performance obligation is recognized as revenue when control is transferred to the customer for the related goods or services. The Company generally recognizes revenue from non-refundable upfront payments over the estimated term of the performance obligation or period in which the underlying benefit is transferred to the customer. If non-refundable license fees have value to the customer on a standalone basis, separate from the undelivered performance obligations, they are recognized upon delivery. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. Consideration in exchange for research and development services performed by the Company on behalf of the licensee is recognized upon performance of such activities at rates consistent with prevailing market rates. Consideration associated with at-risk substantive performance milestones, including sales-based milestones, is recognized as revenue using the most likely amount method when it is probable that a significant reversal of the cumulative revenue recognized will not occur. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such milestones, and if necessary, adjusts its estimate of the overall transaction price. Sales-based royalties received in connection with licenses of intellectual property are subject to a specific exception in the revenue standards, whereby the consideration is not included in the transaction price and recognized in revenue until the customer&#8217;s subsequent sales or usages occur.</span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f67a358e-a476-46e0-b703-4e9f69687bf3" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true" continuedAt="F_f67a358e-a476-46e0-b703-4e9f69687bf3_1"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(k)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development costs: </span></div></div><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development costs are expensed in the period incurred.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span><ix:continuation id="F_f67a358e-a476-46e0-b703-4e9f69687bf3_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expenses consist of costs incurred in performing research and development activities, including personnel-related expenses, consisting of salaries, benefits and stock-based compensation for employees engaged in scientific research and development, third-party expenses incurred in connection with the pre-clinical and clinical development of product candidates including under agreements with clinical research organizations, third-party expenses relating to formulation, process development and  manufacture of drug substance and drug product for use in pre-clinical testing, clinical trials and potential commercial supply, third-party acquisition, license and collaboration fees, laboratory consumables and certain indirect costs incurred in support of overall research and development activities, including facilities, depreciation and information technology costs. The amount of expenses recognized in a period related to service agreements is based on the work performed using the accrual basis of accounting. Third-party service providers generally provide estimates of proportionate performance to allow the Company to determine an appropriate accrual. When determining the adequacy of an accrual, the Company analyzes progress based on the level of services performed, progress of the studies, including the phase or completion of events, and contracted costs. Payments made to third parties under these arrangements in advance of the receipt of the related services are recorded as prepaid expenses until the services are rendered. </span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prepaid expenses are classified as current or non-current assets based on the expected timing of services.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2694b3a8-575e-443c-a9c2-d1e48da7b6d7" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" escape="true"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(l)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-based compensation: </span></div></div><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-based compensation expense is measured at the grant date, based on the estimated fair value of the award, and is recognized as an expense, net of actual forfeitures, over the requisite service period with a corresponding increase in additional paid-in capital.</span></p><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company grants stock options to employees, consultants, directors and officers pursuant to equity incentive plans described in note 9c. Stock-based compensation expense for stock options is amortized on a straight-line basis over the requisite service period for the entire award, which is generally the vesting period of the award. Any consideration received on exercise of stock options is credited to share capital.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company grants performance share units (&#8220;PSUs&#8221;) to certain employees and officers pursuant to equity incentive plans described in note 9c. PSUs vest upon the achievement of certain predefined company-specific performance-based criteria. PSUs are measured at the c</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">losing market price of the Company&#8217;s common shares on the date of grant. Stock-based compensation expense for PSUs is amortized on a straight-line basis over the requisite service period of each separately vesting tranche of the award once it is probable that the performance condition will be achieved.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">91</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_846cbfe8-ebdc-46be-ab72-849c1ab163fe_4"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7a558da2-e4f6-49f6-a361-4f030d6e0bc0" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" escape="true"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(m)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Foreign currency translation: </span></div></div><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The functional and reporting currency of the Company and its subsidiary is the U.S. dollar. Monetary assets and liabilities denominated in a currency other than the U.S. dollar are re-measured into U.S. dollars at the exchange rate prevailing as of the balance sheet date. Non-monetary assets and liabilities acquired in a currency other than U.S. dollars are translated at historical exchange rates prevailing at each transaction date.</span></p><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue and expense transactions ar</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">e translated at the approximate exchange rate prevailing on the date of transaction. Exchange gains and losses on translation are included in the consolidated statements of operations and comprehensive income (loss) as foreign exchange gain (loss).</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6bf1da4a-63d9-4cb5-a326-4f5674c4e167" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(n)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Income taxes: </span></div></div><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deferred income taxes are recognized for the future tax consequences attributable to differences between the carrying amounts of assets and liabilities and their respective tax bases, net operating loss and tax credit carryforwards. Deferred income tax assets and liabilities are measured at enacted rates expected to apply to taxable income in the years in which those temporary differences and carryforwards are expected to be recovered or settled. The effect of a change in tax rates on deferred income tax assets and liabilities is recognized in the consolidated statement of operations and comprehensive income (loss) in the period that includes the enactment date. A valuation allowance is provided when realization of deferred income tax assets does not meet the more-likely-than-not criterion for recognition.</span></p><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not to be sustained upon examination based on the technical merits of the position as well as consideration of the available facts and circumstances. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The interest accrued related to unrecognized tax benefits and penalties is recognized as income tax expense.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2134ddd7-6f25-4eff-801c-379587bbee87" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:EarningsPerSharePolicyTextBlock" escape="true"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(o)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net income (loss) per common share: </span></div></div><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic net income (loss) per common share is calculated using the two-class method required for participating securities. Undistributed earnings (losses) are allocated to common shares and participating securities based on the weighted average shares of each class outstanding during the period.</span></p><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The treasury stock method is used to compute the dilutive effect of the Company&#8217;s stock options, PSUs and warrants. Under this method, the incremental number of common shares used in computing diluted net income (loss) per common share is the difference between the number of common shares assumed issued and purchased using assumed proceeds.</span></p><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The if-converted method is used to compute the dilutive effect of the Company&#8217;s convertible preferred shares. Under the if-converted method, dividends on the preferred shares, if applicable, are added back to earnings attributable to common shareholders, and the preferred shares and paid-in kind dividends are assumed to have been converted at the share price applicable at the end of the period. The if-converted method is applied only if the effect is dilutive.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c4ae5410-02ca-48c9-93e8-a2a5c6816249" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" escape="true"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(p)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Segment and geographic information: </span></div></div><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker (&#8220;CODM&#8221;), in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b70877bb-397a-426f-8c96-e744995b9eec" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:NumberOfOperatingSegments" unitRef="U_Segment" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> operating segment discovering and developing a portfolio of treatments in neurological and psychiatric disorders.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c0bdf5e4-2f86-4c8b-9437-2e963ab96c43" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(q)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recently adopted accounting pronouncements:</span></div></div><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which enhances the disclosures required for operating segments on an interim and annual basis. The Company adopted this ASU in the fourth quarter of 2024 retrospectively to all prior periods presented in the consolidated financial statements. While the Company continues to operate as a single reportable segment, additional disclosures have been incorporated in note 14.</span></p><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(r)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accounting pronouncements not yet adopted: </span></div></div><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accounting standards that have been issued by the Financial Accounting Standards Board or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on our financial statements upon adoption.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">92</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e82e0947-a3ee-4dd4-a283-c9e084e5167c" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:FairValueDisclosuresTextBlock" escape="true"><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fair value of financial instruments:</span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fbe52223-41c1-4f40-86b3-e774935a73c4" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" escape="true"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The level of the fair value hierarchy utilized to determine the fair va</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">lue of cash and cash equivalents and marketable securities consisted of the following:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:25.615%;box-sizing:content-box;"/>
        <td style="width:1.3%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:5.9990000000000006%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.3%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:5.9990000000000006%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.3%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:5.9990000000000006%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.3%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:5.9990000000000006%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.3%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:5.9990000000000006%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.3%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:5.9990000000000006%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.3%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:5.9990000000000006%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.3%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:5.9990000000000006%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and money market fund</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1873a220-9e8d-43a1-84b1-4380bba7877e" contextRef="C_7f8727e8-25d3-49ce-a4eb-f560f9d67b08" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">142,712</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8f878dad-69de-4522-bf78-e0db15b46f12" contextRef="C_cdaa9dc0-7dd9-4606-9431-1abf2c692823" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">142,712</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_79ba99bb-eb33-4625-8603-bdfdde742c29" contextRef="C_de04a46d-af61-488e-a31d-4bcee768b536" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">148,643</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d0600fac-ca24-485e-ab54-f823d1751644" contextRef="C_f75f1b7d-970c-44d9-af0e-c5a826dcce23" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">148,643</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Guaranteed investment certificates</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ffbefff4-eb13-4596-a7d5-9c34cce196d6" contextRef="C_53032a5e-ec82-4a52-98b9-c114209ab7e7" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,147</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2fb7b596-6636-42be-9e4a-06a5718a5067" contextRef="C_18ce0587-947d-4000-ad21-226659cdded6" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,147</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_853dd7ae-d6c3-4fb2-9df0-d276b9fc16b6" contextRef="C_2298e5e3-65b4-4e1c-93f1-f5027b90c559" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,684</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_27a588ee-8822-4d0c-bcee-d79cd9fed845" contextRef="C_9a7e217e-4eb8-4d7c-b2ca-de82b025bdab" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,684</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. treasuries</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cc6a8160-47f1-443a-939c-be0260a903f2" contextRef="C_01a82667-15d7-4024-a57e-2657379f179f" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">130,948</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_919a26b5-829f-4369-b6fb-1c0ede4d53dd" contextRef="C_a4e5a889-56d8-4a0f-bc5c-ed4272cae01a" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">130,948</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3a8332ed-2f80-4aa4-9116-2132689746ca" contextRef="C_ecdb23a3-e394-4b57-b4f0-5e84d7ca4b27" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">252,982</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9b64e65d-a94f-493b-a1e1-06da602191fa" contextRef="C_d9195ae5-00f1-40d7-86d7-25551a0a0739" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">252,982</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_41f0e4b4-ed11-4038-ab46-d1822acb4a4e" contextRef="C_e51a83d7-051a-440a-9383-caa0acb0c6a7" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">97,912</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6765ab86-f3ae-4248-ae1d-4055e1e6e62f" contextRef="C_a581601f-604c-40e0-a538-b4058e27858a" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">97,912</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_253c5e5e-cdce-4818-8446-4f55dcf5ea67" contextRef="C_1aa8c882-c640-42ab-9434-c87e60af198d" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">66,905</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ad456444-12d4-4671-80e0-56fdd9fd53f5" contextRef="C_1c604906-e061-40ec-b25c-b0b029e35f62" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">66,905</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_59df8415-7a02-4ca8-b6c6-511f34f8fba9" contextRef="C_9ee56ce4-a340-480e-9aec-44adf7965a2c" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">119,108</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b72df64b-5c55-411f-836e-447567d7b93f" contextRef="C_63ad59ce-e171-4295-bb49-279aaf68cd61" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">119,108</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c05ff53d-d9eb-47cd-96a4-2d6371c56db9" contextRef="C_7e56dc4c-bf82-4de2-abd8-51bda8f0b0a0" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">397,689</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e79dbb8c-994b-4ddc-96fa-73a0bbf555bd" contextRef="C_c9472f62-0148-495c-b52e-860ba1e4f49e" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">397,689</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ac1287ed-5a38-4669-b73b-415921fa663e" contextRef="C_88dd1245-4241-4674-abff-66b46ec29d01" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">304,545</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_af959500-8a85-46e5-a611-7301245bc555" contextRef="C_27ad495b-a0bb-495a-8e89-83c9f5fe8b65" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">304,545</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_460b4144-6a87-4eef-91de-1eef203a4b0f" contextRef="C_6c905a81-8dbd-4c7f-94d4-609f8be01e6a" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">289,807</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e915c404-151c-45bd-a9cc-888ef01dae6e" contextRef="C_0ee5ccd7-b9d5-48bc-900e-21a7360e15ff" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">464,594</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ee817083-85b0-4db1-bb66-ad8520983277" contextRef="C_3cd561ce-d56f-4072-b50b-523fee0cd886" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">754,401</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_97334216-1bb3-4ec0-9832-54fd04453dc6" contextRef="C_30871dbf-c703-4cc7-943f-7794f870694c" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">409,309</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_863cb05e-6bc0-479f-88f9-470029d47918" contextRef="C_e1049099-ba3b-4285-9482-cc2e1b4be2e0" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">521,565</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c2cba7ec-0536-420e-87f8-4d0739f6bf73" contextRef="C_9fde0c8e-4519-4f2d-bac4-a130605b9e35" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">930,874</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair values of the Company&#8217;s U.S. government securities, commercial paper and corporate debt securities are based on prices obtained from independent pricing sources. Securities with validated quotes from pricing services are reflected within Level 2, as they are primarily based on observable pricing for similar assets or other market observable inputs. Typical inputs used by these pricing services include, but are not limited to, reported trades, benchmark yields, issuer spreads, bids, offers or estimates of cash flow, prepayment spreads and default rates.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024 and December 31, 2023, the Company does not hold any securities classified as Level 3 and there were no securities transferred between Level 1 and 2.</span></p></ix:nonNumeric></div>
  <div><ix:nonNumeric id="F_e3baa447-e1a4-4814-b8ec-583cc764bd70" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" escape="true"><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Marketable securities:</span></div></div><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company had $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a8105c7e-2371-4270-862a-43588e9fc4c4" contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">611,689</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of available-for-sale securities (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#8211; trading securities of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_af98c0ee-551f-430b-b977-8266b764cc0e" contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35" name="us-gaap:TradingSecuritiesDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,867</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and available-for-sale-securities of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8a87fea6-c516-4ccc-bec8-a0d024a7084f" contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">768,364</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively). </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1382048e-073d-459c-b781-1efbe2223c27" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" escape="true" continuedAt="F_1382048e-073d-459c-b781-1efbe2223c27_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amortized cost, unrealized gain (loss) recognized in accumulated other comprehensive loss and fair value of available-for-sale securities consisted of the following:</span></ix:nonNumeric></span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_1382048e-073d-459c-b781-1efbe2223c27_1"><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:34%;box-sizing:content-box;"/>
        <td style="width:1.681%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:8.087%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.681%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:7.907%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.681%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:8.087%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.681%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:7.045999999999999%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:6.906000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.681%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:6.566%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized <br/>Cost</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized Gain (Loss)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair <br/>Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized <br/>Cost</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized <br/>Gain (Loss)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair <br/>Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Contractual maturity of 0 to 1 years:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Guaranteed investment certificates</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4b635088-d69e-4d29-aa8d-4009d227fa11" contextRef="C_0dedc115-eabd-4f39-a7bf-4c55dd4adc43" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,122</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c6fd3ba9-6142-4956-91f7-bbce28eaa7fc" contextRef="C_0dedc115-eabd-4f39-a7bf-4c55dd4adc43" name="xene:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTaxCurrent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">975</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_737161c5-f003-46a6-b3fc-973709831a8e" contextRef="C_0dedc115-eabd-4f39-a7bf-4c55dd4adc43" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,147</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7eb38472-2736-4739-8ce3-fb5b62277a74" contextRef="C_5edde648-d952-4a12-a2fc-5d27c42f48db" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,549</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_39f0851e-d9bc-4566-a1e3-6f4cbb7c4501" contextRef="C_5edde648-d952-4a12-a2fc-5d27c42f48db" name="xene:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTaxCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">135</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_55984f49-2171-49e1-b80b-16958714fa94" contextRef="C_5edde648-d952-4a12-a2fc-5d27c42f48db" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,684</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. treasuries</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ad2e0ef7-1cbd-431e-b021-a9cd1fa35cf6" contextRef="C_ebe1e93e-63c9-48fd-b7f8-764857c13f18" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">72,989</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e2bbed75-adb6-437e-ac60-fe67c7181f58" contextRef="C_ebe1e93e-63c9-48fd-b7f8-764857c13f18" name="xene:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTaxCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">147</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_56375395-02e2-4cd0-8296-e3b9b1737474" contextRef="C_ebe1e93e-63c9-48fd-b7f8-764857c13f18" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">73,136</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7961d9fb-74fc-4058-96c5-2405a96c47e5" contextRef="C_577a2a65-5c5b-4519-baed-db30c894bf0f" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">192,193</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2afd2ddd-325c-4cd8-98bb-08098f688097" contextRef="C_577a2a65-5c5b-4519-baed-db30c894bf0f" name="xene:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTaxCurrent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">249</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6b3e065f-8e8c-41ac-9fb8-4defc7d78788" contextRef="C_577a2a65-5c5b-4519-baed-db30c894bf0f" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">191,944</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_75c9353b-f2fe-4ed9-bafa-43b27de4f38b" contextRef="C_c0de2a82-98b0-4310-ad4c-fc4a77de4ddf" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">98,092</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2abdb6f0-bf5c-4e1b-a396-e37e5da926ea" contextRef="C_c0de2a82-98b0-4310-ad4c-fc4a77de4ddf" name="xene:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTaxCurrent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">180</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1ee7f7b6-59cd-4c7e-9980-1b91b8d0815e" contextRef="C_c0de2a82-98b0-4310-ad4c-fc4a77de4ddf" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">97,912</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_428884af-89f3-4f9e-8fb4-d5ce43a4296e" contextRef="C_50bacaa3-fec8-476a-a9ec-7fcc62c9f5b7" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">66,808</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_33c849b1-0bcd-4ea7-92d8-7bc531d993a5" contextRef="C_50bacaa3-fec8-476a-a9ec-7fcc62c9f5b7" name="xene:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTaxCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">97</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1c2713d0-85e6-4f4e-a4d4-c8d16c45f72a" contextRef="C_50bacaa3-fec8-476a-a9ec-7fcc62c9f5b7" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">66,905</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b74f9354-b05f-46d5-8556-8eb4ab883154" contextRef="C_4b92f893-c873-482f-8d2a-12d3073fc31f" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">119,041</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f1fa8e03-5ace-49a2-8c9f-7775e291a149" contextRef="C_4b92f893-c873-482f-8d2a-12d3073fc31f" name="xene:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTaxCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">67</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c3a60fe6-1772-47a9-8b90-a8335c49c676" contextRef="C_4b92f893-c873-482f-8d2a-12d3073fc31f" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">119,108</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_54171d5c-d2a2-49ad-8b93-dda6159a2522" contextRef="C_9a4e5db1-ae6b-4123-9a4b-819384e01155" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">327,448</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1ab8a106-a566-4c2a-862f-ed63e062ba34" contextRef="C_9a4e5db1-ae6b-4123-9a4b-819384e01155" name="xene:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTaxCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">557</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f30fc5ec-208f-46a8-92be-67e560ad08c0" contextRef="C_9a4e5db1-ae6b-4123-9a4b-819384e01155" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">328,005</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_92bc0a48-67c7-451b-8424-96e98220c1c1" contextRef="C_678bf7e6-b4a8-4a8d-a08d-fd80c5153186" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">58,824</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7075478c-53fd-4985-b6a1-ece67459cbba" contextRef="C_678bf7e6-b4a8-4a8d-a08d-fd80c5153186" name="xene:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTaxCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">100</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_997392ed-fedb-45bd-bfd5-79da039e3412" contextRef="C_678bf7e6-b4a8-4a8d-a08d-fd80c5153186" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">58,924</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Contractual maturity of 1 to 3 years:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. treasuries</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7992a3dc-622e-4ec0-9a42-e3f7b8c267e1" contextRef="C_ebe1e93e-63c9-48fd-b7f8-764857c13f18" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">58,218</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_521bf13a-21b9-4da4-8abd-4baf7396df0b" contextRef="C_ebe1e93e-63c9-48fd-b7f8-764857c13f18" name="xene:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTaxNoncurrent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">406</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_841bdef9-fa45-4b51-8560-e6315410421d" contextRef="C_ebe1e93e-63c9-48fd-b7f8-764857c13f18" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">57,812</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_84bbbbf6-7a1b-4f02-b17b-7773ae5dbca3" contextRef="C_577a2a65-5c5b-4519-baed-db30c894bf0f" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">53,294</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6763b608-20c1-4174-a3f3-2be47c969383" contextRef="C_577a2a65-5c5b-4519-baed-db30c894bf0f" name="xene:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTaxNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">243</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a1c107aa-b5b5-4ee8-ac34-e448a2820edc" contextRef="C_577a2a65-5c5b-4519-baed-db30c894bf0f" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">53,537</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d32a1006-ff6d-4409-a251-7addf532d12f" contextRef="C_9a4e5db1-ae6b-4123-9a4b-819384e01155" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">69,726</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3c99d0c6-14f0-4fef-b719-34e0a03ed290" contextRef="C_9a4e5db1-ae6b-4123-9a4b-819384e01155" name="xene:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTaxNoncurrent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">42</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_66983ec4-64b5-456e-ab7b-c449f3623b5f" contextRef="C_9a4e5db1-ae6b-4123-9a4b-819384e01155" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">69,684</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_51da9246-7872-43ea-9494-318a56951c57" contextRef="C_678bf7e6-b4a8-4a8d-a08d-fd80c5153186" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">238,458</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_110e550d-3448-4b8a-8eaf-2704f33edb11" contextRef="C_678bf7e6-b4a8-4a8d-a08d-fd80c5153186" name="xene:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTaxNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">797</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_941a3b9d-4754-46fb-8410-2502c6b14cad" contextRef="C_678bf7e6-b4a8-4a8d-a08d-fd80c5153186" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">239,255</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_abc294fa-43bd-4835-b39a-2b9ec22fd6af" contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">612,311</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f0858a3a-e6bb-4468-8de7-4fe1d0952f28" contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f" name="xene:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">622</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0f55ef37-c6aa-44a6-8c2d-2ef4e8a16813" contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">611,689</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2c0d70ab-4ebd-4c8d-bd84-b404c2ddd48e" contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">767,451</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2ef28550-4294-4495-872a-413cd42fcc5d" contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35" name="xene:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">913</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_87edfef7-3260-4dd0-ad2a-1a3d93892cc1" contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">768,364</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Allowance for credit losses or impairment on these marketable securities have not been recognized as these securities are high credit quality, investment grade securities that the Company does not intend to sell and will not be required to sell prior to their anticipated recovery, and the decline in fair value is primarily due to changes in interest rates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">93</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:nonNumeric id="F_e2403ccd-a53c-4a3a-8e18-1f8a97952062" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" escape="true"><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">6.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property, plant and equipment:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_15f52cb1-4da6-4be7-aff7-05e79949b88b" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:PropertyPlantAndEquipmentTextBlock" escape="true" continuedAt="F_15f52cb1-4da6-4be7-aff7-05e79949b88b_1"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property, plant and equipment consisted of the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:68.32%;box-sizing:content-box;"/>
        <td style="width:1.52%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.08%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.08%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="5" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0bf52cbb-dacd-4ea8-bd94-e13bf0c18f28" contextRef="C_01045051-1058-4f3f-b914-02cf2190b1d1" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,631</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3a5d5539-0c33-4774-878c-84a0daa74d79" contextRef="C_dd36de89-61c3-47d3-b597-7a827f1ad7ff" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,111</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Office furniture and equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e261307a-19d2-4c2f-92b3-282544a477b4" contextRef="C_1c8819fe-6ad0-42fe-bce0-e8f35f30bcb8" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,285</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4a72f11d-3989-4c97-a1fe-137e1f33fe3b" contextRef="C_ea541069-c8a0-41f5-a186-def6edd37f4a" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,285</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ba9ffe49-62ca-4ae1-a7d2-ea390e3ff803" contextRef="C_31a54459-014b-4693-8a7e-9d5cd1d9fedb" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,463</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_72d336b6-77e8-42f4-8b91-b81ab6693b3c" contextRef="C_855c2687-033c-4d5b-9d65-93762e253c78" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,489</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c27210f2-8073-45e6-8ba9-696f3c381c85" contextRef="C_4e096b75-1c3e-4f4b-a2d5-46dab7c31772" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,363</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d035a59d-ba73-41cb-a6bb-c2bdcaad1e84" contextRef="C_8af453ba-33f4-44f7-9e63-cd2ff108e084" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,019</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: accumulated depreciation and amortization</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f6db06e3-67b8-4880-a55a-155f59b50c27" contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,464</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7460bfc4-6f29-4de8-aca4-19068e6ca198" contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,251</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net book value</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2ce4c6c9-c7e6-4867-bffa-a2615fac31ca" contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,278</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1e939bc1-2481-476c-8532-d038fd68ac2e" contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,653</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <div><ix:continuation id="F_15f52cb1-4da6-4be7-aff7-05e79949b88b_1"></ix:continuation></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_d8dfaacf-e0ea-4c4f-b8aa-8cf1a974dda7" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:LesseeOperatingLeasesTextBlock" escape="true"><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">7.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Leases:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></div></div><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span><ix:nonNumeric id="F_bd2c8b08-a7f9-4062-a13d-0d215f79f77f" contextRef="C_f76418ce-447a-47fa-abce-3e02aca037d2" name="us-gaap:LesseeOperatingLeaseDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_a0537c61-71b0-4915-978f-b5bbcfc84362;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">an</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> operating lease for research laboratories and office space in Burnaby, British Columbia which expires on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_494c9559-2c82-419d-8464-7a39b6002323" contextRef="C_f76418ce-447a-47fa-abce-3e02aca037d2" name="us-gaap:LeaseExpirationDate1" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 30, 2032</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4dceec58-d5b8-4bab-a87b-45c55c39e15c" contextRef="C_b6853865-a835-4d1f-bb65-e80788e06f13" name="xene:LesseeOperatingLeaseNumberOfRenewalOptions" unitRef="U_Option" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> renewal options for </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_15085fc3-0b53-47a9-8229-a45b641f68bf" contextRef="C_ce952f40-3105-427e-bbaa-fffd07f2063c" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:duryear"><ix:nonNumeric id="F_9db72306-09d9-4e52-8e6a-874e690b8b74" contextRef="C_0f230ef8-cad8-4ce7-bee0-026b0567d14a" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</span></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-years each which were not considered in the determination of the right-of-use asset and lease liability.</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_99738259-862a-4d92-8d8f-a2d5d88bcaf5" contextRef="C_ccebda2c-e532-4b8e-ac5b-a03dd5ef7b48" name="us-gaap:LesseeOperatingLeaseDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Company has an additional operating lease for office space in Needham, Massachusetts (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8220;Needham Lease&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">), which commenced in October 2022. The Needham Lease is for a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8aa44486-9685-4d30-a857-31054e4918a2" contextRef="C_7a64b01e-5173-4d9f-837a-bbb2c4168382" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">62-month</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> term and an </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a273dfc0-4152-432d-b4da-df8771cc8e7e" contextRef="C_ccebda2c-e532-4b8e-ac5b-a03dd5ef7b48" name="us-gaap:LesseeOperatingLeaseOptionToTerminate"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">option to terminate one year prior to the expiry date</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which was not considered in the determination of the right-of-use asset and lease liability.</span></ix:nonNumeric></span></ix:nonNumeric></span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><ix:nonNumeric id="F_e75bbeca-765f-411b-b794-0cfcc7c138d0" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:LeaseCostTableTextBlock" escape="true"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The cost components of the operating leases were as follows for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024, 2023 and 2022:</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:59.416%;box-sizing:content-box;"/>
        <td style="width:1.321%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.088%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.088%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.088%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="8" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease cost</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease expense</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_04a8b348-cfc2-4f65-b1a7-2db878541763" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,646</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_16a57ba8-72aa-475e-9535-c54f6cd12c91" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,645</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c01fb1b8-0633-4814-a500-f2a48c63df54" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,126</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Variable lease expense</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c1a45d73-bd9d-4966-a361-d6a7331b7229" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:VariableLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">826</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cbfebd64-0a27-4991-9ad5-212be654e613" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="us-gaap:VariableLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">787</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_64a56835-5cfe-48be-95ec-d5d10f7f7ac6" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="us-gaap:VariableLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">774</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease term and discount rate</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average remaining lease term (years)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_bbb78354-2948-49bc-a8f1-4516f261140e" contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.4</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_1c95cfa4-4a4e-423d-b9d0-ac26fe379363" contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.3</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_cc60d7af-cb74-4aef-8f54-6ed7c440b23f" contextRef="C_959e7299-f8b2-49e1-8078-5dac2b5e2683" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.1</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average discount rate</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_23befde7-785b-4c1a-a6b3-d7f220bf8108" contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">3.8</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8a9a6a9a-6a0b-4c4e-91fb-86c8654b59cf" contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">3.9</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fa06d0bd-5a2e-41ed-8a74-d76018158e5c" contextRef="C_959e7299-f8b2-49e1-8078-5dac2b5e2683" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">4.0</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><div class="item-list-element-wrapper" style="margin-left:11.204%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:justify;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;font-kerning:none;min-width:3.0035136717870174%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Variable lease costs are payments that vary because of changes in facts or circumstances and include common area maintenance and property taxes related to the premises. Variable lease costs are excluded from the calculation of minimum lease payments. </span></div></div></ix:nonNumeric></div><p style="margin-left:5.693%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</span><span><ix:nonNumeric id="F_86166d56-eca2-4db3-87d4-7f1bb7fc996f" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" escape="true" continuedAt="F_86166d56-eca2-4db3-87d4-7f1bb7fc996f_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Future minimum lease payments as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 were as follows:</span></ix:nonNumeric></span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_86166d56-eca2-4db3-87d4-7f1bb7fc996f_1" continuedAt="F_86166d56-eca2-4db3-87d4-7f1bb7fc996f_2"><p style="margin-left:5.733%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.444%;box-sizing:content-box;"/>
        <td style="width:1.8%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:15.757%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Year ending December 31:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cc0a4245-4d2f-4ee6-a8af-9274caf0d316" contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,690</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_08e001cb-d23c-41d1-83eb-542c3229b9b4" contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,755</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a3fce00d-4e3f-4e5e-ad9a-aee728ff3ca5" contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,739</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6eddb810-f9e2-4e70-85b3-2dca3c31fe6e" contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,037</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2029</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bc53ea66-e1ac-4c83-9b84-6da11a24e368" contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,085</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2030 and thereafter</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_135b220c-b02d-4a54-9881-b27c3f47b369" contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,861</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total future minimum lease payments</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_330a75c8-5127-4d5e-93a9-e701584d7945" contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,167</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: imputed interest</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_945dac85-8524-4cdf-af47-527b2c7ccc65" contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,152</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Present value of lease liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_01be45e2-f65a-4821-8ef2-9f42daaea636" contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,015</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div></ix:nonNumeric></div>
  <div><ix:continuation id="F_86166d56-eca2-4db3-87d4-7f1bb7fc996f_2"></ix:continuation></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">94</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_95d069cc-e952-4d3f-ae5c-f5706702f8c0" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" escape="true"><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">8.</span><div style="width:100%;display:inline;" id="report_of_independent"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accounts payable a</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">nd accrued liabilities:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_475ac2e3-61b3-4fe4-8355-046687f72364" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" escape="true"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accounts payable and accrued liabilities consisted of the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:68.32%;box-sizing:content-box;"/>
        <td style="width:1.52%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.08%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.08%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="5" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts payable</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_33377877-0364-4cdc-9127-e14d1e6b599f" contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f" name="us-gaap:AccountsPayableTradeCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,070</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cfb85ae6-844d-4354-bf9d-aa3d9f8d30e7" contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35" name="us-gaap:AccountsPayableTradeCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,598</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued liabilities</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Employee compensation, benefits, and related accruals</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_29cccb7f-2add-4f1b-ae2b-a381aa23974a" contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,928</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0f2e61f8-5e9c-4d90-9f92-f48bb7f87b0e" contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,425</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bda0b8aa-054f-4b14-947e-587be3b0e20c" contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f" name="xene:AccruedResearchAndDevelopmentCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,061</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2cc3b2c1-fc3b-4cb4-9856-642dbcb31196" contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35" name="xene:AccruedResearchAndDevelopmentCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,824</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Income and other taxes</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0d677319-6273-4f91-b4f6-8fddee5f79b1" contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f" name="us-gaap:TaxesPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,686</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_90921a49-00b7-42a7-b083-207d97145cfd" contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35" name="us-gaap:TaxesPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">347</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Professional fees</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3544fb0d-7b85-44dd-9a6d-d5364b9d4b69" contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">762</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b1c12e0a-80c7-47e9-bdda-8d1002f0299d" contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">780</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7e67297c-051c-4e30-9849-fa2d586fddc9" contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">714</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_afb96153-08e2-4dd8-9c44-d66c05024519" contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2415dfa3-8bff-41fe-9175-29e68c6c427e" contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">34,221</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_896fea06-6ea5-499f-ac59-c091090081a6" contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,974</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div><ix:nonNumeric id="F_14b2c51d-f208-4596-a88f-3b2b67be6153" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true" continuedAt="F_14b2c51d-f208-4596-a88f-3b2b67be6153_1"><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">9.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Share capital:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financing:</span></div></div><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">August 2020, the Company entered into an &#8220;at-the-market&#8221; equity offering sales agreement, amended as of March 2022, with Jefferies LLC and Stifel, Nicolaus &amp; Company, Incorporated pursuant to which the Company may sell common shares from time to time (the &#8220;ATM Program&#8221;). In September 2023, pursuant to a prospectus supplement filed in March 2022 (&#8220;March 2022 Prospectus&#8221;), the Company sold an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_88647751-5795-4bb6-9e1e-c08b7d4ccbd8" contextRef="C_e5737a61-1f16-4af6-ac8a-b3e0f4d46fae" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">855,685</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> common shares for proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ea0c2f79-5177-402a-97f8-14f9ca7037a6" contextRef="C_1687d09a-5433-43c2-90f1-f650513a2fa1" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,508</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, net of commissions and transaction expenses. In August 2024, a new prospectus supplement was filed replacing the March 2022 Prospectus, pursuant to which the Company refreshed the ATM Program and may sell common shares having gross proceeds of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5202d596-7e8e-476e-beaa-bf74b92b366e" contextRef="C_580473ec-137a-44c3-af0d-b97a202a4a2e" name="xene:GrossProceedsFromIssuableOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">350,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, from time to time. As of December 31, 2024, the Company has sold an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b30acf93-c69e-42e9-aac3-dab8c6bb21c3" contextRef="C_e41e64f7-0a7c-4d69-9147-98202c4d2812" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">310,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> common shares for proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f1ddd5a5-a433-42d8-a2d1-e01b784306f3" contextRef="C_3c7df611-38a7-4085-9e60-23c55dba93c2" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,083</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, net of commissions and transaction expenses under the ATM Program.</span></p><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In January 2022, in connection with the License and Collaboration Agreement with Neurocrine Biosciences entered in December 2019 and amended in January 2021 (the &#8220;Neurocrine Collaboration Agreement&#8221;), the Company executed a Share Purchase Agreement (&#8220;SPA&#8221;) pursuant to which the Company issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_133e979c-6efd-48b1-aa1c-867d8188dc33" contextRef="C_16c2e333-259f-4e18-b025-1a7840b2cf5d" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">258,986</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> common shares for an aggregate purchase price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9fe4a1a5-17f0-4308-84a0-9b5a05ac68fb" contextRef="C_16c2e333-259f-4e18-b025-1a7840b2cf5d" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,250</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, or $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6b3dc7c4-0c57-4067-8d60-278777093341" contextRef="C_e03fe75c-2f66-4f62-8b71-f0cb7b6dd2c7" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">31.855</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per common share, which represents a premium of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c47015f5-ac66-4a0d-abaf-aa5c5bf58ed9" contextRef="C_16c2e333-259f-4e18-b025-1a7840b2cf5d" name="xene:CollaborateMilestoneAgreementPremiumRelatedToEquityInvestment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">374</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> when compared to the fair value of common shares on the date of issuance. The SPA contain certain other customary terms and conditions, including mutual representations, warranties and covenants. For additional information regarding the Neurocrine Collaboration Agreement, refer to </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">note 10.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In June 2022, the Company completed an underwritten public offering of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d0811a8d-2397-4d8c-9e8b-cdd4fe48607d" contextRef="C_f91f0158-e869-4802-841d-82a3345ebc02" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">9,098,362</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> common shares, including </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e164ac49-4afc-48b3-979f-1db9062f089b" contextRef="C_f90eb819-58f1-4a64-8683-5de3a214bcb5" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,229,508</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares sold upon the full exercise of the underwriters&#8217; over-allotment option, at a public offering price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5b3a49dd-558b-4bb5-ae8c-4ab143fc18bd" contextRef="C_e9b5b17b-a190-4b8c-8268-dec97ce1d7a0" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">30.50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per common share and pre-funded warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e1c1652a-c513-40d7-b01c-6566e73a873f" contextRef="C_e9b5b17b-a190-4b8c-8268-dec97ce1d7a0" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">327,868</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> common shares at $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_458ed1c7-3d46-4067-a176-09e077783420" contextRef="C_e9b5b17b-a190-4b8c-8268-dec97ce1d7a0" name="xene:WarrantsIssuedPricePerPreFundedWarrant" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">30.4999</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per pre-funded warrant (note 9e), with each pre-funded warrant having an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cf7ad05c-f94b-48c5-9cdb-f0e96ffa2e6f" contextRef="C_e9b5b17b-a190-4b8c-8268-dec97ce1d7a0" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4">0.0001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The public offering was completed in June 2022, and the Company received proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_81f4f318-a9af-4948-8192-f75716c7efbe" contextRef="C_f91f0158-e869-4802-841d-82a3345ebc02" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">269,890</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, net of underwriting discounts, commissions and offering expenses.</span></p><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2023, the Company completed</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> an underwritten public offering of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_87e65d2c-97b0-4a00-a02e-5029e5d29c52" contextRef="C_279f5f99-a2c7-4a1f-b98a-9e98fe07b653" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">9,846,157</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> common shares, including </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cdfe7140-1e5c-4d31-acfb-0c7e040ac383" contextRef="C_0514d61f-b883-40b3-87d9-7e278b3a6820" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,384,615</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares sold upon the full exercise of the underwriters' over-allotment option, at a public offering price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f1e104bf-fb7b-44b5-850e-1c9bed2f8975" contextRef="C_0a8f0fd9-0cf5-45b3-8b78-096409d7c4d6" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">32.50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per common share and pre-funded warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_888d511d-14c3-461e-a586-84a3199fb4a7" contextRef="C_0a8f0fd9-0cf5-45b3-8b78-096409d7c4d6" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">769,230</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> common shares at $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c463f524-e04b-4878-ada2-4b21847c15d9" contextRef="C_0a8f0fd9-0cf5-45b3-8b78-096409d7c4d6" name="xene:WarrantsIssuedPricePerPreFundedWarrant" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4" format="ixt:num-dot-decimal">32.4999</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per pre-funded warrant (note 9e), with each pre-funded warrant having an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7a0eb858-a5ca-4f94-aa7e-9a0e632dc3b5" contextRef="C_0a8f0fd9-0cf5-45b3-8b78-096409d7c4d6" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The public offering was completed in December 2023, and the Company received proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_24d754ac-cf41-46be-a41d-96b37d124d6d" contextRef="C_295d7ebf-ecb2-4863-8055-c5d32414b32f" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">323,979</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, net of underwriting discounts, commissions and offering expenses.</span></p><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Authorized share capital:</span></div></div><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s authorized share capital consists of an unlimited number of common and preferred shares without par value.</span></p><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(c)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-based compensation:</span></div></div><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has two equity incentive plans: (i) the 2014 Equity Incentive Plan which was amended and restated in June 2020, June 2022 and June 2024 (the &#8220;Amended and Restated 2014 Plan&#8221;), and (ii) the 2019 Inducement Equity Incentive Plan (the &#8220;2019 Inducement Plan&#8221;).</span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">95</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_14b2c51d-f208-4596-a88f-3b2b67be6153_1" continuedAt="F_14b2c51d-f208-4596-a88f-3b2b67be6153_2"><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2019, the board of directors of the Company adopted the 2019 Inducement Plan and, subject to the adjustment provisions of the 2019 Inducement Plan, reserved </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f277630d-f51b-4d4e-97d2-621ed6cfc2ea" contextRef="C_aec75604-252f-46ec-a913-19116503fa3a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">400,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Company&#8217;s common shares for issuance pursuant to equity awards granted under the 2019 Inducement Plan. The 2019 Inducement Plan was adopted without shareholder approval in accordance with the applicable Nasdaq Listing Rules. The 2019 Inducement Plan provided for the grant of equity-based awards, including share options, share appreciation rights, restricted share awards, restricted share unit awards and performance share awards, and its terms are substantially similar to the Company&#8217;s Amended and Restated 2014 Plan, including with respect to treatment of equity awards in the event of a &#8220;merger&#8221; or &#8220;change of control&#8221; as defined under the 2019 Inducement Plan, but with such other terms and conditions intended to comply with the Nasdaq inducement award exception or to comply with the Nasdaq acquisition and merger exception. The 2019 Inducement Plan was terminated in June 2020. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b237afb8-783a-4968-a79c-a4677773980e" contextRef="C_aec75604-252f-46ec-a913-19116503fa3a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> further options will be granted under the 2019 Inducement Plan, and the 2019 Inducement Plan will continue to govern the options granted thereunder.</span></p><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The shareholders of the Company approved the Amended and Restated 2014 Plan amended in June 2020, June 2022 and June 2024, amending certain provisions of the Company&#8217;s 2014 Plan. The Amended and Restated 2014 Plan permits the grant of stock-based compensation awards to directors, officers, employees and consultants of the Company and the issuance of restricted shares, restricted share units, share appreciation rights and PSUs. Under the Amended and Restated 2014 Plan, options granted generally vest on a graduated basis over a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_68e83bff-ef16-4780-bb59-fdd011d9152d" contextRef="C_b73046f7-b8e0-4dca-8c99-1daba94d7875" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">four-year</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> periods. The exercise price of the options is determined by the board of directors but must at least be equal to the fair market value of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> the common shares on the date of grant. Options may be exercised over a maximum term of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_913d81e5-e7eb-4974-bb6a-314e0edc1df7" contextRef="C_b73046f7-b8e0-4dca-8c99-1daba94d7875" name="xene:MaximumTermOfEachOptionExercised" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ten years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The vesting conditions, vesting period and expiry terms of the PSUs are determined by the board of directors. As of December 31, 2024, a total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2124fb5a-11a6-4005-9da3-68c38ccba30f" contextRef="C_0592fb80-0d71-435e-a735-fefde780f550" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,882,842</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> common shares remain available for issuance pursuant to the Amended and Restated 2014 Plan. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Of this total, the number of common shares that can be issued through restricted share awards, restricted share unit awards, or performance share awards is limited to the aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9da3cd7b-f3db-49c8-864f-d6cca2ceaced" contextRef="C_e0854642-1362-4d48-aab9-14c1634c7adf" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> common shares.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2093aba0-bef7-4b93-92c9-16f8c7f4f4d9" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" escape="true"><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents the components and classification of stock-based compensation expense for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024, 2023 and 2022:</span></p><p style="margin-left:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.089%;box-sizing:content-box;"/>
        <td style="width:1.28%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.598%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.28%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.598%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.28%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.598%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.28%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation expense by award type:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dc46e45f-7899-4900-9ef4-2319619f65e0" contextRef="C_75650c11-6320-415c-9740-299a3731566d" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">48,384</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_35577cc5-24f3-4682-b7df-20649b534daa" contextRef="C_22406e30-26c0-4443-96a7-32b9fcae62e4" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,372</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8bfaa4af-2033-440b-a8bb-37e62d2977d7" contextRef="C_5a4cf558-ec87-4536-9f7e-a17702358f73" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,376</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">PSUs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1033fc69-d539-4bee-8c1a-2899afbce424" contextRef="C_b54bd813-bcee-4527-8ce0-2c924fa24d1d" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,333</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1151f825-8ae4-4f07-8518-e09db91eeded" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">50,717</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_61b18987-77d4-44b7-ac11-cce363fa90cb" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,372</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f5faefd1-8719-4bdb-a48b-d68cf2793099" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,376</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation expense in operating expenses:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1c40afd3-04a2-45c3-93e3-d50e5cfd47e3" contextRef="C_dcfeb94e-b8c0-4a04-9c3a-f7a9d496157a" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,088</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_437dbe81-c6c6-4562-b388-f45a9f416060" contextRef="C_0e65ad73-e8f3-456e-8770-603f8bf6e43d" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,067</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_01010394-25cf-49c6-8a28-1b4ee597987c" contextRef="C_b156f885-8692-4ecf-bf11-f2e6c2c97795" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,766</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ef56af89-209f-4c0d-a692-a987e7a537ac" contextRef="C_8f915973-7e56-4b21-9f25-8542155d2101" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,629</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f37ca0a4-8bba-477c-95cc-cc6bab6a48d6" contextRef="C_28f99d5a-d64c-4e7b-8a46-afb927c32234" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,305</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3a19049f-9141-4e12-a41c-57ca397bf03a" contextRef="C_b17712b6-e1df-4014-af5c-fd1016d8f5cd" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,610</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fb0ca2e8-859a-4e6b-ae45-cf020abdf021" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">50,717</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e15affb4-d693-4255-8d26-ea7efd109a2f" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,372</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ed53ceaf-4db0-4f03-91b0-ef3be7051eef" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,376</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">96</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_14b2c51d-f208-4596-a88f-3b2b67be6153_2" continuedAt="F_14b2c51d-f208-4596-a88f-3b2b67be6153_3"><p style="margin-left:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock options</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e8f22f47-0c1a-40b3-b280-9fb794e483ac" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true"><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents the summary of stock option activity for the period:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:43%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:15.96%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:15.96%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:16.08%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted<br/>Average<br/>Exercise</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Options</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Price ($)</span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Intrinsic</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding, December 31, 2021</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dc4ef384-3f1d-46da-bff6-4bfb89aaca90" contextRef="C_7bc29ce6-ec8e-46b1-9da8-77d97bcac7c2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,638,232</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e24e7583-a360-4a4e-91d0-fa1acdf62d1b" contextRef="C_7bc29ce6-ec8e-46b1-9da8-77d97bcac7c2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">12.55</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_93f681b5-4c1b-4eff-978b-7124be99ef2b" contextRef="C_7bc29ce6-ec8e-46b1-9da8-77d97bcac7c2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">105,405</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_32c25da7-510a-4bfd-8101-06b09e666169" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,315,645</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_40f1f344-f0b8-456d-bd3d-62cd4252aa97" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">30.90</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a60e40d6-f0a7-4664-9557-159b0c1dda9e" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">780,725</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d722f20f-3a0c-4259-9816-37268b701b21" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">9.47</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fed44b0c-52cd-4eae-88c2-338d4f129cc3" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,651</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited, cancelled or expired</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_be2afc5e-184a-40e4-be2c-3cecc1688843" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">55,370</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_197ac13f-1201-439a-a3ac-76f583dca89b" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">24.50</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding, December 31, 2022</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_53a9a176-0cf2-4169-acf5-6366779c73d8" contextRef="C_959e7299-f8b2-49e1-8078-5dac2b5e2683" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">7,117,782</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_101724e2-7f06-49ac-9a56-8ec269444a35" contextRef="C_959e7299-f8b2-49e1-8078-5dac2b5e2683" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">18.75</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f57fae6d-4851-4262-a7f7-d1fc2c85d37c" contextRef="C_959e7299-f8b2-49e1-8078-5dac2b5e2683" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">147,214</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a44b554c-4c93-4ed4-b2ee-6040f6e014ae" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,542,473</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d6670b95-d8d9-420a-b328-d56f43822bc4" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">35.29</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_87ca79e6-4ead-485a-ba2d-df4c28b5870e" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">587,536</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_72bcee06-f3a0-4c9d-bb5b-bdc295aad69a" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">13.58</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ae78d418-87e0-4786-9766-7313bf824e90" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,526</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited, cancelled or expired</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_21c2d6b7-a4e4-4122-92de-1cd0810762a4" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">178,217</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1603deb6-c5bf-4acc-8e57-a36310b2d60d" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">31.49</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding, December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fb079c1f-48a4-409e-bd7f-e4b84cfd5a92" contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">8,894,502</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d851e488-ab29-482c-8f44-1f7e5b343812" contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">23.56</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dc4b1eb4-a4fc-40b4-ae1b-3cbaa989d939" contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">200,122</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6254e2fc-a080-4789-a3af-7cf9cc6b0420" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,062,819</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0d0d5a61-c3a5-48e8-a44a-dade357b5ed6" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">42.93</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_97da7800-5198-4176-93f5-1e6f81beb772" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,040,136</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0a679030-822f-43e3-a105-321729435498" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">12.43</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_62b6908a-ac54-4e4c-9876-eba3774dd7e3" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,416</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited, cancelled or expired</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8c4e4f80-6ff5-4b9b-b276-13c6dcaed42c" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">207,896</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1f8196c2-dd02-4b1c-8d90-2842af03b570" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">38.18</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding, December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_14c58473-386f-4866-a56a-2afd727fd910" contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">10,709,289</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dad7bcd7-a990-434d-9ff3-40b997440293" contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">29.90</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4876a36d-3077-4faf-8610-62c2dde799cd" contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">111,202</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercisable, December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6c98e2f3-d166-40f2-9bc4-45cda3ee7bd4" contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">5,927,638</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_63f7f217-7308-4e74-91e9-c78c0b8a8b49" contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">22.30</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0c7c9b2a-5a1c-4de1-aa0c-eb7157ee3188" contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">100,214</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div class="item-list-element-wrapper" style="margin-left:11.204%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:justify;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;font-kerning:none;min-width:3.0035136717870174%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2024, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_652d3bf9-3a2d-43d3-80ad-544a1cc650dd" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="xene:StockOptionsExercisedForNumberOfCommonSharesForCash" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,144</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#8211; </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8e7de686-ad5b-468e-a3e3-d8ac5f044f40" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="xene:StockOptionsExercisedForNumberOfCommonSharesForCash" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">4,320</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and 2022 &#8211; </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_334ac0f4-fe81-4f01-b449-ef688383ef60" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="xene:StockOptionsExercisedForNumberOfCommonSharesForCash" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">68,930</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) stock options were exercised for the same number of common shares in exchange for cash. In the same period, the Company issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_12b2c0af-47a7-4a01-9807-40b9f3adb057" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="xene:CommonStockIssuedForCashlessExercise" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">729,965</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(2023 &#8211; </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_164abfc9-44a2-4138-95d1-ff75080cab6b" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="xene:CommonStockIssuedForCashlessExercise" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">377,114</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and 2022 &#8211; </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c049626c-b7b9-4407-b89d-22cafc75e7d0" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="xene:CommonStockIssuedForCashlessExercise" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">510,671</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) common shares for the cashless exercise of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_daaeaa7e-5994-4b30-822a-d829f5a3c63d" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="xene:CashlessExerciseOfStockOptions" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,034,992</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(2023 &#8211; </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1348c32d-91c3-444f-bb31-4560365b877c" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="xene:CashlessExerciseOfStockOptions" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">583,216</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and 2022 &#8211; </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4f9aa6bf-bf38-4755-947e-edf8b764639e" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="xene:CashlessExerciseOfStockOptions" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">711,795</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) stock options.</span></div></div></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, stock options outstanding and exercisable had a weighted average remaining contractual life of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a9c07741-091d-4803-80fb-c124327b0f4c" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7.28</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years and </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fe248b17-436e-4ef2-8d1f-834dc21b0f37" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6.21 </span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">years, respectively.</span></p><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value of stock options at the date of grant is estimated using the Black-Scholes option-pricing model which requires multiple subjective inputs. The risk-free interest rate of the options is based on the U.S. Treasury yield curve in effect at the date of grant for a term similar to the expected term of the option. The expected volatility is based on the historical volatility of the Company&#8217;s common shares calculated based on a period of time commensurate with the expected term assumption. Expected life assumptions are based on the Company&#8217;s historical data. The dividend yield is based on the fact that the Company has never paid cash dividends and has no present intention to pay cash dividends. Forfeitures are recognized as they occur.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c57bc58b-ada1-4182-93a4-3b89c3cc313c" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true"><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The weighted average option pricing assumptions are as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.123%;box-sizing:content-box;"/>
        <td style="width:1.281%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.584999999999999%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.281%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.584999999999999%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.281%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.584999999999999%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.281%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Average risk-free interest rate</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fe858673-4fa5-4bf1-b3c5-9d569017044e" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4">4.05</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4eecaad9-3785-4695-95f7-69b8f714e782" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4">3.93</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ef63ad90-0443-45a0-bc57-04ec4725e858" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4">2.39</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cf19897b-a51d-4727-98e6-d708891125ee" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="2">66</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e9d3125c-7f4e-47e7-ae97-2f4feee2ae19" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="2">69</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_382e33c9-149f-4837-9e34-3822b67fbae9" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="2">70</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Average expected term (in years)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_561bb163-6d55-4c24-966e-e843fcb0411c" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.75</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_4a5774d5-68b6-4d66-a1a9-373c7d49e24d" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.94</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_bdddbfc8-18c8-4623-9d69-0e67eafcaf13" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.16</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_32fa4a20-fca9-4a1f-982a-2213bbe25552" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="4">0.00</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_47831a46-f015-4ce1-b7e2-33423eb0d249" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="4">0.00</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0ff06690-f899-4f6c-8f9c-79be82e5c7b3" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="4">0.00</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average fair value of stock options granted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6cf79fef-fc4e-4123-9ebb-9a4f74bbf097" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">26.48</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_018ce381-81dc-4cf3-b0b9-3dd8f5d17caa" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">22.52</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d9bbbed1-cd96-46a5-a777-7fd4807d65c2" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">19.78</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="margin-left:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2164335e-365c-4871-86cc-143a221b9e23" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock" escape="true"><p style="margin-left:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A summary of the Company&#8217;s unvested stock option activity and related information for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 is as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:48.16%;box-sizing:content-box;"/>
        <td style="width:1.02%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:22.9%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.02%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:22.9%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of<br/>Options</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted Average <br/>Grant Date<br/>Fair Value ($)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unvested, January 1, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d0b2e9f2-3f72-4f01-81db-ba3c2946c0a4" contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">4,105,324</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4a42eb4b-d751-49ac-841a-969e945f2027" contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">20.53</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aa9ac6f2-1256-453d-857c-f7d568049b28" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">3,062,819</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_539847e3-d436-45fd-8185-e34646fbe5f9" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">26.48</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_57833d76-a93b-4cae-ba2e-02365046deb7" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,178,816</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1c7be198-4f95-48ca-81dc-41897786a6e8" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">19.91</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited or cancelled</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8478a086-44cf-4b14-83d3-ab568e0cbf05" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">207,676</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d54633d9-333e-464e-b033-0272a802a06c" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">22.04</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unvested, December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_769d1a2b-8786-45d4-9f53-814c05e93d92" contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">4,781,651</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_58f4bce3-6b5f-445f-ab5f-55998bd05c99" contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">24.56</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">97</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_14b2c51d-f208-4596-a88f-3b2b67be6153_3" continuedAt="F_14b2c51d-f208-4596-a88f-3b2b67be6153_4"><p style="margin-left:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The aggregate fair value of options vested during the year ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_abee601f-00c2-46a4-bddd-a0e828d0fff8" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43,375</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#8211; $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_370af6ef-e47a-4371-8717-2f300d76afdc" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,233</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and 2022 &#8211; $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_01cb5fc1-bf3b-431d-8973-68e37cf5913f" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,752</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">).</span></p><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the unrecognized stock-based compensation expense related to the unvested stock options was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0dd293f8-5ffb-478b-a7e8-b0a9bf94d74d" contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">99,779</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> which is expected to be recognized over a weighted average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_206f1235-ad11-4446-bfb6-eabd29eb5143" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.64</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Performance share units	</span></p><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company granted </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_059acf71-67f3-4379-be44-60d22f462cef" contextRef="C_b54bd813-bcee-4527-8ce0-2c924fa24d1d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">210,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> PSUs to officers and certain employees with a weighted average grant date fair value</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_65103e7c-f7a0-4559-880c-6fc9d9c5b40f" contextRef="C_b54bd813-bcee-4527-8ce0-2c924fa24d1d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">43.90</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per unit. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PSUs vest upon the achievement of certain predefined company-specific performance-based criteria on or before December 31, 2027, subject to continued employment to each performance objective achievement date. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ce46828c-cc05-4d38-aa0f-6021dc208e74" contextRef="C_b54bd813-bcee-4527-8ce0-2c924fa24d1d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> PSUs vested during the year ended December 31, 2024.</span></p><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the unrecognized stock-based compensation expense related to the unvested PSUs that is probable to be achieved was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_097f0f22-553e-4c5c-a85b-3ee8f4aac96a" contextRef="C_878cde20-56e4-4ebb-9add-30ed0cd3a427" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,267</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The recognition of this expense is subject to the achievement of the performance-based criteria, which are reassessed at each reporting date. There is $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eeb2c88b-28f8-4605-b5ec-80e34e38590b" contextRef="C_878cde20-56e4-4ebb-9add-30ed0cd3a427" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,609</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of unrecognized stock-based compensation expense related to the PSUs that is not probable to be achieved.</span></p><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(d)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exchange agreement with certain funds affiliated with BVF Partners L.P. (collectively, &#8220;BVF&#8221;):</span></div></div><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2018, the Company and BVF entered into an exchange agreement pursuant to which the Company issued to BVF </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0e007c5d-4852-48cb-8f82-b5feca4ca03a" contextRef="C_32311f37-d351-4094-8188-e5c4e217f4c9" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,868,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Series 1 Preferred Shares in exchange for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a14df433-abc3-4830-9cb2-cf561311a8ec" contextRef="C_ae6f53cc-56cf-4ba7-a7f9-cfdd12d99cbe" name="xene:StockIssuedDuringPeriodCommonSharesCancelled" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,868,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> common shares which were subsequently cancelled by the Company. The Series 1 Preferred Shares were convertible into common shares on a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4c2104fe-7a00-4192-b598-12e031ab9a59" contextRef="C_32311f37-d351-4094-8188-e5c4e217f4c9" name="us-gaap:PreferredStockConversionBasis"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">one-for-one</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> basis, subject to certain restrictions.</span></p><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Series 1 Preferred Shares ranked equally to the common shares in the event of liquidation, dissolution or winding up or other distribution of the assets of the Company among its shareholders and the holders of the Series 1 Preferred Shares were entitled to vote together with the common shares on an as-converted basis and as a single class, subject to certain restrictions.</span></p><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Series 1 Preferred Shares were recorded wholly as equity under ASC 480, with no bifurcation of conversion feature from the host contract, given that the Series 1 Preferred Shares cannot be cash settled and have no redemption features.</span></p><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2018, BVF converted </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_90b59748-f0fc-4e77-bd01-1fb89f053ef2" contextRef="C_9fcee154-e6d6-49cc-9847-f1ad966fc19f" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_5a0ec61d-9a3e-4185-998a-ab5c1b2e3eea" contextRef="C_0031901f-461f-45c7-b720-6eb40956e950" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,852,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Series 1 Preferred Shares in exchange for an equal number of common shares. In March 2022, the remaining outstanding </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f306e76d-8e43-4320-ae26-533bda67a6cb" contextRef="C_71cbb8cb-9965-4745-9068-1c329cd37142" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_2ecb89a8-640f-45de-907a-731d2de14285" contextRef="C_f7541451-edb6-4acb-8f0a-790bab15be88" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,016,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Series 1 Preferred Shares were exchanged for an equal number of common shares.</span></p><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(e)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pre-funded warrants:</span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_18c1f253-541a-4afd-8fb8-2035d55aee82" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="xene:ScheduleOfPreFundedWarrantsActivityTableTextBlock" escape="true"><p style="margin-left:8.787%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the pre-funded warrants activity for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024, 2023, and 2022:</span></p><p style="margin-left:8.8%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.975%;box-sizing:content-box;"/>
        <td style="width:1.25%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:30.775%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of Pre-funded</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">warrants outstanding</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding, December 31, 2021</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bafc9c82-7b56-4460-82a3-7e8074d2a0c0" contextRef="C_7bc29ce6-ec8e-46b1-9da8-77d97bcac7c2" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,775,996</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issued</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_60d748a7-6aa5-433d-9dbb-527acc4fb312" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="xene:NumberOfWarrantsIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">327,868</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7cd5a51a-4e0c-47e4-8a7d-ad9854bb0035" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="xene:NumberOfWarrantsExercised" unitRef="U_shares" decimals="INF" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding, December 31, 2022</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a7aa28f1-87c8-4284-85f7-cdbc3a504fa7" contextRef="C_959e7299-f8b2-49e1-8078-5dac2b5e2683" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,103,864</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issued</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6d31be29-5169-47e2-ab2a-e88f0d72ed00" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="xene:NumberOfWarrantsIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">769,230</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7f6fa339-355f-44de-ac2f-34f86d01096d" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="xene:NumberOfWarrantsExercised" unitRef="U_shares" decimals="INF" sign="-" format="ixt:num-dot-decimal">1,700,013</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding, December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5e4aa73c-153b-4f66-a41e-17cd4a0d5ff4" contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,173,081</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issued</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ad8620fd-02e6-4340-88c0-be4670c649df" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="xene:NumberOfWarrantsIssued" unitRef="U_shares" decimals="INF" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_270ea92d-15db-4b6e-9615-ce337efa0071" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="xene:NumberOfWarrantsExercised" unitRef="U_shares" decimals="INF" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding, December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8c0696a2-5246-4417-a4fb-36bbcda1dac4" contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,173,081</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><div class="item-list-element-wrapper" style="margin-left:9.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:justify;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;font-kerning:none;min-width:2.9590591368023964%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2023, the Company issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cc492a75-6d9b-43f2-85cd-f9b717d0bbd7" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="xene:CommonStockIssuedForPreFundedWarrants" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,700,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> common shares upon the exercise of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8bdb4b60-573b-4775-8578-cd254ac9842a" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="xene:NumberOfWarrantsExercised" unitRef="U_shares" decimals="INF" sign="-" format="ixt:num-dot-decimal">1,700,013</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> pre-funded warrants pursuant to a net exercise mechanism under the warrants.</span></div></div></ix:nonNumeric></div><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each pre-funded warrant is exercisable for the purchase of a common share at the holder's discretion at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6a76bf5a-08a4-41a6-a142-03fdc3e0da1a" contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, subject to certain post-exercise beneficial ownership limitations as provided under the terms of the pre-funded warrant.</span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">98</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_14b2c51d-f208-4596-a88f-3b2b67be6153_4"><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0bb91995-fdc5-4d7c-8d40-053d16ef2eb8" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="xene:WarrantsExerciseDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company may not affect the exercise of any pre-funded warrant, and a holder will not be entitled to exercise any portion of any pre-funded warrant that, upon giving effect to such exercise, would cause: (i) the aggregate number of common shares beneficially owned by such holder, together with its affiliates, to exceed 4.99% of the total number of common shares outstanding immediately after giving effect to the exercise; or (ii) the combined voting power of the Company&#8217;s securities beneficially owned by such holder, together with its affiliates, to exceed 4.99% of the combined voting power of all of the Company&#8217;s securities immediately outstanding after giving effect to the exercise, which percentage may be changed at the holder&#8217;s election to a higher or lower percentage not in excess of 19.99% upon at least 61 days&#8217; notice to the Company.</span></ix:nonNumeric></span></p><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since the pre-funded warrants meet the condition for equity classification, proceeds from issuances of the pre-funded warrants for the year ended December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_427a4222-1f8a-448a-8c40-c7a49c14d959" contextRef="C_4936f148-6a25-41e1-bce8-c9880d5a5e27" name="us-gaap:ProceedsFromIssuanceOfWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,477</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (2022 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8211; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bfd421be-70e0-4290-bcff-81283405e262" contextRef="C_91296a7e-80ef-40a4-84c1-540e6b53ed31" name="us-gaap:ProceedsFromIssuanceOfWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,387</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">), net of underwriting discounts, commissions and offering expenses, are recorded in additional paid-in capital. Upon exercise of the pre-funded warrants, the historical costs recorded in additional paid-in capital along with the exercise price collected from the holder are recorded in common shares. Pre-funded warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8fcb6ae7-54e7-467b-bbd3-38d63aafab6f" contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,173,081</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2023 &#8211; </span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_cc90abb1-1756-43f4-b4df-844700596685" contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,173,081</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and 2022 &#8211;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d8bf3838-07a9-4793-9414-6943eaff3e05" contextRef="C_959e7299-f8b2-49e1-8078-5dac2b5e2683" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,103,864</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) common shares </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">are not included in the number of issued and outstanding common shares as of December 31, 2024.</span></p><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(f)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Warrant: </span></div></div><p style="margin-left:8.787%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In August 2018, a warrant to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_22c31423-39cd-49da-a2f2-cece31b494ad" contextRef="C_5a1c869a-3031-45a1-b8b8-07258801ac33" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">40,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2023 &#8211; </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_14f1bae3-6b63-4aeb-a055-39a90ae6cf24" contextRef="C_4984049b-32ea-46b9-98fa-440cbfdf680d" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">40,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) common shares at a price per common share of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3d6f1ab0-0c23-4999-86c7-5bae3516d4c1" contextRef="C_5a1c869a-3031-45a1-b8b8-07258801ac33" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">9.79</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was issued. The warrant is immediately exercisable, contains a cashless exercise provision and expires in August 2028.</span></p></ix:continuation></div>
  <div><ix:nonNumeric id="F_3e3f34a4-6006-4bab-80cd-64b6307ccc2d" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" escape="true" continuedAt="F_3e3f34a4-6006-4bab-80cd-64b6307ccc2d_1"><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">10.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Collaboration agreements:</span></div></div><p style="margin-left:4.533%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Neurocrine Biosciences license and collaboration agreement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><ix:nonNumeric id="F_10f842c9-6e11-406a-a0fc-186aaccfeb5f" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" escape="true"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue was as follows for the years ended December 31, 2024, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2023 and 2022:</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.449%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.518%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.518%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.518%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="8" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Recognition of the transaction price</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_92a1ec74-9826-4c7f-9eff-8e85944924d1" contextRef="C_0cc08d87-8298-44c1-a950-93f5421805de" name="xene:RecognitionOfTransactionPrice" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3a329517-0994-470a-8917-a43cbe296956" contextRef="C_95fad8c0-4f7c-4bda-85cb-111b56b2cfba" name="xene:RecognitionOfTransactionPrice" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e408482a-a14f-472d-bc1e-e93d9101e93c" contextRef="C_620b04e6-7aa7-4a6e-b3fe-1655d998a981" name="xene:RecognitionOfTransactionPrice" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">372</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development services</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d00c3aab-63e0-4e99-9bc3-2a8eb8514d70" contextRef="C_0cc08d87-8298-44c1-a950-93f5421805de" name="xene:ResearchAndDevelopmentServices" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_974dcb87-4200-4f27-bc8a-ad3731200a4e" contextRef="C_95fad8c0-4f7c-4bda-85cb-111b56b2cfba" name="xene:ResearchAndDevelopmentServices" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2a3d7196-d173-4bf8-bd7a-217c641acaa8" contextRef="C_620b04e6-7aa7-4a6e-b3fe-1655d998a981" name="xene:ResearchAndDevelopmentServices" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,938</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Milestone payments</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_01e888f3-8e9f-4797-ab78-7e11cdf4f33e" contextRef="C_0cc08d87-8298-44c1-a950-93f5421805de" name="xene:MilestonePayment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5d46d81f-0cb5-47b0-8305-370dc8264b28" contextRef="C_95fad8c0-4f7c-4bda-85cb-111b56b2cfba" name="xene:MilestonePayment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_39b921b5-b2eb-4c84-bc26-91e389a52c3a" contextRef="C_38463dbb-8c79-451f-b24c-b502ace3c611" name="xene:MilestonePayment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,124</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Total revenue</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6dd6f495-7fc4-45b0-ad8a-e6c64b689918" contextRef="C_779d7deb-a421-4227-83c3-8ac2dfc35f90" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_481a29a7-3199-4d18-bcc1-db0ab5a96533" contextRef="C_a52ed6c9-11b1-42c8-b685-959088b4d45d" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f7461ae4-54c6-437d-b96e-a6683be02197" contextRef="C_fa095704-4846-4a02-9bc0-f78ed31e8f79" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,434</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2019, the Company entered into the Neurocrine Collaboration Agreement with Neurocrine Biosciences granting the Company an exclusive license to NBI-921352 (formerly XEN901) and certain pre-clinical compounds for development (the &#8220;DTCs&#8221;). The agreement also includes a two-year research collaboration to discover, identify and develop additional novel Nav1.6 and Nav1.2/1.6 inhibitors (&#8220;Research Compounds&#8221;). The Company and Neurocrine Biosciences collaborated on the conduct of two collaboration programs: (a) a joint research collaboration to discover, identify and preclinically develop Research Compounds (the &#8220;Research Program&#8221;), which was completed in June 2022, and (b) a collaborative development program for NBI-921352 and two DTCs selected by the joint steering committee. Under the arrangement, the Company was entitled to funding for certain full-time equivalent and external costs incurred by the Company for the research and development services requested by Neurocrine Biosciences, and these services were priced at estimated fair value.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is eligible to receive pre-commercial and commercial milestone payments with respect to the licensed products totaling up to an additional $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a693516d-fd1f-43b5-bdca-c96d9352c581" contextRef="C_494ce105-0b9f-4d43-a7ae-9d4280f4ce87" name="xene:PotentialMilestonePaymentsReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,667,500</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, comprised of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_67f47cd2-1a50-491c-9b7d-4ad5add40fb2" contextRef="C_7c1e5b7a-577b-4134-b465-b0ccd0cdbae9" name="xene:PotentialMilestonePaymentsReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,067,500</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in additional development and regulatory milestone payments related to NBI-921352 and other licensed Nav1.6 or Nav1.2/1.6 inhibitor products, and up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_50974bf3-fa5e-4c3c-ac16-d7c9f556453c" contextRef="C_b0bfec10-59dd-4234-9f58-271c37fde21d" name="xene:PotentialMilestonePaymentsReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">600,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in additional sales-based milestone payments for multiple products. In addition, the Company is eligible to receive royalties on net sales in and outside the U.S., ranging from (a) for NBI-921352, a low double-digit percentage to a mid-teen percentage and a high-single digit percentage to low double-digit percentage, respectively; (b) for DTCs, a high-single digit percentage to a low double-digit percentage and a mid-single digit percentage to a high-single digit percentage, respectively; and (c) for Research Compounds, a mid-single digit percentage to a high-single digit percentage and a tiered mid-single digit percentage, respectively. Royalty rates are subject to customary reductions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has an option to co-fund </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d2874ab3-9bc6-4ded-adf0-d7d5754167a2" contextRef="C_7e416cfe-b299-48b2-a9f3-089ca9635d44" name="xene:PercentageOfOptionToFundDevelopmentCostsUponAchievementOfCertainMilestones" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the development costs of NBI-921352 or another product candidate in the U.S., exercisable upon achievement of certain milestones, in exchange for increased U.S. royalties. The Company has not exercised this option as of December 31, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">99</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_3e3f34a4-6006-4bab-80cd-64b6307ccc2d_1"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In January 2022, based on the receipt of the U.S. Food and Drug Administration&#8217;s (&#8220;FDA&#8221;) full IND acceptance for NBI-921352, the Company received an aggregate milestone payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0d5e9640-5588-4dcc-b485-afbd2a93c18f" contextRef="C_16c2e333-259f-4e18-b025-1a7840b2cf5d" name="xene:AggregateMilestonePaymentReceived" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in the form of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_682a2743-dd1a-43d2-ad86-54c41dc3c98a" contextRef="C_16c2e333-259f-4e18-b025-1a7840b2cf5d" name="xene:MilestonePaymentReceivedInCash" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,750</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in cash and a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8a91c7d8-91f1-4295-90ca-7b27ddf67b65" contextRef="C_16c2e333-259f-4e18-b025-1a7840b2cf5d" name="xene:MilestonePaymentReceivedInEquityInvestment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,250</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> equity investment in the Company (note 9a). The equity investment was measured at fair value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4659953d-fed0-4515-acd4-7dd0d23bd12d" contextRef="C_16c2e333-259f-4e18-b025-1a7840b2cf5d" name="xene:MilestonePaymentReceivedInEquityInvestmentMeasuredAtFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,876</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> on the date of issuance and the resulting premium of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_35fb5846-db35-4b0c-969e-95e3447bde37" contextRef="C_16c2e333-259f-4e18-b025-1a7840b2cf5d" name="xene:CollaborateMilestoneAgreementPremiumRelatedToEquityInvestment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">374</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, with the cash payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_09d1ca16-e46d-4b97-828f-d8ef1f7ec4fd" contextRef="C_16c2e333-259f-4e18-b025-1a7840b2cf5d" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,750</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, was recognized as revenue in the period as the Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8f821d61-33bb-40c9-a62b-b8a8b328f1e7" contextRef="C_16c2e333-259f-4e18-b025-1a7840b2cf5d" name="xene:PerformanceObligationsRelatedToMilestone" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t have any remaining performance obligations in relation to this milestone on the date it was achieved.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In February 2025, NBI-921355, a Nav1.2 and Nav1.6 sodium channel inhibitor in development for the potential treatment for certain types of epilepsy, has progressed into a Phase 1 clinical study in healthy adult participants, triggering an anticipated $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6554e041-2f03-4e5f-baf6-0e8fd392b5c7" contextRef="C_3e2186d8-8a70-4a7a-821a-ef78292cca8c" name="xene:MilestonePayment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,500</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> milestone payment to the Company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_62569122-e5c8-4aea-8f4b-6ab610f363b4" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:EarningsPerShareTextBlock" escape="true"><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">11.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net loss per common share</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">:</span></div></div><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><ix:nonNumeric id="F_cf7c349b-13b8-436c-8cde-9a4d099acb79" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock" escape="true"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents the calculation of basic and diluted net loss per common share for the years ended December 31, 2024, 2023 and 2022:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:46.109%;box-sizing:content-box;"/>
        <td style="width:1.64%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:14.323%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.64%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:14.323%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.64%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:14.323%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Numerator:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_76ba4724-0de0-44b9-bbbc-3e18635877d8" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">234,330</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7f4f17a3-2892-49fc-a08c-97955407f729" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">182,393</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_65fc303a-4d9e-4435-affa-e9e4ec214e78" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">125,373</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss attributable to preferred shareholders</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_37db3456-00c7-434c-99f0-c9862cb958f6" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="xene:NetIncomeLossAvailableToPreferredStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">437</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss attributable to common shareholders</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f6571758-3911-4ca8-b85e-9d4d9ec72e77" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">234,330</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c25535cb-581d-4990-834e-78b107811b0b" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">182,393</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_17a9c80a-0962-40d7-94e2-ea4721a2876f" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">124,936</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Denominator:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common shares (weighted average)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_58c41eb5-61b5-4939-9ae0-da18743b0be8" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="xene:WeightedAverageNumberOfCommonShares" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">75,721,562</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_416ffaf5-1541-4a81-b987-ffadf8bd4929" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="xene:WeightedAverageNumberOfCommonShares" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">64,739,678</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3187ec8d-a797-4ac9-8724-e956721a4c74" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="xene:WeightedAverageNumberOfCommonShares" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">57,599,510</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Pre-funded warrants (weighted average)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a04abdac-2dc3-483a-af3e-cf3c63f29c1c" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="xene:WeightedAverageNumberOfPrefundedWarrants" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,173,081</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a527cc88-8abb-424b-9eee-ee398ea424eb" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="xene:WeightedAverageNumberOfPrefundedWarrants" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,149,327</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_94676e46-caa0-4ad9-91b3-7eb471be39ba" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="xene:WeightedAverageNumberOfPrefundedWarrants" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,942,632</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average common shares <br/>&#160;&#160;&#160;outstanding &#8211; basic and diluted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4efe65eb-881c-477c-bd74-48a55ddd3e41" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_3986ce2f-7811-4a05-89ac-6873183d86c4" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">77,894,643</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_07a04cec-7181-4225-a2ee-c2d615d3a784" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_e5d46b26-4672-4a8b-8eb6-76e76d30f9a2" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">66,889,005</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_45bcff97-782b-4ba4-91ed-9df58ee3b742" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_c1a5679a-e2cb-46c6-8281-1e088e90bbd5" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">60,542,142</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per common share &#8211; basic and diluted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eb32766b-c46e-44bb-843e-215f69812f15" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_4975cb16-e1d3-4c9d-9e3a-fd1b60b9d3d0" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">3.01</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a7f7cf19-fcc6-4997-9f70-64068ec64afc" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_30f96318-a024-4bcd-8bbb-73f4f471d1ee" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">2.73</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fc6ab22b-dd8d-4299-8118-d1f0648a2d8c" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_a8c21b6f-e9aa-430c-939a-36f79a411362" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">2.06</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The weighted average number of common shares used in the basic and diluted net loss per common share calculations includes the weighted average pre-funded warrants outstanding during the period as they are exercisable at any time for nominal cash consideration (note 9e).</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company reported net losses for each of the years ended December 31, 2024, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and 2022, and therefore excluded all potentially dilutive outstanding securities from the computation of diluted net loss per common share as their inclusion would have had an anti-dilutive effect.</span></p></ix:nonNumeric></div>
  <p style="margin-left:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2cc1c0a4-16cd-4455-a5c5-31af6b769f6f" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true"><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">12.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commitments and contingencies:</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Asset purchase agreement with 1st Order Pharmaceuticals, Inc. (&#8220;1st Order&#8221;):</span></div></div><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In April 2017, the Company acquired azetukalner from 1st Order pursuant to an asset purchase agreement. In August 2020, the Company and 1st Order amended the asset purchase agreement to amend certain definitions in the agreement and to modify the payment schedule for certain milestones. Through December 31, 2024, the Company has paid $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ff99ad22-70da-4817-9d4e-8d8253bce875" contextRef="C_0451fb9b-54f6-4a4b-8ade-92b89ad35f70" name="xene:MilestonePaymentsPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> based on progress against these milestones. Future potential payments to 1st Order include up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8f9c5237-590c-4288-9974-f7a3ea4ac295" contextRef="C_8cda2242-cdda-436c-b1a1-5d38d90e788c" name="xene:FuturePotentialMilestonePayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in regulatory milestones. There are </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e1a4bd5f-ca81-402d-bed6-7e512519941b" contextRef="C_ab08f408-103c-4988-a8d5-e291b741e1ed" name="xene:RoyaltyObligations" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> royalty obligations to 1st Order.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">   </span></p><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Guarantees and indemnifications:</span></div></div><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has entered into license and research agreements with third parties that include indemnification provisions that are customary in the industry. These indemnification provisions generally require the Company to compensate the other party for certain damages and costs incurred as a result of third-party claims or damages arising from these transactions.</span></p><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The maximum amount of potential future indemnification is unlimited; however, the Company currently holds commercial and product liability insurance. This insurance limits the Company&#8217;s exposure and may enable it to recover a portion of any future amounts paid. Historically, the Company has not made any indemnification payments under such agreements and the Company believes that the fair value of these indemnification obligations is minimal. Accordingly, the Company has not recognized any liabilities relating to these obligations for any period presented.</span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">100</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:nonNumeric id="F_d959a4c1-cb17-4bf4-8492-b18cc87941df" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true" continuedAt="F_d959a4c1-cb17-4bf4-8492-b18cc87941df_1"><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">13.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Income taxes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">:</span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_53978bbb-2bde-4fbb-bf1d-a78a8b82a631" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" escape="true"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Loss before income taxes for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024, 2023 and 2022 was as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.863%;box-sizing:content-box;"/>
        <td style="width:1.281%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.764000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.281%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.764000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.281%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.764000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Canada</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d9ebd8c6-2b11-4a44-a639-21677727c2a5" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">243,410</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9273da94-acd8-4faf-b2f4-419026120296" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">174,491</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9dc73a93-4e66-4c8e-a210-bd9e9d9563a1" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">121,335</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">United States</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9411ff31-0bd3-4c2a-a7d7-01bb9a3918ca" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,991</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_35f08f4a-0ce7-4395-8c9d-c12e8a99b60c" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">8,194</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c07b7c46-f687-4657-adf5-25f2b8b0d9a0" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3,920</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss before income taxes</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_60e60843-dd53-49a9-98ff-b04ffaa07dc7" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">238,419</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_91a15758-e3f2-493d-b92b-d96c874c8854" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">182,685</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_38102a4e-831b-4e9a-b706-9fb8c249e0a9" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">125,255</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_15a400b3-e97f-47f6-aa2f-1043510b4e2c" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" escape="true"><p style="margin-left:4.533%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The income tax recovery (expense) is allocated as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.863%;box-sizing:content-box;"/>
        <td style="width:1.281%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.764000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.281%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.764000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.281%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.764000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;Canada</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;United States</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3d92ba24-e23e-45d9-89e2-333e58d6e01d" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,775</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fe847218-5064-4177-af01-1265d2a85de3" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">162</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_54d7785e-2342-49c8-b647-9c12eba706dd" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:CurrentIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,775</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d864d70e-0846-4002-8de6-33057a94ae56" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="us-gaap:CurrentIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">162</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;Canada</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;United States</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_958476f6-63a6-4462-8de0-a080f564ae0d" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">8,864</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9a6e7cfc-ef1b-4d94-a27a-a21704cb9766" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">292</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0f6daea5-8fd1-4109-afde-41a6c42d9173" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">44</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_296ee654-43dd-48a5-bb14-66c164232c75" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">8,864</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0c91d3e7-50e6-4359-a2fa-ced1b2aa4bc7" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">292</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_676628dd-0777-434d-9cca-de4da72ed907" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">44</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Income tax recovery (expense)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6658734b-c168-4eff-83ba-02a771a1b687" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">4,089</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7cca6afc-dbf3-42a6-b5bb-bdea9debfa4c" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">292</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fe0c2baf-9dfe-4e45-ae29-97efe827772a" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">118</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="margin-left:4.533%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s wholly-owned subsidiary, Xenon Pharmaceuticals USA Inc., generates taxable income due to an intercompany service agreement with the Company. All current tax expense and deferred income tax recovery recognized for the years ended December 31, 2024, 2023 and 2022 were attributable to the United States. For the year ended December 31, 2024, the deferred income tax recovery recorded by Xenon Pharmaceuticals USA Inc. is related to the re-assessment of the realizability of its deferred tax assets.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d2f310f0-b34a-45b3-8655-6551b7fd4eb0" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" escape="true"><p style="margin-left:4.533%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reconciliation of the expected Canadian statutory income tax rate to the effective income tax rate is as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.863%;box-sizing:content-box;"/>
        <td style="width:1.281%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.764000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.281%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.764000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.281%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.764000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax at statutory income tax rate</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7168bb54-a342-48ce-b507-5e49f47b21b8" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">27.00</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_89a90e52-21a2-4271-827e-508dc2a14acb" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">27.00</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9c9924b1-d7f6-44dc-885d-e9b997dc719d" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">27.00</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_40846eb3-be33-4797-863f-1d27d2cc996a" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">22.0</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4ae25bf2-abea-4da0-a92c-2b15369bb869" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">24.0</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5eaa3007-58fd-4c58-b63a-c06cf96d10f9" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">24.5</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development and other credits</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0f41eb86-c24d-48d9-a2e5-8c8872f98689" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">1.3</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1cbc4e31-3191-482c-a47d-5a773bb0cf17" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">1.6</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f0800070-2710-4d20-a8ef-77e4b1f9a6f8" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">2.5</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax attributes expired/utilized</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_00ec383e-0c4d-4cd9-bed8-8956ffdeca4f" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="xene:EffectiveIncomeTaxRateReconciliationTaxAttributesExpiredOrUtilized" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">1.1</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e0cd4226-0a95-4a72-b74e-f03adf2217b1" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="xene:EffectiveIncomeTaxRateReconciliationTaxAttributesExpiredOrUtilized" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">0.8</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6de54c00-056a-41ef-978f-d1b957f710bd" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="xene:EffectiveIncomeTaxRateReconciliationTaxAttributesExpiredOrUtilized" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">1.2</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c5e46c8f-4a0f-415b-a788-e4b595059a1a" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">3.4</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_50e53e26-4cf0-4878-98fb-c9ab720f4972" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">3.2</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f083026d-9734-4fa9-a249-5d905dedb45a" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">2.6</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other non-deductible expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_697f3c16-76d2-4246-a149-abd98c8d93d0" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">0.4</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7a070717-5125-470e-8817-4a1868a437d7" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2cdfd69a-dd84-451d-9ca6-0b59a886b7a7" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3c743e50-1780-43ec-97a2-d06636c99734" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_33e8bf15-7de3-4cbd-ab62-ce24906ba49c" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bfcc40fb-3d99-444a-9edd-d77e1bd25573" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">1.1</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Effective income tax rate</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5d935373-2e9e-454b-bee8-c5aaf4a40699" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">1.7</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b6e5e65b-8c0d-45b8-ae21-ca03d83e060a" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a9b2fc99-1d1d-4913-a231-132131d6c573" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">101</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_d959a4c1-cb17-4bf4-8492-b18cc87941df_1"><p style="margin-left:4.533%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deferred income tax assets and liabilities result from the temporary differences between the carrying amount of assets and liabilities recognized for financial statement and income tax purposes. The significant components of the Company&#8217;s net deferred income tax assets are as follows:</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9571d943-1345-4326-ac25-1ec92c183c22" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.313%;box-sizing:content-box;"/>
        <td style="width:1.5%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.843%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.5%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.843%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred income tax assets:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development tax credits</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4d88ecc3-06b8-4e21-b361-3f792ddc9a41" contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">42,830</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_617faa72-fd5d-4090-b6f7-8dcdf09d1903" contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">38,590</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Investment tax credits</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_14e474a2-aeeb-4905-961d-a3bfe0adcca4" contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f" name="xene:DeferredTaxAssetsTaxCreditCarryforwardsInvestment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,818</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d967c22f-5f19-4b42-b6f6-31b22c90a401" contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35" name="xene:DeferredTaxAssetsTaxCreditCarryforwardsInvestment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,695</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-capital losses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f62017ac-796d-479b-9bec-130cde174253" contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">173,352</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1fea6199-34e2-48e1-ad64-744f59b80345" contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">119,765</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciable assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b3149074-ce00-472b-a1e3-5571dbfd7c51" contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,269</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8af31f4d-7213-4407-aee7-f7122a4808ce" contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,311</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred financing fees</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8a0268db-77b7-4107-88c3-8d714249687b" contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f" name="xene:DeferredTaxAssetsDeferredFinancingFees" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,967</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a3ce8411-d870-4935-956a-1785cc2ac23d" contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35" name="xene:DeferredTaxAssetsDeferredFinancingFees" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,831</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_876b648d-9a00-464e-8052-22dfb87f3093" contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,380</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_907cf4d9-9d74-4d9d-aaeb-43c06eef0336" contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,832</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liability</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_02fe8754-33ed-49d4-b7b2-5d21299d260d" contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f" name="xene:DeferredTaxAssetsOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,299</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b6dd677f-1a51-4f73-a7c9-ba776c561b79" contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35" name="xene:DeferredTaxAssetsOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,779</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_32b00fd4-b6a2-4010-8066-445873bdefee" contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,704</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6023991e-4cfc-416c-9a17-9186a925dd25" contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">852</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Total deferred income tax assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0d51d9ca-04cc-4ea3-b469-058e8d116ba2" contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">278,619</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_49df3668-40e8-42b0-a8f5-d0b516b41197" contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">217,655</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Deferred income tax liability:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Operating lease right-of-use asset</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9d7fcb8e-32b1-457e-8eb2-6e2c445805c1" contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,097</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f3cc9f9e-5637-4203-9d40-2ddb7651a649" contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,411</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Less - valuation allowance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8924f50e-2b84-44a8-87c5-baa108830690" contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">266,856</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1e7db189-46d9-420c-91bf-e0408abca428" contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">214,442</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net deferred income tax assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1ddf5284-5efc-430d-99ee-ecb32a3cc609" contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,666</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_225666ee-d7f1-4449-8794-a0d3fa76b4db" contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">802</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The realization of deferred income tax assets is dependent upon the generation of sufficient taxable income during future periods in which the temporary differences are expected to reverse. The valuation allowance is reviewed on a quarterly basis and if the assessment of the &#8220;more likely than not&#8221; criteria changes, the valuation allowance is adjusted accordingly. A full valuation allowance continues to be applied against deferred income tax assets in Canada as the Company has assessed that the realization of such assets does not meet the &#8220;more likely than not&#8221; criteria. Deferred income tax assets recorded on the consolidated balance sheets as of December 31, 2024 and 2023, result from the temporary differences between the amounts of assets and liabilities recognized for financial statement and income tax purposes, net of valuation allowance, related to the operations of Xenon Pharmaceuticals USA Inc.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company has unclaimed tax deductions for scientific research and experimental development expenditures of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eca83ebb-1e2f-41c6-aac3-be986c5a0b5d" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">158,629</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#8211; $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a5b3e91e-95e2-4180-af4a-aeeba8aae2e5" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">142,925</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) with no expiry.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company has $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eecf5914-1b1b-47ef-9081-ddd556a244da" contextRef="C_9eb01a35-61ba-4b6e-af95-b573e9492a46" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,284</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#8211; $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e3797ee0-b360-4c9e-a767-4bf30c32794f" contextRef="C_6f467048-a278-4893-a073-167e3300ed14" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,074</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) of investment tax credits available to offset federal taxes payable and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8ebe65bb-1ad5-434e-b6a7-ab026f7f98e0" contextRef="C_40c485fd-1ab2-4c3b-9ab4-26de3dc49364" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,518</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2023 &#8211; $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9860d241-57e9-42d0-8108-b9576e13ab11" contextRef="C_664789f3-25f8-4a48-9938-65726d2fa13a" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,099</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) of provincial tax credits available to offset provincial taxes payable in the future.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company has non-capital losses, net of uncertain tax positions, carried forward for tax purposes, which are available to reduce taxable income of future years of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4491e9b9-45db-4983-b0cd-7dbbaad0e60e" contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">642,043</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#8211; $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9a0862a1-0469-4e72-b93f-409ff31eae08" contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">422,822</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">).</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The investment tax credits and loss carry forwards expire over various years to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_d1be6160-6c62-483e-bb44-87d26b17b9bb;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2045</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the total amount of the Company&#8217;s unrecognized tax benefits of uncertain tax positions were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9a48eae5-3c9e-4e10-9d80-189be209ddba" contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,850</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#8211; $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5893a50c-86e4-4770-88c9-d1e496f691fa" contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,850</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">). </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If recognized in future periods, the unrecognized tax benefits would not affect the Company&#8217;s effective tax rate. The Company recognizes potential accrued interest and penalties related to unrecognized tax benefits within the income tax provision. Interest and penalties on the unrecognized tax benefits have not been accrued at December 31, 2024 and 2023 as none would be owing due to the availability of non-capital losses to shelter any potential taxable income arising thereon. The Company does not currently expect any significant increases or decreases to these unrecognized tax benefits within 12 months of the reporting date.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company files income tax returns in Canada and the United States, the jurisdictions in which the Company believes that it is subject to tax. In jurisdictions in which the Company does not believe it is subject to tax and therefore does not file income tax returns, the Company can provide no certainty that tax authorities in those jurisdictions will not subject one or more tax years (since the inception of the Company) to examination. Further, while the statute of limitations in each jurisdiction where an income tax return has been filed generally limits the examination period, as a result of loss carry-forwards, the limitation period for examination generally does not expire until several years after the loss carry-forwards are utilized. Other than routine audits by tax authorities for tax credits and tax refunds that the Company claims, the Company is not aware of any other material income tax examination currently in progress by any taxing jurisdiction. Tax years ranging from </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_1acbb9ae-6eb8-45fa-9c42-da9b98b84dfc;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2004</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to 2023 remain subject to examinations in Canada and the United States.</span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">102</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_84fe8b2b-a491-4be6-a239-a235d5df6844" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:SegmentReportingDisclosureTextBlock" escape="true"><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">14.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Segment disclosure:</span></div></div><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company operates as a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_a4a2478d-a313-4066-8e4d-8e8806c474dd;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">single</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> reportable segment dedicated to discovering, developing, and delivering life-changing ion channel therapeutics for patients in need. The Company has no products approved for sale and has not generated any revenue from product sales.</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0d7190cd-9b62-4b7c-83e4-1680b6c8cb1d" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:SegmentReportingExpenseInformationUsedByCodmDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Company&#8217;s </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_d1e546bf-38de-44e9-b552-f72e3c4a430a;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Chief Executive Officer</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> acts as the CODM and manages the Company&#8217;s operations on a consolidated basis. The accounting policies of the segment are the same as those described in the summary of significant accounting policies.</span></ix:nonNumeric></span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The CODM</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">evaluates the Company&#8217;s performance and allocates resources to the operations of the Company on a total company basis. Managing and allocating resources on a consolidated basis enables the CEO to assess the overall level of resources available and how to best deploy these resources across functions, therapeutic areas and research and development projects that are in line with the Company&#8217;s long-term company-wide strategic goals. The CODM uses net loss to monitor budget versus actual results and to analyze cash flows in assessing performance of the segment and allocating resources. The measure of segment assets is reported on the consolidated balance sheet as total consolidated assets, with a majority of these assets located in the United States.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9c96442b-2ac0-4505-8554-17f3c790ab1a" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" escape="true"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents information about reported segment revenues, significant segment expenses, and segment loss:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:46.279%;box-sizing:content-box;"/>
        <td style="width:1.641%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:14.266%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.641%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:14.266%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.641%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:14.266%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_75929e18-d32f-4042-b23b-e50dc08cb3fe" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,434</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Direct external research and development costs</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Azetukalner</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3bedc1f2-5287-42c4-9b43-eacc998a088a" contextRef="C_fb8162b3-a597-4e6d-b07d-93335801c609" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">106,806</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_710ee2a5-f316-4fad-8e07-bf9b742db976" contextRef="C_4dbe77ca-9a85-4dcf-8f71-e478f9594e17" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">89,303</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_765ad926-bc29-421e-a965-c1536e7ce58d" contextRef="C_aae837d9-73f6-4e0d-b04b-74e170785875" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">37,367</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">XEN 496</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_93e2317e-8d52-4500-bacc-b1dca504452f" contextRef="C_31d21974-f2b1-4354-9468-ccf01410882d" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,152</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4bc80e0d-ac13-474a-9830-e982a4e1b6c8" contextRef="C_8a94fa8c-ce7f-4a9e-a9e7-bc7ebbe394c7" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,765</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Pre-clinical, discovery and other programs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f11b68ee-806a-40a8-a2f3-461646141751" contextRef="C_283501b6-a859-4835-8637-5667f1ffb39b" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,546</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_473610f3-eac1-4ad2-9df7-746cecde6f30" contextRef="C_144eba44-d44f-40ad-8b2c-6acd462b2319" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,552</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1d547eb3-3b06-4b72-a528-6aa330aa9807" contextRef="C_8f08380d-a06a-4f90-aa7a-aeae88ce9ee1" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,711</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Personnel-related expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_45791c5e-b58e-49b8-89ec-42487a63fab1" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="xene:PersonnelRelatedExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">68,340</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_77947f60-c839-4f18-bc7f-2745bad711ce" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="xene:PersonnelRelatedExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">47,739</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d0cd9b8e-fa8c-483e-8f1b-3ee49f7f5d76" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="xene:PersonnelRelatedExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">36,088</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7fdf6abb-969d-4ab7-8fd4-acc44882c4ef" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">50,717</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9d32c96c-b822-4ca9-8726-d6da29c13179" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,372</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5168ff61-a058-4749-8865-8c9beeb3c461" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,376</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other research and development costs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7800a468-ef7a-46b4-8c36-ed859776057e" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:OtherResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,232</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9be5baac-d6a1-462e-8e1f-9db14b3294b8" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="us-gaap:OtherResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,560</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_344c347c-8ce3-4aab-a339-408a679755b4" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="us-gaap:OtherResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,274</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other general and administrative costs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2da5f1af-341f-4913-915d-5807fceaace0" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:OtherGeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,657</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b0a672db-2c45-41f4-a525-4865571507cb" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="us-gaap:OtherGeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,376</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_80ebba54-cf8e-4797-a600-623e5717ad12" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="us-gaap:OtherGeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,996</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest income</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0b177868-7bf2-4a92-bbd6-ebbe9d81bdc0" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41,943</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_070a630d-a79d-47ab-9671-099a4b06b13f" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,620</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8bc0ea80-bdbb-4166-87a6-bc7391b42c30" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,713</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other segment items</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1187bada-7afa-4026-8860-e6f676a3a347" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:SegmentReportingOtherItemAmount" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3,025</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_85f1d84d-13ae-45ce-abf7-31d2d4bb9b7c" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="us-gaap:SegmentReportingOtherItemAmount" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">4,041</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a6c728af-6aeb-4ae8-8787-f4809276fb6e" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="us-gaap:SegmentReportingOtherItemAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,943</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2452d3c2-b6b3-4456-b258-2a36ccc0ec27" contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">234,330</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5fcaf90c-3133-4b82-ac96-3d0771b3edc9" contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">182,393</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_380ba679-c75e-4d27-ac51-73c08e259c6f" contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">125,373</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><div class="item-list-element-wrapper" style="margin-left:5.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4%;text-align:justify;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;font-kerning:none;min-width:4.2253372347280465%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other segment items include foreign exchange gain (loss), unrealized fair value gain (loss) on trading securities, and income tax recovery (expense).</span></div></div></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_9"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9. Changes in and Disagreements With Accou</span><span id="item_9_changes_in_disagreements_with_acc"></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ntants on Accounting and Financial Disclosure</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9a"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9A. Controls and Procedures</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Evaluation of disclosure controls and procedures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2024. The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#8217;s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of December 31, 2024, our Chief Executive Officer and our Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were, in design and operation, effective at the reasonable assurance level.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">103</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Management&#8217;s Annual Report on Internal Control over Financial Reporting.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, is responsible for establishing and maintaining adequate internal control over our financial reporting, as such term is defined in Rule 13a-15(f) and Rule 15d-15(f) of the Securities Exchange Act of 1934. Our internal control over financial reporting is a process to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. Our internal control over financial reporting includes those policies and procedures that:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(i)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(ii)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(iii)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The effectiveness of any system of internal control over financial reporting, including ours, is subject to inherent limitations, including the exercise of judgment in designing, implementing, operating, and evaluating the controls and procedures, and the inability to eliminate misconduct completely. Accordingly, any system of internal control over financial reporting, including ours, no matter how well designed and operated, can only provide reasonable, not absolute, assurances. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions or that the degree of compliance with the policies or procedures may deteriorate. Management has assessed the effectiveness of our internal control over financial reporting as of December 31, 2024. In making its assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control &#8211; Integrated Framework (2013) to evaluate the effectiveness of our internal control over financial reporting. Based on this assessment using those criteria, management has concluded that our internal control over financial reporting was effective as of December 31, 2024.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Attestation Report of Independent Registered Public Accounting Firm.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The effectiveness of our internal control over financial reporting as of December 31, 2024 has been audited by KPMG LLP, an independent registered public accounting firm, as stated in their report included elsewhere in this Annual Report on Form 10-K.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Changes in internal control over financial reporting.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> There was no change in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the three months ended December 31, 2024 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_9b"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9B. Other Information</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have a written code of conduct that applies to all of our directors, officers and employees. A copy of the most up-to-date version of our code of conduct is available within the &#8220;Investors&#8221; section on our company website located at </span><span><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">http://www.xenon-pharma.com</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and on SEDAR+ at </span><span><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">www.sedarplus.ca</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. We will post amendments to our code of conduct or waivers of the same for directors and executive officers on the &#8220;Investors&#8221; section on our website located at </span><span><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">https://www.xenon-pharma.com</span><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the three months ended December 31, 2024, no director or officer, as defined in Rule 16a-1(f), </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5a72996a-0739-4f36-856a-cce1541c0888" contextRef="C_33309322-16ac-4275-af41-8afa3963db9f" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_04d9e0bc-6019-411c-b7c6-0d780c8a679d" contextRef="C_33309322-16ac-4275-af41-8afa3963db9f" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adopted</span></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a60d50a0-f3de-41f4-9241-c449a3280b19" contextRef="C_33309322-16ac-4275-af41-8afa3963db9f" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_7f072e32-50c7-4151-a9c1-e628fc9a9006" contextRef="C_33309322-16ac-4275-af41-8afa3963db9f" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">terminated</span></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> a "Rule 10b5-1 trading arrangement" or a "non-Rule 10b5-1 trading arrangement," each as defined in Item 408 of Regulation S-K.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adoption of 2025 Inducement Plan</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 27, 2025, the Board of Directors of the Company approved the 2025 Inducement Equity Incentive Plan (the "2025 Inducement Plan"). Pursuant to the terms of the 2025 Inducement Plan, the Company may grant nonstatutory stock options, stock appreciation rights, restricted stock units, restricted stock, and performance awards as an inducement material to individuals being hired, or rehired following a bona fide period of interruption of employment, as an employee of the Company or any of its subsidiaries. The Company has reserved 775,000 common shares for issuance under the 2025 Inducement Plan. In accordance with Nasdaq Listing Rule 5635(c)(4), the Company did not seek approval of the 2025 Inducement Plan by its shareholders.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The foregoing is a brief description of the material terms of the 2025 Inducement Plan and is qualified in its entirety by reference to the full text of the 2025 Inducement Plan filed as an exhibit to this Annual Report on Form 10-K.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="disclosure_regard_foreign_juris"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9C. </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">104</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_iii"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> III</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_10"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 10. Directors, Executive Officers and Corporate Governance</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by Item 10 of Form 10-K, including discussion of our Insider Trading Policy under the heading "Insider Trading Policies," is incorporated by reference to our Proxy Statement for the 2025 Annual Meeting of Shareholders to be filed with the SEC within 120 days after the end of the fiscal year ended December 31, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="executive_compensation"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 11. Executive Compensation</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by Item 11 of Form 10-K is incorporated by reference to our Proxy Statement for the 2025 Annual Meeting of Shareholders to be filed with the SEC within 120 days after the end of the fiscal year ended December 31, 2024.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_12"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Shareholder Matters</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by Item 12 of Form 10-K is incorporated by reference to our Proxy Statement for the 2025 Annual Meeting of Shareholders to be filed with the SEC within 120 days after the end of the fiscal year ended December 31, 2024.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_13"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 13. Certain Relationships and Related Transactions, and Director Independence</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by Item 13 of Form 10-K is incorporated by reference to our Proxy Statement for the 2025 Annual Meeting of Shareholders to be filed with the SEC within 120 days after the end of the fiscal year ended December 31, 2024.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_14"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 14. Principal Accounting Fees and Services</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by Item 14 of Form 10-K is incorporated by reference to our Proxy Statement for the 2025 Annual Meeting of Shareholders to be filed with the SEC within 120 days after the end of the fiscal year ended December 31, 2024.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">105</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_iv"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IV</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_15"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 15. Exhibits, Financial Statement Schedules</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)(1) Financial Statements &#8212; The financial statements included in Item 8 are filed as part of this Annual Report on Form 10-K.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)(2) Financial Statement Schedules &#8212; All schedules have been omitted because they are not applicable or required, or the information required to be set forth therein is included in the consolidated Financial Statements or notes thereto included in Item 8 of this Annual Report on Form 10-K.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)(3) Exhibits &#8212; The exhibits required by Item 601 of Regulation S-K are listed in paragraph (b) below.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b) Exhibits &#8212; The exhibits listed in the table below are filed herewith or are incorporated by reference to exhibits previously filed with the SEC.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:10.46%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:49%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:5%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.12%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:5%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:15.42%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td rowspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit<br/>Number</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td rowspan="2" style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Description of Document</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="7" style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Incorporated by Reference</span></p></td>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;display:none;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;display:none;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Form</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">File No.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Filing Date</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1582313/000117184314005910/exh_31.htm"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Articles of the Company.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36687</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 15, 2014</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.1A</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1582313/000156459018006921/xene-ex31_8.htm"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Articles of Amendment to the Articles of the Company, creating the Series 1 Preferred Shares.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36687</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 28, 2018</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.2</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1582313/000117184314005910/exh_32.htm"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amended and Restated By-laws of the Company.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36687</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.2</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 15, 2014</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1582313/000119312514363909/d582812dex41.htm"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Form of Common Share Certificate.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1/A</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-198666</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">October 6, 2014</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.2</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1582313/000156459018020000/xene-ex41_7.htm"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Warrant to Purchase Shares, dated August 3, 2018, by and between Xenon Pharmaceuticals Inc. and Silicon Valley Bank.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36687</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">August 7, 2018</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.3</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="xene-ex4_3.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Description of Securities.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.4</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1582313/000156459021050322/xene-ex41_6.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Pre-Funded Warrant</span></a><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36687</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">October 6, 2021</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.5</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1582313/000156459022024065/xene-ex41_11.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Pre-Funded Warrant.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36687</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">June 23, 2022</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.6</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1582313/000095017023067040/xene-ex4_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Pre-Funded Warrant.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36687</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">November 30, 2023</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1#</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1582313/000119312514363909/d582812dex107.htm"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock Option Plan, as amended, and form of option agreement thereunder.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1/A</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-198666</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.7</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">October 6, 2014</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2#</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1582313/000156459022022228/xene-ex101_9.htm"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amended and Restated 2014 Equity Incentive Plan and form of share option agreement used thereunder.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36687</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">June 2, 2022</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.3#</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1582313/000095017024069318/xene-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated 2014 Equity Incentive Plan and form of share option agreement used thereunder.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36687</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">June 5, 2024</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.4#</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1582313/000119312514363909/d582812dex1015.htm"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Form of Director and Executive Officer Indemnification Agreement.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1/A</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-198666</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.15</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">October 6, 2014</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.5&#134;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1582313/000156459017015414/xene-ex102_64.htm"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Asset Purchase Agreement, dated April 25, 2017, by and between the Company and 1st Order Pharmaceuticals, Inc.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36687</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">August 3, 2017</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.6</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1582313/000156459018022911/xene-ex101_6.htm"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Milestone and Royalty Buy-Out Agreement, dated September 7, 2018, by and among Xenon Pharmaceuticals Inc., Valeant Pharmaceuticals Ireland Limited and Valeant Pharmaceuticals Luxembourg S.a.r.l.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36687</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">September 11, 2018</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.7#</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1582313/000156459020009385/xene-ex1024_486.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated Employment Agreement, dated March 19, 2019, by and between the Company and Robin Sherrington.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36687</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 9, 2020</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.8#</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1582313/000156459020051443/xene-ex103_13.htm"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Employment Agreement, dated July 14, 2020, by and between the Company and Christopher Von Seggern.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36687</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.3</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">November 5, 2020</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.9#</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1582313/000156459021001139/xene-ex102_11.htm"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Employment Agreement, dated January 13, 2021, by and between the Company and Ian Mortimer.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36687</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">January 14, 2021</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">106</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:10.46%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:49%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:5%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.12%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:5%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:15.42%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td rowspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit<br/>Number</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td rowspan="2" style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Description of Document</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="7" style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Incorporated by Reference</span></p></td>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;display:none;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;display:none;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Form</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">File No.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Filing Date</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.10#</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1582313/000156459021001139/xene-ex104_9.htm"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Employment Agreement, dated January 13, 2021, by and between the Company and Sherry Aulin.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36687</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.4</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">January 14, 2021</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.11#</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1582313/000156459021056248/xene-ex103_9.htm"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Employment Agreement, dated August 18, 2021, by and between the Company and Christopher Kenney.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36687</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.3</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">November 10, 2021</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.12#</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1582313/000156459019034466/xene-ex101_41.htm"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2019 Inducement Equity Incentive Plan and related form of share option agreement</span></a><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36687</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">September 10, 2019</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.13&#134;&#134;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1582313/000156459019044971/xene-ex101_6.htm"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">License and Collaboration Agreement, dated as of December 2, 2019, by and between Xenon Pharmaceuticals Inc. and Neurocrine Biosciences, Inc.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36687</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 2, 2019</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.14</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1582313/000156459019044971/xene-ex102_33.htm"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Share Purchase Agreement, dated as of December 2, 2019, by and between Xenon Pharmaceuticals Inc. and Neurocrine Biosciences, Inc.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36687</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 2, 2019</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.15&#134;&#134;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1582313/000156459020037862/xene-ex102_140.htm"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amendment No. 1 to Asset Purchase Agreement, dated August 4, 2020, by and between the Company and 1st Order Pharmaceuticals Inc.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36687</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">August 6, 2020</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.16</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1582313/000156459020037867/xene-ex11_7.htm"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">At-the-Market Equity Offering Sales Agreement dated as of August 6, 2020, by and among Xenon Pharmaceuticals Inc., Jefferies LLC and Stifel, Nicolaus &amp; Company, Incorporated.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36687</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">August 6, 2020</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.17</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1582313/000156459022008072/xene-ex11_45.htm"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amendment No. 1 to the At-the-Market Equity Offering Sales Agreement, dated March 1, 2022, by and among Xenon Pharmaceuticals Inc., Jefferies LLC and Stifel, Nicolaus &amp; Company, Incorporated.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36687</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 1, 2022</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.18&#134;&#134;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1582313/000156459021001139/xene-ex101_159.htm"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amendment #1, dated January 13, 2021, to the License and Collaboration Agreement, dated December 2, 2019, by and between Xenon Pharmaceuticals Inc. and Neurocrine Biosciences, Inc.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36687</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">January 14, 2021</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.19</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1582313/000156459021047258/xene-ex101_7.htm"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Share Purchase Agreement, dated as of September 8, 2021, by and between Xenon Pharmaceuticals Inc. and Neurocrine Biosciences, Inc</span></a><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36687</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">September 8, 2021</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.20</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1582313/000156459021058942/xene-ex101_9.htm"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease Agreement, effective November 24, 2021, by and between the Company and Redstone Enterprises Ltd.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36687</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 1, 2021</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.21</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1582313/000156459022001074/xene-ex101_7.htm"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Share Purchase Agreement, dated as of January 11, 2022, by and between Xenon Pharmaceuticals Inc. and Neurocrine Biosciences, Inc.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36687</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">January 12, 2022</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.22&#134;&#134;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1582313/000156459022008060/xene-ex1030_191.htm"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amendment #2, dated February 25, 2022, to the License and Collaboration Agreement, dated December 2, 2019, by and between Xenon Pharmaceuticals Inc. and Neurocrine Biosciences, Inc.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36687</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.30</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 1, 2022</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.23</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#134;&#134;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1582313/000156459022028780/xene-ex101_12.htm"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Consent to Alterations and Lease Modification Agreement between Redstone Enterprises Ltd. and Xenon Pharmaceuticals Inc., effective May 19, 2022.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36687</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">August 9, 2022</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.24#</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1582313/000095017022023283/xene-ex10_1.htm"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Employment Agreement, dated November 4, 2022, by and between the Company and Andrea DiFabio.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36687</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">November 8, 2022</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.25#</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1582313/000095017023007858/xene-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Executive Incentive Compensation Plan.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36687</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 14, 2023</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.26</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1582313/000095017023040681/xene-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consent to Alterations Agreement between Redstone Enterprises Ltd. and Xenon Pharmaceuticals Inc., effective March 27, 2023.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36687</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">August 9, 2023</span></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">107</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:10.46%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:49%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:5%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.12%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:5%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:15.42%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td rowspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit<br/>Number</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td rowspan="2" style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Description of Document</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="7" style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Incorporated by Reference</span></p></td>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;display:none;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;display:none;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Form</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">File No.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Filing Date</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.27</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1582313/000095017024023177/xene-ex10_27.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consent to Alterations Agreement between Redstone Enterprises Ltd. and Xenon Pharmaceuticals Inc., effective August 16, 2023.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36687</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.27</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 29, 2024</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.28#</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1582313/000095017024023177/xene-ex10_28.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Employment Agreement, dated December 15, 2023, by and between the Company and James Empfield.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36687</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.28</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 29, 2024</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.29</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1582313/000095017024057139/xene-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Performance Share Award Agreement</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36687</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">May 9, 2024</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.30#</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="xene-ex10_30.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Letter Agreement, dated January 15, 2025, by and between the Company and Christopher Von Seggern.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.31#</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="xene-ex10_31.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consulting Agreement, dated January 17, 2025, by and between the Company and Christopher Von Seggern.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.32#</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="xene-ex10_32.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">2025 Inducement Equity Incentive Plan and related form agreements.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.33#</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="xene-ex10_33.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Post-Employment Consulting Agreement, dated February 27, 2025, by and between the Company and Sherry Aulin.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="xene-ex19.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Insider Trading Policy.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1582313/000156459017003716/xene-ex211_169.htm"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">List of Subsidiaries of the Company.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36687</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 8, 2017</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="xene-ex23_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consent of KPMG LLP, Independent Registered Public Accounting Firm.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#power_of_attorney"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Powers of Attorney (contained on signature page).</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="xene-ex31_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Rule 13a-14(a) / 15d-14(a) Certification of Principal Executive Officer</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31.2</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="xene-ex31_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Rule 13a-14(a) / 15d-14(a) Certification of Principal Financial Officer</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32.1*</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="xene-ex32_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Section 1350 Certification of Principal Executive Officer</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32.2*</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="xene-ex32_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Section 1350 Certification of Principal Financial Officer</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">97</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1582313/000095017024023177/xene-ex97.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Clawback Policy, effective as of October 2, 2023.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36687</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">97</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 29, 2024</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.INS</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Instance Document &#8211; the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.SCH</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Taxonomy Extension Schema Document with Embedded Linkbases Document</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">104</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#134; Confidential treatment has been granted with respect to certain portions of this exhibit. Omitted portions have been filed separately with the Securities and Exchange Commission.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#134;&#134; Portions of this exhibit have been omitted in accordance with Item 601(b)(10) of Regulation S-K because they are private, confidential and not material.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"># Indicates management contract or compensatory plan.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">* The Certifications attached as Exhibits 32.1 and 32.2 that accompany this Annual Report on Form 10-K are not deemed filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of Xenon Pharmaceuticals Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Form 10-K, irrespective of any general incorporation language contained in such filing.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="form_10k_summary"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 16. </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Form 10-K Summary</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">108</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="signatures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SIGNA</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TURES</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:48%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:3%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:47%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Dated: February 27, 2025</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">XENON PHARMACEUTICALS INC.</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Ian Mortimer</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ian Mortimer</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">President and Chief Executive Officer</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="power_of_attorney"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">POWER OF ATTORNEY</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each person whose signature appears below hereby constitutes and appoints Dawn Svoronos, Ian Mortimer and Sherry Aulin, and each of them severally, as his or her true and lawful attorneys-in-fact and agents, with full power to act without the other and with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities (including his or her capacity as a director and/or officer of Xenon Pharmaceuticals Inc.) to sign any and all amendments and supplements to this report, and any and all other instruments necessary or incidental in connection herewith, and to file the same, with all exhibits thereto, and all other documents in connection therewith, with the Commission.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:32.96%;box-sizing:content-box;"/>
    <td style="width:1.06%;box-sizing:content-box;"/>
    <td style="width:32.96%;box-sizing:content-box;"/>
    <td style="width:1.06%;box-sizing:content-box;"/>
    <td style="width:31.96%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Signature</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Title</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Date</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Ian Mortimer</span></p><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ian Mortimer</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">President, Chief Executive Officer and Director (Principal Executive Officer)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 27, 2025</span></p></td>
   </tr>
   <tr style="height:15.85pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Sherry Aulin</span></p></td>
    <td rowspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
    <td rowspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Financial Officer (Principal Financial and Accounting Officer)</span></p></td>
    <td rowspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
    <td rowspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 27, 2025</span></p></td>
   </tr>
   <tr style="height:7.9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Sherry Aulin</span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;display:none;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;display:none;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:15.85pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Dawn Svoronos</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
    <td rowspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chair of the Board of Directors</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
    <td rowspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 27, 2025</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Dawn Svoronos</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Gillian Cannon</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td rowspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td rowspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 27, 2025</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Gillian Cannon</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Steven Gannon</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td rowspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td rowspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 27, 2025</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Steven Gannon</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Elizabeth Garofalo</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
    <td rowspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
    <td rowspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 27, 2025</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Elizabeth Garofalo</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Justin Gover</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td rowspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td rowspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 27, 2025</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Justin Gover</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Patrick Machado</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
    <td rowspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
    <td rowspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 27, 2025</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Patrick Machado</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Gary Patou</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
    <td rowspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
    <td rowspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 27, 2025</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Gary Patou</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">109</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.3
<SEQUENCE>2
<FILENAME>xene-ex4_3.htm
<DESCRIPTION>EX-4.3
<TEXT>
<html>
 <head>
  <title>EX-4.3</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="z-index:-3;min-height:1in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" id="fis_certification"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 4.3</font></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">DESCRIPTION OF THE REGISTRANT&#x2019;S SECURTIIES</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">REGISTERED PURSUANT TO SECTION 12 OF THE</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECURITIES EXCHANGE ACT OF 1934</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Xenon Pharmaceuticals Inc. has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common shares, no par value per share.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The general terms and provisions of our common shares are summarized below. This summary does not purport to be complete and is subject to, and qualified in its entirety by express reference to, the provisions of our articles of incorporation and by-laws, each of which is included as an exhibit to the Annual Report on Form 10-K to which this description is an Exhibit, and each of which may be amended from time to time. We encourage you to read our articles of incorporation and bylaws and the applicable provisions of the Canada Business Corporations Act (the &#x201c;CBCA&#x201d;) for additional information.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our authorized share capital consists of (i) an unlimited number of common shares and (ii) an unlimited number of preferred shares issuable in series, of which an unlimited number have been designated as Series 1 preferred shares. Our board of directors is authorized, without shareholder approval except as required by the listing standards of The Nasdaq Global Market, to issue additional shares of our common shares or preferred shares.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Common Shares</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Voting Rights. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The holders of our common shares are entitled to one vote for each common share held on all matters submitted to a vote of the shareholders, including the election of directors. Our articles and by-laws do not provide for cumulative voting rights. Because of this, the holders of a plurality of the common shares entitled to vote in any election of directors can elect all of the directors standing for election, if they should so choose.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Dividends. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subject to priority rights that may be applicable to any then outstanding preferred shares, holders of our common shares are entitled to receive dividends, as and when declared by our board of directors in their absolute discretion out of legally available funds.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Liquidation. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the event of our liquidation, dissolution or winding up, holders of our common shares will be entitled to share ratably in the net assets legally available for distribution to shareholders after the payment of all of our debts and other liabilities and the satisfaction of any liquidation preference granted to the holders of any then outstanding preferred shares.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Rights and Preferences</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Holders of common shares have no pre-emptive or conversion rights and our common shares have no provisions for redemption or repurchase for cancellation, surrender or sinking or purchase funds. There are no provisions in our articles or by-laws requiring holders of common shares to contribute additional capital. The rights, preferences and privileges of the holders of common shares are subject to and may be adversely affected by, the rights of the holders of any series of preferred shares that we may designate and issue in the future.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fully Paid and Nonassessable. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All of our outstanding common shares are fully paid and nonassessable. Our board of directors has the authority to issue, without further action by our shareholders, additional common shares.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:1in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Preferred Shares</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our board of directors has the authority to issue, without further action by our shareholders, an unlimited number of preferred shares, issuable in one or more series, and subject to the provisions of the CBCA and the provisions of our Series 1 preferred shares, to fix such rights, preferences, privileges, restrictions and conditions thereon, including dividend and voting rights, as our board of directors may determine, and such rights, preferences and privileges, including dividend rights, voting rights and rights relating to the distribution of our assets in the event of liquidation, dissolution or winding up of our affairs, whether, voluntary or involuntary, or any other distribution of our assets among our shareholders for the purpose of winding up our affairs, may be superior to those of our common shares. Any new series of preferred shares authorized by our board of directors will have rights, preferences and privileges that are substantially the same as our Series 1 preferred shares, the terms of which are described in greater detail below. The issuance of preferred shares, while providing flexibility in connection with possible acquisitions and other corporate purposes, could adversely affect the voting power of holders of common shares and the likelihood that such holders will receive dividend payments and payments upon liquidation. In addition, the issuance of preferred shares could, among other things, have the effect of delaying, deferring or preventing a change in control of our company or other corporate action and could adversely affect the market price of our common shares and the voting and other rights of the holders of our common shares. No rights, privileges, restrictions or conditions attached to a series of preferred shares shall confer on a series a priority in respect of dividends or return of capital over any other series of preferred shares that are then outstanding. If any cumulative dividends or amounts payable on return of capital in respect of a series of preferred shares are not paid in full, all series of the preferred shares participate ratably in respect of accumulated dividends and return of capital.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Series 1 Preferred Shares</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Rank. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the event of our liquidation, dissolution or winding up or other distribution of our assets among our shareholders for the purpose of winding up our affairs, the holders of Series 1 preferred shares are entitled to all of our remaining property and assets </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">pari passu</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> on a share for share basis with the holders of our common shares.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Conversion. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each Series 1 preferred share is convertible into one common share at any time at the holder&#x2019;s option without payment of any additional consideration, provided that any such conversion must be for at least the lesser of (i) 100,000 Series 1 preferred shares, (ii) the remaining number of Series 1 preferred shares then held by such holder and (iii) such other number of Series 1 preferred shares as agreed between us and such holder. Holders of the Series 1 preferred shares are prohibited from converting Series 1 preferred shares into common shares if, as a result of such conversion, the holder, together with its affiliates, would beneficially own more than 9.99% of the total number of common shares issued and outstanding immediately after giving effect to such conversion, which we refer to as the Beneficial Ownership Limitation, provided that the holder may reset the Beneficial Ownership Limitation to a higher or lower number (not to exceed 19.99% of the total number of common shares issued and outstanding immediately after giving effect to a conversion) upon providing written notice to us. Any such notice providing for an increase to the Beneficial Ownership Limitation will be effective 61 days after delivery to us.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each Series 1 preferred share is also convertible into one common share at any time at our option without payment of additional consideration, provided that prior to any such conversion, the holder, together with its affiliates, beneficially owns less than 5.00% of the total number of common shares issued and outstanding and such conversion will not result in the holder, together with its affiliates, beneficially holding more than 5.00% of the total number of common shares issued and outstanding immediately after giving effect to such conversion.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the event of a change of control, holders of Series 1 preferred shares shall be issued one common share for each outstanding Series 1 preferred share held immediately prior to the change of control (without regard to the Beneficial Ownership Limitation), and following such conversion, will be entitled to receive the same kind and amount of securities, cash or property that a holder of common shares is entitled to receive in connection with such change of control.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:1in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Voting Rights. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The holders of the Series 1 preferred shares will not be entitled to receive notice of or to attend any meeting of the shareholders and will not be entitled to vote at any such meeting. Notwithstanding the foregoing, the holders of the Series 1 preferred shares are entitled to receive notice of and attend any meeting of the shareholders and vote on all matters on which the common shares are entitled to vote, voting together with the common shares on an as-converted basis and as a single class, provided that the voting rights of any holder shall not exceed the Beneficial Ownership Limitation notwithstanding any voting or other rights the holder may have at law or otherwise. In no case shall a Series 1 preferred share be entitled to more than one vote on an as-converted basis. Any Series 1 preferred shares that are ineligible to convert into common shares due to the Beneficial Ownership Limitation, measured as of a given record date that applies for a shareholder meeting, shall be deemed to be non-voting securities.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may not, without the affirmative vote of the holders of a majority of the then outstanding Series 1 preferred shares, (i) alter or change adversely the powers, preferences or rights given to the Series 1 preferred shares or alter or amend or repeal any provision of, or add any provision to, our articles or bylaws, or file any articles of amendment, if such action would adversely alter or change the rights, privileges, restrictions and conditions provided for the benefit of the Series 1 preferred shares, or (ii) enter into any agreement with respect to any of the foregoing.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Transferability. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prior to any sale, transfer or other disposition of Series 1 preferred shares, the holder must provide us with prior written notice at least three trading days in advance. No transfers may be affected unless the number of Series 1 preferred shares being transferred is at least the lesser of (i) 100,000 Series 1 preferred shares, (ii) the remaining number of Series 1 preferred shares then held by such holder and (iii) such other number of Series 1 preferred shares as agreed between us and such holder.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Dividends. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Holders of the Series 1 preferred shares are entitled to receive dividends (other than dividends in the form of common shares) on the Series 1 preferred shares (without regard to the Beneficial Ownership Limitation) if, as and when declared by our board of directors on the common shares. All dividends which our board of directors may determine to declare and pay must be declared and paid in equal or equivalent amounts per share on all of the Series 1 preferred shares in priority to the holders of the common shares.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Adjustments. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the common shares are subdivided, consolidated, reclassified or otherwise changed, the Series 1 preferred shares will be subdivided, consolidated, reclassified or otherwise changed in the same proportion and in the same manner. If the common shares are exchanged or changed into other securities, cash or other property, the Series 1 preferred shares when converted will be converted into such other securities, cash or other property in the same manner. If the common shares are converted into or exchanged for the right to receive more than one type of consideration, the consideration for which the Series 1 preferred shares are exchangeable will be deemed to be the weighted average of the types and amounts of consideration received by the holders of common shares.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Redemption. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may not redeem the Series 1 preferred shares.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Preferred Shares Outstanding</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. As of the date of this Annual Report on Form 10-K, there are no Series 1 preferred shares outstanding.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Corporate Governance</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the CBCA, we are required to hold a general meeting of our shareholders at least once every year at a time and place determined by our board of directors, provided that the meeting must not be held later than 15 months after the preceding annual general meeting and no later than six months after the end of the preceding financial year. The CBCA requires that meetings of shareholders shall be held at any place within Canada as our board of directors may from time to time determine. A notice to convene a meeting, specifying the date, time, location, and the means of communication facility, if applicable, by which shareholders and proxyholders may participate in the meeting must be sent to shareholders, to each director and the auditor not less than 21 days prior to the meeting or such other minimum period as required by the applicable securities laws. Under the CBCA, shareholders entitled to notice of a meeting may waive or reduce the period of notice for that meeting, provided applicable securities laws requirements are met.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:1in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the CBCA, all business transacted at a special meeting of shareholders and all business transacted at an annual meeting of shareholders, except consideration of the financial statements, auditor&#x2019;s report, election of directors and re-appointment of the incumbent auditor, is deemed to be special business. Notice of a meeting of shareholders at which special business is to be transacted shall state (a) the nature of that business in sufficient detail to permit the shareholder to form a reasoned judgment thereon; and (b) the text of any special resolution to be submitted to the meeting.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the CBCA, our board of directors has the power at any time to call a special meeting of our shareholders. In addition, the holders of not less than 5% of our issued shares that carry the right to vote at a meeting sought to be held can also requisition our board of directors to call a meeting of our shareholders for the purposes stated in the requisition. If our board of directors does not call the meeting within 21 days after receiving the requisition, any shareholders who signed the requisition can call the meeting and the expenses reasonably incurred by such shareholders in requisitioning, calling and holding the meeting must be reimbursed by us.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Those entitled to vote at a meeting are entitled to attend meetings of our shareholders. Every shareholder entitled to vote may appoint a proxyholder to attend the meeting in the manner and to the extent authorized and with the authority conferred by the proxy. Directors, auditors, legal counsels, secretary (if any), and any other persons invited by the chair of the meeting or with the consent of those at the meeting are entitled to attend any meeting of our shareholders but will not be counted in quorum or be entitled to vote at the meeting unless he or she or it is a shareholder or proxyholder entitled to vote at the meeting.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain Takeover Bid Requirements</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unless such offer constitutes an exempt transaction, an offer made by a person, an &#x201c;offeror&#x201d;, to acquire outstanding shares of a Canadian entity that, when aggregated with the offeror&#x2019;s holdings (and those of persons or companies acting jointly with the offeror), would constitute 20% or more of the outstanding shares in a class, would be subject to the take-over provisions of Canadian securities laws. The foregoing is a limited and general summary of certain aspects of applicable securities law in the provinces and territories of Canada, all in effect as of the date hereof.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to those takeover bid requirements noted above, the acquisition of our shares may trigger the application of statutory regimes including among others, the Investment Canada Act (Canada) and the Competition Act (Canada).</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Limitations on the ability to acquire and hold our common shares may be imposed by the Competition Act (Canada). This legislation permits the Commissioner of Competition, or the Commissioner, to review any acquisition of control over a significant interest in us. This legislation grants the Commissioner of Competition jurisdiction to challenge an acquisition before the Canadian Competition Tribunal on the basis that it would, or would be likely to, substantially prevent or lessen competition in any definable market in Canada.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This legislation requires any person who intends to acquire our common shares to file a notification with the Canadian Competition Bureau if certain financial thresholds are exceeded and if that person (and their affiliates) would hold more than 20% of our common shares. If a person already owns 20% or more of our common shares, a notification must be filed when the acquisition of additional shares would bring that person&#x2019;s holdings to over 50%. Where a notification is required, the legislation prohibits completion of the acquisition until the expiration of a statutory waiting period, unless the Commissioner first provides written notice that the acquisition will not be challenged. Where the waiting period has expired and such a written notice has not been provided, or where a notification is not required, the parties may complete the acquisition, though the Commissioner may still challenge it within one year from completion.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There is no limitation imposed by Canadian law or our articles on the right of non-residents to hold or vote our common shares, other than those imposed by the Investment Canada Act.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:1in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Investment Canada Act requires any person that is a &#x201c;non-Canadian&#x201d; (as defined in the Investment Canada Act) who acquires control of an existing Canadian business, where the acquisition of control is not a reviewable transaction, to file a post-closing notification form with the Investment Review Division of the Canadian government. The Investment Canada Act generally prohibits the implementation of a reviewable transaction unless, after review, the relevant minister is satisfied that the investment is likely to be of net benefit to Canada. Under the Investment Canada Act, direct acquisition of control of us through the acquisition of our common shares (or the acquisition of all or substantially all our assets) by a non-Canadian investor who is a Trade Agreement country investor, including a U.S. investor, but not a state-owned enterprise, would be reviewable only if our enterprise value (as determined pursuant to the Investment Canada Act) exceeds CAD$1.931 billion for 2023 (increasing annually on the basis of a prescribed formula in the Investment Canada Act to reflect changes in the Canadian gross domestic product). If the acquisition of control of us is by a non-Canadian that is not a Trade Agreement country investor or a state-owned enterprise, but is a World Trade Organization member country investor, the acquisition of control would be reviewable only if our enterprise value exceeds CAD$1.287 billion for 2023 (increasing annually on the basis of a prescribed formula in the Investment Canada Act to reflect changes in the Canadian gross domestic product). If the acquisition of control of us is by a state-owned enterprise that is a non-Canadian who is a World Trade Organization member country investor, including a U.S. investor, the acquisition of control would be reviewable only if the value of our assets was equal to or greater than CAD$512 million for 2023 (subject to an annual adjustment on the basis of a prescribed formula in the Investment Canada Act to reflect changes in Canadian gross domestic product).</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The acquisition of a majority of the voting interests of an entity is deemed to be acquisition of control of that entity (more than 50% of voting shares). The acquisition of less than a majority but one-third or more of the voting shares of a corporation or an equivalent undivided ownership interest in the voting shares of a corporation is presumed to be an acquisition of control of that corporation unless it can be established that, on the acquisition, the corporation is not controlled in fact by the acquirer through the ownership of voting shares. The acquisition of less than one-third of the voting shares of a corporation is deemed not to be an acquisition of control of that corporation. Certain transactions in relation to our common shares would be exempt from review by the Investment Canada Act including:</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:3.7%;box-sizing:content-box;"></td>
    <td style="width:2.78%;box-sizing:content-box;"></td>
    <td style="width:93.52%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#149;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">the acquisition of our common shares by a person in the ordinary course of that person&#x2019;s business as a trader or dealer in securities;</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#149;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">the acquisition of control of us in connection with the realization of security granted for a loan or other financial assistance and not for any purpose related to the provisions of the Investment Canada Act; and</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#149;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">the acquisition of control of us by reason of an amalgamation, merger, consolidation or corporate reorganization following which ultimate direct or indirect control in fact of us, through the ownership of our voting shares, remains unchanged.</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the national security regime in the Investment Canada Act, a review on a discretionary basis may also be undertaken by the federal government in respect of a much broader range of investments by a non-Canadian to &#x201c;acquire, in whole or in part, or to establish an entity carrying on all or any part of its operations in Canada.&#x201d; The relevant test is whether such an investment by a non-Canadian could be &#x201c;injurious to national security.&#x201d; Review on national security grounds is at the discretion of the federal government and may occur on a pre- or post-closing basis.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There is no law, governmental decree or regulation in Canada that restricts the export or import of capital or which would affect the remittance of dividends or other payments by us to non-Canadian holders of our common shares or preferred shares, other than withholding tax requirements.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Neither our articles nor by-laws contain any change of control limitations with respect to a merger, acquisition or corporate restructuring that involves us.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This summary is not a comprehensive description of relevant or applicable considerations regarding such requirements and, accordingly, is not intended to be, and should not be interpreted as, legal advice to any prospective purchaser and no representation with respect to such requirements to any prospective purchaser is made. Prospective investors should consult their own Canadian legal advisors with respect to any questions regarding securities law in the provinces and territories of Canada.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:1in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Actions Requiring a Special Majority</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the CBCA, certain corporate actions require the approval of a special majority of shareholders, meaning holders of shares representing not less than 66 &#x2154;% of those votes cast in respect of a shareholder vote addressing such matter. Those items requiring the approval of a special majority generally relate to fundamental changes with respect to our business, and include among others, resolutions: (i) amending our articles; (ii) approving an amalgamation; (iii) approving a continuance; and (iv) providing for a sale, lease or exchange of all or substantially all of our property.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Advance Notice Procedures and Shareholder Proposals</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the CBCA, shareholders may make proposals for matters to be considered at the annual general meeting of shareholders. Such proposals must be sent to us in advance of any proposed meeting by delivering a timely written notice in proper form to each of our directors and to our registered office in accordance with the requirements of the CBCA. The notice must include information on the business the shareholder intends to bring before the meeting.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, our by-laws require that shareholders provide us with advance notice of their intention to nominate any persons, other than those nominated by management, for election to our board of directors at a meeting of shareholders.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These provisions could have the effect of delaying until the next shareholder meeting the nomination of certain persons for director that are favored by the holders of a majority of our outstanding voting securities.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ownership and Exchange Controls</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There is currently no law, governmental decree or regulation in Canada that restricts the export or import of capital, or which would affect the remittance of dividends, interest or other payments by us to non-resident holders of our common shares, other than withholding tax requirements.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There is currently no limitation imposed by Canadian law or our articles or by-laws on the right of non-residents to hold or vote our common shares, other than those imposed by the Investment Canada Act and the Competition Act (Canada). These acts will generally not apply except where a control of an existing Canadian business or company, which has Canadian assets or revenue, or enterprise value (as applicable) over a certain threshold, is acquired and will not apply to trading generally of securities listed on a stock exchange.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Listing</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our common shares are listed on the Nasdaq Global Market under the symbol &#x201c;XENE.&#x201d;</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.30
<SEQUENCE>3
<FILENAME>xene-ex10_30.htm
<DESCRIPTION>EX-10.30
<TEXT>
<html>
 <head>
  <title>EX-10.30</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.30</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CONFIDENTIAL</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">January 15, 2025</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">										</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br>Christopher E. Von Seggern</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">BY EMAIL</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dear Chris:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	This letter is to summarize the terms of the separation package that Xenon Pharmaceuticals USA Inc., a wholly owned subsidiary of Xenon Pharmaceuticals Inc. (collectively, the &#x201c;Company&#x201d;), is willing to offer you.   Please read this letter agreement (the &#x201c;Letter Agreement&#x201d;), which includes a general release, carefully.  If you are willing to agree to its terms, please sign in the space provided below and return it to me so that your separation benefits can begin.   Please note that you have twenty-one (21) days from receipt of this Letter Agreement to sign and return this Letter Agreement.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Separation Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Regardless of whether you choose to sign this Letter Agreement, your employment with the Company terminates as of Friday, January 17, 2025 (the &#x201c;Separation Date&#x201d;).  </font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Final Salary and Vacation Pay</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. You acknowledge that you received or will receive, on or before the Separation Date, pay for time worked through the Separation Date, to the extent not previously paid, as well as pay, at your final base rate of pay, for any unused and accrued vacation time as of the Separation Date, less lawful deductions.   </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Status of Employee Benefits</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. After the Separation Date, except as expressly provided below, you will not be entitled to receive any benefits paid by, or participate in any benefit programs offered by, the Company to its employees. Your coverage, if any, under the Company&#x2019;s</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">health plan will continue through the Separation Date. You have received (or will receive), under separate cover, information concerning your right (if any) to continue your health insurance benefits after that date in accordance with COBRA. </font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Severance Benefits</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In compliance with the promises made herein and in the event you sign this Letter Agreement and return it to me within time period set forth in the Letter Agreement and do not revoke your acceptance pursuant to Paragraph No. 10 below, the Company</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">agrees as follows: </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">a.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company will pay you the total gross amount of $640,000 USD less lawful deductions, representing sixteen (16) months of severance pay at your current base salary. Payment will be made in a lump sum in the Company&#x2019;s first reasonably practicable payroll cycle after the expiration of the revocation period set forth in Paragraph No. 10 below. </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">b.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Provided that you are eligible for and properly elect to continue your health and dental coverage under COBRA, the Company will pay the cost of your COBRA premiums for a sixteen (16)-month period, with such payments ending on the earlier of (i) the end of the sixteen (16)-month period following the Separation Date or (ii) the date on which you commence full-time employment with another employer.  Thereafter, you will be required to pay the full cost of any COBRA coverage for the remainder of the COBRA period. You agree to promptly notify the Company if you commence full-time employment with another employer during the time period that the Company is paying the cost of your COBRA premiums under this subparagraph. Notwithstanding anything to the contrary provided herein, if the payments or benefits to be provided pursuant to this subparagraph would subject the Company or you to adverse penalties or excise taxes, the Company shall arrange to provide you with an alternative payment or benefit that avoids the penalty or excise tax.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">c.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company will pay you an Average Bonus (as defined in your offer letter with the Company dated July 14, 2020 (the &#x201c;Offer Letter&#x201d;)), prorated for the period of 2025 prior to the Separation Date. Payment will be made in a lump sum in the Company&#x2019;s first regular payroll cycle following the later of (i) the expiration of the revocation period set forth in Paragraph No. 10 below, and (ii) the determination by the Board of Directors of the Company (the &#x201c;Board&#x201d;) of the Company&#x2019;s 2024 performance achievement.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">d.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notwithstanding the requirement in the Offer Letter that you remain employed through the date of payment to receive your annual bonus for 2024, subject to approval by the Board or the Compensation Committee of the Board, the Company will pay you your annual bonus for 2024, based on the Board&#x2019;s determination of the corporate performance multiplier for 2024. Such payment will be made in a lump sum in the Company&#x2019;s regular payroll cycle following the later of (i) the expiration of the revocation period set forth in Paragraph No. 10 below, and (ii) the Board&#x2019;s determination of the Company&#x2019;s 2024 performance achievement. </font></div></div>
  <p style="margin-left:16.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">e.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company will pay the amount of $32,000 USD, which represents an amount equal to the contributions to your retirement savings plan that it would have made had you remained employed for the sixteen (16)-month period following the Separation Date.  Payment will be made directly to your retirement savings plan account with the first reasonably practicable payroll cycle after the expiration of the revocation period set forth in Paragraph No. 10.  </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">f.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the terms of your Offer Letter, all unvested stock options and other equity awards granted to you by the Company that are outstanding as of the Separation Date (the &#x201c;Equity Awards&#x201d;) will continue to vest in accordance with their terms for a period of three (3) months following the Separation Date. All vested stock options will be exercisable until the earlier of the original expiry date per the granted equity award agreement and the date that is six (6) months after the Separation Date (the &#x201c;Post-Termination Exercise Period&#x201d;).  All unvested options and other equity awards that remain unvested as of three (3) months following the Separation Date will be </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">automatically forfeited on the date that is three (3) months following the Separation Date for no consideration.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">g.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company will engage you under a consultant agreement in substantially the form attached hereto as Exhibit A (the &#x201c;Consultant Agreement&#x201d;), for a period commencing on your Separation Date and ending on May 1, 2025. If such Consultant Agreement is entered into on the terms as proposed by the Company, all Equity Awards will continue to vest in accordance with their terms through May 1, 2025 (or such earlier date that the Consultant Agreement terminates, but in no event sooner than the expiration of the three (3)-month period following the Separation Date), and the Post-Termination Exercise Period for all vested stock options as of May 1, 2025 (or such earlier date that the Consultant Agreement terminates, but in no event sooner than the expiration of the three (3)-month period following the Separation Date) shall be extended to August 1, 2025. For clarity, all Equity Award that remain unvested as of May 1, 2025 will be automatically forfeited as of such date for no consideration.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Acknowledgement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. You understand and agree that you would not receive the monies and/or benefits specified in Paragraph No. 4 above, except for your execution of this Letter Agreement, which contains a release, and the fulfillment of the promises contained in this Letter Agreement. You further understand and agree that, except as expressly set forth in Paragraph No. 4 above, you will not be entitled to any other compensation or benefits from the Company or its affiliates and that, except for your rights to certain continued vesting of the Equity Awards expressly set forth in Paragraph No. 4 and your rights to exercise your vested stock options, you do not have any rights or entitlements to or with respect to any equity or equity-based award from, or any other equity ownership interest in, the Company or its affiliates.</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">6.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General Release of Claims</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In consideration of the payments to be made by the Company to you as set forth in Paragraph No. 4 above and the promises contained in this Letter Agreement, you voluntarily and of your own freewill hereby release, forever discharge and hold harmless Xenon Pharmaceuticals USA Inc., Xenon Pharmaceuticals Inc., its and their present or former parents, subsidiaries, divisions and affiliates and its and their present or former officers, directors, trustees, employees, agents, insurers, or successors or assigns (collectively, the &#x201c;Released Parties&#x201d;) from any and all claims, demands, rules or regulations, or any other causes of action of whatever nature, whether known or unknown, as of the date of your execution of this Letter Agreement, including, but not limited to any alleged violations of Title VII of the Civil Rights Act of 1964, as amended; Sections 1981 through 1988 of Title 42 of the United States Code, as amended; the Age Discrimination in Employment Act of 1967, as amended; the Older Workers Benefit Protection Act; the Immigration Reform Control Act, as amended; the Employee Retirement Income Security Act of 1974, 29 U.S.C. &#167; 1001, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">et</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">seq</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. (&#34;ERISA&#34;) (except for any vested benefits under any tax qualified benefit plan); the Occupational Safety and Health Act, as amended; the Civil Rights Act of 1866, 29 U.S.C. &#167; 1981, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">et</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">seq.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">; the Rehabilitation Act of 1973, 29 U.S.C. &#167; 701, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">et</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">seq</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.; the Americans With Disabilities Act of 1990, as amended; the Civil Rights Act of 1991; the Family and Medical Leave Act; the Equal Pay Act; the Fair Credit Reporting Act; the Uniformed Services Employment and Reemployment Rights Act of 1994 (&#x201c;USERRA&#x201d;); the Genetic Information Nondiscrimination Act (&#x201c;GINA&#x201d;)</font><font style="color:#1f497d;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Worker Adjustment and Retraining Notification Act (WARN), 29 U.S.C. &#167; 2101 </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">et seq</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.; the Massachusetts Law Against </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Discrimination, G.L. c. 151B; the Massachusetts Wage Payment Statute, G.L. c. 149, &#167;&#167; 148, 148A, 148B, 148C, 149, 150, 150A-150C, 151, 152, 152A, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">et</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">seq</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.; the Massachusetts Wage and Hour laws, G.L. c. 151&#167;1A </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">et</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">seq</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.; the Massachusetts Privacy Statute, G.L. c. 214, &#167; 1B; the Massachusetts Sexual Harassment Statute,  G.L. c. 214, &#167; 1C; the Massachusetts Civil Rights Act, G.L. c. 12 &#167; 11H; the Massachusetts Equal Rights Act, G.L. c. 93 &#167; 102; the Massachusetts Equal Pay Act, G.L. c. 149, &#167; 105A; the Massachusetts Parental Leave Law, G.L. c. 149, &#167; 105D; the Massachusetts Family and Medical Leave Law, G.L. c. 175M; or any other federal or state law, regulation, or ordinance; any public policy, contract, tort, or common law; or any allegation for costs, fees, or other expenses including attorneys&#x2019; fees incurred in these matters.  In addition, if any claim is not subject to release, to the extent permitted by law, you waive any right or ability to be a class or collective action representative or to otherwise participate in any putative or certified class, collective or multi-party action or proceeding based on such a claim in which the Company or any other releasee identified in this Letter Agreement is a party.</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notwithstanding the foregoing, you are not waiving any rights you may have to: (a) your own vested accrued employee benefits under the Company&#x2019;s health, welfare, or retirement benefit plans as of the Separation Date; (b) benefits and/or the right to seek benefits under applicable workers&#x2019; compensation and/or unemployment compensation statutes; (c) pursue claims which by law cannot be waived by signing this Letter Agreement; (d) enforce this Letter Agreement; and/or (e) challenge the validity of this Letter Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">7.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Continuing Obligations, Confidentiality and Non-Disparagement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a.	You acknowledge that you continue to be bound by your obligations under the At-Will Employment, Confidential Information, Invention Assignment, and Arbitration Agreement between you and the Company dated as of August 17, 2020 (the &#x201c;At-Will Employee Agreement&#x201d;) that survive the termination of your employment by necessary implication or the terms thereof, including and specifically your obligations concerning confidentiality, non-solicitation, non-competition and/or assignment of rights to intellectual property by and between you and the Company or any of its affiliates.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">b.	Without limiting Paragraph 7.a above, in connection with your separation from employment and in consideration of the severance benefits described in Paragraph No. 4, including that set forth in Paragraph No. 4.d, for a period of twelve (12) months following the Separation Date (the &#x201c;Restricted Period&#x201d;), you agree you will not (i) serve as a partner, principal, licensor, licensee, employee, consultant, officer, director, manager, agent, affiliate, representative, advisor, promoter, associate, investor, or otherwise for any Competitive Company; (ii) directly or indirectly, own, purchase, organize or take preparatory steps for the organization of any Competitive Company; or (iii) build, design, finance, acquire, lease, operate, manage, control, invest in, work or consult for or otherwise join, participate in or affiliate yourself with any Competitive Company. For the purposes of this Agreement, &#x201c;Competitive Company&#x201d; shall mean any person, partnership, business, corporation, or other entity that engages in on-going clinical development in epilepsy. The foregoing covenant shall cover all activities in the Territory. For purposes of this Agreement, &#x201c;Territory&#x201d; shall mean (i) all counties in the Commonwealth of Massachusetts; (ii) all other states, commonwealths, territories, or districts of the United States of America that the Company or any of its affiliates provided goods or services, had customers, or</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">otherwise conducted business at any time during the two (2)-year period prior to the Separation Date; and (iii) any other countries from which the Company or its affiliates provided goods or services, had customers, or otherwise conducted business at any time during the two (2)-year period prior to the Separation Date. Should you obtain other employment during the twelve (12)-month period immediately following the Separation Date, you agree to provide written notification to the Company as to the name and address of your new employer, the position you expect to hold, and a general description of your duties and responsibilities, at least three (3) business days prior to starting such employment.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">c.	Subject to Paragraph No. 7.d. of this Letter Agreement, you agree that you will continue to protect Confidential Information, as defined herein, and that you will never, directly or indirectly, use or disclose it. As used in this Letter Agreement, &#x201c;Confidential Information&#x201d; means any and all information of the Company or any of its affiliates that is not generally known to the public, including the existence and the terms of this Letter Agreement.  Confidential Information also includes all information received by the Company or any of its affiliates from customers or other third parties with any understanding, express or implied, that the information would not be disclosed.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">d.	Subject to Paragraph No. 12, you agree that you will not at any time (i) make, publish, or communicate any remarks or comments, orally or in writing, (i) to the news media or through social media platforms relating in any way to the Company, whether or not you consider the comment(s) or remark(s) to be disparaging of the Company; and/or (ii) to any person or entity in any forum, which are or reasonably could be construed to be derogatory or disparaging about the Company or its current or former directors, officers, or employees, or which reasonably could be anticipated to be damaging or injurious to the Company&#x2019;s reputation, the reputation of the Company&#x2019;s current or former directors, officers, and employees, or the Company&#x2019;s current or potential business endeavors,  including but not limited to, any statements that disparage any aspect of the Company&#x2019;s operations or business, or do or say anything that could disrupt the good morale of employees of the Company or any of its affiliates.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">e.	You understand and agree that your obligations under this paragraph are material terms of this Letter Agreement, and that the Company shall have the right, in addition to any other damages, to seek and obtain the return of the consideration paid hereunder (without impacting the validity or enforceability of the general release contained herein) in the event you breach any of your obligations under this paragraph.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">f.	In signing this Letter Agreement, you give the Company assurance that you have carefully read and considered all the terms and conditions of this Letter Agreement, including the restraints imposed on you under this Paragraph No. 7.  You agree without reservation that these restraints are necessary for the reasonable and proper protection of the Company and its affiliates, and that each and every one of the restraints is reasonable in respect to subject matter, length of time and geographic area.  You further agree that, were you to breach any of the covenants contained in this this Paragraph No. 7, the damage to the Company and its affiliates would be irreparable.  You therefore agree that the Company, in addition and not in the alternative to any other remedies available to it, shall be entitled to preliminary and permanent injunctive relief against any breach or threatened breach by you of any such covenants, without having to post</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">bond, together with an award of its reasonable attorneys&#x2019; fees incurred in enforcing its rights hereunder.  You further agree that the Restricted Period shall be tolled, and shall not run, during the period of any breach by you of any of the covenants contained in this Paragraph No. 7.  You and the Company further agree that, in the event that any provision of this Paragraph No. 7 is determined by any court of competent jurisdiction to be unenforceable by reason of its being extended over too great a time, too large a geographic area or too great a range of activities, that provision shall be deemed to be modified to permit its enforcement to the maximum extent permitted by law.  It is also agreed that each of the Company&#x2019;s affiliates shall have the right to enforce all of your obligations to that affiliate under this Letter Agreement, including without limitation pursuant to this Paragraph No. 7.  No claimed breach of this Letter Agreement or other violation of law attributed to the Company or any of its affiliates shall operate to excuse you from the performance of his obligations under this Paragraph No. 7.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8.	 </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Return of Company Documents and Other Property</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. You hereby acknowledge and reaffirm the validity of the At-Will Employee Agreement between you and the Company, the terms and conditions of which are incorporated herein by reference and remain in full force and effect for the full term stated therein.  You also affirm that you have returned to the Company all keys, files, records (and copies thereof), equipment (including, but not limited to, computer hardware, software, printers, wireless handheld devices, cellular phones, pagers, etc.), Company identification, Company vehicles and any other Company-owned property in your possession or control and have left intact all electronic Company documents, including but not limited to, those that you developed or helped develop during your employment.  You understand that the Company would not provide you with the monies and benefits under this Letter Agreement but for your reaffirmation of these obligations.  You further understand and agree that your obligations under this paragraph are material terms of this Letter Agreement, and that the Company shall have the right, in addition to any other damages, to seek and obtain the return of the consideration paid hereunder (without impacting the validity or enforceability of the general release contained herein) in the event you breach any of your obligations under this paragraph.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Period of Time to Review this Letter Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. You will be afforded a period of up to twenty-one (21) calendar days to consider the meaning and effect of this Letter Agreement.  You are advised to consult with an attorney, and you acknowledge that you have had the opportunity to do so.  You agree that any modifications, material or otherwise, do not restart or affect in any manner the original twenty-one (21)-day consideration period for the separation proposal made to you.   If you do not sign and return this Letter Agreement within the twenty-one (21)-day consideration period, the Company&#x2019;s offer to provide you with the monies and/or other benefits set forth herein will expire.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">   </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revocation Period</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. You may revoke this Letter Agreement for a period of seven (7) calendar days following the day you execute this Letter Agreement.  Any revocation within this period must be submitted, in writing, to Shelley McCloskey, Executive Vice President, Human Resources and state, &#x201c;I hereby revoke my acceptance of the Letter Agreement.&#x201d; The revocation must be personally delivered to Shelley McCloskey, Executive Vice President, Human Resources, 3650 Gilmore Way, Burnaby, BC, V5G 4W8, or e-mailed (     ) and mailed to her by first class mail and postmarked within seven (7) calendar days of execution of this Letter Agreement.  This Letter Agreement shall not become effective or enforceable until the revocation period has expired.  If the last day of the revocation period is a Saturday, Sunday, or legal holiday in the state in which</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">you reside, then the revocation period shall not expire until the next following day which is not a Saturday, Sunday, or legal holiday.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Miscellaneous</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This Letter Agreement, which will be construed under Massachusetts law, may not be modified, altered, or changed except upon express written consent of both parties wherein specific reference is made to this Letter Agreement. You agree that any claims or causes of action which arise out of or relate in any way to this Letter Agreement shall be instituted and litigated only in, and you voluntarily submit to the jurisdiction over your person by, the courts of the Commonwealth of Massachusetts, or if appropriate, a federal court located in Massachusetts (which courts, for purposes of this Letter Agreement, are the only courts of competent jurisdiction).  </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the fullest extent permitted by applicable law, you and the Company waive the right to a trial by jury with respect to any such claims or causes of action or other proceeding</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12.	Nothing in this Letter Agreement or any other agreement you may have signed or company policy,  prohibits, prevents, or otherwise limits you from (1) reporting possible violations of federal or other law or regulations to any governmental agency, regulatory body, or law enforcement authority (</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">e.g.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, EEOC, MCAD, NLRB, SEC, DOJ, CFTC, U.S. Congress, or an Inspector General), (2) filing a charge or complaint with any such governmental agency, or (3) participating, testifying, or assisting in any investigation, hearing, or other proceeding brought by, in conjunction with, or otherwise under the authority of any such governmental agency.  To the maximum extent permitted by law, you agree that if such an administrative claim is made, you shall not be entitled to recover any individual monetary relief or other individual remedies related to any alleged adverse employment action(s), except nothing in this Letter Agreement prohibits, prevents, or otherwise limits your ability or right to seek or receive any monetary award or bounty from any such governmental agency in connection with protected &#x201c;whistleblower&#x201d; activity. You are also not required to notify or obtain permission from the Company when filing a governmental whistleblower charge or complaint or engaging or participating in protected whistleblower activity.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13.	You affirm that you have been paid and have received all leave (paid or unpaid), compensation, wages, bonuses, commissions, severance pay, and/or benefits to which you may be entitled and that no other leave (paid or unpaid), compensation, wages, bonuses, commissions, severance pay, and/or benefits are due to you, except as provided in this Letter Agreement.  You further affirm that you have no known workplace injuries or occupational diseases and have been provided and/or have not been denied any leave requested under the Family and Medical Leave Act.  You also affirm that you have not been retaliated against for reporting any allegations of wrongdoing by the Company or its officers, including any allegations of corporate fraud.  In addition, you affirm that all decisions regarding your pay and benefits through the date of your execution of this Letter Agreement were not discriminatory based on age, disability, race, color, sex, religion, national origin or any other classification protected by law.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14.	You agree that neither this Letter Agreement, nor the furnishing of consideration for this Letter Agreement, shall be deemed or construed at any time for any purpose as an admission by the Company</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of any liability, wrongdoing, or unlawful conduct of any kind.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">       </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15.	You agree to cooperate with the Company in the investigation, defense or prosecution of any claims, actions or other matters now in existence or which may be brought in the future against or on behalf of the Company. Your cooperation in connection with such claims or actions shall include, but not be limited to, being reasonably available to meet with the Company&#x2019;s counsel to prepare for discovery or any mediation, arbitration, trial, administrative hearing or other proceeding or to act as a witness when reasonably requested by the Company at mutually agreeable times and at locations mutually convenient to you and the Company.  Nothing herein shall require you to provide anything other than truthful information.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16.	It is the intent of the parties that this Letter Agreement and all payments and benefits referenced herein shall be exempt from, and, to the extent not exempt, made in full compliance with, Section 409A of the Internal Revenue Code of 1986, as amended (&#x201c;Section 409A&#x201d;), and to the maximum extent possible this Letter Agreement shall be interpreted and construed in accordance with such intent. Each amount to be paid or benefit to be provided to you pursuant to this Letter Agreement shall be treated as a separate payment for purposes of Section 409A, and your right to receive any installment payments under this Letter Agreement (whether severance payments, reimbursements or otherwise) will be treated as a right to receive a series of separate payments and, accordingly, each installment payment hereunder will at all times be considered a separate and distinct payment. Notwithstanding the foregoing, the Company does not guarantee any particular tax result, and in no event whatsoever will the Company, its affiliates, or their respective officers, directors, employees or agents be liable for any additional tax, interest or penalties that may be imposed on you by Section 409A or damages for failing to comply with Section 409A.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">17.	All payments and benefits made or provided by the Company under this Letter Agreement shall be reduced by any tax or other amounts required to be withheld by the Company under applicable law.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18.	This Letter Agreement, which includes a general release, represents the complete agreement between you and the Company, and fully supersedes any prior agreements or understandings between the parties, other than your At-Will Employee Agreement referred to in Paragraph Nos. 7 and 8.  You acknowledge that you have not relied on any representations, promises, or agreements of any kind made to you in connection with your decision to sign this Letter Agreement, except those set forth herein.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">19.	Should any provision of this Letter Agreement be declared illegal or unenforceable by any court of competent jurisdiction and cannot be modified to be enforceable consistent with the intent of the parties, excluding the general release language, such provision shall immediately become null and void, leaving the remainder of this Letter Agreement in full force and effect.  However, if the general release in Paragraph No. 6 is found to be invalid, you agree to execute a valid release of the claims that are the subject of this Letter Agreement and/or are referred to in the general release in Paragraph No. 6 above.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">20.	This Letter Agreement may be executed in counterparts, each of which when so executed shall be deemed an original, and the counterparts together shall constitute one and the same agreement. A copied, scanned, or faxed signature shall be treated the same as an original.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company would like to extend its appreciation to you for your past service, and its sincere hope for success in your future endeavors.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">						</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:50.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:72pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:13.333%;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Very truly yours,</font></p><p style="margin-left:13.333%;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:72pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:13.333%;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Ian Mortimer</font></p><p style="margin-left:13.333%;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:72pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:13.333%;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ian Mortimer</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:72pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:13.333%;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Executive Officer</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">						</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	You have been advised in writing that you have a period of up to twenty-one (21) calendar days to consider this Letter Agreement and to consult with an attorney prior to the execution of this Letter Agreement.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	Having elected to execute this Letter Agreement, to fulfill the promises set forth herein, and to receive thereby the sums and benefits set forth in Paragraph No. 4 above, you freely and knowingly, and after due consideration, enter into this Letter Agreement by signing below intending to waive, settle, and release all claims (including, without limitation, any claims under the Age Discrimination in Employment Act of 1967) you have or might have against the Company and the Released Parties.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">By signing below, you also hereby immediately (and with contemporaneous effect) resign any directorships, offices or other positions that you may hold, if any, in the Company.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:auto;width:81.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:8.025%;box-sizing:content-box;"></td>
    <td style="width:30.84%;box-sizing:content-box;"></td>
    <td style="width:18.519%;box-sizing:content-box;"></td>
    <td style="width:42.617%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">January 15, 2025</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Christopher E. Von Seggern</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Christopher E. Von Seggern</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit A</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consultant Agreement</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Attached)</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.31
<SEQUENCE>4
<FILENAME>xene-ex10_31.htm
<DESCRIPTION>EX-10.31
<TEXT>
<html>
 <head>
  <title>EX-10.31</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.31</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CONSULTING AGREEMENT</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	This CONSULTING AGREEMENT (</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Agreement&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) is entered into as of January 17, 2025 (</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Effective Date&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">), by and between Xenon Pharmaceuticals USA, Inc. (</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Company&#x201d;),</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and Christopher E. Von Seggern (</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Consultant&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WHEREAS</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, Consultant has offered to provide certain consulting services (</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Services&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) to Company; and</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WHEREAS</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, Company desires to retain Consultant to provide such consulting services as may be reasonably requested from time to time by or on behalf of Company and described in one or more statements of work hereunder;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOW, THEREFORE</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, in consideration of the mutual covenants and agreements set forth herein, the parties hereby agree as follows:</font></p>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consulting Services</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </font></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	(a)	Subject to and upon the terms and conditions set forth in this Agreement, Consultant will perform the Services and deliver the Deliverables described in the statement of work set forth in Attachment A (the </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Statement of Work&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;SOW&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">). As used herein, </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Deliverables&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> means any work product, report, analysis, summaries, recommendations, or other deliverables described in any Statement of Work, including any work-in-process of any of the foregoing.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> 	</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consultant agrees to perform the Services and complete the Deliverables, if any, in accordance with any timeline as may be set forth in the applicable Statement of Work.  Consultant will provide the Services at such times and locations as are mutually agreed upon by Consultant and Company.  In rendering the Services, Consultant will act solely as an independent contractor and this Agreement does not constitute a contract of employment and will not be construed to create any employee/employer relationship between Consultant and Company.  The Consultant shall diligently perform the Services in a professional and competent manner in  accordance with the terms of this Agreement, the attached Statement of Work, and all applicable rules, regulations and laws.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c) 	Consultant agrees not to make any use of any funds, space, personnel, facilities, equipment, employees or other resources of a third party, in performing the Services, nor to take any other action that would result in a third party having any rights in the Deliverables or results of the Services, as defined herein.  Without limiting the foregoing, Consultant agrees that he or she will not utilize in the performance of any Services or incorporate into any Deliverables or materials provided to Company; (i) any confidential information of Consultant or any third party; or (ii) any technology, materials, know-how or inventions, covered by proprietary rights of Consultant or any third party, except as Consultant is freely permitted to do without further compensation by Company to Consultant or any third party.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compensation.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:6pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company agrees to pay Consultant for the Services in accordance with the fee schedule of the Statement of Work.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:6pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Within fifteen (15) days following the end of each calendar month in which Consultant performs Services, Consultant (or Company, on Consultant&#x2019;s behalf) will submit a statement showing, by date, the number of hours spent performing the Services, and the total amount due in payment. The consulting fees will be paid on a monthly basis, within thirty (30) days following receipt of a statement, unless agreed upon in a separate writing.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:6pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company will not withhold any tax or Social Security payments due from Consultant to any governmental taxing authority.  Consultant hereby agrees to timely pay all taxes and fees upon the </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:6pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">income Consultant has earned from Company and indemnify and hold Company harmless against the claims of any governmental taxing authority made in connection with the revenue derived by Consultant under this Agreement.</font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Confidential Information.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:6pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For purposes of this Agreement, the term </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Confidential Information&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> means confidential and/or proprietary information or materials owned or controlled by, in the possession of, or licensed to Company. Without limiting the generality of the foregoing, the term Confidential Information includes all existing and future (i) intellectual property, works of authorship, inventions, discoveries, developments, improvements, modifications, trademarks, trade names, trade secrets, know-how, data, processes, methods, protocols, and procedures; and all rights in, to or under any of the foregoing; in each case, whether or not reduced to practice or writing, or protected or protectable (or registered or registrable) under patent, copyright, trademark, trade secret or any other similar laws (collectively, </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Intellectual Property&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">), that is owned or controlled by, in the possession of, or licensed to Company, or that is required to be assigned or licensed to Company by any person, (ii) information regarding Company&#x2019;s plans for research and development or for new products, (iii) manufacturing or engineering information pertaining to Company or any of its operations or products, (iv) information regarding regulatory, preclinical, or clinical matters pertaining to Company, (v) information regarding business, commercial, financial, budgetary, or Intellectual Property matters pertaining to Company, (vi) information regarding the skills, compensation and other terms of employment or engagement of employees and consultants of Company, (vii) any and all Deliverables, and (viii) any other information that Company may designate as confidential or proprietary.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:6pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Except as otherwise provided in this Section 3, during the Term and for a period of seven (7) years thereafter, Consultant will not disclose or communicate to any third party for any reason, any Confidential Information without the prior written consent of Company.  Notwithstanding anything to the contrary, it is understood that, except to the extent otherwise expressly prohibited by Company, (i) Consultant may disclose or use Confidential Information in performing the Services for Company but only to the extent required or necessary for the performance of such Services in the ordinary course and within the scope of provision of the Services, and (ii) Consultant may disclose Confidential Information pursuant to a request or order of any court or governmental agency, provided that Consultant promptly notifies Company of any such request or order and provides reasonable cooperation (at Company&#x2019;s expense) in the efforts, if any, of Company to contest or limit the scope of such request or order.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:6pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consultant&#x2019;s obligations under the Section 3 will not apply to any Confidential Information  (i) that is or becomes publicly known (as demonstrated by written evidence provided by Consultant) under circumstances involving no breach by Consultant of this Agreement,  (ii) that was or is approved for release in writing by Company, or (iii) is independently developed by Consultant without reference to or reliance upon Confidential Information (and such independent development can be demonstrated by competent evidence).  </font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:6pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consultant will promptly deliver to Company, upon the termination of this Agreement or, if earlier, upon the request of Company, all documents and other tangible media in Consultant&#x2019;s possession or control that contain, reflect, disclose or relate to any Confidential Information.  </font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intellectual Property.  </font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:6pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consultant agrees to and hereby does assign to Company, Consultant&#x2019;s entire right, title and interest in and to all Intellectual Property made, written or conceived by Consultant, jointly or with others, in the performance of Services hereunder, together with such patents or patent applications and copyrights, as may be obtained or filed in any country. All copyrightable works created by Consultant in connection with the Services will be considered &#x201c;work for hire&#x201d; owned by Company to the greatest extent permitted by law. At the request and sole expense of Company, at any time during the term of the Agreement or after the termination or expiration of the Agreement, Consultant will execute all documents </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:6pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">for use in applying for, obtaining and maintaining such patents, trademark or copyrights as Company may desire, and execute and deliver all formal assignments for such Intellectual Property. Consultant will promptly and fully disclose to Company any Intellectual Property arising from Consultant&#x2019;s performance of Services under this Agreement.  For the avoidance of any doubt, as between the parties, Company will have the exclusive right to use or not use the Intellectual Property for any or no reason, in its sole discretion.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:6pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consultant acknowledges and agrees that Company owns and will continue to own all right, title and interest in and to Confidential Information and Deliverables.  Unless expressly provided in this Agreement, no licenses, implied or otherwise, are granted to Consultant hereunder in or to the Deliverables or Company Intellectual Property.  </font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:6pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> All existing templates, databases, models and any additional databases, models, and/or associated data owned or controlled by Consultant and not directly related to the mission of Company will remain the property of Consultant. Consultant will also retain all copyright and intellectual property rights to such materials. Unless specifically agreed upon in writing, Company will not acquire and will have no ongoing rights in or licenses to any of Consultant&#x2019;s existing proprietary templates, databases, or models and/or any modifications made to such templates, databases, or models </font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Conflicting Obligations. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consultant hereby represents that he or she is free to enter into this Agreement and that Consultant&#x2019;s performance of all of the terms of this Agreement and of all of Consultant&#x2019;s duties as a consultant to Company do not and will not breach (i) any agreement to keep in confidence information acquired by Consultant in confidence or in trust, or (ii) any agreement not to compete against the business of any third party.  Consultant further represents that he or she has not made and will not make any agreements in conflict with this Agreement. The Consultant represents and warrants that he/she has not been debarred under the provisions of the Generic Drug Enforcement Act of 1992, 21 U.S.C. Sec. 335a, and that he/she is not under investigation by any governmental agency.  In the event that the Consultant becomes so debarred or comes under an investigation by a governmental agency that would impair his/her ability to properly perform his/her obligations under this Agreement, the Consultant will immediately notify the Company in writing.</font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">6.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Use of Name. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Neither party will use the name of the other party without prior consent; provided, however, that either party may use the name of the other party to the extent reasonably required in or for the performance of the Services. </font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">7.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Return of Company Documents.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  Upon expiration or termination of this Agreement, Consultant will deliver to Company any and all notes, memoranda, specifications, drawings, devices, formulas, and documents, together with all copies thereof, and any other material containing or disclosing any Confidential Information or Company Intellectual Property. </font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">8.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Term.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:6pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Agreement shall take effect as of the Effective Date and continue thereafter in full force and effect until May 1, 2025 unless extended by mutual agreement in writing, or until terminated in accordance with the provisions of Section 8(b) hereof (the </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Term&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">).  </font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:6pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Agreement and the Services provided by Consultant hereunder may be terminated at any time by either Consultant or Company for any reason or no reason. No prior notice of termination is required. </font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:6pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The provisions of Sections 4-7, 8(c) and 9 shall survive the termination of this Agreement.</font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">9.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Miscellaneous.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:6pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Agreement, along with Attachment A, represents the entire Agreement of the parties with respect to the arrangements contemplated hereby, and supersedes all prior agreements.  No prior agreement, whether written or oral, shall be construed to change, amend, alter, repeal or invalidate this </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:6pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Agreement.  This Agreement may be amended only by a written instrument executed in one or more counterparts by the parties.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:6pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No consent to or waiver of any breach or default in the performance of any obligations hereunder shall be deemed or construed to be a consent to or waiver of any other breach or default in the performance of any of the same or any other obligations hereunder.  Failure on the part of either party to complain of any act or failure to act of the other party or to declare the other party in default, irrespective of the duration of such failure, shall not constitute a waiver of rights hereunder and no waiver hereunder shall be effective unless it is in writing, executed by the party waiving the breach or default hereunder.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:6pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Agreement may be assigned by Company to any affiliate of Company and to a successor of its business to which this Agreement relates (whether by purchase or otherwise). </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consultant may assign or transfer any or all of Consultant&#x2019;s rights or obligations under this Agreement only upon Company&#x2019;s prior written consent. This Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective successors and permitted assigns.  </font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:6pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unless otherwise provided herein, any notice, report, payment or document to be given by one party to the other shall be in writing and addressed to the party at the address set forth in the preamble to such other place as any party may designate as to itself by written notice to the other party.  Delivery will be deemed given when such notice is delivered in-person, or by certified or registered mail, or by nationally recognized overnight courier.  Either party may change its address for notices by means of a notice delivered in accordance with this Section 9(d).</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:6pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Agreement shall be governed by and construed in accordance with the substantive laws of the State of Massachusetts without reference to any choice or conflict of laws rule or provision that would result in the application of the substantive law of any other jurisdiction.  </font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:6pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(f)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section headings of this Agreement are for reference only and shall not affect its interpretation.  In the event that any provision of this Agreement should be held unenforceable by a court of competent jurisdiction, such court is hereby authorized to amend such provision so as to be enforceable to the fullest extent permitted by law, and all remaining provisions shall continue in full force without being impaired or invalidated in any way.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:6pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(g)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The parties agree that any breach of this Agreement by Consultant would cause irreparable harm to Company; and that money damages will not provide an adequate remedy.  In the event of a breach or threatened breach of this Agreement by Consultant, Company will, in addition to any other rights and remedies it may have, have the right to seek an injunction without the need to post bond.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:6pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(h)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In performing Consultant&#x2019;s obligations and services under this Agreement, </font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consultant</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> will be an independent contractor and will not represent himself or herself as an agent of the Company. Nothing in this Agreement will be construed to constitute either party as the agent, employee or joint venture partner of the other, nor will either party have the right to bind the other party or make any promises or representations on behalf of the other party. Consultant will be solely responsible for the withholding and payment of social security and other applicable taxes, fees, and/or withholding on payments made to him or her by the Company as described herein and he or she will not be eligible for, and will have no claim against the Company for, fringe benefits, vacation pay, sick leave, retirement benefits, social security, worker&#x2019;s compensation, disability, unemployment insurance benefits, or any other benefit the Company may provide to its employees.</font></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[SIGNATURE PAGE FOLLOWS]</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IN WITNESS WHEREOF,</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> the parties have signed this Consulting Agreement as of the Effective Date, intending it to take effect as a sealed instrument.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:9.52%;box-sizing:content-box;"></td>
    <td style="width:40.48%;box-sizing:content-box;"></td>
    <td style="width:12.02%;box-sizing:content-box;"></td>
    <td style="width:37.98%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:29.5pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="2" style="padding-top:0in;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Christopher E. Von Seggern</font></p></td>
    <td colspan="2" style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Xenon Pharmaceuticals USA, INC.</font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:32.4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">By:</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Christopher E. Von Seggern</font></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Andrea DiFabio</font></p></td>
   </tr>
   <tr style="height:29.5pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Date:</font></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">January 15, 2025</font></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name:</font></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Andrea DiFabio</font></p></td>
   </tr>
   <tr style="height:29.5pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Email:</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Title:</font></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">CLO</font></p></td>
   </tr>
   <tr style="height:29.5pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;padding-right:0.075in;text-align:right;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:right;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Date:</font></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">January 15, 2025</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">						</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">				</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">			</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ATTACHMENT A</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">STATEMENT OF WORK</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.32
<SEQUENCE>5
<FILENAME>xene-ex10_32.htm
<DESCRIPTION>EX-10.32
<TEXT>
<html>
 <head>
  <title>EX-10.32</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">		</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.32</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2025 INDUCEMENT EQUITY INCENTIVE PLAN<br>XENON PHARMACEUTICALS INC.</font></p>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">Article 1</font><div style="width:100%;display:inline;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br>Purpose</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The purpose of this Plan is to promote the interests of Xenon Pharmaceuticals Inc. (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) by assisting the Company in attracting, retaining and motivating employees by providing an inducement material to individuals entering into employment with the Company or any of its subsidiaries.</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company believes that this purpose may best be effected by granting Options or Share Awards to acquire Common Shares without par value in the capital of the Company.  This Plan is intended to meet the requirements of a plan providing for inducement grants under Nasdaq Listing Rule 5635(c)(4) and the official regulations thereunder (together, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Inducement Listing Rule</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) and shall be administered in accordance with such intent.  Each Award under the Plan is intended to qualify as an employment inducement award under the Inducement Listing Rule or to qualify under the exception relating to plans or arrangements relating to an acquisition or merger under Nasdaq Listing Rule 5635(c)(3) and the official guidance thereunder.</font></p>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">Article 2</font><div style="width:100%;display:inline;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br>Interpretation</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In this Plan, unless there is something in the subject matter or context inconsistent therewith:</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Award</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, individually or collectively, an award of Options, an award of Share Appreciation Rights, a Restricted Share Award, a Restricted Share Unit Award, or a Performance Share Award granted under the Plan&#x37e;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Award Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the written or electronic agreement setting forth the terms and provisions applicable to each Award granted under the Plan.  The Award Agreement is subject to the terms and conditions of the Plan&#x37e;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Blackout Period</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any period during which a Participant is prevented from trading the Common Shares pursuant to a policy of the Company, including but not limited to the Company&#x2019;s insider trading policy, as amended and in force from time to time, and any lockup or similar agreement between the Company and a third party restricting the trading of Common Shares&#x37e;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Board of Directors</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the board of directors of the Company&#x37e;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Business Day</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a day, other than Saturday, Sunday and any other day which is a statutory holiday in British Columbia Canada or New York U.S.A.&#x37e;</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">		</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(f)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cause</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; with respect to any Participant, shall mean (i) a Participant&#x2019;s willful misconduct, (ii) a willful failure of a Participant to perform his or her duties, (iii) a Participant&#x2019;s insubordination, theft, dishonesty, or any other willful conduct that is detrimental to the Company or its subsidiaries, (iv) cause for termination of employment or other service contract at common law, or (v) such other cause as the Compensation Committee in good faith reasonably determines provides cause for the discharge of the Participant or termination of the Participant&#x2019;s relationship with the Company&#x37e;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(g)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Change of Control</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means:</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.692662720527998%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the acquisition by any person or persons acting jointly or in concert (as determined by the Securities Act) (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Person</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), whether directly or indirectly, of voting securities of the Company that, together with all other voting securities of the Company held by such Person, constitute in the aggregate more than 50% of all outstanding voting securities of the Company&#x37e; provided, however, that for purposes of this subsection, the acquisition of additional securities by any one Person, who is considered to own more than 50% of all outstanding voting securities of the Company, will not be considered a Change of Control&#x37e;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.692662720527998%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">an amalgamation, arrangement or other form of business combination of the Company with another corporation that results in the holders of voting securities of that other corporation holding, in the aggregate, more than 50% of all outstanding voting securities of the corporation resulting from the business combination&#x37e; provided, however, that for purposes of this subsection, the acquisition of additional securities by any one Person, who is considered to own more than 50% of all outstanding voting securities of the Company, will not be considered a Change of Control&#x37e; or</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.692662720527998%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(iii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a change in the ownership of a substantial portion of the Company&#x2019;s assets which occurs on the date that any Person acquires (or has acquired during the twelve (12) month period ending on the date of the most recent acquisition by such person or persons) assets from the Company that have a total gross fair market value equal to or more than fifty percent (50%) of the total gross fair market value of all of the assets of the Company immediately prior to such acquisition or acquisitions&#x37e; provided, however, that for purposes of this subsection (iii), the following will not constitute a change in the ownership of a substantial portion of the Company&#x2019;s assets: (A) a transfer to a Related Entity, or (B) a transfer of assets by the Company to: (1) a stockholder of the Company (immediately before the asset transfer) in exchange for or with respect to the Company&#x2019;s stock, (2) an entity of which the Company has Control, (3) a Person, that owns, directly or indirectly, fifty percent (50%) or more of the total value or voting power of all the outstanding stock of the Company, or (4) an entity of which a Person described in this subsection (iii)(B)(3) has Control.  For purposes of this subsection (iii), gross fair market value means the value of the assets of the </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">		</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.692662720527998%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company, or the value of the assets being disposed of, determined without regard to any liabilities associated with such assets&#x37e; or</font></div></div>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notwithstanding the foregoing, a transaction will not be deemed a Change of Control for Awards granted to Participants who are subject to U.S. taxation unless the transaction qualifies as a Change of Control event within the meaning of Code Section 409A, as it has been and may be amended from time to time, and any proposed or final Treasury Regulations and U.S. Internal Revenue Service guidance that has been promulgated or may be promulgated thereunder from time to time.</font></p>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further and for the avoidance of doubt, a transaction will not constitute a Change of Control if: (x) its sole purpose is to change the state or jurisdiction of the Company&#x2019;s incorporation, or (y) its sole purpose is to create a holding company that will be owned in substantially the same proportions by the persons who held the Company&#x2019;s securities immediately before such transaction;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(h)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CEO</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the Chief Executive Officer of the Company&#x37e;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Code</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the U.S. Internal Revenue Code of 1986, as amended.  Reference to a specific section of the Code or regulation thereunder shall include such section or regulation, any valid regulation promulgated under such section, and any comparable provision of any future legislation or regulation amending, supplementing or superseding such section or regulation&#x37e;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(j)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Common Shares</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the common shares without par value in the capital of the Company&#x37e;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(k)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compensation Committee</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the compensation committee of the Board of Directors.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(l)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consultant</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a person other than an employee, officer or director of the Company or of any of its subsidiaries that:</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.692662720527998%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">is engaged to provide services to the Company or any of its subsidiaries&#x37e;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.692662720527998%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provides the services under a written contract with the Company or of any of its subsidiaries&#x37e; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.692662720527998%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(iii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">spends or will spend a significant amount of time and attention on the affairs and business of the Company or of any of its subsidiaries;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(m)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Control</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; by a person over a second person means the power to direct, directly or indirectly, the management and policies of the second person by virtue of:</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.692662720527998%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ownership of or direction over voting securities in the second person&#x37e;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.692662720527998%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a written agreement or indenture&#x37e;</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">		</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.692662720527998%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(iii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">being or Controlling the general partner of the second person&#x37e; or</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.692662720527998%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(iv)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">being a trustee of the second person&#x37e;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(n)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Director</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a member of the board of directors of the Company or any of its subsidiaries;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(o)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Eligible Persons</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means employees of the Company or of any of its subsidiaries, and an &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Eligible Person</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall have a corresponding meaning.  However, for the avoidance of doubt, although a person who is an employee of the Company or of any of its subsidiaries also may be a Director, a person who already is serving as a Director prior to becoming an employee of the Company or of any of its subsidiaries will not be an Eligible Person who may be granted an Award under the Plan unless permitted under the Inducement Listing Rule.  The Company shall determine in good faith and in the exercise of its discretion whether an individual has become or has ceased to be an Eligible Person and the effective date of such individual&#x2019;s employment or termination of employment, as the case may be.  For purposes of an individual&#x2019;s rights, if any, under the Plan as of the time of the Company&#x2019;s determination, all such determinations by the Company shall be final, binding and conclusive, notwithstanding that the Company or any court of law or governmental agency subsequently makes a contrary determination&#x37e;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(p)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exchange Act</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the U.S. Securities Exchange Act of 1934, as amended&#x37e;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(q)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exercise Price</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the price per share at which Common Shares may be subscribed for by a Participant pursuant to a particular Option Award Agreement, as further described under paragraph 8.1(c) of the Plan&#x37e;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(r)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fair Market Value Price</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, as of any date, the value of Common Shares determined as follows:</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.692662720527998%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">if the Common Shares are listed on a Stock Exchange, its Fair Market Value Price will be the closing price for such stock (or the closing bid, if no sales were reported) as quoted on such exchange or system on the day of determination, as reported in such other source as the Compensation Committee deems reliable&#x37e;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.692662720527998%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">if the Common Shares are regularly quoted by a recognized securities dealer but selling prices are not reported, the Fair Market Value Price of a Common Share will be the mean between the high bid and low asked prices for the Common Shares on the day of determination (or, if no bids and asks were reported on that date, as applicable, on the last trading date such bids and asks were reported), as reported in such source as the Compensation Committee deems reliable&#x37e; or</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.692662720527998%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(iii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in the absence of an established market for the Common Shares, the Fair Market Value Price will be determined in good faith by the Compensation Committee.</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">		</font></p></div>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notwithstanding the foregoing, if the determination date for the Fair Market Value Price occurs on a day other than a Business Day, the Fair Market Value Price will be the price as determined in accordance with subsections (i) through (iii) above (as applicable) on the next Business Day&#x37e;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(s)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nonqualified Share Option</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means an Option to purchase Common Shares that is not intended to be an &#x201c;incentive stock option&#x201d; under Section 422 of the Code&#x37e;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(t)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Options</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means share options granted hereunder to purchase Common Shares from treasury.  All Options granted under the Plan will be Nonqualified Share Options;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(u)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Participant</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means an Eligible Person to whom an Award is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Award&#x37e;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(v)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Performance Criteria</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the one or more criteria that the Compensation Committee shall select for purposes of establishing the performance goals for a Performance Period&#x37e;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(w)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Performance Period</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means one or more periods of time, which may be of varying and overlapping duration, as the Compensation Committee may select, over which the attainment of one or more performance goals will be measured for the purpose of determining a Participant&#x2019;s right to, and the payment of, a Performance Share Award;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(x)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Performance Share Award</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a bookkeeping entry representing an unfunded and unsecured promise, denominated in Common Shares, to deliver Common Shares or cash measured by the value of Common Shares in the future, granted pursuant to the terms and conditions of Article 9 and subject to the satisfaction of specified performance-based vesting conditions&#x37e;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(y)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means this 2025 Inducement Equity Incentive Plan, as the same may from time to time be supplemented, amended and/or restated and in effect&#x37e;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(z)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Related Entity</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, for a company or corporation, a Person that Controls or is Controlled by the Company or that is Controlled by the same Person that controls that company or corporation&#x37e;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(aa)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restricted Share Award</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means an award of Common Shares which is granted pursuant to the terms and conditions of Article 9 and subject to restrictions requiring that it be forfeited, redelivered or offered for sale to the Company if specified performance or other vesting conditions are not satisfied&#x37e;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(bb)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restricted Share Unit Award</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a bookkeeping entry representing an unfunded and unsecured promise, denominated in Common Shares, to deliver Common Shares or cash measured by the value of Common Shares in the future, granted pursuant to the terms and conditions of Article 9 and subject to the satisfaction of specified service-based vesting conditions&#x37e;</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">		</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(cc)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Retirement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means retirement as an employee and/or officer of the Company or any of its subsidiaries, and if there is any question on whether a cessation of employment is by way of a retirement or not, the determination by the CEO (or in the CEO&#x2019;s absence or in the case of a situation involving the cessation of employment of an executive officer of the Company, the Compensation Committee) shall be conclusive and binding on the Participant&#x37e;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(dd)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rule 16b-3</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means Rule 16b-3 of the Exchange Act or any successor to Rule 16b&#x2011;3, as in effect when discretion is being exercised with respect to the Plan;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(ee)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 16(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means Section 16(b) of the Exchange Act&#x37e;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(ff)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities Act</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Securities Act </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(British Columbia)&#x37e;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(gg)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Service Providers</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means directors, officers, employees or Consultants of the Company or of any of its subsidiaries, and a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Service Provider</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall have a corresponding meaning.  The Company shall determine in good faith and in the exercise of its discretion whether an individual has become or has ceased to be a Service Provider and the effective date of such individual&#x2019;s service or termination of service, as the case may be.  For purposes of an individual&#x2019;s rights, if any, under the Plan as of the time of the Company&#x2019;s determination, all such determinations by the Company shall be final, binding and conclusive, notwithstanding that the Company or any court of law or governmental agency subsequently makes a contrary determination&#x37e;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(hh)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Share Appreciation Right</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a right to receive the appreciation on Common Shares that is granted pursuant to the terms and conditions of Article 9&#x37e;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Share Award</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any Restricted Share Award, Restricted Share Unit Award, Share Appreciation Right, or Performance Share Award granted under the Plan&#x37e;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(jj)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock Exchanges</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means such stock exchanges or other organized market on which the Common Shares are listed or posted for trading, including the Nasdaq Stock Market&#x37e;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(kk)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">subsidiary</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning assigned thereto under the Securities Act (British Columbia) as the same may from time to time be amended or re-enacted&#x37e; and</font></div></div>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any question arising as to the interpretation of this Plan will be determined by the Compensation Committee and, absent manifest error, such determination will be conclusive and binding on the Company and all Participants.</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In this Plan, words importing the singular number only include the plural and vice versa, words importing any gender include all genders and words importing persons include individuals, corporations, limited and unlimited liability companies, general and unlimited </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">		</font></p></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">partnerships, associations, trusts, incorporated organizations, joint ventures and governmental authorities.</font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">Article 3</font><div style="width:100%;display:inline;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br>Administration of Plan</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Plan will be administered by the Compensation Committee so long as the Compensation Committee is the independent compensation committee of the Board of Directors within the meaning of Rule 5635(c)(4) of the Nasdaq Listing Rules and, if the Compensation Committee does not meet such requirement, the Plan will be administered by the &#x201c;Independent Directors&#x201d; (as defined under Rule 5605(a)(2) of the Nasdaq Listing Rules) of the Board of Directors.  The Compensation Committee (or the independent members of the Board of Directors) will have full authority to act as the administrator of the Plan and the power to grant Awards under the Plan pursuant to Section 3.3. References in the Plan to the Compensation Committee shall be deemed to refer to the Compensation Committee that is the independent compensation committee of the Board of Directors within the meaning of Rule 5635(c)(4) of the Nasdaq Listing Rules and/or the &#x201c;Independent Directors&#x201d; (as defined under Rule 5605(a)(2) of the Nasdaq Listing Rules) of the Board of Directors, as applicable. </font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the extent desirable to qualify transactions hereunder as exempt under Rule 16b-3, the transactions contemplated hereunder will be structured to satisfy the requirements for exemption under Rule 16b-3.</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notwithstanding anything in the Plan to the contrary, all Awards granted under the Plan must be approved by a majority of the Company&#x2019;s &#x201c;Independent Directors&#x201d; (as defined under Rule 5605(a)(2) of the Nasdaq Listing Rules) or by the Compensation Committee (which is the independent compensation committee of the Board of Directors within the meaning of Rule 5635(c)(4) of the Nasdaq Listing Rules), in each case acting as the administrator of the Plan.</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.4</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subject to the provisions of the Plan, the Compensation Committee, will have the authority, in its discretion:</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to determine the Fair Market Value Price&#x37e;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">subject to Section 3.3 and Article 7, to select the Eligible Persons to whom Awards may be granted hereunder (which Awards will be intended as a material inducement to the individual becoming an employee of the Company or any of its subsidiaries or to otherwise be permitted under Nasdaq Listing Rule 5635(c) and the official guidance thereunder)&#x37e;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">subject to Section 3.3, to determine the number of Common Shares to be covered by each Award granted hereunder&#x37e;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to approve forms of Award Agreements for use under the Plan&#x37e;</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">		</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">subject to Section 3.3, to determine the terms and conditions, not inconsistent with the terms of the Plan, of any Award granted hereunder.  Such terms and conditions include, but are not limited to, the exercise price, base value from which appreciation is measured, or purchase price, if any, applicable to any Award, the time or times when Awards may be exercised (which may be based on Performance Criteria), any vesting acceleration or waiver of forfeiture restrictions, the form of settlement of an Award (whether in cash, Common Shares or other property) and any restriction or limitation regarding any Award or the Common Shares relating thereto, based in each case on such factors as the Compensation Committee will determine&#x37e;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(f)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to construe and interpret the terms of the Plan and Awards granted pursuant to the Plan&#x37e;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(g)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to prescribe, amend and rescind rules and regulations relating to the Plan, including rules and regulations relating to sub-plans established for the purpose of satisfying applicable foreign laws or for qualifying for favorable tax treatment under applicable foreign laws&#x37e;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(h)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to modify or amend each Award (subject to Article 11 of the Plan), including but not limited to the discretionary authority to extend the post-termination exercisability period of Awards&#x37e;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to allow the satisfaction of withholding tax obligations in such manner as prescribed in paragraph 10.6 of the Plan&#x37e;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(j)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to authorize any person to execute on behalf of the Company any instrument required to effect the grant of an Award previously granted under the Plan&#x37e;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(k)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to allow a Participant to defer the receipt of the payment of cash or the delivery of Common Shares that would otherwise be due to such Participant, as applicable, under an Award&#x37e; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(l)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to make all other determinations deemed necessary or advisable for administering the Plan.</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.5</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Compensation Committee has the authority to determine all questions arising out of the Plan and any Award granted pursuant to the Plan, which interpretations and determinations will be conclusive and binding on the Company and all other affected persons.</font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">Article 4</font><div style="width:100%;display:inline;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br>Regulations</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Compensation Committee may from time to time establish such regulations, make such determinations and interpretations and take such steps in connection with this Plan which, in its opinion, are necessary or desirable for the administration of this Plan.</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">		</font></p></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">Article 5</font><div style="width:100%;display:inline;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br>Compliance with Laws</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Plan, the grant, exercise, vesting, and/or settlement of Awards under the Plan and the Company&#x2019;s obligation to issue Common Shares on exercise, vesting, or settlement of Awards will be subject to all applicable federal, provincial and foreign laws, rules and regulations and the rules of any regulatory authority or Stock Exchange on which the securities of the Company are listed.  The Company shall not be required, or in any way obliged, to grant Awards or issue Common Shares if such grant or issuance would require registration of the Plan or of any Awards or Common Shares under the securities laws of any jurisdiction other than Canada or the United States.  Common Shares issued to a Participant pursuant to the exercise, vesting, or settlement of an Award may be subject to limitations on sale or resale under applicable securities laws.</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Compensation Committee may from time to time take such steps and require such documentation from Eligible Persons or Participants which in its opinion are necessary or desirable to ensure compliance with all applicable laws, the bylaws, rules and regulations of any Stock Exchanges.</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Compensation Committee may also from time to time take such steps which in its opinion are necessary or desirable to restrict the transferability of any Common Shares acquired on the exercise, vesting, or settlement of any Award in order to ensure such compliance, including, where applicable, the endorsement of a legend on any certificate representing Common Shares acquired on the exercise, vesting, or settlement of any Award to the effect that such Common Shares may not be offered, sold or delivered except in compliance with the applicable securities laws and regulations of Canada or the United States.</font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">Article 6</font><div style="width:100%;display:inline;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br>Common Shares subject to Plan</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">6.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subject to adjustment provided for herein and subject to Section 6.3 below, the initial number of Common Shares that may be issued pursuant to the Plan will be 775,000 Common Shares (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Share Reserve</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">6.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Board of Directors will reserve for allotment from time to time out of the authorized but unissued Common Shares sufficient Common Shares to provide for issuance of all Common Shares which are issuable under all outstanding Options or Share Awards.</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">6.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upon the expiry or termination of an Award which has not been exercised in full or, with respect to an Award not requiring exercise that is forfeited to or repurchased by the Company due to failure to vest, the number of unpurchased Common Shares reserved for issuance under that Award (or for Awards other than Options or Share Appreciation Rights the forfeited or repurchased Common Shares) shall become available for issue for the purpose of additional Awards which may be granted under this Plan (unless the Plan has terminated).  With respect to Share Appreciation Rights, only Common Shares actually issued (i.e., the net Common Shares issued) pursuant to a Share Appreciation Right will </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">		</font></p></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">cease to be available under the Plan&#x37e; all remaining Common Shares under Share Appreciation Rights will remain available for future grant or sale under the Plan (unless the Plan has terminated).  Common Shares that have actually been issued under the Plan under any Award will not be returned to the Plan and will not become available for future distribution under the Plan&#x37e; provided, however, that if Common Shares issued pursuant to Restricted Share Awards, Restricted Share Unit Awards, or Performance Share Awards are repurchased by the Company or are forfeited to the Company, such Common Shares will become available for future grant under the Plan.  Common Shares used to pay the exercise price of an Award or to satisfy the tax withholding obligations related to an Award will become available for future grant or sale under the Plan.  To the extent an Award under the Plan is paid out in cash rather than Common Shares, such cash payment will not result in reducing the number of Common Shares available for issuance under the Plan.</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">6.4</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Participation in this Plan will be entirely voluntary and any decision not to participate will not affect an Eligible Person&#x2019;s employment or other service relationship with the Company or any of its subsidiaries.</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">6.5</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nothing in this Plan or in any Award Agreement will confer on any Participant any right to remain as an employee, officer, director or Consultant of the Company or any of its subsidiaries.</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">6.6</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nothing herein or otherwise shall be construed so as to confer on any Participant any rights as a shareholder of the Company with respect to any Common Shares reserved for the purpose of any Award.</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">6.7</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A Participant will only have rights as a shareholder of the Company with respect to Common Shares that the Participant acquires through the exercise of an Option in accordance with its terms.</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">6.8</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A holder of a Share Award will only have rights as a shareholder of the Company with respect to the Common Shares subject to the Share Award as specified and subject to restrictions as set out in the relevant agreement evidencing such Share Award.</font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">Article 7</font><div style="width:100%;display:inline;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br>Eligibility</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">7.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Awards may be granted to individuals who are employees of the Company or any of its subsidiaries so long as the following requirements are met:</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The individual was not previously an employee of the Company or any of its subsidiaries or a Director, or the individual is returning to employment with the Company following a bona-fide period of non-employment with the Company or any of its subsidiaries&#x37e; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The grant of the Award is an inducement material to the individual&#x2019;s entering into employment with the Company or any of its subsidiaries in accordance with the Inducement Listing Rule.</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">		</font></p></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, eligibility for Options and Share Appreciation Rights is limited to Eligible Persons who are providing direct services on the date of grant of the Award to the Company or any of its subsidiaries that would be described in the first sentence of Treasury Regulation Section 1.409A-1(b)(5)(iii)(E).</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notwithstanding the foregoing, an employee of the Company or any of its subsidiaries may be granted an Award in connection with a merger or acquisition to the extent permitted by Nasdaq Listing Rule 5635(c)(3) and the official guidance thereunder, and any such grant will not reduce the number of Common Shares available for issuance under the Plan.</font></p>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">Article 8</font><div style="width:100%;display:inline;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br>Grant of Options</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">8.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subject to Section 3.3, Article 7 and the rules set out below, the Compensation Committee may from time to time grant an Option to any individual as a material inducement to the individual becoming an Eligible Person or as otherwise permitted under Article 7 in connection with a merger or acquisition, in each case, which grant shall become effective only if the individual actually becomes an Eligible Person, as the Compensation Committee deems appropriate:</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Date Option Granted</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The date on which an Option will be deemed to have been granted under this Plan will be the date on which the Compensation Committee authorizes the grant of such Option or such other date as may be specified by the Compensation Committee at the time of such authorization.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Number of Common Shares</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The number of Common Shares that may be purchased under any Option by a Participant will be determined by the Compensation Committee provided that such number may not be greater than the maximum number permitted under the applicable rules and regulations of all regulatory authorities to which the Company is subject, including the Stock Exchanges.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exercise Price</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The exercise price per Common Share under each Option will be determined by the Compensation Committee by reference to the fair market price(s) of the Common Shares on the primary Stock Exchange for which most trading of the Common Shares occurs, generally by reference to the closing market price of the Common Shares, provided that such price may not be less than the lowest price permitted under the applicable rules and regulations of all regulatory authorities to which the Company is subject, including those of the Stock Exchanges.  Notwithstanding the foregoing, the Exercise Price of an Option will be no less than one hundred percent (100%) of the Fair Market Value Price per Common Share on the date of grant.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Award Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Each Option will be evidenced by an Award Agreement, which incorporates such terms and conditions as the Compensation Committee, in its discretion, deems appropriate and consistent with the provisions of this Plan.  Each Award Agreement will be executed (which may be electronic signature) by </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">		</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Eligible Person to whom the Option is granted and on behalf of the Company by any member of the Board of Directors, the CEO or the Corporate Secretary of the Company or such other person as the Compensation Committee may designate for such purpose.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Expiry of Options</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Each Option will expire on the earlier of:</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.692662720527998%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the date specified in the Award Agreement pursuant to which such Option is granted, provided that such date may not be later than the earlier of (A) the date which is the tenth anniversary of the date on which such Option is granted (except in the circumstances where the tenth anniversary falls within, or within five Business Days after, the end of a Blackout Period, then instead of the tenth anniversary, the relevant date shall be the fifth Business Day after the end of such Blackout Period&#x37e; provided, however, that the extension in this subsection 7(e)(i)(A)(1) shall be applied to any Option held by a Participant who is a U.S. taxpayer only to the extent that it would not violate Code Section 409A) and (B) the latest date permitted under the applicable rules and regulations of all regulatory authorities to which the Company is subject, including the Stock Exchanges&#x37e;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.692662720527998%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in the event the Participant ceases to be a Service Provider for any reason, other than death of the Participant, such period of time after the date on which the Participant ceases to be a Service Provider as may be specified by the Compensation Committee, which period may be specified in the specific Award Agreement with respect to such Option (but in no event granted beyond the original expiry date of the Option as provided for in subparagraph (i) above).  In the absence of a specified time in the Award Agreement, the Option will remain exercisable for 90 days following the date the Participant ceases to be a Service Provider due to termination without Cause or resignation (or 180 days following the date Participant ceases to be a Service Provider due to such Participant&#x2019;s Retirement, 365 days following the date Participant ceases to be a Service Provider due to such Participant&#x2019;s disability, and immediately upon Participant ceasing to be a Service Provider due to the termination of such Participant as a Service Provider for Cause).  Unless otherwise provided by the Compensation Committee, if on the date the Participant ceases to be a Service Provider, the Participant is not vested as to his or her entire Option, the Common Shares covered by the unvested portion of the Option will revert to the Plan.  If after the date the Participant ceases to be a Service Provider, the Participant does not exercise his or her Option within the time specified by the Compensation Committee, the Option will terminate, and the Common Shares covered by such Option will revert to the Plan&#x37e;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.692662720527998%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(iii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in the case of the death of a Participant prior to: (A) the Participant ceasing to be a Service Provider&#x37e; or (B) the date which is the number of days determined under subparagraph (ii) above, from the date on which the Participant ceased to be a Service Provider&#x37e; the date which is the 365th day </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">		</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.692662720527998%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">after the date of death of such Participant or such other date as may be specified by the Compensation Committee and which period will be specified in the Award Agreement with respect to such Option (but in no event beyond the original expiry date of the Option as provided for in subparagraph (i) above).  Unless otherwise provided by the Compensation Committee, if at the time of death Participant is not vested as to his or her entire Option, the Common Shares covered by the unvested portion of the Option will immediately revert to the Plan.  If the Option is not so exercised within the time specified herein, the Option will terminate, and the Common Shares covered by such Option will revert to the Plan&#x37e;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.692662720527998%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(iv)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">notwithstanding the foregoing provisions of subparagraphs (ii) and (iii) of this paragraph 8.1(e), the Compensation Committee may, subject to regulatory approval, at any time prior to expiry of an Option extend the period of time within which an Option held by a deceased Participant may be exercised or within which an Option may be exercised by an Participant who has ceased to be a Service Provider, but such an extension shall not be granted beyond the original expiry date of the Option as provided for in subparagraph (i) above&#x37e; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.692662720527998%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(v)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">notwithstanding the foregoing provisions, if the expiry of an Option pursuant to subparagraphs (ii) and (iii) of this paragraph 8.1(e) occurs during the Blackout Period applicable to the Participant or within five Business Days after the last day of a Blackout Period applicable to the Participant, the expiry date for the Option will be the last day of such five Business Day period, except to the extent that it would violate Code Section 409A or in the event of expiry of Options following termination of a Participant&#x2019;s employment or services (for a director) or contract as a Consultant for Cause.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(f)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exercise of Options</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.692662720527998%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Compensation Committee may impose such limitations or conditions on the exercise or vesting of any Option as the Compensation Committee, in its discretion, deems appropriate.  Each Award Agreement will provide that the Option granted thereunder may be exercised by notice signed by the Participant (which may be electronic signature) and accompanied by full payment for the Common Shares being purchased or by other means, including without limitation electronic means via on-line arrangements, as the Compensation Committee may from time to time approve and allow.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.692662720527998%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Compensation Committee will determine the acceptable form of consideration for exercising an Option, including the method of payment.  Such consideration may consist entirely of: (A) cash&#x37e; (B) cheque&#x37e; (C) other Common Shares, provided that such Common Shares have a Fair Market Value Price on the date of surrender equal to the aggregate exercise price of the Common Shares as to which such Option will be exercised and provided </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">		</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.692662720527998%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that accepting such Common Shares will not result in any adverse accounting consequences to the Company, as the Compensation Committee determines in its sole discretion; (D) consideration received by the Company under a broker-assisted (or other) cashless exercise program (whether through a broker or otherwise) implemented by the Company in connection with the Plan&#x37e; (E) by net exercise; (F) such other consideration and method of payment for the issuance of Common Shares to the extent permitted by the applicable securities laws and all applicable rules and regulations of all regulatory authorities to which the Company is subject&#x37e; or (G) any combination of the foregoing methods of payment.</font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">Article 9</font><div style="width:100%;display:inline;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br>Provisions of Share Awards other than Options</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subject to Section 3.3, Article 7 and the rules set out below, the Compensation Committee may in its discretion determine to grant other forms of Awards other than Options under this Plan to any individual as a material inducement to the individual becoming an Eligible Person or as otherwise permitted under Article 7 in connection with a merger or acquisition, in each case, which grant shall become effective only if the individual actually becomes an Eligible Person, on the terms and conditions set out below and all such other forms of share awards will be subject to the Share Reserve:</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">9.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restricted Share Awards</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each Restricted Share Award will be evidenced by an Award Agreement that shall contain such terms and conditions as the Compensation Committee shall deem appropriate.  The terms and conditions of each Award Agreement evidencing a Restricted Share Award may change from time to time, and the terms and conditions of separate Restricted Share Award need not be identical, </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided, however</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that each Award Agreement evidencing a Restricted Share Award shall conform to (through incorporation of the provisions hereof by reference in the agreement or otherwise) the substance of each of the following provisions:</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.692662720527998%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consideration</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  A Restricted Share Award may be awarded in consideration for (A) cash, cheque, bank draft or money order payable to the Company&#x37e; (B) past services actually rendered to the Company or any of its subsidiaries&#x37e; or (C) any other form of legal consideration that may be acceptable to the Compensation Committee, in its sole discretion, and permissible under applicable law.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.692662720527998%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Vesting&#x37e; Other Restrictions</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Common Shares subject to a Restricted Share Award may be subject to forfeiture to or repurchase by the Company in accordance with a vesting schedule (which may include performance-based vesting conditions) or other restrictions to be determined by the Compensation Committee as specified in the Award Agreement evidencing the Restricted Share Award.  Except as otherwise provided in this Plan, Common Shares subject to the Restricted Share Award will be released </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">		</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.692662720527998%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">from escrow as soon as practicable after such Common Shares vest or the restrictions lapse or at such other time as the Compensation Committee may determine.  The Compensation Committee, in its discretion, may accelerate the time at which any vesting conditions or other restrictions will lapse or be removed.  On the date set forth in the Award Agreement, the Common Shares subject to the Restricted Share Award that have not vested or for which restrictions have not lapsed will revert to the Company and again will become available for grant under the Plan.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.692662720527998%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(iii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Voting Rights&#x37e; Dividend and Other Distributions</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Before the Common Shares subject to a Restricted Share Award vest or are otherwise subject to restrictions, Participants holding Common Shares subject to the Restricted Share Award granted hereunder (A) may exercise full voting rights with respect to those Common Shares, unless the Compensation Committee determines otherwise and (B) will be entitled to receive all dividends and other distributions paid with respect to such Common Shares, unless the Compensation Committee provides otherwise.  If any such dividends or distributions are paid in Common Shares, the Common Shares will be subject to the same restrictions on transferability and forfeitability as the Common Shares subject to the Restricted Share Award with respect to which they were paid.</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">9.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restricted Share Unit Awards</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each Restricted Share Unit Award will be evidenced by an Award Agreement that shall contain such terms and conditions as the Compensation Committee shall deem appropriate.  The terms and conditions of each Award Agreement evidencing a Restricted Share Unit Award may change from time to time, and the terms and conditions of separate Restricted Share Unit Award need not be identical, </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided, however</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that each Award Agreement evidencing a Restricted Share Unit Award shall conform to (through incorporation of the provisions hereof by reference in the agreement or otherwise) the substance of each of the following provisions:</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.692662720527998%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consideration</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  At the time of grant of a Restricted Share Unit Award, the Compensation Committee will determine the consideration, if any, to be paid by the Participant upon delivery of each Common Share subject to the Restricted Share Unit Award.  The consideration to be paid (if any) by the Participant for each Common Share subject to a Restricted Share Unit Award may be paid in any form of legal consideration that may be acceptable to the Compensation Committee in its sole discretion and permissible under applicable law.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.692662720527998%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Vesting</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  At the time of the grant of a Restricted Share Unit Award, the Compensation Committee may impose such restrictions or conditions to the vesting of the Restricted Share Unit Award as it, in its sole discretion, deems appropriate.  The Compensation Committee, in its discretion, may accelerate the time at which any vesting conditions or other restrictions will </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">		</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.692662720527998%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">lapse or be removed.  On the date set forth in the Award Agreement, the Restricted Share Unit Award for which restrictions have not lapsed will revert to the Company and again will become available for grant under the Plan.  Except as otherwise provided in the applicable Award Agreement, such portion of the Restricted Share Unit Award that has not vested will be forfeited upon the Participant&#x2019;s termination of services or employment or engagement with the Company.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.692662720527998%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(iii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Payment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Upon meeting the applicable vesting criteria, a Restricted Share Unit Award (or vested portion thereof) may be settled by the delivery of Common Shares, its cash equivalent, or in any combination thereof, as determined by the Compensation Committee and contained in the Award Agreement evidencing the Restricted Share Unit Award.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.692662720527998%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(iv)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additional Restrictions</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  At the time of the grant of a Restricted Share Unit Award, the Compensation Committee, as it deems appropriate, may impose such restrictions or conditions that delay the delivery of the Common Shares (or their cash equivalent) subject to a Restricted Share Unit Award to a time after the vesting of such Restricted Share Unit Award.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.692662720527998%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(v)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dividend Equivalents</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Dividend equivalents may be credited in respect of Common Shares covered by a Restricted Share Unit Award, as determined by the Compensation Committee and contained in the Award Agreement evidencing Restricted Share Unit Award.  At the sole discretion of the Compensation Committee, such dividend equivalents may be converted into additional Common Shares covered by the Restricted Share Unit Award in such manner as determined by the Compensation Committee.  Any additional Common Shares covered by the Restricted Share Unit Award credited by reason of such dividend equivalents will be subject to all the terms and conditions of the underlying Award Agreement to which they relate.</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">9.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Share Appreciation Rights</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each Share Appreciation Right Award will be evidenced by an Award Agreement that shall contain such terms and conditions as the Compensation Committee shall deem appropriate.  The terms and conditions of each Award Agreement evidencing a Share Appreciation Right Award may change from time to time, and the terms and conditions of separate Share Appreciation Right Award need not be identical, </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided, however</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that each Award Agreement evidencing a Share Appreciation Right Award shall conform to (through incorporation of the provisions hereof by reference in the agreement or otherwise) the substance of each of the following provisions:</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.692662720527998%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Term</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  No Share Appreciation Right shall be exercisable after the expiration of ten (10) years from the date of its grant or such shorter period specified in the Share Appreciation Right Award Agreement.</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">		</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.692662720527998%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exercise Price</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The exercise under each Share Appreciation Right will be determined by the Compensation Committee by reference to the fair market price(s) of the Common Shares on the primary Stock Exchange for which most trading of the Common Shares occurs, generally by reference to the closing market price of the Common Shares, provided that such price may not be less than one hundred percent (100%) of the Fair Market Value Price per Common Share on the date of grant.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.692662720527998%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(iii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Calculation of Appreciation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The appreciation distribution payable on the exercise of a Share Appreciation Right will be not greater than an amount equal to the excess of (A) the aggregate Fair Market Value Price (on the date of the exercise of the Share Appreciation Right) of a number of Common Shares equal to the number of Common Share equivalents in which the Participant is vested under such Share Appreciation Right, and with respect to which the Participant is exercising the Share Appreciation Right on such date, over (B) the aggregate Exercise Price of such number of Common Share equivalents being exercised.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.692662720527998%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(iv)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Vesting</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  At the time of the grant of a Share Appreciation Right, the Compensation Committee may impose such restrictions or conditions to the vesting of such Share Appreciation Right as it, in its sole discretion, deems appropriate.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.692662720527998%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(v)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exercise</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  To exercise any outstanding Share Appreciation Right, the Participant must provide notice of exercise to the Company in compliance with the provisions of the Award Agreement evidencing such Share Appreciation Right or by other means, including without limitation electronic means via on-line arrangements, as the Compensation Committee may from time to time approve and allow.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.692662720527998%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(vi)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Payment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The appreciation distribution in respect of a Share Appreciation Right may be paid in Common Shares, in cash, in any combination of the two or in any other form of consideration, as determined by the Compensation Committee and set forth in the Award Agreement evidencing such Share Appreciation Right.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.692662720527998%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(vii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Expiry of Share Appreciation Rights</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Each Share Appreciation Right will expire upon the date determined by the Compensation Committee, in its sole discretion, and set forth in the Award Agreement evidencing Share Appreciation Rights.  Notwithstanding the foregoing, the rules of paragraph 8.1(e) also will apply to Share Appreciation Rights.</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">9.4</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Performance Share Awards</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each Performance Share Award will be evidenced by an Award Agreement that shall contain such terms and conditions as the Compensation Committee shall deem appropriate.  The terms and conditions of each Award Agreement evidencing a </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">17</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">		</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Performance Share Award may change from time to time, and the terms and conditions of separate Performance Share Award need not be identical, </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided, however</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that each Award Agreement evidencing a Performance Share Award shall conform to (through incorporation of the provisions hereof by reference in the agreement or otherwise) the substance of each of the following provisions:</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.692662720527998%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Performance Objectives and Other Terms</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Compensation Committee will set performance objectives or other vesting provisions (including, without limitation, continued status as a Service Provider) in its discretion which, depending on the extent to which they are met, will determine the number or value of Common Shares subject to a Performance Share Award that will be paid out to the Participant.  The time period during which the performance objectives or other vesting provisions must be met will be called the &#x201c;Performance Period.&#x201d;  Each Performance Share Award will be evidenced by an Award Agreement that will specify the Performance Period, and such other terms and conditions as the Compensation Committee, in its sole discretion, will determine.  The Compensation Committee may set performance objectives based upon the achievement of Company-wide, divisional, business unit or individual goals (including, but not limited to, continued employment or service), or any other criterion or criteria determined by the Compensation Committee in its discretion.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.692662720527998%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Vesting</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  After the applicable Performance Period has ended, the holder of Performance Share Award will be entitled to receive a payout of the number of Common Shares subject to the Performance Share Award earned by the Participant over the Performance Period, to be determined as a function of the extent to which the corresponding performance objectives or other vesting provisions have been achieved.  After the grant of a Performance Share Award, the Compensation Committee, in its sole discretion, may reduce or waive any performance objectives or other vesting provisions for such Common Shares subject to the Performance Share Award.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.692662720527998%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(iii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Payment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Upon meeting the applicable vesting criteria, a Performance Share Award (or vested portion thereof) may be settled by the delivery of Common Shares, its cash equivalent, or in any combination thereof, as determined by the Compensation Committee and contained in the Award Agreement evidencing the Performance Share Award.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.692662720527998%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(iv)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Expiry of Performance Share Award</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  On the date set forth in the Award Agreement, all unearned or unvested Common Shares subject to a Performance Share Award will be forfeited to the Company, and again will be available for grant under the Plan.</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">		</font></p></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">Article 10</font><div style="width:100%;display:inline;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br>Provisions applicable to Awards</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">10.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Leave of Absence/Transfer Between Locations</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Unless the Compensation Committee provides otherwise and subject to applicable laws, vesting of Awards granted hereunder will be suspended during any unpaid leave of absence.  A Participant will not cease to be an employee in the case of (a) any leave of absence approved by the Company, (b) transfers between locations of the Company or between the Company, its parent, or any subsidiary, or (c) any statutory-protected leave.</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">10.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restrictions on Transfer</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Unless the Compensation Committee provides otherwise, an Award may not be sold, pledged, assigned, hypothecated, transferred, or disposed of in any manner other than by will or by the laws of descent or distribution and may be exercised, during the lifetime of the Participant, only by the Participant.  If the Compensation Committee makes an Award transferable, such Award will contain such additional terms and conditions as the Compensation Committee deems appropriate.</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">10.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adjustments&#x37e; Dissolution or Liquidation&#x37e; Merger or Change of Control</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adjustments</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  In the event that any dividend or other distribution (whether in the form of cash, Common Shares, other securities, or other property), recapitalization, stock split, reverse stock split, reorganization, merger, consolidation, split-up, spin-off, combination, repurchase, or exchange of Common Shares or other securities of the Company, or other change in the corporate structure of the Company affecting the Common Shares occurs, the Compensation Committee, in order to prevent diminution or enlargement of the benefits or potential benefits intended to be made available under the Plan, will make appropriate adjustments to the number and class of Common Shares that may be delivered under the Plan and/or the number, class, and price of Common Shares covered by each outstanding Award, and the Share Reserve.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dissolution or Liquidation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  In the event of the proposed dissolution or liquidation of the Company, the Compensation Committee will notify each Participant as soon as practicable prior to the effective date of such proposed transaction.  To the extent it has not been previously exercised, an Award will terminate immediately prior to the consummation of such proposed action.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Change of Control</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Subject to the immediately following paragraph, in the event of a merger of the Company with or into another corporation or other entity or a Change of Control, each outstanding Award will be treated as the Compensation Committee determines, including, without limitation, that (i) Awards may be assumed, or substantially equivalent Awards will be substituted, by the acquiring or succeeding corporation (or an affiliate thereof) with appropriate adjustments as to the number and kind of shares and prices&#x37e; (ii) upon written notice to a Participant, that the Participant&#x2019;s Awards will terminate upon or immediately prior to the consummation of such merger or Change of Control&#x37e; (iii) outstanding Awards will vest and become exercisable, realizable, or payable, or restrictions applicable to an </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">19</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">		</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Award will lapse, in whole or in part prior to or upon consummation of such merger or Change of Control, and, to the extent the Compensation Committee determines, terminate upon or immediately prior to the effectiveness of such merger or Change of Control&#x37e; (iv) (A) the termination of an Award in exchange for an amount of cash and/or property, if any, equal to the amount that would have been attained upon the exercise of such Award or realization of the Participant&#x2019;s rights as of the date of the occurrence of the transaction (and, for the avoidance of doubt, if as of the date of the occurrence of the transaction the Compensation Committee determines in good faith that no amount would have been attained upon the exercise of such Award or realization of the Participant&#x2019;s rights, then such Award may be terminated by the Company without payment), or (B) the replacement of such Award with other rights or property selected by the Compensation Committee in its sole discretion&#x37e; or (v) any combination of the foregoing.  In taking any of the actions permitted under this subparagraph (c), the Compensation Committee will not be required to treat all Awards similarly in the transaction.</font></div></div>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the event that the successor corporation does not assume or substitute for the Award consistent with subsection (i) of the immediately preceding paragraph, the Participant will fully vest in and have the right to exercise all of his or her outstanding Options and Share Appreciation Rights, including Common Shares as to which such Awards would not otherwise be vested or exercisable, all restrictions on Restricted Share Awards, Performance Share Awards, and Restricted Share Unit Awards will lapse, and, with respect to Awards with performance-based vesting, all performance goals or other vesting criteria will be deemed achieved at one hundred percent (100%) of target levels and all other terms and conditions met.  In addition, if an Option or Share Appreciation Right is not assumed or substituted in the event of a Change of Control, the Compensation Committee will notify the Participant in writing or electronically that the Option or Share Appreciation Right will be exercisable for a period of time determined by the Compensation Committee in its sole discretion, and the Option or Share Appreciation Right will terminate upon the expiration of such period.</font></p>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the purposes of this subparagraph (c), an Award will be considered assumed if, following the Change of Control, the Award confers the right to purchase or receive, for each Common Share subject to the Award immediately prior to the Change of Control, the consideration (whether stock, cash, or other securities or property) received in the Change of Control by holders of Common Shares for each Common Share held on the effective date of the transaction (and if holders were offered a choice of consideration, the type of consideration chosen by the holders of a majority of the outstanding Common Shares)&#x37e; provided, however, that if such consideration received in the Change of Control is not solely common shares or common stock of the successor corporation or its Parent, the Compensation Committee may, with the consent of the successor corporation, provide for the consideration to be received upon the exercise of an Option or Share Appreciation Rights or upon the payout of a Restricted Share Unit Award or Performance Share Award, for each Common Share subject to such Award, to be solely common shares or common stock of the successor corporation or its parent equal in fair market</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">20</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">		</font></p></div>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">value to the per share consideration received by holders of Common Shares in the Change of Control.</font></p>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notwithstanding anything in this subparagraph (c) to the contrary, an Award that vests, is earned or paid-out upon the satisfaction of one or more performance goals will not be considered assumed if the Company or its successor modifies any of such performance goals without the Participant&#x2019;s consent&#x37e; provided, however, a modification to such performance goals only to reflect the successor corporation&#x2019;s post-Change of Control corporate structure will not be deemed to invalidate an otherwise valid Award assumption.</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">10.4</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Representations and Covenants of Award Holder</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Each Award Agreement will contain representations and covenants of the holder that:</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the holder is an employee of the Company or of a subsidiary of the Company on the date of grant&#x37e;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the holder&#x2019;s participation in the Plan is voluntary&#x37e;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the holder is aware that the grant of the Award and the issuance by the Common Shares thereunder are exempt from the obligation under applicable securities laws to file a prospectus or other registration document (other than a registration statement on Form S-8 with the United States Securities and Exchange Commission) qualifying the distribution of the Awards or the Common Shares to be distributed thereunder under any applicable securities laws and if such exemption for any reason becomes unavailable, the obligation of the Company to grant any Awards or issue any Common Shares upon the exercise, vesting, or settlement of an Award, as the case may be, will cease&#x37e; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the holder or the Legal Representative, as the case may be, will prior to and upon any sale or disposition of any Common Shares purchased pursuant to the exercise of the Share Awards, comply with all applicable securities laws and all applicable rules and regulations of all regulatory authorities to which the Company is subject, including the Stock Exchanges, and will not offer, sell or deliver any of such Common Shares, directly or indirectly, in the United States or to any citizen or resident of, or any company, partnership or other entity created or organized in or under the laws of, the United States, or any estate or trust the income of which is subject to United States federal income taxation regardless of its source, except in compliance with the securities laws of the United States.</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">10.5</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clawback/Recovery</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  All Awards granted under the Plan will be subject to any policy or policies of the Company or any of its affiliates that provides for forfeiture, disgorgement or clawback with respect to incentive compensation that includes Awards under the Plan, including the Xenon Pharmaceuticals Clawback Policy.  In addition, the Compensation Committee may impose such other clawback, recovery or recoupment provisions in an agreement evidencing the grant of the Awards as the Compensation Committee determines necessary or appropriate, including but not limited to a reacquisition right in respect of </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">21</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">		</font></p></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">previously acquired Common Shares.  No recovery of compensation under any clawback policy of the Company will be an event giving rise to a right to resign for &#x201c;good reason&#x201d; or &#x201c;constructive termination&#x201d; (or similar term) under any agreement with the Company or any of its subsidiaries.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each Participant, by accepting or being deemed to have accepted an Award under the Plan, agrees (or will be deemed to have agreed) to the terms of this Section 10.5 and to any clawback, recoupment or similar policy or policies of the Company or any of its affiliates applicable to the Participant and further agrees (or will be deemed to have agreed) to cooperate fully with the Compensation Committee, and to cause any and all permitted transferees of the Participant to cooperate fully with the Compensation Committee, to effectuate any forfeiture or disgorgement described in this Section 10.5. Neither the Compensation Committee nor the Company nor any other person, other than the Participant and his or her permitted transferees, if any, will be responsible for any adverse tax or other consequences to a Participant or his or her permitted transferees, if any, that may arise in connection with this Section 10.5.</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">10.6</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Taxes</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Withholding Requirements</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Prior to the delivery of any Common Shares or cash pursuant to an Award (or exercise thereof) or such earlier time as any tax withholding obligations are due, the Company will have the power and the right to deduct or withhold, or require a Participant to remit to the Company, an amount sufficient to satisfy U.S. or Canadian federal, provincial, state, local, foreign or other taxes required to be withheld with respect to such Award (or exercise thereof).</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Withholding Arrangements</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Compensation Committee, in its sole discretion and pursuant to such procedures as it may specify from time to time, may permit a Participant to satisfy such tax withholding obligation, in whole or in part by (without limitation) (i) paying cash, (ii) electing to have the Company withhold otherwise deliverable cash or Common Shares having a fair market value not in excess of the maximum statutory amount required to be withheld, or (iii) delivering to the Company already-owned Common Shares having a fair market value not in excess of the maximum statutory amount required to be withheld.  The fair market value of the Common Shares to be withheld or delivered will be determined as of the date that the taxes are required to be withheld.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Code Section 409A</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.692662720527998%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Awards will be designed and operated in such a manner that they are either exempt from the application of, or comply with, the requirements of Code Section 409A such that the grant, payment, settlement or deferral will not be subject to the additional tax or interest applicable under Code Section 409A, except as otherwise determined in the sole discretion of the Compensation Committee.  The Plan and each Award Agreement under the Plan is intended to meet the requirements of Code Section 409A and will be construed and interpreted in accordance with such intent, except as otherwise determined in the sole discretion of the Compensation Committee.  To the extent that an Award or payment, or the settlement or </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">22</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">		</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.692662720527998%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">deferral thereof, is subject to Code Section 409A the Award will be granted, paid, settled or deferred in a manner that will meet the requirements of Code Section 409A, such that the grant, payment, settlement or deferral will not be subject to the additional tax or interest applicable under Code Section 409A. In no event will the Company have any obligation under the terms of the Plan to reimburse a Participant for any taxes or other costs that may be imposed on the Participant as a result of Code Section 409A.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.692662720527998%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notwithstanding anything to the contrary in the Plan or any Award Agreement, the Compensation Committee may unilaterally amend, modify or terminate the Plan or any outstanding Award, including, without limitation, changing the form of the Award, if the Compensation Committee determines that such amendment, modification or termination is necessary or desirable to avoid the imposition of an additional tax, interest or penalty under Code Section 409A.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.692662720527998%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(iii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If a Participant is determined on the date of the Participant&#x2019;s termination of employment to be a &#x201c;specified employee&#x201d; within the meaning of that term under Code Section 409A(a)(2)(B), then, with regard to any payment that is considered nonqualified deferred compensation under Code Section 409A, to the extent applicable, payable on account of a &#x201c;separation from service&#x201d;, such payment will be made or provided on the date that is the earlier of (x) the first Business Day following the expiration of the six-month period measured from the date of such &#x201c;separation from service&#x201d; and (y) the date of the Participant&#x2019;s death (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Delay Period</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). Upon the expiration of the Delay Period, all payments delayed pursuant to this Section 10.6(c)(iii) (whether they would have otherwise been payable in a single lump sum or in installments in the absence of such delay) will be paid on the first Business Day following the expiration of the Delay Period in a lump sum and any remaining payments due under the Award will be paid in accordance with the normal payment dates specified for them in the applicable Award Agreement. </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.692662720527998%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(iv)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With regard to any payment considered to be nonqualified deferred compensation under Code Section 409A, to the extent applicable, that is payable upon a change in control of the Company or other similar event, to the extent required to avoid the imposition of any additional tax, interest, or penalty under Code Section 409A, no amount will be payable unless such change in control constitutes a &#x201c;change in control event&#x201d; within the meaning of Section 1.409A-3(i)(5) of the Treasury Regulations. </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.692662720527998%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(v)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For purposes of Code Section 409A, each payment made under the Plan or any Award will be treated as a separate payment.</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">23</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">		</font></p></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">Article 11</font><div style="width:100%;display:inline;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br>Suspension, Amendment or Termination of Plan</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">11.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Plan will become effective upon its adoption by the Board of Directors.  It will continue in effect for a term of ten (10) years from the date adopted by the Board of Directors, unless terminated earlier under paragraph 11.2 of the Plan.</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">11.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Board of Directors or the Compensation Committee will have the right at any time and from time to time to suspend, amend or terminate this Plan or any Award in any manner without consent or approval from Participants or shareholders (provided that no such suspension, amendment or termination may be made that will materially prejudice the rights of any Participant under any Award previously granted to such Participant without consent by such Participant); it being understood that no action taken by the Board of Directors or the Compensation Committee that is permitted under the Plan including, without limitation, under Section 10.3 of the Plan shall be deemed an amendment requiring consent by a Participant.</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">11.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The full powers of the Board of Directors or the Compensation Committee as provided for in this Plan will survive the termination of this Plan until all Awards have been exercised or settled in full or have otherwise expired.</font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">Article 12</font><div style="width:100%;display:inline;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br>Applicable Law</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">12.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The laws of the Province of British Columbia shall apply to the Plan and any Award Agreement evidencing the grant of Awards granted hereunder and will be interpreted and construed in accordance with the laws of the Province of British Columbia.</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">12.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subject to any written agreement between the parties, the parties will submit all their disputes arising out of or in connection with the Plan to the exclusive jurisdiction of the courts of the Province of British Columbia.</font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">Article 13</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">13.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company will obtain stockholder approval of any Plan amendment to the extent that the Board of Directors or the Compensation Committee (in its discretion) determines such approval is necessary and desirable to comply with applicable laws.</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">24</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2025 INDUCEMENT EQUITY INCENTIVE PLAN</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">XENON PHARMACEUTICALS INC.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NONQUALIFIED SHARE OPTION AGREEMENT</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">THIS AGREEMENT made on [________] (the &#x201c;Date of Grant&#x201d;)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AMONG:</font></p>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Xenon Pharmaceuticals Inc.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, a company incorporated under the laws of Canada</font></p>
  <p style="text-indent:-15.385%;padding-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">		(the &#x201c;Company&#x201d;)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AND:</font></p>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;margin-right:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[First Name, Last Name, Title]</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br>(the &#x201c;Optionee&#x201d;)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WHEREAS:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A.		The Optionee is a newly employed employee of the Company or one of its subsidiaries who (i) was not previously an employee of the Company or any of its subsidiaries or a Director, or (ii) is returning to employment with the Company following a bona-fide period of non-employment with the Company or any of its subsidiaries;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">B.		The Company considers that the grant to the Optionee of an option to purchase Common Shares in the Company to be an inducement material to the Optionee&#x2019;s entering into employment with the Company or any of its subsidiaries in accordance with the Inducement Listing Rule; and</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">C.		The Option is granted pursuant to the exception to shareholder approval provided for inducement grants under the Inducement Listing Rule.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOW THEREFORE THIS AGREEMENT WITNESSES THAT in consideration of the mutual premises and respective covenants and agreements herein contained, the parties hereto covenant and agree as follows:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE I</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INTERPRETATION</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Definitions</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In this Agreement, unless there is something in the subject matter or context inconsistent therewith, words and terms used herein will have the meanings set forth herein.  To the extent a capitalized term is used herein and not otherwise defined, it shall have the meaning prescribed under the Plan:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Affiliate&#x201d; has the meaning ascribed thereto under the Canada Business Corporations Act in effect on the date hereof;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Expiry Date&#x201d; means the close of business on [&#x25cf;] or such later date as may be extended pursuant to the terms of the Plan;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(3)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Legal Representative&#x201d; means a committee or duly appointed attorney of the Optionee or of the estate of the Optionee on the grounds that the Optionee is incapable, by reason of physical or mental infirmity, of managing his or her affairs;</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Nonqualified Share Option Agreement - Page </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">1</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> of 12</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(4)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Option Exercise Form&#x201d; has the meaning under Section 2.4 of this Agreement;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(5)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Plan&#x201d; means the 2025 Inducement Equity Incentive Plan of the Company, as the same may from time to time be supplemented or amended and in effect;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(6)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Separate Agreement&#x201d; has the meaning under Section 2.2 of this Agreement;</font></div></div>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interpretation</font></div></div>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the purposes of this Agreement, except as otherwise provided:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(7)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;this Agreement&#x201d; means this Nonqualified Share Option Agreement as it may from time to time be supplemented or amended and in effect, and which is deemed to be an Award Agreement in accordance with the Plan;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(8)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">all references in this Agreement to &#x201c;Articles&#x201d;, &#x201c;Sections&#x201d; and other subdivisions are to the designated Articles, Sections and other subdivisions of this Agreement;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(9)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the words &#x201c;herein&#x201d;, &#x201c;hereof&#x201d;, &#x201c;hereunder&#x201d; and other words of similar import refer to this Agreement as a whole and not to any particular Article, Section or other subdivision;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(10)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the headings are for convenience only and do not form a part of this Agreement and are not intended to interpret, define or limit the scope, extent or intent of this Agreement or any provision hereof;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(11)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the singular of any term includes the plural, and vice versa, the use of any term is equally applicable to any gender and, where applicable, a body corporate, the word &#x201c;or&#x201d; is not exclusive and the word &#x201c;including&#x201d; is not limiting whether or not non&#x2011;limiting language (such as &#x201c;without limitation&#x201d; or &#x201c;but not limited to&#x201d; or words of similar import) is used with reference thereto;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(12)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">where the time for doing an act falls or expires on a day other than a Business Day, the time for doing such act is extended to the next day which is a Business Day;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(13)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any reference to a statute is a reference to the applicable statute and to any regulations made pursuant thereto and includes all amendments made thereto and in force from time to time and any statute or regulation that has the effect of supplementing or superseding such statute or regulation; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(14)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any other capitalized terms not defined herein but defined in the Plan shall have the meaning as set out in the Plan.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE II</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">THE OPTION</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Grant</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subject to the provisions of this Agreement and the Plan, on the Date of Grant set forth above, the Company hereby grants to the Optionee an option to purchase [&#x25cf;]</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Common Shares (the &#x201c;Option&#x201d;) at an exercise price of $[&#x25cf;] per share (the &#x201c;Exercise Price&#x201d;), subject to adjustment pursuant to Section 10.3 of the Plan in respect of transactions occurring after the date hereof. The Common Shares underlying the Option will vest, if at all, in accordance with the terms set forth in Section 2.8 hereof.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Nonqualified Share Option Agreement - Page </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> of 12</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.2	Expiry of Option</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subject to the terms of the Plan, the provisions of this Agreement below, and/or any written employment or service agreement, offer letter, change in control severance agreement, or any other agreement that, prior to the Date of Grant, has been entered into between the Optionee and the Company or any subsidiary of the Company or any Affiliate of the Company (such agreement, a &#x201c;Separate Agreement&#x201d;), the Option will expire upon the earliest to occur of the following:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Expiry Date;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the date which is 90 days after the Optionee ceases to be a Service Provider due to termination of employment by the Company or any of its subsidiaries or any of its Affiliates without Cause or due to voluntary termination of employment by the Optionee (other than Retirement);</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the date which is 180 days from the date the Optionee ceases to be a Service Provider due to Retirement;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the date on which the Optionee ceases to be a Service Provider due to termination of employment by the Company or any of its subsidiaries or any of its Affiliates for Cause or material breach of the Optionee&#x2019;s duty to the Company or any of its subsidiaries or any of its Affiliates;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the date which is 365 days from the date the Optionee ceases to be a Service Provider due to disability; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">6.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the date which is 365 days from the date the Optionee ceases to be a Service Provider due to death; </font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">however, in the event of the death of the Optionee occurring during the time period specified in subsections 2.2(2) and 2.2(3) above, subject to earlier expiry on the Expiry Date, the Option will expire on the date which is 365 days after the date the Optionee ceased to be a Service Provider.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For greater certainty, for the purpose of this Agreement and the Plan, the date on which the employment of the Optionee is terminated without Cause or pursuant to voluntary resignation shall be deemed to be the last day the Optionee actively works in the business of the Company, any of its subsidiaries or any of its Affiliates (or in the case of an alleged constructive dismissal, the date on which the alleged constructive dismissal is alleged to have occurred), and not during or as of the end of any period following such date during which the Optionee is in receipt of, or entitled to receive, statutory, contractual or common law notice of termination or any compensation in lieu of such notice.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, and notwithstanding the above, and for greater certainty for the purposes of this Agreement and the Plan, if the Optionee&#x2019;s employment is terminated by the Company, any of its subsidiaries or any of its Affiliates and prior thereto, concurrently therewith or immediately thereafter the Optionee commences employment with the Company, any of its subsidiaries or any of its Affiliates, as the case may be, the Optionee will not cease to be a Service Provider and the determination of the expiry date of the Option pursuant to subsection 2.2(2) will not apply to such event.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.3	Nontransferability of Option</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Option is not transferable or assignable by the Optionee except as expressly permitted under Section 10.2 of the Plan.</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.4	Manner of Exercise</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subject to the terms of the Plan, the Option may be exercised by (i) delivering to the Company, prior to the expiry of the Option, an option exercise form duly executed by the Optionee or its Legal Representative (the &#x201c;Option Exercise Form&#x201d;) substantially in the form of Schedule &#x201c;A&#x201d; completed and executed in a manner acceptable to the Company, acting reasonably, or (ii) in a manner and pursuant to such procedures as the Board of Directors may</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Nonqualified Share Option Agreement - Page </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">3</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> of 12</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">determine, which will state the election to exercise the Option (with appropriate proof of completion of such exercise procedure) (the &#x201c;Alternative Exercise Procedure&#x201d;). The Option Exercise Form or the completion of the Alternative Exercise Procedure (as applicable) must be accompanied by payment in full for the number of Common Shares in respect of which the Option is being exercised, in cash, bank draft, certified cheque or other form of payment acceptable to the Company, made payable to the Company at its principal place of business at the time of the exercise of the Option.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Payment of the aggregate exercise price will be by any of the following, or a combination thereof, at the election of the Optionee: (a) cash; (b) cheque; (c) consideration received by the Company under a formal cashless exercise (which, for clarity, may include net exercise) program adopted by the Company in connection with the Plan; or (d) surrender of other Common Shares which have a Fair Market Value Price on the date of surrender equal to the aggregate exercise price of the exercised Common Shares, provided that accepting such Common Shares, in the sole discretion of the Board of Directors, will not result in any adverse accounting consequences to the Company.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the time the Optionee exercises the Option, in whole or in part, and at any time thereafter as requested by the Company, the Optionee hereby authorizes withholding from payroll and any other amounts payable to the Optionee by the Company, any of its subsidiaries or any of its Affiliates and otherwise agree to make adequate provision for any sums required to satisfy the U.S. and Canadian federal, provincial, state, local and foreign tax withholding obligations of the Company, its subsidiaries or its Affiliates, if any, which arise in connection with the exercise of the Option.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Optionee may not exercise the Option unless the tax withholding obligations of the Company, any of its subsidiaries and/or any of its Affiliate are satisfied. Accordingly, the Optionee may not be able to exercise the Option when desired even though the Option is vested, and the Company will have no obligation to issue a certificate for such Common Shares, unless such obligations are satisfied.</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.5	Issuance of Shares</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company will have no obligation to issue Common Shares upon the exercise of the Option unless the Board of Directors is satisfied that the issuance of such Common Shares to the Optionee will be exempt from all registration or qualification requirements of applicable securities laws and will be permitted under the applicable rules and regulations of all regulatory authorities to which the Company is subject, including any stock exchange or other organized market on which the Common Shares may from time to time be listed or posted for trading.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.6	Compliance with Laws</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Board of Directors may from time to time take such steps and require such documentation from the Optionee which in its opinion is necessary or desirable to ensure compliance with all applicable laws.  The Board of Directors may also from time to time take such steps which in its opinion are necessary or desirable to restrict the transferability of any Common Shares acquired on the exercise of any Option in order to ensure such compliance, including the endorsement of a legend on any certificate representing Common Shares acquired on the exercise of the Option to the effect that such Common Shares may not be offered, sold or delivered except in compliance with the applicable securities laws and regulations of Canada or the United States.</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.7	Delivery of Share Certificates</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subject to Sections 2.5 and 2.6, the Company will, as soon as practicable after receipt of the Option Exercise Form or the confirmation of the completion of the Alternative Exercise Procedure and the payment referred to in Section 2.4 issue and deliver a certificate or certificates representing the Common Shares so purchased.</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.8	Vesting Conditions; Cessation of Employment</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Vesting Conditions</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Except as provided in Section 2.8(2) and Section 2.8(3) below , the Option shall vest as to &frac14; (one quarter) of the underlying Common Shares on first anniversary of the Date of Grant, and as to 1/48 (one forty-eighth) of the underlying Common Shares in equal monthly</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Nonqualified Share Option Agreement - Page </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">4</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> of 12</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">installments for 48 months thereafter, with such monthly vesting to occur on the last day of the applicable month; provided, that no portion of the Option shall vest pursuant to this Agreement unless the Optionee has continuously remained a Service Provider from the Date of Grant through the applicable vesting date.</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(2)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cessation of Employment</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Except as expressly provided for in this Agreement or in a Separate Agreement, if the Optionee ceases to be a Service Provider for any reason, including due to termination of employment by the Company or any of its subsidiaries or any of its Affiliates without Cause or alleged constructive dismissal or due to voluntary termination by the Optionee, all Common Shares subject to the Option granted under this Agreement which are not yet vested and exercisable as provided for above will automatically and immediately be cancelled for no consideration on the effective date of such termination, which shall be deemed to be the last day the Optionee actively works in the business of the Company, any of its subsidiaries or any of its Affiliates (or in the case of an alleged constructive dismissal, the date on which the alleged constructive dismissal is alleged to have occurred), and no statutory, contractual or common law notice entitlement or any entitlement to compensation in lieu of such notice shall operate to extend the vesting of the Option past said deemed termination date.</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(3)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Change of </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Control. Notwithstanding anything to the contrary in the Plan or this Agreement, if the Optionee ceases to be a Service Provider due to a termination of employment by the Company without Cause or the Optionee terminates his or her employment for Good Reason (but only if the Optionee is party to a Separate Agreement that contains a definition of &#x201c;Good Reason&#x201d;), in either case within the twelve (12) month period following a Change of Control, to the extent any portion of the Option is outstanding and unvested immediately prior to such termination of employment, such outstanding and unvested portion of the Option, if any, will automatically vest in full upon such termination of employment.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, and notwithstanding the above, and for greater certainty for the purposes of this Agreement and the Plan, if the Optionee&#x2019;s employment is terminated by the Company, any of its subsidiaries or any of its Affiliates and prior thereto, concurrently therewith or immediately thereafter the Optionee commences employment with the Company, any of its subsidiaries or any of its Affiliates, as the case may be, the Optionee will not cease to be a Service Provider and the vesting of the Option will not change as a result of such event.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, and notwithstanding the above, the Board of Directors may at its discretion accelerate the vesting of the Option, provided that the Board of Directors determines that such acceleration is appropriate and in the best interest of the Company in the circumstances and it is agreed and acknowledged that there is no obligation on the Board of Directors to exercise such discretion nor shall the Board of Directors be required to provide reasons for exercise or non-exercise of such discretion.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.9          Forfeiture; Recovery of Compensation</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Compensation Committee may cancel, rescind, withhold or otherwise limit or restrict the Option at any time if the Optionee is not in compliance with all applicable provisions of this Agreement and the Plan. By accepting this Option, the Optionee expressly acknowledges and agrees that his or her rights under this Agreement, and those of any permitted transferee of this Agreement, including the right to any Common Shares acquired under this Agreement or proceeds from the disposition thereof, are subject to the Xenon Pharmaceuticals Clawback Policy, as such policy may be amended and in effect from time to time (and any successor or similar policy), to the extent applicable, and Section 10.5 of the Plan (including any successor provision). Nothing in the preceding sentence shall be construed as limiting the general application of Section 5.12 of this Agreement.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.10       Taxes</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Optionee expressly acknowledges and agrees that the Optionee&#x2019;s rights hereunder, including the right to be issued Common Shares upon exercises of the Option, are subject to the satisfaction of all taxes required to be withheld with respect to the Option. Unless otherwise determined by the Company, the Optionee shall satisfy his or</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Nonqualified Share Option Agreement - Page </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">5</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> of 12</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">her tax withholding obligations by remitting to the Company by cash or check an amount sufficient to satisfy all taxes required to be withheld. The Optionee authorizes the Company and its subsidiaries to withhold any amounts due in respect of any required tax withholdings or payments by withholding from any amounts otherwise owed to the Optionee, but nothing in this Section 2.10 shall be construed as relieving the Optionee of any liability for satisfying his or her tax obligations relating to the Option.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notwithstanding anything in this Agreement to the contrary, the Optionee acknowledges and agrees that the Optionee shall remain fully responsible for satisfying his or her tax obligations relating to the Option in all cases.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE III</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ADJUSTMENTS</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adjustments</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Agreement will be amended by the Company unilaterally (without the need of consent or notice to the Optionee) upon the occurrence of the events referred to in Section 10.3(a) of the Plan so that the rights of the Optionee hereunder, including the number of Common Shares that may be purchased on the exercise of the Option and the Exercise Price at which such Common Shares may be purchased, will be adjusted in accordance with the provisions set forth in the Plan.  Successive adjustments will be made in the case of the occurrence of more than one such event as provided for therein, but, in the case of each such event, only from and after the occurrence of such event.  Without limiting the other provisions of this Agreement, this Option is subject to the provisions of Section 10.3 of the Plan.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE IV</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">COVENANTS AND REPRESENTATIONS</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Representations and Covenants of the Company</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company hereby covenants that it will reserve or cause to be reserved for allotment sufficient Common Shares for issue to the Optionee of all Common Shares which may become issuable from time to time under the Option.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company represents that the Optionee is a bona fide employee of the Company or of a subsidiary of the Company on the Date of Grant.</font></div></div>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4.2	Representations and Covenants of the Optionee</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Optionee hereby represents and covenants that:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Optionee is an employee of the Company or of a subsidiary of the Company on the Date of Grant;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Optionee&#x2019;s participation in the Plan is voluntary;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(3)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Optionee is aware that the grant of the Option and the issuance by the Company of Common Shares thereunder are exempt from the obligation under applicable securities laws to file a prospectus or other registration document (other than a registration statement on Form S-8 with the United States Securities and Exchange Commission) qualifying the distribution of the Option or the Common Shares to be distributed thereunder under any applicable securities laws and if such exemption for any reason becomes unavailable, the obligation of the Company to grant any Option or issue any Common Shares upon the exercise of an Option will cease; </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(4)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">if the Optionee ceases to be a Service Provider due to termination of employment by the Company, any of its subsidiaries or any of its Affiliates without cause or alleged constructive dismissal or due to voluntary termination by the Optionee, the Optionee will not make any claims for continued vesting of the Option past the effective date of such termination, which shall be deemed to be the </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Nonqualified Share Option Agreement - Page </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">6</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> of 12</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">last day the Optionee actively works in the business of the Company, any of its subsidiaries or any of its Affiliates (or in the case of an alleged constructive dismissal, the date on which the alleged constructive dismissal is alleged to have occurred), and will not make any claims for compensation in lieu of statutory, contractual or common law notice or damages relating thereto;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(5)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">if the Optionee or the Legal Representative of the Optionee exercises the Option, the Optionee or the Legal Representative, as the case may be, will prior to and upon any sale or disposition of any Common Shares purchased upon the exercise of the Option, comply with all applicable securities laws and all applicable rules and regulations of all regulatory authorities to which the Company is subject, including any stock exchange or other organized market on which the Common Shares may be listed or posted for trading, and will not offer, sell or deliver any of such Common Shares, directly or indirectly, in the United States or to any citizen or resident of, or any company, partnership or other entity created or organized in or under the laws of, the United States, or any estate or trust the income of which is subject to United States federal income taxation regardless of its source, except in compliance with the securities laws of the United States; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(6)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Optionee agrees that the Company does not have a duty to design or administer the Plan or its other compensation programs in a manner that minimizes the Optionee&#x2019;s tax liabilities and the Optionee will not make any claim against the Company, any of its subsidiaries, any of its Affiliates or any of their respective officers, directors or employees related to tax liabilities arising from the Option or any of the Optionee&#x2019;s other compensation.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE V</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">MISCELLANEOUS</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.1	Section 409A</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Option is intended to be exempt from Section 409A of the Code and shall be construed and administered in accordance with that intent. Notwithstanding the foregoing, in no event will the Company have any liability relating to the failure or alleged failure of any payment or benefit under this Agreement to comply with, or be exempt from, the requirements of Section 409A of the Code.</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.2	Notices</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any notice or other communication required or permitted to be delivered under this Agreement will be considered delivered only if in writing and when it is actually delivered (which delivery may be by telex, telecopy or other telecommunications device) to the attention of the party to whom it is intended at the principal business address of the Company, if addressed to the Company, or to the address specified above, if to the Optionee, or to such other address as such party may designate to the other party by notice in writing delivered in accordance with this Section 5.2.</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.3	Interpretation; Administration</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any question arising as to the interpretation of this Agreement will be determined by the Board of Directors and/or the Compensation Committee and, absent manifest error, such determination will be conclusive and binding on the Company and the Optionee.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Either the Board of Directors or the Compensation Committee may administer and make determinations under this Agreement and references to the Board of Directors in this Agreement shall refer to the Board of Directors and/or the Compensation Committee, as applicable.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Nonqualified Share Option Agreement - Page </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">7</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> of 12</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.4	Further Assurances</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each of the parties hereto will, on demand by the other party hereto, execute and deliver all such further documents and instruments and do all such further acts and things as the party may either before or after the execution and delivery of this Agreement reasonably request to evidence, carry out and give full effect to the terms, conditions, intent and meaning of this Agreement.</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.5	Severability</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If any provision of this Agreement is determined to be void, illegal or unenforceable, such provision will be construed to be separate and severable from this Agreement and will not impair the validity, legality or enforceability of any other provision of this Agreement and the remainder of this Agreement will continue to be binding on the parties hereto as if such provision had been deleted.</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.6	No Assignment</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Neither this Agreement nor the Option may be assigned, transferred or charged in whole or in part by the Optionee, and any purported assignment, transfer or charge shall cause this Agreement and the Option to lapse forthwith and be null and void after that time.</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.7	Burden and Benefit</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Agreement will be binding upon and will enure to the benefit of the Company and its successors and assigns and the Optionee and, if applicable, his or her Legal Representative.</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.8	Time</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Time will be of the essence in this Agreement.</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.9	Effect on Employment</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Neither the grant of the Option, nor the issuance of Common Shares upon the exercise of the Option, will give the Optionee any right to be retained in the employ or service of the Company or any of its Affiliates, affect the right of the Company or any of its Affiliates to discharge or discipline the Optionee at any time, or affect any right of the Optionee to terminate his or her employment at any time.</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.10	Governing Law and Jurisdiction</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Agreement and all matters arising hereunder will be governed by and construed in accordance with the laws of the Province of British Columbia.  Subject to any written agreement between the parties, the parties will submit all their disputes arising out of or in connection with this Agreement to the exclusive jurisdiction of the courts of British Columbia.</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.11	Electronic Delivery and Acceptance</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company may, in its sole discretion, decide to deliver any documents related to Options awarded under the Plan or future awards that may be awarded under the Plan by electronic means or request the Optionee&#x2019;s consent to participate in the Plan by electronic means, including, without limitation, by posting them on a website maintained by the Company or a third party under contract with the Company or through such methods indicated in this Agreement.  The Optionee hereby consents to receive such documents by electronic delivery and agrees to participate in the Plan through any on-line or electronic system established and maintained by the Company or a third party designated by the Company.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the Company posts such documents on a website, it shall notify the Optionee by e-mail or such other reasonable manner as then determined by the Company.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Nonqualified Share Option Agreement - Page </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">8</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> of 12</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.12	Incorporation of the Terms of the Plan</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Agreement shall be deemed to have incorporated all the terms of the Plan and the Option granted hereunder shall be subject to the terms of the Plan.  Except as expressly provided herein, in the event of any conflict between the provisions of this Agreement and the terms of the Plan, the terms of the Plan shall govern.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Nonqualified Share Option Agreement - Page </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">9</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> of 12</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year first above written.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">XENON PHARMACEUTICALS INC.<br></font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:-4.167%;padding-left:4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">By:   _____________________________<br>Title: Corporate Secretary</font></p>
  <p style="text-indent:4.173%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.173%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">_________________________________<br></font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[First Name Last_Name]</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Nonqualified Share Option Agreement - Page </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">10</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> of 12</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule A, Option Exercise Form</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">OPTION EXERCISE FORM<br>FOR OPTIONS UNDER THE 2025 INDUCEMENT EQUITY INCENTIVE PLAN</font></p>
  <p style="font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:7.64%;box-sizing:content-box;"></td>
    <td style="width:92.36%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">TO:</font></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Xenon Pharmaceuticals Inc.<br>3650 Gilmore Way</font></p><p style="font-size:10pt;margin-top:0.25pt;font-family:Times New Roman;margin-bottom:0;margin-right:45.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Burnaby, BC, V5G 4W8</font></p><p style="font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The undersigned hereby irrevocably gives notice, pursuant to the 2025 Inducement Equity Incentive Plan of Xenon Pharmaceuticals Inc. (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), as the same may, from time to time, be supplemented or amended and in effect (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) and the share option agreement(s) between the Company and the undersigned as listed on Exhibit A hereto (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Share Option Agreement(s)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), of the exercise of the option(s) (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Option(s)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) granted to the undersigned pursuant to the Plan and the Share Option Agreement(s) and hereby irrevocably agrees to purchase common shares as listed in Exhibit A by way of:</font></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:39.46%;box-sizing:content-box;"></td>
    <td style="width:60.54%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">[Choose (check off) one of the following]</font></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x25a1;  Net exercise OR</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">&#x25a1;  </font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash exercise</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:39%;box-sizing:content-box;"></td>
    <td style="width:61%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">[Complete the following, as applicable]</font></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="padding-top:0in;text-indent:36pt;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="margin-left:6.667%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total exercise price enclosed herewith: $____________</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:36pt;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total taxes $____________</font></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x25a1;  Enclosed herewith OR</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x25a1;  Deducted from next paycheque</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x25a1;  If permitted by the Company, withholding from proceeds of a sale of common shares acquired upon the exercise of the Option arranged by the Company (on the undersigned&#x2019;s behalf pursuant to this authorization without further consent)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The undersigned tenders to the Company herewith an amount equal to the total exercise price for the common shares being purchased plus any amounts necessary to satisfy the tax withholding obligations in connection with such purchase.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The undersigned directs the Company to issue the Direct Registration Statement evidencing the common shares in the name of the undersigned to be sent electronically to the undersigned to the following e-mail address:</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <table style="margin-left:44.5%;border-spacing:0;table-layout:auto;width:49.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;box-sizing:content-box;"></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:3pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Nonqualified Share Option Agreement - Page </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">11</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> of 12</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Until the issuance (as evidenced by the appropriate entry on the books of the Company or of a duly authorized transfer agent of the Company) of the common shares, no right to vote or receive dividends or any other rights as a shareholder will exist with respect to the common shares subject to the Option(s), notwithstanding the exercise of the Option(s).  The common shares so acquired will be issued in the name so designated above as soon as practicable after exercise of the Option(s).  No adjustment will be made for a dividend or other right for which the record date is prior to the date of issuance, except as provided in Section 10.3(a) of the Plan.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The undersigned understands that the undersigned may suffer adverse tax consequences as a result of the purchase or disposition of the common shares.  The undersigned represents that the undersigned has consulted with any tax consultants the undersigned deems advisable in connection with the purchase or disposition of the common shares and that the undersigned is not relying on the Company for any tax advice.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This notice and all matters arising hereunder will be governed by and construed in accordance with the laws of the Province of British Columbia.  Subject to any written agreement between the parties, the parties will submit all their disputes arising out of or in connection with this notice to the exclusive jurisdiction of the courts of British Columbia.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;" id="text1"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">DATED the ______ day of ____________, </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">______</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:auto;width:84.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:46.1%;box-sizing:content-box;"></td>
    <td style="width:8.02%;box-sizing:content-box;"></td>
    <td style="width:45.88%;box-sizing:content-box;"></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:3pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.075in;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:3pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:3pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:3pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Signature of Witness</font></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:3pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:3pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Signature of Participant</font></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:3pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:3pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.075in;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:3pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:3pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:3pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Name of Witness (</font><font style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">please print</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</font></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:3pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:3pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Name of Participant (</font><font style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">please print</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Return the Option Exercise Form, along with (as applicable) your certified cheque, bank draft or money order to:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Xenon Pharmaceuticals Inc.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3650 Gilmore Way, Burnaby, B.C.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Canada  V5G 4W8</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Nonqualified Share Option Agreement - Page </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">12</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> of 12</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2025 INDUCEMENT EQUITY INCENTIVE PLAN</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">XENON PHARMACEUTICALS INC.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RESTRICTED SHARE UNIT AWARD AGREEMENT</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">THIS AGREEMENT made on [________] (the &#x201c;Date of Grant&#x201d;)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AMONG:</font></p>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Xenon Pharmaceuticals Inc.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, a company incorporated under the laws of Canada</font></p>
  <p style="text-indent:-15.385%;padding-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">		(the &#x201c;Company&#x201d;)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AND:</font></p>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;margin-right:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[First Name, Last Name, Title]</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br>(the &#x201c;Grantee&#x201d;)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WHEREAS:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A.		The Grantee is a newly employed employee of the Company or one of its subsidiaries who (i) was not previously an employee of the Company or any of its subsidiaries or a Director, or (ii) is returning to employment with the Company following a bona-fide period of non-employment with the Company or any of its subsidiaries;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">B.		The Company considers that the grant to the Grantee of a Restricted Share Unit Award to be an inducement material to the Grantee&#x2019;s entering into employment with the Company or any of its subsidiaries in accordance with the Inducement Listing Rule; and</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">C.		This Restricted Share Unit Award is granted pursuant to the exception to shareholder approval provided for inducement grants under the Inducement Listing Rule.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOW THEREFORE THIS AGREEMENT WITNESSES THAT in consideration of the mutual premises and respective covenants and agreements herein contained, the parties hereto covenant and agree as follows:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE I</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INTERPRETATION</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Definitions</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In this Agreement, unless there is something in the subject matter or context inconsistent therewith, words and terms used herein will have the meanings set forth herein.  To the extent a capitalized term is used herein and not otherwise defined, it shall have the meaning prescribed under the Plan:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(15)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Affiliate&#x201d; has the meaning ascribed thereto under the Canada Business Corporations Act in effect on the date hereof; </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(16)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Legal Representative&#x201d; means a committee or duly appointed attorney of the Grantee or of the estate of the Grantee on the grounds that the Grantee is incapable, by reason of physical or mental infirmity, of managing his or her affairs;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(17)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Plan&#x201d; means the 2025 Inducement Equity Incentive Plan of the Company, as the same may from time to time be supplemented or amended and in effect;</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restricted Share Unit Agreement - Page </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">1</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> of 9</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(18)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Separate Agreement&#x201d; has the meaning under Section 2.6(2) of this Agreement;</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interpretation</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the purposes of this Agreement, except as otherwise provided:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(19)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;this Agreement&#x201d; means this Restricted Share Unit Award Agreement as it may from time to time be supplemented or amended and in effect, and which is deemed to be an Award Agreement in accordance with the Plan;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(20)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">all references in this Agreement to &#x201c;Articles&#x201d;, &#x201c;Sections&#x201d; and other subdivisions are to the designated Articles, Sections and other subdivisions of this Agreement;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(21)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the words &#x201c;herein&#x201d;, &#x201c;hereof&#x201d;, &#x201c;hereunder&#x201d; and other words of similar import refer to this Agreement as a whole and not to any particular Article, Section or other subdivision;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(22)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the headings are for convenience only and do not form a part of this Agreement and are not intended to interpret, define or limit the scope, extent or intent of this Agreement or any provision hereof;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(23)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the singular of any term includes the plural, and vice versa, the use of any term is equally applicable to any gender and, where applicable, a body corporate, the word &#x201c;or&#x201d; is not exclusive and the word &#x201c;including&#x201d; is not limiting whether or not non&#x2011;limiting language (such as &#x201c;without limitation&#x201d; or &#x201c;but not limited to&#x201d; or words of similar import) is used with reference thereto;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(24)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">where the time for doing an act falls or expires on a day other than a Business Day, the time for doing such act is extended to the next day which is a Business Day;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(25)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any reference to a statute is a reference to the applicable statute and to any regulations made pursuant thereto and includes all amendments made thereto and in force from time to time and any statute or regulation that has the effect of supplementing or superseding such statute or regulation; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(26)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any other capitalized terms not defined herein but defined in the Plan shall have the meaning as set out in the Plan.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE II</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">THE RSUS</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Grant</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subject to the provisions of this Agreement and the Plan, on the Date of Grant set forth above, the Company hereby grants to the Grantee a Restricted Share Unit Award consisting of [&#149;] restricted share units (the &#x201c;RSUs&#x201d;), giving the Grantee the conditional right to receive, on the terms and conditions provided herein and in the Plan, one Common Share with respect to each RSU forming part of this Award, subject to adjustment pursuant to Section 10.3 of the Plan in respect of transactions occurring after the date hereof.  The RSUs will vest, if at all, in accordance with the terms set forth on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit A</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> hereto.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.2	Nontransferability of RSUs</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Restricted Share Unit Award is not transferable or assignable by the Grantee except as expressly permitted under Section 10.2 of the Plan.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.3	Issuance of Shares</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company will have no obligation to issue Common Shares upon the vesting or settlement of the RSUs unless the Board of Directors is satisfied that the issuance of such Common Shares to the Grantee will be exempt from</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restricted Share Unit Agreement - Page </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> of 9</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">all registration or qualification requirements of applicable securities laws and will be permitted under the applicable rules and regulations of all regulatory authorities to which the Company is subject, including any stock exchange or other organized market on which the Common Shares may from time to time be listed or posted for trading.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.4	Compliance with Laws</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Board of Directors may from time to time take such steps and require such documentation from the Grantee which in its opinion is necessary or desirable to ensure compliance with all applicable laws.  The Board of Directors may also from time to time take such steps which in its opinion are necessary or desirable to restrict the transferability of any Common Shares acquired on the settlement of any RSUs in order to ensure such compliance, including the endorsement of a legend on any certificate representing Common Shares acquired on the settlement of the RSUs to the effect that such Common Shares may not be offered, sold or delivered except in compliance with the applicable securities laws and regulations of Canada or the United States.</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.5	Delivery of Share Certificates</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subject to Sections 2.3 and 2.4, the Company will, as soon as practicable after the issuance of any Common Shares in settlement of the RSUs, issue and deliver a certificate or certificates representing the Common Shares so issued.</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.6	Vesting Conditions; Cessation of Employment; Change of Control</font></p>
  <div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Vesting Conditions</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Except as provided in Section 2.6(2) and Section 2.6(3) below, the RSUs shall vest on the applicable &#x201c;Vesting Date&#x201d; (as such term is defined in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit A</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">); </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that no RSUs shall vest pursuant to this Agreement unless the Grantee has continuously remained a Service Provider from the Date of Grant through the applicable Vesting Date.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cessation of Employment</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Except as expressly provided for in this Agreement or in a written employment or service agreement, offer letter, change in control severance agreement, or any other agreement that, prior to the Date of Grant, has been entered into between the Grantee and the Company or any subsidiary of the Company or any Affiliate of the Company (such agreement, a &#x201c;Separate Agreement&#x201d;), if the Grantee ceases to be a Service Provider for any reason, including due to termination of employment by the Company or any of its subsidiaries or any of its Affiliates without Cause or alleged constructive dismissal or due to voluntary termination by the Grantee, all outstanding RSUs granted under this Agreement will automatically and immediately be cancelled for no consideration on the effective date of such termination, which shall be deemed to be the last day the Grantee actively works in the business of the Company, any of its subsidiaries or any of its Affiliates (or in the case of an alleged constructive dismissal, the date on which the alleged constructive dismissal is alleged to have occurred), and no statutory, contractual or common law notice entitlement or any entitlement to compensation in lieu of such notice shall operate to extend the vesting of the RSUs past said deemed termination date.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(3)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Change of Control</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Notwithstanding anything to the contrary in the Plan or this Agreement, in the event of a Change of Control, the treatment of the RSUs in connection with such Change of Control shall be as set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit A</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For greater certainty, for the purpose of this Agreement and the Plan, the date on which the employment of the Grantee is terminated without Cause or pursuant to voluntary resignation shall be deemed to be the last day the Grantee actively works in the business of the Company, any of its subsidiaries or any of its Affiliates (or in the case of an alleged constructive dismissal, the date on which the alleged constructive dismissal is alleged to have occurred), and not during or as of the end of any period following such date during which the Grantee is in receipt of, or entitled to receive, statutory, contractual or common law notice of termination or any compensation in lieu of such notice.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, and notwithstanding the above, and for greater certainty for the purposes of this Agreement and the Plan, if the Grantee&#x2019;s employment is terminated by the Company, any of its subsidiaries or any of its Affiliates and</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restricted Share Unit Agreement - Page </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">3</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> of 9</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">prior thereto, concurrently therewith or immediately thereafter the Grantee commences employment with the Company, any of its subsidiaries or any of its Affiliates, as the case may be, the Grantee will not cease to be a Service Provider and the vesting of the RSUs will not change as a result of such event.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, and notwithstanding the above, the Board of Directors may at its discretion accelerate the vesting of the RSUs, provided that the Board of Directors determines that such acceleration is appropriate and in the best interest of the Company in the circumstances and it is agreed and acknowledged that there is no obligation on the Board of Directors to exercise such discretion nor shall the Board of Directors be required to provide reasons for exercise or non-exercise of such discretion.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.7          Settlement of RSUs</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company shall, as soon as practicable upon the vesting of a RSU hereunder but in no event later than March 15</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the year following the year in which the applicable RSU vests, with respect to each such RSU that so vests, transfer one (1) Common Share to the Grantee (or, in the event of the Grantee&#x2019;s death, to the person to whom this Restricted Share Unit Award has passed by will or the laws of descent and distribution).</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.8          Forfeiture; Recovery of Compensation</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Board of Directors may cancel, rescind, withhold or otherwise limit or restrict this Restricted Share Unit Award at any time if the Grantee is not in compliance with all applicable provisions of this Agreement and the Plan. By accepting this Restricted Share Unit Award, the Grantee expressly acknowledges and agrees that his or her rights under this Restricted Share Unit Award, and those of any permitted transferee of this Restricted Share Unit Award, including the right to any Common Shares acquired under this Restricted Share Unit Award or proceeds from the disposition thereof, are subject to the Xenon Pharmaceuticals Clawback Policy, as such policy may be amended and in effect from time to time (and any successor or similar policy), to the extent applicable, and Section 10.5 of the Plan (including any successor provision). Nothing in the preceding sentence shall be construed as limiting the general application of Section 5.12 of this Agreement.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.9        Dividends; Other Rights</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Restricted Share Unit Award shall not be interpreted to bestow upon the Grantee any equity interest or ownership in the Company or any Affiliate prior to the date on which the Company delivers Common Shares (if any) to the Grantee. The Grantee is not entitled to vote any Common Shares by reason of the granting of this Restricted Share Unit Award nor is the Grantee entitled to receive or be credited with any dividends declared and payable on any Common Share prior to the date on which any such share is delivered to the Grantee hereunder. The Grantee shall have the rights of a shareholder only as to those Common Shares, if any, that are actually delivered under this Restricted Share Unit Award.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.10       Taxes</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Grantee expressly acknowledges that the vesting and/or settlement of the RSUs acquired hereunder may give rise to &#x201c;wages&#x201d; subject to withholding. The Grantee expressly acknowledges and agrees that the Grantee&#x2019;s rights hereunder, including the right to receive Common Shares following the vesting of any portion of the Restricted Share Unit Award, are subject to the satisfaction of all taxes required to be withheld with respect to the Restricted Share Unit Award. Unless otherwise determined by the Company the Company shall satisfy the applicable taxes required to be withheld in connection with the vesting and/or settlement of the RSUs by withholding from the Common Shares that would otherwise be delivered in connection with the vesting and/or settlement of the RSUs hereunder a number of Common Shares having a fair market value equal to the minimum statutory amount required to be withheld to satisfy such tax withholding obligations. The Grantee authorizes the Company and its subsidiaries to withhold any amounts due in respect of any required tax withholdings or payments by withholding from any amounts otherwise owed to the Grantee, but nothing in this Section 2.10 shall be construed as relieving the Grantee of any liability for satisfying his or her tax obligations relating to the Restricted Share Unit Award.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restricted Share Unit Agreement - Page </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">4</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> of 9</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notwithstanding anything in this Agreement to the contrary, the Grantee acknowledges and agrees that the Grantee shall remain fully responsible for satisfying his or her tax obligations relating to the Restricted Share Unit Award in all cases.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE III</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ADJUSTMENTS</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adjustments</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Agreement will be amended by the Company unilaterally (without the need of consent or notice to the Grantee) upon the occurrence of the events referred to in Section 10.3(a) of the Plan so that the rights of the Grantee hereunder, including the number of Common Shares subject to the Restricted Share Unit Award, will be adjusted in accordance with the provisions set forth in the Plan.  Successive adjustments will be made in the case of the occurrence of more than one such event as provided for therein, but, in the case of each such event, only from and after the occurrence of such event.  Without limiting the other provisions of this Agreement, this Restricted Share Unit Award is subject to the provisions of Section 10.3 of the Plan.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE IV</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">COVENANTS AND REPRESENTATIONS</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Representations and Covenants of the Company</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(3)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company hereby covenants that it will reserve or cause to be reserved for allotment sufficient Common Shares for issue to the Grantee of all Common Shares which may become issuable from time to time under the Restricted Share Unit Award.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(4)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company represents that the Grantee is a bona fide employee of the Company or of a subsidiary of the Company on the Date of Grant.</font></div></div>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4.2	Representations and Covenants of the Grantee</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Grantee hereby represents and covenants that:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(7)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Grantee is an employee of the Company or of a subsidiary of the Company on the Date of Grant;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(8)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Grantee&#x2019;s participation in the Plan is voluntary;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(9)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Grantee is aware that the grant of the Restricted Share Unit Award and the issuance by the Company of Common Shares thereunder are exempt from the obligation under applicable securities laws to file a prospectus or other registration document (other than a registration statement on Form S-8 with the United States Securities and Exchange Commission) qualifying the distribution of the RSUs or the Common Shares to be distributed thereunder under any applicable securities laws and if such exemption for any reason becomes unavailable, the obligation of the Company to grant any RSUs or issue any Common Shares upon the vesting or settlement of any RSUs will cease; </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(10)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">if the Grantee ceases to be a Service Provider due to termination of employment by the Company, any of its subsidiaries or any of its Affiliates without cause or alleged constructive dismissal or due to voluntary termination by the Grantee, the Grantee will not make any claims for continued vesting of RSUs past the effective date of such termination, which shall be deemed to be the last day the Grantee actively works in the business of the Company, any of its subsidiaries or any of its Affiliates (or in the case of an alleged constructive dismissal, the date on which the alleged constructive dismissal is alleged to have occurred), and will not make any claims for compensation in lieu of statutory, contractual or common law notice or damages relating thereto;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(11)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">if the Grantee or the Legal Representative of the Grantee receives any Common Shares in respect </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restricted Share Unit Agreement - Page </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">5</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> of 9</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of the RSUs, the Grantee or the Legal Representative, as the case may be, will prior to and upon any sale or disposition of any Common Shares received in respect of the RSUs, comply with all applicable securities laws and all applicable rules and regulations of all regulatory authorities to which the Company is subject, including any stock exchange or other organized market on which the Common Shares may be listed or posted for trading, and will not offer, sell or deliver any of such Common Shares, directly or indirectly, in the United States or to any citizen or resident of, or any company, partnership or other entity created or organized in or under the laws of, the United States, or any estate or trust the income of which is subject to United States federal income taxation regardless of its source, except in compliance with the securities laws of the United States; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(12)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Grantee agrees that the Company does not have a duty to design or administer the Plan or its other compensation programs in a manner that minimizes the Grantee&#x2019;s tax liabilities and the Grantee will not make any claim against the Company, any of its subsidiaries, any of its Affiliates or any of their respective officers, directors or employees related to tax liabilities arising from the RSUs or any of the Grantee&#x2019;s other compensation.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE V</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">MISCELLANEOUS</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.1	Section 409A</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Restricted Share Unit Award is intended to be exempt from Section 409A of the Code as a short-term deferral thereunder and shall be construed and administered in accordance with that intent. Notwithstanding the foregoing, in no event will the Company have any liability relating to the failure or alleged failure of any payment or benefit under this Agreement to comply with, or be exempt from, the requirements of Section 409A of the Code.</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.2	Notices</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any notice or other communication required or permitted to be delivered under this Agreement will be considered delivered only if in writing and when it is actually delivered (which delivery may be by telex, telecopy or other telecommunications device) to the attention of the party to whom it is intended at the principal business address of the Company, if addressed to the Company, or to the address specified above, if to the Grantee, or to such other address as such party may designate to the other party by notice in writing delivered in accordance with this Section 5.2.</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.3	Interpretation; Administration</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any question arising as to the interpretation of this Agreement will be determined by the Board of Directors and/or the Compensation Committee and, absent manifest error, such determination will be conclusive and binding on the Company and the Grantee. Either the Board of Directors or the Compensation Committee may administer and make determinations under this Agreement and references to the Board of Directors in this Agreement shall refer to the Board of Directors and/or the Compensation Committee, as applicable.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.4	Further Assurances</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each of the parties hereto will, on demand by the other party hereto, execute and deliver all such further documents and instruments and do all such further acts and things as the party may either before or after the execution and delivery of this Agreement reasonably request to evidence, carry out and give full effect to the terms, conditions, intent and meaning of this Agreement.</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.5	Severability</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If any provision of this Agreement is determined to be void, illegal or unenforceable, such provision will be construed to be separate and severable from this Agreement and will not impair the validity, legality or enforceability of any other provision of this Agreement and the remainder of this Agreement will continue to be binding on the parties hereto as if such provision had been deleted.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restricted Share Unit Agreement - Page </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">6</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> of 9</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.6	No Assignment</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Neither this Agreement nor the Restricted Share Unit Award may be assigned, transferred or charged in whole or in part by the Grantee, and any purported assignment, transfer or charge shall cause this Agreement and the Restricted Share Unit Award to lapse forthwith and be null and void after that time.</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.7	Burden and Benefit</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Agreement will be binding upon and will enure to the benefit of the Company and its successors and assigns and the Grantee and, if applicable, his or her Legal Representative.</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.8	Time</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Time will be of the essence in this Agreement.</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.9	Effect on Employment</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Neither the grant of this Restricted Share Unit Award, nor the issuance of Common Shares upon the vesting or settlement of any RSUs, will give the Grantee any right to be retained in the employ or service of the Company or any of its Affiliates, affect the right of the Company or any of its Affiliates to discharge or discipline the Grantee at any time, or affect any right of the Grantee to terminate his or her employment at any time.</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.10	Governing Law and Jurisdiction</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Agreement and all matters arising hereunder will be governed by and construed in accordance with the laws of the Province of British Columbia.  Subject to any written agreement between the parties, the parties will submit all their disputes arising out of or in connection with this Agreement to the exclusive jurisdiction of the courts of British Columbia.</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.11	Electronic Delivery and Acceptance</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company may, in its sole discretion, decide to deliver any documents related to RSUs awarded under the Plan or future awards that may be awarded under the Plan by electronic means or request the Grantee&#x2019;s consent to participate in the Plan by electronic means, including, without limitation, by posting them on a website maintained by the Company or a third party under contract with the Company or through such methods indicated in this Agreement.  The Grantee hereby consents to receive such documents by electronic delivery and agrees to participate in the Plan through any on-line or electronic system established and maintained by the Company or a third party designated by the Company.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the Company posts such documents on a website, it shall notify the Grantee by e-mail or such other reasonable manner as then determined by the Company.</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.12	Incorporation of the Terms of the Plan</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Agreement shall be deemed to have incorporated all the terms of the Plan and the RSUs granted hereunder shall be subject to the terms of the Plan.  Except as expressly provided herein, in the event of any conflict between the provisions of this Agreement and the terms of the Plan, the terms of the Plan shall govern.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restricted Share Unit Agreement - Page </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">7</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> of 9</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year first above written.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">XENON PHARMACEUTICALS INC.<br></font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:-4.167%;padding-left:4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">By:   _____________________________<br>Title: Corporate Secretary</font></p>
  <p style="text-indent:4.173%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.173%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">_________________________________<br></font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[First Name Last_Name]</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restricted Share Unit Agreement - Page </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">8</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> of 9</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit A</font></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The RSUs will vest as to twenty-five percent (25%) of the RSUs on each of the first four (4) anniversaries of the Date of Grant (each such vesting date, a &#x201c;Vesting Date&#x201d;), subject to the Grantee continuously remaining a Service Provider through the applicable Vesting Date.  </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Treatment of RSUs on a Change of Control</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Notwithstanding anything in this Exhibit A, if the Grantee ceases to be a Service Provider due to a termination of employment by the Company without Cause or the Grantee terminates his or her employment for Good Reason (but only if the Grantee is party to a Separate Agreement that contains a definition of &#x201c;Good Reason&#x201d;), in either case within the twelve (12) month period following a Change of Control, to the extent any RSUs are outstanding and unvested immediately prior to such termination of employment, such outstanding RSUs, if any, will automatically vest in full upon such termination of employment.</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restricted Share Unit Agreement - Page </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">9</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> of 9</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2025 INDUCEMENT EQUITY INCENTIVE PLAN</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">XENON PHARMACEUTICALS INC.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PERFORMANCE SHARE AWARD AGREEMENT</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">THIS AGREEMENT made on [________] (the &#x201c;Date of Grant&#x201d;)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AMONG:</font></p>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Xenon Pharmaceuticals Inc.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, a company incorporated under the laws of Canada</font></p>
  <p style="text-indent:-15.385%;padding-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">		(the &#x201c;Company&#x201d;)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AND:</font></p>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;margin-right:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[First Name, Last Name, Title]</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br>(the &#x201c;Grantee&#x201d;)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WHEREAS:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A.		The Grantee is a newly employed employee of the Company or one of its subsidiaries who (i) was not previously an employee of the Company or any of its subsidiaries or a Director, or (ii) is returning to employment with the Company following a bona-fide period of non-employment with the Company or any of its subsidiaries;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">B.		The Company considers that the grant to the Grantee of a Performance Share Award to be an inducement material to the Grantee&#x2019;s entering into employment with the Company or any of its subsidiaries in accordance with the Inducement Listing Rule; and</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">C.		This Performance Share Award is granted pursuant to the exception to shareholder approval provided for inducement grants under the Inducement Listing Rule.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOW THEREFORE THIS AGREEMENT WITNESSES THAT in consideration of the mutual premises and respective covenants and agreements herein contained, the parties hereto covenant and agree as follows:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE I</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INTERPRETATION</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Definitions</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In this Agreement, unless there is something in the subject matter or context inconsistent therewith, words and terms used herein will have the meanings set forth herein.  To the extent a capitalized term is used herein and not otherwise defined, it shall have the meaning prescribed under the Plan:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(27)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Affiliate&#x201d; has the meaning ascribed thereto under the Canada Business Corporations Act in effect on the date hereof;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(28)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Legal Representative&#x201d; means a committee or duly appointed attorney of the Grantee or of the estate of the Grantee on the grounds that the Grantee is incapable, by reason of physical or mental infirmity, of managing his or her affairs;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(29)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Plan&#x201d; means the 2025 Inducement Equity Incentive Plan of the Company, as the same may from time to time be supplemented or amended and in effect;</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Performance Share Award Agreement - Page </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">1</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> of 9</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(30)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Separate Agreement&#x201d; has the meaning under Section 2.6(2) of this Agreement;</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interpretation</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the purposes of this Agreement, except as otherwise provided:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(31)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;this Agreement&#x201d; means this Performance Share Award Agreement as it may from time to time be supplemented or amended and in effect, and which is deemed to be an Award Agreement in accordance with the Plan;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(32)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">all references in this Agreement to &#x201c;Articles&#x201d;, &#x201c;Sections&#x201d; and other subdivisions are to the designated Articles, Sections and other subdivisions of this Agreement;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(33)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the words &#x201c;herein&#x201d;, &#x201c;hereof&#x201d;, &#x201c;hereunder&#x201d; and other words of similar import refer to this Agreement as a whole and not to any particular Article, Section or other subdivision;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(34)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the headings are for convenience only and do not form a part of this Agreement and are not intended to interpret, define or limit the scope, extent or intent of this Agreement or any provision hereof;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(35)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the singular of any term includes the plural, and vice versa, the use of any term is equally applicable to any gender and, where applicable, a body corporate, the word &#x201c;or&#x201d; is not exclusive and the word &#x201c;including&#x201d; is not limiting whether or not non&#x2011;limiting language (such as &#x201c;without limitation&#x201d; or &#x201c;but not limited to&#x201d; or words of similar import) is used with reference thereto;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(36)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">where the time for doing an act falls or expires on a day other than a Business Day, the time for doing such act is extended to the next day which is a Business Day;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(37)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any reference to a statute is a reference to the applicable statute and to any regulations made pursuant thereto and includes all amendments made thereto and in force from time to time and any statute or regulation that has the effect of supplementing or superseding such statute or regulation; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(38)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any other capitalized terms not defined herein but defined in the Plan shall have the meaning as set out in the Plan.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE II</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">THE PSUS</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Grant</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subject to the provisions of this Agreement and the Plan, on the Date of Grant set forth above, the Company hereby grants to the Grantee a Performance Share Award consisting of [&#149;] performance-based restricted share units (the &#x201c;PSUs&#x201d;), giving the Grantee the conditional right to receive, on the terms and conditions provided herein and in the Plan, one Common Share with respect to each PSU forming part of  this Award, subject to adjustment pursuant to Section 10.3 of the Plan in respect of transactions occurring after the date hereof.  The percentage of the total number of PSUs that may be earned by the Grantee will be determined in accordance with </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit A</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> hereto.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.2	Nontransferability of PSUs</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Performance Share Award is not transferable or assignable by the Grantee except as expressly permitted under Section 10.2 of the Plan.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.3	Issuance of Shares</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company will have no obligation to issue Common Shares upon the vesting or settlement of the PSUs unless the Board of Directors is satisfied that the issuance of such Common Shares to the Grantee will be exempt from</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Performance Share Award Agreement - Page </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> of 9</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">all registration or qualification requirements of applicable securities laws and will be permitted under the applicable rules and regulations of all regulatory authorities to which the Company is subject, including any stock exchange or other organized market on which the Common Shares may from time to time be listed or posted for trading.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.4	Compliance with Laws</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Board of Directors may from time to time take such steps and require such documentation from the Grantee which in its opinion is necessary or desirable to ensure compliance with all applicable laws.  The Board of Directors may also from time to time take such steps which in its opinion are necessary or desirable to restrict the transferability of any Common Shares acquired on the settlement of any PSUs in order to ensure such compliance, including the endorsement of a legend on any certificate representing Common Shares acquired on the settlement of the PSUs to the effect that such Common Shares may not be offered, sold or delivered except in compliance with the applicable securities laws and regulations of Canada or the United States.</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.5	Delivery of Share Certificates</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subject to Sections 2.3 and 2.4, the Company will, as soon as practicable after the issuance of any Common Shares in settlement of the PSUs, issue and deliver a certificate or certificates representing the Common Shares so issued.</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.6	Vesting Conditions; Cessation of Employment; Change of Control</font></p>
  <div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(4)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Vesting Conditions</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Except as provided in Section 2.6(2) and Section 2.6(3) below, the PSUs shall vest on the applicable &#x201c;Vesting Date&#x201d; (as such term is defined in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit A</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) based on achievement of the applicable Milestone (as such term is defined in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit A</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">); </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that no PSUs shall vest pursuant to this Agreement unless the Grantee has continuously remained a Service Provider from the Date of Grant through the applicable Vesting Date.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(5)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cessation of Employment</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Except as expressly provided for in this Agreement or in a written employment or service agreement, offer letter, change in control severance agreement, or any other agreement that, prior to the Date of Grant, has been entered into between the Grantee and the Company or any subsidiary of the Company or any Affiliate of the Company (such agreement, a &#x201c;Separate Agreement&#x201d;), if the Grantee ceases to be a Service Provider for any reason, including due to termination of employment by the Company or any of its subsidiaries or any of its Affiliates without Cause or alleged constructive dismissal or due to voluntary termination by the Grantee, all outstanding PSUs granted under this Agreement will automatically and immediately be cancelled for no consideration on the effective date of such termination, which shall be deemed to be the last day the Grantee actively works in the business of the Company, any of its subsidiaries or any of its Affiliates (or in the case of an alleged constructive dismissal, the date on which the alleged constructive dismissal is alleged to have occurred), and no statutory, contractual or common law notice entitlement or any entitlement to compensation in lieu of such notice shall operate to extend the vesting of the PSUs past said deemed termination date.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(6)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Change of Control</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Notwithstanding anything to the contrary in the Plan or this Agreement, in the event of a Change of Control, the treatment of the PSUs in connection with such Change of Control shall be as set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit A</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For greater certainty, for the purpose of this Agreement and the Plan, the date on which the employment of the Grantee is terminated without Cause or pursuant to voluntary resignation shall be deemed to be the last day the Grantee actively works in the business of the Company, any of its subsidiaries or any of its Affiliates (or in the case of an alleged constructive dismissal, the date on which the alleged constructive dismissal is alleged to have occurred), and not during or as of the end of any period following such date during which the Grantee is in receipt of, or entitled to receive, statutory, contractual or common law notice of termination or any compensation in lieu of such notice.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Performance Share Award Agreement - Page </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">3</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> of 9</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, and notwithstanding the above, and for greater certainty for the purposes of this Agreement and the Plan, if the Grantee&#x2019;s employment is terminated by the Company, any of its subsidiaries or any of its Affiliates and prior thereto, concurrently therewith or immediately thereafter the Grantee commences employment with the Company, any of its subsidiaries or any of its Affiliates, as the case may be, the Grantee will not cease to be a Service Provider and the vesting of the PSUs will not change as a result of such event.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, and notwithstanding the above, the Board of Directors may at its discretion accelerate the vesting of the PSUs, provided that the Board of Directors determines that such acceleration is appropriate and in the best interest of the Company in the circumstances and it is agreed and acknowledged that there is no obligation on the Board of Directors to exercise such discretion nor shall the Board of Directors be required to provide reasons for exercise or non-exercise of such discretion.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.7          Settlement of PSUs</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company shall, as soon as practicable upon the vesting of a PSU hereunder but in no event later than March 15</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the year following the year in which the applicable PSU vests and in no event later than December 31, [&#149;], with respect to each such PSU that so vests, transfer one (1) Common Share to the Grantee (or, in the event of the Grantee&#x2019;s death, to the person to whom this Performance Share Award has passed by will or the laws of descent and distribution).</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.8          Forfeiture; Recovery of Compensation</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Board of Directors may cancel, rescind, withhold or otherwise limit or restrict this Performance Share Award at any time if the Grantee is not in compliance with all applicable provisions of this Agreement and the Plan. By accepting this Performance Share Award, the Grantee expressly acknowledges and agrees that his or her rights under this Performance Share Award, and those of any permitted transferee of this Performance Share Award, including the right to any Common Shares acquired under this Performance Share Award or proceeds from the disposition thereof, are subject to the Xenon Pharmaceuticals Clawback Policy, as such policy may be amended and in effect from time to time (and any successor or similar policy), to the extent applicable, and Section 10.5 of the Plan (including any successor provision). Nothing in the preceding sentence shall be construed as limiting the general application of Section 5.12 of this Agreement.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.9        Dividends; Other Rights</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Performance Share Award shall not be interpreted to bestow upon the Grantee any equity interest or ownership in the Company or any Affiliate prior to the date on which the Company delivers Common Shares (if any) to the Grantee. The Grantee is not entitled to vote any Common Shares by reason of the granting of this Performance Share Award nor is the Grantee entitled to receive or be credited with any dividends declared and payable on any Common Share prior to the date on which any such share is delivered to the Grantee hereunder. The Grantee shall have the rights of a shareholder only as to those Common Shares, if any, that are actually delivered under this Performance Share Award.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Performance Share Award Agreement - Page </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">4</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> of 9</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.10       Taxes</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	The Grantee expressly acknowledges that the vesting and/or settlement of the PSUs acquired hereunder may give rise to &#x201c;wages&#x201d; subject to withholding. The Grantee expressly acknowledges and agrees that the Grantee&#x2019;s rights hereunder, including the right to receive Common Shares following the vesting of any portion of the Performance Share Award, are subject to the satisfaction of all taxes required to be withheld with respect to the Performance Share Award. Unless otherwise determined by the Company, the Company shall satisfy the applicable taxes required to be withheld in connection with the vesting and/or settlement of the PSUs by withholding from the Common Shares that would otherwise be delivered in connection with the vesting and/or settlement of the PSUs hereunder a number of Common Shares having a fair market value equal to the minimum statutory amount required to be withheld to satisfy such tax withholding obligations. The Grantee authorizes the Company and its subsidiaries to withhold any amounts due in respect of any required tax withholdings or payments by withholding from any amounts otherwise owed to the Grantee, but nothing in this Section 2.10 shall be construed as relieving the Grantee of any liability for satisfying his or her tax obligations relating to the Performance Share Award.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notwithstanding anything in this Agreement to the contrary, the Grantee acknowledges and agrees that the Grantee shall remain fully responsible for satisfying his or her tax obligations relating to the Performance Share Award in all cases.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE III</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ADJUSTMENTS</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adjustments</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Agreement will be amended by the Company unilaterally (without the need of consent or notice to the Grantee) upon the occurrence of the events referred to in Section 10.3(a) of the Plan so that the rights of the Grantee hereunder, including the number of Common Shares subject to the Performance Share Award, will be adjusted in accordance with the provisions set forth in the Plan.  Successive adjustments will be made in the case of the occurrence of more than one such event as provided for therein, but, in the case of each such event, only from and after the occurrence of such event.  Without limiting the other provisions of this Agreement, this Performance Share Award is subject to the provisions of Section 10.3 of the Plan.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE IV</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">COVENANTS AND REPRESENTATIONS</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Representations and Covenants of the Company</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(5)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company hereby covenants that it will reserve or cause to be reserved for allotment sufficient Common Shares for issue to the Grantee of all Common Shares which may become issuable from time to time under the Performance Share Award.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(6)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company represents that the Grantee is a bona fide employee of the Company or of a subsidiary of the Company on the Date of Grant.</font></div></div>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4.2	Representations and Covenants of the Grantee</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Grantee hereby represents and covenants that:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(13)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Grantee is an employee of the Company or of a subsidiary of the Company on the Date of Grant;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(14)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Grantee&#x2019;s participation in the Plan is voluntary;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(15)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Grantee is aware that the grant of the Performance Share Award and the issuance by the Company of Common Shares thereunder are exempt from the obligation under applicable securities laws to file a prospectus or other registration document (other than a registration statement on Form </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Performance Share Award Agreement - Page </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">5</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> of 9</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">S-8 with the United States Securities and Exchange Commission) qualifying the distribution of the PSUs or the Common Shares to be distributed thereunder under any applicable securities laws and if such exemption for any reason becomes unavailable, the obligation of the Company to grant any PSUs or issue any Common Shares upon the vesting or settlement of any PSUs will cease;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(16)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">if the Grantee ceases to be a Service Provider due to termination of employment by the Company, any of its subsidiaries or any of its Affiliates without cause or alleged constructive dismissal or due to voluntary termination by the Grantee, the Grantee will not make any claims for continued vesting of PSUs past the effective date of such termination, which shall be deemed to be the last day the Grantee actively works in the business of the Company, any of its subsidiaries or any of its Affiliates (or in the case of an alleged constructive dismissal, the date on which the alleged constructive dismissal is alleged to have occurred), and will not make any claims for compensation in lieu of statutory, contractual or common law notice or damages relating thereto;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(17)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">if the Grantee or the Legal Representative of the Grantee receives any Common Shares in respect of the PSUs, the Grantee or the Legal Representative, as the case may be, will prior to and upon any sale or disposition of any Common Shares received in respect of the PSUs, comply with all applicable securities laws and all applicable rules and regulations of all regulatory authorities to which the Company is subject, including any stock exchange or other organized market on which the Common Shares may be listed or posted for trading, and will not offer, sell or deliver any of such Common Shares, directly or indirectly, in the United States or to any citizen or resident of, or any company, partnership or other entity created or organized in or under the laws of, the United States, or any estate or trust the income of which is subject to United States federal income taxation regardless of its source, except in compliance with the securities laws of the United States; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(18)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Grantee agrees that the Company does not have a duty to design or administer the Plan or its other compensation programs in a manner that minimizes the Grantee&#x2019;s tax liabilities and the Grantee will not make any claim against the Company, any of its subsidiaries, any of its Affiliates or any of their respective officers, directors or employees related to tax liabilities arising from the PSUs or any of the Grantee&#x2019;s other compensation.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE V</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">MISCELLANEOUS</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.1	Section 409A</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Performance Share Award is intended to be exempt from Section 409A of the Code as a short-term deferral thereunder and shall be construed and administered in accordance with that intent. Notwithstanding the foregoing, in no event will the Company have any liability relating to the failure or alleged failure of any payment or benefit under this Agreement to comply with, or be exempt from, the requirements of Section 409A of the Code.</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.2	Notices</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any notice or other communication required or permitted to be delivered under this Agreement will be considered delivered only if in writing and when it is actually delivered (which delivery may be by telex, telecopy or other telecommunications device) to the attention of the party to whom it is intended at the principal business address of the Company, if addressed to the Company, or to the address specified above, if to the Grantee, or to such other address as such party may designate to the other party by notice in writing delivered in accordance with this Section 5.2.</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.3	Interpretation; Administration</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any question arising as to the interpretation of this Agreement will be determined by the Board of Directors and/or the Compensation Committee and, absent manifest error, such determination will be conclusive and binding on the Company and the Grantee. Either the Board of Directors or the Compensation Committee may administer and</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Performance Share Award Agreement - Page </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">6</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> of 9</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">make determinations under this Agreement and references to the Board of Directors in this Agreement shall refer to the Board of Directors and/or the Compensation Committee, as applicable.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.4	Further Assurances</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each of the parties hereto will, on demand by the other party hereto, execute and deliver all such further documents and instruments and do all such further acts and things as the party may either before or after the execution and delivery of this Agreement reasonably request to evidence, carry out and give full effect to the terms, conditions, intent and meaning of this Agreement.</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.5	Severability</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If any provision of this Agreement is determined to be void, illegal or unenforceable, such provision will be construed to be separate and severable from this Agreement and will not impair the validity, legality or enforceability of any other provision of this Agreement and the remainder of this Agreement will continue to be binding on the parties hereto as if such provision had been deleted.</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.6	No Assignment</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Neither this Agreement nor the Performance Share Award may be assigned, transferred or charged in whole or in part by the Grantee, and any purported assignment, transfer or charge shall cause this Agreement and the Performance Share Award to lapse forthwith and be null and void after that time.</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.7	Burden and Benefit</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Agreement will be binding upon and will enure to the benefit of the Company and its successors and assigns and the Grantee and, if applicable, his or her Legal Representative.</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.8	Time</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Time will be of the essence in this Agreement.</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.9	Effect on Employment</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Neither the grant of this Performance Share Award, nor the issuance of Common Shares upon the vesting or settlement of any PSUs, will give the Grantee any right to be retained in the employ or service of the Company or any of its Affiliates, affect the right of the Company or any of its Affiliates to discharge or discipline the Grantee at any time, or affect any right of the Grantee to terminate his or her employment at any time.</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.10	Governing Law and Jurisdiction</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Agreement and all matters arising hereunder will be governed by and construed in accordance with the laws of the Province of British Columbia.  Subject to any written agreement between the parties, the parties will submit all their disputes arising out of or in connection with this Agreement to the exclusive jurisdiction of the courts of British Columbia.</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.11	Electronic Delivery and Acceptance</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company may, in its sole discretion, decide to deliver any documents related to PSUs awarded under the Plan or future awards that may be awarded under the Plan by electronic means or request the Grantee&#x2019;s consent to participate in the Plan by electronic means, including, without limitation, by posting them on a website maintained by the Company or a third party under contract with the Company or through such methods indicated in this Agreement.  The Grantee hereby consents to receive such documents by electronic delivery and agrees to participate in the Plan through any on-line or electronic system established and maintained by the Company or a third party designated by the Company.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Performance Share Award Agreement - Page </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">7</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> of 9</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the Company posts such documents on a website, it shall notify the Grantee by e-mail or such other reasonable manner as then determined by the Company.</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.12	Incorporation of the Terms of the Plan</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Agreement shall be deemed to have incorporated all the terms of the Plan and the PSUs granted hereunder shall be subject to the terms of the Plan.  Except as expressly provided herein, in the event of any conflict between the provisions of this Agreement and the terms of the Plan, the terms of the Plan shall govern.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Performance Share Award Agreement - Page </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">8</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> of 9</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year first above written.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">XENON PHARMACEUTICALS INC.<br></font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:-4.167%;padding-left:4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">By:   _____________________________<br>Title: Corporate Secretary</font></p>
  <p style="text-indent:4.173%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.173%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">_________________________________<br></font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[First Name Last_Name]</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Performance Share Award Agreement - Page </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">9</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> of 9</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.33
<SEQUENCE>6
<FILENAME>xene-ex10_33.htm
<DESCRIPTION>EX-10.33
<TEXT>
<html>
 <head>
  <title>EX-10.33</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.33</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">POST-EMPLOYMENT CONSULTING AGREEMENT</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	This CONSULTING AGREEMENT (</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Agreement&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) shall be binding and effective as of the date of the last signature below (</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Effective Date&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">), by and between Xenon Pharmaceuticals Inc. (</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Company&#x201d;),</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and Sherry Aulin (</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Consultant&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WHEREAS</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, Consultant is currently an employee Company with a planned resignation date of June 30, 2025; and</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WHEREAS</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, Company desires to retain Consultant for the two (2) month post-employment period commencing on July 1, 2025 through August 31, 2025 (&#x201c;Consulting Term&#x201d; or &#x201c;Term&#x201d;) in order to provide such consulting services as may be reasonably requested from time to time by or on behalf of Company and described in one or more statements of work hereunder.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOW, THEREFORE</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, in consideration of the mutual covenants and agreements set forth herein, the parties hereby agree as follows:</font></p>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consulting Services</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </font></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	(a)	Subject to and upon the terms and conditions set forth in this Agreement, Consultant will perform the Services and deliver the Deliverables described in the statement of work set forth in Attachment A (the </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Statement of Work&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;SOW&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">). As used herein, </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Deliverables&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> means any work product, report, analysis, summaries, recommendations, or other deliverables described in any Statement of Work, including any work-in-process of any of the foregoing.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> 	</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consultant agrees to perform the Services and complete the Deliverables, if any, during the Term in accordance with any timeline as may be set forth in the applicable Statement of Work.  Consultant will provide the Services at such times and locations as are mutually agreed upon by Consultant and Company.  In rendering the Services, Consultant will act solely as an independent contractor and this Agreement does not constitute a contract of employment and will not be construed to create any employee/employer relationship between Consultant and Company.  The Consultant shall diligently perform the Services in a professional and competent manner in accordance with the terms of this Agreement, the attached Statement of Work, and all applicable rules, regulations and laws.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c) 	Consultant agrees not to make any use of any funds, space, personnel, facilities, equipment, employees or other resources of a third party, in performing the Services, nor to take any other action that would result in a third party having any rights in the Deliverables or results of the Services, as defined herein.  Without limiting the foregoing, Consultant agrees that she will not utilize in the performance of any Services or incorporate into any Deliverables or materials provided to Company; (i) any confidential information of Consultant or any third party; or (ii) any technology, materials, know-how or inventions, covered by proprietary rights of Consultant or any third party, except as Consultant is freely permitted to do without further compensation by Company to Consultant or any third party.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.	Compensation &amp; Indemnification</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:6pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company agrees to pay Consultant for the Services in accordance with the fee schedule of the Statement of Work.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:6pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Within fifteen (15) days following the end of each calendar month in which Consultant performs Services, Consultant will submit a statement showing, by date, the number of hours spent performing the Services, and the total amount due in payment. The consulting fees will be paid on a monthly basis, within thirty (30) days following receipt of a statement, unless agreed upon in a separate writing.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:6pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company will not withhold any employment related tax or social security payments due from Consultant to any governmental taxing authority (except as may be expressly required by law).  Consultant hereby agrees to timely pay all taxes and fees upon the income Consultant has earned from </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:6pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company and indemnify and hold Company harmless against the claims of any governmental taxing authority made in connection with the revenue derived by Consultant under this Agreement.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:6pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The parties represent (a) that the compensation set forth herein is consistent with fair market value in arms&#x2019; length and (b) the Services to be performed by the Consultant under this Agreement do not exceed those which are reasonably necessary to accomplish the commercially reasonable business purposes of such Services.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:6pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company hereby waives any and all claims against Consultant arising out of or in connection with the Services provided by Consultant to the Company or on its behalf, unless <br>resulting from Consultant&#x2019;s gross negligence or willful misconduct, and agrees to indemnify, defend and hold Consultant harmless from and against any and all threatened or actual claims, suits, <br>liabilities, damages, costs and expenses (including attorney&#x2019;s fees), brought by a third party, brought against or incurred by Consultant arising out of or in connection with such Services, provided (a) Consultant notifies the Company in writing promptly after becoming aware of any such claim or action, (b) Consultant cooperates reasonably with the Company (at its expense), in connection with such claim or action, and (c) the Company shall have sole control over the defense and/or settlement <br>thereof. Nothing in this provision 2(e) shall be construed to preclude or in any way limit any applicable indemnification coverage that may be available to the Consultant under any other Company issued indemnification, including indemnification granted to the Consultant in connection with her prior employment with the Company.</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Confidential Information.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:6pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For purposes of this Agreement, the term </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Confidential Information&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> means confidential and/or proprietary information or materials owned or controlled by, in the possession of, or licensed to Company. Without limiting the generality of the foregoing, the term Confidential Information includes all existing and future (i) intellectual property, works of authorship, inventions, discoveries, developments, improvements, modifications, trademarks, trade names, trade secrets, know-how, data, processes, methods, protocols, and procedures; and all rights in, to or under any of the foregoing; in each case, whether or not reduced to practice or writing, or protected or protectable (or registered or registrable) under patent, copyright, trademark, trade secret or any other similar laws (collectively, </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Intellectual Property&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">), that is owned or controlled by, in the possession of, or licensed to Company, or that is required to be assigned or licensed to Company by any person, (ii) information regarding Company&#x2019;s plans for research and development or for new products, (iii) manufacturing or engineering information pertaining to Company or any of its operations or products, (iv) information regarding regulatory, preclinical, or clinical matters pertaining to Company, (v) information regarding business, commercial, financial, budgetary, or Intellectual Property matters pertaining to Company, (vi) information regarding the skills, compensation and other terms of employment or engagement of employees and consultants of Company, (vii) any and all Deliverables, and (viii) any other information that Company may designate as confidential or proprietary.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:6pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Except as otherwise provided in this Section 3, during the Term and for a period of seven (7) years thereafter, Consultant will not disclose or communicate to any third party for any reason, any Confidential Information without the prior written consent of Company.  Notwithstanding anything to the contrary, it is understood that, except to the extent otherwise expressly prohibited by Company, (i) Consultant may disclose or use Confidential Information in performing the Services for Company but only to the extent required or necessary for the performance of such Services in the ordinary course and within the scope of provision of the Services, and (ii) Consultant may disclose Confidential Information pursuant to a request or order of any court or governmental agency, provided that Consultant promptly notifies Company of any such request or order and provides reasonable cooperation (at Company&#x2019;s expense) in the efforts, if any, of Company to contest or limit the scope of such request or order.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:6pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consultant&#x2019;s obligations under the Section 3 will not apply to any Confidential Information  (i) that is or becomes publicly known (as demonstrated by written evidence provided by Consultant) under </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:6pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">circumstances involving no breach by Consultant of this Agreement,  (ii) that was or is approved for release in writing by Company, or (iii) is independently developed by Consultant without reference to or reliance upon Confidential Information (and such independent development can be demonstrated by competent evidence).</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:6pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consultant will promptly deliver to Company, upon the termination of this Agreement or, if earlier, upon the request of Company, all documents and other tangible media in Consultant&#x2019;s possession or control that contain, reflect, disclose or relate to any Confidential Information.  </font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intellectual Property.  </font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:6pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consultant agrees to and hereby does assign to Company, Consultant&#x2019;s entire right, title and interest in and to all Intellectual Property made, written or conceived by Consultant, jointly or with others, in the performance of Services hereunder, together with such patents or patent applications and copyrights, as may be obtained or filed in any country. All copyrightable works created by Consultant in connection with the Services will be considered &#x201c;work for hire&#x201d; owned by Company to the greatest extent permitted by law. At the request and sole expense of Company, at any time during the term of the Agreement or after the termination or expiration of the Agreement, Consultant will execute all documents for use in applying for, obtaining and maintaining such patents, trademark or copyrights as Company may desire, and execute and deliver all formal assignments for such Intellectual Property. Consultant will promptly and fully disclose to Company any Intellectual Property arising from Consultant&#x2019;s performance of Services under this Agreement.  For the avoidance of any doubt, as between the parties, Company will have the exclusive right to use or not use the Intellectual Property for any or no reason, in its sole discretion.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:6pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consultant acknowledges and agrees that Company owns and will continue to own all right, title and interest in and to Confidential Information and Deliverables.  Unless expressly provided in this Agreement, no licenses, implied or otherwise, are granted to Consultant hereunder in or to the Deliverables or Company Intellectual Property.  </font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:6pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> All existing templates, databases, models and any additional databases, models, and/or associated data owned or controlled by Consultant and not directly related to the mission of Company will remain the property of Consultant. Consultant will also retain all copyright and intellectual property rights to such materials. Unless specifically agreed upon in writing, Company will not acquire and will have no ongoing rights in or licenses to any of Consultant&#x2019;s existing proprietary templates, databases, or models and/or any modifications made to such templates, databases, or models </font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Conflicting Obligations. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consultant hereby represents that he or she is free to enter into this Agreement and that Consultant&#x2019;s performance of all of the terms of this Agreement and of all of Consultant&#x2019;s duties as a consultant to Company do not and will not breach (i) any agreement to keep in confidence information acquired by Consultant in confidence or in trust, or (ii) any agreement not to compete against the business of any third party.  Consultant further represents that he or she has not made and will not make any agreements in conflict with this Agreement. The Consultant represents and warrants that he/she has not been debarred under the provisions of the Generic Drug Enforcement Act of 1992, 21 U.S.C. Sec. 335a, and that he/she is not under investigation by any governmental agency.  In the event that the Consultant becomes so debarred or comes under an investigation by a governmental agency that would impair his/her ability to properly perform his/her obligations under this Agreement, the Consultant will immediately notify the Company in writing.</font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">6.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Use of Name. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Neither party will use the name of the other party without prior consent; provided, however, that either party may use the name of the other party to the extent reasonably required in or for the performance of the Services. </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">7.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Return of Company Documents.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  Upon expiration or termination of this Agreement, Consultant will deliver to Company any and all notes, memoranda, specifications, drawings, devices, formulas, and documents, together with all copies thereof, and any other material containing or disclosing any Confidential Information or Company Intellectual Property. </font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">8.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Term.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:6pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Agreement shall take effect as of the Effective Date and continue thereafter in full force and effect until August 31, 2025, unless extended by mutual agreement in writing, or until terminated in accordance with the provisions of Section 8(b) hereof (the </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Term&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">).  </font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:6pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Agreement and the Services provided by Consultant hereunder may be terminated at any time by either Consultant or Company for any reason or no reason. No prior notice of termination is required. </font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:6pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The provisions of Sections 4-7, 8(c) and 9 shall survive the termination of this Agreement.</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">9.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Miscellaneous.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:6pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Agreement, along with Attachment A, represents the entire Agreement of the parties with respect to the consulting arrangements contemplated hereby, and supersedes all prior agreements, except those agreements specifically relating to the Consultant&#x2019;s employment relationship with the Company which were entered into prior to the date of this Agreement, including the Employee Non-Disclosure, Non-Solicitation and Non-Competition Agreement executed  as of March 20, 2019.  No prior agreement, whether written or oral, shall be construed to change, amend, alter, repeal or invalidate this Agreement.  This Agreement may be amended only by a written instrument executed in one or more counterparts by the parties.  </font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:6pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No consent to or waiver of any breach or default in the performance of any obligations hereunder shall be deemed or construed to be a consent to or waiver of any other breach or default in the performance of any of the same or any other obligations hereunder.  Failure on the part of either party to complain of any act or failure to act of the other party or to declare the other party in default, irrespective of the duration of such failure, shall not constitute a waiver of rights hereunder and no waiver hereunder shall be effective unless it is in writing, executed by the party waiving the breach or default hereunder.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:6pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Agreement may be assigned by Company to any affiliate of Company and to a successor of its business to which this Agreement relates (whether by purchase or otherwise). </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consultant may assign or transfer any or all of Consultant&#x2019;s rights or obligations under this Agreement only upon Company&#x2019;s prior written consent. This Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective successors and permitted assigns.  </font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:6pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unless otherwise provided herein, any notice, report, payment or document to be given by one party to the other shall be in writing and addressed to the party at the address set forth in the preamble to such other place as any party may designate as to itself by written notice to the other party.  Delivery will be deemed given when such notice is delivered in-person, or by certified or registered mail, or by nationally recognized overnight courier.  Either party may change its address for notices by means of a notice delivered in accordance with this Section 9(d).</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:6pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Agreement shall be governed by and construed in accordance with the substantive laws of British Columbia without reference to any choice or conflict of laws rule or provision that would result in the application of the substantive law of any other jurisdiction.  </font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:6pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(f)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section headings of this Agreement are for reference only and shall not affect its interpretation.  In the event that any provision of this Agreement should be held unenforceable by a court of competent jurisdiction, such court is hereby authorized to amend such provision so as to be enforceable to the fullest extent permitted by law, and all remaining provisions shall continue in full force without being impaired or invalidated in any way.</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:6pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(g)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The parties agree that any breach of this Agreement by Consultant would cause irreparable harm to Company; and that money damages will not provide an adequate remedy.  In the event of a breach or threatened breach of this Agreement by Consultant, Company will, in addition to any other rights and remedies it may have, have the right to seek an injunction without the need to post bond.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:6pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(h)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In performing Consultant&#x2019;s obligations and services under this Agreement, </font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consultant</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> will be an independent contractor and will not represent himself or herself as an agent of the Company. Nothing in this Agreement will be construed to constitute either party as the agent, employee or joint venture partner of the other, nor will either party have the right to bind the other party or make any promises or representations on behalf of the other party. Consultant will be solely responsible for the withholding and payment of social security and other applicable taxes, fees, and/or withholding on payments made to him or her by the Company as described herein and he or she will not be eligible for, and will have no claim against the Company for, fringe benefits, vacation pay, sick leave, retirement benefits, social security, worker&#x2019;s compensation, disability, unemployment insurance benefits, or any other benefit the Company may provide to its employees.</font></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[SIGNATURE PAGE FOLLOWS]</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IN WITNESS WHEREOF,</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> the parties have signed this Consulting Agreement as of the Effective Date, intending it to take effect as a sealed instrument.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:50%;box-sizing:content-box;"></td>
    <td style="width:50%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:29.5pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;padding-right:0.075in;text-align:right;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Sherry Aulin</font></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;padding-right:0.075in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Xenon Pharmaceuticals INC.</font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:32.4pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">By: /s/ Sherry Aulin</font></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">By: </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">/s/ Ian Mortimer</font></p></td>
   </tr>
   <tr style="height:29.5pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Date: 27-Feb-2025</font></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name: Ian Mortimer</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:29.5pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Email:</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Title: CEO</font></p></td>
   </tr>
   <tr style="height:29.5pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Date: 27-Feb-2025</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ATTACHMENT A</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">STATEMENT OF WORK</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-19
<SEQUENCE>7
<FILENAME>xene-ex19.htm
<DESCRIPTION>EX-19
<TEXT>
<html>
 <head>
  <title>EX-19</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="z-index:-3;min-height:1in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 19</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">XENON PHARMACEUTICALS INC.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INSIDER TRADING POLICY</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Guidelines with Respect to</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain Transactions in Securities</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.65in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TABLE OF CONTENTS</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:4.167%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Page</font></p>
  <table style="border-spacing:0;table-layout:auto;width:92.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:12.08%;box-sizing:content-box;"></td>
    <td style="width:84.56%;box-sizing:content-box;"></td>
    <td style="width:3.36%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:11pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:36pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-7.143%;padding-left:6.667%;font-size:11pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">I.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">INTRODUCTION</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</font></p></td>
   </tr>
   <tr style="height:11pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:54pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">A.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">Persons Covered by this Policy</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</font></p></td>
   </tr>
   <tr style="height:11pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:54pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">B.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">Legal Prohibitions on Insider Trading</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</font></p></td>
   </tr>
   <tr style="height:11pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:54pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">C.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">Detection and Prosecution of Insider Trading</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</font></p></td>
   </tr>
   <tr style="height:11pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:54pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">D.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">Penalties for Violation of Insider Trading Laws and this Policy</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</font></p></td>
   </tr>
   <tr style="height:11pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:54pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">E.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">Compliance Officer</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</font></p></td>
   </tr>
   <tr style="height:11pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:54pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">F.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">Reporting Violations</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</font></p></td>
   </tr>
   <tr style="height:11pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:54pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">G.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">Personal Responsibility</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</font></p></td>
   </tr>
   <tr style="height:11pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:36pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-7.143%;padding-left:6.667%;font-size:11pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">II.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">TRANSACTIONS COVERED BY THIS POLICY</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</font></p></td>
   </tr>
   <tr style="height:11pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:54pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">A.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">Types of Transactions Covered by this Policy</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</font></p></td>
   </tr>
   <tr style="height:11pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:54pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">B.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">Responsibilities Regarding the Nonpublic Information of Other Companies</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</font></p></td>
   </tr>
   <tr style="height:11pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:54pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">C.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">Applicability of this Policy After Your Departure</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</font></p></td>
   </tr>
   <tr style="height:11pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:54pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">D.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">No Exceptions Based on Personal Circumstances</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</font></p></td>
   </tr>
   <tr style="height:11pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:36pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-7.143%;padding-left:6.667%;font-size:11pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">III.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">MATERIAL NONPUBLIC INFORMATION</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</font></p></td>
   </tr>
   <tr style="height:11pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:54pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">A.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">&#x201c;Material&#x201d; Information</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</font></p></td>
   </tr>
   <tr style="height:11pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:54pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">B.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">&#x201c;Nonpublic&#x201d; Information</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</font></p></td>
   </tr>
   <tr style="height:11pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:36pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-7.143%;padding-left:6.667%;font-size:11pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">IV.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">POLICIES REGARDING MATERIAL NONPUBLIC INFORMATION</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6</font></p></td>
   </tr>
   <tr style="height:11pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:54pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">A.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">Confidentiality of Nonpublic Information</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6</font></p></td>
   </tr>
   <tr style="height:11pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:54pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">B.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">No Trading on Material Nonpublic Information</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6</font></p></td>
   </tr>
   <tr style="height:11pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:54pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">C.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">No Disclosing Material Nonpublic Information for the Benefit of Others</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6</font></p></td>
   </tr>
   <tr style="height:11pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:54pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">D.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">Obligation to Disclose Material Nonpublic Information to the Company</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</font></p></td>
   </tr>
   <tr style="height:11pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:54pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">E.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">Responding to Outside Inquiries for Information</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</font></p></td>
   </tr>
   <tr style="height:11pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:36pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-7.143%;padding-left:6.667%;font-size:11pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">V.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">TRADING BLACKOUT PERIODS</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</font></p></td>
   </tr>
   <tr style="height:11pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:54pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">A.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">Quarterly Blackout Periods</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</font></p></td>
   </tr>
   <tr style="height:11pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:54pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">B.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">Special Blackout Periods</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8</font></p></td>
   </tr>
   <tr style="height:11pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:54pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">C.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">No &#x201c;Safe Harbors&#x201d;</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8</font></p></td>
   </tr>
   <tr style="height:11pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:36pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-7.143%;padding-left:6.667%;font-size:11pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">VI.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">PRE-CLEARANCE OF TRADES</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8</font></p></td>
   </tr>
   <tr style="height:11pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:36pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-7.143%;padding-left:6.667%;font-size:11pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">VII.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">ADDITIONAL RESTRICTIONS AND GUIDANCE</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9</font></p></td>
   </tr>
   <tr style="height:11pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:54pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">A.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">Short Sales</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9</font></p></td>
   </tr>
   <tr style="height:11pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:54pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">B.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">Derivative Securities and Hedging Transactions</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9</font></p></td>
   </tr>
   <tr style="height:11pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:54pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">C.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">Using Company Securities as Collateral for Loans</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</font></p></td>
   </tr>
   <tr style="height:11pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:54pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">D.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">Holding Company Securities in Margin Accounts</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</font></p></td>
   </tr>
   <tr style="height:11pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:54pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">E.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">Placing Open Orders with Brokers</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</font></p></td>
   </tr>
   <tr style="height:11pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:36pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-7.143%;padding-left:6.667%;font-size:11pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">VIII.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">LIMITED EXCEPTIONS</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</font></p></td>
   </tr>
   <tr style="height:11pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:54pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">A.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">Transactions Pursuant to a Trading Plan that Complies with SEC Rules and applicable Canadian securities laws</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11</font></p></td>
   </tr>
   <tr style="height:11pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:54pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">B.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">Receipt and Vesting of Stock Options, Restricted Share Units, Restricted Shares and Share Appreciation Rights</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12</font></p></td>
   </tr>
   <tr style="height:11pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:54pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">C.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">Exercise of Stock Options for Cash</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12</font></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">i</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <table style="border-spacing:0;table-layout:auto;width:92.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:12.08%;box-sizing:content-box;"></td>
    <td style="width:84.56%;box-sizing:content-box;"></td>
    <td style="width:3.36%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:11pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:54pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">D.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">Purchases from the Employee Stock Purchase Plan</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12</font></p></td>
   </tr>
   <tr style="height:11pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:54pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">E.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">Share Splits, Share Dividends and Similar Transactions</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12</font></p></td>
   </tr>
   <tr style="height:11pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:54pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">F.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">Inheritance and Change in Form of Ownership</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12</font></p></td>
   </tr>
   <tr style="height:11pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:54pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">G.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">Other Exceptions</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12</font></p></td>
   </tr>
   <tr style="height:11pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:36pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-7.143%;padding-left:6.667%;font-size:11pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">IX.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">INSIDER TRADING REPORTING; COMPLIANCE WITH SECTION 16 OF THE EXCHANGE ACT AND NI 55-104</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13</font></p></td>
   </tr>
   <tr style="height:11pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:54pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">A.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">Obligations Under Section 16 and NI 55-104</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13</font></p></td>
   </tr>
   <tr style="height:11pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:54pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">B.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">Notification Requirements to Facilitate Reporting Requirements</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13</font></p></td>
   </tr>
   <tr style="height:11pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:54pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">C.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">Personal Responsibility</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13</font></p></td>
   </tr>
   <tr style="height:11pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:36pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-7.143%;padding-left:6.667%;font-size:11pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">ADDITIONAL INFORMATION</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14</font></p></td>
   </tr>
   <tr style="height:11pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:54pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">A.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">Availability of Policy</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14</font></p></td>
   </tr>
   <tr style="height:11pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:54pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">B.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">Amendments</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14</font></p></td>
   </tr>
   <tr style="height:11pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:54pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">C.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">Ancillary Documents</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SCHEDULE A (Requirements for Trading Plans)</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ii</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INTRODUCTION</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Xenon Pharmaceuticals Inc. (together with its subsidiaries, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) prohibits the unauthorized disclosure of any nonpublic information acquired in the course of your service with the Company and the misuse of material nonpublic information in securities trading. Any such actions will be deemed violations of this Insider Trading Policy (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Policy</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">A.	Persons Covered by this Policy</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Policy applies to all directors, officers, employees, consultants, contractors and advisors of the Company. References in this Policy to &#x201c;you&#x201d; (as well as general references to directors, officers, employees, consultants, contractors and advisors of the Company) should also be understood to include members of your immediate family (your spouse, partner, parents and minor children, no matter where they live), persons with whom you share a household, persons that are your economic dependents and any other individuals or entities (including, without limitation, any partnerships, trusts, corporations, RRSPs and similar entities) whose transactions in securities you influence, direct or control (including, for example, a venture or other investment fund, if you influence, direct or control transactions by the fund). You are responsible for making sure that these other individuals and entities comply with this Policy.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">B.	Legal Prohibitions on Insider Trading</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Provisions of U.S. federal securities laws, Canadian provincial securities laws and Canadian federal criminal laws and other applicable laws prohibit directors, officers, employees, consultants and other individuals who possess material nonpublic information from trading on the basis of that information. Transactions will be considered &#x201c;on the basis of&#x201d; material nonpublic information if the person who engaged in the transaction was in possession of the material nonpublic information at the time of the transaction. It is not a defense that the person did not &#x201c;use&#x201d; the information for purposes of the transaction.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disclosing material nonpublic information directly or indirectly to others who then trade based on that information, or making recommendations or expressing opinions as to transactions in securities while in possession of material nonpublic information (which is sometimes referred to as &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">tipping</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), is illegal. Further, recommending or encouraging a third party to purchase or sell securities while in possession of material nonpublic information (which is sometimes referred to as &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">recommending</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) is also illegal. Both the person who provides the information, recommendation or opinion, and the person who trades based on it, may be liable for tipping or recommending, as the case may be.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These illegal activities are commonly referred to as &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">insider trading</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;. State securities laws and securities laws of other jurisdictions also impose restrictions on insider trading.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, a company, as well as individual directors, officers and other supervisory personnel, may be subject to liability as &#x201c;controlling persons&#x201d; for failure to take appropriate steps to prevent insider trading by those under their supervision, influence or control.</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">C.	Detection and Prosecution of Insider Trading</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The U.S. Securities and Exchange Commission (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SEC</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), the Canadian securities regulators, the Financial Industry Regulatory Authority and The Nasdaq Stock Market use sophisticated electronic surveillance techniques to investigate and detect insider trading, and the SEC, Canadian securities regulators, the U.S. Department of Justice and the Canadian law enforcement agencies pursue insider trading violations vigorously. Cases involving trading through foreign accounts, trading by family members</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Page </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</font><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and friends, controlling person liability and trading involving only a small number of shares have all been successfully prosecuted.</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">D.	Penalties for Violation of Insider Trading Laws and this Policy</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Civil and criminal penalties</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Potential penalties for insider trading violations under applicable U.S. and Canadian securities laws include:</font></p>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.	damages in a private lawsuit;</font></p>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.	disgorging any profits made or losses avoided;</font></p>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.	imprisonment;</font></p>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4.	substantial criminal fines;</font></p>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.	substantial civil fines based on the profit gained or loss avoided;</font></p>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6.	a bar against serving as an officer or director of a public company;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7.	a bar against acting as or becoming a registrant who seeks to sell securities, offer investment advice or manage an investment fund;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8.	trading bans; and</font></p>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9.	an injunction against future violations.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Civil and criminal penalties also apply to tipping and recommending, as applicable. Large penalties have also been imposed in tipping and recommending cases even when the disclosing person did not trade or gain any benefit from another person&#x2019;s trading.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">No speculation.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> If you are found to contravene applicable Canadian laws prohibiting speculative trading in the Company&#x2019;s securities, you may be found liable under Canadian criminal law on a summary conviction to a fine not exceeding the greater of one million Canadian dollars and three times the profit made, or to imprisonment for a term not exceeding six months, or to both.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Controlling person liability</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Insider trading can also expose companies and individual directors, officers, other supervisory personnel and anyone with power to influence or control another person to &#x201c;controlling person liability&#x201d; under the U.S. securities laws. The Company may have &#x201c;controlling person&#x201d; liability for a trading violation, with attendant civil and criminal penalties, if the controlling person knew or recklessly disregarded the fact that the controlled person was likely to engage in the illegal transaction and failed to take appropriate steps to prevent the act. The controlling person avoids private, civil penalties for another&#x2019;s illegal trade if the controlling person establishes that he or she acted in good faith and did not induce the inside trade.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Company disciplinary actions</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. If the Company has a reasonable basis to conclude that you have failed to comply with this Policy, you may be subject to disciplinary action by the Company, up to and including dismissal for cause, regardless of whether or not your failure to comply with this Policy results in a violation of law. It is not necessary for the Company to wait for the filing or conclusion of any civil or criminal action against an alleged violator before taking disciplinary action. In addition, the Company may</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Page </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</font><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">give stop transfer and other instructions to the Company&#x2019;s transfer agent to enforce compliance with this Policy and/or notify the relevant authorities.</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">E.	Compliance Officer</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Please direct any questions, requests or reports as to any of the matters discussed in this Policy to the Company&#x2019;s Insider Trading Compliance Officer, who is the Company&#x2019;s Chief Financial Officer (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CFO</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). The CFO is generally responsible for the administration of this Policy. The CFO may select others to assist with the execution of his or her duties, including but not limited to the Company&#x2019;s Chief Legal Officer (CLO). The CFO will review and either approve or prohibit all proposed trades by individuals as designated from time to time by the CFO and/or CLO as being subject to quarterly blackouts or the pre-clearance process in accordance with the procedures set forth herein.</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">F.	Reporting Violations</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It is your responsibility to help enforce this Policy. You should be alert to possible violations and promptly report violations or suspected violations of this Policy to either the CFO or the CLO. If your situation requires that your identity be kept secret, your anonymity will be preserved to the greatest extent reasonably possible. If you wish to remain anonymous, you may use the forums set forth in Section B of the Company&#x2019;s Non-Retaliation Policy (Policy Regarding Reporting of Accounting, Auditing and Code of Conduct Matters). If you make an anonymous report, please provide as much detail as possible, including any evidence that you believe may be relevant to the issue.</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">G.	Personal Responsibility</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The ultimate responsibility for complying with this Policy and applicable laws and regulations rests with you. You should use your best judgment at all times and consult with your legal and financial advisors, as needed. You should seek assistance if you have any questions at all. The rules relating to insider trading can be complex, and a violation of insider trading laws can carry severe consequences.</font></p>
  <p style="font-size:10pt;margin-top:24pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">II.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TRANSACTIONS COVERED BY THIS POLICY</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">A.	Types of Transactions Covered by this Policy</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Except as discussed in the section entitled &#x201c;Limited Exceptions&#x201d;, this Policy applies to </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">all</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> transactions </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">involving</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> the securities of the Company or the securities of other companies as to which you possess material nonpublic information obtained in the course of your service with the Company. This Policy therefore applies to purchases, sales, dispositions in the form of a gift, distributions to holders of interests in an entity if the entity is subject to this Policy and other transfers of common shares, options, warrants, preferred shares, debt securities (such as debentures, bonds and notes) and other securities. This Policy also applies to any arrangements that affect economic exposure to changes in the prices of these securities. These arrangements may include, among other things, transactions in derivative securities (such as exchange-traded put or call options), speculating, hedging transactions, short sales and certain decisions with respect to participation in benefit plans (and, for greater certainty, any associated sale of securities to fund tax obligations). This Policy also applies to any offers with respect to the transactions discussed above. You should note that there are no exceptions from insider trading laws or this Policy based on the size of the transaction.</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">B.	Responsibilities Regarding the Nonpublic Information of Other Companies</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Page </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</font><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Policy prohibits the unauthorized disclosure or other misuse of any nonpublic information of other companies with which the Company has a business relationship, such as the Company&#x2019;s collaborators, distributors, vendors, customers, suppliers and competitors or such companies with which the Company may be negotiating major transactions, such as an acquisition, investment or sale. This Policy also prohibits insider trading, tipping or recommending based on the material nonpublic information of other companies.</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">C.	Applicability of this Policy After Your Departure</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You are expected to comply with this Policy until such time as you are no longer affiliated with the Company </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">and</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> you no longer possess any material nonpublic information subject to this Policy. In addition, if you are subject to a trading blackout under this Policy at the time you cease to be affiliated with the Company, you are expected to abide by the applicable trading restrictions until at least the end of the relevant blackout period.</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">D.	No Exceptions Based on Personal Circumstances</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There may be instances where you suffer financial harm or other hardship or are otherwise required to forgo a planned transaction because of the restrictions imposed by this Policy. Personal financial emergency or other personal circumstances are not mitigating factors under securities laws and will not excuse a failure to comply with this Policy.</font></p>
  <p style="font-size:10pt;margin-top:24pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">III.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">MATERIAL NONPUBLIC INFORMATION</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">A.	&#x201c;Material&#x201d; Information</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Information should be regarded as material if there is a substantial likelihood that a reasonable investor would consider it important in deciding whether to buy, hold or sell securities or would view the information as significantly altering the total mix of information in the marketplace about the issuer of the security. In general, any information that could reasonably be expected to affect the market price of a security is likely to be material. Either positive or negative information may be material.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It is not possible to define all categories of &#x201c;material&#x201d; information. However, some examples of information that would often be regarded as material include information with respect to:</font></p>
  <p style="margin-left:6.667%;text-indent:-5.66%;padding-left:5%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.	financial results, financial condition, earnings pre-announcements, guidance, projections or forecasts, particularly if inconsistent with the Company&#x2019;s guidance or the expectations of the investment community;</font></p>
  <p style="margin-left:6.667%;text-indent:-5.66%;padding-left:5%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.	restatements of financial results, or material impairments, write-offs or restructurings;</font></p>
  <p style="margin-left:6.667%;text-indent:-5.66%;padding-left:5%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.	changes in independent auditors, or notification that the Company may no longer rely on an audit report;</font></p>
  <p style="margin-left:6.667%;text-indent:-5.66%;padding-left:5%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4.	business plans or budgets;</font></p>
  <p style="margin-left:6.667%;text-indent:-5.66%;padding-left:5%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.	creation of significant financial obligations, or any significant default under or acceleration of any financial obligation;</font></p>
  <p style="margin-left:6.667%;text-indent:-5.66%;padding-left:5%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6.	impending bankruptcy or financial liquidity problems;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Page </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</font><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:6.667%;text-indent:-5.66%;padding-left:5%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7.	significant developments involving business relationships, including execution, modification or termination of significant agreements or orders with customers, suppliers, distributors, manufacturers or other business partners;</font></p>
  <p style="margin-left:6.667%;text-indent:-5.66%;padding-left:5%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8.	product introductions, modifications, defects or recalls or significant pricing changes or other product announcements of a significant nature;</font></p>
  <p style="margin-left:6.667%;text-indent:-5.66%;padding-left:5%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9.	significant developments relating to research and development, the Company&#x2019;s clinical studies (including, without limitation, the status and results of such studies and communications with regulatory agencies), or intellectual property;</font></p>
  <p style="margin-left:6.667%;text-indent:-5.66%;padding-left:5%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10.	significant legal or regulatory developments, whether positive or negative, actual or threatened, including with respect to litigation;</font></p>
  <p style="margin-left:6.667%;text-indent:-5.66%;padding-left:5%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11.	major events involving the Company&#x2019;s securities, including calls of securities for redemption, adoption of share repurchase programs, option repricings, stock splits, changes in dividend policies, public or private securities offerings, modification to the rights of security holders or notice of delisting;</font></p>
  <p style="margin-left:6.667%;text-indent:-5.66%;padding-left:5%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12.	significant corporate events, such as a pending or proposed merger, licensing transaction, joint venture or tender offer, a significant investment, the acquisition or disposition of a significant business or asset or a change in control of the Company;</font></p>
  <p style="margin-left:6.667%;text-indent:-5.66%;padding-left:5%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13.	significant data breaches or other cybersecurity events;</font></p>
  <p style="margin-left:6.667%;text-indent:-5.66%;padding-left:5%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14.	updates regarding any prior material disclosure that has materially changed;</font></p>
  <p style="margin-left:6.667%;text-indent:-5.66%;padding-left:5%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15.	the existence of a special blackout period; and</font></p>
  <p style="margin-left:6.667%;text-indent:-5.66%;padding-left:5%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16.	major personnel changes, such as changes in Board composition or senior management or lay-offs.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It is important to note that &#x201c;materiality&#x201d; is different for different companies. Information that is not material to the Company may be material to another company and vice versa. If you have any questions as to whether information should be considered &#x201c;material,&#x201d; you should consult with the CFO. In general, it is advisable to resolve any questions as to the materiality of any information by assuming that the information is material.</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">B.	&#x201c;Nonpublic&#x201d; Information</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Information is considered nonpublic if the information has not been broadly disseminated to the public for a sufficient period to be reflected in the price of the security. Information that is widely known within the Company may still be considered nonpublic for purposes of this Policy. As a general rule, information should be considered nonpublic until at least one full trading day has elapsed after the information is broadly disseminated to the public. Information can be broadly disseminated to the public in a number of ways, including in a press release, a public filing with the SEC or with applicable Canadian securities regulators, a pre-announced, public webcast or another broad, non-exclusionary form of public communication. However, depending upon the form of the announcement and the nature of the information, it is possible that information may be fully absorbed by the marketplace in varying lengths of time. Any questions as to whether information is nonpublic should be directed to the CFO.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Page </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</font><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The term &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">trading day</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a day on which the national stock exchange on which the Company&#x2019;s securities are then publicly traded is open for trading. A &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">full</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; trading day has elapsed when, after the public disclosure, trading in the relevant security has opened and then closed.</font></p>
  <p style="font-size:10pt;margin-top:24pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IV.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">POLICIES REGARDING MATERIAL NONPUBLIC INFORMATION</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">A.	Confidentiality of Nonpublic Information</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Except as discussed in the section entitled &#x201c;Limited Exceptions,&#x201d; the unauthorized use or disclosure of nonpublic information, material or not, relating to the Company or other companies is prohibited. All nonpublic information you acquire in the course of your service with the Company may only be used for legitimate Company business purposes. In addition, nonpublic information of others should be handled in accordance with the terms of any relevant nondisclosure agreements and any applicable common law principles, and the use of any such nonpublic information should be limited to the purpose for which it was disclosed.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You must use all reasonable efforts to safeguard nonpublic information in the Company&#x2019;s possession. You may not disclose nonpublic information about the Company or any other company unless required by law or unless (i) disclosure is required for legitimate Company business purposes, (ii) you are authorized to disclose the information and (iii) appropriate steps have been taken to prevent misuse of that information (for example, entering into an appropriate nondisclosure agreement that restricts the disclosure and use of the information, if applicable). This restriction also applies to internal communications within the Company and to communications with agents of the Company. In cases where disclosing nonpublic information to third parties is necessary, you should coordinate with the Chief Legal Officer.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, all officers, employees, consultants, contractors and advisors of the Company are required to sign and comply with any employment, confidential information invention assignment and/or arbitration agreement(s) with the Company to which they are subject.</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">B.	No Trading on Material Nonpublic Information</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Except as discussed in the section entitled &#x201c;Limited Exceptions&#x201d;, you may not, directly or indirectly through others, engage in any transaction involving the Company&#x2019;s securities </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">while in possession of</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> material nonpublic information relating to the Company. It is not an excuse that you did not &#x201c;use&#x201d; the information in your transaction.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Similarly, you may not engage in transactions involving the securities of any other company if you are in possession of nonpublic information that may be material to such other company (except to the extent the transactions are analogous to those presented in the section entitled &#x201c;Limited Exceptions&#x201d;). For example, you may be involved in a proposed transaction involving a prospective business relationship or transaction with another company. If information about that transaction constitutes material nonpublic information for that other company, you would be prohibited from engaging in transactions involving the securities of that other company (as well as transactions involving Company securities, if that information is material to the Company).</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">C.	No Disclosing Material Nonpublic Information for the Benefit of Others</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You may not disclose material nonpublic information concerning the Company or any other company, whether the information is based on fact or speculation, to friends, family members or any other person or entity not authorized to receive such information. In addition, you may not make</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Page </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</font><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">recommendations or express opinions on the basis of material nonpublic information as to trading in the securities of companies to which such information relates. You are prohibited from engaging in these actions whether or not you derive any profit or personal benefit from doing so. This prohibition against disclosure of material nonpublic information includes disclosure (even anonymous disclosure) via the internet, blogs, investor forums or chat rooms where companies and their prospects are discussed.</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">D.	Obligation to Disclose Material Nonpublic Information to the Company</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You must disclose any material nonpublic information that you are in possession of when requesting permission to engage in a transaction involving the Company&#x2019;s securities, including those discussed in the section entitled &#x201c;Limited Exceptions&#x201d;. If you are a member of senior management, the information must be disclosed to the Chief Executive Officer or CFO, and if you are the Chair of the Board of Directors, Chief Executive Officer, CFO or a director, you must disclose the information to the Board of Directors, before requesting permission to engage in any transaction related to the Company&#x2019;s securities.</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">E.	Responding to Outside Inquiries for Information</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the event you receive an inquiry for information from someone outside of the Company, such as a stock analyst, you should refer the inquiry to the CFO. The Company is required under Regulation FD (Fair Disclosure) of the U.S. federal securities laws and applicable Canadian securities laws to avoid the selective disclosure of material nonpublic information. In general, when a public company discloses material nonpublic information, it must provide broad, non-exclusionary access to the information. Violations of this requirement can subject the Company to enforcement actions by the SEC and Canadian securities regulators, which may result in injunctions and severe monetary penalties. The Company has established procedures for releasing material information in a manner that is designed to achieve broad public dissemination of the information immediately upon its release in compliance with applicable law. Please consult the Company&#x2019;s External Communications Policy for more details.</font></p>
  <p style="font-size:10pt;margin-top:24pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">V.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TRADING BLACKOUT PERIODS</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To limit the likelihood of trading at times when there is a significant risk of insider trading exposure, the Company has instituted quarterly trading blackout periods and may institute special trading blackout periods from time to time.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It is important to note that whether or not you are subject to blackout periods, you remain subject to the prohibitions on trading on the basis of material nonpublic information and any other applicable restrictions in this Policy. It is your responsibility to know if you are subject to any trading blackout prior to trading in the Company&#x2019;s securities. You can do so by reviewing your email and/or confirming with the CFO.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">   </font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">A.	Quarterly Blackout Periods</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Except as discussed in the section entitled &#x201c;Limited Exceptions,&#x201d; all directors and officers, and specified other employees, consultants, contractors and advisors identified by the Company from time to time, must refrain from conducting transactions involving the Company&#x2019;s securities during quarterly blackout periods. Even if you are not specifically identified as being subject to quarterly blackout periods, you should exercise caution when engaging in transactions during quarterly blackout periods because of the heightened risk of insider trading exposure.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Page </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</font><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Quarterly blackout periods begin at the end of the last day of each fiscal quarter and end at the close of business on the first full trading day following the public disclosure of the financial results for that fiscal quarter. This period is a particularly sensitive time for transactions involving the Company&#x2019;s securities from the perspective of compliance with applicable securities laws due to the fact that, during this period, individuals often possess or have access to material nonpublic information relevant to the expected financial results for the quarter.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Individuals subject to quarterly blackout periods are as designated from time to time by the CEO, the CFO or the CLO.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">B.	Special Blackout Periods</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, the Company may also prohibit directors, officers, employees, consultants, contractors and advisors from engaging in transactions involving the Company&#x2019;s securities when, in the judgment of the CFO, CLO or the Board of Directors, a trading blackout is warranted. The Company will generally impose special blackout periods when there are material developments known to the Company that have not yet been disclosed to the public. For example, the Company may impose a special blackout period in anticipation of announcing interim earnings guidance or a significant transaction or business development. However, special blackout periods may be declared for any reason.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company will notify those persons subject to a special blackout period via email. No person who has been so identified and notified by the Company may engage in any transaction involving the Company&#x2019;s securities until instructed otherwise by the CFO or CLO, and should not disclose to others, within or outside the Company, the imposition of the special blackout period.</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">C.	No &#x201c;Safe Harbors&#x201d;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are no unconditional &#x201c;safe harbors&#x201d; for trades made at particular times, and all persons subject to this Policy should exercise good judgment at all times. Even when a quarterly or special blackout period is not in effect, you may be prohibited from engaging in transactions involving the Company&#x2019;s securities because you possess material nonpublic information or are otherwise restricted from trading under this Policy.</font></p>
  <p style="font-size:10pt;margin-top:24pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">VI.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PRE-CLEARANCE OF TRADES</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Except as discussed in the section entitled &#x201c;Limited Exceptions&#x201d;, directors and officers should refrain from engaging in any transaction involving the Company&#x2019;s securities without first obtaining pre-clearance of the transaction from the CFO. In addition, the Company has determined that certain other employees, consultants, contractors and advisors of the Company who may have regular or special access to material nonpublic information should refrain from engaging in any transaction involving the Company&#x2019;s securities without first obtaining pre-clearance of the transaction from the CFO. The CFO may not engage in a transaction involving the Company&#x2019;s securities unless the Chief Executive Officer, Chair of the Board, Chair of the Audit Committee or their respective delegate has pre-cleared the transaction. Individuals subject to pre-clearance requirements are as designated from time to time by the CFO or CLO.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If you are subject to pre-clearance requirements, notification is required not only for trades by yourself but also for any proposed trades by any other person or entity if you have control or direction over such Company securities (for example, if you have the authority to direct the sale or acquisition of Company securities by a personal holding company, spouse, partner or minor child).</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Page </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</font><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The pre-clearance request must be made on the form provided by the CFO. Approval of any transaction involving the Company&#x2019;s securities will be provided in writing (in hard copy or electronically). Any approval granted with respect to a proposed transaction will be valid for a period of five full trading days, or such other period as set forth in the approval, unless revoked prior to that time. Should you, at any time prior to effecting your trade (but after pre-clearance has been granted), come into possession of any material nonpublic information or believe that you have come into possession of information that may constitute material nonpublic information, you cannot trade and must consult with the CFO as soon as possible regarding this information, and the pre-clearance process must be completed again in light of this new information before you may make the requested trade.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These pre-clearance procedures are intended to decrease insider trading risks associated with transactions by individuals with regular or special access to material nonpublic information. In addition, requiring pre-clearance of transactions by directors and officers facilitates compliance with Rule 144 resale restrictions under the Securities Act of 1933, as amended, and applicable Canadian securities laws, and the liability and reporting provisions under Section 16 of the Securities Exchange Act of 1934, as amended (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exchange Act</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), and applicable Canadian securities laws, as well as under Regulation Blackout Trading Restriction (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Regulation BTR</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). Pre-clearance of a trade, however, is not a defense to a claim of insider trading and does not excuse you from otherwise complying with insider trading laws or this Policy. Further, pre-clearance of a transaction does not constitute an affirmation by the Company or the CFO that you are not in possession of material nonpublic information.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The CFO is under no obligation to approve a transaction submitted for pre-clearance, and may determine, in his or her sole discretion, not to permit the transaction.</font></p>
  <p style="font-size:10pt;margin-top:24pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">VII.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ADDITIONAL RESTRICTIONS AND GUIDANCE</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This section addresses certain types of transactions that may expose you and the Company to significant risks. You should understand that, even though a transaction may not be expressly prohibited by this section, you are responsible for ensuring that the transaction otherwise complies with other provisions in this Policy that may apply to the transaction, such as the general prohibition against insider trading as well as pre-clearance procedures and blackout periods, to the extent applicable.</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">A.	Short Sales</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You are prohibited from engaging in short sales (</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">i.e</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">., the sale of a security that must be borrowed to make delivery) and &#x201c;selling short against the box&#x201d; </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">(i.e</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">., a sale with a delayed delivery) with respect to Company securities. Short sales may signal to the market possible bad news about the Company or a general lack of confidence in the Company&#x2019;s prospects, and an expectation that the value of the Company&#x2019;s securities will decline. In addition, short sales are effectively a bet against the Company&#x2019;s success and may reduce the seller&#x2019;s incentive to improve the Company&#x2019;s performance. Short sales may also create a suspicion that the seller is engaged in insider trading.</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">B.	Derivative Securities and Hedging Transactions</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You are prohibited from engaging in transactions in publicly-traded options, such as puts and calls, and other derivative securities with respect to the Company&#x2019;s securities. This prohibition extends to any hedging or similar transaction designed to decrease the risks associated with holding Company securities. Compensatory stock options, share appreciation rights, share units subject to time-based or performance-based restrictions, other securities issued pursuant to Company benefit plans or other compensatory</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Page </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</font><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">arrangements with the Company, and broad-based index options, futures or baskets are not subject to this prohibition.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Transactions in derivative securities may reflect a short-term and speculative interest in the Company&#x2019;s securities and may create the appearance of impropriety, even where a transaction does not involve trading on inside information. Trading in derivatives may also focus attention on short-term performance at the expense of the Company&#x2019;s long-term objectives. In addition, the application of securities laws to derivatives transactions can be complex, and persons engaging in derivatives transactions run an increased risk of violating securities laws.</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">C.	Using Company Securities as Collateral for Loans</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Individuals subject to this Policy are prohibited from pledging Company securities as collateral for loans. If you default on the loan, the lender may sell the pledged securities as collateral in a foreclosure sale. The sale, even though not initiated at your request, is still considered a sale for your benefit and, if made at a time when you are in possession of material nonpublic information or otherwise are not permitted to trade in Company securities, may result in inadvertent insider trading violations, Section 16 and Regulation BTR violations (for officers and directors), violations of this Policy, violations of Canadian securities laws and unfavorable publicity for you and the Company. For these same reasons, even if you are not prohibited from pledging Company securities as collateral for loans, you should exercise caution when doing so.</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">D.	Holding Company Securities in Margin Accounts</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If you are required to comply with Section 16 of the Exchange Act or Part 3 or Part 4 of National Instrument 55-104 </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Insider Reporting Requirements and Exemptions</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NI 55-104</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) or the blackout periods or preclearance requirements under this Policy, you may not hold Company securities in margin accounts. Under typical margin arrangements, if you fail to meet a margin call, the broker may be entitled to sell securities held in the margin account without your consent. The sale, even though not initiated at your request, is still considered a sale for your benefit and, if made at a time when you are in possession of material nonpublic information or are otherwise not permitted to trade, may result in inadvertent insider trading violations, Section 16 and Regulation BTR violations (for officers and directors), violations of this Policy, violations of applicable Canadian securities laws and unfavorable publicity for you and the Company. For these same reasons, even if you are not prohibited from holding Company securities in margin accounts, you should exercise caution when doing so.</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">E.	Placing Open Orders with Brokers</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Except in accordance with an approved trading plan (as discussed below), you should exercise caution when placing open orders, such as limit orders or stop orders, with brokers, particularly where the order is likely to remain outstanding for an extended period of time. Open orders may result in the execution of a trade at a time when you are in possession of material nonpublic information or otherwise are not permitted to trade in Company securities, which may result in inadvertent insider trading violations, Section 16 and Regulation BTR violations (for officers and directors), violations of this Policy, violations of applicable Canadian securities laws and unfavorable publicity for you and the Company. If you are subject to blackout periods or pre-clearance requirements, you should so inform any broker with whom you place any open order at the time it is placed.</font></p>
  <p style="font-size:10pt;margin-top:24pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">VIII.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LIMITED EXCEPTIONS</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Page </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</font><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following are certain limited exceptions to the restrictions imposed by the Company under this Policy. Please be aware that even if a transaction is subject to an exception to this Policy, you will need to separately assess whether the transaction complies with applicable law. For example, even if a transaction is indicated as exempt from this Policy, you may need to comply with the &#x201c;short-swing&#x201d; trading restrictions under Section 16 of the Exchange Act, to the extent applicable. You are responsible for complying with applicable law at all times. If there is a Regulation BTR blackout (and no quarterly or special blackout period), then the limited exceptions set forth in Regulation BTR will apply.</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">A.	Transactions Pursuant to a Trading Plan that Complies with SEC Rules and applicable Canadian securities laws</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The SEC has enacted rules that provide an affirmative defense against alleged violations of U.S. federal insider trading laws for transactions pursuant to trading plans that meet certain requirements. In general, these rules, as set forth in Rule 10b5-1 under the Exchange Act, provide for an affirmative defense if you enter into a contract, provide instructions or adopt a written plan for trading securities when you are not in possession of material nonpublic information. The contract, instructions or plan must (i) specify the amount, price and date of the transaction, (ii) specify an objective method for determining the amount, price and date of the transaction and/or (iii) place any subsequent discretion for determining the amount, price and date of the transaction in another person who is not, at the time of the transaction, in possession of material nonpublic information.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Applicable Canadian securities laws contain similar defenses for automatic securities purchase plans in which a person has agreed to participate in prior to obtaining knowledge of any material nonpublic information. Canadian securities laws permit trades to be made under certain automatic trading plans despite the fact that the insider may be in possession of material nonpublic information as long as such automatic trading plans are compliant with applicable securities laws</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Such plans must not be adopted during a trading blackout or at a time when the insider is in possession of material nonpublic information.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Transactions made pursuant to a written trading plan that (i) complies with the affirmative defense set forth in Rule 10b5-1, (ii) complies with Canadian securities law and (iii) is approved by the CFO are not subject to the restrictions in this Policy against trades made while in possession of material nonpublic information or to the pre-clearance procedures or blackout periods established under this Policy. In approving a trading plan, the CFO may, in furtherance of the objectives expressed in this Policy, impose criteria in addition to those set forth in Rule 10b5-1, under Canadian securities law or the Requirements for Trading Plans set forth in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule A</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Therefore, you must confer with the CFO prior to entering into any trading plan.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The SEC rules and applicable Canadian securities laws regarding trading plans are complex and must be complied with completely to be effective. The description provided above is only a summary, and the Company strongly advises that you consult with your legal advisor if you intend to adopt a trading plan. While trading plans are subject to review and approval by the Company, the individual adopting the trading plan is ultimately responsible for compliance with Rule 10b5-1 and applicable Canadian securities laws and ensuring that the trading plan complies with this Policy.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Trading plans must be filed with the CFO and must be accompanied with an executed certificate stating that (i) the trading plan complies with Rule 10b5-1, applicable Canadian securities laws, and any other criteria established by the Company and (ii) the individual applying for approval of their trading plan is not in possession of material nonpublic information. The Company will not publicly disclose information regarding trading plans that you may enter or have entered into without first obtaining your consent, unless otherwise required by law, including periodic reporting requirements under the Exchange Act.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Page </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</font><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">B.	Receipt and Vesting of Stock Options, Restricted Share Units, Restricted Shares and Share Appreciation Rights</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The trading restrictions under this Policy do not apply to your acceptance or purchase of stock options, restricted share units, restricted shares or share appreciation rights issued or offered by the Company. The trading restrictions under this Policy also do not apply to the vesting, cancellation or forfeiture of stock options, restricted share units, restricted share or share appreciation rights in accordance with applicable plans and agreements. However, the trading restrictions do apply to any subsequent sales of any such securities.</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">C.	Exercise of Stock Options for Cash</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The trading restrictions under this Policy do not apply to the exercise of stock options for cash under the Company&#x2019;s stock option plans and the holding of the shares issued upon such cash exercise (referred to as an exercise-and-hold transaction). Likewise, the trading restrictions under this Policy do not apply to the exercise of stock options in a share-for-share exercise with the Company or an election to have the Company withhold securities to cover tax obligations in connection with an option exercise, if permitted by the Company, so long as the exercise or election is irrevocable and made in writing at a time when a trading blackout is not in place and you are not in possession of material nonpublic information. However, the trading restrictions under this Policy do apply to (i) the sale of any securities issued upon the exercise of a stock option, (ii) a cashless exercise of a stock option through a broker, since this involves selling a portion of the underlying shares to cover the costs of exercise, and (iii) any other market sale for the purpose of generating the cash needed to pay the exercise price of an option.</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">D.	Purchases from the Employee Stock Purchase Plan</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The trading restrictions in this Policy do not apply to elections with respect to participation in any employee stock purchase plan or Company-sponsored retirement plan adopted by the Company or to purchases of securities under any such plan. However, the trading restrictions do apply to any subsequent sales of any such securities.</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">E.	Share Splits, Share Dividends and Similar Transactions</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The trading restrictions under this Policy do not apply to a change in the number of securities held as a result of a share split or share dividend applying equally to all securities of a class, or similar transactions.</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">F.	Inheritance and Change in Form of Ownership</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The trading restrictions under this Policy do not apply to transfers by will or the laws of descent and distribution or, provided that prior written notice is provided to the CFO, distributions or transfers (such as certain tax planning or estate planning transfers) that effect only a change in the form of beneficial interest without changing your pecuniary interest in the Company&#x2019;s securities.</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">G.	Other Exceptions</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any other exception from this Policy must be approved by the CFO or CLO, in consultation with the Board of Directors or an independent committee of the Board of Directors.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Page </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</font><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:24pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IX.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INSIDER TRADING REPORTING; COMPLIANCE WITH SECTION 16 OF THE EXCHANGE ACT AND NI 55-104</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">A.	Obligations Under Section 16 and NI 55-104</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 16 of the Exchange Act, and the related rules and regulations, set forth (i) reporting obligations, (ii) limitations on &#x201c;short-swing&#x201d; transactions and (iii) limitations on short sales and other transactions applicable to directors, officers, large shareholders and certain other persons.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In Canada, subject to certain exceptions, officers, directors and persons beneficially owning or controlling more than 10% of the voting rights of the Company, and directors and senior officers of a company that is itself an insider or a subsidiary of the Company (referred to as &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Reporting Insiders</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), are required to file an initial insider trading report within ten (10) calendar days of becoming a Reporting Insider as well as subsequent insider trading reports within five (5) calendar days of a change in ownership position in any securities of the Company (this includes the grant of options or other convertible securities or the exercise of options or other convertible securities). Such insider trading reports are to be made by the Reporting Insider to the Canadian securities regulatory authorities pursuant to the System for Electronic Disclosure by Insiders (which is commonly referred to as &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SEDI</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). Section 16 of the Exchange Act requires the corresponding filings to be made within ten (10) business days for initial insider trading report and two (2) business days of a change in ownership position.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has determined that certain persons are required to comply with Section 16 of the Exchange Act, NI 55-104 and the related rules and regulations, because of their positions with the Company. The Nominating &amp; Corporate Governance Committee or the CFO may from time to time designate other persons as being subject to Section 16 of the Exchange Act, NI 55-104 to reflect the election of new officers or directors, any change in the responsibilities of officers or other employees and any promotions, demotions, resignations or departures.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if you are not designated as such by the Company, you may be subject to Section 16 or NI 55-104 reporting obligations because of your shareholdings, for example.</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">B.	Notification Requirements to Facilitate Reporting Requirements</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To facilitate timely reporting of transactions pursuant to Section 16 requirements and NI 55-104 requirements, each Reporting Insider and each person subject to Section 16 reporting requirements must provide, or must ensure that his or her broker provides, the Company with detailed information (</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">e.g</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">., trade date, number of shares, exact price, </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">etc</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.) regarding his or her transactions involving the Company&#x2019;s securities, including gifts, transfers, pledges and transactions pursuant to a trading plan, both prior to (to confirm compliance with pre-clearance procedures, if applicable) and promptly following execution.</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">C.	Personal Responsibility</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The obligation to file reports required under Section 16 of the Exchange Act or under NI 55-104, and to otherwise comply with Section 16 of the Exchange Act and applicable Canadian securities laws, including NI 55-104, is personal. The Company is not responsible for the failure to comply with Section 16 requirements or any requirements under Canadian securities laws, including NI 55-104.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Page </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</font><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:24pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">X.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ADDITIONAL INFORMATION</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">A.	Availability of Policy</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Policy will be made available to all directors, officers, employees, consultants, contractors and advisors of the Company when they commence service with the Company. Each director, officer, employee, consultant, contractor and advisor of the Company is required, if requested, to acknowledge that he or she understands, and agrees to comply with, this Policy.</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">B.	Amendments</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is committed to continuously reviewing and updating its policies and procedures. The Company therefore reserves the right to amend, alter or terminate this Policy at any time and for any reason, subject to applicable law. A current copy of the Company&#x2019;s policies regarding insider trading may be obtained by contacting the CFO.</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">C.	Ancillary Documents</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Attached as </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule A</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> are the Company&#x2019;s Requirements for Trading Plans.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">* * *</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Page </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</font><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SCHEDULE A</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Page </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15</font><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">XENON PHARMACEUTICALS INC.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">REQUIREMENTS FOR TRADING PLANS</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For transactions under a trading plan to be exempt from (i) the prohibitions in the company&#x2019;s insider trading policy with respect to transactions made while in possession of material nonpublic information and (ii) the pre-clearance procedures and blackout periods established under the insider trading policy, the trading plan must comply with the affirmative defense set forth in Exchange Act Rule 10b5&#x2011;1 and Canadian securities law requirements. Amongst other requirements:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.	The trading plan must be in writing and signed by the person adopting the trading plan.</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.	The trading plan must be adopted at a time when:</font></p>
  <p style="margin-left:13.333%;text-indent:-6.122%;padding-left:5%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a)	the person adopting the trading plan is not in possession of any material nonpublic information; and</font></p>
  <p style="margin-left:13.333%;text-indent:-6.122%;padding-left:5%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">b)	there is no quarterly, special or other trading blackout in effect that applies to the person adopting the plan.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.	The trading plan must be entered in good faith and not as part of a plan or scheme to evade the prohibitions of Rule 10b5&#x2011;1 or applicable Canadian law, and the person adopting the trading plan must act in good faith with respect to the trading plan.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4.	The trading plan must include representations that, on the date of adoption of the trading plan, the person adopting the trading plan:</font></p>
  <p style="margin-left:10%;text-indent:-3.846%;padding-left:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a)	is not in possession of material nonpublic information about the securities or the company; and</font></p>
  <p style="margin-left:10%;text-indent:-3.846%;padding-left:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">b)	is adopting the trading plan in good faith and not as part of a plan or scheme to evade the prohibitions of Rule 10b5-1 or applicable Canadian law.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.	The person adopting the trading plan may not have entered into or altered a corresponding or hedging transaction or position with respect to the securities subject to the trading plan and must agree not to enter into any such transaction while the trading plan is in effect.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6.	The first trade under the trading plan may not occur until the expiration of a cooling-off period ending upon the later of (i) 90 calendar days after the adoption of the trading plan and (ii) one full business day after the filing by the company of its financial results in a Form 10-Q or Form 10-K for the completed fiscal quarter in which the trading plan was adopted (but, in any event, this required cooling-off period is subject to a maximum of 120 days after the adoption of the trading plan).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7.	The trading plan must have a minimum term of one year (starting from the date of adoption of the trading plan).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8.	All transactions during the term of the trading plan (except for the other &#x201c;Limited Exceptions&#x201d; identified in the Company&#x2019;s Insider Trading Policy and </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">bona fide </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">gifts) must be conducted through the trading plan. In addition, the person adopting the trading plan may not have an outstanding (and may not subsequently enter into any additional) trading plan except as permitted by Rule 10b5-1. For example, as contemplated by Rule 10b5-1, a person may adopt a new trading plan before the scheduled termination date of an existing trading plan, so long as the first scheduled trade under the new trading plan</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A-1</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">does not occur prior to the last scheduled trade(s) of the existing trading plan and otherwise complies with these guidelines. Termination of the existing trading plan prior to its scheduled termination date may impact the timing of the first trade or the availability of the affirmative defense for the new trading plan; therefore, persons adopting a new trading plan are advised to exercise caution and consult with the CFO prior to the early termination of an existing trading plan.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9.	Any modification or change to the amount, price or timing of transactions under the trading plan is deemed the termination of the trading plan and the adoption of a new trading plan (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Modification</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). Therefore, a Modification is subject to the same conditions as a new trading plan as set forth in Sections 1 through 8 herein.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10.	Unless prior approval of the Board of Directors or an independent committee of the Board of Directors has been obtained, within the one year period preceding the adoption or a Modification of a trading plan, a person may not have otherwise adopted or entered into a Modification of a plan more than once.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11.	A person may adopt a trading plan designed to cover a single trade only once in any consecutive 12-month period except as permitted by Rule 10b5-1.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12.	If the person that adopted the trading plan terminates the plan prior to its stated duration, he or she may not trade in the company&#x2019;s securities until after the expiration of 30 calendar days following termination, and then only in accordance with the insider trading policy.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13.	The company must be promptly notified of any Modification or termination of the trading plan, including any suspension of trading under the trading plan.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14.	The company must have authority to require the suspension or cancellation of the trading plan at any time.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15.	If the trading plan grants discretion to a stockbroker or other person with respect to the execution of trades under the trading plan:</font></p>
  <p style="margin-left:13.333%;text-indent:-6.122%;padding-left:5%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a)	trades made under the trading plan must be executed by someone other than the stockbroker or other person that executes trades in other securities for the person adopting the trading plan;</font></p>
  <p style="margin-left:13.333%;text-indent:-6.122%;padding-left:5%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">b)	the person adopting the trading plan may not confer with the person administering the trading plan regarding the company or its securities; and</font></p>
  <p style="margin-left:13.333%;text-indent:-6.122%;padding-left:5%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">c)	the person administering the trading plan must provide prompt notice to the company of the execution of a transaction pursuant to the plan.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16.	All transactions under the trading plan must be in accordance with applicable law and it is the individual&#x2019;s sole responsibility to ensure that your trading plan complies with the applicable laws.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">17.	The trading plan (including any Modification) must meet such other requirements as the CFO may determine.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18.	The trading plan must be filed with the company&#x2019;s Legal Department with an executed certificate stating that the trading plan complies with Rule 10b5-1, applicable Canadian securities laws and the criteria set forth above.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A-</font><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>8
<FILENAME>xene-ex23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html>
 <head>
  <title>EX-23.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.5in;z-index:-3;min-height:0.7in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 23.1</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:18pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">The Board of Directors<br>Xenon Pharmaceuticals Inc.	</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">We consent to the use of:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">our report dated February 27, 2025 on the consolidated financial statements of Xenon Pharmaceuticals Inc.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">(the &#x201c;Entity&#x201d;) which comprise the consolidated balance sheets as of December 31, 2024 and 2023, the related consolidated statements of operations and comprehensive loss, shareholders&#x2019; equity and cash flows for each of the years in the three-year period ended December 31, 2024, and the related notes (collectively the &#x201c;consolidated financial statements&#x201d;), and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">our report dated February 27, 2025 on the effectiveness of the Entity&#x2019;s internal control over financial reporting as of December 31, 2024</font></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">each of which is included in the Annual Report on Form 10-K of the Entity for the fiscal year ended December 31, 2024.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">We also consent to the incorporation by reference of such reports in the Registration Statements (Nos. 333-279962, 333-265377, 333-238895, 333-237036, 333-233758, 333-230103, 333-223497, 333-216543, 333-210050, 333-202765, 333-199860) on Form S-8, and No. 333-281451 on Form S-3 of the Entity.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">/s/ KPMG LLP</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:18pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Chartered Professional Accountants</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:30pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">February 27, 2025<br>Vancouver, Canada</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:5.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>9
<FILENAME>xene-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" id="fis_certification"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 31.1</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATIONS</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I, Ian Mortimer, certify that:</font></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.	I have reviewed this Annual Report on Form 10-K of Xenon Pharmaceuticals Inc.;</font></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4.	The registrant&#x2019;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d&#x2013;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a&#x2013;15(f) and 15d&#x2013;15(f)) for the registrant and have:</font></p>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">c)	Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">d)	Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.	The registrant&#x2019;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></p>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></p>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.46%;box-sizing:content-box;"></td>
    <td style="width:5.04%;box-sizing:content-box;"></td>
    <td style="width:3.04%;box-sizing:content-box;"></td>
    <td style="width:46.46%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: February 27, 2025</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Ian Mortimer</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ian Mortimer</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.148%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">President and Chief Executive Officer</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="d564546dex312_htm"><font id="fis_exhibit_31_2"></font><font id="eolpage85"></font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>10
<FILENAME>xene-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31.2</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" id="fis_certification_2"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 31.2</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATIONS</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I, Sherry Aulin, certify that:</font></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.	I have reviewed this Annual Report on Form 10-K of Xenon Pharmaceuticals Inc.;</font></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4.	The registrant&#x2019;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d&#x2013;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a&#x2013;15(f) and 15d&#x2013;15(f)) for the registrant and have:</font></p>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">c)	Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">d)	Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.	The registrant&#x2019;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></p>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></p>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.46%;box-sizing:content-box;"></td>
    <td style="width:5.04%;box-sizing:content-box;"></td>
    <td style="width:3.04%;box-sizing:content-box;"></td>
    <td style="width:46.46%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: February 27, 2025</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Sherry Aulin</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Sherry Aulin</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.148%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Financial Officer</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(Principal Financial and Accounting Officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="fis_exhibit_32"><font id="d564546dex321_htm"></font><font id="eolpage86"></font>&#160;</p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>11
<FILENAME>xene-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 32.1</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="fis_certification_3"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">XENON PHARMACEUTICALS INC.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18 U.S.C. SECTION 1350,</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AS ADOPTED PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the Annual Report of Xenon Pharmaceuticals Inc. (the &#x201c;Company&#x201d;) on Form 10-K for the year ended December 31, 2024, as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I, Ian Mortimer, President and Chief Executive Officer</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Principal Executive Officer) of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:</font></p>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1)	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></p>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.46%;box-sizing:content-box;"></td>
    <td style="width:5.04%;box-sizing:content-box;"></td>
    <td style="width:3.04%;box-sizing:content-box;"></td>
    <td style="width:46.46%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date:   February 27, 2025</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Ian Mortimer</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ian Mortimer</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">President and Chief Executive Officer</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This certification accompanies the Report to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Xenon Pharmaceuticals Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Report), irrespective of any general incorporation language contained in such filing.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>12
<FILENAME>xene-ex32_2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html>
 <head>
  <title>EX-32.2</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 32.2</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="fis_certification_4"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">XENON PHARMACEUTICALS INC.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18 U.S.C. SECTION 1350,</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AS ADOPTED PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the Annual Report of Xenon Pharmaceuticals Inc. (the &#x201c;Company&#x201d;) on Form 10-K for the year ended December 31, 2024, as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I, Sherry Aulin, Chief Financial Officer (Principal Financial and Accounting Officer) of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:</font></p>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1)	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></p>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.46%;box-sizing:content-box;"></td>
    <td style="width:5.04%;box-sizing:content-box;"></td>
    <td style="width:3.04%;box-sizing:content-box;"></td>
    <td style="width:46.46%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date:  February 27, 2025</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Sherry Aulin</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Sherry Aulin</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Financial Officer</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(Principal Financial and Accounting Officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This certification accompanies the Report to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Xenon Pharmaceuticals Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Report), irrespective of any general incorporation language contained in such filing.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>img255015816_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img255015816_0.jpg
M_]C_X  02D9)1@ ! @$#J@.J  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" H2%?D# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH *H:E=/9VDD\8!9>@/3H3[^E7ZS-7 -C*",CC^1H \WO?'>I6S$)#
M"0#W"^Y_N'M[]:SO^%C:K_SPA_)?_B*H:=#'=:S/%.HD03 !3Z%1D?K_ )YK
MUY/#NCE%)LHLX]* /,/^%C:K_P \(?R7_P"(H_X6-JO_ #PA_)?_ (BO4?\
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MO_/"'\E_^(H_X6-JO_/"'\E_^(KU'_A'=&_Y\8OR-'_".Z-_SXQ?D: /+O\
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M"'\E_P#B*/\ A8VJ_P#/"'\E_P#B*]1_X1W1O^?&+\C1_P ([HW_ #XQ?D:
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MA#^2_P#Q%>H_\([HW_/C%^1H_P"$=T;_ )\8OR- 'EW_  L;5?\ GA#^2_\
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M?\+&U7_GA#^2_P#Q%>H_\([HW_/C%^1H_P"$=T;_ )\8OR- 'EW_  L;5?\
MGA#^2_\ Q%'_  L;5?\ GA#^2_\ Q%>H_P#".Z-_SXQ?D:/^$=T;_GQB_(T
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MQB_(T >7?\+&U7_GA#^2_P#Q%'_"QM5_YX0_DO\ \17J/_".Z-_SXQ?D:/\
MA'=&_P"?&+\C0!Y=_P +&U7_ )X0_DO_ ,11_P +&U7_ )X0_DO_ ,17J/\
MPCNC?\^,7Y&C_A'=&_Y\8OR- 'EW_"QM5_YX0_DO_P 11_PL;5?^>$/Y+_\
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MC:K_ ,\(?R7_ .(H_P"%C:K_ ,\(?R7_ .(KU'_A'=&_Y\8OR-'_  CNC?\
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MU'_A'=&_Y\8OR-'_  CNC?\ /C%^1H \N_X6-JO_ #PA_)?_ (BC_A8VJ_\
M/"'\E_\ B*]1_P"$=T;_ )\8OR-'_".Z-_SXQ?D: /+O^%C:K_SPA_)?_B*/
M^%C:K_SPA_)?_B*]1_X1W1O^?&+\C1_PCNC?\^,7Y&@#R[_A8VJ_\\(?R7_X
MBC_A8VJ_\\(?R7_XBO4?^$=T;_GQB_(UA:YH>EP0;HK2-#M/('UY_2@#B_\
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M"'\E_P#B*/\ A8VJ_P#/"'\E_P#B*]1_X1W1O^?&+\C1_P ([HW_ #XQ?D:
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M '/^(?\ CQE_S_ :\O\ "O\ R%;O_KLO_H*UZAXA_P"/&7_/\!KR_P *_P#(
M5N_^NR_^@K0![>O0?0?RI:1>@^@_E2T %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %8VN?\>,OT'_ +-6S6-KG_'C+]!_[-0!
MYAHG_(5E_P"NP_\ 0:]G7H/H/Y5XQHG_ "%9?^NP_P#0:]G7H/H/Y4 +1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %<_P")/^09<_\ 7/\ J*Z"N?\ $G_(,N?^N?\ 44 >5>$O^0G)]4_K7N:?
M<7_=7^0KPSPE_P A.3ZI_6O<T^XO^ZO\A0 ZBBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *YWQ#_ ,>W_ 3_ ":N
MBKG?$/\ Q[?\!/\ )J .(\)_\AM_]P_S:O6:\F\)_P#(;?\ W#_-J]9H ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ KB/&_P#QXQ_4_P!*[>N(\;_\>,?U/]* .=\"?>_[:M_Z&:]9KR;P)][_
M +:M_P"AFO6: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH *S=6_P"/&7\/Y&M*LW5O^/&7\/Y&@#QK
M1O\ D.S_ /7=?_05KW2/[B_2O"]&_P"0[/\ ]=U_]!6O=(_N+]* 'T444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% '/^(?^/&7_/\  :\O\*_\A6[_
M .NR_P#H*UZAXA_X\9?\_P !KR_PK_R%;O\ Z[+_ .@K0![>O0?0?RI:1>@^
M@_E2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %8VN?\>,OT'_LU;-8VN?\ 'C+]!_[-0!YAHG_(5E_Z[#_T&O9UZ#Z#^5>,
M:)_R%9?^NP_]!KV=>@^@_E0 M%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 5S_B3_D&7/_7/^HKH*Y_Q)_R#+G_K
MG_44 >5>$O\ D)R?5/ZU[FGW%_W5_D*\,\)?\A.3ZI_6O<T^XO\ NK_(4 .H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "N=\0_\>W_ 3_)JZ*N=\0_\>W_ 3_)J .(\)_\ (;?_ '#_ #:O6:\F
M\)_\AM_]P_S:O6: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *XCQO_P >,?U/]*[>N(\;_P#'C']3_2@#G? G
MWO\ MJW_ *&:]9KR;P)][_MJW_H9KUF@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "LW5O^/&7\/Y&
MM*LW5O\ CQE_#^1H \:T;_D.S_\ 7=?_ $%:]TC^XOTKPO1O^0[/_P!=U_\
M05KW2/[B_2@!]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!S_B'_
M (\9?\_P&O+_  K_ ,A6[_Z[+_Z"M>H>(?\ CQE_S_ :\O\ "O\ R%;O_KLO
M_H*T >WKT'T'\J6D7H/H/Y4M !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !6-KG_'C+]!_P"S5LUC:Y_QXR_0?^S4 >8:)_R%
M9?\ KL/_ $&O9UZ#Z#^5>,:)_P A67_KL/\ T&O9UZ#Z#^5 "T444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *XC
MQO\ \>,?U/\ 2NWKB/&__'C']3_2@#G? GWO^VK?^AFO6:\F\"?>_P"VK?\
MH9KUF@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M(NY&'LR\CZU_GG>$O@Y\</\ A;MD8_"WBF"Z34]*:6]?0-36!D6_R?WC1*F
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MRSW$QPD:#JQ]J^5!_P %"/V13KG_  C@^,/A[^V?.C@^Q;V\SS97V1ICU9N
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M@KY8^('[;7[,WPNU$Z5XY^*&B:#?K-Y!M[IRKB7)&SMSD'\J^CO$O_('N_\
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M5 '\1N@?\E_A_P"PEH__ *<WK^ZW]D[_ ))=H7_8(TG_ -)$K^%+0/\ DO\
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M<*">H'J17\;O_!+#]K?XA^'O&VE^#/$7B#4[ZRNM3BM1:W,BA(HD*8CVJ%X
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M>N*]3_;M_P""7&K_  ZT"Y^(5SX]CO7CLFU*6S,:!RTBLQ0D62<C&/O#Z\4
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M(_2EJO:!EM+57)++;P!B>I81J"3[DYJQ0 4444 %%%% !1110 4444 %%%%
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M/S=J /N[Q_\ %#P=\,]*FUGQ?J/]G6$$+SR3;4.(X\[CAY8AQCIFOSO\2_\
M!9K]@3PEJ4NDZW\6?LM["SK)%]GTTX*,4;EM90\,".0*_DT_;\_X*$?&;]H/
MXLZE\.O FL:_HFG6^MFQ$=C*CQ744Y?]VH=I200P &!T^AKU3]FO_@A;\4?V
MI_",'C[Q+\2KOPU=7I9FAU&VB\WYT,NXDZ=/G<?]KO\ D ?U9?"[_@JG^QA\
M8M5@T7P'\2O[6U"YF%O##Y%@NZ5NBYCU28]_2OT%TK5;+6K*+4-/D\VUF_U;
M\<\ _P +,.A'>O\ .W_:G_X)_P#QL_X)\:UI^I^'O&>LZE"C/=-JEA#%'' (
MA)B5G^R08!\L#.T]0>M?M?\ \$9O^"@GB7QU=V7@/X@:]=ZS<6NE@_:-2G!,
MDTMM*B8"E?FWQ@CY<9H _JJHJ"UG6ZMK>Y3&RX@BG7'(VRQK(,'Z-4] !7D_
MQE^(EA\-O NN^)+N=86TZT,ZEPI7CN=QQ^E>L5^47_!5?XES> /@3XOEBA>4
MOH,DGR''3>?[P]!^.#ZX /XY/^"EW[8?CGX\_''Q!X2349D\-#5K?[$UE?SQ
M"0S7DBE6BA$:8(5!C>PP3D8K]5/^".G_  31\-_$&QL/B]XQL+BXCL-25'%Q
M;F[MG6>>67=(D[^6Y(ML_,C'ELD@FOYT/!4S?%GXS:9J$\!W7VN:3OC?YCAK
MY3S][KN]>?Y?Z+7_  3M\ V_P^^!=AIMM;+;+=0:1=LBKM#,]I+(6QZDRD_C
MZ8% 'U+HWP3^%NBZ+::)#X!\%S06D'D)--X4T)IF7).YF:R=BW/4N:^1_C1_
MP39^ ?QJU4ZOJUA%H-P9XIPNA:19V*AHI5E4#['-9@#<N.%'!].*_0RB@#\Q
M/VC?A%H'P4_9K\8>%_#<]S<6*:$EN&NMV\)"K;<;I9B#Q_>K^%&#_DZ8?]C'
MH_\ Z<6K_0%_;Q_Y(AXS_P"P2W_H,E?Y_4'_ "=,/^QCT?\ ].+4 ?Z#G[&E
MU:V?P1TJ>\*B!+'1]Q90P_X\">C<= >M>,_&#_@H7^P)\+/$7]A?$[5O"T&N
M?:VM=E[X9\-7DOVE58L/,O+A),X5N<9XKTG]E;_DWRQ_Z\='_P#3<]?Q4_\
M!5/_ )+N_P#V-$W_ *)GH _NE^ 7[0_P ^-FD6VJ_!F\TJYTR="\#:=I>FZ>
MFU4WDA+"1T&$'8]/:J'QR_;.^ /[.L;2_%7Q;_8*+$9B?+MG_=J"Q/[Z\M^P
MK\@?^"(W_)+-!_Z]7_\ 20U\X?\ !=/_ )!C_P#8*E_]$O0!^_GP4_;D_9T_
M:#M+V]^%_C+^W+>PL9-1N7\JU79:QQF5Y/W-[<=$4GD@>I%>/_$__@JS^Q9\
M']8DT+QW\2_[*U*+?OA\BP;'EL%?_6:K"W!(ZJ/SK^$7]DKXR_&>QO1X(^&5
MQK]G/K,*Z-/<:3Y9,<5ZIM][AR?E56)/R'@<@XK]6-:_X(;_ !O^*OP]O?B[
MXR^+VIW&L2;;A-&U"" W;1WD4EUM 73#PNQ4/[WC(/7F@#^I+X*?\%'_ -E#
M]H/43I7PO\??VY>B5(3'Y-FG[R0(RC,6HW!Y#KV[U]TEEVES]W;N)_V<9_E7
M^75H>J_%S]D+XV-HEIK&M:+%H?B,6\MR@CA34!# &WC*#CH.%4_(..]?WH_\
M$T?VGW^.WP*\/R:QJ)U'7Y;:62>>>7?<LHLXV&[!*XR&/0<Y[F@#Z _:%_:M
M_9=^!D;/\;+_ $6U00F5O[2T;2-1'E 9)(U"5.,=J\V^ G[=?[$7QKU9],^#
M>I^&[G4E"%ET_P .^'[!\/RGSV,[L>.?05^)W_!=7_CQE_[!,G_H@U^?_P#P
M1+_Y*;<?]NG_ *": /[O(I$DBCEC(\N2-)(R!@;&4,IQT VD<=J\4^+/[0_P
MM^">FRZM\0M=_L>RAA:=Y=D+8B0D,V);B <%3U(]:\[_ &F?CMI'P/\ A)<^
M)KV[@@EL].M\+)(48$V)8'(*X'R^OIFOX)/VI/VN/CI^T_\ &/5?!WA_Q-XA
MFTB[\03Z?;6EL\4L+P21%EC0$,2N6)Y.<CWH _LHO?\ @MI_P3UT^Z-G=?%_
MRYU(4I]GTP\EBH_YC0/4>E?4'P-_;Q_9L_:+FC@^%7C3^WI)9?(1?*M4S)NV
M8_<WUQ_%Z9/M7\D_P#_X-[_B%\=/ASIWQ%UKXHS>%]0OXY96TF^MHA<1-%!'
M.JG_ (EDW+,Y4?O.HZCK7:_#+_@GI^U!^QO\9/#UOX2\3>*O$&APW,DUQ-I=
MM +9BCQ,N\_98#SEC_/CF@#^UV_O[;3;:6[NW\N"&-I)&X.U%&2>2/YU\-?%
M_P#X*3?LE_ N[FLOB/\ $#^QKBW!,J>39/M Z_ZW48#^E?&G[84G[16J_LW>
M"H/!$OBFV\57ME<1:H]A'"UZ&<X!F5@1P,G 'Z5^('PT_P"",O[2G[7%O<:_
M\4?BUK_A^XNKV>-K77K>W$@B:63!^739_E"J,?-Z=: /Z#(/^"WW_!.ZXF2W
MB^,6Z61MJK]GTOD_AK9/Z5]P? W]J[X*_M%VD%[\*O$W]O6]Q"9XG\N!-T83
MS"W[FZN!]P$]2.#S7\8G[4O_  0-\<?LW>#-0\::?\2I/%KZ9I\FH&VM+>/<
M3&Q78?\ B76^">,?,.HY'%?#G[#7[4/QA^ GQ7T?1)O$.N:=9+>:59/I+/'&
MD<<UV8)%88R R-M/S'(7ZT ?Z1_B7_D#W?\ N_T-?P*_\%@/^2RW7_8Q#_T9
M)7]P'PJ^(T?Q*^$>CZVH_>OH>E/<.6W,\TMFC.[')^9FR3TY-?P__P#!8#_D
MLMU_V,0_]&24 ?M+_P $*O\ D1=&_P"NX_D:_ICK^9S_ ((5?\B+HW_7<?R-
M?TQT %%%% !1110 4444 %%%% !1110 5C:Y_P >,OT'_LU;-8VN?\>,OT'_
M +-0!YAHG_(5E_Z[#_T&O9UZ#Z#^5>,:)_R%9?\ KL/_ $&O9UZ#Z#^5 "T4
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4U_N-_NM_(TZFO
M]QO]UOY&@#^:/_@NU_R3GQ%_V!Q_Z1M7\XW_  2VTS3=2^.6C0ZCI]C?Q-KV
MFJT5[:07494[<@I/'(I![@C!K^CG_@NU_P DY\1?]@<?^D;5_.I_P2I_Y+MH
MO_8?TW_V6@#_ $ O%7P#^&'C/P'#I,W@7PA;B?1;<F6U\+Z)%-N;3U&0\=G&
M^<G.=V<\YK^!K_@K-^S+I/[._P 6H[C1(I;6/Q)J=Y=(H0P(@*3D")$<A0/*
MX"A0.U?Z'5WK-CH7@^TO]0NHK2WCT6W+2RL50;;!"02 >U?P+_\ !;7XI:#\
M2/BUH\&@ZY::M_8M_>07$=K*93"RQW(VN-HP?G7\?K0!]P?\$"?C=K%KXUN?
M"FHZA/+IT'AN1(89[J:6,/)8WJ#;%(Q13E5Y'/ ]!7NO_!>+#:/=RCD3Z!#,
M#Z^981/G_P >^GZU\N_\$"/A)JVO?$J^UB4S65F/#37"32(!&YALK^0H"5/7
M '_ A]1]0?\ !>,>7H=S #G[-X=MX"WJ8]/A0M^)7(Z$=Q0!\ ?\$4;VWT_Q
M_JEW=/Y<$$EJ\C==JA;?)ZC^=?U;?%7_ (*@?L=_ C5(_#'Q)^(W]BZQ;VL!
MEM_(L6VC8B]9=3@;K_LBO\^/]F'5?C#=>)XO#GPPO-=T^[UJYAL);O251F@,
MH4+(_F*PX"C'RG/ QV'[:^)/^"'_ ,>_BO\ #F7XN^/_ (S:MJ.NO;O*VD:E
M! UYY:6WVE%(72^G 4?O#^% ']2/P1_X*,?LJ?M#:C'I?PM\>_V[>23"W2/R
MK-<RM@!?W.HW![CMGT%?<U?Y<?AOQ!\7OV0_C%)I5KK&M:&NAZ[-;^<HCA6^
M^SG_ %JG;R#C/ 7[O2O[Y_\ @FI^TX_QY^ WA9M4U ZCXE.G3W%Y<32[[IR+
M2&0>8 2O4.>G<_@ ?HYKFOZ9X=L9=1U6?R+2$ R28!V@ACW91T4]Z_/KXF_\
M%7/V*OA%J<ND>.?B9_95]!,8)(O(L&Q*H)*YDU6$]CVKX1_X*LZ=^T[KZ7NC
M?!^[\76EO<Z:,/H<4+H)OL\:\"16^;<S'H1G-?E?X#_X('_&_P#:+T2S\6?$
M/XTZCI>IZA +V:TUBWMQ/%*YP4?&E2X89Y&XCGKZ@'[ZZ?\ \%M?^">FJ74=
MG9_%_P V>5TC1/L^F<O(P11QK1(RQQTK]"_A)\;_ (=_&_1?[?\ AWK']L:9
MY<<OG[8E^23&PXBGG'.1_%7\%_[;'_!&KX@_L:>&9_&&F>,KKQF;*X"JEE;Q
M@_(RL'!%C;?=SNZ]16Y_P2K_ &S/BM\.?C'X7\#ZUXEUF?1[G64M;O3)Y46%
M8XV3$,B@*0%Z=<^O2@#_ $#R0 2>@!)^@YKYW^,G[4_P9^ ME/?_ !*\2?V+
M;6T8EF?9 VU"F_/[VZ@'W>>HK"^+_P 8VTCX)ZQX]TZ%@3H.L74*PMRCVUDT
MJD'?V)'?/Y5_GT?M/_M9_&+]J/XO:OX?C\2ZW;::NI:QIATQGC>.06M^;13M
M(D. B$#YA\K=^P!_:K/_ ,%MO^">=M>/82_%_;<QR>6R?9],X? ./^0UGOZ5
M]A_ C]LCX"?M(I"_PF\6?\) MPGF1'R[9-R %L_N;RX[#/>OY&_A#_P;P>-?
MBU\-]%^)TOQ?_LRXUO2DU=+&2WB\T.SM'Y?.EO\ -A<_?/UXKZ:_9(_8>_:.
M_8Y^,]MIUCXC\2Z_X<LU@A$MK!"MHP,S(Y!%M"<;.3@?=H _KOKDO%WC?P[X
M'TR?5_$5Y]CL;:*6:67"G;'"NZ0X=T' ]Q7(ZMXU'@KX96WB36CBXLM(MIKM
M9VVN9?+^??@C#9Y.#BOXBO\ @J!_P4J^*_Q2^*6L_"3X;:IKGAZWL-62W^T:
M;,C17L-Q</'Y*AWFR'5-I^5>&ZT ?U&^,_\ @L3^P?X!U:71?$WQ6^PZA TB
M20^1IQPT3['&7U>,G#'TK4^'O_!7']A[XHZO;Z)X.^*']I:C=3K;0P^1IXW3
M.H95_=ZM*>0<\*?Y5_)U^R=_P1C^+G[:7AT>.O%?Q!U'PM<7%T(R=4MXM[K.
M9&\[/V"X&&\L-G/<<>G%?M<?\$L?C%^P2NF^*/"_CG5/$*_/>S7VFP0JMD(#
M.@ED;[%;X7]RH!P>'% '^@=X?\0Z7XGTV'5M'G^TV,_^KEP!NX#?PLPZ,#UK
M;K^-_P#X(T_\%$?&>H^,].^'GQ&\27VLV\5DJB34IQL:61)8EP$*_-N1>WH.
M@K^Q'2[^/5-.LM1AQY5[;17,>#D;95##![C!XH OTC9*L!U(./KBEHH _F=_
MX*\?L-?M7?M,^*_ /_"H=+UR]T&RO9_[=_L_6=9LHUMGCU( R164+QR@M+!Q
M(0,D$= *_+KXD?\ !&#3/A5\&!XZ^*DGB/3/&*I=F[MI;B^GC5X+:.5!ON;N
M%B#*[@DPC/Z5_=/7Y2?\%3O^2':E_OZC_P"DT5 '\%_[-VE6^B?M"Z=I-JS-
M!I^NWEI$SYW-'!=(B%LECG:!GD\]Z_TE_P!D;_D@/@'_ +!J_P#H*5_F]_ ?
M_DYE/^QFU+_TM6O](3]D;_D@/@'_ +!J_P#H*4 ?2E%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !7/^)/^09<_P#7/^HKH*Y_Q)_R
M#+G_ *Y_U% 'E7A+_D)R?5/ZU[FGW%_W5_D*\,\)?\A.3ZI_6O<T^XO^ZO\
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MM*LW5O\ CQE_#^1H \:T;_D.S_\ 7=?_ $%:]TC^XOTKPO1O^0[/_P!=U_\
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M_DL&D_\ 7U/_ .E@K^G/]L?_ )-^UG_L6)?_ $::_F,_X)3?\E@TG_KZG_\
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MW_N(P?\ IQ%?W%_L<_\ )*O#_P#V!;'_ -!% 'UU1110 56O?^/.[_Z]I_\
MT4]6:K7O_'G=_P#7M/\ ^BGH _CN_P""Q'_(ZVW_ %QN/_0#71_\$</^1NE_
MZ](?_0&KG/\ @L1_R.MM_P!<;C_T UT?_!'#_D;I?^O2'_T!J /Z[K+_ (\[
M3_KV@_\ 125^ _\ P6:&?"&D#_IQNO\ T9>U^_%E_P >=I_U[0?^BDK\"/\
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MU'XH2^$M$UC4]+T]K:Z@D%C>-$FZ P0@E4/WN6.#T[T ?O9\1?\ @L;^R?\
M"[5)]'UJYU%I[>8P,;(Q/'N7T,=NXQQQCBORN_;J_P""J?[-7Q]\!7WA_P &
MG4WO[AV*&YC4C!4 <FW4]O6ODW]C/_@F#<?M@V<^N^-/&6N6"/;I>)<.\TQD
MWB/+%@C'JY%>A_M??\$<_ _[./@J[\3Z9X^U#5I[=B!!,LP4X4,?O(.YQ^%
M'Q#^PSJ$.I?'O0;VU)$%QX@:6/M\KE2,@8]/ZXK^W>Y)/P2O<G/_ !(]6_\
M2(U_$'^PIIJ:3\=_#^GHY=;77VA#GJP3 SS]:_M\N?\ DB5[_P!@/5O_ $B-
M '\)_P"VU9&]^-5_".2]SJN/;_3$']:_H\_X)+?LJ?#BQ\)P>+[G2EDU2ZT^
MWOC)(D+CSP85!PZ,<8'2OYUOVQO^2YWG_7SJO_I='7]:/_!++_DD^E_]@.W_
M /0HZ /U+CT?3865HK*UB**%!CMX4.%Z<J@_S]:_)C_@JV OPEUX 8 T4@ <
M<".3TK]>J_(;_@JY_P DFU__ + Q_P#0)* /Y,/V4_\ DM.F_P#86TK_ -*!
M7]]/P1_Y$+1?^P9I?_I%'7\"W[*?_):=-_["VE?^E K^^GX(_P#(A:+_ -@S
M2_\ TBCH \M_;!_Y)'XK_P"P%<_^C5K^%CQ!IMMJ?Q[$%TN^/^U++C@_\Q$^
MH]J_NG_;!_Y)'XK_ .P%<_\ HU:_AHU#_DX ?]A2R_\ 3@U ']MG[#6A:;I'
MPGT=;*WCC$FD:<S$1H"28P<Y51WKXL_X*W>'=,NOADEU- C2@W;[MBYW94@Y
M(SQGUK[K_8N_Y)1H?_8'TW_T4*^,/^"LO_)*4^EW_P"R4 ?S$?L$YA_:*TA8
MV90-0NU 5B.!J" #C%?U8?MJ_$2\\"_LQ6CVTQC^U>#)2QRW.+F?N.OW!U!K
M^5#]@W_DXS2?^PC>?^G%*_J+_;S\+3>)/V8-/6+?^Y\%R@[0>]S<=\=]P_#]
M0#^.7P7\5?#3_%2/Q=XW\V?3EO+660H 7(@O&F?[ROVZ<9SGGT_J'^#7_!9W
M]BSX;>#-'T%%UJ&>UTVRM[D1Q1J#/#$%D(*V@_B![FOY7/AS\&['QA\1(O!N
MK7\FG02W5O$;@;MP^T7+0D\#MU[<\?3^B?X>?\$ OA=XV\,:3KW_  M75$?4
M-/M+QXT6XPC7$2R%>(R#@G''% "_MK?\%9/V4?CS\.[CP[X9759-3:TNXXC<
M1(0)9E(0Y^S*>I]>W/6OPL_8U\7ZEIGQYL+S1Y'59K^XFAQN_P!7-?JZ9"\_
M=8=N3FOZ#/\ B'3^%_\ T5?5_P KC_XU7L/P6_X(6?#?X/\ C.P\7VOQ$U#4
MYK'&VVFCF*-B19.0T8'&W Y'% 'Z1^,[F:^_902\N"3//X'5Y"<\L;DY///.
M/UK^%GX_:2NL_'>ZL6&Y+C4M/AD''*2ZC)&P&?521^-?WI?&_08?"_P"UWP]
M;OYD&E>%WM(WQC<J3ALX/3)/Z5_"7\7?^3AV_P"POI7_ *=7H _K"_X)?_LL
M_#?P;\.K3Q+!I*-JKK9W@DFB@D4R3*TKD[D)QN(_+WK]A8]*T^%S)#:6T+'_
M )Y011G\T4'UKX:_X)^?\D<T[_KPTW_T2:^]: #I1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% '/^(?^/&7_/\  :\O\*_\A6[_ .NR_P#H
M*UZAXA_X\9?\_P !KR_PK_R%;O\ Z[+_ .@K0![>O0?0?RI:1>@^@_E2T %%
M%% !1110 4444 %%%% !1110!#<?ZB;_ *YO_P"@FOY"?^"]_P!W6_\ KS7_
M -%I7]>UQ_J)O^N;_P#H)K^0G_@O?]W6_P#KS7_T6E '\TW[//[37QD_9ZU\
M:U\*6F344NEN1Y5K=7)\Y @4[;=2V?E7M7Z#^//^"L__  4+^.&CGP9XDDU2
M2POV:V*)H>N1D_; MNV6,8&",=2,5UG_  1O\#^$/&/Q2CM?%/AW2M=MSKMM
M&8=2M4N4*%+?*D..AR<_6O[JH?V7OV>8'62'X.^ XW1@RLFA6P964Y!!QU!Y
M% '\'_[*?_!*/]H7]HGQ?:^,=>TZ-M#U&^DO-4%]%<13-)>3"5MHN)%.#E^J
M\=Z_MO\ V2?V5_"_[-/PSTG0M,L1:ZS!I@M=19=FUB HX*C/11W-?4&@^"?"
M7A:(0>'?#VEZ-"N,1V%JD"C'3 7TSQ717/\ Q[R_[AH _D"_X+W*6;6P/^>*
M?^@I7YE?\$D_V:?"'Q>^*6FWWBNQ^UQZ=K<!3_5D;62($8<$'.\C^M?IO_P7
MK_UFM?\ 7%/_ $&.OFG_ ((=_P#(]?\ <8MO_;:@#^U?P7\,/!_@/P[9>&="
MTBSBTVP.;</:6QD!VQKRPB&>(UQ[\U^2G_!8CXJ7?PU^ OC"+3Y?LR?V9%)M
MC!49^QS-T3 &,\=@#7[65^%/_!;#P1-XJ^!'C Q%_P#D%1KA,\D64J]AUX_K
M0!_%9\#/C%X%T#XSVGCSXC">?3EUVUU"<P@,[118\PX='_E7]>/PN_X+U_L&
M?#[PGIWA^T&OP+;6ULDB)$BCS(X$C?[MD!RP-?QY_ /]G[2?BQ\4;+P%K>K2
MZ1#<ZM;:<UPF[>JSD;FX&<CGM_C7]/'@_P#X-I_A#XGT.RU=?C'K'^E6]O,0
MJW.%,T*R$?ZKMNQ^% 'DW_!1[_@KE^R3^T]\--7\/>!UU9]:N-(DM+1KJ)-H
MF8OCYC:H1G=V8?4=:_%S_@FAXU\0>'?CGI"Z1,R">^T:WEQOP89+PHXPN."C
M$<_2OZ)/^(8?X2?]%CUK_OFZ_P#C5?2'[.'_  0*^&/[/GC2W\8V/Q(U'6I[
M>6UE6WN(Y]NZUD:5#\T8&2QZD]J /TK^.'[;GPG_ &4/AIX?\1_%%[Y;:#PE
MH-_<FT&6Q-H]M<MC,<G."?7GK7Y[_P#$1+^PQ_SW\1_]\C_Y#K[9_;+_ ."?
M'AG]KWP.O@K6O%-WH%NNB6.BBXMQ(6\JRL$L5?"*2"RH&Z?D:_'/_B&'^$G_
M $6/6O\ OFZ_^-4 ?>'P[_X+Q?L:?$SQ%:^&O#\VOG4+MXXXA*H"[I9!$O\
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M5@S$Q6\\)&<]C$.O\J /TTHHHH ^&_V\?^2(>,_^P2W_ *#)7^?U!_R=,/\
ML8]'_P#3BU?Z O[>/_)$/&?_ &"6_P#09*_S^H/^3IA_V,>C_P#IQ:@#^_\
M_96_Y-\L?^O'1_\ TW/7\5/_  53_P"2[O\ ]C1-_P"B9Z_M6_96_P"3?+'_
M *\='_\ 3<]?Q4_\%4_^2[O_ -C1-_Z)GH _H8_X(C?\DLT'_KU?_P!)#7SE
M_P %T?\ D&O_ -@J3_T4U?1O_!$;_DEF@_\ 7J__ *2&OG+_ (+H_P#(-?\
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M]=Q_(U_3'7\SG_!"K_D1=&_Z[C^1K^F.@ HHHH **** "BBB@ HHHH ****
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MF_9'^-GQ9^ WQ?TC1H]6UJSCAU"QM&TP7C1PJKWH@8[ 0.02#].GH ?W6_\
M!3?XD77P_P#V=O'.J6$XC,.BF:-XV.T_NY""I3@CCL?SK_/GT+XLZ!>?&ZV\
M?>-S)<6!US3[V\9 &=H(+GS9?OJV3MS@$'\:_N1_;:34/BU^PO>7]PL@NKSP
M!ILLC EG>22U8LS$9R23U_E7\)W@SX/6?BCXK6/@'5[^33XKO6+#3I9P&WQI
M=7 A9^ 3E0<CCK0!_8?\"/\ @NG^P9\)? FE>&+=->MY+>QT]+D1PQJ#<06J
MQRD;;+D>87P2>]>&_MP_\%H/V,_V@?A'XG\(^&5UF76M0T&XL;!KF*,JMS+-
MN7+-:*0-I/(8'WZUC_#/_@V\^$/CWPII?B)?C#JZF^L+"Z=$6YVH]W:I.R<1
M8^5F(X]*]!_XAA_A)_T6/6O^^;K_ .-4 ?RZ_L=>-=8\+_&S0[OP](\;3ZQI
M<1(W_P"IEU)5(.PC^&0CZ=<5_IP?!>[FOOA/\/;NY.9[CPIHTLI.<EWLXV;.
M>>I[\^M?@1\&?^#=WX5?"+Q=8^*H/B?J>JRV4]K.MO<1W!1FM9A,GWHP.2 /
MH*_HF\*Z##X7\-Z)X=@<RPZ+IMKIT4AX+I:Q+$K8/(R%S0!OT444 %?E)_P5
M._Y(=J7^_J/_ *315^K=?E)_P5._Y(=J7^_J/_I-%0!_"%\!_P#DYE/^QFU+
M_P!+5K_2$_9&_P"2 ^ ?^P:O_H*5_F]_ ?\ Y.93_L9M2_\ 2U:_TA/V1O\
MD@/@'_L&K_Z"E 'TI1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 5S_B3_ )!ES_US_J*Z"N?\2?\ (,N?^N?]10!Y5X2_Y"<GU3^M
M>YI]Q?\ =7^0KPSPE_R$Y/JG]:]S3[B_[J_R% #J*** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *SM5_X\;G_KA-_P"BVK1K.U7_ (\;G_KA
M-_Z+:@#^"/\ X+M$CXJ>'2.HO+O_ -%W=?G)^RE^W/\ M+?LL:DVH_!.2Y2Z
M:R:S;R=/OKL_9VBEA/%HI.-DK\XQ7Z._\%V/^2K>'/\ K]N__1=W7U?_ ,$!
MOA7\.?'OC*XA\9^#- \2Q#PS-*(]7L(KM1(-/OF#XD_B#*ISZ@4 ?F+\5/\
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M/_X-D/A'>V-K=CXQZUBX@CF&%N<?.H/_ #RJY_Q##_"3_HL>M?\ ?-U_\:H
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M/>"2W#);NZJ48+;GE2<B0],U^W5 !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5SOB'_ (]O^ G^35T5<[XA_P"/;_@)_DU '$>$
M_P#D-O\ [A_FU>LUY-X3_P"0V_\ N'^;5ZS0 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4U_NG\/YBG4U_NG\/YB@#^*K_@X<_X^?"?_
M &&9O_1EQ7X-?LN_M:_';]F/Q3:^)_@T\R:S;1F.'R;.\NSL))QLM06(R?\
M.:_>7_@X<_X^?"?_ &&9O_1EQ7@G_!"3X?>"/''QVT6Q\7^%]'\16;V;,]OJ
MMG'=1,?,;DH_!- 'SK\0_P#@JM_P4$_:"T*\^'/BA]5ETWQ% =/N$31-;BS&
MYW$;FC '3KD=.M=?^R#_ ,$@OV@_CUXDT+Q=KFFP'09+W3[ZX%['-%<&UM[B
M.YN0?M$JDDP@X!7ELC&*_NRM?V7_ -GFW:.:#X/> XI4P5D30K964C.""!P:
M]8T#PAX8\+0I;^'=#T[1H47:D5A;I BKC& %XQCB@#P[]FK]G3P;^S9\-=/\
M%^#[$V4;V6G2ZHAV8;4HK7%TRE /E,\DQ&<Y!')K^-+_ (+Q#=X\T\'OKDO\
M[BO[NY_]4W^?6OX1?^"\'_(^Z=_V')?YW% 'V'_P;\^#]$-UH>OO:QR:@8G3
MS)(XW& '/\2D]3^%?U2?&G3;34OAUXBL;F)'MYK%D=-BE=N>@4@C''3'2OYA
M/^#?G_D'Z'_NR?\ H+U_43\6O^1&UW_KT;^= '^:O^WAI=IHW[:/BNPL4$5O
M!KVFB-% 4+_Q,K@<!0 .@[5_;;_P1:=W_9@N"[LY&I6 !9BQ V:CQDDU_%'_
M ,%!O^3WO&/_ &'M-_\ 3G<U_:+_ ,$<=0CTO]E"^O)6"I'J5AECT'[K4S_2
M@#]0?B9\5?A[\,=+N-;\5WFDQ16L+W#B6>Q2?;&2#M$I+ELYZ#/7BORI\?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MEU%M2\$ZGK=U,T2Q$7QD*[4& ?GO[CG!]!0!^A-E_P >=I_U[0?^BDK\"/\
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MD:YZX10HS^ J2@##\2VDE]X?UJTB/[RYTK4($XS\TUK(B_7DCCO7\.'_  5
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M0/[,?@G]HK01X>\87=];68$@W66_?^\QG[MQ >,<?-_2@#^(C]@W_DXS2?\
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M!<_\>\O^X:GIDB"1&0]&!!_'\J /Y /^"]?^LUK_ *XI_P"@QU\T_P#!#O\
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M_:3^+%W<:C<>*M.\&S6L-Q:VVJZ7J-O" /M,CJ);@QH245 <*#TZU[Y\/O\
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MX=MYX#J5M/:S!I1EODN"6)Z\9R*_CA@_Y.F'_8QZ/_Z<6K_2#^('P/\ !_Q
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M=!Z#'XU^)_\ @W5_8Z\4>(-1\0W?B#Q?;W.HW!N)8;<3QP(Q !5$36XT"\=
MBCVH _$W]O?_ (*]>)?VM?#=_H7P5\->,M*T^Y8NJ_V=J=Q&L94"0DBWA'W
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M\$/#'P#\%P^"/"EQ=7.F0-&R27F[S<QHR+G=-,>C'/S]:]HH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y_Q)_R#+G_ *Y_U%=!7/\
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M G^34 <1X3_Y#;_[A_FU>LUY-X3_ .0V_P#N'^;5ZS0 4444 %%%% !1110
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M75\U_IMQ )Q+-&=ZR3*HVG!.<$'KR"*_HN\#_P#!O'^Q]X&UF'6K#7?%=Y/
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MN:?<7_=7^0H =1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %<[XA_P"/;_@)_DU=%7.^(?\ CV_X"?Y-0!Q'A/\
MY#;_ .X?YM7K->3>$_\ D-O_ +A_FU>LT %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Q'C?\ X\8_J?Z5V]<1
MXW_X\8_J?Z4 <[X$^]_VU;_T,UZS7DW@3[W_ &U;_P!#->LT %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7.^(?^/;_ ("?Y-71
M5SOB'_CV_P" G^34 <1X3_Y#;_[A_FU>LUY-X3_Y#;_[A_FU>LT %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
MQ'C?_CQC^I_I7;UQ'C?_ (\8_J?Z4 <[X$^]_P!M6_\ 0S7K->3>!/O?]M6_
M]#->LT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5FZM_QXR_A_(UI5FZM_P >,OX?R- 'C6C?\AV?
M_KNO_H*U[I']Q?I7A>C?\AV?_KNO_H*U[I']Q?I0 ^BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH Y_Q#_P >,O\ G^ UY?X5_P"0K=_]=E_]!6O4
M/$/_ !XR_P"?X#7E_A7_ )"MW_UV7_T%: /;UZ#Z#^5+2+T'T'\J6@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K&US_ (\9
M?H/_ &:MFL;7/^/&7Z#_ -FH \PT3_D*R_\ 78?^@U[.O0?0?RKQC1/^0K+_
M -=A_P"@U[.O0?0?RH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH *Y_P 2?\@RY_ZY_P!1705S_B3_ )!ES_US
M_J* /*O"7_(3D^J?UKW-/N+_ +J_R%>&>$O^0G)]4_K7N:?<7_=7^0H =111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M /O"BO@__AY7^QM_T5[1_P X_P#X_1_P\K_8V_Z*]H_YQ_\ Q^@#[PHKX/\
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M'E?[&W_17M'_ #C_ /C]'_#RO]C;_HKVC_G'_P#'Z /O"BO@_P#X>5_L;?\
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MT?\ ./\ ^/T?\/*_V-O^BO:/^<?_ ,?H ^\**^#_ /AY7^QM_P!%>T?\X_\
MX_1_P\K_ &-O^BO:/^<?_P ?H ^\**^#_P#AY7^QM_T5[1_SC_\ C]'_  \K
M_8V_Z*]H_P"<?_Q^@#[PHKX/_P"'E?[&W_17M'_./_X_1_P\K_8V_P"BO:/^
M<?\ \?H ^\**^#_^'E?[&W_17M'_ #C_ /C]'_#RO]C;_HKVC_G'_P#'Z /O
M"BO@_P#X>5_L;?\ 17M'_./_ ./T?\/*_P!C;_HKVC_G'_\ 'Z /O"BO@_\
MX>5_L;?]%>T?\X__ (_1_P /*_V-O^BO:/\ G'_\?H ^\**^#_\ AY7^QM_T
M5[1_SC_^/T?\/*_V-O\ HKVC_G'_ /'Z /O"BO@__AY7^QM_T5[1_P X_P#X
M_1_P\K_8V_Z*]H_YQ_\ Q^@#[PHKX/\ ^'E?[&W_ $5[1_SC_P#C]'_#RO\
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M]%>T?\X__C]'_#RO]C;_ **]H_YQ_P#Q^@#[PHKX/_X>5_L;?]%>T?\ ./\
M^/T?\/*_V-O^BO:/^<?_ ,?H ^\**^#_ /AY7^QM_P!%>T?\X_\ X_1_P\K_
M &-O^BO:/^<?_P ?H ^\**^#_P#AY7^QM_T5[1_SC_\ C]'_  \K_8V_Z*]H
M_P"<?_Q^@#[PHKX/_P"'E?[&W_17M'_./_X_1_P\K_8V_P"BO:/^<?\ \?H
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MYQ__ !^@#[PHKX/_ .'E?[&W_17M'_./_P"/T?\ #RO]C;_HKVC_ )Q__'Z
M/O"BO@__ (>5_L;?]%>T?\X__C]'_#RO]C;_ **]H_YQ_P#Q^@#[PHKX/_X>
M5_L;?]%>T?\ ./\ ^/T?\/*_V-O^BO:/^<?_ ,?H ^\**^#_ /AY7^QM_P!%
M>T?\X_\ X_1_P\K_ &-O^BO:/^<?_P ?H ^\**^#_P#AY7^QM_T5[1_SC_\
MC]'_  \K_8V_Z*]H_P"<?_Q^@#[PHKX/_P"'E?[&W_17M'_./_X_1_P\K_8V
M_P"BO:/^<?\ \?H ^\**^#_^'E?[&W_17M'_ #C_ /C]'_#RO]C;_HKVC_G'
M_P#'Z /O"BO@_P#X>5_L;?\ 17M'_./_ ./T?\/*_P!C;_HKVC_G'_\ 'Z /
MO"BO@_\ X>5_L;?]%>T?\X__ (_1_P /*_V-O^BO:/\ G'_\?H ^\**^#_\
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M;_HKVC_G'_\ 'Z /O"BO@_\ X>5_L;?]%>T?\X__ (_1_P /*_V-O^BO:/\
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M_./_ ./T?\/*_P!C;_HKVC_G'_\ 'Z /O"LW5O\ CQE_#^1KXA_X>5_L;?\
M17M'_./_ ./U0U+_ (*4?L<RVDB)\7M'+'H,ISP?^FWO0!]$:-_R'9_^NZ_^
M@K7ND?W%^E?ECI7_  41_9(AU>:>3XK:2L33!@Q*= H!/^N]>*]>3_@I7^QL
M% _X6_HQ('.#'_\ 'J /O.BO@_\ X>5_L;?]%>T?\X__ (_1_P /*_V-O^BO
M:/\ G'_\?H ^\**^#_\ AY7^QM_T5[1_SC_^/T?\/*_V-O\ HKVC_G'_ /'Z
M /O"BO@__AY7^QM_T5[1_P X_P#X_1_P\K_8V_Z*]H_YQ_\ Q^@#[PHKX/\
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M'E?[&W_17M'_ #C_ /C]'_#RO]C;_HKVC_G'_P#'Z /O"BO@_P#X>5_L;?\
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MT?\ ./\ ^/T?\/*_V-O^BO:/^<?_ ,?H ^\**^#_ /AY7^QM_P!%>T?\X_\
MX_1_P\K_ &-O^BO:/^<?_P ?H ^\**^#_P#AY7^QM_T5[1_SC_\ C]'_  \K
M_8V_Z*]H_P"<?_Q^@#[PHKX/_P"'E?[&W_17M'_./_X_1_P\K_8V_P"BO:/^
M<?\ \?H ^\**^#_^'E?[&W_17M'_ #C_ /C]'_#RO]C;_HKVC_G'_P#'Z /O
M"BO@_P#X>5_L;?\ 17M'_./_ ./T?\/*_P!C;_HKVC_G'_\ 'Z /O"BO@_\
MX>5_L;?]%>T?\X__ (_1_P /*_V-O^BO:/\ G'_\?H ^\**^#_\ AY7^QM_T
M5[1_SC_^/T?\/*_V-O\ HKVC_G'_ /'Z /O"BO@__AY7^QM_T5[1_P X_P#X
M_1_P\K_8V_Z*]H_YQ_\ Q^@#[PHKX/\ ^'E?[&W_ $5[1_SC_P#C]'_#RO\
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M"BO@_P#X>5_L;?\ 17M'_./_ ./T?\/*_P!C;_HKVC_G'_\ 'Z /O"BO@_\
MX>5_L;?]%>T?\X__ (_1_P /*_V-O^BO:/\ G'_\?H ^\**^#_\ AY7^QM_T
M5[1_SC_^/T?\/*_V-O\ HKVC_G'_ /'Z /O"BO@__AY7^QM_T5[1_P X_P#X
M_1_P\K_8V_Z*]H_YQ_\ Q^@#[PHKX/\ ^'E?[&W_ $5[1_SC_P#C]'_#RO\
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MP?\ \/*_V-O^BO:/^<?_ ,?H_P"'E?[&W_17M'_./_X_0!]X45\'_P##RO\
M8V_Z*]H_YQ__ !^C_AY7^QM_T5[1_P X_P#X_0!]X45\'_\ #RO]C;_HKVC_
M )Q__'Z/^'E?[&W_ $5[1_SC_P#C] 'WA17P?_P\K_8V_P"BO:/^<?\ \?H_
MX>5_L;?]%>T?\X__ (_0!]X45\'_ /#RO]C;_HKVC_G'_P#'Z/\ AY7^QM_T
M5[1_SC_^/T ?>%%?!_\ P\K_ &-O^BO:/^<?_P ?H_X>5_L;?]%>T?\ ./\
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M8NN_\%)/V.[BPGBA^+NCL[)@*"F2<_\ 7:@#Z5\)?\A.3ZI_6O<T^XO^ZO\
M(5^67AK_ (*(?LD6M^\L_P 5](C0[2"2G;/_ $VZ\UZZO_!2O]C<*H_X6]H_
MW1W3T_Z[4 ?>5%?!_P#P\K_8V_Z*]H_YQ_\ Q^C_ (>5_L;?]%>T?\X__C]
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M!]X45\'_ /#RO]C;_HKVC_G'_P#'Z/\ AY7^QM_T5[1_SC_^/T ?>%%?!_\
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M ?>%%?!__#RO]C;_ **]H_YQ_P#Q^C_AY7^QM_T5[1_SC_\ C] 'WA17P?\
M\/*_V-O^BO:/^<?_ ,?H_P"'E?[&W_17M'_./_X_0!]X45\'_P##RO\ 8V_Z
M*]H_YQ__ !^C_AY7^QM_T5[1_P X_P#X_0!]X45\'_\ #RO]C;_HKVC_ )Q_
M_'Z/^'E?[&W_ $5[1_SC_P#C] 'WA17P?_P\K_8V_P"BO:/^<?\ \?H_X>5_
ML;?]%>T?\X__ (_0!]X45\'_ /#RO]C;_HKVC_G'_P#'Z/\ AY7^QM_T5[1_
MSC_^/T ?>%%?!_\ P\K_ &-O^BO:/^<?_P ?H_X>5_L;?]%>T?\ ./\ ^/T
M?>%%?!__  \K_8V_Z*]H_P"<?_Q^C_AY7^QM_P!%>T?\X_\ X_0!]X45\'_\
M/*_V-O\ HKVC_G'_ /'Z/^'E?[&W_17M'_./_P"/T ?>%%?!_P#P\K_8V_Z*
M]H_YQ_\ Q^C_ (>5_L;?]%>T?\X__C] 'WA17P?_ ,/*_P!C;_HKVC_G'_\
M'Z/^'E?[&W_17M'_ #C_ /C] 'WA17P?_P /*_V-O^BO:/\ G'_\?H_X>5_L
M;?\ 17M'_./_ ./T ?>%%?!__#RO]C;_ **]H_YQ_P#Q^C_AY7^QM_T5[1_S
MC_\ C] 'WA17P?\ \/*_V-O^BO:/^<?_ ,?H_P"'E?[&W_17M'_./_X_0!]X
M45\'_P##RO\ 8V_Z*]H_YQ__ !^C_AY7^QM_T5[1_P X_P#X_0!]X45\'_\
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M_P /*_V-O^BO:/\ G'_\?H ^\**^#_\ AY7^QM_T5[1_SC_^/T?\/*_V-O\
MHKVC_G'_ /'Z /O"BO@__AY7^QM_T5[1_P X_P#X_1_P\K_8V_Z*]H_YQ_\
MQ^@#[PHKX/\ ^'E?[&W_ $5[1_SC_P#C]'_#RO\ 8V_Z*]H_YQ__ !^@#[PH
MKX/_ .'E?[&W_17M'_./_P"/T?\ #RO]C;_HKVC_ )Q__'Z /O"BO@__ (>5
M_L;?]%>T?\X__C]'_#RO]C;_ **]H_YQ_P#Q^@#[PHKX/_X>5_L;?]%>T?\
M./\ ^/T?\/*_V-O^BO:/^<?_ ,?H ^\**^#_ /AY7^QM_P!%>T?\X_\ X_1_
MP\K_ &-O^BO:/^<?_P ?H ^\**^#_P#AY7^QM_T5[1_SC_\ C]'_  \K_8V_
MZ*]H_P"<?_Q^@#[PHKX/_P"'E?[&W_17M'_./_X_1_P\K_8V_P"BO:/^<?\
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MC_G'_P#'Z /O"BO@_P#X>5_L;?\ 17M'_./_ ./T?\/*_P!C;_HKVC_G'_\
M'Z /O"BO@_\ X>5_L;?]%>T?\X__ (_1_P /*_V-O^BO:/\ G'_\?H ^\**^
M#_\ AY7^QM_T5[1_SC_^/T?\/*_V-O\ HKVC_G'_ /'Z /O"BO@__AY7^QM_
MT5[1_P X_P#X_1_P\K_8V_Z*]H_YQ_\ Q^@#[PHKX/\ ^'E?[&W_ $5[1_SC
M_P#C]'_#RO\ 8V_Z*]H_YQ__ !^@#[PHKX/_ .'E?[&W_17M'_./_P"/T?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !7IWP5_P"2N?#;_L=/#W_IRMZ\QKT[
MX*_\E<^&W_8Z>'O_ $Y6] '^D?X#_P"1'\&?]BIX=_\ 319UU=<IX#_Y$?P9
M_P!BIX=_]-%G75T ?FK_ ,%;/^3'/BM_UQB_](=4K^"&O[WO^"MG_)CGQ6_Z
MXQ?^D.J5_!#0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %>G?!7_DKGPV_['3P]_P"G*WKS&O3O@K_R5SX;?]CIX>_]
M.5O0!_I'^ _^1'\&?]BIX=_]-%G75URG@/\ Y$?P9_V*GAW_ --%G75T ?FK
M_P %;/\ DQSXK?\ 7&+_ -(=4K^"&O[WO^"MG_)CGQ6_ZXQ?^D.J5_!#0 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !113XXY)7"1(SN>B
MJ,D_0"@!E%:$FE:E$GF26-RD>,[VB<+CUSBL^@ HHHH **** "BBB@ HHHH
M**** "BBE )( !))P .I- "45HKI&ILGF+8W1C_OB)BO3/7'IS5!T9&*.I5E
M.&5A@@^A':@!M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%.5&=@J*68\!0,D_05V>G_#CQ[JT"7.F^$=>OK>09CF
MMM.N)8W'!RK(A!'(YZ4 <5174:OX)\7: I?6_#FL:6BC+-?64UNH&,Y)D4#&
M.<^E<O0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MK:07NC/JL#,ML<6*[K<QM'_<EY);J: /P3B_8N^.<R+)'X=RK $'%QT(R/\
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M^S(N@SVP.K9BMIMA\L;B=AP"?MF>HQU]Z_*/_@@P<VWB0^OB!C^=Q7]9-_\
M\@ZZ_P"N$G\C0!_!-_P4/_9?\%?LV_$J7PYX-:\:R-I)<C[5D/N_=-WEDX_>
M$@9/;BOS>4Y -?N#_P %H/\ DM;_ /8)?_T"VK\/4^Z/Q_F: '4444 %%%%
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M2T.Q+&VM;R]A0OG=L@N7B7J3V'KU[FN&KUOX\_\ )3=;_P"PCJO_ *7O7DE
M!1110 44A( R> *]E^"_P1\9_&OQ19>'_#>CZC=6]VRC[=9QQNJ'S%0_>8GC
M<3]SMUH \>6-W^XCO_NJ6_D#7KG@?X'?$#XA+$WAS29+D2J&3=',,@C(^[$W
M;^7%?U/_ +&G_!(+PIX,TW3/$WCZZLO$,M[#!>R:3JMJY,!)56MVV6L0_A).
M)#U^]7[)^'OV9O@7X8ACBTCX:>&;(QC"M!;3*0,8 &9SP/I0!_"MHO\ P3O_
M &E=>M_M.G^%5DB&.3]J'7ITMCZ&N0\3?L2_'CPFTBZQX<\DQ9#[1<G&,YZP
M"O\ 0;M/AUX(L$\NS\-:9;Q_W8XG _5S67J'P?\ AEJI8ZCX,T6\+9W&:&1L
MYZYQ*.M '^;OXD^'GBCPK*\.KZ?+"\>=V(Y2!@X[H*XAE920P*D<$$$']:_T
M5_B1^QG\!_'NAW6F+\._"]A>7 <+?BUG,B%E9<Y\V3H3G[AQCBOYN?VW_P#@
MD1K7P\>_\8> [^YUVTF\[4'T[2[8".T4APL'[RTAX&U2/G;[W4T ?SVT5T7B
M?PKKGA'4Y]*U[3;K3;NW($D-TJJZDLRC(5F'52 <D?2N=H **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ KWC]F9]#E^,W@?3=>(^RWNLQHZLJ.K(8W)RK$*>1T_
M_57@];GA'5CX=\7:%X@5O+;3+M9Q(#@H0K+D'C&,_KVXH _T!O@A^SI\)=7^
M'.EW5OI&G3Q7,<L?F/IEBS$-!$,YVL<@-D<_E7XK_P#!6C]BO2/#]G>>+O!.
MEA+2STP/,\=NL*+,]NCL,194?,C8SV[>GZA_\$P_B\?B1\%_"Q>]^TR-:2RE
M2^\@"T@;/IVSW_(5]4_M<_#*S^)OP8\4Z";..:^O(52*;86E4""X7"]1_$O\
M/84 ?YSD]O+97,UE.-LUN=KKZ'CCL>_H/\&5[[^TI\-+GX8_$[Q)IEP' CU%
MH%#*% QCH H]/<5X%UH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\G/^)/\ KB?_ $HEK^[3Q+_R+^J?]>;_ ,UK^$O_ (*J?\G/^)/^N)_]*):
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MS\O^J?\ W30!_5O_ ,$0O^1-T#_KV/\ Z3"OZ4T^XO\ NK_(5_-9_P $0O\
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M@O[(/AO]EWQM!I'A[4[O4(+V&:Z+7'F?+\J/M4.[?*-YQCC'T%?FPIW*#ZT
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MC"_C:[UF]L0_[U(5N Q7<,8S;RCH2.A_P_EN))Y))/J3DTE '^A=^SM^W/\
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MQ^X"?O=><=: /@J*":<[8899FZ;8HWD.?3" FK;:1JJ+O?3-01/[S65RJ_\
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M=6U*R4DI:W+Q*3U( ')_/_.* /Z1?^"+'QS.F3Z?X -YM6PTK_4E^AEMI8\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^"H?P?GEC@B^QR2RLJ1QK? N[,<!57.22> !U-?PD#5M54!5U/4  , "]N0
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M_P"D\=?/?_!2'_DU_P")W_8OR_SKZ$_9Q_Y)IHO_ %ZVW_I/'7SW_P %(?\
MDU_XG?\ 8OR_SH _S_[W_72_C_(U_61_P03_ .2(ZO\ ]C4W_I7JM?R;WO\
MKI?Q_D:_K(_X()_\D1U?_L:F_P#2O5: /Z&O$O\ R+^J?]>;_P UK^%7_@J/
M9W&H?M4Z[9VL3S33^7$J1J6;,MY)&#@>[5_=3XF./#VJGTLG/_H/I7\Y.N?L
M/ZI\>/VVK_Q9XETR1_ YMHIX;E$=F-Q!>33 $$*F/E0G#GK@B@#F_P#@DO\
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M\+7+!I=*O&MV(  )'/&./_K<]*_TF_$FDIKFD7.G2*'2=<%2,@\,.A^O>O\
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M]IGX/:[X=\110>._"ZR68>$)_:]L6F*G&4&_YLYXQ^O6OY//^"C7_!03Q/\
M%WQQK/AGP=K,B^$P[B.:UNI;:<RI*8V&ZW*G "=I.>]?DW:?$/QA9M,T?B'6
MCY[EY%.K7^TDX)R//(/(]/:@#ZH_X*!ZWINO_M&>.]0TJ[@OK2>\0QW%M(LL
M3_Z1<GY74D$<CIGJ.:^(:OZEJ5YJMU)>7LTD\\IR\DLCRNQR3R[EF/7N:H4
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M7/\ #.F^*[JWT_PSJ_V.VN$.R)IRK('8LH(]5&.G>OW&_:Y^#M_\9?@UXO\
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MJ_A_5;#4;:Y7?&]G<I.A 56)#*2" #G.>F*S_BO\/['XG>"=4\':E%'-::D
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M^2*>'?\ L!Z7_P"DZU[Q^TW_ ,DI\6_]B_JG_I.U>#_\$\_^2*>'?^P'I?\
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MH!CH>W:OK_\ X(HG/Q0\4GUU2V/_ )"T^@#^V<1)<6)@<!DFMFB=3T9)(RC
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M4"D&!W.2<MU9.@QS7\47QI_:*\?_ !;\9:GKVH:[J44<UX;F$6FIWL48.20
ML<B*.3V&,?2@#^M#_@IQ\9/AQXH^!>MVVA^+] U*XE;<L%GJ4$\AS W148D]
M?S_7^+G66$GB#6Y%.5>]D96'1@0O(//%=+>>/?%&H69L;S6=3NH#C*W&HW<X
M.!CE99&4\>U<:3N9G.2SG+$G))]Z /K?]AK5_P"P_CA;70;!FN-+BSD@_-=2
MC'4#^+]/PK^_CX,Z@=1\#:%.223I&E]\];./_#WK_.^_9QU;^Q?BEHMQN"^;
MJVCQ]<9W7ZCGU^]^0_"O]!']F:__ +0^&>@S YSH^D<^YLD[]* /D/\ X*@^
M"E\7?"<Y"G[%IMY(-PSWD/'Y]L'WK^%SQ;IO]C>(+ZPX 6YN<8]IG'^>?Z5_
MH#?MUZ?)??"77-BAO+T6])SV&&YZ9[U_ U\6H6@\=ZG&PP1<W/\ Z4/_ )Z\
M4 >?4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M(TCI&H)9V5% !)+,0H  Y))(  Y- '3>#?"FI>-O$6G^&M(MYKK4-1?R[>"
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MP?X@UJ?[3J6J:-#=7DV#^\F:656;YF8\A1U8_P J^"O^"L__ ";@/^PC<?\
MH%I0!_"_XG_Y#NI_]?MS_P"C#7[5?\$+?^2T^-_^O"/_ -$O7XJ^)_\ D.ZG
M_P!?MS_Z,-?M5_P0M_Y+3XW_ .O"/_T2] ']FEM_QYQ_]<$_]%+7\D?_  7-
M_P"1G\#?]=[G_P!%ZC7];EM_QYQ_]<$_]%+7\D?_  7-_P"1G\#?]=[G_P!%
MZC0!_/MX:_Y&OPE_V-&@?^G6TK_11_9-_P"2/^"O^Q8T/_T@AK_.N\-?\C7X
M2_[&C0/_ $ZVE?Z*/[)O_)'_  5_V+&A_P#I!#0!SG[:O_)%_&'_ &+>J_\
MHHU_GQ>-/^1GUO\ ["NI?^EL]?Z#O[:O_)%_&'_8MZK_ .BC7^?%XT_Y&?6_
M^PKJ7_I;/0!R,_\ JG^@_F*_LP_X(J,Q^ G@P$G'V*4X_P"W"VK^,^?_ %3_
M $'\Q7]EW_!%/_D@O@S_ *\I?_3?:T ?N\O0?0?RK_/G_P""DQQ^U5\62/\
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MN,7_ * M '\A_P#P61_Y&6'_ +"4_P#[5K^>WNW^\W_H1K^A+_@LC_R,L/\
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M-NBI(_T:R''^_>5^<D?W%^E?HU_P2S_Y.-NO^O:Q_P#0[R@#^\OPASX=T?\
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MP>^(5[)J7C7X?>'O$=]+_K+K4K>665^2?F*S(.I)Z=:XK_AD']F;_HC'@O\
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M +%_5/\ TG:@#_/:^//_ "4W6_\ L(ZK_P"E[UY)7K?QY_Y*;K?_ &$=5_\
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M5D^Q7APV<9^S2>E?P<?&?3X+C]L;3M/78L,_C&^0\': -WXX_P ]>O\ <_\
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M_:,>3QZ8K_08_92C:+X6:"K@@_V/HYY!'_+D@Z'Z4 <I^VD0/A+XCR0,Z%?
M9]<&OX"?C.0?B#JF#G_2;K_TI>O[S?V]M2:P^$NLA9%C\W1KT?,P7/W^.HZX
M[>E?P1?%28W'C?4I2=V;FYR1R/\ CX?O^/\ GI0!P=%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M+^AYQ7\7OBG]M_XNZGX@U2_M_$FMQPW-RTB)%J]VD:@JHPJJX '';Z5^U_\
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MH/Y5_GU?\%(AG]JWXKCU\02#\Z_OY;Q+H$4>^35[%$ &6:= !QW.:_S_ /\
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M<Y!Q7Z0?%GQ%H0\%ZJ3JMD ;6Y )G0<FVE'KZT ?Y^O[7O\ R6SQS_V,M_\
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MVT3R>6%,X;^]SDG/.W]17Y.?\%DM;TB?PAI,<.HVLKG2IP%2522?]*. ![4
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M[S89FR<GU8GIWK#H _7[_@C'_P EC\3?]?5M_P"@V]?V_:?_ ,>5K_U[P?\
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M#_P1@U*PTWXH^)S?W<%H)-5MBAGD";_W5A]W/7H?RH _MU3_ (\Q_P!>Y_\
M19K^5O\ X+=?\AK2O^P;)_Z*%?U%1>(]!>Q#)JUDR_9SR)U(_P!7FOY9?^"U
M^JZ;?:WIGV.]M[G;IT@;RI ^"8NAQ0!_-?!_JE_SZ5]-?L8_\G'>%O\ =_\
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MS"D,$)A1)I9 H4H4^Z%8 [2?T]*^3Z* /T[O?^"KW[2]]:O:2WEB(Y, E99
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M:5Y6)^KL34-% !1110!^OW_!&/\ Y+'XF_Z^K;_T&WK^WNS_ .0=!_UZ1?\
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MX'2O,Z* /U)\&_\ !6W]ISP3##!IEUI\B0*JK]HED<D#'4M"V>E>N)_P7/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 ?H'_P $Y/C[X5_9Z^)F
MHZUXMBN9;74[NW\K[,Q4J%6,'>1%-@?*>2!V[<U_6QH?_!3;X":AH,-XCS1J
MMLBF.2_A5\B$#[K6JGM_=Z]J_@HCEEA8/%(\;@Y#(Q5@1T((((/O6TGBGQ+$
MGEQZ]JR1XQL6_N57'IM$@&* /VG_ ."I7[7OPY^/>I:=;>$(;M6L$GMY7FD\
MQ2S), 5(MXACYQR&(]Z_#6%2D:J>H']!5ZXO+N[;?=7,]PV2=TTKR-D]>7)/
M.:K4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %>Y_LX^,?"'@'XH^%_%'C"SGN[;2=42Z @/
MSB,*P./W,W/)[?XUX92@E2&!((Z$<$?0T ?VG_#G_@K]^S7X?\%65D-,UI!;
M12N$$Q!&V).W]F]]M?C%_P %)/\ @HKX6_:4OI-/^'JZG9::^GFSFCO?-.Z6
M.&.+()M[=<$JV,KC!ZX%?BRNI:@B[%O;I4P1L$\@7!ZC ;&#Z549V<EG9F8]
M2Q))_$T ,R[L9)3NE?EV]3[<D_F3^%+110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %>G?!7_DKGPV_P"QT\/?^G*WKS&O3O@K_P E
M<^&W_8Z>'O\ TY6] '^D?X#_ .1'\&?]BIX=_P#319UU=<IX#_Y$?P9_V*GA
MW_TT6==70!^:O_!6S_DQSXK?]<8O_2'5*_@AK^][_@K9_P F.?%;_KC%_P"D
M.J5_!#0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %>G?!7_ )*Y\-O^QT\/?^G*WKS&O3O@K_R5SX;?]CIX>_\ 3E;T
M ?Z1_@/_ )$?P9_V*GAW_P!-%G75URG@/_D1_!G_ &*GAW_TT6==70!^>?\
MP4]\,:[X]_8^^)/A/PEIT^M^(=1AC%EIEH UQ<8L]00[%8J#AI$'7^(8K^+B
M/]A;]J^5%=/@QXK96&01! 01_P!_J_OC\57,R:E"%; \OW]$YZUZUH;%]+M&
M;DF,9/K0!_GB_P##"7[6/_1%O%G_ (#P_P#QZC_AA+]K'_HBWBS_ ,!X?_CU
M?Z*%% '^=?\ \,)?M8_]$6\6?^ \/_QZC_AA+]K'_HBWBS_P'A_^/5_HH44
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M  'A_P#CU?Z*%% '^=?_ ,,)?M8_]$6\6?\ @/#_ /'J/^&$OVL?^B+>+/\
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M_#"7[6/_ $1;Q9_X#P__ !ZC_AA+]K'_ *(MXL_\!X?_ (]7^BA10!_G7_\
M#"7[6/\ T1;Q9_X#P_\ QZC_ (82_:Q_Z(MXL_\  >'_ ./5_HH44 ?YU_\
MPPE^UC_T1;Q9_P" \/\ \>H_X82_:Q_Z(MXL_P# >'_X]7^BA10!_G7_ /#"
M7[6/_1%O%G_@/#_\>H_X82_:Q_Z(MXL_\!X?_CU?Z*%% '^=?_PPE^UC_P!$
M6\6?^ \/_P >H_X82_:Q_P"B+>+/_ >'_P"/5_HH44 ?YU__  PE^UC_ -$6
M\6?^ \/_ ,>H_P"&$OVL?^B+>+/_  'A_P#CU?Z*%% '^=?_ ,,)?M8_]$6\
M6?\ @/#_ /'J/^&$OVL?^B+>+/\ P'A_^/5_HH44 ?YU_P#PPE^UC_T1;Q9_
MX#P__'J/^&$OVL?^B+>+/_ >'_X]7^BA10!_G7_\,)?M8_\ 1%O%G_@/#_\
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M10!_G7_\,)?M8_\ 1%O%G_@/#_\ 'J/^&$OVL?\ HBWBS_P'A_\ CU?Z*%%
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M \/_ ,>H_P"&$OVL?^B+>+/_  'A_P#CU?Z*%% '^=?_ ,,)?M8_]$6\6?\
M@/#_ /'J/^&$OVL?^B+>+/\ P'A_^/5_HH44 ?YU_P#PPE^UC_T1;Q9_X#P_
M_'J/^&$OVL?^B+>+/_ >'_X]7^BA10!_G7_\,)?M8_\ 1%O%G_@/#_\ 'J/^
M&$OVL?\ HBWBS_P'A_\ CU?Z*%% '^=?_P ,)?M8_P#1%O%G_@/#_P#'J/\
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M_P##"7[6/_1%O%G_ (#P_P#QZC_AA+]K'_HBWBS_ ,!X?_CU?Z*%% '^=?\
M\,)?M8_]$6\6?^ \/_QZC_AA+]K'_HBWBS_P'A_^/5_HH44 ?YU__#"7[6/_
M $1;Q9_X#P__ !ZC_AA+]K'_ *(MXL_\!X?_ (]7^BA10!_G7_\ #"7[6/\
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M!X?_ (]7^BA10!_G7_\ #"7[6/\ T1;Q9_X#P_\ QZC_ (82_:Q_Z(MXL_\
M >'_ ./5_HH44 ?YU_\ PPE^UC_T1;Q9_P" \/\ \>H_X82_:Q_Z(MXL_P#
M>'_X]7^BA10!_G7_ /#"7[6/_1%O%G_@/#_\>H_X82_:Q_Z(MXL_\!X?_CU?
MZ*%% '^=?_PPE^UC_P!$6\6?^ \/_P >H_X82_:Q_P"B+>+/_ >'_P"/5_HH
M44 ?YU__  PE^UC_ -$6\6?^ \/_ ,>H_P"&$OVL?^B+>+/_  'A_P#CU?Z*
M%% '^=?_ ,,)?M8_]$6\6?\ @/#_ /'J/^&$OVL?^B+>+/\ P'A_^/5_HH44
M ?YU_P#PPE^UC_T1;Q9_X#P__'J/^&$OVL?^B+>+/_ >'_X]7^BA10!_G7_\
M,)?M8_\ 1%O%G_@/#_\ 'J/^&$OVL?\ HBWBS_P'A_\ CU?Z*%% '^=?_P ,
M)?M8_P#1%O%G_@/#_P#'J/\ AA+]K'_HBWBS_P !X?\ X]7^BA10!_G7_P##
M"7[6/_1%O%G_ (#P_P#QZC_AA+]K'_HBWBS_ ,!X?_CU?Z*%% '^=?\ \,)?
MM8_]$6\6?^ \/_QZC_AA+]K'_HBWBS_P'A_^/5_HH44 ?YU__#"7[6/_ $1;
MQ9_X#P__ !ZC_AA+]K'_ *(MXL_\!X?_ (]7^BA10!_G7_\ #"7[6/\ T1;Q
M9_X#P_\ QZC_ (82_:Q_Z(MXL_\  >'_ ./5_HH44 ?YU_\ PPE^UC_T1;Q9
M_P" \/\ \>H_X82_:Q_Z(MXL_P# >'_X]7^BA10!_G7_ /#"7[6/_1%O%G_@
M/#_\>H_X82_:Q_Z(MXL_\!X?_CU?Z*%% '^=?_PPE^UC_P!$6\6?^ \/_P >
MH_X82_:Q_P"B+>+/_ >'_P"/5_HH44 ?YU__  PE^UC_ -$6\6?^ \/_ ,>H
M_P"&$OVL?^B+>+/_  'A_P#CU?Z*%% '^=?_ ,,)?M8_]$6\6?\ @/#_ /'J
M/^&$OVL?^B+>+/\ P'A_^/5_HH44 ?YU_P#PPE^UC_T1;Q9_X#P__'J/^&$O
MVL?^B+>+/_ >'_X]7^BA10!_G7_\,)?M8_\ 1%O%G_@/#_\ 'J/^&$OVL?\
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MP_\ QZC_ (82_:Q_Z(MXL_\  >'_ ./5_HH44 ?YU_\ PPE^UC_T1;Q9_P"
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MPE^UC_T1;Q9_X#P__'J/^&$OVL?^B+>+/_ >'_X]7^BA10!_G7_\,)?M8_\
M1%O%G_@/#_\ 'J/^&$OVL?\ HBWBS_P'A_\ CU?Z*%% '^=?_P ,)?M8_P#1
M%O%G_@/#_P#'J/\ AA+]K'_HBWBS_P !X?\ X]7^BA10!_G7_P##"7[6/_1%
MO%G_ (#P_P#QZC_AA+]K'_HBWBS_ ,!X?_CU?Z*%% '^=?\ \,)?M8_]$6\6
M?^ \/_QZC_AA+]K'_HBWBS_P'A_^/5_HH44 ?YU__#"7[6/_ $1;Q9_X#P__
M !ZC_AA+]K'_ *(MXL_\!X?_ (]7^BA10!_G7_\ #"7[6/\ T1;Q9_X#P_\
MQZC_ (82_:Q_Z(MXL_\  >'_ ./5_HH44 ?YU_\ PPE^UC_T1;Q9_P" \/\
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M ,>K_10HH _SK_\ AA+]K'_HBWBS_P !X?\ X]1_PPE^UC_T1;Q9_P" \/\
M\>K_ $4** /\Z_\ X82_:Q_Z(MXL_P# >'_X]1_PPE^UC_T1;Q9_X#P__'J_
MT4** /\ .O\ ^&$OVL?^B+>+/_ >'_X]1_PPE^UC_P!$6\6?^ \/_P >K_10
MHH _SK_^&$OVL?\ HBWBS_P'A_\ CU'_  PE^UC_ -$6\6?^ \/_ ,>K_10H
MH _SK_\ AA+]K'_HBWBS_P !X?\ X]1_PPE^UC_T1;Q9_P" \/\ \>K_ $4*
M* /\Z_\ X82_:Q_Z(MXL_P# >'_X]1_PPE^UC_T1;Q9_X#P__'J_T4** /\
M.O\ ^&$OVL?^B+>+/_ >'_X]1_PPE^UC_P!$6\6?^ \/_P >K_10HH _SK_^
M&$OVL?\ HBWBS_P'A_\ CU'_  PE^UC_ -$6\6?^ \/_ ,>K_10HH _SK_\
MAA+]K'_HBWBS_P !X?\ X]1_PPE^UC_T1;Q9_P" \/\ \>K_ $4** /\Z_\
MX82_:Q_Z(MXL_P# >'_X]1_PPE^UC_T1;Q9_X#P__'J_T4** /\ .O\ ^&$O
MVL?^B+>+/_ >'_X]1_PPE^UC_P!$6\6?^ \/_P >K_10HH _SK_^&$OVL?\
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MX?\ X]1_PPE^UC_T1;Q9_P" \/\ \>K_ $4** /\Z_\ X82_:Q_Z(MXL_P#
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M \/_ ,>K_10HH _SK_\ AA+]K'_HBWBS_P !X?\ X]1_PPE^UC_T1;Q9_P"
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MZ_\ X82_:Q_Z(MXL_P# >'_X]1_PPE^UC_T1;Q9_X#P__'J_T4** /\ .O\
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M'_X]1_PPE^UC_P!$6\6?^ \/_P >K_10HH _SK_^&$OVL?\ HBWBS_P'A_\
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M !ZO]%"B@#_.O_X82_:Q_P"B+>+/_ >'_P"/4?\ #"7[6/\ T1;Q9_X#P_\
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M_#"7[6/_ $1;Q9_X#P__ !ZO]%"B@#_.O_X82_:Q_P"B+>+/_ >'_P"/4?\
M#"7[6/\ T1;Q9_X#P_\ QZO]%"B@#_.O_P"&$OVL?^B+>+/_  'A_P#CU'_#
M"7[6/_1%O%G_ (#P_P#QZO\ 10HH _SK_P#AA+]K'_HBWBS_ ,!X?_CU'_#"
M7[6/_1%O%G_@/#_\>K_10HH _P Z_P#X82_:Q_Z(MXL_\!X?_CU'_#"7[6/_
M $1;Q9_X#P__ !ZO]%"B@#_.O_X82_:Q_P"B+>+/_ >'_P"/4?\ #"7[6/\
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M?\,)?M8_]$6\6?\ ?B'_ ./5_?-H%S*VKW"LV0LP '/]T>]>TKT'T'\J /\
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M_#"7[6/_ $1;Q9_X#P__ !ZO]%"B@#_.O_X82_:Q_P"B+>+/_ >'_P"/4?\
M#"7[6/\ T1;Q9_X#P_\ QZO]%"B@#_.O_P"&$OVL?^B+>+/_  'A_P#CU'_#
M"7[6/_1%O%G_ (#P_P#QZO\ 10HH _SK_P#AA+]K'_HBWBS_ ,!X?_CU'_#"
M7[6/_1%O%G_@/#_\>K_10HH _P Z_P#X82_:Q_Z(MXL_\!X?_CU'_#"7[6/_
M $1;Q9_X#P__ !ZO]%"B@#_.O_X82_:Q_P"B+>+/_ >'_P"/4?\ #"7[6/\
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M%"B@#_.O_P"&$OVL?^B+>+/_  'A_P#CU'_#"7[6/_1%O%G_ (#P_P#QZO\
M10HH _SK_P#AA+]K'_HBWBS_ ,!X?_CU'_#"7[6/_1%O%G_@/#_\>K_10HH
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MJ$/]: /\\*+]B']J:=ML7P=\4NPZ@0P<?^1JN?\ #"7[6/\ T1;Q9_WXA_\
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M  'A_P#CU?Z*%% '^=?_ ,,)?M8_]$6\6?\ @/#_ /'J/^&$OVL?^B+>+/\
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M_#"7[6/_ $1;Q9_X#P__ !ZC_AA+]K'_ *(MXL_\!X?_ (]7^BA10!_G7_\
M#"7[6/\ T1;Q9_X#P_\ QZC_ (82_:Q_Z(MXL_\  >'_ ./5_HH44 ?YU_\
MPPE^UC_T1;Q9_P" \/\ \>H_X82_:Q_Z(MXL_P# >'_X]7^BA10!_G7_ /#"
M7[6/_1%O%G_@/#_\>H_X82_:Q_Z(MXL_\!X?_CU?Z*%% '^=?_PPE^UC_P!$
M6\6?^ \/_P >H_X82_:Q_P"B+>+/_ >'_P"/5_HH44 ?YU__  PE^UC_ -$6
M\6?^ \/_ ,>H_P"&$OVL?^B+>+/_  'A_P#CU?Z*%% '^=?_ ,,)?M8_]$6\
M6?\ @/#_ /'J/^&$OVL?^B+>+/\ P'A_^/5_HH44 ?YU_P#PPE^UC_T1;Q9_
MX#P__'J/^&$OVL?^B+>+/_ >'_X]7^BA10!_G7_\,)?M8_\ 1%O%G_@/#_\
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M10!_G7_\,)?M8_\ 1%O%G_@/#_\ 'J/^&$OVL?\ HBWBS_P'A_\ CU?Z*%%
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MM8_]$6\6?^ \/_QZO]%"B@#_ #K_ /AA+]K'_HBWBS_P'A_^/4?\,)?M8_\
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M!X?_ (]1_P ,)?M8_P#1%O%G_@/#_P#'J_T4** /\Z__ (82_:Q_Z(MXL_\
M >'_ ./4?\,)?M8_]$6\6?\ @/#_ /'J_P!%"B@#_.O_ .&$OVL?^B+>+/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K
MGO$O_(,G_P!P_P!:Z&N>\2_\@R?_ '#_ %H \P\*?\A*3_@/\Q7MR?<7_=7^
M0KQ'PI_R$I/^ _S%>W)]Q?\ =7^0H =1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %<MXK_Y!TW_ %R?^35U-<MX
MK_Y!TW_7)_Y-0!Y]\/O^/\?[K_UKVJO%?A]_Q_C_ '7_ *U[50 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M:0^.W_14O%O_ (,/_M='_#2'QV_Z*EXM_P#!A_\ :Z /[T_[6TK_ *">G_\
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M^@GI_P#X&VW_ ,<H_M;2O^@GI_\ X&VW_P <K^"S_AI#X[?]%2\6_P#@P_\
MM='_  TA\=O^BI>+?_!A_P#:Z /[T_[6TK_H)Z?_ .!MM_\ '*/[6TK_ *">
MG_\ @;;?_'*_@L_X:0^.W_14O%O_ (,/_M='_#2'QV_Z*EXM_P#!A_\ :Z /
M[T_[6TK_ *">G_\ @;;?_'*/[6TK_H)Z?_X&VW_QROX+/^&D/CM_T5+Q;_X,
M/_M='_#2'QV_Z*EXM_\ !A_]KH _O3_M;2O^@GI__@;;?_'*/[6TK_H)Z?\
M^!MM_P#'*_@L_P"&D/CM_P!%2\6_^##_ .UT?\-(?';_ **EXM_\&'_VN@#^
M]/\ M;2O^@GI_P#X&VW_ ,<H_M;2O^@GI_\ X&VW_P <K^"S_AI#X[?]%2\6
M_P#@P_\ M='_  TA\=O^BI>+?_!A_P#:Z /[T_[6TK_H)Z?_ .!MM_\ '*/[
M6TK_ *">G_\ @;;?_'*_@L_X:0^.W_14O%O_ (,/_M='_#2'QV_Z*EXM_P#!
MA_\ :Z /[T_[6TK_ *">G_\ @;;?_'*/[6TK_H)Z?_X&VW_QROX+/^&D/CM_
MT5+Q;_X,/_M='_#2'QV_Z*EXM_\ !A_]KH _O3_M;2O^@GI__@;;?_'*/[6T
MK_H)Z?\ ^!MM_P#'*_@L_P"&D/CM_P!%2\6_^##_ .UT?\-(?';_ **EXM_\
M&'_VN@#^]/\ M;2O^@GI_P#X&VW_ ,<H_M;2O^@GI_\ X&VW_P <K^"S_AI#
MX[?]%2\6_P#@P_\ M='_  TA\=O^BI>+?_!A_P#:Z /[T_[6TK_H)Z?_ .!M
MM_\ '*/[6TK_ *">G_\ @;;?_'*_@L_X:0^.W_14O%O_ (,/_M='_#2'QV_Z
M*EXM_P#!A_\ :Z /[T_[6TK_ *">G_\ @;;?_'*/[6TK_H)Z?_X&VW_QROX+
M/^&D/CM_T5+Q;_X,/_M='_#2'QV_Z*EXM_\ !A_]KH _O3_M;2O^@GI__@;;
M?_'*/[6TK_H)Z?\ ^!MM_P#'*_@L_P"&D/CM_P!%2\6_^##_ .UT?\-(?';_
M **EXM_\&'_VN@#^]/\ M;2O^@GI_P#X&VW_ ,<H_M;2O^@GI_\ X&VW_P <
MK^"S_AI#X[?]%2\6_P#@P_\ M='_  TA\=O^BI>+?_!A_P#:Z /[T_[6TK_H
M)Z?_ .!MM_\ '*/[6TK_ *">G_\ @;;?_'*_@L_X:0^.W_14O%O_ (,/_M='
M_#2'QV_Z*EXM_P#!A_\ :Z /[T_[6TK_ *">G_\ @;;?_'*/[6TK_H)Z?_X&
MVW_QROX+/^&D/CM_T5+Q;_X,/_M='_#2'QV_Z*EXM_\ !A_]KH _O3_M;2O^
M@GI__@;;?_'*QM;U;2C8RXU/3SP/^7VV]_\ II7\(O\ PTA\=O\ HJ7BW_P8
M?_:ZKW7[1OQS>)@WQ0\6,#U!U#K]?W= ']M?A[5=+_MBY/\ :5ACSQS]LM\?
M='_32O;UU;2L#_B9Z?T'_+[;>G_72OX!K+]H7XV)<.Z?$OQ4K%LDB_YSQS]R
MNG_X:0^.P_YJEXM_\&'_ -KH _O3_M;2O^@GI_\ X&VW_P <H_M;2O\ H)Z?
M_P"!MM_\<K^"S_AI#X[?]%2\6_\ @P_^UT?\-(?';_HJ7BW_ ,&'_P!KH _O
M3_M;2O\ H)Z?_P"!MM_\<H_M;2O^@GI__@;;?_'*_@L_X:0^.W_14O%O_@P_
M^UT?\-(?';_HJ7BW_P &'_VN@#^]/^UM*_Z">G_^!MM_\<H_M;2O^@GI_P#X
M&VW_ ,<K^"S_ (:0^.W_ $5+Q;_X,/\ [71_PTA\=O\ HJ7BW_P8?_:Z /[T
M_P"UM*_Z">G_ /@;;?\ QRC^UM*_Z">G_P#@;;?_ !ROX+/^&D/CM_T5+Q;_
M .##_P"UT?\ #2'QV_Z*EXM_\&'_ -KH _O3_M;2O^@GI_\ X&VW_P <H_M;
M2O\ H)Z?_P"!MM_\<K^"S_AI#X[?]%2\6_\ @P_^UT?\-(?';_HJ7BW_ ,&'
M_P!KH _O3_M;2O\ H)Z?_P"!MM_\<H_M;2O^@GI__@;;?_'*_@L_X:0^.W_1
M4O%O_@P_^UT?\-(?';_HJ7BW_P &'_VN@#^]/^UM*_Z">G_^!MM_\<H_M;2O
M^@GI_P#X&VW_ ,<K^"S_ (:0^.W_ $5+Q;_X,/\ [71_PTA\=O\ HJ7BW_P8
M?_:Z /[T_P"UM*_Z">G_ /@;;?\ QRC^UM*_Z">G_P#@;;?_ !ROX+/^&D/C
MM_T5+Q;_ .##_P"UT?\ #2'QV_Z*EXM_\&'_ -KH _O3_M;2O^@GI_\ X&VW
M_P <H_M;2O\ H)Z?_P"!MM_\<K^"S_AI#X[?]%2\6_\ @P_^UT?\-(?';_HJ
M7BW_ ,&'_P!KH _O3_M;2O\ H)Z?_P"!MM_\<H_M;2O^@GI__@;;?_'*_@L_
MX:0^.W_14O%O_@P_^UT?\-(?';_HJ7BW_P &'_VN@#^]/^UM*_Z">G_^!MM_
M\<H_M;2O^@GI_P#X&VW_ ,<K^"S_ (:0^.W_ $5+Q;_X,/\ [71_PTA\=O\
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M_M;2O^@GI_\ X&VW_P <H_M;2O\ H)Z?_P"!MM_\<K^"S_AI#X[?]%2\6_\
M@P_^UT?\-(?';_HJ7BW_ ,&'_P!KH _O3_M;2O\ H)Z?_P"!MM_\<H_M;2O^
M@GI__@;;?_'*_@L_X:0^.W_14O%O_@P_^UT?\-(?';_HJ7BW_P &'_VN@#^]
M/^UM*_Z">G_^!MM_\<H_M;2O^@GI_P#X&VW_ ,<K^"S_ (:0^.W_ $5+Q;_X
M,/\ [71_PTA\=O\ HJ7BW_P8?_:Z /[T_P"UM*_Z">G_ /@;;?\ QRC^UM*_
MZ">G_P#@;;?_ !ROX+/^&D/CM_T5+Q;_ .##_P"UT?\ #2'QV_Z*EXM_\&'_
M -KH _O3_M;2O^@GI_\ X&VW_P <H_M;2O\ H)Z?_P"!MM_\<K^"S_AI#X[?
M]%2\6_\ @P_^UT?\-(?';_HJ7BW_ ,&'_P!KH _O3_M;2O\ H)Z?_P"!MM_\
M<H_M;2O^@GI__@;;?_'*_@L_X:0^.W_14O%O_@P_^UT?\-(?';_HJ7BW_P &
M'_VN@#^]/^UM*_Z">G_^!MM_\<H_M;2O^@GI_P#X&VW_ ,<K^"S_ (:0^.W_
M $5+Q;_X,/\ [71_PTA\=O\ HJ7BW_P8?_:Z /[T_P"UM*_Z">G_ /@;;?\
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M /@;;?\ QRC^UM*_Z">G_P#@;;?_ !ROX+/^&D/CM_T5+Q;_ .##_P"UT?\
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M_P"UT?\ #2'QV_Z*EXM_\&'_ -KH _O3_M;2O^@GI_\ X&VW_P <H_M;2O\
MH)Z?_P"!MM_\<K^"S_AI#X[?]%2\6_\ @P_^UT?\-(?';_HJ7BW_ ,&'_P!K
MH _O3_M;2O\ H)Z?_P"!MM_\<H_M;2O^@GI__@;;?_'*_@L_X:0^.W_14O%O
M_@P_^UT?\-(?';_HJ7BW_P &'_VN@#^]/^UM*_Z">G_^!MM_\<H_M;2O^@GI
M_P#X&VW_ ,<K^"S_ (:0^.W_ $5+Q;_X,/\ [71_PTA\=O\ HJ7BW_P8?_:Z
M /[T_P"UM*_Z">G_ /@;;?\ QRN>\2ZOI7]FSC^T]/SLZ?;;;/?MYM?PF_\
M#2'QV_Z*EXM_\&'_ -KJE??M&_'-X2'^*'BQ@<Y!U#KQ_P!<Z /[<?"NJZ6-
M2DSJ5@/N_P#+Y;^O_73V->VIJVE;%_XF>G_=7_E]MO0?]-*_@(T[]H7XVQSN
M4^)GBI3M'(O_ &_ZYUTP_:0^.P&!\4O%N!P/^)A_]KH _O3_ +6TK_H)Z?\
M^!MM_P#'*/[6TK_H)Z?_ .!MM_\ '*_@L_X:0^.W_14O%O\ X,/_ +71_P -
M(?';_HJ7BW_P8?\ VN@#^]/^UM*_Z">G_P#@;;?_ !RC^UM*_P"@GI__ (&V
MW_QROX+/^&D/CM_T5+Q;_P"##_[71_PTA\=O^BI>+?\ P8?_ &N@#^]/^UM*
M_P"@GI__ (&VW_QRC^UM*_Z">G_^!MM_\<K^"S_AI#X[?]%2\6_^##_[71_P
MTA\=O^BI>+?_  8?_:Z /[T_[6TK_H)Z?_X&VW_QRC^UM*_Z">G_ /@;;?\
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M /@;;?\ QROX+/\ AI#X[?\ 14O%O_@P_P#M='_#2'QV_P"BI>+?_!A_]KH
M_O3_ +6TK_H)Z?\ ^!MM_P#'*/[6TK_H)Z?_ .!MM_\ '*_@L_X:0^.W_14O
M%O\ X,/_ +71_P -(?';_HJ7BW_P8?\ VN@#^]/^UM*_Z">G_P#@;;?_ !RC
M^UM*_P"@GI__ (&VW_QROX+/^&D/CM_T5+Q;_P"##_[71_PTA\=O^BI>+?\
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M_P"BI>+?_!A_]KH _O3_ +6TK_H)Z?\ ^!MM_P#'*/[6TK_H)Z?_ .!MM_\
M'*_@L_X:0^.W_14O%O\ X,/_ +71_P -(?';_HJ7BW_P8?\ VN@#^]/^UM*_
MZ">G_P#@;;?_ !RC^UM*_P"@GI__ (&VW_QROX+/^&D/CM_T5+Q;_P"##_[7
M1_PTA\=O^BI>+?\ P8?_ &N@#^]/^UM*_P"@GI__ (&VW_QRC^UM*_Z">G_^
M!MM_\<K^"S_AI#X[?]%2\6_^##_[71_PTA\=O^BI>+?_  8?_:Z /[T_[6TK
M_H)Z?_X&VW_QRC^UM*_Z">G_ /@;;?\ QROX+/\ AI#X[?\ 14O%O_@P_P#M
M='_#2'QV_P"BI>+?_!A_]KH _O3_ +6TK_H)Z?\ ^!MM_P#'*/[6TK_H)Z?_
M .!MM_\ '*_@L_X:0^.W_14O%O\ X,/_ +71_P -(?';_HJ7BW_P8?\ VN@#
M^]/^UM*_Z">G_P#@;;?_ !RC^UM*_P"@GI__ (&VW_QROX+/^&D/CM_T5+Q;
M_P"##_[71_PTA\=O^BI>+?\ P8?_ &N@#^]/^UM*_P"@GI__ (&VW_QRC^UM
M*_Z">G_^!MM_\<K^"S_AI#X[?]%2\6_^##_[71_PTA\=O^BI>+?_  8?_:Z
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M)Z?_ .!MM_\ '*_@L_X:0^.W_14O%O\ X,/_ +71_P -(?';_HJ7BW_P8?\
MVN@#^]/^UM*_Z">G_P#@;;?_ !RC^UM*_P"@GI__ (&VW_QROX+/^&D/CM_T
M5+Q;_P"##_[71_PTA\=O^BI>+?\ P8?_ &N@#^]/^UM*_P"@GI__ (&VW_QR
MC^UM*_Z">G_^!MM_\<K^"S_AI#X[?]%2\6_^##_[71_PTA\=O^BI>+?_  8?
M_:Z /[T_[6TK_H)Z?_X&VW_QRC^UM*_Z">G_ /@;;?\ QROX+/\ AI#X[?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %9NK?\>,OX?R-:59NK?\ 'C+^
M'\C0!X[HO_(9N?\ KX7_ -!2O;H/]4O^?2O$=%_Y#-S_ -?"_P#H*5[=!_JE
M_P ^E $U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6/XA_Y 6L?]@V\_
M])Y*V*Q_$/\ R M8_P"P;>?^D\E '\47_!2G_DX*+_KTO/\ T99U\#V/^M?Z
M?T%??'_!2G_DX*+_ *]+S_T99U\#V/\ K7^G]!0!NT444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %0S_ZIO\^M35#/_JF_
MSZT 8]K_ *YO][^@K>K!M?\ 7-_O?T%;U !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %5;O_5?G5JJMW_JOSH
MR['_ %TG^Z/Y5O5@V/\ KI/]T?RK>H **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JI=_</T']:MU4N_N'Z#^M
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M )&K>\+?\%T/^"@FJ>)- TZ[0?9;_6M*LKC&DZF/W%U?0P3<FVX_=NW/0=Z
M/[R**\/_ &??&NO>/OAGX3\2^(_^0IJOA_2K^[^1D_TBZM8Y9OE8 C#L>HSZ
MU[A0 4444 %%%% !1110 4444 %%%% !1110 4444 <MXV\2Q^#O">O^*983
M<1Z%IL^H/ ,YE6  E!@@Y.?45^&NG?\ !<?PCJ'QI/P?'PPO4NA(8_[1+RE,
MBZ-MG'VO'4;ON_X5^S7QV_Y(]\1/^Q8U#_T%:_@8\-?\GRG_ *^F_P#3HU '
M^@KX*\3Q^,/#6C^(HH#;QZM8PWJ0MUC$P)"GD],>M=77D7P+_P"26^"O^P!9
M?^@FO7: "BBB@ HKA/'_ ,1/#7PWT*X\0>);V&UL;99'D+311L!$AD; D8<[
M1WK\#?VKO^"YGPG\'SZAH'PDU>[E\06!EM'5XQ-&;R+(8+Y*,6&['3MS0!_1
M;17\'?B?_@O%^W6^K7+>&AOTHD?9F;2M1;*Y.<E;8CICO[8J+P]_P7D_;LBU
M*%O$9$>F\^<W]EZ@F.5Z%[7'3=W_ $YH _O)HK^>+]D+_@N!\*/B)<:9X7^)
MVLW">*=1>&R10J11"^DPQ#&5%VKC=U(]^.*_?3PEXPT3QII-OK.AW45U97*J
MT<D<L<H.Y X&Z-B"=K T =31110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%1R2Q0J7EDCB0#):1U10/4LQ  ]R:HPZSH]Q+Y-OJVFSS<_NH;ZUEE
MXZ_NTE9N._% &E10"",@@@]".0?QHH **** "BBO&/C7\;O!WP0\):IXK\7W
MJVEEIMHUW)^\B21HU.#L5R"Q^@[4 >ST5_(C^U7_ ,%Y?%UMK-_8_L\:E)<Q
MQS@P++:RSMY/F'M;Q/SL!KX*D_X+P?\ !0C>QC13'N;:3I&I\J3\O_+MZ8H
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MV;4FB.3Y1X)[UV'[#O[;]O\ ME> ;+QS:>";[PE!>3-$+:[#Y7:I;<2\TIY
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MB'XN_P""SWACP9\=K7X+:U\-;VSEN_$K^'H]9N7ECA9D@>;[0N;G:5(0C[F
M>HK]E_!/C'3?&^A6NNZ9+%);W7*>4^]?NJW!R>@8<YK^3#_@MI^SW;?"?QWX
M%^+7ABTD@OUOKG7;B=5( E$6I1!B8^G 4#=SUK]3O^".W[2-W\8/@+X0BUJ]
M$^JO;-+,I?+8^Q6S9(8[NJM_(T ?MC10#D CN,_G10 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M2MP';V/ZU^KG_!.CXT?M(?&?P%I7B;XW&R:74--6X#6R2KF;8I/^L4=R>,4
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!6/XA_Y 6L?]@V\_])Y*V*Q_$/\ R M8_P"P;>?^D\E '\47_!2G_DX*+_KT
MO/\ T99U\#V/^M?Z?T%??'_!2G_DX*+_ *]+S_T99U\#V/\ K7^G]!0!NT44
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %0
MS_ZIO\^M35#/_JF_SZT 8]K_ *YO][^@K>K!M?\ 7-_O?T%;U !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5;
MO_5?G5JJMW_JOSH R['_ %TG^Z/Y5O5@V/\ KI/]T?RK>H **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%/(^;N#0!_H$PRI/&DL;!E=58$=,, ?ZU)7QO^QC\?K7XX_"C1-?GO(Y]3N
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MP"^$FF>(?ACK[Z#JL\\Z27"+*Q94:/:,1S0GC)_BK\W/V"_^"K?BJU^".O\
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MX\_#B;6OB9K[:[J"Z5:W"S.LBXEDEME9OWDTQY$C?Q?CZ@'Z@>,?^12\3?\
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MXYXC)]!Z?IC^P+_P5\^(VL>*+#P%\?-*\;WFN>7!%<7.HZ+K>GPF:X9H4/\
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MNX&#S6O^TIXKUOP3\&/&GB;P[=&RU?3-/,UG<@,?+?GYOE9#^3"@#\<? /\
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M<Y'%?N%_P1T_;F_:B_:.\<:M8?%KQC>>(M+@TU)H/,MKQ(MYBD9F$DMU.AY
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_5+AV>1[*%26!!_X\T_O<T ?R\?\%SO^0AIW_7G<?^@3U]M_\$*_^22>&_\
ML#2?^D25\2?\%SO^0AIW_7G<?^@3U]M_\$*_^22>&_\ L#2?^D24 ?T,T444
M >._'+_D0-9_Z\;_ /\ 222OX'/B+I&F:W^V]H=AJUE!J%G/XPU%)K:Y3S(I
M%W_=92>1SZU_?'\<O^1 UG_KQO\ _P!))*_@M\8?\GT^'?\ L<M0_P#0Q0!_
M9Y^SQ^RO^SKJ7PH\-7E_\'O!%W=2PDR3S:2C2.?+A.6._GDFO;O^&2/V:/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *AG_P!4W^?6IJAG_P!4W^?6@#'M?]<W^]_0
M5O5@VO\ KF_WOZ"MZ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "JMW_JOSJU56[_U7YT 9=C_ *Z3_='\JWJP
M;'_72?[H_E6]0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !52[^X?H/ZU;JI=_</T']: ,W3O]8/I_[-6[6%IW
M^L'T_P#9JW: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4F0Y#[QTXXK['KY<_:4_:H\ ?LW>$[OQ)XGU33!+#:SSV]A<W)BENI8<X@C
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MNDQ\L8. /08^J?\ @W^^..K^)O ?B?0-;NWD:SUA+&S26X>9A##.T:A?,^X
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M["_AEM$U'XL^$=,31&T+2<LVAVB:7$DKVV\G%AY*@YAX. >"17YG_P##5?\
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M^PA^U+^QCX\O-<^#%WXJOK*\U*>]E/ANR1HT502@8F*/_GFN._(%?27[.O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M'@G4+NVANO$5TLXM99;,$" X#+;RX891>#W K[[_ .",?P&\!_$?XGZ?XO\
M%6J7USK4UG;3207!DNH]\/G3+S/<GJY(_P!7TZ^E>+? W]E#QW^V]XC^*7C:
M^GO9(+2];4=.$\(D$RS"PC_<MY;EO]<_)(S@UQG@O7/B)^P!^TXVG:B^JVNB
MVUSIE@J,H@@'F7\UNW380"KCCICMR* /]%[PQIMGI.@:186,4<=O:Z?:P1^7
M&D>Y(HE520H )P/4_6MZOD?]D/X^Z1\<OAEHFM6DT0FBTK35F42%W:5H%W$Y
M+<Y4YY_^O])>,Y[RV\*>(+C3UD>]ATN[DM5B&9&F6,E @_O9Z>] '345_&O^
MV+^T=^WUX=^*U]I_@+PW\4KC14-SY4FEV2O;_+,H7:?,'.WIQC'XX^33^U7_
M ,%,@N1X4^,F<?\ /@O\O._/C\!V /[VJ*_DH_X)_?'[]N'Q9\3X;'XG^'_B
M3::,8+9FDUJS6* ,S3[\L)#R %S[8_#^L+0Y)I=&TN2Y#"XDL+5Y@XPPD:%"
MX8=F#$Y]Z --_NG\/YBOX[?^#A'_ )"FJ?[MO_.*O[$G^Z?P_F*_CM_X.$?^
M0IJG^[;_ ,XJ /L/_@AU_P B!)_UZ6/_ *';5_2C7\UW_!#K_D0)/^O2Q_\
M0[:OZ4: /R6_X*M:[::;\#?%T$]R\+OI\;!58@'_ $6<YP&'J!FOY2_^"3AB
MN_VL?%T^%E237K)E9P&)^2$@Y.>GU^E?UC?\%3?#DFL? KQ?,FG/=E+"-0Z)
MNVG[+.,$CZ=_2OY&_P#@F'K]IX/_ &M/%$&H[+7S/$5E&B3$J0=D0P.>>GKZ
MXYH _P!"W2U5=-L H"C[%:\  ?\ +"/TJ]7/^%]4M]7T33KNV='C:RM,,AW*
M<V\9X-=!0 5X#^TTBO\ "#Q(KJKJ57*L P/[BYZ@Y%>_5\R?M<^(++P[\$/%
M6H7<L:+"B$J[;>MO='^0]10!_ =XXOVTC]LWS+6&)3)X]M=P"JHX0^B_S_#%
M?WN_L@W\NH_!/2;B4!6-K$I"].+)/0#^5?P;>%8[?XK?MI:@+.-72R\<VKY3
MYP1Y:G/?^]^O3KC^_/\ 9QT'_A'?A3IFG[=FRRA.,8_Y<U'3 ^OXT ?S(?\
M!<[_ )"&G?\ 7G<?^@3U]M_\$*_^22>&_P#L#2?^D25\2?\ !<[_ )"&G?\
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M!_P4M^+G[7/VG_A.=#T/3C$D++_9R6Z\R>1G/E6%MWD/Z5^Z"'<BL>I4$_B
M:\0^'/[-WP5^$N[_ (5]X#T?PUOVAOL".N=NT+G<[=-H_*O<0,# Z#@4 %-9
M@BL['"J"Q/H ,FG5^?O[;W[;'@7]F3P!JEW=:AI]YK%U97UK#9+<E+J"X,92
M,A0R#=O88&3SD8ZT ?)7_!6;]MK1_@?\+_$?ABWU&WAU*2V$R))Y2R$&UDSA
MB2XYD'3':OYD_P#@GA^S?XO_ &GOVA[_ .(^N:=/<Z2OBN'5X+D-+,@@DM;:
M,N%*!0-TC#@XS[UQ^O77QK_X*8_'@00IX@3PQ?7=[9$R0B>S"+>I!%\Q\TX\
MM3M'H.QXK^R_]@+]BG0/V:/AUI$=Q;6EQJU[I$"W$@CV31SI*N2X")\VV$=<
MX!H ^Y?AIX)LO 'A2P\.6"E;>U1-JE=I!$:(>,GCY?\ ZU=_1THH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH *Q_$/\ R M8_P"P;>?^D\E;%8_B
M'_D!:Q_V#;S_ -)Y* /XHO\ @I3_ ,G!1?\ 7I>?^C+.O@>Q_P!:_P!/Z"OO
MC_@I3_R<%%_UZ7G_ *,LZ^!['_6O]/Z"@#=HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *AG_ -4W^?6IJAG_ -4W^?6@
M#'M?]<W^]_05O5@VO^N;_>_H*WJ "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH *JW?^J_.K55;O_5?G0!EV/^ND
M_P!T?RK>K!L?]=)_NC^5;U !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %5+O[A^@_K5NJEW]P_0?UH S=._P!8
M/I_[-6[6%IW^L'T_]FK=H **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHJ2*)Y
MI$BC4L[G:J@9)/L* /3_ (0?#S6OB1XQTS0]%M&O)S>63RQJ6!$)N4\QOE5N
MBJQY Z=1UK^UG]E#X-:=\(/AMH]E9QM'<:EI=C/>HR;-MP8U:09S\V&XR0#Q
MTK\;/^"3_P"RP7O--^+.OV@GL;JV,*6MQ%@+(L;R*^=H)(,B\;NWI7]&4$$5
MM#';P((XH4$<:#HJ*,!1[ 4 2T444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<1XW_ ./&
M/ZG^E=O7$>-_^/&/ZG^E '.^!/O?]M6_]#->LUY-X$^]_P!M6_\ 0S7K- '@
M_BS_ )"</_7,?R2O8- _Y!-G_P!<Q7C_ (L_Y"</_7,?R2O8- _Y!-G_ -<Q
M0!L4444 %%%% !1110 5_''_ ,%[?^0IIG_8V6O_ *<H:_L<K^.3_@OY%<V,
MMC?O"WE+XGAD1C]URE_"V/QXH _4;_@A-_R;'??]A^#_ -#U&OW5K^ +]BG_
M (+3>,/V.OAQ-\/M(^'%CXAMYKY+TW<[Q!@R&X(7#W$9P?/P>.W;O]J_\1-7
MQ'_Z(MI?_?VW_P#DJ@#^RBBOXW(/^#F;XC37%O"?@OI:B:>*$GS+<X\QU3/_
M !]CIG/>OZ&O^"?W[9>K_MB>!-1\6ZOX=A\/2V1A"V\!0JWFMMYVR2#CZT ?
M'W_!<+_DA&D?]?%W_P"A1U^&W_!$O]H3P!X"^,NE^"?$%V;75KK7+^XC:22.
M* (=4;[SR%5!_?KU8=#BOW)_X+A?\D(TC_KXN_\ T*.OX\_@-^SA\4_B/9ZE
MXT^$#ZW+XTM=9O(+"TT1S%=.!=7!8HX7CYXD[]^AYH _TP='UG3];L+;4-.N
MH+FWN8A+&T,T4ORDE028V8<D5Q/Q7\<Z%X%\%>(=5UJ\@MH5T;5@IDGBB.];
M"8@?O&'))& !G-?Q@?#'_@L!^TM^Q781^"?B-\-;_5[RSC735DUZXBDF\R$B
M1C\TZ?-A&SQZUXI^T_\ \%=?CM^VMI$G@CPOX3O?"]S>7 ?;HMU'&[),R)Y6
M$FDRKA2I&.=WO0!X!\=?&47[2?[8D.A>'W>\<>)]7L8<DN#MNQ&-I4<@]L'D
M=,FO[N/V'_!%SX"_9T^'_AZ]C\J[L-.\N5,$8.R(8YY['KZ'O7\L'_!)7_@F
M3X_\4_$?2OCI\5=.U70;K0]8^VP6=_&734XIYD<SR,$(.\+N)+#[Q]Z_M(T?
M2[?1M/M].M42."W7:B(-JJ,#@#MTH _CZ_X.!?\ DHT__8+M_P#T5;5^I?\
MP1._Y)'<?]@2R_\ 1]G7Y:?\' O_ "4:?_L%V_\ Z*MJ_4O_ ((G?\DCN/\
ML"67_H^SH _:GQC_ ,BEXF_[%_6O_39=5_GV?&+_ )/HTS_L9=:_]+8J_P!!
M/QC_ ,BEXF_[%_6O_39=5_GV?&+_ )/HTS_L9=:_]+8J /[I_P!D_P#Y(9X'
M_P"P:O\ [+7X=?\ !>;X.:CK'PM\1>/[2U:5;=$AW(CN>(-W10>OEYZ>]?N+
M^R?_ ,D,\#_]@U?_ &6K?[2OP(T+]H+X::OX$UI85@O4D?S9(S(0WD2(H PW
M]['3TH _EM_X-^_BMX>TRZ^(GA;Q6NF_:[F]@LK&*^AM-VX-IK8 N5W9PK9
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M*X!D906VJ<#KDBOX9_@-_P %T?C-^S/X>B\#Z_X ;Q'=Z7:Q:=)-JMQ$\R/
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MP4KT_P",%Q\,]$O_ (0P:S<ZII4TM[>0Z/-Y4DD4+B39(>ZL%P?:OP*\"_\
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M 4444 %9NK?\>,OX?R-:59NK?\>,OX?R- 'CNB_\AFY_Z^%_]!2O;H/]4O\
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MI_:XY88P'S9SQ78)\H9X+ D8'&:_J#T+1K30=*LM*LXTC@LH%@C6-=JA%)(
M'8<UY;\=_A3I7Q=\!:MX;U58VB^PZC)&)$W@RM:,% &#R2B@<>GI0!_)#_P1
M?_;1\1>%_%#?"KQKJ:PP)K\FFQ0R2&,^19W)A48E/93V'XXK^S32=4L]<T^#
M4+-EEM;E=R'*N&7CTR".:_SN?VOOA/XR_8P_:2MO&.AQW]EI4&IZCJ3^23!
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M:*_'[_@F]_P4F\1?MNV.GW>L^#;7PT;RU:X*P,C;2L328^2:3NN.OO[5^P-
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !6/XA_Y 6L?]@V\_])Y*
MV*Q_$/\ R M8_P"P;>?^D\E '\47_!2G_DX*+_KTO/\ T99U\#V/^M?Z?T%?
M?'_!2G_DX*+_ *]+S_T99U\#V/\ K7^G]!0!NT444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %0S_ZIO\^M35#/_JF_SZT
M8]K_ *YO][^@K>K!M?\ 7-_O?T%;U !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M,+\CW% 'ZM? WX6:/\(? 6F>$=&MEM[6T1'"E5#;FAC4\@?[([U[%2    =
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M]W!-;3H?XXIXVBD7O]Y'8=#UZ5\,:M_P3:_9&UOQG'X_U'X:V\_BB*XFNDU
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M@F'6&G+&0N\ W;\[OOVLG7)ZYKZOHH _+J3_ ((X?L!RN9'^#=HS-U)ELO\
MY65Z;\-O^"9W['_PFU&'5? WPRM](O;>7SHI4DM25DSNW?)8QG.0#P17WQ10
M!EZ3HVGZ'9PV&FP""V@7;'&,84<>@ [>E:E%5;VX2UM9YY&VK'%(^?\ =1F]
M1Z4 ?A;_ ,%K_C;9?#GX80:"TQ>;Q'HES;I'#)EMP>Z?#*@8_P#+$G!]NW7\
MR_\ @A?^SQK>L>(['XSR*B:=K&DB*-)4VR@I;SR\EF#?\O*_P]17C/\ P4W^
M-&O_ +3?[2_@WX16A2XL=.\67&@3+;R8D$;6U]+AEB0$G,HXSZ<D5_2]_P $
MZ/V;[3X ?!#POX>2U:&>RB9&,L9$F#:V\?+,2Q^Z<9_QH _0^SB,%K;PGK%#
M''_WRH']*LT44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9NK?\>,OX
M?R-:59NK?\>,OX?R- 'CNB_\AFY_Z^%_]!2O;H/]4O\ GTKQ'1?^0S<_]?"_
M^@I7MT'^J7_/I0!-1110 4444 %13P1W$;12KN1AAAZU+10!\*?%G_@F_P#L
MD_&W7CXE^(OPWM];U<W:WIN7>U!^THYD63]Y8RG(8Y^]^->^_"/]G?X4_ [2
MX]&^&_AV/0K")E=(4:-@&3.T_NX8AQD]N]>W44 %-=5=61AE75E8>JL""/Q!
MIU% 'R)\;?V&OV;OVAI#+\5? L/B)S&8B9'MU^0C!'[RTFZCBMOX)_L=? /]
MGJ%;?X5^#8?#L21+"JQM"<1J  !Y=M#V'T]J^H** $ "@*.B@ ?0# I:** "
MBBB@ ZU\H?'7]BC]GC]H^62;XM^"8?$DDNW>TCP+G;C'^MM9_05]7T4 ?/GP
M;_9>^#7P$L3IWPQ\+QZ!:,B1F.-H2-L94J/W=O"."H[=J^@Z** "FLH=2K<A
MA@_2G44 >!?$S]F7X/?%U9E\=^&(]86<$2!VB&X$8(^>"7C''.:^1=5_X) _
ML':S</=:A\'[2:>1R[.9++EFZGG33UK]-Z* /SP\%_\ !++]BWX?W\>I>%OA
M7;:==Q&-DD62T.#$=R?=L$/!/K^M?<GA;P5X=\&V,>G>'[%;*TA6-(XU*G:L
M2[4'RJHX7CITKJZ* "D(# J>C @_0C!I:* /E?XT?L8?L^_M ;?^%H^"X?$&
MU&C'F/ /D;(*_O+6;@[C7R['_P $:O\ @G_&H1/@S:!1T'FV7_RLK]2J* /R
MX_X<W?L!?]$:M/\ O[9?_*RMGP]_P2-_85\+:K9ZUHOPBM;34+"X2YM9A)9$
MQS)]UN--4G&?[PK]+J* .)T/X>^%?#GAQ?"NDZ<MMHBQM$+0%<;'C\HCA%7[
MG'W:^)_B)_P2T_8M^*>MR>(?&OPKMM5U62:2=[AI+0$RRY+M\]A(W.3_ !=Z
M_0ZB@#\N/^'-W[ 7_1&K3_O[9?\ RLH_X<W?L!?]$:M/^_ME_P#*ROU'HH _
M-SPC_P $FOV'O ^L6NN^&_A+:V.I65PMU;SK)9G9,@PK873T/ ]&%??&F>"O
M#NCZ%_PC=A8K#I'E/#]F!7'ER1>2PX4#E./NX]JZNB@#\\?B+_P2T_8M^*NN
M/XB\;?"NVU;5GEDG:Y>2T!,DIR[8:PD/)YY:N&_X<W?L!?\ 1&K3_O[9?_*R
MOU'HH _+C_AS=^P%_P!$:M/^_ME_\K*:_P#P1K_8 <$-\&;0@\?ZVR_^5E?J
M310!\Q_ K]C_ . W[-\,,'PD\'Q>&XK>,Q1+&T+;4*E,?NK:#^$D=ASTKZ<H
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Q_$/_("UC_L&WG_I
M/)6Q6/XA_P"0%K'_ &#;S_TGDH _BB_X*4_\G!1?]>EY_P"C+.O@>Q_UK_3^
M@K[X_P""E/\ R<%%_P!>EY_Z,LZ^!['_ %K_ $_H* -VBBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J&?_5-_GUJ:H9_]
M4W^?6@#'M?\ 7-_O?T%;U8-K_KF_WOZ"MZ@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M$FG1R(1*[F1G^:1AEG)8\=37N=% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@G&*^AK*QM=/@6ULX4@@3[L:?=' '&<GH!5JB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *S=6_P"/&7\/Y&M*LW5O^/&7\/Y&@#QW1?\ D,W/
M_7PO_H*5[=!_JE_SZ5XCHO\ R&;G_KX7_P!!2O;H/]4O^?2@":BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P#HJ]O_ -^H_P#Y74?\.+=?_P"BKV__ 'ZC_P#E=7](U% '\W/_  XMU_\
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M_P"BKV__ 'ZC_P#E=7](U% '\W/_  XMU_\ Z*O;_P#?J/\ ^5U'_#BW7_\
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M_P .+=?_ .BKV_\ WZC_ /E=1_PXMU__ **O;_\ ?J/_ .5U?TC44 ?S<_\
M#BW7_P#HJ]O_ -^H_P#Y74?\.+=?_P"BKV__ 'ZC_P#E=7](U% '\W/_  XM
MU_\ Z*O;_P#?J/\ ^5U'_#BW7_\ HJ]O_P!^H_\ Y75_2-10!_-S_P .+=?_
M .BKV_\ WZC_ /E=1_PXMU__ **O;_\ ?J/_ .5U?TC44 ?S<_\ #BW7_P#H
MJ]O_ -^H_P#Y74?\.+=?_P"BKV__ 'ZC_P#E=7](U% '\W/_  XMU_\ Z*O;
M_P#?J/\ ^5U'_#BW7_\ HJ]O_P!^H_\ Y75_2-10!_-S_P .+=?_ .BKV_\
MWZC_ /E=5#4?^"&NO6UL\A^*UN0N/^64?/7_ *A_^?2OZ5:QM<_X\9?H/_9J
M /YC-*_X(H:[=7\L ^*$"E) I/E1\\ _\^'^<5Z*/^"%NOD _P#"U[?D#_EE
M'_\ *ZOW6\/?\ABY_P"NX_\ 017N"]!]!_*@#^;K_AQ;K_\ T5>W_P"_4?\
M\KJ/^'%NO_\ 15[?_OU'_P#*ZOZ1J* /YN?^'%NO_P#15[?_ +]1_P#RNH_X
M<6Z__P!%7M_^_4?_ ,KJ_I&HH _FY_X<6Z__ -%7M_\ OU'_ /*ZC_AQ;K__
M $5>W_[]1_\ RNK^D:B@#^;G_AQ;K_\ T5>W_P"_4?\ \KJ/^'%NO_\ 15[?
M_OU'_P#*ZOZ1J* /YN?^'%NO_P#15[?_ +]1_P#RNH_X<6Z__P!%7M_^_4?_
M ,KJ_I&HH _FY_X<6Z__ -%7M_\ OU'_ /*ZC_AQ;K__ $5>W_[]1_\ RNK^
MD:B@#^;G_AQ;K_\ T5>W_P"_4?\ \KJ/^'%NO_\ 15[?_OU'_P#*ZOZ1J* /
MYN?^'%NO_P#15[?_ +]1_P#RNH_X<6Z__P!%7M_^_4?_ ,KJ_I&HH _FY_X<
M6Z__ -%7M_\ OU'_ /*ZC_AQ;K__ $5>W_[]1_\ RNK^D:B@#^;G_AQ;K_\
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M;K__ $5>W_[]1_\ RNK^D:B@#^;G_AQ;K_\ T5>W_P"_4?\ \KJ/^'%NO_\
M15[?_OU'_P#*ZOZ1J* /YN?^'%NO_P#15[?_ +]1_P#RNH_X<6Z__P!%7M_^
M_4?_ ,KJ_I&HH _FY_X<6Z__ -%7M_\ OU'_ /*ZC_AQ;K__ $5>W_[]1_\
MRNK^D:B@#^;G_AQ;K_\ T5>W_P"_4?\ \KJ/^'%NO_\ 15[?_OU'_P#*ZOZ1
MJ* /YN?^'%NO_P#15[?_ +]1_P#RNH_X<6Z__P!%7M_^_4?_ ,KJ_I&HH _F
MY_X<6Z__ -%7M_\ OU'_ /*ZC_AQ;K__ $5>W_[]1_\ RNK^D:B@#^;G_AQ;
MK_\ T5>W_P"_4?\ \KJ/^'%NO_\ 15[?_OU'_P#*ZOZ1J* /YN?^'%NO_P#1
M5[?_ +]1_P#RNH_X<6Z__P!%7M_^_4?_ ,KJ_I&HH _FY_X<6Z__ -%7M_\
MOU'_ /*ZC_AQ;K__ $5>W_[]1_\ RNK^D:B@#^;G_AQ;K_\ T5>W_P"_4?\
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M6Z__ -%7M_\ OU'_ /*ZC_AQ;K__ $5>W_[]1_\ RNK^D:B@#^;G_AQ;K_\
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M8H^Q)_Y\#Z?Y[>A?\.+=?_Z*O;_]^H__ )75^[GP^_X_Q_NO_6O:J /YN?\
MAQ;K_P#T5>W_ ._4?_RNH_X<6Z__ -%7M_\ OU'_ /*ZOZ1J* /YN?\ AQ;K
M_P#T5>W_ ._4?_RNH_X<6Z__ -%7M_\ OU'_ /*ZOZ1J* /YN?\ AQ;K_P#T
M5>W_ ._4?_RNH_X<6Z__ -%7M_\ OU'_ /*ZOZ1J* /YN?\ AQ;K_P#T5>W_
M ._4?_RNH_X<6Z__ -%7M_\ OU'_ /*ZOZ1J* /YN?\ AQ;K_P#T5>W_ ._4
M?_RNH_X<6Z__ -%7M_\ OU'_ /*ZOZ1J* /YN?\ AQ;K_P#T5>W_ ._4?_RN
MH_X<6Z__ -%7M_\ OU'_ /*ZOZ1J* /YN?\ AQ;K_P#T5>W_ ._4?_RNH_X<
M6Z__ -%7M_\ OU'_ /*ZOZ1J* /YN?\ AQ;K_P#T5>W_ ._4?_RNH_X<6Z__
M -%7M_\ OU'_ /*ZOZ1J* /YN?\ AQ;K_P#T5>W_ ._4?_RNH_X<6Z__ -%7
MM_\ OU'_ /*ZOZ1J* /YN?\ AQ;K_P#T5>W_ ._4?_RNH_X<6Z__ -%7M_\
MOU'_ /*ZOZ1J* /YN?\ AQ;K_P#T5>W_ ._4?_RNH_X<6Z__ -%7M_\ OU'_
M /*ZOZ1J* /YN?\ AQ;K_P#T5>W_ ._4?_RNH_X<6Z__ -%7M_\ OU'_ /*Z
MOZ1J* /YN?\ AQ;K_P#T5>W_ ._4?_RNH_X<6Z__ -%7M_\ OU'_ /*ZOZ1J
M* /YN?\ AQ;K_P#T5>W_ ._4?_RNH_X<6Z__ -%7M_\ OU'_ /*ZOZ1J* /Y
MN?\ AQ;K_P#T5>W_ ._4?_RNH_X<6Z__ -%7M_\ OU'_ /*ZOZ1J* /YN?\
MAQ;K_P#T5>W_ ._4?_RNH_X<6Z__ -%7M_\ OU'_ /*ZOZ1J* /YN?\ AQ;K
M_P#T5>W_ ._4?_RNKVGX)?\ !'1?AIXKM?$&O^-+/Q%#:7-K<Q6TD:#;);R!
MPR[;.(Y) /+=0*_=VB@#*T32;71-+L=-M(DBBL[.UM0$&%/V:!(0<>^W/XUJ
MT44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 5Q'C?_CQC^I_I7;UQ'C?_ (\8
M_J?Z4 <[X$^]_P!M6_\ 0S7K->3>!/O?]M6_]#->LT >#^+/^0G#_P!<Q_)*
M]@T#_D$V?_7,5X_XL_Y"</\ US'\DKV#0/\ D$V?_7,4 ;%%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6;JW
M_'C+^'\C6E6;JW_'C+^'\C0!X[HO_(9N?^OA?_04KVZ#_5+_ )]*\1T7_D,W
M/_7PO_H*5[=!_JE_SZ4 34444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% '/^(?^/&7_/\  :\Q\+?\A.Y_Z[#^25Z=XA_X\9?\_P !KS'PM_R$[G_K
ML/Y)0![:O0?0?RI:1>@^@_E2T %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %8VN?\>,OT'_LU;-8VN?\ 'C+]!_[-0!Y/X>_Y
M#%S_ -=Q_P"@BO<%Z#Z#^5>'^'O^0Q<_]=Q_Z"*]P7H/H/Y4 +1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<]X
ME_Y!D_\ N'^M=#7/>)?^09/_ +A_K0!YAX4_Y"4G_ ?YBO;D^XO^ZO\ (5XC
MX4_Y"4G_  '^8KVY/N+_ +J_R% #J*** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ KEO%?_(.F_P"N3_R:NIKEO%?_
M "#IO^N3_P FH \^^'W_ !_C_=?^M>U5XK\/O^/\?[K_ -:]JH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KB
M/&__ !XQ_4_TKMZXCQO_ ,>,?U/]* .=\"?>_P"VK?\ H9KUFO)O GWO^VK?
M^AFO6: /!_%G_(3A_P"N8_DE>P:!_P @FS_ZYBO'_%G_ "$X?^N8_DE>P:!_
MR";/_KF* -BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ K-U;_CQE_#^1K2K-U;_CQE_#^1H \=T7_D,W/_7P
MO_H*5[=!_JE_SZ5XCHO_ "&;G_KX7_T%*]N@_P!4O^?2@":BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH Y_Q#_QXR_Y_@->8^%O^0G<_]=A_)*].
M\0_\>,O^?X#7F/A;_D)W/_78?R2@#VU>@^@_E2TB]!]!_*EH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *QM<_X\9?H/_9JV
M:QM<_P"/&7Z#_P!FH \G\/?\ABY_Z[C_ -!%>X+T'T'\J\/\/?\ (8N?^NX_
M]!%>X+T'T'\J %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "N>\2_\ (,G_ -P_UKH:Y[Q+_P @R?\ W#_6@#S#
MPI_R$I/^ _S%>W)]Q?\ =7^0KQ'PI_R$I/\ @/\ ,5[<GW%_W5_D* '4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !7+>*_^0=-_UR?^35U-<MXK_P"0=-_UR?\ DU 'GWP^_P"/\?[K_P!:]JKQ
M7X??\?X_W7_K7M5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %<1XW_P"/&/ZG^E=O7$>-_P#CQC^I_I0!SO@3
M[W_;5O\ T,UZS7DW@3[W_;5O_0S7K- '@_BS_D)P_P#7,?R2O8- _P"039_]
M<Q7C_BS_ )"</_7,?R2O8- _Y!-G_P!<Q0!L4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9NK?\ 'C+^'\C6
ME6;JW_'C+^'\C0!X[HO_ "&;G_KX7_T%*]N@_P!4O^?2O$=%_P"0S<_]?"_^
M@I7MT'^J7_/I0!-1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <_X
MA_X\9?\ /\!KS'PM_P A.Y_Z[#^25Z=XA_X\9?\ /\!KS'PM_P A.Y_Z[#^2
M4 >VKT'T'\J6D7H/H/Y4M !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !6-KG_ !XR_0?^S5LUC:Y_QXR_0?\ LU 'D_A[_D,7
M/_7<?^@BO<%Z#Z#^5>'^'O\ D,7/_7<?^@BO<%Z#Z#^5 "T444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7/>)?\
MD&3_ .X?ZUT-<]XE_P"09/\ [A_K0!YAX4_Y"4G_  '^8KVY/N+_ +J_R%>(
M^%/^0E)_P'^8KVY/N+_NK_(4 .HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "N6\5_\ (.F_ZY/_ ":NIKEO%?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ K-U;_ (\9?P_D:TJS=6_X\9?P_D: /'=%_P"0S<_]
M?"_^@I7MT'^J7_/I7B.B_P#(9N?^OA?_ $%*]N@_U2_Y]* )J*** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@#G_$/_ !XR_P"?X#7F/A;_ )"=S_UV
M'\DKT[Q#_P >,O\ G^ UYCX6_P"0G<_]=A_)* /;5Z#Z#^5+2+T'T'\J6@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K&US_
M (\9?H/_ &:MFL;7/^/&7Z#_ -FH \G\/?\ (8N?^NX_]!%>X+T'T'\J\/\
M#W_(8N?^NX_]!%>X+T'T'\J %HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "N>\2_P#(,G_W#_6NAKGO$O\ R#)_
M]P_UH \P\*?\A*3_ (#_ #%>W)]Q?]U?Y"O$?"G_ "$I/^ _S%>W)]Q?]U?Y
M"@!U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 5RWBO_ )!TW_7)_P"35U-<MXK_ .0=-_UR?^34 >??#[_C_'^Z
M_P#6O:J\5^'W_'^/]U_ZU[50 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !7$>-_P#CQC^I_I7;UQ'C?_CQC^I_
MI0!SO@3[W_;5O_0S7K->3>!/O?\ ;5O_ $,UZS0!X/XL_P"0G#_US'\DKV#0
M/^039_\ 7,5X_P"+/^0G#_US'\DKV#0/^039_P#7,4 ;%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6;JW_'
MC+^'\C6E6;JW_'C+^'\C0!X[HO\ R&;G_KX7_P!!2O;H/]4O^?2O$=%_Y#-S
M_P!?"_\ H*5[=!_JE_SZ4 34444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M9]_Z*OX3_P# N;_Y'H_X:A_9]_Z*OX3_ / N;_Y'K^#/[=>_\_EU_P"!$O\
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M/^&H?V??^BK^$_\ P+F_^1Z/^&H?V??^BK^$_P#P+F_^1Z_@S^W7O_/Y=?\
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M .1Z/^&H?V??^BK^$_\ P+F_^1Z_@S^W7O\ S^77_@1+_P#%T?;KW_G\NO\
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M1Z_@S^W7O_/Y=?\ @1+_ /%T?;KW_G\NO_ B7_XN@#^\S_AJ']GW_HJ_A/\
M\"YO_D>C_AJ']GW_ **OX3_\"YO_ )'K^#/[=>_\_EU_X$2__%T?;KW_ )_+
MK_P(E_\ BZ /[S/^&H?V??\ HJ_A/_P+F_\ D>C_ (:A_9]_Z*OX3_\  N;_
M .1Z_@S^W7O_ #^77_@1+_\ %T?;KW_G\NO_  (E_P#BZ /[S/\ AJ']GW_H
MJ_A/_P "YO\ Y'H_X:A_9]_Z*OX3_P# N;_Y'K^#/[=>_P#/Y=?^!$O_ ,71
M]NO?^?RZ_P# B7_XN@#^\S_AJ']GW_HJ_A/_ ,"YO_D>C_AJ']GW_HJ_A/\
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M:A_9]_Z*OX3_ / N;_Y'K^#/[=>_\_EU_P"!$O\ \71]NO?^?RZ_\")?_BZ
M/[S/^&H?V??^BK^$_P#P+F_^1Z/^&H?V??\ HJ_A/_P+F_\ D>OX,_MU[_S^
M77_@1+_\71]NO?\ G\NO_ B7_P"+H _O,_X:A_9]_P"BK^$__ N;_P"1Z/\
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M=>_\_EU_X$2__%T?;KW_ )_+K_P(E_\ BZ /[S/^&H?V??\ HJ_A/_P+F_\
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MY_+K_P ")?\ XN@#^\S_ (:A_9]_Z*OX3_\  N;_ .1Z/^&H?V??^BK^$_\
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MU#^S[_T5?PG_ .!<W_R/7\&?VZ]_Y_+K_P ")?\ XNC[=>_\_EU_X$2__%T
M?WF?\-0_L^_]%7\)_P#@7-_\CT?\-0_L^_\ 15_"?_@7-_\ (]?P9_;KW_G\
MNO\ P(E_^+H^W7O_ #^77_@1+_\ %T ?WF?\-0_L^_\ 15_"?_@7-_\ (]'_
M  U#^S[_ -%7\)_^!<W_ ,CU_!G]NO?^?RZ_\")?_BZ/MU[_ ,_EU_X$2_\
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M^!<W_P CT?\ #4/[/O\ T5?PG_X%S?\ R/7\&?VZ]_Y_+K_P(E_^+H^W7O\
MS^77_@1+_P#%T ?WF?\ #4/[/O\ T5?PG_X%S?\ R/1_PU#^S[_T5?PG_P"!
M<W_R/7\&?VZ]_P"?RZ_\")?_ (NC[=>_\_EU_P"!$O\ \70!_>9_PU#^S[_T
M5?PG_P"!<W_R/1_PU#^S[_T5?PG_ .!<W_R/7\&?VZ]_Y_+K_P ")?\ XNC[
M=>_\_EU_X$2__%T ?WF?\-0_L^_]%7\)_P#@7-_\CT?\-0_L^_\ 15_"?_@7
M-_\ (]?P9_;KW_G\NO\ P(E_^+H^W7O_ #^77_@1+_\ %T ?WF?\-0_L^_\
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MPU#^S[_T5?PG_P"!<W_R/7\&?VZ]_P"?RZ_\")?_ (NC[=>_\_EU_P"!$O\
M\70!_>9_PU#^S[_T5?PG_P"!<W_R/1_PU#^S[_T5?PG_ .!<W_R/7\&?VZ]_
MY_+K_P ")?\ XNC[=>_\_EU_X$2__%T ?WF?\-0_L^_]%7\)_P#@7-_\CT?\
M-0_L^_\ 15_"?_@7-_\ (]?P9_;KW_G\NO\ P(E_^+H^W7O_ #^77_@1+_\
M%T ?WF?\-0_L^_\ 15_"?_@7-_\ (]'_  U#^S[_ -%7\)_^!<W_ ,CU_!G]
MNO?^?RZ_\")?_BZ/MU[_ ,_EU_X$2_\ Q= ']YG_  U#^S[_ -%7\)_^!<W_
M ,CT?\-0_L^_]%7\)_\ @7-_\CU_!G]NO?\ G\NO_ B7_P"+H^W7O_/Y=?\
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M .!<W_R/1_PU#^S[_P!%7\)_^!<W_P CU_!G]NO?^?RZ_P# B7_XNC[=>_\
M/Y=?^!$O_P 70!_>9_PU#^S[_P!%7\)_^!<W_P CT?\ #4/[/O\ T5?PG_X%
MS?\ R/7\&?VZ]_Y_+K_P(E_^+H^W7O\ S^77_@1+_P#%T ?WF?\ #4/[/O\
MT5?PG_X%S?\ R/7,^)_VG?@#)82JGQ5\*,QB8 "[ESSD?\\/>OX6?MU[_P _
MEU_X$2__ !=4[N]O"AS=W)X[SRGU_P!N@#^W;P)^TM\!H+[=+\4O"L8VMRUW
M+WSC_EAWKV+_ (:A_9]_Z*OX3_\  N;_ .1Z_@5TZ]O!(,7=R./^>\OK_OUO
M?;KW_G\NO_ B7_XN@#^\S_AJ']GW_HJ_A/\ \"YO_D>C_AJ']GW_ **OX3_\
M"YO_ )'K^#/[=>_\_EU_X$2__%T?;KW_ )_+K_P(E_\ BZ /[S/^&H?V??\
MHJ_A/_P+F_\ D>C_ (:A_9]_Z*OX3_\  N;_ .1Z_@S^W7O_ #^77_@1+_\
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M?V??^BK^$_\ P+F_^1Z_@S^W7O\ S^77_@1+_P#%T?;KW_G\NO\ P(E_^+H
M_O,_X:A_9]_Z*OX3_P# N;_Y'H_X:A_9]_Z*OX3_ / N;_Y'K^#/[=>_\_EU
M_P"!$O\ \71]NO?^?RZ_\")?_BZ /[S/^&H?V??^BK^$_P#P+F_^1Z/^&H?V
M??\ HJ_A/_P+F_\ D>OX,_MU[_S^77_@1+_\71]NO?\ G\NO_ B7_P"+H _O
M,_X:A_9]_P"BK^$__ N;_P"1Z/\ AJ']GW_HJ_A/_P "YO\ Y'K^#/[=>_\
M/Y=?^!$O_P 71]NO?^?RZ_\  B7_ .+H _O,_P"&H?V??^BK^$__  +F_P#D
M>C_AJ']GW_HJ_A/_ ,"YO_D>OX,_MU[_ ,_EU_X$2_\ Q='VZ]_Y_+K_ ,")
M?_BZ /[S/^&H?V??^BK^$_\ P+F_^1Z/^&H?V??^BK^$_P#P+F_^1Z_@S^W7
MO_/Y=?\ @1+_ /%T?;KW_G\NO_ B7_XN@#^\S_AJ']GW_HJ_A/\ \"YO_D>C
M_AJ']GW_ **OX3_\"YO_ )'K^#/[=>_\_EU_X$2__%T?;KW_ )_+K_P(E_\
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M8:8ZR2+YAD@MW@?"G#$;K<C.#VYR:^MJ "BBB@ HHHH **** "BBB@ HHHH
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M2/!^D>+]/MY+:UU> 3Q0RYWHIQP=P4]^X'^/>4 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *S=6_P"/&7\/Y&M*LW5O^/&7\/Y&@#QW1?\ D,W/_7PO
M_H*5[=!_JE_SZ5XCHO\ R&;G_KX7_P!!2O;H/]4O^?2@":BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ K'\0_\@+6/^P;>?\ I/)6Q6/XA_Y 6L?]@V\_
M])Y* /XHO^"E/_)P47_7I>?^C+.O@>Q_UK_3^@K[X_X*4_\ )P47_7I>?^C+
M.O@>Q_UK_3^@H W:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "H9_]4W^?6IJAG_U3?Y]: ,>U_US?[W]!6]6#:_ZYO\
M>_H*WJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH *JW?\ JOSJU56[_P!5^= &78_ZZ3_='\JWJP;'_72?[H_E
M6]0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !52[^X?H/ZU;JI=_</T']: ,W3O]8/I_[-6[6%IW^L'T_]FK=H
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "E!*D,#@@@@^XI** /V,_X)?\ [34_@/QY
MH7@'5[TV^@WUVUQ<2RRY12+E<90D9^69^O7!(ZU_5EI&IVVLZ;9ZI9R++;7L
M0FAD7[KH20"/;BO\^/POXDU/PKJ]OJ^DW+6MY;_ZN5<[ERRMQ@@]5!^M?V,?
M\$_/VC-.^+_PXTS0WN@VI^&M(A@O'EERTLQD1OE5N^)QP#G@GF@#]%J*** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ KB/&_\ QXQ_4_TKMZXCQO\ \>,?U/\ 2@#G
M? GWO^VK?^AFO6:\F\"?>_[:M_Z&:]9H \'\6?\ (3A_ZYC^25[!H'_()L_^
MN8KQ_P 6?\A.'_KF/Y)7L&@?\@FS_P"N8H V**** "BBB@ HHHH *_ C_@JK
M_P %,?B_^QU96K?#"TT:[O'U=;*9-1$940FXCBR-UE<\[6;L.1UK]]Z_CA_X
M+X(KZEIR. RMXKME93T*G4800?8C@T ?,0_X.+_VTF^[H/A$_2*$_P#N%-+_
M ,1%O[:G_0 \)_\ ?F'_ .4M?K1_P1A_9;_9]^)O[.]YK7CWX5>%O%&J+K<,
M2WNIV]R\PC+7X*YBN8ACY5[?PBOV;_X8/_9 _P"B!^!/_ 2]_P#DV@#^0>P_
MX.)_VT;B_L+:30/">RYO;6!\10@A)IDC8C_B2CH&/<?45_5K^P/^TGXW_:1^
M&P\5^-[:SM]0^SVDNVS "%I@-W2& 8!/'RUZ*G["/[(4;I(GP$\"*\;JZ,+2
M]RKH0RL/]-Z@@$5]"^#_  !X-\ 6/]F^#?#VG^'K':J_9M/1TCVK]T8DDD.!
MVP: .PHHHH **** "HY9%AC>5SA8U+,?0 9J2FN@=&1@"K*5(/0@CO0!^!7_
M  49_P""KVM_LF_$4^"/"T^F//\ 81=!+U8"Q.(">7@F.,R^_P!*^M?^"<_[
M<]Q^V#H&MW^I3VCWNCVT+S):+$%261[4$?(D?&+CNOMZ&O$_V_\ _@D7IO[:
MOBY_%EOXWM_"%XUJMLK"'?( !$"<MI]YU,62,]:^J/V$_P!AC2_V,O#-[H5K
MK5OKUQ?VD-O<7L<?EM*\3P,9'_T:V'/D*/N>G ZT ?<7C'_D4O$W_8OZU_Z;
M+JO\^SXQ?\GT:9_V,NM?^EL5?Z"?C'_D4O$W_8OZU_Z;+JO\^SXQ?\GT:9_V
M,NM?^EL5 ']T_P"R?_R0SP/_ -@U?_9:^D*^;_V3_P#DAG@?_L&K_P"RU](4
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MY[XJ_P#!-;]EWQWX;O=&T'X4>#/#-[<JHBU"VM+OS(2$=<C?-..K!ON'[HH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MJCJ.HVNE6DE[>/Y<$7WVXXX)[D#H#WJ]7P__ ,%"/B*WPW_9E\=>(+/4CI^H
MV<<;0O&X68 VEZ^5)!'55/Y4 ?R7_P#!1CXW>)/VB?VL]&^$\;I=:)I/CV+2
M]L<C,XMY5G=LJJ8SF7INQ[CM_5W^P+\ =)^!OP9T/0M.@:$*D%QB2,*VZ6V1
MCSECC+'O]:_D8_X)Q>#'_:-_:N\:>)M8E.HRZ/XGM=166X D8N(;8Y!"G_GH
M?3OZU_=SX5TJ/1M%LK&-0JQ6\"@+P/EA1>G;I0!5\<ZU=>'O"^JZO9A6N;.
MR1!_N[@>_!_D:_DE_;'_ ."X_P"U/\"OBWXD\%>$])\,3:9I5RL-NUTL)E*M
M-(A+9TN4YP@_B-?UA?%?_D0?$'_7H?YU_G[?M;:;8:Q^V_?6&IVL5Y9W'B_0
MH9K>8$QR12ZQ(DB,%*DAE)4\YQWH ^DQ_P '%W[:9 (T#PET!_U4)Z_]P6@_
M\'%W[:@!/]@>$^/^F,/_ ,I*_J0_9X_8D_91UGX9^&[[5/@=X)O;N?0]#EEG
MFM;PN\DNFQ22.Q6\ R[DL>.IKW3_ (8._9 _Z('X$_\  2]_^3: /YYO^"=_
M_!:7]I_]I_X]P?#CQYH_AZVT22R2<R6<<8EWEY01\NEV_9!_'WZ5_5]H]W)?
M:787DH DN;:.5P.@9QDXX''X5X/X+_9)_9O^'6L+K_@GX0^$O#FLJH1=0TZW
MNDN H)( 9[J1< DX^7C->S^(]<T[PAH%WJ]X\-KI^FP[G:0E8HXU!P"1SCCZ
MT 97CSXA^&/AOHUQKWBF]%EIUM#-<2RY3*QP)OD.'=!PO/) ]Z_"3]JO_@N3
M\&OA_)J.E_"3Q59ZIK5H)H4@NX[+:;F#,<JG;)<G F!&=N<'I7Y2_P#!6;_@
MH]XN\<_$"^^#?P]OK^PMXM:CT^.^TJ="EZEY=>1Y06223((7&/+4X:ND_P""
M<O\ P2*UGXQI8?%3XJ:G.(I;P32:3K=LK"ZBO)6N1*3'9L2I1 <B4$AQGN0
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M3G/K0!Y:/^#C#]M$]-"\(GZ1P'^6BTO_ !$7?MJ!D!T#PGAG53^ZA'!8 _\
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M48Y[6Y4M%(F_[K!64XY/ (H ^D!_P<7?MIGIH'A(_2*$_P#N%H_XB+?VU/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *Q_$/\ R M8_P"P;>?^D\E;%8_B'_D!:Q_V#;S_ -)Y* /XHO\
M@I3_ ,G!1?\ 7I>?^C+.O@>Q_P!:_P!/Z"OOC_@I3_R<%%_UZ7G_ *,LZ^![
M'_6O]/Z"@#=HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH *AG_ -4W^?6IJAG_ -4W^?6@#'M?]<W^]_05O5@VO^N;_>_H
M*WJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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METGQ#<V)AM[@179M4GU (J0S2W$K8CMT&0A&<#C.*^A/^"X7_)"-(_Z^+O\
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M,\#_ /8-7_V6OH:]O;73[:6[O)X;:"%'=Y)Y4A0!%+$%Y"J@X![U\\_LG_\
M)#/ _P#V#5_]EKX6_P""M_[3%Q\$?V>O$K:'?&WUY&Q$L4ODS['MY<[7!!ZD
M=/QH \%_;0_X+/?"[X/WFK>"?!5SJC^,;22?3H6LR]W&;^(%_E2UMV9AM X#
MYSWQ7X<WW_!83_@H[XP\1:@/ FIZW;Z-% UQ +CP_P"(!\J":1@&#QJ2450
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M^GP^)_\ @H-^U]_PA^N:KJ?V:[O+V,&.YDE/EP:F(0 JD\;% QB@#ZW^*_\
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M_8L:A_Z"M?P,>&O^3Y3_ -?3?^G1J /[X_@7_P DM\%?]@"R_P#037KM>1?
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MU>//^"<7P<\6>/G\>:18Z=X4NVN;:X%MHVG1VD:_9K@W"J/("@ D[2!QCVH
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MWP7\<:G+X)\.2:@/#6JS"\?2[9K@2K&=L@D*;MPSP<YK^,;_ ()>>'="UO\
M;XM-*U?2;'4M-^TZF/L-Y;QSVW&JD#]TX*\#@<<#B@#ZJ\,_\%+/^"I\LVE6
MRZ]?"P;:@4Z'KW^JPV!G[1MSWSC']/ZM_P!@KXD?%KXH? SPIXI^+MRUQXHO
MXI#?N\%Q;LS+:VKJ?+N'>0?O)'^\>_J*][\.?!/X2+HVF2#X=>$@XMD.X:-:
M!LY/.?+KU?2M%TG0K2.PT?3K33;.+B*VLX4@ACX ^5$ 4< #@=!0!IT444 1
M3J7@F0=7BD4?5D8#]37\57_!>SX6^*=-\7>&]6:TEFM+E;FX66"WED2-"ET
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M ."NO_!4*/2K3Q"-8UC^S9YE!B_X1WQ$9@BM&SY7S<@;'QDKZ]<5]Y_L@_\
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M1!\0?]>A_G7^>+^WOXMN? ?[6GB3Q/:0I<3Z9KVGZA'"^-KO9ZC-.JG((PQ
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L?Q#_R
M M8_[!MY_P"D\E;%8_B'_D!:Q_V#;S_TGDH _BB_X*4_\G!1?]>EY_Z,LZ^!
M['_6O]/Z"OOC_@I3_P G!1?]>EY_Z,LZ^!['_6O]/Z"@#=HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *AG_U3?Y]:FJ&
M?_5-_GUH Q[7_7-_O?T%;U8-K_KF_P![^@K>H **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JK=_P"J_.K55;O_
M %7YT 9=C_KI/]T?RK>K!L?]=)_NC^5;U !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/L;73+*VT^RC$-K9PI!;Q#&$BC&U%& !P!CI5RB@#\-?^"X7_)"-(_Z^+O\
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M_M+^#_'/C#P)XV6^D\9Z5J&I:A?Z#?PK)LERSN\D6 !W))K_ $=O^$!\"?\
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M'N#T[5^</_!OPBQIXM51@+XIF4>P%VX_I7Z8?\%WO^39&_[#;?\ MI7YI?\
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M(XYKZ.L/#'A739/-TSP]X?L)AQYEAI.FVL@'IOM[>-OUKP7]L  ?L\_$,
M:4P  P /FX '2@#^'+]FK_D];6_^PKI?_I9/7]]WPY_Y$_0/^P-I7_I##7\"
M/[-7_)ZVM_\ 85TO_P!+)Z_ON^'/_(GZ!_V!M*_](8: .W=U12[L%51EF8X
M'J3VK\#/^"PW[=UM\)?AWJ7P[\&:L++Q>UV]K+/:W&Z5X;HQVWEB-&4\Y< 9
M.2:_4W]K;]H/PU\ OA3XIUW5=02SU<Z'<W&B(QC"RW*2!5#;V!Q\DG16Z=*_
MA_T33?B%_P %+/VM9I]5%Q>Z=+<VM]LM)[@P%+;499B?+C5(_NQ\\<@'/% '
MVA_P2/\ V*-8^-WQ$NOCC\0=.DGGL?$<NIV\VHVQADF2ZG5M\32@LRL "",Y
M')-?V>^']#LO#VEVVEV$2PV]LNV-%QA1@#C '8?YYKP#]F#X&:'\$_AOX>\/
M:=816LT.CV$-UBVCB<S11J&+,HW,Q(Y+')^O3Z:H ^%O^"BO_)L/C'ZC_P!(
M[ROXZ_\ @G3_ ,G:>)?^QYM__2*QK^Q7_@HH"?V8O&( ).1TY_Y<[ROXOOV#
M_&FA^$OVO-4M=9N/L\NJ>/8([0':-["RM>NYE(_U;=CTH _T#?#O_(*MO^N:
M?^@BLSQU_P BSJ/^X/Y-5GPC>P7^B6EQ;N'B>--I!!_@4]B?6N2^,GBO1O!O
MP^UWQ!KERMMIUA")+B3<F57#G(#,H/0]Z /\_/\ ;:_Y2!1?]E)T7_TY&O[U
MOV7_ /DDWAG_ + VB_\ IL@K_/\ OVJ_&>A^-_V[;+6- N#=6-U\1M%>&3Y?
MF4ZB3GY68<9]:_T ?V7_ /DDWAG_ + VB_\ IL@H _(/_@NO_P DVT;_ + U
MW_Z'>U\$?\$%/^/[3/\ L$M_Z3SU][_\%U_^2;:-_P!@:[_]#O:^"/\ @@I_
MQ_:9_P!@EO\ TGGH _KVM_\ 40_]<T_]!%<K\0)'A\$^*)8SAX]&O64^C"(D
M&NJM_P#40_\ 7-/_ $$5B>++!M4\-:WIR E[W3KBW4#J3(A4 ?G0!_G9_P#!
M3[6];N/V@]0NX9Y)+Z(S^444L_R7494*,YX*CZ_I7K7PC_;M_;G\'>#=%T7P
MII7Q*ETFRT^*VM'L-!U2:W:!&)4QR1C:RYZ,#_\ 69_P5V^'VK?"C]I"2]DM
M-J86<^<I9"LEU;R<AU*\AO0@CBOZO?\ @FAK/PU\?_ /P5&?#GA:^U"R\+V*
MWAFT+1YI!,9>2SO;,[,0Z\GGM0!_,K_P\8_X*'_] ?XK_P#A-ZS_ (U\_P#Q
MZ_:G_;V^-_A^\\,^(/#OQ0O=%OX!%=V<WAO5MLH"%<'<IR,,1T/6O]!;_A ?
M G_0E>$O_"<T?_Y#I#X"\!@9/@OPB!ZGPYHP'YFSH _C@_X(3?!'XG>#OBEX
MSU[Q=X2\0Z)'J,-NRMJFEW5F&(BB'!F1<XP?>OZA/VQ?V8;+]IKX/7_@0I;1
MWMU"'6>ZV; 5M2@!#\=??/;I7U=I_A[PWIC%M*T/0]/8]6T_3+"T8X]3;01D
MX]ZV"\8^5G0=L%E'X8)H _@ ^,?[)?[5_P"P9\0+[6/A5<Z[+9WVJ37KGP[I
M<]TJ+&OR[VM6P.8AC/'(]:^W_P!FK_@N3XS^#4&E:+^T%X9\9:YJ!>&RNIKZ
MSOK7;-.4MUE<2(^U4D;<2>, Y[D_U]Z[X-\,>);2>TU;0]&ODG0HTEUI=C=.
M >25::%R"?4$=:_&']NC_@D[\$/BGX;\1>-+*SN;37(++4]4:+3[:*T@1K&W
MDO8]@MYX@N'4YPG0<=* /NG]F']N;X5_M,Z-;:CX>U#3].N[GR5CTR>_C-XS
M2@Y B8K)E6&"-O!..M?;:LKJ&4AE/((.0:_SK/V)/&GCCX#_ +:WAWP#HVI7
M[Z3!X@UBW^SW.H7;(R6>JP0QAHF>1#A21@C'/O7^@C\+=;N]?\&:+J5[C[1<
MV@DDQTW$CCD#^E 'HE%%% #)/]6_^XW\C7\6O_!Q/!-_PLVQ;RGV_P#"+ISM
M..;#3N_2O[3:_D2_X.(?"^HW_BR'5K:V1[2W\+0I))MY#?V?8<<+C^ ]^U '
MVW_P1'N;=_A/I<:S1M(N@P!D# LIW1\$=1U'6OZ$5Z#Z#^5?R]_\$(_$UA=^
M'[_2X[EWN++3+>.6,ME4/^C' !;CJ.,"OZ@T^ZO^Z/Y"@#SSXK_\B#X@_P"O
M0_SK_/N_; T33?$?[;&I:1J]NMU87GBW1+:>!L;7AGU>2.5#D$8920<@CGI7
M^@C\5_\ D0?$'_7H?YU_ )^U)_R?5<?]CIX?_P#3V] ']6OP#_X)<_L3^)?A
MSX>U76/@[I-W?76BZ+<3S.8LO+<:?%+*QS;'[SL6Z]Z]J/\ P29_82(P?@IH
MY!]X?_D6OIW]F7_DE'A;_L7_  __ .FJ&OH2@#Y)^$/[#O[-7P+U./5_AE\.
M[#PYJ$2;$GMS'N"\\?+#&?XCWKXB_P""NWA:+4O@;XGNUTZ6Y^Q:$526.,LL
M0$;C!*CC%?LG7R9^VKX!N/B#^SU\0=!TVT2[U6]TIH;2-D#$MA^ =KL.O84
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M** "BBB@!"0 23@#DDU^67_!2S]KK0/@/\)/$-FE_#!KBQ[XF2X590K6\O1
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MVWO!'Q4OM&\$:5\2)=(C-SY;:=H6J3P?+, @5XAM/R],=N.E?)Y_X*,?\%$
MI(T?XKYQ_P!"WK/^?TZ5_=!<^#/!][(9;SPIX:NY3UDN="TN>0YZY>6U=N?K
M5?\ X0'P)_T)7A+_ ,)S1_\ Y#H _EF_8#_;._;(^)/Q.BTCXCZ;\0(=),%L
MQ?5]%U&U@W.\X;YYAMR JY_48K^K+1)IKC1],GN-PGFL;:24."&\QXE9]P/(
M;<3D'O5*S\(^%-/D\VP\,>'K&7IYEGHNFVTF/3?#;(W<]^]=  % 50  ,
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M6Q6/XA_Y 6L?]@V\_P#2>2@#^*+_ (*4_P#)P47_ %Z7G_HRSKX'L?\ 6O\
M3^@K[X_X*4_\G!1?]>EY_P"C+.O@>Q_UK_3^@H W:*** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "H9_P#5-_GUJ:H9_P#5
M-_GUH Q[7_7-_O?T%;U8-K_KF_WOZ"MZ@ HHHH **** "BBB@ HHHH ****
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M#:@^1$&0/:NMH _CG_X.!?\ DHT__8+M_P#T5;5^I?\ P1._Y)'<?]@2R_\
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MWV^-7_!-']E;X^W\VH_$3P:VI7,ZLLC(;100V,_?M)#V'?\ 2OGNS_X(:_L
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MXQG/7] _B)_P<%Z_XQ\.W?A;X>_!*ZU'6=;M?LT%WI5PK7%G.W(*"37@N[@
M?*_7VK]@OB;_ ,$B_P!C#XMZU<:]XR\!R7NHW)<R2H]DH)=R[<-9.>6]35+X
M=?\ !'S]BCX7:M!K/A/P#):7UO,+B)W>R8"10 #A;)3T'K0!_$W^US+^T%\0
MS:?%SXHV/BK2=,\0:O:I%IFM"W,,$RW4$GRF%IB6W7,8_P!:W*@^Y_J*_P""
M!(Q\!=:![>(%'Y7.H5^J'QC_ &!OV=/CIX3T[P9\0/"IU'0]+O5O[2W3[*I2
MX5X) V7MI%QOMHSPH/'7H:] _9X_92^#_P"S!X?N/#/PGT-M&TJYN?M<L+-"
M29MTK[LPPPC[TK]5SSUH [GX[?\ )'OB)_V+&H?^@K7\#'AK_D^4_P#7TW_I
MT:O]"CQ!H>G^)=%U+0-5B\[3M6M9+.\BX_>02X#KR".<=P:_/.U_X)3?L@6?
MCX_$F'P1*OB@N7^U[[/&XS>>>/L>_P"^2?OYH ^Q_@7_ ,DM\%?]@"R_]!->
MNUC:!H.G>&M)L=%TJ(PV&G6\=K;1D@[(HQA5X"CCV K9H *AN+>&ZADM[B-9
M8)E*2QOG:Z'JK8(.#]:FHH _G9_X*K_\$L;;XW1:O\4O [);:Y*6:/2=-MR]
MR#"/.5E,EO(O+\?ZWK[5_.M\)_B?^V+^PYXW9-3T#X@2^'-(U%Q]@F-E#:7]
MK 1L&!/"VPA<CYE/'M@_Z)KHLBE'4,K @@@'@C!Z@]J^9OB[^R/\%_C<,>//
M#RZA\C1_(+=?E8$$?/!)U!- '\T.C_\ !RMJOA>PATG5_@'-<WML-LLMQ<KY
MC' 'S;?$*#@@X( Z\]:XWXA_\'!/Q"^-6D7/AWP%\%-5TC5+U0D%QI=Q$TZ,
MJM&=HDUR8<NP.-IY K]LM8_X(A?L$ZY>RW]_\.)I+B8YD826')R3WL#W-==X
M _X(\?L3?#34[?5O"W@"2TO+9MT3L]D0"7#GA;%3R5'>@#^13P+^S+^UI^VY
M\6[75?B-H?CK3_#EUKD5Q#+J\-G+:0VLT>&93$;AA&&=NQ.3TQ7]HO[$7[&?
M@_\ 99^&NC^&[2ST^]UFT16DU>.%X[A@T**4.4A& P;_ )9CJ>M?77@SX>^&
M/ >G0:7X>L4M;2VB$,2[(\JBG(&41<_E7;T    P. *_AA_X+*?\G*M_V.VF
M_P#IS6O[GJ^!OC;_ ,$V?V7/V@/%'_"7_$?PA)JFM?;XM1-PKVH'VJ&7SD?]
MY:2MQ)@_>S[T >2?\$I?^2 V?_72P_\ 1,U?JI7DGPB^"?@/X)>'4\+^ M.;
M3=)C,;+ 3&<&)65/]7'&. Q[5ZW0!^"W_!=[_DV1O^PVW_MI7YI?\&_7W?%W
M_8U3_P#I9)7]2?[0/[,GPI_:8\*GP=\5-&;6-$,YN/LZF('S3L^;,L,R_P "
M_P .>.O>O+OV=/V!/V=/V6_MG_"I/"[Z+]ONVO;C>ULV^X9S(6_=6T/\1SW_
M %H \9_X*6ZE\8=&^&FA:M\(HM?GU'3IY+N^AT'R?.EAA</LD\YE&UE!'# X
M[BOPW^&/_!<3XM_ 0R>$/BI\%=>O;B"ZEWZKK<T*N(X99$Y\G6XAAE96QY8X
M';I7]>U[86VH6=Q8W4:R6]S"\$JD YCD4JPY!'(/I7P!\7?^"8?[)_QNO9[_
M ,>>"WU"XN-_FM&UHF=YRWW[.0]>G./:@#\4?B/_ ,'%T,NAG1O#_P '4O=1
MUVV:WC:UN<RVLQ9F! ;7%&[$?H^ WKC'Y):#\(OCK_P4:_:83QSJW@GQ-X5T
M2YU#2M6&ISQ6\MM)]EU)[YHMXEOFY55XV]&!W=Q_53IO_!#W]@;2=0MM3L_A
MQ,EU:2B:%S)8':X! /%@#T)'6OT.^$G[/?PT^">E6VC> ]'&G65HNR%&$)91
ML"?>2&,?= '2@"G^SS\,8_AG\,?#'AB7$KV6@Z59W!9=I:2WM41BXVIR6!SQ
MP?2OY[_^"PG_  3AUWQ5(OQ5^&6GW.I^(;O49-3GAT:W5KJW>&1G1F::)5R"
M<@[V]J_J+  &!P!5>ZM8+VWEMKB-9(IHVC=6 .588(Y!% '\'?[*_P#P4H_:
M&_8#TY?#'Q0^&_BOQ+;Z?>.=NM26T:>3'(ZH,1:E9X4(0!QT&/K^I-K_ ,'%
M^AS:$-0'PFMC?_9A*NGBZ;S6E)P8A_Q.\9[_ 'QT/-?LI\;/^"<G[,'Q_N)[
MGXC>#SJ<MP")&0VB9!QG_66DG88ZU\T0?\$,_P!@&WN([F/X;SB6-MZGS;#
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MO_\ 7^</^'%/_!/O_HFLW_?S3^__ '#Z /RF3_@YV\M%1?V>P%10JC[3T X
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M** "BBB@ HHHH **** "LW5O^/&7\/Y&M*LW5O\ CQE_#^1H \=T7_D,W/\
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M@#Q/]C_]G+1?V?OAEHOAFTM[<WED@#7*1,DC P1(0050#[IS\O4GTKZ_HHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Q_$/_("UC_L&WG_ *3R
M5L5C^(?^0%K'_8-O/_2>2@#^*+_@I3_R<%%_UZ7G_HRSKX'L?]:_T_H*^^/^
M"E/_ "<%%_UZ7G_HRSKX'L?]:_T_H* -VBBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ J&?_5-_GUJ:H9_]4W^?6@#'M?]
M<W^]_05O5@VO^N;_ 'OZ"MZ@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "JMW_ *K\ZM55N_\ 5?G0!EV/^ND_
MW1_*MZL&Q_UTG^Z/Y5O4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 54N_N'Z#^M6ZJ7?W#]!_6@#-T[_6#Z?^
MS5NUA:=_K!]/_9JW: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_2_P#X)X?L
MTZA\7?B+9:_<6\OV#POJMM>31M&'BN(A'&"K'8Y"YG!X*XQR:_/OP;X4U/QE
MKEMH>DQ-+>7.?+58VD)PRKPJ\GEA[5_9/^P1^SUIWP:^&FE:K%9+;:GXDT>&
M346VJK/*'5267 93B!.&)Z"@#[GT/1=-T'3K?3M+M(K*UACC58(00@(15) )
M)[>M:]%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 5Q'C?_CQC^I_I7;UQ'C?_ (\8
M_J?Z4 <[X$^]_P!M6_\ 0S7K->3>!/O?]M6_]#->LT >#^+/^0G#_P!<Q_)*
M]@T#_D$V?_7,5X_XL_Y"</\ US'\DKV#0/\ D$V?_7,4 ;%%%% !1110 444
M4 %%%% !1110 4444 ?AK_P7"_Y(1I'_ %\7?_H4=?E7_P $%O\ D=+7_L9-
M0_\ 3I<5_61\5?@I\-_C5I$6A_$?P[;>(=,A+-';7&-JE\%B,JPR2 >E>?\
MPC_9$^ 7P,NEO/AEX$L/#=PD[W"R6VW(FDD,KMQ&O5V+$>M 'TJO0?0?RI:*
M* "BBB@ HHHH **** "BBB@ HHHH **** *6I?\ (.O_ /KRNO\ T1)7^?G^
MV?\ \GO:1_V/=[_Z)EK_ $%Y$61'C<921&1QZJX*L/Q!(KX\\3_L$_LM>,?%
M4?C3Q#\,M+O_ !'%>-?)J,@3S%N7!#2<PDY()'7//6@"?]AW_DWGP;_NR?\
MI+:5]?5S?A3PEH/@K1K;0/#=C'IVE6F?L]K'C9'E54XP!V11T[5TE !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M3S1>E"AF_P!5G.TD=:^KM.TZSTJU2SL85@MX_N1KT' '\@* +U%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !6;JW_ !XR_A_(UI5FZM_QXR_A_(T
M>.Z+_P AFY_Z^%_]!2O;H/\ 5+_GTKQ'1?\ D,W/_7PO_H*5[=!_JE_SZ4 3
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M]$[\6_\ @FN__C= 'F%%>G_\*5^+7_1._%O_ ()KO_XW1_PI7XM?]$[\6_\
M@FN__C= 'F%%>G_\*5^+7_1._%O_ ()KO_XW1_PI7XM?]$[\6_\ @FN__C=
M'F%%>G_\*5^+7_1._%O_ ()KO_XW1_PI7XM?]$[\6_\ @FN__C= 'F%%>G_\
M*5^+7_1._%O_ ()KO_XW1_PI7XM?]$[\6_\ @FN__C= 'F%%>G_\*5^+7_1.
M_%O_ ()KO_XW1_PI7XM?]$[\6_\ @FN__C= 'F%%>G_\*5^+7_1._%O_ ()K
MO_XW1_PI7XM?]$[\6_\ @FN__C= 'F%%>G_\*5^+7_1._%O_ ()KO_XW1_PI
M7XM?]$[\6_\ @FN__C= 'F%%>G_\*5^+7_1._%O_ ()KO_XW1_PI7XM?]$[\
M6_\ @FN__C= 'F%%>G_\*5^+7_1._%O_ ()KO_XW1_PI7XM?]$[\6_\ @FN_
M_C= 'F%%>G_\*5^+7_1._%O_ ()KO_XW1_PI7XM?]$[\6_\ @FN__C= 'F%%
M>G_\*5^+7_1._%O_ ()KO_XW1_PI7XM?]$[\6_\ @FN__C= 'F%%>G_\*5^+
M7_1._%O_ ()KO_XW1_PI7XM?]$[\6_\ @FN__C= 'F%%>G_\*5^+7_1._%O_
M ()KO_XW1_PI7XM?]$[\6_\ @FN__C= 'F%%>G_\*5^+7_1._%O_ ()KO_XW
M1_PI7XM?]$[\6_\ @FN__C= 'F%%>G_\*5^+7_1._%O_ ()KO_XW1_PI7XM?
M]$[\6_\ @FN__C= 'F%%>G_\*5^+7_1._%O_ ()KO_XW1_PI7XM?]$[\6_\
M@FN__C= 'F%%>G_\*5^+7_1._%O_ ()KO_XW1_PI7XM?]$[\6_\ @FN__C=
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MKT__ (4K\6O^B=^+?_!-=_\ QNC_ (4K\6O^B=^+?_!-=_\ QN@#S"BO3_\
MA2OQ:_Z)WXM_\$UW_P#&Z/\ A2OQ:_Z)WXM_\$UW_P#&Z /,**]/_P"%*_%K
M_HG?BW_P37?_ ,;H_P"%*_%K_HG?BW_P37?_ ,;H \PHKT__ (4K\6O^B=^+
M?_!-=_\ QNC_ (4K\6O^B=^+?_!-=_\ QN@#S"BO3_\ A2OQ:_Z)WXM_\$UW
M_P#&Z/\ A2OQ:_Z)WXM_\$UW_P#&Z /,**]/_P"%*_%K_HG?BW_P37?_ ,;H
M_P"%*_%K_HG?BW_P37?_ ,;H \PHKT__ (4K\6O^B=^+?_!-=_\ QNC_ (4K
M\6O^B=^+?_!-=_\ QN@#S"BO3_\ A2OQ:_Z)WXM_\$UW_P#&Z/\ A2OQ:_Z)
MWXM_\$UW_P#&Z /,**]/_P"%*_%K_HG?BW_P37?_ ,;H_P"%*_%K_HG?BW_P
M37?_ ,;H \PHKT__ (4K\6O^B=^+?_!-=_\ QNC_ (4K\6O^B=^+?_!-=_\
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M37?_ ,;H_P"%*_%K_HG?BW_P37?_ ,;H \PHKT__ (4K\6O^B=^+?_!-=_\
MQNC_ (4K\6O^B=^+?_!-=_\ QN@#S"BO3_\ A2OQ:_Z)WXM_\$UW_P#&Z/\
MA2OQ:_Z)WXM_\$UW_P#&Z /,*J7?W#]!_6O6O^%*_%K_ *)WXM_\$UW_ /&Z
MI7OP7^+"1,S_  ]\6*H').CW8]?^F= 'D&G?ZP?3_P!FK=KK=+^#GQ4DE C\
M >*G.#PND71[D]D]*Z+_ (4K\6O^B=^+?_!-=_\ QN@#S"BO3_\ A2OQ:_Z)
MWXM_\$UW_P#&Z/\ A2OQ:_Z)WXM_\$UW_P#&Z /,**]/_P"%*_%K_HG?BW_P
M37?_ ,;H_P"%*_%K_HG?BW_P37?_ ,;H \PHKT__ (4K\6O^B=^+?_!-=_\
MQNC_ (4K\6O^B=^+?_!-=_\ QN@#S"BO3_\ A2OQ:_Z)WXM_\$UW_P#&Z/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>U>(?^/&7_/\!KS'PM_R$[G_ *[#^24 >G#PIX7P/^*;T#H/^8/IW_R-2_\
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MVKR[P]_R&+G_ *[C_P!!%>X+T'T'\J ,'_A%/"W_ $+6@?\ @GT[_P"1J/\
MA%/"W_0M:!_X)]._^1JWZ* ,#_A%/"W_ $+6@?\ @GT[_P"1J/\ A%/"W_0M
M:!_X)]._^1JWZ* ,#_A%/"W_ $+6@?\ @GT[_P"1J/\ A%/"W_0M:!_X)]._
M^1JWZ* ,#_A%/"W_ $+6@?\ @GT[_P"1J/\ A%/"W_0M:!_X)]._^1JWZ* ,
M#_A%/"W_ $+6@?\ @GT[_P"1J/\ A%/"W_0M:!_X)]._^1JWZ* ,#_A%/"W_
M $+6@?\ @GT[_P"1J/\ A%/"W_0M:!_X)]._^1JWZ* ,#_A%/"W_ $+6@?\
M@GT[_P"1J/\ A%/"W_0M:!_X)]._^1JWZ* ,#_A%/"W_ $+6@?\ @GT[_P"1
MJ/\ A%/"W_0M:!_X)]._^1JWZ* ,#_A%/"W_ $+6@?\ @GT[_P"1J/\ A%/"
MW_0M:!_X)]._^1JWZ* ,#_A%/"W_ $+6@?\ @GT[_P"1J/\ A%/"W_0M:!_X
M)]._^1JWZ* ,#_A%/"W_ $+6@?\ @GT[_P"1J/\ A%/"W_0M:!_X)]._^1JW
MZ* ,#_A%/"W_ $+6@?\ @GT[_P"1J/\ A%/"W_0M:!_X)]._^1JWZ* ,#_A%
M/"W_ $+6@?\ @GT[_P"1J/\ A%/"W_0M:!_X)]._^1JWZ* ,#_A%/"W_ $+6
M@?\ @GT[_P"1J/\ A%/"W_0M:!_X)]._^1JWZ* ,#_A%/"W_ $+6@?\ @GT[
M_P"1J/\ A%/"W_0M:!_X)]._^1JWZ* ,#_A%/"W_ $+6@?\ @GT[_P"1J/\
MA%/"W_0M:!_X)]._^1JWZ* ,#_A%/"W_ $+6@?\ @GT[_P"1J/\ A%/"W_0M
M:!_X)]._^1JWZ* ,#_A%/"W_ $+6@?\ @GT[_P"1J/\ A%/"W_0M:!_X)]._
M^1JWZ* ,#_A%/"W_ $+6@?\ @GT[_P"1J/\ A%/"W_0M:!_X)]._^1JWZ* ,
M#_A%/"W_ $+6@?\ @GT[_P"1J/\ A%/"W_0M:!_X)]._^1JWZ* ,#_A%/"W_
M $+6@?\ @GT[_P"1J/\ A%/"W_0M:!_X)]._^1JWZ* ,#_A%/"W_ $+6@?\
M@GT[_P"1J/\ A%/"W_0M:!_X)]._^1JWZ* ,#_A%/"W_ $+6@?\ @GT[_P"1
MJ/\ A%/"W_0M:!_X)]._^1JWZ* ,#_A%/"W_ $+6@?\ @GT[_P"1J/\ A%/"
MW_0M:!_X)]._^1JWZ* ,#_A%/"W_ $+6@?\ @GT[_P"1J/\ A%/"W_0M:!_X
M)]._^1JWZ* ,#_A%/"W_ $+6@?\ @GT[_P"1J/\ A%/"W_0M:!_X)]._^1JW
MZ* ,#_A%/"W_ $+6@?\ @GT[_P"1J/\ A%/"W_0M:!_X)]._^1JWZ* ,#_A%
M/"W_ $+6@?\ @GT[_P"1J/\ A%/"W_0M:!_X)]._^1JWZ* ,#_A%/"W_ $+6
M@?\ @GT[_P"1J/\ A%/"W_0M:!_X)]._^1JWZ* ,#_A%/"W_ $+6@?\ @GT[
M_P"1J/\ A%/"W_0M:!_X)]._^1JWZ* ,#_A%/"W_ $+6@?\ @GT[_P"1J/\
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M_P"A:T#_ ,$^G?\ R-6_10!@?\(IX6_Z%K0/_!/IW_R-1_PBGA;_ *%K0/\
MP3Z=_P#(U;]% &!_PBGA;_H6M _\$^G?_(U'_"*>%O\ H6M _P#!/IW_ ,C5
MOT4 8'_"*>%O^A:T#_P3Z=_\C4?\(IX6_P"A:T#_ ,$^G?\ R-6_10!@?\(I
MX6_Z%K0/_!/IW_R-1_PBGA;_ *%K0/\ P3Z=_P#(U;]% &!_PBGA;_H6M _\
M$^G?_(U'_"*>%O\ H6M _P#!/IW_ ,C5OT4 8'_"*>%O^A:T#_P3Z=_\C4?\
M(IX6_P"A:T#_ ,$^G?\ R-6_10!@?\(IX6_Z%K0/_!/IW_R-1_PBGA;_ *%K
M0/\ P3Z=_P#(U;]% &!_PBGA;_H6M _\$^G?_(U'_"*>%O\ H6M _P#!/IW_
M ,C5OT4 8'_"*>%O^A:T#_P3Z=_\C4?\(IX6_P"A:T#_ ,$^G?\ R-6_10!@
M?\(IX6_Z%K0/_!/IW_R-1_PBGA;_ *%K0/\ P3Z=_P#(U;]% &!_PBGA;_H6
MM _\$^G?_(U'_"*>%O\ H6M _P#!/IW_ ,C5OT4 8'_"*>%O^A:T#_P3Z=_\
MC4?\(IX6_P"A:T#_ ,$^G?\ R-6_10!@?\(IX6_Z%K0/_!/IW_R-1_PBGA;_
M *%K0/\ P3Z=_P#(U;]% &!_PBGA;_H6M _\$^G?_(U'_"*>%O\ H6M _P#!
M/IW_ ,C5OT4 8'_"*>%O^A:T#_P3Z=_\C4?\(IX6_P"A:T#_ ,$^G?\ R-6_
M10!@?\(IX6_Z%K0/_!/IW_R-1_PBGA;_ *%K0/\ P3Z=_P#(U;]% &!_PBGA
M;_H6M _\$^G?_(U'_"*>%O\ H6M _P#!/IW_ ,C5OT4 8'_"*>%O^A:T#_P3
MZ=_\C4?\(IX6_P"A:T#_ ,$^G?\ R-6_10!@?\(IX6_Z%K0/_!/IW_R-1_PB
MGA;_ *%K0/\ P3Z=_P#(U;]% &!_PBGA;_H6M _\$^G?_(U'_"*>%O\ H6M
M_P#!/IW_ ,C5OT4 8'_"*>%O^A:T#_P3Z=_\C4?\(IX6_P"A:T#_ ,$^G?\
MR-6_10!@?\(IX6_Z%K0/_!/IW_R-1_PBGA;_ *%K0/\ P3Z=_P#(U;]% &!_
MPBGA;_H6M _\$^G?_(U'_"*>%O\ H6M _P#!/IW_ ,C5OT4 8'_"*>%O^A:T
M#_P3Z=_\C4?\(IX6_P"A:T#_ ,$^G?\ R-6_10!@?\(IX6_Z%K0/_!/IW_R-
M1_PBGA;_ *%K0/\ P3Z=_P#(U;]% &!_PBGA;_H6M _\$^G?_(U'_"*>%O\
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M ()]._\ D:M^B@# _P"$4\+?]"UH'_@GT[_Y&H_X13PM_P!"UH'_ ()]._\
MD:M^B@# _P"$4\+?]"UH'_@GT[_Y&H_X13PM_P!"UH'_ ()]._\ D:M^B@#
M_P"$4\+?]"UH'_@GT[_Y&H_X13PM_P!"UH'_ ()]._\ D:M^B@# _P"$4\+?
M]"UH'_@GT[_Y&H_X13PM_P!"UH'_ ()]._\ D:M^B@# _P"$4\+?]"UH'_@G
MT[_Y&H_X13PM_P!"UH'_ ()]._\ D:M^B@# _P"$4\+?]"UH'_@GT[_Y&H_X
M13PM_P!"UH'_ ()]._\ D:M^B@# _P"$4\+?]"UH'_@GT[_Y&H_X13PM_P!"
MUH'_ ()]._\ D:M^B@# _P"$4\+?]"UH'_@GT[_Y&H_X13PM_P!"UH'_ ()]
M._\ D:M^B@# _P"$4\+?]"UH'_@GT[_Y&H_X13PM_P!"UH'_ ()]._\ D:M^
MB@# _P"$4\+?]"UH'_@GT[_Y&H_X13PM_P!"UH'_ ()]._\ D:M^B@# _P"$
M4\+?]"UH'_@GT[_Y&H_X13PM_P!"UH'_ ()]._\ D:M^B@# _P"$4\+?]"UH
M'_@GT[_Y&H_X13PM_P!"UH'_ ()]._\ D:M^B@# _P"$4\+?]"UH'_@GT[_Y
M&H_X13PM_P!"UH'_ ()]._\ D:M^B@# _P"$4\+?]"UH'_@GT[_Y&H_X13PM
M_P!"UH'_ ()]._\ D:M^B@# _P"$4\+?]"UH'_@GT[_Y&I\?AGPW$P>+P]H<
M3J0RO'I-@C*PZ$,MN"".Q!R*W** $ "@*H"JH 50   !@  <  < #@"EHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ KB/&__'C']3_2NWKB/&__ !XQ_4_T
MH YWP)][_MJW_H9KUFO)O GWO^VK?^AFO6: /!_%G_(3A_ZYC^25[!H'_()L
M_P#KF*\?\6?\A.'_ *YC^25[!H'_ "";/_KF* -BBBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K-U;_CQE_#^
M1K2K-U;_ (\9?P_D: /'=%_Y#-S_ -?"_P#H*5[=!_JE_P ^E>(Z+_R&;G_K
MX7_T%*]N@_U2_P"?2@":BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH Y_Q#_QXR_Y_@->8^%O^0G<_P#78?R2O3O$/_'C+_G^ UYCX6_Y"=S_ -=A
M_)* /;5Z#Z#^5+2+T'T'\J6@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ K&US_CQE^@_]FK9K&US_CQE^@_]FH \G\/?\ABY
M_P"NX_\ 017N"]!]!_*O#_#W_(8N?^NX_P#017N"]!]!_*@!:*** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KGO$O
M_(,G_P!P_P!:Z&N>\2_\@R?_ '#_ %H \P\*?\A*3_@/\Q7MR?<7_=7^0KQ'
MPI_R$I/^ _S%>W)]Q?\ =7^0H =1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %<MXK_Y!TW_ %R?^35U-<MXK_Y!
MTW_7)_Y-0!Y]\/O^/\?[K_UKVJO%?A]_Q_C_ '7_ *U[50 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7$>-_^
M/&/ZG^E=O7$>-_\ CQC^I_I0!SO@3[W_ &U;_P!#->LUY-X$^]_VU;_T,UZS
M0!X/XL_Y"</_ %S'\DKV#0/^039_]<Q7C_BS_D)P_P#7,?R2O8- _P"039_]
M<Q0!L4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %9NK?\>,OX?R-:59NK?\>,OX?R- 'CNB_\AFY_Z^%_]!2O
M;H/]4O\ GTKQ'1?^0S<_]?"_^@I7MT'^J7_/I0!-1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 <_XA_X\9?\_P !KS'PM_R$[G_KL/Y)7IWB'_CQ
ME_S_  &O,?"W_(3N?^NP_DE 'MJ]!]!_*EI%Z#Z#^5+0 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 5C:Y_QXR_0?^S5LUC:Y
M_P >,OT'_LU 'D_A[_D,7/\ UW'_ *"*]P7H/H/Y5X?X>_Y#%S_UW'_H(KW!
M>@^@_E0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 5SWB7_D&3_P"X?ZUT-<]XE_Y!D_\ N'^M 'F'A3_D)2?\
M!_F*]N3[B_[J_P A7B/A3_D)2?\  ?YBO;D^XO\ NK_(4 .HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N6\5_\
M@Z;_ *Y/_)JZFN6\5_\ (.F_ZY/_ ":@#S[X??\ '^/]U_ZU[57BOP^_X_Q_
MNO\ UKVJ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "N(\;_\ 'C']3_2NWKB/&_\ QXQ_4_TH YWP)][_ +:M
M_P"AFO6:\F\"?>_[:M_Z&:]9H \'\6?\A.'_ *YC^25[!H'_ "";/_KF*\?\
M6?\ (3A_ZYC^25[!H'_()L_^N8H V**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "LW5O^/&7\/Y&M*LW5O^/&
M7\/Y&@#QW1?^0S<_]?"_^@I7MT'^J7_/I7B.B_\ (9N?^OA?_04KVZ#_ %2_
MY]* )J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#G_$/_'C+_G^
MUYCX6_Y"=S_UV'\DKT[Q#_QXR_Y_@->8^%O^0G<_]=A_)* /;5Z#Z#^5+2+T
M'T'\J6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %<MXK_Y!TW_7)_Y-74URWBO_ )!TW_7)_P"34 >?
M?#[_ (_Q_NO_ %KVJO%?A]_Q_C_=?^M>U4 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Q'C?_ (\8_J?Z5V]<
M1XW_ ./&/ZG^E '.^!/O?]M6_P#0S7K->3>!/O?]M6_]#->LT >#^+/^0G#_
M -<Q_)*]@T#_ )!-G_US%>/^+/\ D)P_]<Q_)*]@T#_D$V?_ %S% &Q1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 5FZM_P >,OX?R-:59NK?\>,OX?R- 'CNB_\ (9N?^OA?_04KVZ#_ %2_
MY]*\1T7_ )#-S_U\+_Z"E>W0?ZI?\^E $U%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!S_B'_CQE_P _P&O,?"W_ "$[G_KL/Y)7IWB'_CQE_P _
MP&O,?"W_ "$[G_KL/Y)0![:O0?0?RI:1>@^@_E2T %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %8VN?\ 'C+]!_[-6S6-KG_'
MC+]!_P"S4 >3^'O^0Q<_]=Q_Z"*]P7H/H/Y5X?X>_P"0Q<_]=Q_Z"*]P7H/H
M/Y4 +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %<]XE_P"09/\ [A_K70USWB7_ )!D_P#N'^M 'F'A3_D)2?\
M ?YBO;D^XO\ NK_(5XCX4_Y"4G_ ?YBO;D^XO^ZO\A0 ZBBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y;Q7_P @
MZ;_KD_\ )JZFN6\5_P#(.F_ZY/\ R:@#S[X??\?X_P!U_P"M>U5XK\/O^/\
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M?\A.'_KF/Y)7L&@?\@FS_P"N8H V**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "LW5O\ CQE_#^1K2K-U;_CQ
ME_#^1H \=T7_ )#-S_U\+_Z"E>W0?ZI?\^E>(Z+_ ,AFY_Z^%_\ 04KVZ#_5
M+_GTH FHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_#X[]J?_ )Z:+_WS_P#<U'_#X[]J?_GIHO\ WS_]S5^2]% 'ZT?\/COVI_\
MGIHO_?/_ -S4?\/COVI_^>FB_P#?/_W-7Y+T4 ?K1_P^._:G_P">FB_]\_\
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MC_GWYKN1_P %C?VIP /,T7C_ &?_ +FK\>;7_7-_O?T%;U 'ZT?\/COVI_\
MGIHO_?/_ -S4?\/COVI_^>FB_P#?/_W-7Y+T4 ?K1_P^._:G_P">FB_]\_\
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M:G_YZ:+_ -\__<U?DO10!^M'_#X[]J?_ )Z:+_WS_P#<U'_#X[]J?_GIHO\
MWS_]S5^2]% 'ZT?\/COVI_\ GIHO_?/_ -S4?\/COVI_^>FB_P#?/_W-7Y+T
M4 ?K1_P^._:G_P">FB_]\_\ W-1_P^._:G_YZ:+_ -\__<U?DO10!^M'_#X[
M]J?_ )Z:+_WS_P#<U'_#X[]J?_GIHO\ WS_]S5^2]% 'ZT?\/COVI_\ GIHO
M_?/_ -S4?\/COVI_^>FB_P#?/_W-7Y+T4 ?K1_P^._:G_P">FB_]\_\ W-1_
MP^._:G_YZ:+_ -\__<U?DO10!^M'_#X[]J?_ )Z:+_WS_P#<U'_#X[]J?_GI
MHO\ WS_]S5^2]% 'ZT?\/COVI_\ GIHO_?/_ -S4?\/COVI_^>FB_P#?/_W-
M7Y+T4 ?K1_P^._:G_P">FB_]\_\ W-1_P^._:G_YZ:+_ -\__<U?DO10!^M'
M_#X[]J?_ )Z:+_WS_P#<U'_#X[]J?_GIHO\ WS_]S5^2]% 'ZT?\/COVI_\
MGIHO_?/_ -S4?\/COVI_^>FB_P#?/_W-7Y+T4 ?K1_P^._:G_P">FB_]\_\
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M &XMU!9VUM/*7N'A@\ZW4IAF&,+'P3W'&*_66@ HHHH **** "BBB@ HHHH
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M>&H;B;[/$\JPD-+N"[1YEQ#SDXZ_2OE\_P#!8G]@0$@_&>QR.#^ZM/\ Y84
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M\DDUZM0 4444 %%%% !1110 4444 %%%% !13)9$ACDED.U(D>1SZ(BEF/X
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MTBBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %8_B'_D!:Q_V#;S_T
MGDK8K'\0_P#("UC_ +!MY_Z3R4 ?Q1?\%*?^3@HO^O2\_P#1EG7P/8_ZU_I_
M05]\?\%*?^3@HO\ KTO/_1EG7P/8_P"M?Z?T% &[1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 5#/_JF_SZU-4,_^J;_/
MK0!CVO\ KF_WOZ"MZL&U_P!<W^]_05O4 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 55N_]5^=6JJW?^J_.@#+
ML?\ 72?[H_E6]6#8_P"ND_W1_*MZ@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "JEW]P_0?UJW52[^X?H/ZT 9
MNG?ZP?3_ -FK=K"T[_6#Z?\ LU;M !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M']3_ $KMZXCQO_QXQ_4_TH YWP)][_MJW_H9KUFO)O GWO\ MJW_ *&:]9H
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M'QV_:!\ ?L\>%U\7?$*[EM-)8R@21!2V8@A?AB!T<4 >XT5\$?L__P#!1O\
M9S_:1-P/AYKD\XMM1GTR5KLP1*MS;SRV\BEM^ /,A<<G.!FO+OC/_P %=_V1
MO@7K5WH/C7Q)=17UG</;3"V-M(@D3)//F'C ZT ?J117P?\ LU?\%$OV>?VJ
MI8(?A;K%S>O<(7C%P(5.T G)"L<# //M7O'Q9_:,^&GP:LC?^,-8@MX1!YY$
M5S;%PF"<%3)G.!TQGVZT >\45^-?B;_@N9^Q!X5U2YTG4O$VI?:K5MLHB2!U
M!R1U#GC*FM/PA_P6W_8I\:7$=MI'B;4#+(Q51,MN@R&V]W!Z^U '[ T5Y]\/
M/B;X4^)N@6'B+PO?PW=AJ-LMU;D31/)Y3MM&Y8W;!S_2O0: /YGO^"^?_(OV
M_P#V C_Z(-<+_P $'_\ D%V__8$7_P!)Q7=?\%\_^1?M_P#L!'_T0:X7_@@_
M_P @NW_[ B_^DXH _J,NX9I[%HX)#'(T/RL.Q\LX_'./ZU_"?^W_ / _]J6]
M_:8N[GP_I'C#5M*U'QC,]I=V.FO-;6<+6TFURRC 7<I )/5A7]W:$")">@C4
MGZ!0:_,7XQ?\%-/V/_A!XZMO _CMK<>([G4VTV(-I>G3-]L5)'/SRQE_NQMR
M#G/% $W_  3"\$_$#P9^S[X6T[Q[+?-JL(/GI?Q&&89M8 -RD9'S CZ\<\FO
MTXKR;X0_%;P3\6_"MEXI\#%3HU[_ ,>^V&*$?ZM'^Y$ H^5EZ#'O7+_'C]I/
MX<?L[>';WQ-\0KR:TTRPM_M,[PA"PBVELX8CG - 'T#17XFS_P#!>_\ 8/MY
MG@D\4ZIOCX8".W/?_?%1?\/]?V#/^AIU7_OW;?\ QR@#]MZ*_(GX9?\ !:K]
MC'XL>*])\'^%?$>HSZOK-ZEA9QND&UIW1G )#9QM4DD9K]9=,U.UU:RCOK5L
MP2C*L>., \]NAH T:*\:^*GQW^'WP?TFYUCQ?JUO;VMI'YLH2YM_,"[2W"M(
M#G /&.M?F=XE_P""Y_[#_A;5+K2=2\3:G]JLW*2B)+=U!&><ASQQU/?KZT ?
MLM17Y7?"7_@L%^R#\9M4M])\(^);M[JY8+&+DVT0R6V<DN/XCBOTR\.^)-*\
M4:;:ZKI-S%<6MY"L\3)+'(=CG )V,V.?SH WZ**YKQ5XLT7P=I-SK.MWD-K:
M6J[I#)-%&V,$Y D9<\"@#I:9)_JY/]QO_037Y)?$K_@M+^QC\+-?OO#GB;Q-
M>IJ&GSF"X6#[,Z"09S@ASD<&NN^"?_!6W]DOX_:U%X=\"^)+F74+I&\I;MK:
M).NSDF08Y/Y?E0!^"O\ P<*?\ASP7_UQNO\ T5?5^H?_  0A_P"34OAU_P!>
M%Q_Z;;.ORH_X+^ZQI^N:AX%OM.N8;B">UGE1HY8Y/E:.^ SL9L5^J_\ P0A_
MY-2^'7_7A<?^FVSH _>FBBB@ KB/B-X6F\:>#-<\,P3K;2ZK:FW29L80D@Y.
M<CMZ5V]% '\I7[1/_!OK\0_C/\0=9\8V7Q5TS3H=4D5UMY$@W1XEEDP<P,?^
M6F.IKY[N_P#@V@^)UK TQ^,>DL%ZC9;^A)_Y=_:O[.:S-7_X\)OI_P"RM0!_
MEX_'+]F35/@K\:1\'K[68=1O3XA70?[0C"[/,8,?-^557&%/;VQ7[!? S_@W
M_P#B%\:_!UCXNLOBGIFFPWJHRV\B0%E#QK)WA8]&QU[5\E?M_P#_ "?4G_92
M(O\ T7+7]KO_  3^_P"2)>'_ /KE!_Z2QT ?SI:=_P &T/Q.LM0MKP_&/266
M!MQ79;Y/?_GWK^E+]BO]F'5?V8/A5X=^'^JZU#K5QHMJT#W<(4+(6ABBR JJ
M.L9/'K7VE7%^,_'OAOP)I<^K:_?P6UK;Q2S2;IX4;;"N]AAW'..@H [2BOR.
M^(W_  6E_8Q^&&L2Z)XD\37J7L+3*X@^S.N86"/SO]2/?VKE_#W_  73_8<\
M2W:V>G>*-1,SR+&-ZVRC<PR.KC H _9FBOG?X,_M._"SXZ:7;:MX'UF*YM[K
MF-9KBW60C;N^XLA/3VZU]#JRL RD,IY!!!!_$4 +17A_QS^/_@']GSPT/%7Q
M NI;32B)2)(0I;$(!?AB!QD5\_?L\?\ !13]G?\ :9NVL_AQK<T\B7TVGLUX
MT$2"X@GDMW4L7"@"2-AR>E 'WC17YY?';_@II^S+^SU>&Q\>^(I(9Q(\1%I)
M;2@,@<G_ ):'^X:^??!__!<C]B'QMKD7A_1O$^H-?3/&B"5;94S(_EKEM_'S
M=: /V/IK@E6 ."0<'WKS7X=?%GP=\3](M]9\+:A%=VEQ%%-&1-"[[)1E<B-R
M0>V,9S7IE '\J/\ P7#^%?QY\2>*[O5OAY8^(M9TU=*2/['H]DUR&D\B#^Z.
MH*MWZFO6O^"*GPJ^-_A#3?$5U\1H]=L8KJ&VDMK75K1K=HP#8 H P'=')[X[
M5^N?[4?[;7[._P"S"TP^,31 PP+-)YEC9W6(RBN.;E&_A8=?I74_LW_M9?!#
M]HS3YM0^%!B:UAA260QVEK;#9(8PO%NJCK(E 'UN. /H*6BL;6]>TOP_937^
MIW<%M! NYS+-%&<<G(#LO84 ;-%?EW\8O^"N?[)'P0U>ZT7QGXDN8[RSF,$H
MMFMI5W@D'!$AR!@US'PR_P""S_[&GQ6UNVT'PQXFO'OKIML0G-LB9WA.27&/
MF(H _6NBN6\*>,="\9:3::QH=Y#=6E[ MQ$4FBD8(QVC<(W;!S_GI74T %%%
M% !7Q_\ M;_M5>%/V:? VJ:[K<ULUVFFR7=I:M/Y4\S(Q&V)0RECA6/!' -?
M6>HWD=C9W-S*P58H99,GC&R-G_I7\-?_  65_:ZU+XN_$:W^'&CZE(TND:A=
MZ,((I70,RQW+!76,C=_K>^2<4 >0_'S_ (*&?M,?M@_%'4O#GPCU;Q78>'[^
M> 0:7I\3W$=M#=7,J2,068[?*V[CSPA/3->^_#;_ ((4_'O]HC28_%GBGXE?
MV3>W:QSM#JMO#'-FZ7S&)#PL>O7TZ=<5^A?_  1&_88\&:+\//#/Q@\2Z69?
M%>KZ>8;PW4"30YCLTD3"SAL,)+J0YV@]#UZ?TV6=C:6$$5M:6\,$4,:1JL,4
M<0VHH4<(JCH* /XM/$O_  ;X?&_X.V,OBOPS\6;>ZU'3XGO8$T^&!YS-!RH0
M+ ,L>W-<[^RW^T9^U]^R_P#'K3? _P 5-4\9:]X5M0L+PW5J\5HVVX6%#N!7
M V$$=/EQ7]NDD44RE98XY5(P5D174@]00P((_"OEWXI_LA?"/XM:W_;_ (CT
MM([_ .3]Y:6MO$?D96'S($;JOU]Z ,3X@>-5\=_LM^(M>\EX'O\ PDETZ/G<
M#(ZY!R2<C_..E?Q$>!_^3X=8_P"PEHG_ *=KNO[EOC/X.TKP3^SOXTT/1U=;
M.Q\.FVA#XR(XW7;T)K^&GP/_ ,GPZQ_V$M$_].UW0!_>[\%/^2?^&O\ L!:-
M_P"F^"O6Z\D^"G_)/_#7_8"T;_TWP5ZT2%!+$ #DDD  >I)X% "T5X%\8/VD
M?AE\$M,N-5\:ZO%;6UL&,@BGMS(-HW'Y6D!Z?KQ7YM:Y_P %W?V&- O[G3K[
MQ1J0N+69X90JVY7>G7!WG(]Z /VBHK\E/ G_  6?_8T^(=Y:V.@^)KUIKN6&
M&$3?9D!>9PB9/F<<D9ZXK],/ _Q&\+_$#2X=6\.ZA!=6L\<4D96>"1BLR;TR
M(W8@XZC'!ZT =W117P_^TE_P4 ^ ?[+-V]E\4=5NK&9)HH&$"QGYY9%C7[[#
MNP_"@#[@HKY<^&G[7GP>^*G@NZ\=^&M94Z':6T=U*]S-;Q2>5+C:5!D&>H]O
M>OCOXG?\%FOV-?A1K=YH'BCQ->)?6+^7,+?[-(@;<R\$2'NI]: /UGHK\N?@
MO_P5V_9&^.NJVVC^"?$MS)=W4K11"Z:VB7<L@C.29!CYC7Z6:%K^F^(M/M]2
MTRXCGMKF,2Q,DB/E"2 <HQ[@T -\2P7%SH.KPVKE)WTR_6,J,G>UI*$P/7<1
MCWK^$S]MOX&?M47W[2&_0M'\87^G7>NZC)!?6>FR2V]M$[DIEU&,8/'7M7]Y
M-S-';V\]Q+_JH(99I/\ KG$C._\ XZIK\Q/BC_P4X_8^^&'CNV\#>,7MQXCN
M;F6VAW:9ITI\V+A_WDD9DZ^E '2_\$X/"'CGPG\"_!]EXWDO?[3BTXI<1WT7
ME3*_DQ ;U(R#D'_.*_1RO+?A5\3_  ;\4_#&G>)?!94Z1J$1EM=L44(V!0QP
MD0"CAAT&/TKU*@ HKS3XB_%GP;\+]'NM;\4:G;VUI9V[W,H%Q )!&C;3A6D!
MSD'C':OR^\8?\%Q/V(_!.K3:-K/B?4%NX6".(A;.N2^S@ASD9!_"@#]C**_/
M#X$?\%-_V8_VAKR&Q\ ^(I9IYYA @NI+:++LP4#_ %@[FOT%L[VVOH4N+6:.
M:*095HW5P1[%20?SH M4444 %>#_ +1?QATGX*?"_P 1^-]0EB+:/;B<6IDV
M22C9(_RC()X3U[U[Q7X]_P#!7)[E?@1XO\AIE']D#/ELX7/D2]=IQGTS0!_+
MC^TI^V9\??VO_C5JO@3P#XAU^+0KK6(K2.RM5:>&UM[J1@<@EL(%/)/3KBOJ
M3P!_P;U_&/XM:'!XJU3XHVNF7-ZD4[6][#"LN;E/.;<&@/.6YY/)]Z^7/^"/
M"^'I/VG_ !>?$1@)%S9_9S=^2W[S'R[?M'0Y[BO[]/#GV :/IXT_R/)^Q6FW
MR/+VX\A,?ZOC.* /XD/B1_P0Y_:%_9PT74/%'@OXD2:K?65NUY'!H]O%)/+(
MC!55 D2DL0HXSG%?M-_P2&'Q]TWP)H&D?%H^(C/!8,9CJ]JT!\PVBCD-W++G
MIUP.:_=Z:TM;E2EQ;6]PA&"LT,<JD>A616!'MBH[;3M/LQBTL;.U Z"VMH(!
M^42** +2_=7/7:/Y4ZBN'\:_$/PQX!TNXU;Q!J%O;6MK#)/+NN(4<)&,M\KN
M#G'08YH [BBOR-^(?_!:;]C'X::Q/HGB'Q+?B]@+JZVXMY%S&Q4X(<]Q5'P)
M_P %MOV*OB'JUOHV@^)M0-Y<SBWC6<6\:^81D DN,?\ UJ /V J*9'>-E1BK
M'HP[5P/P_P#B?X4^)6CVNN>&;^&ZLKM2T1$T+O@(K\A'/9A^M>AT ?Q-?\%4
M_@S^TOJWQPFO?".E^*]7TR\\3!K=M-T]YX;:(M(!(64<*.QS7[B?\$C_  !\
M4/!WP?TB'XA'5(KU9U,D&I0&"4*8VZJ>0!Q^/M7T'\?O^"BW[*?P%\30>&OB
M8T U>>_%A$'T[3[@_:26 ^:="PY4\YS7U%\#/CQ\-/CAX;M_$?PY*'2;A@(M
MEO! ,E=WW855>GM0![Y17C_Q@^-O@KX)>'+[Q1XUN9+;3-/MFN[AXPI80KP6
M&X@=0?;WK\M-2_X+S_L)Z7?RZ==>*-4%Q#]]1';\<D=W]0>] '[5T5^)'_#_
M %_8,_Z&G5?^_=M_\<KJ_!'_  7#_8E\?^(M-\,Z#XEU*74]4O(K&U1D@VM-
M+]T$AL_6@#]C**Y;PUXOTCQ5H:>(-+D9]/>#[0KMC/E^5YV>./N?K7P)\6/^
M"IO[+OP:\96O@;QCKE[;:Y=W4EI%%&L)4RQ@EAEF!Z ]/;/6@#])**\H^$WQ
MD\'_ !E\-V'BGP=<27&EZC&9+=Y-H9E"*Y/RDCHPKU>@ HKXZ_:7_;A^"7[*
M=E:7_P 5-3N;&"]#F$P*A)$9D#9WD#K&WY5/^S%^VQ\%OVL]!MO$7PHU*YO]
M/NV9(GG6,$E02?N$CI_GB@#Z^HKFO%WBK2_!7A_4/$FLNT>FZ;$9KEUP65!G
MD9X[5^?'A_\ X*K?LL>)/B)??#+3M>O6\2:?+%%<1.L(C5IG=%YW9QF-LT ?
MI917PS\<_P#@H1^SU^SY8KJ'CW7V@@:RAOQ]FEMI&\B>!+A#CS,[O+D7C'6O
M!OA#_P %D/V//C7XD3PMX,\17]QJDEVEFL<JP*IFD4,HR'Z$,/?VH _5^BLS
M2M6M-9LH[^S?=;RJ&5CCH5#=0<="*\_^)'QA\$_"S2;K6?%.J6]M:6D7FRXN
M( X7!/W6D!SQZ>E 'J=%?CMXQ_X+@?L2^"-6NM&UCQ+J/VNT?9*(5MY%#9(X
M(<^AKH_AC_P69_8W^*^K6^C>&/$MZUY<L5C6X^SQKG>$Y)<8&6'^>: /UFHK
MD_"/C30?&NE6FL:%>0W-I>0"XB9)8W/ELVT$A&..:ZSIUH **\0^+G[07PZ^
M"VFSZIXTU6*UM[>'SI D]OO"!2Q^5I <X'I7YL^(O^"YW[$'AG4Y=*U'Q+J?
MVF*01OY:0.NXDC@ASZ4 ?LK17P3\ _\ @HW^SC^T9<6UK\/M?DGFNGV1K=/;
MQ$DMMZ>9GK[5]WVUS#=0QSP.LD<BAT96# J>ARI(_+B@">BBB@ J.5_+BED_
MN1N__?*EOZ5)7$?$+Q$OACPOJ.J,ZQB.WG&YB /]3(>IXZT ?R/?\%HOVC_^
M%D>/_"OPLTX2+*]Y<Z*ZAR0[".]?[NX\<CC'O7ZL?\$;O@,OPS^!OA&[N[,1
MW9LGB>5H]C'_ $* #L,\L?SS[5_,3^T7KFK?%3]O3PO K"YM+;XC7$;@,6&P
MVEQU RO\>:_NE_97\-6WAOX0^'K*&%8C$'& @7&8+<= !V'/>@#Z1 P,#H.!
M7\J__!=>]N7T+2[7S6V/=SQJ#T&9)1_]?_#%?U45_*=_P73_ .09HW_7_-_Z
M-EH _&W]B+_@DCXP_;)\/+XCT7QY9>'XKJ]FC$4ZQ%E/F2<G?&Y_A/<\U^A5
MU_P;3?%/3(7U"'XPZ6\UJ/,C5$MRY(XPH%N.>:^W/^""_P#R2_3_ /L)S_\
MHR>OZ7" 1@@$'J",@_@: /\ .P^.WPK_ &N?^"?'BI(M%\9^(AI>C:G9K)J5
MC;!+2[MX;M!-$LBJ@(:%6!P.CBOZ3_\ @DI_P4D_X:-\*6WAWQ?<S'Q!!>0:
M29M1G(F=[222VE<*SGAG0-^7'2O=?^"P/PDT;QC\ 7N%L+4WJ7&H7#RB"%9"
M(X[609EVAS@JV,GO7\K?_!*G4-8\%?M-:=X?LY'2UD\4ZL6C1W"$IJ^!PIV_
MQ'% '^A;'(DJ+)&RNC#*LIR"/8U\>_M<_M<^!OV8/ .I^)M<O;&XO[9)8UTL
MW(CNPQA)5P@8,,,1CD5[1<^+/^$8^%%YXHN)-KZ9HD]^78]#$ <\]<$^E?PG
M?\%1/VJ_%/[27QJO_!.@ZC-<17%S';M;PS2A"HO$@8^7$<9P""0O]: +GQ^_
MX*1_M/?M0?$*^\-_![4_%UKHMQJEQ9/;Z9&]S$(FSY:'YVX!8<=2?U]N^$O_
M  1N_:9_:DT>U\0>-/B-=Z)<:A$T\L&M6T44JL$$N&#Q.>IP!ZY[C-?K3_P2
M5_X)S> /AYX-T_Q_K>CM+KNJ6MGJY:\@2=3/*8RQ'G[SCY?0=,U_0]9Z=8Z?
M$L-G:6UM&HP%@@BB 'H!&J@"@#^-G_B&G^*NF?Z?;?&/2A<)\RLB6^[)^8XQ
M;CJ1ZU\9_%'X!?MT_L/Z[$W@OQ/XQUG2=)N_],ET2P,D$EM!N#$M&JX0[5Y'
MMGUK^_\ (!Z@'Z\UQOBWP%X8\::/J&BZWI&G7%MJ5M);3O)86LLNR3&XJ[Q%
M@W'7<#[T ?BG_P $I_VQOB%\<O!&G:%\1[76AKTT4L,]QJZ.DO$+1$LK,0!N
M!.<=??BN<_;L_P""0'C']K?7$UG2/'UCH2'SV\N98B<3!L#YXF.1NK]7?A3^
MR/\ "SX/:H-6\(VDMM< N0NQ(T!=BQPJ-@<GCCTKZB10BJHZ*,"@#^,R/_@V
M6^)\46#\9-).U<_<MNP_Z]_:ORH_;T_X)M>)OV';B6#7?%]IXE\JP%]NMQ&,
MJ88YMOR1IVD ]>.]?Z13_<;_ '6_D:_CZ_X.(?\ D(W?_8N+_P"D%K0!^8O[
M&7_!)7Q?^U]HBZSHWCNRT"-K6*Y$<ZQ$XD\OY?GB;IY@_*OT-;_@V6^)[[#_
M ,+DT@896/R6W8@X_P"/?VK[4_X(:_\ (AQ?]@FU_G:U_2^O0?0?RH _$_\
MX)V_\$NO%7[%Z70UOQK9^(1/>+= P"(8"NKE3LB3TQ^5>C_\%"/^"B7A;]E_
MPKJ-G T=UKLR7=C%';7!%S;W#CRH92BL""LAW*.>1]:_0_XW>/X?AI\./$?B
M^601#2+0S[SCY< \\_2O\_']MOXQ:Y^U=^TW-X?T^[FO;*Y\5Z8MS$LLI46\
M^H$2;44[1\F[L ?H,T =E+\:OVPOV\?'D^EZ#XB\7KX8U.\O+?:+=IK1$-UY
M42%R7!"QY51UQ7W!X7_X-U?C%\1]*M/$>K_%>SLKK4H1=S07D,"3([$J5<-
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M@_\ ^"J7[+.K_LO?&.[^(_A"RN+.2U2:Z26-94C!N)8;H\Q<=0?Z]* /[P_
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M'Q/8(1\9-(X*M]RW[$'_ )]Z^G?^"$__ "*]S_UX6?\ [:5_4FGW%_W5_D*
M/PS_ .">W_!*/Q;^QO??:M9\<V7B$?;ENML"Q#A7W;?DC3L,5^YU%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %8_B'_ ) 6L?\
M8-O/_2>2MBL?Q#_R M8_[!MY_P"D\E '\47_  4I_P"3@HO^O2\_]&6=? ]C
M_K7^G]!7WQ_P4I_Y."B_Z]+S_P!&6=? ]C_K7^G]!0!NT444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %0S_P"J;_/K4U0S
M_P"J;_/K0!CVO^N;_>_H*WJP;7_7-_O?T%;U !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5;O_5?G5JJMW_JO
MSH R['_72?[H_E6]6#8_ZZ3_ '1_*MZ@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "JEW]P_0?UJW52[^X?H/Z
MT 9NG?ZP?3_V:MVL+3O]8/I_[-6[0 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M[NV1D[(3WY_R?:@#^;K_ (.!?^2C3_\ 8+M__15M7ZE_\$3O^21W'_8$LO\
MT?9U^6G_  <"_P#)1I_^P7;_ /HJVK]2_P#@B=_R2.X_[ EE_P"C[.@#]J?&
M/_(I>)O^Q?UK_P!-EU7^?9\8O^3Z-,_[&76O_2V*O]!/QC_R*7B;_L7]:_\
M39=5_GV?&+_D^C3/^QEUK_TMBH _NG_9/_Y(9X'_ .P:O_LM9_[6'[1&D?LW
M_"G6?'VH-;2&Q62(0W#[5+-!(ZG.Y.<J,?-[5H?LG_\ )#/ _P#V#5_]EK\(
M_P#@O9\6-2T[X=^(/ 4-Q(EM-''.T8#E#^XP>00O <YH _%'Q1\4?VF_V_\
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M>2/?%?N=_P $Y?A1X*^'7[.G@J#PKI8L(XXI(U7=&V%-I:*1\D4?;^9K]!:
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M\'_\$M/@A#\,/@#X*U)[,6M_K7AJW>[)01R%Q+@AT(#*?W0^]R !GCBOU,H
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ME1:?=-862ZPT+1-'<7\,8$TJ^4BC:TA<C+/P?O'J?7_B_P#\DN\>?]BQJO\
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M6YCB!.FX^=D"CYAC/4"OVE^-7_!2;X"?!29X=8U&VUAH]Y)TC6+.Z'R9R/\
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M"_!74?$5O*T<\5FB[T#$_/8R$_=.>HXK_/ON_BWX9TK]M5O'GCZVN-1L=/\
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M!\7BKX$^.BZ(S6/A;5)4+%1@A2>-WU[4 ?SJ?\$1?VUO%U]XDTCX)>.->O\
M5]02221[C5+D23JL<CP[" 5X& /N<8K^O&WNHY;.*Z+ 1O&)-W;!]/Z?X5_G
MA_\ !-9;_P -?MYQ+;RA)$FOER.1@:I(".&[#/\ A7]Z?B#Q-=:%\%;KQ )&
M%Q9:#'<!U!)W;@,@#)[]J /P:_X+"?\ !175?AW;77PD\!73VOB2WU3^SS-I
MEP(KV4WMS%:1(<R8Y=6"_*,DGZ5^5?[)'_!-+X]?MXZ=>>+/C'XZ\8^%;>\U
M.86Z:JXFCDL+JXG,$J^7:W \MH%C9><E6'%?&7[='Q5LO$7[8NJ>)_%PFO\
M3[?Q-H=\\:[EDVVFMR7$GWDD.2JC'R]<U_2A\ _^"R7[*OPV^'OA_P /IH.M
MQ2VFC:/;S[)VP9K:PBBD/RZ2<9<$XSWQSC) /&?$?_!N%X0GT"U2Q^+<T-_I
M<!=)HH)1+<2J6(Y_LT\G<!VS^5?CC\9/A_\ 'G_@F7\;HH-%\3^*M?\ "NFR
MVL?FF=(;-@UTBMP\5L?N$GIC'%?TQC_@NM^RX2!_8^O#/?SY/ZZ2!^M?B?\
M\%5O^"A_[.'[3'@_4-+\&^']8A\637"RQW]S(SP[%V$#G38!G</^>P/?K0!_
M2Q_P3\_:K@_:,^%NDWTAC_M#3M)LH[X"3?+]H8(K^:=[#=EAGFO%O^"Q@S^S
MU;CUFOA^8MA7Y1?\&\?C3Q-JNC_$"TOKEVLHM6CBMD9)%Q")K8*,LQ4C!/(
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MWS=\#-?Q(_LP>%!\9OV]-%;7U2\TNY\6:X+F&0J&</JT0_Y:;NF2#E6QQUH
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MW-]+E#YLS179+';$A_@7J2>.M?L)_P $(N?V4OAW_P!>%Q_Z;;.@#]Z:***
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M[."4(C:];1R 9P0+?3N.&']T>O\ /(!_=GK!W:)JK?WM*OC^=I*:_@B_;_\
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MXX7<37'6,0S8'+'_ *!1]?4]*_JGK$\1:W8^'M%U35[^Y@MH-/T^]O6:>:.
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M@]A7\0__  4J_P"3J?#O_8?O?_07K^\O45":5?(OW4T^Z4?1;9P/T%?P:?\
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MMBM\'*KG* 8'2O[Y_A[HEY\1/V=!:7Y$]U-I&H@;QC+OI05<*Q)SN/'4Y]Z
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M\,X)7IM_QK^(7]DG07^+'[<L4FK6 O+*269S'.HDCW#4F;)&3V&.O-?VF_\
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M.  R?W]Q_P#&*_E+U?\ X-O_ -KF_P!6U&^B\9>"!%=W]Y<QAI++<$N+B25
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M!2O;H/\ 5+_GTKQ'1?\ D,W/_7PO_H*5[=!_JE_SZ4 34444 %%%% !1110
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MXO\ NK_(5_+9_P $)_\ D5[G_KPL_P#VTK^I-/N+_NK_ "% #J*** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Q_$/\ R M8_P"P
M;>?^D\E;%8_B'_D!:Q_V#;S_ -)Y* /XHO\ @I3_ ,G!1?\ 7I>?^C+.O@>Q
M_P!:_P!/Z"OOC_@I3_R<%%_UZ7G_ *,LZ^!['_6O]/Z"@#=HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *AG_ -4W^?6I
MJAG_ -4W^?6@#'M?]<W^]_05O5@VO^N;_>_H*WJ "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MC"?Q7XT\1:)=^'VA58]'GNX0[.UD")/LVH6V?^/@D9!YQQTK]IO^(</]F_\
MZ*AX_P#_  /U;_Y=U^$W_!.O]JC4/V%/CCK?P_\ %>FWL%EKWBA;"[N;@-;P
M01PI;R%ICO4!?]& Z''3'I_;-\._VR?V?_'FA6FJ1_$[P?9W5P"S6#ZJGGQ*
M%1LNI!(^\1G/53^(!^.#_P#!N!^S;(I5_B;X]=3U5[W564_4'6B#^5>@_"C_
M (-_/V;?A1XOTGQAI?C+Q1?WVD:A;:C;QW;7<B&6V(* ^9JDHP2.?E..>#FO
MUVUG]JC]GS18F>\^+7@J*0+N6*35XU=P?0;?I7S!X8_X*/\ PL\9?$2Z\!>&
MI=.UE[>_BLEOK"\,R2>;TD&' (_ ?2@#[XL-#M_#OAF32K5F>&STI[>-F^\4
M@LS$I.2>2%R>3]37\!_[9_\ R>]I'_8]WO\ Z)EK_0$N)Q=:+<W"C"S:;-*!
MZ"2U9Q^6[W^M?YU__!3.\U6P_:0UB\T1YH]5@\4W[V3VXS,)?+D'[L=S@T ?
MW3_L._\ )O/@W_=D_P#26TKZ^K^0K_@ES_P5FC\ Z#H'P5^+-G=V]SHT")/K
M>LS-;PN]Q$L&XYE"C8UON/R=&&>F*_H^NOVVOV=+?PPOB!?BIX*DF-M!.; :
MNGG S1>84VXSE#A3SUS0!\/_ /!8_P :6WA7X*K;SI QU/2KZ!#*B.06:4#;
MO!P?E[$'K[U_/_\ \$+=-O;O]I:TU".'-LYO2'[9:[F; P,?RKD_^"MG_!0J
MY_::\5VWPR\ BY-OH6K26<$]C*T\6J+*\K*D&78-NWXRH'3/J:_6S_@A+^S+
MJ?A7X8:-\2/$^A7&DZ\UTRE;^W,-T8Y%>0/@@_*V01SSZ>@!_20;.VO+ 6=[
M;PW-O)$$FM[B))HG']UXY%9&&>S _2OS#_:T_P""5?P+_:GBNY]:!\-W;2O=
MQOH.GQ6;M,K":--]I-:M@NH&,D<GCL?8_P!J[]M?PW^ROK'AG2M?T8WT&OQF
M0WC2-'%:*JR,2Y$B@ ^7U(.,UTOPK_;?^ 'Q)\.V.M-\1O".D7-XI9M.GU5!
M/" JL-RG<1DMCKV- '\G/[5__!'GXX_ )+_5O@-?>.KW0[-))3<PZYKED%E*
M^8HQ!/,HY#\[N",XIO\ P3^_X*:?&3X'?$_2/@G\2R&>35[3P[<R:Q>O?7:%
MU1G;?>1&0N-IYW;O>OZN_CI^U7^SMHO@/5CJ/Q'\&ZIE%8:6-50RW"F.4@JH
M )&.,Y_B'X?PF:A:M\7_ -OJWU;X>Z)-?Z2WQ+LKA[C2T:X@@MS']]WR0(P2
M.<XYXH _T+;XZ!\5/A[=2%8+^ROM%N' DBCE3S)].9OE1@RY#,-I'^%?P,?M
M0^&-2_9)_;)L_'T,<EC;GQ?J.K0*Q:*!HR69?DP(]HVD@ $<9QSBO[W/@EX>
MGT#X?:/IMX"7^P6JR*PVG#6L892.W<5_.#_P7M_9BMM>M=(\?>'M-2U31-)E
MN;^6&+<))&CF!9B0=I)(_+K0!^D_A7]L.PUC]A>S^)M_?017?BGPKK]O&ZE,
M><^D1!-C9&&W7 P5 (/3D"OY2?V#?!6N?M%_M\Z1J>O1SZMH<OB;Q+$\MW))
M>(L;^([81J$FWIMV(0!D# P!BO!Y?VZO$<_[.W@K]GK3%U"T;196M3=*S>7.
M+M;.WV!=Y7GR"/NC.[GK7]"G_!"+]EJ6S\)R?%G78 -6M_$DEQ#)<1[9S'>7
MM[=94[1E3Y2'.?3MT /Z8? 7AJT\(^%-&T&RB2&#3K1;>.-(UC55#,V J@ =
M?_UUV--5=JA?05S/C#Q/;>$="O\ 7+I0\5C:75TR$XW"V@>8J",'+!,#ZY[4
M =117\Z&I?\ !P)\/=.^,5Q\)V^&%XTMOK=UH[ZIYLPB#6S[#*?]*P Q_P!G
M\!7[M?!KXHV/Q?\  >C>.-.MQ:VNL1&6.'<6V *C=223]\#K_P#7 /5:***
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MG_)(_ G_ &+]M_Z&]?P3K_R?5;?]?FI?^G:&O[V/V?/^21^!/^Q?MO\ T-Z
M/:J^.?V]?^38?B)_UYK_ .B;FOL:OCG]O7_DV'XB?]>:_P#HFYH _BY_8,_Y
M/ \0?]C!IW_H=?WV^&/^0%I7_8.L/_22*OX$OV#/^3P/$'_8P:=_Z'7]]OAC
M_D!:5_V#K#_TDBH _G@_X+Z_\B;X<_[ ]Q_*^KPC_@@'_P @_2O^P))_Z0R5
M[O\ \%]?^1-\.?\ 8'N/Y7U>$?\ ! /_ )!^E?\ 8$D_](9* /ZLT^XO^ZO\
MA7YH?\%._P#DA>O_ /8 U+^35^EZ?<7_ '5_D*_-#_@IW_R0O7_^P!J7\FH
M_EV_X(J_\G;6O_7QJ/\ Z<)*_NMT[_CQM?\ KDO]:_A2_P""*O\ R=M:_P#7
MQJ/_ *<)*_NMT[_CQM?^N2_UH ^<_P!K#_DD'BS_ +%SQ'_Z:+BOX0?V /\
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M,2+>,?/P#UD;N>OUH _<#1["+3--L;.%51+>SM8 JJ% $,*1@8'3 &*TZ0#
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M"=UIDEGHPFUV]^S8CTU7L=X#NPVL(E88 XQQVH D_P"(</\ 9O\ ^BH>/_\
MP/U;_P"7=5YO^#;?]F2X8-<?$?QQ,00<RW.I2$X.>=^LG/XU^YT'[2OP%N+8
M7<?Q6\&M 4WF4:K&4"CJ<[>E>'?%S]OS]GSX9Z(VJVGQ!\)>(IEF6$6=GJJ/
M*2Q R%4J>"<=>H_, XK]C3_@G#\+?V+[+4++P'K6J:FFHS)-,U^)=VY&1AS)
M=SD_<&>1G^?C/_!8[_DWF#_KK?\ _H-M7W'^SY^TKX?^/VF76J:';1PV]OL*
MM'(9%D5RH#!BS<$-Q_G/PY_P6._Y-Y@_ZZW_ /Z#;4 ?@-_P1&_Y+!%_V-VL
M?^GRXK^VJP_X](?]VOXE?^"(W_)8(O\ L;M8_P#3Y<5_;58?\>D/^[0!Y9\;
M?B99_"KP+JGBB]FCA2"TO#&9 I4RQVSNB_,0.6VC\?2OX5_VG?VL/C[^VC^T
M3'\./#EWJ>G62:]?:+9IH&KWEB;B&-BD;NM@L6YB&&<[B#T/-?VC_MM>$-1\
M9_!36M+TR*66=8+Z8K$F]MJVC'./3Y:_A<_9Y\>Z3\$/VVK+_A,K!8H(?'5\
MTM]>DPQ6ZK,"6D;(P..>./>@#]L_@5_P0/\ #7Q'\)Z;K/Q>\??$+3=;NX3)
M>0MK&M3A)MB-C,FJPGER1]T$8)KL_BK_ ,&]O[//@WP;J.NVGQ)\<W,UK@K#
M/>ZF\;9CE;E7UEU/* <J>#7[H_#;]J[X":_X4T_4$^)GA"T$D9=H'U6,-$ J
ML=V03T/?I@U^>G_!1'_@I/\ "?X>^ -<\*>"]9TCQKJUQ;K/ VAWWVF3<+:3
M,:HCIE@TH7IU!ZT ?R2? SX>:;\+?VT=#\'Z5<3W=EHOQ#M;&":X+&5XUM=X
M9RSR-G+$<L?K7^BA\,/^1/TK_KWA_P#1,=?YS?[.OC:7XA?MB^'O$TUM+:-J
MOQ M;LPRYWH6MBFT@LW3'J>.E?Z,GPP_Y$_2O^O>'_T3'0!_/!_P7S_Y%^W_
M .P$?_1!KA?^"#__ ""[?_L"+_Z3BNZ_X+Y_\B_;_P#8"/\ Z(-<+_P0?_Y!
M=O\ ]@1?_2<4 ?U*_P#+O_VQ_P#9*_@>_P""FW_)VNA_]CW-_P"DUU7]\/\
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M5_:;\-_VR/@%XZ\/V&J+\3O!]K<W4/FRV3ZJGG0' .'4@D'GU_\ K@'XZO\
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M$4_^2T6O_8SZK_Z=Y*_H'_X+!_\ ) H_^N>H_P#H$5?S\?\ !%/_ )+1:_\
M8SZK_P"G>2@#^W#2_P#D'VG_ %R'\S7*_$?_ )$SQ'_V!-7_ /3=<5U6E_\
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MD_$#_<C_ /2&^K^6?_@C/_R<5\2/^QCM_P#TFT^OZF/^"J__ ":3\0/]R/\
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M'_I=-0!_>=\$/^1 T'_L$:1_Z0QUZ_7D'P0_Y$#0?^P1I'_I#'7K] '\Q?\
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M# &GZ;9V8  Q@"WAC &.,#C%;W3I110!\V?M3_#VU\??"'QG:3J6DA\.W_D
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MMG_LY>(]$L-6F^+7@C3I+VW6=K2?6(UDA)8C8X(."  <$]Z /JJBOSN^/?\
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M.?ESQSFOU(^)_B*#X;_#2^U8RA8-%LH8!+(?X(H64,Q.>2(^<YR:]9K\<?\
M@K7\?S\*_@]XGTB*]^S2W6EI,H63:3_HTC9P2!_'G/\ C0!_)/\ MWZ]XN_:
ME_:+U[0_ ,+ZWJEEXCC,-O#*X(ED=F0 1+(03N&,+D9Z'%>Q?#S]AS_@J#H6
MB6R>%? 'B.+3VCBDB^S:[K5NA5XPR$)%8%0=I!X)^I[=Y_P2=^#^J_%+]H?Q
M%\0=3BEOK6\O[/48GDCW+\BH=P;!R3DDGWK^[/1+"WTW2K"TMXEB2*SM4*KT
MRD"+_2@#^%,?L?\ _!6H'/\ P@_BS_PIO$'X_P#+A7SO\</V"?\ @HMJ&D7.
MM?$;X?:W_9\:S7$DUYJVJW840*)9& N+$#*J V<_E7^B37F_Q6\)V?C#P3X@
MTR\A293HNKF-7&1O>PF Q[Y48H _A"_X)*?%;6_@9\;-%\#^);F6PO)M=NO.
MLY9Y&'F17ZB0;9-H^5I".5&/I7]Z7A;4HO%O@^SO@^Z+5+0G>O.5;@D8[\?G
M7^>I^U5HFJ_LV_MC:;XKB@GM-,M;_5[N0(GEQD2WMM,&+<=0&Y'7-?VK_P#!
M/;X]67QD^#7A22W8--!HR2RGS"Y.=I.?F..O_P"K- '\YW_!>3X%7EIKVJ>*
M=.BGFABEAD+DOM&R6.5LY+#L3U_3&?IS_@A[^T_HE]X?F\!2:C$;VV^R:88,
MIO$D;0$K][)(R<^F:_5__@HW^R8?VA/AAK4%@J?VE(DKJPC$DI"0L0 I5LY(
MX_\ KU_$]X6U3XI_\$_OCO<7L]CK<.EQ>))KAPD!ABN(H@I# @QY7]WUSVY&
M* /])ZBOQN_8E_X*I_"'XU^#])C\8^(M%\)ZB;9IIY]:U'R79A"K[&WN^#E2
M/J>U??M_^U[^S?9V;W2_&+P+,R@'REUF(L<C)XVYXZ?6@#Z4J*?_ %$W_7*3
M_P! :OYXOVQ?^"S'@_P;++X.^'%HOB#5+R673K6_T.Z:<^>V_P N5 LJ@GY<
M< CN*^CO^";'Q>^,?QB\.VWBCQZ=>CM+H7!\C58B@"M'(Z<DDX"D8Y],GT /
MR?\ ^"YW_(0T[_KSN/\ T">OL;_@B/I%GKWP/TG2;^*.>WOO#5[:.LL:RA4N
M--$3%5<$ X;M@^XKXY_X+G?\A#3O^O.X_P#0)Z^V_P#@A7_R23PW_P!@:3_T
MB2@#\Z/^"R/_  3>?PGJ6K?%OX;0ZAYME933M-:&>T6.XNXTNG7= [ $21-C
MOP*V_P#@CO\ \%#9_".HO\)/'NL!)[/[+HD,=[.+J59&$#G!G(96R6'!SU^E
M?U;_ !D^$7A[XO\ A#4O"^N6-M<QWZJK&X&5VK')'@C!'1\=.U?P??M^_LR>
M.?V/_CG%\0?!FE:E9Z1_PDS:E(^GVNV*2WA25<[P!\N8P,YZ\4 ?Z ^A:YI_
MB'3H-2TV83VT\:,L@Q@[T5^Q(Z-ZUL5^!O\ P27_ ."B/AWXX>!]#\'>([Z&
MPUY442'4+DK/\D(C"E"[=60@<=3[U^]T,T4\230NLD4JAXY$.5=3R&4]P: '
MMT/T/\J_DK_X.&O^0+KG_8$3_P!(TK^M1NA^A_E7\E?_  <-?\@77/\ L")_
MZ1I0!Z!_P0G_ .17N?\ KPL__;2OZDT^XO\ NK_(5_+9_P $)_\ D5[G_KPL
M_P#VTK^I-/N+_NK_ "% #J*** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH *Q_$/\ R M8_P"P;>?^D\E;%8_B'_D!:Q_V#;S_ -)Y
M* /XHO\ @I3_ ,G!1?\ 7I>?^C+.O@>Q_P!:_P!/Z"OOC_@I3_R<%%_UZ7G_
M *,LZ^!['_6O]/Z"@#=HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *AG_ -4W^?6IJAG_ -4W^?6@#'M?]<W^]_05O5@V
MO^N;_>_H*WJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH *JW?^J_.K55;O_5?G0!EV/^ND_P!T?RK>K!L?]=)_
MNC^5;U !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %5+O[A^@_K5NJEW]P_0?UH S=._P!8/I_[-6[6%IW^L'T_
M]FK=H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ I0"3@<DTE>G_"+P)J'Q!\=^
M'/#MG;RRIJ>J0V<LJ)N2$.KMN?J .!G@_K0!^H?_  2[_9@NO'OCZR\8>(--
M)\-/:I)!=/'YL9N(O,E "L%3.?+.0V1GFOZK=)TRWT?3;+3+556"QMX[:(*H
M7Y(E"KP!QP*^6_V0/@38_!#X5:-X<:&)]1MPKO=*NUBKP1#;P%'8]A[]:^M:
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MD(TC_KXN_P#T*.OP;_X)3?LO_#?]IV.Y\"_$2TDGTG4_$-^LYMU3SOEU"ZB
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M'_P2-_:N\1?M167Q/L-'TYO#,&M:E>O,S2^9Y-S=1R1G&<<JI-?UX44 >-_
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MH%"X^2,8P.GW:_E1_P""#/P"'C.^\4?$CQ-I@:_L/$;7EG<7<6^3;+<+\R.
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M!C&?:H;7_@C1_P %"?%$]K!XV!6R@(C!MM6U-6\HYSG]^H)RQ[],=Z_N(HH
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M,-O(D2;,;7<X(QGT^F!0!ZS1110 4444 %%%% !1110 4444 %%%% !1110
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M_L#^.?V6_"MM#\3M,MK;7/[,2&X: ;LW"H@^\_S=0>O/XU^URJ%55'10%'T
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M>K75\5TU[=F\N:\EN%'[K4+HY"OSP>>PK][**  #  ]!BBBB@ HHHH ****
M"BBB@ HHHH **** "BBB@"O=Q-/:74"D!IK>:)2>@:2-D!/MDC-?S ?M ?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@"*<2-%((2%E*_(QZ!NW<?SK
M^</_ (*,?\$G_P!I;]KWXP7GB_PKXQ\-V7A2YNK686&H/;K.%BNQ-)_K=6MS
MEHQC_4]>W8_T@T4 ?GY^P=^Q[<?LH> %\,Z@;&349[>U%[-9-"T<MS%@R/\
MNI)!@MD\NWU-?H'110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 ?-O[3GP"TKX^?#;Q'X4GMH9-5U#2I++39[AHUBAE
M>0-N?S,#&TMU=>W/:OPP_8\_X)!_M(?LV_M ZC\0Y/%WAD>";BSM[:UTVU>U
M:YC,<E\7R(]7<X*7$0'[@?=/7H/Z8:* *&E6\UIIEA:W#!Y[>SMX9G'1I8XE
M1V')X+ D<FK]%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 5\!?M[?LV?$[]I+X?0>$_ASK6GZ1=%+B*Z?
M4#&L<D<W&!YEW:C[I.?F/T[5]^T4 ?B%_P $Y_\ @F%XH_93F75?B-=:/JVN
M+J=S>"ZTY[5AY4]S+/M_=75V<_.N?GZCIGI^W,420QI%&,(@VJ/05)10 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9NK?\>,OX
M?R-:59NK?\>,OX?R- 'CNB_\AFY_Z^%_]!2O;H/]4O\ GTKQ'1?^0S<_]?"_
M^@I7MT'^J7_/I0!-1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5C^(?\
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MS-/_ ."<'[6<]W)%'\.I6=7P1YEWUQT_X\/Z5V'_  [+_;!_Z)K-_P!_;O\
M^0* /@.BOOS_ (=E_M@_]$UF_P"_EW_\KZ/^'9?[8/\ T36;_OY=_P#ROH ^
M Z*^_/\ AV7^V#_T36;_ +^7?_ROH_X=E_M@_P#1-9O^_EW_ /*^@#X#HK[\
M_P"'9?[8/_1-9O\ OY=__*^C_AV7^V#_ -$UF_[^7?\ \KZ /@.BOOS_ (=E
M_M@_]$UF_P"_EW_\KZ/^'9?[8/\ T36;_OY=_P#ROH ^ Z*^_/\ AV7^V#_T
M36;_ +^7?_ROH_X=E_M@_P#1-9O^_EW_ /*^@#X#HK[\_P"'9?[8/_1-9O\
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M /*^@#X#HK[\_P"'9?[8/_1-9O\ OY=__*^C_AV7^V#_ -$UF_[^7?\ \KZ
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MOOS_ (=E_M@_]$UF_P"_EW_\KZ/^'9?[8/\ T36;_OY=_P#ROH ^ Z*^_/\
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M3_V:MVOL_1/^";_[6E[/LM_AU*[ $X\R[]?^O UUO_#LO]L'_HFLW_?R[_\
ME?0!\!T5]^?\.R_VP?\ HFLW_?R[_P#E?1_P[+_;!_Z)K-_W\N__ )7T ? =
M%??G_#LO]L'_ *)K-_W\N_\ Y7T?\.R_VP?^B:S?]_+O_P"5] 'P'17WY_P[
M+_;!_P"B:S?]_+O_ .5]'_#LO]L'_HFLW_?R[_\ E?0!\!T5]^?\.R_VP?\
MHFLW_?R[_P#E?1_P[+_;!_Z)K-_W\N__ )7T ? =%??G_#LO]L'_ *)K-_W\
MN_\ Y7T?\.R_VP?^B:S?]_+O_P"5] 'P'17WY_P[+_;!_P"B:S?]_+O_ .5]
M'_#LO]L'_HFLW_?R[_\ E?0!\!T5]^?\.R_VP?\ HFLW_?R[_P#E?1_P[+_;
M!_Z)K-_W\N__ )7T ? =%??G_#LO]L'_ *)K-_W\N_\ Y7T?\.R_VP?^B:S?
M]_+O_P"5] 'P'17WY_P[+_;!_P"B:S?]_+O_ .5]'_#LO]L'_HFLW_?R[_\
ME?0!\!T5]^?\.R_VP?\ HFLW_?R[_P#E?1_P[+_;!_Z)K-_W\N__ )7T ? =
M%??G_#LO]L'_ *)K-_W\N_\ Y7T?\.R_VP?^B:S?]_+O_P"5] 'P'17WY_P[
M+_;!_P"B:S?]_+O_ .5]'_#LO]L'_HFLW_?R[_\ E?0!\!T5]^?\.R_VP?\
MHFLW_?R[_P#E?1_P[+_;!_Z)K-_W\N__ )7T ? =%??G_#LO]L'_ *)K-_W\
MN_\ Y7T?\.R_VP?^B:S?]_+O_P"5] 'P'17WY_P[+_;!_P"B:S?]_+O_ .5]
M'_#LO]L'_HFLW_?R[_\ E?0!\!T5]^?\.R_VP?\ HFLW_?R[_P#E?1_P[+_;
M!_Z)K-_W\N__ )7T ? =7-/LY=0O;6RA!,MS/%!& I8EY7"* HY))/2OO#_A
MV7^V#_T36;_OY=__ "OKWCX ?\$POCX?'.E7OQ$\&76E:7I^H6-XLJ/=,K>1
M,)75PUK I7Y!D$G@\CT /T._X)5_LL_\(SX?L_B3KMBJ:U97Z-:SRQB*4032
M2S+M63,A&V*(@@XQCU&/W.KB_ /A#3_!7AK2]%T^WBMTM]/L(94BB2(>;!:Q
MQL6" 9;<&R3R3Z=*[2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N(\;_ /'C
M']3_ $KMZXCQO_QXQ_4_TH YWP)][_MJW_H9KUFO)O GWO\ MJW_ *&:]9H
M\'\6?\A.'_KF/Y)7L&@?\@FS_P"N8KQ_Q9_R$X?^N8_DE>P:!_R";/\ ZYB@
M#8HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *S=6_X\9?P_D:TJS=6_X\9?P_D: /'=%_Y#-S_P!?"_\ H*5[
M=!_JE_SZ5XCHO_(9N?\ KX7_ -!2O;H/]4O^?2@":BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH Y_P 0_P#'C+_G^ UYCX6_Y"=S_P!=A_)*].\0
M_P#'C+_G^ UYCX6_Y"=S_P!=A_)* /;5Z#Z#^5+2+T'T'\J6@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K&US_CQE^@_P#9
MJV:QM<_X\9?H/_9J /)_#W_(8N?^NX_]!%>X+T'T'\J\/\/?\ABY_P"NX_\
M017N"]!]!_*@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ KGO$O_(,G_W#_6NAKGO$O_(,G_W#_6@#S#PI_P A
M*3_@/\Q7MR?<7_=7^0KQ'PI_R$I/^ _S%>W)]Q?]U?Y"@!U%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5RWBO\
MY!TW_7)_Y-74URWBO_D'3?\ 7)_Y-0!Y]\/O^/\ '^Z_]:]JKQ7X??\ '^/]
MU_ZU[50 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !7$>-_^/&/ZG^E=O7$>-_^/&/ZG^E '.^!/O?]M6_]#->L
MUY-X$^]_VU;_ -#->LT >#^+/^0G#_US'\DKV#0/^039_P#7,5X_XL_Y"</_
M %S'\DKV#0/^039_]<Q0!L4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %9NK?\>,OX?R-:59NK?\ 'C+^'\C0
M!X[HO_(9N?\ KX7_ -!2O;H/]4O^?2O$=%_Y#-S_ -?"_P#H*5[=!_JE_P ^
ME $U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!S_ (A_X\9?\_P&
MO,?"W_(3N?\ KL/Y)7IWB'_CQE_S_ :\Q\+?\A.Y_P"NP_DE 'MJ]!]!_*EI
M%Z#Z#^5+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5C:Y_QXR_0?^S5LUC:Y_QXR_0?^S4 >3^'O^0Q<_\ 7<?^@BO<%Z#Z
M#^5>'^'O^0Q<_P#7<?\ H(KW!>@^@_E0 M%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 5SWB7_D&3_[A_K70USWB
M7_D&3_[A_K0!YAX4_P"0E)_P'^8KVY/N+_NK_(5XCX4_Y"4G_ ?YBO;D^XO^
MZO\ (4 .HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "N6\5_\@Z;_KD_\FKJ:Y;Q7_R#IO\ KD_\FH \^^'W_'^/
M]U_ZU[57BOP^_P"/\?[K_P!:]JH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ KB/&__'C']3_2NWKB/&__ !XQ
M_4_TH YWP)][_MJW_H9KUFO)O GWO^VK?^AFO6: /!_%G_(3A_ZYC^25[!H'
M_()L_P#KF*\?\6?\A.'_ *YC^25[!H'_ "";/_KF* -BBBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K-U;_CQ
ME_#^1K2K-U;_ (\9?P_D: /'=%_Y#-S_ -?"_P#H*5[=!_JE_P ^E>(Z+_R&
M;G_KX7_T%*]N@_U2_P"?2@":BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH Y_Q#_QXR_Y_@->8^%O^0G<_P#78?R2O3O$/_'C+_G^ UYCX6_Y"=S_
M -=A_)* /;5Z#Z#^5+2+T'T'\J6@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ K&US_CQE^@_]FK9K&US_CQE^@_]FH \G\/?
M\ABY_P"NX_\ 017N"]!]!_*O#_#W_(8N?^NX_P#017N"]!]!_*@!:*** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K
MGO$O_(,G_P!P_P!:Z&N>\2_\@R?_ '#_ %H \P\*?\A*3_@/\Q7MR?<7_=7^
M0KQ'PI_R$I/^ _S%>W)]Q?\ =7^0H =1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %<MXK_Y!TW_ %R?^35U-<MX
MK_Y!TW_7)_Y-0!Y]\/O^/\?[K_UKVJO%?A]_Q_C_ '7_ *U[50 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7$
M>-_^/&/ZG^E=O7$>-_\ CQC^I_I0!SO@3[W_ &U;_P!#->LUY-X$^]_VU;_T
M,UZS0!X/XL_Y"</_ %S'\DKV#0/^039_]<Q7C_BS_D)P_P#7,?R2O8- _P"0
M39_]<Q0!L4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %9NK?\>,OX?R-:59NK?\>,OX?R- 'CNB_\AFY_Z^%_
M]!2O;H/]4O\ GTKQ'1?^0S<_]?"_^@I7MT'^J7_/I0!-1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 <_XA_X\9?\_P !KS'PM_R$[G_KL/Y)7IWB
M'_CQE_S_  &O,?"W_(3N?^NP_DE 'MJ]!]!_*EI%Z#Z#^5+0 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5C:Y_QXR_0?^S5L
MUC:Y_P >,OT'_LU 'D_A[_D,7/\ UW'_ *"*]P7H/H/Y5X?X>_Y#%S_UW'_H
M(KW!>@^@_E0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 5SWB7_D&3_P"X?ZUT-<]XE_Y!D_\ N'^M 'F'A3_D
M)2?\!_F*]N3[B_[J_P A7B/A3_D)2?\  ?YBO;D^XO\ NK_(4 .HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N6
M\5_\@Z;_ *Y/_)JZFN6\5_\ (.F_ZY/_ ":@#S[X??\ '^/]U_ZU[57BOP^_
MX_Q_NO\ UKVJ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "N(\;_\ 'C']3_2NWKB/&_\ QXQ_4_TH YWP)][_
M +:M_P"AFO6:\F\"?>_[:M_Z&:]9H \'\6?\A.'_ *YC^25[!H'_ "";/_KF
M*\?\6?\ (3A_ZYC^25[!H'_()L_^N8H V**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "LW5O^/&7\/Y&M*LW5
MO^/&7\/Y&@#QW1?^0S<_]?"_^@I7MT'^J7_/I7B.B_\ (9N?^OA?_04KVZ#_
M %2_Y]* )J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#G_$/_'C+
M_G^ UYCX6_Y"=S_UV'\DKT[Q#_QXR_Y_@->8^%O^0G<_]=A_)* /;5Z#Z#^5
M+2+T'T'\J6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ K&US_CQE^@_]FK9K&US_ (\9?H/_ &:@#R?P]_R&+G_KN/\ T$5[
M@O0?0?RKP_P]_P ABY_Z[C_T$5[@O0?0?RH 6BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y[Q+_P @R?\ W#_6
MNAKGO$O_ "#)_P#</]: /,/"G_(2D_X#_,5[<GW%_P!U?Y"O$?"G_(2D_P"
M_P Q7MR?<7_=7^0H =1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %<MXK_Y!TW_7)_Y-74URWBO_ )!TW_7)_P"3
M4 >??#[_ (_Q_NO_ %KVJO%?A]_Q_C_=?^M>U4 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Q'C?_ (\8_J?Z
M5V]<1XW_ ./&/ZG^E '.^!/O?]M6_P#0S7K->3>!/O?]M6_]#->LT >#^+/^
M0G#_ -<Q_)*]@T#_ )!-G_US%>/^+/\ D)P_]<Q_)*]@T#_D$V?_ %S% &Q1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %9NK?\>,OX?R-:59NK?\ 'C+^'\C0!X[HO_(9N?\ KX7_ -!2
MO;H/]4O^?2O$=%_Y#-S_ -?"_P#H*5[=!_JE_P ^E $U%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?S>44 ?TA_\ #]/0_P#HDT__ ']D_P#EE1_P_3T/_HDT_P#W]D_^65?S>44
M?TA_\/T]#_Z)-/\ ]_9/_EE1_P /T]#_ .B33_\ ?V3_ .65?S>44 ?TA_\
M#]/0_P#HDT__ ']D_P#EE1_P_3T/_HDT_P#W]D_^65?S>44 ?TA_\/T]#_Z)
M-/\ ]_9/_EE1_P /T]#_ .B33_\ ?V3_ .65?S>44 ?TA_\ #]/0_P#HDT__
M ']D_P#EE1_P_3T/_HDT_P#W]D_^65?S>44 ?TA_\/T]#_Z)-/\ ]_9/_EE1
M_P /T]#_ .B33_\ ?V3_ .65?S>44 ?TA_\ #]/0_P#HDT__ ']D_P#EE1_P
M_3T/_HDT_P#W]D_^65?S>44 ?TA_\/T]#_Z)-/\ ]_9/_EE1_P /T]#_ .B3
M3_\ ?V3_ .65?S>44 ?TA_\ #]/0_P#HDT__ ']D_P#EE1_P_3T/_HDT_P#W
M]D_^65?S>44 ?TA_\/T]#_Z)-/\ ]_9/_EE1_P /T]#_ .B33_\ ?V3_ .65
M?S>44 ?TA_\ #]/0_P#HDT__ ']D_P#EE1_P_3T/_HDT_P#W]D_^65?S>44
M?TA_\/T]#_Z)-/\ ]_9/_EE1_P /T]#_ .B33_\ ?V3_ .65?S>44 ?TA_\
M#]/0_P#HDT__ ']D_P#EE1_P_3T/_HDT_P#W]D_^65?S>44 ?TA_\/T]#_Z)
M-/\ ]_9/_EE1_P /T]#_ .B33_\ ?V3_ .65?S>44 ?TA_\ #]/0_P#HDT__
M ']D_P#EE1_P_3T/_HDT_P#W]D_^65?S>44 ?TA_\/T]#_Z)-/\ ]_9/_EE1
M_P /T]#_ .B33_\ ?V3_ .65?S>44 ?TA_\ #]/0_P#HDT__ ']D_P#EE1_P
M_3T/_HDT_P#W]D_^65?S>44 ?TA_\/T]#_Z)-/\ ]_9/_EE1_P /T]#_ .B3
M3_\ ?V3_ .65?S>44 ?TA_\ #]/0_P#HDT__ ']D_P#EE1_P_3T/_HDT_P#W
M]D_^65?S>44 ?TA_\/T]#_Z)-/\ ]_9/_EE1_P /T]#_ .B33_\ ?V3_ .65
M?S>44 ?TA_\ #]/0_P#HDT__ ']D_P#EE1_P_3T/_HDT_P#W]D_^65?S>44
M?TA_\/T]#_Z)-/\ ]_9/_EE1_P /T]#_ .B33_\ ?V3_ .65?S>44 ?TA_\
M#]/0_P#HDT__ ']D_P#EE1_P_3T/_HDT_P#W]D_^65?S>44 ?TA_\/T]#_Z)
M-/\ ]_9/_EE1_P /T]#_ .B33_\ ?V3_ .65?S>44 ?TA_\ #]/0_P#HDT__
M ']D_P#EE1_P_3T/_HDT_P#W]D_^65?S>44 ?TA_\/T]#_Z)-/\ ]_9/_EE1
M_P /T]#_ .B33_\ ?V3_ .65?S>44 ?TA_\ #]/0_P#HDT__ ']D_P#EE1_P
M_3T/_HDT_P#W]D_^65?S>44 ?TA_\/T]#_Z)-/\ ]_9/_EE1_P /T]#_ .B3
M3_\ ?V3_ .65?S>44 ?TA_\ #]/0_P#HDT__ ']D_P#EE1_P_3T/_HDT_P#W
M]D_^65?S>44 ?TA_\/T]#_Z)-/\ ]_9/_EE1_P /T]#_ .B33_\ ?V3_ .65
M?S>44 ?TA_\ #]/0_P#HDT__ ']D_P#EE1_P_3T/_HDT_P#W]D_^65?S>44
M?TA_\/T]#_Z)-/\ ]_9/_EE5#4O^"Y>AW-K)'_PJB==P SYLGO\ ]1&OYRZA
MG_U3?Y]: /Z -(_X+8:):ZA-.?A;.P>7=CS7XX _Z" KTD?\%TM#  _X5-/P
M,?ZV3_Y95_,]:_ZYO][^@K>H _I#_P"'Z>A_]$FG_P"_LG_RRH_X?IZ'_P!$
MFG_[^R?_ "RK^;RB@#^D/_A^GH?_ $2:?_O[)_\ +*C_ (?IZ'_T2:?_ +^R
M?_+*OYO** /Z0_\ A^GH?_1)I_\ O[)_\LJ/^'Z>A_\ 1)I_^_LG_P LJ_F\
MHH _I#_X?IZ'_P!$FG_[^R?_ "RH_P"'Z>A_]$FG_P"_LG_RRK^;RB@#^D/_
M (?IZ'_T2:?_ +^R?_+*C_A^GH?_ $2:?_O[)_\ +*OYO** /Z0_^'Z>A_\
M1)I_^_LG_P LJ/\ A^GH?_1)I_\ O[)_\LJ_F\HH _I#_P"'Z>A_]$FG_P"_
MLG_RRH_X?IZ'_P!$FG_[^R?_ "RK^;RB@#^D/_A^GH?_ $2:?_O[)_\ +*C_
M (?IZ'_T2:?_ +^R?_+*OYO** /Z0_\ A^GH?_1)I_\ O[)_\LJ/^'Z>A_\
M1)I_^_LG_P LJ_F\HH _I#_X?IZ'_P!$FG_[^R?_ "RH_P"'Z>A_]$FG_P"_
MLG_RRK^;RB@#^D/_ (?IZ'_T2:?_ +^R?_+*C_A^GH?_ $2:?_O[)_\ +*OY
MO** /Z0_^'Z>A_\ 1)I_^_LG_P LJ/\ A^GH?_1)I_\ O[)_\LJ_F\HH _I#
M_P"'Z>A_]$FG_P"_LG_RRH_X?IZ'_P!$FG_[^R?_ "RK^;RB@#^D/_A^GH?_
M $2:?_O[)_\ +*C_ (?IZ'_T2:?_ +^R?_+*OYO** /Z0_\ A^GH?_1)I_\
MO[)_\LJ/^'Z>A_\ 1)I_^_LG_P LJ_F\HH _I#_X?IZ'_P!$FG_[^R?_ "RH
M_P"'Z>A_]$FG_P"_LG_RRK^;RB@#^D/_ (?IZ'_T2:?_ +^R?_+*C_A^GH?_
M $2:?_O[)_\ +*OYO** /Z0_^'Z>A_\ 1)I_^_LG_P LJ/\ A^GH?_1)I_\
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M_P"_LG_RRH_X?IZ'_P!$FG_[^R?_ "RK^;RB@#^D/_A^GH?_ $2:?_O[)_\
M+*C_ (?IZ'_T2:?_ +^R?_+*OYO** /Z0_\ A^GH?_1)I_\ O[)_\LJ/^'Z>
MA_\ 1)I_^_LG_P LJ_F\HH _I#_X?IZ'_P!$FG_[^R?_ "RH_P"'Z>A_]$FG
M_P"_LG_RRK^;RB@#^D/_ (?IZ'_T2:?_ +^R?_+*C_A^GH?_ $2:?_O[)_\
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M_P"_LG_RRH_X?IZ'_P!$FG_[^R?_ "RK^;RB@#^D/_A^GH?_ $2:?_O[)_\
M+*C_ (?IZ'_T2:?_ +^R?_+*OYO** /Z0_\ A^GH?_1)I_\ O[)_\LJ/^'Z>
MA_\ 1)I_^_LG_P LJ_F\HH _I#_X?IZ'_P!$FG_[^R?_ "RH_P"'Z>A_]$FG
M_P"_LG_RRK^;RB@#^D/_ (?IZ'_T2:?_ +^R?_+*C_A^GH?_ $2:?_O[)_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M5[U\<;F:T^'6L30,4D7;M8=1^YG/J/2O\ZO]I7X>ZQ\8OVLO$G@_3KN*VO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MUC*8$UY93@[@!U SGO7]C/\ P3)^-$?Q1^#'AJ,W8F>QT"$D-)D@^8">"?\
M;% 'Z?T444 8VN>(-)\.6,VI:Q=QV=G;Q232S2?=2.)=TC'V5>37RC'^WU^R
MC+XMB\#I\6=#;Q/,TBQZ8&_?,T4B12 ?-_#(ZJ?<UXW_ ,%+OB_%\,/@KJ%S
M%>+#-=V.J6^U9 '8M $ V@[N2WIZBOY,O^";OP2U+]IG]I^Q^(=W&)HK;Q%K
M%GYEQ&<[6UI0,-(>FVW]/IUH _OGTG5;#6].M-5TRX6ZL+V(36UPGW98R2 P
M]B0:GO;VVT^WDNKN5888D>1W;HJ1J7<GV502:YKP%H \+^$-!T   :98K; +
MC:-KNW&.,?-7SU^V1\3(_AC\(=7UPW(@=K:_A!#[6R;4@8YYY<<=^E &-XY_
MX*!?LF?#?4GTGQE\6]"T74(W>-[>X?#AXSAP1NZ@U[/\*?V@?A-\;+1+WX:>
M+;'Q-;20^>DMF<@Q;=V[J>,<U_G&?'O0?''[3/C[QCXDTF*]GM=)UW48FD^R
MS2J 9F4'>, ?@>?TK]GO^"+W[2/_  K'QO/\*=9EFBO-.M(-/='+1+OFC:(8
M5N /E/K0!_9W15/3[E+RQL[I&#+<6MO."#GB6))/_9JN4 (2%!)X !)/L!DU
MY/XX^.'PQ^'$,EQXQ\3V6C11*7D>X. J@$DGD= /I7E_[7GC7Q=X%^%=[JW@
MQ;YM7*W<<?V"WFN)PWD+Y9\N#Y\!V_SUK^3&Z^$?_!0#]M3QCKNDS>,M4T31
MFUB\L8H]=TJ\M8_LXF>.+#7=Y I0+T;&,#)XYH _J$O_ /@IE^Q7IMQ):WOQ
ML\.P3Q-MDC9\,IYZY8>E=OX"_;M_9:^)NHPZ5X)^*FBZW?W!Q#;VS$NYW!<#
MYC_$0*_E(U;_ (-R?VGM2BNM;O\ XC>%[B<Q//(-UGYC[ 6P%_M'<6/0=>>E
M?FI\:/V?/VD/^">7BO[1IVMSP7VF#SUU+3[.4P(JNDA^>&<KD\,!O.0/K0!_
MI*V=W;W]M#>6L@EM[A!)%(O1T)(!'X@U9K^:W_@D?_P4QU?XQZ=_PA/Q$U2\
MU76+2.UTVVEG:5 DY:!V.)"_59'XW=_K7]*"LK@,I!![@@^_:@!U%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !6/XA_Y 6L?]@V\_])Y*V*Q_$/\ R M8_P"P;>?^
MD\E '\47_!2G_DX*+_KTO/\ T99U\#V/^M?Z?T%??'_!2G_DX*+_ *]+S_T9
M9U\#V/\ K7^G]!0!NT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %0S_ZIO\^M35#/_JF_SZT 8]K_ *YO][^@K>K!M?\
M7-_O?T%;U !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %5;O_5?G5JJMW_JOSH R['_ %TG^Z/Y5O5@V/\ KI/]
MT?RK>H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ JI=_</T']:MU4N_N'Z#^M &;IW^L'T_P#9JW:PM._U@^G_
M +-6[0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MS_O*&_K4E?+O[(OQ7@^,'P=T'Q;%<K<?:8XH]ZOOR5MX2?FR<GGU[>_/U"2
M,G@"@#X;_;V^/FB_ WX*>)KO5;];*37=!UC3K-CL!:XFM7AC"EG4J=\@ *\@
M\^E?R#_\$Q_@M?\ [1'[5\7Q \1K<ZAH_P#;^OQ_:9I)KM?+DUHO& LK; OE
MQ<#=@ 8' -?=G_!<O]I^3QCJNE?!+0)634M.\30V,PMI=TL@NKQ(@K1ER.=A
M&-H_P_0;_@BK^S4GPQ_9ZGUWQ'I'E>)+C5?M]O=W<6RZ$%U]ON05*X4JP>,Y
MQSP3WH _EJ^,6A6OAO\ ;XM-$LUVVVF_%#[-"N H55T]VQM'3ECQG%?WT_LG
M?\D>T#_<'_HB"OX-OVBO^4BUU_V5IO\ TVFO[R?V3O\ DCV@?[@_]$04 ?2Q
M( )/05\H_%S]M3X ? ^2ZB^(?BO^R'LRXG&RV;:4SN'[V\AY&#P<=#65^W9/
M\0+?]FOXB2_#)M47QBFG@Z2='56O_-\N;_4!QM)W;>#W_&OY=OA;_P $M/VL
MOVO'GU7XH_%_Q;X5^V0FXDM=>AM<[F4LT9VZ9<\G)!^;GUZY /W=E_X+>?\
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M^+6F_&7P#I?C+3/*^SWR( (G+KN\F.0\EFS]X=^.:_GA_P"#@$?N=*/IH/\
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M">9G]S<S_P &3P2/>OYT]$_X-UKG4O#T5S=_%FW35;VU20W<D">=%.QY8_\
M$IQNP#G@]>,5QWPD_8 _:B_8S^-$>G^'?B)XK\6>%;6[TZT1=/AMA9&!KR2&
M=Q_H-JVWR2-QX^44 ?UW Y ([C/YU!<W$5I;RW,[;88$,DC<<*O4\D#CZBN0
M\"2WR^$]$?5VD6[72=.^U-/@2>?]EC\W?CC=O#9QQG\*_G)_X*P_\%/;_P
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M^3W[@']6&I_\%KO^"?VD7C6-[\6/+N$D,;)Y.F<.'V$<ZN/XO:OHOP!^VG\
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M^7[>OPQ\1_L^_MD-XHT:RN]%T+_A/;2>*:",1VTL$<K9VL>=O'/3^=?V1_\
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MKQ')JEG>7L.V98+V\O+I3&R[1L*LA'X'/-?BE_P4L 7]M^-0,*/B/;8'XRT
M?V+?\$^/^2(Z#_USM?\ TFCKZ^^*G_(A^(?^O-OYBOD'_@GQ_P D1T'_ *YV
MO_I-'7U]\5/^1#\0_P#7FW\Q0!_ -^UM_P GT7?_ &-_AK_T_M7]VG[,?_))
M_"?_ &+GA[_TU6]?PE_M;?\ )]%W_P!C?X:_]/[5_=I^S'_R2?PG_P!BYX>_
M]-5O0!]!R0Q3*4FBCE0C!21%D4@]058$$>Q%?(W[57[)GPT_:,^'&K^%?$6B
MV%IN@N[I;S3]*LTO6E2W9D7SXE@FVET7/[WUX/2OKVHYD$D,L9&1)&Z$>H92
MI'ZT ?YL/QQ^&7B;]B?]I>WUS2Y+_3=(TCQ)>7%H3=W-O%-;1$^6TT88QMD+
MR#O SU.*_MV_X)L_M*V?QY^!?A#5I;Y+G4[JR::<(5?'^CP/]X'<><_PCW[U
M^ O_  <$_"NPT;7/#NJ6%G';-<V$]S,\:D%W:.8[FSGDD?C^E?1?_!!3QK=R
M^#-%\..9#'9Z*S*21MYM#TP?]CV_I0!_1O\ 'G_DFNM?\!_]$W%?P,77_)_<
M/_93[?\ ])Q7]\GQU.?ACJQ]4C/YV\]?P-W7_)_</_93[?\ ])Q0!_?O\&_^
M1%TG_KWM_P#TFBKTZ:WM[A2EQ!#.AX*31)*I'H5=6!_$5YC\&_\ D1=)_P"O
M>W_])HJ]4H ^ ?VW?V+?AE^TA\,=8LM7T>SL+S2--U+4+.?2M*LX;B:ZB@,T
M2336_P!GE93)& <LXP3\IR0?X1=0L_%O["G[3L.LQ7%[IEEI%[J<D$4EW<Q6
MSPIJ,+Q/)"3Y1)C5225;@MS@\_Z5FH6Z7=C=VKJ&2XMY864C(99$*D$>A!K^
M&/\ X+[_  OL_#/Q?>[TZT2U1M$:=_*4@,\D-E(6)/J22?KW'4 _K3_8B^.E
MA\:/@SX,UJ.\2YO)O#\%S=%2K?.\S#.X,2>"HR0.OO7VA/$)H)H6^[+%)$?I
M(A0_H:_GL_X(D>-[K5?AA;:3*)-FG:):PH6/!'F6[<8/0[_;I]*_H7'('T%
M'\;_ /P7N^%]MX(\:Z!XITI9([D:9+>;QNC(=X0Q.Y22.V2,5^H'_!%CXO7G
MBSX&>$-%OI_,EL]&R0S[VR;>+DDC)(QW/Y=O+O\ @NSX'L_$'@N;5YQ%YUCH
M)$9926Y@8<8!]/7\*^3_ /@A#\1@^JW?A$RX73-(157=\HS"V,#([KZ?C0!_
M7"#D ^H!_.EJ*$[H86_O11G\T!J6@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@7;&B(J*!Z!5 4?@*\"_9K^#.B?!_P"'>@:-I=E;VI;2-.\Y84*XE2W7=N!
MYR3GWKZ+H **** "N)^(7_(JZC_NC_T%Z[:N)^(7_(JZC_NC_P!!>@#^#[]L
M/38-:_:VO='N8HYHM1\96MHRR(LF!+*R\!@<'TZ?454_;N_91U7X3^$K?XC>
M#K"2W,%MILOVB(26NW=!!.Q#P D=#D9'T]'_ +8FI_V1^V7:3%/,+>/K# Z8
MQ.WH?4'TK^FSQ-\$]$_:%_8X:PFT2"YU6:RM2MPT;23!4TQ@ !EA@$ _=[4
M?('_  1D_;BT3QMX73X>ZOK@GUG2X+32/L\DJRNMPC6Y*9DDWCAO[N3Z>O\
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MUG:7OC2VM8(Y2L2%1!;Y"X()'[L]>X]* /\ 0^B;?%&_]^-&_P"^E!_K3R0
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MN)QC:RC.>W6OX<?V\/'<W[2G[6EWX#AE:ZB34M-N=@82+\FJGL2W_/+T]\T
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
MC^(?^0%K'_8-O/\ TGDK8K'\0_\ ("UC_L&WG_I/)0!_%%_P4I_Y."B_Z]+S
M_P!&6=? ]C_K7^G]!7WQ_P %*?\ DX*+_KTO/_1EG7P/8_ZU_I_04 ;M%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4,_
M^J;_ #ZU-4,_^J;_ #ZT 8]K_KF_WOZ"MZL&U_US?[W]!6]0 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !56[_
M -5^=6JJW?\ JOSH R['_72?[H_E6]6#8_ZZ3_='\JWJ "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *J7?W#]!
M_6K=5+O[A^@_K0!FZ=_K!]/_ &:MVL+3O]8/I_[-6[0 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ KB/&_P#QXQ_4_P!*[>N(\;_\>,?U/]* .=\"?>_[:M_Z
M&:]9KR;P)][_ +:M_P"AFO6: /!_%G_(3A_ZYC^25[!H'_()L_\ KF*\?\6?
M\A.'_KF/Y)7L&@?\@FS_ .N8H V**** "BBB@ HHHH *_CC_ ."]O_(4TS_L
M;+7_ -.4-?V.5_''_P %[?\ D*:9_P!C9:_^G*&@#]1_^"$W_)L=]_V'X/\
MT/4:^ ?^"^/[/=U9'P/X[\-V!6>*>XU.]N(H2Q#!M23<[1 %>-G+'\:^_O\
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M>G3\_P":;_@B%\$M/^+/[2=]J?BZT^WV$>AV]];%E#D7$"ZE<(V9 ^<,B'U
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MLO%>IVT#?NR@B_M9EP5D1\\1K^5?TC_\%I?^39[3_L)7O_H-A7X4_P#!#/\
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MI82 1Z> P./5FXK^E_\ X*+:3=WG[.NHVEC"TTD4=T2J]=J6B#/?LO\ G@4
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MC_@VU^&ETGEW/QM\33IU"R/=L,_B#0!^*'_!)+XDZM;?MS>&-,\.RO'X>O\
M5M5O$B(?!CEUJVDASMVIGRY<'@=<BO\ 0-T":2XT;3YY3F22W#,?4[F&?R%?
MAW^R9_P0]^&?[*_Q*T;XD:/X^U'7-1T=V:**Y2?Y]TT4V"SC'6("OW/T^T6P
ML[>S5BRV\8C#'J0"3G]: +E%%% !7\Y/_!=W_DD'BC_KWB_])6K^C:OYR?\
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M@$\YCQ]?QH _>'_@AFC_ /"$73%' .EVF"5.#\]H.#C!K^E%>@^@_E7X[_\
M!)'X*+X!^!'A+5IXVBNM7\,VTLJ,N"'\\+@D@$\1#_ZXP1^Q/2@#\3_^"Q_A
M_3]2^"OB>_N4+3VVB8C(QQF)QW'I7XB?\$+!Y?QK\4QKD*NGP8 _ZY2U^T'_
M  6?\43:1\(/$&FI"KI=Z)EG./E_<R=/QK\;/^"%&G7TWQA\37OD-Y4FG0D-
MVP(I3GVXQUH _M6M/^/2U_Z]X?\ T6M6*KV@Q:VP/46\(/\ W[6K% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M='_@MI^SKIVO?#Z/Q/IVF0RW]M87MZ\T< \U9%>Y 8N!UP0<YSR.?4 ^L?\
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M Z $?SH YK]K[]IGP=^SY\.-8U?7-4@AN+C3+^.TCBNX5F%PL9"9CW%\[N@
MSZ>E?PF_$KQEX[_X*!_M*KI=BE[J?AB\N;NU(>WNI$(COXH5&_'E_<4\_K7K
MW[3G[1/QB_X*#?&V;PCX+?59?#)UZU .EWC_ &?[)<3G?B-"P*;3TX']/Z7?
M^":'_!-7PK^S]X4TGQ-XFTZ&\\2;K>\*ZE:>9.?M*&X?]XZ@\,P!]?7U /J+
M_@GW^RGHW[/GPLT..+3DM;W4M$MOM/RH&\U)4)R,;@1Y(Z\_6OT7J*""&UAC
MM[>)(88EV1Q1J%1%'.U5' ')J6@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Q_
M$/\ R M8_P"P;>?^D\E;%8_B'_D!:Q_V#;S_ -)Y* /XHO\ @I3_ ,G!1?\
M7I>?^C+.O@>Q_P!:_P!/Z"OOC_@I3_R<%%_UZ7G_ *,LZ^!['_6O]/Z"@#=H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*AG_ -4W^?6IJAG_ -4W^?6@#'M?]<W^]_05O5@VO^N;_>_H*WJ "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\L'BB_N[>[T^RDT'44O3%=31M!!-BU2;Y4E=6SD=.O>OY _B?KWQC_X*2?M
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M ++'A']J#P4_A[Q/<:A;R6-K<?V>=/>1)&G?<5!:.>!A\Q/(+'T%?RM?&_\
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MV+P&/.#T!^E?R/6W_!*_]L*/]JE_B.W@ #PL9MPO=]]T^WF;./[/V_ZOG[]
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M#G- '[5?"/\ ;!^"OQ&\'V7B$^/O">DM+ A-I?Z_I\,ZD0+(<I+,CCN.1_\
M7_//]OO_ (*M_##X.^&M2\">$)/^$H\5:_9R)I5[X:O/[1%O.JL>5LDFR3C@
M;ESG\_YJI/\ @C;_ ,%.K*Y%OI?ASQ5#IZS[0L'B;Q3 @@,FTE4BM@N?+]./
MPK]5/V-?^"(7B:'7]$\8_M$CQ1'K.D31S1VU]J&K:G;L<CS%==0N8U*@9X:-
M@<=/4 _FT\:_$GQ1\6?VF/#'C'Q/:ZE!>ZIXY\.R2C4;>:";<-6B?#I, P.7
M./?Z5_H]?LJ\?"'PI_V+WAW_ --,%?R^_M;_ /!(?]H[6OVCM.\2?!WX?17W
M@33O&6BZE#>K'<6Y^P6NJI//(5M[&6,;8%!_UI7CD]*_JI^ /A+6_!?PYT#0
MM?MOLNHV6CZ-:W$.6.R:TT^*"9?F5#\LBD<J#["@#\)_^"Y'[)VH?$7P;HOB
MKPOISR2Z/:7=]J#P0&=F^>]7YM@RO$J=?;UK\X/^".O[>6B? :^TOX&>-DN=
M.3302]S?.]E9JSE[?[\JB,$&,$\Y ]*_LS\=^"-#^(7A?6?"FOVL$]AK5E)8
MSO);Q3R112,K,8C(,JV5_A9>IYY-?S9_M=_\$+_#^K76I^*O@D/$4OB6X>5H
MDM9KVQ7!9I%P]G=R, '8X 3@8]Z /Z%?#/Q_^$7B32K/4;7XB>#C]IMXIC&/
M$&FEXS(H;8X\_(89P00#GJ :K>)OVB_@UX:T^]OKGXC^"Y&L[>6=K=?$6FB9
MO*4ML5//+%CC  !/]?XH=*_X)6_\%2O UW?6WA?PUXDN].:YD-LUSXE\4-^Y
M#'R\!K28#C' ./YUZ%X0_P""/G[>/C?7(;KXIV?C/2[2\GB%^MIXG\4;$A9_
MWVU2+93P3@848H _JN^$/[<OPT^,GBE/#'A@1W$TES-;K<P72W$1:&?R2047
M:=QY&#C%>Z_M!.)?@?\ $:0=&\-7!'_?Z"OSW_89_P""8W@G]EV'3=<&K^)[
MKQ#;/%<21:K>7MRGG.?.F!:YOYR0)>.4YZXZ"OTB^+_AO4?$OPK\9^&=%A^T
M:EJFAS65C"=W[R9I8F5?E#MT4] 30!_ EX+_ .3X[[_KXL/_ $ZW5?WP?!'_
M ))QX4_[ .E_^DJ5_)QX9_X)7_MAZ?\ M477Q&N?A^$\+236CK>^9>\K'?SS
M/Q_9^SB.13]_\J_K?^%NA:CX=\%^'])U2+R;VQTFPMKB/GY)88%1UY"G@CT'
M^(!Z)1110 4444 ?+?[9?AEO%W[/?CK05A:X-[:!1$JERV(IQPH!S]ZOX,OA
MO<3?!O\ ;-.FC=8>?XQTNU*.#&2&G"E2#CTQ^F*_T5O$.E1:UI5SITT:RQW"
M[61T#JPP>JMD'KZ5_GZ_\%&? .K_  T_;87Q-#:_9+(?$+3IX73=$C+'=,>5
M"A<>OY=LT ?WI_![4UU;P+H-VK;]^E:82V0<EK*)NOXUZE7P;^P+\4)OB-\%
M]#OIGC=HK;3K4E"I_P!59B/LHY^09SC//I7WE0!_+/\ \%[/^123_L9(_P#T
MLL:Z[_@@/_R3'Q!_V,3?^E=U7OW_  5M_8Q^/'[3'AY;'X3>&!KMP-;2[V;K
MD?N%N;60M^YM9S]V)CTKHO\ @D5^R!\</V8_ NL:/\6_#8T*^NM9-U#&&N&W
M0FXN'W?OK:W/W74]".<4 ?N!?6L=]:7%I* T5Q$T3J>A5A@@_6OXH_\ @NK^
MSU=Z'\4]3\<Z1ITD6FPVRL)T@9HA,K12C]Z%"@@J3CZ]L5_;-7YO_P#!1_\
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ME7WKW\B$<DDGH>_YYH _9.(;8HU](T'Y*!3Z!P /2B@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *S=6_X\9?P_D:TJS=6_
MX\9?P_D: /'=%_Y#-S_U\+_Z"E>W0?ZI?\^E>(Z+_P AFY_Z^%_]!2O;H/\
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MX);: 1SZ<@4 ?Y??Q$^,WC)="UKP'KEQ>QV]K/+IR6UQ'+%B&R,ELB@.>@4
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !4,_P#JF_SZU-4,_P#JF_SZT 8]K_KF_P![^@K>
MK!M?]<W^]_05O4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0E;<R0223@+*XV%OW:X .<8P*_L'\)^'[?PQX>TG0[9%2/3;"WLP%QM @0(
M,<8XXKX8_8 _9UC^#?PET,:OIZVGB-!^^+0KYOEM!&!F9P)2,D\$?KFOT)H
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "N(\;_\>,?U/]*[>N(\;_\ 'C']3_2@#G?
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "H9_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !6;JW_'C+^'\C6E6;JW_ !XR_A_(T >.Z+_R&;G_ *^%_P#04KVZ
M#_5+_GTKQ'1?^0S<_P#7PO\ Z"E>W0?ZI?\ /I0!-1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MO%O_ (([[_XS0!YQ17H__"G_ (I_]$^\6_\ @COO_C-'_"G_ (I_]$^\6_\
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M_"G_ (I_]$^\6_\ @COO_C-'_"G_ (I_]$^\6_\ @COO_C- 'G%%>C_\*?\
MBG_T3[Q;_P"".^_^,T?\*?\ BG_T3[Q;_P"".^_^,T ><45Z/_PI_P"*?_1/
MO%O_ (([[_XS1_PI_P"*?_1/O%O_ (([[_XS0!YQ17H__"G_ (I_]$^\6_\
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M[_XS0!YQ17H__"G_ (I_]$^\6_\ @COO_C-'_"G_ (I_]$^\6_\ @COO_C-
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M?>+?_!'??_&:/^%/_%/_ *)]XM_\$=]_\9H \XJI=_</T']:]2_X4_\ %/\
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M1WW_ ,9H_P"%/_%/_HGWBW_P1WW_ ,9H \XHKT?_ (4_\4_^B?>+?_!'??\
MQFC_ (4_\4_^B?>+?_!'??\ QF@#SBBO1_\ A3_Q3_Z)]XM_\$=]_P#&:/\
MA3_Q3_Z)]XM_\$=]_P#&: /.**]'_P"%/_%/_HGWBW_P1WW_ ,9H_P"%/_%/
M_HGWBW_P1WW_ ,9H \XHKT?_ (4_\4_^B?>+?_!'??\ QFC_ (4_\4_^B?>+
M?_!'??\ QF@#SBBO1_\ A3_Q3_Z)]XM_\$=]_P#&:/\ A3_Q3_Z)]XM_\$=]
M_P#&: /.**]'_P"%/_%/_HGWBW_P1WW_ ,9H_P"%/_%/_HGWBW_P1WW_ ,9H
M \XHKT?_ (4_\4_^B?>+?_!'??\ QFC_ (4_\4_^B?>+?_!'??\ QF@#SBBO
M1_\ A3_Q3_Z)]XM_\$=]_P#&:/\ A3_Q3_Z)]XM_\$=]_P#&: /.**]'_P"%
M/_%/_HGWBW_P1WW_ ,9H_P"%/_%/_HGWBW_P1WW_ ,9H \XHKT?_ (4_\4_^
MB?>+?_!'??\ QFC_ (4_\4_^B?>+?_!'??\ QF@#SBBO1_\ A3_Q3_Z)]XM_
M\$=]_P#&:/\ A3_Q3_Z)]XM_\$=]_P#&: /.**]'_P"%/_%/_HGWBW_P1WW_
M ,9H_P"%/_%/_HGWBW_P1WW_ ,9H \XJ6"&2XFB@B4O)*ZHBCJ68@ ?B3BO0
MO^%/_%/_ *)]XM_\$=]_\9KW;X ?LO?$OQ[X]T6TO/"FNZ7:6NJ:?/<OJ&E7
M,,4D*W"M(FZ5%!RJD>G/<4 ?JI_P2C_9;>YO-+^*NO:=DZ9?F)89XM\3QO<-
M(I((V@%;<$=^>W?^CN&&*WB2&"-(HHQM2- %55]% X ]J\A^!_PSTKX6^!M+
MT'2K6.T1['3IKA(\8:X%HOFL< 8)=W)&.IKV*@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "N(\;_\>,?U/]*[>N(\;_\ 'C']3_2@#G? GWO^VK?^AFO6:\F\
M"?>_[:M_Z&:]9H \'\6?\A.'_KF/Y)7L&@?\@FS_ .N8KQ_Q9_R$X?\ KF/Y
M)7L&@?\ ()L_^N8H V**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "LW5O^/&7\/Y&M*LW5O\ CQE_#^1H \=T
M7_D,W/\ U\+_ .@I7MT'^J7_ #Z5XCHO_(9N?^OA?_04KVZ#_5+_ )]* )J*
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "D(!!! ((P01D$>A!X(I:* .$
M\4^&O#EW:RS7?A_1+J89 FN-*L)I<%22/,D@9^H!Z]J\L\+^$O"IU.Y!\,^'
MR/.'71M-/9?6VKV[Q#_QXR_Y_@->8^%O^0G<_P#78?R2@#TH>#_".!_Q2WAS
MH/\ F":9_P#(M+_PAWA'_H5O#G_@CTS_ .1:Z)>@^@_E2T <Y_PAWA'_ *%;
MPY_X(],_^1:/^$.\(_\ 0K>'/_!'IG_R+71T4 <Y_P (=X1_Z%;PY_X(],_^
M1:/^$.\(_P#0K>'/_!'IG_R+71T4 <Y_PAWA'_H5O#G_ ((],_\ D6C_ (0[
MPC_T*WAS_P $>F?_ "+71T4 <Y_PAWA'_H5O#G_@CTS_ .1:/^$.\(_]"MX<
M_P#!'IG_ ,BUT=% '.?\(=X1_P"A6\.?^"/3/_D6C_A#O"/_ $*WAS_P1Z9_
M\BUT=% '.?\ "'>$?^A6\.?^"/3/_D6C_A#O"/\ T*WAS_P1Z9_\BUT=% '.
M?\(=X1_Z%;PY_P""/3/_ )%H_P"$.\(_]"MX<_\ !'IG_P BUT=% '.?\(=X
M1_Z%;PY_X(],_P#D6C_A#O"/_0K>'/\ P1Z9_P#(M='10!SG_"'>$?\ H5O#
MG_@CTS_Y%H_X0[PC_P!"MX<_\$>F?_(M='10!SG_  AWA'_H5O#G_@CTS_Y%
MH_X0[PC_ -"MX<_\$>F?_(M='10!SG_"'>$?^A6\.?\ @CTS_P"1:/\ A#O"
M/_0K>'/_  1Z9_\ (M='10!SG_"'>$?^A6\.?^"/3/\ Y%H_X0[PC_T*WAS_
M ,$>F?\ R+71T4 <Y_PAWA'_ *%;PY_X(],_^1:/^$.\(_\ 0K>'/_!'IG_R
M+71T4 <Y_P (=X1_Z%;PY_X(],_^1:/^$.\(_P#0K>'/_!'IG_R+71T4 <Y_
MPAWA'_H5O#G_ ((],_\ D6C_ (0[PC_T*WAS_P $>F?_ "+71T4 <Y_PAWA'
M_H5O#G_@CTS_ .1:/^$.\(_]"MX<_P#!'IG_ ,BUT=% '.?\(=X1_P"A6\.?
M^"/3/_D6C_A#O"/_ $*WAS_P1Z9_\BUT=% '.?\ "'>$?^A6\.?^"/3/_D6C
M_A#O"/\ T*WAS_P1Z9_\BUT=% '.?\(=X1_Z%;PY_P""/3/_ )%H_P"$.\(_
M]"MX<_\ !'IG_P BUT=% '.?\(=X1_Z%;PY_X(],_P#D6C_A#O"/_0K>'/\
MP1Z9_P#(M='10!SG_"'>$?\ H5O#G_@CTS_Y%H_X0[PC_P!"MX<_\$>F?_(M
M='10!SG_  AWA'_H5O#G_@CTS_Y%H_X0[PC_ -"MX<_\$>F?_(M='10!SG_"
M'>$?^A6\.?\ @CTS_P"1:/\ A#O"/_0K>'/_  1Z9_\ (M='10!SG_"'>$?^
MA6\.?^"/3/\ Y%H_X0[PC_T*WAS_ ,$>F?\ R+71T4 <Y_PAWA'_ *%;PY_X
M(],_^1:/^$.\(_\ 0K>'/_!'IG_R+71T4 <Y_P (=X1_Z%;PY_X(],_^1:/^
M$.\(_P#0K>'/_!'IG_R+71T4 <Y_PAWA'_H5O#G_ ((],_\ D6C_ (0[PC_T
M*WAS_P $>F?_ "+71T4 <Y_PAWA'_H5O#G_@CTS_ .1:/^$.\(_]"MX<_P#!
M'IG_ ,BUT=% '.?\(=X1_P"A6\.?^"/3/_D6C_A#O"/_ $*WAS_P1Z9_\BUT
M=% '.?\ "'>$?^A6\.?^"/3/_D6C_A#O"/\ T*WAS_P1Z9_\BUT=% '.?\(=
MX1_Z%;PY_P""/3/_ )%H_P"$.\(_]"MX<_\ !'IG_P BUT=% '.?\(=X1_Z%
M;PY_X(],_P#D6C_A#O"/_0K>'/\ P1Z9_P#(M='10!SG_"'>$?\ H5O#G_@C
MTS_Y%H_X0[PC_P!"MX<_\$>F?_(M='10!SG_  AWA'_H5O#G_@CTS_Y%K'UO
MP?X2%C+CPOX=' Z:)I@]?^G6N[K&US_CQE^@_P#9J /!_#WA/PJ=7N0?#/A\
M@3@ '1M.P!M' 'V:O;5\'>$<#_BEO#G0?\P/3/3_ *]:\R\/?\ABY_Z[C_T$
M5[@O0?0?RH YW_A#O"/_ $*WAS_P1Z9_\BT?\(=X1_Z%;PY_X(],_P#D6NCH
MH YS_A#O"/\ T*WAS_P1Z9_\BT?\(=X1_P"A6\.?^"/3/_D6NCHH YS_ (0[
MPC_T*WAS_P $>F?_ "+1_P (=X1_Z%;PY_X(],_^1:Z.B@#G/^$.\(_]"MX<
M_P#!'IG_ ,BT?\(=X1_Z%;PY_P""/3/_ )%KHZ* .<_X0[PC_P!"MX<_\$>F
M?_(M'_"'>$?^A6\.?^"/3/\ Y%KHZ* .<_X0[PC_ -"MX<_\$>F?_(M'_"'>
M$?\ H5O#G_@CTS_Y%KHZ* .<_P"$.\(_]"MX<_\ !'IG_P BT?\ "'>$?^A6
M\.?^"/3/_D6NCHH YS_A#O"/_0K>'/\ P1Z9_P#(M'_"'>$?^A6\.?\ @CTS
M_P"1:Z.B@#G/^$.\(_\ 0K>'/_!'IG_R+1_PAWA'_H5O#G_@CTS_ .1:Z.B@
M#G/^$.\(_P#0K>'/_!'IG_R+1_PAWA'_ *%;PY_X(],_^1:Z.B@#G/\ A#O"
M/_0K>'/_  1Z9_\ (M'_  AWA'_H5O#G_@CTS_Y%KHZ* .<_X0[PC_T*WAS_
M ,$>F?\ R+1_PAWA'_H5O#G_ ((],_\ D6NCHH YS_A#O"/_ $*WAS_P1Z9_
M\BT?\(=X1_Z%;PY_X(],_P#D6NCHH YS_A#O"/\ T*WAS_P1Z9_\BT?\(=X1
M_P"A6\.?^"/3/_D6NCHH YS_ (0[PC_T*WAS_P $>F?_ "+1_P (=X1_Z%;P
MY_X(],_^1:Z.B@#G/^$.\(_]"MX<_P#!'IG_ ,BT?\(=X1_Z%;PY_P""/3/_
M )%KHZ* .<_X0[PC_P!"MX<_\$>F?_(M'_"'>$?^A6\.?^"/3/\ Y%KHZ* .
M<_X0[PC_ -"MX<_\$>F?_(M'_"'>$?\ H5O#G_@CTS_Y%KHZ* .<_P"$.\(_
M]"MX<_\ !'IG_P BT?\ "'>$?^A6\.?^"/3/_D6NCHH YS_A#O"/_0K>'/\
MP1Z9_P#(M'_"'>$?^A6\.?\ @CTS_P"1:Z.B@#G/^$.\(_\ 0K>'/_!'IG_R
M+1_PAWA'_H5O#G_@CTS_ .1:Z.B@#G/^$.\(_P#0K>'/_!'IG_R+1_PAWA'_
M *%;PY_X(],_^1:Z.B@#G/\ A#O"/_0K>'/_  1Z9_\ (M'_  AWA'_H5O#G
M_@CTS_Y%KHZ* .<_X0[PC_T*WAS_ ,$>F?\ R+1_PAWA'_H5O#G_ ((],_\
MD6NCHH YS_A#O"/_ $*WAS_P1Z9_\BT?\(=X1_Z%;PY_X(],_P#D6NCHH YS
M_A#O"/\ T*WAS_P1Z9_\BT?\(=X1_P"A6\.?^"/3/_D6NCHH YS_ (0[PC_T
M*WAS_P $>F?_ "+1_P (=X1_Z%;PY_X(],_^1:Z.B@#G/^$.\(_]"MX<_P#!
M'IG_ ,BT?\(=X1_Z%;PY_P""/3/_ )%KHZ* .<_X0[PC_P!"MX<_\$>F?_(M
M'_"'>$?^A6\.?^"/3/\ Y%KHZ* .<_X0[PC_ -"MX<_\$>F?_(M'_"'>$?\
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M]"MX<_\ !'IG_P BT?\ "'>$?^A6\.?^"/3/_D6NCHH YS_A#O"/_0K>'/\
MP1Z9_P#(M'_"'>$?^A6\.?\ @CTS_P"1:Z.B@#G/^$.\(_\ 0K>'/_!'IG_R
M+1_PAWA'_H5O#G_@CTS_ .1:Z.B@#G/^$.\(_P#0K>'/_!'IG_R+1_PAWA'_
M *%;PY_X(],_^1:Z.B@#G/\ A#O"/_0K>'/_  1Z9_\ (M'_  AWA'_H5O#G
M_@CTS_Y%KHZ* .<_X0[PC_T*WAS_ ,$>F?\ R+1_PAWA'_H5O#G_ ((],_\
MD6NCHH YS_A#O"/_ $*WAS_P1Z9_\BT?\(=X1_Z%;PY_X(],_P#D6NCHH YS
M_A#O"/\ T*WAS_P1Z9_\BT?\(=X1_P"A6\.?^"/3/_D6NCHH YS_ (0[PC_T
M*WAS_P $>F?_ "+1_P (=X1_Z%;PY_X(],_^1:Z.B@#G/^$.\(_]"MX<_P#!
M'IG_ ,BT?\(=X1_Z%;PY_P""/3/_ )%KHZ* .<_X0[PC_P!"MX<_\$>F?_(M
M'_"'>$?^A6\.?^"/3/\ Y%KHZ* .<_X0[PC_ -"MX<_\$>F?_(M'_"'>$?\
MH5O#G_@CTS_Y%KHZ* .<_P"$.\(_]"MX<_\ !'IG_P BT?\ "'>$?^A6\.?^
M"/3/_D6NCHH YS_A#O"/_0K>'/\ P1Z9_P#(M'_"'>$?^A6\.?\ @CTS_P"1
M:Z.B@#G/^$.\(_\ 0K>'/_!'IG_R+1_PAWA'_H5O#G_@CTS_ .1:Z.B@#G/^
M$.\(_P#0K>'/_!'IG_R+7+^*?"'A-=/FV^%_#H_=-TT331V/I;5Z77+>*_\
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M]"MX<_\ !'IG_P BUT=% '.?\(=X1_Z%;PY_X(],_P#D6C_A#O"/_0K>'/\
MP1Z9_P#(M='10!SG_"'>$?\ H5O#G_@CTS_Y%H_X0[PC_P!"MX<_\$>F?_(M
M='10!SG_  AWA'_H5O#G_@CTS_Y%H_X0[PC_ -"MX<_\$>F?_(M='10!SG_"
M'>$?^A6\.?\ @CTS_P"1:/\ A#O"/_0K>'/_  1Z9_\ (M='10!SG_"'>$?^
MA6\.?^"/3/\ Y%H_X0[PC_T*WAS_ ,$>F?\ R+71T4 <Y_PAWA'_ *%;PY_X
M(],_^1:/^$.\(_\ 0K>'/_!'IG_R+71T4 <Y_P (=X1_Z%;PY_X(],_^1:/^
M$.\(_P#0K>'/_!'IG_R+71T4 <Y_PAWA'_H5O#G_ ((],_\ D6K%OX:\.6C^
M9:>']$M9!T>WTJPA?CD?-' K<'GK6W10 @         &  .  !P !T%+110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !7$>-_^/&/ZG^E=O7$>-_^/&/ZG^E
M'.^!/O?]M6_]#->LUY-X$^]_VU;_ -#->LT >#^+/^0G#_US'\DKV#0/^039
M_P#7,5X_XL_Y"</_ %S'\DKV#0/^039_]<Q0!L4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9NK?\>,OX?R-
M:59NK?\ 'C+^'\C0!X[HO_(9N?\ KX7_ -!2O;H/]4O^?2O$=%_Y#-S_ -?"
M_P#H*5[=!_JE_P ^E $U%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0!S_ (A_X\9?\_P&O,?"W_(3N?\ KL/Y)7IWB'_CQE_S_ :\Q\+?\A.Y_P"N
MP_DE 'MJ]!]!_*EI%Z#Z#^5+0 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5C:Y_QXR_0?^S5LUC:Y_QXR_0?^S4 >3^'O^0Q
M<_\ 7<?^@BO<%Z#Z#^5>'^'O^0Q<_P#7<?\ H(KW!>@^@_E0 M%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5SWB
M7_D&3_[A_K70USWB7_D&3_[A_K0!YAX4_P"0E)_P'^8KVY/N+_NK_(5XCX4_
MY"4G_ ?YBO;D^XO^ZO\ (4 .HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "N6\5_\@Z;_KD_\FKJ:Y;Q7_R#IO\
MKD_\FH \^^'W_'^/]U_ZU[57BOP^_P"/\?[K_P!:]JH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KB/&__'C'
M]3_2NWKB/&__ !XQ_4_TH YWP)][_MJW_H9KUFO)O GWO^VK?^AFO6: /!_%
MG_(3A_ZYC^25[!H'_()L_P#KF*\?\6?\A.'_ *YC^25[!H'_ "";/_KF* -B
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ K-U;_CQE_#^1K2K-U;_ (\9?P_D: /'=%_Y#-S_ -?"_P#H*5[=
M!_JE_P ^E>(Z+_R&;G_KX7_T%*]N@_U2_P"?2@":BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH Y_Q#_QXR_Y_@->8^%O^0G<_P#78?R2O3O$/_'C
M+_G^ UYCX6_Y"=S_ -=A_)* /;5Z#Z#^5+2+T'T'\J6@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K&US_CQE^@_]FK9K&US
M_CQE^@_]FH \G\/?\ABY_P"NX_\ 017N"]!]!_*O#_#W_(8N?^NX_P#017N"
M]!]!_*@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ KGO$O_(,G_P!P_P!:Z&N>\2_\@R?_ '#_ %H \P\*?\A*
M3_@/\Q7MR?<7_=7^0KQ'PI_R$I/^ _S%>W)]Q?\ =7^0H =1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<MXK_Y
M!TW_ %R?^35U-<MXK_Y!TW_7)_Y-0!Y]\/O^/\?[K_UKVJO%?A]_Q_C_ '7_
M *U[50 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !7$>-_^/&/ZG^E=O7$>-_\ CQC^I_I0!SO@3[W_ &U;_P!#
M->LUY-X$^]_VU;_T,UZS0!X/XL_Y"</_ %S'\DKV#0/^039_]<Q7C_BS_D)P
M_P#7,?R2O8- _P"039_]<Q0!L4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %9NK?\>,OX?R-:59NK?\>,OX?R
M- 'CNB_\AFY_Z^%_]!2O;H/]4O\ GTKQ'1?^0S<_]?"_^@I7MT'^J7_/I0!-
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 <_XA_X\9?\_P !KS'P
MM_R$[G_KL/Y)7IWB'_CQE_S_  &O,?"W_(3N?^NP_DE 'MJ]!]!_*EI%Z#Z#
M^5+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 5C:Y_QXR_0?^S5LUC:Y_P >,OT'_LU 'D_A[_D,7/\ UW'_ *"*]P7H/H/Y
M5X?X>_Y#%S_UW'_H(KW!>@^@_E0 M%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 5SWB7_D&3_P"X?ZUT-<]XE_Y!
MD_\ N'^M 'F'A3_D)2?\!_F*]N3[B_[J_P A7B/A3_D)2?\  ?YBO;D^XO\
MNK_(4 .HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "N6\5_\@Z;_ *Y/_)JZFN6\5_\ (.F_ZY/_ ":@#S[X??\
M'^/]U_ZU[57BOP^_X_Q_NO\ UKVJ@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "N(\;_\ 'C']3_2NWKB/&_\
MQXQ_4_TH YWP)][_ +:M_P"AFO6:\F\"?>_[:M_Z&:]9H \'\6?\A.'_ *YC
M^25[!H'_ "";/_KF*\?\6?\ (3A_ZYC^25[!H'_()L_^N8H V**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L
MW5O^/&7\/Y&M*LW5O^/&7\/Y&@#QW1?^0S<_]?"_^@I7MT'^J7_/I7B.B_\
M(9N?^OA?_04KVZ#_ %2_Y]* )J*** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^;W_  \4\'?]"O?_ /D2C_AXIX._Z%>__P#(E 'Z0T5^;W_#Q3P=_P!"O?\
M_D2C_AXIX._Z%>__ /(E 'Z0T5^;W_#Q3P=_T*]__P"1*/\ AXIX._Z%>_\
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M_-[_ (>*>#O^A7O_ /R)1_P\4\'?]"O?_P#D2@#](:*_-[_AXIX._P"A7O\
M_P B4?\ #Q3P=_T*]_\ ^1* /TAHK\WO^'BG@[_H5[__ ,B4?\/%/!W_ $*]
M_P#^1* /TAHK\WO^'BG@[_H5[_\ \B4?\/%/!W_0KW__ )$H _2&BOS>_P"'
MBG@[_H5[_P#\B4?\/%/!W_0KW_\ Y$H _2&BOS>_X>*>#O\ H5[_ /\ (E'_
M  \4\'?]"O?_ /D2@#](:*_-[_AXIX._Z%>__P#(E'_#Q3P=_P!"O?\ _D2@
M#](:*_-[_AXIX._Z%>__ /(E'_#Q3P=_T*]__P"1* /TAHK\WO\ AXIX._Z%
M>_\ _(E'_#Q3P=_T*]__ .1* /TAHK\WO^'BG@[_ *%>_P#_ ")1_P /%/!W
M_0KW_P#Y$H _2&BOS>_X>*>#O^A7O_\ R)1_P\4\'?\ 0KW_ /Y$H _2&BOS
M>_X>*>#O^A7O_P#R)1_P\4\'?]"O?_\ D2@#](:*_-[_ (>*>#O^A7O_ /R)
M1_P\4\'?]"O?_P#D2@#](:*_-[_AXIX._P"A7O\ _P B4?\ #Q3P=_T*]_\
M^1* /TAHK\WO^'BG@[_H5[__ ,B4?\/%/!W_ $*]_P#^1* /TAHK\WO^'BG@
M[_H5[_\ \B4?\/%/!W_0KW__ )$H _2&BOS>_P"'BG@[_H5[_P#\B4?\/%/!
MW_0KW_\ Y$H _2&BOS>_X>*>#O\ H5[_ /\ (E'_  \4\'?]"O?_ /D2@#](
M:*_-[_AXIX._Z%>__P#(E'_#Q3P=_P!"O?\ _D2@#](:*_-[_AXIX._Z%>__
M /(E'_#Q3P=_T*]__P"1* /TAHK\WO\ AXIX._Z%>_\ _(E'_#Q3P=_T*]__
M .1* /TAHK\WO^'BG@[_ *%>_P#_ ")1_P /%/!W_0KW_P#Y$H _2&N>\2_\
M@R?_ '#_ %K\_P#_ (>*>#O^A7O_ /R)61K7_!0OPA=V<L*^&+Y2ZD GS?\
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M>#O^A7O_ /R)1_P\4\'?]"O?_P#D2@#](:*_-[_AXIX._P"A7O\ _P B4?\
M#Q3P=_T*]_\ ^1* /TAHK\WO^'BG@[_H5[__ ,B4?\/%/!W_ $*]_P#^1* /
MTAHK\WO^'BG@[_H5[_\ \B4?\/%/!W_0KW__ )$H _2&BOS>_P"'BG@[_H5[
M_P#\B4?\/%/!W_0KW_\ Y$H _2&BOS>_X>*>#O\ H5[_ /\ (E'_  \4\'?]
M"O?_ /D2@#](:*_-[_AXIX._Z%>__P#(E'_#Q3P=_P!"O?\ _D2@#](:*_-[
M_AXIX._Z%>__ /(E'_#Q3P=_T*]__P"1* /TAHK\WO\ AXIX._Z%>_\ _(E'
M_#Q3P=_T*]__ .1* /TAHK\WO^'BG@[_ *%>_P#_ ")1_P /%/!W_0KW_P#Y
M$H _2&BOS>_X>*>#O^A7O_\ R)1_P\4\'?\ 0KW_ /Y$H _2&BOS>_X>*>#O
M^A7O_P#R)1_P\4\'?]"O?_\ D2@#](:*_-[_ (>*>#O^A7O_ /R)1_P\4\'?
M]"O?_P#D2@#](:*^0?A7^UUX5^)U^UA;Z>^FS>8L:"X=E,C,%(VAP"?O=N>#
MQ7UZK!@&!!! /'/49H 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "N6\5_P#(.F_ZY/\ R:NI
MKEO%?_(.F_ZY/_)J //OA]_Q_C_=?^M>U5XK\/O^/\?[K_UKVJ@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 451U+4[#1[*?4=3N8[.RMEWSW,Q(CB3^\Q )
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M]RTVCNBW'DPQQ2D$R1N N$;/U/X 'Z!I-#+_ *J:*3M\DB/SZ?*34M?RX_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ K-U;_ (\9?P_D:TJS=6_X\9?P_D: /'=%_P"0S<_]?"_^@I7M
MT'^J7_/I7B.B_P#(9N?^OA?_ $%*]N@_U2_Y]* )J*** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBJEW?6EA'YMY<1V\8!.^0D# ZG@'I0!;HK%T_
MQ%HNJMMT_4;>Z;<5VQ,2=P.".5'?BMJ@ HHHH **** "BBB@ HHHH ***H7V
MJ:?ID9EO[J*V0#<6D) QSSP#Z4 7Z*R=.UW2-74-IM_!=@C(,18\=>ZCMS6M
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %4-5_Y!M__P!>EQ_Z*:K]4-5_Y!M__P!>EQ_Z*:@#^>S]
MKC_DIZ_]<;C_ -"MZ^9+'_6O]/Z"OIO]KC_DIZ_]<;C_ -"MZ^9+'_6O]/Z"
M@#=HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *AG_ -4W^?6IJAG_ -4W^?6@#'M?]<W^]_05O5@VO^N;_>_H*WJ "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M2X2[MH+J(AHYXDE1EZ%7&01[58H **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KEO%?_(.F_P"N3_R:
MNIKEO%?_ "#IO^N3_P FH \^^'W_ !_C_=?^M>U5XK\/O^/\?[K_ -:]JH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZW#Y]P[W,8C;6,QCYR5 $<> ,C &.10!^<7P;\/ZSX)^/GPV@NY-MS%XI@3
M#*5<07'52Q(X'0D=J_T+?V;;^YU'X7Z+<W3^9*\:Y;G_ )XPGN3ZU_##\5=#
MM_#?[;MCH=J MOIOQ)%O$ -H"K8R-@*.G+'BO[DOV7O^24:'_P!<T_\ 1$%
M'T5102!R:^?/B+^U%\%OA2\\?CCQ;;Z.UL6$PE$?R;<[L[IDZ8- 'T'17YW/
M_P %4?V)(W:-_B_IP=6*$;;?AE.TC_C\['BO5? O[=/[-'Q(O[33/"'Q"L]4
MO+Z58;:*-8@9)&!8*-MPYZ#/0T ?7E!S@XZ]JCBE29!)&=R-T/KP#_6I* /X
M[?\ @K'J?QMM?BI>)HUIK-YIC:\!IXL-)U.Z6/\ >O@LUN'7;T/0#!].3^PO
M_!'5_'LW[/%O)XXCNXM0_M0?N[RTN;241$7&W]W<GS.!MR2,=,]J^O\ XX_'
MS]D?X97L,?QDG\*6][/="&%M6TC3[N1KDL0 &N6!W;NXYKV/X)_$7X0?$;PP
MNL_!^72IO#K2A%;2K2WM(/,.['[NW)3.%;GKZ4 >UT45@^(?$NC^%K!]3UNZ
M6TLXUD=Y6Q@+$N]SR1T7GK0!O45\)^*O^"D?[(7@S4'TOQ#\4K"QO8W>-X76
M$D-&=KCFZ4\$8Z5GZ/\ \%./V-->N!:Z9\6-/N9F8*$58/O'H.+LT ??E%><
M> /BQX&^)VGQZIX-UF/5K*4A4FC"X)()'W7<=!ZUZ/0 45YI\3_B[X#^#NAK
MXB^(&M1:'I+NT:W4H4J739N'S.@R/,3OW%>:?"O]KKX#_&A9W^'?C2VUU;:Z
MDLIC$(QLN(I'B>,[9I.0\;#\* /I:BOC#XA?\% /V6?A=JMQHOC7XD66D:C:
M3&">"18<I*.JG=<H?T_2O0/@_P#M8_ SX[-$OPR\96WB$S9\OR1&-V.OW)I.
MF#GZ4 ?1]%'6B@ K^//_ (+>W=_JGB;PYIIEX_MB2*$<X4LUS[].OM^%?V&5
M_'C_ ,%HO^1]\+_]AYOYW5 'Q3^SK_P2/_:(_:4\$6GCOP5J^@6^DWDGEQI>
MO&)0=F_G=J4!Z8_A[U[[=_\ ! G]KJQ@DNGU[PJRQ#<0KPEC] -8)/X"OWO_
M ."/O_)LF@_]?7_MNM?KLRJZE74,IZJP!!^H/% '\#_B/X3?MB_L+7SW.EW\
MHELW6%I]+TW4+A%$9V[M]I=2 *H)))8@#//6OTJ_X)\?\%??&^K^*])^'OQ\
M\07FH:A<W;1K+(+FTMX[6WN%@$<CW;3HC*DD8(:1<;3D<<?TP_$7X/>!OB)H
M.JZ1K7AS1;EM0L+RU-S/IMM--&US \0D1V3<'0MN5@<@@$<BOXH?^"F7[%-Y
M^RW\4)]9\"2ZBFD3P7>KRZE"\UJ]I-=O!>>3$R,2B*99 H5@,(,#@  ']R'A
M/Q5I7C'0]/U[2+B*>SU& 7$)CFCF^0D@$M&<'IUP*Z6OP'_X(Z?M=CXG>$)O
M FO:GYMUX4TRWLHFEE\V:60FW?\ >,Q+EOWYY.?3U%?ONI# ,#D$ @^QH 6B
MJE]?6VFVLMY>2"*WA7=)(>BCUY(_G7R'\0?V]OV8/A=>RZ?XT^(MEI%U!)Y4
MD<@ARK[BN#NN4[CTH ^QZ*_/O3/^"H7[%VKWD=C8?%K3I[F7[D86#)Y _P"?
ML]R*^P_ ?Q0\%_$JQ34O!^KQ:K:/$)EECVX,;$ -\KOZCOWH ]!HHKP;XP?M
M*_![X$",_$WQ3!X>$L/GIYPC.Z/;NW#?+'VH ]YHKR;X=_&[X<?%3PY%XK\$
MZ_#J^AS6S7<=Y&%"M B!V?Y9'& IR?FZ5X;\1/V^_P!ESX5ZJ^C>-_B-9:/J
M"!F:"40D@*0&ZW*=,CMWH ^RZ*^&/"7_  4>_9%\<7\>F>&_BA8:A>2RB&.)
M%@RTC#<%XNFYQSTK[,T#Q%I/B;3XM4T:Z6[LIN8YEQAN W&"1T(/6@#;HHKY
M.^(/[;?[./PO\2)X2\:>/;32==DO([!+*18MQNI',:1_-<(<EAC[OX4 ?6-%
M>*ZI^T'\*M'\(/XZO_$L$'AF-4=M1(38%DC,J'F4#YD!8?-VKYN@_P""F_[&
MMQK</AZ+XKZ>^JSW'V6.V"P9:?;NV?\ 'WG.!GIGVH ^^Z*Y7P?XT\.^.]&M
MM?\ #-\FHZ7=C,%R@&U_E5OX68?=<'K6[J.HVFE6DM[>RB&VA&9)#T4<GN1Z
M'O0!=HKXS\??M^_LM_#*^ET[QE\1[+2;N&4PR12"'*R D;?FN4/;TKB=*_X*
M?_L8:U>QZ?IWQ9T^XNI<;(U6#))(4#B[)SD@=* /T"HK@O WQ+\'?$:P34_"
M6JQZG9O&LJRIM */@*?E=AR2.]=[0 45DZWKFF^'=.GU75K@6UC;#,TS8P@P
M3DY([*>]?''C'_@HC^R=X#O9=/\ $_Q-L=.NH9#')&ZP$JXZCFZ7T]* /MVB
MOBKP+_P4'_94^)&I1:3X0^)-EJM].0(H(UAW-D[1C;<OU/'3ZU]D:?J%IJEG
M;W]E*)K:ZB6:&08P\;9PPP3P<'O0!=HJ.:5((99Y3MCAC>61O[J1J7<_@JDU
M\H_$3]MS]G#X67$MKXV\?6>D3P[O,201979][.ZX3IWH ^LJ*^!]!_X*9_L<
M>);^'3-'^*VGW5Y<2K#%$JP9:1_NKQ=GK[ _RK[0\*>,?#_C73(M7\.WR7UA
M, 8YUP VY0PZ,PY!SUH \#_;#C\4R? 3X@#PJ[+J7]C/]G"1R2R&3</NQQLK
ML?IZ_G_&K\#S^T?=_M'1V#6NMPS0:MI#WMW-HNKQVTD'V]_,"2OMC^ZK\[V
MW#(ZY_NI\7ZOX>T'P]J6J^*FMTT&S@,NH-=1I+ (0<$R(^$89_O$"OB'PO\
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MO4?SK^/O_@C;^UKJ?A;QKI7P9\2ZO-+%)>S.S7MRT\R>7<F$(/-8MM428 !
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M'"#Y;ISR?:OM*SO+>_MXKJU<2031I+&XZ,DBAT/4]5(/XT 6J*** "OY:?\
M@M%^T5:^++SP]\*-+FF^W6>NC3YXRS,C>?.R[0H"]>A!)[U_3KXIUM?#VB7F
MK/M"VR[B6Q@<$]_I7\*_[9GBC4_B7^VY'91)Y]HGQ TS<@;**C739PH& ,=1
MW_*@#^@/_@CM\#?^$"^#]GJ-_:".]FU'[4K[ AVS^=+T.3@[QR#C\C7[B@
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M( %*S1+(N,$CD'- '1T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M (*G?M[^"-6MY_B;J_B:_P!)$L*SBW\/^(E&WS!YGS-+<+]P]U[]QQ7[A_\
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MT8 CZ$9%> _&SXF_ WX<V"7?Q@DT2&R:%I$;5K&UNT\H;BQ"W) QE6XZ<$4
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M2Q_UK_3^@H W:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "H9_P#5-_GUJ:H9_P#5-_GUH Q[7_7-_O?T%;U8-K_KF_WO
MZ"MZ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "JMW_JOSJU56[_U7YT 9=C_KI/\ ='\JWJP;'_72?[H_E6]0
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %;_AK6KC0M6M;Z!RAC
MG@8D9R DH8]".V?Z^M8%*#@@CL<_E0!_05^S;\4(?B#X1B+7(:738(+4K(X#
MDH-AVJV&/3MD5]*U^%'[*OQ8N/"?BK3M(NK@Q:=>7>;AFD. NX=CC(Y/&<9]
M*_<?2]3M-7LH;^RE$UM.,QR#HPXY_6@#0HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N6\5_P#(.F_Z
MY/\ R:NIKEO%?_(.F_ZY/_)J //OA]_Q_C_=?^M>U5XK\/O^/\?[K_UKVJ@
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M9>_Y)1H?_7-/_1$%?Q&_'[_D_P!G_P"RI'_TWM7]N7[+W_)*-#_ZYI_Z(@H
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MO$(DGTV:6PE9Y3,YD"916!SP, 5^VWQC\4'P3\/M8U^$K$;%%VD *JC9*0
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MX)3^&K3QGXLNO#NH1)/;7.OZNS1R?=)_M&Y4=>/XL'\?Q_=__@H]_P D:O\
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M;!7XW^"(++7M2^TZU86-M;W'VB;]\;DM'ORC,2&P^".O?C-='_P51_Y(./\
MKZO/_0;.OP2_X))ZWJVD_'7QMH0FD%I#XN-JD1EDVA%%H<!<[0/;&#UK][_^
M"J(_XL*I];N]_P#0;3_#]: /R9_X(N?\C#J__8Y:G_Z=;JOZJ*_E7_X(N?\
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M!,G*.EYM/7/W?\10!^</_!$__C^?_L9=1_\ 3G=5_1)\>@6^$OCH#OH,X_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !4,_P#JF_SZU-4,_P#JF_SZ
MT 8]K_KF_P![^@K>K!M?]<W^]_05O4 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_DE>P:!_R";/_KF*\?\ %G_(3A_ZYC^25[!H'_()L_\ KF* -BBBB@ HHHH
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M-3[H_'^9IU !1110 5_'C_P6B_Y'WPO_ -AYOYW5?V'5_'A_P6C(7QYX7+$
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MMQJGC30)7-[;W$$FX:K&PW+<*KCE^_.?R/\ H%?LQ?\ )*/#'_8"T'_TV0T
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M]=K#_P!.5S7]PWP;_P"2?^&/^P'IG_I.M 'JE%%% !1110!\+?\ !1+21?\
M[+GQ'D,FS;8 8_[87/L>N*_D/_X)XZH?#?[2^LQ"/S_M&J6$1/3;N8#/5>__
M .HU_9[^V#X>/BGX!>-M%$1G-W:A1&JERW[J<?= )/WJ_B3^%MW-\)?VMSIZ
M9LO/\5Z;:LC@QD@S;=N"%],=,\8QWH _O@\'3?:/#^F2XV[K&R./3-M&?ZUU
M%>;_  JU)=4\&:+=*VX/ING$GKRUG$3W/7K7I% '\T/_  7 _P"163_L8D_]
M*[*NI_X(:_\ ).M=_P"P^W_I1=5RW_!<#_D5D_[&)/\ TKLJZG_@AK_R3K7?
M^P^W_I1=4 ?M%^U-\+]+^)?PD\865]8P7MS;>'M0:Q25"[B<QDKY>.C9/&:_
MB8^#NLZ_^RO^UXESKDMUH.F17ER!%<,(H=LFI_*<#G[K+CVQFO[[[^TCOK.Y
MLY5W1W,31.O'*L,$<\5_&]_P6E^!<_A[XK:CXNTNPDBT^&W203+"S(LRO'*#
MYJJJ?>&<9SQG- 'ZG?MY_MBZ9X>_9CTJPTV\AO9/&W@I)#+',0RL[3-D99,G
M,(Y^;\:_-7_@C;^S?<>+OBA-\8]6>2YM-9T=#%#<)OC22&&\G!5E3[P-PO\
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M_P#"+_D2M*_Z][?_ -)XJ].KP3X3>/\ P)%X+TM)/&OA*-A;V^5?Q)HR,/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !6;JW_ !XR_A_(UI5FZM_QXR_A
M_(T >.Z+_P AFY_Z^%_]!2O;H/\ 5+_GTKQ'1?\ D,W/_7PO_H*5[=!_JE_S
MZ4 34444 %%%% !1110!^=?_  4>_P"2-7__ &#=2_\ 1=?AY_P1\_Y*8/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5#/_ *IO\^M35#/_ *IO\^M &/:_
MZYO][^@K>K!M?]<W^]_05O4 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[X'_ !(^"'P2N?#?Q(T&30=7?58IUM92Y8QJUX2WSQ1'I(A^[CYAS7ZH444
M?D)_P5/_ &.M6_:)^%5S'X)T+^U/%4M^9L6\16X9$,++F6-'D*Y5N,8[]Z_)
MO_@G3_P3-^-7PY^+FE^+/BAX&N-(M-$UII+:2X621)+82(%=O-@0<JI/?ZU_
M6_10!4L;."PMH[6WC2**,85(U"*OT5>!]!Q_.G7B-);3(@RS(P ]RIJS10!_
M&W\8_P#@GK^U7XA_;'F^(6E?#B[N?"I^()U8:D&N-AL?L1C\X 6C+C>0/OX]
MZ_JW^ 'AO5_"OPZTG2-;M3:7]NBB6%B25(BB7N%/53VKVVB@#Q+X^? _PU\?
M/AWK_P /O$@$-IKMM]GEO(X@]Q"NUUS$X*.#ANBN.F*_E"_:'_X)#_'/X5^*
M[N^_9WM?%.J0B\79<6=_J-DTL*,V"S0&7(*]B3^-?V544 ?Q":3^QA_P4HU]
MH] UW0_'6FZ5)M22]B\1:V)41?D #+"A VDD_-CBOL _\$<_%R_"?Q-J^H3>
M)=?\>WFAFXM+#5;J^O'_ +3,L*^4LEQ)*P)C#$D)GGH<U_5W10!_,3_P20_8
MN_:%^ GQ3DUKXF^![GP_IG]D_9UN)3,09/*O%VCS+:(=9%[]#7].40*Q1J1@
MA0"/?%.=UC1I'8*B*SNQ. JJ"S,3V  ))]!7D/B;X]_"'PD98M;^(7A;3[N/
M(-K=ZG%%-E>&&P\Y!ZCK0!_+;_P6S_Y&G0?^QDB_]*6K]8?^"-'_ ";9:?\
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MPCFNXI2#))&LT[32!0[D'##)4<<#'Z%44 10PQ6\:PP1I%$@VI'&JHBCT"J
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M!X%_98\%:5I.E6T=UJ=G$8Y-1N[1#?R*843#W,A>9@#N(!8X);OQ7W_10 @
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M$_A_JTUGX,TKQWK6EQS3>3+<>(=;(,:2$0@!HY0 5/'.!C@$=/[;Z* /XCO
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MI9?\$_?^"E]S>P6M]IGQ$6QD?;,Q\3:^0(^^5V8QTQ[CBO[SJ* /Y3_V8O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZ)9R7+:8^BW"W$=S968AGF96W 2212QN>?5C^E?J[10!\_?L_P#[/^@?L_\
MA*+PEH%_=7]I%()%EN2Y?(#*!\\DAQACW_QK@_VI/V0O"'[4FC1:-XIU:^TR
M&.V>V#V9D#%7\PD_NY8CD>8>_;\OKVB@#XC_ &2_V(_!/[)FD6>D>$]:U#58
M;.V:V1[TREF5HA$2?,GF/09ZY]Z^W*** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JAJO_ "#;_P#Z
M]+C_ -%-5^J&J_\ (-O_ /KTN/\ T4U '\]G[7'_ "4]?^N-Q_Z%;U\R6/\
MK7^G]!7TW^UQ_P E/7_KC<?^A6]?,EC_ *U_I_04 ;M%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4,_^J;_/K4U0S_ZI
MO\^M &/:_P"N;_>_H*WJP;7_ %S?[W]!6]0 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !56[_U7YU:JK=_ZK\Z
M ,NQ_P!=)_NC^5;U8-C_ *Z3_='\JWJ "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHIR*7=4 )+,J@#J<D#^M '6>"/#-UXK\06&D6D1EEN9/+
M55SDDD XQ]:_?KX"?#NW\#^"])B>V6#4?L^RX_=A7^ZH^9L!CWZ_UX^"OV,O
M@P=4G3Q9>PB-M-N5=%E0*S!G&"N1GH.QQVZU^M4<:1*$0;5'0"@!]%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 5RWBO_D'3?]<G_DU=37+>*_\ D'3?]<G_ )-0!Y]\/O\ C_'^Z_\
M6O:J\5^'W_'^/]U_ZU[50 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !7$>-_\ CQC^I_I7;UQ'C?\ X\8_J?Z4
M <[X$^]_VU;_ -#->LUY-X$^]_VU;_T,UZS0!X/XL_Y"</\ US'\DKV#0/\
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MK]I** /QU_X)D?LB?%S]FS0X;+XDZ=!8SIIOV<B$R$>9Y2KCYU4]1Z5^Q(X
M^@I:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "LW5O^/&7\/Y&M*LW5O^/&7\/Y&@#QW1
M?^0S<_\ 7PO_ *"E>W0?ZI?\^E>(Z+_R&;G_ *^%_P#04KVZ#_5+_GTH FHH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !4,_\ JF_SZU-4,_\ JF_SZT 8]K_KF_WO
MZ"MZL&U_US?[W]!6]0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "N(\;_ /'C']3_ $KMZXCQO_QXQ_4_
MTH YWP)][_MJW_H9KUFO)O GWO\ MJW_ *&:]9H \'\6?\A.'_KF/Y)7L&@?
M\@FS_P"N8KQ_Q9_R$X?^N8_DE>P:!_R";/\ ZYB@#8HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *S=6_X\9?
MP_D:TJS=6_X\9?P_D: /'=%_Y#-S_P!?"_\ H*5[=!_JE_SZ5XCHO_(9N?\
MKX7_ -!2O;H/]4O^?2@":BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P#QJC_A#_"G_0N:)_X++/\ ^-4 ?S.?\(WXB_Z &M?^"N^_^,4?\(WXB_Z
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M^%/^A<T3_P %EG_\:H_X0_PI_P!"YHG_ (++/_XU0!_,Y_PC?B+_ * &M?\
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MB?\ @LL__C5'_"'^%/\ H7-$_P#!99__ !J@#^9S_A&_$7_0 UK_ ,%=]_\
M&*/^$;\1?] #6O\ P5WW_P 8K^F/_A#_  I_T+FB?^"RS_\ C5'_  A_A3_H
M7-$_\%EG_P#&J /YG/\ A&_$7_0 UK_P5WW_ ,8H_P"$;\1?] #6O_!7??\
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M UK_ ,%=]_\ &*/^$;\1?] #6O\ P5WW_P 8K^F/_A#_  I_T+FB?^"RS_\
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MB?\ @LL__C5'_"'^%/\ H7-$_P#!99__ !J@#^9S_A&_$7_0 UK_ ,%=]_\
M&*/^$;\1?] #6O\ P5WW_P 8K^F/_A#_  I_T+FB?^"RS_\ C5'_  A_A3_H
M7-$_\%EG_P#&J /YG/\ A&_$7_0 UK_P5WW_ ,8H_P"$;\1?] #6O_!7??\
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M UK_ ,%=]_\ &*/^$;\1?] #6O\ P5WW_P 8K^F/_A#_  I_T+FB?^"RS_\
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MN:)_X++/_P"-4?\ "'^%/^A<T3_P66?_ ,:H _F<_P"$;\1?] #6O_!7??\
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M/^$;\1?] #6O_!7??_&*_IC_ .$/\*?]"YHG_@LL_P#XU1_PA_A3_H7-$_\
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M] #6O_!7??\ QBC_ (1OQ%_T -:_\%=]_P#&*_IC_P"$/\*?]"YHG_@LL_\
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M HHHH **** "BBB@ HHHH *Y;Q7_ ,@Z;_KD_P#)JZFN6\5_\@Z;_KD_\FH
M\^^'W_'^/]U_ZU[57BOP^_X_Q_NO_6O:J "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ K-U;_CQE_#^1K2K-U;_CQE_#^1H \=T7_D,W/_ %\+_P"@I7MT'^J7_/I7
MB.B_\AFY_P"OA?\ T%*]N@_U2_Y]* )J*** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@#G_ !#_ ,>,O^?X#7F/A;_D)W/_ %V'\DKT[Q#_ ,>,O^?X
M#7F/A;_D)W/_ %V'\DH ]M7H/H/Y4M(O0?0?RI: "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "L;7/^/&7Z#_ -FK9K&US_CQ
ME^@_]FH \G\/?\ABY_Z[C_T$5[@O0?0?RKP_P]_R&+G_ *[C_P!!%>X+T'T'
M\J %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MCPK_ -_Y?_C5?YVM% '^B5_PWI^R7_T6CPK_ -_Y?_C5'_#>G[)?_1:/"O\
MW_E_^-5_G:T4 ?Z)7_#>G[)?_1:/"O\ W_E_^-4?\-Z?LE_]%H\*_P#?^7_X
MU7^=K10!_HE?\-Z?LE_]%H\*_P#?^7_XU1_PWI^R7_T6CPK_ -_Y?_C5?YVM
M% '^B5_PWI^R7_T6CPK_ -_Y?_C5'_#>G[)?_1:/"O\ W_E_^-5_G:T4 ?Z)
M7_#>G[)?_1:/"O\ W_E_^-4?\-Z?LE_]%H\*_P#?^7_XU7^=K10!_HE?\-Z?
MLE_]%H\*_P#?^7_XU1_PWI^R7_T6CPK_ -_Y?_C5?YVM% '^B5_PWI^R7_T6
MCPK_ -_Y?_C5'_#>G[)?_1:/"O\ W_E_^-5_G:T4 ?Z)7_#>G[)?_1:/"O\
MW_E_^-4?\-Z?LE_]%H\*_P#?^7_XU7^=K10!_HE?\-Z?LE_]%H\*_P#?^7_X
MU1_PWI^R7_T6CPK_ -_Y?_C5?YVM% '^B5_PWI^R7_T6CPK_ -_Y?_C5'_#>
MG[)?_1:/"O\ W_E_^-5_G:T4 ?Z)7_#>G[)?_1:/"O\ W_E_^-4?\-Z?LE_]
M%H\*_P#?^7_XU7^=K10!_HE?\-Z?LE_]%H\*_P#?^7_XU1_PWI^R7_T6CPK_
M -_Y?_C5?YVM% '^B5_PWI^R7_T6CPK_ -_Y?_C5'_#>G[)?_1:/"O\ W_E_
M^-5_G:T4 ?Z)7_#>G[)?_1:/"O\ W_E_^-4?\-Z?LE_]%H\*_P#?^7_XU7^=
MK10!_HE?\-Z?LE_]%H\*_P#?^7_XU1_PWI^R7_T6CPK_ -_Y?_C5?YVM% '^
MB5_PWI^R7_T6CPK_ -_Y?_C5'_#>G[)?_1:/"O\ W_E_^-5_G:T4 ?Z)7_#>
MG[)?_1:/"O\ W_E_^-4?\-Z?LE_]%H\*_P#?^7_XU7^=K10!_HE?\-Z?LE_]
M%H\*_P#?^7_XU1_PWI^R7_T6CPK_ -_Y?_C5?YVM% '^B5_PWI^R7_T6CPK_
M -_Y?_C5'_#>G[)?_1:/"O\ W_E_^-5_G:T4 ?Z)7_#>G[)?_1:/"O\ W_E_
M^-4?\-Z?LE_]%H\*_P#?^7_XU7^=K10!_HE?\-Z?LE_]%H\*_P#?^7_XU1_P
MWI^R7_T6CPK_ -_Y?_C5?YVM% '^B5_PWI^R7_T6CPK_ -_Y?_C5'_#>G[)?
M_1:/"O\ W_E_^-5_G:T4 ?Z)7_#>G[)?_1:/"O\ W_E_^-4?\-Z?LE_]%H\*
M_P#?^7_XU7^=K10!_HE?\-Z?LE_]%H\*_P#?^7_XU1_PWI^R7_T6CPK_ -_Y
M?_C5?YVM% '^B5_PWI^R7_T6CPK_ -_Y?_C5'_#>G[)?_1:/"O\ W_E_^-5_
MG:T4 ?Z)7_#>G[)?_1:/"O\ W_E_^-4?\-Z?LE_]%H\*_P#?^7_XU7^=K10!
M_HE?\-Z?LE_]%H\*_P#?^7_XU1_PWI^R7_T6CPK_ -_Y?_C5?YVM% '^B5_P
MWI^R7_T6CPK_ -_Y?_C5'_#>G[)?_1:/"O\ W_E_^-5_G:T4 ?Z)7_#>G[)?
M_1:/"O\ W_E_^-4?\-Z?LE_]%H\*_P#?^7_XU7^=K10!_H:ZK^W+^RMJ%N]O
M9_&'PQ/,_P!U$FE)/RD<?NL=3S7(:+^U]^SEI=Y-=7_Q2\/6\$DF])'EEVLH
M"Y(Q&?0U_ )9WMQ83+/;/LD3[K=<<@^H[@&MV_\ &.O:E;I:W=V9(8UV*N&X
M4YXY<CN>U '^A"O[>G[)>!_Q>CPKP,?Z^;J/^V5+_P -Z?LE_P#1:/"O_?\
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M[)?_ $6CPK_W_E_^-5_G:T4 ?Z)7_#>G[)?_ $6CPK_W_E_^-4?\-Z?LE_\
M1:/"O_?^7_XU7^=K10!_HE?\-Z?LE_\ 1:/"O_?^7_XU1_PWI^R7_P!%H\*_
M]_Y?_C5?YVM% '^B5_PWI^R7_P!%H\*_]_Y?_C5'_#>G[)?_ $6CPK_W_E_^
M-5_G:T4 ?Z)7_#>G[)?_ $6CPK_W_E_^-4?\-Z?LE_\ 1:/"O_?^7_XU7^=K
M10!_HE?\-Z?LE_\ 1:/"O_?^7_XU1_PWI^R7_P!%H\*_]_Y?_C5?YVM% '^B
M5_PWI^R7_P!%H\*_]_Y?_C5'_#>G[)?_ $6CPK_W_E_^-5_G:T4 ?Z)7_#>G
M[)?_ $6CPK_W_E_^-4?\-Z?LE_\ 1:/"O_?^7_XU7^=K10!_HE?\-Z?LE_\
M1:/"O_?^7_XU1_PWI^R7_P!%H\*_]_Y?_C5?YVM% '^B5_PWI^R7_P!%H\*_
M]_Y?_C5'_#>G[)?_ $6CPK_W_E_^-5_G:T4 ?Z)7_#>G[)?_ $6CPK_W_E_^
M-4?\-Z?LE_\ 1:/"O_?^7_XU7^=K10!_HE?\-Z?LE_\ 1:/"O_?^7_XU1_PW
MI^R7_P!%H\*_]_Y?_C5?YVM% '^B5_PWI^R7_P!%H\*_]_Y?_C5'_#>G[)?_
M $6CPK_W_E_^-5_G:T4 ?Z)7_#>G[)?_ $6CPK_W_E_^-4?\-Z?LE_\ 1:/"
MO_?^7_XU7^=K10!_HE?\-Z?LE_\ 1:/"O_?^7_XU1_PWI^R7_P!%H\*_]_Y?
M_C5?YVM% '^B5_PWI^R7_P!%H\*_]_Y?_C5'_#>G[)?_ $6CPK_W_E_^-5_G
M:T4 ?Z)7_#>G[)?_ $6CPK_W_E_^-4?\-Z?LE_\ 1:/"O_?^7_XU7^=K10!_
MHE?\-Z?LE_\ 1:/"O_?^7_XU1_PWI^R7_P!%H\*_]_Y?_C5?YVM% '^B5_PW
MI^R7_P!%H\*_]_Y?_C5'_#>G[)?_ $6CPK_W_E_^-5_G:T4 ?Z)7_#>G[)?_
M $6CPK_W_E_^-4?\-Z?LE_\ 1:/"O_?^7_XU7^=K10!_HE?\-Z?LE_\ 1:/"
MO_?^7_XU1_PWI^R7_P!%H\*_]_Y?_C5?YVM% '^B5_PWI^R7_P!%H\*_]_Y?
M_C5'_#>G[)?_ $6CPK_W_E_^-5_G:T4 ?Z)7_#>G[)?_ $6CPK_W_E_^-4?\
M-Z?LE_\ 1:/"O_?^7_XU7^=K10!_HE?\-Z?LE_\ 1:/"O_?^7_XU1_PWI^R7
M_P!%H\*_]_Y?_C5?YVM% '^B5_PWI^R7_P!%H\*_]_Y?_C54-1_;G_94O;9X
M+7XQ^%YI7'RHLTN3C/\ TR]\5_GB59M;N>SE6:!]DB]#SQSGL1W - ']_>E_
MM>_LZ:=?37MY\4/#\%M))YB2O+)M*!0-V?+Z9_E7HJ_MZ?LEX'_%Z/"O Q_K
MYNH_[95_GP7OC3Q!J%JMG=7GF0(NQ4PW"\G'+GN3VKE  ,X[G/XT ?Z)?_#>
MG[)?_1:/"O\ W_E_^-4?\-Z?LE_]%H\*_P#?^7_XU7^=K10!_HE?\-Z?LE_]
M%H\*_P#?^7_XU1_PWI^R7_T6CPK_ -_Y?_C5?YVM% '^B5_PWI^R7_T6CPK_
M -_Y?_C5'_#>G[)?_1:/"O\ W_E_^-5_G:T4 ?Z)7_#>G[)?_1:/"O\ W_E_
M^-4?\-Z?LE_]%H\*_P#?^7_XU7^=K10!_HE?\-Z?LE_]%H\*_P#?^7_XU1_P
MWI^R7_T6CPK_ -_Y?_C5?YVM% '^B5_PWI^R7_T6CPK_ -_Y?_C5'_#>G[)?
M_1:/"O\ W_E_^-5_G:T4 ?Z)7_#>G[)?_1:/"O\ W_E_^-4?\-Z?LE_]%H\*
M_P#?^7_XU7^=K10!_HE?\-Z?LE_]%H\*_P#?^7_XU1_PWI^R7_T6CPK_ -_Y
M?_C5?YVM% '^B5_PWI^R7_T6CPK_ -_Y?_C5'_#>G[)?_1:/"O\ W_E_^-5_
MG:T4 ?Z)7_#>G[)?_1:/"O\ W_E_^-4?\-Z?LE_]%H\*_P#?^7_XU7^=K10!
M_HE?\-Z?LE_]%H\*_P#?^7_XU1_PWI^R7_T6CPK_ -_Y?_C5?YVM% '^B5_P
MWI^R7_T6CPK_ -_Y?_C5'_#>G[)?_1:/"O\ W_E_^-5_G:T4 ?Z)7_#>G[)?
M_1:/"O\ W_E_^-4?\-Z?LE_]%H\*_P#?^7_XU7^=K10!_HE?\-Z?LE_]%H\*
M_P#?^7_XU1_PWI^R7_T6CPK_ -_Y?_C5?YVM% '^B5_PWI^R7_T6CPK_ -_Y
M?_C5'_#>G[)?_1:/"O\ W_E_^-5_G:T4 ?Z)7_#>G[)?_1:/"O\ W_E_^-4?
M\-Z?LE_]%H\*_P#?^7_XU7^=K10!_HE?\-Z?LE_]%H\*_P#?^7_XU1_PWI^R
M7_T6CPK_ -_Y?_C5?YVM% '^B5_PWI^R7_T6CPK_ -_Y?_C5'_#>G[)?_1:/
M"O\ W_E_^-5_G:T4 ?Z)7_#>G[)?_1:/"O\ W_E_^-4?\-Z?LE_]%H\*_P#?
M^7_XU7^=K10!_HE?\-Z?LE_]%H\*_P#?^7_XU1_PWI^R7_T6CPK_ -_Y?_C5
M?YVM% '^B5_PWI^R7_T6CPK_ -_Y?_C5'_#>G[)?_1:/"O\ W_E_^-5_G:T4
M ?Z)7_#>G[)?_1:/"O\ W_E_^-4?\-Z?LE_]%H\*_P#?^7_XU7^=K10!_HE?
M\-Z?LE_]%H\*_P#?^7_XU1_PWI^R7_T6CPK_ -_Y?_C5?YVM% '^B5_PWI^R
M7_T6CPK_ -_Y?_C5'_#>G[)?_1:/"O\ W_E_^-5_G:T4 ?Z)7_#>G[)?_1:/
M"O\ W_E_^-4?\-Z?LE_]%H\*_P#?^7_XU7^=K10!_HE?\-Z?LE_]%H\*_P#?
M^7_XU1_PWI^R7_T6CPK_ -_Y?_C5?YVM% '^B5_PWI^R7_T6CPK_ -_Y?_C5
M'_#>G[)?_1:/"O\ W_E_^-5_G:T4 ?Z)7_#>G[)?_1:/"O\ W_E_^-4?\-Z?
MLE_]%H\*_P#?^7_XU7^=K10!_HE?\-Z?LE_]%H\*_P#?^7_XU1_PWI^R7_T6
MCPK_ -_Y?_C5?YVM% '^B5_PWI^R7_T6CPK_ -_Y?_C5'_#>G[)?_1:/"O\
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M_P!_Y?\ XU1_PWI^R7_T6CPK_P!_Y?\ XU7^=K10!_HE?\-Z?LE_]%H\*_\
M?^7_ .-4?\-Z?LE_]%H\*_\ ?^7_ .-5_G:T4 ?Z)7_#>G[)?_1:/"O_ '_E
M_P#C5'_#>G[)?_1:/"O_ '_E_P#C5?YVM% '^B5_PWI^R7_T6CPK_P!_Y?\
MXU1_PWI^R7_T6CPK_P!_Y?\ XU7^=K10!_HE?\-Z?LE_]%H\*_\ ?^7_ .-4
M?\-Z?LE_]%H\*_\ ?^7_ .-5_G:T4 ?Z)7_#>G[)?_1:/"O_ '_E_P#C5'_#
M>G[)?_1:/"O_ '_E_P#C5?YVM% '^B5_PWI^R7_T6CPK_P!_Y?\ XU1_PWI^
MR7_T6CPK_P!_Y?\ XU7^=K10!_HE?\-Z?LE_]%H\*_\ ?^7_ .-4?\-Z?LE_
M]%H\*_\ ?^7_ .-5_G:T4 ?Z)7_#>G[)?_1:/"O_ '_E_P#C5'_#>G[)?_1:
M/"O_ '_E_P#C5?YVM% '^B5_PWI^R7_T6CPK_P!_Y?\ XU1_PWI^R7_T6CPK
M_P!_Y?\ XU7^=K10!_HE?\-Z?LE_]%H\*_\ ?^7_ .-4?\-Z?LE_]%H\*_\
M?^7_ .-5_G:T4 ?Z)7_#>G[)?_1:/"O_ '_E_P#C5'_#>G[)?_1:/"O_ '_E
M_P#C5?YVM% '^B5_PWI^R7_T6CPK_P!_Y?\ XU1_PWI^R7_T6CPK_P!_Y?\
MXU7^=K10!_HE?\-Z?LE_]%H\*_\ ?^7_ .-4?\-Z?LE_]%H\*_\ ?^7_ .-5
M_G:T4 ?Z)7_#>G[)?_1:/"O_ '_E_P#C5'_#>G[)?_1:/"O_ '_E_P#C5?YV
MM% '^B5_PWI^R7_T6CPK_P!_Y?\ XU1_PWI^R7_T6CPK_P!_Y?\ XU7^=K10
M!_HE?\-Z?LE_]%H\*_\ ?^7_ .-4?\-Z?LE_]%H\*_\ ?^7_ .-5_G:T4 ?Z
M)7_#>G[)?_1:/"O_ '_E_P#C5'_#>G[)?_1:/"O_ '_E_P#C5?YVM% '^B5_
MPWI^R7_T6CPK_P!_Y?\ XU1_PWI^R7_T6CPK_P!_Y?\ XU7^=K10!_HE?\-Z
M?LE_]%H\*_\ ?^7_ .-4?\-Z?LE_]%H\*_\ ?^7_ .-5_G:T4 ?Z)7_#>G[)
M?_1:/"O_ '_E_P#C5'_#>G[)?_1:/"O_ '_E_P#C5?YVM% '^B5_PWI^R7_T
M6CPK_P!_Y?\ XU1_PWI^R7_T6CPK_P!_Y?\ XU7^=K10!_HE?\-Z?LE_]%H\
M*_\ ?^7_ .-4?\-Z?LE_]%H\*_\ ?^7_ .-5_G:T4 ?Z)7_#>G[)?_1:/"O_
M '_E_P#C5'_#>G[)?_1:/"O_ '_E_P#C5?YVM% '^B5_PWI^R7_T6CPK_P!_
MY?\ XU6-K7[<'[+6JVLEO8?%_P ,W,SHRJD<TI)8@X'^KZ\U_GG5?L-2N],F
M6>SD\N16# \]1TZ$4 ?W\>%_VP?V<?#]R+C5_BEX>LH<$>9++*!ELXZ1GU'Y
MUZ'_ ,-Z?LE_]%H\*_\ ?^7_ .-5_GMZQXOUW78/L^I77GQ9!VD-V]RY]*YF
M@#_1*_X;T_9+_P"BT>%?^_\ +_\ &J/^&]/V2_\ HM'A7_O_ "__ !JO\[6B
M@#_1*_X;T_9+_P"BT>%?^_\ +_\ &J/^&]/V2_\ HM'A7_O_ "__ !JO\[6B
M@#_1*_X;T_9+_P"BT>%?^_\ +_\ &J/^&]/V2_\ HM'A7_O_ "__ !JO\[6B
M@#_1*_X;T_9+_P"BT>%?^_\ +_\ &J/^&]/V2_\ HM'A7_O_ "__ !JO\[6B
M@#_1*_X;T_9+_P"BT>%?^_\ +_\ &J/^&]/V2_\ HM'A7_O_ "__ !JO\[6B
M@#_1*_X;T_9+_P"BT>%?^_\ +_\ &J/^&]/V2_\ HM'A7_O_ "__ !JO\[6B
M@#_1*_X;T_9+_P"BT>%?^_\ +_\ &J/^&]/V2_\ HM'A7_O_ "__ !JO\[6B
M@#_1*_X;T_9+_P"BT>%?^_\ +_\ &J/^&]/V2_\ HM'A7_O_ "__ !JO\[6B
M@#_1*_X;T_9+_P"BT>%?^_\ +_\ &J/^&]/V2_\ HM'A7_O_ "__ !JO\[6B
M@#_1*_X;T_9+_P"BT>%?^_\ +_\ &J/^&]/V2_\ HM'A7_O_ "__ !JO\[6B
M@#_1*_X;T_9+_P"BT>%?^_\ +_\ &J/^&]/V2_\ HM'A7_O_ "__ !JO\[6B
M@#_1*_X;T_9+_P"BT>%?^_\ +_\ &J/^&]/V2_\ HM'A7_O_ "__ !JO\[6B
M@#_1*_X;T_9+_P"BT>%?^_\ +_\ &J/^&]/V2_\ HM'A7_O_ "__ !JO\[6B
M@#_1*_X;T_9+_P"BT>%?^_\ +_\ &J/^&]/V2_\ HM'A7_O_ "__ !JO\[6B
M@#_1*_X;T_9+_P"BT>%?^_\ +_\ &J/^&]/V2_\ HM'A7_O_ "__ !JO\[6B
M@#_1*_X;T_9+_P"BT>%?^_\ +_\ &J/^&]/V2_\ HM'A7_O_ "__ !JO\[6B
M@#_1*_X;T_9+_P"BT>%?^_\ +_\ &J/^&]/V2_\ HM'A7_O_ "__ !JO\[6B
M@#_1*_X;T_9+_P"BT>%?^_\ +_\ &J/^&]/V2_\ HM'A7_O_ "__ !JO\[6B
M@#_1*_X;T_9+_P"BT>%?^_\ +_\ &J/^&]/V2_\ HM'A7_O_ "__ !JO\[6B
M@#_1*_X;T_9+_P"BT>%?^_\ +_\ &J/^&]/V2_\ HM'A7_O_ "__ !JO\[6B
M@#_1*_X;T_9+_P"BT>%?^_\ +_\ &J/^&]/V2_\ HM'A7_O_ "__ !JO\[6B
M@#_1*_X;T_9+_P"BT>%?^_\ +_\ &J/^&]/V2_\ HM'A7_O_ "__ !JO\[6B
M@#_1*_X;T_9+_P"BT>%?^_\ +_\ &J/^&]/V2_\ HM'A7_O_ "__ !JO\[6B
M@#_1*_X;T_9+_P"BT>%?^_\ +_\ &J/^&]/V2_\ HM'A7_O_ "__ !JO\[6B
M@#_1*_X;T_9+_P"BT>%?^_\ +_\ &J/^&]/V2_\ HM'A7_O_ "__ !JO\[6B
M@#_1*_X;T_9+_P"BT>%?^_\ +_\ &J/^&]/V2_\ HM'A7_O_ "__ !JO\[6B
M@#_1*_X;T_9+_P"BT>%?^_\ +_\ &J/^&]/V2_\ HM'A7_O_ "__ !JO\[6B
M@#_1*_X;T_9+_P"BT>%?^_\ +_\ &J/^&]/V2_\ HM'A7_O_ "__ !JO\[6B
M@#_1*_X;T_9+_P"BT>%?^_\ +_\ &J/^&]/V2_\ HM'A7_O_ "__ !JO\[6B
M@#_1*_X;T_9+_P"BT>%?^_\ +_\ &J/^&]/V2_\ HM'A7_O_ "__ !JO\[6B
M@#_1*_X;T_9+_P"BT>%?^_\ +_\ &J/^&]/V2_\ HM'A7_O_ "__ !JO\[6B
M@#_1*_X;T_9+_P"BT>%?^_\ +_\ &J/^&]/V2_\ HM'A7_O_ "__ !JO\[6B
M@#_1*_X;T_9+_P"BT>%?^_\ +_\ &J/^&]/V2_\ HM'A7_O_ "__ !JO\[6B
M@#_1*_X;T_9+_P"BT>%?^_\ +_\ &J/^&]/V2_\ HM'A7_O_ "__ !JO\[6B
M@#_1*_X;T_9+_P"BT>%?^_\ +_\ &J/^&]/V2_\ HM'A7_O_ "__ !JO\[6B
M@#_1*_X;T_9+_P"BT>%?^_\ +_\ &JQM6_;-_9H\5&UTO0/BOX<U*_N)D@AM
MK>:4R22RL%C0 Q@99B .:_SSJ]?^ VJWNF?%SX>?8Y?+\_QCH$<G4[D;48%(
MX([$^M '^BKX#AD,,-T%/D7 2>&3L\4P\R-U]F1@P]C7JE<AX"B1?!/@]P/F
M?PMX?=O=FTFT8G\R?_U\UU] 'YJ_\%;/^3'/BM_UQB_](=4K^"&O[WO^"MG_
M "8Y\5O^N,7_ *0ZI7\$- !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 5Z=\%?\ DKGPV_['3P]_Z<K>O,:].^"O_)7/
MAM_V.GA[_P!.5O0!_I'^ _\ D1_!G_8J>'?_ $T6==77*> _^1'\&?\ 8J>'
M?_319UU= 'YJ_P#!6S_DQSXK?]<8O_2'5*_@AK^][_@K9_R8Y\5O^N,7_I#J
ME?P0T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !7IWP5_Y*Y\-O^QT\/?\ IRMZ\QKT[X*_\E<^&W_8Z>'O_3E;T ?Z
M1_@/_D1_!G_8J>'?_319UU=<IX#_ .1'\&?]BIX=_P#319UU= 'YJ_\ !6S_
M ),<^*W_ %QB_P#2'5*_@AK^][_@K9_R8Y\5O^N,7_I#JE?P0T %%%% !111
M0 4444 %%%211O-)'%&,O(ZH@]68@*.,]2: (Z*]%@^%?C2YC66+2RR.JLIW
M/RK#(/$9ZBI'^$WC>-6=M*(51DG=)T_[]4 >;45H:GI=YI%TUG?1^5.GWDYX
MYQW _E6?0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 444C':"?04 +17[6_\$^O^"9_A;]J_P=IWB_Q3=ZQ9:?=R
M&-YK![A5!"EC@17-N.!CN/<8K])_B#_P0<^!/A[PM?:KH7B3Q5=:C;6WF)#+
M+>[#*.JG_B:R<=/X#]/0 _DKHKW+]H;X5P_!SXG^(/ D!F,>CRA%,Y8R$&25
M/F+LYS^[YR?_ *_GW@'P%XG^)OBBQ\'>#K ZGK^H@FTLP6!DVO&AY1)&X:5!
MPAZT <=17[ ^%/\ @D)^T;K>C6.I77@B]1KJ 2D+->[<DD<8M5]/3_ZWRA^T
MC^Q%\9/V=6N-0\7>&9M-T.%Q&+J5[ACYA(&");=!_$/X^] 'Q;12D$$@]124
M %%%% !1110 4444 %%:V@:)J/B;6],\.Z/!]IU75[E;2PMP2#-.RLP3*JQY
M"D\*QXZ5^IGPY_X),_M(^,-!M=7NO ]VGV@9S'+>A?N*W:U4=SZ_6@#\G:*_
M0G]H;_@G=\=?@3ILFO:SX2N+31+2V^T7MU-)=-Y2[=V?WEL!CANK#IVK\^&4
MHQ5A@CK0 VBBB@ HHHH **** "BBB@ HHHH **** "BBO:/V>/ABOQF^+OAO
MX<OYNW6V93Y!82_++;Q_*496_P"6W4$=O? !XO17]:/P[_X(.? W7_#EGJ7B
M/Q'XJL]0N+82/##+>[!)G&!_Q-(N/^ _A7YR_M__ /!,[P7^ROX:OO$GA*_U
MF^L[:01I+?O<,"3@\B6[N!R#W- 'XD44YP%=U'\+$<]:;0 445)%$\TL<,8W
M22L%1?4F@".BN_M/AEXPO81<6^FEXB,ALOTQG/$9'3WKD]2TB^TF4P7L/E2*
M2I'/4=>H!_2@#,HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BMG1] U/793#IMN9W#;2 2.>/0'UKVG2/V8?C'KEI%?:=X:
M::WFSL?=-S@ ]K=AT([T ?/M%>W^)/V=_BIX3MGN]<\/M:01KO=RTIPI&?XH
M%[=NM>+W-O+:S/!,NV1#AAZ'\0* (**0G )]!FOT8_X)_P#[&NF?M;:KJ=OJ
M\E_#8Z9?);3RV+S*R(QB!)\F6+)S)_>'UZ4 ?G117]>EQ_P0+_9\BT.:\7Q1
MXL.HQVUQ*(3+?;=\<)>,'_B;]"PY^7VK^?/]MW]EC3?V8O'T?A;2Y+R6UEMY
M;A'O&E9RBB%D.9993RLHXW'K0!\+T4@.0#ZC-+0 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M( G<2^,#KUC% '!44^2-XF*.,,I((]"#@C\Z90 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M.'9O+9?E(  Y9NOKCG%?B-<3O<RO-(<NYR30!#1110 44Y59SA%9CZ*"Q_(
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M=2YR>O-?F37Z^_\ !('_ )*MJO\ V$;3_P!%VM ']<.B_L>?LY0Z=;1I\,-
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MV"JY'./F]Z^I/^"47_!/NW\2_9/B;X]TH2Z;>V]OJ6CML!)DB5"N]9,C&X]
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M E%3?9[C_GA-_P!^G_\ B:C9'3AE93Z,I'\P* &T444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
MZ=\%?^2N?#;_ +'3P]_Z<K>O,:].^"O_ "5SX;?]CIX>_P#3E;T ?Z1_@/\
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M4^,R[)&J&4V\FXD #=_Q[\GC/^%>$^/_ /@@5X2"7>J:1\1K^69DDD2SBCE
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MBAFE@D+9'7G[..?7^E>?_$#_ (('^"=3DO=5TWXBWL,C1R21VD$4RKN16=5
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M<6]KXRU.& $L0L0NE" '<1C'0X%?V$>%O^0)9?[G]!0!_/=_P6G_ .09JO\
MV#T_])5K^2ZX_P"/JX_W_P"E?UH_\%I_^09JO_8/3_TE6OY+;I@MQ<,>@?\
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MV7<FXY!/ Y_6OZS/^"%W_))="_ZZR?\ HJOY/O%__(>U_P#ZZ2?^@I7]8/\
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M+^(5XDZ12S0V<,4JAY$5F2,?Z/\ Q'"]?K7X;_M1_L!?%+]GVZOKI- U:_\
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M2 2 6R/L^.#QUR3T]:_H+\#> /#'PXT.UT?P_9QZ=I]C"41=R!(XP!G+!44
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MRX'&#[''%?U*5QM_\0O!.ES/;ZAXETNTG1MCQ33[75@,[2-IYQ0!_)[\.?\
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M'-?Z(+?L(_LG.2S?!CPJS'J3!-D_^1:;_P ,'_LF_P#1%_"G_?B;_P".T ?
MW_!'+XYZS\5?AWK&C:I<M<CPII]K9Q/).TTF%DM.79P6S^_.<DGU/K^O'Q-T
M.QU[P+XKL[ZWAN4_X1O7C&D\,<RB0Z7<A659 0&#!2&'((!'(&,?X;?!/X7_
M  ABO(/ASX0TSPM%?X^UIIZ.HGVE"-^]VZ>6G3 ^45VGBQXX_"_B-I6")_8.
MK[F;@ ?V?<9R?I0!_G,?M+>$'\(_%?QE;M&8TN/$VNS(I! "-?S. J]  &X
M'2N:\&? _P"(OC^(S>&=&-]&$\S.Z4?+US\D,G8U]$_M^7.F3_&#6GTR:&55
MU/5A*822%D^TD$,>.=VX$9K^LG_@G%^S_P#"2[_9B^&?B*[\(:1<ZOJFA))>
MW3(YFE;*_-(0P&?_ *W7K0!_'9_PR%\=?^A4/_?R?_Y%H_X9"^.O_0J'_OY/
M_P#(M?Z"'_"A_A-_T)>E?]\/_P#%T?\ "A_A-_T)>E?]\/\ _%T ?YU'CCX,
M>/\ X=6RW?BK2#I\#2>4KEI#ER54#YX8QU8=^]8/P[\,KXO\6Z;X?</MO&(.
MS._AT7 VD$?>]>_Y_P!E?_!57X$?"FP^!=M?V'AC2=,O%O[EQ<JKJ[E/L3*H
M)8]^@QU/%?RJ_LH:!#K'[3WAW1%56@DU.]B5<97;'?0(HQUQM/'3.>_< _N%
M_87^'VD>"/V?/A[!96=O!<_V'&D\JVL44\A#=9)57S'/ ^\2>!S7H_[3/Q?L
MO@I\,=5\87UQ';1117$"R2[-HD:W;;]\@9R1@]175_ _2ET;X9^%M/0 +;:>
MD> , ?,3T[?_ *J_//\ X+*:Q+HO[(>LW<)8/_:.W*G!P810!_(M^U%^T;XW
M^*_Q)\2WLOB#5HK"/6;LV2VFKWT<+P-PO[J.6.,#G@8(Z$=Z^;+#QGXLTVZ@
MN[3Q+X@@E@FBF4Q:SJ,18Q.'"L4N1E21@@Y&">#6+J%PUW>W-PY)::5G.>3D
MGO5.@#])_!G_  4\^.G@WX7ZE\+(8;/4](U*2*26]U*[:ZO4,23H DMQ:3R@
M8N&X$P'RKQTQ^?7C+Q/?>,=<U3Q%J*JEYJ<QN)E0Y4.0!P=JCMS\HKG:9)]Q
MOI0!_9G_ ,$._P#DVC0?^OQ__11K]J?'G_(JZM_UP_J*_%;_ ((=_P#)M&@_
M]?C_ /HHU^U/CS_D5=6_ZX?U% '\!O\ P42_Y.B^(/\ U\I_Z475:W_!,#_D
M\_X;_P"Y-_Z7Z763_P %$O\ DZ+X@_\ 7RG_ *475:W_  3 _P"3S_AO_N3?
M^E^ET ?WV>&/^0)8?]<%_FU?@S_P6\_Y(W??]A-?_0K>OWF\,?\ ($L/^N"_
MS:OP9_X+>?\ )&[[_L)K_P"A6] '\?-WTD^O]*_NE_X)(_\ )K?P[_[!;_\
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M@\_.?2@#_/WAA%OXMT&$=%\1Z4!^&IVX_P _EVK_ $,/V+O^2+>"O^Q8T?\
M])4K_/;NTV>.=&4'('B73,'_ +BUO7^A)^Q=_P D6\%?]BQH_P#Z2I0!])>-
MO%NG>"_#FK:_J4P@@TVPN;UG8 @+;QM(20Q P IZ\5_']_P46_X*6^)/B/XF
MU;P9\/\ 5Q_PCX%Q:S7NG7;65S'<6["W95:S&X8;S,GS1R!QU-?U#_M=S21?
M![Q<8V*D^'=7!QW!MG%?YZ?Q&)/C3Q 2<G^VM7Y/_7].: -_PY\9_B%X:\6Z
M9XNA\6^)9;C3;\7WD2^(-5:"5@C)ME1[ED=#NR0R,,\X]/[>O^"8_P"T-J/Q
MR^ 7A77=?FC;6+M&,ZH_F<"UMW'S%48Y+-G*^]?P5W'^ID_W?ZBO[!O^"(\T
MG_"DO"<6\^6+=P%[?\></^- '[T^)]+36M%O-/>-9EN$P8W4.K#!ZJP(/7IB
MOX!O^"C&DKH_[3/Q'LDB6%8=7*A$0(H^>0<*H '3\?KFO]!<=!]!_*OX#O\
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MKKG@SP-<;"38VMS)E1Z2:B.<8_OY]L5_'G<Q&%IHR,;3)Q^+#^G^>E?VB_\
M!9[_ )$#PY_V#[K_ -&WM?QA:G_Q\W'UD_\ 0GH _I _X()_\@OQ;_V'V_\
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M$^.W@_5=3C:6"TOWA>-D\R%@+B!1NC8[&^Z>JG_'UG_@LY_R=;\0C_TVC_\
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M_P"N5Q_Z-U&@#\TO^",_QS_X1WXJ6/P_N;TQ6D5L9!$9.C,TJ#Y"0/X1TZ<
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M3I?$7_8!A_\ 16J4 ?W&Z;_R#['_ *]+?_T4E?S=_P#!;O\ Y%_PW_UUG_\
M1D]?TB:;_P @^Q_Z]+?_ -%)7\W?_!;O_D7_  W_ -=9_P#T9/0!_*,O5_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_:V^)NN?"#X$^,_'WAR3R]7T2U$MJ^UGPQCF;[J?,>4' KY&_P""5_QK\/\
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M9\L09;J5I9"-Q/!9CCTK]JOV6?\ @K%XC^"WP^T/P)?:J8M.T*P%I9QJ&)0
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MU?\ R0[5_P#K]7_T6M?MOX._Y%_3_P#KBO\ ,U^)'_!:O_DAVK_]?J_^BUH
M_C9F_P"/B?\ W_\ &F4^;_CXG_W_ /&F4 %?K[_P2!_Y*MJO_81M/_1=K7Y!
M5^OO_!('_DJVJ_\ 81M/_1=K0!_;UI7_ !XVW_7"'_T6M?ST?\%P?^/30O\
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M_P!>TW_H+5_*G_P03_Y!?BW_ +#[?^CQ7]5FI?\ (,O?^O:;_P!!:@#^*_\
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M444 %?H-_P $S?\ DO+?[UA_Z,FK\^:_0;_@F;_R7EO]ZP_]&34 ?WJ>!_\
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M%=J]\VIW]Q?2$EY&DZD'@LQ[?7_/< _0?_@F;_R<!X*_[#(_]&15_>EX6_Y
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M7QW_ .">G[0/@[QGJ5OH?@#6=3TU'5+>Z"?)(3+(N!E0>A4].X["OH/]B_\
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M^"FW_)J7C_\ W(?_ $COZ^^-&TBTT2PAT^SBCB@A!")&NU1P!P.W [5\#_\
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M]:_ +_@DU^RAXQ^&6CV?B7Q7IU]I5S>Z:%DMKA3\CB$#'W0.K'N/:OW^5=D
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MF:*[L;#5G6*:-\AD+N=V,Y Z?IVH ^2?^"<./^&K=#([HQ_.\2O[_P#X>_\
M(F>'?^P9!_-Z_@#_ ."<0Q^U5X?_ -J$,?JUS$?Z_P#US7]_GP]_Y$SP[_V#
M(/YO0!^+_P#P6<_Y([!_V%9O_0[*OXRI?^/W4/\ K\G_ /1TE?V:_P#!9S_D
MCL'_ &%9O_0[*OXRI?\ C]U#_K\G_P#1TE !117HWPD^']]\4_&MMX/TV.26
M[N$#HD()D.7"#I[GL#U[T 4_ 7Q%\3_#?6;37?#-[+;7UE,)X3YTJIY@X&0C
M 8[U^V'[-?\ P64^)GA"/3M)^).MB32+?RU=8!*9"#M63E@_)"C'Z5\5?$C_
M ()R?'7PAHEIKNE>"]:U&QFM!=2S[#LC0YP>5''  Z9S7Q)KWPU\:^&)##KF
MB7-A*&"E)1@AB< ?B>* /[P/V9?^"B?P5_:*ALK/PYJ4QU2<Q6[1W4L49:X7
M$<Q565&*^:#SCH1ZU^@3I:ZE:%75)K>X0@Y"NK*>O7(.?;(K^!#_ ()]^#/C
M/_PT-X*O_#MMK:>'(I7^U_99F2U,IN;3&]1P3Q(<]CD]:_O"^&Z7T7@S0X]2
M$@O5M%$XE.7WY.=Q]N/Y=J /YL_^"R'[.>E&?6/'ECIZ1-_J_,2-$!P0^/D
M&>>N,_C7\OTT?D7-Q;?\\)&CQZ;3CGWS_D5_:%_P5_\ $VG6WPIU?2Y$@-R)
MV;<P!DP448Z@X]/?I7\8FHG?JVI2#[KW,A&.G)'^1[4 5J*** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MKT[X*_\ )7/AM_V.GA[_ -.5O7F->G?!7_DKGPV_['3P]_Z<K>@#_2/\!_\
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M\7OBMK_QE\:ZQXX\2QPQZIK5P;BY2!MT8<DG"D1Q<?,?X!]!0!Y?1110 4C
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MP S&HZXQVH ^(/ _BRX\">+X/%-HSI<6,TVQHPQ<9F5N-OS=8^WI[\_W(_\
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MW=K-\!/!,<-Q!*\?A>R$B)*C,A%QT9025//0@5]9_M!30P?#C7VFECB4Z1K
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MQ74'B.2+2HKF-HF32+^:!=I&T';;VUH,X_\ UT ?UW_ _P#;O\#?&CXF>*O
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *].^"O\ R5SX;?\ 8Z>'O_3E;UYC7IWP5_Y*Y\-O
M^QT\/?\ IRMZ /\ 2/\  ?\ R(_@S_L5/#O_ *:+.NKKE/ ?_(C^#/\ L5/#
MO_IHLZZN@#\U?^"MG_)CGQ6_ZXQ?^D.J5_!#7][W_!6S_DQSXK?]<8O_ $AU
M2OX(: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ KT[X*_\ )7/AM_V.GA[_ -.5O7F->G?!7_DKGPV_['3P]_Z<K>@#
M_2/\!_\ (C^#/^Q4\._^FBSKJZY3P'_R(_@S_L5/#O\ Z:+.NKH _-7_ (*V
M?\F.?%;_ *XQ?^D.J5_!#7][W_!6S_DQSXK?]<8O_2'5*_@AH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O3O@K_R5
MSX;?]CIX>_\ 3E;UYC7IWP5_Y*Y\-O\ L=/#W_IRMZ /](_P'_R(_@S_ +%3
MP[_Z:+.NKKE/ ?\ R(_@S_L5/#O_ *:+.NKH _-7_@K9_P F.?%;_KC%_P"D
M.J5_!#7]^_\ P5'\.ZWXQ_8V^)OAWPOIMSK>N7L48M-,L4$EU.19:BI\M&90
M<%T'4<L*_B37]D?]I5P&7X->-&4]"+"+!_\ )B@#YTHKZ-_X9%_:7_Z(SXU_
M\ (O_DBC_AD7]I?_ *(SXU_\ (O_ )(H ^<J*^C?^&1?VE_^B,^-?_ "+_Y(
MH_X9%_:7_P"B,^-?_ "+_P"2* /G*BOHW_AD7]I?_HC/C7_P B_^2*/^&1?V
ME_\ HC/C7_P B_\ DB@#YRHKZ-_X9%_:7_Z(SXU_\ (O_DBC_AD7]I?_ *(S
MXU_\ (O_ )(H ^<J*^C?^&1?VE_^B,^-?_ "+_Y(H_X9%_:7_P"B,^-?_ "+
M_P"2* /G*BOHW_AD7]I?_HC/C7_P B_^2*/^&1?VE_\ HC/C7_P B_\ DB@#
MYRHKZ-_X9%_:7_Z(SXU_\ (O_DBC_AD7]I?_ *(SXU_\ (O_ )(H ^<J*^C?
M^&1?VE_^B,^-?_ "+_Y(H_X9%_:7_P"B,^-?_ "+_P"2* /G*BOHW_AD7]I?
M_HC/C7_P B_^2*/^&1?VE_\ HC/C7_P B_\ DB@#YRHKZ-_X9%_:7_Z(SXU_
M\ (O_DBC_AD7]I?_ *(SXU_\ (O_ )(H ^<J*^C?^&1?VE_^B,^-?_ "+_Y(
MH_X9%_:7_P"B,^-?_ "+_P"2* /G*BOHW_AD7]I?_HC/C7_P B_^2*/^&1?V
ME_\ HC/C7_P B_\ DB@#YRHKZ-_X9%_:7_Z(SXU_\ (O_DBC_AD7]I?_ *(S
MXU_\ (O_ )(H ^<J*^C?^&1?VE_^B,^-?_ "+_Y(H_X9%_:7_P"B,^-?_ "+
M_P"2* /G*BOHW_AD7]I?_HC/C7_P B_^2*/^&1?VE_\ HC/C7_P B_\ DB@#
MYRHKZ-_X9%_:7_Z(SXU_\ (O_DBC_AD7]I?_ *(SXU_\ (O_ )(H ^<J*^C?
M^&1?VE_^B,^-?_ "+_Y(H_X9%_:7_P"B,^-?_ "+_P"2* /G*BOHW_AD7]I?
M_HC/C7_P B_^2*/^&1?VE_\ HC/C7_P B_\ DB@#YRHKZ-_X9%_:7_Z(SXU_
M\ (O_DBC_AD7]I?_ *(SXU_\ (O_ )(H ^<J*^C?^&1?VE_^B,^-?_ "+_Y(
MH_X9%_:7_P"B,^-?_ "+_P"2* /G*BOHW_AD7]I?_HC/C7_P B_^2*/^&1?V
ME_\ HC/C7_P B_\ DB@#YRHKZ-_X9%_:7_Z(SXU_\ (O_DBC_AD7]I?_ *(S
MXU_\ (O_ )(H ^<J*^C?^&1?VE_^B,^-?_ "+_Y(H_X9%_:7_P"B,^-?_ "+
M_P"2* /G*BOHW_AD7]I?_HC/C7_P B_^2*/^&1?VE_\ HC/C7_P B_\ DB@#
MYRHKZ-_X9%_:7_Z(SXU_\ (O_DBC_AD7]I?_ *(SXU_\ (O_ )(H ^<J*^C?
M^&1?VE_^B,^-?_ "+_Y(H_X9%_:7_P"B,^-?_ "+_P"2* /G*BOHW_AD7]I?
M_HC/C7_P B_^2*/^&1?VE_\ HC/C7_P B_\ DB@#YRHKZ-_X9%_:7_Z(SXU_
M\ (O_DBC_AD7]I?_ *(SXU_\ (O_ )(H ^<J*^C?^&1?VE_^B,^-?_ "+_Y(
MH_X9%_:7_P"B,^-?_ "+_P"2* /G*BOHW_AD7]I?_HC/C7_P B_^2*/^&1?V
ME_\ HC/C7_P B_\ DB@#YRHKZ-_X9%_:7_Z(SXU_\ (O_DBC_AD7]I?_ *(S
MXU_\ (O_ )(H ^<J*^C?^&1?VE_^B,^-?_ "+_Y(H_X9%_:7_P"B,^-?_ "+
M_P"2* /G*BOHW_AD7]I?_HC/C7_P B_^2*/^&1?VE_\ HC/C7_P B_\ DB@#
MYRHKZ-_X9%_:7_Z(SXU_\ (O_DBC_AD7]I?_ *(SXU_\ (O_ )(H ^<J*^C?
M^&1?VE_^B,^-?_ "+_Y(H_X9%_:7_P"B,^-?_ "+_P"2* /G*BOHW_AD7]I?
M_HC/C7_P B_^2*/^&1?VE_\ HC/C7_P B_\ DB@#YRHKZ-_X9%_:7_Z(SXU_
M\ (O_DBC_AD7]I?_ *(SXU_\ (O_ )(H ^<J*^C?^&1?VE_^B,^-?_ "+_Y(
MH_X9%_:7_P"B,^-?_ "+_P"2* /G*BOHW_AD7]I?_HC/C7_P B_^2*/^&1?V
ME_\ HC/C7_P B_\ DB@#YRHKZ-_X9%_:7_Z(SXU_\ (O_DBC_AD7]I?_ *(S
MXU_\ (O_ )(H ^<J*^C?^&1?VE_^B,^-?_ "+_Y(H_X9%_:7_P"B,^-?_ "+
M_P"2* /G*BOHW_AD7]I?_HC/C7_P B_^2*/^&1?VE_\ HC/C7_P B_\ DB@#
MYRHKZ-_X9%_:7_Z(SXU_\ (O_DBC_AD7]I?_ *(SXU_\ (O_ )(H ^<J*^C?
M^&1?VE_^B,^-?_ "+_Y(H_X9%_:7_P"B,^-?_ "+_P"2* /G*BOHW_AD7]I?
M_HC/C7_P B_^2*/^&1?VE_\ HC/C7_P B_\ DB@#YRHKZ-_X9%_:7_Z(SXU_
M\ (O_DBC_AD7]I?_ *(SXU_\ (O_ )(H ^<J*^C?^&1?VE_^B,^-?_ "+_Y(
MH_X9%_:7_P"B,^-?_ "+_P"2* /G*BOHW_AD7]I?_HC/C7_P B_^2*/^&1?V
ME_\ HC/C7_P B_\ DB@#YRHKZ-_X9%_:7_Z(SXU_\ (O_DBC_AD7]I?_ *(S
MXU_\ (O_ )(H ^<J*^C?^&1?VE_^B,^-?_ "+_Y(H_X9%_:7_P"B,^-?_ "+
M_P"2* /G*BOHW_AD7]I?_HC/C7_P B_^2*/^&1?VE_\ HC/C7_P B_\ DB@#
MYRHKZ-_X9%_:7_Z(SXU_\ (O_DBC_AD7]I?_ *(SXU_\ (O_ )(H ^<J*^C?
M^&1?VE_^B,^-?_ "+_Y(H_X9%_:7_P"B,^-?_ "+_P"2* /G*BOHW_AD7]I?
M_HC/C7_P B_^2*/^&1?VE_\ HC/C7_P B_\ DB@#YRHKZ-_X9%_:7_Z(SXU_
M\ (O_DBC_AD7]I?_ *(SXU_\ (O_ )(H ^<J*^C?^&1?VE_^B,^-?_ "+_Y(
MH_X9%_:7_P"B,^-?_ "+_P"2* /G*BOHW_AD7]I?_HC/C7_P B_^2*/^&1?V
ME_\ HC/C7_P B_\ DB@#YRHKZ-_X9%_:7_Z(SXU_\ (O_DBC_AD7]I?_ *(S
MXU_\ (O_ )(H ^<J*^C?^&1?VE_^B,^-?_ "+_Y(H_X9%_:7_P"B,^-?_ "+
M_P"2* /G*BOHW_AD7]I?_HC/C7_P B_^2*/^&1?VE_\ HC/C7_P B_\ DB@#
MYRHKZ-_X9%_:7_Z(SXU_\ (O_DBC_AD7]I?_ *(SXU_\ (O_ )(H ^<J*^C?
M^&1?VE_^B,^-?_ "+_Y(H_X9%_:7_P"B,^-?_ "+_P"2* /G*BOHW_AD7]I?
M_HC/C7_P B_^2*/^&1?VE_\ HC/C7_P B_\ DB@#YRHKZ-_X9%_:7_Z(SXU_
M\ (O_DBC_AD7]I?_ *(SXU_\ (O_ )(H ^<J*^C?^&1?VE_^B,^-?_ "+_Y(
MH_X9%_:7_P"B,^-?_ "+_P"2* /G*BOHW_AD7]I?_HC/C7_P B_^2*/^&1?V
ME_\ HC/C7_P B_\ DB@#YRHKZ-_X9%_:7_Z(SXU_\ (O_DBC_AD7]I?_ *(S
MXU_\ (O_ )(H ^<J*^C?^&1?VE_^B,^-?_ "+_Y(H_X9%_:7_P"B,^-?_ "+
M_P"2* /G*BOHW_AD7]I?_HC/C7_P B_^2*/^&1?VE_\ HC/C7_P B_\ DB@#
MYRHKZ-_X9%_:7_Z(SXU_\ (O_DBC_AD7]I?_ *(SXU_\ (O_ )(H ^<J*^C?
M^&1?VE_^B,^-?_ "+_Y(H_X9%_:7_P"B,^-?_ "+_P"2* /G*BOHW_AD7]I?
M_HC/C7_P B_^2*/^&1?VE_\ HC/C7_P B_\ DB@#YRHKZ-_X9%_:7_Z(SXU_
M\ (O_DBC_AD7]I?_ *(SXU_\ (O_ )(H ^<J*^C?^&1?VE_^B,^-?_ "+_Y(
MH_X9%_:7_P"B,^-?_ "+_P"2* /G*BOHW_AD7]I?_HC/C7_P B_^2*/^&1?V
ME_\ HC/C7_P B_\ DB@#YRHKZ-_X9%_:7_Z(SXU_\ (O_DBC_AD7]I?_ *(S
MXU_\ (O_ )(H ^<J*^C?^&1?VE_^B,^-?_ "+_Y(H_X9%_:7_P"B,^-?_ "+
M_P"2* /G*BOHW_AD7]I?_HC/C7_P B_^2*/^&1?VE_\ HC/C7_P B_\ DB@#
MYRHKZ-_X9%_:7_Z(SXU_\ (O_DBC_AD7]I?_ *(SXU_\ (O_ )(H ^<J*^C?
M^&1?VE_^B,^-?_ "+_Y(H_X9%_:7_P"B,^-?_ "+_P"2* /G*BOHW_AD7]I?
M_HC/C7_P B_^2*/^&1?VE_\ HC/C7_P B_\ DB@#YRHKZ-_X9%_:7_Z(SXU_
M\ (O_DBC_AD7]I?_ *(SXU_\ (O_ )(H ^<J*^C?^&1?VE_^B,^-?_ "+_Y(
MH_X9%_:7_P"B,^-?_ "+_P"2* /G*BOHW_AD7]I?_HC/C7_P B_^2*/^&1?V
ME_\ HC/C7_P B_\ DB@#YRHKZ-_X9%_:7_Z(SXU_\ (O_DBC_AD7]I?_ *(S
MXU_\ (O_ )(H ^<J*^C?^&1?VE_^B,^-?_ "+_Y(H_X9%_:7_P"B,^-?_ "+
M_P"2* /G*BOHW_AD7]I?_HC/C7_P B_^2*/^&1?VE_\ HC/C7_P B_\ DB@#
MYRHKZ-_X9%_:7_Z(SXU_\ (O_DBC_AD7]I?_ *(SXU_\ (O_ )(H ^<J*^C?
M^&1?VE_^B,^-?_ "+_Y(H_X9%_:7_P"B,^-?_ "+_P"2* /G*BOHW_AD7]I?
M_HC/C7_P B_^2*/^&1?VE_\ HC/C7_P B_\ DB@#YRHKZ-_X9%_:7_Z(SXU_
M\ (O_DBC_AD7]I?_ *(SXU_\ (O_ )(H ^<J*^C?^&1?VE_^B,^-?_ "+_Y(
MH_X9%_:7_P"B,^-?_ "+_P"2* /G*BOHW_AD7]I?_HC/C7_P B_^2*/^&1?V
ME_\ HC/C7_P B_\ DB@#YRHKZ-_X9%_:7_Z(SXU_\ (O_DBC_AD7]I?_ *(S
MXU_\ (O_ )(H ^<J*^C?^&1?VE_^B,^-?_ "+_Y(H_X9%_:7_P"B,^-?_ "+
M_P"2* /G*BOHW_AD7]I?_HC/C7_P B_^2*/^&1?VE_\ HC/C7_P B_\ DB@#
MYRHKZ-_X9%_:7_Z(SXU_\ (O_DBC_AD7]I?_ *(SXU_\ (O_ )(H ^<J*^C?
M^&1?VE_^B,^-?_ "+_Y(H_X9%_:7_P"B,^-?_ "+_P"2* /G*BOHW_AD7]I?
M_HC/C7_P B_^2*/^&1?VE_\ HC/C7_P B_\ DB@#YRHKZ-_X9%_:7_Z(SXU_
M\ (O_DBC_AD7]I?_ *(SXU_\ (O_ )(H ^<J*^C?^&1?VE_^B,^-?_ "+_Y(
MH_X9%_:7_P"B,^-?_ "+_P"2* /G*BOHW_AD7]I?_HC/C7_P B_^2*/^&1?V
ME_\ HC/C7_P B_\ DB@#YRHKZ-_X9%_:7_Z(SXU_\ (O_DBC_AD7]I?_ *(S
MXU_\ (O_ )(H ^<J*^C?^&1?VE_^B,^-?_ "+_Y(H_X9%_:7_P"B,^-?_ "+
M_P"2* /G*BOHW_AD7]I?_HC/C7_P B_^2*/^&1?VE_\ HC/C7_P B_\ DB@#
MYRHKZ-_X9%_:7_Z(SXU_\ (O_DBC_AD7]I?_ *(SXU_\ (O_ )(H ^<J*^C?
M^&1?VE_^B,^-?_ "+_Y(H_X9%_:7_P"B,^-?_ "+_P"2* /G*BOHW_AD7]I?
M_HC/C7_P B_^2*/^&1?VE_\ HC/C7_P B_\ DB@#YRHKZ-_X9%_:7_Z(SXU_
M\ (O_DBC_AD7]I?_ *(SXU_\ (O_ )(H ^<J*^C?^&1?VE_^B,^-?_ "+_Y(
MH_X9%_:7_P"B,^-?_ "+_P"2* /G*BOHW_AD7]I?_HC/C7_P B_^2*/^&1?V
ME_\ HC/C7_P B_\ DB@#YRHKZ-_X9%_:7_Z(SXU_\ (O_DBC_AD7]I?_ *(S
MXU_\ (O_ )(H ^<J*^C?^&1?VE_^B,^-?_ "+_Y(H_X9%_:7_P"B,^-?_ "+
M_P"2* /G*BOHW_AD7]I?_HC/C7_P B_^2*/^&1?VE_\ HC/C7_P B_\ DB@#
MYRHKZ-_X9%_:7_Z(SXU_\ (O_DBC_AD7]I?_ *(SXU_\ (O_ )(H ^<J*^C?
M^&1?VE_^B,^-?_ "+_Y(H_X9%_:7_P"B,^-?_ "+_P"2* /G*BOHW_AD7]I?
M_HC/C7_P B_^2*/^&1?VE_\ HC/C7_P B_\ DB@#YRHKZ-_X9%_:7_Z(SXU_
M\ (O_DBC_AD7]I?_ *(SXU_\ (O_ )(H ^<J*^C?^&1?VE_^B,^-?_ "+_Y(
MH_X9%_:7_P"B,^-?_ "+_P"2* /G*BOHW_AD7]I?_HC/C7_P B_^2*/^&1?V
ME_\ HC/C7_P B_\ DB@#YRHKZ-_X9%_:7_Z(SXU_\ (O_DBC_AD7]I?_ *(S
MXU_\ (O_ )(H ^<J*^C?^&1?VE_^B,^-?_ "+_Y(H_X9%_:7_P"B,^-?_ "+
M_P"2* /G*BOHW_AD7]I?_HC/C7_P B_^2*/^&1?VE_\ HC/C7_P B_\ DB@#
MYRHKZ-_X9%_:7_Z(SXU_\ (O_DBC_AD7]I?_ *(SXU_\ (O_ )(H ^<J*^C?
M^&1?VE_^B,^-?_ "+_Y(H_X9%_:7_P"B,^-?_ "+_P"2* /G*BOHW_AD7]I?
M_HC/C7_P B_^2*/^&1?VE_\ HC/C7_P B_\ DB@#YRHKZ-_X9%_:7_Z(SXU_
M\ (O_DBC_AD7]I?_ *(SXU_\ (O_ )(H ^<J*^C?^&1?VE_^B,^-?_ "+_Y(
MH_X9%_:7_P"B,^-?_ "+_P"2* /G*BOHW_AD7]I?_HC/C7_P B_^2*/^&1?V
ME_\ HC/C7_P B_\ DB@#YRHKZ-_X9%_:7_Z(SXU_\ (O_DBC_AD7]I?_ *(S
MXU_\ (O_ )(H ^<J*^C?^&1?VE_^B,^-?_ "+_Y(H_X9%_:7_P"B,^-?_ "+
M_P"2* /G*BOHW_AD7]I?_HC/C7_P B_^2*/^&1?VE_\ HC/C7_P B_\ DB@#
MYRHKZ-_X9%_:7_Z(SXU_\ (O_DBC_AD7]I?_ *(SXU_\ (O_ )(H ^<J*^C?
M^&1?VE_^B,^-?_ "+_Y(H_X9%_:7_P"B,^-?_ "+_P"2* /G*BOHW_AD7]I?
M_HC/C7_P B_^2*/^&1?VE_\ HC/C7_P B_\ DB@#YRHKZ-_X9%_:7_Z(SXU_
M\ (O_DBC_AD7]I?_ *(SXU_\ (O_ )(H ^<J*^C?^&1?VE_^B,^-?_ "+_Y(
MH_X9%_:7_P"B,^-?_ "+_P"2* /G*BOHW_AD7]I?_HC/C7_P B_^2*/^&1?V
ME_\ HC/C7_P B_\ DB@#YRHKZ-_X9%_:7_Z(SXU_\ (O_DBC_AD7]I?_ *(S
MXU_\ (O_ )(H ^<J*^C?^&1?VE_^B,^-?_ "+_Y(H_X9%_:7_P"B,^-?_ "+
M_P"2* /G*BOHW_AD7]I?_HC/C7_P B_^2*/^&1?VE_\ HC/C7_P B_\ DB@#
MYRHKZ-_X9%_:7_Z(SXU_\ (O_DBC_AD7]I?_ *(SXU_\ (O_ )(H ^<J*^C?
M^&1?VE_^B,^-?_ "+_Y(H_X9%_:7_P"B,^-?_ "+_P"2* /G*BOHW_AD7]I?
M_HC/C7_P B_^2*/^&1?VE_\ HC/C7_P B_\ DB@#YRHKZ-_X9%_:7_Z(SXU_
M\ (O_DBC_AD7]I?_ *(SXU_\ (O_ )(H ^<J*^C?^&1?VE_^B,^-?_ "+_Y(
MH_X9%_:7_P"B,^-?_ "+_P"2* /G*BOHW_AD7]I?_HC/C7_P B_^2*/^&1?V
ME_\ HC/C7_P B_\ DB@#YRHKZ-_X9%_:7_Z(SXU_\ (O_DBC_AD7]I?_ *(S
MXU_\ (O_ )(H ^<J*^C?^&1?VE_^B,^-?_ "+_Y(H_X9%_:7_P"B,^-?_ "+
M_P"2* /G*BOHW_AD7]I?_HC/C7_P B_^2*/^&1?VE_\ HC/C7_P B_\ DB@#
MYRHKZ-_X9%_:7_Z(SXU_\ (O_DBC_AD7]I?_ *(SXU_\ (O_ )(H ^<J*^C?
M^&1?VE_^B,^-?_ "+_Y(H_X9%_:7_P"B,^-?_ "+_P"2* /G*BOHW_AD7]I?
M_HC/C7_P B_^2*/^&1?VE_\ HC/C7_P B_\ DB@#YRHKZ-_X9%_:7_Z(SXU_
M\ (O_DBC_AD7]I?_ *(SXU_\ (O_ )(H ^<J*^C?^&1?VE_^B,^-?_ "+_Y(
MH_X9%_:7_P"B,^-?_ "+_P"2* /G*BOHW_AD7]I?_HC/C7_P B_^2*/^&1?V
ME_\ HC/C7_P B_\ DB@#YRHKZ-_X9%_:7_Z(SXU_\ (O_DBC_AD7]I?_ *(S
MXU_\ (O_ )(H ^<J*^C?^&1?VE_^B,^-?_ "+_Y(H_X9%_:7_P"B,^-?_ "+
M_P"2* /G*BOHW_AD7]I?_HC/C7_P B_^2*/^&1?VE_\ HC/C7_P B_\ DB@#
MYRHKZ-_X9%_:7_Z(SXU_\ (O_DBC_AD7]I?_ *(SXU_\ (O_ )(H ^<J*^C?
M^&1?VE_^B,^-?_ "+_Y(H_X9%_:7_P"B,^-?_ "+_P"2* /G*BOHW_AD7]I?
M_HC/C7_P B_^2*/^&1?VE_\ HC/C7_P B_\ DB@#YRHKZ-_X9%_:7_Z(SXU_
M\ (O_DBC_AD7]I?_ *(SXU_\ (O_ )(H ^<J*^C?^&1?VE_^B,^-?_ "+_Y(
MH_X9%_:7_P"B,^-?_ "+_P"2* /G*BOHW_AD7]I?_HC/C7_P B_^2*/^&1?V
ME_\ HC/C7_P B_\ DB@#YRHKZ-_X9%_:7_Z(SXU_\ (O_DBC_AD7]I?_ *(S
MXU_\ (O_ )(H ^<J*^C?^&1?VE_^B,^-?_ "+_Y(H_X9%_:7_P"B,^-?_ "+
M_P"2* /G*BOHW_AD7]I?_HC/C7_P B_^2*/^&1?VE_\ HC/C7_P B_\ DB@#
MYRHKZ-_X9%_:7_Z(SXU_\ (O_DBC_AD7]I?_ *(SXU_\ (O_ )(H ^<J*^C?
M^&1?VE_^B,^-?_ "+_Y(H_X9%_:7_P"B,^-?_ "+_P"2* /G*BOHW_AD7]I?
M_HC/C7_P B_^2*/^&1?VE_\ HC/C7_P B_\ DB@#YRHKZ-_X9%_:7_Z(SXU_
M\ (O_DBC_AD7]I?_ *(SXU_\ (O_ )(H ^<J*^C?^&1?VE_^B,^-?_ "+_Y(
MH_X9%_:7_P"B,^-?_ "+_P"2* /G*BOHW_AD7]I?_HC/C7_P B_^2*/^&1?V
ME_\ HC/C7_P B_\ DB@#YRHKZ-_X9%_:7_Z(SXU_\ (O_DBC_AD7]I?_ *(S
MXU_\ (O_ )(H ^<J*^C?^&1?VE_^B,^-?_ "+_Y(H_X9%_:7_P"B,^-?_ "+
M_P"2* /G*BOHW_AD7]I?_HC/C7_P B_^2*/^&1?VE_\ HC/C7_P B_\ DB@#
MYRHKZ-_X9%_:7_Z(SXU_\ (O_DBC_AD7]I?_ *(SXU_\ (O_ )(H ^<J*^C?
M^&1?VE_^B,^-?_ "+_Y(H_X9%_:7_P"B,^-?_ "+_P"2* /G*BOHW_AD7]I?
M_HC/C7_P B_^2*/^&1?VE_\ HC/C7_P B_\ DB@#YRHKZ-_X9%_:7_Z(SXU_
M\ (O_DBC_AD7]I?_ *(SXU_\ (O_ )(H ^<J*^C?^&1?VE_^B,^-?_ "+_Y(
MH_X9%_:7_P"B,^-?_ "+_P"2* /G*BOHW_AD7]I?_HC/C7_P B_^2*/^&1?V
ME_\ HC/C7_P B_\ DB@#YRHKZ-_X9%_:7_Z(SXU_\ (O_DBC_AD7]I?_ *(S
MXU_\ (O_ )(H ^<J*^C?^&1?VE_^B,^-?_ "+_Y(H_X9%_:7_P"B,^-?_ "+
M_P"2* /G*BOHW_AD7]I?_HC/C7_P B_^2*/^&1?VE_\ HC/C7_P B_\ DB@#
MYRHKZ-_X9%_:7_Z(SXU_\ (O_DBC_AD7]I?_ *(SXU_\ (O_ )(H ^<J*^C?
M^&1?VE_^B,^-?_ "+_Y(H_X9%_:7_P"B,^-?_ "+_P"2* /G*BOHW_AD7]I?
M_HC/C7_P B_^2*/^&1?VE_\ HC/C7_P B_\ DB@#YRHKZ-_X9%_:7_Z(SXU_
M\ (O_DBC_AD7]I?_ *(SXU_\ (O_ )(H ^<J*^C?^&1?VE_^B,^-?_ "+_Y(
MH_X9%_:7_P"B,^-?_ "+_P"2* /G*BOHW_AD7]I?_HC/C7_P B_^2*/^&1?V
ME_\ HC/C7_P B_\ DB@#YRHKZ-_X9%_:7_Z(SXU_\ (O_DBC_AD7]I?_ *(S
MXU_\ (O_ )(H ^<J*^C?^&1?VE_^B,^-?_ "+_Y(H_X9%_:7_P"B,^-?_ "+
M_P"2* /G*BOHW_AD7]I?_HC/C7_P B_^2*/^&1?VE_\ HC/C7_P B_\ DB@#
MYRHKZ-_X9%_:7_Z(SXU_\ (O_DBC_AD7]I?_ *(SXU_\ (O_ )(H ^<J*^C?
M^&1?VE_^B,^-?_ "+_Y(H_X9%_:7_P"B,^-?_ "+_P"2* /G*BOHW_AD7]I?
M_HC/C7_P B_^2*/^&1?VE_\ HC/C7_P B_\ DB@#YRHKZ-_X9%_:7_Z(SXU_
M\ (O_DBC_AD7]I?_ *(SXU_\ (O_ )(H ^<J*^C?^&1?VE_^B,^-?_ "+_Y(
MH_X9%_:7_P"B,^-?_ "+_P"2* /G*BOHW_AD7]I?_HC/C7_P B_^2*/^&1?V
ME_\ HC/C7_P B_\ DB@#YRHKZ-_X9%_:7_Z(SXU_\ (O_DBC_AD7]I?_ *(S
MXU_\ (O_ )(H ^<J*^C?^&1?VE_^B,^-?_ "+_Y(H_X9%_:7_P"B,^-?_ "+
M_P"2* /G*BOHMOV1_P!I51EO@WXT4>]A$/\ VXJ-?V3?VD')5/@]XR9AU L8
ML_\ I1[T ?/%%?1O_#(O[2__ $1GQK_X 1?_ "11_P ,B_M+_P#1&?&O_@!%
M_P#)% 'SE17T;_PR+^TO_P!$9\:_^ $7_P D4?\ #(O[2_\ T1GQK_X 1?\
MR10!\Y45]&_\,B_M+_\ 1&?&O_@!%_\ )%'_  R+^TO_ -$9\:_^ $7_ ,D4
M ?.5%?1O_#(O[2__ $1GQK_X 1?_ "11_P ,B_M+_P#1&?&O_@!%_P#)% 'S
ME17T;_PR+^TO_P!$9\:_^ $7_P D4?\ #(O[2_\ T1GQK_X 1?\ R10!\Y45
M]&_\,B_M+_\ 1&?&O_@!%_\ )%'_  R+^TO_ -$9\:_^ $7_ ,D4 ?.5%?1O
M_#(O[2__ $1GQK_X 1?_ "11_P ,B_M+_P#1&?&O_@!%_P#)% 'SE17T;_PR
M+^TO_P!$9\:_^ $7_P D4?\ #(O[2_\ T1GQK_X 1?\ R10!\Y45]&_\,B_M
M+_\ 1&?&O_@!%_\ )%'_  R+^TO_ -$9\:_^ $7_ ,D4 ?.5%?1O_#(O[2__
M $1GQK_X 1?_ "11_P ,B_M+_P#1&?&O_@!%_P#)% 'SE17T;_PR+^TO_P!$
M9\:_^ $7_P D4?\ #(O[2_\ T1GQK_X 1?\ R10!\Y45]&_\,B_M+_\ 1&?&
MO_@!%_\ )%'_  R+^TO_ -$9\:_^ $7_ ,D4 ?.5%?1O_#(O[2__ $1GQK_X
M 1?_ "11_P ,B_M+_P#1&?&O_@!%_P#)% 'SE17T;_PR+^TO_P!$9\:_^ $7
M_P D4?\ #(O[2_\ T1GQK_X 1?\ R10!\Y45]&_\,B_M+_\ 1&?&O_@!%_\
M)%'_  R+^TO_ -$9\:_^ $7_ ,D4 ?.5%?1O_#(O[2__ $1GQK_X 1?_ "11
M_P ,B_M+_P#1&?&O_@!%_P#)% 'SE17T;_PR+^TO_P!$9\:_^ $7_P D4?\
M#(O[2_\ T1GQK_X 1?\ R10!\Y45]&_\,B_M+_\ 1&?&O_@!%_\ )%'_  R+
M^TO_ -$9\:_^ $7_ ,D4 ?.5%?1O_#(O[2__ $1GQK_X 1?_ "11_P ,B_M+
M_P#1&?&O_@!%_P#)% 'SE17T;_PR+^TO_P!$9\:_^ $7_P D4?\ #(O[2_\
MT1GQK_X 1?\ R10!\Y45]&_\,B_M+_\ 1&?&O_@!%_\ )%'_  R+^TO_ -$9
M\:_^ $7_ ,D4 ?.5%?1O_#(O[2__ $1GQK_X 1?_ "11_P ,B_M+_P#1&?&O
M_@!%_P#)% 'SE17T;_PR+^TO_P!$9\:_^ $7_P D4?\ #(O[2_\ T1GQK_X
M1?\ R10!\Y45]&_\,B_M+_\ 1&?&O_@!%_\ )%'_  R+^TO_ -$9\:_^ $7_
M ,D4 ?.5%?1O_#(O[2__ $1GQK_X 1?_ "11_P ,B_M+_P#1&?&O_@!%_P#)
M% 'SE17T;_PR+^TO_P!$9\:_^ $7_P D4?\ #(O[2_\ T1GQK_X 1?\ R10!
M\Y45]&_\,B_M+_\ 1&?&O_@!%_\ )%'_  R+^TO_ -$9\:_^ $7_ ,D4 ?.5
M%?1O_#(O[2__ $1GQK_X 1?_ "11_P ,B_M+_P#1&?&O_@!%_P#)% 'SE17T
M;_PR+^TO_P!$9\:_^ $7_P D4?\ #(O[2_\ T1GQK_X 1?\ R10!\Y45]&_\
M,B_M+_\ 1&?&O_@!%_\ )%'_  R+^TO_ -$9\:_^ $7_ ,D4 ?.5%?1O_#(O
M[2__ $1GQK_X 1?_ "11_P ,B_M+_P#1&?&O_@!%_P#)% 'SE17T;_PR+^TO
M_P!$9\:_^ $7_P D4?\ #(O[2_\ T1GQK_X 1?\ R10!\Y45]&_\,B_M+_\
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M 1?_ "10!\Y45]&_\,B_M+_]$9\:_P#@!%_\D4?\,B_M+_\ 1&?&O_@!%_\
M)% 'SE17T;_PR+^TO_T1GQK_ . $7_R11_PR+^TO_P!$9\:_^ $7_P D4 ?.
M5%?1O_#(O[2__1&?&O\ X 1?_)%'_#(O[2__ $1GQK_X 1?_ "10!\Y45]&_
M\,B_M+_]$9\:_P#@!%_\D4?\,B_M+_\ 1&?&O_@!%_\ )% 'SE17T;_PR+^T
MO_T1GQK_ . $7_R11_PR+^TO_P!$9\:_^ $7_P D4 ?.5%?1O_#(O[2__1&?
M&O\ X 1?_)%'_#(O[2__ $1GQK_X 1?_ "10!\Y45]&_\,B_M+_]$9\:_P#@
M!%_\D4?\,B_M+_\ 1&?&O_@!%_\ )% 'SE17T;_PR+^TO_T1GQK_ . $7_R1
M1_PR+^TO_P!$9\:_^ $7_P D4 ?.5%?1O_#(O[2__1&?&O\ X 1?_)%'_#(O
M[2__ $1GQK_X 1?_ "10!\Y45]&_\,B_M+_]$9\:_P#@!%_\D4?\,B_M+_\
M1&?&O_@!%_\ )% 'SE17T;_PR+^TO_T1GQK_ . $7_R11_PR+^TO_P!$9\:_
M^ $7_P D4 ?.5%?1O_#(O[2__1&?&O\ X 1?_)%'_#(O[2__ $1GQK_X 1?_
M "10!\Y45]&_\,B_M+_]$9\:_P#@!%_\D4?\,B_M+_\ 1&?&O_@!%_\ )% '
MSE17T;_PR+^TO_T1GQK_ . $7_R11_PR+^TO_P!$9\:_^ $7_P D4 ?.5%?1
MO_#(O[2__1&?&O\ X 1?_)%'_#(O[2__ $1GQK_X 1?_ "10!\Y45]&_\,B_
MM+_]$9\:_P#@!%_\D4?\,B_M+_\ 1&?&O_@!%_\ )% 'SE17T;_PR+^TO_T1
MGQK_ . $7_R11_PR+^TO_P!$9\:_^ $7_P D4 ?.5%?1O_#(O[2__1&?&O\
MX 1?_)%'_#(O[2__ $1GQK_X 1?_ "10!\Y45]&_\,B_M+_]$9\:_P#@!%_\
MD4?\,B_M+_\ 1&?&O_@!%_\ )% 'SE17T;_PR+^TO_T1GQK_ . $7_R136_9
M'_:40$M\&_&B@<DFPB'_ +<4 ?.E%?0Z?LF?M(.<)\'O&3'T%C#_ /)%3?\
M#(O[2W_1&?&O_@!%_P#)% 'SE17T;_PR+^TO_P!$9\:_^ $7_P D4?\ #(O[
M2_\ T1GQK_X 1?\ R10!\Y45]&_\,B_M+_\ 1&?&O_@!%_\ )%'_  R+^TO_
M -$9\:_^ $7_ ,D4 ?.5%?1O_#(O[2__ $1GQK_X 1?_ "11_P ,B_M+_P#1
M&?&O_@!%_P#)% 'SE17T;_PR+^TO_P!$9\:_^ $7_P D4?\ #(O[2_\ T1GQ
MK_X 1?\ R10!\Y45]&_\,B_M+_\ 1&?&O_@!%_\ )%'_  R+^TO_ -$9\:_^
M $7_ ,D4 ?.5%?1O_#(O[2__ $1GQK_X 1?_ "11_P ,B_M+_P#1&?&O_@!%
M_P#)% 'SE17T;_PR+^TO_P!$9\:_^ $7_P D4?\ #(O[2_\ T1GQK_X 1?\
MR10!\Y45]&_\,B_M+_\ 1&?&O_@!%_\ )%'_  R+^TO_ -$9\:_^ $7_ ,D4
M ?.5%?1O_#(O[2__ $1GQK_X 1?_ "11_P ,B_M+_P#1&?&O_@!%_P#)% 'S
ME17T;_PR+^TO_P!$9\:_^ $7_P D4?\ #(O[2_\ T1GQK_X 1?\ R10!\Y45
M]&_\,B_M+_\ 1&?&O_@!%_\ )%'_  R+^TO_ -$9\:_^ $7_ ,D4 ?.5%?1O
M_#(O[2__ $1GQK_X 1?_ "11_P ,B_M+_P#1&?&O_@!%_P#)% 'SE17T;_PR
M+^TO_P!$9\:_^ $7_P D4?\ #(O[2_\ T1GQK_X 1?\ R10!\Y45]&_\,B_M
M+_\ 1&?&O_@!%_\ )%'_  R+^TO_ -$9\:_^ $7_ ,D4 ?.5%?1O_#(O[2__
M $1GQK_X 1?_ "11_P ,B_M+_P#1&?&O_@!%_P#)% 'SE17T;_PR+^TO_P!$
M9\:_^ $7_P D4?\ #(O[2_\ T1GQK_X 1?\ R10!\Y45]&_\,B_M+_\ 1&?&
MO_@!%_\ )%'_  R+^TO_ -$9\:_^ $7_ ,D4 ?.5%?1O_#(O[2__ $1GQK_X
M 1?_ "11_P ,B_M+_P#1&?&O_@!%_P#)% 'SE17T;_PR+^TO_P!$9\:_^ $7
M_P D4?\ #(O[2_\ T1GQK_X 1?\ R10!\Y45]&_\,B_M+_\ 1&?&O_@!%_\
M)%'_  R+^TO_ -$9\:_^ $7_ ,D4 ?.5%?1O_#(O[2__ $1GQK_X 1?_ "11
M_P ,B_M+_P#1&?&O_@!%_P#)% 'SE17T;_PR+^TO_P!$9\:_^ $7_P D4?\
M#(O[2_\ T1GQK_X 1?\ R10!\Y45]&_\,B_M+_\ 1&?&O_@!%_\ )%'_  R+
M^TO_ -$9\:_^ $7_ ,D4 ?.5%?1O_#(O[2__ $1GQK_X 1?_ "11_P ,B_M+
M_P#1&?&O_@!%_P#)% 'SE17T;_PR+^TO_P!$9\:_^ $7_P D4?\ #(O[2_\
MT1GQK_X 1?\ R10!\Y45]&_\,B_M+_\ 1&?&O_@!%_\ )%'_  R+^TO_ -$9
M\:_^ $7_ ,D4 ?.5%?1O_#(O[2__ $1GQK_X 1?_ "11_P ,B_M+_P#1&?&O
M_@!%_P#)% 'SE17T;_PR+^TO_P!$9\:_^ $7_P D4?\ #(O[2_\ T1GQK_X
M1?\ R10!\Y45]&_\,B_M+_\ 1&?&O_@!%_\ )%'_  R+^TO_ -$9\:_^ $7_
M ,D4 ?.5%?1O_#(O[2__ $1GQK_X 1?_ "11_P ,B_M+_P#1&?&O_@!%_P#)
M% 'SE17T;_PR+^TO_P!$9\:_^ $7_P D4?\ #(O[2_\ T1GQK_X 1?\ R10!
M\Y45]&_\,B_M+_\ 1&?&O_@!%_\ )%'_  R+^TO_ -$9\:_^ $7_ ,D4 ?.5
M%?1O_#(O[2__ $1GQK_X 1?_ "11_P ,B_M+_P#1&?&O_@!%_P#)% 'SE17T
M;_PR+^TO_P!$9\:_^ $7_P D4?\ #(O[2_\ T1GQK_X 1?\ R10!\Y45]&_\
M,B_M+_\ 1&?&O_@!%_\ )%'_  R+^TO_ -$9\:_^ $7_ ,D4 ?.5%?1O_#(O
M[2__ $1GQK_X 1?_ "136_9(_:409?X-^-%'O8Q#_P!N* /G2BOH>/\ 9,_:
M0E.(_@]XR<^@L8C_ .W%3?\ #(O[2_\ T1GQK_X 1?\ R10!\Y45]&_\,B_M
M+_\ 1&?&O_@!%_\ )%'_  R+^TO_ -$9\:_^ $7_ ,D4 ?.5%?1O_#(O[2__
M $1GQK_X 1?_ "11_P ,B_M+_P#1&?&O_@!%_P#)% 'SE17T;_PR+^TO_P!$
M9\:_^ $7_P D4?\ #(O[2_\ T1GQK_X 1?\ R10!\Y45]&_\,B_M+_\ 1&?&
MO_@!%_\ )%'_  R+^TO_ -$9\:_^ $7_ ,D4 ?.5%?1O_#(O[2__ $1GQK_X
M 1?_ "11_P ,B_M+_P#1&?&O_@!%_P#)% 'SE17T;_PR+^TO_P!$9\:_^ $7
M_P D4?\ #(O[2_\ T1GQK_X 1?\ R10!\Y45]&_\,B_M+_\ 1&?&O_@!%_\
M)%'_  R+^TO_ -$9\:_^ $7_ ,D4 ?.5%?1O_#(O[2__ $1GQK_X 1?_ "11
M_P ,B_M+_P#1&?&O_@!%_P#)% 'SE17T;_PR+^TO_P!$9\:_^ $7_P D4?\
M#(O[2_\ T1GQK_X 1?\ R10!\Y45]&_\,B_M+_\ 1&?&O_@!%_\ )%'_  R+
M^TO_ -$9\:_^ $7_ ,D4 ?.5%?1O_#(O[2__ $1GQK_X 1?_ "11_P ,B_M+
M_P#1&?&O_@!%_P#)% 'SE17T;_PR+^TO_P!$9\:_^ $7_P D4?\ #(O[2_\
MT1GQK_X 1?\ R10!\Y45]&_\,B_M+_\ 1&?&O_@!%_\ )%'_  R+^TO_ -$9
M\:_^ $7_ ,D4 ?.5%?1O_#(O[2__ $1GQK_X 1?_ "11_P ,B_M+_P#1&?&O
M_@!%_P#)% 'SE17T;_PR+^TO_P!$9\:_^ $7_P D4?\ #(O[2_\ T1GQK_X
M1?\ R10!\Y45]&_\,B_M+_\ 1&?&O_@!%_\ )%'_  R+^TO_ -$9\:_^ $7_
M ,D4 ?.5%?1O_#(O[2__ $1GQK_X 1?_ "11_P ,B_M+_P#1&?&O_@!%_P#)
M% 'SE17T;_PR+^TO_P!$9\:_^ $7_P D4?\ #(O[2_\ T1GQK_X 1?\ R10!
M\Y45]&_\,B_M+_\ 1&?&O_@!%_\ )%'_  R+^TO_ -$9\:_^ $7_ ,D4 ?.5
M%?1O_#(O[2__ $1GQK_X 1?_ "11_P ,B_M+_P#1&?&O_@!%_P#)% 'SE17T
M;_PR+^TO_P!$9\:_^ $7_P D4?\ #(O[2_\ T1GQK_X 1?\ R10!\Y45]&_\
M,B_M+_\ 1&?&O_@!%_\ )%'_  R+^TO_ -$9\:_^ $7_ ,D4 ?.5%?1O_#(O
M[2__ $1GQK_X 1?_ "11_P ,B_M+_P#1&?&O_@!%_P#)% 'SE17T;_PR+^TO
M_P!$9\:_^ $7_P D4?\ #(O[2_\ T1GQK_X 1?\ R10!\Y45]&_\,B_M+_\
M1&?&O_@!%_\ )%'_  R+^TO_ -$9\:_^ $7_ ,D4 ?.5%?1O_#(O[2__ $1G
MQK_X 1?_ "11_P ,B_M+_P#1&?&O_@!%_P#)% 'SE17T;_PR+^TO_P!$9\:_
M^ $7_P D4?\ #(O[2_\ T1GQK_X 1?\ R10!\Y45]&_\,B_M+_\ 1&?&O_@!
M%_\ )%'_  R+^TO_ -$9\:_^ $7_ ,D4 ?.5%?1O_#(O[2__ $1GQK_X 1?_
M "11_P ,B_M+_P#1&?&O_@!%_P#)% 'SE17T;_PR+^TO_P!$9\:_^ $7_P D
M4?\ #(O[2_\ T1GQK_X 1?\ R10!\Y45]&_\,B_M+_\ 1&?&O_@!%_\ )%'_
M  R+^TO_ -$9\:_^ $7_ ,D4 ?.5%?1O_#(O[2__ $1GQK_X 1?_ "11_P ,
MB_M+_P#1&?&O_@!%_P#)% 'SE17T;_PR+^TO_P!$9\:_^ $7_P D4?\ #(O[
M2_\ T1GQK_X 1?\ R10!\Y45]&_\,B_M+_\ 1&?&O_@!%_\ )%'_  R+^TO_
M -$9\:_^ $7_ ,D4 ?.5%?1O_#(O[2__ $1GQK_X 1?_ "11_P ,B_M+_P#1
M&?&O_@!%_P#)% 'SE7IWP5_Y*Y\-O^QT\/?^G*WKO_\ AD7]I?\ Z(SXU_\
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M/_P&@_\ B*N44 4_[.T__GQL_P#P&@_^(H_L[3_^?&S_ / :#_XBKE% %/\
ML[3_ /GQL_\ P&@_^(H_L[3_ /GQL_\ P&@_^(JY10!3_L[3_P#GQL__  &@
M_P#B*/[.T_\ Y\;/_P !H/\ XBKE% %/^SM/_P"?&S_\!H/_ (BC^SM/_P"?
M&S_\!H/_ (BKE% %/^SM/_Y\;/\ \!H/_B*/[.T__GQL_P#P&@_^(JY10!3_
M +.T_P#Y\;/_ ,!H/_B*/[.T_P#Y\;/_ ,!H/_B*N44 4_[.T_\ Y\;/_P !
MH/\ XBC^SM/_ .?&S_\  :#_ .(JY10!3_L[3_\ GQL__ :#_P"(H_L[3_\
MGQL__ :#_P"(JY10!3_L[3_^?&S_ / :#_XBC^SM/_Y\;/\ \!H/_B*N44 4
M_P"SM/\ ^?&S_P# :#_XBC^SM/\ ^?&S_P# :#_XBKE% %/^SM/_ .?&S_\
M :#_ .(H_L[3_P#GQL__  &@_P#B*N44 4_[.T__ )\;/_P&@_\ B*/[.T__
M )\;/_P&@_\ B*N44 4_[.T__GQL_P#P&@_^(H_L[3_^?&S_ / :#_XBKE%
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M(JY10!3_ +.T_P#Y\;/_ ,!H/_B*/[.T_P#Y\;/_ ,!H/_B*N44 4_[.T_\
MY\;/_P !H/\ XBC^SM/_ .?&S_\  :#_ .(JY10!3_L[3_\ GQL__ :#_P"(
MH_L[3_\ GQL__ :#_P"(JY10!3_L[3_^?&S_ / :#_XBC^SM/_Y\;/\ \!H/
M_B*N44 4_P"SM/\ ^?&S_P# :#_XBC^SM/\ ^?&S_P# :#_XBKE% %/^SM/_
M .?&S_\  :#_ .(H_L[3_P#GQL__  &@_P#B*N44 4_[.T__ )\;/_P&@_\
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M_P"(H_L[3_\ GQL__ :#_P"(JY10!3_L[3_^?&S_ / :#_XBC^SM/_Y\;/\
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M_P#P&@_^(JY10!3_ +.T_P#Y\;/_ ,!H/_B*/[.T_P#Y\;/_ ,!H/_B*N44
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MN44 4_[.T_\ Y\;/_P !H/\ XBC^SM/_ .?&S_\  :#_ .(JY10!3_L[3_\
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MC^SM/_Y\;/\ \!H/_B*N44 4_P"SM/\ ^?&S_P# :#_XBC^SM/\ ^?&S_P#
M:#_XBKE% %/^SM/_ .?&S_\  :#_ .(H_L[3_P#GQL__  &@_P#B*N44 4_[
M.T__ )\;/_P&@_\ B*/[.T__ )\;/_P&@_\ B*N44 4_[.T__GQL_P#P&@_^
M(H_L[3_^?&S_ / :#_XBKE% %/\ L[3_ /GQL_\ P&@_^(H_L[3_ /GQL_\
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M% %/^SM/_P"?&S_\!H/_ (BC^SM/_P"?&S_\!H/_ (BKE% %/^SM/_Y\;/\
M\!H/_B*/[.T__GQL_P#P&@_^(JY10!3_ +.T_P#Y\;/_ ,!H/_B*/[.T_P#Y
M\;/_ ,!H/_B*N44 4_[.T_\ Y\;/_P !H/\ XBC^SM/_ .?&S_\  :#_ .(J
MY10!3_L[3_\ GQL__ :#_P"(H_L[3_\ GQL__ :#_P"(JY10!3_L[3_^?&S_
M / :#_XBC^SM/_Y\;/\ \!H/_B*N44 4_P"SM/\ ^?&S_P# :#_XBC^SM/\
M^?&S_P# :#_XBKE% %/^SM/_ .?&S_\  :#_ .(H_L[3_P#GQL__  &@_P#B
M*N44 4_[.T__ )\;/_P&@_\ B*/[.T__ )\;/_P&@_\ B*N44 4_[.T__GQL
M_P#P&@_^(H_L[3_^?&S_ / :#_XBKE% %/\ L[3_ /GQL_\ P&@_^(H_L[3_
M /GQL_\ P&@_^(JY10!3_L[3_P#GQL__  &@_P#B*/[.T_\ Y\;/_P !H/\
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M/[.T_P#Y\;/_ ,!H/_B*N44 4_[.T_\ Y\;/_P !H/\ XBC^SM/_ .?&S_\
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M!3_L[3_^?&S_ / :#_XBC^SM/_Y\;/\ \!H/_B*N44 4_P"SM/\ ^?&S_P#
M:#_XBC^SM/\ ^?&S_P# :#_XBKE% %/^SM/_ .?&S_\  :#_ .(H_L[3_P#G
MQL__  &@_P#B*N44 4_[.T__ )\;/_P&@_\ B*/[.T__ )\;/_P&@_\ B*N4
M4 4_[.T__GQL_P#P&@_^(H_L[3_^?&S_ / :#_XBKE% %/\ L[3_ /GQL_\
MP&@_^(H_L[3_ /GQL_\ P&@_^(JY10!3_L[3_P#GQL__  &@_P#B*/[.T_\
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M_P#GQL__  &@_P#B*N44 4_[.T__ )\;/_P&@_\ B*/[.T__ )\;/_P&@_\
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M_P"(JY10!3_L[3_^?&S_ / :#_XBC^SM/_Y\;/\ \!H/_B*N44 4_P"SM/\
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M_P#Y\;/_ ,!H/_B*/[.T_P#Y\;/_ ,!H/_B*N44 4_[.T_\ Y\;/_P !H/\
MXBC^SM/_ .?&S_\  :#_ .(JY10!3_L[3_\ GQL__ :#_P"(H_L[3_\ GQL_
M_ :#_P"(JY10!3_L[3_^?&S_ / :#_XBC^SM/_Y\;/\ \!H/_B*N44 4_P"S
MM/\ ^?&S_P# :#_XBC^SM/\ ^?&S_P# :#_XBKE% %/^SM/_ .?&S_\  :#_
M .(H_L[3_P#GQL__  &@_P#B*N44 4_[.T__ )\;/_P&@_\ B*/[.T__ )\;
M/_P&@_\ B*N44 4_[.T__GQL_P#P&@_^(H_L[3_^?&S_ / :#_XBKE% %/\
ML[3_ /GQL_\ P&@_^(H_L[3_ /GQL_\ P&@_^(JY10!3_L[3_P#GQL__  &@
M_P#B*/[.T_\ Y\;/_P !H/\ XBKE% %/^SM/_P"?&S_\!H/_ (BC^SM/_P"?
M&S_\!H/_ (BKE% %/^SM/_Y\;/\ \!H/_B*/[.T__GQL_P#P&@_^(JY10!3_
M +.T_P#Y\;/_ ,!H/_B*/[.T_P#Y\;/_ ,!H/_B*N44 4_[.T_\ Y\;/_P !
MH/\ XBC^SM/_ .?&S_\  :#_ .(JY10!3_L[3_\ GQL__ :#_P"(H_L[3_\
MGQL__ :#_P"(JY10!3_L[3_^?&S_ / :#_XBC^SM/_Y\;/\ \!H/_B*N44 4
M_P"SM/\ ^?&S_P# :#_XBC^SM/\ ^?&S_P# :#_XBKE% %/^SM/_ .?&S_\
M :#_ .(H_L[3_P#GQL__  &@_P#B*N44 4_[.T__ )\;/_P&@_\ B*/[.T__
M )\;/_P&@_\ B*N44 4_[.T__GQL_P#P&@_^(H_L[3_^?&S_ / :#_XBKE%
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M?_@-!_\ $5<HH I_V=I__/C9_P#@-!_\11_9VG_\^-G_ . T'_Q%7** *?\
M9VG_ //C9_\ @-!_\11_9VG_ //C9_\ @-!_\15RB@"G_9VG_P#/C9_^ T'_
M ,11_9VG_P#/C9_^ T'_ ,15RB@"G_9VG_\ /C9_^ T'_P 11_9VG_\ /C9_
M^ T'_P 15RB@"G_9VG_\^-G_ . T'_Q%']G:?_SXV?\ X#0?_$5<HH I_P!G
M:?\ \^-G_P" T'_Q%']G:?\ \^-G_P" T'_Q%7** *?]G:?_ ,^-G_X#0?\
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M_P 15RB@"G_9VG_\^-G_ . T'_Q%']G:?_SXV?\ X#0?_$5<HH I_P!G:?\
M\^-G_P" T'_Q%']G:?\ \^-G_P" T'_Q%7** *?]G:?_ ,^-G_X#0?\ Q%']
MG:?_ ,^-G_X#0?\ Q%7** *?]G:?_P ^-G_X#0?_ !%']G:?_P ^-G_X#0?_
M !%7** *?]G:?_SXV?\ X#0?_$4?V=I__/C9_P#@-!_\15RB@"G_ &=I_P#S
MXV?_ (#0?_$4?V=I_P#SXV?_ (#0?_$5<HH I_V=I_\ SXV?_@-!_P#$4?V=
MI_\ SXV?_@-!_P#$5<HH I_V=I__ #XV?_@-!_\ $4?V=I__ #XV?_@-!_\
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M T'_ ,11_9VG_P#/C9_^ T'_ ,15RB@"G_9VG_\ /C9_^ T'_P 11_9VG_\
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M?_@-!_\ $5<HH I_V=I__/C9_P#@-!_\11_9VG_\^-G_ . T'_Q%7** *?\
M9VG_ //C9_\ @-!_\11_9VG_ //C9_\ @-!_\15RB@"G_9VG_P#/C9_^ T'_
M ,11_9VG_P#/C9_^ T'_ ,15RB@"G_9VG_\ /C9_^ T'_P 11_9VG_\ /C9_
M^ T'_P 15RB@"G_9VG_\^-G_ . T'_Q%']G:?_SXV?\ X#0?_$5<HH I_P!G
M:?\ \^-G_P" T'_Q%']G:?\ \^-G_P" T'_Q%7** *?]G:?_ ,^-G_X#0?\
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M_P 15RB@"G_9VG_\^-G_ . T'_Q%']G:?_SXV?\ X#0?_$5<HH I_P!G:?\
M\^-G_P" T'_Q%']G:?\ \^-G_P" T'_Q%7** *?]G:?_ ,^-G_X#0?\ Q%']
MG:?_ ,^-G_X#0?\ Q%7** *?]G:?_P ^-G_X#0?_ !%']G:?_P ^-G_X#0?_
M !%7** *?]G:?_SXV?\ X#0?_$4?V=I__/C9_P#@-!_\15RB@"G_ &=I_P#S
MXV?_ (#0?_$4?V=I_P#SXV?_ (#0?_$5<HH I_V=I_\ SXV?_@-!_P#$4?V=
MI_\ SXV?_@-!_P#$5<HH I_V=I__ #XV?_@-!_\ $4?V=I__ #XV?_@-!_\
M$5<HH I_V=I__/C9_P#@-!_\11_9VG_\^-G_ . T'_Q%7** *?\ 9VG_ //C
M9_\ @-!_\16'X@M+*'3YG2RLP0G_ #[0^_\ L5U%<]XE_P"09/\ [A_K0!YK
MX:>*:_>-[2S*C;Q]FA]<?W,=^?RKUU=/T\JI^PV?W1_RZP^G^Y7COA3_ )"4
MG_ ?YBO;D^XO^ZO\A0!5_L[3_P#GQL__  &@_P#B*/[.T_\ Y\;/_P !H/\
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M/[.T_P#Y\;/_ ,!H/_B*N44 4_[.T_\ Y\;/_P !H/\ XBC^SM/_ .?&S_\
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M!3_L[3_^?&S_ / :#_XBC^SM/_Y\;/\ \!H/_B*N44 4_P"SM/\ ^?&S_P#
M:#_XBC^SM/\ ^?&S_P# :#_XBKE% %/^SM/_ .?&S_\  :#_ .(H_L[3_P#G
MQL__  &@_P#B*N44 4_[.T__ )\;/_P&@_\ B*/[.T__ )\;/_P&@_\ B*N4
M4 4_[.T__GQL_P#P&@_^(H_L[3_^?&S_ / :#_XBKE% %/\ L[3_ /GQL_\
MP&@_^(KG/$EK9V]C*\=E9AEC8C_1H>HR>R>W]:Z^N6\5_P#(.F_ZY/\ R:@#
M@O!#0WE]MFM+-EVMQ]EAQQG_ &/\_P O6O[.T_\ Y\;/_P !H/\ XBO(?A]_
MQ_C_ '7_ *U[50!3_L[3_P#GQL__  &@_P#B*/[.T_\ Y\;/_P !H/\ XBKE
M% %/^SM/_P"?&S_\!H/_ (BC^SM/_P"?&S_\!H/_ (BKE% %/^SM/_Y\;/\
M\!H/_B*/[.T__GQL_P#P&@_^(JY10!3_ +.T_P#Y\;/_ ,!H/_B*/[.T_P#Y
M\;/_ ,!H/_B*N44 4_[.T_\ Y\;/_P !H/\ XBC^SM/_ .?&S_\  :#_ .(J
MY10!3_L[3_\ GQL__ :#_P"(H_L[3_\ GQL__ :#_P"(JY10!3_L[3_^?&S_
M / :#_XBC^SM/_Y\;/\ \!H/_B*N44 4_P"SM/\ ^?&S_P# :#_XBC^SM/\
M^?&S_P# :#_XBKE% %/^SM/_ .?&S_\  :#_ .(H_L[3_P#GQL__  &@_P#B
M*N44 4_[.T__ )\;/_P&@_\ B*/[.T__ )\;/_P&@_\ B*N44 4_[.T__GQL
M_P#P&@_^(H_L[3_^?&S_ / :#_XBKE% %/\ L[3_ /GQL_\ P&@_^(H_L[3_
M /GQL_\ P&@_^(JY10!3_L[3_P#GQL__  &@_P#B*/[.T_\ Y\;/_P !H/\
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M/[.T_P#Y\;/_ ,!H/_B*N44 4_[.T_\ Y\;/_P !H/\ XBC^SM/_ .?&S_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#G_$/_'C+_G^ UYCX
M6_Y"=S_UV'\DKT[Q#_QXR_Y_@->8^%O^0G<_]=A_)* /;5Z#Z#^5+2+T'T'\
MJ6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MK&US_CQE^@_]FK9K&US_ (\9?H/_ &:@#R?P]_R&+G_KN/\ T$5[@O0?0?RK
MP_P]_P ABY_Z[C_T$5[@O0?0?RH 6BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH *Y[Q+_P @R?\ W#_6NAKGO$O_
M "#)_P#</]: /,/"G_(2D_X#_,5[<GW%_P!U?Y"O$?"G_(2D_P" _P Q7MR?
M<7_=7^0H =1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %<MXK_Y!TW_7)_Y-74URWBO_ )!TW_7)_P"34 >??#[_
M (_Q_NO_ %KVJO%?A]_Q_C_=?^M>U4 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5Q'C?_ (\8_J?Z5V]<1XW_
M ./&/ZG^E '.^!/O?]M6_P#0S7K->3>!/O?]M6_]#->LT >#^+/^0G#_ -<Q
M_)*]@T#_ )!-G_US%>/^+/\ D)P_]<Q_)*]@T#_D$V?_ %S% &Q1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <_XA_X\
M9?\ /\!KS'PM_P A.Y_Z[#^25Z=XA_X\9?\ /\!KS'PM_P A.Y_Z[#^24 >V
MKT'T'\J6D7H/H/Y4M !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !6-KG_ !XR_0?^S5LUC:Y_QXR_0?\ LU 'D_A[_D,7/_7<
M?^@BO<%Z#Z#^5>'^'O\ D,7/_7<?^@BO<%Z#Z#^5 "T444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M: /!_%G_ "$X?^N8_DE>P:!_R";/_KF*\?\ %G_(3A_ZYC^25[!H'_()L_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MU)2,NT%K=RPQ%@-)8[BB@GDUS/\ Q$2?ML_] /PQ_P!^5_\ E/7A_P#P3G\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M &D_CC;_  "^'UWXTN+!-16..\"P.Q0%H(5D&#YL/)+@?>_+K0!]"4$@#)(
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M1110 455OKD6=E>79&X6MK<7)7U$$3RD=NNW'45^ O[4_P#P6,N/@C\7-,\
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M-N]U")6A/6,DD;3RWIGJ>O6M&@ HHHH ***\]\;?%?X=?#=(9/'/B[2/#*7
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MX#_,5[<GW%_W5_D* '4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M')K1KX6_;]^..C_"#X">/OMFHI8ZIJ/ABY.EJ6"R23"XCP(VRI4[8GY&>AH
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MKG\?NGQI^RC\#/%N@W6C?\*T\%Z?]HBEC^TVWA^PCE7?$T>59(@01G(P>HH
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MQ_@ ?B[^VW_P6VM?".O:CX/^!]UK*:_;_:+>)+6&ZOLW5JP@EVQV4*L1YW0
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M=O8>E?T^V7[(WP+M/#$?AP_#CP;)LM8+<WCZ!8F<^3%Y>\N8BVYNK'.20.E
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MPF,Q2O\ >/ _U9]O6O4Z_+O_ (*T^-SX6_9'\>^1=-:W(6-D>-]D@'V*^/#
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M[=/K7\TO_!)SQ_\ ##PQ\;/%GBWQQK5K8_;K.)DFN41RTBQRG.YG7)!/U!H
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M(@^P*YX*@$'&2*Z#Q3IG[;?[;NGV^L^'+/Q?H.DS);P)=>']7O+52JHBJ_\
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MZ#^5+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M 4444 %%%% !1110 5C:Y_QXR_0?^S5LUC:Y_P >,OT'_LU 'D_A[_D,7/\
MUW'_ *"*]P7H/H/Y5X?X>_Y#%S_UW'_H(KW!>@^@_E0 M%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5SWB7_D&3
M_P"X?ZUT-<]XE_Y!D_\ N'^M 'F'A3_D)2?\!_F*]N3[B_[J_P A7B/A3_D)
M2?\  ?YBO;D^XO\ NK_(4 .HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "N6\5_\@Z;_ *Y/_)JZFN6\5_\ (.F_
MZY/_ ":@#S[X??\ '^/]U_ZU[57BOP^_X_Q_NO\ UKVJ@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N(\;_\
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M[5_0W\ ?V7_A/^SMH*Z5\._"]GH,ES;QQZD]KMQ<RH5.\[44=43'IMKZ-HH
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M(/?\BA#_ -@-?_29: /Z3KC_ (])_P#KWE_]%M7^?U^WY_R>EHG_ &4&Y_\
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MU7Q-\;Z%\0?V<?&OBGPY<&YTG5_!]U>64QVYDA:6-0?E9AU!Z$]*_A5^'O\
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M5ISP23:PFH:?)M?YH)I@ZOEU3JH[9'O7]4'Q'C6+X=>,HUZ+X;U;';_ESEH
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M\#FOXC/^"CO_ "=UH'_8Z7/_ *2W5?WS7$445C=)%''&@M9@%C144 1/@!5
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M_P#(= '^:A\0O"O[6G[0WQ%L=>\>>!OB#J.H2W]FTE[>^'[]<1K>1.0S.IP
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MP #]1&T#1?A_X!N+'3+6.TT_2--$2QIPJQ(XP!@  9(Z#K7\:G[2EI9_%?\
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M?@7XO.O6D=S(/#-^;,N0#')O/(R#TPWYU_.G_P $@OA1H^M?&:/QA#IZ$/\
M:%$@4'&VXG8?-CWS@G-?H7_P6D_:Q\.>%_ UMX*T'4T;5M0M+O3;N O'Q*SW
M)"_*S$Y"J<8S[5YI_P $(?"-Q=_#_1_%.IP;;J>:XR^TG(96<<L!_>[CT^M
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M>X,0Q)X;D$<=:_K1TS3+32[**RLXA#!'&B*BXP JA?3T]J_(S_@D9H6G:?\
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M*F* /)/VKSH0^$_B8ZY;QW$(T+63$LC;<.+*0@C/'7'XBOY'?V$?ACH'C/\
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M8WWEN)6QP,DD>@]/\:_#_P#X+.^(=.LOA)J%G/+MF-_&NW(_B\L=R#SD?Y%
M'AO_  1:\3V\ECXET](6'EW\<(8YQ\LD/Z?@,]:_I5K^;+_@BWX<L%TSQ)J$
M9?=+?13*><?-)"/7],?SK^DV@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N6\5_\
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MJW_H9KUFO)O GWO^VK?^AFO6: /!_%G_ "$X?^N8_DE>P:!_R";/_KF*\?\
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MV+XD>!/ [Z;XIAO[C4DO"]F0+JYG%Q*^([*-\-*-WW\]LU^A<<:1(L:#"J,
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M_@EW^R/\=_'DOQ'^(G@9]5\437UKJ+WH>S&;FSNC>0/^]L97^6<[OOY]\\T
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MS@=0:_/E/^"5G['T?CP_$A? ;CQ26#_;=]E][S3-G'V'=_K#G[] 'UE\ /\
MDEW@[_L V/\ Z *]JK#\.^'=,\+Z39:+I$)@L=/MX[6VC)!VQ1C"CY54<#T
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M4>BJH4=,=@*\%^-G[-/PI_: TI-'^).A_P!KV*(\:Q@P@[9"Q89E@E'.X]J
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MXN_\%CO'/QDT"7P=\)/A3J&L3:G%+87&HZ%-$[V<-VOEFZ?S=6'RQJ2W$;'
M/RGH?V#^-/\ P2]_9(^/NJMK/Q&\#-JM\S2,TJM9KDR_?_UEC*>?K6E\%/\
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MJK+;QH5\NUN!,>6*\$?[6?>OZB["PMM-M8;2T3RX((TBC7CA$&%' '0"O/\
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M#G'3 _GC^O;QMX%\._$#1IM!\2V@O-.G25)(ODR5F3RW&71QRG'2OS3\2?\
M!&+]A3Q7K\OB76/AO)/JLMQ+<O,)+  RS-OD;!TYCR>>O'O0!^&_[57[<7QV
M_;)T+6='\(_#SQ)X5\-V=K=7*:[I\EL]G=VS(6?!.H73[%4<YB4X([U\_?\
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M5\0^*M%EO+"U!AC@CMO*M]1N7DD#/):-M$=R"WS=!G':OU1^'_\ P7IT#3?
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7/>)?\
MD&3_ .X?ZUT-<]XE_P"09/\ [A_K0!YAX4_Y"4G_  '^8KVY/N+_ +J_R%>(
M^%/^0E)_P'^8KVY/N+_NK_(4 .HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "N6\5_\ (.F_ZY/_ ":NIKEO%?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110!X;^T&OBZY^&GBK3O!V
MFMJ6JW^B7<%O"A*NT[XV*I"M@G'4#/YU_/A^R-^P'\8K[]HX_%+XM^%;_1HS
MYREK@RS1X%U)+&<O'&,G*G^M?U T4 96AZ='I&D:?ID7$=C:QVZ<8^5!@<5J
MT44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %<]XE_Y!D_\ N'^M=#7/>)?^
M09/_ +A_K0!YAX4_Y"4G_ ?YBO;D^XO^ZO\ (5XCX4_Y"4G_  '^8KVY/N+_
M +J_R% #J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ KEO%?_(.F_P"N3_R:NIKEO%?_ "#IO^N3_P FH \^^'W_
M !_C_=?^M>U5XK\/O^/\?[K_ -:]JH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KB/&__ !XQ_4_TKMZXCQO_
M ,>,?U/]* .=\"?>_P"VK?\ H9KUFO)O GWO^VK?^AFO6: /!_%G_(3A_P"N
M8_DE>P:!_P @FS_ZYBO'_%G_ "$X?^N8_DE>P:!_R";/_KF* -BBBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MBBB@ HHHH *Y[Q+_ ,@R?_</]:Z&N>\2_P#(,G_W#_6@#S#PI_R$I/\ @/\
M,5[<GW%_W5_D*\1\*?\ (2D_X#_,5[<GW%_W5_D* '4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7+>*_\ D'3?
M]<G_ )-74URWBO\ Y!TW_7)_Y-0!Y]\/O^/\?[K_ -:]JKQ7X??\?X_W7_K7
MM5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %<1XW_ ./&/ZG^E=O7$>-_^/&/ZG^E '.^!/O?]M6_]#->LUY-
MX$^]_P!M6_\ 0S7K- '@_BS_ )"</_7,?R2O8- _Y!-G_P!<Q7C_ (L_Y"</
M_7,?R2O8- _Y!-G_ -<Q0!L4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?]$\'_?=C_\ *^OT;HH _.3_ (=5_L<?]$\'_?=C_P#*^C_AU7^QQ_T3P?\
M?=C_ /*^OT;HH _.3_AU7^QQ_P!$\'_?=C_\KZ/^'5?[''_1/!_WW8__ "OK
M]&Z* /SD_P"'5?[''_1/!_WW8_\ ROH_X=5_L<?]$\'_ 'W8_P#ROK]&Z* /
MSD_X=5_L<?\ 1/!_WW8__*^C_AU7^QQ_T3P?]]V/_P KZ_1NB@#\Y/\ AU7^
MQQ_T3P?]]V/_ ,KZ/^'5?[''_1/!_P!]V/\ \KZ_1NB@#\Y/^'5?[''_ $3P
M?]]V/_ROH_X=5_L<?]$\'_?=C_\ *^OT;HH _.B#_@EA^QW;3I<1?#[;)&<J
M=]CQ]/\ B7^U?87PS^#/@/X2:?#I?@G2_P"S;."+R8X\QG"8QC]W%&.G'3^5
M>JT4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 5C:Y_P >,OT'_LU;-8VN?\>,OT'_ +-0!Y/X>_Y#%S_UW'_H(KW!>@^@
M_E7A_A[_ )#%S_UW'_H(KW!>@^@_E0 M%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M.'_KF/Y)7L&@?\@FS_ZYBO'_ !9_R$X?^N8_DE>P:!_R";/_ *YB@#8HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "L;7/\ CQE^@_\ 9JV:QM<_X\9?H/\ V:@#R?P]
M_P ABY_Z[C_T$5[@O0?0?RKP_P /?\ABY_Z[C_T$5[@O0?0?RH 6BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y
M[Q+_ ,@R?_</]:Z&N>\2_P#(,G_W#_6@#S#PI_R$I/\ @/\ ,5[<GW%_W5_D
M*\1\*?\ (2D_X#_,5[<GW%_W5_D* '4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !7+>*_\ D'3?]<G_ )-74URW
MBO\ Y!TW_7)_Y-0!Y]\/O^/\?[K_ -:]JKQ7X??\?X_W7_K7M5 !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<
M1XW_ ./&/ZG^E=O7$>-_^/&/ZG^E '.^!/O?]M6_]#->LUY-X$^]_P!M6_\
M0S7K- '@_BS_ )"</_7,?R2O8- _Y!-G_P!<Q7C_ (L_Y"</_7,?R2O8- _Y
M!-G_ -<Q0!L4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% '/^(?\ CQE_S_ :\Q\+?\A.Y_Z[#^25Z=XA_P"/&7_/\!KS
M'PM_R$[G_KL/Y)0![:O0?0?RI:1>@^@_E2T %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %8VN?\>,OT'_ +-6S6-KG_'C+]!_
M[-0!Y/X>_P"0Q<_]=Q_Z"*]P7H/H/Y5X?X>_Y#%S_P!=Q_Z"*]P7H/H/Y4 +
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %<]XE_Y!D_^X?ZUT-<]XE_Y!D_^X?ZT >8>%/^0E)_P'^8KVY/N+_N
MK_(5XCX4_P"0E)_P'^8KVY/N+_NK_(4 .HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "N6\5_P#(.F_ZY/\ R:NI
MKEO%?_(.F_ZY/_)J //OA]_Q_C_=?^M>U5XK\/O^/\?[K_UKVJ@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N
M(\;_ /'C']3_ $KMZXCQO_QXQ_4_TH YWP)][_MJW_H9KUFO)O GWO\ MJW_
M *&:]9H \'\6?\A.'_KF/Y)7L&@?\@FS_P"N8KQ_Q9_R$X?^N8_DE>P:!_R"
M;/\ ZYB@#8HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** .?\ $/\ QXR_Y_@->8^%O^0G<_\ 78?R2O3O$/\ QXR_Y_@-
M>8^%O^0G<_\ 78?R2@#VU>@^@_E2TB]!]!_*EH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *Y[Q+_R#)_]P_UKH:Y[Q+_R#)_]P_UH \P\*?\ (2D_X#_,5[<G
MW%_W5_D*\1\*?\A*3_@/\Q7MR?<7_=7^0H =1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<MXK_ .0=-_UR?^35
MU-<MXK_Y!TW_ %R?^34 >??#[_C_ !_NO_6O:J\5^'W_ !_C_=?^M>U4 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 5Q'C?_CQC^I_I7;UQ'C?_CQC^I_I0!SO@3[W_;5O_0S7K->3>!/O?]M6
M_P#0S7K- '@_BS_D)P_]<Q_)*]@T#_D$V?\ US%>/^+/^0G#_P!<Q_)*]@T#
M_D$V?_7,4 ;%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M:_\ ]$HM_P#O['_\L:/^'Z6O_P#1*+?_ +^Q_P#RQH _I&HK^;G_ (?I:_\
M]$HM_P#O['_\L:/^'Z6O_P#1*+?_ +^Q_P#RQH _I&HK^;G_ (?I:_\ ]$HM
M_P#O['_\L:/^'Z6O_P#1*+?_ +^Q_P#RQH _I&HK^;G_ (?I:_\ ]$HM_P#O
M['_\L:/^'Z6O_P#1*+?_ +^Q_P#RQH _I&HK^;G_ (?I:_\ ]$HM_P#O['_\
ML:/^'Z6O_P#1*+?_ +^Q_P#RQH _I&HK^;G_ (?I:_\ ]$HM_P#O['_\L:/^
M'Z6O_P#1*+?_ +^Q_P#RQH _I&HK^;G_ (?I:_\ ]$HM_P#O['_\L:/^'Z6O
M_P#1*+?_ +^Q_P#RQH _I&HK^;G_ (?I:_\ ]$HM_P#O['_\L:/^'Z6O_P#1
M*+?_ +^Q_P#RQH _I&HK^;G_ (?I:_\ ]$HM_P#O['_\L:/^'Z6O_P#1*+?_
M +^Q_P#RQH _I&HK^;G_ (?I:_\ ]$HM_P#O['_\L:/^'Z6O_P#1*+?_ +^Q
M_P#RQH _I&HK^;G_ (?I:_\ ]$HM_P#O['_\L:/^'Z6O_P#1*+?_ +^Q_P#R
MQH _I&HK^;G_ (?I:_\ ]$HM_P#O['_\L:/^'Z6O_P#1*+?_ +^Q_P#RQH _
MI&HK^;G_ (?I:_\ ]$HM_P#O['_\L:/^'Z6O_P#1*+?_ +^Q_P#RQH _I&HK
M^;G_ (?I:_\ ]$HM_P#O['_\L:/^'Z6O_P#1*+?_ +^Q_P#RQH _I&HK^;G_
M (?I:_\ ]$HM_P#O['_\L:/^'Z6O_P#1*+?_ +^Q_P#RQH _I&HK^;G_ (?I
M:_\ ]$HM_P#O['_\L:/^'Z6O_P#1*+?_ +^Q_P#RQH _I&HK^;G_ (?I:_\
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MD_\ )J //OA]_P ?X_W7_K7M5>*_#[_C_'^Z_P#6O:J "BBB@ HHHH ****
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M>G6@#\]/VM/^"IWP2_9!\3S>%O'VA^(-0OH;N"T:335N#&9)[A;=2/+TVZ&
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 9>I?ZIOQ_\
M0:_C]_X*J_\ )1-._P"PU+_Z#=5_8%J7^J;\?_0:_C]_X*J_\E$T[_L-2_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"N6\5_\ (.F_ZY/_ ":NIKEO%?\ R#IO^N3_ ,FH \^^'W_'^/\ =?\ K7M5
M>*_#[_C_ !_NO_6O:J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH *XCQO_ ,>,?U/]*[>N(\;_ /'C']3_ $H
MYWP)][_MJW_H9KUFO)O GWO^VK?^AFO6: /!_%G_ "$X?^N8_DE>P:!_R";/
M_KF*\?\ %G_(3A_ZYC^25[!H'_()L_\ KF* -BBBB@ HHHH **** "OXW_\
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M>)/^W3_VM7]\FB?\@?2_^P?9?^DL5?P-_P#!'W_DYSQ)_P!NG_M:O[Y-$_Y
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MX);_ +:OB7]K#X)>&/$'Q!O;:?QO?1/+J"6Q 3:MK!*"JD!Q\YDSE?I7ZO4
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M\<"OUUAFCN(TEB971QE2I!!&2.H^E '\;_\ P7J_Y*9?_P#7_8?^EL=?J?\
M\$8/^233?]>MC_[+7Y8?\%ZO^2F7_P#U_P!A_P"EL=?J?_P1@_Y)--_UZV/_
M ++0!^ZU%%% !1110!^+/_!8[_DA?BS_ + 9_P#1;U^*7_!!;_DLOBK_ +!4
M/_HF>OVM_P""QW_)"_%G_8#/_HMZ_%+_ ((+?\EE\5?]@J'_ -$ST ?VFV__
M ![P?]<8O_0%J:J\)VVL3#J+=#^48-?RR_MB?\%6_P!I7X+?M%:'\//#%_ID
M/AJ\\6OI-T)PP<6:V]S)]XQE0=T:\D@4 ?U145_//\3/^"TO@7X=_#A=.O\
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MZ-B0#D''.#TXH ^1OVV?V58?VKOA@/ 2WEOITZW,]PMU< %0\JVX4_,KC*M
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M(SQ@Y\V),\$]N.?2OV5U/4K32;&ZU"]ECAM[.WFN96=U3]W"C2/@L0,[5.*
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M$SX@Z9\-?".M^*]3,;0Z/IMUJ'DNVTSBV0N8U((.6Z#!KNK:,0V\,0&!'&B
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M?!/XI_\ "V_!&A^+O[)GT@:OIL5^+6X!#Q^8Y38068Y&,GG-?"^K_P#!*_\
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M)P?-'OZ-0!^HE%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5SWB7_D&3_P"X?ZUT-<]XE_Y!D_\ N'^M
M 'F'A3_D)2?\!_F*]N3[B_[J_P A7B/A3_D)2?\  ?YBO;D^XO\ NK_(4 .H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M2#"HH51Z =J )**** "J>H6-OJ-G<V5S&DL5S!- ZN,KMFC:-LCZ,<^U7**
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M9_82_9O;PC#X<_X55X+%REG:6[:E_9?[YFM[80O(3O\ O2GYV.WD^E?QB_\
M!4O]D33?V4OBOI_CKPM<>1#J7B![RQL[6,P16@B$ZA8<QJ%P8R1R<;C["O\
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MH>L^ /"?BJ[2*)I+_4-,+S%O)"L"6\LYW$G[N,]^*_*S_@A3_P BM_W!X_\
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M;@?^OG4O_1%I7\V'_!''_DO#_P#8Y:K_ .G9Z /[CM+_ ./&#_='\A7\CO\
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M_:!^"?A"#PYX?\+?$N.SB8.GV3P?XJFB)"$*P>&PV$$'((/([GOVFM?MH?\
M!0G]KB6Z^'?AK4?&.@Z+X@9M+O8]>\*^)+.&2&7#@/)>2V<2J&"DEOER,'V
M/./VV/$3?M@?MM:AIW@F4ZK%;>)?#FJF33SY@\F'Q!-<,^#G "0%CQTSWK^S
MO]F;0[;X4?!3PXGB&[%C;6GA[0Q<3W.56)H]/C#!L#/!#=B./PK\BO\ @FI_
MP2FN?@[>67Q0^+-MIFK>-;VR6"_O[?[.DDDD43O&2AEN90!+<R-@N>IKZ]_X
M*B_M%Z=\!OV??%'A[3VGM=7.DV[6$L1;;&D=G+@$(F3@,G\0Z?D ?G'_ ,%
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MX'BK5OB+XGNM$AU_5[4Z1/>F6R9%U>14!7RS\JI%M7YNA(]Z_I<^,/QM\)?
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M>;X9MQC;@\3]^ <\>F* /T]HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7/>)?^09/_N'^
MM=#7/>)?^09/_N'^M 'F'A3_ )"4G_ ?YBO;D^XO^ZO\A7B/A3_D)2?\!_F*
M]N3[B_[J_P A0 ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *Y;Q7_R#IO^N3_R:NIKEO%?_(.F_P"N3_R:@#S[
MX??\?X_W7_K7M5>*_#[_ (_Q_NO_ %KVJ@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MP><^M 'T;_P1WF2?]ICQ#+&=RL+,@^O^N]*_OGT<XT73CZ:;:'\K2*OX O\
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MC(6YCY!B_N_G0!_9+#\'?A1#%'$/AMX$81HJ!CX2T+)"C&3_ *#U/>OXX?\
M@N)8^"M+\8:7IWAK1=%TBYM_$\0FBTK2['3]J_:^A^R11<8R,$5]D_%O_@OW
M%XP\-7GA7X:?"?6[C7M6@"6>H:29II;67:> /MN-VYA_">G>OYUOVJ=4^.'C
MKQ#IGQ*^)R>(;6P\2:O#-:6.M0>689?.&0/O$MEN?F/(H _L&_X(:_\ )KH_
M[#$?_M[7[>R1I*C1R*&1QAE8 @CKR#D$9[&OQ#_X(;8_X9=7_L,1_P KS^N:
M_;^@#^.+_@NY^RM:>&/&5[^T+80S1W.H^(K)#M5H[<"WU.&XRH4[!C[0<D*,
M8!^GT=_P3M_;-M]._8J^(^OZOJBQW?A1[6PM]\@;8EN+N(#<S K@1 8QQZ8
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MGM7URG_!S/X&6W,3?!;4F<J1O\Z?.2,#_E^'3ZT ?T?_ +1.K:#HOPOUN_\
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M@>*_T1M4\(:7JOAF[\-W-M%);7&G7-DJ,#L5I[1K;=CVR#T[5_%!_P %._\
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M3USZU^/O_! ;XKV&A_&'QCHNK3Q6Z'3XK>V.$W.[PE0"3M/)..I-?UU_M2_
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M:Q9>+O#:7,MS&L<K9UVWC^951 #N5NV?PZ_Z)?[)?_)$O /_ &*/A[_TW0T
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MO_I)94 ?J?7\?'_!PQ]SP)_U^W'_ *%?5_8/7\?'_!PQ]SP)_P!?MQ_Z%?4
M??\ _P $"?\ DU/PU_U^2?\ H@5_017\^_\ P0)_Y-3\-?\ 7Y)_Z(%?T$4
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M_HF>OVM_X+'?\D+\6?\ 8#/_ *+>OQ2_X(+?\EE\5?\ 8*A_]$ST ?VE1_\
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M  2@_P"2">$O^Q9T_P#]')7\ZW_!?7_DX!_^O*V_]&6M?T4_\$H/^2">$O\
ML6=/_P#1R4 ;O_!6S_DW _\ 7SJ7_HBTK^;#_@CC_P EX?\ ['+5?_3L]?TG
M_P#!6S_DW _]?.I?^B+2OYL/^"./_)>'_P"QRU7_ -.ST ?W':7_ ,>,'^Z/
MY"OY&_\ @OK_ ,C/J+=DCA=O95:(D_D*_KDTO_CQ@_W1_(5_)!_P7O ?Q3J4
M1./.BAB!]#(8T'_H6: /HK_@AW\:_AYJOA+5?#UEK2RZI:1VUG/;@1_+.'M"
M4R)B>A'51].17],:L' 93D&O\ZKX=_ []HW]EZS\)?%?X6:KXBU+1=9MH?$&
MK66@VZ2(L;;P(IV")@[HDYW$\CFOU=^''_!PO<?"OPW!X5^(?PKU[4_$%G#)
M%<W5\TT<Q=XEC1F47J@%9$9AQUXZ4 ?T2?MZ_$K1OAU^SQXUU74;T6DEM C@
MG P#;W39R67L :_AT_9STJ]^/'[8LFN: 'U&WL?&=A?3RQLWRQC:2Q*%ACYA
MW[_6O1_VUO\ @I9\6_VW[F72?ASX>\3V6@WUJ;2X\/V2-<)<R>6D(.UII"2#
MO &['S'I7ZP_\$6O^"=7BGP!-=?%GQTL\<WB:UM[^#3=0MQ%/9R(L*[6_=@A
MLH3RS8]\< '],_@+2WTCX>06<BE6CT-5(.3RNG8/)]#_ )[#^%C_ (*!?\G?
M:#_V-=[_ .BYZ_ODNK=+;1KR"-0JQZ;<( .GR6KKQ^5?P-_\% O^3OM!_P"Q
MKO?_ $7/0!_8!_P3R_Y-\\&?]<)/_26UK[$^(/\ R*VH?1?_ $%Z^._^">7_
M ";YX,_ZX2?^DMK7W5J=A'J5G):2@,DF,@]#U']: /\ .=_:4GCM_P#@H582
MRMM1/BI:LQXX C?W%?WV?LSZE::C\+]"EM9/,0VEF >!R+2('N>XK^)#_@J!
M^SQX_P#AK^TA?_%*R\-:M+IL'BTZS#<PVI\HQ0I(N]9./ER.N?Q]/K3]FC_@
MOYI'P.\!Z=X)\1?#/4]>U"T*0&Y,DP+,$6   7:#(;GIVH _M K^2_\ X+U^
M )K'1X_%823%QKH=&RQ0F.Z@88YP.6'3G\^/V"_8*_;VN_VO[#5M9'@C4_#%
MK!<)Y NP^UXY'0*REII,J _7V]:]1_;Y_9#TW]J7X5WFA#[-;WVEVVH:C$\J
M!WFECA$T<: J^79X0JC'4@9H _#W_@W^^.NAOX'N?!>KZBL.LW/BJ86UIN4E
MXH[_ %"+/+JW'F1C&TCYCSTK^KR*1)HUDC.Y'&5/M7^<??\ PU_:2_82^,KZ
M[X?T?Q;!X>TO4=3N&EL[(QVS#[>LL;[P4^\BL5.1D'-?L)\-/^#C33/ /AO3
MO#_B[X4ZOJ^K:?:K;7=U/),LDLRL278"]0 D$<;>G:@#^MK7+V&PTC4KJ=@D
M<-A>2LQQ@".VD<YR1V%?P/?\%8OB?I'QJ^.UIX0T&ZCO+N&_OM->.((&$L>Y
M&7Y&9@<D=??BOJ+]I;_@N'X__:5\+7'A?X+^ _%'A?4K]W1;C3!)*_DSJL;)
MA[J0%2I;^'G/;K7 _P#!.+_@G?\ %3]H#XJ6WQA^+5KJEE#I^N-J$MKK]H(V
MODN)%+.K%'R&!SPRT ?T._\ !(CX=7_@/]FGP#9WT+PR1Z4R,KEB0?LT"C[P
M&><]J_+S_@X#^YJ?_8%C_P#2..OZ?OA]X$T?X?>'+#P[HUI#:VMBA2-(00@7
M:J\ ^R^E?S _\' ?W-3_ .P+'_Z1QT >S_\ !#C_ )$^_P#^P=:_^A6=?TH+
MT'T'\J_FO_X(<?\ (GW_ /V#K7_T*SK^E!>@^@_E0 M5+RPL=0B,-_9VM["0
M08KJWBN(R#P04E1U(/<8P:\5_:2N_$UE\'?%USX/:[7Q!%9YL#8KNN1)M?'E
MCG)SC]*_F%LO^"L/QQ_9@\>ZIIWQ3\ >-/$VFPR+;1S7L+QP*061I 4N(NA&
M3UH _HT^.O[%_P &_CIH=]HVM>&M"TD7JD/=Z7H.GP70)1E)$L$=O)D[LD[\
MD@'K7\:__!3S]@BQ_8I\4:-XO^'6K:_;C5;R>_79=WMFA$2W:+M$=TZX'V89
M[<5^PMS_ ,'%?PYM- ?4W^&$[7,:JAL_/F\XOL;=Q]L'1A@\]37XO?MA_M<_
M$W_@I'XP\*>'_!_PY\4V.F/?O:"XBMGGM[2"X2\8,S-/+A 9P.0>2.* /WV_
MX(@_'?QC\1O@9X3LO$<\MVWD.[7%S=274SD6D7WI)07(RO=C_.OZ"%.5!]0#
M^8K\=O\ @DI^R9K'[.?P,\+:7XB=Y-4MHF6;SHA'+\UK"H# (O0Y[<<YK]BN
ME !3).8W'^PW\C3Z#R"/6@#^._\ X+2Z9>:5\8_A5J-[%Y5H=:N)O,Y_U?D:
MISR .WKCWK]U/^"76L6&K?LZ>#YK&831O&Y5ACM9VIYP3V-?FG_P7K\#S+:_
M#WQ39Z;+>)I%M<W=R88]P4 :HOS'C'WU].HR<U]/?\$3_B39>+/V;?!-JEN+
M2=;61VB8G<H^PVIZ;F/8C\,]* /VRU[6;70=,N-4O)!%;VXR[G& ,$\Y('8]
MQ7\0/[1UW;?&3]O'4K&V*ZG96'C[3I)() )83%Y[,P:)MZ,I!SM8;3WK^P;]
MK'Q"/"_P-\8:V9?*%I;AO,SC'[J<YS_P&OX^?V*-%N_BO^VM\0-8:WENX8-<
ML[Q)=N]<+AMP/MZ_U% ']??P9^"WPQLO NBPW/PZ\$S2C3M.+O/X6T220M]C
MCW$L]DS$DY))/)YKV6Q^&GP[TR03:=X$\'V$JG<LMGX;T>VD##N'ALT8'WS6
MEX3LO[/T/3K?;MV65HN/]VWC7],5TE $4,$-N@C@BCAC7HD2+&@^BH !^5?R
MO_\ !P'XEU>"^@\-Z>N^._\ #D;,F\@D_8K?^':<\O\ G^-?U2U_-5_P76^
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MXQ^- &[1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M 9>I?ZIOQ_\ 0:_C]_X*J_\ )1-._P"PU+_Z#=5_8%J7^J;\?_0:_C]_X*J_
M\E$T[_L-2_\ H-U0!^8B]!]!_*EI%Z#Z#^5+0 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %-.6^1!EVX4>IIU>G_"#P!??$
M7QMH>CV,<DGG:@ENZHN[.Y&;D8/M_D4 ?IG_ ,$SOV<]3\:^,K+Q!>174%I]
MFAN4DA>4*S0B2;!"L@QPN<9X/(YK^KS1K(:=I.G6 )(L[.WMP6^\1%&J<Y[\
M<U\@?L8_ O3_ (2?##0[:6PC@UB%"DTQ39,5-O"N",  9+=AWK[1H **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *QM<_X\9?H/_9JV:QM
M<_X\9?H/_9J /)_#W_(8N?\ KN/_ $$5[@O0?0?RKP_P]_R&+G_KN/\ T$5[
M@O0?0?RH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *Y[Q+_R#)_\ </\ 6NAKGO$O_(,G_P!P_P!: /,/"G_(
M2D_X#_,5[<GW%_W5_D*\1\*?\A*3_@/\Q7MR?<7_ '5_D* '4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7+>*_
M^0=-_P!<G_DU=37+>*_^0=-_UR?^34 >??#[_C_'^Z_]:]JKQ7X??\?X_P!U
M_P"M>U4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 5Q'C?_CQC^I_I7;UQ'C?_ (\8_J?Z4 <[X$^]_P!M6_\
M0S7K->3>!/O?]M6_]#->LT >#^+/^0G#_P!<Q_)*]@T#_D$V?_7,5X_XL_Y"
M</\ US'\DKV#0/\ D$V?_7,4 ;%%%% !1110 4444 %?!7[3'_!.OX _M5SP
MS_$ZPOKEX+Y+]/LS(,3QRK,I.XCC>HS[5]ZT4 ?-_P"S;^R[\-/V6_!\G@GX
M:6UQ;:-+<K=LEP5+^:IF(/RD]YG/7TKZ0HHH .O6OBS]I[]A#X&_M8M;O\4=
M+EN'MK8VT;6J1*WEE=IR3M.2._YU]IT4 ?FI^S3_ ,$KOV8_V5O$MYXJ^&6E
MW]OJ=[$L4S7)C9=J*RC&"3T8U^E$4:Q1QQ+]V-$C7_=10H_0"GT4 <QXM\(:
M'XUT34-!UZRM[NRU&V:UF\Z"&9UC=@QV&5&VG([8ZFORF^(O_!$[]C;XF:[=
M>(-?T34UOKLYE-J88DY=G. K+CEC^&/05^P%% 'Y,_"G_@C5^R'\(-7MM9\,
M:+J#W=K-YT?VT0SIOW!N0Y;(X'!KV#X[?\$U?V</V@]%T30?'&BS?8M!NEN[
M$645O"PE5U<;BH3(RH[].N:_0:B@#YU_9R_9D^''[,/@T>!_AM;7%MHHN!<;
M+@J7\P>9C[I/'[QN_P#6OHJBB@#,UG2+/7=,OM)OXEEM-0L[JRG5E5OW-W \
M$N P(R8W8 ^M?CWXW_X(:?L6>/?$6I>)M;T356U'5;ZYO[IHC"J&>[E:64@;
MAP78U^R]% '@?P&_9R^'G[.WA+3/!OP_M)+;2=*MA:VPE""3RP /G*]3@#OC
MKZU[Y110 4444 %?GQ^TU_P37_9X_:NN(;GXH6&H73P7#7,8@=<"1F9CPS 8
MRQ[5^@]% 'X<?\0__P"PI_T ]9_[[B_^+H_XA_\ ]A3_ * >L_\ ?</_ ,77
M[CT4 ?AP/^#?_P#84!!_L/6>/]N+_P"+K]!?V4OV)?@W^Q[X:O?"OPFL[NUT
MR^OC?S+=,I8SF2:7/RDC&Z>3\Z^PJ* ,K7-'M/$&D:CHM^I:SU.UDM+E1C)B
MD&& SQGBORS\:?\ !'']D;QWXZ/Q UO1]1?73*LNZ/RA%O683@X)[.*_6&B@
M#A_A_P" -!^&_AO2_"WAV(PZ9I%E%86BL &$$/W =O!(KMG4.C(>CJRGZ,"#
M^AIU% 'YS?M1?\$Q/V<?VMO$MOXJ^*EEJ=UJ5M9BRC^S2*$\D)#'@AF'.V!!
MTKZ+_9^_9>^&7[-WA^V\-_#NQ>UL+6U6TC\U(Q(8D((W,@R3P.<U]'44 %%%
M% !1110 5C:YH6G>(;&33M3MXKFUE5U:.:*.5<.NT_+(K+G!]*V:* /S8^,'
M_!+#]E_XUSW$_B[0Y]]R7,GV2*WBYDSNQM"^O%?+_P#Q#_\ ["G_ $ ]9_[[
MB_\ BZ_<>B@#\R?@9_P2?_98_9_U"VU+P3H5P;BUE\V/[=%;S+N,GF'(8/WX
M'H*_2#1]$TS0K."QTVTM[6&",1((8(H25!R ?*10?_U>@K6HH *Y[Q'X7T7Q
M3IUQINL6-M=V]PFQS-;PS,%Z8!E1L<'%=#10!^47Q?\ ^".O[(WQIUFZUSQ9
MH=Z+R[F\Z7[(D$2;]Q;A5V@#GTKRW0O^"#/[#_A_48=3L=#U;[1"1M\QHF7A
M@W(+D=1Z5^U]% 'SQ\'OV8_A=\$M.BTWP;HUO%##$L4;SVELTJJA4J0X3<#E
M1SGIQ7T, %&   .@  'Y"EHH " >",CT-?-?QP_95^%'Q^TJ72?'.CQ303)(
MCR06UN)B)<[LR% Q/)P2<BOI2B@#\0+O_@@1^PQ>7,MU+H>L^9-,\[8>( .[
MF1L?/TW$_A7W3\ ?V"_@/^SG L'@+1 BH$"M>6]M*Z^64*D,58@_(.0>F?6O
MM:B@#\UOCU_P2P_9C_:(^)4GQ3\>:5?2>)9+^SU%GM?*CA%Q97GVV$A05X$W
M)XZ5]]>!_!6C^ /#VF>&="1TT[2K&UT^U5\;A!9Q+#$#CC(11FNOHH ^</VC
M/V7OAK^T[X>M_#7Q(M[BXTZV618UMRH8"0DMG<1UR:\8_9K_ ."=?P _98OH
M[_X96%];3QSR3J;ED(WRR&5ONL>-S$_C7WM10 B@* !T' JEJ6FV>K65S87U
MO%<6]U!-;R)-$DHV3QM$Y D5@#M8X.*O44 ?E9\9?^"0'[)?QPUN;7O&&B7I
MO9WE=S:)!$A,S;GX4KW'\ZYCX6_\$5/V./A)KD>O^&-#U#[;%/'.OVH02Q[X
ML;?E8L,<#M7Z]44 ?,/Q5_9*^$OQ>^%TGPC\3Z4J^%961VBLX((9<QQ>4IRB
MH,[.O/\ 6O.?V6O^"?WP)_9%DUZ3X4V-[:MXAN1=7_VED.Z0&)OEVDX&84K[
MDHH IZC8PZGI]]IMR";?4+.ZL9P.IANX'@E ]RDC8K\O=;_X)#_LIZ_\2(?B
MC?:7J;>)8)[FXCD5H_+$EU.D\IQNSS(@(K]3J* .2\$^#-'\!^'=-\,Z&CII
MVEP"WME<C<(P2<'''>NJD19$>-ONR(R-_NL"I_0T^B@#\X?V@?\ @E[^S7^T
MCXCL/%'Q#TW4+C4M/DDE@:W9%4-(&#9RP[.WKUKZW^!_P+\%? 'P1I/@'P+#
M-!H6C1F*T2<@NJM''&<D$CE8EKV>B@ KX1_:E_X)Y_ 3]KH::/BK87MU_9<C
M2VWV9D&&<R%L[F'!\UN*^[J* /E_]F7]DOX6?LH^"K3P)\+[6YMM$LI#)"ER
M5+ABNTD[21TKZ@HHH **** "L+7/#>C>(;2:SU2PM+J*>.2-_.MH)B5D4HW,
MB-V)K=HH _+#XP_\$A/V3/C9JTFL>+M#NQ=2R22-]C2WA7,I)887;QDUXA9_
M\$"?V&+*ZM[N+0]8\VWF29-S1$%XV#+GY^1D#([U^WU% 'RG\$/V.?@S\ ]/
M@T[P5H< @@9&0WEI:ROF/.WYF1CQGUKZHBAB@18X8HXD485(T5% ] J@ #V
M J2B@#\^_P!I3_@FU^SQ^U/X@E\2?$S3[^YU&6YBNG:W9 IEAF6=#\S#C>H)
MS_+BO?\ X"_LU?#O]G70/^$<\ 6\]OI^V)=LY4MB+[O0D5]"T4 %>"_M _L[
M> /VD? NH_#[XA03W&@ZGC[2D!42'$;QC!8@?=D->]44 ?G?^S1_P3-_9R_9
M5UC6-;^&.GW]M>:W<)<WK7#(0TB"  C:Q_Y]X^OO7Z'!%"[,97&"#R",8((/
M!!'!%.HH ^4/V@_V-O@U^TE:26?Q!T:.2.6#[.[6=M;1N4*[22P126(ZG.<\
MYZ5^>Y_X()?L/&^2_P#['UP2I(LH FC";E.1E0X&/;%?MO10!\.?"/\ X)^?
M #X,:2NC>$M$Q:J" UU;VTDG*LGWBK'HQ[_KS7C&B_\ !(K]E/0?BF/B[8:1
MJ$?BH:T==#@Q+ +TQ^5D*K#"A>P'I7ZE44 4M/L(--MDM+<$11_=!Z] /Z"O
MD#]I_P#8:^"W[68"_%*SN[H"U%F/LQ0?NA&(Q]X@YVJ!7V910!\B?LW?L6_!
M[]ERR^P_#2SNK:'[.+;%R5)\L */ND\X KZ['  ]*** /._B?\,O#GQ9\(:U
MX*\4QR2Z/KMFUC>I'C<T+,&(&<#J*^!/@=_P28_9:^ 'C^Z^(_@72]2A\0WE
MO';2R3-&8S'&9RH #$];B3\,"OT_HH K6=I%96T%K""(H(HX4!_NQJ$7] ,U
M^<'QM_X)8_LR_'OQG'XZ\<:;J,VM1ZDNJ*\+1A/M*EB#\QZ?,>V:_2BB@#R#
MX._!3P;\$?#%OX3\&0RPZ7;%3&DQ!8%4V#IG^$?Y[>OT44 ?+G[37[(_PJ_:
MN\+0>$/BA:W-SI5O<FZC6V*AQ*6B<GYB.\*?E7G7[+G_  3Z^ _[(]G<67PJ
ML;VUAN=0DU*07)0DW$L\MPQ&TGCS)G/XU]T44 ( %  Z"N3\6^"/#OC33IM,
MUW3K2Z@G5U=I+:"60AU*'YI$8]#W-=;10!^2/Q2_X(Q?L?\ Q;UB76_$VB:@
MM[+-).QM!!$H>3.[ 4K@<\>E<#HG_!![]B30;M;RTTC6VE4JP$LL;KE3D?*7
M(^O%?M910!\F_!#]C/X,? .VCM?!&B1(D4BRH]U:VTCAE+,/F*,<98YYKZNC
MBCA18XD2-%&%5%55 ZX 4  ?05)10!\#_M+_ /!.C]G_ /:JU>76OB=87US>
M2RQ3,UNR ;XI!*OWF!QN4?TKV?\ 9_\ V7/AI^S?H;:!\/;:XM[%DC0B<J6V
MQ$%?NDCMCV[5](T4 %%%% !1110!\^_'K]FWX>?M%>&[[POX_MY[C3+^V^RS
MK 5#&+!& 6.,X-?/?[-'_!-C]GC]E;7[WQ'\,=/O[;4+^!;>=KAD*E%5E&-K
M$YPQ_&OT&HH 8J*J",?="!!_N@;?Y5^9_P 7_P#@E+^S!\:_'%MX_P#&.F:C
M-KMKJ3:I')$R!!<LCQD\MTQ(W;K7Z9T4 >4_"3X/>$O@SX6LO"/A"*6+2K$8
M@64@L/W:Q\D'^Z@[FO5J** /DW]IW]C?X1_M8Z#9^'OBC:75UI]E*\L*VQ4,
M'<AB<L1W%<Q^R]^P7\#_ -DK31I?PLL;RVMA=O> 7+(3YTDCR,?E)_BD;_.*
M^V:* .=\5^&--\8>&]6\+ZLK-INL6C6=VJ_>,+,KG&>^4%?FGIG_  2'_93T
MGXC2_$^UTO4QXDF>%WD+1^66@FDG0CYLCYY&S7ZG44 8GA[0+'PUI5EI&G*R
MVEC:PVD(;J(H$$:9]]H K9=0ZLAZ,"#^-.HH _.7]IK_ ()A?LV_M7>*#XM^
M*&G:A<ZH8UCW6S(%VH4*_>(/!C6OJOX)_ 'P+\!O#-CX4\#P30:7I]G'90+,
M5+"&(AD!QGD$ Y_QKV^B@#QCXX? OP5\?O"9\&^.H)I](+ROMA(#YF5%?J1U
M$:U\D_ 7_@E]^S9^SKXE/BGX?Z;J%OJ9U";4MT[(5^T3SF=SPQ.#(2:_1VB@
M"*"%8(EB3[J# S7P[^TQ_P $^_@1^U7?OJ'Q/L;VYN',9)MF4#,;*R]6'=1G
M\Z^YZ* /E_P=^R3\)?!7@0?#W2]*$FA#3H],5;J""65;:-@RA6=6P01V(ZU\
M*_$;_@B'^QC\3O$%YXD\0Z'J7V^^96F^S^1''E7=QM52H'S.>@Z<5^Q5% 'Y
M6_!;_@D#^R7\"]5MM7\':'=FYM9C-&+V.WF7>SB0Y#;@1N [8]J_3?0?#VE^
M&]/M],TNVBM[:VC$<:QQ1Q@*/9% _P#UUMT4 1S1+/#+ _W)HY(GQUVR*4;]
M":_,KXH?\$G_ -EWXM>.[;XA>*=,U&37K6]DOXWB:,)Y\H8,>3D##'@"OTYH
MH \R^%GPI\+_  B\+Z?X2\*121:5IJE+=)2"P!1$.<$C.(UKTVBB@#Y^^.O[
M-?PT_:#T0Z#X]TN.XM##) 6A@@\TI*6+$NRAB<L<'/>OS$N?^"!7[#%W>_;Y
M=#UCSO/%QP\0&\2>:.C=-P'^>*_;RB@#YK^ '[*_PO\ V<-%_L+X>6,EK9>7
M%&1*L8<K%C:24ZG@5])D!@58 @C!! ((/4$'@@^AI:* / /C+^S9\,?CCH]W
MHOC/1[>6UO$"3-!:6HEP$9.',88$AB3SR:_,W7?^""_[#WB'4+G4K[0]7^T7
M4AED\MHE7<0!@ ....F*_;&B@#\HOA)_P1T_9%^#6I0:GX4T.]-Q;E2GVM+>
M5<H=PR&W=_;/J:_33PMX.T'P?IT&F:)86UK;V\4<*>5;PQ$K&,*3Y:+D^_M7
M4T4 %?%/[3_[!WP0_:R$P^*5E>77GVXMG^S,H_=A%C ^9A_"H_6OM:B@#Y)_
M9S_8R^$/[,-A+IWPWM+JVMYHDA87!4G8A0C&TGG]VOMQ7UMTHHH 8\:2J4D1
M)$;AD=0ZD>A5@0?Q%?%_QV_8.^!/[0GG_P#"<Z+N-PS/(UI;VT;%G.2=P53^
MM?:=% 'XA77_  0*_8;NYGFDTC7<N[2%1-'MW.Q8X&_&,D]J^SO@+_P3O_9Z
M_9WV_P#"":(P9=FU[V"VF8>7LP0S*Q!^0<C'?K7W?10!!;VT%K&L4$4<4:C
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% &7J7^J;\?_0:_C]_X*J_\E$T[_L-2_\ H-U7]@6I?ZIOQ_\ 0:_C
M]_X*J_\ )1-._P"PU+_Z#=4 ?F(O0?0?RI:1>@^@_E2T %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ KGO$O_(,G_P!P_P!:Z&N>\2_\@R?_ '#_ %H \P\*?\A*
M3_@/\Q7MR?<7_=7^0KQ'PI_R$I/^ _S%>W)]Q?\ =7^0H =1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<MXK_Y
M!TW_ %R?^35U-<MXK_Y!TW_7)_Y-0!Y]\/O^/\?[K_UKVJO%?A]_Q_C_ '7_
M *U[50 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !7$>-_^/&/ZG^E=O7$>-_\ CQC^I_I0!SO@3[W_ &U;_P!#
M->LUY-X$^]_VU;_T,UZS0!X/XL_Y"</_ %S'\DKV#0/^039_]<Q7C_BS_D)P
M_P#7,?R2O8- _P"039_]<Q0!L4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% &7J7^J;\?_0:_C]_X*J_\E$T[_L-2_P#H
M-U7]@6I?ZIOQ_P#0:_C]_P""JO\ R433O^PU+_Z#=4 ?F(O0?0?RI:1>@^@_
ME2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %6+*
MTFO[VTLX$>1[BXCAVQJ6;YV"CA03W_SUJL2%!)Z"OL[]C7X':Y\4?B+INS3C
M<Z?;W]E/*X#$"$2!G; 0@C&3@L!0!^RO_!+G]EU=)TW3?B#JEBJ/!<*/WL8C
MF(=FDR _SX^3/3\@:_>J*)(8TBC&U$&U1Z =J\Z^%GP_TGX>>$]-T72HU2/[
M'9/+B)8R)1;(''!/\3-SQ7I- !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 5C:Y_QXR_0?\ LU;-8VN?\>,OT'_LU 'D_A[_ )#%
MS_UW'_H(KW!>@^@_E7A_A[_D,7/_ %W'_H(KW!>@^@_E0 M%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5SWB7_D
M&3_[A_K70USWB7_D&3_[A_K0!YAX4_Y"4G_ ?YBO;D^XO^ZO\A7B/A3_ )"4
MG_ ?YBO;D^XO^ZO\A0 ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH *Y;Q7_ ,@Z;_KD_P#)JZFN6\5_\@Z;_KD_
M\FH \^^'W_'^/]U_ZU[57BOP^_X_Q_NO_6O:J "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *XCQO\ \>,?U/\
M2NWKB/&__'C']3_2@#G? GWO^VK?^AFO6:\F\"?>_P"VK?\ H9KUF@#P?Q9_
MR$X?^N8_DE>P:!_R";/_ *YBO'_%G_(3A_ZYC^25[!H'_()L_P#KF* -BBBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Q
MM9E$-L\A&0.W_ :_$#]J/_@G#J_[4/BV+5;+QI#H2VFHM<&-T1BP99/E^:VE
M_P">H[]OPK]N/$/_ !XR_P"?X#7F/A;_ )"=S_UV'\DH _"!?^"%_B7 _P"+
MJVO0?\LHO3_KQI?^'%_B7_HJMK_WZB_^0:_I+7H/H/Y4M '\V?\ PXO\2_\
M15;7_OU%_P#(-'_#B_Q+_P!%5M?^_47_ ,@U_2910!_-G_PXO\2_]%5M?^_4
M7_R#1_PXO\2_]%5M?^_47_R#7])E% '\V?\ PXO\2_\ 15;7_OU%_P#(-'_#
MB_Q+_P!%5M?^_47_ ,@U_2910!_-G_PXO\2_]%5M?^_47_R#1_PXO\2_]%5M
M?^_47_R#7])E% '\V?\ PXO\2_\ 15;7_OU%_P#(-'_#B_Q+_P!%5M?^_47_
M ,@U_2910!_-G_PXO\2_]%5M?^_47_R#1_PXO\2_]%5M?^_47_R#7])E% '\
MV?\ PXO\2_\ 15;7_OU%_P#(-'_#B_Q+_P!%5M?^_47_ ,@U_2910!_-G_PX
MO\2_]%5M?^_47_R#1_PXO\2_]%5M?^_47_R#7])E% '\V?\ PXO\2_\ 15;7
M_OU%_P#(-'_#B_Q+_P!%5M?^_47_ ,@U_2910!_-G_PXO\2_]%5M?^_47_R#
M1_PXO\2_]%5M?^_47_R#7])E% '\V?\ PXO\2_\ 15;7_OU%_P#(-'_#B_Q+
M_P!%5M?^_47_ ,@U_2910!_-G_PXO\2_]%5M?^_47_R#1_PXO\2_]%5M?^_4
M7_R#7])E% '\V?\ PXO\2_\ 15;7_OU%_P#(-'_#B_Q+_P!%5M?^_47_ ,@U
M_2910!_-G_PXO\2_]%5M?^_47_R#1_PXO\2_]%5M?^_47_R#7])E% '\V?\
MPXO\2_\ 15;7_OU%_P#(-'_#B_Q+_P!%5M?^_47_ ,@U_2910!_-G_PXO\2_
M]%5M?^_47_R#1_PXO\2_]%5M?^_47_R#7])E% '\V?\ PXO\2_\ 15;7_OU%
M_P#(-'_#B_Q+_P!%5M?^_47_ ,@U_2910!_-G_PXO\2_]%5M?^_47_R#1_PX
MO\2_]%5M?^_47_R#7])E% '\V?\ PXO\2_\ 15;7_OU%_P#(-'_#B_Q+_P!%
M5M?^_47_ ,@U_2910!_-G_PXO\2_]%5M?^_47_R#1_PXO\2_]%5M?^_47_R#
M7])E% '\V?\ PXO\2_\ 15;7_OU%_P#(-'_#B_Q+_P!%5M?^_47_ ,@U_291
M0!_-@_\ P0M\3-Q_PM6UQW'EQ_\ R#7Z:_L=?L)6?[,_F2ZGJEIX@N'M5@$J
MH P=5VA\K%%T/-?HU10 BJ%554850% ] !@#\ *6BB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7+>*_^
M0=-_UR?^35U-<MXK_P"0=-_UR?\ DU 'GWP^_P"/\?[K_P!:]JKQ7X??\?X_
MW7_K7M5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %<1XW_P"/&/ZG^E=O7$>-_P#CQC^I_I0!SO@3[W_;5O\
MT,UZS7DW@3[W_;5O_0S7K- '@_BS_D)P_P#7,?R2O8- _P"039_]<Q7C_BS_
M )"</_7,?R2O8- _Y!-G_P!<Q0!L4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% '/^(?^/&7_ #_ :\Q\+?\ (3N?^NP_
MDE>G>(?^/&7_ #_ :\Q\+?\ (3N?^NP_DE 'MJ]!]!_*EI%Z#Z#^5+0 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5C:Y_P >
M,OT'_LU;-8VN?\>,OT'_ +-0!Y/X>_Y#%S_UW'_H(KW!>@^@_E7A_A[_ )#%
MS_UW'_H(KW!>@^@_E0 M%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MX#_,5[<GW%_W5_D* '4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !7+>*_\ D'3?]<G_ )-74URWBO\ Y!TW_7)_
MY-0!Y]\/O^/\?[K_ -:]JKQ7X??\?X_W7_K7M5 !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<1XW_ ./&/ZG^
ME=O7$>-_^/&/ZG^E '.^!/O?]M6_]#->LUY-X$^]_P!M6_\ 0S7K- '@_BS_
M )"</_7,?R2O8- _Y!-G_P!<Q7C_ (L_Y"</_7,?R2O8- _Y!-G_ -<Q0!L4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M '/^(?\ CQE_S_ :\Q\+?\A.Y_Z[#^25Z=XA_P"/&7_/\!KS'PM_R$[G_KL/
MY)0![:O0?0?RI:1>@^@_E2T %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %8VN?\>,OT'_ +-6S6-KG_'C+]!_[-0!Y/X>_P"0
MQ<_]=Q_Z"*]P7H/H/Y5X?X>_Y#%S_P!=Q_Z"*]P7H/H/Y4 +1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<]XE_
MY!D_^X?ZUT-<]XE_Y!D_^X?ZT >8>%/^0E)_P'^8KVY/N+_NK_(5XCX4_P"0
ME)_P'^8KVY/N+_NK_(4 .HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "N6\5_P#(.F_ZY/\ R:NIKEO%?_(.F_ZY
M/_)J //OA]_Q_C_=?^M>U5XK\/O^/\?[K_UKVJ@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N(\;_ /'C']3_
M $KMZXCQO_QXQ_4_TH YWP)][_MJW_H9KUFO)O GWO\ MJW_ *&:]9H \'\6
M?\A.'_KF/Y)7L&@?\@FS_P"N8KQ_Q9_R$X?^N8_DE>P:!_R";/\ ZYB@#8HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M.?\ $/\ QXR_Y_@->8^%O^0G<_\ 78?R2O3O$/\ QXR_Y_@->8^%O^0G<_\
M78?R2@#VU>@^@_E2TB]!]!_*EH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *QM<_X\9?H/\ V:MFL;7/^/&7Z#_V:@#R?P]_
MR&+G_KN/_017N"]!]!_*O#_#W_(8N?\ KN/_ $$5[@O0?0?RH 6BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y[
MQ+_R#)_]P_UKH:Y[Q+_R#)_]P_UH \P\*?\ (2D_X#_,5[<GW%_W5_D*\1\*
M?\A*3_@/\Q7MR?<7_=7^0H =1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %<MXK_ .0=-_UR?^35U-<MXK_Y!TW_
M %R?^34 >??#[_C_ !_NO_6O:J\5^'W_ !_C_=?^M>U4 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M4 %%%% !1110 4444 %%%% !1110 45EWFN:)I[;+_6-*L7! *7FH6ELP).
M-LTR')/ XZ\5:M;ZRO4WV5Y:W:?W[6XAN$YZ?-$[CGZT 6J*** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BLR\
MUO1=/;9?ZOI=BP(!6\O[2V8$\ 8FE0Y)Z<58M=0L+Y=]E>VEXG]ZUN8;A?\
MOJ)W'ZT 6Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^_\ !_\ &*/^&P_VE?\ HK?BC_O_  ?_ !BOFFB@#Z6_X;#_ &E?^BM^*/\
MO_!_\8H_X;#_ &E?^BM^*/\ O_!_\8KYIHH ^EO^&P_VE?\ HK?BC_O_  ?_
M !BC_AL/]I7_ **WXH_[_P '_P 8KYIHH ^EO^&P_P!I7_HK?BC_ +_P?_&*
M/^&P_P!I7_HK?BC_ +_P?_&*^::* /I;_AL/]I7_ **WXH_[_P '_P 8H_X;
M#_:5_P"BM^*/^_\ !_\ &*^::* /I;_AL/\ :5_Z*WXH_P"_\'_QBC_AL/\
M:5_Z*WXH_P"_\'_QBOFFB@#Z6_X;#_:5_P"BM^*/^_\ !_\ &*/^&P_VE?\
MHK?BC_O_  ?_ !BOFFB@#Z6_X;#_ &E?^BM^*/\ O_!_\8H_X;#_ &E?^BM^
M*/\ O_!_\8KYIHH ^EO^&P_VE?\ HK?BC_O_  ?_ !BC_AL/]I7_ **WXH_[
M_P '_P 8KYIHH ^EO^&P_P!I7_HK?BC_ +_P?_&*/^&P_P!I7_HK?BC_ +_P
M?_&*^::* /I;_AL/]I7_ **WXH_[_P '_P 8H_X;#_:5_P"BM^*/^_\ !_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KGO$O_(,
MG_W#_6NAKGO$O_(,G_W#_6@#S#PI_P A*3_@/\Q7MR?<7_=7^0KQ'PI_R$I/
M^ _S%>W)]Q?]U?Y"@!U%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 5RWBO\ Y!TW_7)_Y-74URWBO_D'3?\ 7)_Y
M-0!Y]\/O^/\ '^Z_]:]JKQ7X??\ '^/]U_ZU[50 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\%N_BU\3/!GQ?O[3PIXX\1Z!;+K6GHL&EZC-:QA#J42E0J$#!4D$>AK]??\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MC!KZ%H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M"*]P7H/H/Y4 +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %<]XE_P"09/\ [A_K70USWB7_ )!D_P#N'^M 'F'A
M3_D)2?\  ?YBO;D^XO\ NK_(5XCX4_Y"4G_ ?YBO;D^XO^ZO\A0 ZBBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MRKKYXX9)R588_O9&:_T5/A3IVB:?X-TJ+0[>VALUCQ$+>WA@&W:G185"CC'
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MX_:M)=]"N%:1KFVS$SE99G&XN>FP#/..#0!^^WQ9_P""IO['GP4U*?2?'_Q
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M^'[:YT][^[OM9M75IK8*L["9?+*?<7!&-F HX K_ $.2,@@]#P:_E5_X.#?
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MG'([?WDQH$14'11BOBG]N+X$>'/C1\(-:TW5-,M+J6SL=7U /-&SG?#9&92
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M_?CK3[J)]<_93U[2-&DN(X6UBZ)6V57D"%]P\0L<*AW_ '#QVH _IHK\H?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<]
MXE_Y!D_^X?ZUT-<]XE_Y!D_^X?ZT >8>%/\ D)2?\!_F*]N3[B_[J_R%>(^%
M/^0E)_P'^8KVY/N+_NK_ "% #J*** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ KEO%?_(.F_ZY/_)JZFN6\5_\@Z;_
M *Y/_)J //OA]_Q_C_=?^M>U5XK\/O\ C_'^Z_\ 6O:J "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?QKJ&A:%::19Q/()'D6!7BXRW!/YYH _.W_@C[_R<YXD_P"W3_VM7]\FB?\
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M.L4MUX;NU@4]7;SYN!^1_(U_-+_P0AT?4)?VN;^_2W9K5]"^67L2#J1/Z$4
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M .FV&@#\R/\ @N+_ ,D4T3_KE>_^A/7Y9?\ !!S_ )&VS_["E]_Z735^IO\
MP7%_Y(IHG_7*]_\ 0GK\LO\ @@Y_R-MG_P!A2^_]+IJ /[&HO]4G^Z*_B$_X
M+D?\G$ZC_P!C;HO_ *?17]O<7^J3_=%?Q"?\%R/^3B=1_P"QMT7_ -/HH _H
M(_X)&?\ )"8OII__ *+EK]=Z_(C_ ()&?\D)B^FG_P#HN6OUWH _GF_X+S_\
MFY^(?^OM?_1(KX;_ .#<C_CW^*O_ &%8/_1FGU]R?\%Y_P#DW/Q#_P!?:_\
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M\SO^"\/_ "6C4?\ L.:=_P"G2&OV>_X(X_\ )&?^V-A_(T ?M<B(BA4554#
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M3I'P!\!:%X%T>^DO[30].33XIY P9T1R^XAN>I[\T ?RJ_\ !>K_ )*9?_\
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M<.05VJ.GUSVK^\&OXM?^"XWC*PU/QK::%!#;BZM?$01V15$KL9WP'QR3VYH
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MW9(BS%9" <K&ISA!US^E?QP?M!_\GPZ7_P!=]<_].5A7]PG['O\ R1+P+_V
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MB+7[JZOO$>L/#JMXFI(\D]O>2,LDL8>09R&&"1U'X5^P^LHJ:-J:HH518W.
M!@?ZIJ /XH/VQ]+U+PE^WEX;OBT43BPOI5=0% 5[O2G&2".<>_OVS7]<W[+F
MI3ZC\(?!<LT@D9M$B)(;=_RVDZ<^WZU_)?\ \%*8KJ?]LK0XK(.;EM(N=GED
MAO\ 6:7T(Y]/RK^IK]BF"]@^"G@E;P.&_P"$?@'SG)R)GS_6@#[%HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,O4O\ 5-^/_H-?
MQ^_\%5?^2B:=_P!AJ7_T&ZK^P+4O]4WX_P#H-?Q^_P#!57_DHFG?]AJ7_P!!
MNJ /S$7H/H/Y4M(O0?0?RI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ IKC*L/:G4^"![NZ@LXQF2Y?RT ZDD$@#\J /TP
M_P""<GQ0\2^#?B/9VFE23^4\-M;D(DTB[)7EC/W 0!M/TQVK^P3P]=27NA:1
M=S9\VYT^UGDR"#ODA5FR#SU/?FOY^O\ @EI^RXT,6F>.]:T\FWN;,+')/#N3
MS$A:08++US(,8[X-?T+VT"6MO#;Q@!((DB0 8 5%"@ #H !0!/1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_K\MO^"5W[.?Q0_9P^! \&?%+1AHVNC4DG^S*9F'EC[2"V9886Z2)_#7ZDT
M?@3_ ,%R?@!_PG/P'7Q#I5F'U5-;DNI)4C$DGEV[V,^2 ,X&USG/KGO7\Q_P
M'_;^N_V??@#\4?@9<QZC)K>OZI*EG>P+,(;;R)KM-KA05!'FKP6!&WI7]_\
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M>^B1P2"C/ [J&RK#!.>#Z5_ G#_P1J_X*?6ZK'#H7B>&)2,1Q>)O%$:+]$2
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MU_\ (LZS_P!CI>_^G?4J_6K_ (*X_LL?%_\ :=^#NF^%?A-H2ZWK%OJTES)
M6F4"(RV3ALPP3-R(7_A[5\N?\$>?V$OVAOV6-#U.S^+WA9=#GN/$UUJ,2JUR
M<VTFHWLZ/^^MH.L<R'C/7KWH _9?]J+X86OQ/^#OC/1I+5;F[D\.7T%D"H9E
MF?!7:N"6/)P .]?P7:-=>)/^"?W[7<OBO7M,U(6L-PT)\FVFB CFU%^2R@C
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M^(7@'0/B3X4UGPCXAM89M/UJS:RN)'MXIIHXF96)B,@RIRO\++U/- '\<_\
MP1Q_;]T/X)OH_P "O'"7&F)H=C&ANM1D>RM \\+6W#2@(-IM06 ;@8Z9%?UT
M>'?V@?@]XBTRTU"U^(W@YA<6\,QC77]/9HS*@;8P$YPRDD$'!S7\\/[7/_!"
MW0]3NM3\3_ V/Q!)XBNGD$:6T][9+M1B\7SV=U(W+._\)QVXK\N=&_X)3_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %<MXK_Y!TW_7)_Y-74URWBO_ )!TW_7)_P"34 >?
M?#[_ (_Q_NO_ %KVJO%?A]_Q_C_=?^M>U4 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Q'C?_ (\8_J?Z5V]<
M1XW_ ./&/ZG^E '.^!/O?]M6_P#0S7K->3>!/O?]M6_]#->LT >#^+/^0G#_
M -<Q_)*]@T#_ )!-G_US%>/^+/\ D)P_]<Q_)*]@T#_D$V?_ %S% &Q1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MB@ HHHH **** "BBB@ HHHH **** "L;7/\ CQE^@_\ 9JV:QM<_X\9?H/\
MV:@#R?P]_P ABY_Z[C_T$5[@O0?0?RKP_P /?\ABY_Z[C_T$5[@O0?0?RH 6
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH *Y[Q+_ ,@R?_</]:Z&N>\2_P#(,G_W#_6@#S#PI_R$I/\ @/\ ,5[<
MGW%_W5_D*\1\*?\ (2D_X#_,5[<GW%_W5_D* '4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7+>*_\ D'3?]<G_
M )-74URWBO\ Y!TW_7)_Y-0!Y]\/O^/\?[K_ -:]JKQ7X??\?X_W7_K7M5 !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %<1XW_ ./&/ZG^E=O7$>-_^/&/ZG^E '.^!/O?]M6_]#->LUY-X$^]
M_P!M6_\ 0S7K- '@_BS_ )"</_7,?R2O8- _Y!-G_P!<Q7C_ (L_Y"</_7,?
MR2O8- _Y!-G_ -<Q0!L4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% &7J7^J;\?\ T&OX_?\ @JK_ ,E$T[_L-2_^@W5?
MU\:\[)92LIPPZ'_@)_PKXL\0_LN?!/XN:[)>>/?!MGKEQ#<^9')/MRKD#+#=
M&QYWMW[T ?Q/KT'T'\J6O[>E_P"">W[)^!_Q:[3.@_YY^G_7"E_X=[?LG_\
M1+M,_P#(?_QB@#^(2BO[>_\ AWM^R?\ ]$NTS_R'_P#&*/\ AWM^R?\ ]$NT
MS_R'_P#&* /XA**_M[_X=[?LG_\ 1+M,_P#(?_QBC_AWM^R?_P!$NTS_ ,A_
M_&* /XA**_M[_P"'>W[)_P#T2[3/_(?_ ,8H_P"'>W[)_P#T2[3/_(?_ ,8H
M _B$HK^WO_AWM^R?_P!$NTS_ ,A__&*/^'>W[)__ $2[3/\ R'_\8H _B$HK
M^WO_ (=[?LG_ /1+M,_\A_\ QBC_ (=[?LG_ /1+M,_\A_\ QB@#^(2BO[>_
M^'>W[)__ $2[3/\ R'_\8H_X=[?LG_\ 1+M,_P#(?_QB@#^(2BO[>_\ AWM^
MR?\ ]$NTS_R'_P#&*/\ AWM^R?\ ]$NTS_R'_P#&* /XA**_M[_X=[?LG_\
M1+M,_P#(?_QBC_AWM^R?_P!$NTS_ ,A__&* /XA**_M[_P"'>W[)_P#T2[3/
M_(?_ ,8H_P"'>W[)_P#T2[3/_(?_ ,8H _B$HK^WO_AWM^R?_P!$NTS_ ,A_
M_&*/^'>W[)__ $2[3/\ R'_\8H _B$HK^WO_ (=[?LG_ /1+M,_\A_\ QBC_
M (=[?LG_ /1+M,_\A_\ QB@#^(2BO[>_^'>W[)__ $2[3/\ R'_\8H_X=[?L
MG_\ 1+M,_P#(?_QB@#^(2BO[>_\ AWM^R?\ ]$NTS_R'_P#&*/\ AWM^R?\
M]$NTS_R'_P#&* /XA**_M[_X=[?LG_\ 1+M,_P#(?_QBC_AWM^R?_P!$NTS_
M ,A__&* /XA**_M[_P"'>W[)_P#T2[3/_(?_ ,8H_P"'>W[)_P#T2[3/_(?_
M ,8H _B$HK^WO_AWM^R?_P!$NTS_ ,A__&*/^'>W[)__ $2[3/\ R'_\8H _
MB$HK^WO_ (=[?LG_ /1+M,_\A_\ QBC_ (=[?LG_ /1+M,_\A_\ QB@#^(2B
MO[>_^'>W[)__ $2[3/\ R'_\8H_X=[?LG_\ 1+M,_P#(?_QB@#^(2BO[>_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ KGO$O_(,G_W#_6NAKGO$O_(,G_W#_6@#S#PI_P A*3_@/\Q7MR?<7_=7
M^0KQ'PI_R$I/^ _S%>W)]Q?]U?Y"@!U%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 5RWBO\ Y!TW_7)_Y-74URWB
MO_D'3?\ 7)_Y-0!Y]\/O^/\ '^Z_]:]JKQ7X??\ '^/]U_ZU[50 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7
M$>-_^/&/ZG^E=O7$>-_^/&/ZG^E '.^!/O?]M6_]#->LUY-X$^]_VU;_ -#-
M>LT >#^+/^0G#_US'\DKV#0/^039_P#7,5X_XL_Y"</_ %S'\DKV#0/^039_
M]<Q0!L4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% '/\ B'_CQE_S_ :\Q\+?\A.Y_P"NP_DE>G>(?^/&7_/\!KS'PM_R
M$[G_ *[#^24 >VKT'T'\J6D7H/H/Y4M !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !6-KG_'C+]!_[-6S6-KG_'C+]!_[-0!Y
M/X>_Y#%S_P!=Q_Z"*]P7H/H/Y5X?X>_Y#%S_ -=Q_P"@BO<%Z#Z#^5 "T444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !7/>)?^09/_N'^M=#7/>)?^09/_N'^M 'F'A3_ )"4G_ ?YBO;D^XO^ZO\
MA7B/A3_D)2?\!_F*]N3[B_[J_P A0 ZBBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y;Q7_R#IO^N3_R:NIKEO%?
M_(.F_P"N3_R:@#S[X??\?X_W7_K7M5>*_#[_ (_Q_NO_ %KVJ@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@BBOY]_^'MWQ+_Z$[2?_ "!_\9H_X>W?$O\ Z$[2?_('_P 9H _H(HK^??\
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MH_X>W?$O_H3M)_\ ('_QF@#^@BBOY]_^'MWQ+_Z$[2?_ "!_\9H_X>W?$O\
MZ$[2?_('_P 9H _H(HK^??\ X>W?$O\ Z$[2?_('_P 9H_X>W?$O_H3M)_\
M('_QF@#^@BBOY]_^'MWQ+_Z$[2?_ "!_\9H_X>W?$O\ Z$[2?_('_P 9H _H
M(HK^??\ X>W?$O\ Z$[2?_('_P 9H_X>W?$O_H3M)_\ ('_QF@#^@BBOY]_^
M'MWQ+_Z$[2?_ "!_\9H_X>W?$O\ Z$[2?_('_P 9H _H(HK^??\ X>W?$O\
MZ$[2?_('_P 9H_X>W?$O_H3M)_\ ('_QF@#^@BBOY]_^'MWQ+_Z$[2?_ "!_
M\9H_X>W?$O\ Z$[2?_('_P 9H _H(HK^??\ X>W?$O\ Z$[2?_('_P 9H_X>
MW?$O_H3M)_\ ('_QF@#^@BBOY]_^'MWQ+_Z$[2?_ "!_\9H_X>W?$O\ Z$[2
M?_('_P 9H _H(HK^??\ X>W?$O\ Z$[2?_('_P 9H_X>W?$O_H3M)_\ ('_Q
MF@#^@BBOY]_^'MWQ+_Z$[2?_ "!_\9H_X>W?$O\ Z$[2?_('_P 9H _H(HK^
M??\ X>W?$O\ Z$[2?_('_P 9H_X>W?$O_H3M)_\ ('_QF@#^@BBOY]_^'MWQ
M+_Z$[2?_ "!_\9H_X>W?$O\ Z$[2?_('_P 9H _H(HK^??\ X>W?$O\ Z$[2
M?_('_P 9H_X>W?$O_H3M)_\ ('_QF@#^@BBOY]_^'MWQ+_Z$[2?_ "!_\9H_
MX>W?$O\ Z$[2?_('_P 9H _H(HK^??\ X>W?$O\ Z$[2?_('_P 9H_X>W?$O
M_H3M)_\ ('_QF@#^@BBOY]_^'MWQ+_Z$[2?_ "!_\9H_X>W?$O\ Z$[2?_('
M_P 9H _H(HK^??\ X>W?$O\ Z$[2?_('_P 9H_X>W?$O_H3M)_\ ('_QF@#^
M@BBOY]_^'MWQ+_Z$[2?_ "!_\9H_X>W?$O\ Z$[2?_('_P 9H _H(HK^??\
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MH_X>W?$O_H3M)_\ ('_QF@#^@BBOY]_^'MWQ+_Z$[2?_ "!_\9H_X>W?$O\
MZ$[2?_('_P 9H _H(HK^??\ X>W?$O\ Z$[2?_('_P 9H_X>W?$O_H3M)_\
M('_QF@#^@BBOY]_^'MWQ+_Z$[2?_ "!_\9H_X>W?$O\ Z$[2?_('_P 9H _H
M(HK^??\ X>W?$O\ Z$[2?_('_P 9H_X>W?$O_H3M)_\ ('_QF@#^@BBOY]_^
M'MWQ+_Z$[2?_ "!_\9H_X>W?$O\ Z$[2?_('_P 9H _H(HK^??\ X>W?$O\
MZ$[2?_('_P 9H_X>W?$O_H3M)_\ ('_QF@#^@BBOY]_^'MWQ+_Z$[2?_ "!_
M\9H_X>W?$O\ Z$[2?_('_P 9H _H(HK^??\ X>W?$O\ Z$[2?_('_P 9H_X>
MW?$O_H3M)_\ ('_QF@#^@BBOY]_^'MWQ+_Z$[2?_ "!_\9H_X>W?$O\ Z$[2
M?_('_P 9H _H(HK^??\ X>W?$O\ Z$[2?_('_P 9H_X>W?$O_H3M)_\ ('_Q
MF@#^@BBOY]_^'MWQ+_Z$[2?_ "!_\9H_X>W?$O\ Z$[2?_('_P 9H _H(HK^
M??\ X>W?$O\ Z$[2?_('_P 9H_X>W?$O_H3M)_\ ('_QF@#^@BBOY]_^'MWQ
M+_Z$[2?_ "!_\9H_X>W?$O\ Z$[2?_('_P 9H _H(HK^??\ X>W?$O\ Z$[2
M?_('_P 9H_X>W?$O_H3M)_\ ('_QF@#^@BBOY]_^'MWQ+_Z$[2?_ "!_\9H_
MX>W?$O\ Z$[2?_('_P 9H _H(HK^??\ X>W?$O\ Z$[2?_('_P 9H_X>W?$O
M_H3M)_\ ('_QF@#^@BBOY]_^'MWQ+_Z$[2?_ "!_\9H_X>W?$O\ Z$[2?_('
M_P 9H _H(HK^??\ X>W?$O\ Z$[2?_('_P 9H_X>W?$O_H3M)_\ ('_QF@#^
M@BBOY]_^'MWQ+_Z$[2?_ "!_\9H_X>W?$O\ Z$[2?_('_P 9H _H(HK^??\
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MH_X>W?$O_H3M)_\ ('_QF@#^@BBOY]_^'MWQ+_Z$[2?_ "!_\9H_X>W?$O\
MZ$[2?_('_P 9H _H(HK^??\ X>W?$O\ Z$[2?_('_P 9H_X>W?$O_H3M)_\
M('_QF@#^@BBOY]_^'MWQ+_Z$[2?_ "!_\9H_X>W?$O\ Z$[2?_('_P 9H _H
M(HK^??\ X>W?$O\ Z$[2?_('_P 9H_X>W?$O_H3M)_\ ('_QF@#^@BBOY]_^
M'MWQ+_Z$[2?_ "!_\9H_X>W?$O\ Z$[2?_('_P 9H _H(HK^??\ X>W?$O\
MZ$[2?_('_P 9H_X>W?$O_H3M)_\ ('_QF@#^@BBOY]_^'MWQ+_Z$[2?_ "!_
M\9H_X>W?$O\ Z$[2?_('_P 9H _H(HK^??\ X>W?$O\ Z$[2?_('_P 9H_X>
MW?$O_H3M)_\ ('_QF@#^@BBOY]_^'MWQ+_Z$[2?_ "!_\9H_X>W?$O\ Z$[2
M?_('_P 9H _H(HK^??\ X>W?$O\ Z$[2?_('_P 9H_X>W?$O_H3M)_\ ('_Q
MF@#^@BBOY]_^'MWQ+_Z$[2?_ "!_\9H_X>W?$O\ Z$[2?_('_P 9H _H(HK^
M??\ X>W?$O\ Z$[2?_('_P 9H_X>W?$O_H3M)_\ ('_QF@#^@BBOY]_^'MWQ
M+_Z$[2?_ "!_\9H_X>W?$O\ Z$[2?_('_P 9H _H(HK^??\ X>W?$O\ Z$[2
M?_('_P 9H_X>W?$O_H3M)_\ ('_QF@#^@BBOY]_^'MWQ+_Z$[2?_ "!_\9H_
MX>W?$O\ Z$[2?_('_P 9H _H(HK^??\ X>W?$O\ Z$[2?_('_P 9H_X>W?$O
M_H3M)_\ ('_QF@#^@BBOY]_^'MWQ+_Z$[2?_ "!_\9H_X>W?$O\ Z$[2?_('
M_P 9H _H(HK^??\ X>W?$O\ Z$[2?_('_P 9H_X>W?$O_H3M)_\ ('_QF@#^
M@BBOY]_^'MWQ+_Z$[2?_ "!_\9H_X>W?$O\ Z$[2?_('_P 9H _H(HK^??\
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MH_X>W?$O_H3M)_\ ('_QF@#^@BBOY]_^'MWQ+_Z$[2?_ "!_\9H_X>W?$O\
MZ$[2?_('_P 9H _H(HK^??\ X>W?$O\ Z$[2?_('_P 9H_X>W?$O_H3M)_\
M('_QF@#^@BBOY]_^'MWQ+_Z$[2?_ "!_\9H_X>W?$O\ Z$[2?_('_P 9H _H
M(HK^??\ X>W?$O\ Z$[2?_('_P 9H_X>W?$O_H3M)_\ ('_QF@#^@BBOY]_^
M'MWQ+_Z$[2?_ "!_\9H_X>W?$O\ Z$[2?_('_P 9H _H(HK^??\ X>W?$O\
MZ$[2?_('_P 9H_X>W?$O_H3M)_\ ('_QF@#^@BBOY]_^'MWQ+_Z$[2?_ "!_
M\9H_X>W?$O\ Z$[2?_('_P 9H _H(HK^??\ X>W?$O\ Z$[2?_('_P 9H_X>
MW?$O_H3M)_\ ('_QF@#^@BBOY]_^'MWQ+_Z$[2?_ "!_\9H_X>W?$O\ Z$[2
M?_('_P 9H _H(HK^??\ X>W?$O\ Z$[2?_('_P 9H_X>W?$O_H3M)_\ ('_Q
MF@#^@BBOY]_^'MWQ+_Z$[2?_ "!_\9H_X>W?$O\ Z$[2?_('_P 9H _H(HK^
M??\ X>W?$O\ Z$[2?_('_P 9H_X>W?$O_H3M)_\ ('_QF@#^@BBOY]_^'MWQ
M+_Z$[2?_ "!_\9H_X>W?$O\ Z$[2?_('_P 9H _H(HK^??\ X>W?$O\ Z$[2
M?_('_P 9H_X>W?$O_H3M)_\ ('_QF@#^@BBOY]_^'MWQ+_Z$[2?_ "!_\9H_
MX>W?$O\ Z$[2?_('_P 9H _H(HK^??\ X>W?$O\ Z$[2?_('_P 9H_X>W?$O
M_H3M)_\ ('_QF@#^@BBOY]_^'MWQ+_Z$[2?_ "!_\9H_X>W?$O\ Z$[2?_('
M_P 9H _H(HK^??\ X>W?$O\ Z$[2?_('_P 9H_X>W?$O_H3M)_\ ('_QF@#^
M@BBOY]_^'MWQ+_Z$[2?_ "!_\9H_X>W?$O\ Z$[2?_('_P 9H _H(HK^??\
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MH_X>W?$O_H3M)_\ ('_QF@#^@BBOY]_^'MWQ+_Z$[2?_ "!_\9H_X>W?$O\
MZ$[2?_('_P 9H _H(HK^??\ X>W?$O\ Z$[2?_('_P 9H_X>W?$O_H3M)_\
M('_QF@#^@BBOY]_^'MWQ+_Z$[2?_ "!_\9H_X>W?$O\ Z$[2?_('_P 9H _H
M(HK^??\ X>W?$O\ Z$[2?_('_P 9H_X>W?$O_H3M)_\ ('_QF@#^@BBOY]_^
M'MWQ+_Z$[2?_ "!_\9H_X>W?$O\ Z$[2?_('_P 9H _H(HK^??\ X>W?$O\
MZ$[2?_('_P 9H_X>W?$O_H3M)_\ ('_QF@#^@BBOY]_^'MWQ+_Z$[2?_ "!_
M\9H_X>W?$O\ Z$[2?_('_P 9H _H(HK^??\ X>W?$O\ Z$[2?_('_P 9H_X>
MW?$O_H3M)_\ ('_QF@#^@BBOY]_^'MWQ+_Z$[2?_ "!_\9H_X>W?$O\ Z$[2
M?_('_P 9H _H(HK^??\ X>W?$O\ Z$[2?_('_P 9H_X>W?$O_H3M)_\ ('_Q
MF@#^@BBOY]_^'MWQ+_Z$[2?_ "!_\9H_X>W?$O\ Z$[2?_('_P 9H _H(HK^
M??\ X>W?$O\ Z$[2?_('_P 9H_X>W?$O_H3M)_\ ('_QF@#^@BBOY]_^'MWQ
M+_Z$[2?_ "!_\9H_X>W?$O\ Z$[2?_('_P 9H _H(HK^??\ X>W?$O\ Z$[2
M?_('_P 9H_X>W?$O_H3M)_\ ('_QF@#^@BBOY]_^'MWQ+_Z$[2?_ "!_\9H_
MX>W?$O\ Z$[2?_('_P 9H _H(HK^??\ X>W?$O\ Z$[2?_('_P 9H_X>W?$O
M_H3M)_\ ('_QF@#^@BBOY]_^'MWQ+_Z$[2?_ "!_\9H_X>W?$O\ Z$[2?_('
M_P 9H _H(HK^??\ X>W?$O\ Z$[2?_('_P 9H_X>W?$O_H3M)_\ ('_QF@#^
M@BBOY]_^'MWQ+_Z$[2?_ "!_\9H_X>W?$O\ Z$[2?_('_P 9H _H(HK^??\
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MH_X>W?$O_H3M)_\ ('_QF@#^@BBOY]_^'MWQ+_Z$[2?_ "!_\9H_X>W?$O\
MZ$[2?_('_P 9H _H(HK^??\ X>W?$O\ Z$[2?_('_P 9H_X>W?$O_H3M)_\
M('_QF@#^@BBOY]_^'MWQ+_Z$[2?_ "!_\9H_X>W?$O\ Z$[2?_('_P 9H _H
M(HK^??\ X>W?$O\ Z$[2?_('_P 9H_X>W?$O_H3M)_\ ('_QF@#^@BBOY]_^
M'MWQ+_Z$[2?_ "!_\9H_X>W?$O\ Z$[2?_('_P 9H _H(HK^??\ X>W?$O\
MZ$[2?_('_P 9H_X>W?$O_H3M)_\ ('_QF@#^@BBOY]_^'MWQ+_Z$[2?_ "!_
M\9H_X>W?$O\ Z$[2?_('_P 9H _H(HK^??\ X>W?$O\ Z$[2?_('_P 9H_X>
MW?$O_H3M)_\ ('_QF@#^@BBOY]_^'MWQ+_Z$[2?_ "!_\9H_X>W?$O\ Z$[2
M?_('_P 9H _H(HK^??\ X>W?$O\ Z$[2?_('_P 9H_X>W?$O_H3M)_\ ('_Q
MF@#^@BBOY]_^'MWQ+_Z$[2?_ "!_\9H_X>W?$O\ Z$[2?_('_P 9H _H(HK^
M??\ X>W?$O\ Z$[2?_('_P 9H_X>W?$O_H3M)_\ ('_QF@#^@BBOY]_^'MWQ
M+_Z$[2?_ "!_\9H_X>W?$O\ Z$[2?_('_P 9H _H(HK^??\ X>W?$O\ Z$[2
M?_('_P 9H_X>W?$O_H3M)_\ ('_QF@#^@BBOY]_^'MWQ+_Z$[2?_ "!_\9H_
MX>W?$O\ Z$[2?_('_P 9H _H(HK^??\ X>W?$O\ Z$[2?_('_P 9H_X>W?$O
M_H3M)_\ ('_QF@#^@BBOY]_^'MWQ+_Z$[2?_ "!_\9H_X>W?$O\ Z$[2?_('
M_P 9H _H(HK^??\ X>W?$O\ Z$[2?_('_P 9H_X>W?$O_H3M)_\ ('_QF@#^
M@BBOY]_^'MWQ+_Z$[2?_ "!_\9H_X>W?$O\ Z$[2?_('_P 9H _H(HK^??\
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MH_X>W?$O_H3M)_\ ('_QF@#^@BBOY]_^'MWQ+_Z$[2?_ "!_\9H_X>W?$O\
MZ$[2?_('_P 9H _H(HK^??\ X>W?$O\ Z$[2?_('_P 9H_X>W?$O_H3M)_\
M('_QF@#^@BBOY]_^'MWQ+_Z$[2?_ "!_\9H_X>W?$O\ Z$[2?_('_P 9H _H
M(HK^??\ X>W?$O\ Z$[2?_('_P 9H_X>W?$O_H3M)_\ ('_QF@#^@BBOY]_^
M'MWQ+_Z$[2?_ "!_\9H_X>W?$O\ Z$[2?_('_P 9H _H(HK^??\ X>W?$O\
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M_D#_ .,T ?T$45_/O_P]N^)?_0G:3_Y _P#C-'_#V[XE_P#0G:3_ .0/_C-
M']!%%?S[_P##V[XE_P#0G:3_ .0/_C-'_#V[XE_]"=I/_D#_ .,T ?T$45_/
MO_P]N^)?_0G:3_Y _P#C-'_#V[XE_P#0G:3_ .0/_C- ']!%%?S[_P##V[XE
M_P#0G:3_ .0/_C-'_#V[XE_]"=I/_D#_ .,T ?T$45_/O_P]N^)?_0G:3_Y
M_P#C-'_#V[XE_P#0G:3_ .0/_C- ']!%%?S[_P##V[XE_P#0G:3_ .0/_C-'
M_#V[XE_]"=I/_D#_ .,T ?T$45_/O_P]N^)?_0G:3_Y _P#C-'_#V[XE_P#0
MG:3_ .0/_C- ']!%%?S[_P##V[XE_P#0G:3_ .0/_C-'_#V[XE_]"=I/_D#_
M .,T ?T$45_/O_P]N^)?_0G:3_Y _P#C-'_#V[XE_P#0G:3_ .0/_C- ']!%
M%?S[_P##V[XE_P#0G:3_ .0/_C-'_#V[XE_]"=I/_D#_ .,T ?T$45_/O_P]
MN^)?_0G:3_Y _P#C-'_#V[XE_P#0G:3_ .0/_C- ']!%%?S[_P##V[XE_P#0
MG:3_ .0/_C-'_#V[XE_]"=I/_D#_ .,T ?T$45_/O_P]N^)?_0G:3_Y _P#C
M-'_#V[XE_P#0G:3_ .0/_C- ']!%%?S[_P##V[XE_P#0G:3_ .0/_C-'_#V[
MXE_]"=I/_D#_ .,T ?T$45_/O_P]N^)?_0G:3_Y _P#C-'_#V[XE_P#0G:3_
M .0/_C- ']!%%?S[_P##V[XE_P#0G:3_ .0/_C-'_#V[XE_]"=I/_D#_ .,T
M ?T$45_/O_P]N^)?_0G:3_Y _P#C-'_#V[XE_P#0G:3_ .0/_C- ']!%8VN?
M\>,OT'_LU?@A_P /;OB7_P!"=I/_ ) _^,UHZ5_P58\<:S<I9ZQX8TJSM).)
M)E\C*X(P>(QV)[T ?L-X>_Y#%S_UW'_H(KW!>@^@_E7XG:U_P4&TS0-+35]"
M;3[_ %:>(S36;"+"3 LH3G=Q@#MW_$^3I_P5N^)N,-X.TD8) _U'0'@_ZGN,
M=J /Z"J*_GW_ .'MWQ+_ .A.TG_R!_\ &:/^'MWQ+_Z$[2?_ "!_\9H _H(H
MK^??_A[=\2_^A.TG_P @?_&:/^'MWQ+_ .A.TG_R!_\ &: /Z"**_GW_ .'M
MWQ+_ .A.TG_R!_\ &:/^'MWQ+_Z$[2?_ "!_\9H _H(HK^??_A[=\2_^A.TG
M_P @?_&:/^'MWQ+_ .A.TG_R!_\ &: /Z"**_GW_ .'MWQ+_ .A.TG_R!_\
M&:/^'MWQ+_Z$[2?_ "!_\9H _H(HK^??_A[=\2_^A.TG_P @?_&:/^'MWQ+_
M .A.TG_R!_\ &: /Z"**_GW_ .'MWQ+_ .A.TG_R!_\ &:/^'MWQ+_Z$[2?_
M "!_\9H _H(HK^??_A[=\2_^A.TG_P @?_&:/^'MWQ+_ .A.TG_R!_\ &: /
MZ"**_GW_ .'MWQ+_ .A.TG_R!_\ &:/^'MWQ+_Z$[2?_ "!_\9H _H(HK^??
M_A[=\2_^A.TG_P @?_&:/^'MWQ+_ .A.TG_R!_\ &: /Z"**_GW_ .'MWQ+_
M .A.TG_R!_\ &:/^'MWQ+_Z$[2?_ "!_\9H _H(HK^??_A[=\2_^A.TG_P @
M?_&:/^'MWQ+_ .A.TG_R!_\ &: /Z"**_GW_ .'MWQ+_ .A.TG_R!_\ &:/^
M'MWQ+_Z$[2?_ "!_\9H _H(HK^??_A[=\2_^A.TG_P @?_&:/^'MWQ+_ .A.
MTG_R!_\ &: /Z"**_GW_ .'MWQ+_ .A.TG_R!_\ &:/^'MWQ+_Z$[2?_ "!_
M\9H _H(HK^??_A[=\2_^A.TG_P @?_&:/^'MWQ+_ .A.TG_R!_\ &: /Z"**
M_GW_ .'MWQ+_ .A.TG_R!_\ &:/^'MWQ+_Z$[2?_ "!_\9H _H(HK^??_A[=
M\2_^A.TG_P @?_&:/^'MWQ+_ .A.TG_R!_\ &: /Z"**_GW_ .'MWQ+_ .A.
MTG_R!_\ &:/^'MWQ+_Z$[2?_ "!_\9H _H(HK^??_A[=\2_^A.TG_P @?_&:
M/^'MWQ+_ .A.TG_R!_\ &: /Z"**_GW_ .'MWQ+_ .A.TG_R!_\ &:/^'MWQ
M+_Z$[2?_ "!_\9H _H(HK^??_A[=\2_^A.TG_P @?_&:/^'MWQ+_ .A.TG_R
M!_\ &: /Z"**_GW_ .'MWQ+_ .A.TG_R!_\ &:/^'MWQ+_Z$[2?_ "!_\9H
M_H(HK^??_A[=\2_^A.TG_P @?_&:/^'MWQ+_ .A.TG_R!_\ &: /Z"**_GW_
M .'MWQ+_ .A.TG_R!_\ &:/^'MWQ+_Z$[2?_ "!_\9H _H(HK^??_A[=\2_^
MA.TG_P @?_&:/^'MWQ+_ .A.TG_R!_\ &: /Z"**_GW_ .'MWQ+_ .A.TG_R
M!_\ &:/^'MWQ+_Z$[2?_ "!_\9H _H(HK^??_A[=\2_^A.TG_P @?_&:/^'M
MWQ+_ .A.TG_R!_\ &: /Z"**_GW_ .'MWQ+_ .A.TG_R!_\ &:/^'MWQ+_Z$
M[2?_ "!_\9H _H(HK^??_A[=\2_^A.TG_P @?_&:/^'MWQ+_ .A.TG_R!_\
M&: /Z"**_GW_ .'MWQ+_ .A.TG_R!_\ &:/^'MWQ+_Z$[2?_ "!_\9H _H(H
MK^??_A[=\2_^A.TG_P @?_&:/^'MWQ+_ .A.TG_R!_\ &: /Z"**_GW_ .'M
MWQ+_ .A.TG_R!_\ &:/^'MWQ+_Z$[2?_ "!_\9H _H(HK^??_A[=\2_^A.TG
M_P @?_&:/^'MWQ+_ .A.TG_R!_\ &: /Z"**_GW_ .'MWQ+_ .A.TG_R!_\
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M1_P]N^)?_0G:3_Y _P#C- ']!%%?S[_\/;OB7_T)VD_^0/\ XS1_P]N^)?\
MT)VD_P#D#_XS0!_0117\^_\ P]N^)?\ T)VD_P#D#_XS1_P]N^)?_0G:3_Y
M_P#C- ']!%%?S[_\/;OB7_T)VD_^0/\ XS1_P]N^)?\ T)VD_P#D#_XS0!_0
M117\^_\ P]N^)?\ T)VD_P#D#_XS1_P]N^)?_0G:3_Y _P#C- ']!%%?S[_\
M/;OB7_T)VD_^0/\ XS1_P]N^)?\ T)VD_P#D#_XS0!_0117\^_\ P]N^)?\
MT)VD_P#D#_XS1_P]N^)?_0G:3_Y _P#C- ']!%%?S[_\/;OB7_T)VD_^0/\
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M!%%?S[_\/;OB7_T)VD_^0/\ XS1_P]N^)?\ T)VD_P#D#_XS0!_0117\^_\
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M1_P]N^)?_0G:3_Y _P#C- ']!%%?S[_\/;OB7_T)VD_^0/\ XS1_P]N^)?\
MT)VD_P#D#_XS0!_0117\^_\ P]N^)?\ T)VD_P#D#_XS1_P]N^)?_0G:3_Y
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M@?\ QF@#^@BBOY]_^'MWQ+_Z$[2?_('_ ,9H_P"'MWQ+_P"A.TG_ ,@?_&:
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MHK^??_A[=\2_^A.TG_R!_P#&:/\ A[=\2_\ H3M)_P#('_QF@#^@BBOY]_\
MA[=\2_\ H3M)_P#('_QFC_A[=\2_^A.TG_R!_P#&: /Z"*XCQO\ \>,?U/\
M2OPN_P"'MWQ+_P"A.TG_ ,@?_&:[SX>_\%*_$/Q)U^S\/^*-%TW2(;NYM[:V
MEC\G=)+<.$"C$:?Q$#J3SQ0!^N?@3[W_ &U;_P!#->LUYOX&TZ:.QLKV1"!=
MP6]VI[%;B)9@1[$.#]*](H ^+_V_O^38?'G_ %S3_P!);ZOY3Z_JP_;^_P"3
M8?'G_7-/_26^K^4^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH *[;X;?\E \&?]C)I'_I;%7$UVWPV_Y*!X,_[&32/_
M $MBH _LL\*_\BQX<_[ .C_^F^WK>K!\*_\ (L>'/^P#H_\ Z;[>MZ@#XO\
MV_O^38?'G_7-/_26^K^4^OZL/V_O^38?'G_7-/\ TEOJ_E/H **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **U-+T35];F%OI&G76HSMRL5I$TKD9QD*
MN3UKKS\)OB6$WGP/XCV8SN_LV?;CUSMQB@#SRBM'4M(U/1YWMM4L;FPN(SAX
M;J)HG4YQAE;!!R.E9U !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %=M\-O^2@>#/\ L9-(_P#2V*N)KMOAM_R4#P9_V,FD?^EL5 ']
MEGA7_D6/#G_8!T?_ --]O6]6#X5_Y%CPY_V ='_]-]O6]0!\7_M_?\FP^//^
MN:?^DM]7\I]?U8?M_?\ )L/CS_KFG_I+?5_*?0 4444 %%%% !1110 5VW@S
MX?\ B+QW??V=X?M3<W'R_+M<CYNF2JG'3FN)K]\/^"<GPJ\-S:3;>(M0L+.^
MFN]/)VS1EF1EB)# C:,Y;/4_0T ?F;'^Q%\<Y8TD70XMLB*ZY\_.UU##/[KT
M->;^+_V=OB3X)ADFUO2S$D2LSE5E( 7(/)0>G^&:_KP7PYH:J%73+8*H"@!3
M@ # 'WNPKCO%_P */!?BS1M1TR\T#36DO;9X$N)(69HBY!+C#'D<]CUQB@#^
M,QE9&*L"K X(((/!QT--K[5_;-^!,_PG^)&K0:?:N=$C.([J--ENS-*PPH(4
MY QV].O2OBJ@  R<#J>!7MOP[^ 'Q"^)]H+WPMIPN8/,\K<PE WY(QE48=5/
M^%>/Z<JO?6BL 5:>,$'H06'%?TN?\$]_"_A^7X0-<R:3:-<"_C'FE#OZ7!Z[
MO7F@#\-_$G[(GQA\*Z9=:MJNCI':6D)GF=?.)6-2 3S&!U/TKYBEC>)VC<89
M200<CH2._P!*_L2^-'AG0)/A?XT9]*M&9-$F*DH<J?-BZ?-7\DWQ)MX;;Q5?
MQ6\:Q1J[;4084?O'Z"@#A8XWE<(@+,QP !D_E7T5X-_9;^*WCK3X=3T'25FM
M9T\R-V$PRO!SQ&1T([UP7P:TB#7?B-X?TNZ57@N9\.KC*GYEZC!SQ7]7'P1\
M"^&M'^'^A6T&DV89+;!D6-@6X0=SZ=J /YN/^&'_ (Z_] .+\Y__ (S4<O[$
M?QSAC>1]$BVH-QQY_3_OU7]57_"/:)_T#;;_ +Y/_P 52-X<T-@5;3+4J>""
MAP?_ !Z@#^2.\_9?^*EB\D<^DX:)2S868C"@DX_=^QKQ[7_!VN^'+AK;4K*:
M.12P.(I<94D'DH.]?V4R^ O!LY9I?#NFR%@0Q:)CD'.1]_ODUY?XV_9P^&'C
M"PN+4^%-%M;B9-JW0MW+H2""<[FP>G8^M '\?Q5E.&!4^A!!_(TE?IK^V+^Q
MG??"V5O$7AT3:C97EP[/;VT06*UA5B&;YHXS@=3\S8%?F8Z-&[QN"KHS(P/4
M,I((/T(H EMK>6[GCMX5W22MM0#G)^E?2/A/]D_XN>,]+@U?1=(2:SN03&["
M89PJL>D9[,.E>4?"F"*Y^(GA2">-989=359(W&5<>6YP1]:_K'^"'A7P[!X!
MTD0Z19QC#<*A'_+.$?WO>@#^8KQ?^RI\6?!&EW&KZ[I*06=LH:5U$IP""P^]
M&!T!KYQFA>"1HI!AU."*_K3_ &K?#>A+\%/%DPTRU$J0#:^P[A^ZGZ?-[#\J
M_E0\91I%XAU!(U"*)F 4#  S0!RU%%% !1110 $X!/H,U^A_["'P4\/_ !+\
M=6+:_&[VLD1W;0&&02>A..W^>*_.]NA^A_E7[$?\$RX)?^$ET^;8?+V.-W;)
MW4 ?JG#^R1\+8X4B%G\JJ%&;>$\#WW<_C^-?B[^WK\#/#?PWU2[U;0XGC2>^
M6$94(N#,J\ $]G[5_2..@^@_E7\^/_!2GQI:7_B+4/#4;QF>RU!)'4'YP/M
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M,*1QZ7:H@'RJ$( _\>H _E@_X8?^.O\ T XOSG_^,T?\,/\ QU_Z <7YS_\
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MX#(*_FC^)VA6GASQEKFE661;VFJ7MM$&Z^7%,ZKGKSQZXK^QGQC_ ,BYK/\
MV"M3_P#2*:OY OCA_P E&\3_ /8<U+_THDH \CHHHH  "> ,GT%>S^ /@/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M -=F_G7]8_[5W_)$/%W_ %P7_P!%3U_)QXV_Y&/4?^NS?SH Y.BBB@ HHHH
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M< <=^/?[CT']E/X<Z':QVR:=87/EH$WS6$+,<=R6#$G]?>@#^3C_ (1[7_\
MH!ZQ_P""R]_^,54FTS4K<$SZ?>P!>IFM)XP/J7C4#\:_KQ_X9O\ AV0P.BZ5
M\RD?\@VWXR",_=KQ7QW^PG\-O%]E>P[A8M<JP!M;98BN[/W?+=<<_P"% '\M
M=%?>_P"U'^QOJGP0>34--@O+C1'N?*MKR<R_O%#A2</N'1E.<D]?2O@IT:-V
M1AAE8J1[@D']10 @!8@ $DG  &23Z #DGZ5=33-2D&Y-/OG4]&2TN&'YB,BM
M_P"'VEQ:WX\\*:/<$B#4=6AMI2.RLLC$C_OD5_2-\.OV+/AU/X:LY)MCN\:,
M2]JK')C0]2Y)Y;^E '\R<UK<VYQ<6\\!/($T,D1(]<.JU);V%]=G%I97=T?2
MWMIIS^42-7[(?M<_LBV5EXV\+^'_  ;;/<'58"&6*/RCO*=,)N/4_CZ&OJ[]
MG#]A'PGX.T/3]7\0Q--J\T0^U65[!Y\<;*HZ"4D<DD9VCIC!H _G,ET#78%+
MS:+JT*#J\NG7D:CORSP@#CGK6<+>=V:-()FD&046-V<''0J%+ ^V,U_6;\4?
MV<_A]JWA2[MUT?3+1A&JB:WT^WCD&V)E^\BJ><9Z_K7XL? OX$>'_&GQI\;:
M'>,5L]$U\6\(";E,?D6C'*Y ',IX.0.M &E_P3,L;VW^,A>>SNH4_LS[TMO-
M&OW;G^)T4=QW[U_1]!_J8_\ <7^5?.WPO_9Q\'_#34TUG1E3[3Y(BR(%C.T@
MGJ"?[YKZ- "@ = ,4 ?AE_P4KL[N>*V\BUN9O]//^J@ED_Y:_P"PIK\6SI6I
MKO+:=?J-[<M9W '7U,8%?V#?$?X'>&/B4JKK*H0LAD&Z%9.<Y[D=_P#/>O /
M$?[$WPW?2[@(L:-L=MRVBA@0K'J&SU]_\* /Y;&5D)5U96'!# J0?0@@$5/#
M9W=P,P6MS./6&"60?FBL*])^-^@6WA3X@>*]&LCF#3]5FMXCC&46-&''KDGO
MCK7ZI?L*?LT^$/B3\/-&\1ZT<W%W&=ZM")!D01MU9L=7/;_  'XT2:;J,2EY
M;"]C0=6DM9T4?5FC 'YU3P2=H!W9QC!SGTQUS7](G[0?['/@?1OA;XCU/2(U
M;4+:W!@5+94).R0_>#9'W1V-? GP$_8$U;X@:G_:'BJUOM-T8[)K2XB,N)0,
M,1@&,8'^\<\T ?F)#I6IW&/(TV_GST\FSN),_39&U2R:'K40S+H^J1CUDT^[
M0?FT(K^I#P'^P_\ #7P9%;[534&C1"1=VJ2Y;:,@^8S]\YZ_TKM/$?[)GPX\
M0P"%["QM,*5W06$*'!SS\NWGD_SYH _DKDBEB8I+')$XZK(C(P^JL 1^51U^
MS'[4_P#P3^;08+WQ)X#@O-2</(\D $J1)!#F1W"J9%&$9ST'W>3CFOQXU73;
MG2+ZYL+R,Q3VT\L$B'JKQ.4<'@<@@T 9U%'2O5OAI\'_ !G\4=2M['PSI4NH
M><P&8RP."X4XVHW3F@#RZ*":8XAAEE/3$4;R'/IA 36@FAZW(,QZ/JKCU33[
MMA^:PFOWF^!7_!-WPU8:;:ZIXJN+V#4)HHYI;69))(TE)4,@#2 8&"?NU]R:
M)^RG\.-&MTMTTZQN-G\<UA S'@#DL&/;/K[T ?R:/H>M1?ZS1]4C_P!_3[M/
M_0H16?)#-"=LL4D3#J)$9"/P8 U_6KX@_9,^&^NC#V%E;?*%/DV$*= !GY=N
M#^?05^??[1O_  3KTR#3KC6O!)O+^["23RVZ+(B(5S@ *SK@X'1>OZ 'X545
MV?C;P-K_ ($U>?2-?LGLKJ)G_=ODG:KE02653TP>G3FN(F8K&[#J!G]: +L5
ME>3@&"TN9@>AB@ED!^A1&I\FG:A"I>6PO(D'5I+6=%'U9D 'YU^UO[$'[,7@
M[XA_#S0_$>LG=<7ML[.C0B101!&_!W ?Q^@[FO?OVD_V/?!6A?"?Q!JNB1*^
MHVR(($2V5"W[J<_>4DCE5[?X4 ?SF1PRRMLBBDD?.-L:,[9/0;5!.?;%:B^'
MM?==ZZ'K#)UWKIEZRX]=P@(_6OV _9@_8)3Q#?'Q#XPAN[.S!CNK+*R/%. $
M&TJS*NTDM_>Z<>WZS:?^SG\/--T8Z8NB:5,%B*^=)IML9?\ 5[<[BK-G(!SD
M_I0!_(1-;7-LVVXMY[=@<%9HI(FR.HQ(JG/X5!7Z1?M\?"C0/AWXEL#HJ)&M
M\99G1(EB1?D<[0JY&/E''XU^;L8,C1HHR\KK&BCNS':!^)('XT %6HK&]G_U
M%G=39Z>5;S29_P"^$:OK_P" 7[('CGXO:C9RW>D7<'AV9PEQ?P-+E-S@+C:J
MCE0Y'S#D#VK]H/AK_P $^_AWX5T^R>YGENKE8U,J7<!EPX/(R\ASGOQ_A0!_
M-:/#^O$9&B:N1ZC3;PC\Q#5>72M4A!,VFW\0'4RV=Q&!]2T8Q7]<MK^S/\.K
M:$0C2-,?Y2NYM.MRW*D9Y4^O6O-?%G[$7PU\3V]S"ZQV?G@C=;VB1LN2?NE&
M4\=>.<T ?RK%64D,"I'4$$$?4'FDK],?VF_V%M?^'5Q>ZGX1L;W4M*21W6>0
MR@>3&Q+M@AQPA!P#V'-?FK=6T]G<2VURGES0R21NA[-&Q1A^# CWQD4 044A
M(4$GH!DU]-_L^?LW^*_C3K5IY&G7#:#*8G%Y 9 3AB6'R*.B#)&_\NP!\XPZ
M=J%QC[/8WD^>GDVT\N?IL1LU:.@:Z!N.BZL%]3IMX!^9AQ7],'PO_8*^'WA3
M3[">[9KJZ$$3S175N)0)< LO[QVR 1CI_P#7]YN_V8OAU=6IMCI.FQ@JR[TT
MZ ,-W?( /'UH _D.U"UN;>/;<6\\#;U^6:&2(\'GAU4\=Z_J)_88_P"2;:+_
M -@B#_T;7@_[1O\ P3M\.ZYH-]K/@XW,^N)@6^GVT;Q1OE68G$;$?>51PG?\
M_KG]EGX?:U\/_"=IHVK6DEM+9V,5N5DW;MRNK?Q*#W/U]!0!](^,?^1<UG_L
M%:G_ .D4U?R!?'#_ )*-XG_[#FI?^E$E?U^^,?\ D7-9_P"P5J?_ *135_(%
M\</^2C>)_P#L.:E_Z424 >1T444 ==\._P#DH/A'_L*+_P"BI:_K0_9S_P"2
M?:1_NM_Z)BK^2_X=_P#)0?"/_847_P!%2U_6A^SG_P D^TC_ '6_]$Q4 =;\
M:?$>J^%/AUKVN:+/]FU&RA#P3?-\K;9#GY64]0.A%?@!XE_X* _M#:%XIU&S
MD\7-]AAF"Q1JET2J\\$B[(.?H,X%?O%^T;_R2/Q3_P!>X_\ 0):_DW^)_P#R
M-VK_ /79?YM0!^G?PS_X*6^)X=9M%\;ZM>7UBQ1)DC%R,EG"YRQE]3_"?TK]
MN/AG\0])^(OAO3M<TR3,=W9QW)5W5I ')&& "D'IU (_*OXQ&)4H58J1(A!4
MX(PP/M7]%O\ P3I\77^L>&+RRN97=+*V@BBW2%L#?!TR>/O=NWL: /TN\8:#
M9>(?#^J6%]%YJ/I]\J+QP[VT@4\@]P*_E9_:N^%[?#_QW?((DB2[NKVZ0( /
MDDE\P<C@G##)QT/K7]9$X!AF#?=,4@;/3!0@Y_"OYXO^"F-I86_CFP^R,&W:
M>S/@ 88Q0D]#S@D\\9/>@#\I8HI9CB&.24^D:,Y_)035O^RM4QG^S;_'K]CN
M,?GY=?8G[#WPLTCXK>,]5L-98K#9-$R83?D$*2,9'KT]^]?N:?V)_AM_9CX6
M/<+1F#?9$W%A!D<[L]<4 ?RQ-'(C;'C='Z;&1E;/IM(!_2M"#1=9NE#6NDZG
M<J1D-!874RD>H,<3 C\:_3#3OV,;[QM\6M2T^UM+D:%8:]+!<7$(=0D "X;:
MN!U8<$CZU^PGPN_9&^'GP_TF"R^PVFIO'&T>^^LHIG.4"9+2[SGC.: /Y1[G
M2M4LQF[TV_M1C.;FSN(!CU_>QKQ[U0K^B#]M_P" '@O3/ .M>(]/LK2RN;.U
M41QVMI'"IS"YS^[V\Y0<XSSU%?ST7L:PW=Q&I.U& &?3&: *U2Q0S3';#%+*
MW]V*-I#^2@FNY\!_#7Q9\1=3M]+\+Z:^H7$SJ-B;L["P!(VHQZ9(K]I/V>_^
M"<FC1Z=:ZOXQ>]M+]XXIS;2I))'O;;N3#N@VC'=<=..1@ _#--!UR0;DT;5G
M4]"FG7C _B(2*5M UU!N;1-751U+:;> #\3"!7]:&C?LM_#G1[**S32]/N!&
M,>9+I\#.> .2P8GH.IJWJ/[,GPZU"QDLVTG38A)UDCTZW#KPPX( /?/7J* /
MY%Y;&]@YGL[J$>LMO-'_ .AHM5:_ID^)G_!/CX>^)])NGL[B6WO(('>VCMH#
M'YDN<JI,<B]<G''X<5^)_P >_P!E?QM\(+R[N9-)N1HD3L%O)C)S\W'WD/52
M/XOPZT ?)=%*RE696X9201Z$=JN:=I]UJE]:V%G&99[JXAMT09R7F=44< XR
M6'/Z4 5$1Y&"1JSN>BHI9C]%4$G\JT(]&U>;F+2M2E'K'8W3_P#H,1K];_V9
M?^">LOB9;#Q)XXCOM-+&)TA'FM$\$V)%<J613F-4/0_>//2OU!\*_L<?#?PS
M$$2VMKP[0N;BRB<\>N\MU _"@#^50^']>49;1-74>ITV\ _,PU =(U4<'3-0
M!]#97/\ \:K^N6\_9G^'5Y 8#I&F1YSEDTZW!Y&."%!_'KQFN!G_ &+?AI/(
M\ABA7<Q; M$ &?HP_P /RH _E8_LG51UTS4/_ .Y_P#C=5)8)X#MFAEA;TEC
M>,_DX!K^JI_V)OAHR.@2(;U*Y%HF1D8R/FK\7_V]_@IH'PB\;QZ;H+EX)-.^
MTG*; &,=NV,;F[R'O_6@#\](X9ICMABDE/3$<;2'/IA035LZ5J@&3IM^!ZFS
MN ..O/EXK[5_84^%&B_%GQ)K-OK3$1V%S$J )O!#);$Y!(P"9#@<_K7[<WW[
M$_PV32+QD2/?'8W+H?LB9WK;N5YW]V ^G2@#^65HY%;8R.KYQL96#9]-I&<^
MV*T(-$UFY7?;:1J=PIY#06%W*I'KNCB8?K7Z8^&?V+KWQS\4;JV2TN4\/VNM
M75O<7,(D CB67:IPN!T&<;ACCKQ7[#_#/]DGX>>!-)@LCI]GJ+I"8B][8Q2O
M]W;DF7S"3[YZT ?RA7&EZG9Y^UZ=?6N.3]HM+B# ]3YL:XJC7] O[=GP"\&Z
M-X$U?Q)IMI:V5S;QA4CM;6.%?]0S9^3:,_+Z=^O>OQ:^%/PDU_XK^+'T;0[.
M6[MH+Y;>^DB+!H49$.[Y0W.73H1U]J /)(X9ICMAAEE8]%CC>0_DH)K030=<
MD&8]&U5QZIIUXP_-82*_?OX/_P#!-/P7IEG::MKM_?KJ!"^;:S+))&NT!AD-
M-CDL1C:/K7VKHW[+/PYTBU2V73-/N-J*F^73X&8A1C)+!CG\: /Y,O\ A'M?
M'70]8_\ !9>__&*IS:=J%N"UQ8WD"CJ9K6>(#ZET4"OZ\'_9N^';Q21G1=+'
MF*R$C3;?@,,9!V@Y'^>]>$?$']@CX;>,M/N;=938O+N8&TMO*8$@X ,<BGJ<
M<$=N] '\O5%?;'[3/[)NL?!+4=]O;7<FF7,LC03SM)\T*B3#_/NZF,]^W6OB
M?GOP>_\ DT *JL[!44LQZ*H+,?H!DG\*NKI>IN-R:=?,IZ%;2X8'\1&17??!
M70;?Q7\4O#GAV\.+:^E*R$#/&^(=._#'O7]&G@3]BSX<S^&]/FF5&DDA^8M:
MJS9X[ECSQUH _F%EMKBW.V>WFA;KB6*2,X]<.JFDB@FF.(8993G&(HWD.?3"
M@G-?K?\ M4_LD2)\1!X>\#6#WAEMT<)%&8R0S1@D! WKSC/-?0OP+_X)O>&;
M33['5_%%S?0W\D45Q);3++)&)25#)AI N !G[OO0!^#B:#KD@W1Z-JSKZIIU
MXP_,0D57N-+U.U!-UIU]; <DW%I<0@#U/F1K7];6C?LM_#G1[1+5-+T^<("
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M[)_:6_9=UWX-ZU<"&RN6TP":?SYC(3L)5T.&!X*L3P>E?&Y!!(/!'4>E $;
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MOB#X!USX>:_<Z'KEN8+B*2;8NU@/+60JI^8 ]"/\: +GPB_Y*5X0_P"PHO\
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M\$:O=6VG0CQ!;VACT\06\4:LY1AEC&JL3G!S@G/X4 ?RAU[9^SS_ ,E0T?\
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MA(QDGTZ_X5_.5^W/^TOXM\1>,-6\%1WIBTS2+QDM_(E>)RI=CABFW(^I/\Z
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MP[_Y*#X1_P"PHO\ Z*EK^M#]G/\ Y)]I'^ZW_HF*@#0_:-_Y)'XI_P"O<?\
MH$M?R;_$_P#Y&[5_^NR_S:O["O'GA>W\9>&-1\/709H;Z/8X7J1AAQR.S'\<
M5^:VN_\ !-OP#KFL2ZA=6UX?M$P:4JQ'RYYX\P>I^G3K0!_/)8Z5J6L7,-GI
MEG<7MS)+&!#;QF20J7 )"CG ]:_IR_8:^$=WX&\#VVH7L;03:MI]O.T3IL=&
MWQY5UP#D"/GTSWJS\-/^"?7P8^'NKVNOV-M=R:A;A=J7*K+&2"&.5:1@?F4=
M1QV]_NC3M/L](LH+.U1(;>WC$: !4 1>G3  Y]<4 2:G*(=-U"8G BL;N4GT
M$<$CY_2OYA_VZ/&D?B?Q[(J3"0VIN;8X;)'ELB8[]-N#_/O7[??M8?M"V'PD
M\%7;V5["NH7*W=A(I>-AMGC2$8 +')\UL' ^M?R^>/\ Q9=>,/$>I:K<2>8;
MB]NY@<D\2RL_&?P/'&/PH ^\_P#@F-_R4'Q)](O_ $%*_I.M@&MHU(R&B0$>
MH,:@C\J_FS_X)D_\E#\2_2'_ - CK^DVUXMXCZ1I_P"@+0!S%CX7\->&9+_5
M(+:WL#<N9[VX)VJS':"[L0 .@Y_#TQX=X\_:G^'W@C4&T^;4]-NY$F2)MEVI
M(WR!-QP1@#D\^GY^*_MN_M%?\*M\,RZ'8W0ANM;L9(U^8*V\>8<J<;ACR^W?
MTK^;?Q3XSUOQ3JUQJE[J%VTDY!.VZGQD,S<#>!U8\X^E '[O_M@?M(>"O%_P
MRUG2M,O;*>XO+2(HD-R'<$P/E<9/(+8Q[5^!5O9R:YXBMM-M@6?4KN.WC*C<
M0S\#C_$51DOKV4;9;RZD4]5DN)7'Y,Y%>^_LP^$X_%?Q)T8RQ^8+#5K27INY
M!!Y![<].>HH _;_]A/\ 9QTSP3X/T[6M:TZ.76BRO]JD39*$=-X'3W'^>GZ4
M:A?6>B:=+>7,D=O:6D>YY)&"1QH.['H ,]:Q/!6GQ:=H%C;Q1K&JVUN,*JKR
M(4'0 '\_6OBK]NOXQ7?P]\&W6A6UP(#KFFNN0VU\_.V5((8?<Z@T <A\9?\
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M^RSPK_R+'AS_ + .C_\ IOMZWJP?"O\ R+'AS_L Z/\ ^F^WK>H ^+_V_O\
MDV'QY_US3_TEOJ_E/K^K#]O[_DV'QY_US3_TEOJ_E/H **** "BBB@ HHHH
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MFW4UG=1N-D\#;9%_<3'@D'N ?PK^8CQ#\6OB3%KFI)'XRUM%2Y8*HN1@#:O
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M ,)/^2E^$?\ L*C_ -%R5_7!\%?^1"TGZ-_Z+@H XO\ :N_Y(AXN_P"N"_\
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M?Y_F] 'S17ZG?\$QO^0_K_\ U_1?^V=?EC7ZG?\ !,;_ )#^O_\ 7]%_[9T
M?T71?<'X?R%?@=_P5A_Y'_P__P!@9?\ TGMZ_?&+[@_#^0K\#O\ @K#_ ,C_
M .'_ /L#+_Z3V] 'SI_P3OTZVU#XB:D;EU3R)+=H]P/)PO P/ZYK^G'3$5+*
MV5>@@A ^@C4 CV-?RO?L/:^N@_$8 OL^V7EM$.0,YVC')YR/KG^?]36ARB;3
M+.0<[[6W;/7.8E.?UH P/%EUX(MS /%ITX%@?(^W*QR/FX7'_ NOUKAO[3^!
M_KX=_P"_;U\+?\%(->\9:#;^';SPO/)!%%:227+I#-(HP+G[S1N@7G;U/IZX
MK\1F_:$^*:$J==P1_L2__'Z /ZHQJGP14Y#>'@1W$;BNEM?B-\.;*%(+37M-
M@AC&U(XRZHH] -M?R:_\-#?%+_H/?^.2_P#Q^C_AH;XI?]![_P <E_\ C] '
M]&/[6_Q5\$CX4ZC':Z]8W-PSL! K-N(,9'< =^YK^8#QO>1WNM:S<1$%)KJ6
M12O0@D=*ZSQ#\7?'/BBT>RUG5/M-NYRR;9!S_P "E<?F#7E]TQ:*5FY)7)/O
MQ0!_2S_P3B_Y(MX5_P"O23_TE@K]!_%C%=$NRIP<=?\ @+U^?'_!.+_DBWA7
M_KTD_P#26"OT&\6_\@.[^G_LCT ?R7_M1DGXN^+23G.K.3_WRM?.E?17[4?_
M "5WQ;_V%G_]!6OG6@"&<D1/@9X_S^?3\:_HF_X)NZ7:Q^!-%OED3SYK%MZ@
M'</]'7J<=\GH<]<=17\[<PS$X'I_45^]7_!-'Q*)]*M-&\S+6^G%MF>G[AL9
M';[OTX_"@#]F5Z#Z#^5>3:OJ'PDCO9UUAM#^VB0B<7".9/,XSN]^:]87E5/^
MR/Y5_-7^U[\1OB;X1^)GB$6>H2VMC+JL@MMT%PJ[-O9O,56Y!Y '\Z /WH_M
M/X(>OAW_ +]O5BUU[X,V4R7%I<:#!-&<I)&CJRGU!K^5/_AH;XI?]![_ ,<E
M_P#C]'_#0WQ2_P"@]_XY+_\ 'Z /ZTA\4/ *C \1Z> /]IL?^@U^-_\ P4>^
M(?AG6;R>QTG4[2^:33E :)F)SY$8(Y [MUP1D?C7Y>G]H7XI$$'7<@C'W)>_
M_;Q7G?B7QGK_ (MN?M>N7?VJ<+LWX<?*0!CYG?T'>@#[N_X)T:=!?^.M9EE(
MS#?P&/(R<^7;=.O0$\#K7]+UDH2VB4= J_\ H(%?S!_\$_=:CT?QY=1,X3[9
MJ," ;@,_NX.,'J?EX^E?T\Z<XDM(6!SE$/X%5]* /Q%_X*L75Q#KWAR*-W6-
M]-.\#H?W/?CMU_PK\15)(!/).?YU_0=_P4K^'MWXDM;;7X8#)%IFFG<P0MC]
MT1U' Z8!]:_GWGB,$SQ,I4IV((QV_I_GL 4;O_5?\#3^=?U(?L,?\DVT7_L$
M0?\ HVOY@K32;W69X[&PMYKB>1UVI##),QPP'"Q@D\D=.E?U2?L9^%-3T#X:
M: U^AC:71X2$=&C=<2GAE8Y!XZ$ XYQ0!]5^,?\ D7-9_P"P5J?_ *135_(%
M\</^2C>)_P#L.:E_Z425_7[XQ_Y%S6?^P5J?_I%-7\@7QP_Y*-XG_P"PYJ7_
M *424 >1T444 ==\._\ DH/A'_L*+_Z*EK^M#]G/_DGVD?[K?^B8J_DO^'?_
M "4'PC_V%%_]%2U_6A^SG_R3[2/]UO\ T3%0![EJFJZ?HME+J.IW,=I9P#,L
M\I(1!@G)P">Q[5XQJ/[3'P0TUIXKGXA:%'<0@[H7EE#;A_#_ *K&?QJ7]HW_
M ))'XI_Z]Q_Z!+7\F_Q/_P"1NU?_ *[+_-J /Z8/$O[;GPLTBWEEL/$>CW\B
M$A(TD?+8SCKMQDXZG\P:^+?C3_P4K2#3IM,\-Z3#</=PM%]KM90&@.6(<;KE
M>> .C#GI7X5T4 >M?$KXQ^,/B7J$]WK&K:A);3,'%G/,KQHP8MN &<'[O\1Z
M?GY*3DDGJ>3110!^E?\ P3)_Y*'XE^D/_H$=?TEV_P#QZ)_UQ7_T6M?S:?\
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M!=Y_(U_*!XU_Y&2]_P"N]S_Z.:OZO_VHO^2>ZM_V"[S^1K^4#QK_ ,C)>_\
M7>Y_]'-0!BZ7_P A2R_ZZK_)J_J+_84_Y)!X<_Z]V_\ 2:WK^732_P#D*67_
M %U7^35_47^PI_R2#PY_U[M_Z36] 'U!\6/^1'U;_='_ *!)7\GG[0W_ "4;
MQ#_V$?\ V6OZP_BQ_P B/JW^Z/\ T"2OY//VAO\ DHWB'_L(_P#LM 'A5?1?
M[+,,\GQ?\(-"6"KJB;@N,$8.,Y_S[5\Z5]8?L=V4MU\4O#TL8)2+5%W$ GJ
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MS_%7XU:M_P $W=<O-1O+H6>I$3S,X(:XQR![^V*_<?\ X6;\/_\ H;M#_P#
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M_MW2=.FFMXY6MIKQ1*C-U1E8DY'ID_6O8$\5^$M34QQ:WIMRI'2.X5N#U_\
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M_P#3C:U_81^S[_R3KP]_V!M*_P#2.*OX]['C7/#KGA(]=TIW8]%5=0MF9CZ
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MB7B7XC^*/%)SJ.I7>-V[:EW/C).3QO'!K@J* '.[R'<[L[>KL6/YDDTVBB@
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M-G!7;^>/Y5\X#@ >E% '4^)?%^L>*[HW>K7#S2LS,2TDC\MUQO)P/:N6HHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "NV^&W_ "4#P9_V,FD?^EL5<37;
M?#;_ )*!X,_[&32/_2V*@#^RSPK_ ,BQX<_[ .C_ /IOMZWJP?"O_(L>'/\
ML Z/_P"F^WK>H ^/?VWM-O?%/[/OC+PYH,#:CK5[&GV:QAYEE_T:[7Y0<#JZ
MC\:_G&B_95^/DR+)'\.M:=&&58)'@C\7K^H/Q9_R$X?^N8_DE>P:!_R";/\
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MB/\ ^+H_X90^/_\ T3C6_P#OB/\ ^+K^O>B@#^0C_AE#X_\ _1.-;_[XC_\
MBZ/^&4/C_P#]$XUO_OB/_P"+K^O>B@#^0C_AE#X__P#1.-;_ .^(_P#XNC_A
ME#X__P#1.-;_ .^(_P#XNOZ]Z* /Y"/^&4/C_P#]$XUO_OB/_P"+H_X90^/_
M /T3C6_^^(__ (NOZ]Z* /Y"/^&4/C__ -$XUO\ [XC_ /BZ/^&4/C__ -$X
MUO\ [XC_ /BZ_KWHH _D(_X90^/_ /T3C6_^^(__ (NC_AE#X_\ _1.-;_[X
MC_\ BZ_KWHH _D(_X90^/_\ T3C6_P#OB/\ ^+H_X90^/_\ T3C6_P#OB/\
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M0^/_ /T3C6_^^(__ (NC_AE#X_\ _1.-;_[XC_\ BZ_KWHH _D(_X90^/_\
MT3C6_P#OB/\ ^+H_X90^/_\ T3C6_P#OB/\ ^+K^O>B@#^0C_AE#X_\ _1.-
M;_[XC_\ BZ/^&4/C_P#]$XUO_OB/_P"+K^O>B@#^0C_AE#X__P#1.-;_ .^(
M_P#XNC_AE#X__P#1.-;_ .^(_P#XNOZ]Z* /Y"/^&4/C_P#]$XUO_OB/_P"+
MH_X90^/_ /T3C6_^^(__ (NOZ]Z* /Y"/^&4/C__ -$XUO\ [XC_ /BZ/^&4
M/C__ -$XUO\ [XC_ /BZ_KWHH _D(_X90^/_ /T3C6_^^(__ (NC_AE#X_\
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M/_\ T3C6_P#OB/\ ^+H_X90^/_\ T3C6_P#OB/\ ^+K^O>B@#^0C_AE#X_\
M_1.-;_[XC_\ BZ/^&4/C_P#]$XUO_OB/_P"+K^O>B@#^0C_AE#X__P#1.-;_
M .^(_P#XNC_AE#X__P#1.-;_ .^(_P#XNOZ]Z* /Y"/^&4/C_P#]$XUO_OB/
M_P"+H_X90^/_ /T3C6_^^(__ (NOZ]Z* /Y"/^&4/C__ -$XUO\ [XC_ /BZ
M/^&4/C__ -$XUO\ [XC_ /BZ_KWHH _D(_X90^/_ /T3C6_^^(__ (NC_AE#
MX_\ _1.-;_[XC_\ BZ_KWHH _D(_X90^/_\ T3C6_P#OB/\ ^+H_X90^/_\
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M_KWHH _D(_X90^/_ /T3C6_^^(__ (NC_AE#X_\ _1.-;_[XC_\ BZ_KWHH
M_D(_X90^/_\ T3C6_P#OB/\ ^+H_X90^/_\ T3C6_P#OB/\ ^+K^O>B@#^0C
M_AE#X_\ _1.-;_[XC_\ BZ/^&4/C_P#]$XUO_OB/_P"+K^O>B@#^0C_AE#X_
M_P#1.-;_ .^(_P#XNC_AE#X__P#1.-;_ .^(_P#XNOZ]Z* /Y"/^&4/C_P#]
M$XUO_OB/_P"+H_X90^/_ /T3C6_^^(__ (NOZ]Z* /Y"/^&4/C__ -$XUO\
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M^(__ (NC_AE#X_\ _1.-;_[XC_\ BZ_KWHH _D(_X90^/_\ T3C6_P#OB/\
M^+H_X90^/_\ T3C6_P#OB/\ ^+K^O>B@#^0C_AE#X_\ _1.-;_[XC_\ BZ/^
M&4/C_P#]$XUO_OB/_P"+K^O>B@#^0C_AE#X__P#1.-;_ .^(_P#XNC_AE#X_
M_P#1.-;_ .^(_P#XNOZ]Z* /Y"/^&4/C_P#]$XUO_OB/_P"+H_X90^/_ /T3
MC6_^^(__ (NOZ]Z* /Y"/^&4/C__ -$XUO\ [XC_ /BZ/^&4/C__ -$XUO\
M[XC_ /BZ_KWHH _D(_X90^/_ /T3C6_^^(__ (NC_AE#X_\ _1.-;_[XC_\
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MB/\ ^+H_X90^/_\ T3C6_P#OB/\ ^+K^O>B@#^0C_AE#X_\ _1.-;_[XC_\
MBZ/^&4/C_P#]$XUO_OB/_P"+K^O>B@#^0C_AE#X__P#1.-;_ .^(_P#XNC_A
ME#X__P#1.-;_ .^(_P#XNOZ]Z* /Y"/^&4/C_P#]$XUO_OB/_P"+H_X90^/_
M /T3C6_^^(__ (NOZ]Z* /Y"/^&4/C__ -$XUO\ [XC_ /BZ/^&4/C__ -$X
MUO\ [XC_ /BZ_KWHH _D(_X90^/_ /T3C6_^^(__ (NC_AE#X_\ _1.-;_[X
MC_\ BZ_KWHH _D(_X90^/_\ T3C6_P#OB/\ ^+H_X90^/_\ T3C6_P#OB/\
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M0^/_ /T3C6_^^(__ (NC_AE#X_\ _1.-;_[XC_\ BZ_KWHH _D(_X90^/_\
MT3C6_P#OB/\ ^+H_X90^/_\ T3C6_P#OB/\ ^+K^O>B@#^0C_AE#X_\ _1.-
M;_[XC_\ BZ/^&4/C_P#]$XUO_OB/_P"+K^O>B@#^0C_AE#X__P#1.-;_ .^(
M_P#XNC_AE#X__P#1.-;_ .^(_P#XNOZ]Z* /Y"/^&4/C_P#]$XUO_OB/_P"+
MH_X90^/_ /T3C6_^^(__ (NOZ]Z* /Y"/^&4/C__ -$XUO\ [XC_ /BZ/^&4
M/C__ -$XUO\ [XC_ /BZ_KWHH _D(_X90^/_ /T3C6_^^(__ (NC_AE#X_\
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M/_\ T3C6_P#OB/\ ^+H_X90^/_\ T3C6_P#OB/\ ^+K^O>B@#^0C_AE#X_\
M_1.-;_[XC_\ BZ/^&4/C_P#]$XUO_OB/_P"+K^O>B@#^0C_AE#X__P#1.-;_
M .^(_P#XNC_AE#X__P#1.-;_ .^(_P#XNOZ]Z* /Y"/^&4/C_P#]$XUO_OB/
M_P"+H_X90^/_ /T3C6_^^(__ (NOZ]Z* /Y"/^&4/C__ -$XUO\ [XC_ /BZ
M/^&4/C__ -$XUO\ [XC_ /BZ_KWHH _D(_X90^/_ /T3C6_^^(__ (NC_AE#
MX_\ _1.-;_[XC_\ BZ_KWHH _D(_X90^/_\ T3C6_P#OB/\ ^+H_X90^/_\
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M0^/_ /T3C6_^^(__ (NC_AE#X_\ _1.-;_[XC_\ BZ_KWHH _D(_X90^/_\
MT3C6_P#OB/\ ^+H_X90^/_\ T3C6_P#OB/\ ^+K^O>B@#^0C_AE#X_\ _1.-
M;_[XC_\ BZ/^&4/C_P#]$XUO_OB/_P"+K^O>B@#^0C_AE#X__P#1.-;_ .^(
M_P#XNC_AE#X__P#1.-;_ .^(_P#XNOZ]Z* /Y"/^&4/C_P#]$XUO_OB/_P"+
MH_X90^/_ /T3C6_^^(__ (NOZ]Z* /Y"/^&4/C__ -$XUO\ [XC_ /BZ/^&4
M/C__ -$XUO\ [XC_ /BZ_KWHH _D(_X90^/_ /T3C6_^^(__ (NC_AE#X_\
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M/_\ T3C6_P#OB/\ ^+H_X90^/_\ T3C6_P#OB/\ ^+K^O>B@#^0C_AE#X_\
M_1.-;_[XC_\ BZ/^&4/C_P#]$XUO_OB/_P"+K^O>B@#^0C_AE#X__P#1.-;_
M .^(_P#XNC_AE#X__P#1.-;_ .^(_P#XNOZ]Z* /Y"/^&4/C_P#]$XUO_OB/
M_P"+H_X90^/_ /T3C6_^^(__ (NOZ]Z* /Y"/^&4/C__ -$XUO\ [XC_ /BZ
M/^&4/C__ -$XUO\ [XC_ /BZ_KWHH _D(_X90^/_ /T3C6_^^(__ (NC_AE#
MX_\ _1.-;_[XC_\ BZ_KWHH _D(_X90^/_\ T3C6_P#OB/\ ^+H_X90^/_\
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M_KWHH _D(_X90^/_ /T3C6_^^(__ (NC_AE#X_\ _1.-;_[XC_\ BZ_KWHH
M_D(_X90^/_\ T3C6_P#OB/\ ^+H_X90^/_\ T3C6_P#OB/\ ^+K^O>B@#^0C
M_AE#X_\ _1.-;_[XC_\ BZ/^&4/C_P#]$XUO_OB/_P"+K^O>B@#^0C_AE#X_
M_P#1.-;_ .^(_P#XNC_AE#X__P#1.-;_ .^(_P#XNOZ]Z* /Y"/^&4/C_P#]
M$XUO_OB/_P"+H_X90^/_ /T3C6_^^(__ (NOZ]Z* /Y"/^&4/C__ -$XUO\
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M\0_\>,O^?X#7.V?W[7_>_K0!_*5_PRA\?_\ HG&M_P#?$?\ \71_PRA\?_\
MHG&M_P#?$?\ \77]>R]!]!_*EH _D(_X90^/_P#T3C6_^^(__BZ/^&4/C_\
M]$XUO_OB/_XNOZ]Z* /Y"/\ AE#X_P#_ $3C6_\ OB/_ .+H_P"&4/C_ /\
M1.-;_P"^(_\ XNOZ]Z* /Y"/^&4/C_\ ]$XUO_OB/_XNC_AE#X__ /1.-;_[
MXC_^+K^O>B@#^0C_ (90^/\ _P!$XUO_ +XC_P#BZ/\ AE#X_P#_ $3C6_\
MOB/_ .+K^O>B@#^0C_AE#X__ /1.-;_[XC_^+H_X90^/_P#T3C6_^^(__BZ_
MKWHH _D(_P"&4/C_ /\ 1.-;_P"^(_\ XNC_ (90^/\ _P!$XUO_ +XC_P#B
MZ_KWHH _D(_X90^/_P#T3C6_^^(__BZ/^&4/C_\ ]$XUO_OB/_XNOZ]Z* /Y
M"/\ AE#X_P#_ $3C6_\ OB/_ .+H_P"&4/C_ /\ 1.-;_P"^(_\ XNOZ]Z*
M/Y"/^&4/C_\ ]$XUO_OB/_XNC_AE#X__ /1.-;_[XC_^+K^O>B@#^0C_ (90
M^/\ _P!$XUO_ +XC_P#BZ/\ AE#X_P#_ $3C6_\ OB/_ .+K^O>B@#^0C_AE
M#X__ /1.-;_[XC_^+H_X90^/_P#T3C6_^^(__BZ_KWHH _D(_P"&4/C_ /\
M1.-;_P"^(_\ XNC_ (90^/\ _P!$XUO_ +XC_P#BZ_KWHH _D(_X90^/_P#T
M3C6_^^(__BZ/^&4/C_\ ]$XUO_OB/_XNOZ]Z* /Y"/\ AE#X_P#_ $3C6_\
MOB/_ .+H_P"&4/C_ /\ 1.-;_P"^(_\ XNOZ]Z* /Y"/^&4/C_\ ]$XUO_OB
M/_XNC_AE#X__ /1.-;_[XC_^+K^O>B@#^0C_ (90^/\ _P!$XUO_ +XC_P#B
MZ/\ AE#X_P#_ $3C6_\ OB/_ .+K^O>B@#^0C_AE#X__ /1.-;_[XC_^+H_X
M90^/_P#T3C6_^^(__BZ_KWHH _D(_P"&4/C_ /\ 1.-;_P"^(_\ XNC_ (90
M^/\ _P!$XUO_ +XC_P#BZ_KWHH _D(_X90^/_P#T3C6_^^(__BZ/^&4/C_\
M]$XUO_OB/_XNOZ]Z* /Y"/\ AE#X_P#_ $3C6_\ OB/_ .+H_P"&4/C_ /\
M1.-;_P"^(_\ XNOZ]Z* /Y"/^&4/C_\ ]$XUO_OB/_XNC_AE#X__ /1.-;_[
MXC_^+K^O>B@#^0C_ (90^/\ _P!$XUO_ +XC_P#BZ/\ AE#X_P#_ $3C6_\
MOB/_ .+K^O>B@#^0C_AE#X__ /1.-;_[XC_^+H_X90^/_P#T3C6_^^(__BZ_
MKWHH _D(_P"&4/C_ /\ 1.-;_P"^(_\ XNC_ (90^/\ _P!$XUO_ +XC_P#B
MZ_KWHH _D(_X90^/_P#T3C6_^^(__BZ/^&4/C_\ ]$XUO_OB/_XNOZ]Z* /Y
M"/\ AE#X_P#_ $3C6_\ OB/_ .+H_P"&4/C_ /\ 1.-;_P"^(_\ XNOZ]Z*
M/Y"/^&4/C_\ ]$XUO_OB/_XNC_AE#X__ /1.-;_[XC_^+K^O>B@#^0C_ (90
M^/\ _P!$XUO_ +XC_P#BZ/\ AE#X_P#_ $3C6_\ OB/_ .+K^O>B@#^0C_AE
M#X__ /1.-;_[XC_^+H_X90^/_P#T3C6_^^(__BZ_KWHH _D(_P"&4/C_ /\
M1.-;_P"^(_\ XNC_ (90^/\ _P!$XUO_ +XC_P#BZ_KWHH _D(_X90^/_P#T
M3C6_^^(__BZ/^&4/C_\ ]$XUO_OB/_XNOZ]Z* /Y"/\ AE#X_P#_ $3C6_\
MOB/_ .+H_P"&4/C_ /\ 1.-;_P"^(_\ XNOZ]Z* /Y"/^&4/C_\ ]$XUO_OB
M/_XNC_AE#X__ /1.-;_[XC_^+K^O>B@#^0C_ (90^/\ _P!$XUO_ +XC_P#B
MZCD_95^/D2EY/AUK:J.I,:8]?[U?U]UC:Y_QXR_0?^S4 ?R(1?LS?&^>0Q1>
M =8>13@J$3(/'!^;W_R*T?\ AE#X_G_FG&M_]\1__%U_4-X>_P"0Q<_]=Q_Z
M"*]P7H/H/Y4 ?R$_\,H?'_\ Z)QK?_?$?_Q='_#*'Q__ .B<:W_WQ'_\77]>
M]% '\A'_  RA\?\ _HG&M_\ ?$?_ ,71_P ,H?'_ /Z)QK?_ 'Q'_P#%U_7O
M10!_(1_PRA\?_P#HG&M_]\1__%T?\,H?'_\ Z)QK?_?$?_Q=?U[T4 ?R$?\
M#*'Q_P#^B<:W_P!\1_\ Q='_  RA\?\ _HG&M_\ ?$?_ ,77]>]% '\A'_#*
M'Q__ .B<:W_WQ'_\71_PRA\?_P#HG&M_]\1__%U_7O10!_(1_P ,H?'_ /Z)
MQK?_ 'Q'_P#%T?\ #*'Q_P#^B<:W_P!\1_\ Q=?U[T4 ?R$?\,H?'_\ Z)QK
M?_?$?_Q='_#*'Q__ .B<:W_WQ'_\77]>]% '\A'_  RA\?\ _HG&M_\ ?$?_
M ,71_P ,H?'_ /Z)QK?_ 'Q'_P#%U_7O10!_(1_PRA\?_P#HG&M_]\1__%T?
M\,H?'_\ Z)QK?_?$?_Q=?U[T4 ?R$?\ #*'Q_P#^B<:W_P!\1_\ Q='_  RA
M\?\ _HG&M_\ ?$?_ ,77]>]% '\A'_#*'Q__ .B<:W_WQ'_\71_PRA\?_P#H
MG&M_]\1__%U_7O10!_(1_P ,H?'_ /Z)QK?_ 'Q'_P#%T?\ #*'Q_P#^B<:W
M_P!\1_\ Q=?U[T4 ?R$?\,H?'_\ Z)QK?_?$?_Q='_#*'Q__ .B<:W_WQ'_\
M77]>]% '\A'_  RA\?\ _HG&M_\ ?$?_ ,71_P ,H?'_ /Z)QK?_ 'Q'_P#%
MU_7O10!_(1_PRA\?_P#HG&M_]\1__%T?\,H?'_\ Z)QK?_?$?_Q=?U[T4 ?R
M$?\ #*'Q_P#^B<:W_P!\1_\ Q='_  RA\?\ _HG&M_\ ?$?_ ,77]>]% '\A
M'_#*'Q__ .B<:W_WQ'_\71_PRA\?_P#HG&M_]\1__%U_7O10!_(1_P ,H?'_
M /Z)QK?_ 'Q'_P#%T?\ #*'Q_P#^B<:W_P!\1_\ Q=?U[T4 ?R$?\,H?'_\
MZ)QK?_?$?_Q='_#*'Q__ .B<:W_WQ'_\77]>]% '\A'_  RA\?\ _HG&M_\
M?$?_ ,71_P ,H?'_ /Z)QK?_ 'Q'_P#%U_7O10!_(1_PRA\?_P#HG&M_]\1_
M_%T?\,H?'_\ Z)QK?_?$?_Q=?U[T4 ?R$?\ #*'Q_P#^B<:W_P!\1_\ Q='_
M  RA\?\ _HG&M_\ ?$?_ ,77]>]% '\A'_#*'Q__ .B<:W_WQ'_\71_PRA\?
M_P#HG&M_]\1__%U_7O10!_(1_P ,H?'_ /Z)QK?_ 'Q'_P#%T?\ #*'Q_P#^
MB<:W_P!\1_\ Q=?U[T4 ?R$?\,H?'_\ Z)QK?_?$?_Q='_#*'Q__ .B<:W_W
MQ'_\77]>]% '\A'_  RA\?\ _HG&M_\ ?$?_ ,71_P ,H?'_ /Z)QK?_ 'Q'
M_P#%U_7O10!_(1_PRA\?_P#HG&M_]\1__%T?\,H?'_\ Z)QK?_?$?_Q=?U[T
M4 ?R$?\ #*'Q_P#^B<:W_P!\1_\ Q='_  RA\?\ _HG&M_\ ?$?_ ,77]>]%
M '\A'_#*'Q__ .B<:W_WQ'_\71_PRA\?_P#HG&M_]\1__%U_7O10!_(1_P ,
MH?'_ /Z)QK?_ 'Q'_P#%T?\ #*'Q_P#^B<:W_P!\1_\ Q=?U[T4 ?R$?\,H?
M'_\ Z)QK?_?$?_Q='_#*'Q__ .B<:W_WQ'_\77]>]% '\A'_  RA\?\ _HG&
MM_\ ?$?_ ,71_P ,H?'_ /Z)QK?_ 'Q'_P#%U_7O10!_(1_PRA\?_P#HG&M_
M]\1__%T?\,H?'_\ Z)QK?_?$?_Q=?U[T4 ?R$?\ #*'Q_P#^B<:W_P!\1_\
MQ='_  RA\?\ _HG&M_\ ?$?_ ,77]>]% '\A'_#*'Q__ .B<:W_WQ'_\71_P
MRA\?_P#HG&M_]\1__%U_7O10!_(1_P ,H?'_ /Z)QK?_ 'Q'_P#%U%+^RO\
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MB/\ ^+H_X90^/_\ T3C6_P#OB/\ ^+K^O>B@#^0C_AE#X_\ _1.-;_[XC_\
MBZ/^&4/C_P#]$XUO_OB/_P"+K^O>B@#^0C_AE#X__P#1.-;_ .^(_P#XNC_A
ME#X__P#1.-;_ .^(_P#XNOZ]Z* /Y"/^&4/C_P#]$XUO_OB/_P"+H_X90^/_
M /T3C6_^^(__ (NOZ]Z* /Y"/^&4/C__ -$XUO\ [XC_ /BZ/^&4/C__ -$X
MUO\ [XC_ /BZ_KWHH _D(_X90^/_ /T3C6_^^(__ (NC_AE#X_\ _1.-;_[X
MC_\ BZ_KWHH _D(_X90^/_\ T3C6_P#OB/\ ^+H_X90^/_\ T3C6_P#OB/\
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M0^/_ /T3C6_^^(__ (NC_AE#X_\ _1.-;_[XC_\ BZ_KWHH _D(_X90^/_\
MT3C6_P#OB/\ ^+H_X90^/_\ T3C6_P#OB/\ ^+K^O>B@#^0C_AE#X_\ _1.-
M;_[XC_\ BZ/^&4/C_P#]$XUO_OB/_P"+K^O>B@#^0C_AE#X__P#1.-;_ .^(
M_P#XNC_AE#X__P#1.-;_ .^(_P#XNOZ]Z* /Y"/^&4/C_P#]$XUO_OB/_P"+
MH_X90^/_ /T3C6_^^(__ (NOZ]Z* /Y"/^&4/C__ -$XUO\ [XC_ /BZ/^&4
M/C__ -$XUO\ [XC_ /BZ_KWHH _D(_X90^/_ /T3C6_^^(__ (NC_AE#X_\
M_1.-;_[XC_\ BZ_KWHH _D(_X90^/_\ T3C6_P#OB/\ ^+J&;]ECX\VZ%YOA
MWK2*!DDHF,?@]?U^URWBO_D'3?\ 7)_Y-0!_)#:_LR_'"];9;> -8E;T5$_^
M*Q^M:'_#*'Q__P"B<:W_ -\1_P#Q=?U&_#[_ (_Q_NO_ %KVJ@#^0C_AE#X_
M_P#1.-;_ .^(_P#XNC_AE#X__P#1.-;_ .^(_P#XNOZ]Z* /Y"/^&4/C_P#]
M$XUO_OB/_P"+H_X90^/_ /T3C6_^^(__ (NOZ]Z* /Y"/^&4/C__ -$XUO\
M[XC_ /BZ/^&4/C__ -$XUO\ [XC_ /BZ_KWHH _D(_X90^/_ /T3C6_^^(__
M (NC_AE#X_\ _1.-;_[XC_\ BZ_KWHH _D(_X90^/_\ T3C6_P#OB/\ ^+H_
MX90^/_\ T3C6_P#OB/\ ^+K^O>B@#^0C_AE#X_\ _1.-;_[XC_\ BZ/^&4/C
M_P#]$XUO_OB/_P"+K^O>B@#^0C_AE#X__P#1.-;_ .^(_P#XNC_AE#X__P#1
M.-;_ .^(_P#XNOZ]Z* /Y"/^&4/C_P#]$XUO_OB/_P"+H_X90^/_ /T3C6_^
M^(__ (NOZ]Z* /Y"/^&4/C__ -$XUO\ [XC_ /BZ/^&4/C__ -$XUO\ [XC_
M /BZ_KWHH _D(_X90^/_ /T3C6_^^(__ (NC_AE#X_\ _1.-;_[XC_\ BZ_K
MWHH _D(_X90^/_\ T3C6_P#OB/\ ^+H_X90^/_\ T3C6_P#OB/\ ^+K^O>B@
M#^0C_AE#X_\ _1.-;_[XC_\ BZ/^&4/C_P#]$XUO_OB/_P"+K^O>B@#^0C_A
ME#X__P#1.-;_ .^(_P#XNC_AE#X__P#1.-;_ .^(_P#XNOZ]Z* /Y"/^&4/C
M_P#]$XUO_OB/_P"+H_X90^/_ /T3C6_^^(__ (NOZ]Z* /Y"/^&4/C__ -$X
MUO\ [XC_ /BZ/^&4/C__ -$XUO\ [XC_ /BZ_KWHH _D(_X90^/_ /T3C6_^
M^(__ (NC_AE#X_\ _1.-;_[XC_\ BZ_KWHH _D(_X90^/_\ T3C6_P#OB/\
M^+H_X90^/_\ T3C6_P#OB/\ ^+K^O>B@#^0C_AE#X_\ _1.-;_[XC_\ BZ/^
M&4/C_P#]$XUO_OB/_P"+K^O>B@#^0C_AE#X__P#1.-;_ .^(_P#XNC_AE#X_
M_P#1.-;_ .^(_P#XNOZ]Z* /Y"/^&4/C_P#]$XUO_OB/_P"+H_X90^/_ /T3
MC6_^^(__ (NOZ]Z* /Y"/^&4/C__ -$XUO\ [XC_ /BZ/^&4/C__ -$XUO\
M[XC_ /BZ_KWHH _D(_X90^/_ /T3C6_^^(__ (NC_AE#X_\ _1.-;_[XC_\
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MB/\ ^+H_X90^/_\ T3C6_P#OB/\ ^+K^O>B@#^0C_AE#X_\ _1.-;_[XC_\
MBZ/^&4/C_P#]$XUO_OB/_P"+K^O>B@#^0C_AE#X__P#1.-;_ .^(_P#XNC_A
ME#X__P#1.-;_ .^(_P#XNOZ]Z* /Y"/^&4/C_P#]$XUO_OB/_P"+H_X90^/_
M /T3C6_^^(__ (NOZ]Z* /Y"/^&4/C__ -$XUO\ [XC_ /BZ/^&4/C__ -$X
MUO\ [XC_ /BZ_KWHH _D(_X90^/_ /T3C6_^^(__ (NC_AE#X_\ _1.-;_[X
MC_\ BZ_KWHH _D(_X90^/_\ T3C6_P#OB/\ ^+H_X90^/_\ T3C6_P#OB/\
M^+K^O>B@#^0C_AE#X_\ _1.-;_[XC_\ BZZ7P5^S+\<-&\:>$[_4O &L6MI;
M:_I<T\TB)MCBCNXF=SACPJ@DU_6E7$>-_P#CQC^I_I0!H>$KNWD\/:#;I*K2
MP:-ID$J#JDL5E!'(A]U=2#]#73UY-X$^]_VU;_T,UZS0!X/XL_Y"</\ US'\
MDKV#0/\ D$V?_7,5X_XL_P"0G#_US'\DKV#0/^039_\ 7,4 ;%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6
M;JW_ !XR_A_(UI5FZM_QXR_A_(T <.__ !\67_71?Y&O1X_N+]*\X?\ X^++
M_KHO\C7H\?W%^E #Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#G
M_$/_ !XR_P"?X#7.V?W[7_>_K71>(?\ CQE_S_ :YVS^_:_[W]: /05Z#Z#^
M5+2+T'T'\J6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ K&US_CQE^@_]FK9K&US_CQE^@_]FH \G\/?\ABY_P"NX_\ 017N
M"]!]!_*O#_#W_(8N?^NX_P#017N"]!]!_*@!:*** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KGO$O_(,G_P!P_P!:
MZ&N>\2_\@R?_ '#_ %H \P\*?\A*3_@/\Q7MR?<7_=7^0KQ'PI_R$I/^ _S%
M>W)]Q?\ =7^0H =1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %<MXK_Y!TW_ %R?^35U-<MXK_Y!TW_7)_Y-0!Y]
M\/O^/\?[K_UKVJO%?A]_Q_C_ '7_ *U[50 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7$>-_^/&/ZG^E=O7$>
M-_\ CQC^I_I0!SO@3[W_ &U;_P!#->LUY-X$^]_VU;_T,UZS0!X/XL_Y"</_
M %S'\DKV#0/^039_]<Q7C_BS_D)P_P#7,?R2O8- _P"039_]<Q0!L4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %9NK?\>,OX?R-:59NK?\>,OX?R- '#O_Q\67_71?Y&O1X_N+]*\X?_ (^+
M+_KHO\C7H\?W%^E #Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *Y[Q+_P @R?\ W#_6NAKGO$O_ "#)_P#</]: /,/"G_(2D_X#
M_,5[<GW%_P!U?Y"O$?"G_(2D_P" _P Q7MR?<7_=7^0H =1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<MXK_Y!
MTW_7)_Y-74URWBO_ )!TW_7)_P"34 >??#[_ (_Q_NO_ %KVJO%?A]_Q_C_=
M?^M>U4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 5Q'C?_ (\8_J?Z5V]<1XW_ ./&/ZG^E '.^!/O?]M6_P#0
MS7K->3>!/O?]M6_]#->LT >#^+/^0G#_ -<Q_)*]@T#_ )!-G_US%>/^+/\
MD)P_]<Q_)*]@T#_D$V?_ %S% &Q1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 5FZM_P >,OX?R-:59NK?\>,O
MX?R- '#O_P ?%E_UT7^1KT>/[B_2O.'_ ./BR_ZZ+_(UZ/']Q?I0 ^BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH Q=:_X]9/Q_\ 0#7Y(_M7?\AC
M1_\ KZ;^4U?K=K7_ !ZR?C_Z :_)']J[_D,:/_U]-_*:@#YF7H/H/Y4M(O0?
M0?RI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "J]U_J7_#^=6*KW7^I?\/YT <S8?\ 'ZW^\/Y+77GK^"_R%<A8?\?K?[P_
MDM=>>OX+_(4 )1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 49(Y'![444 ?7'[-OQ/'AK
M6DLKR1S%,L5L@RP ,F4Z@$ <CK@8R.G(_5^SN8[NUM[B-U=9H8I,JP;'F(KX
M.#P>:_G]T74I=*U"VNXFVLD\+D[BOW'![?2OUW_9\^(L'BCP[%;W5PK7P>*&
M.,$'*H&3)R0<\+T7_&@#Z4HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N>\2_\
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M^5V[RR_=V8^]^?2OY8?^"R__ "<#=_\ 8W:+_P"GU:_>[_@EI_R1&'_>L/\
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MJ\.:I'K&BZ=?QOO6YM8Y@V0<AAP<CUH W**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "LW5O^/&7\/Y&M*LW5O^/&7\/Y&@#AW_X^++_KHO\
M(UZ/']Q?I7G#_P#'Q9?]=%_D:]'C^XOTH ?1110 4444 %%%% !17R!^V-\7
M?%OP?^'5UXA\(SQV^H1V=Y,KR D!X4)3I[U_,-X:_P""U7[4-C\1GT_Q=KMF
MWAJ&_NK>58HYM^R.\,2=<CB,'^= ']G%%?,W[,7QYTOXZ> =&\06UVMQ>S:7
M#=7QW+_K9) IX&"."O4=Z^F: "BOR+_X*:?M:?%?]FK0)[_X;WUO:3II@N5,
MP<CS3#OS\A'&:W?^";'[4WQ0_:/\)VVJ_$2]@N[J33!<LT(<#S/+5L_,?4T
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !7/>)?^09/_N'^M=#7/>)?^09/_N'^M 'F
M'A3_ )"4G_ ?YBO;D^XO^ZO\A7B/A3_D)2?\!_F*]N3[B_[J_P A0 ZBBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M *Y;Q7_R#IO^N3_R:NIKEO%?_(.F_P"N3_R:@#S[X??\?X_W7_K7M5>*_#[_
M (_Q_NO_ %KVJ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MOCWX"_#+XE7/VSQ?H$>IS^8DN]S&/GC8.I^:%^C 'K0!_&Q\._V,?VGOVO\
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M_P#7$?\ H$E '\.<O_)]%Q_V/6E_^CJ_NO\ AK_R)^A_]@K3/_2&&OX4)?\
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MX_EL7B%S&N\8DZ*[_=8D\&OW8L;ZVU"WCN;66.:*1596B=9%(8 \,I(/7L:
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M2"WV.%<3-/'(J'Y@"K.N"#FOZ6OA[X^T7XC>&M.\3:)/%-9:E#YT)BF28;,
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MNN6*B9_. CAU.W@10O. %  '8<8K^US]GSP9;^!_AEX8T.VB6)+&P6$!5V\
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MB]<_^C(J_A_\+?\ )YUS_P!=[3_TY3U_<!\=O^20?$#_ +%ZY_\ 1D5?P_\
MA;_D\ZY_Z[VG_IRGH _M_P#@K_R3SPM_V [#_P!%+7K5>2_!7_DGGA;_ + =
MA_Z*6NY\4>)M*\):+J&MZM=VUK;:?9W%XWVB>.#S%MXS(R(7(RQ P  3D]#0
M!T-%?SA_M<_\%D-)T?4-2\#_  ILM>;Q,K3PVTVEQW=\3);L87*):P G,A4X
M5O3UK\I3^W?_ ,%*/%T^LZMX>USQS8Z7;NTUM#+X;U[<T!V *A,L>[YG/W5[
M?6@#^Y:BOXJ/A!_P5<_:O^&6M6,GQTG\:WNEM/;V\S76B:S91%WE6-B7G$J
M8=2<]OKFOZB_V4/VN_!'[2/A*UU71;J**ZB@MH[B"XNXVG:=UP_[M@C@[P<@
M@G)YH ^S**Y/QWJ%SIG@SQ-J5C)Y5U9:-?7-M*.=DL4+,C#!'0C/!'UK^633
M?^"@W[0VG?M?6G@W7OB/]G\#!K_S[.Z=X+?$-]#&H,LMX(E(C+#E>1DX- ']
M8]%?SF_M,?\ !76'2O#47AGX96FO:AXN%D]F^H:+%=ZE']OW2.)<6<+\% H_
MUG)(P3D"OQJU;_@HK_P4GGO#>6.J?$"VTY75V#>%_$(58E;<^6,B@ 1@Y.,#
MOQG !_>/17\AO[)W_!97Q[I'BK2O#/QPU'7-3N+FXV3R7,-[:QQ;)%#K(9Q*
M$(W8(8@C!K^IOX1?%GP]\7/"6E^*M!GB>UU.W$\:"=)75<#[Q4 ]\\@<4 >K
MT5XQ\<_C5X;^!?@;4/&_B,B2RL0RM"DHCE+>4[@CY7/\/]VOY>/VA?\ @KK\
M7_'7B?4-!^ C>*K9[:\FM3)I^GZE?QHVTE"3;)&H W)W_P#K ']=U%?P_1_M
MN_\ !2OPZ;;7-9U_QO?:6+B)I[6+PWKQD\F-UDFW8F<@-&Q&2O0'MFOV@_8H
M_P""C?B+XX^'6\&Z]IGB2Q\<7%PEE!?:K97]J%FB=X9FV74*'#2%2?WGXT ?
MO#17\;W[2G[??[8?PF_:;M_"_P#PL:\M?""^,+2RFM/(NTB-@TC"2/?]LV;2
M!C)7 YXZBOZB?V8/C!!\7/ASI.OF_BOKJ:WM%FF299"TK6RM*3@MR7!.,^OI
M0!],445^9/\ P4R_:8US]GKX/Q:[X1U@Z7K<E[<6WF0R$R@_Z(D>41T88:5L
M9/Y4 ?IM7*^.=-&L>$/$.EF,2B^TRXM_+(R'W@<8[YQTK^9'_@F9^UO^UM^T
M;\1H]0\3^/[K5/"%MX@OK*ZLY(+DAH4U!XXEWO>. %CC*@[,?3M_479K(]G&
MMR=\C+B0X////7- '\.W[7]E=_LX_M>MKMK:?V<%EA4E!Y*@37\;'T/1^?\
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M;-TZX."./R /Z1'_ ."B/['\<HA?XR>'1(2%"^8<Y8X Z]S7M7@#]HOX._%
M*? _C/3M=#,$7[*V<L3@#D^M?SU67_!"OQ"=!5KV]\/RZVB2.UUOM,&01AHR
M!]H)XDR?O\&OC3QU\._VCO\ @G%XTLKMO%(D\,0>9?SP:7#(Z>7E)D!>WNI%
M!"DCE>>?2@#^TQ75U#J<J1D&O#_B1^TA\&OA)<M:?$#QKIOAVX7;F.[8@_-@
M+^>1^=>!_L/_ +3%K^T#\,M"U*26635&TU;B\>9FWLV%/*L P//0Y/6OP_\
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MN)(G^ZXZ'H?ZU_#I\4OV+OVGOV"]0C\1Z5XGBD@A+7PDTFV:=8U0%AN:UNW
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M \%'PWXNU:SU.Y$T31R6A0QB*+S0%^2:8<*R@<]J^VZ "BBB@ HHHH ****
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KEO%?\
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M:?<8D)\QW)D))'5F->H_\%AM.L[CX2>(KB:!))H]' 21A\RXMWZ=OTK\>O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P#!37X":S\"_C#<_$/P/;SZ7:_VYIR&XTZ,*ODPZFDCKN91\NR4YYZ$XZT
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M/-)CM-0T=YX$NXK*&%XF<^8KLMO@%<\'VZU_2.A#(C#D%5(^A - 'R1^V/\
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MTO6O!U_'>VYT^">411Q1QQB0X 1(9'4+R, !1SP*^-_^"H'_ "0MO^NFH?\
MHNWK\_\ _@CK\2M9N='U;0+B\GN+:S:WM(BS#9L5[?&.G&">U?H!_P %0/\
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MM@.\EDO]/4_CE3_G- ']1/BOP9JOQ/\ V4]-@M8Y+J]NO"%P@ :0LTCR/C+
M,Q)]<?A7\O\ X+^,_P 0OV$_CO+_ &OI&G6>GVLK"2:^5'=8GNWWM_I%H>0C
M$CYN/45_8A^S]9_\66\$V5Y#P=&6.:&08X,CDJPKQC]H3]B+X1?'/2KR.[\+
M:);ZW=K(O]JS12-*NY<+S\Z\-\Q^2@#R7]G7_@IK^SE\9+'1-(M_&D,GBBZ@
M@AGL88;-42]('F1 I> X!.!^['/&!W_2+3[^VU.UCO+-_,@E&4?@9Z'L2.X[
MU_(1^TM_P2J^)W[-7]K_ !%^&WCN],=HTNJ06VCP1#[."25C#-9(1MP!G<>.
MYKZ*_P""8'[=_CR3Q4/A?\1YM5UG4-/M(H99=3D D\V>.2)7*I(@#!H\_=Z]
MJ /M[_@KK\1]<\(?!OQ1;:8P"&SBDYD*'=]CG)Z*W=CCV[5^>W_!('X,Z?XF
M\3^)/&VIVPGO;B6WU#=-$LP6399KE6DS@8&20HS^//V/_P %CHKG4_@OKMY;
MV[NMSH]G< (,@"?37D"\GL'Q^%>!?\$9?'NDP+KVCRSP1W2V]O;F-G(DW[;0
MX(Z9Q0!_2M!$D,4<<:*BJBJ%50JX"@=% %5YM-TZX<23Z?93R+]UYK6"5Q]&
M>-F'X&K:'*J1T*@C\0#3J .+\>1QQ>"O$B11I&BZ)J6U(U5$'^BR=%4 #\!7
M\7OBO_D_30_][4O_ $Y6%?VB_$#_ )$SQ-_V!-2_])9*_BZ\5_\ )^FA_P"]
MJ7_IRL* /["O UU]B^!^AW8;:8/#:R;NF,3.,\?6OX\_^"E_Q9F/Q\U4S7/V
MBVM;VUN!#._FPYAOC)S&^],?(,Y'3]/Z_P#PO&\OP!TV.-2[OX6VJJ\EB9FX
M%?QS?M?^'X7_ &NM0B\5:?MTB6\L(V%ZI6!C)J<BLN5.?F4@'ZT ?5/P,_X+
M$6_PI\'V'A^Q_P"$>MS;65K;.!:Z?$S- @4E\6V220"2223W[UZUJO\ P7.D
MU+3-0LII?#[BYM)H0K0V+9,B%<8-MR.?IR:_4W]FO]C?]D[Q;\-_#^I7'PG\
M(ZM<RZ/827%P8KAF:5XE+,Q$R\DYS@8S7T-_PP9^R1_T1+PC_P!^+G_Y(H _
MBRU?X^S_ !X_:6TCQ5%%8VRNDD>_38X;<?/=6IS_ */'$,_*3GWSZU_9GX-=
MV_9&4N[.1X#3EV9CG[9ZL2>?K76Z3^Q+^RWH=Y'?Z5\'/"MG=Q<QSQ03AUY!
MX)G/<#KZ5WWQ;TC3="^#GB_3=)M(K*RM?#\D-O;P@A(HQ/$0B@DX )S0!_&G
MX3\*:7XP_;AU2QU:*.6!'L)=CQ)*I8:E>'E7.WG8 >N1Q7]IGPJ\*Z'X<\$^
M&H-*TVPLU_L;3\FVLK:W9B+=/F8PQJ68]22<Y[U_&U\*/^3[=8_W;#_TXW]?
MVC^"/^1/\-?]@:P_])TH ^4OVX- T[6OA)KR7D$3^7HNI,K-#&Y!\EN06&01
M@8(-?SB?\$S;^?PQ^TC;:98$_9VU74WP3MP?[4(X !  R>_2OZ5OVR?^23^(
M?^P)J7_HEJ_F;_X)X_\ )T=I_P!A/4__ $Z4 ?T!?M\^.]7\+_ ?7+G3R!)<
M^&97<ERO/G-W"G^X.1C-?S[_ /!+CX96OQ9^.<OC/7H3<WEQIT$[+(@N(PT1
MO)U*^9\OWFX(4$8QZ"OW9_X*+VUQ<?L_ZH((GE(\+2YV#./W\G7\Q7XN_P#!
M'7QGIF@?$Y=+OYX;>Z724C:*5RK@M%=)C [YZ>M '];.B6,.FZ5I]E!''&EM
M9V\($:*@Q'&JCA0!VJU/I]A=8^U65I<X.1Y]M#-@^H\Q&P?<4MC,MQ9VLZ$%
M)8(I%(Z$.@8$>W/'M5J@#R+XPZE#X:\":G=VR1VB1PS@"!%A4?N)#P(PH'Y?
MB*_AJ^.WQR;0?VE;CQ)=R0WL>A^+KFY OMMS$BK$PQMG610/G/RXQSGO7]O?
M[1=M<77PTUB*VB>:4PSX1!EC_H\G:OXLO _A+PYJO[7-]IGQ"TNVFT^]\=RQ
M?9M4#+'/$85)4!6&1\I/KD&@#]&/ _\ P6V7PEX;LM&LW\.P1VV<1QVUA&HR
MD:<*ML!T7''I4/C_ /X+;-XM\*ZCHTS^'IS=* (WM[!P1M=2,-:GKN[BOW#\
M _L0?LC:OX9L;Y?@WX/O!+G]^L-P0_R1GKYXSPP/3O79_P##!G[)'_1$O"/_
M 'XN?_DB@#^.K]DSXB7/Q$_:DD\4H(K6/5/$]A<8L@(8F4E>-L"QH1GMC!'3
MCBOZ<_V]/@SKWQ5^ KQ:'9R7EU]CLY50-)SY5C&QY17/\/H??-?9/AC]C[]F
M[P;?1ZEX9^%'AK2+V*198[BUAF5UD3[K M,PR,9Z?7-?0-UHNEWMB=-N;.*6
MR,?E_9V!,>P)Y87&0<!>.O:@#^-/]D7]N;7OV/OB#JW@SQY;Z5H^@3ZT;2_N
MIH[=YXH(?*8NAGMHCN!C'69>^6]?Z<?@1^W9^S_\?1#:>!O%RZKJ;Q"5X5BM
M5 0J6!S%>2G^%OX>U>+?M/\ _!-/X3?';3[X:+H>A^&M8NXI VII"YE\^3(,
MQ+),">?[O;G/?^=KX_\ [$/QW_83OXO%'@;QYK=Y86NH01NVDQ0I&]M!<Q^:
MN3:Q$*8G;=R#CWZ@']K4<BRQI*ARDB*ZGU5@&!_(T^OQ$_X)=?MO:Q\9O#:>
M%?%$5U>:O%?IIIOKR3=*K6DLUK)P)2O+("WRGI^%?MW0 4444 %%%% !1110
M 4444 8NM?\ 'K)^/_H!K\D?VKO^0QH__7TW\IJ_6[6O^/63\?\ T U^2/[5
MW_(8T?\ Z^F_E-0!\S+T'T'\J6D7H/H/Y4M !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !5>Z_P!2_P"'\ZL57NO]2_X?SH Y
MFP_X_6_WA_):Z\]?P7^0KD+#_C];_>'\EKKSU_!?Y"@!**** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !7+>*_^0=-_UR?^35U-<MXK_P"0=-_UR?\ DU 'GWP^_P"/\?[K_P!:
M]JKQ7X??\?X_W7_K7M5 !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M!X/_ #USTK^XS2?^018?]@^U_P#26.OX9O\ @C=87M[\<M6>&)I=D5JSL.2
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M$+7\LO\ P3N^-'A#X8?M%_V1XDF>&?5O%L[6\FY8XE!D0Y=V!4<#N17]3?\
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M5_:5^&5AXYU72(=(N+N0(UM"5V+F,/D;21W]: /RS_X+@*6\-Z<HZG19,?\
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M1KT>/[B_2O.'_P"/BR_ZZ+_(UZ/']Q?I0 ^BBB@ HHHH **** /SH_X*0_\
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M,=J ,S]NKX%_\+B^$&N:786JSZG,&*;E#<+!(.F">N!7\KOP"^-/B?\ 8?\
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M/+C(PH/ SV'->@_L^?\ !&SX5_!/6VU?4?$7_": P");;5[9[B-759 LH65
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M@9(QS].M>:Q?\&^OPXANQ<1_%;6$B\WS/LZBX\O[^XC'E8P1\OTK]$_V;_\
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M5<8P=Z1@'AK?</F'''IU-<'_ ,/=O#/Q/\>Z/X;^$YUHV]Y<-;S-/9W+)O'
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*0G R>U+5_3+"74KR.TB4LTG3;UZ@?U% 'M7P-\ W7BCQ):3&+?:V]W&\ORD
M_(0">HQ_$,G\Z_8_0M'L]#T^&PLD\N%%4A>.NT#L!Z?K7SQ^SM\-X?"VAQZA
M/"K2:A:H^9%R4;*#Y<]#\AYZ]>E?3] !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5SW
MB7_D&3_[A_K70USWB7_D&3_[A_K0!YAX4_Y"4G_ ?YBO;D^XO^ZO\A7B/A3_
M )"4G_ ?YBO;D^XO^ZO\A0 ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH *Y;Q7_ ,@Z;_KD_P#)JZFN6\5_\@Z;
M_KD_\FH \^^'W_'^/]U_ZU[57BOP^_X_Q_NO_6O:J "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *XCQO\ \>,?
MU/\ 2NWKB/&__'C']3_2@#G? GWO^VK?^AFO6:\F\"?>_P"VK?\ H9KUF@#P
M?Q9_R$X?^N8_DE>P:!_R";/_ *YBO'_%G_(3A_ZYC^25[!H'_()L_P#KF* -
MBBBB@ HHHH **** "OF;XO?LA_ ;XZ21S?$OP9;^()([E;M&E:(%9U<2!_G@
ME_B -?3-% 'DOPE^"'PX^"&A/X;^&^@Q:#I#S"=K6(H5,H\S#?)%&/\ EH_;
MO7K5%% !7S_\8_V8?@S\>C$?B=X4@\0^3"8(_-,8VQ%=NWYX9>U?0%% 'R+\
M(?V&OV;/@9J\^N?#7P#:Z!J5RBQS7$30DNJ@@ [+:(]">]?7"(L:*BC"HJHH
M]%4  ?@ *=10!FZQI%AKNFW>DZG"+BQOH3!<PG&)(B0Q4Y!')4=0:^)/%_\
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ML_/;2=QFO)]$_P""7O[&'AW4(M4TKX46-M>PY,<H>WRN2&.,62]U!ZU^@M%
M'&^#_ /A?P)IT&E>&=.33[*WB$,4*[2%C4Y"_*J\9YZ5V5%% '@_QB_9K^$'
MQXC2'XF^%X?$,<</D(LIC&(\%=OSPR]CCT]JC^$7[,WP=^!L*V_PV\+0Z!$L
M7DA8C&?W>W;M^2&,?=XZ5[Y10  8&!T' K/U;2[+6]-O-)U&(3V-_"T%S"<8
MDB8@E3D$<D#L:T** /@[QA_P35_9 \=ZO/KGB;X766H:E<<RW#/;@M\Q;^*S
M8]6/<XS7>_";]B']G'X(W:WWPX\!VV@W*3>>LD30DB7=NW?);1]P#^%?6E%
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M"+0H?#?@/1H]&TBW8-%:QE"JD+MS\L<8Z<?=%>ET4 ?SU_\ !<+_ )%G3O\
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M10!\(^&O^";7[(7A*:&?0OAA96<L#(\;*]O\K(0RGBT7H0".]?8OA?P;X?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5FZM_P >,OX?R-:5
M9NK?\>,OX?R- '#O_P ?%E_UT7^1KT>/[B_2O.'_ ./BR_ZZ+_(UZ/']Q?I0
M ^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Q=:_X]9/Q_\ 0#7Y
M(_M7?\AC1_\ KZ;^4U?K=K7_ !ZR?C_Z :_)']J[_D,:/_U]-_*:@#YF7H/H
M/Y4M(O0?0?RI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"N>\2_\ (,G_ -P_UKH:Y[Q+_P @R?\ W#_6@#S#PI_R$I/^ _S%>W)]Q?\
M=7^0KQ'PI_R$I/\ @/\ ,5[<GW%_W5_D* '4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7+>*_^0=-_UR?^35U-
M<MXK_P"0=-_UR?\ DU 'GWP^_P"/\?[K_P!:]JKQ7X??\?X_W7_K7M5 !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %<1XW_P"/&/ZG^E=O7$>-_P#CQC^I_I0!SO@3[W_;5O\ T,UZS7DW@3[W
M_;5O_0S7K- '@_BS_D)P_P#7,?R2O8- _P"039_]<Q7C_BS_ )"</_7,?R2O
M8- _Y!-G_P!<Q0!L4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!S'BOP;X8\<:1
M<Z%XKT>TUO2+Q0MS8WBLT,J@,N&"LIQAF'7H:\\\!_LZ_!7X8W]WJ?@/X>Z#
MX:OK['VNYTZ*9))\  ;R\S@\ #@#@5[510 @   '    ]ATI:** "BBB@ HH
MHH \X\>?"/X<?$Z)8/'GA/2_$L21F)4U%)' C((V@)(G&"?SJEX$^"7PK^&0
M"^!/!>D>&PJ>6!I\<B83;MV_/(_&,C\:]4HH  ,# Z#@4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ K-U;_ (\9?P_D:TJS=6_X\9?P_D: .'?_ (^+
M+_KHO\C7H\?W%^E></\ \?%E_P!=%_D:]'C^XOTH ?1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P"+K]X/(@_YXQ?]^T_PH\B#_GC%_P!^T_PH _!__A6/C_\ Z%35_P#OP/\
MXNC_ (5CX_\ ^A4U?_OP/_BZ_>#R(/\ GC%_W[3_  H\B#_GC%_W[3_"@#\'
M_P#A6/C_ /Z%35_^_ _^+H_X5CX__P"A4U?_ +\#_P"+K]X/(@_YXQ?]^T_P
MH\B#_GC%_P!^T_PH _!__A6/C_\ Z%35_P#OP/\ XNC_ (5CX_\ ^A4U?_OP
M/_BZ_>#R(/\ GC%_W[3_  H\B#_GC%_W[3_"@#\'_P#A6/C_ /Z%35_^_ _^
M+H_X5CX__P"A4U?_ +\#_P"+K]X/(@_YXQ?]^T_PH\B#_GC%_P!^T_PH _!_
M_A6/C_\ Z%35_P#OP/\ XNC_ (5CX_\ ^A4U?_OP/_BZ_>#R(/\ GC%_W[3_
M  H\B#_GC%_W[3_"@#\'_P#A6/C_ /Z%35_^_ _^+H_X5CX__P"A4U?_ +\#
M_P"+K]X/(@_YXQ?]^T_PH\B#_GC%_P!^T_PH _!__A6/C_\ Z%35_P#OP/\
MXNC_ (5CX_\ ^A4U?_OP/_BZ_>#R(/\ GC%_W[3_  H\B#_GC%_W[3_"@#\'
M_P#A6/C_ /Z%35_^_ _^+H_X5CX__P"A4U?_ +\#_P"+K]X/(@_YXQ?]^T_P
MH\B#_GC%_P!^T_PH _!__A6/C_\ Z%35_P#OP/\ XNC_ (5CX_\ ^A4U?_OP
M/_BZ_>#R(/\ GC%_W[3_  H\B#_GC%_W[3_"@#\'_P#A6/C_ /Z%35_^_ _^
M+H_X5CX__P"A4U?_ +\#_P"+K]X/(@_YXQ?]^T_PH\B#_GC%_P!^T_PH _!_
M_A6/C_\ Z%35_P#OP/\ XNC_ (5CX_\ ^A4U?_OP/_BZ_>#R(/\ GC%_W[3_
M  H\B#_GC%_W[3_"@#\'_P#A6/C_ /Z%35_^_ _^+H_X5CX__P"A4U?_ +\#
M_P"+K]X/(@_YXQ?]^T_PH\B#_GC%_P!^T_PH _!__A6/C_\ Z%35_P#OP/\
MXNC_ (5CX_\ ^A4U?_OP/_BZ_>#R(/\ GC%_W[3_  H\B#_GC%_W[3_"@#\'
M_P#A6/C_ /Z%35_^_ _^+H_X5CX__P"A4U?_ +\#_P"+K]X/(@_YXQ?]^T_P
MH\B#_GC%_P!^T_PH _!__A6/C_\ Z%35_P#OP/\ XNC_ (5CX_\ ^A4U?_OP
M/_BZ_>#R(/\ GC%_W[3_  H\B#_GC%_W[3_"@#\'_P#A6/C_ /Z%35_^_ _^
M+H_X5CX__P"A4U?_ +\#_P"+K]X/(@_YXQ?]^T_PH\B#_GC%_P!^T_PH _!_
M_A6/C_\ Z%35_P#OP/\ XNC_ (5CX_\ ^A4U?_OP/_BZ_>#R(/\ GC%_W[3_
M  H\B#_GC%_W[3_"@#\'_P#A6/C_ /Z%35_^_ _^+H_X5CX__P"A4U?_ +\#
M_P"+K]X/(@_YXQ?]^T_PH\B#_GC%_P!^T_PH _!__A6/C_\ Z%35_P#OP/\
MXNC_ (5CX_\ ^A4U?_OP/_BZ_>#R(/\ GC%_W[3_  H\B#_GC%_W[3_"@#\'
M_P#A6/C_ /Z%35_^_ _^+H_X5CX__P"A4U?_ +\#_P"+K]X/(@_YXQ?]^T_P
MH\B#_GC%_P!^T_PH _!__A6/C_\ Z%35_P#OP/\ XNC_ (5CX_\ ^A4U?_OP
M/_BZ_>#R(/\ GC%_W[3_  H\B#_GC%_W[3_"@#\'_P#A6/C_ /Z%35_^_ _^
M+H_X5CX__P"A4U?_ +\#_P"+K]X/(@_YXQ?]^T_PH\B#_GC%_P!^T_PH _!_
M_A6/C_\ Z%35_P#OP/\ XNC_ (5CX_\ ^A4U?_OP/_BZ_>#R(/\ GC%_W[3_
M  H\B#_GC%_W[3_"@#\'_P#A6/C_ /Z%35_^_ _^+H_X5CX__P"A4U?_ +\#
M_P"+K]X/(@_YXQ?]^T_PH\B#_GC%_P!^T_PH _!__A6/C_\ Z%35_P#OP/\
MXNC_ (5CX_\ ^A4U?_OP/_BZ_>#R(/\ GC%_W[3_  H\B#_GC%_W[3_"@#\'
M_P#A6/C_ /Z%35_^_ _^+H_X5CX__P"A4U?_ +\#_P"+K]X/(@_YXQ?]^T_P
MH\B#_GC%_P!^T_PH _!__A6/C_\ Z%35_P#OP/\ XNC_ (5CX_\ ^A4U?_OP
M/_BZ_>#R(/\ GC%_W[3_  H\B#_GC%_W[3_"@#\'_P#A6/C_ /Z%35_^_ _^
M+H_X5CX__P"A4U?_ +\#_P"+K]X/(@_YXQ?]^T_PH\B#_GC%_P!^T_PH _!_
M_A6/C_\ Z%35_P#OP/\ XNC_ (5CX_\ ^A4U?_OP/_BZ_>#R(/\ GC%_W[3_
M  H\B#_GC%_W[3_"@#\'_P#A6/C_ /Z%35_^_ _^+H_X5CX__P"A4U?_ +\#
M_P"+K]X/(@_YXQ?]^T_PH\B#_GC%_P!^T_PH _!__A6/C_\ Z%35_P#OP/\
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M#_,5[<GW%_W5_D*\1\*?\A*3_@/\Q7MR?<7_ '5_D* '4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7+>*_^0=-
M_P!<G_DU=37+>*_^0=-_UR?^34 >??#[_C_'^Z_]:]JKQ7X??\?X_P!U_P"M
M>U4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 5Q'C?_CQC^I_I7;UQ'C?_ (\8_J?Z4 <[X$^]_P!M6_\ 0S7K
M->3>!/O?]M6_]#->LT >#^+/^0G#_P!<Q_)*]@T#_D$V?_7,5X_XL_Y"</\
MUS'\DKV#0/\ D$V?_7,4 ;%%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !6;JW_'C+^'\C6E6;JW_'C+^'\C0!
MP[_\?%E_UT7^1KT>/[B_2O.'_P"/BR_ZZ+_(UZ/']Q?I0 ^BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH Y_Q#_QXR_Y_@-<[9_?M?][^M=%XA_X\
M9?\ /\!KG;/[]K_O?UH ]!7H/H/Y4M(O0?0?RI: "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "L;7/^/&7Z#_ -FK9K&US_CQ
ME^@_]FH \G\/?\ABY_Z[C_T$5[@O0?0?RKP_P]_R&+G_ *[C_P!!%>X+T'T'
M\J %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %<1XW_X\8_J?Z5V]<1XW_X\8_J?Z4 <[X$^]_VU;_T,UZS7DW@3[W_;
M5O\ T,UZS0!X/XL_Y"</_7,?R2O8- _Y!-G_ -<Q7B_BFX#:A"WI'_1>O/\
MA^7-==IOC6"TLH+=H5)C3!.3S[_>H ]2HKSO_A/K?_GBOYG_ .*H_P"$^M_^
M>*_F?_BJ /1**\[_ .$^M_\ GBOYG_XJC_A/K?\ YXK^9_\ BJ /1**\[_X3
MZW_YXK^9_P#BJ/\ A/K?_GBOYG_XJ@#T2BO._P#A/K?_ )XK^9_^*H_X3ZW_
M .>*_F?_ (J@#T2BO._^$^M_^>*_F?\ XJC_ (3ZW_YXK^9_^*H ]$HKSO\
MX3ZW_P">*_F?_BJ/^$^M_P#GBOYG_P"*H ]$HKSO_A/K?_GBOYG_ .*H_P"$
M^M_^>*_F?_BJ /1**\[_ .$^M_\ GBOYG_XJC_A/K?\ YXK^9_\ BJ /1**\
M[_X3ZW_YXK^9_P#BJ/\ A/K?_GBOYG_XJ@#T2BO._P#A/K?_ )XK^9_^*H_X
M3ZW_ .>*_F?_ (J@#T2BO._^$^M_^>*_F?\ XJC_ (3ZW_YXK^9_^*H ]$HK
MSO\ X3ZW_P">*_F?_BJ/^$^M_P#GBOYG_P"*H ]$HKSO_A/K?_GBOYG_ .*H
M_P"$^M_^>*_F?_BJ /1**\[_ .$^M_\ GBOYG_XJC_A/K?\ YXK^9_\ BJ /
M1**\[_X3ZW_YXK^9_P#BJ/\ A/K?_GBOYG_XJ@#T2BO._P#A/K?_ )XK^9_^
M*H_X3ZW_ .>*_F?_ (J@#T2BO._^$^M_^>*_F?\ XJC_ (3ZW_YXK^9_^*H
M]$HKSO\ X3ZW_P">*_F?_BJ/^$^M_P#GBOYG_P"*H ]$HKSO_A/K?_GBOYG_
M .*H_P"$^M_^>*_F?_BJ /1**\[_ .$^M_\ GBOYG_XJC_A/K?\ YXK^9_\
MBJ /1**\[_X3ZW_YXK^9_P#BJ/\ A/K?_GBOYG_XJ@#T2BO._P#A/K?_ )XK
M^9_^*H_X3ZW_ .>*_F?_ (J@#T2BO._^$^M_^>*_F?\ XJC_ (3ZW_YXK^9_
M^*H ]$HKSO\ X3ZW_P">*_F?_BJ/^$^M_P#GBOYG_P"*H ]$HKSO_A/K?_GB
MOYG_ .*H_P"$^M_^>*_F?_BJ /1**\[_ .$^M_\ GBOYG_XJC_A/K?\ YXK^
M9_\ BJ /1**\[_X3ZW_YXK^9_P#BJ/\ A/K?_GBOYG_XJ@#T2BO._P#A/K?_
M )XK^9_^*H_X3ZW_ .>*_F?_ (J@#T2BO._^$^M_^>*_F?\ XJC_ (3ZW_YX
MK^9_^*H ]$HKSO\ X3ZW_P">*_F?_BJ/^$^M_P#GBOYG_P"*H ]$HKSO_A/K
M?_GBOYG_ .*H_P"$^M_^>*_F?_BJ /1**\[_ .$^M_\ GBOYG_XJC_A/K?\
MYXK^9_\ BJ /1**\[_X3ZW_YXK^9_P#BJ/\ A/K?_GBOYG_XJ@#T2BO._P#A
M/K?_ )XK^9_^*H_X3ZW_ .>*_F?_ (J@#T2BO._^$^M_^>*_F?\ XJC_ (3Z
MW_YXK^9_^*H ]$HKSO\ X3ZW_P">*_F?_BJ/^$^M_P#GBOYG_P"*H ]$HKSO
M_A/K?_GBOYG_ .*H_P"$^M_^>*_F?_BJ /1**\[_ .$^M_\ GBOYG_XJC_A/
MK?\ YXK^9_\ BJ /1**\[_X3ZW_YXK^9_P#BJ/\ A/K?_GBOYG_XJ@#T2BO.
M_P#A/K?_ )XK^9_^*H_X3ZW_ .>*_F?_ (J@#T2BO._^$^M_^>*_F?\ XJC_
M (3ZW_YXK^9_^*H ]$HKSO\ X3ZW_P">*_F?_BJ/^$^M_P#GBOYG_P"*H ]$
MHKSO_A/K?_GBOYG_ .*H_P"$^M_^>*_F?_BJ /1**\[_ .$^M_\ GBOYG_XJ
MC_A/K?\ YXK^9_\ BJ /1**\[_X3ZW_YXK^9_P#BJ/\ A/K?_GBOYG_XJ@#T
M2BO._P#A/K?_ )XK^9_^*H_X3ZW_ .>*_F?_ (J@#T2BO._^$^M_^>*_F?\
MXJC_ (3ZW_YXK^9_^*H ]$HKSO\ X3ZW_P">*_F?_BJ/^$^M_P#GBOYG_P"*
MH ]$HKSO_A/K?_GBOYG_ .*H_P"$^M_^>*_F?_BJ /1**\[_ .$^M_\ GBOY
MG_XJC_A/K?\ YXK^9_\ BJ /1**\[_X3ZW_YXK^9_P#BJ/\ A/K?_GBOYG_X
MJ@#T2BO._P#A/K?_ )XK^9_^*H_X3ZW_ .>*_F?_ (J@#T2BO._^$^M_^>*_
MF?\ XJC_ (3ZW_YXK^9_^*H ]$HKSO\ X3ZW_P">*_F?_BJ/^$^M_P#GBOYG
M_P"*H ]$HKSO_A/K?_GBOYG_ .*H_P"$^M_^>*_F?_BJ /1**\[_ .$^M_\
MGBOYG_XJC_A/K?\ YXK^9_\ BJ /1**\[_X3ZW_YXK^9_P#BJ/\ A/K?_GBO
MYG_XJ@#T2BO._P#A/K?_ )XK^9_^*H_X3ZW_ .>*_F?_ (J@#T2BO._^$^M_
M^>*_F?\ XJC_ (3ZW_YXK^9_^*H ]$HKSO\ X3ZW_P">*_F?_BJ/^$^M_P#G
MBOYG_P"*H ]$HKSO_A/K?_GBOYG_ .*H_P"$^M_^>*_F?_BJ /1**\[_ .$^
MM_\ GBOYG_XJC_A/K?\ YXK^9_\ BJ /1**\[_X3ZW_YXK^9_P#BJ/\ A/K?
M_GBOYG_XJ@#T2BO._P#A/K?_ )XK^9_^*H_X3ZW_ .>*_F?_ (J@#T2BO._^
M$^M_^>*_F?\ XJC_ (3ZW_YXK^9_^*H ]$HKSO\ X3ZW_P">*_F?_BJ/^$^M
M_P#GBOYG_P"*H ]$HKSO_A/K?_GBOYG_ .*H_P"$^M_^>*_F?_BJ /1**\[_
M .$^M_\ GBOYG_XJC_A/K?\ YXK^9_\ BJ /1**\[_X3ZW_YXK^9_P#BJ/\
MA/K?_GBOYG_XJ@#T2BO._P#A/K?_ )XK^9_^*H_X3ZW_ .>*_F?_ (J@#T2B
MO._^$^M_^>*_F?\ XJC_ (3ZW_YXK^9_^*H ]$HKSO\ X3ZW_P">*_F?_BJ/
M^$^M_P#GBOYG_P"*H ]$HKSO_A/K?_GBOYG_ .*H_P"$^M_^>*_F?_BJ /1*
M*\[_ .$^M_\ GBOYG_XJC_A/K?\ YXK^9_\ BJ /1**\[_X3ZW_YXK^9_P#B
MJ/\ A/K?_GBOYG_XJ@#T2BO._P#A/K?_ )XK^9_^*H_X3ZW_ .>*_F?_ (J@
M#T2BO._^$^M_^>*_F?\ XJC_ (3ZW_YXK^9_^*H ]$HKSO\ X3ZW_P">*_F?
M_BJ/^$^M_P#GBOYG_P"*H ]$HKSO_A/K?_GBOYG_ .*H_P"$^M_^>*_F?_BJ
M /1**\[_ .$^M_\ GBOYG_XJC_A/K?\ YXK^9_\ BJ /1**\[_X3ZW_YXK^9
M_P#BJ/\ A/K?_GBOYG_XJ@#T2BO._P#A/K?_ )XK^9_^*H_X3ZW_ .>*_F?_
M (J@#T2BO._^$^M_^>*_F?\ XJC_ (3ZW_YXK^9_^*H ]$HKSO\ X3ZW_P">
M*_F?_BJ/^$^M_P#GBOYG_P"*H ]$HKSO_A/K?_GBOYG_ .*H_P"$^M_^>*_F
M?_BJ /1**\[_ .$^M_\ GBOYG_XJC_A/K?\ YXK^9_\ BJ /1**\[_X3ZW_Y
MXK^9_P#BJ/\ A/K?_GBOYG_XJ@#T2BO._P#A/K?_ )XK^9_^*H_X3ZW_ .>*
M_F?_ (J@#T2BO._^$^M_^>*_F?\ XJC_ (3ZW_YXK^9_^*H ]$HKSO\ X3ZW
M_P">*_F?_BJ/^$^M_P#GBOYG_P"*H ]$HKSO_A/K?_GBOYG_ .*H_P"$^M_^
M>*_F?_BJ /1**\[_ .$^M_\ GBOYG_XJC_A/K?\ YXK^9_\ BJ /1**\[_X3
MZW_YXK^9_P#BJ/\ A/K?_GBOYG_XJ@#T2BO._P#A/K?_ )XK^9_^*H_X3ZW_
M .>*_F?_ (J@#T2BO._^$^M_^>*_F?\ XJC_ (3ZW_YXK^9_^*H ]$HKSO\
MX3ZW_P">*_F?_BJ/^$^M_P#GBOYG_P"*H ]$HKSO_A/K?_GBOYG_ .*H_P"$
M^M_^>*_F?_BJ /1**\[_ .$^M_\ GBOYG_XJC_A/K?\ YXK^9_\ BJ /1**\
M[_X3ZW_YXK^9_P#BJ/\ A/K?_GBOYG_XJ@#T2BO._P#A/K?_ )XK^9_^*H_X
M3ZW_ .>*_F?_ (J@#T2BO._^$^M_^>*_F?\ XJC_ (3ZW_YXK^9_^*H ]$HK
MSO\ X3ZW_P">*_F?_BJ/^$^M_P#GBOYG_P"*H ]$HKSO_A/K?_GBOYG_ .*H
M_P"$^M_^>*_F?_BJ /1**\[_ .$^M_\ GBOYG_XJC_A/K?\ YXK^9_\ BJ /
M1**\[_X3ZW_YXK^9_P#BJ/\ A/K?_GBOYG_XJ@#T2BO._P#A/K?_ )XK^9_^
M*H_X3ZW_ .>*_F?_ (J@#T2BO._^$^M_^>*_F?\ XJC_ (3ZW_YXK^9_^*H
M]$HKSO\ X3ZW_P">*_F?_BJ/^$^M_P#GBOYG_P"*H ]$HKSO_A/K?_GBOYG_
M .*H_P"$^M_^>*_F?_BJ /1**\[_ .$^M_\ GBOYG_XJC_A/K?\ YXK^9_\
MBJ /1**\[_X3ZW_YXK^9_P#BJ/\ A/K?_GBOYG_XJ@#T2BO._P#A/K?_ )XK
M^9_^*H_X3ZW_ .>*_F?_ (J@#T2BO._^$^M_^>*_F?\ XJC_ (3ZW_YXK^9_
M^*H ]$HKSO\ X3ZW_P">*_F?_BJ/^$^M_P#GBOYG_P"*H ]$HKSO_A/K?_GB
MOYG_ .*H_P"$^M_^>*_F?_BJ /1**\[_ .$^M_\ GBOYG_XJC_A/K?\ YXK^
M9_\ BJ /1**\[_X3ZW_YXK^9_P#BJ/\ A/K?_GBOYG_XJ@#T2BO._P#A/K?_
M )XK^9_^*H_X3ZW_ .>*_F?_ (J@#T2BO._^$^M_^>*_F?\ XJC_ (3ZW_YX
MK^9_^*H ]$HKSO\ X3ZW_P">*_F?_BJ/^$^M_P#GBOYG_P"*H ]$HKSO_A/K
M?_GBOYG_ .*H_P"$^M_^>*_F?_BJ /1**\[_ .$^M_\ GBOYG_XJC_A/K?\
MYXK^9_\ BJ /1**\[_X3ZW_YXK^9_P#BJ/\ A/K?_GBOYG_XJ@#T2BO._P#A
M/K?_ )XK^9_^*H_X3ZW_ .>*_F?_ (J@#T2BO._^$^M_^>*_F?\ XJC_ (3Z
MW_YXK^9_^*H ]$HKSO\ X3ZW_P">*_F?_BJ/^$^M_P#GBOYG_P"*H ]$HKSO
M_A/K?_GBOYG_ .*H_P"$^M_^>*_F?_BJ /1**\[_ .$^M_\ GBOYG_XJC_A/
MK?\ YXK^9_\ BJ /1**\[_X3ZW_YXK^9_P#BJ/\ A/K?_GBOYG_XJ@#T2BO.
M_P#A/K?_ )XK^9_^*H_X3ZW_ .>*_F?_ (J@#T2BO._^$^M_^>*_F?\ XJC_
M (3ZW_YXK^9_^*H ]$HKSO\ X3ZW_P">*_F?_BJ/^$^M_P#GBOYG_P"*H ]$
MHKSO_A/K?_GBOYG_ .*H_P"$^M_^>*_F?_BJ /1**\[_ .$^M_\ GBOYG_XJ
MC_A/K?\ YXK^9_\ BJ /1**\[_X3ZW_YXK^9_P#BJ/\ A/K?_GBOYG_XJ@#T
M2BO._P#A/K?_ )XK^9_^*H_X3ZW_ .>*_F?_ (J@#T2BO._^$^M_^>*_F?\
MXJC_ (3ZW_YXK^9_^*H ]$HKSO\ X3ZW_P">*_F?_BJ/^$^M_P#GBOYG_P"*
MH ]$HKSO_A/K?_GBOYG_ .*H_P"$^M_^>*_F?_BJ /1**\[_ .$^M_\ GBOY
MG_XJC_A/K?\ YXK^9_\ BJ /1**\[_X3ZW_YXK^9_P#BJ/\ A/K?_GBOYG_X
MJ@#T2BO._P#A/K?_ )XK^9_^*H_X3ZW_ .>*_F?_ (J@#T2BO._^$^M_^>*_
MF?\ XJC_ (3ZW_YXK^9_^*H ]$HKSO\ X3ZW_P">*_F?_BJ/^$^M_P#GBOYG
M_P"*H ]$HKSO_A/K?_GBOYG_ .*H_P"$^M_^>*_F?_BJ /1**\[_ .$^M_\
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M /%4?\)];_\ /%?S/_Q5 'HE%>=_\)];_P#/%?S/_P 51_PGUO\ \\5_,_\
MQ5 'HE%>=_\ "?6__/%?S/\ \51_PGUO_P \5_,__%4 >B45YW_PGUO_ ,\5
M_,__ !5'_"?6_P#SQ7\S_P#%4 >B45YW_P )];_\\5_,_P#Q5'_"?6__ #Q7
M\S_\50!Z)17G?_"?6_\ SQ7\S_\ %4?\)];_ //%?S/_ ,50!Z)17G?_  GU
MO_SQ7\S_ /%4?\)];_\ /%?S/_Q5 'HE%>=_\)];_P#/%?S/_P 51_PGUO\
M\\5_,_\ Q5 'HE%>=_\ "?6__/%?S/\ \51_PGUO_P \5_,__%4 >B45YW_P
MGUO_ ,\5_,__ !5'_"?6_P#SQ7\S_P#%4 >B45YW_P )];_\\5_,_P#Q5'_"
M?6__ #Q7\S_\50!Z)17G?_"?6_\ SQ7\S_\ %4?\)];_ //%?S/_ ,50!Z)1
M7G?_  GUO_SQ7\S_ /%4?\)];_\ /%?S/_Q5 'HE%>=_\)];_P#/%?S/_P 5
M1_PGUO\ \\5_,_\ Q5 'HE%>=_\ "?6__/%?S/\ \51_PGUO_P \5_,__%4
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M45YW_P )];_\\5_,_P#Q5'_"?6__ #Q7\S_\50!Z)17G?_"?6_\ SQ7\S_\
M%4?\)];_ //%?S/_ ,50!Z)17G?_  GUO_SQ7\S_ /%4?\)];_\ /%?S/_Q5
M 'HE%>=_\)];_P#/%?S/_P 51_PGUO\ \\5_,_\ Q5 'HE%>=_\ "?6__/%?
MS/\ \51_PGUO_P \5_,__%4 >B45YW_PGUO_ ,\5_,__ !5'_"?6_P#SQ7\S
M_P#%4 >B45YW_P )];_\\5_,_P#Q5'_"?6__ #Q7\S_\50!Z)17G?_"?6_\
MSQ7\S_\ %4?\)];_ //%?S/_ ,50!Z)17G?_  GUO_SQ7\S_ /%4?\)];_\
M/%?S/_Q5 'HE%>=_\)];_P#/%?S/_P 51_PGUO\ \\5_,_\ Q5 'HE%>=_\
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M /%4?\)];_\ /%?S/_Q5 'HE%>=_\)];_P#/%?S/_P 51_PGUO\ \\5_,_\
MQ5 'HE%>=_\ "?6__/%?S/\ \51_PGUO_P \5_,__%4 >B45YW_PGUO_ ,\5
M_,__ !5'_"?6_P#SQ7\S_P#%4 >B45YW_P )];_\\5_,_P#Q5'_"?6__ #Q7
M\S_\50!Z)17G?_"?6_\ SQ7\S_\ %4?\)];_ //%?S/_ ,50!Z)17G?_  GU
MO_SQ7\S_ /%4?\)];_\ /%?S/_Q5 'HE%>=_\)];_P#/%?S/_P 51_PGUO\
M\\5_,_\ Q5 'HE%>=_\ "?6__/%?S/\ \51_PGUO_P \5_,__%4 >B45YW_P
MGUO_ ,\5_,__ !5'_"?6_P#SQ7\S_P#%4 >B45YW_P )];_\\5_,_P#Q5'_"
M?6__ #Q7\S_\50!Z)17G?_"?6_\ SQ7\S_\ %4?\)];_ //%?S/_ ,50!Z)1
M7G?_  GUO_SQ7\S_ /%4?\)];_\ /%?S/_Q5 'HE%>=_\)];_P#/%?S/_P 5
M1_PGUO\ \\5_,_\ Q5 'HE%>=_\ "?6__/%?S/\ \51_PGUO_P \5_,__%4
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M_P )];_\\5_,_P#Q5 'HE%>=_P#"?6__ #Q7\S_\51_PGUO_ ,\5_,__ !5
M'HE%>=_\)];_ //%?S/_ ,51_P )];_\\5_,_P#Q5 'HE%>=_P#"?6__ #Q7
M\S_\51_PGUO_ ,\5_,__ !5 'HE%>=_\)];_ //%?S/_ ,51_P )];_\\5_,
M_P#Q5 'HE%>=_P#"?6__ #Q7\S_\51_PGUO_ ,\5_,__ !5 'HE%>=_\)];_
M //%?S/_ ,51_P )];_\\5_,_P#Q5 'HE%>=_P#"?6__ #Q7\S_\51_PGUO_
M ,\5_,__ !5 'HE%>=_\)];_ //%?S/_ ,51_P )];_\\5_,_P#Q5 'HE%>=
M_P#"?6__ #Q7\S_\51_PGUO_ ,\5_,__ !5 'HE%>=_\)];_ //%?S/_ ,51
M_P )];_\\5_,_P#Q5 'HE%>=_P#"?6__ #Q7\S_\51_PGUO_ ,\5_,__ !5
M'HE%>=_\)];_ //%?S/_ ,51_P )];_\\5_,_P#Q5 'HE%>=_P#"?6__ #Q7
M\S_\51_PGUO_ ,\5_,__ !5 'HE%>=_\)];_ //%?S/_ ,51_P )];_\\5_,
M_P#Q5 'HE%>=_P#"?6__ #Q7\S_\51_PGUO_ ,\5_,__ !5 'HE%>=_\)];_
M //%?S/_ ,51_P )];_\\5_,_P#Q5 'HE%>=_P#"?6__ #Q7\S_\51_PGUO_
M ,\5_,__ !5 'HE%>=_\)];_ //%?S/_ ,51_P )];_\\5_,_P#Q5 'HE%>=
M_P#"?6__ #Q7\S_\51_PGUO_ ,\5_,__ !5 'HE%>=_\)];_ //%?S/_ ,51
M_P )];_\\5_,_P#Q5 'HE%>=_P#"?6__ #Q7\S_\51_PGUO_ ,\5_,__ !5
M'HE%>=_\)];_ //%?S/_ ,51_P )];_\\5_,_P#Q5 'HE%>=_P#"?6__ #Q7
M\S_\51_PGUO_ ,\5_,__ !5 'HE%>=_\)];_ //%?S/_ ,51_P )];_\\5_,
M_P#Q5 'HE%>=_P#"?6__ #Q7\S_\51_PGUO_ ,\5_,__ !5 'HE%>=_\)];_
M //%?S/_ ,51_P )];_\\5_,_P#Q5 'HE%>=_P#"?6__ #Q7\S_\51_PGUO_
M ,\5_,__ !5 'HE%>=_\)];_ //%?S/_ ,51_P )];_\\5_,_P#Q5 'HE%>=
M_P#"?6__ #Q7\S_\51_PGUO_ ,\5_,__ !5 'HE%>=_\)];_ //%?S/_ ,51
M_P )];_\\5_,_P#Q5 'HE%>=_P#"?6__ #Q7\S_\51_PGUO_ ,\5_,__ !5
M'HE<]XE_Y!D_^X?ZUSG_  GUO_SQ7\S_ /%5E:OXSAO;26!85&Y<9!.>?;=0
M!D>%/^0E)_P'^8KVY/N+_NK_ "%?/.AZLEC=O,R@@X[\<'/J/YGH?:O0U\>V
MX 'DKP .I[#_ 'J /1:*\[_X3ZW_ .>*_F?_ (JC_A/K?_GBOYG_ .*H ]$H
MKSO_ (3ZW_YXK^9_^*H_X3ZW_P">*_F?_BJ /1**\[_X3ZW_ .>*_F?_ (JC
M_A/K?_GBOYG_ .*H ]$HKSO_ (3ZW_YXK^9_^*H_X3ZW_P">*_F?_BJ /1**
M\[_X3ZW_ .>*_F?_ (JC_A/K?_GBOYG_ .*H ]$HKSO_ (3ZW_YXK^9_^*H_
MX3ZW_P">*_F?_BJ /1**\[_X3ZW_ .>*_F?_ (JC_A/K?_GBOYG_ .*H ]$H
MKSO_ (3ZW_YXK^9_^*H_X3ZW_P">*_F?_BJ /1**\[_X3ZW_ .>*_F?_ (JC
M_A/K?_GBOYG_ .*H ]$HKSO_ (3ZW_YXK^9_^*H_X3ZW_P">*_F?_BJ /1**
M\[_X3ZW_ .>*_F?_ (JC_A/K?_GBOYG_ .*H ]$HKSO_ (3ZW_YXK^9_^*H_
MX3ZW_P">*_F?_BJ /1**\[_X3ZW_ .>*_F?_ (JC_A/K?_GBOYG_ .*H ]$H
MKSO_ (3ZW_YXK^9_^*H_X3ZW_P">*_F?_BJ /1**\[_X3ZW_ .>*_F?_ (JC
M_A/K?_GBOYG_ .*H ]$HKSO_ (3ZW_YXK^9_^*H_X3ZW_P">*_F?_BJ /1**
M\[_X3ZW_ .>*_F?_ (JC_A/K?_GBOYG_ .*H ]$HKSO_ (3ZW_YXK^9_^*H_
MX3ZW_P">*_F?_BJ /1**\[_X3ZW_ .>*_F?_ (JC_A/K?_GBOYG_ .*H ]$H
MKSO_ (3ZW_YXK^9_^*H_X3ZW_P">*_F?_BJ /1**\[_X3ZW_ .>*_F?_ (JC
M_A/K?_GBOYG_ .*H ]$HKSO_ (3ZW_YXK^9_^*H_X3ZW_P">*_F?_BJ /1**
M\[_X3ZW_ .>*_F?_ (JC_A/K?_GBOYG_ .*H ]$HKSO_ (3ZW_YXK^9_^*H_
MX3ZW_P">*_F?_BJ /1**\[_X3ZW_ .>*_F?_ (JC_A/K?_GBOYG_ .*H ]$H
MKSO_ (3ZW_YXK^9_^*H_X3ZW_P">*_F?_BJ /1**\[_X3ZW_ .>*_F?_ (JC
M_A/K?_GBOYG_ .*H ]$HKSO_ (3ZW_YXK^9_^*H_X3ZW_P">*_F?_BJ /1**
M\[_X3ZW_ .>*_F?_ (JC_A/K?_GBOYG_ .*H ]$HKSO_ (3ZW_YXK^9_^*H_
MX3ZW_P">*_F?_BJ /1**\[_X3ZW_ .>*_F?_ (JC_A/K?_GBOYG_ .*H ]$H
MKSO_ (3ZW_YXK^9_^*H_X3ZW_P">*_F?_BJ /1**\[_X3ZW_ .>*_F?_ (JC
M_A/K?_GBOYG_ .*H ]$HKSO_ (3ZW_YXK^9_^*H_X3ZW_P">*_F?_BJ /1**
M\[_X3ZW_ .>*_F?_ (JC_A/K?_GBOYG_ .*H ]$KEO%?_(.F_P"N3_R:L3_A
M/K?_ )XK^9_^*K&UKQ?#?VKPK$!N0KD$\9X_O'U__7TH I?#[_C_ !_NO_6O
M:J^>O"^LII%UYKH'&&')QUS[C/X5Z#_PGUO_ ,\5_,__ !5 'HE%>=_\)];_
M //%?S/_ ,51_P )];_\\5_,_P#Q5 'HE%>=_P#"?6__ #Q7\S_\51_PGUO_
M ,\5_,__ !5 'HE%>=_\)];_ //%?S/_ ,51_P )];_\\5_,_P#Q5 'HE%>=
M_P#"?6__ #Q7\S_\51_PGUO_ ,\5_,__ !5 'HE%>=_\)];_ //%?S/_ ,51
M_P )];_\\5_,_P#Q5 'HE%>=_P#"?6__ #Q7\S_\51_PGUO_ ,\5_,__ !5
M'HE%>=_\)];_ //%?S/_ ,51_P )];_\\5_,_P#Q5 'HE%>=_P#"?6__ #Q7
M\S_\51_PGUO_ ,\5_,__ !5 'HE%>=_\)];_ //%?S/_ ,51_P )];_\\5_,
M_P#Q5 'HE%>=_P#"?6__ #Q7\S_\51_PGUO_ ,\5_,__ !5 'HE%>=_\)];_
M //%?S/_ ,51_P )];_\\5_,_P#Q5 'HE%>=_P#"?6__ #Q7\S_\51_PGUO_
M ,\5_,__ !5 'HE%>=_\)];_ //%?S/_ ,51_P )];_\\5_,_P#Q5 'HE%>=
M_P#"?6__ #Q7\S_\51_PGUO_ ,\5_,__ !5 'HE%>=_\)];_ //%?S/_ ,51
M_P )];_\\5_,_P#Q5 'HE%>=_P#"?6__ #Q7\S_\51_PGUO_ ,\5_,__ !5
M'HE%>=_\)];_ //%?S/_ ,51_P )];_\\5_,_P#Q5 'HE%>=_P#"?6__ #Q7
M\S_\51_PGUO_ ,\5_,__ !5 'HE%>=_\)];_ //%?S/_ ,51_P )];_\\5_,
M_P#Q5 'HE%>=_P#"?6__ #Q7\S_\51_PGUO_ ,\5_,__ !5 'HE%>=_\)];_
M //%?S/_ ,51_P )];_\\5_,_P#Q5 'HE%>=_P#"?6__ #Q7\S_\51_PGUO_
M ,\5_,__ !5 'HE%>=_\)];_ //%?S/_ ,51_P )];_\\5_,_P#Q5 'HE%>=
M_P#"?6__ #Q7\S_\51_PGUO_ ,\5_,__ !5 'HE%>=_\)];_ //%?S/_ ,51
M_P )];_\\5_,_P#Q5 'HE%>=_P#"?6__ #Q7\S_\51_PGUO_ ,\5_,__ !5
M'HE%>=_\)];_ //%?S/_ ,51_P )];_\\5_,_P#Q5 'HE%>=_P#"?6__ #Q7
M\S_\51_PGUO_ ,\5_,__ !5 'HE%>=_\)];_ //%?S/_ ,51_P )];_\\5_,
M_P#Q5 'HE%>=_P#"?6__ #Q7\S_\51_PGUO_ ,\5_,__ !5 'HE%>=_\)];_
M //%?S/_ ,51_P )];_\\5_,_P#Q5 'HE%>=_P#"?6__ #Q7\S_\51_PGUO_
M ,\5_,__ !5 'HE%>=_\)];_ //%?S/_ ,51_P )];_\\5_,_P#Q5 'HE%>=
M_P#"?6__ #Q7\S_\51_PGUO_ ,\5_,__ !5 'HE%>=_\)];_ //%?S/_ ,51
M_P )];_\\5_,_P#Q5 'HE<1XW_X\8_J?Z52_X3ZW_P">*_F?_BJYWQ%XKBU.
MV6)(@I4GG)_Q/I0!=\"?>_[:M_Z&:]9KQ_P)./.6/NTA(Z_WCG\L_P!*]@H
M\PU?P9<7LZ21*H4+CD\YX_P/I^E5T\ MM7<B;L<]/\:]7HH \J_X0(_W$_3_
M !H_X0(_W$_3_&O5:* /*O\ A C_ '$_3_&C_A C_<3]/\:]5HH \J_X0(_W
M$_3_ !H_X0(_W$_3_&O5:* /*O\ A C_ '$_3_&C_A C_<3]/\:]5HH \J_X
M0(_W$_3_ !H_X0(_W$_3_&O5:* /*O\ A C_ '$_3_&C_A C_<3]/\:]5HH
M\J_X0(_W$_3_ !H_X0(_W$_3_&O5:* /*O\ A C_ '$_3_&C_A C_<3]/\:]
M5HH \J_X0(_W$_3_ !H_X0(_W$_3_&O5:* /*O\ A C_ '$_3_&C_A C_<3]
M/\:]5HH \J_X0(_W$_3_ !H_X0(_W$_3_&O5:* /*O\ A C_ '$_3_&C_A C
M_<3]/\:]5HH \J_X0(_W$_3_ !H_X0(_W$_3_&O5:* /*O\ A C_ '$_3_&C
M_A C_<3]/\:]5HH \J_X0(_W$_3_ !H_X0(_W$_3_&O5:* /*O\ A C_ '$_
M3_&C_A C_<3]/\:]5HH \J_X0(_W$_3_ !H_X0(_W$_3_&O5:* /*O\ A C_
M '$_3_&C_A C_<3]/\:]5HH \J_X0(_W$_3_ !H_X0(_W$_3_&O5:* /*O\
MA C_ '$_3_&C_A C_<3]/\:]5HH \J_X0(_W$_3_ !H_X0(_W$_3_&O5:* /
M*O\ A C_ '$_3_&C_A C_<3]/\:]5HH \J_X0(_W$_3_ !H_X0(_W$_3_&O5
M:* /*O\ A C_ '$_3_&C_A C_<3]/\:]5HH \J_X0(_W$_3_ !H_X0(_W$_3
M_&O5:* /*O\ A C_ '$_3_&C_A C_<3]/\:]5HH \J_X0(_W$_3_ !H_X0(_
MW$_3_&O5:* /*O\ A C_ '$_3_&C_A C_<3]/\:]5HH \J_X0(_W$_3_ !H_
MX0(_W$_3_&O5:* /*O\ A C_ '$_3_&C_A C_<3]/\:]5HH \J_X0(_W$_3_
M !H_X0(_W$_3_&O5:* /*O\ A C_ '$_3_&C_A C_<3]/\:]5HH \J_X0(_W
M$_3_ !H_X0(_W$_3_&O5:* /*O\ A C_ '$_3_&C_A C_<3]/\:]5HH \J_X
M0(_W$_3_ !H_X0(_W$_3_&O5:* /*O\ A C_ '$_3_&C_A C_<3]/\:]5HH
M\J_X0(_W$_3_ !H_X0(_W$_3_&O5:* /*O\ A C_ '$_3_&C_A C_<3]/\:]
M5HH \J_X0(_W$_3_ !H_X0(_W$_3_&O5:* /*O\ A C_ '$_3_&C_A C_<3]
M/\:]5HH \J_X0(_W$_3_ !H_X0(_W$_3_&O5:* /*O\ A C_ '$_3_&C_A C
M_<3]/\:]5HH \J_X0(_W$_3_ !H_X0(_W$_3_&O5:* /*O\ A C_ '$_3_&C
M_A C_<3]/\:]5HH \J_X0(_W$_3_ !H_X0(_W$_3_&O5:* /*O\ A C_ '$_
M3_&C_A C_<3]/\:]5HH \J_X0(_W$_3_ !H_X0(_W$_3_&O5:* /*O\ A C_
M '$_3_&C_A C_<3]/\:]5HH \J_X0(_W$_3_ !H_X0(_W$_3_&O5:* /*O\
MA C_ '$_3_&C_A C_<3]/\:]5HH \J_X0(_W$_3_ !H_X0(_W$_3_&O5:* /
M*O\ A C_ '$_3_&C_A C_<3]/\:]5HH \J_X0(_W$_3_ !H_X0(_W$_3_&O5
M:* /*O\ A C_ '$_3_&C_A C_<3]/\:]5HH \J_X0(_W$_3_ !H_X0(_W$_3
M_&O5:* /*O\ A C_ '$_3_&C_A C_<3]/\:]5HH \J_X0(_W$_3_ !H_X0(_
MW$_3_&O5:* /*O\ A C_ '$_3_&C_A C_<3]/\:]5HH \J_X0(_W$_3_ !H_
MX0(_W$_3_&O5:* /*O\ A C_ '$_3_&C_A C_<3]/\:]5HH \J_X0(_W$_3_
M !H_X0(_W$_3_&O5:* /*O\ A C_ '$_3_&C_A C_<3]/\:]5HH \J_X0(_W
M$_3_ !H_X0(_W$_3_&O5:* /*O\ A C_ '$_3_&C_A C_<3]/\:]5HH \J_X
M0(_W$_3_ !H_X0(_W$_3_&O5:* /*O\ A C_ '$_3_&C_A C_<3]/\:]5HH
M\J_X0(_W$_3_ !H_X0(_W$_3_&O5:* /*O\ A C_ '$_3_&C_A C_<3]/\:]
M5HH \J_X0(_W$_3_ !H_X0(_W$_3_&O5:* /*O\ A C_ '$_3_&C_A C_<3]
M/\:]5HH \J_X0(_W$_3_ !H_X0(_W$_3_&O5:* /*O\ A C_ '$_3_&C_A C
M_<3]/\:]5HH \J_X0(_W$_3_ !H_X0(_W$_3_&O5:* /*O\ A C_ '$_3_&C
M_A C_<3]/\:]5HH \J_X0(_W$_3_ !H_X0(_W$_3_&O5:* /*O\ A C_ '$_
M3_&C_A C_<3]/\:]5HH \J_X0(_W$_3_ !H_X0(_W$_3_&O5:* /*O\ A C_
M '$_3_&C_A C_<3]/\:]5HH \J_X0(_W$_3_ !H_X0(_W$_3_&O5:* /*O\
MA C_ '$_3_&C_A C_<3]/\:]5HH \J_X0(_W$_3_ !H_X0(_W$_3_&O5:* /
M*O\ A C_ '$_3_&C_A C_<3]/\:]5HH \J_X0(_W$_3_ !H_X0(_W$_3_&O5
M:* /*O\ A C_ '$_3_&C_A C_<3]/\:]5HH \J_X0(_W$_3_ !H_X0(_W$_3
M_&O5:* /*O\ A C_ '$_3_&C_A C_<3]/\:]5HH \J_X0(_W$_3_ !H_X0(_
MW$_3_&O5:* /*O\ A C_ '$_3_&C_A C_<3]/\:]5HH \J_X0(_W$_3_ !H_
MX0(_W$_3_&O5:* /*O\ A C_ '$_3_&C_A C_<3]/\:]5HH \J_X0(_W$_3_
M !H_X0(_W$_3_&O5:* /*O\ A C_ '$_3_&C_A C_<3]/\:]5HH \J_X0(_W
M$_3_ !H_X0(_W$_3_&O5:* /*O\ A C_ '$_3_&C_A C_<3]/\:]5HH \J_X
M0(_W$_3_ !H_X0(_W$_3_&O5:* /*O\ A C_ '$_3_&C_A C_<3]/\:]5HH
M\J_X0(_W$_3_ !H_X0(_W$_3_&O5:* /*O\ A C_ '$_3_&C_A C_<3]/\:]
M5HH \J_X0(_W$_3_ !H_X0(_W$_3_&O5:* /*O\ A C_ '$_3_&C_A C_<3]
M/\:]5HH \J_X0(_W$_3_ !H_X0(_W$_3_&O5:* /*O\ A C_ '$_3_&C_A C
M_<3]/\:]5HH \J_X0(_W$_3_ !H_X0(_W$_3_&O5:* /*O\ A C_ '$_3_&C
M_A C_<3]/\:]5HH \J_X0(_W$_3_ !H_X0(_W$_3_&O5:* /*O\ A C_ '$_
M3_&C_A C_<3]/\:]5HH \J_X0(_W$_3_ !H_X0(_W$_3_&O5:* /*O\ A C_
M '$_3_&C_A C_<3]/\:]5HH \J_X0(_W$_3_ !H_X0(_W$_3_&O5:* /*O\
MA C_ '$_3_&C_A C_<3]/\:]5HH \J_X0(_W$_3_ !H_X0(_W$_3_&O5:* /
M*O\ A C_ '$_3_&C_A C_<3]/\:]5HH \J_X0(_W$_3_ !H_X0(_W$_3_&O5
M:* /*O\ A C_ '$_3_&C_A C_<3]/\:]5HH \J_X0(_W$_3_ !H_X0(_W$_3
M_&O5:* /*O\ A C_ '$_3_&C_A C_<3]/\:]5HH \J_X0(_W$_3_ !H_X0(_
MW$_3_&O5:* /*O\ A C_ '$_3_&C_A C_<3]/\:]5HH \J_X0(_W$_3_ !H_
MX0(_W$_3_&O5:* /*O\ A C_ '$_3_&C_A C_<3]/\:]5HH \J_X0(_W$_3_
M !H_X0(_W$_3_&O5:* /*O\ A C_ '$_3_&C_A C_<3]/\:]5HH \J_X0(_W
M$_3_ !H_X0(_W$_3_&O5:* /*O\ A C_ '$_3_&C_A C_<3]/\:]5HH \J_X
M0(_W$_3_ !H_X0(_W$_3_&O5:* /*O\ A C_ '$_3_&C_A C_<3]/\:]5HH
M\J_X0(_W$_3_ !H_X0(_W$_3_&O5:* /*O\ A C_ '$_3_&C_A C_<3]/\:]
M5HH \J_X0(_W$_3_ !H_X0(_W$_3_&O5:* /*O\ A C_ '$_3_&C_A C_<3]
M/\:]5HH \J_X0(_W$_3_ !H_X0(_W$_3_&O5:* /*O\ A C_ '$_3_&C_A C
M_<3]/\:]5HH \J_X0(_W$_3_ !H_X0(_W$_3_&O5:* /*O\ A C_ '$_3_&C
M_A C_<3]/\:]5HH \J_X0(_W$_3_ !H_X0(_W$_3_&O5:* /*O\ A C_ '$_
M3_&C_A C_<3]/\:]5HH \J_X0(_W$_3_ !H_X0(_W$_3_&O5:* /*O\ A C_
M '$_3_&C_A C_<3]/\:]5HH \J_X0(_W$_3_ !H_X0(_W$_3_&O5:* /*O\
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M0(_W$_3_ !H_X0(_W$_3_&O5:* /*O\ A C_ '$_3_&C_A C_<3]/\:]5HH
M\J_X0(_W$_3_ !H_X0(_W$_3_&O5:* /*O\ A C_ '$_3_&C_A C_<3]/\:]
M5HH \J_X0(_W$_3_ !H_X0(_W$_3_&O5:* /*O\ A C_ '$_3_&C_A C_<3]
M/\:]5HH \J_X0(_W$_3_ !H_X0(_W$_3_&O5:* /*O\ A C_ '$_3_&C_A C
M_<3]/\:]5HH \J_X0(_W$_3_ !H_X0(_W$_3_&O5:* /*O\ A C_ '$_3_&C
M_A C_<3]/\:]5HH \J_X0(_W$_3_ !H_X0(_W$_3_&O5:* /*O\ A C_ '$_
M3_&C_A C_<3]/\:]5HH \J_X0(_W$_3_ !H_X0(_W$_3_&O5:* /*O\ A C_
M '$_3_&C_A C_<3]/\:]5HH \J_X0(_W$_3_ !H_X0(_W$_3_&O5:* /*O\
MA C_ '$_3_&C_A C_<3]/\:]5HH \J_X0(_W$_3_ !H_X0(_W$_3_&O5:* /
M*O\ A C_ '$_3_&C_A C_<3]/\:]5HH \J_X0(_W$_3_ !H_X0(_W$_3_&O5
M:* /*O\ A C_ '$_3_&C_A C_<3]/\:]5HH \J_X0(_W$_3_ !H_X0(_W$_3
M_&O5:* /*O\ A C_ '$_3_&C_A C_<3]/\:]5HH \J_X0(_W$_3_ !H_X0(_
MW$_3_&O5:* /*O\ A C_ '$_3_&C_A C_<3]/\:]5HH \J_X0(_W$_3_ !H_
MX0(_W$_3_&O5:* /*O\ A C_ '$_3_&C_A C_<3]/\:]5HH \J_X0(_W$_3_
M !H_X0(_W$_3_&O5:* /*O\ A C_ '$_3_&C_A C_<3]/\:]5HH \J_X0(_W
M$_3_ !H_X0(_W$_3_&O5:* /*O\ A C_ '$_3_&C_A C_<3]/\:]5HH \J_X
M0(_W$_3_ !H_X0(_W$_3_&O5:* /*O\ A C_ '$_3_&C_A C_<3]/\:]5HH
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M0(_W$_3_ !H_X0(_W$_3_&O5:* /*O\ A C_ '$_3_&C_A C_<3]/\:]5HH
M\J_X0(_W$_3_ !H_X0(_W$_3_&O5:* /*O\ A C_ '$_3_&C_A C_<3]/\:]
M5HH \J_X0(_W$_3_ !H_X0(_W$_3_&O5:* /*O\ A C_ '$_3_&C_A C_<3]
M/\:]5HH \J_X0(_W$_3_ !H_X0(_W$_3_&O5:* /*O\ A C_ '$_3_&C_A C
M_<3]/\:]5HH \J_X0(_W$_3_ !H_X0(_W$_3_&O5:* /*O\ A C_ '$_3_&C
M_A C_<3]/\:]5HH \J_X0(_W$_3_ !H_X0(_W$_3_&O5:* /*O\ A C_ '$_
M3_&C_A C_<3]/\:]5HH \J_X0(_W$_3_ !H_X0(_W$_3_&O5:* /*O\ A C_
M '$_3_&C_A C_<3]/\:]5HH \J_X0(_W$_3_ !H_X0(_W$_3_&O5:* /*O\
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M$?[B?I_C1_P@1_N)^G^->JT4 >5?\($?[B?I_C1_P@1_N)^G^->JT4 >5?\
M"!'^XGZ?XT?\($?[B?I_C7JM% 'E7_"!'^XGZ?XT?\($?[B?I_C7JM% 'E7_
M  @1_N)^G^-'_"!'^XGZ?XUZK10!Y5_P@1_N)^G^-0R^ 9<?NU0''MU^F?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L&3Q)I":B^D&[3^T4
M0O\ 9^-V.<=^Y'I6O<I));RI"VR5D(1O[K=CVK\+/VZ_@7^USI'C34/C#\._
MC*GAWPQ%M)T="GF^5!(;B5?]>C?/%E?N_3F@#W']L']O7XC?L\_&'X??#K0/
M"5CJMGXQW>9<W'E[XP$9P4+H3SCL>G-?H-\.OB<-?\ Z#XJ\5)%I%WJ^%,"X
MVB0B+"@#:.6DQ[>E?QF_'/\ ;]L]?^(G@B^\<:??ZYKOPY7^S;R_?S-US=6Z
M>7--'PW#DYX)'N:^K_@]\6OVB?VTM>TO1?A5\1+CP5H&E7EIJ4=C=YVBU219
MGB'F2Q\M'#MZ9R>E '];MK>6][$)K=Q)&0"&'<$9!_$5XQ\7/VB_A'\#/[+_
M .%F>*K7PY_;#%-/^T[?](9?-!"[I$[PR>OW:B_9^\$>./ G@BUTCQYX@7Q%
MJYCM7-ZNW!"PL''RLW4LIZ]O?C\,/^"\'3X-?]?$O_H>K4 ?T"?#GXH>"OBM
MX?M_%'@;6(=:T6Z8K#>0[=CD*&XVLP^Z0>O>O0*_++_@DO\ \FL^%?\ KN?_
M $D@K]3: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKSWXKZI>Z+\
M.?&6J:=,;>^L= O[FUF7[T4T4>4<<CD'GK0!Z%17\LG[(?[8G[0?C?\ ;CM_
MAYXE\>W^H^$G6^W:5)O\H^5J'E)UE(X3Y?N].F!7]2%@[26=M(YRSQ*S'U)S
M0!SWC'QKX>\":1/K7B2_CTZPABGE:>3&T""/S')R0.!COWKYF^&/[<W[/'Q3
M\3'P?X8\>Z?J7B%[VXLH;"'8)'EMYS Z<2L<K)A3D=Z]:^._PNF^+7@?4?"T
M$T4$UW9:A;Q238V))=VQA1SD@85L$_2OQT_9 _X)(^-OV>OC:GQ0U[Q7I6JV
MD?B#4]62V@\GS%AO=2-XD8V.S95, ]\C':@#]]$=9%#H<J>AIU1Q1B*-8U&
MHP,5)0 4444 %%%% !1110 445_.Y_P6#_:A^-?P-\3+:?#/QE>>'(#H:W&R
MWW8\W[):OOXD3G<['\: /Z(Z*^.OV(/'7B?XA? +X>>)?%FI2ZIK.J>'8;J]
MNY<[YIS,ZEVRS<D =STK[%H **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** ,[5[QM.TN_OD4,]I:33JIZ,T:%@#[$BOQ#\=_\
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MZ*02Q ,,$<X)'7O7\W'[*G[87[07C/\ ;1\2^ O$7CR_O_"UIIUO+;Z9)O\
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M+QMXVO=9TS3_ !3)9VEM-NVQ6X-L/+7,C#'SMV'6@#^E>BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MX5^'?%B3I)%?V9G9PQ8 !4;.>>,-ZT ?-'_!0O\ :MU;]EWX(Z_XT\*2VO\
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M /!7#X(?";6?A]HGB7P##H6AZ]I$T^I37^EI,+N9X',B;BZR+N'08"XS6_\
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M> =$TFY\,7L=U8W,UPKM*+!PRR.,6$V#@#&7'7K@5^U>@_!_X8^&+X:IX?\
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M.?#OX3>&;36OA]X>U+Q!#:E+W5+FUF%W<-Y<:@RD21C(.XCY%ZDXH _!H?\
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MXWC^'_[:VN>(9;<7$-CXULKN16.%"PW3LV3O3C ['ZD4 ?V<?"#_ )$;0?\
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ME::?XLO+N.PT^TM$A"O=$(SH=R6[8"[SPI]QWK]Z;._M[ZU%Y;ON@8%@W'0
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MOE[]C/X?Z9^TS^T5XK\:_$76X;[3?#_C:ZDBTW5@TL+V[R1J(E,<+$(/,/\
MRT! []J_JKT+PC\ -%T>+1K32_"L%E&C1BVCCN!%L=0C+@GH5&#STH _'?\
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MW_!1G]LWXG?LO6/A&[\"Q:>ZZQK\&GWQO N$MGNHXI"N8)N=C''3ZYYK]/\
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M9@NP92+&4!MT:8.\9SU-?S-?!S]HGXV>$?CCJ7Q$\':?8W'C6]MHH;F"93Y
MC5[MEP!:R$DM-+_RR'0=Z_O$_:-\ ^#-?^$'C6]UCP[IVH7,>ARR1S7$;LZ,
M98QN!#J,X)SQWK^3K]CGP3X3U+]N[Q5HE]H5A<Z5#I=LT5C*C&!&-QJX)50X
M()"*#ST44 ?>/[+W[?O[?7Q!^(WA/PUXL\,^'X?"5R4M[RXA203")#"B%2=+
MC )0MGYQC%?N]\4OB3XF\$_"#5_&-O'"-<L-!OM15'_U8N+>/<@.8S\N>OR8
M]C76^#_@_P##+1;#2+[2O!FBV-VEE;.MQ!#(LBL8D)8$RD9)YZ=:\W_:UBCA
M^"OC:.-0B+X8U8*HZ#]R: /R_P#V(?\ @HG\:OC]\23X6\80:5'IXU&^MLVH
M7?Y=O>O"G(M8SG8HS\WYU^Y-_KMGHVA2ZYJD@BM+6V^T7,G VH" 2,E1QD=Q
M7\G/_!*W_DM[#_J,ZM_Z<I:_:7_@HW\:KOX6? [6;.QE>"[U;P[*(9HW"/&X
MD8Y4%@"1Y?<&@#YJ_;%_X*X^$_A->WGACX9:O;WWBNUN1$;6X2!T EE\F'[G
MGMRZOSL[=>M?FW?_ /!7']O[^S+OQ!8^&_#KZ+"Y=)FB?<8'WM$2!I)&2BY/
M)_PU/^"6?[+]G\=O%\?Q:^)=K'XML=9TY'6VUF,S1":*.XN!(&B6,EMUPASO
M."H.*_ILM?V:/@5%I<6EM\,O##6@ABCD@-M/L?8@49'GY]?SH _"_P#9 _X+
M-WWC;Q+#X8^.]]8Z3J-[-!9V<5I'$H>[E"C83)%;'!;/8GVQ7]$/ACQ5I7B[
M1H-:T:<7%I/ DJ/E>=\0D'"EA@@CO7\PO_!5K]D/PW\(;WPO\1_AUHUGHG_$
MW_M&6'286C\J."64@%I W  [/7Z*_P#!*+XV:C\3/@U8KJ=S+<7$5PUKF:0.
MV(8Y(L'!/ V?R':@#"_;V_;V^*O[-GQ&\!>'_"L6FG1-=GD75)+H+YB1I'<M
ME"UO)CF)>K#'OTKQWQ[_ ,%B]%T[P'86?A?5+:Y^)S2O%>V#10M;J7$"0;2J
MR-S*9@<Q#@<CC%?+_P#P6O@N;OQOX!L[1FCN[@3K!)'C>K&.\^9>HSCU'U-?
M0O\ P3 _84\&:OX)T'XD_$.PT_Q1=:I9L'L]6MW=XY8[=)%E)C2(;@\P/$A&
M5Z#C(!\>:E_P6"_;7\,ZA]O\2:)H%MX:W/,+A83N^RNWF0,=VEH,F @GY_<'
MN?VY_8F_X*">!?VF]&@LVU>*;Q7:6D;:M;1"%4BN'V':NUE;[KCJ@_'OZ=^T
M5^RI\%=?^$VN:9;^ ?#EA<F"**&]2WFWPJD$L8V_O7&/N]5/ K^;/]BB<?!S
M]K/Q]X9L;WR;%O$EO9011?)$$\J#A5(4X^7IS[^E ']D%Y?V]C:2WL[;8(H7
MG9N.$2,R$\D?P@GK7XH_M6_\%8?"7PZU.]\(_##5HK[Q;;2362VMQ%"R?;XM
MV4)43M@<?P?AU%?K7K>@W7COP5'IMGJCZ9+=VD:FZC.2!+;*K YCD_O'C'H:
M^+OAW_P3L^%OA'Q)K/BKQM;:+XUNM1U&34%FU.WE9[8NRDJK)%;>A!Y;.[J*
M /PYU;_@K/\ M]Z>$U8^'/#PT%I WG&)]_DH0TK8_LG'"'(Y_P *_1G]AG_@
MJ]I'QOU*S\%_$[4[6T\;WUXT$%E:I"J,D4YAEZK V0SQ#B/O^!_2;Q5\'_V:
M6\/ZQI4_A'P=!_Q+;Z..-H;D&%Y+:15< 2-@J0"#STK^4[XI>"_#WP4_;F\)
MR>!+RU2QDBU"\\C3 T<0>6\TN55 D13E2[#D^ISWH _L]N+V#4="FO;9M\$]
MJSQMZJ>_%?R+_MN?\GRW/_;C_P"G 5_4/\&=9GUKX1Z+>7!8R3:-O8N<DDL>
M<@GV_#Z5_+Q^VY_R?+<_]N/_ *<!0!_43^SE_P DN\)_]@*P_P#12U[W7@G[
M.7_)+O"?_8"L/_12U[W0!\)?MZ?M"^-?V=O@KXG\=^"([236-)C1K9;L#RR3
M:W$IW9CE'WHU_A/T[5^=OPU_X*ZQ0^!;S4_BGJ-E8^(;G2S+H\-HD+))>Y3"
MME(3MPLO1#G&<5]/?\%:F5?V8_'+, 5$*9!Z?\>-WUK\*O\ @FC^RHWQU\:Z
MGJ/BV^-SHVAWD%Q;Z??1[[>6 QVY,*!(20I,KGEU)YY&: /=O&W_  5R_;%O
M=0N-4^&VC:'?>$]S&WN;B$^841F8G"Z;*.(\' ?GZ9KZ+_8Y_P""PVM?$3Q=
M9^!OC5>:?IGB#4+\6EI;VB1*'VNJN"7AMCP"?X3G\Q7[5:1^RQ\#-*T'^QXO
MAOX9,9MFC#"VF #/#Y>_'G#G//3\*_F,_P""GW[/&A_LW_%[POX\\%VUMI*Q
M";4S%IT31;6="X&77C;C^]CMF@#^MW2O$%IKFAKK6FR"6WEA>2%QC!VKN&<%
MAW'>OQ*_:Q_X*(_%OX'_ +1FD_#G28]+7PI=::]U<RW 7SQ(K60X+6SC&)Y.
M-X[?A]5?\$[/BQ>?$SX ^&KV]FDFGDT>:1VD8,Q/V>-N2&//7^E?@7_P6$CU
M2?\ :%M;?1//34WT9_)>VV^< 5L!\N[CDD$YZ''X@'VG\9?^"P_C)=/T;3?@
MU-IVJ^*1&8=;M[B*,QQ7F9RJ(4@N#M*>0<[%Y)X[GZ-_86_;A_:-^-/B6#1O
MBUI>F62O;"63[&C*0Q5R.ME;]U'MU_&G_P $W_V'_ MEX!TWQEXZT'3/$6H:
M]I=O?XU.W=I8)3)&A&Y!$"Q6(Y^9OO''&*_7W3?A5\-O!L5WJ?A[P?H^E7-O
M9SR":TBD1\11.^/FE8=CV[T <%\<OVD/ ?P)\*SZ]XRU,6!BLEN_^61^4H7/
M$DB]AZ5_/5\6/^"SOQIUKQ9?Z1\ (M*UJRAN MN]W$N6A8G#;H[.Y'W0.0QY
M/7%>;_\ !33XK>(_C#\>/"_PIT;5+NQLM0%QILT%LZM$YB5(QN0^:?XCG R,
M^E?LC^PQ^Q/\*/!OPJ\,W7B;P+H6LZV]CBYU"]M9?M,T@1,.Y5XAD')&% Y_
M"@#\5[O_ (+)_MK^!];MX?B'HOA^QTLHLDTD4+;A&Q1@?GTN,?<8G[PK]WOV
M+_\ @H#\._VF]#BA@UF.?Q+:6T*ZK;H(52.\=HLJNUP<;9D/*+UZ'@GV3XQ_
ML;_ [XB^$[_2_P#A7GAJUOI8F$5_]FG,L06)U 7]ZXZD<[#T_ _RF^")]<_9
M0_:_/A;3)KJST?Q!X^-E##"5BMVMX[/>H52%8KFV[\\4 ?VUS31P0RW$C 11
M1O*[<<)&I=CSZ*I-?E+^V-_P4P^&_P"S]:7NDZ3K<9\5B%S9VLJP.C2QJ=P/
MSNW#;>B'KC'I]'?%[XR/X6^ =SXO5R9+NPU.W5]^"KG3UVL"& R&ER.<=.O2
MOY@_V5_A;J?[6G[2=UXI\77$VN:%I7B[5+2;3K]1/:O";\HL;;$+!0JX'S@X
M_0 ]FG_X*[_MR^));W4O V@^'[S08T>X@FEB8.8%&XDA=+<?=P?O8Y[5WO[/
MW_!;7XH-XTLM%_:".EZ+IS2F.Z:TBC5E_?+&,&6UM>Q_O#/KZ_T-^#OV7/@;
MX>T"UTN+X:>&5"0F*7;;3CS%( *MF?)!'!Z?EU_)O_@J-^P[\.4^%FN>// ?
MA32- U*V91&FEVTBS9$32,P+F0<M'G[_ %Z<4 ?L)X#^,WA_XG?#U/%_@V\6
M^\_2TOH6;9@^8X4$A&<=_>OYQO\ @I[^UO\ M-VD^M^"1I&E_P#""PS3):W.
MP^>?.<Q29)LO^>:1'_6GDGI7J_\ P1^^-FL:K+XM\ :W=7%Q%H4\&DI!<.I5
M51K%MH53P,N>..I/<"OT(_X*8?#CP-+\$[O5)/#.F/J#-J#-=M&YE)2"!E)/
MF8X8DCCJ30!_)O\ L=_M4?M&_!B\U6X^$>E:;?27FM7-]="[5FQ>2W4LL@&+
M.XX$C-C@''./3^H7]A#]JK]J7XU:C>)\7]%TNQLTA1X&LT8$L54MG-C;]SCD
MU^77_!''X?>"_%.L>+4\0^'-.U9(O&NI0QK=QNP2)=4N4"#;(O 4 >N!UK^I
MO2/ W@7P9#+<Z-H&F:)#%&6FEMXW14C7&2Q+N<# H [.,ED1F^\44G'3) )Q
M^-/KR>]^.7PCTR9K6^\>:%:SIE6BDFF#+M.T@X@(X(QUJ*V^/7P>O+B*UMOB
M!H$UQ,VR*))IR[MZ*# !G@]2* /6)YX[:":XE;;%!%)-(QQPD2,[GGT52:_)
MO]LC_@IM\.O@#;7VC:)K<3>+%A9K2UE6!T:1$^<$;G; =E&=A/)]J^POVH?B
MS;>!/A'JWB/3;E+B*\TW6+>"XA?"[S8E592Q3)4R@].X]37\KO[(7PHU']K+
M]HV3Q?XQN)=?T/3O%>M6,VG7X$UL\7]K-&D;;$W!52!E \P<>I% 'L,__!77
M]NGQ"U_JO@O0/#]WH$*-<032Q,'-N "20NEN">1_%^->C?L[_P#!;/XDW'C*
MST3]H%]+T6RD=8IS:11@AVE\L8,EK:^HX+ ]Z_H6\(_LN_ [0/#]II4?PT\,
MJJV_DS8MIAYB]PW[\<<=L5^1?_!4K]B#X>6GPRU/Q[X!\*Z3H&HV]RK(FEVT
MB2@1J)2P+F0?>4DY;GKB@#]D_!?QCT+XD_#]?%W@V[6^\[38KV%B4P3(1MSL
M9\9SCI[5_-K_ ,%//VN?VG+:?6O!LFD:6O@F&:6*SN C^>PF<Q29/V'&1&D9
M_P!:>IZ=3[E_P2!^.&KZ[%XF\"ZU<W%Q'HMY%I*Q7,@*[8GMOE"JPQ]X^A]N
MM?=__!3?X;^!9?@S/J<GAG3'OV_M!FNFC<RDK%$RDGS,9#$D<=: /Y2?V./V
MK?VD/@O-?R?"'2M,OC<ZW=WT_P!L1FQ>3WMQ<2J,6=Q\HFDD X!P!@=J_J)_
M8-_:E_:B^-5WJ ^,&C:78VT44;VQLD8%BPBW9W65OW9NY]N@K\P/^"-7P\\$
M^*+O7U\0^&]-U81^-]7A07<;N%B76K]%0;9%^4* H'H!7]1FD>"? W@N":YT
M?0M,T."./=/+;I(BK&N.6R[G P.@H [1"2BD]2JD_4@9_6G5Y/>?'3X1:=.U
MM>^/=!MITR&BDFG#+@X(.(".",=:9:_'GX/WMQ%:6GC_ $">YF;;%"DTY=V]
M # !GZF@#U*]NX+"SNKZY;9;VEO-<S-Q\L4,;2.>2!PJD]:_%G]L[_@JUX-^
M#9O_  W\.M8M[KQC'%)]EM+A('1I85V2@[3.W$S(.$/X5]X?M<_&33OAW\']
M7UZVO86@U/2M6M;>X20JK.]H8QL)VG(,J]>^*_F>_8,^!UG^U)\=)?'_ (QE
M36=-L_%.N636&H*9H98FUN0(#LCSM"6VT?O!D-SWP =Q!_P5H_;[OXY]:L?#
MGAY_#T:FX6<Q/O\ LHP"W&E$9R?[U?>G[$O_  58UKXU^*+/P5\2)K2U\0O&
M&GM[:%%4$DIP3%"WWU/\(SC K]=M"_9F^".EZ';:.?AQX;DACMQ!*IMYMLB@
MG((\X<'N!BO-K3]BKX/Z)X[/C?PKX3T#P]<[558[&WF1UPY?@L9 ,Y.?F.3F
M@#ZCNO$^FZ=X=7Q)?3"/3Q:I=/*=HQ&XR#R0/S('O7XF?M@_\%</#'PJO[KP
MQ\,=6M[[Q3;7!MWM;B.%T#O)Y<0RHG;!*G/R?GTKZ/\ ^"D?Q@N/A'\$->T;
M39GMKB70@MO-"^QT*HY!3+#'0=0>E?CA_P $Q/V7+'XX>.+OXG_$>UB\56>L
M6<=U%;ZQ$9HTDC267>#&D9)RXZN>1S[@'/ZA_P %<?V_UTJZ\167AOPZVBQ2
M-LF,3[O*<R-$2/[)(R8TSU//!)ZU]9_L@_\ !9N\\<^)(?"OQSOK'2M6O;N&
MQLH;2.%0]PZQLRDO%;' 'F'HQXK]SK?]FGX%QZ7%I;?#+PRUH(84D@-M/Y;L
MD83+ 7 .>6[]S7\Z_P#P50_9$\-?!W5_"GQ&^'>C6>B>3>2ZM/'I,+1B,1_;
M8P&,H/ "K@ASC(Y]0#^GCPSXKTKQ=HD6N:+.+BSGBWQR94Y/EAQD*6'<=S7X
M^_MV_M[?%7]F_P")GA3PYX8BTTZ'JD+RW\ET%\Q=L8;Y-UO)W)XW#^6-W_@E
M-\;-3^)7P9T6+4[F:>X\N8-YSAWPELH .">A4\].*_-O_@M-'<W'Q!\+VUD7
M2ZEL)!$\>-ZGR>V?\/3ZT ?3WC7_ (+(:-:>!-+M_#&J6US\2)5>*]L6BA:!
M;A@@A4;5D;!<L"3$,?D*^)[_ /X+"?MK>&[UM0\1Z+X?MO#8D9Q<+"=WV=WW
MPMEM+5<F'D_-CTS7V'_P3&_85\%:MX-T3XA>/M.TWQ+/JMBLPM-4MY':&5(E
M8-F-(ANW/G[YY'Y_I_\ M&?LI_!77OA9JVF6W@'PY87'E*B7<=O-O0);RH-N
M97[X/W<\=Z /.OV*O^"@?@3]IC14MGU>.;Q19VT2:K;0K"J17KM&2BA65B-D
MJ'E%ZYP!7Z33W$=M;S7,K;8H(9)Y&XXCB1I'/)QPJD]:_C5_8GN!\(/VI_&_
MANRO/*L9_&J6<-O&=D2QK9V+;54J#C*$X[>E?U%?M!_%>#X>_!V_\32S)&L^
MGW]NDA<K\[6.T8.X<@R XZ9XH ^'/VS/^"HW@3X')>Z!X.UJ&;Q@L<B6EI.D
M#(US$"&5OFE;A@/X#QVSQ7Y0P?\ !6K]O;6C-J^A>'?#LWAY4,Z3M$^_[.@W
M.<#2F&0O3YN_6O,_V5OA5#^UE^T=?>*?$MRNJ:5I?C#4[=K"\4S030M>[54[
M$)VA5XPX_*OZK/"O[,'P3T'0;;1Q\.O#;I'$8I/]&F D4@ @_OAD$<=!0!^-
M_P"QM_P5G\4?%;QKIO@7XJ2V=EKEW(RO!:PHHPDRQ-@M! ?O,.U?OFGB;3D\
M,KXHN)=FG"R^VO*<#$.[;GD@=2!U_$U\N7'[%'P9MO&]OXT\-^#O#OA^\MT*
MK]CMIEDW%D<N&9I!DLF>O4UYI^WG\4)/@Y\"]<TO3Y##+/X:GAMI8FV-&5G+
M!DR1_P \\<@XH ^:/VL?^"J7A/X::E>>#_AGJ\%]XR@N!"MI.D#H3++Y,(RO
MGL,R*PY3IZG-?"UY_P %"O\ @I0NGW'B:V\(^&CX:4?:(K@I)O-K+EX6Q_8Y
M&2@!^_\ 0]:\J_X)J?!SPG\9OB GQ1^)VJ6.M+J%FDALM9620)+$+BX5RT40
MRP:53_K#C;7],]KX6^ 4>D0Z,^F^%I+)+>*![<I<>4ZQIM&1D<8SCD&@#\M/
MV/?^"I\7Q0UP^#?BO?VFG^*X/*M[JUMDB55NY0-J#<D# %L_P@_T_9C5?$RC
MPU+K>ENLF;4SQ,2"#NMS*A.-PYX_ST_DA_X*%_#WP[\)OCEX?\7?#6]M-#BU
M3QE9--%HP:)6A6Y(V,98VXQCHW.!S7]"G[+?C:X\9_L]17MY=O>7"6441>1@
MSD+8.IY&!SMY_P#KT ?FK:_\%6/B9H'QB\5^&?&[:59^$M \1S6/G1B+SA81
MI$=QW6Z L&<@_.>W-8'Q[_X*]>/KO5;S3/V<FT_7)89-\8O8EP;82'+$QV]U
MSY:,>_/?K7Y*_%+P5J7Q$_:XU#POI]W-96NI^.;BSO6BP4*F#=F0%)"PR%X
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MCL=(_P"$<T;5TM[6:W&)#:/'9-N;%E&,[IW ^8\8YK]\U)*@GJ0"?KBOP_\
M^"2GP3M=#\#2>++BTCANM<TRVOVD9"'=S);)DD#!/[K'I^=?N". !Z4 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M7]+OP?\ ^"AW[-7CGPEHUU'\0M/:_&G60OX$$1\B[,*^=$<3G[C@CH.F<=:
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MO;+' 7)Z^E?BU_P2E_;A\)?!.VC^#WBIKU(H-4O9?M +Q6'%Q-&N+AH6@_\
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M^*M*ATF[=+E;2&#;LELY+^S:&7Y50?/&L;9QW[T ?VN_!_\ Y)[X7_[!,/\
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M1Z=OZ"OQ&_;/^//_  V]^T1X7\+> KI=:TJ47&F V3C8ZQF"%"R1%P2P^O\
M*OZ:?V//A1<_"GX"^'= O+=[:ZLM%>&6-P0P;8@P<X/;N/YXH _G6_;LQ_PW
MEIV!_P PU/P_TFS_ ,GWS7]1'[.'_)*/!G_8!M?_ $9)7\NW[=7_ "?CIW_8
M.7_TJLZ_J)_9P_Y)1X,_[ -K_P"C)* .,_;#_P"20ZY_V#-:_P#3>U?S&?\
M!,;_ ).*U/\ ['K7?_3S)7].?[8?_)(=<_[!FM?^F]J_F,_X)C?\G%:G_P!C
MUKO_ *>9* /WQ_;M^ 'QZ^.W@SP]I?P:U?3=,O+-I&N6OR=A1F<C'^F6O.".
MY.:_%F3_ ()7_P#!1UI'8>-?"H#.S#D]"Q(_YCWH?3\*_K&TS_CQM_\ <%7Z
M /PM_8?_ &*?VNO@GKTM[\4O$>B:A927L<Q6S)+^4/*R.=3N?[K?P_A7G_\
MP6X1E^&7A3S#EO\ A-].R>W.JZ1]??N>./K_ $)5_/E_P6]_Y)IX5_['?3O_
M $ZZ10!]&_\ !*( ?"23  _TJVZ?6XK]@*_'_P#X)1_\DDD_Z^K;^=Q7[ 4
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M$;.3]]<9- 'T]_P1,@U@>!],EW8T_P JZVH5/7R7YR6QTQV_7FO+?^"O>/\
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M'4IU![U],6O_  4A^!?BCXC6G@3P-XPT[6KBY0E540B3S%DCC*#$LAX=R/\
M/'0?ML_#*/XS? 37=4A0S2IX7FFME120S/<;1C:/1SVH _EV_81^!'[;'Q$\
M-:=>? CQAH6BZ;-;NUM!?EA*D8A#$,HU6SQ^[P,;17Z0+^QI_P %:%(8?$OP
MGGKG$O\ \T=?(?[!/[6UO^R?\46^&_Q%EMM \/Z9:I EW<E-QEE-Q;E2'\L\
M;$P-W4^U?TO:%^W7^S9K&CV^J0_$&Q>-K>&29@(\*[H"1_K\=<]^U 'X ^+O
M^"5__!0KXI:[HM]\1_&'A75+73=2AO2J\,-DFYB-^N3#/)QQ7[G_ +.WP/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M3#I[D2I;6A8@19B!^>WBZA: /I+6O^"&@?3[A= UC1--U,QG[+=@0 Q2]FZ
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M_;;XD?"B^\9_"W5/ =I>1VUS?:+>:8EP^W8CW,917.>,#C->\44 ?BW^Q_\
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M ,$8A8?%'PSXW\!:KI'A[3])TV&"_M(Q!ON;T1V7G7 R ?GE@F<X&,R<>_\
M0310!Y5\-O -WX+\":;X5NKE+BXLM/%H\ZXVLV[.X8XQCZ]*_)[X^_\ !,'Q
MM\6_V@I?B]I_B[3[+3W^SXL9?*\S]U<B8]?FY Q]:_;:B@#SGX7^#+GP+X2T
M;P]=3K<RZ;IUO9O*F-KM"H4L,=CBO1J** /R8_X*XL5_9?\ '1'7RH__ $AO
M*_)K_@G[^RO\-/C_ .&?%%CXF\/65]JL>G*FFWER%_T6X<VI\T;E/0._<?>(
MK]9O^"N$<DG[+_CI8XWD8Q1X5$9B?]!O.@4$FOC_ /X(\PS10Z_YD4L>;: #
M?&R<XL^/F YH \R\;?\ !$?XSZEJLJ^#_B=I.A^&V?=%I8%OA$9LLO+#@I\O
M3MBOMK]CO_@E+X6^ E\FO>/(M)\4>)+>Y6ZM=3C$6^*3<&=@4!/./7]>O[,+
MT'T'\J6@#.BTVWM-/;3[*-8(1$\<:#[J[EQ7XV?M5_\ !,[QI\?/C?IWQ1TG
MQ;I^FV-G8-:-9SB+S&8M:'<-QSC_ $<_]]"OVDHH \B^"WP[N_AGX'T+PO>W
M27<^E:;'9231XVNR2,Y88XQ@]J]=HHH \%^.'[/GP_\ CEH5WIGB[0K75+B:
MW^SPRW 7$:;2N/F4\8K\"/B;_P $,?'FH>,-2U[X5^.='\(6-U.)+>V06^8H
MP6(4Y*'@$ 5_3C10!_,7X._X(>?%23Q'9ZE\3_B-I/BS3855)[206_[Q R<<
M,W15QT^E?M_^SM^R!\*/V>]'BMO"OABPT[4Y;>--0N[8+_I,R%/WAVHO41IZ
M]!7UK10!'-%'/#+!*H:*:-XI%[-'(I1U^A4D5^7O[7?_  36^&W[0NGZA-H>
MC:7I/B*YA<1:G/Y99)I%(>0[UZEB#UK]1J* /Y6;;_@AA^T3I$LT&A?&32K#
M2I08Q:*+?;Y)!#(?G'4<'BOK/]F__@C)H/@'5+35/B_)HWC>XAE\R5R(<N?,
MW_PJ_<#ISQZ5^^=% '&>"/ ?AKX?Z+9Z'X9TZ+3;"SMEMHH(L;5B1MP48 &
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0!2O].L=3MY+74+6*[MY4,<D4P+(Z-U4@$<'O7B&L_LM_L]^(;E[S6_A-X2U
M*ZDR7GN;.9G;)R<D7"CD\\"O?** /F^#]D']F:VD6:W^#'@N*5#E76QG#*?4
M$W)KVGPWX+\*^#[2*P\,:'8Z+9PC;%;V4;)'&" ,*&9L#  Z]A73T4 %%%%
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M922I9C,P)!)QQWKUY$5%5$ 5$5451T55 "@>P  %.HH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
F**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>img255015816_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img255015816_1.jpg
M_]C_X  02D9)1@ ! @$!2@%*  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" /A"A\# 2(  A$! Q$!_\0
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MGXF_\#-*_P#E-1_PH#P;_P!!/Q-_X&:5_P#*:O<J* /#?^% >#?^@GXF_P#
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M7_RFKW*B@#PW_A0'@W_H)^)O_ S2O_E-1_PH#P;_ -!/Q-_X&:5_\IJ]RHH
M\-_X4!X-_P"@GXF_\#-*_P#E-1_PH#P;_P!!/Q-_X&:5_P#*:O<J* /#?^%
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M-1_PH#P;_P!!/Q-_X&:5_P#*:O<J* /#?^% >#?^@GXF_P# S2O_ )34?\*
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MGXF_\#-*_P#E-1_PH#P;_P!!/Q-_X&:5_P#*:O<J* /#?^% >#?^@GXF_P#
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M7_RFKW*B@#PW_A0'@W_H)^)O_ S2O_E-1_PH#P;_ -!/Q-_X&:5_\IJ]RHH
M\-_X4!X-_P"@GXF_\#-*_P#E-1_PH#P;_P!!/Q-_X&:5_P#*:O<J* /#?^%
M>#?^@GXF_P# S2O_ )34?\* \&_]!/Q-_P"!FE?_ "FKW*B@#PW_ (4!X-_Z
M"?B;_P #-*_^4U'_  H#P;_T$_$W_@9I7_RFKW*B@#PW_A0'@W_H)^)O_ S2
MO_E-1_PH#P;_ -!/Q-_X&:5_\IJ]RHH \-_X4!X-_P"@GXF_\#-*_P#E-1_P
MH#P;_P!!/Q-_X&:5_P#*:O<J* /#?^% >#?^@GXF_P# S2O_ )34?\* \&_]
M!/Q-_P"!FE?_ "FKW*B@#PW_ (4!X-_Z"?B;_P #-*_^4U'_  H#P;_T$_$W
M_@9I7_RFKW*B@#PW_A0'@W_H)^)O_ S2O_E-1_PH#P;_ -!/Q-_X&:5_\IJ]
MRHH \-_X4!X-_P"@GXF_\#-*_P#E-1_PH#P;_P!!/Q-_X&:5_P#*:O<J* /#
M?^% >#?^@GXF_P# S2O_ )34?\* \&_]!/Q-_P"!FE?_ "FKW*B@#PW_ (4!
MX-_Z"?B;_P #-*_^4U'_  H#P;_T$_$W_@9I7_RFKW*B@#PW_A0'@W_H)^)O
M_ S2O_E-1_PH#P;_ -!/Q-_X&:5_\IJ]RHH \-_X4!X-_P"@GXF_\#-*_P#E
M-1_PH#P;_P!!/Q-_X&:5_P#*:O<J* /#?^% >#?^@GXF_P# S2O_ )34?\*
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MGXF_\#-*_P#E-1_PH#P;_P!!/Q-_X&:5_P#*:O<J* /#?^% >#?^@GXF_P#
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MWQX_Z$KPS_X%VW_S6T?V]\>/^A*\,_\ @7;?_-;7N5% 'AO]O?'C_H2O#/\
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M_P"!=M_\UM>Y44 >&_V]\>/^A*\,_P#@7;?_ #6T?V]\>/\ H2O#/_@7;?\
MS6U[E10!X;_;WQX_Z$KPS_X%VW_S6T?V]\>/^A*\,_\ @7;?_-;7N5% 'AO]
MO?'C_H2O#/\ X%VW_P UM']O?'C_ *$KPS_X%VW_ ,UM>Y44 >&_V]\>/^A*
M\,_^!=M_\UM']O?'C_H2O#/_ (%VW_S6U[E10!X;_;WQX_Z$KPS_ .!=M_\
M-;1_;WQX_P"A*\,_^!=M_P#-;7N5% 'AO]O?'C_H2O#/_@7;?_-;1_;WQX_Z
M$KPS_P"!=M_\UM>Y44 >&_V]\>/^A*\,_P#@7;?_ #6T?V]\>/\ H2O#/_@7
M;?\ S6U[E10!X;_;WQX_Z$KPS_X%VW_S6T?V]\>/^A*\,_\ @7;?_-;7N5%
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M1_;WQX_Z$KPS_P"!=M_\UM>Y44 >&_V]\>/^A*\,_P#@7;?_ #6T?V]\>/\
MH2O#/_@7;?\ S6U[E10!X;_;WQX_Z$KPS_X%VW_S6T?V]\>/^A*\,_\ @7;?
M_-;7N5% 'AO]O?'C_H2O#/\ X%VW_P UM']O?'C_ *$KPS_X%VW_ ,UM>Y44
M >&_V]\>/^A*\,_^!=M_\UM']O?'C_H2O#/_ (%VW_S6U[E10!X;_;WQX_Z$
MKPS_ .!=M_\ -;1_;WQX_P"A*\,_^!=M_P#-;7N5% 'AO]O?'C_H2O#/_@7;
M?_-;1_;WQX_Z$KPS_P"!=M_\UM>Y44 >&_V]\>/^A*\,_P#@7;?_ #6T?V]\
M>/\ H2O#/_@7;?\ S6U[E10!X;_;WQX_Z$KPS_X%VW_S6T?V]\>/^A*\,_\
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MWQX_Z$KPS_X%VW_S6T?V]\>/^A*\,_\ @7;?_-;7N5% 'AO]O?'C_H2O#/\
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M_P"!=M_\UM>Y44 >&_V]\>/^A*\,_P#@7;?_ #6T?V]\>/\ H2O#/_@7;?\
MS6U[E10!X;_;WQX_Z$KPS_X%VW_S6T?V]\>/^A*\,_\ @7;?_-;7N5% 'AO]
MO?'C_H2O#/\ X%VW_P UM']O?'C_ *$KPS_X%VW_ ,UM>Y44 >&_V]\>/^A*
M\,_^!=M_\UM']O?'C_H2O#/_ (%VW_S6U[E10!X;_;WQX_Z$KPS_ .!=M_\
M-;1_;WQX_P"A*\,_^!=M_P#-;7N5% 'AO]O?'C_H2O#/_@7;?_-;1_;WQX_Z
M$KPS_P"!=M_\UM>Y44 >&_V]\>/^A*\,_P#@7;?_ #6T?V]\>/\ H2O#/_@7
M;?\ S6U[E10!X;_;WQX_Z$KPS_X%VW_S6T?V]\>/^A*\,_\ @7;?_-;7N5%
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M1_;WQX_Z$KPS_P"!=M_\UM>Y44 >&_V]\>/^A*\,_P#@7;?_ #6T?V]\>/\
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M>/\ H2O#/_@7;?\ S6U[E10!X;_;WQX_Z$KPS_X%VW_S6T?V]\>/^A*\,_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MKYG_ &BO^9/_ .Y@_P#<'7TQ7S/^T5_S)_\ W,'_ +@Z .F^ '_(FZG_ -C-
M>?\ IJT:O<J\-^ '_(FZG_V,UY_Z:M&KW*@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^9_P!HK_F3
M_P#N8/\ W!U],5\S_M%?\R?_ -S!_P"X.@#IO@!_R)NI_P#8S7G_ *:M&KW*
MO#?@!_R)NI_]C->?^FK1J]RH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M8E%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M+77%\/\ ] 5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M"I&DVFM?\$^?VK+.]19(8?A9J&K(K+O N] U+3-=L' )&&BOM.MY$;/R.BN
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M?_ ;4/\ Y#H ]"HKSW_A:WP^_P"AEM?_  &U#_Y#H_X6M\/O^AEM?_ ;4/\
MY#H ]"HKSW_A:WP^_P"AEM?_  &U#_Y#H_X6M\/O^AEM?_ ;4/\ Y#H ]"HK
MSW_A:WP^_P"AEM?_  &U#_Y#H_X6M\/O^AEM?_ ;4/\ Y#H ]"HKSW_A:WP^
M_P"AEM?_  &U#_Y#H_X6M\/O^AEM?_ ;4/\ Y#H ]"HKSW_A:WP^_P"AEM?_
M  &U#_Y#H_X6M\/O^AEM?_ ;4/\ Y#H ]"HKSW_A:WP^_P"AEM?_  &U#_Y#
MH_X6M\/O^AEM?_ ;4/\ Y#H ]"HKSW_A:WP^_P"AEM?_  &U#_Y#H_X6M\/O
M^AEM?_ ;4/\ Y#H ]"HKSW_A:WP^_P"AEM?_  &U#_Y#H_X6M\/O^AEM?_ ;
M4/\ Y#H ]"HKSW_A:WP^_P"AEM?_  &U#_Y#H_X6M\/O^AEM?_ ;4/\ Y#H
M]"HKSW_A:WP^_P"AEM?_  &U#_Y#H_X6M\/O^AEM?_ ;4/\ Y#H ]"HKSW_A
M:WP^_P"AEM?_  &U#_Y#H_X6M\/O^AEM?_ ;4/\ Y#H ]"HKSW_A:WP^_P"A
MEM?_  &U#_Y#H_X6M\/O^AEM?_ ;4/\ Y#H ]"HKSW_A:WP^_P"AEM?_  &U
M#_Y#H_X6M\/O^AEM?_ ;4/\ Y#H ]"HKSW_A:WP^_P"AEM?_  &U#_Y#H_X6
MM\/O^AEM?_ ;4/\ Y#H ]"HKSW_A:WP^_P"AEM?_  &U#_Y#H_X6M\/O^AEM
M?_ ;4/\ Y#H ]"HKSW_A:WP^_P"AEM?_  &U#_Y#H_X6M\/O^AEM?_ ;4/\
MY#H ]"HKSW_A:WP^_P"AEM?_  &U#_Y#H_X6M\/O^AEM?_ ;4/\ Y#H ]"HK
MSW_A:WP^_P"AEM?_  &U#_Y#H_X6M\/O^AEM?_ ;4/\ Y#H ]"HKSW_A:WP^
M_P"AEM?_  &U#_Y#H_X6M\/O^AEM?_ ;4/\ Y#H ]"HKSW_A:WP^_P"AEM?_
M  &U#_Y#H_X6M\/O^AEM?_ ;4/\ Y#H ]"HKSW_A:WP^_P"AEM?_  &U#_Y#
MH_X6M\/O^AEM?_ ;4/\ Y#H ]"HKSW_A:WP^_P"AEM?_  &U#_Y#H_X6M\/O
M^AEM?_ ;4/\ Y#H ]"HKSW_A:WP^_P"AEM?_  &U#_Y#H_X6M\/O^AEM?_ ;
M4/\ Y#H ]"HKSW_A:WP^_P"AEM?_  &U#_Y#H_X6M\/O^AEM?_ ;4/\ Y#H
M]"HKSW_A:WP^_P"AEM?_  &U#_Y#H_X6M\/O^AEM?_ ;4/\ Y#H ]"HKSW_A
M:WP^_P"AEM?_  &U#_Y#H_X6M\/O^AEM?_ ;4/\ Y#H ]"HKSW_A:WP^_P"A
MEM?_  &U#_Y#H_X6M\/O^AEM?_ ;4/\ Y#H ]"HKSW_A:WP^_P"AEM?_  &U
M#_Y#H_X6M\/O^AEM?_ ;4/\ Y#H ]"HKSW_A:WP^_P"AEM?_  &U#_Y#H_X6
MM\/O^AEM?_ ;4/\ Y#H ]"HKSW_A:WP^_P"AEM?_  &U#_Y#H_X6M\/O^AEM
M?_ ;4/\ Y#H ]"HKSW_A:WP^_P"AEM?_  &U#_Y#H_X6M\/O^AEM?_ ;4/\
MY#H ]"HKSW_A:WP^_P"AEM?_  &U#_Y#H_X6M\/O^AEM?_ ;4/\ Y#H ]"HK
MSW_A:WP^_P"AEM?_  &U#_Y#H_X6M\/O^AEM?_ ;4/\ Y#H ]"HKSW_A:WP^
M_P"AEM?_  &U#_Y#H_X6M\/O^AEM?_ ;4/\ Y#H ]"HKSW_A:WP^_P"AEM?_
M  &U#_Y#H_X6M\/O^AEM?_ ;4/\ Y#H ]"HKSW_A:WP^_P"AEM?_  &U#_Y#
MH_X6M\/O^AEM?_ ;4/\ Y#H ]"HKSW_A:WP^_P"AEM?_  &U#_Y#H_X6M\/O
M^AEM?_ ;4/\ Y#H ]"HKSW_A:WP^_P"AEM?_  &U#_Y#H_X6M\/O^AEM?_ ;
M4/\ Y#H ]"HKSW_A:WP^_P"AEM?_  &U#_Y#H_X6M\/O^AEM?_ ;4/\ Y#H
M]"HKSW_A:WP^_P"AEM?_  &U#_Y#H_X6M\/O^AEM?_ ;4/\ Y#H ]"HKSW_A
M:WP^_P"AEM?_  &U#_Y#H_X6M\/O^AEM?_ ;4/\ Y#H ]"HKSW_A:WP^_P"A
MEM?_  &U#_Y#H_X6M\/O^AEM?_ ;4/\ Y#H ]"HKSW_A:WP^_P"AEM?_  &U
M#_Y#H_X6M\/O^AEM?_ ;4/\ Y#H ]"HKSW_A:WP^_P"AEM?_  &U#_Y#H_X6
MM\/O^AEM?_ ;4/\ Y#H ]"HKSW_A:WP^_P"AEM?_  &U#_Y#H_X6M\/O^AEM
M?_ ;4/\ Y#H ]"HKSW_A:WP^_P"AEM?_  &U#_Y#H_X6M\/O^AEM?_ ;4/\
MY#H ]"HKSW_A:WP^_P"AEM?_  &U#_Y#H_X6M\/O^AEM?_ ;4/\ Y#H ]"HK
MSW_A:WP^_P"AEM?_  &U#_Y#H_X6M\/O^AEM?_ ;4/\ Y#H ]"HKSW_A:WP^
M_P"AEM?_  &U#_Y#H_X6M\/O^AEM?_ ;4/\ Y#H ]"HKSW_A:WP^_P"AEM?_
M  &U#_Y#H_X6M\/O^AEM?_ ;4/\ Y#H ]"HKSW_A:WP^_P"AEM?_  &U#_Y#
MH_X6M\/O^AEM?_ ;4/\ Y#H ]"HKSW_A:WP^_P"AEM?_  &U#_Y#H_X6M\/O
M^AEM?_ ;4/\ Y#H ]"HKSW_A:WP^_P"AEM?_  &U#_Y#H_X6M\/O^AEM?_ ;
M4/\ Y#H ]"HKSW_A:WP^_P"AEM?_  &U#_Y#H_X6M\/O^AEM?_ ;4/\ Y#H
M]"HKSW_A:WP^_P"AEM?_  &U#_Y#H_X6M\/O^AEM?_ ;4/\ Y#H ]"HKSW_A
M:WP^_P"AEM?_  &U#_Y#H_X6M\/O^AEM?_ ;4/\ Y#H ]"HKSW_A:WP^_P"A
MEM?_  &U#_Y#H_X6M\/O^AEM?_ ;4/\ Y#H ]"HKSW_A:WP^_P"AEM?_  &U
M#_Y#H_X6M\/O^AEM?_ ;4/\ Y#H ]"HKSW_A:WP^_P"AEM?_  &U#_Y#H_X6
MM\/O^AEM?_ ;4/\ Y#H ]"HKSW_A:WP^_P"AEM?_  &U#_Y#H_X6M\/O^AEM
M?_ ;4/\ Y#H ]"HKSW_A:WP^_P"AEM?_  &U#_Y#H_X6M\/O^AEM?_ ;4/\
MY#H ]"HKSW_A:WP^_P"AEM?_  &U#_Y#H_X6M\/O^AEM?_ ;4/\ Y#H ]"HK
MSW_A:WP^_P"AEM?_  &U#_Y#H_X6M\/O^AEM?_ ;4/\ Y#H ]"HKSW_A:WP^
M_P"AEM?_  &U#_Y#H_X6M\/O^AEM?_ ;4/\ Y#H ]"HKSW_A:WP^_P"AEM?_
M  &U#_Y#H_X6M\/O^AEM?_ ;4/\ Y#H ]"HKSW_A:WP^_P"AEM?_  &U#_Y#
MH_X6M\/O^AEM?_ ;4/\ Y#H ]"HKSW_A:WP^_P"AEM?_  &U#_Y#H_X6M\/O
M^AEM?_ ;4/\ Y#H ]"HKSW_A:WP^_P"AEM?_  &U#_Y#H_X6M\/O^AEM?_ ;
M4/\ Y#H ]"HKSW_A:WP^_P"AEM?_  &U#_Y#H_X6M\/O^AEM?_ ;4/\ Y#H
M]"HKSW_A:WP^_P"AEM?_  &U#_Y#H_X6M\/O^AEM?_ ;4/\ Y#H ]"HKSW_A
M:WP^_P"AEM?_  &U#_Y#H_X6M\/O^AEM?_ ;4/\ Y#H ]"HKSW_A:WP^_P"A
MEM?_  &U#_Y#H_X6M\/O^AEM?_ ;4/\ Y#H ]"HKSW_A:WP^_P"AEM?_  &U
M#_Y#H_X6M\/O^AEM?_ ;4/\ Y#H ]"HKSW_A:WP^_P"AEM?_  &U#_Y#H_X6
MM\/O^AEM?_ ;4/\ Y#H ]"HKSW_A:WP^_P"AEM?_  &U#_Y#H_X6M\/O^AEM
M?_ ;4/\ Y#H ]"HKSW_A:WP^_P"AEM?_  &U#_Y#H_X6M\/O^AEM?_ ;4/\
MY#H ]"HKSW_A:WP^_P"AEM?_  &U#_Y#H_X6M\/O^AEM?_ ;4/\ Y#H ]"HK
MSW_A:WP^_P"AEM?_  &U#_Y#H_X6M\/O^AEM?_ ;4/\ Y#H ]"HKSW_A:WP^
M_P"AEM?_  &U#_Y#H_X6M\/O^AEM?_ ;4/\ Y#H ]"HKSW_A:WP^_P"AEM?_
M  &U#_Y#H_X6M\/O^AEM?_ ;4/\ Y#H ]"HKSW_A:WP^_P"AEM?_  &U#_Y#
MH_X6M\/O^AEM?_ ;4/\ Y#H ]"HKSW_A:WP^_P"AEM?_  &U#_Y#H_X6M\/O
M^AEM?_ ;4/\ Y#H ]"HKSW_A:WP^_P"AEM?_  &U#_Y#H_X6M\/O^AEM?_ ;
M4/\ Y#H ]"HKSW_A:WP^_P"AEM?_  &U#_Y#H_X6M\/O^AEM?_ ;4/\ Y#H
M]"HKSW_A:WP^_P"AEM?_  &U#_Y#H_X6M\/O^AEM?_ ;4/\ Y#H ]"HKSW_A
M:WP^_P"AEM?_  &U#_Y#H_X6M\/O^AEM?_ ;4/\ Y#H ]"HKSW_A:WP^_P"A
MEM?_  &U#_Y#H_X6M\/O^AEM?_ ;4/\ Y#H ]"HKSW_A:WP^_P"AEM?_  &U
M#_Y#H_X6M\/O^AEM?_ ;4/\ Y#H ]"HKSW_A:WP^_P"AEM?_  &U#_Y#H_X6
MM\/O^AEM?_ ;4/\ Y#H ]"HKSW_A:WP^_P"AEM?_  &U#_Y#H_X6M\/O^AEM
M?_ ;4/\ Y#H ]"HKSW_A:WP^_P"AEM?_  &U#_Y#H_X6M\/O^AEM?_ ;4/\
MY#H ]"HKSW_A:WP^_P"AEM?_  &U#_Y#H_X6M\/O^AEM?_ ;4/\ Y#H ]"HK
MSW_A:WP^_P"AEM?_  &U#_Y#H_X6M\/O^AEM?_ ;4/\ Y#H ]"HKSW_A:WP^
M_P"AEM?_  &U#_Y#H_X6M\/O^AEM?_ ;4/\ Y#H ]"HKSW_A:WP^_P"AEM?_
M  &U#_Y#H_X6M\/O^AEM?_ ;4/\ Y#H ]"HKSW_A:WP^_P"AEM?_  &U#_Y#
MH_X6M\/O^AEM?_ ;4/\ Y#H ]"HKSW_A:WP^_P"AEM?_  &U#_Y#H_X6M\/O
M^AEM?_ ;4/\ Y#H ]"HKSW_A:WP^_P"AEM?_  &U#_Y#H_X6M\/O^AEM?_ ;
M4/\ Y#H ]"HKSW_A:WP^_P"AEM?_  &U#_Y#H_X6M\/O^AEM?_ ;4/\ Y#H
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MW_0RVO\ X#:A_P#(='_"UOA]_P!#+:_^ VH?_(= 'H5%>>_\+6^'W_0RVO\
MX#:A_P#(='_"UOA]_P!#+:_^ VH?_(= 'H5%>>_\+6^'W_0RVO\ X#:A_P#(
M='_"UOA]_P!#+:_^ VH?_(= 'H5%>>_\+6^'W_0RVO\ X#:A_P#(='_"UOA]
M_P!#+:_^ VH?_(= 'H5%>>_\+6^'W_0RVO\ X#:A_P#(='_"UOA]_P!#+:_^
M VH?_(= 'H5%>>_\+6^'W_0RVO\ X#:A_P#(='_"UOA]_P!#+:_^ VH?_(=
M'H5%>>_\+6^'W_0RVO\ X#:A_P#(='_"UOA]_P!#+:_^ VH?_(= 'H5%>>_\
M+6^'W_0RVO\ X#:A_P#(='_"UOA]_P!#+:_^ VH?_(= 'H5%>>_\+6^'W_0R
MVO\ X#:A_P#(='_"UOA]_P!#+:_^ VH?_(= 'H5%>>_\+6^'W_0RVO\ X#:A
M_P#(='_"UOA]_P!#+:_^ VH?_(= 'H5%>>_\+6^'W_0RVO\ X#:A_P#(='_"
MUOA]_P!#+:_^ VH?_(= 'H5%>>_\+6^'W_0RVO\ X#:A_P#(='_"UOA]_P!#
M+:_^ VH?_(= 'H5%>>_\+6^'W_0RVO\ X#:A_P#(='_"UOA]_P!#+:_^ VH?
M_(= 'H5%>>_\+6^'W_0RVO\ X#:A_P#(='_"UOA]_P!#+:_^ VH?_(= 'H5%
M>>_\+6^'W_0RVO\ X#:A_P#(='_"UOA]_P!#+:_^ VH?_(= 'H5%>>_\+6^'
MW_0RVO\ X#:A_P#(='_"UOA]_P!#+:_^ VH?_(= 'H5%>>_\+6^'W_0RVO\
MX#:A_P#(='_"UOA]_P!#+:_^ VH?_(= 'H5%>>_\+6^'W_0RVO\ X#:A_P#(
M='_"UOA]_P!#+:_^ VH?_(= 'H5%>>_\+6^'W_0RVO\ X#:A_P#(='_"UOA]
M_P!#+:_^ VH?_(= 'H5%>>_\+6^'W_0RVO\ X#:A_P#(='_"UOA]_P!#+:_^
M VH?_(= 'H5%>>_\+6^'W_0RVO\ X#:A_P#(='_"UOA]_P!#+:_^ VH?_(=
M'H5%>>_\+6^'W_0RVO\ X#:A_P#(='_"UOA]_P!#+:_^ VH?_(= 'H5%>>_\
M+6^'W_0RVO\ X#:A_P#(='_"UOA]_P!#+:_^ VH?_(= 'H5%>>_\+6^'W_0R
MVO\ X#:A_P#(='_"UOA]_P!#+:_^ VH?_(= 'H5%>>_\+6^'W_0RVO\ X#:A
M_P#(='_"UOA]_P!#+:_^ VH?_(= 'H5%>>_\+6^'W_0RVO\ X#:A_P#(='_"
MUOA]_P!#+:_^ VH?_(= 'H5%>>_\+6^'W_0RVO\ X#:A_P#(==;HVMZ7X@LE
MU'1[Q+ZR:22%9XTEC4R1$"1=LT<;Y4D G;@]B: -6BBB@ HHHH *^9_VBO\
MF3_^Y@_]P=?3%?,_[17_ #)__<P?^X.@#IO@!_R)NI_]C->?^FK1J]RKPWX
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M+X\O]+GFM[F?3([RVL=(T/2+&YNK6&ZOH?#^@Z0=2GCA;4FNQ:VBV^U^V/\
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MI;J;RH(QF2XN[RXN+Z_O)WEO-0U"YNK^^GN+RYGGD /YQ?\ @E5XLTG]EO\
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M_P %]O\ _$4?\*^\$?\ 0JZ'_P""^W_^(KL** ./_P"%?>"/^A5T/_P7V_\
M\11_PK[P1_T*NA_^"^W_ /B*["B@#C_^%?>"/^A5T/\ \%]O_P#$4?\ "OO!
M'_0JZ'_X+[?_ .(KL** ./\ ^%?>"/\ H5=#_P#!?;__ !%'_"OO!'_0JZ'_
M ."^W_\ B*["B@#C_P#A7W@C_H5=#_\ !?;_ /Q%'_"OO!'_ $*NA_\ @OM_
M_B*["B@#C_\ A7W@C_H5=#_\%]O_ /$4?\*^\$?]"KH?_@OM_P#XBNPHH X_
M_A7W@C_H5=#_ /!?;_\ Q%'_  K[P1_T*NA_^"^W_P#B*["B@#C_ /A7W@C_
M *%70_\ P7V__P 11_PK[P1_T*NA_P#@OM__ (BNPHH X_\ X5]X(_Z%70__
M  7V_P#\11_PK[P1_P!"KH?_ (+[?_XBNPHH X__ (5]X(_Z%70__!?;_P#Q
M%'_"OO!'_0JZ'_X+[?\ ^(KL** ./_X5]X(_Z%70_P#P7V__ ,11_P *^\$?
M]"KH?_@OM_\ XBNPHH X_P#X5]X(_P"A5T/_ ,%]O_\ $4?\*^\$?]"KH?\
MX+[?_P"(KL** ./_ .%?>"/^A5T/_P %]O\ _$4?\*^\$?\ 0JZ'_P""^W_^
M(KL** ./_P"%?>"/^A5T/_P7V_\ \11_PK[P1_T*NA_^"^W_ /B*["B@#C_^
M%?>"/^A5T/\ \%]O_P#$4?\ "OO!'_0JZ'_X+[?_ .(KL** ./\ ^%?>"/\
MH5=#_P#!?;__ !%'_"OO!'_0JZ'_ ."^W_\ B*["B@#C_P#A7W@C_H5=#_\
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M ,%]O_\ $4?\*^\$?]"KH?\ X+[?_P"(KL** ./_ .%?>"/^A5T/_P %]O\
M_$4?\*^\$?\ 0JZ'_P""^W_^(KL** ./_P"%?>"/^A5T/_P7V_\ \11_PK[P
M1_T*NA_^"^W_ /B*["B@#C_^%?>"/^A5T/\ \%]O_P#$4?\ "OO!'_0JZ'_X
M+[?_ .(KL** ./\ ^%?>"/\ H5=#_P#!?;__ !%'_"OO!'_0JZ'_ ."^W_\
MB*["B@#C_P#A7W@C_H5=#_\ !?;_ /Q%'_"OO!'_ $*NA_\ @OM__B*["B@#
MC_\ A7W@C_H5=#_\%]O_ /$4?\*^\$?]"KH?_@OM_P#XBNPHH X__A7W@C_H
M5=#_ /!?;_\ Q%'_  K[P1_T*NA_^"^W_P#B*["B@#C_ /A7W@C_ *%70_\
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MB@#C_P#A7W@C_H5=#_\ !?;_ /Q%'_"OO!'_ $*NA_\ @OM__B*["B@#C_\
MA7W@C_H5=#_\%]O_ /$4?\*^\$?]"KH?_@OM_P#XBNPHH X__A7W@C_H5=#_
M /!?;_\ Q%'_  K[P1_T*NA_^"^W_P#B*["B@#C_ /A7W@C_ *%70_\ P7V_
M_P 11_PK[P1_T*NA_P#@OM__ (BNPHH X_\ X5]X(_Z%70__  7V_P#\11_P
MK[P1_P!"KH?_ (+[?_XBNPHH X__ (5]X(_Z%70__!?;_P#Q%'_"OO!'_0JZ
M'_X+[?\ ^(KL** ./_X5]X(_Z%70_P#P7V__ ,11_P *^\$?]"KH?_@OM_\
MXBNPHH X_P#X5]X(_P"A5T/_ ,%]O_\ $4?\*^\$?]"KH?\ X+[?_P"(KL**
M ./_ .%?>"/^A5T/_P %]O\ _$4?\*^\$?\ 0JZ'_P""^W_^(KL** ./_P"%
M?>"/^A5T/_P7V_\ \11_PK[P1_T*NA_^"^W_ /B*["B@#C_^%?>"/^A5T/\
M\%]O_P#$4?\ "OO!'_0JZ'_X+[?_ .(KL** ./\ ^%?>"/\ H5=#_P#!?;__
M !%'_"OO!'_0JZ'_ ."^W_\ B*["B@#C_P#A7W@C_H5=#_\ !?;_ /Q%'_"O
MO!'_ $*NA_\ @OM__B*["B@#C_\ A7W@C_H5=#_\%]O_ /$4?\*^\$?]"KH?
M_@OM_P#XBNPHH X__A7W@C_H5=#_ /!?;_\ Q%'_  K[P1_T*NA_^"^W_P#B
M*["B@#C_ /A7W@C_ *%70_\ P7V__P 11_PK[P1_T*NA_P#@OM__ (BNPHH
MX_\ X5]X(_Z%70__  7V_P#\11_PK[P1_P!"KH?_ (+[?_XBNPHH X__ (5]
MX(_Z%70__!?;_P#Q%'_"OO!'_0JZ'_X+[?\ ^(KL** ./_X5]X(_Z%70_P#P
M7V__ ,11_P *^\$?]"KH?_@OM_\ XBNPHH X_P#X5]X(_P"A5T/_ ,%]O_\
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M /Q%=A10!Q__  K[P1_T*NA_^"^W_P#B*/\ A7W@C_H5=#_\%]O_ /$5V%%
M''_\*^\$?]"KH?\ X+[?_P"(H_X5]X(_Z%70_P#P7V__ ,17844 <?\ \*^\
M$?\ 0JZ'_P""^W_^(H_X5]X(_P"A5T/_ ,%]O_\ $5V%% ''_P#"OO!'_0JZ
M'_X+[?\ ^(H_X5]X(_Z%70__  7V_P#\17844 <?_P *^\$?]"KH?_@OM_\
MXBC_ (5]X(_Z%70__!?;_P#Q%=A10!Q__"OO!'_0JZ'_ ."^W_\ B*/^%?>"
M/^A5T/\ \%]O_P#$5V%% ''_ /"OO!'_ $*NA_\ @OM__B*/^%?>"/\ H5=#
M_P#!?;__ !%=A10!Q_\ PK[P1_T*NA_^"^W_ /B*/^%?>"/^A5T/_P %]O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MVH%S>>*K7P/IOA'QU<&0LS^9X_\ !*>'/&N"[O( -? 65VE4"1BQ_&'XZ_\
M!J/^P'\0#=W_ ,%OB#\<OV?=5E\S[)IMOKVF?%+P-9[V+)NT;QI9+XUN?*R$
M3=\28]T8Q)OE/FU_4%10!_GN_'?_ (--?VVO WVR_P#@/\:/@?\ 'K2;?S?(
MT[69-?\ @[XYO\;C!]FT75X/%G@J/S%4K-]L^)-KY,KQ+']HB,L\/XP_'?\
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M&;@E (Z_9WX%?\'>WA"Y-G8?M,_L>^)-&">6+_Q7\"O'NF>)C<;F E-G\/\
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MBBB@ HHHH *^9_VBO^9/_P"Y@_\ <'7TQ7S/^T5_S)__ ','_N#H Z;X ?\
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MI9W<A555!+,S$@*J@$DD@  DG%?"/QS_ ."H'_!/7]FXW<'QC_; ^!?AK5[
MR"^\+:7XVL/'/CBT\LL&^T^ O '_  E'C2$,Z21Q&305$TL<L,)>6-T7_++^
M-_[;_P"V'^TFUTOQX_:;^.'Q3L+QI#)H'BWXD>*;_P )Q"8YECL?!PU*+PKI
ML$AP7M].T>U@.!F/@8^6Z /]$;XX_P#!UQ^P#X!-W8_!KX>_';X^ZK"7^R:C
M;>'M)^&/@B\"@A2VL^,]3/C.V,C;=H?X<2 1[V<JZK%)^-?QR_X.T?VT/&AO
M;+X$? KX&_ W2KG>+>_\1R>)?C'XTT]=Q\HVVL7EQX&\'RNJD"5KWX>722,
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MJ\-^ '_(FZG_ -C->?\ IJT:O<J "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_"/9>(_''AM?A-X5O(&('VJQ\4?%:Z\%Z#J%JN3NFT_4+I=R/&NZ5&C'[)?
MS_@TQ_;6\;&SO?CM\;_@;\"])N0IN+#0?^$C^,/C?3_^>@N=&T^U\&>#92 1
MY?V+XC70=@X<PJ$:3_0<HH _EV^!O_!J'^P1X"%E??&GXE?'7X^:M#L^V:>=
M;T;X6^!KW:%WXT7PEIUWXTM?,?=_J_B2^V,J@^=3,_[)? O_ ();_P#!._\
M9M%G+\'OV/?@;X>U33S$;'Q1K?@VT^(/CBS,(78;;Q[\1F\6>-(2S*DDWEZ\
MOVB6..:?S)8T=?O>B@!L<:1(D42)''&BQQQQJ$2-$ 5$1% 5450%55 "@
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M4 ?XZ_QR_8F_:]_9HDN1\>_V:?C9\*;.U9E;7?&'PZ\3:;X5GV/Y;/I_B_\
ML^3PMJD(D(3S]-UB[@W$*),D9^7Z_P!L:2-)4>*5$DCD1HY(Y%#I(C@JZ.C
MJR,I*LK A@2""#7P#\=?^"5?_!.C]I,WD_Q?_8\^".N:KJ'F?;O$WAWPI'\-
M_&EX96+,UUXX^&<_@_QA.X8LT<DNN,\+/(T3(9'+ '^73\"OV\/VS_V939Q?
M ;]J#XW?#+3+'RQ!X9\._$+Q$O@MEB8-$EUX&OKV\\'7R1'(CCOM#N$17D15
M"22*W[/? K_@Z:_X*2_#(V=E\5;7X+?M%Z3'Y:7ESXS\"+X'\730QMD_8M;^
M%EYX1\/6URZ?NVN+_P %ZNI #M"TI:1OW8^._P#P:<?L/^.C>7_P*^,/QQ^
MFK7)E-OINIW&A?%_P+IX8$PBWT77+;PUXUF$;G][]L^)5R9HE1%,,@>:3\8?
MCM_P:A_MZ^ #>W_P2^)/P._:!TB$R_8].&L:K\*?'5Z$!:(G1?%UI>>"K4S
M!,2?$IQ'*P#'RLS  _63X$?\'<'[+/BHVEC^T/\ LU_&/X.WTX2&76/AYKGA
MCXR>%X)AP]W?G41\,/$ME92*I=8=-\/^([N"62.V*W$:O?#]H/@5_P %F?\
M@F'^T4;.W^'O[8WPDT[6+T(D/AWXGZE??!G7WNV"[M.MM/\ BO8>#CJMZCL8
MPFB2:G%<E'DLIKF >:?\UWXZ_P#!,7_@H+^S4+N?XS?LA?'+PMI-AYGVWQ3I
MW@N_\:^!K7R@6;SO'O@/_A)_!:90-)'G7OWL<<LD6](I&3X3H _VNM,U33-;
MT^TU;1M1L-7TJ_A6XL=3TR[M[_3[VW?.R>TO+626VN87P=LL,CHV#AC5ZO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'\(?#_PU:X^S>'O!'AK1?"FAV^!M'D:3H-E86$6% 4>7;K@#'2NOHH ****
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M(02N6)%YHGQ1LO%?B*YMUW9C@L?&VDE-J@2F,%#^,'QV_P"#2#]JCPJM]?\
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M9LII68PFQBVQ+^SWP(_X.??^"87Q9-E9>/\ 7_BS^SKK%P8H)8_BE\.KW6M
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M^BI:E_WZO?\ Y84?\*X^(G_14M2_[]7O_P L* /<J*\-_P"%<?$3_HJ6I?\
M?J]_^6%'_"N/B)_T5+4O^_5[_P#+"@#W*BO#?^%<?$3_ **EJ7_?J]_^6%'_
M  KCXB?]%2U+_OU>_P#RPH ]RHKPW_A7'Q$_Z*EJ7_?J]_\ EA1_PKCXB?\
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M7_?J]_\ EA1_PKCXB?\ 14M2_P"_5[_\L* /<J*\-_X5Q\1/^BI:E_WZO?\
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MJ7_?J]_^6%'_  KCXB?]%2U+_OU>_P#RPH ]RHKPW_A7'Q$_Z*EJ7_?J]_\
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M^BI:E_WZO?\ Y84?\*X^(G_14M2_[]7O_P L* /<J*\-_P"%<?$3_HJ6I?\
M?J]_^6%'_"N/B)_T5+4O^_5[_P#+"@#W*BO#?^%<?$3_ **EJ7_?J]_^6%'_
M  KCXB?]%2U+_OU>_P#RPH ]RHKPW_A7'Q$_Z*EJ7_?J]_\ EA1_PKCXB?\
M14M2_P"_5[_\L* /<J*\-_X5Q\1/^BI:E_WZO?\ Y84?\*X^(G_14M2_[]7O
M_P L* /<J*\-_P"%<?$3_HJ6I?\ ?J]_^6%'_"N/B)_T5+4O^_5[_P#+"@#W
M*BO#?^%<?$3_ **EJ7_?J]_^6%'_  KCXB?]%2U+_OU>_P#RPH ]RHKPW_A7
M'Q$_Z*EJ7_?J]_\ EA39/AY\08D>67XJZA''&C2222)>(D:("SN[MJ(54506
M9F("@$D@"@#W2BOQC_:._P""G?[#_P"RO]NM/BM_P4$\ S>)+#S8YO!'PXO=
M4^+?C6*]CR%T[4/#WPTG\477A^\E; C_ .$H.AVRJRS3W,,!\T?@S^T)_P '
M4/A[19+W2OV7OA?\4/'LJ^9!;>,/C-KUG\/])CF3<%O+?P=X3U3QKJVLZ?*P
M#0QWGB;PE?&)@\\%M*#  #]#O^#J?XZ:Y\./V"? /PGT*[:S7X\?&K2=.\4[
M)Y8VO_!OP[T;4?&<^EF*,HLL<WC*+P/?2-,[Q(NG>6;>1YTEM_\ .L))))))
M)R2>I)Y)_.OT2_;M_P""H_[6W_!1.;PK!^T/XG\-S>&? NH:UJG@SP9X1\.1
MZ1H?AZ]\00V5MJLUO?ZG>:[XLOC<VVFV,!CU?Q+J$*+;J\<4<KR._P"=E !1
M110 4I))R<DGN<G/;O\ 2DK^G'_@VY_X)Y_#']L?XD_M">/OC5\.?"'C_P #
M_"3PGX'TO1;+Q[H)\2>'!XU\;ZWJU_:R1Z)=RIH^K3V6@^#]16]AU&WOX;6'
M5K02VP^W0N0#^;?P=X&\:_$/7+;PQ\/_  ?XI\<^);W/V/P]X.\/ZMXFUR[P
MRJ?LVDZ+:7M_/AF53Y5N_P S*.I&?U7^!W_!!G_@JO\ 'C['=:-^R=XP^'>B
MW01I-;^-^HZ%\'UL8W("R77AKQOJ.F>.Y!SDQV'A*]F51N>)05)_TFOA[^S+
M:?"/0T\,_"F\\*_#'PW&(A'X?^'O@O2_!>AH(%9( FD^&QIM@HA1F2(+;@1J
MS*F 2*[S_A7'Q$_Z*EJ7_?J]_P#EA0!_%Y\"_P#@T/\ C-J_V.^_:2_:U^''
M@6(;)KOP]\&?!?B/XE7T\;9)L_\ A)O&4_PRL]*ND4KYMS%X<\0VRRI)#"ES
M$4NS^R/P-_X-@_\ @E_\*!97?CSPY\6OVA]7M]DTTOQ3^)-_HVB->*HR]OH'
MPHM/AU&;%9 7BT_6+W7$93Y5[->QY!_;+_A7'Q$_Z*EJ7_?J]_\ EA1_PKCX
MB?\ 14M2_P"_5[_\L* .<^"/[&G[)G[-D-M'\!/V;?@G\);BVB$(UCP/\-O"
MFA^);H ;?,U3Q5:Z6OB36+DH%C:[U75;VZ>-$C:8I&BK]*UX;_PKCXB?]%2U
M+_OU>_\ RPH_X5Q\1/\ HJ6I?]^KW_Y84 >Y45X;_P *X^(G_14M2_[]7O\
M\L*/^%<?$3_HJ6I?]^KW_P"6% 'N5%>&_P#"N/B)_P!%2U+_ +]7O_RPH_X5
MQ\1/^BI:E_WZO?\ Y84 >Y45X;_PKCXB?]%2U+_OU>__ "PH_P"%<?$3_HJ6
MI?\ ?J]_^6% 'N5%>&_\*X^(G_14M2_[]7O_ ,L*/^%<?$3_ **EJ7_?J]_^
M6% 'N5%>&_\ "N/B)_T5+4O^_5[_ /+"C_A7'Q$_Z*EJ7_?J]_\ EA0![E17
MAO\ PKCXB?\ 14M2_P"_5[_\L*/^%<?$3_HJ6I?]^KW_ .6% 'N5%>&_\*X^
M(G_14M2_[]7O_P L*/\ A7'Q$_Z*EJ7_ 'ZO?_EA0![E17AO_"N/B)_T5+4O
M^_5[_P#+"C_A7'Q$_P"BI:E_WZO?_EA0![E17AO_  KCXB?]%2U+_OU>_P#R
MPH_X5Q\1/^BI:E_WZO?_ )84 >Y45X;_ ,*X^(G_ $5+4O\ OU>__+"C_A7'
MQ$_Z*EJ7_?J]_P#EA0![E17AO_"N/B)_T5+4O^_5[_\ +"C_ (5Q\1/^BI:E
M_P!^KW_Y84 >Y45X;_PKCXB?]%2U+_OU>_\ RPH_X5Q\1/\ HJ6I?]^KW_Y8
M4 >Y45X;_P *X^(G_14M2_[]7O\ \L*/^%<?$3_HJ6I?]^KW_P"6% 'N5%>&
M_P#"N/B)_P!%2U+_ +]7O_RPH_X5Q\1/^BI:E_WZO?\ Y84 >Y45X;_PKCXB
M?]%2U+_OU>__ "PH_P"%<?$3_HJ6I?\ ?J]_^6% 'N5%>&_\*X^(G_14M2_[
M]7O_ ,L*/^%<?$3_ **EJ7_?J]_^6% 'N5%>&_\ "N/B)_T5+4O^_5[_ /+"
MC_A7'Q$_Z*EJ7_?J]_\ EA0![E17AO\ PKCXB?\ 14M2_P"_5[_\L*/^%<?$
M3_HJ6I?]^KW_ .6% 'N5%>&_\*X^(G_14M2_[]7O_P L*/\ A7'Q$_Z*EJ7_
M 'ZO?_EA0![E17AO_"N/B)_T5+4O^_5[_P#+"C_A7'Q$_P"BI:E_WZO?_EA0
M![E17AO_  KCXB?]%2U+_OU>_P#RPH_X5Q\1/^BI:E_WZO?_ )84 >Y45X;_
M ,*X^(G_ $5+4O\ OU>__+"C_A7'Q$_Z*EJ7_?J]_P#EA0![E17AO_"N/B)_
MT5+4O^_5[_\ +"C_ (5Q\1/^BI:E_P!^KW_Y84 >Y45X;_PKCXB?]%2U+_OU
M>_\ RPH_X5Q\1/\ HJ6I?]^KW_Y84 >Y45X;_P *X^(G_14M2_[]7O\ \L*/
M^%<?$3_HJ6I?]^KW_P"6% 'N5%>&_P#"N/B)_P!%2U+_ +]7O_RPH_X5Q\1/
M^BI:E_WZO?\ Y84 >Y45X;_PKCXB?]%2U+_OU>__ "PH_P"%<?$3_HJ6I?\
M?J]_^6% 'N5%>&_\*X^(G_14M2_[]7O_ ,L*/^%<?$3_ **EJ7_?J]_^6% '
MN5%>&_\ "N/B)_T5+4O^_5[_ /+"C_A7'Q$_Z*EJ7_?J]_\ EA0![E17AO\
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MJ7_?J]_^6% 'N5%>&_\ "N/B)_T5+4O^_5[_ /+"C_A7'Q$_Z*EJ7_?J]_\
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M^*?A[Q3X=T"'7IT=(+?5M6MK3QYX6M5@<J\SVTO@OP+/)%,CO%:&*4G][**
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MB&XO_"/BNS4W5HD^R"6^T348M4\+ZQ-9V+ZYH6IBQM5A /\ ("HK^T+XV_\
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MD:.:\T[3KB*VM=)\&^';FYBB=] \):;I5O>QVNGMK]QKM_8PZ@?TNH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MO\./AP]_#'J8\/C4XX;OQ#XANX=/U#QKJ&GZ7>7FEZ59:5I6E6/[:4 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !7S/^T5_S)__ ','_N#KZ8KYG_:*_P"9/_[F#_W!T =-\ /^1-U/_L9K
MS_TU:-7N5>&_ #_D3=3_ .QFO/\ TU:-7N5 !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M;:::6&*3]\?V<_\ @T>^/?B0Z?JW[4O[2_PZ^%NGN8KBZ\(_"+0=8^*'BB2
MX\S3KSQ#X@/@3PUH.H %LWFG6OC>PC*J$2Y$C&+^\RB@#\(_V<O^#<7_ ();
M_L_M8:EK/PC\0?M#>*+'RW77_C_XLN?%-@\PPTP?P%X<MO"/PVO;61P/+@UO
MPCK$L,2K']JD9IY9_P!I_ /PV^'7PI\.VOA#X7> ?!7PV\)V./L7A?P#X6T+
MP=X=L\(L8^RZ)X=L-.TVWPB(@\JV3"(J]% ':T4 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !7S/\ M%?\R?\ ]S!_[@Z^F*^9
M_P!HK_F3_P#N8/\ W!T =-\ /^1-U/\ [&:\_P#35HU>Y5X;\ /^1-U/_L9K
MS_TU:-7N5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 45^>G[1G_!5W_@G;^RF=0M/C1^UE\)M)\0Z:98[SP1X3UJ3X
MF>/[:YCRJVE[X(^&]MXK\2Z5--*/)BDUG3=.M0X=YKF&&*:6/\#OVC/^#N'X
M">&QJ&D_LM?LT?$7XI:@@EM[7Q=\7=>T?X7^%XYQGR]1L_#WA\>._$NO:>2%
MQ9ZC=>"+^0,Q=[8QJ)0#^ORO-_BA\8_A'\$?#DGC#XS?%'X>?";PI$9%?Q)\
M2?&?AWP1H8>)!(\2ZIXEU'3;)YE0@^2DS2G<H5"64'_-;_:-_P"#CK_@J1^T
M M_INC?%SP_^SSX7OO,1M ^ 'A.V\+7Z0G*PE/'OB.Y\7?$FRNHT)\R?1/%V
MCQ32LTGV6-5@B@_%CQ]\2?B+\5O$5UXO^*/C[QK\2?%E]G[;XH\?>*==\8^(
MKS+M(?M6M^(K_4=2N,N[N?-N7R[LW5B2 ?Z2'[1W_!RW_P $PO@5]NTWP9X[
M\<?M)^*+3S8?[*^"?@VZET**\7(B6Y\<^/)_!7A:[L'.UI-1\*WWBH1Q$F.W
MGF4P5^ _[1O_  =I_M6>-6O]*_9F^ GPJ^!>CS>9#;>(O'5_JGQC\=Q(H*Q7
MUE^Y\$^"=-N)B!,]CJ7A3Q5;VP;[,MU=^7]JE_EM^'?PM^)WQ>\16_A#X3?#
MGQW\4/%EWM^R^%_AWX0\0>-?$5SO<1K]GT3PUI^IZE-N<A%\NV;<Y"C)(%?M
MC^SG_P &V_\ P5%^/1T_4/$GPP\*?LZ>%[TQ2?VY\=_&%IHNIBU.&G*>!/!]
MMXS\>6E]''D067B#P[X?CGN"D4EY;0^;<P@'YX?M&?\ !27]N_\ :S-_#\?_
M -J?XO>.]$U,RF]\&1^)9?"7PZF\[=O'_"M?!$7AOP$@*L8QL\.*5A)B!$9*
MU\15_>Y^SE_P:1?LY^%&L-7_ &H?VC_B7\7]1B\NXN/"?PNT72/A/X0:; $F
MG:AJVJOX[\6:U8+EL7>E77@B^E?RW"VZ))#-^^'[./\ P2T_X)\?LGFQN_@=
M^RA\)/#GB'3A&;/QOK^@GXA?$.WD0JS2VOC_ .(=QXI\7V!FE59IH=.UBSM6
MD2(K;JL$"1 '^97^S=_P2Y_X*!?M:"RN_@5^RI\5_$_A[4#$;7QOKFB)\/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M TF[\2^7$D,*^,=),WAWQJMM%&J1I:)XMTC65M%1(U^S"+$:?='TW0 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?QC\8OB;\/\ X4^$K;?Y_B?XD>,O#O@C0(C&H=U;5_$NHZ98!U4@^7Y^\[E
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M6[+78=3?PUXA329;B>31M5NY=!\0:9KFEQD6*:CH\E]IRVEKJ"Z3I=CXP?\
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ME=?_ "JKW*B@#PW_ (7!K'_1-O$WY77_ ,JJ/^%P:Q_T3;Q-^5U_\JJ]RHH
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M=?\ RJH_X7!K'_1-O$WY77_RJKW*B@#PW_A<&L?]$V\3?E=?_*JC_A<&L?\
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M\JJ]RHH \-_X7!K'_1-O$WY77_RJH_X7!K'_ $3;Q-^5U_\ *JO<J* /#?\
MA<&L?]$V\3?E=?\ RJH_X7!K'_1-O$WY77_RJKW*B@#PW_A<&L?]$V\3?E=?
M_*JC_A<&L?\ 1-O$WY77_P JJ]RHH \-_P"%P:Q_T3;Q-^5U_P#*JC_A<&L?
M]$V\3?E=?_*JO<J* /#?^%P:Q_T3;Q-^5U_\JJ/^%P:Q_P!$V\3?E=?_ "JK
MW*B@#PW_ (7!K'_1-O$WY77_ ,JJ/^%P:Q_T3;Q-^5U_\JJ]RHH \-_X7!K'
M_1-O$WY77_RJH_X7!K'_ $3;Q-^5U_\ *JO<J* /#?\ A<&L?]$V\3?E=?\
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M$GC/6[O6;^*U$DDD&F::MPYM-#T6S,KKIN@Z';:=HNEPD6^G6-M JH/&!<7
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MGC]I'_@J/_P3\_9+:^L_CK^U9\)_#/B+3ED-WX&T/7'^('Q$MW0LBQW7P_\
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ME=?_ "JKW*B@#PW_ (7!K'_1-O$WY77_ ,JJ/^%P:Q_T3;Q-^5U_\JJ]RHH
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M=?\ RJH_X7!K'_1-O$WY77_RJKW*B@#PW_A<&L?]$V\3?E=?_*JC_A<&L?\
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M\JJ]RHH \-_X7!K'_1-O$WY77_RJH_X7!K'_ $3;Q-^5U_\ *JO<J* /#?\
MA<&L?]$V\3?E=?\ RJH_X7!K'_1-O$WY77_RJKW*B@#PW_A<&L?]$V\3?E=?
M_*JC_A<&L?\ 1-O$WY77_P JJ]RHH \-_P"%P:Q_T3;Q-^5U_P#*JC_A<&L?
M]$V\3?E=?_*JO<J* /#?^%P:Q_T3;Q-^5U_\JJ/^%P:Q_P!$V\3?E=?_ "JK
MW*B@#PW_ (7!K'_1-O$WY77_ ,JJ/^%P:Q_T3;Q-^5U_\JJ]RHH \-_X7!K'
M_1-O$WY77_RJH_X7!K'_ $3;Q-^5U_\ *JO<J* /#?\ A<&L?]$V\3?E=?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "OF?]HK_F3_ /N8/_<'7TQ7
MS/\ M%?\R?\ ]S!_[@Z .F^ '_(FZG_V,UY_Z:M&KW*O#?@!_P B;J?_ &,U
MY_Z:M&KW*@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5\S_M%?\ ,G_]S!_[@Z^F*^9_VBO^9/\
M^Y@_]P= '3? #_D3=3_[&:\_]-6C5[E7AOP _P"1-U/_ +&:\_\ 35HU>Y4
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_+EX[\=^,
M_$7C+Q-K.M>*-=O]1O=<U.6>XGU2])'^FS".&%!,([>UMXPL-K:P+';VMND=
MO;QQPQHB\G_PD&O?]!O5_P#P97O_ ,>H\0?\A[6_^POJ7_I;-610!K_\)!KW
M_0;U?_P97O\ \>H_X2#7O^@WJ_\ X,KW_P"/5D44 ;UKXJ\46-Q!>67B37K.
M[MI4FMKJUUC4+>XMYHR&CE@GBN$EBE1@&22-E92 5(-?TZ?"C5;_ %WX6_#;
M7-5N7O-4UGP#X.U74KN3'F75_J/AW3KR\N9,8&^>XFDE? QN8U_+;7]0/P1_
MY(Q\(O\ LF'@'_U%-)H ]/HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *^9_VBO\ F3_^Y@_]P=?3%?,_[17_
M #)__<P?^X.@#IO@!_R)NI_]C->?^FK1J]RKPWX ?\B;J?\ V,UY_P"FK1J]
MRH **** "BBOGGPQ^U%\(?&'[1OQ)_95T+5]4N?C#\)O"6A>-/&FE2:%J,.C
MV.B^(K7P]?:>+?7WB&FW=]]B\5^'KJ6SCE$@BU(>5YSVFH+: 'T-1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%?F#^WW_P5Y_8I_X)V:7=67QD^(B>)OBRUE]I
MT7X#_#8V7B?XHZ@TT*2V4VLZ<+VVTOP+I%TDB3PZQXWU/0H+ZU6X?0HM;NX/
ML+_PF_\ !1'_ (. _P!M?]NL:YX$\,ZR_P"S1^S]J)N+0_"_X6ZU?Q^(O$^E
M2Y3[-\2?B8D>FZ_XHCGB>6&]T/1;7PIX.OK:1(=3\-:C/ MZX!_8-_P41_X.
M$OV*OV'3K_@+P/JT7[3_ .T%IGGV3?#GX8ZW9-X.\+:O$S1O;?$?XI10ZIH.
MASV<T<]OJ'A_PW:^+O%VGW\ L-9T+1%F^W0_PH?M[_\ !6K]M+_@HEK-S'\;
MOB/+HOPOCOA=Z#\"OAY]L\,?"G1A!.TUC+?:*EY<WWC+6+-B9(/$'C?4O$.J
MVLKRKI<VF631V,7YT^'?#GB'QAKND>%O"6@ZUXH\3:_?VVE:%X<\.Z7?:WKN
MMZI>2+#9Z;I&D:9!=:AJ5_=S,L5M9V=O-<3R,J11NQ /]4W_  3M_P"#7/X]
M?&DZ#\2OVZ->U#]G/X:3F#4(OA)X?;3=2^.OB:Q8I(D&LW$R:EX9^%EO=PNL
MA_M2'Q/XMMFCGT[5/"&@7;)=P@'\RWP6^!?QC_:,^(&D?"SX%?#3QC\5OB%K
MK'^SO"O@G0[W7-3-O&\:7.I7JVL;0:5HUAYJ2:IKFJS66CZ5;DW6I7UK;JTJ
M_P!DW_!.[_@U4TRP_L3XF?\ !1CQ>NKW@^S7]O\ LW?"O7I(M*@8?.UC\3?B
MAIK1W>I-AC%>:%\-I["WAGBCGMOB'JEK)+9G^J_]E?\ 8S_9E_8I^'\7PU_9
MF^$/A7X7>'76W?6+O2K62\\4^+;VV1DCU3QIXQU26]\4>+=34.ZPW6O:K??8
MH7^QZ<EG8QPVL?T[0!YU\*?A%\+O@7X%T/X8_!KX?>$/AA\/O#=O]GT3PAX(
MT'3O#NA6*D+YTZV.FP0137]Y(OVC4=2N1-J&IW;RWNH75S=S2S/Z+110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 445@Z_XJ\,>%+4WWBCQ'H/ANR"LQO-?UC3]'M0J
M_>8W&HW%M$%7^(E\#N10!O45\G>+/VW?V;O"8E0^/D\27D6[%EX3TK4M:,NW
M_GEJ26T&AMDX"EM54-G(.T%A\P^+/^"G7AZ$2Q>!OA=K.HL=RP7OBO6K+1EC
M_NR2Z9I$.N-.">#"NK6Q .?.R-I /U/HK\$_%G_!0G]H;Q$)HM'OO"_@F"3<
MJ_\ ".^'H;JZ6)N-K77B:;7\2E<@SV\-LZL=\(A8*5^8?%GQ?^*GCH2IXO\
MB)XQ\0V\VX26.I>(=3FTS:WWECTL7"Z=$C?Q)%:HA[B@#^C/Q9\=?@WX&$H\
M4_$WP9I5Q#N\RP;7K&[U8;/O :/82W6J.1T(2S8[B%^\0#\P^+/^"BOP#T(2
MQ^'X_%_C:X7<L#Z5H?\ 9.GR,.AEN?$=QI-]#$W0/'I=Q(#C,.WYA^$E=9X8
M\!^-_&LXMO!_@_Q/XHF+;"GA_0M3U?8?XC*UA:SI"B#YI))61(T!>1E0$@ Y
M_4;H7VH7]ZJ&-;R\NKH1DAC&+B=Y@A8 !BH?:2  2,X'2J=230R6\LL$R-'-
M#(\,L;##1R1L4D1AV964J1Z@U'0 4444 %?U _!'_DC'PB_[)AX!_P#44TFO
MY?J_J!^"/_)&/A%_V3#P#_ZBFDT >GT444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %?,_[17_,G_\ <P?^X.OI
MBOF?]HK_ )D__N8/_<'0!TWP _Y$W4_^QFO/_35HU>Y5X;\ /^1-U/\ [&:\
M_P#35HU>Y4 %%%% 'Y!?MY?\% _C!\+OCM\,OV+?V/\ X<:!\2/VGOBGID>N
M->^+IIAX5\$:',NIW44EQ81W>DQZC?G1=!U_Q'J=Y>ZW9:=X:T/38+ZXLM<?
M45M;/X>T+]DO_@LY^S]\;/BC^V/X6U3]E;XR?%GXN:9HMM\1? VGW^IA];TG
MP]9:1!INA65IKOAGX8Z7IGV&RT73]/']@^.K:XO&LU9[J^F:.>3O?^"EGP*_
M:=^!'[:7PL_X*7?LS> ;KXN6GA#PY9>'_B;X$TFSO]4UBT@T_3M9\,:G<W6D
M:8T^L7GASQ-X(UY]-.J:)INH/X/U71VU_5K5K1X&KZC_ &9?^"V'[&OQ_N]+
M\+>+];U7]GSXC7\T5@_AKXJQQ6OAJ;5WD,4EGI?Q#LMWAT0I*4@BE\6+X-O+
MFX;R8=-9P P!^F?@[Q9XRU3X.^%?'/BWP/=:#\0=1^&FA^+/$WPVM[C[1>Z+
MXRN_"UKK&L^!X+I5N//NM.UN2YT&*X59O,EA60+)NPWXD0:?_P %XOVGK;_A
M8.A>,?@A^Q7X6O96OO#?PN\3:;;7'B\V7^LTIO$3WOPS^*VNVMP/)1-6MM7O
M?"UP\ES,T_@R&'R]/MOZ $=)$62-E='571T8,CHP#*RLI(96!!5@2"""#@TI
M( ))  !)).  .223P !U- 'X0?L%?M^_M3C]K7Q-^P!^W?HN@S_&73]-U;4/
M!OQ!\-Z9I>D_\)'/I&A+XO>UU&VT"+3_  QJ6CZWX+CO/$GA[7="T;1)K<6,
MVDZSI37\\G]E_<O_  47_;DT;]A+X$_\+ CT6V\7_$CQAK*^#OA5X+NIIH[/
M5_$LUK->7.JZT+-TU ^&_#ME%]KU1+!H[J_O+C2="AN]-FUF+4K/\J?V=[H?
MML_\%N/B)^TU\/86O/@G^RWX7O\ P=;^-((D?2/%&NMX(UWX8:=;6]VH9+HZ
MWJ_B#QOXGT"Y@9DG\-^%[.[EEB^UVT$VA_P5OGM?&_\ P4?_ ."7GPCUD_;/
M#R_$3PAK6J:1,7:TNK/QC\:/!FCZE%)"&5<ZA8>#7L7D'S+'Z@;2 =)IWPW_
M ."_7C'P?'\:U_:*^#W@O7;[1(?$VB_L^3>$_!]KJ<-G=P1:D/!^J0:E\)=1
MTG3O$#0RR620ZYXQU&^L[O;9W_B?2YHWGL_M/_@ES_P4 U7]MKX=>-=#^)OA
MVT\'_'_X*:O8^'OB=HEA:W&GZ;JD.H'4;;2O$MAIE[--=Z3=3WVB:UI7B'0W
MEN$TG5M.\Z*6"SU6RL;3]2J_FS_8+C;P-_P7"_;_ / VE*D&A>)O"OQ$\6WE
MG ?+@&L7WQ ^%WBJ*[\M8TC9XI?%^NQ%-@*-J$K+,X5C, >\_M7?MU?M5_%7
M]K.\_8,_X)VV?A/3_B%X/TV74OB[\;?&%A::QH?@BXM[2TN[VQMH]0TKQ'H6
MG:;H3:EI6D:WJNI>&_$M_?>+-3B\,:5HUI<Z=-<ZE\\_&'XW_P#!7+_@FD/!
M7Q>_:,^)OPT_:N^ .J>)K#0?'&G:#H6E:9J'AZ[U,W+_ &=-:L_ '@;Q!I$V
MH6\$J^'-9G;7O#46K00Z=JFCVC7EI!J>Q_P0SGM?'O[1/_!2OXPWY^WZ]XA^
M*?AQK74YR\EU'8>+?&WQH\2:M'YSL2T>HW-EHDCJ1E3IL6#@X'Z<?\%6O#=C
MXJ_X)Y_M3:=?PQ3167P\3Q) )54B.^\(^(M#\46,T9,<FV6.[TB$QLH5MWR^
M9&&+J ?:?PU^(7A?XM?#SP/\4/!5Z^H>$?B%X4T'QEX;O)8Q#/-HWB/3+;5;
M W5N'D-M>);W21WEHSL]K=)-;R'?$U=M7Y=_\$8_$-_XC_X)N?LYW&I2--<:
M7;_$?P]',SER]AH/Q9\=:;I48##*+::7!9V*)N8;+964JK"-/U$H **** "B
MBLB?Q!H-M-);W.MZ1;SQ,4EAGU*SBFC<=5DCDF5T8=U90?:@#7HK#_X2?PU_
MT,.A_P#@VL/_ )(H_P"$G\-?]##H?_@VL/\ Y(H W**P_P#A)_#7_0PZ'_X-
MK#_Y(H_X2?PU_P!##H?_ (-K#_Y(H W**P_^$G\-?]##H?\ X-K#_P"2*/\
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M*/\ A)_#7_0PZ'_X-K#_ .2* -RBL/\ X2?PU_T,.A_^#:P_^2*/^$G\-?\
M0PZ'_P"#:P_^2* -RBL/_A)_#7_0PZ'_ .#:P_\ DBC_ (2?PU_T,.A_^#:P
M_P#DB@#<HK#_ .$G\-?]##H?_@VL/_DBC_A)_#7_ $,.A_\ @VL/_DB@#<HK
M#_X2?PU_T,.A_P#@VL/_ )(H_P"$G\-?]##H?_@VL/\ Y(H W**P_P#A)_#7
M_0PZ'_X-K#_Y(H_X2?PU_P!##H?_ (-K#_Y(H W**P_^$G\-?]##H?\ X-K#
M_P"2*/\ A)_#7_0PZ'_X-K#_ .2* -RBL/\ X2?PU_T,.A_^#:P_^2*/^$G\
M-?\ 0PZ'_P"#:P_^2* -RBL/_A)_#7_0PZ'_ .#:P_\ DBC_ (2?PU_T,.A_
M^#:P_P#DB@#<HK#_ .$G\-?]##H?_@VL/_DBC_A)_#7_ $,.A_\ @VL/_DB@
M#<HK#_X2?PU_T,.A_P#@VL/_ )(H_P"$G\-?]##H?_@VL/\ Y(H W**P_P#A
M)_#7_0PZ'_X-K#_Y(H_X2?PU_P!##H?_ (-K#_Y(H W**P_^$G\-?]##H?\
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MPU_T,.A_^#:P_P#DB@#<HK#_ .$G\-?]##H?_@VL/_DBC_A)_#7_ $,.A_\
M@VL/_DB@#<HK#_X2?PU_T,.A_P#@VL/_ )(H_P"$G\-?]##H?_@VL/\ Y(H
MW**P_P#A)_#7_0PZ'_X-K#_Y(H_X2?PU_P!##H?_ (-K#_Y(H W**P_^$G\-
M?]##H?\ X-K#_P"2*/\ A)_#7_0PZ'_X-K#_ .2* -RBL/\ X2?PU_T,.A_^
M#:P_^2*/^$G\-?\ 0PZ'_P"#:P_^2* -RBL/_A)_#7_0PZ'_ .#:P_\ DBC_
M (2?PU_T,.A_^#:P_P#DB@#<HK#_ .$G\-?]##H?_@VL/_DBC_A)_#7_ $,.
MA_\ @VL/_DB@#<HK#_X2?PU_T,.A_P#@VL/_ )(H_P"$G\-?]##H?_@VL/\
MY(H W**P_P#A)_#7_0PZ'_X-K#_Y(H_X2?PU_P!##H?_ (-K#_Y(H W**P_^
M$G\-?]##H?\ X-K#_P"2*/\ A)_#7_0PZ'_X-K#_ .2* -RBL/\ X2?PU_T,
M.A_^#:P_^2*/^$G\-?\ 0PZ'_P"#:P_^2* -RBL/_A)_#7_0PZ'_ .#:P_\
MDBC_ (2?PU_T,.A_^#:P_P#DB@#<HK#_ .$G\-?]##H?_@VL/_DBC_A)_#7_
M $,.A_\ @VL/_DB@#<HK#_X2?PU_T,.A_P#@VL/_ )(H_P"$G\-?]##H?_@V
ML/\ Y(H W**P_P#A)_#7_0PZ'_X-K#_Y(H_X2?PU_P!##H?_ (-K#_Y(H W*
M*P_^$G\-?]##H?\ X-K#_P"2*/\ A)_#7_0PZ'_X-K#_ .2* -RBL/\ X2?P
MU_T,.A_^#:P_^2*/^$G\-?\ 0PZ'_P"#:P_^2* -RBL/_A)_#7_0PZ'_ .#:
MP_\ DBC_ (2?PU_T,.A_^#:P_P#DB@#<HK#_ .$G\-?]##H?_@VL/_DBC_A)
M_#7_ $,.A_\ @VL/_DB@#<HK#_X2?PU_T,.A_P#@VL/_ )(H_P"$G\-?]##H
M?_@VL/\ Y(H W**P_P#A)_#7_0PZ'_X-K#_Y(H_X2?PU_P!##H?_ (-K#_Y(
MH W**P_^$G\-?]##H?\ X-K#_P"2*/\ A)_#7_0PZ'_X-K#_ .2* -RBL/\
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MK#_Y(H_X2?PU_P!##H?_ (-K#_Y(H W**P_^$G\-?]##H?\ X-K#_P"2*/\
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M*/\ A)_#7_0PZ'_X-K#_ .2* -RBL/\ X2?PU_T,.A_^#:P_^2*/^$G\-?\
M0PZ'_P"#:P_^2* -RBL/_A)_#7_0PZ'_ .#:P_\ DBC_ (2?PU_T,.A_^#:P
M_P#DB@#<HK#_ .$G\-?]##H?_@VL/_DBC_A)_#7_ $,.A_\ @VL/_DB@#<HK
M#_X2?PU_T,.A_P#@VL/_ )(H_P"$G\-?]##H?_@VL/\ Y(H W**P_P#A)_#7
M_0PZ'_X-K#_Y(H_X2?PU_P!##H?_ (-K#_Y(H W**P_^$G\-?]##H?\ X-K#
M_P"2*/\ A)_#7_0PZ'_X-K#_ .2* -RBL/\ X2?PU_T,.A_^#:P_^2*/^$G\
M-?\ 0PZ'_P"#:P_^2* -RBL/_A)_#7_0PZ'_ .#:P_\ DBC_ (2?PU_T,.A_
M^#:P_P#DB@#<HK#_ .$G\-?]##H?_@VL/_DBC_A)_#7_ $,.A_\ @VL/_DB@
M#<HK#_X2?PU_T,.A_P#@VL/_ )(H_P"$G\-?]##H?_@VL/\ Y(H W**P_P#A
M)_#7_0PZ'_X-K#_Y(H_X2?PU_P!##H?_ (-K#_Y(H W**P_^$G\-?]##H?\
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MPU_T,.A_^#:P_P#DB@#<HK#_ .$G\-?]##H?_@VL/_DBC_A)_#7_ $,.A_\
M@VL/_DB@#<HK#_X2?PU_T,.A_P#@VL/_ )(H_P"$G\-?]##H?_@VL/\ Y(H
MW**P_P#A)_#7_0PZ'_X-K#_Y(H_X2?PU_P!##H?_ (-K#_Y(H W**P_^$G\-
M?]##H?\ X-K#_P"2*/\ A)_#7_0PZ'_X-K#_ .2* -RBL/\ X2?PU_T,.A_^
M#:P_^2*/^$G\-?\ 0PZ'_P"#:P_^2* -RBL/_A)_#7_0PZ'_ .#:P_\ DBC_
M (2?PU_T,.A_^#:P_P#DB@#<HK#_ .$G\-?]##H?_@VL/_DBC_A)_#7_ $,.
MA_\ @VL/_DB@#<HK#_X2?PU_T,.A_P#@VL/_ )(H_P"$G\-?]##H?_@VL/\
MY(H W**P_P#A)_#7_0PZ'_X-K#_Y(H_X2?PU_P!##H?_ (-K#_Y(H W**P_^
M$G\-?]##H?\ X-K#_P"2*/\ A)_#7_0PZ'_X-K#_ .2* -RBL/\ X2?PU_T,
M.A_^#:P_^2*/^$G\-?\ 0PZ'_P"#:P_^2* -RBL/_A)_#7_0PZ'_ .#:P_\
MDBC_ (2?PU_T,.A_^#:P_P#DB@#<HK#_ .$G\-?]##H?_@VL/_DBC_A)_#7_
M $,.A_\ @VL/_DB@#<HK#_X2?PU_T,.A_P#@VL/_ )(H_P"$G\-?]##H?_@V
ML/\ Y(H W**P_P#A)_#7_0PZ'_X-K#_Y(H_X2?PU_P!##H?_ (-K#_Y(H W*
M*P_^$G\-?]##H?\ X-K#_P"2*/\ A)_#7_0PZ'_X-K#_ .2* -RBL/\ X2?P
MU_T,.A_^#:P_^2*/^$G\-?\ 0PZ'_P"#:P_^2* -RBL/_A)_#7_0PZ'_ .#:
MP_\ DBC_ (2?PU_T,.A_^#:P_P#DB@#<HK#_ .$G\-?]##H?_@VL/_DBC_A)
M_#7_ $,.A_\ @VL/_DB@#<HK#_X2?PU_T,.A_P#@VL/_ )(H_P"$G\-?]##H
M?_@VL/\ Y(H W**P_P#A)_#7_0PZ'_X-K#_Y(H_X2?PU_P!##H?_ (-K#_Y(
MH W**P_^$G\-?]##H?\ X-K#_P"2*/\ A)_#7_0PZ'_X-K#_ .2* -RBL/\
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ML'CFAFBL%DBEC<!DD1E=& 92" :]3'B;PR  /$&A    #5=/  '   N,  <
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M /!M8?\ R10!N45A_P#"3^&O^AAT/_P;6'_R11_PD_AK_H8=#_\ !M8?_)%
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M4 >4_P#"EOA]_P! NZ_\&FH?_)%'_"EOA]_T"[K_ ,&FH?\ R17JU% 'E/\
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M4 >4_P#"EOA]_P! NZ_\&FH?_)%'_"EOA]_T"[K_ ,&FH?\ R17JU% 'E/\
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M4 >4_P#"EOA]_P! NZ_\&FH?_)%'_"EOA]_T"[K_ ,&FH?\ R17JU% 'E/\
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M4 >4_P#"EOA]_P! NZ_\&FH?_)%'_"EOA]_T"[K_ ,&FH?\ R17JU% 'E/\
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M4 >4_P#"EOA]_P! NZ_\&FH?_)%'_"EOA]_T"[K_ ,&FH?\ R17JU% 'E/\
MPI;X??\ 0+NO_!IJ'_R11_PI;X??] NZ_P#!IJ'_ ,D5ZM10!Y3_ ,*6^'W_
M $"[K_P::A_\D4?\*6^'W_0+NO\ P::A_P#)%>K44 >4_P#"EOA]_P! NZ_\
M&FH?_)%'_"EOA]_T"[K_ ,&FH?\ R17JU% 'E/\ PI;X??\ 0+NO_!IJ'_R1
M1_PI;X??] NZ_P#!IJ'_ ,D5ZM10!Y3_ ,*6^'W_ $"[K_P::A_\D4?\*6^'
MW_0+NO\ P::A_P#)%>K44 >4_P#"EOA]_P! NZ_\&FH?_)%'_"EOA]_T"[K_
M ,&FH?\ R17JU% 'E/\ PI;X??\ 0+NO_!IJ'_R11_PI;X??] NZ_P#!IJ'_
M ,D5ZM10!Y3_ ,*6^'W_ $"[K_P::A_\D4?\*6^'W_0+NO\ P::A_P#)%>K4
M4 >4_P#"EOA]_P! NZ_\&FH?_)%'_"EOA]_T"[K_ ,&FH?\ R17JU% 'E/\
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MLK2)(+6SL[6"6."VM;:"..&WMX8TBAB1(XT5%51[!10!Y3_PI;X??] NZ_\
M!IJ'_P D4?\ "EOA]_T"[K_P::A_\D5ZM10!Y3_PI;X??] NZ_\ !IJ'_P D
M4?\ "EOA]_T"[K_P::A_\D5ZM10!Y3_PI;X??] NZ_\ !IJ'_P D4?\ "EOA
M]_T"[K_P::A_\D5ZM10!Y3_PI;X??] NZ_\ !IJ'_P D4?\ "EOA]_T"[K_P
M::A_\D5ZM10!Y3_PI;X??] NZ_\ !IJ'_P D4?\ "EOA]_T"[K_P::A_\D5Z
MM10!Y3_PI;X??] NZ_\ !IJ'_P D4?\ "EOA]_T"[K_P::A_\D5ZM10!Y3_P
MI;X??] NZ_\ !IJ'_P D4?\ "EOA]_T"[K_P::A_\D5ZM10!Y3_PI;X??] N
MZ_\ !IJ'_P D4?\ "EOA]_T"[K_P::A_\D5ZM10!Y3_PI;X??] NZ_\ !IJ'
M_P D4?\ "EOA]_T"[K_P::A_\D5ZM10!Y3_PI;X??] NZ_\ !IJ'_P D4?\
M"EOA]_T"[K_P::A_\D5ZM10!Y3_PI;X??] NZ_\ !IJ'_P D4?\ "EOA]_T"
M[K_P::A_\D5ZM10!Y3_PI;X??] NZ_\ !IJ'_P D4?\ "EOA]_T"[K_P::A_
M\D5ZM10!Y3_PI;X??] NZ_\ !IJ'_P D4?\ "EOA]_T"[K_P::A_\D5ZM10!
MY3_PI;X??] NZ_\ !IJ'_P D4?\ "EOA]_T"[K_P::A_\D5ZM10!Y3_PI;X?
M?] NZ_\ !IJ'_P D4?\ "EOA]_T"[K_P::A_\D5ZM10!Y3_PI;X??] NZ_\
M!IJ'_P D4?\ "EOA]_T"[K_P::A_\D5ZM10!Y3_PI;X??] NZ_\ !IJ'_P D
M4?\ "EOA]_T"[K_P::A_\D5ZM10!Y3_PI;X??] NZ_\ !IJ'_P D4?\ "EOA
M]_T"[K_P::A_\D5ZM10!Y3_PI;X??] NZ_\ !IJ'_P D4?\ "EOA]_T"[K_P
M::A_\D5ZM10!Y3_PI;X??] NZ_\ !IJ'_P D4?\ "EOA]_T"[K_P::A_\D5Z
MM10!Y3_PI;X??] NZ_\ !IJ'_P D4?\ "EOA]_T"[K_P::A_\D5ZM10!Y3_P
MI;X??] NZ_\ !IJ'_P D4?\ "EOA]_T"[K_P::A_\D5ZM10!Y3_PI;X??] N
MZ_\ !IJ'_P D4?\ "EOA]_T"[K_P::A_\D5ZM10!Y3_PI;X??] NZ_\ !IJ'
M_P D4?\ "EOA]_T"[K_P::A_\D5ZM10!Y3_PI;X??] NZ_\ !IJ'_P D4?\
M"EOA]_T"[K_P::A_\D5ZM10!Y3_PI;X??] NZ_\ !IJ'_P D4?\ "EOA]_T"
M[K_P::A_\D5ZM10!Y3_PI;X??] NZ_\ !IJ'_P D4?\ "EOA]_T"[K_P::A_
M\D5ZM10!Y3_PI;X??] NZ_\ !IJ'_P D4?\ "EOA]_T"[K_P::A_\D5ZM10!
MY3_PI;X??] NZ_\ !IJ'_P D4?\ "EOA]_T"[K_P::A_\D5ZM10!Y3_PI;X?
M?] NZ_\ !IJ'_P D4?\ "EOA]_T"[K_P::A_\D5ZM10!Y3_PI;X??] NZ_\
M!IJ'_P D4?\ "EOA]_T"[K_P::A_\D5ZM10!Y3_PI;X??] NZ_\ !IJ'_P D
M4?\ "EOA]_T"[K_P::A_\D5ZM10!Y3_PI;X??] NZ_\ !IJ'_P D4?\ "EOA
M]_T"[K_P::A_\D5ZM10!Y3_PI;X??] NZ_\ !IJ'_P D4?\ "EOA]_T"[K_P
M::A_\D5ZM10!Y3_PI;X??] NZ_\ !IJ'_P D4?\ "EOA]_T"[K_P::A_\D5Z
MM10!Y3_PI;X??] NZ_\ !IJ'_P D4?\ "EOA]_T"[K_P::A_\D5ZM10!Y3_P
MI;X??] NZ_\ !IJ'_P D4?\ "EOA]_T"[K_P::A_\D5ZM10!Y3_PI;X??] N
MZ_\ !IJ'_P D4?\ "EOA]_T"[K_P::A_\D5ZM10!Y3_PI;X??] NZ_\ !IJ'
M_P D4?\ "EOA]_T"[K_P::A_\D5ZM10!Y3_PI;X??] NZ_\ !IJ'_P D4?\
M"EOA]_T"[K_P::A_\D5ZM10!Y3_PI;X??] NZ_\ !IJ'_P D4?\ "EOA]_T"
M[K_P::A_\D5ZM10!Y3_PI;X??] NZ_\ !IJ'_P D4?\ "EOA]_T"[K_P::A_
M\D5ZM10!Y3_PI;X??] NZ_\ !IJ'_P D4?\ "EOA]_T"[K_P::A_\D5ZM10!
MY3_PI;X??] NZ_\ !IJ'_P D4?\ "EOA]_T"[K_P::A_\D5ZM10!Y3_PI;X?
M?] NZ_\ !IJ'_P D4?\ "EOA]_T"[K_P::A_\D5ZM10!Y3_PI;X??] NZ_\
M!IJ'_P D4?\ "EOA]_T"[K_P::A_\D5ZM10!Y3_PI;X??] NZ_\ !IJ'_P D
M4?\ "EOA]_T"[K_P::A_\D5ZM10!Y3_PI;X??] NZ_\ !IJ'_P D4?\ "EOA
M]_T"[K_P::A_\D5ZM10!Y3_PI;X??] NZ_\ !IJ'_P D4?\ "EOA]_T"[K_P
M::A_\D5ZM10!Y3_PI;X??] NZ_\ !IJ'_P D4?\ "EOA]_T"[K_P::A_\D5Z
MM10!Y3_PI;X??] NZ_\ !IJ'_P D4?\ "EOA]_T"[K_P::A_\D5ZM10!Y3_P
MI;X??] NZ_\ !IJ'_P D4?\ "EOA]_T"[K_P::A_\D5ZM10!Y3_PI;X??] N
MZ_\ !IJ'_P D4?\ "EOA]_T"[K_P::A_\D5ZM10!Y3_PI;X??] NZ_\ !IJ'
M_P D4?\ "EOA]_T"[K_P::A_\D5ZM10!Y3_PI;X??] NZ_\ !IJ'_P D4?\
M"EOA]_T"[K_P::A_\D5ZM10!Y3_PI;X??] NZ_\ !IJ'_P D4?\ "EOA]_T"
M[K_P::A_\D5ZM10!Y3_PI;X??] NZ_\ !IJ'_P D4?\ "EOA]_T"[K_P::A_
M\D5ZM10!Y3_PI;X??] NZ_\ !IJ'_P D4?\ "EOA]_T"[K_P::A_\D5ZM10!
MY3_PI;X??] NZ_\ !IJ'_P D4?\ "EOA]_T"[K_P::A_\D5ZM10!Y3_PI;X?
M?] NZ_\ !IJ'_P D4?\ "EOA]_T"[K_P::A_\D5ZM10!Y3_PI;X??] NZ_\
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M[D$@8&[ ["MNB@ HHHH **** "OF?]HK_F3_ /N8/_<'7TQ7S/\ M%?\R?\
M]S!_[@Z .F^ '_(FZG_V,UY_Z:M&KW*O#?@!_P B;J?_ &,UY_Z:M&KW*@ H
MHHH QO$7ASP]XOT+5O"_BW0=&\4>&=?L+G2M=\.^(M+L=;T+6M,O(VAN]-U;
M2-3@N=/U*PNHF:*YL[RWFMYXV9)8V4D4>'O#OA_PCH6D^%_">A:-X8\,Z!I]
MMI.A>'?#VEV6BZ%HNEV42P6>FZ3I&FP6VGZ;I]I"B0VUG9V\-O!$JQQ1HB@#
M9HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MG@F19(9H9$EAEC<!DDCD0LCHRD%75BK @@D5+0 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MI6BO@77?^"CGP"TLNFEV/C[Q(XW".33= L+*U8AF +R:WK6F7,:,%# K9R.
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M?^.^I;'U?5_A_P"'(CCS([O6M4U"]7(?B.'2M#N[.0J57>&U&(;9%*-(5=5
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M*(=!AP2P8D%=@!^VM%?!'@G_ (**? GQ'Y,'B>'Q1X"O'VK+)JFEG6=(5V(
M$5_X?>_OF0$_-+<Z/9HGWF(4%A]=>#?BE\-_B%&)/!'CGPMXG8H9'MM'UJQN
M[^!0,G[5IJ3?VA9L%^8I=6T+A<,5VD$@'>T444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %?,_P"T5_S)_P#W,'_N#KZ8KYG_ &BO^9/_ .Y@_P#<'0!TWP _Y$W4
M_P#L9KS_ --6C5[E7AOP _Y$W4_^QFO/_35HU>Y4 %%%% !17SC^TG^UK^S]
M^R/X3L_&/Q[^(FE^";#5IYK3P_IAAO-7\3^)KJV-N+N+P[X8T>WO=;U9+#[7
M:-J=Y;69T_2DNK634[NT2Y@:3^>OX#?\%<O@';_\%'/VEOC3\1OBK\5="_9W
M^(W@OP5X.^$ND:MIOBS5O"N@WNBZ7X%T_6=?U'P+H]UK1T&6[OO#NM:A!J%A
MHUWJ#1:WJ)G2V>^N(& /ZHJ*Q?#?B+0_&'AW0?%OAC5+/7/#7BG1=+\1>'M:
MT^43V&L:'K=C!J>DZI8S# FL]0L+JWN[:4 "2&9''!KY9_:S_;J_9N_8M\-Q
M:W\:_&RV^MZA!Y_AWX<^&4M=<^(_BF,2/$TVC^&FO;$0:<CQRI)KNNWVB^'H
MIX_LDFKI>RP6TH!]@45X-^S)^T1X'_:O^!W@;X__  WL/$VE^#/'\?B!]'T_
MQC8:=IGB2T;PSXKUWP=J<6J66D:OKVFPR#6/#VH& V>KWT4UH;>?S5:1HH^=
M_:S_ &M?A-^QA\+(?B]\9&\2'PO=^*M(\&V-MX3T>+6]:O==UJTU2_M;>"TN
M+_3+5(H[#1=3O+B>YO[>-(K5DC,MQ+!!* ?3=%?AO_Q$%_L'_P#0(^/G_AO?
M#G_S>U^G?[+'[47PT_; ^$EC\:/A-!XIM_"&H:WK>@0Q>+]%30M8%_H%RMK?
M$VL%]J5I-:L[H8+JTO[F)CYD,C174%S;P@'T;17Q)^V!_P %!OV:_P!B.ST9
M/C)XDU:\\7>)+:2^\-_#7P-I</B/Q]K6G1RRVQU./2[B_P!*TS2]+EO(9;&S
MU+Q#K.C66H7T-S:Z?/=36-\MM\H_!W_@N!^QK\4?'FC_  Z\3Z?\7?@3KGB&
M\ALM#U#XS^$=&T/PS?37]]<6>DK-K?A[Q5XG&C+>-%$D]_KUII>A65W+);R:
MS)#;R79 /V)HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ML[5%8A6DN)XHU8@,P) K^B?PA^S7\!_ HB;PY\+/",-Q!CR;_4].7Q#JD3
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M11TH ]L_X;Y_::_Z''2/_"/\,?\ RLH_X;Y_::_Z''2/_"/\,?\ RLKXTHH
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M)%$@) +.ZKD@9YKY^\7_ +4=AX),L>K_ !K^&UY=1;E-GX;'_"67'FKUA?\
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M\?\ 09\,_P#?JV_^55 'N5%>&_8?CQ_T&?#/_?JV_P#E51]A^/'_ $&?#/\
MWZMO_E50![E17AOV'X\?]!GPS_WZMO\ Y54?8?CQ_P!!GPS_ -^K;_Y54 >Y
M45X;]A^/'_09\,_]^K;_ .55'V'X\?\ 09\,_P#?JV_^55 'N5%>&_8?CQ_T
M&?#/_?JV_P#E51]A^/'_ $&?#/\ WZMO_E50![E17AOV'X\?]!GPS_WZMO\
MY54?8?CQ_P!!GPS_ -^K;_Y54 >Y45X;]A^/'_09\,_]^K;_ .55'V'X\?\
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M /<P?^X.@#IO@!_R)NI_]C->?^FK1J]RKPWX ?\ (FZG_P!C->?^FK1J]RH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M->&"**-/?** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M 'V/16'H'B?PWXKL5U/POX@T3Q)IS[2M_H.JV.KV3;P2N+K3Y[B$[@"0-^2
M<=#6Y0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M J2BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "OF?]HK_F3_ /N8/_<'7TQ7S/\ M%?\R?\ ]S!_[@Z
M.F^ '_(FZG_V,UY_Z:M&KW*O#?@!_P B;J?_ &,UY_Z:M&KW*@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MG&X$*R_(7C;_ ()D>([82W'P[^)&D:LN&>+3/%VFW6BSJ%R1$-5TDZQ!<RN
M C/IFGQ;R [1IF0 '4>"/^"G-@_DV_Q'^&=U;$%!/JO@K58KM6R ',>@ZY]C
M:((067/B*<N&V84Q[I?KWP3^V1^SKXY\F*S^(NFZ!?2[0=/\8Q3^%Y8G?[L;
M7VJ)%HLTA/RA;75;C+87.64-^+?C;]DK]H7P%YTFK_#/7=1L8BQ_M+PLD/BN
MS:)<YN'709;Z\LX1@EFU"TLV0 ,Z*K*3\\7%O/:S2VUU!-;7$+M'-!<1O#-#
M(IPR2Q2*KQNIX974,#U% ']8%E?V.IVL5[IMY::A93KO@N[*XAN[69/[T5Q
M\D4B_P"TCL/>K5?RL^%O'7C7P/=?;O!OBWQ'X6NBP=YM UG4-):4@ 8N%LKB
M%+A&4!'CG62.1,HZLA*U]9^"?^"@/[0GA3R8-8U/0?'=C%M0Q>)]&ABO1"
M534] ?1KF2;J1<:@-0?<29!( % !^^=%?F5X)_X*8^ M1\FW\?> O$?AF=L(
M]]X?O++Q-IRMD9FFAN1H6H6\)&28[>'4YD.%'F@EQ]?^"?VF_@-\01$GAOXG
M>&6O)@H33-9NW\-:JTAP##%IWB&/3+JYD1CM;[)'<1M@O&[QX<@'NU%(K*ZJ
MZ,&5@&5E(965AD,I&0000002"#D4M !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%8>O>)_#7A6T.H>)_$.A^'+ 9S?:]JUAH]H-HRV;G4+BW
MA&T$$_/P#S0!N45\E>+_ -M_]F_PCYL7_"='Q1>Q;O\ 0O"&EW^M>9M)'[K5
M#%:Z ^2,+_Q-QD8;[I#'Y8\8?\%.]/3S8? 'PNO+G.[R=2\8:W!9;,9">;HF
MBPW_ )F[(9@GB"+9@H#)NWH ?JY4-Q<6]I!+<W4\-M;0H9)KBXE2&")!U>66
M1ECC0=V9@!W-?@'XP_;W_:-\5>;'9>(]'\&6DN0UMX3T&TA<(1@*FH:T=;U6
M%AP3);7T#ENA53LKY>\4>/?''C:<W/C'QAXG\4S%MX?Q!KNIZL(SDD"%+ZYG
M2!$SB..%4CB7"1JJ * #^B/Q?^U/^S[X'$RZW\5/"\US""'L?#]U)XJOA*,@
M026WAJ'57MYF;"E;KR%CR'F>./+CY8\7_P#!2_X9:9YL7@OP/XM\53IN5+C5
MI].\+:;*W\#Q2J^NZBT9ZL)],M9.P7G</Q6KUKPA\!OC-X\\IO"GPS\8ZK;3
M[?*U'^Q;NQTAM^-I_MG4DL]*4$$-EKP +\QPO- 'U3XP_P""COQPUPR0^%M,
M\(>"+8Y\F:UTV77M73<,?O+O7)[C2I=O!3;H,/S;MY=2%7Y7\7_'KXS^//,7
MQ7\3/&.J6TV?,T\:S=:?I#;LY_XDVF/9:4"02N19@A3M&%XKZF\'_P#!./XX
MZYY4WBC4?"'@BW8+YL%YJ<FNZM'G!(2UT*"ZTJ7;R&SKL8W !-ZDLOU-X/\
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M3M 3 [8K=HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OF?]HK_F3_
M /N8/_<'7TQ7S/\ M%?\R?\ ]S!_[@Z .F^ '_(FZG_V,UY_Z:M&KW*O#?@!
M_P B;J?_ &,UY_Z:M&KW*@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M"GFLR^;%X*^%6F66"P@OO%'B&ZU3S%_A:72])LM(\H]-R)K$P])* /U[I"0
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M3X%B;>L#>'_ 6O:E=Q1[[@QO+-XO\:^)+6>Y"2Q++(MC!;2/:Q/'9PA[B.8
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M#\'>"[9M_E3I97/B'5X@W"YNM4G72I"@P03H2AFY(V_( #]Q:\\\7?%OX7^
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MS>98:MXL2[C_ .%C^*8=K/%)]MUVQ@\.6=U!)):WVB^%-*U&W*_;I=W[N_\
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MWJZ;XS\237]Q9M>R:IXLD75-1\&ZF+RV71+ >'?]&#IJHU#^O/P=XN\.^/\
MPEX8\=>$-4MM;\*>,O#^C^*/#>L6C%K75-"U[3[?5-*OX"0&\J[L;J"=0P5U
M#[756!  .DHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "OF?]HK_ )D__N8/_<'7TQ7S/^T5_P R?_W,
M'_N#H Z;X ?\B;J?_8S7G_IJT:O<J\-^ '_(FZG_ -C->?\ IJT:O<J "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?)#G1_BY\)8 8TW;;K_B?^--#/D2X!C4@7(WKYMO&0VWRO5O^"2__!131?\
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M_P#G55_ W10!_>?J?_!;K_@FQ8>1]E^/&JZUYOF^9_9GPA^,D7V;R_+V^?\
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M!  (W=Y':21F=W9G=W8L[NQ+,S,Q)9F))9B22223DU]D_L#?M8ZI^QA^T]X
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MU<,K X*L#9@@@@@@C(/!I/\ A!?&_P#T)WBK_P )[5__ )#H _N0_P"'Y?\
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M1S)+':+)(%=F4>[T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %?$?[;?[0/C?X$^%?!W_"!#3;;6?%VK:I;RZOJ-
MG'J)TZRT:VLYI4L[*<_9'NKR:_@7S[N.YBAMX9T6V,T\5Q;?;E?E=_P5 _Y
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M ?O/X@\=^"?":LWB?Q?X9\/%5W%-9US3--E88R D-W<Q2R,W\"1HSN2%16)
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M/+;W>IKX8L=&MI!"8V\J[NHB[2PHH:6XB60 ^B6955F9@JJ"S,Q 55 R68G
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MX:\D;ZK\$? 7@IG@EE:/Q-\<OA3=O#)'.(DMI#X-\3^+8S//&?M,30R2VRP
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MO$HH _A-M/\ @A=_P48N;F*";X7^#;"*1BKWEW\5O 3VT VD[Y5L=9O;LJ2
MH$%K,^YAE0NYAT/_  X4_P""@W_0N_"S_P .;IG_ ,A5_<C10!_$1IW_  0
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M!\^>S\$^%[&VD;<Q4Q6LVHZA+" A52KWDY9@SAE#!%_I.HH _G#L_P#@V_\
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MN>#4DF?>ZVNO^/K&W4D 8BM++Q=;VD"<?ZN"&- <D+DDG]&J* /S=_X=#_\
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MU'1->T^WU72KZ)9%5UCN["[@N$5U5PL@#*#D4 ;U%%% !1110 4444 %%%%
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MEM9M=7L(;K2%\/P:Q)JS:G;2P313V M#=PR0RI)$K1N  2_\$5?^49G[-/\
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M0,JJ++Q9XFN;OQ=XKTY"H7S(=,\1:]J>GP3LJ27$-M'/*B22,H^LJ "BBB@
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MX7OX(_YY:Y_X 6__ ,G4?\+W\$?\\M<_\ +?_P"3J]>^PV7_ #YVO_@/%_\
M$4?8;+_GSM?_  'B_P#B* /(?^%[^"/^>6N?^ %O_P#)U'_"]_!'_/+7/_ "
MW_\ DZO7OL-E_P ^=K_X#Q?_ !%'V&R_Y\[7_P !XO\ XB@#R'_A>_@C_GEK
MG_@!;_\ R=1_PO?P1_SRUS_P M__ ).KU[[#9?\ /G:_^ \7_P 11]ALO^?.
MU_\  >+_ .(H \A_X7OX(_YY:Y_X 6__ ,G4?\+W\$?\\M<_\ +?_P"3J]>^
MPV7_ #YVO_@/%_\ $4?8;+_GSM?_  'B_P#B* /(?^%[^"/^>6N?^ %O_P#)
MU?F9_P %%_B5HOC)?@]INBK?JEN?B!?77VRVC@!:,>";>W\MDFF)(%S<;@2@
MP0<-CY?V1^PV7_/G:_\ @/%_\17Y5?\ !3[3K2/3/@S>Q0Q12Q7WCNU'E1QQ
MAH[JW\)RON*J"2&LXMO..6]J /R.HHHH **** .<\4>,/"O@G3AJ_B[Q#H_A
MO37G6UBN]8O[>PBN+IHY9EM+;SY$:ZNFAAFF6VMUEG:*&:01E(G9?F_Q5^VU
M^SYX625O^$HOM>>$.731-'NQ&2BERL=]K?\ 8NF2_*,^9%?/"HSND7:^W]7/
MV0_V;O@?^TS\2=6\*?'KX;^'/BEX4\->$KGQ=I/AOQ5!/=Z/!XEL_$'AW3[/
M5)K**X@AO6@L-1U.R:TOTN;">WU"XCN+656 'ZJ>'_\ @F[_ ,$]_"S1RZ'^
MP[^R5:7D2SHNIR_L]?"F_P!9,=P[/-$^MZCX5N]7EB<L0(I;UXT3$:*L:JH
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M\+W\$?\ /+7/_ "W_P#DZO7OL-E_SYVO_@/%_P#$4?8;+_GSM?\ P'B_^(H
M\A_X7OX(_P">6N?^ %O_ /)U'_"]_!'_ #RUS_P M_\ Y.KU[[#9?\^=K_X#
MQ?\ Q%'V&R_Y\[7_ ,!XO_B* /(?^%[^"/\ GEKG_@!;_P#R=1_PO?P1_P \
MM<_\ +?_ .3J]>^PV7_/G:_^ \7_ ,11]ALO^?.U_P# >+_XB@#R'_A>_@C_
M )Y:Y_X 6_\ \G4?\+W\$?\ /+7/_ "W_P#DZO7OL-E_SYVO_@/%_P#$4?8;
M+_GSM?\ P'B_^(H \A_X7OX(_P">6N?^ %O_ /)U'_"]_!'_ #RUS_P M_\
MY.KU[[#9?\^=K_X#Q?\ Q%'V&R_Y\[7_ ,!XO_B* /(?^%[^"/\ GEKG_@!;
M_P#R=1_PO?P1_P \M<_\ +?_ .3J]>^PV7_/G:_^ \7_ ,11]ALO^?.U_P#
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M]>^PV7_/G:_^ \7_ ,11]ALO^?.U_P# >+_XB@#R'_A>_@C_ )Y:Y_X 6_\
M\G4?\+W\$?\ /+7/_ "W_P#DZO7OL-E_SYVO_@/%_P#$4?8;+_GSM?\ P'B_
M^(H \A_X7OX(_P">6N?^ %O_ /)U'_"]_!'_ #RUS_P M_\ Y.KU[[#9?\^=
MK_X#Q?\ Q%'V&R_Y\[7_ ,!XO_B* /(?^%[^"/\ GEKG_@!;_P#R=1_PO?P1
M_P \M<_\ +?_ .3J]>^PV7_/G:_^ \7_ ,11]ALO^?.U_P# >+_XB@#R'_A>
M_@C_ )Y:Y_X 6_\ \G4?\+W\$?\ /+7/_ "W_P#DZO7OL-E_SYVO_@/%_P#$
M4?8;+_GSM?\ P'B_^(H \A_X7OX(_P">6N?^ %O_ /)U'_"]_!'_ #RUS_P
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M \7_ ,11]ALO^?.U_P# >+_XB@#R'_A>_@C_ )Y:Y_X 6_\ \G4?\+W\$?\
M/+7/_ "W_P#DZO7OL-E_SYVO_@/%_P#$4?8;+_GSM?\ P'B_^(H \A_X7OX(
M_P">6N?^ %O_ /)U'_"]_!'_ #RUS_P M_\ Y.KU[[#9?\^=K_X#Q?\ Q%'V
M&R_Y\[7_ ,!XO_B* /(?^%[^"/\ GEKG_@!;_P#R=1_PO?P1_P \M<_\ +?_
M .3J]>^PV7_/G:_^ \7_ ,11]ALO^?.U_P# >+_XB@#R'_A>_@C_ )Y:Y_X
M6_\ \G4?\+W\$?\ /+7/_ "W_P#DZO7OL-E_SYVO_@/%_P#$4?8;+_GSM?\
MP'B_^(H \A_X7OX(_P">6N?^ %O_ /)U'_"]_!'_ #RUS_P M_\ Y.KU[[#9
M?\^=K_X#Q?\ Q%'V&R_Y\[7_ ,!XO_B* /(?^%[^"/\ GEKG_@!;_P#R=1_P
MO?P1_P \M<_\ +?_ .3J]>^PV7_/G:_^ \7_ ,11]ALO^?.U_P# >+_XB@#R
M'_A>_@C_ )Y:Y_X 6_\ \G4?\+W\$?\ /+7/_ "W_P#DZO7OL-E_SYVO_@/%
M_P#$4?8;+_GSM?\ P'B_^(H \A_X7OX(_P">6N?^ %O_ /)U'_"]_!'_ #RU
MS_P M_\ Y.KU[[#9?\^=K_X#Q?\ Q%'V&R_Y\[7_ ,!XO_B* /(?^%[^"/\
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M7OX(_P">6N?^ %O_ /)U'_"]_!'_ #RUS_P M_\ Y.KU[[#9?\^=K_X#Q?\
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M\+W\$?\ /+7/_ "W_P#DZO7OL-E_SYVO_@/%_P#$4?8;+_GSM?\ P'B_^(H
M\A_X7OX(_P">6N?^ %O_ /)U'_"]_!'_ #RUS_P M_\ Y.KU[[#9?\^=K_X#
MQ?\ Q%'V&R_Y\[7_ ,!XO_B* /(?^%[^"/\ GEKG_@!;_P#R=1_PO?P1_P \
MM<_\ +?_ .3J]>^PV7_/G:_^ \7_ ,11]ALO^?.U_P# >+_XB@#R'_A>_@C_
M )Y:Y_X 6_\ \G4?\+W\$?\ /+7/_ "W_P#DZO7OL-E_SYVO_@/%_P#$4?8;
M+_GSM?\ P'B_^(H \A_X7OX(_P">6N?^ %O_ /)U'_"]_!'_ #RUS_P M_\
MY.KU[[#9?\^=K_X#Q?\ Q%'V&R_Y\[7_ ,!XO_B* /(?^%[^"/\ GEKG_@!;
M_P#R=1_PO?P1_P \M<_\ +?_ .3J]>^PV7_/G:_^ \7_ ,11]ALO^?.U_P#
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M]>^PV7_/G:_^ \7_ ,11]ALO^?.U_P# >+_XB@#R'_A>_@C_ )Y:Y_X 6_\
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M_P ^=K_X#Q?_ !% 'D/_  O?P1_SRUS_ , +?_Y.H_X7OX(_YY:Y_P" %O\
M_)U>O?8;+_GSM?\ P'B_^(H^PV7_ #YVO_@/%_\ $4 >0_\ "]_!'_/+7/\
MP M__DZC_A>_@C_GEKG_ ( 6_P#\G5Z]]ALO^?.U_P# >+_XBC[#9?\ /G:_
M^ \7_P 10!Y#_P +W\$?\\M<_P# "W_^3J/^%[^"/^>6N?\ @!;_ /R=7KWV
M&R_Y\[7_ ,!XO_B*/L-E_P ^=K_X#Q?_ !% 'D/_  O?P1_SRUS_ , +?_Y.
MH_X7OX(_YY:Y_P" %O\ _)U>O?8;+_GSM?\ P'B_^(H^PV7_ #YVO_@/%_\
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M_P ^=K_X#Q?_ !% 'D/_  O?P1_SRUS_ , +?_Y.H_X7OX(_YY:Y_P" %O\
M_)U>O?8;+_GSM?\ P'B_^(H^PV7_ #YVO_@/%_\ $4 >0_\ "]_!'_/+7/\
MP M__DZC_A>_@C_GEKG_ ( 6_P#\G5Z]]ALO^?.U_P# >+_XBC[#9?\ /G:_
M^ \7_P 10!Y#_P +W\$?\\M<_P# "W_^3J/^%[^"/^>6N?\ @!;_ /R=7KWV
M&R_Y\[7_ ,!XO_B*/L-E_P ^=K_X#Q?_ !% 'D/_  O?P1_SRUS_ , +?_Y.
MH_X7OX(_YY:Y_P" %O\ _)U>O?8;+_GSM?\ P'B_^(H^PV7_ #YVO_@/%_\
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M_P ^=K_X#Q?_ !% 'D/_  O?P1_SRUS_ , +?_Y.H_X7OX(_YY:Y_P" %O\
M_)U>O?8;+_GSM?\ P'B_^(H^PV7_ #YVO_@/%_\ $4 >0_\ "]_!'_/+7/\
MP M__DZC_A>_@C_GEKG_ ( 6_P#\G5Z]]ALO^?.U_P# >+_XBC[#9?\ /G:_
M^ \7_P 10!Y#_P +W\$?\\M<_P# "W_^3J/^%[^"/^>6N?\ @!;_ /R=7KWV
M&R_Y\[7_ ,!XO_B*/L-E_P ^=K_X#Q?_ !% 'D/_  O?P1_SRUS_ , +?_Y.
MH_X7OX(_YY:Y_P" %O\ _)U>O?8;+_GSM?\ P'B_^(H^PV7_ #YVO_@/%_\
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M_P ^=K_X#Q?_ !% 'D/_  O?P1_SRUS_ , +?_Y.H_X7OX(_YY:Y_P" %O\
M_)U>O?8;+_GSM?\ P'B_^(H^PV7_ #YVO_@/%_\ $4 >0_\ "]_!'_/+7/\
MP M__DZC_A>_@C_GEKG_ ( 6_P#\G5Z]]ALO^?.U_P# >+_XBC[#9?\ /G:_
M^ \7_P 10!Y#_P +W\$?\\M<_P# "W_^3J/^%[^"/^>6N?\ @!;_ /R=7KWV
M&R_Y\[7_ ,!XO_B*/L-E_P ^=K_X#Q?_ !% 'D/_  O?P1_SRUS_ , +?_Y.
MH_X7OX(_YY:Y_P" %O\ _)U>O?8;+_GSM?\ P'B_^(H^PV7_ #YVO_@/%_\
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M_P ^=K_X#Q?_ !% 'D/_  O?P1_SRUS_ , +?_Y.H_X7OX(_YY:Y_P" %O\
M_)U>O?8;+_GSM?\ P'B_^(H^PV7_ #YVO_@/%_\ $4 >0_\ "]_!'_/+7/\
MP M__DZC_A>_@C_GEKG_ ( 6_P#\G5Z]]ALO^?.U_P# >+_XBC[#9?\ /G:_
M^ \7_P 10!Y#_P +W\$?\\M<_P# "W_^3J/^%[^"/^>6N?\ @!;_ /R=7KWV
M&R_Y\[7_ ,!XO_B*/L-E_P ^=K_X#Q?_ !% 'D/_  O?P1_SRUS_ , +?_Y.
MH_X7OX(_YY:Y_P" %O\ _)U>O?8;+_GSM?\ P'B_^(H^PV7_ #YVO_@/%_\
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M6&*VM;:"-(8((TBB1415'MOV&R_Y\[7_ ,!XO_B*/L-E_P ^=K_X#Q?_ !%
M'D/_  O?P1_SRUS_ , +?_Y.H_X7OX(_YY:Y_P" %O\ _)U>O?8;+_GSM?\
MP'B_^(H^PV7_ #YVO_@/%_\ $4 >0_\ "]_!'_/+7/\ P M__DZC_A>_@C_G
MEKG_ ( 6_P#\G5Z]]ALO^?.U_P# >+_XBC[#9?\ /G:_^ \7_P 10!Y#_P +
MW\$?\\M<_P# "W_^3J/^%[^"/^>6N?\ @!;_ /R=7KWV&R_Y\[7_ ,!XO_B*
M/L-E_P ^=K_X#Q?_ !% 'D/_  O?P1_SRUS_ , +?_Y.H_X7OX(_YY:Y_P"
M%O\ _)U>O?8;+_GSM?\ P'B_^(H^PV7_ #YVO_@/%_\ $4 >0_\ "]_!'_/+
M7/\ P M__DZC_A>_@C_GEKG_ ( 6_P#\G5Z]]ALO^?.U_P# >+_XBC[#9?\
M/G:_^ \7_P 10!Y#_P +W\$?\\M<_P# "W_^3J/^%[^"/^>6N?\ @!;_ /R=
M7KWV&R_Y\[7_ ,!XO_B*/L-E_P ^=K_X#Q?_ !% 'D/_  O?P1_SRUS_ , +
M?_Y.H_X7OX(_YY:Y_P" %O\ _)U>O?8;+_GSM?\ P'B_^(H^PV7_ #YVO_@/
M%_\ $4 >0_\ "]_!'_/+7/\ P M__DZC_A>_@C_GEKG_ ( 6_P#\G5Z]]ALO
M^?.U_P# >+_XBC[#9?\ /G:_^ \7_P 10!Y#_P +W\$?\\M<_P# "W_^3J/^
M%[^"/^>6N?\ @!;_ /R=7KWV&R_Y\[7_ ,!XO_B*/L-E_P ^=K_X#Q?_ !%
M'D/_  O?P1_SRUS_ , +?_Y.H_X7OX(_YY:Y_P" %O\ _)U>O?8;+_GSM?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "OF?]HK_ )D__N8/_<'7TQ7S/^T5_P R?_W,'_N#H Z;X ?\B;J?_8S7
MG_IJT:O<J\-^ '_(FZG_ -C->?\ IJT:O<J "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KYG_:*_P"9
M/_[F#_W!U],5\S_M%?\ ,G_]S!_[@Z .F^ '_(FZG_V,UY_Z:M&KW*O#?@!_
MR)NI_P#8S7G_ *:M&KW*@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH *^9_VBO\ F3_^Y@_]P=?3%?,_
M[17_ #)__<P?^X.@#IO@!_R)NI_]C->?^FK1J]RKPWX ?\B;J?\ V,UY_P"F
MK1J]RH **** "BBB@ HHK'\0^(=#\):!KGBKQ/J^GZ!X:\,Z/J?B'Q#KVKW<
M-AI6B:'HME/J6K:OJ=]</';V>GZ;86UQ>7MW.Z0V]M#+-*ZHC$ &Q17*>!O'
M?@SXF>%-%\=_#WQ1H?C3P;XCMI+O0?$_AO4;;5M$U:VBN9[.6:PU"SDEM[A(
MKNVN+64QN?+N()87"R1LHZN@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ KYG_:*_YD__ +F#_P!P=?3%?,_[17_,G_\ <P?^X.@#
MIO@!_P B;J?_ &,UY_Z:M&KW*O#?@!_R)NI_]C->?^FK1J]RH **** "BBB@
M"&XN+>TMY[N[GAM;6UAEN+FYN)4AM[>WA1I)IYYI&6.*&&-6DEED94C16=V"
M@D?SI_M"_P#!1;XW_MU>%/VA?V<OV!?V4?%GQA^'M_X8\2_"_P 7_'C4]<M-
M!T=[?Q+87>AZD_AG3+S^SM'1;[3Y[BZT+^U_%_\ ;6K:5<K?W7A+38(I%?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-XF_\";7_P"1J]RHH \-_P"%%Z/_ -#-XF_\";7_ .1J/^%%Z/\ ]#-XF_\
M FU_^1J]RHH \-_X47H__0S>)O\ P)M?_D:C_A1>C_\ 0S>)O_ FU_\ D:O<
MJ* /#?\ A1>C_P#0S>)O_ FU_P#D:C_A1>C_ /0S>)O_  )M?_D:O<J* /#?
M^%%Z/_T,WB;_ ,";7_Y&H_X47H__ $,WB;_P)M?_ )&KW*B@#PW_ (47H_\
MT,WB;_P)M?\ Y&H_X47H_P#T,WB;_P ";7_Y&KW*B@#PW_A1>C_]#-XF_P#
MFU_^1J/^%%Z/_P!#-XF_\";7_P"1J]RHH \-_P"%%Z/_ -#-XF_\";7_ .1J
M/^%%Z/\ ]#-XF_\  FU_^1J]RHH \-_X47H__0S>)O\ P)M?_D:C_A1>C_\
M0S>)O_ FU_\ D:O<J* /#?\ A1>C_P#0S>)O_ FU_P#D:C_A1>C_ /0S>)O_
M  )M?_D:O<J* /#?^%%Z/_T,WB;_ ,";7_Y&H_X47H__ $,WB;_P)M?_ )&K
MW*B@#PW_ (47H_\ T,WB;_P)M?\ Y&H_X47H_P#T,WB;_P ";7_Y&KW*B@#P
MW_A1>C_]#-XF_P# FU_^1J/^%%Z/_P!#-XF_\";7_P"1J]RHH \-_P"%%Z/_
M -#-XF_\";7_ .1J/^%%Z/\ ]#-XF_\  FU_^1J]RHH \-_X47H__0S>)O\
MP)M?_D:C_A1>C_\ 0S>)O_ FU_\ D:O<J* /#?\ A1>C_P#0S>)O_ FU_P#D
M:C_A1>C_ /0S>)O_  )M?_D:O<J* /#?^%%Z/_T,WB;_ ,";7_Y&H_X47H__
M $,WB;_P)M?_ )&KW*B@#PW_ (47H_\ T,WB;_P)M?\ Y&H_X47H_P#T,WB;
M_P ";7_Y&KW*B@#PW_A1>C_]#-XF_P# FU_^1J/^%%Z/_P!#-XF_\";7_P"1
MJ]RHH \-_P"%%Z/_ -#-XF_\";7_ .1J/^%%Z/\ ]#-XF_\  FU_^1J]RHH
M\-_X47H__0S>)O\ P)M?_D:C_A1>C_\ 0S>)O_ FU_\ D:O<J* /#?\ A1>C
M_P#0S>)O_ FU_P#D:C_A1>C_ /0S>)O_  )M?_D:O<J* /#?^%%Z/_T,WB;_
M ,";7_Y&H_X47H__ $,WB;_P)M?_ )&KW*B@#PW_ (47H_\ T,WB;_P)M?\
MY&H_X47H_P#T,WB;_P ";7_Y&KW*B@#PW_A1>C_]#-XF_P# FU_^1J/^%%Z/
M_P!#-XF_\";7_P"1J]RHH \-_P"%%Z/_ -#-XF_\";7_ .1J/^%%Z/\ ]#-X
MF_\  FU_^1J]RHH \-_X47H__0S>)O\ P)M?_D:C_A1>C_\ 0S>)O_ FU_\
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MRHH \-_X47H__0S>)O\ P)M?_D:C_A1>C_\ 0S>)O_ FU_\ D:O<J* /#?\
MA1>C_P#0S>)O_ FU_P#D:C_A1>C_ /0S>)O_  )M?_D:O<J* /#?^%%Z/_T,
MWB;_ ,";7_Y&H_X47H__ $,WB;_P)M?_ )&KW*B@#PW_ (47H_\ T,WB;_P)
MM?\ Y&H_X47H_P#T,WB;_P ";7_Y&KW*B@#PW_A1>C_]#-XF_P# FU_^1J/^
M%%Z/_P!#-XF_\";7_P"1J]RHH \-_P"%%Z/_ -#-XF_\";7_ .1J/^%%Z/\
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M-XF_\";7_P"1J]RHH \-_P"%%Z/_ -#-XF_\";7_ .1J/^%%Z/\ ]#-XF_\
M FU_^1J]RHH \-_X47H__0S>)O\ P)M?_D:C_A1>C_\ 0S>)O_ FU_\ D:O<
MJ* /#?\ A1>C_P#0S>)O_ FU_P#D:C_A1>C_ /0S>)O_  )M?_D:O<J* /#?
M^%%Z/_T,WB;_ ,";7_Y&H_X47H__ $,WB;_P)M?_ )&KW*B@#PW_ (47H_\
MT,WB;_P)M?\ Y&H_X47H_P#T,WB;_P ";7_Y&KW*B@#PW_A1>C_]#-XF_P#
MFU_^1J/^%%Z/_P!#-XF_\";7_P"1J]RHH \-_P"%%Z/_ -#-XF_\";7_ .1J
M/^%%Z/\ ]#-XF_\  FU_^1J]RHH \-_X47H__0S>)O\ P)M?_D:C_A1>C_\
M0S>)O_ FU_\ D:O<J* /#?\ A1>C_P#0S>)O_ FU_P#D:C_A1>C_ /0S>)O_
M  )M?_D:O<J* /#?^%%Z/_T,WB;_ ,";7_Y&H_X47H__ $,WB;_P)M?_ )&K
MW*B@#PW_ (47H_\ T,WB;_P)M?\ Y&H_X47H_P#T,WB;_P ";7_Y&KW*B@#P
MW_A1>C_]#-XF_P# FU_^1J/^%%Z/_P!#-XF_\";7_P"1J]RHH \-_P"%%Z/_
M -#-XF_\";7_ .1J/^%%Z/\ ]#-XF_\  FU_^1J]RHH \-_X47H__0S>)O\
MP)M?_D:C_A1>C_\ 0S>)O_ FU_\ D:O<J* /#?\ A1>C_P#0S>)O_ FU_P#D
M:C_A1>C_ /0S>)O_  )M?_D:O<J* /#?^%%Z/_T,WB;_ ,";7_Y&H_X47H__
M $,WB;_P)M?_ )&KW*B@#PW_ (47H_\ T,WB;_P)M?\ Y&H_X47H_P#T,WB;
M_P ";7_Y&KW*B@#PW_A1>C_]#-XF_P# FU_^1J/^%%Z/_P!#-XF_\";7_P"1
MJ]RHH \-_P"%%Z/_ -#-XF_\";7_ .1J/^%%Z/\ ]#-XF_\  FU_^1J]RHH
M\-_X47H__0S>)O\ P)M?_D:C_A1>C_\ 0S>)O_ FU_\ D:O<J* /#?\ A1>C
M_P#0S>)O_ FU_P#D:C_A1>C_ /0S>)O_  )M?_D:O<J* /#?^%%Z/_T,WB;_
M ,";7_Y&H_X47H__ $,WB;_P)M?_ )&KW*B@#PW_ (47H_\ T,WB;_P)M?\
MY&H_X47H_P#T,WB;_P ";7_Y&KW*B@#PW_A1>C_]#-XF_P# FU_^1J/^%%Z/
M_P!#-XF_\";7_P"1J]RHH \-_P"%%Z/_ -#-XF_\";7_ .1J/^%%Z/\ ]#-X
MF_\  FU_^1J]RHH \-_X47H__0S>)O\ P)M?_D:C_A1>C_\ 0S>)O_ FU_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!7S/^T5_S)__ ','_N#KZ8KYG_:*_P"9/_[F#_W!T =-\ /^1-U/_L9KS_TU
M:-7N5>&_ #_D3=3_ .QFO/\ TU:-7N5 !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\S_M%?\R?_P!S
M!_[@Z^F*^9_VBO\ F3_^Y@_]P= '3? #_D3=3_[&:\_]-6C5[E7AOP _Y$W4
M_P#L9KS_ --6C5[E0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MVDV@W]W?WND7NCW*27]Y;SVL[@'YB_LK?#;PA_P4Y_X*4_M9_M"?'/1QX_\
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M (%VW_S6T?V]\>/^A*\,_P#@7;?_ #6T >Y45X;_ &]\>/\ H2O#/_@7;?\
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M>/\ H2O#/_@7;?\ S6T?V]\>/^A*\,_^!=M_\UM 'N5%>&_V]\>/^A*\,_\
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M_P!"5X9_\"[;_P":V@#W*BO#?[>^/'_0E>&?_ NV_P#FMH_M[X\?]"5X9_\
M NV_^:V@#W*BO#?[>^/'_0E>&?\ P+MO_FMH_M[X\?\ 0E>&?_ NV_\ FMH
M]RHKPW^WOCQ_T)7AG_P+MO\ YK:/[>^/'_0E>&?_  +MO_FMH ]RHKPW^WOC
MQ_T)7AG_ ,"[;_YK:/[>^/'_ $)7AG_P+MO_ )K: /<J*\-_M[X\?]"5X9_\
M"[;_ .:VC^WOCQ_T)7AG_P "[;_YK: /<J*\-_M[X\?]"5X9_P# NV_^:VC^
MWOCQ_P!"5X9_\"[;_P":V@#W*BO#?[>^/'_0E>&?_ NV_P#FMH_M[X\?]"5X
M9_\  NV_^:V@#W*BO#?[>^/'_0E>&?\ P+MO_FMH_M[X\?\ 0E>&?_ NV_\
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M_P!"5X9_\"[;_P":V@#W*BO#?[>^/'_0E>&?_ NV_P#FMH_M[X\?]"5X9_\
M NV_^:V@#W*BO#?[>^/'_0E>&?\ P+MO_FMH_M[X\?\ 0E>&?_ NV_\ FMH
M]RHKPW^WOCQ_T)7AG_P+MO\ YK:/[>^/'_0E>&?_  +MO_FMH ]RHKPW^WOC
MQ_T)7AG_ ,"[;_YK:/[>^/'_ $)7AG_P+MO_ )K: /<J*\-_M[X\?]"5X9_\
M"[;_ .:VC^WOCQ_T)7AG_P "[;_YK: /<J*\-_M[X\?]"5X9_P# NV_^:VC^
MWOCQ_P!"5X9_\"[;_P":V@#W*BO#?[>^/'_0E>&?_ NV_P#FMH_M[X\?]"5X
M9_\  NV_^:V@#W*BO#?[>^/'_0E>&?\ P+MO_FMH_M[X\?\ 0E>&?_ NV_\
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M?]"5X9_\"[;_ .:VC^WOCQ_T)7AG_P "[;_YK: /<J*\-_M[X\?]"5X9_P#
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M=M_\UM 'N5%>&_V]\>/^A*\,_P#@7;?_ #6T?V]\>/\ H2O#/_@7;?\ S6T
M>Y45X;_;WQX_Z$KPS_X%VW_S6T?V]\>/^A*\,_\ @7;?_-;0![E17AO]O?'C
M_H2O#/\ X%VW_P UM']O?'C_ *$KPS_X%VW_ ,UM 'N5%>&_V]\>/^A*\,_^
M!=M_\UM']O?'C_H2O#/_ (%VW_S6T >Y45X;_;WQX_Z$KPS_ .!=M_\ -;1_
M;WQX_P"A*\,_^!=M_P#-;0![E17AO]O?'C_H2O#/_@7;?_-;1_;WQX_Z$KPS
M_P"!=M_\UM 'N5%>&_V]\>/^A*\,_P#@7;?_ #6T?V]\>/\ H2O#/_@7;?\
MS6T >Y45X;_;WQX_Z$KPS_X%VW_S6T?V]\>/^A*\,_\ @7;?_-;0![E17AO]
MO?'C_H2O#/\ X%VW_P UM']O?'C_ *$KPS_X%VW_ ,UM 'N5%>&_V]\>/^A*
M\,_^!=M_\UM']O?'C_H2O#/_ (%VW_S6T >Y45X;_;WQX_Z$KPS_ .!=M_\
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M\-_M[X\?]"5X9_\  NV_^:VC^WOCQ_T)7AG_ ,"[;_YK: /<J*\-_M[X\?\
M0E>&?_ NV_\ FMH_M[X\?]"5X9_\"[;_ .:V@#W*BO#?[>^/'_0E>&?_  +M
MO_FMH_M[X\?]"5X9_P# NV_^:V@#W*BO#?[>^/'_ $)7AG_P+MO_ )K:/[>^
M/'_0E>&?_ NV_P#FMH ]RHKPW^WOCQ_T)7AG_P "[;_YK:/[>^/'_0E>&?\
MP+MO_FMH ]RHKPW^WOCQ_P!"5X9_\"[;_P":VC^WOCQ_T)7AG_P+MO\ YK:
M/<J*\-_M[X\?]"5X9_\  NV_^:VC^WOCQ_T)7AG_ ,"[;_YK: /<J*\-_M[X
M\?\ 0E>&?_ NV_\ FMH_M[X\?]"5X9_\"[;_ .:V@#W*BO#?[>^/'_0E>&?_
M  +MO_FMH_M[X\?]"5X9_P# NV_^:V@#W*BO#?[>^/'_ $)7AG_P+MO_ )K:
M/[>^/'_0E>&?_ NV_P#FMH ]RHKPW^WOCQ_T)7AG_P "[;_YK:/[>^/'_0E>
M&?\ P+MO_FMH ]RHKPW^WOCQ_P!"5X9_\"[;_P":VC^WOCQ_T)7AG_P+MO\
MYK: /<J*\-_M[X\?]"5X9_\  NV_^:VC^WOCQ_T)7AG_ ,"[;_YK: /<J*\-
M_M[X\?\ 0E>&?_ NV_\ FMH_M[X\?]"5X9_\"[;_ .:V@#W*BO#?[>^/'_0E
M>&?_  +MO_FMH_M[X\?]"5X9_P# NV_^:V@#W*BO#?[>^/'_ $)7AG_P+MO_
M )K:Z?X=^--4\4G7].US3[?3]:\-WJ6>H)9D_9#)+-?0>5$&NKTF2WDL)4ED
M6XDAE+*T)V\D ]+HHHH **** "OF?]HK_F3_ /N8/_<'7TQ7S/\ M%?\R?\
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MBKW*LJ?0](N=5M-;GL()=6L8F@M+Y@QGMX6$X:.,[@H4BYG!RI/[QN>F-6@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KYG_
M &BO^9/_ .Y@_P#<'7TQ7S/^T5_S)_\ W,'_ +@Z .F^ '_(FZG_ -C->?\
MIJT:O<J\-^ '_(FZG_V,UY_Z:M&KW*@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KY>_:\_:
MQ^'G[&GP@F^+OQ%TSQ/X@M;GQ%I/@SPOX6\':?#J/B/Q7XR\00W\VC:%I\=U
M<V=G;^?#IE_=W5W<W*B"SL[C[+!?W[6>G7?U#6)KT7AQ+(:SXGCT1-.\+O+X
ME75=>2Q6R\.R:99W9FU\7VH 0:0^GZ?-?&751+;M:6<MWOGC@>;(!^#7B_\
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M %^Z>/6;VTO+FP\BTFTK^S[M)[FX_%__ ()1?\I1?^"JO_94_BO_ .M#^,J
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MW5OHVFRB.(Z5_:^GW]OJJ?O57\R/_!93X5_#CX,:_P#\$Q?A[\*?!/ASX?\
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MU_PSXS@7[/'J=O8B_D+ZCJ>IW<H!_4Y17B'QV_:!^'O[//P-\:?M ^/;V=?
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MZ_XD\3ZW]I.E:-IZ7=U8V%N98K.\N[F\O[VVM[:RL[ET^TW?V:RN?R \1?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MCZ/%J%E=ZG93^&O">L6^C27FM:9<>)FTVZTI #][**^0?VW_ -L7P)^P_P#
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M*[O=2TZRN-2U33M(\3:U->W=SI5])!IF@^%-;E2TMGN-2N-+6XT\WGQ?;?\
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MNCFXTN^M/".E))HDGR1X.A+MT<+M.U;$+ODQYC?E!^V#J-__ ,%(/VZ/ O[
MO@^]O6_9X_9TU"U^*G[6NOZ9/)%:ZUX@L-D>F_#N.^MFV-<6D=]'X=2-;E)[
M?7O$'B;49=/EN?AY$] 'MW_!.K_@K%>_MX?&#QK\(]3_ &>Y?@_=>%?AQ<_$
MNWUB3XCS>+FU'3&\0^%=)T_3I-(N/A_X2DMC=6'BRRU2'6$O[BWO(81)!81P
MW<4D?['U_.'^P)IVGZ1_P6S_ &_])TFQM-,TO2_AKXCT[3=-L+>&SL=/T^R\
M:_!>VL[&RM+=(X+6TM+>*."VMX(TA@AC2*-%154?T>4 %%%% !1110 4444
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MTE[B"U0:WHVF:E\9M9TV\NH7^U7$4#)XE@MY+BUBO='F%C=17?U7_P $SOV
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MO:>)? /B?PQ]LBU76-!DU32M0N?#UY;ZA#I>IV]]%% 5$]LUS!<)SFM^,?\
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MKFK75W?W"0QQ6=FLL6GZ=!:Z;9VEK#[M0 4444 %%%% !1110 4444 %%%%
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M\;^,?$LUI!J.FQW]IHD>D^%;75YC90ZIXADTEI)1^Z?[/_P3\'_LX_!CX=?
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M+Z?<W4DNA:7:C0HO#\?B2*\1YY)VU"XTEH(C&ERZ?HQ10!_-W_P3?_Y3)?\
M!2K_ +J;_P"KF\+U_2$[I&C22,J(BL[N[!41%!9F9F("JH!+,2  "2<"OYL%
M_98_X*A?LU_MW?M6?M)_LO\ P<^"?Q#T/XX^(O%*:9>_$KQAI_V!_"WB/Q/I
MWC"&6#1K'XB^ M<T_6;2\LH=/N3J$DUJ1%=^1;S1RVUY7H'Q%^$7_!<#]L72
M;CX8_%+Q!\ /V3?AEK*I9>,KSX8ZQJ,FM>(-%D61+ZPAETCQ1\1/$EU!=Q2F
M&^T9/%G@[3-7MPUCJ-T]A-<03@'E7_!,2_M_VA?^"M7[=W[3_@]EU/X8Z7I/
MBGPQH_B&&(M::G)XG\:^&M,\&7UK,JQ(L6N^&?AOX@U> .IN#;/'YJ^8TCUY
MC\4;+]J[Q5_P72^/-C^S5XA^$G@_XNZ/\,_#Z>%=1^,T>MWWA"/P2GPE^%[Z
ME%I@T3P[XEO!KNH1ZI=7:*-,%K;K-KL#W22(OF_OY^Q;^QK\+?V(/@W9?"7X
M:_:M5N+J];7O&_C?5X;>+7_''BF>WAM[C5;]+8&*QT^UMX(K'0M#@DFMM'TZ
M)8VN+[4;C4M5U'XA_;[_ &"_CGXM^/7P\_;E_8D\3>'?"W[3/PZTZ+1=>\,^
M(C!9Z1\3=&A@GTFUWZA?,='34H_#VI:EX:UBPUQ;2RUOPXUBEOK>BZCH5E_:
M(!YU\4OV=?\ @MK\8OAOX[^%/CCXT_L&WO@_XB^%-=\&^)+:TL?B59WCZ/XA
MTZXTR]:RO(_@XSV=]%#<--97:*S6UU'%.JL4VGR?]I_]G3XK_L??\$)/&/P&
M\9^)/#OB+Q1X0UC0?^$FU'P5=ZQ=>'K7P]XO_:6TGQ)'I^CWVLZ3H&K7EN9-
M<L(M2>\T;3U,E[J=JL,UG&ES<>X+^TE_P6]UV&;PSI_[ WP0\)^)5CCAN?&N
MO?%/PW?^$+!IXW;[=;:79?%Q[K4!&K)L@T_5M:>VN !>VTJ"6%?T2U'X%>,/
MCQ^Q]>_ 3]JW5_#VO>/?B%\,Y_#'Q0\0^![4Q:#;^++M6N;3Q!X7M9K+2 7\
M-:O%I>JZ5Y^GV<,VH:5#)-;"&1D8 XO_ ()G6N@V?[ G[)L/AQ((]/?X,>%+
MJX6W@BMXSKU_!)?>*7:.'Y&GE\3W&KRW4[?O;FY>:XG_ '\LE?8?B^/Q1+X3
M\41>")])M?&DOAW6X_"%SKZSOH5OXH?3;E= GUI+6*:Z;28M6-I)J*VT,L[6
M:S"&*20JA_G5^"'@+_@LG_P3R\,ZC\ /A5\%OA3^U5\%M(U_5W^&?BB[\2Z-
MI-UHL.N7-SJ[)#IMU\0_!OB+2]'O-3O+S5-7TG6].U2VTS69]0MM,\6#3I[*
MXNOU3_87\&?MP:9:?%+XB?MP^._"^I>,/B7JGABY\'?";P0T,OA7X-Z%H-KK
M4=YI5G/9-+ICW^N3ZK:B_%GJ7B65H=#T^ZO_ !9K5Y=21:> ?%__  C_ /P7
MU_Z'G]C#_P !-0_^8^OV.\!S>,-)^&7@RX^,&I>&O^$_TSP)X=F^*.L:"[V7
M@_\ X3"R\/V;^-M2T:34$M9+3PU_;4>IW6G/?1VSP:7Y+7*0LCJO=U^3'_!7
M/X*_MH?M#_!?PC\(/V2X;.;0O%.LZU_PNV ^+="\':EJOANTM-./AWP\-1UO
M4=.%QX?U6^GU2;Q%IUE+YM__ &?IEI>%]+GOK6[ /AKX_?$7Q_\ \%D_CV/V
M4_V=M5U#0?V(?A'XCTS5_CW\<+&&2.S^(.KZ;=&2VTOPW<3PFVU*!)(YD\"Z
M5*DUKJFIP2_$'5;>YT71M!V_T.?#[P%X2^%G@?PG\./ >BVGA[P;X(T#3/#/
MAK1;)=L&GZ1I%K':6D.XYDGG:.,2W5W.TES>W4DUW=2RW,\LK_S]_L]>&_\
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M61V/84 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M7I'BK2UL]7UGXUW^DR7+76AV-O?75QX51+JV>Z,-AI\TL1MO4/V*M,_X+!_
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MM)>WO@[P+=75I+92:C:7FJV.F7&KZG8:?/)IGANSL=!\->&?!]H]PNCZ1=W
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MJO[2O[+'P0^..O:9!I'B#X@>"++4O$-C:)+%8KX@L+F[T/7;G3H9@)8-,O\
M5M+O+_38':8P6%S;P_:;H(+F7\9/C)\'/^"N_P#P4ATS1_@W\<OA[\+?V/OV
M>+W5],UOQO)IOB72O%'B#Q5!I&I17UA:WNEZ+XR\7:SJLVEW4-OJ>DZ!?1^"
M=#N-8LK75-5U"22STK[-^^GPC^%WA+X)_##P%\(_ EK/9^#_ (<^%=&\(^'X
M;N87-ZVG:+916<5SJ%T$B%UJ5ZT;WNHW0BB%S?7%Q.(XQ)L !Z)1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 ?$O[1?_  3I_8Z_:O\ &D/Q&^._PA_X3/QS:^&;/PC:^([?QW\2?"MQ
M;Z'IUWJ=]I]N=/\ "'C#0M%NI[.[UB_FBO+_ $R[NI%ECMKB6>TM[>WB_#K]
ML[X5>+?^",/C3X.?'[]D#XH?$"#X(>-_'MQH'C[]G/QEXJN]?\%7MY#9IK-Q
M:V4-ZLJR6GB'0-.U2Q37+ZTN_%_A74K>&]T_Q)<Q:@EE8_7K>*_^"Y?[-^J:
MKX:'PR^#7[:O@6+4KJ3P_P"/EUC0?"WB^/29+Z1M/L=0LSXJ^'FH&Z%E,D=V
M)_"GB<VDT//B:^@B\Z[\]N_V*O\ @H!_P4.^-OPN\<_\%"](^'?P2^ OPAUA
M=;T[X$^!-=T_7;[Q3<R/;37T,T^@>(_&=LH\0G2K"PUS6=:\7"_TO1)KFQ\,
M:'I]U?ZA=( ?T-6%Y%J-C9ZA LJ0WUI;WD*3Q-#.L5S"DT:S0O\ /%*J.!)$
MWS1N&1N0:_GM_P"#CC_DUWX&_P#9?(O_ %7GC2OW5^+^H_$[2/A=X]U/X+^'
M_#_BKXLV/A;5[CX>>'?%=X^G^&]8\61VDAT:QUN[2_TIXM-EN_+^TA=5TLRQ
M@Q?VEI_F?:X?YM/VU?V?O^"SO[=W@+PI\._B[^SI^SEX<T3P?XO7QIIEU\./
M'&F:1JD^J+HVJ:&+>^G\3?&7Q?:2Z?\ 9-6N9#%;V-K<?:$@?[5Y2R0R ']/
MNA?\@/1O^P5IW_I)#7Y3_'C1/^"R=Q\7O'4W[/WB_P#93LO@U)JT;?#^T\7V
MFIGQ/;Z(;"S_ '6N%_#-]NU%;W[6+AH[J:!F^:V*VYB1>N_9*\>?\%4M6^)V
MF^'_ -K?X"?LZ^!O@U%X9U.*7Q/\-/$-S/XKM->LK:W&@QFTF^+'CN.^L[UH
MYK:]B31K,Q&5+L:A"MN;2[_3^@#\_P#X:6/[8%A^R9\?8_VTM9^%>M?$R3P]
M\3Y/#TWPEANX=#M_ _\ PKF%+&#4S=:9I0?63KJ>(99/(MI(UT^33]UR\IDA
MM_B+_@WC_P"3&_&G_9R/CS_U /A37[3_ !+\/7WB[X<^/_"FEM FI^)_!/BK
MP]ISW3M%;+?:UH5_IMHUQ(B2-' MQ<QF9UCD9(PS*C$!3_-U^QK\&?\ @M/^
MP[\*=3^#_P )_P!G#]FOQ#X:U;QMJWCVYOOB)XVL-6UU-8UG2/#^BW5M!<^&
MOC5X2T]=-CM?#=C);PR:9)=+<2W;R7DL<D,4 !^_'[6'Q7\.? _]FOXW_%/Q
M3?0V&D^$?AMXINXWG*C[;K-[ID^E>&]&@#I(CWNO>(K_ $K1;"-T:.2]OX$D
M 1F(_)?_ (-Z_A]K?A;]C'QSXVU"S:"/XE_&CQ'J?AG[1'+;QZEH?ACPYX;\
M+B^2Z,<GF6K^)K#Q'IIDA@E6"73;C!EDWPQ<!XJ_8'_X*6?M_P#B;P\O[>WQ
MB\#?!OX%:-J,.I7OP6^"EX]Y<ZE/;W3S#9902:OX?DOV@)M=.\3>+?&'C6X\
M.(XFTWP]/)/J"W/[Z?#;X<^#/A%X"\)?#+X>:':^&O!/@?0K#P[X:T2SWF&Q
MTS3X1%$KRRL\]U=3L'N;Z_NI)KS4+Z:XOKR::ZN)I7 /Y)/^"3F@?\%&_%>@
M_M&:[^R;X^_9L\%S7GQ6MV^+-K\;K+Q9=>)KSQ9)9ZA>6TNGOH?@CQ9$ND0O
M>:O&%N;NWN/[0:^)A=2)6^UOVK/V O\ @KM^V=X T/X:?'+XQ?L17_ACP_XQ
ML?'&FMX<;XFZ#JEMKEAH^N:#&XOK?X-M)+:/IWB+45GL7*PSS"UF<B2UA=>_
M\9?L8_MQ_L5?M1_%/]H;_@G?I/@#XJ_#+X^:G-K?Q%_9Z\9:OI/A6/2]=EN+
MS4FEL;O6_$'A73)=/L-:UC7=2\+7^D^)-)O=&L]7NO#-[H6I:9;17MYZCH/Q
MC_X+4_&#6?#FC6W[+GP*_9F\+3ZYIA\4^/?&GC72O&.K6^BV^H0S:M%HNAZ9
MXM\07<-S<6$<]I&U]X*U*.>2XB:UO+ J]Y;@'R-_P7#T;4;7Q;_P3#\$^-=0
MCUGPBOC3Q#HWC:_E1H['7-1L]3^!6DZKJ&HVLK21)'/ID^L36J2,[+#?:G&[
M.H)K^F,         #  '   X  Z"OSW_ ."D_P"PS8_MW_ '_A7VGZQIGA;X
ME>#]<B\8?##Q7JUO<2Z=9ZW':SV.HZ%K,EDLE_!X?\3:?.;6_GLX;N6PO[72
M-9&GZDVDI87/Y^>$_BC_ ,%[?"OA+2/@Q<_LS_!?Q%XELM,M-!T[]H#7O%OA
M&[3^SK>-K3_A)/$=MIWQ2@TO4->MX45ED;PQ9SW,EO'<WOA/69KF0W@!^PG[
M4EI^TQ>?"'58?V2=3^'6D_&7^UM#;3+OXH17<OAC^Q%OT_MZ+%I9:CMU%[(Y
MM&N+62#:LZ@I<- Z_GK\,]!_X+=I\1O 4GQ1\;?LB2_#./QEX9D^(<.AV>IG
M7)_ \>LV;^*X-$">%+<_VS/H2W\6E;KFVC_M![?S;FWBWS)^B'[*_@/XQ_#/
MX"> /!O[07Q)3XN?&73X?$-_X^\?0?:#::OJ_B+Q;KWB6*QTXW-KI\K:5X:T
M_5[+PMI+#3=*A?3=%M&MM(TFW,6G6OT%0!YA\9/C)\-_@!\-_%'Q9^+/BBP\
M(^!O"-@U]JVK7S$L[$B.TTW3;2,-=:IK.J7316.DZ38Q37VHWTT-M;0O(X%?
M@W^S;\,/B9_P5=_:@T+]NK]H+PU>^#_V3_@[JD]M^S#\(-:43#QI>Z7J23+X
MDU:VDC-I?Z6-8L+;5?%NJ(C67B#7-,TGP98RZGX>\-:D3/\ \%5OV/O^"@_[
M5O[17@^Y^&_@;PE\2?V:?AK9^&=7\,?#WQ+\0M'\,>%?$?BS:]QXLNO&6BQ>
M+?"?B:]N+PN?#R7MGJEA/9^'0\6@W^FW6I:M<77J.B?$?_@N[X:T?2O#WA[]
MC[]A[0M T+3K+2-%T72-6NM.TK2-*TZWCM-/TW3=/M/VCH;6RL;*UABMK2TM
MHHX+>"-(HD5%50 ?I%^WC\?M=_9=_9$^.7QS\+:8-6\4>"?"MK'X:MWA^TV]
MKXB\5>(-&\%Z'K5];;6%UIGAW5/$5KK^JVK>6MSIVFW4#30+(9H_YP_^"<__
M  57_8M_8O\ @SJNC^-/!/[2?C;X[?$_Q5JGCWXW?$/3?"/PUU"V\2>);R[N
MSI]CIVJ:S\7M+UJ]T;1[&XDECFU2QM;F\U[5?$>LM:VG]K&T@_IL_9:U[]I?
MQ)\(M,U3]K7P3\/_ (?_ !F?5]<AU3P[\,[Z:_\ "L6BPWK+H%W!+/XG\8O'
M>75CA[V$>(+U1*OF!;4R&T@^B: /XL/V;/\ @J#\ ?@]_P %&_VJ/VO/$_A'
MXOWOPU^./AG6]$\)Z+H>@>#+KQQIMUJ?B;P!K,$OB/3+_P ?Z;H-I;I:^%=1
M29M,\2ZO*L\UFD<,D<D\MO\ V:^&M>L_%7AS0/$^G17D&G^(]$TK7K&'4;9[
M+4(;/6+&#4+6*^LY"9+2\C@N$2ZMG)>"</$Q+(:_'G]E']DCX_\ PS_X*H_M
ME_M)>-? L>C_  8^*WA'7=+\ >,5\4^#M1;Q!?:EXI^&NK6\ \.Z7K][XITK
M;9^'M7:676]$TV%9+41K(YGM_-_:"@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ KYG_:*_YD_P#[F#_W!U],5\S_ +17_,G_ /<P?^X.
M@#IO@!_R)NI_]C->?^FK1J]RKPWX ?\ (FZG_P!C->?^FK1J]RH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "OF?]HK_F3_ /N8/_<'7TQ7S/\ M%?\R?\ ]S!_[@Z .F^ '_(FZG_V
M,UY_Z:M&KW*O#?@!_P B;J?_ &,UY_Z:M&KW*@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KYG_:*_YD_P#[F#_W!U],
M5\S_ +17_,G_ /<P?^X.@#IO@!_R)NI_]C->?^FK1J]RKPWX ?\ (FZG_P!C
M->?^FK1J]RH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M2&19$6XLKWQO<6=W S*!+:W<$UM<1EHIXI(G=&_N9_X-M?\ @HW^T/\ MU_
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M@>-_"^GV6F^*_%/B'4?"7BJP@U3P[X@F\+>$?#^N^)M+TW6-/N8KNQGU?2;
M31%R #%,$^4/^"P_@SPI\._^"5OQ9\#>!M TSPMX0\+-\&-&\.^'=&MDL]+T
M?2[/XP^ TMK&QMD^6*")>%49))+,2Q).+_P3._X)Y?LT:7^R;\,/B7\2?AWX
M3^.GQ&^//PR\&^-O%OBSXN>&-(\;7.G:+XC\,Z9<Z'X$\-VWB6'68=$\/>&-
M#;3]'5[$Q7>K2V*W=U)#9PZ1I.C@'Z,^!OVM?V:_B1\'=3_: \'?&?P-J?P=
MT*.X?Q!XZNM5&AZ7X;DM$MY)[+Q-;Z_%I>I^'-55+NS9='URPL-5E^W6(BLW
M-[:B;QOX0?\ !3+]A?X\>/K+X7_"[]H7PSKWCK5+R33]'T+4M!\<>#SKNH1F
M0"PT#4O&OA?P[I&O7MP8W^Q6NCW][/J VFQCN Z;OY[_ -E3]A3X:^-?^"H/
M[4G[(GB#6_%O_#,_P@UZ_P#C0OP:M=>U,>%O&]SX?USP]8?#_P /^+5^V(]]
M8>%=.^)UY:F]E6?6+^RM)=.FU!%U&\N7^I_^"Z/[*GP-^$?[//PJ^/GP7^&W
M@KX/?$3P%\7_  KX6M-6^&?AK1_ XO-!U+0O$6I6<=Y;>&K+3;>[U+0-:\,Z
M'>:!J=S&]WI4"ZA;6LR1790 ']&'C#QGX1^'OAK5_&?CSQ1X?\&>$= M3>ZY
MXG\4ZO8:#H.D6@=(A<:CJVISVUC:1--)'"C3SH))I8X8]TDB*WYYW'_!8K_@
MFW;:Y+X>D_:=T1K^&X:U>XM_ 'Q<N]#,JIO+1>)[7X?S>&Y[<CA;R'5I+1G^
M19R_RU[_ .,?AO\ "7]K?]ESP1:_M':3;ZS\/_$W@_X;_%7Q;9WOB'4?".E+
M=V&CZ7XP>YUC5-"U/1&MM'M;AI9]0A>\@T\6R.THC2)'C^"_B+\;?^"'NF>"
M];^!VO:W^RC:^%[JQOM"N++P#\/]/UQ+"86HL'U;2?%?@/P?K45OX@M=ZSV7
MB:TU:34C?1&\COIKB.5P ?L#X.\9^$?B'X8T;QKX#\3Z#XR\(>(K-=0T'Q/X
M8U6RUO0M7LS(\7VC3]4TZ:XL[J-)HI8)3%*QBN(9H)0DT4B+Y7\>_P!I_P"
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M;#3/$NF^<(9/*UBRN;NW\B..QO+2%[B.?\8/^"S'QH^''B#]M']D3]F/X_\
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M\5>"_#/@W3[F%)XC>Z3'X@\4W?B*]L)?+2?4O#>A2QS!K=PH!]VM_P %??\
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MMGN7BCNK=I?Y[?\ @A'^Q'\&/COX,\:_M ?&O2HOBA'\._B-JO@'X?\ PO\
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M4MH0Q2"#RXH@D2)&@!]V?M&?MK?LN?LF?V+'^T%\8-!^'U]XBBDN-%T5M/\
M$?BCQ)?644I@?4D\,>"]%\1^(H]*%PKVXU:?3(M-:XBF@6Z,T,J)P&E_\%)_
MV'M:^#WB/X\Z5^T'X8O_ (8^$-4TC1O%.K6^B^,WU[P_J&OWJZ=HD6K^ ?\
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M16MA;W?AC2=4N8[>".58X_/U"_N[J5@NZ228EF(50OQQ_P )!KW_ $&]7_\
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M_P ./XQ_^7-'_"_?CM_T6KXM?^''\8__ "YH _IVHK^8G_A?OQV_Z+5\6O\
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M6\UW>7EW-';6MI:VT;37%S<W$S)#!;P0H\LTTKI'%&C.[*JDC\Y=?_X*\?\
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M )$W4_\ L9KS_P!-6C5[E0 4444 %%%% !1110 4444 %%%% !1110 4444
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MVNK:<]UI]Y'+!*]EJ=C:7ULS(3%<V\4BD,HH ^>_V /^3&_V0?\ LV[X-?\
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M&^$K'2O$WAR+3M3\=>%-/AT.XE\1^(?%6F"QLM'OM0L3/9.VISV=Y/I$-_\
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M'\2^(M4L?#WPO\-ZJ\SW]]HVCZ)$-6LH;F>ZU*\#7*Z+<V<OX2U_H4_ML?\
M!-+]GC]O'4_!6O?%[4?B3X<\1>!-.U#1M)UWX;^(M$T>]NM&U&Z2^?2]4MO$
MWA;QAI,]O;WJRW-K-;:;9WZ/<SI)>2P&.*/X4_XAT_V)O^BH_M3?^%M\)?\
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ML]*T?2[=+6SM8FFDFN)W6*,-/=W<]Q>WMPTMW>W%Q=SS32?S]_L*_P#*</\
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M6YGM=5O-$UEDG*V,;2_F'^T'XC_9GT7]O3]MS1_^"GO@CXW:OXBU[QYHMW\
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MJ  ?,7Q]^"'QH_:!_P""1-Q\)O&=KJNK?'_5OV9_A9KVO:9J,-Q+XHUCXF>
M++P;\0;S0;Z*1#<2>,=:UKPO)H=ZI"K-XBO9U9U@D+CY5_X);_\ !3;]EWPS
M^R#X#^$'QV^*F@?!_P")WP)TG5O!NNZ+XZ^V:*-7T/0]4U"70-0\/2S03+JE
MY'HDMGH]_H$#GQ%'KFF7Z1:/]CGT^6X_H!KY,^(7[!_[&OQ5\73^/?B#^S3\
M'_$OC&]OGU/5?$-UX-TNVU'7M1EF2>:_\2R:?%:+XFO)Y(U\^Y\0)J4T\>Z&
M9WA=XV /YZ-5_:IT7]L7_@LK^QG\6_ ?A#Q+HWPCTB?4?AC\-O&7B/3[S2Q\
M4;3PBGQ#U77_ !?I%C>VMO)::4FL^*I=)M;9VGNHXK".35!IVK37VB:5[-_P
M5JU+PS_P\E_8BTK]JB348_V+5\,VFHZC#>R:N_@:Z\9CQ+XO@\23ZY#:".%O
MLS'X8P>+A")Y+?P7<QO-(+>]N8%_H'N?@#\$+OQ+\//&$_PF^'Q\3_"33VTG
MX7ZU'X4T:"]^'^E/"]O_ &;X0>"TB70+!8)'BBM--6W@A1BL4: UJ?%3X.?"
MGXX>%Y/!?Q@^'GA#XD^%I)TNUT7QCH6GZY9VU[&CQQ:A8"]AEDTW4H4DD2'4
M=/DMKZ%))%BN$5V! /P$_P""FW[0G_!.K2/V1OB/\"_V:M.^!'C?XG^.-$TQ
M/#6G?LW>$/ WB&R\&Z+X;U71?$?B+Q9K_BCP%82:+X<TG2/#6@7-M=!-2?5R
MLD*26":3;ZI?Z=][?L6_#IOB_P#\$BOAK\)DN(+23XG_ ++/C'X>Q7=R&-O:
M3>,]&\5>'8KN;8KN([:345G8HC.HC)0%@!7U7X _8E_9(^%NA>,_#7@']GGX
M6>'=&^(FC77ASQQ:V_A:QNI/%'AV]B$-WX>UB]U%;R_N]!G50\FC/=?V:TY:
MY^R_:&:4^^^#/!?A+X=^%M$\$>!/#FC^$?"'AJQ33= \-Z!8P:9HVCV$;.Z6
MFGV%JD<%M KR.XCC11O=F.68D@'\WW_!'?\ ;E^#?[-/PE\<?L??M5^++/X#
M_$WX5?%#Q?/IT'Q$BF\/:1<Z7JKVLVK:+<ZS<[K*P\1:'XHMM=:ZM-3?3HKW
M3=2T>31I=3D74!:_.?\ P4B_;>^'G[7_ .U7^Q5I/P7TK7-;^%7PB^/-CI-K
M\8[K3=3TSPSX^\::_P"+OA7<>(M#\)1ZC86LEQ9^$=/TW09;N^G>.ZO9?$$4
MT>G0:2=)U36_Z6?B_P#L8_LI?'S7!XH^,'[/_P +_'?BDI!%-XIU?PM81^*+
MR"T@^RVEKJ/B.P2SUK4K.SMP(K.SU"^N;6U4#[/#&0"/Q3_X+'^!?!?PV^(O
M_!*[P5\/?"?AWP1X0T+XZ^)+;1_#/A31M/T#0M-A;Q?\"I'2STO3+>VLX#+*
M[S3ND0>>>22>9GED=V /Z1J\(_:>^"&F_M(_L^?%[X&:I<I80_$KP1K'AZRU
M*52\6DZZ\(O/#6LRQJDC2Q:-XAM=+U22%$+RI:-&A5F##W>B@#^5S_@FO^W_
M *;_ ,$]HO%_["'[=^G>)OA/)\/O%WB'4_!'C*]T;6_$&BZ+;:]=+J%]X;N+
M'P]IVIZI+X:UO7)-1\6^$O&&AV.JZ'J@\1ZA/?7-A8+:WTOZ>?&C_@M/^PK\
M,/#4E[X+^(MS\=?&MXL</ASX??"_1-<N]0UC4+K;'9P7FO:KI5AX?T:W:XDA
MCN?-O;K6$5W-AH6IW$9M3]__ !B_9R^ W[05A::=\;/A#\/_ (G0:<KKI<_B
M_P ,Z9JVI:0LKAYAHVLS0?VOHXG91]H_LR^M//&5FWJ2#P_PG_8I_9*^!NM)
MXE^%'[/'PH\%^)H79[7Q/IWA'3+CQ-8%U".FF>(M2BOM9TN*50/-AT^^MH92
MH:1&8 @ _(G_ (+4> ?BCXK^#_[(/[;'@KP3?VVO_LY>)-/\>>-O!DUM>7NK
M^%+'QDO@/Q7!<:XT-K:W!TWP5XI\%V>A:].;.VFM6UUM0DM[2UM[Y[?[M\"?
M\%<OV!/&?PRT_P")-_\ M >$O!+RZ-%J6L^!?%DEW9^/]!OO)W7NB2>%[:TN
MM2UN^L[A9+9)O#4.KV.H;4N-.N;FWFBD;])98HKB*6">*.:":-XIH9462*6*
M12DD4L;ADDCD1BCHX*LI*L""17QG>_\ !.C]A+4/$2^*+K]DSX$OJHD,S)'\
M/="M]&FE9Y9'DN?#5M:Q>&[MG>9VD-SI,ID.S?N$<80 _)W_ ()S6?B7]L[_
M (*0?M(_\%'4\-:WX<^"-KHTOPV^#UUX@TJ6QF\3SQ:3H'@FUNM-9Y;BW,VF
M>%?"E]J/B^*SNKN+3=?\86VEPW+B*ZCAUOVM/^4^O[!O_9 [+_TY?M15_0-H
M.@:%X6T;3/#GAC1=)\.>'M$LH--T;0=!TZSTC1M(TZU016MAIFEZ?#;V-A96
MT2K'!:VD$4$* )'&J@"N"USX'_![Q+\3O#/QI\0?#3P7K/Q:\&:7_8OA/XBZ
MEH&GW?B_P]I(;66&G:3KDT+7UE9J_B+772"&541]7U!T"M<RE@#YM_X*8?\
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MV$/B8/#^G#QI_8_V,Z?_ &<=?$']H&U^P'[%Y9F(^R8M_P#4@(/PU_X+7?\
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M_=&^T&]UC1].U.[T2]:2WE-YI%Q>V\\VFW1EM+60W%F\,IDMK=R^Z&,KO44
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 5\S_M%?\ ,G_]S!_[@Z^F*^9_VBO^9/\ ^Y@_]P= '3? #_D3=3_[
M&:\_]-6C5[E7AOP _P"1-U/_ +&:\_\ 35HU>Y4 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7S/^T5
M_P R?_W,'_N#KZ8KYG_:*_YD_P#[F#_W!T =-\ /^1-U/_L9KS_TU:-7N5?+
MWP@\>^$_"WAJ^T_7M5^P7DVNW-Y'#]AU*YW6TEAID"2>99V=Q$N9;>9=C.)!
MLW% K*6]5_X7#\.?^AB_\I&N_P#RLH ],HKS/_A</PY_Z&+_ ,I&N_\ RLH_
MX7#\.?\ H8O_ "D:[_\ *R@#TRBO,_\ A</PY_Z&+_RD:[_\K*/^%P_#G_H8
MO_*1KO\ \K* /3**\S_X7#\.?^AB_P#*1KO_ ,K*/^%P_#G_ *&+_P I&N__
M "LH ],HKS/_ (7#\.?^AB_\I&N__*RC_A</PY_Z&+_RD:[_ /*R@#TRBO,_
M^%P_#G_H8O\ RD:[_P#*RC_A</PY_P"AB_\ *1KO_P K* /3**\S_P"%P_#G
M_H8O_*1KO_RLH_X7#\.?^AB_\I&N_P#RLH ],HKS/_A</PY_Z&+_ ,I&N_\
MRLH_X7#\.?\ H8O_ "D:[_\ *R@#TRBO,_\ A</PY_Z&+_RD:[_\K*/^%P_#
MG_H8O_*1KO\ \K* /3**\S_X7#\.?^AB_P#*1KO_ ,K*/^%P_#G_ *&+_P I
M&N__ "LH ],HKS/_ (7#\.?^AB_\I&N__*RC_A</PY_Z&+_RD:[_ /*R@#TR
MBO,_^%P_#G_H8O\ RD:[_P#*RC_A</PY_P"AB_\ *1KO_P K* /3**\S_P"%
MP_#G_H8O_*1KO_RLH_X7#\.?^AB_\I&N_P#RLH ],HKS/_A</PY_Z&+_ ,I&
MN_\ RLH_X7#\.?\ H8O_ "D:[_\ *R@#TRBO,_\ A</PY_Z&+_RD:[_\K*/^
M%P_#G_H8O_*1KO\ \K* /3**\S_X7#\.?^AB_P#*1KO_ ,K*/^%P_#G_ *&+
M_P I&N__ "LH ],HKS/_ (7#\.?^AB_\I&N__*RC_A</PY_Z&+_RD:[_ /*R
M@#TRBO,_^%P_#G_H8O\ RD:[_P#*RC_A</PY_P"AB_\ *1KO_P K* /3**\S
M_P"%P_#G_H8O_*1KO_RLH_X7#\.?^AB_\I&N_P#RLH ],HKS/_A</PY_Z&+_
M ,I&N_\ RLH_X7#\.?\ H8O_ "D:[_\ *R@#TRBO,_\ A</PY_Z&+_RD:[_\
MK*/^%P_#G_H8O_*1KO\ \K* /3**\S_X7#\.?^AB_P#*1KO_ ,K*/^%P_#G_
M *&+_P I&N__ "LH ],HKS/_ (7#\.?^AB_\I&N__*RC_A</PY_Z&+_RD:[_
M /*R@#TRBO,_^%P_#G_H8O\ RD:[_P#*RC_A</PY_P"AB_\ *1KO_P K* /3
M**\S_P"%P_#G_H8O_*1KO_RLH_X7#\.?^AB_\I&N_P#RLH ],HKS/_A</PY_
MZ&+_ ,I&N_\ RLH_X7#\.?\ H8O_ "D:[_\ *R@#TRBO,_\ A</PY_Z&+_RD
M:[_\K*/^%P_#G_H8O_*1KO\ \K* /3**\S_X7#\.?^AB_P#*1KO_ ,K*/^%P
M_#G_ *&+_P I&N__ "LH ],HKS/_ (7#\.?^AB_\I&N__*RC_A</PY_Z&+_R
MD:[_ /*R@#TRBO,_^%P_#G_H8O\ RD:[_P#*RC_A</PY_P"AB_\ *1KO_P K
M* /3**\S_P"%P_#G_H8O_*1KO_RLH_X7#\.?^AB_\I&N_P#RLH ],HKS/_A<
M/PY_Z&+_ ,I&N_\ RLH_X7#\.?\ H8O_ "D:[_\ *R@#TRBO,_\ A</PY_Z&
M+_RD:[_\K*/^%P_#G_H8O_*1KO\ \K* /3**\S_X7#\.?^AB_P#*1KO_ ,K*
M/^%P_#G_ *&+_P I&N__ "LH ],HKS/_ (7#\.?^AB_\I&N__*RC_A</PY_Z
M&+_RD:[_ /*R@#TRBO,_^%P_#G_H8O\ RD:[_P#*RC_A</PY_P"AB_\ *1KO
M_P K* /3**\S_P"%P_#G_H8O_*1KO_RLH_X7#\.?^AB_\I&N_P#RLH ],HKS
M/_A</PY_Z&+_ ,I&N_\ RLH_X7#\.?\ H8O_ "D:[_\ *R@#TRBO,_\ A</P
MY_Z&+_RD:[_\K*/^%P_#G_H8O_*1KO\ \K* /3**\S_X7#\.?^AB_P#*1KO_
M ,K*/^%P_#G_ *&+_P I&N__ "LH ],HKS/_ (7#\.?^AB_\I&N__*RC_A</
MPY_Z&+_RD:[_ /*R@#TRBO,_^%P_#G_H8O\ RD:[_P#*RC_A</PY_P"AB_\
M*1KO_P K* /3**\S_P"%P_#G_H8O_*1KO_RLH_X7#\.?^AB_\I&N_P#RLH ]
M,HKS/_A</PY_Z&+_ ,I&N_\ RLH_X7#\.?\ H8O_ "D:[_\ *R@#TRBO,_\
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M\I&N_P#RLH ],HKS/_A</PY_Z&+_ ,I&N_\ RLH_X7#\.?\ H8O_ "D:[_\
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M "D:[_\ *R@#TRBO,_\ A</PY_Z&+_RD:[_\K*/^%P_#G_H8O_*1KO\ \K*
M/3**\S_X7#\.?^AB_P#*1KO_ ,K*/^%P_#G_ *&+_P I&N__ "LH ],HKS/_
M (7#\.?^AB_\I&N__*RC_A</PY_Z&+_RD:[_ /*R@#TRBO,_^%P_#G_H8O\
MRD:[_P#*RC_A</PY_P"AB_\ *1KO_P K* /3**\S_P"%P_#G_H8O_*1KO_RL
MH_X7#\.?^AB_\I&N_P#RLH ],HKS/_A</PY_Z&+_ ,I&N_\ RLH_X7#\.?\
MH8O_ "D:[_\ *R@#TRBO,_\ A</PY_Z&+_RD:[_\K*/^%P_#G_H8O_*1KO\
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M_H8O_*1KO_RLH_X7#\.?^AB_\I&N_P#RLH ],HKS/_A</PY_Z&+_ ,I&N_\
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MPY_Z&+_RD:[_ /*R@#TRBO,_^%P_#G_H8O\ RD:[_P#*RC_A</PY_P"AB_\
M*1KO_P K* /3**\S_P"%P_#G_H8O_*1KO_RLH_X7#\.?^AB_\I&N_P#RLH ]
M,HKS/_A</PY_Z&+_ ,I&N_\ RLH_X7#\.?\ H8O_ "D:[_\ *R@#TRBO,_\
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M\I&N_P#RLH ],HKS/_A</PY_Z&+_ ,I&N_\ RLH_X7#\.?\ H8O_ "D:[_\
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A** "BBB@ HHHH **** "N@\+?\AZP_[>O_2.XHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>15
<FILENAME>xene-20241231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-02-27T16:25:54.2653+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.xenon-pharma.com/20241231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2024" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:xene="http://www.xenon-pharma.com/20241231" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd" namespace="http://xbrl.sec.gov/ecd-sub/2024"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" namespace="http://fasb.org/srt/2024"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" namespace="http://xbrl.sec.gov/dei/2024"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" namespace="http://fasb.org/us-gaap/2024"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" namespace="http://www.xbrl.org/dtr/type/2022-03-31"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd" namespace="http://xbrl.sec.gov/cyd/2024"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd" namespace="http://xbrl.sec.gov/ecd/2024"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" namespace="http://fasb.org/us-types/2024"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2023/calculation-1.1.xsd" namespace="https://xbrl.org/2023/calculation-1.1"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" id="Role_StatementConsolidatedBalanceSheets">
        <link:definition>100010 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" id="Role_StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>100020 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss2" id="StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss2">
        <link:definition>100030 - Statement - Consolidated Statements of Operations and Comprehensive Loss 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>100040 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity" id="StatementConsolidatedStatementsOfShareholdersEquity">
        <link:definition>100050 - Statement - Consolidated Statements of Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" id="Role_StatementConsolidatedStatementsOfCashFlows">
        <link:definition>100060 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance" id="DisclosureCybersecurityRiskManagementStrategyAndGovernance">
        <link:definition>100070 - Disclosure - Cybersecurity Risk Management, Strategy, and Governance</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureNatureOfBusiness" id="Role_DisclosureNatureOfBusiness">
        <link:definition>995455 - Disclosure - Nature of the Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentation" id="Role_DisclosureBasisOfPresentation">
        <link:definition>995465 - Disclosure - Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPolicies" id="Role_DisclosureSignificantAccountingPolicies">
        <link:definition>995475 - Disclosure - Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureChangesInSignificantAccountingPolicies" id="Role_DisclosureChangesInSignificantAccountingPolicies">
        <link:definition>995485 - Disclosure - Changes in Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstruments1" id="DisclosureFairValueOfFinancialInstruments1">
        <link:definition>995495 - Disclosure - Fair Value of Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureMarketableSecurities" id="DisclosureMarketableSecurities">
        <link:definition>995505 - Disclosure - Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipment" id="Role_DisclosurePropertyPlantAndEquipment">
        <link:definition>995515 - Disclosure - Property, Plant and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureLeases" id="Role_DisclosureLeases">
        <link:definition>995525 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureAccountsPayableAndAccruedLiabilities" id="DisclosureAccountsPayableAndAccruedLiabilities">
        <link:definition>995535 - Disclosure - Accounts Payable and Accrued Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureTermLoan" id="Role_DisclosureTermLoan">
        <link:definition>995545 - Disclosure - Term Loan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapital" id="Role_DisclosureShareCapital">
        <link:definition>995555 - Disclosure - Share Capital</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureConcentrationsOfMarketRisk" id="Role_DisclosureConcentrationsOfMarketRisk">
        <link:definition>995565 - Disclosure - Concentrations of Market Risk</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCollaborationAgreements" id="Role_DisclosureCollaborationAgreements">
        <link:definition>995575 - Disclosure - Collaboration Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureNetLossPerCommonShare" id="DisclosureNetLossPerCommonShare">
        <link:definition>995585 - Disclosure - Net Loss Per Common Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>995595 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>995605 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureSegmentDisclosure1" id="DisclosureSegmentDisclosure1">
        <link:definition>995615 - Disclosure - Segment Disclosure</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies" id="Role_DisclosureSignificantAccountingPoliciesPolicies">
        <link:definition>995625 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesTables" id="Role_DisclosureSignificantAccountingPoliciesTables">
        <link:definition>995635 - Disclosure - Significant Accounting Policies  (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsTables" id="DisclosureFairValueOfFinancialInstrumentsTables">
        <link:definition>995645 - Disclosure - Fair Value of Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureMarketableSecuritiesTables" id="DisclosureMarketableSecuritiesTables">
        <link:definition>995655 - Disclosure - Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentTables" id="Role_DisclosurePropertyPlantAndEquipmentTables">
        <link:definition>995665 - Disclosure - Property, Plant and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureLeasesTables" id="Role_DisclosureLeasesTables">
        <link:definition>995675 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureAccountsPayableAndAccruedLiabilitiesTables" id="DisclosureAccountsPayableAndAccruedLiabilitiesTables">
        <link:definition>995685 - Disclosure - Accounts Payable and Accrued Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalTables" id="Role_DisclosureShareCapitalTables">
        <link:definition>995695 - Disclosure - Share Capital (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCollaborationAgreementsTables" id="Role_DisclosureCollaborationAgreementsTables">
        <link:definition>995705 - Disclosure - Collaboration Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureNetLossPerCommonShareTables" id="DisclosureNetLossPerCommonShareTables">
        <link:definition>995715 - Disclosure - Net Loss Per Common Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables" id="Role_DisclosureIncomeTaxesTables">
        <link:definition>995725 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureSegmentDisclosureTables" id="DisclosureSegmentDisclosureTables">
        <link:definition>995735 - Disclosure - Segment Disclosure (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureLeasesFutureMinimumLeasePaymentsDetails2" id="Role_DisclosureLeasesFutureMinimumLeasePaymentsDetails2">
        <link:definition>995745 - Disclosure - Leases - Future Minimum Lease Payments (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureNatureOfBusinessDetails" id="Role_DisclosureNatureOfBusinessDetails">
        <link:definition>995755 - Disclosure - Nature of the business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationDetails" id="Role_DisclosureBasisOfPresentationDetails">
        <link:definition>995765 - Disclosure - Basis of Presentation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPropertyPlantAndEquipmentEstimatedUsefulLivesDetails" id="Role_DisclosureSignificantAccountingPoliciesPropertyPlantAndEquipmentEstimatedUsefulLivesDetails">
        <link:definition>995775 - Disclosure - Significant Accounting Policies - Property Plant and Equipment Estimated Useful Lives (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesDetails" id="Role_DisclosureSignificantAccountingPoliciesDetails">
        <link:definition>995785 - Disclosure - Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureChangesInSignificantAccountingPoliciesDetails" id="DisclosureChangesInSignificantAccountingPoliciesDetails">
        <link:definition>995795 - Disclosure - Changes in Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFinancialAssetsMeasuredAtFairValueOnARecurringBasisDetails" id="DisclosureFairValueOfFinancialInstrumentsScheduleOfFinancialAssetsMeasuredAtFairValueOnARecurringBasisDetails">
        <link:definition>995805 - Disclosure - Fair Value of Financial Instruments - Schedule of Financial Assets Measured at Fair Value on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails" id="DisclosureMarketableSecuritiesAdditionalInformationDetails">
        <link:definition>995815 - Disclosure - Marketable Securities - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAmortizedCostUnrealizedGainLossRecognizedInAociAndFairValueOfAvailableforsaleSecuritiesDetails" id="DisclosureMarketableSecuritiesSummaryOfAmortizedCostUnrealizedGainLossRecognizedInAociAndFairValueOfAvailableforsaleSecuritiesDetails">
        <link:definition>995825 - Disclosure - Marketable Securities - Summary of Amortized Cost, Unrealized Gain (Loss) Recognized in AOCI and Fair Value of Available-for-Sale Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails" id="Role_DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails">
        <link:definition>995835 - Disclosure - Property, Plant and Equipment - Summary of Property, Plant and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureLeasesDetails" id="Role_DisclosureLeasesDetails">
        <link:definition>995845 - Disclosure - Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureLeasesScheduleOfCostComponentsOfOperatingLeaseDetails" id="Role_DisclosureLeasesScheduleOfCostComponentsOfOperatingLeaseDetails">
        <link:definition>995855 - Disclosure - Leases - Schedule of Cost Components of Operating Lease (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureLeasesFutureMinimumLeasePaymentsDetails" id="Role_DisclosureLeasesFutureMinimumLeasePaymentsDetails">
        <link:definition>995865 - Disclosure - Leases - Future Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureAccountsPayableAndAccruedLiabilitiesAccountsPayableAndAccruedLiabilitiesDetails" id="DisclosureAccountsPayableAndAccruedLiabilitiesAccountsPayableAndAccruedLiabilitiesDetails">
        <link:definition>995875 - Disclosure - Accounts Payable and Accrued Liabilities - Accounts Payable and Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalDetails" id="Role_DisclosureShareCapitalDetails">
        <link:definition>995885 - Disclosure - Share Capital (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalStockBasedCompensationExpensesDetails" id="Role_DisclosureShareCapitalStockBasedCompensationExpensesDetails">
        <link:definition>995895 - Disclosure - Share Capital - Stock Based Compensation Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalStockOptionActivityDetails" id="Role_DisclosureShareCapitalStockOptionActivityDetails">
        <link:definition>995905 - Disclosure - Share Capital - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalStockOptionActivityParentheticalDetails" id="Role_DisclosureShareCapitalStockOptionActivityParentheticalDetails">
        <link:definition>995915 - Disclosure - Share Capital - Stock Option Activity (Parenthetical) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalFairValueAssumptionsForStockOptionsDetails" id="Role_DisclosureShareCapitalFairValueAssumptionsForStockOptionsDetails">
        <link:definition>995925 - Disclosure - Share Capital - Fair Value Assumptions for Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureShareCapitalSummaryOfUnvestedStockOptionActivityDetails" id="DisclosureShareCapitalSummaryOfUnvestedStockOptionActivityDetails">
        <link:definition>995935 - Disclosure - Share Capital - Summary of UnVested Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureShareCapitalScheduleOfPrefundedWarrantsDetails" id="DisclosureShareCapitalScheduleOfPrefundedWarrantsDetails">
        <link:definition>995945 - Disclosure - Share Capital - Schedule of Pre-Funded Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureShareCapitalScheduleOfPrefundedWarrantsParentheticalDetails" id="DisclosureShareCapitalScheduleOfPrefundedWarrantsParentheticalDetails">
        <link:definition>995955 - Disclosure - Share capital - Schedule of Pre-Funded Warrants (Parenthetical) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureConcentrationsOfMarketRiskDetails" id="Role_DisclosureConcentrationsOfMarketRiskDetails">
        <link:definition>995965 - Disclosure - Concentrations of Market Risk (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCollaborationAgreementsScheduleOfCollaborationRevenueDetails" id="Role_DisclosureCollaborationAgreementsScheduleOfCollaborationRevenueDetails">
        <link:definition>995975 - Disclosure - Collaboration Agreements - Schedule of Collaboration Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCollaborationAgreementsDetails" id="Role_DisclosureCollaborationAgreementsDetails">
        <link:definition>995985 - Disclosure - Collaboration Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfBasicAndDilutedNetLossPerCommonShareDetails" id="DisclosureNetLossPerCommonShareScheduleOfBasicAndDilutedNetLossPerCommonShareDetails">
        <link:definition>995995 - Disclosure - Net Loss Per Common Share - Schedule of Basic and Diluted Net Loss Per Common Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails" id="DisclosureNetLossPerCommonShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails">
        <link:definition>996005 - Disclosure - Net Loss Per Common Share - Schedule of Antidilutive Securities Excluded from Computation of Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetails" id="Role_DisclosureCommitmentsAndContingenciesDetails">
        <link:definition>996015 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfLossBeforeIncomeTaxesDetails" id="DisclosureIncomeTaxesScheduleOfLossBeforeIncomeTaxesDetails">
        <link:definition>996025 - Disclosure - Income Taxes - Schedule of Loss before Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxRecoveryExpenseDetails" id="DisclosureIncomeTaxesScheduleOfIncomeTaxRecoveryExpenseDetails">
        <link:definition>996035 - Disclosure - Income Taxes - Schedule of Income Tax Recovery (Expense) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails" id="Role_DisclosureIncomeTaxesDetails">
        <link:definition>996045 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" id="DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails">
        <link:definition>996055 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfNetDeferredIncomeTaxAssetsDetails" id="DisclosureIncomeTaxesScheduleOfNetDeferredIncomeTaxAssetsDetails">
        <link:definition>996065 - Disclosure - Income Taxes - Schedule of Net Deferred Income Tax Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureSegmentDisclosureAdditionalInformationDetails" id="DisclosureSegmentDisclosureAdditionalInformationDetails">
        <link:definition>996075 - Disclosure - Segment Disclosure - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureSegmentDisclosureSummaryOfNetLossRelatedToSegmentExpensesDetails" id="DisclosureSegmentDisclosureSummaryOfNetLossRelatedToSegmentExpensesDetails">
        <link:definition>996085 - Disclosure - Segment Disclosure - Summary of Net Loss Related To Segment Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:href="xene-20241231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" xlink:href="xene-20241231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:href="xene-20241231.xsd#Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="xene-20241231.xsd#Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity" xlink:href="xene-20241231.xsd#StatementConsolidatedStatementsOfShareholdersEquity" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" xlink:href="xene-20241231.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance" xlink:href="xene-20241231.xsd#DisclosureCybersecurityRiskManagementStrategyAndGovernance" xlink:type="simple"/>
        <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureNatureOfBusiness" xlink:href="xene-20241231.xsd#Role_DisclosureNatureOfBusiness" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentation" xlink:href="xene-20241231.xsd#Role_DisclosureBasisOfPresentation" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPolicies" xlink:href="xene-20241231.xsd#Role_DisclosureSignificantAccountingPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureChangesInSignificantAccountingPolicies" xlink:href="xene-20241231.xsd#Role_DisclosureChangesInSignificantAccountingPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstruments1" xlink:href="xene-20241231.xsd#DisclosureFairValueOfFinancialInstruments1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureMarketableSecurities" xlink:href="xene-20241231.xsd#DisclosureMarketableSecurities" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipment" xlink:href="xene-20241231.xsd#Role_DisclosurePropertyPlantAndEquipment" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureLeases" xlink:href="xene-20241231.xsd#Role_DisclosureLeases" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureAccountsPayableAndAccruedLiabilities" xlink:href="xene-20241231.xsd#DisclosureAccountsPayableAndAccruedLiabilities" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureTermLoan" xlink:href="xene-20241231.xsd#Role_DisclosureTermLoan" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapital" xlink:href="xene-20241231.xsd#Role_DisclosureShareCapital" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureConcentrationsOfMarketRisk" xlink:href="xene-20241231.xsd#Role_DisclosureConcentrationsOfMarketRisk" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCollaborationAgreements" xlink:href="xene-20241231.xsd#Role_DisclosureCollaborationAgreements" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureNetLossPerCommonShare" xlink:href="xene-20241231.xsd#DisclosureNetLossPerCommonShare" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:href="xene-20241231.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:href="xene-20241231.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureSegmentDisclosure1" xlink:href="xene-20241231.xsd#DisclosureSegmentDisclosure1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies" xlink:href="xene-20241231.xsd#Role_DisclosureSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesTables" xlink:href="xene-20241231.xsd#Role_DisclosureSignificantAccountingPoliciesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsTables" xlink:href="xene-20241231.xsd#DisclosureFairValueOfFinancialInstrumentsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureMarketableSecuritiesTables" xlink:href="xene-20241231.xsd#DisclosureMarketableSecuritiesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentTables" xlink:href="xene-20241231.xsd#Role_DisclosurePropertyPlantAndEquipmentTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureLeasesTables" xlink:href="xene-20241231.xsd#Role_DisclosureLeasesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureAccountsPayableAndAccruedLiabilitiesTables" xlink:href="xene-20241231.xsd#DisclosureAccountsPayableAndAccruedLiabilitiesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalTables" xlink:href="xene-20241231.xsd#Role_DisclosureShareCapitalTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCollaborationAgreementsTables" xlink:href="xene-20241231.xsd#Role_DisclosureCollaborationAgreementsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureNetLossPerCommonShareTables" xlink:href="xene-20241231.xsd#DisclosureNetLossPerCommonShareTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:href="xene-20241231.xsd#Role_DisclosureIncomeTaxesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureSegmentDisclosureTables" xlink:href="xene-20241231.xsd#DisclosureSegmentDisclosureTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureNatureOfBusinessDetails" xlink:href="xene-20241231.xsd#Role_DisclosureNatureOfBusinessDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationDetails" xlink:href="xene-20241231.xsd#Role_DisclosureBasisOfPresentationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPropertyPlantAndEquipmentEstimatedUsefulLivesDetails" xlink:href="xene-20241231.xsd#Role_DisclosureSignificantAccountingPoliciesPropertyPlantAndEquipmentEstimatedUsefulLivesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesDetails" xlink:href="xene-20241231.xsd#Role_DisclosureSignificantAccountingPoliciesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureChangesInSignificantAccountingPoliciesDetails" xlink:href="xene-20241231.xsd#DisclosureChangesInSignificantAccountingPoliciesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFinancialAssetsMeasuredAtFairValueOnARecurringBasisDetails" xlink:href="xene-20241231.xsd#DisclosureFairValueOfFinancialInstrumentsScheduleOfFinancialAssetsMeasuredAtFairValueOnARecurringBasisDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails" xlink:href="xene-20241231.xsd#DisclosureMarketableSecuritiesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAmortizedCostUnrealizedGainLossRecognizedInAociAndFairValueOfAvailableforsaleSecuritiesDetails" xlink:href="xene-20241231.xsd#DisclosureMarketableSecuritiesSummaryOfAmortizedCostUnrealizedGainLossRecognizedInAociAndFairValueOfAvailableforsaleSecuritiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails" xlink:href="xene-20241231.xsd#Role_DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureLeasesDetails" xlink:href="xene-20241231.xsd#Role_DisclosureLeasesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureLeasesScheduleOfCostComponentsOfOperatingLeaseDetails" xlink:href="xene-20241231.xsd#Role_DisclosureLeasesScheduleOfCostComponentsOfOperatingLeaseDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureLeasesFutureMinimumLeasePaymentsDetails" xlink:href="xene-20241231.xsd#Role_DisclosureLeasesFutureMinimumLeasePaymentsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureAccountsPayableAndAccruedLiabilitiesAccountsPayableAndAccruedLiabilitiesDetails" xlink:href="xene-20241231.xsd#DisclosureAccountsPayableAndAccruedLiabilitiesAccountsPayableAndAccruedLiabilitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalDetails" xlink:href="xene-20241231.xsd#Role_DisclosureShareCapitalDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalStockBasedCompensationExpensesDetails" xlink:href="xene-20241231.xsd#Role_DisclosureShareCapitalStockBasedCompensationExpensesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalStockOptionActivityDetails" xlink:href="xene-20241231.xsd#Role_DisclosureShareCapitalStockOptionActivityDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalStockOptionActivityParentheticalDetails" xlink:href="xene-20241231.xsd#Role_DisclosureShareCapitalStockOptionActivityParentheticalDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalFairValueAssumptionsForStockOptionsDetails" xlink:href="xene-20241231.xsd#Role_DisclosureShareCapitalFairValueAssumptionsForStockOptionsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureShareCapitalSummaryOfUnvestedStockOptionActivityDetails" xlink:href="xene-20241231.xsd#DisclosureShareCapitalSummaryOfUnvestedStockOptionActivityDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureShareCapitalScheduleOfPrefundedWarrantsDetails" xlink:href="xene-20241231.xsd#DisclosureShareCapitalScheduleOfPrefundedWarrantsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureShareCapitalScheduleOfPrefundedWarrantsParentheticalDetails" xlink:href="xene-20241231.xsd#DisclosureShareCapitalScheduleOfPrefundedWarrantsParentheticalDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureConcentrationsOfMarketRiskDetails" xlink:href="xene-20241231.xsd#Role_DisclosureConcentrationsOfMarketRiskDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCollaborationAgreementsScheduleOfCollaborationRevenueDetails" xlink:href="xene-20241231.xsd#Role_DisclosureCollaborationAgreementsScheduleOfCollaborationRevenueDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCollaborationAgreementsDetails" xlink:href="xene-20241231.xsd#Role_DisclosureCollaborationAgreementsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfBasicAndDilutedNetLossPerCommonShareDetails" xlink:href="xene-20241231.xsd#DisclosureNetLossPerCommonShareScheduleOfBasicAndDilutedNetLossPerCommonShareDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails" xlink:href="xene-20241231.xsd#DisclosureNetLossPerCommonShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetails" xlink:href="xene-20241231.xsd#Role_DisclosureCommitmentsAndContingenciesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfLossBeforeIncomeTaxesDetails" xlink:href="xene-20241231.xsd#DisclosureIncomeTaxesScheduleOfLossBeforeIncomeTaxesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxRecoveryExpenseDetails" xlink:href="xene-20241231.xsd#DisclosureIncomeTaxesScheduleOfIncomeTaxRecoveryExpenseDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails" xlink:href="xene-20241231.xsd#Role_DisclosureIncomeTaxesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:href="xene-20241231.xsd#DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfNetDeferredIncomeTaxAssetsDetails" xlink:href="xene-20241231.xsd#DisclosureIncomeTaxesScheduleOfNetDeferredIncomeTaxAssetsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureSegmentDisclosureAdditionalInformationDetails" xlink:href="xene-20241231.xsd#DisclosureSegmentDisclosureAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureSegmentDisclosureSummaryOfNetLossRelatedToSegmentExpensesDetails" xlink:href="xene-20241231.xsd#DisclosureSegmentDisclosureSummaryOfNetLossRelatedToSegmentExpensesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss2" xlink:href="xene-20241231.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss2" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureLeasesFutureMinimumLeasePaymentsDetails2" xlink:href="xene-20241231.xsd#Role_DisclosureLeasesFutureMinimumLeasePaymentsDetails2" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#IndividualsOnly" xlink:type="simple"/>
        <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TradingArrangmentsOnly" xlink:type="simple"/>
        <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd#eedm" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_ClinicalDevelopementAndOtherMilestoneMember" xlink:label="xene_ClinicalDevelopementAndOtherMilestoneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_UnderwrittenPublicOfferingMember" xlink:label="xene_UnderwrittenPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="us-gaap_LesseeOperatingLeaseDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PriorPeriodReclassificationAdjustment" xlink:label="us-gaap_PriorPeriodReclassificationAdjustment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_Rule10B51TradingPlanMember" xlink:label="xene_Rule10B51TradingPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_MilestonePayment" xlink:label="xene_MilestonePayment"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_MilestonePaymentReceivedInEquityInvestmentMeasuredAtFairValue" xlink:label="xene_MilestonePaymentReceivedInEquityInvestmentMeasuredAtFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemAmount" xlink:label="us-gaap_SegmentReportingOtherItemAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LatestTaxYearMember" xlink:label="us-gaap_LatestTaxYearMember"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_CashlessExerciseOfStockOptions" xlink:label="xene_CashlessExerciseOfStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_GrossProceedsFromIssuableOfCommonStock" xlink:label="xene_GrossProceedsFromIssuableOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_FirstRenewalOptionMember" xlink:label="xene_FirstRenewalOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorizedUnlimited" xlink:label="us-gaap_PreferredStockSharesAuthorizedUnlimited"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_ProceedsFromUpfrontFee" xlink:label="xene_ProceedsFromUpfrontFee"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_StockIssuedDuringPeriodSharesConversionOfPreFundedWarrantsToCommonShares" xlink:label="xene_StockIssuedDuringPeriodSharesConversionOfPreFundedWarrantsToCommonShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorOpinionTextBlock" xlink:label="dei_AuditorOpinionTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_XEN496Member" xlink:label="xene_XEN496Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_GuaranteedInvestmentCertificatesMember" xlink:label="xene_GuaranteedInvestmentCertificatesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_AtMarketEquityOfferingMember" xlink:label="xene_AtMarketEquityOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_WarrantsExerciseDescription" xlink:label="xene_WarrantsExerciseDescription"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_FuturePotentialMilestonePayments" xlink:label="xene_FuturePotentialMilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_CommonStockIssuedForPreFundedWarrants" xlink:label="xene_CommonStockIssuedForPreFundedWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_NeedhamMassachusettsMember" xlink:label="xene_NeedhamMassachusettsMember"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_TermLoansMember" xlink:label="xene_TermLoansMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" xlink:label="xene_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_TwoThousandFourteenAmendedAndRestatedStockOptionPlanMember" xlink:label="xene_TwoThousandFourteenAmendedAndRestatedStockOptionPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_PaciraBiosciencesMember" xlink:label="xene_PaciraBiosciencesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_PotentialMilestonePaymentsReceivable" xlink:label="xene_PotentialMilestonePaymentsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_AzetukalnerMember" xlink:label="xene_AzetukalnerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesTradingUnrealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesTradingUnrealizedGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxesPayableCurrent" xlink:label="us-gaap_TaxesPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockNoParValue" xlink:label="us-gaap_PreferredStockNoParValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_WarrantsIssuedPricePerPreFundedWarrant" xlink:label="xene_WarrantsIssuedPricePerPreFundedWarrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradingSecuritiesDebt" xlink:label="us-gaap_TradingSecuritiesDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardExpirationDate" xlink:label="us-gaap_TaxCreditCarryforwardExpirationDate"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_MaximumTermOfEachOptionExercised" xlink:label="xene_MaximumTermOfEachOptionExercised"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_JefferiesLLCStifelNicolausCompanyIncorporatedAndGuggenheimSecuritiesLLCMember" xlink:label="xene_JefferiesLLCStifelNicolausCompanyIncorporatedAndGuggenheimSecuritiesLLCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_WeightedAverageNumberOfCommonShares" xlink:label="xene_WeightedAverageNumberOfCommonShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration" xlink:label="us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_CollaborateMilestoneAgreementPremiumRelatedToEquityInvestment" xlink:label="xene_CollaborateMilestoneAgreementPremiumRelatedToEquityInvestment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardTable" xlink:label="us-gaap_TaxCreditCarryforwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_SecondRenewalOptionMember" xlink:label="xene_SecondRenewalOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_StockOptionActivityAbstract" xlink:label="xene_StockOptionActivityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_AggregateMilestonePaymentReceived" xlink:label="xene_AggregateMilestonePaymentReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SubsidiariesMember" xlink:label="srt_SubsidiariesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductConcentrationRiskMember" xlink:label="us-gaap_ProductConcentrationRiskMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_PreFundedWarrantsExercised" xlink:label="xene_PreFundedWarrantsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_SignificantAccountingPoliciesLineItems" xlink:label="xene_SignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_MilestonePaymentReceivedInCash" xlink:label="xene_MilestonePaymentReceivedInCash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DescriptionOfInterestRateRiskExposure" xlink:label="us-gaap_DescriptionOfInterestRateRiskExposure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_PreFundsWarrantsOutstandingDateIssuanceDecemberTwoThousandTwentyThreeMember" xlink:label="xene_PreFundsWarrantsOutstandingDateIssuanceDecemberTwoThousandTwentyThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_CanadaAndUnitedStatesRevenueAgencyMember" xlink:label="xene_CanadaAndUnitedStatesRevenueAgencyMember"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_IanMortimerMember" xlink:label="xene_IanMortimerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_BurnabyBritishColumbiaMember" xlink:label="xene_BurnabyBritishColumbiaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_DeferredTaxAssetsTaxCreditCarryforwardsInvestment" xlink:label="xene_DeferredTaxAssetsTaxCreditCarryforwardsInvestment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_StockOptionsExercisedForNumberOfCommonSharesForCash" xlink:label="xene_StockOptionsExercisedForNumberOfCommonSharesForCash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_ClinicalDevelopmentMilestonesMember" xlink:label="xene_ClinicalDevelopmentMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RisksInherentInServicingAssetsAndServicingLiabilitiesTypeDomain" xlink:label="us-gaap_RisksInherentInServicingAssetsAndServicingLiabilitiesTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_PurchasesOfPropertyPlantAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities" xlink:label="xene_PurchasesOfPropertyPlantAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorizedUnlimited" xlink:label="us-gaap_CommonStockSharesAuthorizedUnlimited"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarliestTaxYearMember" xlink:label="us-gaap_EarliestTaxYearMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_JefferiesLLCStifelNicolausCompanyIncorporatedJPMorganSecuritiesLLCBofASecuritiesIncAndRBCCapitalMarketsLLCMember" xlink:label="xene_JefferiesLLCStifelNicolausCompanyIncorporatedJPMorganSecuritiesLLCBofASecuritiesIncAndRBCCapitalMarketsLLCMember"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_UpfrontPaymentReceivedInEquityInvestment" xlink:label="xene_UpfrontPaymentReceivedInEquityInvestment"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_RegulatoryMilestoneMember" xlink:label="xene_RegulatoryMilestoneMember"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" xlink:label="xene_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:label="us-gaap_AccountingChangesAndErrorCorrectionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_PreFundsWarrantsOutstandingDateIssuanceMarchTwoThousandTwentyOneMember" xlink:label="xene_PreFundsWarrantsOutstandingDateIssuanceMarchTwoThousandTwentyOneMember"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_CashReceivedForLeaseIncentives" xlink:label="xene_CashReceivedForLeaseIncentives"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_ProvincialTaxCreditMember" xlink:label="xene_ProvincialTaxCreditMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:label="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="us-gaap_EarningsPerShareBasicLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_InterestReceivableAndAccretionOfDiscountsOnMarketableSecurities" xlink:label="xene_InterestReceivableAndAccretionOfDiscountsOnMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_CommonStockIssuedForCashlessExercise" xlink:label="xene_CommonStockIssuedForCashlessExercise"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:label="us-gaap_ForeignCurrencyExchangeRateTranslation1"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax" xlink:label="xene_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_RoyaltyObligations" xlink:label="xene_RoyaltyObligations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_NeurocrineBiosciencesMember" xlink:label="xene_NeurocrineBiosciencesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_StockIssuedDuringPeriodValueConversionOfPreFundedWarrant" xlink:label="xene_StockIssuedDuringPeriodValueConversionOfPreFundedWarrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtRestatementRecoveryAnalysisFlag" xlink:label="dei_DocumentFinStmtRestatementRecoveryAnalysisFlag"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_FairValueAssumptionsForStockOptionsAbstract" xlink:label="xene_FairValueAssumptionsForStockOptionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" xlink:label="xene_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_BVFPartnersLPMember" xlink:label="xene_BVFPartnersLPMember"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_FairValueOfPreFundedWarrantsExercised" xlink:label="xene_FairValueOfPreFundedWarrantsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_AggregatePriceOfTransactionAllocatedToPerformanceObligations" xlink:label="xene_AggregatePriceOfTransactionAllocatedToPerformanceObligations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_OtherMilestonesMember" xlink:label="xene_OtherMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PhantomShareUnitsPSUsMember" xlink:label="us-gaap_PhantomShareUnitsPSUsMember"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_DeferredTaxAssetsDeferredFinancingFees" xlink:label="xene_DeferredTaxAssetsDeferredFinancingFees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradingActivityByTypeAxis" xlink:label="us-gaap_TradingActivityByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_EffectiveIncomeTaxRateReconciliationTaxAttributesExpiredOrUtilized" xlink:label="xene_EffectiveIncomeTaxRateReconciliationTaxAttributesExpiredOrUtilized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_UpfrontPaymentInCash" xlink:label="xene_UpfrontPaymentInCash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="us-gaap_PrepaidExpenseNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTaxCurrent" xlink:label="xene_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTaxCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_AmendedAndRestatedStockOptionPlanMember" xlink:label="xene_AmendedAndRestatedStockOptionPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradingActivityByTypeDomain" xlink:label="us-gaap_TradingActivityByTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_TwoThousandNineteenInducementEquityIncentivePlanMember" xlink:label="xene_TwoThousandNineteenInducementEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConversionBasis" xlink:label="us-gaap_PreferredStockConversionBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_PreFundsWarrantsOutstandingDateIssuanceJuneTwoThousandTwentyTwoMember" xlink:label="xene_PreFundsWarrantsOutstandingDateIssuanceJuneTwoThousandTwentyTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_FirstOrderPharmaceuticalsIncMember" xlink:label="xene_FirstOrderPharmaceuticalsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseOptionToTerminate" xlink:label="us-gaap_LesseeOperatingLeaseOptionToTerminate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestRateRiskMember" xlink:label="us-gaap_InterestRateRiskMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:label="xene_LesseeOperatingLeaseNumberOfRenewalOptions"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_MilestonePaymentDueOnInitiationOfPhase1bClinicalTrial" xlink:label="xene_MilestonePaymentDueOnInitiationOfPhase1bClinicalTrial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_Rule10B51TradingPlanOneMember" xlink:label="xene_Rule10B51TradingPlanOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_ResearchEquipmentMember" xlink:label="xene_ResearchEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_MedpaceClinicalDevelopmentServiceAgreementMember" xlink:label="xene_MedpaceClinicalDevelopmentServiceAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_LicenseAndCollaborationAgreementMember" xlink:label="xene_LicenseAndCollaborationAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_JefferiesLLCAndStifelNicolausCompanyIncorporatedMember" xlink:label="xene_JefferiesLLCAndStifelNicolausCompanyIncorporatedMember"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_JefferiesLLCStifelNicolausCompanyIncorporatedJPMorganSecuritiesLLCAndSVBSecuritiesLLCMember" xlink:label="xene_JefferiesLLCStifelNicolausCompanyIncorporatedJPMorganSecuritiesLLCAndSVBSecuritiesLLCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_ShareCapitalTable" xlink:label="xene_ShareCapitalTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_WeightedAverageNumberOfPrefundedWarrants" xlink:label="xene_WeightedAverageNumberOfPrefundedWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_StockIssuedDuringPeriodCommonSharesCancelled" xlink:label="xene_StockIssuedDuringPeriodCommonSharesCancelled"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:label="us-gaap_MarketableSecuritiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_VariableConsiderationAllocatedToPerformanceObligation" xlink:label="xene_VariableConsiderationAllocatedToPerformanceObligation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateTransitionOptionElectedExtensibleList" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateTransitionOptionElectedExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_Series1PreferredSharesMember" xlink:label="xene_Series1PreferredSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardLineItems" xlink:label="us-gaap_TaxCreditCarryforwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_ScheduleOfPreFundedWarrantsActivityTableTextBlock" xlink:label="xene_ScheduleOfPreFundedWarrantsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_JefferiesLLCSVBLeerinkLLCAndStifelNicolausCompanyIncorporatedMember" xlink:label="xene_JefferiesLLCSVBLeerinkLLCAndStifelNicolausCompanyIncorporatedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis" xlink:label="us-gaap_ManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentCreditMember" xlink:label="us-gaap_InvestmentCreditMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="dei_EntityIncorporationDateOfIncorporation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockNoParValue" xlink:label="us-gaap_CommonStockNoParValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_UnfavorableChangeInInterestRatesOfMarketableSecurities" xlink:label="xene_UnfavorableChangeInInterestRatesOfMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_BasisOfPresentationLineItems" xlink:label="xene_BasisOfPresentationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_CollaborateAgreementPremiumRelatedToEquityInvestment" xlink:label="xene_CollaborateAgreementPremiumRelatedToEquityInvestment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_RecognitionOfTransactionPrice" xlink:label="xene_RecognitionOfTransactionPrice"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_PerformanceObligationsRelatedToMilestone" xlink:label="xene_PerformanceObligationsRelatedToMilestone"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_PercentageOfOptionToFundDevelopmentCostsUponAchievementOfCertainMilestones" xlink:label="xene_PercentageOfOptionToFundDevelopmentCostsUponAchievementOfCertainMilestones"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LegalCostsPolicyTextBlock" xlink:label="us-gaap_LegalCostsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_Pre-ClinicalDiscoveryAndOtherProgramsMember" xlink:label="xene_Pre-ClinicalDiscoveryAndOtherProgramsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignExchangeMember" xlink:label="us-gaap_ForeignExchangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccounting" xlink:label="us-gaap_BasisOfAccounting"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_MilestonePaymentsPaid" xlink:label="xene_MilestonePaymentsPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTaxNoncurrent" xlink:label="xene_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTaxNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_MilestonePaymentReceivedInEquityInvestment" xlink:label="xene_MilestonePaymentReceivedInEquityInvestment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_PersonnelRelatedExpenses" xlink:label="xene_PersonnelRelatedExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_AssetPurchaseAgreementMember" xlink:label="xene_AssetPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_NumberOfWarrantsIssued" xlink:label="xene_NumberOfWarrantsIssued"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_CashAndMoneyMarketFundMember" xlink:label="xene_CashAndMoneyMarketFundMember"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_IncreaseDecreaseInFairValueOfMarketableSecurities" xlink:label="xene_IncreaseDecreaseInFairValueOfMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription" xlink:label="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_BasisOfPresentationTable" xlink:label="xene_BasisOfPresentationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_ShareCapitalLineItems" xlink:label="xene_ShareCapitalLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="us-gaap_RevenueFromContractWithCustomerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_AccruedResearchAndDevelopmentCurrent" xlink:label="xene_AccruedResearchAndDevelopmentCurrent"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_NetIncomeLossAvailableToPreferredStockholdersBasic" xlink:label="xene_NetIncomeLossAvailableToPreferredStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_ResearchAndDevelopmentServices" xlink:label="xene_ResearchAndDevelopmentServices"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_NumberOfWarrantsExercised" xlink:label="xene_NumberOfWarrantsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_ExchangeAgreementMember" xlink:label="xene_ExchangeAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_SignificantAccountingPoliciesTable" xlink:label="xene_SignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_SalesBasedMilestoneMember" xlink:label="xene_SalesBasedMilestoneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_CommitmentsAndContingenciesTable" xlink:label="xene_CommitmentsAndContingenciesTable"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_LesseeNumberOfOperatingLeases" xlink:label="xene_LesseeNumberOfOperatingLeases"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_DeferredTaxAssetsOperatingLeaseLiability" xlink:label="xene_DeferredTaxAssetsOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_StockIssuedDuringPeriodSharesConversionOfPreFundedWarrant" xlink:label="xene_StockIssuedDuringPeriodSharesConversionOfPreFundedWarrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_FairValueOfStockOptionsExercisedOnCashlessBasis" xlink:label="xene_FairValueOfStockOptionsExercisedOnCashlessBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="us-gaap_RisksAndUncertaintiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_CommitmentsAndContingenciesLineItems" xlink:label="xene_CommitmentsAndContingenciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_PreFundsWarrantsOutstandingDateIssuanceOctoberTwoThousandTwentyOneMember" xlink:label="xene_PreFundsWarrantsOutstandingDateIssuanceOctoberTwoThousandTwentyOneMember"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Board of Directors Oversight [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accounts receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Office Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office Furniture and Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_ClinicalDevelopementAndOtherMilestoneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Clinical developement and other milestone.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_ClinicalDevelopementAndOtherMilestoneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Clinical Developement And Other Milestone [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring and Nonrecurring [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive income (loss):</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_UnderwrittenPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Underwritten public offering.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_UnderwrittenPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Underwritten Public Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_UnderwrittenPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwritten Public Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized stock-based compensation cost to be achieved</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Operating Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating segment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Amortized Cost, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Contractual maturity of 0 to 1 years, Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Contractual maturity of 0 to 1 years, Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective Income Tax Rate Reconciliation, Tax Credit, Percent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development and other credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Research and development and other credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options exercisable, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted Average Exercise Price, Exercisable Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority, Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance (in Shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance (in Shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value, Forfeited or cancelled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Level 2 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PriorPeriodReclassificationAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prior Period Reclassification Adjustment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PriorPeriodReclassificationAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prior period reclassification adjustment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Gross [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred income tax liability:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_Rule10B51TradingPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Rule10B 51Trading Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_Rule10B51TradingPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Rule10B 51Trading Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_Rule10B51TradingPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rule10B 5-1 Trading Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_MilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_MilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_MilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_MilestonePaymentReceivedInEquityInvestmentMeasuredAtFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payment received in equity investment measured at fair value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_MilestonePaymentReceivedInEquityInvestmentMeasuredAtFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payment Received In Equity Investment Measured At Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_MilestonePaymentReceivedInEquityInvestmentMeasuredAtFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity investment measure at fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term Debt, Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OpenTaxYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Open Tax Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OpenTaxYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax year open for income tax examination</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingOtherItemAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Other Segment Item, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingOtherItemAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other segment items</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward, Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Leases [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LatestTaxYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Latest Tax Year [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LatestTaxYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Latest Tax Year [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_CashlessExerciseOfStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of share options (or share units) exercised via net exercise (cashless) method during the current period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_CashlessExerciseOfStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cashless Exercise Of Stock Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_CashlessExerciseOfStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cashless exercise of stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_GrossProceedsFromIssuableOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Gross proceeds from issuable of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_GrossProceedsFromIssuableOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gross Proceeds From Issuable Of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_GrossProceedsFromIssuableOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Gross proceeds from issuable of common stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Noncash Investing and Financing Items [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosures of non-cash transactions:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Federal, State and Local, Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Federal, State and Local, Tax Expense (Benefit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">United States</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Processes Integrated [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Benchmark [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk Benchmark</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_FirstRenewalOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">First Renewal Option [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_FirstRenewalOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">First renewal option.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title and Position [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorizedUnlimited_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Authorized, Unlimited [Fixed List]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorizedUnlimited_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred shares, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_ProceedsFromUpfrontFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from upfront fee.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_ProceedsFromUpfrontFee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Upfront Fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_ProceedsFromUpfrontFee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from upfront fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Available For Sale Securities [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_StockIssuedDuringPeriodSharesConversionOfPreFundedWarrantsToCommonShares_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock issued upon conversion of pre-funded warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_StockIssuedDuringPeriodSharesConversionOfPreFundedWarrantsToCommonShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Conversion Of Pre-funded Warrants To Common Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_StockIssuedDuringPeriodSharesConversionOfPreFundedWarrantsToCommonShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares conversion of pre-funded warrants to common shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorOpinionTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Opinion [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Capital [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration of Market Risk</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common shares, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_XEN496Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">XEN496 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_XEN496Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">XEN496.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_XEN496Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">XEN496</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_GuaranteedInvestmentCertificatesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Guaranteed investment certificates.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_GuaranteedInvestmentCertificatesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Guaranteed Investment Certificates [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Shares [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_AtMarketEquityOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">At -the -market equity offering.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_AtMarketEquityOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">At Market Equity Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_AtMarketEquityOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">At-The-Market Equity Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_AtMarketEquityOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">ATM [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss before income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_WarrantsExerciseDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants exercise description.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_WarrantsExerciseDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Exercise Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_WarrantsExerciseDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants exercise description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_FuturePotentialMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Future potential milestone payments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_FuturePotentialMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Future Potential Milestone Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_FuturePotentialMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Future potential payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_CommonStockIssuedForPreFundedWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock issued for pre-funded warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_CommonStockIssuedForPreFundedWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Issued For Pre Funded Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_CommonStockIssuedForPreFundedWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock issued for pre-funded warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common shares reserved for issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Exercisable, Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss per common share - basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_NeedhamMassachusettsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Needham Massachusetts.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_NeedhamMassachusettsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Needham Massachusetts [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_TermLoansMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Term loans.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_TermLoansMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Term Loans [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_TermLoansMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term Loan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments, Debt and Equity Securities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Contractual maturity of 0 to 1 years, Unrealized Gain (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Contractual maturity of 0 to 1 years, Unrealized Gain (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt securities, available-for-sale, accumulated gross unrealized loss, before tax, current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_TwoThousandFourteenAmendedAndRestatedStockOptionPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">2014 Amended and restated stock option plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_TwoThousandFourteenAmendedAndRestatedStockOptionPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Fourteen Amended And Restated Stock Option Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_TwoThousandFourteenAmendedAndRestatedStockOptionPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amended and Restated 2014 Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_PaciraBiosciencesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pacira biosciences.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_PaciraBiosciencesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pacira Biosciences [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_PaciraBiosciencesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pacira BioSciences [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Options Outstanding, Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Options Outstanding, Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Options Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_PotentialMilestonePaymentsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Potential milestone payments receivable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_PotentialMilestonePaymentsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Potential Milestone Payments Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_PotentialMilestonePaymentsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Potential milestone payments receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update and Change in Accounting Principle [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_AzetukalnerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Azetukalner</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_AzetukalnerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Azetukalner [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_AzetukalnerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Azetukalner.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCountry_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Country</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCountry_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Country</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Term of Contract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxPeriodDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Period [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxPeriodDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-capital losses carried forward for tax purposes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net book value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, plant and equipment, net (note 6)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2028</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Recurring Basis [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Income and Expenses [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income (expense):</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesTradingUnrealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized fair value gain (loss) on trading securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesTradingUnrealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unrealized fair value (gain) loss on trading securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesTradingUnrealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Trading, Unrealized Gain (Loss), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesTradingUnrealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Trading, Unrealized Gain (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxesPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Taxes Payable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxesPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Taxes Payable, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxesPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income and other taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockNoParValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, No Par Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockNoParValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred shares, without par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee-related Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee compensation, benefits, and related accruals</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Employee-related Liabilities, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Plant And Equipment [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income (expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other income (expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Antidilutive Securities Excluded from Computation of Diluted Net Loss Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_WarrantsIssuedPricePerPreFundedWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants issued price per pre funded warrant.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_WarrantsIssuedPricePerPreFundedWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants issued price per pre funded warrant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_WarrantsIssuedPricePerPreFundedWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrants issued price per pre funded warrant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_WarrantsIssuedPricePerPreFundedWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Price per Pre-Funded Warrant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Average risk-free interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TradingSecuritiesDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Trading</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TradingSecuritiesDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Trading marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update and Change in Accounting Principle [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in Significant Accounting Policies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Current income tax recovery (expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Expiration Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carry forward, Expiration Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_MaximumTermOfEachOptionExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum term of each option exercised.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_MaximumTermOfEachOptionExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Term Of Each Option Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_MaximumTermOfEachOptionExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum term of each option exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_JefferiesLLCStifelNicolausCompanyIncorporatedAndGuggenheimSecuritiesLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Jefferies LLC, Stifel, Nicolaus &amp; Company, Incorporated and Guggenheim Securities, LLC.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_JefferiesLLCStifelNicolausCompanyIncorporatedAndGuggenheimSecuritiesLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Jefferies L L C Stifel Nicolaus Company Incorporated And Guggenheim Securities L L C [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_JefferiesLLCStifelNicolausCompanyIncorporatedAndGuggenheimSecuritiesLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Jefferies, Stifel and Guggenheim Securities, LLC [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability, long-term (note 7)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Debt Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital, Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Contractual maturity of 1 to 3 years, Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss for the year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Options, Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options (in Shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Options Exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of Options Exercisable, End of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_WeightedAverageNumberOfCommonShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Common Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_WeightedAverageNumberOfCommonShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Weighted average number of common shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_WeightedAverageNumberOfCommonShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common shares (weighted average)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Financial Statement Error Correction [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">External general and administrative costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Expense Information Used by CODM, Type [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Furniture and Fixtures [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office Furniture and Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Processes Integrated [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred shares, issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_CollaborateMilestoneAgreementPremiumRelatedToEquityInvestment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborate milestone agreement premium related to equity investment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_CollaborateMilestoneAgreementPremiumRelatedToEquityInvestment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborate Milestone Agreement Premium Related To Equity Investment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_CollaborateMilestoneAgreementPremiumRelatedToEquityInvestment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Premium</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for operating lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercise of stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Stock Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Options, Unvested, Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Options, Unvested, Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payables and Accruals [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive loss (note 6)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Net of Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Other comprehensive (loss) income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration Agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Shares, Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Shares, Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_SecondRenewalOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Second Renewal Option [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_SecondRenewalOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Second renewal option.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Income Tax Recovery (Expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_StockOptionActivityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock option activity.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_StockOptionActivityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Option Activity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Foreign Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Canada</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_AggregateMilestonePaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Aggregate milestone payment received.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_AggregateMilestonePaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate Milestone Payment Received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_AggregateMilestonePaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone Payment Received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Collaboration Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expiration Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease expiration date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SubsidiariesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiaries [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SubsidiariesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Xenon Pharmaceuticals USA Inc. [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProductConcentrationRiskMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product Concentration Risk [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProductConcentrationRiskMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product Concentration Risk [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ConsolidatedEntitiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidated Entities [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ConsolidatedEntitiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consolidated Entities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_PreFundedWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-funded warrants exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_PreFundedWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-funded Warrants Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_PreFundedWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pre-funded warrants exercised.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Assets, Fair Value Disclosure, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related and Nonrelated Parties [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Future Minimum Lease Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_SignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Significant accounting policies.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_SignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_SignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Accounting Policies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_MilestonePaymentReceivedInCash_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payment received in cash.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_MilestonePaymentReceivedInCash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payment Received In Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_MilestonePaymentReceivedInCash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone Payment Received in Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Paper [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of restricted share awards, restricted share unit awards or performance awards available for issue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average grant date fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized stock-based compensation expected to be recognized over a period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effect of exchange rate changes on cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Income Location, Balance [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DescriptionOfInterestRateRiskExposure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Description of Interest Rate Risk Exposure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DescriptionOfInterestRateRiskExposure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest rate risk, description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Average expected term (in years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxPeriodAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Period [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxPeriodAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Canada</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Foreign Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">United States</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently adopted accounting pronouncements/Accounting pronouncements not yet adopted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AOCI Attributable to Parent [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Loss [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_PreFundsWarrantsOutstandingDateIssuanceDecemberTwoThousandTwentyThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">December 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_PreFundsWarrantsOutstandingDateIssuanceDecemberTwoThousandTwentyThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre Funds Warrants Outstanding Date Issuance December Two Thousand Twenty Three [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_PreFundsWarrantsOutstandingDateIssuanceDecemberTwoThousandTwentyThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pre funds warrants outstanding date issuance december two thousand twenty three.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_CanadaAndUnitedStatesRevenueAgencyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Canada and United States revenue agency.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_CanadaAndUnitedStatesRevenueAgencyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Canada And United States Revenue Agency [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_CanadaAndUnitedStatesRevenueAgencyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Canada and United States Revenue Agency [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_IanMortimerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Ian Mortimer [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_IanMortimerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Ian Mortimer.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Trade, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Discount rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted average discount rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Forfeited, cancelled and expired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Amount offered for issuance of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common shares and pre-funded warrants, net (note 9a and note 9e)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net of Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred income tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Chief Executive Officer [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_BurnabyBritishColumbiaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Burnaby, British Columbia.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_BurnabyBritishColumbiaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Burnaby British Columbia [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_BurnabyBritishColumbiaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Burnaby, British Columbia [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Stock Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseContractualTermAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Contractual Term [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_DeferredTaxAssetsTaxCreditCarryforwardsInvestment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment tax credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_DeferredTaxAssetsTaxCreditCarryforwardsInvestment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Credit Carryforwards, Investment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_DeferredTaxAssetsTaxCreditCarryforwardsInvestment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets, tax credit carryforwards, investment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Government Agencies Debt Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">U.S. Government Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_StockOptionsExercisedForNumberOfCommonSharesForCash_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of share options (or share units) exercised for number of common shares for cash during the period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_StockOptionsExercisedForNumberOfCommonSharesForCash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Options Exercised For Number Of Common Shares For Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_StockOptionsExercisedForNumberOfCommonSharesForCash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options exercised for Number of Common Shares for cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, at Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_ClinicalDevelopmentMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Clinical development milestones.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_ClinicalDevelopmentMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Clinical Development Milestones [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_ClinicalDevelopmentMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Clinical Development Milestones [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2029</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Cost Components of Operating Lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management, Strategy, and Governance [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RisksInherentInServicingAssetsAndServicingLiabilitiesTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Risks Inherent in Servicing Assets and Servicing Liabilities, Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RisksInherentInServicingAssetsAndServicingLiabilitiesTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risks Inherent in Servicing Assets and Servicing Liabilities, Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development tax credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Direct external research and development costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unclaimed Tax Deductions Related To Scientific Research And Experimental Development Expenditures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Options, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Options granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_PurchasesOfPropertyPlantAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchases Of Property, Plant And Equipment Included In Accounts Payable And Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_PurchasesOfPropertyPlantAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Purchases of property, plant and equipment included in accounts payable and accrued liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_PurchasesOfPropertyPlantAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchases of property, plant and equipment included in accounts payable and accrued liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorizedUnlimited_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized, Unlimited [Fixed List]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorizedUnlimited_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common shares, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarliestTaxYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earliest Tax Year [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarliestTaxYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Earliest Tax Year [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, plant and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Gross, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Gross, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Gross, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Leases [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assumptions for Stock Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_JefferiesLLCStifelNicolausCompanyIncorporatedJPMorganSecuritiesLLCBofASecuritiesIncAndRBCCapitalMarketsLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">J.P. Morgan, Jefferies, BofA Securities, Inc., Stifel, and RBC Capital Markets, LLC [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_JefferiesLLCStifelNicolausCompanyIncorporatedJPMorganSecuritiesLLCBofASecuritiesIncAndRBCCapitalMarketsLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Jefferies L L C Stifel Nicolaus Company Incorporated J P Morgan Securities L L C Bof A Securities Inc And R B C Capital Markets L L C [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_JefferiesLLCStifelNicolausCompanyIncorporatedJPMorganSecuritiesLLCBofASecuritiesIncAndRBCCapitalMarketsLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Jefferies LLC Stifel Nicolaus Company Incorporated J P Morgan Securities LLC BofA Securities Inc and RBC Capital Markets LLC.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_UpfrontPaymentReceivedInEquityInvestment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront payment received in equity investment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_UpfrontPaymentReceivedInEquityInvestment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Payment Received In Equity Investment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_UpfrontPaymentReceivedInEquityInvestment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront payment received in equity investment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_RegulatoryMilestoneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Regulatory milestone.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_RegulatoryMilestoneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Regulatory Milestone [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_RegulatoryMilestoneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Regulatory Milestone [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of property plant and equipment estimated useful lives.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Property Plant And Equipment Estimated Useful Lives Table [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Plant and Equipment Estimated Useful Lives</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingChangesAndErrorCorrectionsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Changes and Error Corrections [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants exercise price per common share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unrealized foreign exchange (gain) loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrealized Gain (Loss), Foreign Currency Transaction, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_PreFundsWarrantsOutstandingDateIssuanceMarchTwoThousandTwentyOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">March 2021</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_PreFundsWarrantsOutstandingDateIssuanceMarchTwoThousandTwentyOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre Funds Warrants Outstanding Date Issuance March Two Thousand Twenty One [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_PreFundsWarrantsOutstandingDateIssuanceMarchTwoThousandTwentyOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pre funds warrants outstanding date issuance march two thousand twenty one.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_CashReceivedForLeaseIncentives_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash received for lease incentives</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_CashReceivedForLeaseIncentives_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash received for lease incentives</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_CashReceivedForLeaseIncentives_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash received for lease incentives.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_ProvincialTaxCreditMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Provincial tax credit.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_ProvincialTaxCreditMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Provincial Tax Credit [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_ProvincialTaxCreditMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Provincial Tax Credit [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investing activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Category of Item Purchased [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Category of Item Purchased</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities (note 5)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_InterestReceivableAndAccretionOfDiscountsOnMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Receivable and Accretion Of Discounts On Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_InterestReceivableAndAccretionOfDiscountsOnMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Interest Receivable and Accretion Of Discounts On Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_InterestReceivableAndAccretionOfDiscountsOnMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest receivable and accretion of discounts on marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_InterestReceivableAndAccretionOfDiscountsOnMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest receivable and accretion of discounts on marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_CommonStockIssuedForCashlessExercise_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of common stock issued in exchange for share options (or share units) exercised via net exercise (cashless) method during the current period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_CommonStockIssuedForCashlessExercise_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Issued For Cashless Exercise</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_CommonStockIssuedForCashlessExercise_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock issued for cashless exercise</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Effective Income Tax Rate Reconciliation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management, Strategy, and Governance [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ConsolidatedEntitiesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidated Entities [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ConsolidatedEntitiesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consolidated Entities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyExchangeRateTranslation1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Currency Exchange Rate, Translation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyExchangeRateTranslation1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign exchange rate translation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized Gain (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Accumulated Gross Unrealized Gain (Loss) Before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Available for sale debt securities accumulated gross unrealized gain (loss) before tax.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation, Depletion and Amortization, Nonproduction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Depletion and Amortization, Nonproduction, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation of property, plant and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities and shareholders&#8217; equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other non-deductible expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ICFR Auditor Attestation Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ICFR Auditor Attestation Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective income tax rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_RoyaltyObligations_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalty obligations.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_RoyaltyObligations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Obligations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_RoyaltyObligations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty obligations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive securities excluded from computation of EPS</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_NeurocrineBiosciencesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Neurocrine biosciences.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_NeurocrineBiosciencesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Neurocrine Biosciences [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_NeurocrineBiosciencesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Neurocrine Biosciences [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2030 and thereafter</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Research and Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other research and development costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_StockIssuedDuringPeriodValueConversionOfPreFundedWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Conversion Of Pre Funded Warrant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_StockIssuedDuringPeriodValueConversionOfPreFundedWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period value conversion of pre funded warrant.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_StockIssuedDuringPeriodValueConversionOfPreFundedWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of pre-funded warrants (note 9e)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Income tax recovery (expense) (note 13)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income tax expense (recovery)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Income tax recovery (expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority, Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority, Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total shareholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFinStmtRestatementRecoveryAnalysisFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Financial Statement Restatement Recovery Analysis [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_FairValueAssumptionsForStockOptionsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value assumptions for stock options.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_FairValueAssumptionsForStockOptionsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assumptions For Stock Options [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Contractual maturity of 1 to 3 years, Unrealized Gain (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Contractual maturity of 1 to 3 years, Unrealized Gain (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt securities, available-for-sale, accumulated gross unrealized loss, before tax, noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred income tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_BVFPartnersLPMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">BVF Partners L P.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_BVFPartnersLPMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">B V F Partners L P [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_BVFPartnersLPMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">BVF Partners L.P [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_FairValueOfPreFundedWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of pre-funded warrants exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_FairValueOfPreFundedWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair value of pre-funded warrants exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_FairValueOfPreFundedWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair Value Of Pre-funded Warrants Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Outstanding, ending</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Outstanding, beginning</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable lease expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management, Strategy, and Governance [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_AggregatePriceOfTransactionAllocatedToPerformanceObligations_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Aggregate price of transaction allocated to performance obligations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_AggregatePriceOfTransactionAllocatedToPerformanceObligations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate Price Of Transaction Allocated To Performance Obligations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_AggregatePriceOfTransactionAllocatedToPerformanceObligations_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Transaction price allocated to performance obligations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized stock-based compensation cost not to be achieved</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Based Compensation Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Deferred income tax recovery (expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred income tax recovery</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_OtherMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Other milestones.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_OtherMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Milestones [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_OtherMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Milestones [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PhantomShareUnitsPSUsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">PSUs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PhantomShareUnitsPSUsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Phantom Share Units (PSUs) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_DeferredTaxAssetsDeferredFinancingFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of deferred tax asset attributable to taxable temporary differences from deferred financing costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_DeferredTaxAssetsDeferredFinancingFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Deferred Financing Fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_DeferredTaxAssetsDeferredFinancingFees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred financing fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Unrealized Gain (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unrealized Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leases [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of estimates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of preferred shares (note 9d)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense (note 9c)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Leasing Arrangements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Operating lease right-of-use-asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TradingActivityByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Activity [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TradingActivityByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value, Vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_EffectiveIncomeTaxRateReconciliationTaxAttributesExpiredOrUtilized_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Tax attributes expired/utilized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_EffectiveIncomeTaxRateReconciliationTaxAttributesExpiredOrUtilized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Attributes Expired Or Utilized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_EffectiveIncomeTaxRateReconciliationTaxAttributesExpiredOrUtilized_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax rate reconciliation, tax attributes expired or utilized.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_EffectiveIncomeTaxRateReconciliationTaxAttributesExpiredOrUtilized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax attributes expired/utilized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: accumulated depreciation and amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Fair Value of Financial Instruments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted average fair value of options granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and shareholders&#8217; equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use asset, net (note 7)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Options, Vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosures:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss per common share - diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold Improvements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_UpfrontPaymentInCash_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront payment in cash.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_UpfrontPaymentInCash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Payment In Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_UpfrontPaymentInCash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront payment received in cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by (used in) investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common shares and pre-funded warrants, net (note 9a and note 9e) (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized tax benefits of uncertain tax positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Unrecognized Tax Benefits, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Unrecognized Tax Benefits, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average Grant Date Fair Value, Unvested, Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average Grant Date Fair Value, Unvested, Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Property, Plant and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciable assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants outstanding to purchase common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Pre-Funded Warrants to Purchase Common Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Amortized Cost, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Contractual maturity of 1 to 3 years, Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Contractual maturity of 1 to 3 years, Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Prepaid Expense, Noncurrent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses, long-term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nature of the business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Assets Measured at Fair Value on a Recurring Basis [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, plant and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate fair value of options vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: imputed interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Noncash Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-Based Payment Arrangement, Noncash Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Basic and Diluted Net Loss Per Common Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related and Nonrelated Parties [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTaxCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contractual maturity of 0 to 1 years, Unrealized Gain (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTaxCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities Available For Sale Accumulated Gross Unrealized Gain (Loss) Before Tax Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTaxCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt securities available for sale accumulated gross unrealized gain (loss) before tax current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_AmendedAndRestatedStockOptionPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amended and restated stock option plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_AmendedAndRestatedStockOptionPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amended And Restated Stock Option Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_AmendedAndRestatedStockOptionPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amended and Restated Stock Option Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TradingActivityByTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Activity, by Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TradingActivityByTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Activity, by Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_TwoThousandNineteenInducementEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand nineteen inducement equity incentive plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_TwoThousandNineteenInducementEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Nineteen Inducement Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_TwoThousandNineteenInducementEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 Inducement Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockConversionBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Conversion Basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockConversionBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred shares convertible into common shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Reportable Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of reportable segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_PreFundsWarrantsOutstandingDateIssuanceJuneTwoThousandTwentyTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">June 2022</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_PreFundsWarrantsOutstandingDateIssuanceJuneTwoThousandTwentyTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre Funds Warrants Outstanding Date Issuance June Two Thousand Twenty Two [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_PreFundsWarrantsOutstandingDateIssuanceJuneTwoThousandTwentyTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pre funds warrants outstanding date issuance june two thousand twenty two.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Early Adoption [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle, early adoption</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Common Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted average common shares outstanding - basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted average common shares outstanding - basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_FirstOrderPharmaceuticalsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">1st Order Pharmaceuticals, Inc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_FirstOrderPharmaceuticalsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">First Order Pharmaceuticals Inc [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_FirstOrderPharmaceuticalsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">1st Order Pharmaceuticals, Inc. [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToTerminate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Option to Terminate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToTerminate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating lease, option to terminate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestRateRiskMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Rate Risk [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestRateRiskMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest Rate Risk [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Useful Life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, Plant and Equipment, Useful Life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Amount offered for issuance of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale proceeds of common shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Sale and Maturity of Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Level 1 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_LesseeOperatingLeaseNumberOfRenewalOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, number of renewal options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_LesseeOperatingLeaseNumberOfRenewalOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Number of Renewal Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_LesseeOperatingLeaseNumberOfRenewalOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease number of renewal options.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_MilestonePaymentDueOnInitiationOfPhase1bClinicalTrial_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payment due on initiation of Phase 1b clinical trial.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_MilestonePaymentDueOnInitiationOfPhase1bClinicalTrial_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payment Due On Initiation Of Phase1b Clinical Trial</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_MilestonePaymentDueOnInitiationOfPhase1bClinicalTrial_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payment due on initiation of Phase 1b clinical trial</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable and accrued liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated by Reference [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_Rule10B51TradingPlanOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Rule10B 51Trading Plan One [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_Rule10B51TradingPlanOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Rule10B 51Trading Plan One [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_Rule10B51TradingPlanOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rule10B 5-1 Trading Plan One [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_ResearchEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research equipment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_ResearchEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_ResearchEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Outstanding Weighted Average Remaining Contractual Life in Years</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net income (loss) per common share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Purchase Commitment, Category of Item Purchased [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term Purchase Commitment, Category of Item Purchased</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_MedpaceClinicalDevelopmentServiceAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Medpace clinical development service agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_MedpaceClinicalDevelopmentServiceAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Medpace Clinical Development Service Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_MedpaceClinicalDevelopmentServiceAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Priority Access Agreement with Medpace Inc. [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Nonvested Share Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Unvested Stock Option Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_LicenseAndCollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License and Collaboration Agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_LicenseAndCollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License And Collaboration Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_LicenseAndCollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License and Collaboration Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment, Long-Lived Asset, Held-for-Use</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of Long-Lived Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Impairment, Long-Lived Asset, Held-for-Use, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Impairment charges recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of long-lived assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_JefferiesLLCAndStifelNicolausCompanyIncorporatedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Jefferies LLC and Stifel, Nicolaus &amp; Company, Incorporated member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_JefferiesLLCAndStifelNicolausCompanyIncorporatedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Jefferies L L C And Stifel Nicolaus Company Incorporated [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_JefferiesLLCAndStifelNicolausCompanyIncorporatedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Jefferies and Stifel [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_JefferiesLLCAndStifelNicolausCompanyIncorporatedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Jefferies and Stifel [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_JefferiesLLCStifelNicolausCompanyIncorporatedJPMorganSecuritiesLLCAndSVBSecuritiesLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Jefferies, Stifel, J.P. Morgan Securities LLC and SVB Securities LLC [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_JefferiesLLCStifelNicolausCompanyIncorporatedJPMorganSecuritiesLLCAndSVBSecuritiesLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Jefferies L L C Stifel Nicolaus Company Incorporated J P Morgan Securities L L C And S V B Securities L L C [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_JefferiesLLCStifelNicolausCompanyIncorporatedJPMorganSecuritiesLLCAndSVBSecuritiesLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Jefferies L L C, Stifel Nicolaus Company Incorporated, J.P.Morgan Securities LLC and SVB Securities LLC.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale proceeds from issuance of pre funded warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_ShareCapitalTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Capital [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_ShareCapitalTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share capital.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_ShareCapitalTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Capital [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Role of Management [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_WeightedAverageNumberOfPrefundedWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Prefunded Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_WeightedAverageNumberOfPrefundedWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Weighted average number of prefunded warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_WeightedAverageNumberOfPrefundedWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-funded warrants (weighted average)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-Sale, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading securities available-for-sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_StockIssuedDuringPeriodCommonSharesCancelled_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Common Shares Cancelled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_StockIssuedDuringPeriodCommonSharesCancelled_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period common shares cancelled.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_StockIssuedDuringPeriodCommonSharesCancelled_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares cancelled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Option Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities, long-term (note 5)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shareholders&#8217; equity:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_VariableConsiderationAllocatedToPerformanceObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Variable consideration allocated to performance obligation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_VariableConsiderationAllocatedToPerformanceObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Consideration Allocated To Performance Obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_VariableConsiderationAllocatedToPerformanceObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable consideration allocated to performance obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateTransitionOptionElectedExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Transition Option Elected [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateTransitionOptionElectedExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in Accounting Principle, Accounting Standards Update, Transition Option Elected [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_Series1PreferredSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series 1 preferred shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_Series1PreferredSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series1 Preferred Shares [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_Series1PreferredSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series1 Preferred Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment and geographic information</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Property, Plant and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_ScheduleOfPreFundedWarrantsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Pre-Funded Warrants Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_ScheduleOfPreFundedWarrantsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Pre Funded Warrants Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_ScheduleOfPreFundedWarrantsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of pre funded warrants activity.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_JefferiesLLCSVBLeerinkLLCAndStifelNicolausCompanyIncorporatedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Jefferies LLC SVB leerink LLC and stifel nicolaus company incorporated.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_JefferiesLLCSVBLeerinkLLCAndStifelNicolausCompanyIncorporatedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Jefferies L L C S V B Leerink L L C And Stifel Nicolaus Company Incorporated [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_JefferiesLLCSVBLeerinkLLCAndStifelNicolausCompanyIncorporatedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Jefferies LLC SVB Leerink LLC and Stifel Nicolaus Company Incorporated [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer, Including Assessed Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue (note 10)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (decrease) in cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Servicing Assets and Servicing Liabilities Risk [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Servicing Assets and Servicing Liabilities Risk</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per common share (note 11):</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseContractualTermDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Contractual Term [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentCreditMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Tax Credit Carryforward [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentCreditMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment Tax credit [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LicenseAndServiceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License and Service [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LicenseAndServiceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration Revenue [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationDateOfIncorporation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, Date of Incorporation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationDateOfIncorporation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Date of incorporation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued, Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate purchase price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockNoParValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, No Par Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockNoParValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common shares, without par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_UnfavorableChangeInInterestRatesOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unfavorable change in interest rates of marketable securities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_UnfavorableChangeInInterestRatesOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unfavorable Change In Interest Rates Of Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_UnfavorableChangeInInterestRatesOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unfavorable change in interest rates of marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Professional fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_BasisOfPresentationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Basis of presentation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_BasisOfPresentationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis Of Presentation [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_BasisOfPresentationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial instruments and fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss attributable to common shareholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per common share - basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss attributable to common shareholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Exercisable Weighted Average Remaining Contractual Life in Years</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts Payable and Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, Plant and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term Debt, Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, and Short-Term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents and marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, and Short-Term Investments, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_CollaborateAgreementPremiumRelatedToEquityInvestment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborate agreement premium related to equity investment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_CollaborateAgreementPremiumRelatedToEquityInvestment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborate Agreement Premium Related To Equity Investment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_CollaborateAgreementPremiumRelatedToEquityInvestment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborate agreement premium related to equity investment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Adoption Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle, adoption date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other General and Administrative Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other general and administrative costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Options, Forfeited, cancelled or expired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_RecognitionOfTransactionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Recognition of transaction price.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_RecognitionOfTransactionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Recognition Of Transaction Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_RecognitionOfTransactionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recognition of the transaction price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_PerformanceObligationsRelatedToMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Performance obligation related to milestone</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_PerformanceObligationsRelatedToMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Performance Obligations Related To Milestone</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_PerformanceObligationsRelatedToMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Performance obligations in relation to this milestone.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and cash equivalents, end of year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and cash equivalents, beginning of year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from public offerings, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance Initial Public Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit available to offset taxes payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_PercentageOfOptionToFundDevelopmentCostsUponAchievementOfCertainMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of option to fund development costs upon achievement of certain milestones.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_PercentageOfOptionToFundDevelopmentCostsUponAchievementOfCertainMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Option To Fund Development Costs Upon Achievement Of Certain Milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_PercentageOfOptionToFundDevelopmentCostsUponAchievementOfCertainMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of option to co-fund development costs upon achievement of certain milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LegalCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Legal Costs, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LegalCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intellectual property</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Canadian federal and provincial tax rates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Tax at statutory income tax rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Conversion of shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of preferred shares (note 9d) (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred shares, outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Shares Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Shares Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_Pre-ClinicalDiscoveryAndOtherProgramsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-clinical Discovery And Other Programs [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_Pre-ClinicalDiscoveryAndOtherProgramsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pre-clinical discovery and other programs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_Pre-ClinicalDiscoveryAndOtherProgramsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-clinical, discovery and other programs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Loss before Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignExchangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Exchange [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignExchangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign Currency Exchange Risk [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccounting_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis of Accounting [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccounting_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Net Deferred Income Tax Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability (note 7)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Over-Allotment Option [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Over Allotment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property, plant and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_MilestonePaymentsPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payments paid.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_MilestonePaymentsPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payments Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_MilestonePaymentsPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payment paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTaxNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contractual maturity of 1 to 3 years, Unrealized Gain (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTaxNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities Available For Sale Accumulated Gross Unrealized Gain (Loss) Before Tax Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTaxNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt securities available for sale accumulated gross unrealized gain (loss) before tax noncurrent.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_MilestonePaymentReceivedInEquityInvestment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payment received in equity investment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_MilestonePaymentReceivedInEquityInvestment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payment Received In Equity Investment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_MilestonePaymentReceivedInEquityInvestment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone Payment Received in Equity Investment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration of credit risk:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets (note 13)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Assets, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_PersonnelRelatedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Personnel Related Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_PersonnelRelatedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Personnel related expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_PersonnelRelatedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Personnel-related expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm ID</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Firm ID</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Shares [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common Shares [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts Payable and Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset, Periodic Reduction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash operating lease expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well-known Seasoned Issuer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well-known Seasoned Issuer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Contractual maturity of 0 to 1 years, Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign currency translation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Income Location, Balance [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_AssetPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Asset purchase agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_AssetPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Purchase Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_AssetPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Purchase Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_NumberOfWarrantsIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_NumberOfWarrantsIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Warrants Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_NumberOfWarrantsIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of warrants issued.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_CashAndMoneyMarketFundMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash and money market fund.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_CashAndMoneyMarketFundMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Money Market Fund [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_IncreaseDecreaseInFairValueOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase (Decrease) in fair value of marketable securities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_IncreaseDecreaseInFairValueOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Fair Value Of Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_IncreaseDecreaseInFairValueOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Decrease in the fair value of marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PerformanceSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Performance Shares [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PerformanceSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">PSUs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Federal, State and Local, Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Current Federal, State and Local, Tax Expense (Benefit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">United States</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Number of Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Options, Forfeited or cancelled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title and Position [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Reporting, Expense Information Used by CODM, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Expense Information Used by CODM, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_BasisOfPresentationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Basis of presentation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_BasisOfPresentationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis Of Presentation [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_BasisOfPresentationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis Of Presentation [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Canada</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common shares, without par value; unlimited shares authorized; issued and outstanding: 76,416,086 (December 31, 2023 - 75,370,977) (note 9)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_ShareCapitalLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share capital.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_ShareCapitalLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Capital [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_ShareCapitalLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Capital [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income, Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer Benchmark [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total Revenues [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Schedule of Financial Assets Measured at Fair Value on a Recurring Basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_AccruedResearchAndDevelopmentCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research and Development, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_AccruedResearchAndDevelopmentCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued research and development, current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_AccruedResearchAndDevelopmentCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_NetIncomeLossAvailableToPreferredStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Net income (loss) available to preferred stockholders basic.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_NetIncomeLossAvailableToPreferredStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss Available To Preferred Stockholders Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_NetIncomeLossAvailableToPreferredStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net loss attributable to preferred shareholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_NetIncomeLossAvailableToPreferredStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income Loss Available To Preferred Stockholders Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Present value of lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Lease, Liability, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Summary of Amortized Cost, Unrealized Gain (Losses) Recognized in AOCI and Fair Value of Available-for-Sale Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-capital losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Operating Loss Carryforwards, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (note 12)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_ResearchAndDevelopmentServices_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development services.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_ResearchAndDevelopmentServices_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_ResearchAndDevelopmentServices_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted average common shares outstanding - diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant accounting policies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Net Loss Related To Segment Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Receivable, after Allowance for Credit Loss, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_NumberOfWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_NumberOfWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of warrants exercised.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_NumberOfWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Warrants Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_NumberOfWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of pre-funded warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Renewal Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease extension term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total future minimum lease payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Third Party Engaged [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_ExchangeAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Exchange agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_ExchangeAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Exchange Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_ExchangeAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exchange Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Denominator:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_SignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Significant accounting policies.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_SignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_SignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Accounting Policies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Benchmark [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk Benchmark</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Information [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_SalesBasedMilestoneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sales-based milestone.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_SalesBasedMilestoneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sales Based Milestone [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_SalesBasedMilestoneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales Based Milestone [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term Loan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Treasury Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">U.S. Treasuries [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Foreign exchange gain (loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain (Loss), Foreign Currency Transaction, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Foreign Currency Transaction Gain (Loss), before Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign exchange (loss) gain</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_CommitmentsAndContingenciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitments and contingencies.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_CommitmentsAndContingenciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_CommitmentsAndContingenciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments And Contingencies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_LesseeNumberOfOperatingLeases_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee, number of operating leases.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_LesseeNumberOfOperatingLeases_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Number Of Operating Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_LesseeNumberOfOperatingLeases_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financing activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average Exercise Price Outstanding, Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average Exercise Price Outstanding, Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average common shares outstanding (note 4):</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_DeferredTaxAssetsOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_DeferredTaxAssetsOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_DeferredTaxAssetsOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets, operating lease liability.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred income tax assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use asset obtained in exchange for new operating lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less - valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 3 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Level 3 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Remaining Lease Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining lease term (years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted average remaining lease term (years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_StockIssuedDuringPeriodSharesConversionOfPreFundedWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Conversion Of Pre Funded Warrant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_StockIssuedDuringPeriodSharesConversionOfPreFundedWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares conversion of pre funded warrant.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_StockIssuedDuringPeriodSharesConversionOfPreFundedWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of pre-funded warrants (note 9e) (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized gain (loss) on available-for-sale securities (note 5)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_FairValueOfStockOptionsExercisedOnCashlessBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The aggregate grant-date fair value of stock options exercised via net exercise (cashless) during the reporting period as calculated by applying the disclosed option pricing methodology.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_FairValueOfStockOptionsExercisedOnCashlessBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Of Stock Options Exercised On Cashless Basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_FairValueOfStockOptionsExercisedOnCashlessBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of stock options exercised on a cashless basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle, material impact</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RisksAndUncertaintiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Risks and Uncertainties [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_CommitmentsAndContingenciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitments and contingencies.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_CommitmentsAndContingenciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_CommitmentsAndContingenciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments And Contingencies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable and Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable and accrued liabilities (note 8)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_PreFundsWarrantsOutstandingDateIssuanceOctoberTwoThousandTwentyOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">October 2021</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_PreFundsWarrantsOutstandingDateIssuanceOctoberTwoThousandTwentyOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre Funds Warrants Outstanding Date Issuance October Two Thousand Twenty One [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="xene_PreFundsWarrantsOutstandingDateIssuanceOctoberTwoThousandTwentyOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pre funds warrants outstanding date issuance october two thousand twenty one.</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_ClinicalDevelopementAndOtherMilestoneMember" xlink:to="xene_ClinicalDevelopementAndOtherMilestoneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_UnderwrittenPublicOfferingMember" xlink:to="xene_UnderwrittenPublicOfferingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDescription" xlink:to="us-gaap_LesseeOperatingLeaseDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PriorPeriodReclassificationAdjustment" xlink:to="us-gaap_PriorPeriodReclassificationAdjustment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_Rule10B51TradingPlanMember" xlink:to="xene_Rule10B51TradingPlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_MilestonePayment" xlink:to="xene_MilestonePayment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_MilestonePaymentReceivedInEquityInvestmentMeasuredAtFairValue" xlink:to="xene_MilestonePaymentReceivedInEquityInvestmentMeasuredAtFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LongtermDebtTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OpenTaxYear" xlink:to="us-gaap_OpenTaxYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingOtherItemAmount" xlink:to="us-gaap_SegmentReportingOtherItemAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LatestTaxYearMember" xlink:to="us-gaap_LatestTaxYearMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_CashlessExerciseOfStockOptions" xlink:to="xene_CashlessExerciseOfStockOptions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_GrossProceedsFromIssuableOfCommonStock" xlink:to="xene_GrossProceedsFromIssuableOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_FirstRenewalOptionMember" xlink:to="xene_FirstRenewalOptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorizedUnlimited" xlink:to="us-gaap_PreferredStockSharesAuthorizedUnlimited_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_ProceedsFromUpfrontFee" xlink:to="xene_ProceedsFromUpfrontFee_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_StockIssuedDuringPeriodSharesConversionOfPreFundedWarrantsToCommonShares" xlink:to="xene_StockIssuedDuringPeriodSharesConversionOfPreFundedWarrantsToCommonShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorOpinionTextBlock" xlink:to="dei_AuditorOpinionTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_XEN496Member" xlink:to="xene_XEN496Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_GuaranteedInvestmentCertificatesMember" xlink:to="xene_GuaranteedInvestmentCertificatesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_AtMarketEquityOfferingMember" xlink:to="xene_AtMarketEquityOfferingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_WarrantsExerciseDescription" xlink:to="xene_WarrantsExerciseDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_FuturePotentialMilestonePayments" xlink:to="xene_FuturePotentialMilestonePayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_CommonStockIssuedForPreFundedWarrants" xlink:to="xene_CommonStockIssuedForPreFundedWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_NeedhamMassachusettsMember" xlink:to="xene_NeedhamMassachusettsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_TermLoansMember" xlink:to="xene_TermLoansMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" xlink:to="xene_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_TwoThousandFourteenAmendedAndRestatedStockOptionPlanMember" xlink:to="xene_TwoThousandFourteenAmendedAndRestatedStockOptionPlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_PaciraBiosciencesMember" xlink:to="xene_PaciraBiosciencesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_PotentialMilestonePaymentsReceivable" xlink:to="xene_PotentialMilestonePaymentsReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_AzetukalnerMember" xlink:to="xene_AzetukalnerMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_TaxPeriodDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesTradingUnrealizedGainLoss" xlink:to="us-gaap_DebtSecuritiesTradingUnrealizedGainLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxesPayableCurrent" xlink:to="us-gaap_TaxesPayableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockNoParValue" xlink:to="us-gaap_PreferredStockNoParValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_WarrantsIssuedPricePerPreFundedWarrant" xlink:to="xene_WarrantsIssuedPricePerPreFundedWarrant_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradingSecuritiesDebt" xlink:to="us-gaap_TradingSecuritiesDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardExpirationDate" xlink:to="us-gaap_TaxCreditCarryforwardExpirationDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_MaximumTermOfEachOptionExercised" xlink:to="xene_MaximumTermOfEachOptionExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_JefferiesLLCStifelNicolausCompanyIncorporatedAndGuggenheimSecuritiesLLCMember" xlink:to="xene_JefferiesLLCStifelNicolausCompanyIncorporatedAndGuggenheimSecuritiesLLCMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_WeightedAverageNumberOfCommonShares" xlink:to="xene_WeightedAverageNumberOfCommonShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration" xlink:to="us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_CollaborateMilestoneAgreementPremiumRelatedToEquityInvestment" xlink:to="xene_CollaborateMilestoneAgreementPremiumRelatedToEquityInvestment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardTable" xlink:to="us-gaap_TaxCreditCarryforwardTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_SecondRenewalOptionMember" xlink:to="xene_SecondRenewalOptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_StockOptionActivityAbstract" xlink:to="xene_StockOptionActivityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_AggregateMilestonePaymentReceived" xlink:to="xene_AggregateMilestonePaymentReceived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SubsidiariesMember" xlink:to="srt_SubsidiariesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductConcentrationRiskMember" xlink:to="us-gaap_ProductConcentrationRiskMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_PreFundedWarrantsExercised" xlink:to="xene_PreFundedWarrantsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_SignificantAccountingPoliciesLineItems" xlink:to="xene_SignificantAccountingPoliciesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_MilestonePaymentReceivedInCash" xlink:to="xene_MilestonePaymentReceivedInCash_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperMember" xlink:to="us-gaap_CommercialPaperMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DescriptionOfInterestRateRiskExposure" xlink:to="us-gaap_DescriptionOfInterestRateRiskExposure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_PreFundsWarrantsOutstandingDateIssuanceDecemberTwoThousandTwentyThreeMember" xlink:to="xene_PreFundsWarrantsOutstandingDateIssuanceDecemberTwoThousandTwentyThreeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_CanadaAndUnitedStatesRevenueAgencyMember" xlink:to="xene_CanadaAndUnitedStatesRevenueAgencyMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_IanMortimerMember" xlink:to="xene_IanMortimerMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableTradeCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_BurnabyBritishColumbiaMember" xlink:to="xene_BurnabyBritishColumbiaMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_DeferredTaxAssetsTaxCreditCarryforwardsInvestment" xlink:to="xene_DeferredTaxAssetsTaxCreditCarryforwardsInvestment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_StockOptionsExercisedForNumberOfCommonSharesForCash" xlink:to="xene_StockOptionsExercisedForNumberOfCommonSharesForCash_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_ClinicalDevelopmentMilestonesMember" xlink:to="xene_ClinicalDevelopmentMilestonesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RisksInherentInServicingAssetsAndServicingLiabilitiesTypeDomain" xlink:to="us-gaap_RisksInherentInServicingAssetsAndServicingLiabilitiesTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_PurchasesOfPropertyPlantAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities" xlink:to="xene_PurchasesOfPropertyPlantAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorizedUnlimited" xlink:to="us-gaap_CommonStockSharesAuthorizedUnlimited_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarliestTaxYearMember" xlink:to="us-gaap_EarliestTaxYearMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_JefferiesLLCStifelNicolausCompanyIncorporatedJPMorganSecuritiesLLCBofASecuritiesIncAndRBCCapitalMarketsLLCMember" xlink:to="xene_JefferiesLLCStifelNicolausCompanyIncorporatedJPMorganSecuritiesLLCBofASecuritiesIncAndRBCCapitalMarketsLLCMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_UpfrontPaymentReceivedInEquityInvestment" xlink:to="xene_UpfrontPaymentReceivedInEquityInvestment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_RegulatoryMilestoneMember" xlink:to="xene_RegulatoryMilestoneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" xlink:to="xene_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:to="us-gaap_AccountingChangesAndErrorCorrectionsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_PreFundsWarrantsOutstandingDateIssuanceMarchTwoThousandTwentyOneMember" xlink:to="xene_PreFundsWarrantsOutstandingDateIssuanceMarchTwoThousandTwentyOneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_CashReceivedForLeaseIncentives" xlink:to="xene_CashReceivedForLeaseIncentives_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_ProvincialTaxCreditMember" xlink:to="xene_ProvincialTaxCreditMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_EarningsPerShareBasicLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_InterestReceivableAndAccretionOfDiscountsOnMarketableSecurities" xlink:to="xene_InterestReceivableAndAccretionOfDiscountsOnMarketableSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_CommonStockIssuedForCashlessExercise" xlink:to="xene_CommonStockIssuedForCashlessExercise_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="srt_ConsolidatedEntitiesDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:to="us-gaap_ForeignCurrencyExchangeRateTranslation1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax" xlink:to="xene_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_RoyaltyObligations" xlink:to="xene_RoyaltyObligations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_NeurocrineBiosciencesMember" xlink:to="xene_NeurocrineBiosciencesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_StockIssuedDuringPeriodValueConversionOfPreFundedWarrant" xlink:to="xene_StockIssuedDuringPeriodValueConversionOfPreFundedWarrant_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtRestatementRecoveryAnalysisFlag" xlink:to="dei_DocumentFinStmtRestatementRecoveryAnalysisFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_FairValueAssumptionsForStockOptionsAbstract" xlink:to="xene_FairValueAssumptionsForStockOptionsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" xlink:to="xene_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_BVFPartnersLPMember" xlink:to="xene_BVFPartnersLPMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_FairValueOfPreFundedWarrantsExercised" xlink:to="xene_FairValueOfPreFundedWarrantsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_AggregatePriceOfTransactionAllocatedToPerformanceObligations" xlink:to="xene_AggregatePriceOfTransactionAllocatedToPerformanceObligations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_OtherMilestonesMember" xlink:to="xene_OtherMilestonesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PhantomShareUnitsPSUsMember" xlink:to="us-gaap_PhantomShareUnitsPSUsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_DeferredTaxAssetsDeferredFinancingFees" xlink:to="xene_DeferredTaxAssetsDeferredFinancingFees_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradingActivityByTypeAxis" xlink:to="us-gaap_TradingActivityByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_EffectiveIncomeTaxRateReconciliationTaxAttributesExpiredOrUtilized" xlink:to="xene_EffectiveIncomeTaxRateReconciliationTaxAttributesExpiredOrUtilized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_UpfrontPaymentInCash" xlink:to="xene_UpfrontPaymentInCash_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseNoncurrent" xlink:to="us-gaap_PrepaidExpenseNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTaxCurrent" xlink:to="xene_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTaxCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_AmendedAndRestatedStockOptionPlanMember" xlink:to="xene_AmendedAndRestatedStockOptionPlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradingActivityByTypeDomain" xlink:to="us-gaap_TradingActivityByTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_TwoThousandNineteenInducementEquityIncentivePlanMember" xlink:to="xene_TwoThousandNineteenInducementEquityIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConversionBasis" xlink:to="us-gaap_PreferredStockConversionBasis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_PreFundsWarrantsOutstandingDateIssuanceJuneTwoThousandTwentyTwoMember" xlink:to="xene_PreFundsWarrantsOutstandingDateIssuanceJuneTwoThousandTwentyTwoMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_FirstOrderPharmaceuticalsIncMember" xlink:to="xene_FirstOrderPharmaceuticalsIncMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToTerminate" xlink:to="us-gaap_LesseeOperatingLeaseOptionToTerminate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestRateRiskMember" xlink:to="us-gaap_InterestRateRiskMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:to="xene_LesseeOperatingLeaseNumberOfRenewalOptions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_MilestonePaymentDueOnInitiationOfPhase1bClinicalTrial" xlink:to="xene_MilestonePaymentDueOnInitiationOfPhase1bClinicalTrial_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_Rule10B51TradingPlanOneMember" xlink:to="xene_Rule10B51TradingPlanOneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_ResearchEquipmentMember" xlink:to="xene_ResearchEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_MedpaceClinicalDevelopmentServiceAgreementMember" xlink:to="xene_MedpaceClinicalDevelopmentServiceAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_LicenseAndCollaborationAgreementMember" xlink:to="xene_LicenseAndCollaborationAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_JefferiesLLCAndStifelNicolausCompanyIncorporatedMember" xlink:to="xene_JefferiesLLCAndStifelNicolausCompanyIncorporatedMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_JefferiesLLCStifelNicolausCompanyIncorporatedJPMorganSecuritiesLLCAndSVBSecuritiesLLCMember" xlink:to="xene_JefferiesLLCStifelNicolausCompanyIncorporatedJPMorganSecuritiesLLCAndSVBSecuritiesLLCMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_ShareCapitalTable" xlink:to="xene_ShareCapitalTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_WeightedAverageNumberOfPrefundedWarrants" xlink:to="xene_WeightedAverageNumberOfPrefundedWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_StockIssuedDuringPeriodCommonSharesCancelled" xlink:to="xene_StockIssuedDuringPeriodCommonSharesCancelled_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesNoncurrent" xlink:to="us-gaap_MarketableSecuritiesNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_VariableConsiderationAllocatedToPerformanceObligation" xlink:to="xene_VariableConsiderationAllocatedToPerformanceObligation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateTransitionOptionElectedExtensibleList" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateTransitionOptionElectedExtensibleList_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_Series1PreferredSharesMember" xlink:to="xene_Series1PreferredSharesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="us-gaap_TaxCreditCarryforwardLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_ScheduleOfPreFundedWarrantsActivityTableTextBlock" xlink:to="xene_ScheduleOfPreFundedWarrantsActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_JefferiesLLCSVBLeerinkLLCAndStifelNicolausCompanyIncorporatedMember" xlink:to="xene_JefferiesLLCSVBLeerinkLLCAndStifelNicolausCompanyIncorporatedMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis" xlink:to="us-gaap_ManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="us-gaap_LeaseContractualTermDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentCreditMember" xlink:to="us-gaap_InvestmentCreditMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseAndServiceMember" xlink:to="us-gaap_LicenseAndServiceMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationDateOfIncorporation" xlink:to="dei_EntityIncorporationDateOfIncorporation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockNoParValue" xlink:to="us-gaap_CommonStockNoParValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_UnfavorableChangeInInterestRatesOfMarketableSecurities" xlink:to="xene_UnfavorableChangeInInterestRatesOfMarketableSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_BasisOfPresentationLineItems" xlink:to="xene_BasisOfPresentationLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_CollaborateAgreementPremiumRelatedToEquityInvestment" xlink:to="xene_CollaborateAgreementPremiumRelatedToEquityInvestment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_RecognitionOfTransactionPrice" xlink:to="xene_RecognitionOfTransactionPrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_PerformanceObligationsRelatedToMilestone" xlink:to="xene_PerformanceObligationsRelatedToMilestone_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_PercentageOfOptionToFundDevelopmentCostsUponAchievementOfCertainMilestones" xlink:to="xene_PercentageOfOptionToFundDevelopmentCostsUponAchievementOfCertainMilestones_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalCostsPolicyTextBlock" xlink:to="us-gaap_LegalCostsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_Pre-ClinicalDiscoveryAndOtherProgramsMember" xlink:to="xene_Pre-ClinicalDiscoveryAndOtherProgramsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignExchangeMember" xlink:to="us-gaap_ForeignExchangeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccounting" xlink:to="us-gaap_BasisOfAccounting_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_MilestonePaymentsPaid" xlink:to="xene_MilestonePaymentsPaid_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTaxNoncurrent" xlink:to="xene_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTaxNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_MilestonePaymentReceivedInEquityInvestment" xlink:to="xene_MilestonePaymentReceivedInEquityInvestment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_PersonnelRelatedExpenses" xlink:to="xene_PersonnelRelatedExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_AssetPurchaseAgreementMember" xlink:to="xene_AssetPurchaseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_NumberOfWarrantsIssued" xlink:to="xene_NumberOfWarrantsIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_CashAndMoneyMarketFundMember" xlink:to="xene_CashAndMoneyMarketFundMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_IncreaseDecreaseInFairValueOfMarketableSecurities" xlink:to="xene_IncreaseDecreaseInFairValueOfMarketableSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PerformanceSharesMember" xlink:to="us-gaap_PerformanceSharesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription" xlink:to="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_BasisOfPresentationTable" xlink:to="xene_BasisOfPresentationTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_ShareCapitalLineItems" xlink:to="xene_ShareCapitalLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerMember" xlink:to="us-gaap_RevenueFromContractWithCustomerMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_AccruedResearchAndDevelopmentCurrent" xlink:to="xene_AccruedResearchAndDevelopmentCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_NetIncomeLossAvailableToPreferredStockholdersBasic" xlink:to="xene_NetIncomeLossAvailableToPreferredStockholdersBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_ResearchAndDevelopmentServices" xlink:to="xene_ResearchAndDevelopmentServices_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_NumberOfWarrantsExercised" xlink:to="xene_NumberOfWarrantsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_ExchangeAgreementMember" xlink:to="xene_ExchangeAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_SignificantAccountingPoliciesTable" xlink:to="xene_SignificantAccountingPoliciesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingInformationLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_SalesBasedMilestoneMember" xlink:to="xene_SalesBasedMilestoneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_CommitmentsAndContingenciesTable" xlink:to="xene_CommitmentsAndContingenciesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_LesseeNumberOfOperatingLeases" xlink:to="xene_LesseeNumberOfOperatingLeases_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_DeferredTaxAssetsOperatingLeaseLiability" xlink:to="xene_DeferredTaxAssetsOperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_StockIssuedDuringPeriodSharesConversionOfPreFundedWarrant" xlink:to="xene_StockIssuedDuringPeriodSharesConversionOfPreFundedWarrant_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_FairValueOfStockOptionsExercisedOnCashlessBasis" xlink:to="xene_FairValueOfStockOptionsExercisedOnCashlessBasis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="us-gaap_RisksAndUncertaintiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_CommitmentsAndContingenciesLineItems" xlink:to="xene_CommitmentsAndContingenciesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xene_PreFundsWarrantsOutstandingDateIssuanceOctoberTwoThousandTwentyOneMember" xlink:to="xene_PreFundsWarrantsOutstandingDateIssuanceOctoberTwoThousandTwentyOneMember_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtRestatementRecoveryAnalysisFlag" xlink:label="dei_DocumentFinStmtRestatementRecoveryAnalysisFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorOpinionTextBlock" xlink:label="dei_AuditorOpinionTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFinStmtRestatementRecoveryAnalysisFlag" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="73.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="74.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="75.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="76.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="77.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="78.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="79.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="80.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="81.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="82.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCountry" order="83.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="84.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName" order="85.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId" order="86.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation" order="87.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="88.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorOpinionTextBlock" order="89.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:label="us-gaap_MarketableSecuritiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="us-gaap_PrepaidExpenseNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_MarketableSecuritiesNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PrepaidExpenseNoncurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockNoParValue" xlink:label="us-gaap_PreferredStockNoParValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorizedUnlimited" xlink:label="us-gaap_PreferredStockSharesAuthorizedUnlimited"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockNoParValue" xlink:label="us-gaap_CommonStockNoParValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorizedUnlimited" xlink:label="us-gaap_CommonStockSharesAuthorizedUnlimited"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockNoParValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorizedUnlimited" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockNoParValue" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorizedUnlimited" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesTradingUnrealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesTradingUnrealizedGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_NetIncomeLossAvailableToPreferredStockholdersBasic" xlink:label="xene_NetIncomeLossAvailableToPreferredStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_DebtSecuritiesTradingUnrealizedGainLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareAbstract" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="xene_NetIncomeLossAvailableToPreferredStockholdersBasic" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_StockIssuedDuringPeriodValueConversionOfPreFundedWarrant" xlink:label="xene_StockIssuedDuringPeriodValueConversionOfPreFundedWarrant"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_StockIssuedDuringPeriodSharesConversionOfPreFundedWarrant" xlink:label="xene_StockIssuedDuringPeriodSharesConversionOfPreFundedWarrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_13"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_14"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="xene_StockIssuedDuringPeriodValueConversionOfPreFundedWarrant" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="xene_StockIssuedDuringPeriodSharesConversionOfPreFundedWarrant" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_13" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_14" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_InterestReceivableAndAccretionOfDiscountsOnMarketableSecurities" xlink:label="xene_InterestReceivableAndAccretionOfDiscountsOnMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_FairValueOfStockOptionsExercisedOnCashlessBasis" xlink:label="xene_FairValueOfStockOptionsExercisedOnCashlessBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_FairValueOfPreFundedWarrantsExercised" xlink:label="xene_FairValueOfPreFundedWarrantsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_CashReceivedForLeaseIncentives" xlink:label="xene_CashReceivedForLeaseIncentives"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_PurchasesOfPropertyPlantAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities" xlink:label="xene_PurchasesOfPropertyPlantAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesTradingUnrealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesTradingUnrealizedGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_6"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="xene_InterestReceivableAndAccretionOfDiscountsOnMarketableSecurities" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="xene_FairValueOfStockOptionsExercisedOnCashlessBasis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="xene_FairValueOfPreFundedWarrantsExercised" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="xene_CashReceivedForLeaseIncentives" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="xene_PurchasesOfPropertyPlantAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DebtSecuritiesTradingUnrealizedGainLoss" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_6" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember" xlink:label="ecd_AllTradingArrangementsMember"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_Rule10B51TradingPlanMember" xlink:label="xene_Rule10B51TradingPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_Rule10B51TradingPlanOneMember" xlink:label="xene_Rule10B51TradingPlanOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="ecd_AllIndividualsMember"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_IanMortimerMember" xlink:label="xene_IanMortimerMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllTradingArrangementsMember" xlink:to="xene_Rule10B51TradingPlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllTradingArrangementsMember" xlink:to="xene_Rule10B51TradingPlanOneMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllIndividualsMember" xlink:to="xene_IanMortimerMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureNatureOfBusiness" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccounting" xlink:label="us-gaap_BasisOfAccounting"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccounting" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureChangesInSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:label="us-gaap_AccountingChangesAndErrorCorrectionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:to="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstruments1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureMarketableSecurities" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipment" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureLeases" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureAccountsPayableAndAccruedLiabilities" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureTermLoan" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapital" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureConcentrationsOfMarketRisk" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="us-gaap_RisksAndUncertaintiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCollaborationAgreements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureNetLossPerCommonShare" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureSegmentDisclosure1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LegalCostsPolicyTextBlock" xlink:label="us-gaap_LegalCostsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_MarketableSecuritiesPolicy" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LegalCostsPolicyTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" xlink:label="xene_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="xene_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureMarketableSecuritiesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureLeasesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureAccountsPayableAndAccruedLiabilitiesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_ScheduleOfPreFundedWarrantsActivityTableTextBlock" xlink:label="xene_ScheduleOfPreFundedWarrantsActivityTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="xene_ScheduleOfPreFundedWarrantsActivityTableTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCollaborationAgreementsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureNetLossPerCommonShareTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="us-gaap_EarningsPerShareBasicLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasicLineItems" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureSegmentDisclosureTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureNatureOfBusinessDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NetIncomeLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SubsidiariesMember" xlink:label="srt_SubsidiariesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_BasisOfPresentationTable" xlink:label="xene_BasisOfPresentationTable"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_BasisOfPresentationLineItems" xlink:label="xene_BasisOfPresentationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="dei_EntityIncorporationDateOfIncorporation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PriorPeriodReclassificationAdjustment" xlink:label="us-gaap_PriorPeriodReclassificationAdjustment"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="srt_SubsidiariesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="xene_BasisOfPresentationTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xene_BasisOfPresentationLineItems" xlink:to="dei_EntityIncorporationDateOfIncorporation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xene_BasisOfPresentationTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xene_BasisOfPresentationLineItems" xlink:to="us-gaap_PriorPeriodReclassificationAdjustment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xene_BasisOfPresentationTable" xlink:to="xene_BasisOfPresentationLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPropertyPlantAndEquipmentEstimatedUsefulLivesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_ResearchEquipmentMember" xlink:label="xene_ResearchEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="xene_ResearchEquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductConcentrationRiskMember" xlink:label="us-gaap_ProductConcentrationRiskMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_SignificantAccountingPoliciesLineItems" xlink:label="xene_SignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_NeurocrineBiosciencesMember" xlink:label="xene_NeurocrineBiosciencesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_SignificantAccountingPoliciesTable" xlink:label="xene_SignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="us-gaap_RevenueFromContractWithCustomerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_PaciraBiosciencesMember" xlink:label="xene_PaciraBiosciencesMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ProductConcentrationRiskMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xene_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xene_NeurocrineBiosciencesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="xene_SignificantAccountingPoliciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xene_SignificantAccountingPoliciesTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_RevenueFromContractWithCustomerMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xene_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xene_PaciraBiosciencesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xene_SignificantAccountingPoliciesTable" xlink:to="srt_CounterpartyNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xene_SignificantAccountingPoliciesTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xene_SignificantAccountingPoliciesTable" xlink:to="xene_SignificantAccountingPoliciesLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureChangesInSignificantAccountingPoliciesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateTransitionOptionElectedExtensibleList" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateTransitionOptionElectedExtensibleList"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateTransitionOptionElectedExtensibleList" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFinancialAssetsMeasuredAtFairValueOnARecurringBasisDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_CashAndMoneyMarketFundMember" xlink:label="xene_CashAndMoneyMarketFundMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_GuaranteedInvestmentCertificatesMember" xlink:label="xene_GuaranteedInvestmentCertificatesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="xene_CashAndMoneyMarketFundMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CommercialPaperMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="xene_GuaranteedInvestmentCertificatesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradingSecuritiesDebt" xlink:label="us-gaap_TradingSecuritiesDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_TradingSecuritiesDebt" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAmortizedCostUnrealizedGainLossRecognizedInAociAndFairValueOfAvailableforsaleSecuritiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_GuaranteedInvestmentCertificatesMember" xlink:label="xene_GuaranteedInvestmentCertificatesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax" xlink:label="xene_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" xlink:label="xene_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTaxCurrent" xlink:label="xene_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTaxCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" xlink:label="xene_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTaxNoncurrent" xlink:label="xene_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTaxNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="xene_GuaranteedInvestmentCertificatesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="xene_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="xene_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="xene_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTaxCurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="xene_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="xene_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTaxNoncurrent" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_ResearchEquipmentMember" xlink:label="xene_ResearchEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="xene_ResearchEquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureLeasesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_LesseeNumberOfOperatingLeases" xlink:label="xene_LesseeNumberOfOperatingLeases"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_FirstRenewalOptionMember" xlink:label="xene_FirstRenewalOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_BurnabyBritishColumbiaMember" xlink:label="xene_BurnabyBritishColumbiaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_SecondRenewalOptionMember" xlink:label="xene_SecondRenewalOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_NeedhamMassachusettsMember" xlink:label="xene_NeedhamMassachusettsMember"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:label="xene_LesseeOperatingLeaseNumberOfRenewalOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="us-gaap_LesseeOperatingLeaseDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseOptionToTerminate" xlink:label="us-gaap_LesseeOperatingLeaseOptionToTerminate"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementGeographicalAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="xene_LesseeNumberOfOperatingLeases" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="xene_FirstRenewalOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="xene_BurnabyBritishColumbiaMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LeaseContractualTermAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="xene_SecondRenewalOptionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="xene_NeedhamMassachusettsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="xene_LesseeOperatingLeaseNumberOfRenewalOptions" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDescription" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToTerminate" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureLeasesScheduleOfCostComponentsOfOperatingLeaseDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_VariableLeaseCost" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureLeasesFutureMinimumLeasePaymentsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureAccountsPayableAndAccruedLiabilitiesAccountsPayableAndAccruedLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_AccruedResearchAndDevelopmentCurrent" xlink:label="xene_AccruedResearchAndDevelopmentCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxesPayableCurrent" xlink:label="us-gaap_TaxesPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableTradeCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrentAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="xene_AccruedResearchAndDevelopmentCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_TaxesPayableCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_AmendedAndRestatedStockOptionPlanMember" xlink:label="xene_AmendedAndRestatedStockOptionPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_TermLoansMember" xlink:label="xene_TermLoansMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_LicenseAndCollaborationAgreementMember" xlink:label="xene_LicenseAndCollaborationAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_AtMarketEquityOfferingMember" xlink:label="xene_AtMarketEquityOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_Series1PreferredSharesMember" xlink:label="xene_Series1PreferredSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_ExchangeAgreementMember" xlink:label="xene_ExchangeAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_BVFPartnersLPMember" xlink:label="xene_BVFPartnersLPMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_JefferiesLLCAndStifelNicolausCompanyIncorporatedMember" xlink:label="xene_JefferiesLLCAndStifelNicolausCompanyIncorporatedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_ShareCapitalTable" xlink:label="xene_ShareCapitalTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_ShareCapitalLineItems" xlink:label="xene_ShareCapitalLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConversionBasis" xlink:label="us-gaap_PreferredStockConversionBasis"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_TwoThousandNineteenInducementEquityIncentivePlanMember" xlink:label="xene_TwoThousandNineteenInducementEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_UnderwrittenPublicOfferingMember" xlink:label="xene_UnderwrittenPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_PreFundsWarrantsOutstandingDateIssuanceMarchTwoThousandTwentyOneMember" xlink:label="xene_PreFundsWarrantsOutstandingDateIssuanceMarchTwoThousandTwentyOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_JefferiesLLCStifelNicolausCompanyIncorporatedAndGuggenheimSecuritiesLLCMember" xlink:label="xene_JefferiesLLCStifelNicolausCompanyIncorporatedAndGuggenheimSecuritiesLLCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_TwoThousandFourteenAmendedAndRestatedStockOptionPlanMember" xlink:label="xene_TwoThousandFourteenAmendedAndRestatedStockOptionPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_PreFundsWarrantsOutstandingDateIssuanceOctoberTwoThousandTwentyOneMember" xlink:label="xene_PreFundsWarrantsOutstandingDateIssuanceOctoberTwoThousandTwentyOneMember"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_JefferiesLLCSVBLeerinkLLCAndStifelNicolausCompanyIncorporatedMember" xlink:label="xene_JefferiesLLCSVBLeerinkLLCAndStifelNicolausCompanyIncorporatedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_PreFundsWarrantsOutstandingDateIssuanceJuneTwoThousandTwentyTwoMember" xlink:label="xene_PreFundsWarrantsOutstandingDateIssuanceJuneTwoThousandTwentyTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_NeurocrineBiosciencesMember" xlink:label="xene_NeurocrineBiosciencesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_PreFundsWarrantsOutstandingDateIssuanceDecemberTwoThousandTwentyThreeMember" xlink:label="xene_PreFundsWarrantsOutstandingDateIssuanceDecemberTwoThousandTwentyThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_JefferiesLLCStifelNicolausCompanyIncorporatedJPMorganSecuritiesLLCAndSVBSecuritiesLLCMember" xlink:label="xene_JefferiesLLCStifelNicolausCompanyIncorporatedJPMorganSecuritiesLLCAndSVBSecuritiesLLCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_JefferiesLLCStifelNicolausCompanyIncorporatedJPMorganSecuritiesLLCBofASecuritiesIncAndRBCCapitalMarketsLLCMember" xlink:label="xene_JefferiesLLCStifelNicolausCompanyIncorporatedJPMorganSecuritiesLLCBofASecuritiesIncAndRBCCapitalMarketsLLCMember"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_WarrantsIssuedPricePerPreFundedWarrant" xlink:label="xene_WarrantsIssuedPricePerPreFundedWarrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_MaximumTermOfEachOptionExercised" xlink:label="xene_MaximumTermOfEachOptionExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_GrossProceedsFromIssuableOfCommonStock" xlink:label="xene_GrossProceedsFromIssuableOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_NumberOfWarrantsExercised" xlink:label="xene_NumberOfWarrantsExercised"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_WarrantsExerciseDescription" xlink:label="xene_WarrantsExerciseDescription"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_CollaborateMilestoneAgreementPremiumRelatedToEquityInvestment" xlink:label="xene_CollaborateMilestoneAgreementPremiumRelatedToEquityInvestment"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_StockIssuedDuringPeriodCommonSharesCancelled" xlink:label="xene_StockIssuedDuringPeriodCommonSharesCancelled"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_StockIssuedDuringPeriodSharesConversionOfPreFundedWarrantsToCommonShares" xlink:label="xene_StockIssuedDuringPeriodSharesConversionOfPreFundedWarrantsToCommonShares"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_PreFundedWarrantsExercised" xlink:label="xene_PreFundedWarrantsExercised"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="xene_AmendedAndRestatedStockOptionPlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="xene_TermLoansMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="xene_LicenseAndCollaborationAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="xene_AtMarketEquityOfferingMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="xene_Series1PreferredSharesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="xene_ExchangeAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="xene_BVFPartnersLPMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xene_JefferiesLLCAndStifelNicolausCompanyIncorporatedMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="xene_ShareCapitalTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xene_ShareCapitalTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xene_ShareCapitalLineItems" xlink:to="us-gaap_PreferredStockConversionBasis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="xene_TwoThousandNineteenInducementEquityIncentivePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="xene_UnderwrittenPublicOfferingMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="xene_PreFundsWarrantsOutstandingDateIssuanceMarchTwoThousandTwentyOneMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xene_JefferiesLLCStifelNicolausCompanyIncorporatedAndGuggenheimSecuritiesLLCMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xene_ShareCapitalTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xene_ShareCapitalLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="xene_TwoThousandFourteenAmendedAndRestatedStockOptionPlanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="xene_PreFundsWarrantsOutstandingDateIssuanceOctoberTwoThousandTwentyOneMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xene_JefferiesLLCSVBLeerinkLLCAndStifelNicolausCompanyIncorporatedMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xene_ShareCapitalTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xene_ShareCapitalLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="xene_PreFundsWarrantsOutstandingDateIssuanceJuneTwoThousandTwentyTwoMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xene_NeurocrineBiosciencesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xene_ShareCapitalTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xene_ShareCapitalLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="xene_PreFundsWarrantsOutstandingDateIssuanceDecemberTwoThousandTwentyThreeMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xene_JefferiesLLCStifelNicolausCompanyIncorporatedJPMorganSecuritiesLLCAndSVBSecuritiesLLCMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xene_ShareCapitalTable" xlink:to="srt_CounterpartyNameAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xene_ShareCapitalLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xene_JefferiesLLCStifelNicolausCompanyIncorporatedJPMorganSecuritiesLLCBofASecuritiesIncAndRBCCapitalMarketsLLCMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xene_ShareCapitalTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xene_ShareCapitalLineItems" xlink:to="xene_WarrantsIssuedPricePerPreFundedWarrant" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xene_ShareCapitalTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xene_ShareCapitalLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xene_ShareCapitalTable" xlink:to="srt_RangeAxis" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xene_ShareCapitalLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xene_ShareCapitalTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xene_ShareCapitalLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xene_ShareCapitalTable" xlink:to="us-gaap_PlanNameAxis" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xene_ShareCapitalLineItems" xlink:to="xene_MaximumTermOfEachOptionExercised" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xene_ShareCapitalTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xene_ShareCapitalLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xene_ShareCapitalTable" xlink:to="xene_ShareCapitalLineItems" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xene_ShareCapitalLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xene_ShareCapitalLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xene_ShareCapitalLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xene_ShareCapitalLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xene_ShareCapitalLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xene_ShareCapitalLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xene_ShareCapitalLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xene_ShareCapitalLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xene_ShareCapitalLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xene_ShareCapitalLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xene_ShareCapitalLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xene_ShareCapitalLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xene_ShareCapitalLineItems" xlink:to="xene_GrossProceedsFromIssuableOfCommonStock" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xene_ShareCapitalLineItems" xlink:to="xene_NumberOfWarrantsExercised" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xene_ShareCapitalLineItems" xlink:to="xene_WarrantsExerciseDescription" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xene_ShareCapitalLineItems" xlink:to="xene_CollaborateMilestoneAgreementPremiumRelatedToEquityInvestment" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xene_ShareCapitalLineItems" xlink:to="xene_StockIssuedDuringPeriodCommonSharesCancelled" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xene_ShareCapitalLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xene_ShareCapitalLineItems" xlink:to="xene_StockIssuedDuringPeriodSharesConversionOfPreFundedWarrantsToCommonShares" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xene_ShareCapitalLineItems" xlink:to="xene_PreFundedWarrantsExercised" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalStockBasedCompensationExpensesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_StockOptionActivityAbstract" xlink:label="xene_StockOptionActivityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PhantomShareUnitsPSUsMember" xlink:label="us-gaap_PhantomShareUnitsPSUsMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xene_StockOptionActivityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PhantomShareUnitsPSUsMember" order="5.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalStockOptionActivityDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_10"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_10" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalStockOptionActivityParentheticalDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:label="us-gaap_ForeignCurrencyExchangeRateTranslation1"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_StockOptionsExercisedForNumberOfCommonSharesForCash" xlink:label="xene_StockOptionsExercisedForNumberOfCommonSharesForCash"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_CommonStockIssuedForCashlessExercise" xlink:label="xene_CommonStockIssuedForCashlessExercise"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_CashlessExerciseOfStockOptions" xlink:label="xene_CashlessExerciseOfStockOptions"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ForeignCurrencyExchangeRateTranslation1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="xene_StockOptionsExercisedForNumberOfCommonSharesForCash" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="xene_CommonStockIssuedForCashlessExercise" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="xene_CashlessExerciseOfStockOptions" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalFairValueAssumptionsForStockOptionsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_FairValueAssumptionsForStockOptionsAbstract" xlink:label="xene_FairValueAssumptionsForStockOptionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xene_FairValueAssumptionsForStockOptionsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xene_FairValueAssumptionsForStockOptionsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xene_FairValueAssumptionsForStockOptionsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xene_FairValueAssumptionsForStockOptionsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xene_FairValueAssumptionsForStockOptionsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureShareCapitalSummaryOfUnvestedStockOptionActivityDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_4"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_9"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_9" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureShareCapitalScheduleOfPrefundedWarrantsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_PreFundsWarrantsOutstandingDateIssuanceMarchTwoThousandTwentyOneMember" xlink:label="xene_PreFundsWarrantsOutstandingDateIssuanceMarchTwoThousandTwentyOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_ShareCapitalTable" xlink:label="xene_ShareCapitalTable"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_ShareCapitalLineItems" xlink:label="xene_ShareCapitalLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_PreFundsWarrantsOutstandingDateIssuanceOctoberTwoThousandTwentyOneMember" xlink:label="xene_PreFundsWarrantsOutstandingDateIssuanceOctoberTwoThousandTwentyOneMember"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_NumberOfWarrantsIssued" xlink:label="xene_NumberOfWarrantsIssued"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_PreFundsWarrantsOutstandingDateIssuanceJuneTwoThousandTwentyTwoMember" xlink:label="xene_PreFundsWarrantsOutstandingDateIssuanceJuneTwoThousandTwentyTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_NumberOfWarrantsExercised" xlink:label="xene_NumberOfWarrantsExercised"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_PreFundsWarrantsOutstandingDateIssuanceDecemberTwoThousandTwentyThreeMember" xlink:label="xene_PreFundsWarrantsOutstandingDateIssuanceDecemberTwoThousandTwentyThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_3"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="xene_PreFundsWarrantsOutstandingDateIssuanceMarchTwoThousandTwentyOneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="xene_ShareCapitalTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xene_ShareCapitalTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xene_ShareCapitalLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="xene_PreFundsWarrantsOutstandingDateIssuanceOctoberTwoThousandTwentyOneMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xene_ShareCapitalTable" xlink:to="xene_ShareCapitalLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xene_ShareCapitalLineItems" xlink:to="xene_NumberOfWarrantsIssued" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="xene_PreFundsWarrantsOutstandingDateIssuanceJuneTwoThousandTwentyTwoMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xene_ShareCapitalLineItems" xlink:to="xene_NumberOfWarrantsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="xene_PreFundsWarrantsOutstandingDateIssuanceDecemberTwoThousandTwentyThreeMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xene_ShareCapitalLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureShareCapitalScheduleOfPrefundedWarrantsParentheticalDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_ShareCapitalTable" xlink:label="xene_ShareCapitalTable"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_ShareCapitalLineItems" xlink:label="xene_ShareCapitalLineItems"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_PreFundedWarrantsExercised" xlink:label="xene_PreFundedWarrantsExercised"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_CommonStockIssuedForPreFundedWarrants" xlink:label="xene_CommonStockIssuedForPreFundedWarrants"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_NumberOfWarrantsExercised" xlink:label="xene_NumberOfWarrantsExercised"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_StockIssuedDuringPeriodSharesConversionOfPreFundedWarrantsToCommonShares" xlink:label="xene_StockIssuedDuringPeriodSharesConversionOfPreFundedWarrantsToCommonShares"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="xene_ShareCapitalTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xene_ShareCapitalTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xene_ShareCapitalLineItems" xlink:to="xene_PreFundedWarrantsExercised" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xene_ShareCapitalTable" xlink:to="xene_ShareCapitalLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xene_ShareCapitalLineItems" xlink:to="xene_CommonStockIssuedForPreFundedWarrants" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xene_ShareCapitalLineItems" xlink:to="xene_NumberOfWarrantsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xene_ShareCapitalLineItems" xlink:to="xene_StockIssuedDuringPeriodSharesConversionOfPreFundedWarrantsToCommonShares" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureConcentrationsOfMarketRiskDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradingActivityByTypeAxis" xlink:label="us-gaap_TradingActivityByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RisksInherentInServicingAssetsAndServicingLiabilitiesTypeDomain" xlink:label="us-gaap_RisksInherentInServicingAssetsAndServicingLiabilitiesTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestRateRiskMember" xlink:label="us-gaap_InterestRateRiskMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradingActivityByTypeDomain" xlink:label="us-gaap_TradingActivityByTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignExchangeMember" xlink:label="us-gaap_ForeignExchangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis" xlink:label="us-gaap_ManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="us-gaap_RisksAndUncertaintiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_UnfavorableChangeInInterestRatesOfMarketableSecurities" xlink:label="xene_UnfavorableChangeInInterestRatesOfMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_IncreaseDecreaseInFairValueOfMarketableSecurities" xlink:label="xene_IncreaseDecreaseInFairValueOfMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DescriptionOfInterestRateRiskExposure" xlink:label="us-gaap_DescriptionOfInterestRateRiskExposure"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_TradingActivityByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RisksInherentInServicingAssetsAndServicingLiabilitiesTypeDomain" xlink:to="us-gaap_InterestRateRiskMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TradingActivityByTypeAxis" xlink:to="us-gaap_TradingActivityByTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TradingActivityByTypeDomain" xlink:to="us-gaap_ForeignExchangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis" xlink:to="us-gaap_RisksInherentInServicingAssetsAndServicingLiabilitiesTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="us-gaap_ConcentrationRiskTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="xene_UnfavorableChangeInInterestRatesOfMarketableSecurities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="xene_IncreaseDecreaseInFairValueOfMarketableSecurities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_DescriptionOfInterestRateRiskExposure" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCollaborationAgreementsScheduleOfCollaborationRevenueDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_NeurocrineBiosciencesMember" xlink:label="xene_NeurocrineBiosciencesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_RecognitionOfTransactionPrice" xlink:label="xene_RecognitionOfTransactionPrice"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_PaciraBiosciencesMember" xlink:label="xene_PaciraBiosciencesMember"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_ResearchAndDevelopmentServices" xlink:label="xene_ResearchAndDevelopmentServices"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_MilestonePayment" xlink:label="xene_MilestonePayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseAndServiceMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xene_NeurocrineBiosciencesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xene_RecognitionOfTransactionPrice" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xene_PaciraBiosciencesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xene_ResearchAndDevelopmentServices" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xene_MilestonePayment" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCollaborationAgreementsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_LicenseAndCollaborationAgreementMember" xlink:label="xene_LicenseAndCollaborationAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_NeurocrineBiosciencesMember" xlink:label="xene_NeurocrineBiosciencesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_RegulatoryMilestoneMember" xlink:label="xene_RegulatoryMilestoneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_ProceedsFromUpfrontFee" xlink:label="xene_ProceedsFromUpfrontFee"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_PaciraBiosciencesMember" xlink:label="xene_PaciraBiosciencesMember"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_SalesBasedMilestoneMember" xlink:label="xene_SalesBasedMilestoneMember"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_UpfrontPaymentInCash" xlink:label="xene_UpfrontPaymentInCash"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_UpfrontPaymentReceivedInEquityInvestment" xlink:label="xene_UpfrontPaymentReceivedInEquityInvestment"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_PotentialMilestonePaymentsReceivable" xlink:label="xene_PotentialMilestonePaymentsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_PercentageOfOptionToFundDevelopmentCostsUponAchievementOfCertainMilestones" xlink:label="xene_PercentageOfOptionToFundDevelopmentCostsUponAchievementOfCertainMilestones"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_CollaborateAgreementPremiumRelatedToEquityInvestment" xlink:label="xene_CollaborateAgreementPremiumRelatedToEquityInvestment"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_AggregatePriceOfTransactionAllocatedToPerformanceObligations" xlink:label="xene_AggregatePriceOfTransactionAllocatedToPerformanceObligations"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_VariableConsiderationAllocatedToPerformanceObligation" xlink:label="xene_VariableConsiderationAllocatedToPerformanceObligation"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_AggregateMilestonePaymentReceived" xlink:label="xene_AggregateMilestonePaymentReceived"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_MilestonePaymentReceivedInCash" xlink:label="xene_MilestonePaymentReceivedInCash"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_MilestonePaymentReceivedInEquityInvestment" xlink:label="xene_MilestonePaymentReceivedInEquityInvestment"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_MilestonePaymentReceivedInEquityInvestmentMeasuredAtFairValue" xlink:label="xene_MilestonePaymentReceivedInEquityInvestmentMeasuredAtFairValue"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_CollaborateMilestoneAgreementPremiumRelatedToEquityInvestment" xlink:label="xene_CollaborateMilestoneAgreementPremiumRelatedToEquityInvestment"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_PerformanceObligationsRelatedToMilestone" xlink:label="xene_PerformanceObligationsRelatedToMilestone"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_ResearchAndDevelopmentServices" xlink:label="xene_ResearchAndDevelopmentServices"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_MilestonePayment" xlink:label="xene_MilestonePayment"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_MilestonePaymentDueOnInitiationOfPhase1bClinicalTrial" xlink:label="xene_MilestonePaymentDueOnInitiationOfPhase1bClinicalTrial"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="xene_LicenseAndCollaborationAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xene_NeurocrineBiosciencesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="xene_RegulatoryMilestoneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xene_ProceedsFromUpfrontFee" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xene_PaciraBiosciencesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="xene_SalesBasedMilestoneMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xene_UpfrontPaymentInCash" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xene_UpfrontPaymentReceivedInEquityInvestment" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xene_PotentialMilestonePaymentsReceivable" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xene_PercentageOfOptionToFundDevelopmentCostsUponAchievementOfCertainMilestones" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xene_CollaborateAgreementPremiumRelatedToEquityInvestment" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xene_AggregatePriceOfTransactionAllocatedToPerformanceObligations" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xene_VariableConsiderationAllocatedToPerformanceObligation" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xene_AggregateMilestonePaymentReceived" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xene_MilestonePaymentReceivedInCash" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xene_MilestonePaymentReceivedInEquityInvestment" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xene_MilestonePaymentReceivedInEquityInvestmentMeasuredAtFairValue" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xene_CollaborateMilestoneAgreementPremiumRelatedToEquityInvestment" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xene_PerformanceObligationsRelatedToMilestone" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xene_ResearchAndDevelopmentServices" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xene_MilestonePayment" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xene_MilestonePaymentDueOnInitiationOfPhase1bClinicalTrial" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfBasicAndDilutedNetLossPerCommonShareDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="us-gaap_EarningsPerShareBasicLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_NetIncomeLossAvailableToPreferredStockholdersBasic" xlink:label="xene_NetIncomeLossAvailableToPreferredStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_WeightedAverageNumberOfCommonShares" xlink:label="xene_WeightedAverageNumberOfCommonShares"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_WeightedAverageNumberOfPrefundedWarrants" xlink:label="xene_WeightedAverageNumberOfPrefundedWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasicLineItems" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="xene_NetIncomeLossAvailableToPreferredStockholdersBasic" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="xene_WeightedAverageNumberOfCommonShares" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="xene_WeightedAverageNumberOfPrefundedWarrants" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_EarningsPerShareBasic" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_PerformanceSharesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_AssetPurchaseAgreementMember" xlink:label="xene_AssetPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:label="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_FirstOrderPharmaceuticalsIncMember" xlink:label="xene_FirstOrderPharmaceuticalsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_ClinicalDevelopmentMilestonesMember" xlink:label="xene_ClinicalDevelopmentMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_MedpaceClinicalDevelopmentServiceAgreementMember" xlink:label="xene_MedpaceClinicalDevelopmentServiceAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_CommitmentsAndContingenciesTable" xlink:label="xene_CommitmentsAndContingenciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_CommitmentsAndContingenciesLineItems" xlink:label="xene_CommitmentsAndContingenciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_FuturePotentialMilestonePayments" xlink:label="xene_FuturePotentialMilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_RegulatoryMilestoneMember" xlink:label="xene_RegulatoryMilestoneMember"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_MilestonePaymentsPaid" xlink:label="xene_MilestonePaymentsPaid"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_OtherMilestonesMember" xlink:label="xene_OtherMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_RoyaltyObligations" xlink:label="xene_RoyaltyObligations"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_ClinicalDevelopementAndOtherMilestoneMember" xlink:label="xene_ClinicalDevelopementAndOtherMilestoneMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="xene_AssetPurchaseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xene_FirstOrderPharmaceuticalsIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="xene_ClinicalDevelopmentMilestonesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="xene_MedpaceClinicalDevelopmentServiceAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="xene_CommitmentsAndContingenciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xene_CommitmentsAndContingenciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xene_CommitmentsAndContingenciesLineItems" xlink:to="xene_FuturePotentialMilestonePayments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="xene_RegulatoryMilestoneMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xene_CommitmentsAndContingenciesTable" xlink:to="srt_CounterpartyNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xene_CommitmentsAndContingenciesLineItems" xlink:to="xene_MilestonePaymentsPaid" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="xene_OtherMilestonesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xene_CommitmentsAndContingenciesTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xene_CommitmentsAndContingenciesLineItems" xlink:to="xene_RoyaltyObligations" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="xene_ClinicalDevelopementAndOtherMilestoneMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xene_CommitmentsAndContingenciesTable" xlink:to="srt_RangeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xene_CommitmentsAndContingenciesTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xene_CommitmentsAndContingenciesTable" xlink:to="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xene_CommitmentsAndContingenciesTable" xlink:to="xene_CommitmentsAndContingenciesLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfLossBeforeIncomeTaxesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxRecoveryExpenseDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_CanadaAndUnitedStatesRevenueAgencyMember" xlink:label="xene_CanadaAndUnitedStatesRevenueAgencyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentCreditMember" xlink:label="us-gaap_InvestmentCreditMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LatestTaxYearMember" xlink:label="us-gaap_LatestTaxYearMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardTable" xlink:label="us-gaap_TaxCreditCarryforwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardLineItems" xlink:label="us-gaap_TaxCreditCarryforwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_ProvincialTaxCreditMember" xlink:label="xene_ProvincialTaxCreditMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarliestTaxYearMember" xlink:label="us-gaap_EarliestTaxYearMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardExpirationDate" xlink:label="us-gaap_TaxCreditCarryforwardExpirationDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="xene_CanadaAndUnitedStatesRevenueAgencyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_InvestmentCreditMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_LatestTaxYearMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_TaxCreditCarryforwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="xene_ProvincialTaxCreditMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_EarliestTaxYearMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardTable" xlink:to="us-gaap_TaxPeriodAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardTable" xlink:to="us-gaap_TaxCreditCarryforwardLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="us-gaap_TaxCreditCarryforwardExpirationDate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="us-gaap_OpenTaxYear" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_EffectiveIncomeTaxRateReconciliationTaxAttributesExpiredOrUtilized" xlink:label="xene_EffectiveIncomeTaxRateReconciliationTaxAttributesExpiredOrUtilized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="xene_EffectiveIncomeTaxRateReconciliationTaxAttributesExpiredOrUtilized" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfNetDeferredIncomeTaxAssetsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_DeferredTaxAssetsTaxCreditCarryforwardsInvestment" xlink:label="xene_DeferredTaxAssetsTaxCreditCarryforwardsInvestment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_DeferredTaxAssetsDeferredFinancingFees" xlink:label="xene_DeferredTaxAssetsDeferredFinancingFees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_DeferredTaxAssetsOperatingLeaseLiability" xlink:label="xene_DeferredTaxAssetsOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="xene_DeferredTaxAssetsTaxCreditCarryforwardsInvestment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="xene_DeferredTaxAssetsDeferredFinancingFees" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="xene_DeferredTaxAssetsOperatingLeaseLiability" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureSegmentDisclosureAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription" xlink:label="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration" xlink:label="us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="srt_TitleOfIndividualAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefExecutiveOfficerMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_SegmentReportingInformationLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_NumberOfReportableSegments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureSegmentDisclosureSummaryOfNetLossRelatedToSegmentExpensesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_AzetukalnerMember" xlink:label="xene_AzetukalnerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_XEN496Member" xlink:label="xene_XEN496Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_Pre-ClinicalDiscoveryAndOtherProgramsMember" xlink:label="xene_Pre-ClinicalDiscoveryAndOtherProgramsMember"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_PersonnelRelatedExpenses" xlink:label="xene_PersonnelRelatedExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemAmount" xlink:label="us-gaap_SegmentReportingOtherItemAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="xene_AzetukalnerMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_SegmentReportingInformationLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="xene_XEN496Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="xene_Pre-ClinicalDiscoveryAndOtherProgramsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="xene_PersonnelRelatedExpenses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ShareBasedCompensation" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_InvestmentIncomeInterest" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingOtherItemAmount" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_NetIncomeLoss" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_StockIssuedDuringPeriodValueConversionOfPreFundedWarrant" xlink:label="xene_StockIssuedDuringPeriodValueConversionOfPreFundedWarrant"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_StockIssuedDuringPeriodSharesConversionOfPreFundedWarrant" xlink:label="xene_StockIssuedDuringPeriodSharesConversionOfPreFundedWarrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="xene_StockIssuedDuringPeriodValueConversionOfPreFundedWarrant" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="xene_StockIssuedDuringPeriodSharesConversionOfPreFundedWarrant" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="ecd_AllIndividualsMember"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_IanMortimerMember" xlink:label="xene_IanMortimerMember"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllIndividualsMember" xlink:to="xene_IanMortimerMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember" xlink:label="ecd_AllTradingArrangementsMember"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_Rule10B51TradingPlanMember" xlink:label="xene_Rule10B51TradingPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_Rule10B51TradingPlanOneMember" xlink:label="xene_Rule10B51TradingPlanOneMember"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllTradingArrangementsMember" xlink:to="xene_Rule10B51TradingPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllTradingArrangementsMember" xlink:to="xene_Rule10B51TradingPlanOneMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationDetails">
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_BasisOfPresentationLineItems" xlink:label="xene_BasisOfPresentationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_BasisOfPresentationTable" xlink:label="xene_BasisOfPresentationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SubsidiariesMember" xlink:label="srt_SubsidiariesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="dei_EntityIncorporationDateOfIncorporation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PriorPeriodReclassificationAdjustment" xlink:label="us-gaap_PriorPeriodReclassificationAdjustment"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="xene_BasisOfPresentationLineItems" xlink:to="xene_BasisOfPresentationTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="srt_SubsidiariesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xene_BasisOfPresentationLineItems" xlink:to="dei_EntityIncorporationDateOfIncorporation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="xene_BasisOfPresentationTable" xlink:to="srt_ConsolidatedEntitiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xene_BasisOfPresentationLineItems" xlink:to="us-gaap_PriorPeriodReclassificationAdjustment" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPropertyPlantAndEquipmentEstimatedUsefulLivesDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_ResearchEquipmentMember" xlink:label="xene_ResearchEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="xene_ResearchEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesDetails">
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_SignificantAccountingPoliciesLineItems" xlink:label="xene_SignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_SignificantAccountingPoliciesTable" xlink:label="xene_SignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductConcentrationRiskMember" xlink:label="us-gaap_ProductConcentrationRiskMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_NeurocrineBiosciencesMember" xlink:label="xene_NeurocrineBiosciencesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="us-gaap_RevenueFromContractWithCustomerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_PaciraBiosciencesMember" xlink:label="xene_PaciraBiosciencesMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="xene_SignificantAccountingPoliciesLineItems" xlink:to="xene_SignificantAccountingPoliciesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ProductConcentrationRiskMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xene_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xene_NeurocrineBiosciencesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="xene_SignificantAccountingPoliciesTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_RevenueFromContractWithCustomerMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xene_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xene_PaciraBiosciencesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="xene_SignificantAccountingPoliciesTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="xene_SignificantAccountingPoliciesTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFinancialAssetsMeasuredAtFairValueOnARecurringBasisDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_CashAndMoneyMarketFundMember" xlink:label="xene_CashAndMoneyMarketFundMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_GuaranteedInvestmentCertificatesMember" xlink:label="xene_GuaranteedInvestmentCertificatesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="xene_CashAndMoneyMarketFundMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CommercialPaperMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="xene_GuaranteedInvestmentCertificatesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAmortizedCostUnrealizedGainLossRecognizedInAociAndFairValueOfAvailableforsaleSecuritiesDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_GuaranteedInvestmentCertificatesMember" xlink:label="xene_GuaranteedInvestmentCertificatesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax" xlink:label="xene_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" xlink:label="xene_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTaxCurrent" xlink:label="xene_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTaxCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" xlink:label="xene_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTaxNoncurrent" xlink:label="xene_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTaxNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="xene_GuaranteedInvestmentCertificatesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="xene_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="xene_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="xene_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTaxCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="xene_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="xene_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTaxNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_ResearchEquipmentMember" xlink:label="xene_ResearchEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="xene_ResearchEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureLeasesDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_LesseeNumberOfOperatingLeases" xlink:label="xene_LesseeNumberOfOperatingLeases"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_FirstRenewalOptionMember" xlink:label="xene_FirstRenewalOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_BurnabyBritishColumbiaMember" xlink:label="xene_BurnabyBritishColumbiaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_SecondRenewalOptionMember" xlink:label="xene_SecondRenewalOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_NeedhamMassachusettsMember" xlink:label="xene_NeedhamMassachusettsMember"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:label="xene_LesseeOperatingLeaseNumberOfRenewalOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="us-gaap_LesseeOperatingLeaseDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseOptionToTerminate" xlink:label="us-gaap_LesseeOperatingLeaseOptionToTerminate"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="xene_LesseeNumberOfOperatingLeases" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="xene_FirstRenewalOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="xene_BurnabyBritishColumbiaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LeaseContractualTermAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="xene_SecondRenewalOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="xene_NeedhamMassachusettsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="xene_LesseeOperatingLeaseNumberOfRenewalOptions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LeaseExpirationDate1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToTerminate" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalDetails">
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_ShareCapitalLineItems" xlink:label="xene_ShareCapitalLineItems"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_ShareCapitalTable" xlink:label="xene_ShareCapitalTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_AmendedAndRestatedStockOptionPlanMember" xlink:label="xene_AmendedAndRestatedStockOptionPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_TermLoansMember" xlink:label="xene_TermLoansMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_LicenseAndCollaborationAgreementMember" xlink:label="xene_LicenseAndCollaborationAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_AtMarketEquityOfferingMember" xlink:label="xene_AtMarketEquityOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_Series1PreferredSharesMember" xlink:label="xene_Series1PreferredSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_ExchangeAgreementMember" xlink:label="xene_ExchangeAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_BVFPartnersLPMember" xlink:label="xene_BVFPartnersLPMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_JefferiesLLCAndStifelNicolausCompanyIncorporatedMember" xlink:label="xene_JefferiesLLCAndStifelNicolausCompanyIncorporatedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConversionBasis" xlink:label="us-gaap_PreferredStockConversionBasis"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_TwoThousandNineteenInducementEquityIncentivePlanMember" xlink:label="xene_TwoThousandNineteenInducementEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_UnderwrittenPublicOfferingMember" xlink:label="xene_UnderwrittenPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_PreFundsWarrantsOutstandingDateIssuanceMarchTwoThousandTwentyOneMember" xlink:label="xene_PreFundsWarrantsOutstandingDateIssuanceMarchTwoThousandTwentyOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_JefferiesLLCStifelNicolausCompanyIncorporatedAndGuggenheimSecuritiesLLCMember" xlink:label="xene_JefferiesLLCStifelNicolausCompanyIncorporatedAndGuggenheimSecuritiesLLCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_TwoThousandFourteenAmendedAndRestatedStockOptionPlanMember" xlink:label="xene_TwoThousandFourteenAmendedAndRestatedStockOptionPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_PreFundsWarrantsOutstandingDateIssuanceOctoberTwoThousandTwentyOneMember" xlink:label="xene_PreFundsWarrantsOutstandingDateIssuanceOctoberTwoThousandTwentyOneMember"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_JefferiesLLCSVBLeerinkLLCAndStifelNicolausCompanyIncorporatedMember" xlink:label="xene_JefferiesLLCSVBLeerinkLLCAndStifelNicolausCompanyIncorporatedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_PreFundsWarrantsOutstandingDateIssuanceJuneTwoThousandTwentyTwoMember" xlink:label="xene_PreFundsWarrantsOutstandingDateIssuanceJuneTwoThousandTwentyTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_NeurocrineBiosciencesMember" xlink:label="xene_NeurocrineBiosciencesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_PreFundsWarrantsOutstandingDateIssuanceDecemberTwoThousandTwentyThreeMember" xlink:label="xene_PreFundsWarrantsOutstandingDateIssuanceDecemberTwoThousandTwentyThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_JefferiesLLCStifelNicolausCompanyIncorporatedJPMorganSecuritiesLLCAndSVBSecuritiesLLCMember" xlink:label="xene_JefferiesLLCStifelNicolausCompanyIncorporatedJPMorganSecuritiesLLCAndSVBSecuritiesLLCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_JefferiesLLCStifelNicolausCompanyIncorporatedJPMorganSecuritiesLLCBofASecuritiesIncAndRBCCapitalMarketsLLCMember" xlink:label="xene_JefferiesLLCStifelNicolausCompanyIncorporatedJPMorganSecuritiesLLCBofASecuritiesIncAndRBCCapitalMarketsLLCMember"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_WarrantsIssuedPricePerPreFundedWarrant" xlink:label="xene_WarrantsIssuedPricePerPreFundedWarrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_MaximumTermOfEachOptionExercised" xlink:label="xene_MaximumTermOfEachOptionExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_GrossProceedsFromIssuableOfCommonStock" xlink:label="xene_GrossProceedsFromIssuableOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_NumberOfWarrantsExercised" xlink:label="xene_NumberOfWarrantsExercised"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_WarrantsExerciseDescription" xlink:label="xene_WarrantsExerciseDescription"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_CollaborateMilestoneAgreementPremiumRelatedToEquityInvestment" xlink:label="xene_CollaborateMilestoneAgreementPremiumRelatedToEquityInvestment"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_StockIssuedDuringPeriodCommonSharesCancelled" xlink:label="xene_StockIssuedDuringPeriodCommonSharesCancelled"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_StockIssuedDuringPeriodSharesConversionOfPreFundedWarrantsToCommonShares" xlink:label="xene_StockIssuedDuringPeriodSharesConversionOfPreFundedWarrantsToCommonShares"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_PreFundedWarrantsExercised" xlink:label="xene_PreFundedWarrantsExercised"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="xene_ShareCapitalLineItems" xlink:to="xene_ShareCapitalTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="xene_AmendedAndRestatedStockOptionPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="xene_TermLoansMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="xene_LicenseAndCollaborationAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="xene_AtMarketEquityOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="xene_Series1PreferredSharesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="xene_ExchangeAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="xene_BVFPartnersLPMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xene_JefferiesLLCAndStifelNicolausCompanyIncorporatedMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="xene_ShareCapitalTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xene_ShareCapitalLineItems" xlink:to="us-gaap_PreferredStockConversionBasis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="xene_TwoThousandNineteenInducementEquityIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="xene_UnderwrittenPublicOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="xene_PreFundsWarrantsOutstandingDateIssuanceMarchTwoThousandTwentyOneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xene_JefferiesLLCStifelNicolausCompanyIncorporatedAndGuggenheimSecuritiesLLCMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="xene_ShareCapitalTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xene_ShareCapitalLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="xene_TwoThousandFourteenAmendedAndRestatedStockOptionPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="xene_PreFundsWarrantsOutstandingDateIssuanceOctoberTwoThousandTwentyOneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xene_JefferiesLLCSVBLeerinkLLCAndStifelNicolausCompanyIncorporatedMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="xene_ShareCapitalTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xene_ShareCapitalLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="xene_PreFundsWarrantsOutstandingDateIssuanceJuneTwoThousandTwentyTwoMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xene_NeurocrineBiosciencesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="xene_ShareCapitalTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xene_ShareCapitalLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="xene_PreFundsWarrantsOutstandingDateIssuanceDecemberTwoThousandTwentyThreeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xene_JefferiesLLCStifelNicolausCompanyIncorporatedJPMorganSecuritiesLLCAndSVBSecuritiesLLCMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="xene_ShareCapitalTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xene_ShareCapitalLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xene_JefferiesLLCStifelNicolausCompanyIncorporatedJPMorganSecuritiesLLCBofASecuritiesIncAndRBCCapitalMarketsLLCMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="xene_ShareCapitalTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xene_ShareCapitalLineItems" xlink:to="xene_WarrantsIssuedPricePerPreFundedWarrant" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="xene_ShareCapitalTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xene_ShareCapitalLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="xene_ShareCapitalTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xene_ShareCapitalLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="xene_ShareCapitalTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xene_ShareCapitalLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="xene_ShareCapitalTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xene_ShareCapitalLineItems" xlink:to="xene_MaximumTermOfEachOptionExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="xene_ShareCapitalTable" xlink:to="us-gaap_LongtermDebtTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xene_ShareCapitalLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xene_ShareCapitalLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xene_ShareCapitalLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xene_ShareCapitalLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xene_ShareCapitalLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xene_ShareCapitalLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xene_ShareCapitalLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xene_ShareCapitalLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xene_ShareCapitalLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xene_ShareCapitalLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xene_ShareCapitalLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xene_ShareCapitalLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xene_ShareCapitalLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xene_ShareCapitalLineItems" xlink:to="xene_GrossProceedsFromIssuableOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xene_ShareCapitalLineItems" xlink:to="xene_NumberOfWarrantsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xene_ShareCapitalLineItems" xlink:to="xene_WarrantsExerciseDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xene_ShareCapitalLineItems" xlink:to="xene_CollaborateMilestoneAgreementPremiumRelatedToEquityInvestment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xene_ShareCapitalLineItems" xlink:to="xene_StockIssuedDuringPeriodCommonSharesCancelled" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="28" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xene_ShareCapitalLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="29" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xene_ShareCapitalLineItems" xlink:to="xene_StockIssuedDuringPeriodSharesConversionOfPreFundedWarrantsToCommonShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="30" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xene_ShareCapitalLineItems" xlink:to="xene_PreFundedWarrantsExercised" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalStockBasedCompensationExpensesDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PhantomShareUnitsPSUsMember" xlink:label="us-gaap_PhantomShareUnitsPSUsMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PhantomShareUnitsPSUsMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureShareCapitalScheduleOfPrefundedWarrantsDetails">
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_ShareCapitalLineItems" xlink:label="xene_ShareCapitalLineItems"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_ShareCapitalTable" xlink:label="xene_ShareCapitalTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_PreFundsWarrantsOutstandingDateIssuanceMarchTwoThousandTwentyOneMember" xlink:label="xene_PreFundsWarrantsOutstandingDateIssuanceMarchTwoThousandTwentyOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_PreFundsWarrantsOutstandingDateIssuanceOctoberTwoThousandTwentyOneMember" xlink:label="xene_PreFundsWarrantsOutstandingDateIssuanceOctoberTwoThousandTwentyOneMember"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_NumberOfWarrantsIssued" xlink:label="xene_NumberOfWarrantsIssued"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_PreFundsWarrantsOutstandingDateIssuanceJuneTwoThousandTwentyTwoMember" xlink:label="xene_PreFundsWarrantsOutstandingDateIssuanceJuneTwoThousandTwentyTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_NumberOfWarrantsExercised" xlink:label="xene_NumberOfWarrantsExercised"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_PreFundsWarrantsOutstandingDateIssuanceDecemberTwoThousandTwentyThreeMember" xlink:label="xene_PreFundsWarrantsOutstandingDateIssuanceDecemberTwoThousandTwentyThreeMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="xene_ShareCapitalLineItems" xlink:to="xene_ShareCapitalTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="xene_PreFundsWarrantsOutstandingDateIssuanceMarchTwoThousandTwentyOneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="xene_ShareCapitalTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xene_ShareCapitalLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="xene_PreFundsWarrantsOutstandingDateIssuanceOctoberTwoThousandTwentyOneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xene_ShareCapitalLineItems" xlink:to="xene_NumberOfWarrantsIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="xene_PreFundsWarrantsOutstandingDateIssuanceJuneTwoThousandTwentyTwoMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xene_ShareCapitalLineItems" xlink:to="xene_NumberOfWarrantsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="xene_PreFundsWarrantsOutstandingDateIssuanceDecemberTwoThousandTwentyThreeMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureShareCapitalScheduleOfPrefundedWarrantsParentheticalDetails">
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_ShareCapitalLineItems" xlink:label="xene_ShareCapitalLineItems"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_ShareCapitalTable" xlink:label="xene_ShareCapitalTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_PreFundedWarrantsExercised" xlink:label="xene_PreFundedWarrantsExercised"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_CommonStockIssuedForPreFundedWarrants" xlink:label="xene_CommonStockIssuedForPreFundedWarrants"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_NumberOfWarrantsExercised" xlink:label="xene_NumberOfWarrantsExercised"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_StockIssuedDuringPeriodSharesConversionOfPreFundedWarrantsToCommonShares" xlink:label="xene_StockIssuedDuringPeriodSharesConversionOfPreFundedWarrantsToCommonShares"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="xene_ShareCapitalLineItems" xlink:to="xene_ShareCapitalTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="xene_ShareCapitalTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xene_ShareCapitalLineItems" xlink:to="xene_PreFundedWarrantsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xene_ShareCapitalLineItems" xlink:to="xene_CommonStockIssuedForPreFundedWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xene_ShareCapitalLineItems" xlink:to="xene_NumberOfWarrantsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xene_ShareCapitalLineItems" xlink:to="xene_StockIssuedDuringPeriodSharesConversionOfPreFundedWarrantsToCommonShares" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureConcentrationsOfMarketRiskDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradingActivityByTypeAxis" xlink:label="us-gaap_TradingActivityByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RisksInherentInServicingAssetsAndServicingLiabilitiesTypeDomain" xlink:label="us-gaap_RisksInherentInServicingAssetsAndServicingLiabilitiesTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestRateRiskMember" xlink:label="us-gaap_InterestRateRiskMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradingActivityByTypeDomain" xlink:label="us-gaap_TradingActivityByTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradingActivityByTypeDomain" xlink:label="us-gaap_TradingActivityByTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignExchangeMember" xlink:label="us-gaap_ForeignExchangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis" xlink:label="us-gaap_ManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RisksInherentInServicingAssetsAndServicingLiabilitiesTypeDomain" xlink:label="us-gaap_RisksInherentInServicingAssetsAndServicingLiabilitiesTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_UnfavorableChangeInInterestRatesOfMarketableSecurities" xlink:label="xene_UnfavorableChangeInInterestRatesOfMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_IncreaseDecreaseInFairValueOfMarketableSecurities" xlink:label="xene_IncreaseDecreaseInFairValueOfMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DescriptionOfInterestRateRiskExposure" xlink:label="us-gaap_DescriptionOfInterestRateRiskExposure"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_TradingActivityByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RisksInherentInServicingAssetsAndServicingLiabilitiesTypeDomain" xlink:to="us-gaap_InterestRateRiskMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TradingActivityByTypeAxis" xlink:to="us-gaap_TradingActivityByTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TradingActivityByTypeAxis" xlink:to="us-gaap_TradingActivityByTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TradingActivityByTypeDomain" xlink:to="us-gaap_ForeignExchangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis" xlink:to="us-gaap_RisksInherentInServicingAssetsAndServicingLiabilitiesTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis" xlink:to="us-gaap_RisksInherentInServicingAssetsAndServicingLiabilitiesTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="xene_UnfavorableChangeInInterestRatesOfMarketableSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="xene_IncreaseDecreaseInFairValueOfMarketableSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_DescriptionOfInterestRateRiskExposure" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCollaborationAgreementsScheduleOfCollaborationRevenueDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_NeurocrineBiosciencesMember" xlink:label="xene_NeurocrineBiosciencesMember"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_RecognitionOfTransactionPrice" xlink:label="xene_RecognitionOfTransactionPrice"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_PaciraBiosciencesMember" xlink:label="xene_PaciraBiosciencesMember"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_ResearchAndDevelopmentServices" xlink:label="xene_ResearchAndDevelopmentServices"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_MilestonePayment" xlink:label="xene_MilestonePayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseAndServiceMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xene_NeurocrineBiosciencesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xene_RecognitionOfTransactionPrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xene_PaciraBiosciencesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xene_ResearchAndDevelopmentServices" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xene_MilestonePayment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCollaborationAgreementsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_LicenseAndCollaborationAgreementMember" xlink:label="xene_LicenseAndCollaborationAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_NeurocrineBiosciencesMember" xlink:label="xene_NeurocrineBiosciencesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_RegulatoryMilestoneMember" xlink:label="xene_RegulatoryMilestoneMember"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_ProceedsFromUpfrontFee" xlink:label="xene_ProceedsFromUpfrontFee"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_PaciraBiosciencesMember" xlink:label="xene_PaciraBiosciencesMember"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_SalesBasedMilestoneMember" xlink:label="xene_SalesBasedMilestoneMember"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_UpfrontPaymentInCash" xlink:label="xene_UpfrontPaymentInCash"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_UpfrontPaymentReceivedInEquityInvestment" xlink:label="xene_UpfrontPaymentReceivedInEquityInvestment"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_PotentialMilestonePaymentsReceivable" xlink:label="xene_PotentialMilestonePaymentsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_PercentageOfOptionToFundDevelopmentCostsUponAchievementOfCertainMilestones" xlink:label="xene_PercentageOfOptionToFundDevelopmentCostsUponAchievementOfCertainMilestones"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_CollaborateAgreementPremiumRelatedToEquityInvestment" xlink:label="xene_CollaborateAgreementPremiumRelatedToEquityInvestment"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_AggregatePriceOfTransactionAllocatedToPerformanceObligations" xlink:label="xene_AggregatePriceOfTransactionAllocatedToPerformanceObligations"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_VariableConsiderationAllocatedToPerformanceObligation" xlink:label="xene_VariableConsiderationAllocatedToPerformanceObligation"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_AggregateMilestonePaymentReceived" xlink:label="xene_AggregateMilestonePaymentReceived"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_MilestonePaymentReceivedInCash" xlink:label="xene_MilestonePaymentReceivedInCash"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_MilestonePaymentReceivedInEquityInvestment" xlink:label="xene_MilestonePaymentReceivedInEquityInvestment"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_MilestonePaymentReceivedInEquityInvestmentMeasuredAtFairValue" xlink:label="xene_MilestonePaymentReceivedInEquityInvestmentMeasuredAtFairValue"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_CollaborateMilestoneAgreementPremiumRelatedToEquityInvestment" xlink:label="xene_CollaborateMilestoneAgreementPremiumRelatedToEquityInvestment"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_PerformanceObligationsRelatedToMilestone" xlink:label="xene_PerformanceObligationsRelatedToMilestone"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_ResearchAndDevelopmentServices" xlink:label="xene_ResearchAndDevelopmentServices"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_MilestonePayment" xlink:label="xene_MilestonePayment"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_MilestonePaymentDueOnInitiationOfPhase1bClinicalTrial" xlink:label="xene_MilestonePaymentDueOnInitiationOfPhase1bClinicalTrial"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="xene_LicenseAndCollaborationAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xene_NeurocrineBiosciencesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="xene_RegulatoryMilestoneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xene_ProceedsFromUpfrontFee" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xene_PaciraBiosciencesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="xene_SalesBasedMilestoneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xene_UpfrontPaymentInCash" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xene_UpfrontPaymentReceivedInEquityInvestment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xene_PotentialMilestonePaymentsReceivable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xene_PercentageOfOptionToFundDevelopmentCostsUponAchievementOfCertainMilestones" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xene_CollaborateAgreementPremiumRelatedToEquityInvestment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xene_AggregatePriceOfTransactionAllocatedToPerformanceObligations" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xene_VariableConsiderationAllocatedToPerformanceObligation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xene_AggregateMilestonePaymentReceived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xene_MilestonePaymentReceivedInCash" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xene_MilestonePaymentReceivedInEquityInvestment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xene_MilestonePaymentReceivedInEquityInvestmentMeasuredAtFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xene_CollaborateMilestoneAgreementPremiumRelatedToEquityInvestment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xene_PerformanceObligationsRelatedToMilestone" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xene_ResearchAndDevelopmentServices" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xene_MilestonePayment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xene_MilestonePaymentDueOnInitiationOfPhase1bClinicalTrial" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_PerformanceSharesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetails">
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_CommitmentsAndContingenciesLineItems" xlink:label="xene_CommitmentsAndContingenciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_CommitmentsAndContingenciesTable" xlink:label="xene_CommitmentsAndContingenciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_AssetPurchaseAgreementMember" xlink:label="xene_AssetPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:label="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_FirstOrderPharmaceuticalsIncMember" xlink:label="xene_FirstOrderPharmaceuticalsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_ClinicalDevelopmentMilestonesMember" xlink:label="xene_ClinicalDevelopmentMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_MedpaceClinicalDevelopmentServiceAgreementMember" xlink:label="xene_MedpaceClinicalDevelopmentServiceAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_FuturePotentialMilestonePayments" xlink:label="xene_FuturePotentialMilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_RegulatoryMilestoneMember" xlink:label="xene_RegulatoryMilestoneMember"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_MilestonePaymentsPaid" xlink:label="xene_MilestonePaymentsPaid"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_OtherMilestonesMember" xlink:label="xene_OtherMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_RoyaltyObligations" xlink:label="xene_RoyaltyObligations"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_ClinicalDevelopementAndOtherMilestoneMember" xlink:label="xene_ClinicalDevelopementAndOtherMilestoneMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="xene_CommitmentsAndContingenciesLineItems" xlink:to="xene_CommitmentsAndContingenciesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="xene_AssetPurchaseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xene_FirstOrderPharmaceuticalsIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="xene_ClinicalDevelopmentMilestonesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="xene_MedpaceClinicalDevelopmentServiceAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="xene_CommitmentsAndContingenciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xene_CommitmentsAndContingenciesLineItems" xlink:to="xene_FuturePotentialMilestonePayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="xene_RegulatoryMilestoneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="xene_CommitmentsAndContingenciesTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xene_CommitmentsAndContingenciesLineItems" xlink:to="xene_MilestonePaymentsPaid" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="xene_OtherMilestonesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="xene_CommitmentsAndContingenciesTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xene_CommitmentsAndContingenciesLineItems" xlink:to="xene_RoyaltyObligations" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="xene_ClinicalDevelopementAndOtherMilestoneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="xene_CommitmentsAndContingenciesTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="xene_CommitmentsAndContingenciesTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="xene_CommitmentsAndContingenciesTable" xlink:to="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardLineItems" xlink:label="us-gaap_TaxCreditCarryforwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardTable" xlink:label="us-gaap_TaxCreditCarryforwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_CanadaAndUnitedStatesRevenueAgencyMember" xlink:label="xene_CanadaAndUnitedStatesRevenueAgencyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentCreditMember" xlink:label="us-gaap_InvestmentCreditMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LatestTaxYearMember" xlink:label="us-gaap_LatestTaxYearMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_ProvincialTaxCreditMember" xlink:label="xene_ProvincialTaxCreditMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarliestTaxYearMember" xlink:label="us-gaap_EarliestTaxYearMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardExpirationDate" xlink:label="us-gaap_TaxCreditCarryforwardExpirationDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="us-gaap_TaxCreditCarryforwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="xene_CanadaAndUnitedStatesRevenueAgencyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_InvestmentCreditMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_LatestTaxYearMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TaxCreditCarryforwardTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="xene_ProvincialTaxCreditMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_EarliestTaxYearMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TaxCreditCarryforwardTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TaxCreditCarryforwardTable" xlink:to="us-gaap_TaxPeriodAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="us-gaap_TaxCreditCarryforwardExpirationDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="us-gaap_OpenTaxYear" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureSegmentDisclosureAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription" xlink:label="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration" xlink:label="us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="srt_TitleOfIndividualAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefExecutiveOfficerMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_NumberOfReportableSegments" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureSegmentDisclosureSummaryOfNetLossRelatedToSegmentExpensesDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_AzetukalnerMember" xlink:label="xene_AzetukalnerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_XEN496Member" xlink:label="xene_XEN496Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_Pre-ClinicalDiscoveryAndOtherProgramsMember" xlink:label="xene_Pre-ClinicalDiscoveryAndOtherProgramsMember"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_PersonnelRelatedExpenses" xlink:label="xene_PersonnelRelatedExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemAmount" xlink:label="us-gaap_SegmentReportingOtherItemAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="xene_AzetukalnerMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="xene_XEN496Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="xene_Pre-ClinicalDiscoveryAndOtherProgramsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="xene_PersonnelRelatedExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ShareBasedCompensation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_InvestmentIncomeInterest" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingOtherItemAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeDomain" xlink:label="us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UsefulLifeDescriptionOfTermDomain" xlink:label="us-gaap_UsefulLifeDescriptionOfTermDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeDomain" xlink:to="srt_ChiefExecutiveOfficerMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_UsefulLifeDescriptionOfTermDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_MarketableSecuritiesNoncurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet" order="4" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="4" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PrepaidExpenseNoncurrent" order="5" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:label="us-gaap_MarketableSecuritiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="us-gaap_PrepaidExpenseNoncurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss2">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_DebtSecuritiesTradingUnrealizedGainLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="1" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="xene_NetIncomeLossAvailableToPreferredStockholdersBasic" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeInterest" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="3" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesTradingUnrealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesTradingUnrealizedGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_NetIncomeLossAvailableToPreferredStockholdersBasic" xlink:label="xene_NetIncomeLossAvailableToPreferredStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="xene_InterestReceivableAndAccretionOfDiscountsOnMarketableSecurities" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationAndAmortization" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" order="6" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DebtSecuritiesTradingUnrealizedGainLoss" order="7" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="8" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="9" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="10" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="11" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_InterestReceivableAndAccretionOfDiscountsOnMarketableSecurities" xlink:label="xene_InterestReceivableAndAccretionOfDiscountsOnMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesTradingUnrealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesTradingUnrealizedGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureLeasesFutureMinimumLeasePaymentsDetails2">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="2" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAmortizedCostUnrealizedGainLossRecognizedInAociAndFairValueOfAvailableforsaleSecuritiesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xlink:to="xene_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:to="xene_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTaxCurrent" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xlink:to="xene_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTaxNoncurrent" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="xene_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:to="xene_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" order="4" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" xlink:label="xene_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTaxCurrent" xlink:label="xene_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTaxCurrent"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTaxNoncurrent" xlink:label="xene_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTaxNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax" xlink:label="xene_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" xlink:label="xene_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureLeasesFutureMinimumLeasePaymentsDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="5" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureAccountsPayableAndAccruedLiabilitiesAccountsPayableAndAccruedLiabilitiesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="xene_AccruedResearchAndDevelopmentCurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_TaxesPayableCurrent" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="5" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="6" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_AccruedResearchAndDevelopmentCurrent" xlink:label="xene_AccruedResearchAndDevelopmentCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxesPayableCurrent" xlink:label="us-gaap_TaxesPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCollaborationAgreementsScheduleOfCollaborationRevenueDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="xene_RecognitionOfTransactionPrice" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="xene_ResearchAndDevelopmentServices" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="xene_MilestonePayment" order="2" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_RecognitionOfTransactionPrice" xlink:label="xene_RecognitionOfTransactionPrice"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_ResearchAndDevelopmentServices" xlink:label="xene_ResearchAndDevelopmentServices"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_MilestonePayment" xlink:label="xene_MilestonePayment"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfBasicAndDilutedNetLossPerCommonShareDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="xene_NetIncomeLossAvailableToPreferredStockholdersBasic" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_NetIncomeLossAvailableToPreferredStockholdersBasic" xlink:label="xene_NetIncomeLossAvailableToPreferredStockholdersBasic"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfLossBeforeIncomeTaxesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxRecoveryExpenseDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="xene_EffectiveIncomeTaxRateReconciliationTaxAttributesExpiredOrUtilized" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" order="7" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_EffectiveIncomeTaxRateReconciliationTaxAttributesExpiredOrUtilized" xlink:label="xene_EffectiveIncomeTaxRateReconciliationTaxAttributesExpiredOrUtilized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfNetDeferredIncomeTaxAssetsDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="xene_DeferredTaxAssetsTaxCreditCarryforwardsInvestment" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="3" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="xene_DeferredTaxAssetsDeferredFinancingFees" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="xene_DeferredTaxAssetsOperatingLeaseLiability" order="7" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" order="8" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_DeferredTaxAssetsTaxCreditCarryforwardsInvestment" xlink:label="xene_DeferredTaxAssetsTaxCreditCarryforwardsInvestment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_DeferredTaxAssetsDeferredFinancingFees" xlink:label="xene_DeferredTaxAssetsDeferredFinancingFees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_DeferredTaxAssetsOperatingLeaseLiability" xlink:label="xene_DeferredTaxAssetsOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureSegmentDisclosureSummaryOfNetLossRelatedToSegmentExpensesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="xene_PersonnelRelatedExpenses" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_ShareBasedCompensation" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" order="3" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense" order="4" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InvestmentIncomeInterest" order="8" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_SegmentReportingOtherItemAmount" order="9" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" order="10" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="xene-20241231.xsd#xene_PersonnelRelatedExpenses" xlink:label="xene_PersonnelRelatedExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemAmount" xlink:label="us-gaap_SegmentReportingOtherItemAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
        </link:calculationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="xene_MilestonePaymentsPaid" name="MilestonePaymentsPaid" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="xene_StockIssuedDuringPeriodValueConversionOfPreFundedWarrant" name="StockIssuedDuringPeriodValueConversionOfPreFundedWarrant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="xene_SignificantAccountingPoliciesTable" name="SignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="xene_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" name="ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="xene_BasisOfPresentationLineItems" name="BasisOfPresentationLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="xene_PreFundsWarrantsOutstandingDateIssuanceJuneTwoThousandTwentyTwoMember" name="PreFundsWarrantsOutstandingDateIssuanceJuneTwoThousandTwentyTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="xene_PerformanceObligationsRelatedToMilestone" name="PerformanceObligationsRelatedToMilestone" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="xene_MilestonePayment" name="MilestonePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="xene_WarrantsExerciseDescription" name="WarrantsExerciseDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="xene_PreFundsWarrantsOutstandingDateIssuanceOctoberTwoThousandTwentyOneMember" name="PreFundsWarrantsOutstandingDateIssuanceOctoberTwoThousandTwentyOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="xene_StockOptionsExercisedForNumberOfCommonSharesForCash" name="StockOptionsExercisedForNumberOfCommonSharesForCash" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="xene_NumberOfWarrantsExercised" name="NumberOfWarrantsExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="xene_DeferredTaxAssetsDeferredFinancingFees" name="DeferredTaxAssetsDeferredFinancingFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="xene_AggregateMilestonePaymentReceived" name="AggregateMilestonePaymentReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="xene_TwoThousandFourteenAmendedAndRestatedStockOptionPlanMember" name="TwoThousandFourteenAmendedAndRestatedStockOptionPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="xene_JefferiesLLCStifelNicolausCompanyIncorporatedJPMorganSecuritiesLLCAndSVBSecuritiesLLCMember" name="JefferiesLLCStifelNicolausCompanyIncorporatedJPMorganSecuritiesLLCAndSVBSecuritiesLLCMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="xene_CashReceivedForLeaseIncentives" name="CashReceivedForLeaseIncentives" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="xene_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" name="DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="xene_PersonnelRelatedExpenses" name="PersonnelRelatedExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="xene_VariableConsiderationAllocatedToPerformanceObligation" name="VariableConsiderationAllocatedToPerformanceObligation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="xene_IanMortimerMember" name="IanMortimerMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="xene_Pre-ClinicalDiscoveryAndOtherProgramsMember" name="Pre-ClinicalDiscoveryAndOtherProgramsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="xene_UnfavorableChangeInInterestRatesOfMarketableSecurities" name="UnfavorableChangeInInterestRatesOfMarketableSecurities" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="xene_AccruedResearchAndDevelopmentCurrent" name="AccruedResearchAndDevelopmentCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="xene_PurchasesOfPropertyPlantAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities" name="PurchasesOfPropertyPlantAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="xene_NumberOfWarrantsIssued" name="NumberOfWarrantsIssued" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="xene_CommonStockIssuedForCashlessExercise" name="CommonStockIssuedForCashlessExercise" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="xene_StockIssuedDuringPeriodSharesConversionOfPreFundedWarrant" name="StockIssuedDuringPeriodSharesConversionOfPreFundedWarrant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="xene_PreFundedWarrantsExercised" name="PreFundedWarrantsExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="xene_MilestonePaymentDueOnInitiationOfPhase1bClinicalTrial" name="MilestonePaymentDueOnInitiationOfPhase1bClinicalTrial" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="xene_JefferiesLLCAndStifelNicolausCompanyIncorporatedMember" name="JefferiesLLCAndStifelNicolausCompanyIncorporatedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="xene_InterestReceivableAndAccretionOfDiscountsOnMarketableSecurities" name="InterestReceivableAndAccretionOfDiscountsOnMarketableSecurities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="xene_AssetPurchaseAgreementMember" name="AssetPurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="xene_NetIncomeLossAvailableToPreferredStockholdersBasic" name="NetIncomeLossAvailableToPreferredStockholdersBasic" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="xene_MedpaceClinicalDevelopmentServiceAgreementMember" name="MedpaceClinicalDevelopmentServiceAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="xene_PreFundsWarrantsOutstandingDateIssuanceMarchTwoThousandTwentyOneMember" name="PreFundsWarrantsOutstandingDateIssuanceMarchTwoThousandTwentyOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="xene_ProvincialTaxCreditMember" name="ProvincialTaxCreditMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="xene_GrossProceedsFromIssuableOfCommonStock" name="GrossProceedsFromIssuableOfCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="xene_ResearchAndDevelopmentServices" name="ResearchAndDevelopmentServices" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="xene_RoyaltyObligations" name="RoyaltyObligations" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="xene_DeferredTaxAssetsOperatingLeaseLiability" name="DeferredTaxAssetsOperatingLeaseLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="xene_ExchangeAgreementMember" name="ExchangeAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="xene_FairValueAssumptionsForStockOptionsAbstract" name="FairValueAssumptionsForStockOptionsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="xene_UnderwrittenPublicOfferingMember" name="UnderwrittenPublicOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="xene_XEN496Member" name="XEN496Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="xene_CollaborateMilestoneAgreementPremiumRelatedToEquityInvestment" name="CollaborateMilestoneAgreementPremiumRelatedToEquityInvestment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="xene_UpfrontPaymentInCash" name="UpfrontPaymentInCash" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="xene_WeightedAverageNumberOfCommonShares" name="WeightedAverageNumberOfCommonShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="xene_AzetukalnerMember" name="AzetukalnerMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="xene_ScheduleOfPreFundedWarrantsActivityTableTextBlock" name="ScheduleOfPreFundedWarrantsActivityTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="xene_MilestonePaymentReceivedInEquityInvestment" name="MilestonePaymentReceivedInEquityInvestment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="xene_CommitmentsAndContingenciesLineItems" name="CommitmentsAndContingenciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="xene_MaximumTermOfEachOptionExercised" name="MaximumTermOfEachOptionExercised" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="xene_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax" name="AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="xene_FairValueOfPreFundedWarrantsExercised" name="FairValueOfPreFundedWarrantsExercised" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="xene_ClinicalDevelopmentMilestonesMember" name="ClinicalDevelopmentMilestonesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="xene_PaciraBiosciencesMember" name="PaciraBiosciencesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="xene_EffectiveIncomeTaxRateReconciliationTaxAttributesExpiredOrUtilized" name="EffectiveIncomeTaxRateReconciliationTaxAttributesExpiredOrUtilized" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="xene_Rule10B51TradingPlanOneMember" name="Rule10B51TradingPlanOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="xene_LesseeNumberOfOperatingLeases" name="LesseeNumberOfOperatingLeases" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="xene_PreFundsWarrantsOutstandingDateIssuanceDecemberTwoThousandTwentyThreeMember" name="PreFundsWarrantsOutstandingDateIssuanceDecemberTwoThousandTwentyThreeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="xene_MilestonePaymentReceivedInCash" name="MilestonePaymentReceivedInCash" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="xene_CollaborateAgreementPremiumRelatedToEquityInvestment" name="CollaborateAgreementPremiumRelatedToEquityInvestment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="xene_GuaranteedInvestmentCertificatesMember" name="GuaranteedInvestmentCertificatesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="xene_SalesBasedMilestoneMember" name="SalesBasedMilestoneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="xene_RecognitionOfTransactionPrice" name="RecognitionOfTransactionPrice" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="xene_FirstRenewalOptionMember" name="FirstRenewalOptionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="xene_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTaxCurrent" name="DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTaxCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="xene_CashAndMoneyMarketFundMember" name="CashAndMoneyMarketFundMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="xene_JefferiesLLCSVBLeerinkLLCAndStifelNicolausCompanyIncorporatedMember" name="JefferiesLLCSVBLeerinkLLCAndStifelNicolausCompanyIncorporatedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="xene_UpfrontPaymentReceivedInEquityInvestment" name="UpfrontPaymentReceivedInEquityInvestment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="xene_WeightedAverageNumberOfPrefundedWarrants" name="WeightedAverageNumberOfPrefundedWarrants" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="xene_FairValueOfStockOptionsExercisedOnCashlessBasis" name="FairValueOfStockOptionsExercisedOnCashlessBasis" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="xene_CanadaAndUnitedStatesRevenueAgencyMember" name="CanadaAndUnitedStatesRevenueAgencyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="xene_JefferiesLLCStifelNicolausCompanyIncorporatedJPMorganSecuritiesLLCBofASecuritiesIncAndRBCCapitalMarketsLLCMember" name="JefferiesLLCStifelNicolausCompanyIncorporatedJPMorganSecuritiesLLCBofASecuritiesIncAndRBCCapitalMarketsLLCMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="xene_Rule10B51TradingPlanMember" name="Rule10B51TradingPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="xene_ShareCapitalLineItems" name="ShareCapitalLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="xene_CommitmentsAndContingenciesTable" name="CommitmentsAndContingenciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="xene_ShareCapitalTable" name="ShareCapitalTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="xene_ProceedsFromUpfrontFee" name="ProceedsFromUpfrontFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="xene_SecondRenewalOptionMember" name="SecondRenewalOptionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="xene_DeferredTaxAssetsTaxCreditCarryforwardsInvestment" name="DeferredTaxAssetsTaxCreditCarryforwardsInvestment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="xene_FuturePotentialMilestonePayments" name="FuturePotentialMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="xene_BurnabyBritishColumbiaMember" name="BurnabyBritishColumbiaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="xene_WarrantsIssuedPricePerPreFundedWarrant" name="WarrantsIssuedPricePerPreFundedWarrant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="xene_AtMarketEquityOfferingMember" name="AtMarketEquityOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="xene_ResearchEquipmentMember" name="ResearchEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="xene_CommonStockIssuedForPreFundedWarrants" name="CommonStockIssuedForPreFundedWarrants" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="xene_JefferiesLLCStifelNicolausCompanyIncorporatedAndGuggenheimSecuritiesLLCMember" name="JefferiesLLCStifelNicolausCompanyIncorporatedAndGuggenheimSecuritiesLLCMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="xene_LesseeOperatingLeaseNumberOfRenewalOptions" name="LesseeOperatingLeaseNumberOfRenewalOptions" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="xene_PotentialMilestonePaymentsReceivable" name="PotentialMilestonePaymentsReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="xene_AmendedAndRestatedStockOptionPlanMember" name="AmendedAndRestatedStockOptionPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="xene_StockIssuedDuringPeriodCommonSharesCancelled" name="StockIssuedDuringPeriodCommonSharesCancelled" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="xene_NeedhamMassachusettsMember" name="NeedhamMassachusettsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="xene_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" name="DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="xene_StockOptionActivityAbstract" name="StockOptionActivityAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="xene_CashlessExerciseOfStockOptions" name="CashlessExerciseOfStockOptions" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="xene_TermLoansMember" name="TermLoansMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="xene_LicenseAndCollaborationAgreementMember" name="LicenseAndCollaborationAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="xene_BasisOfPresentationTable" name="BasisOfPresentationTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="xene_StockIssuedDuringPeriodSharesConversionOfPreFundedWarrantsToCommonShares" name="StockIssuedDuringPeriodSharesConversionOfPreFundedWarrantsToCommonShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="xene_IncreaseDecreaseInFairValueOfMarketableSecurities" name="IncreaseDecreaseInFairValueOfMarketableSecurities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="xene_NeurocrineBiosciencesMember" name="NeurocrineBiosciencesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="xene_PercentageOfOptionToFundDevelopmentCostsUponAchievementOfCertainMilestones" name="PercentageOfOptionToFundDevelopmentCostsUponAchievementOfCertainMilestones" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="xene_RegulatoryMilestoneMember" name="RegulatoryMilestoneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="xene_ClinicalDevelopementAndOtherMilestoneMember" name="ClinicalDevelopementAndOtherMilestoneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="xene_AggregatePriceOfTransactionAllocatedToPerformanceObligations" name="AggregatePriceOfTransactionAllocatedToPerformanceObligations" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="xene_SignificantAccountingPoliciesLineItems" name="SignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="xene_Series1PreferredSharesMember" name="Series1PreferredSharesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="xene_TwoThousandNineteenInducementEquityIncentivePlanMember" name="TwoThousandNineteenInducementEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="xene_BVFPartnersLPMember" name="BVFPartnersLPMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="xene_OtherMilestonesMember" name="OtherMilestonesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="xene_MilestonePaymentReceivedInEquityInvestmentMeasuredAtFairValue" name="MilestonePaymentReceivedInEquityInvestmentMeasuredAtFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="xene_FirstOrderPharmaceuticalsIncMember" name="FirstOrderPharmaceuticalsIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="xene_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTaxNoncurrent" name="DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTaxNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45905592533840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Feb. 24, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">XENON PHARMACEUTICALS INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,542,811<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,946.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">XENE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001582313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtRestatementRecoveryAnalysisFlag', window );">Document Financial Statement Restatement Recovery Analysis [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Shares, without par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-0661854<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">200-3650 Gilmore Way<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Burnaby<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">BC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">484-3300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">V5G 4W8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">Z4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">KPMG LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Vancouver, BC, Canada<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Portions of the Registrant&#8217;s Definitive Proxy Statement relating to the 2024 Annual Meeting of Shareholders, which will be filed with the Securities and Exchange Commission subsequent to the date hereof, are incorporated by reference into Part III of this Report. Such Proxy Statement will be filed with the Securities and Exchange Commission not later than 120 days following the end of the Registrant&#8217;s fiscal year ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorOpinionTextBlock', window );">Auditor Opinion [Text Block]</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Opinion on the Consolidated Financial Statements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have audited the accompanying consolidated balance sheets of Xenon Pharmaceuticals Inc. (the Company) as of December 31, 2024 and 2023, the related consolidated statements of operations and comprehensive loss, shareholders&#8217; equity, and cash flows for each of the years in the three-year period ended December 31, 2024 and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the years in the three-year period ended December 31, 2024, in conformity with U.S. generally accepted accounting principles.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company&#8217;s internal control over financial reporting as of December 31, 2024, based on criteria established in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Internal Control &#8211; Integrated Framework (2013)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> issued by the Committee of Sponsoring Organizations of the Treadway Commission, and our report dated February 27, 2025 expressed an unqualified opinion on the effectiveness of the Company&#8217;s internal control over financial reporting.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorOpinionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X<br> -Number 210<br> -Section 2<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorOpinionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtRestatementRecoveryAnalysisFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement periods include restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtRestatementRecoveryAnalysisFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45905599071616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 142,712<span></span>
</td>
<td class="nump">$ 148,643<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities (note 5)</a></td>
<td class="nump">484,193<span></span>
</td>
<td class="nump">489,439<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">1,469<span></span>
</td>
<td class="nump">874<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">6,890<span></span>
</td>
<td class="nump">6,006<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">635,264<span></span>
</td>
<td class="nump">644,962<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Marketable securities, long-term (note 5)</a></td>
<td class="nump">127,496<span></span>
</td>
<td class="nump">292,792<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset, net (note 7)</a></td>
<td class="nump">7,939<span></span>
</td>
<td class="nump">9,193<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net (note 6)</a></td>
<td class="nump">10,278<span></span>
</td>
<td class="nump">9,653<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax assets (note 13)</a></td>
<td class="nump">9,666<span></span>
</td>
<td class="nump">802<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseNoncurrent', window );">Prepaid expenses, long-term</a></td>
<td class="nump">7,496<span></span>
</td>
<td class="nump">7,396<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">798,139<span></span>
</td>
<td class="nump">964,798<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued liabilities (note 8)</a></td>
<td class="nump">34,221<span></span>
</td>
<td class="nump">25,974<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability (note 7)</a></td>
<td class="nump">1,369<span></span>
</td>
<td class="nump">1,299<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">35,590<span></span>
</td>
<td class="nump">27,273<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, long-term (note 7)</a></td>
<td class="nump">7,646<span></span>
</td>
<td class="nump">9,604<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">43,236<span></span>
</td>
<td class="nump">36,877<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common shares, without par value; unlimited shares authorized; issued and outstanding: 76,416,086 (December 31, 2023 - 75,370,977) (note 9)</a></td>
<td class="nump">1,456,836<span></span>
</td>
<td class="nump">1,436,374<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">199,149<span></span>
</td>
<td class="nump">156,764<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(899,470)<span></span>
</td>
<td class="num">(665,140)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(1,612)<span></span>
</td>
<td class="num">(77)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders' equity</a></td>
<td class="nump">754,903<span></span>
</td>
<td class="nump">927,921<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders&#8217; equity</a></td>
<td class="nump">798,139<span></span>
</td>
<td class="nump">964,798<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (note 12)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45905590616560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNoParValue', window );">Common shares, without par value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorizedUnlimited', window );">Common shares, shares authorized</a></td>
<td class="text">Unlimited<span></span>
</td>
<td class="text">Unlimited<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, Issued</a></td>
<td class="nump">76,416,086<span></span>
</td>
<td class="nump">75,370,977<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, Outstanding</a></td>
<td class="nump">76,416,086<span></span>
</td>
<td class="nump">75,370,977<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNoParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount per share of no-par value common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNoParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorizedUnlimited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether number of common shares permitted to be issued is unlimited. Acceptable value is "Unlimited".</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorizedUnlimited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>us-types:authorizedUnlimitedItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45905595179968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue (note 10)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,434<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 210,394<span></span>
</td>
<td class="nump">$ 167,512<span></span>
</td>
<td class="nump">105,767<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">68,904<span></span>
</td>
<td class="nump">46,542<span></span>
</td>
<td class="nump">32,810<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">279,298<span></span>
</td>
<td class="nump">214,054<span></span>
</td>
<td class="nump">138,577<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(279,298)<span></span>
</td>
<td class="num">(214,054)<span></span>
</td>
<td class="num">(129,143)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">41,943<span></span>
</td>
<td class="nump">27,620<span></span>
</td>
<td class="nump">8,713<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesTradingUnrealizedGainLoss', window );">Unrealized fair value gain (loss) on trading securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,550<span></span>
</td>
<td class="num">(2,934)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange gain (loss)</a></td>
<td class="num">(1,064)<span></span>
</td>
<td class="nump">199<span></span>
</td>
<td class="num">(1,891)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income (expense)</a></td>
<td class="nump">40,879<span></span>
</td>
<td class="nump">31,369<span></span>
</td>
<td class="nump">3,888<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(238,419)<span></span>
</td>
<td class="num">(182,685)<span></span>
</td>
<td class="num">(125,255)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax recovery (expense) (note 13)</a></td>
<td class="nump">4,089<span></span>
</td>
<td class="nump">292<span></span>
</td>
<td class="num">(118)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(234,330)<span></span>
</td>
<td class="num">(182,393)<span></span>
</td>
<td class="num">(125,373)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xene_NetIncomeLossAvailableToPreferredStockholdersBasic', window );">Net loss attributable to preferred shareholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(437)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common shareholders</a></td>
<td class="num">(234,330)<span></span>
</td>
<td class="num">(182,393)<span></span>
</td>
<td class="num">(124,936)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized gain (loss) on available-for-sale securities (note 5)</a></td>
<td class="num">(1,535)<span></span>
</td>
<td class="nump">2,923<span></span>
</td>
<td class="num">(2,010)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (235,865)<span></span>
</td>
<td class="num">$ (179,470)<span></span>
</td>
<td class="num">$ (127,383)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per common share (note 11):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic</a></td>
<td class="num">$ (3.01)<span></span>
</td>
<td class="num">$ (2.73)<span></span>
</td>
<td class="num">$ (2.06)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted</a></td>
<td class="num">$ (3.01)<span></span>
</td>
<td class="num">$ (2.73)<span></span>
</td>
<td class="num">$ (2.06)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Weighted-average common shares outstanding (note 4):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic</a></td>
<td class="nump">77,894,643<span></span>
</td>
<td class="nump">66,889,005<span></span>
</td>
<td class="nump">60,542,142<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted</a></td>
<td class="nump">77,894,643<span></span>
</td>
<td class="nump">66,889,005<span></span>
</td>
<td class="nump">60,542,142<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesTradingUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in net income (trading).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-14<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesTradingUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482014/830-20-35-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481839/830-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xene_NetIncomeLossAvailableToPreferredStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net income (loss) available to preferred stockholders basic.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xene_NetIncomeLossAvailableToPreferredStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xene_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45905599573408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Shareholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Convertible Preferred Shares [Member]</div></th>
<th class="th"><div>Common Shares [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss [Member]</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 550,033<span></span>
</td>
<td class="nump">$ 7,732<span></span>
</td>
<td class="nump">$ 783,170<span></span>
</td>
<td class="nump">$ 117,495<span></span>
</td>
<td class="num">$ (357,374)<span></span>
</td>
<td class="num">$ (990)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,016,000<span></span>
</td>
<td class="nump">51,634,752<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the year</a></td>
<td class="num">(125,373)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(125,373)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common shares and pre-funded warrants, net (note 9a and note 9e)</a></td>
<td class="nump">277,766<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 268,379<span></span>
</td>
<td class="nump">9,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common shares and pre-funded warrants, net (note 9a and note 9e) (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,357,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of preferred shares (note 9d)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (7,732)<span></span>
</td>
<td class="nump">$ 7,732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of preferred shares (note 9d) (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,016,000)<span></span>
</td>
<td class="nump">1,016,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation expense (note 9c)</a></td>
<td class="nump">20,376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,855<span></span>
</td>
<td class="num">(5,150)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in Shares)</a></td>
<td class="nump">780,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">579,601<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive (loss) income</a></td>
<td class="num">$ (2,010)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,010)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">721,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,065,136<span></span>
</td>
<td class="nump">142,108<span></span>
</td>
<td class="num">(482,747)<span></span>
</td>
<td class="num">(3,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,587,701<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the year</a></td>
<td class="num">(182,393)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(182,393)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common shares and pre-funded warrants, net (note 9a and note 9e)</a></td>
<td class="nump">353,487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 330,010<span></span>
</td>
<td class="nump">23,477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common shares and pre-funded warrants, net (note 9a and note 9e) (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,701,842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xene_StockIssuedDuringPeriodValueConversionOfPreFundedWarrant', window );">Conversion of pre-funded warrants (note 9e)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,913<span></span>
</td>
<td class="num">(35,913)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xene_StockIssuedDuringPeriodSharesConversionOfPreFundedWarrant', window );">Conversion of pre-funded warrants (note 9e) (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation expense (note 9c)</a></td>
<td class="nump">32,372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,315<span></span>
</td>
<td class="num">(5,280)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in Shares)</a></td>
<td class="nump">587,536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">381,434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive (loss) income</a></td>
<td class="nump">$ 2,923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,923<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">927,921<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,436,374<span></span>
</td>
<td class="nump">156,764<span></span>
</td>
<td class="num">(665,140)<span></span>
</td>
<td class="num">(77)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,370,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the year</a></td>
<td class="num">(234,330)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(234,330)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common shares and pre-funded warrants, net (note 9a and note 9e)</a></td>
<td class="nump">12,083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common shares and pre-funded warrants, net (note 9a and note 9e) (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">310,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation expense (note 9c)</a></td>
<td class="nump">50,717<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,717<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,379<span></span>
</td>
<td class="num">(8,332)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in Shares)</a></td>
<td class="nump">1,040,136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">735,109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive (loss) income</a></td>
<td class="num">$ (1,535)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,535)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2024</a></td>
<td class="nump">$ 754,903<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,456,836<span></span>
</td>
<td class="nump">$ 199,149<span></span>
</td>
<td class="num">$ (899,470)<span></span>
</td>
<td class="num">$ (1,612)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,416,086<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482739/220-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xene_StockIssuedDuringPeriodSharesConversionOfPreFundedWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares conversion of pre funded warrant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xene_StockIssuedDuringPeriodSharesConversionOfPreFundedWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xene_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xene_StockIssuedDuringPeriodValueConversionOfPreFundedWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value conversion of pre funded warrant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xene_StockIssuedDuringPeriodValueConversionOfPreFundedWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xene_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45905599567264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (234,330)<span></span>
</td>
<td class="num">$ (182,393)<span></span>
</td>
<td class="num">$ (125,373)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xene_InterestReceivableAndAccretionOfDiscountsOnMarketableSecurities', window );">Interest receivable and accretion of discounts on marketable securities</a></td>
<td class="nump">816<span></span>
</td>
<td class="num">(5,785)<span></span>
</td>
<td class="num">(2,598)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation of property, plant and equipment</a></td>
<td class="nump">2,560<span></span>
</td>
<td class="nump">2,061<span></span>
</td>
<td class="nump">1,405<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Non-cash operating lease expense</a></td>
<td class="nump">1,254<span></span>
</td>
<td class="nump">1,213<span></span>
</td>
<td class="nump">819<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income tax recovery</a></td>
<td class="num">(8,864)<span></span>
</td>
<td class="num">(292)<span></span>
</td>
<td class="num">(44)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">50,717<span></span>
</td>
<td class="nump">32,372<span></span>
</td>
<td class="nump">20,376<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized', window );">Unrealized foreign exchange (gain) loss</a></td>
<td class="nump">745<span></span>
</td>
<td class="num">(640)<span></span>
</td>
<td class="nump">2,729<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesTradingUnrealizedGainLoss', window );">Unrealized fair value (gain) loss on trading securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,550)<span></span>
</td>
<td class="nump">2,934<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(614)<span></span>
</td>
<td class="nump">130<span></span>
</td>
<td class="nump">1,757<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(984)<span></span>
</td>
<td class="nump">1,574<span></span>
</td>
<td class="num">(10,495)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">8,531<span></span>
</td>
<td class="nump">3,931<span></span>
</td>
<td class="nump">8,062<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="num">(1,220)<span></span>
</td>
<td class="nump">267<span></span>
</td>
<td class="num">(600)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(181,389)<span></span>
</td>
<td class="num">(151,112)<span></span>
</td>
<td class="num">(101,028)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment</a></td>
<td class="num">(3,075)<span></span>
</td>
<td class="num">(5,617)<span></span>
</td>
<td class="num">(2,894)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchase of marketable securities</a></td>
<td class="num">(532,268)<span></span>
</td>
<td class="num">(793,907)<span></span>
</td>
<td class="num">(551,137)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from marketable securities</a></td>
<td class="nump">700,343<span></span>
</td>
<td class="nump">688,139<span></span>
</td>
<td class="nump">260,626<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">165,000<span></span>
</td>
<td class="num">(111,385)<span></span>
</td>
<td class="num">(293,405)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from public offerings, net</a></td>
<td class="nump">12,083<span></span>
</td>
<td class="nump">353,487<span></span>
</td>
<td class="nump">277,766<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">47<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="nump">705<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">12,130<span></span>
</td>
<td class="nump">353,522<span></span>
</td>
<td class="nump">278,471<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="num">(1,672)<span></span>
</td>
<td class="nump">376<span></span>
</td>
<td class="num">(2,484)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Increase (decrease) in cash and cash equivalents</a></td>
<td class="num">(5,931)<span></span>
</td>
<td class="nump">91,401<span></span>
</td>
<td class="num">(118,446)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents, beginning of year</a></td>
<td class="nump">148,643<span></span>
</td>
<td class="nump">57,242<span></span>
</td>
<td class="nump">175,688<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents, end of year</a></td>
<td class="nump">142,712<span></span>
</td>
<td class="nump">148,643<span></span>
</td>
<td class="nump">57,242<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for operating lease</a></td>
<td class="nump">1,672<span></span>
</td>
<td class="nump">1,624<span></span>
</td>
<td class="nump">919<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xene_CashReceivedForLeaseIncentives', window );">Cash received for lease incentives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosures of non-cash transactions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xene_FairValueOfStockOptionsExercisedOnCashlessBasis', window );">Fair value of stock options exercised on a cashless basis</a></td>
<td class="nump">$ 8,305<span></span>
</td>
<td class="nump">5,250<span></span>
</td>
<td class="nump">4,491<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xene_FairValueOfPreFundedWarrantsExercised', window );">Fair value of pre-funded warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,913<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xene_PurchasesOfPropertyPlantAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities', window );">Purchases of property, plant and equipment included in accounts payable and accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">391<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use asset obtained in exchange for new operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,019<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesTradingUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in net income (trading).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-14<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesTradingUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossUnrealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xene_CashReceivedForLeaseIncentives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received for lease incentives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xene_CashReceivedForLeaseIncentives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xene_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xene_FairValueOfPreFundedWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value Of Pre-funded Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xene_FairValueOfPreFundedWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xene_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xene_FairValueOfStockOptionsExercisedOnCashlessBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate grant-date fair value of stock options exercised via net exercise (cashless) during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xene_FairValueOfStockOptionsExercisedOnCashlessBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xene_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xene_InterestReceivableAndAccretionOfDiscountsOnMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest Receivable and Accretion Of Discounts On Marketable Securities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xene_InterestReceivableAndAccretionOfDiscountsOnMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xene_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xene_PurchasesOfPropertyPlantAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchases of property, plant and equipment included in accounts payable and accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xene_PurchasesOfPropertyPlantAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xene_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45905599221872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management, Strategy, and Governance<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><p id="item_1c_cybersecurity" style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1C. Cybers</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ecurity</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We rely on both internal information technology systems and networks, and those of third-party vendors and contractors, to acquire, transmit, store and otherwise process information in connection with our business activities. Our ability to effectively manage our business depends on the security, reliability and adequacy of our and our third-party contractors&#8217; and vendors&#8217; technology systems. As such, we have implemented an information security program designed to identify, assess, and manage risks from cybersecurity threats.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We perform risk assessments relating to cybersecurity and technology risks at least annually. Our cybersecurity risk management program has been developed based on industry standards, including those published by the National Institute of Standards and Technology (&#8220;NIST&#8221;). Highlights of the program include:</span></p><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Corporate policies and procedures that guide our use of information systems, confidentiality and security strategy;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Identifying critical assets and high-risk threats, and implementing technical prevention and detection controls and response and recovery practices;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A third-party risk management process to assist in making risk-informed technology product and services decisions on third parties</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> who provide, manage, store or have access to material data or information, including the completion of security questionnaires and independent assessments of controls, audits and/or contract terms;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Defined data loss </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">prevention standards in place to detect and prevent data loss, including requiring third-party service providers with access to personal, confidential or proprietary information to implement and maintain comprehensive cybersecurity practices consistent with applicable legal standards and industry best practices</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Security awareness training for employees to identify cybersecurity concerns and take appropriate actions; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Evaluating our program&#8217;s effectiveness by performing regular internal and third-party assessments of our controls, including external penetration testing and consultation on security enhancements.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks identified through our cybersecurity program are assessed to determine the potential impact and likelihood of occurrence and mitigation plans are developed and implemented accordingly.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Audit Committee of our Board of Directors bears the primary responsibility for oversight of cybersecurity risks. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Audit Committee is composed of board members with diverse expertise, including risk management, technology and finance, equipping them to oversee cybersecurity risks effectively.</span></span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Management&#8217;s oversight is performed through an IT Strategy Committee, a subset of executive management including our Chief Financial Officer, or CFO, and Chief Legal Officer, and relevant functional expertise, including our Senior Vice President, Information Systems, or SVP, IS. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our SVP, IS, is the primary member of the IT Steering Committee charged with responsibility for assessing, monitoring and managing our cybersecurity risks</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></span></span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With over 20 years of experience in information technology strategy and operations, his background includes extensive experience as an IT executive at various companies.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At least annually, the SVP, IS, and the CFO provide a comprehensive report to the Audit Committee regarding cybersecurity risk assessments, planned enhancements to our cyber security program</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and incident reports and remediation, if any</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The SVP, IS, oversees processes for the regular monitoring of our information systems, including potential vulnerabilities. In the event of a cybersecurity incident, the IT organization and designated members of executive management follow an established Cybersecurity Incident Response Plan. This plan includes immediate actions to contain the threat, mitigate the impact and assess materiality, and requires retrospective review and identification of corrective actions to reduce future risk.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the fiscal year ended December 31, 2024, we </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">did not experience any material impact</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to our business, financial position or operations resulting from previously identified cyberattacks or other information security incidents, but we cannot provide assurance that they will not be materially affected in the future by such risks or any future material breaches. For a discussion of these risks, see &#8220;Item 1A&#8212;Risk Factors&#8212;Risk Related to Our Business and Industry&#8212;Our business and operations could suffer in the event of an actual or perceived information security incident such as a cybersecurity breach, system failure, or other compromise of our systems and/or information, including information held by a third-party contractor or vendor.&#8221;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag', window );">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Audit Committee of our Board of Directors bears the primary responsibility for oversight of cybersecurity risks. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Audit Committee is composed of board members with diverse expertise, including risk management, technology and finance, equipping them to oversee cybersecurity risks effectively.</span></span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Management&#8217;s oversight is performed through an IT Strategy Committee, a subset of executive management including our Chief Financial Officer, or CFO, and Chief Legal Officer, and relevant functional expertise, including our Senior Vice President, Information Systems, or SVP, IS. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our SVP, IS, is the primary member of the IT Steering Committee charged with responsibility for assessing, monitoring and managing our cybersecurity risks</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></span></span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With over 20 years of experience in information technology strategy and operations, his background includes extensive experience as an IT executive at various companies.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At least annually, the SVP, IS, and the CFO provide a comprehensive report to the Audit Committee regarding cybersecurity risk assessments, planned enhancements to our cyber security program</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and incident reports and remediation, if any</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Audit Committee is composed of board members with diverse expertise, including risk management, technology and finance, equipping them to oversee cybersecurity risks effectively.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At least annually, the SVP, IS, and the CFO provide a comprehensive report to the Audit Committee regarding cybersecurity risk assessments, planned enhancements to our cyber security program</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and incident reports and remediation, if any</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskRoleOfManagementTextBlock', window );">Cybersecurity Risk Role of Management [Text Block]</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Management&#8217;s oversight is performed through an IT Strategy Committee, a subset of executive management including our Chief Financial Officer, or CFO, and Chief Legal Officer, and relevant functional expertise, including our Senior Vice President, Information Systems, or SVP, IS. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our SVP, IS, is the primary member of the IT Steering Committee charged with responsibility for assessing, monitoring and managing our cybersecurity risks</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With over 20 years of experience in information technology strategy and operations, his background includes extensive experience as an IT executive at various companies.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At least annually, the SVP, IS, and the CFO provide a comprehensive report to the Audit Committee regarding cybersecurity risk assessments, planned enhancements to our cyber security program</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and incident reports and remediation, if any</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Management&#8217;s oversight is performed through an IT Strategy Committee, a subset of executive management including our Chief Financial Officer, or CFO, and Chief Legal Officer, and relevant functional expertise, including our Senior Vice President, Information Systems, or SVP, IS. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our SVP, IS, is the primary member of the IT Steering Committee charged with responsibility for assessing, monitoring and managing our cybersecurity risks</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock', window );">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With over 20 years of experience in information technology strategy and operations, his background includes extensive experience as an IT executive at various companies.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskRoleOfManagementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskRoleOfManagementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45905692973280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (234,330)<span></span>
</td>
<td class="num">$ (182,393)<span></span>
</td>
<td class="num">$ (125,373)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45905591349376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45905590616560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of the Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Nature of the business</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nature of the business:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></div></div><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Xenon Pharmaceuticals Inc. (the &#8220;Company&#8221;), incorporated in 1996 under the predecessor to the Business Corporations Act (British Columbia) and continued federally in 2000 under the Canada Business Corporations Act, is a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing ion channel therapeutics for patients in need.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has incurred significant operating losses since inception. As of December 31, 2024, the Company had an accumulated deficit of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">899,470</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and a net loss of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">234,330</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for the year ended December 31, 2024. Management expects to continue to incur significant expenses in excess of revenue and to incur operating losses for the foreseeable future. To date, the Company has financed its operations primarily through the sale of equity securities, funding received from collaboration and license agreements, and debt financings.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Until such time as the Company can generate substantial product revenue, if ever, management expects to finance the Company&#8217;s cash needs through a combination of collaboration agreements, equity and debt financings. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The continuation of research and development activities and the future commercialization of its products are dependent on the Company&#8217;s ability to successfully raise additional funds when needed. It is not possible to predict either the outcome of future research and development programs or the Company&#8217;s ability to continue to fund these programs in the future.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45905590610928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccounting', window );">Basis of Presentation</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basis of presentation:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></div></div><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These consolidated financial statements are presented in U.S. dollars and have been prepared in accordance with generally accepted accounting principles in the United States ("GAAP").</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has one wholly-owned subsidiary as of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, Xenon Pharmaceuticals USA Inc., which was incorporated in Delaware on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 2, 2016</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All intercompany transactions and balances have been eliminated on consolidation. Certain information has been reclassified to conform with the financial presentation adopted for the current year.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Correction of prior period error</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2024, the Company identified a presentation error related to the accretion of discounts on marketable securities, which was incorrectly presented within proceeds from marketable securities as part of net cash provided by (used in) investing activities in the consolidated statements of cash flows. As a result, a correction was made to the prior periods to reclassify the amount of accretion of discounts on marketable securities within net cash used in operating activities, resulting in an increase in net cash used in operating activities and a corresponding decrease in net cash used in investing activities for the years ended December 31, 2023 and 2022 of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,785</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,598</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively, from the previously reported amounts. The Company evaluated the materiality of the presentation error, both quantitatively and qualitatively, and concluded it was not material to the consolidated financial statements for any prior period. These presentation changes had no effect on the previously reported consolidated balance sheets, consolidated statements of operations and comprehensive loss, or consolidated statements of shareholders&#8217; equity.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccounting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccounting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45905692881856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant accounting policies</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Significant accounting policies:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Use of estimates: </span></div></div><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant areas of estimates include, but are not limited to, revenue recognition including estimated timing of completion of performance obligations and the determination of stock-based compensation. These estimates and assumptions take into account historical and forward-looking factors that the Company believes are reasonable. Estimates and assumptions are reviewed quarterly. All revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash and cash equivalents: </span></div></div><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash equivalents are highly liquid investments that are readily convertible into cash with terms to maturity of three months or less when acquired. Cash equivalents are recorded at cost plus accrued interest, which approximates the fair value.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(c)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Marketable securities: </span></div></div><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Marketable securities are debt securities with original maturities exceeding three months and accrue interest based on a fixed interest rate for the term. Effective July 1, 2022, the Company classifies its marketable securities as either trading securities or available-for-sale securities. Marketable securities are carried at fair value.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fair value gains and losses for marketable securities classified as trading securities are recorded through the consolidated statement of operations. These securities are classified as current assets as the Company has the intent and ability to convert these securities into cash without penalty within the next 12 months.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unrealized fair value gains and losses for marketable securities classified as available-for-sale are recorded through other comprehensive income (loss) in shareholders' equity. When the fair value of an available-for-sale security falls below the amortized cost basis, it is evaluated to determine if any of the decline in value is attributable to credit loss. Decreases in fair value attributable to credit loss are recorded directly to the consolidated statement of operations with a corresponding allowance for credit losses, limited to the amount that the fair value is less than the amortized cost basis. If the credit quality subsequently improves the allowance is reversed up to a maximum of the previously recorded credit losses. When the Company intends to sell an impaired available-for-sale security, or if it is more likely than not that the Company will be required to sell the security prior to recovering the amortized cost basis, the entire fair value adjustment will immediately be recognized in the consolidated statement of operations with no corresponding allowance for credit losses. Realized gains and losses and credit losses, if any, on available-for-sale securities are included in interest income, based on the specific identification method. Available-for-sale securities are also adjusted for amortization of premiums and accretion of discounts to maturity, with such amortization and accretion included within interest income. Available-for-sale securities with a remaining maturity date greater than one year are classified as non-current assets.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(d)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intellectual property:</span></div></div><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The costs incurred in establishing and maintaining patents for intellectual property developed internally are expensed in the period incurred.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(e)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property, plant and equipment: </span></div></div><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property, plant and equipment are stated at cost less accumulated depreciation and/or accumulated impairment losses, if any. Repairs and maintenance costs, which do not improve or extend the life of the respective asset, are expensed in the period incurred. Upon retirement or sale, the cost of the disposed asset and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is recognized as a component of income or loss for the period.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property, plant and equipment are amortized over their estimated useful lives using the straight-line method based on the following rates:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:49.12%;box-sizing:content-box;"></td>
          <td style="width:1.78%;box-sizing:content-box;"></td>
          <td style="width:49.1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Asset</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Rate</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research equipment</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Office furniture and equipment</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer equipment</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_47b3f612-5e00-48af-b88b-1d3d02b7448e;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Over the lesser of lease term or<br/>   estimated useful life</span></span></span></p></td>
         </tr>
        </table></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(f)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Impairment of long-lived assets: </span></div></div></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company monitors its long-lived assets for indicators of impairment. If such indicators are present, the Company assesses the recoverability of affected assets by determining whether the carrying value of such assets is less than the sum of the undiscounted future cash flows of the assets. If such assets are found not to be recoverable, the Company measures the amount of such impairment by comparing the carrying value of the assets to the fair value of the assets, with the fair value generally determined based on the present value of the expected future cash flows associated with the assets. The Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t recognize any impairment charges through </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></div><p style="margin-left:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(g)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Leases:</span></div></div><p style="margin-left:9.2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company determines if an arrangement contains a lease at the inception of a contract. The lease classification is determined at lease commencement, which is the date the underlying asset is available for use by the Company. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Leases classified as operating leases are recorded as lease liabilities based on the present value of minimum lease payments over the lease term, discounted using the lessor&#8217;s rate implicit in the lease or the Company&#8217;s incremental borrowing rate, if the lessor&#8217;s implicit rate is not readily determinable. The lease term includes all periods covered by renewal and termination options where the Company is reasonably certain to exercise the renewal options or not to exercise the termination options. Corresponding right-of-use assets are recognized consisting of the lease liabilities, initial direct costs and any lease incentive payments. Lease liabilities are drawn down as lease payments are made and right-of-use assets are depreciated over the term of the lease. Operating lease expenses are recognized on a straight-line basis over the term of the lease, consisting of interest accrued on the lease liability and depreciation of the right-of-use asset, adjusted for changes in index-based variable lease payments in the period of change. Lease payments on short-term operating leases with lease terms twelve months or less are expensed on a straight-line basis over the lease term. The Company has elected to not separate non-lease elements embedded in its lease agreements.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(h)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Concentration of credit risk: </span></div></div><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents and marketable securities. The Company's investments are limited to investment-grade securities with strong credit ratings with the objective to preserve capital and maintain liquidity. Cash and cash equivalents were held at major financial institutions in Canada and the United States which may at times be in excess of federally insured limits. The Company does not believe that it is subject to credit risk beyond the standard credit risk associated with commercial banking relationships.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(i)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial instruments and fair value: </span></div></div><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company measures certain financial instruments and other items at fair value.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To determine the fair value, the Company uses the fair value hierarchy for inputs used to measure fair value of financial assets and liabilities. This hierarchy prioritizes the inputs to valuation techniques used to measure fair value into three levels: Level 1 (highest priority), Level 2, and Level 3 (lowest priority).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Level 1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> - Unadjusted quoted prices in active markets for identical instruments.</span></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Level 2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates, yield curves, etc.), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs). </span></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Level 3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> - Inputs are unobservable and reflect the Company&#8217;s assumptions as to what market participants would use in pricing the asset or liability. The Company develops these inputs based on the best information available. </span></div></div><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. Changes in the observability of valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy. The carrying amount of accounts receivable, accounts payable and accrued liabilities approximates fair value due to the nature and short-term of those instruments. The Company&#8217;s cash and cash equivalents and marketable securities are measured at fair value on a recurring basis and the level of fair value hierarchy utilized is described in note 4.</span></p></div><div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(j)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue recognition: </span></div></div><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognizes the amount of revenue to which it expects to be entitled, for the transfer of promised goods or  services to customers under a five-step model: (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when or as a performance obligation is satisfied. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer.</span></p><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Collaboration agreements may require the Company to deliver various rights and/or services, including intellectual property rights or licenses and research and development services. Under such collaboration agreements, the Company is generally eligible to receive non-refundable upfront payments, funding for research and development services, milestone payments, and royalties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In contracts where the Company has more than one performance obligation to provide its customer with goods or services, each performance obligation is evaluated to determine whether it is distinct based on whether (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available and (ii) the good or service is separately identifiable from other promises in the contract. The consideration under the contract is then allocated between the distinct performance obligations based on their respective relative standalone selling prices. The estimated standalone selling price of each deliverable reflects the Company&#8217;s best estimate of what the selling price would be if the deliverable was regularly sold on a standalone basis and is determined by reference to market rates for the good or service when sold to others or by using an adjusted market assessment approach if selling price on a standalone basis is not available.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The consideration allocated to each distinct performance obligation is recognized as revenue when control is transferred to the customer for the related goods or services. The Company generally recognizes revenue from non-refundable upfront payments over the estimated term of the performance obligation or period in which the underlying benefit is transferred to the customer. If non-refundable license fees have value to the customer on a standalone basis, separate from the undelivered performance obligations, they are recognized upon delivery. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. Consideration in exchange for research and development services performed by the Company on behalf of the licensee is recognized upon performance of such activities at rates consistent with prevailing market rates. Consideration associated with at-risk substantive performance milestones, including sales-based milestones, is recognized as revenue using the most likely amount method when it is probable that a significant reversal of the cumulative revenue recognized will not occur. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such milestones, and if necessary, adjusts its estimate of the overall transaction price. Sales-based royalties received in connection with licenses of intellectual property are subject to a specific exception in the revenue standards, whereby the consideration is not included in the transaction price and recognized in revenue until the customer&#8217;s subsequent sales or usages occur.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(k)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development costs: </span></div></div><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development costs are expensed in the period incurred.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expenses consist of costs incurred in performing research and development activities, including personnel-related expenses, consisting of salaries, benefits and stock-based compensation for employees engaged in scientific research and development, third-party expenses incurred in connection with the pre-clinical and clinical development of product candidates including under agreements with clinical research organizations, third-party expenses relating to formulation, process development and  manufacture of drug substance and drug product for use in pre-clinical testing, clinical trials and potential commercial supply, third-party acquisition, license and collaboration fees, laboratory consumables and certain indirect costs incurred in support of overall research and development activities, including facilities, depreciation and information technology costs. The amount of expenses recognized in a period related to service agreements is based on the work performed using the accrual basis of accounting. Third-party service providers generally provide estimates of proportionate performance to allow the Company to determine an appropriate accrual. When determining the adequacy of an accrual, the Company analyzes progress based on the level of services performed, progress of the studies, including the phase or completion of events, and contracted costs. Payments made to third parties under these arrangements in advance of the receipt of the related services are recorded as prepaid expenses until the services are rendered. </span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prepaid expenses are classified as current or non-current assets based on the expected timing of services.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(l)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-based compensation: </span></div></div><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-based compensation expense is measured at the grant date, based on the estimated fair value of the award, and is recognized as an expense, net of actual forfeitures, over the requisite service period with a corresponding increase in additional paid-in capital.</span></p><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company grants stock options to employees, consultants, directors and officers pursuant to equity incentive plans described in note 9c. Stock-based compensation expense for stock options is amortized on a straight-line basis over the requisite service period for the entire award, which is generally the vesting period of the award. Any consideration received on exercise of stock options is credited to share capital.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company grants performance share units (&#8220;PSUs&#8221;) to certain employees and officers pursuant to equity incentive plans described in note 9c. PSUs vest upon the achievement of certain predefined company-specific performance-based criteria. PSUs are measured at the c</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">losing market price of the Company&#8217;s common shares on the date of grant. Stock-based compensation expense for PSUs is amortized on a straight-line basis over the requisite service period of each separately vesting tranche of the award once it is probable that the performance condition will be achieved.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(m)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Foreign currency translation: </span></div></div><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The functional and reporting currency of the Company and its subsidiary is the U.S. dollar. Monetary assets and liabilities denominated in a currency other than the U.S. dollar are re-measured into U.S. dollars at the exchange rate prevailing as of the balance sheet date. Non-monetary assets and liabilities acquired in a currency other than U.S. dollars are translated at historical exchange rates prevailing at each transaction date.</span></p><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue and expense transactions ar</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">e translated at the approximate exchange rate prevailing on the date of transaction. Exchange gains and losses on translation are included in the consolidated statements of operations and comprehensive income (loss) as foreign exchange gain (loss).</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(n)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Income taxes: </span></div></div><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deferred income taxes are recognized for the future tax consequences attributable to differences between the carrying amounts of assets and liabilities and their respective tax bases, net operating loss and tax credit carryforwards. Deferred income tax assets and liabilities are measured at enacted rates expected to apply to taxable income in the years in which those temporary differences and carryforwards are expected to be recovered or settled. The effect of a change in tax rates on deferred income tax assets and liabilities is recognized in the consolidated statement of operations and comprehensive income (loss) in the period that includes the enactment date. A valuation allowance is provided when realization of deferred income tax assets does not meet the more-likely-than-not criterion for recognition.</span></p><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not to be sustained upon examination based on the technical merits of the position as well as consideration of the available facts and circumstances. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The interest accrued related to unrecognized tax benefits and penalties is recognized as income tax expense.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(o)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net income (loss) per common share: </span></div></div><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic net income (loss) per common share is calculated using the two-class method required for participating securities. Undistributed earnings (losses) are allocated to common shares and participating securities based on the weighted average shares of each class outstanding during the period.</span></p><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The treasury stock method is used to compute the dilutive effect of the Company&#8217;s stock options, PSUs and warrants. Under this method, the incremental number of common shares used in computing diluted net income (loss) per common share is the difference between the number of common shares assumed issued and purchased using assumed proceeds.</span></p><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The if-converted method is used to compute the dilutive effect of the Company&#8217;s convertible preferred shares. Under the if-converted method, dividends on the preferred shares, if applicable, are added back to earnings attributable to common shareholders, and the preferred shares and paid-in kind dividends are assumed to have been converted at the share price applicable at the end of the period. The if-converted method is applied only if the effect is dilutive.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(p)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Segment and geographic information: </span></div></div><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker (&#8220;CODM&#8221;), in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> operating segment discovering and developing a portfolio of treatments in neurological and psychiatric disorders.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(q)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recently adopted accounting pronouncements:</span></div></div><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which enhances the disclosures required for operating segments on an interim and annual basis. The Company adopted this ASU in the fourth quarter of 2024 retrospectively to all prior periods presented in the consolidated financial statements. While the Company continues to operate as a single reportable segment, additional disclosures have been incorporated in note 14.</span></p><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(r)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accounting pronouncements not yet adopted: </span></div></div><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accounting standards that have been issued by the Financial Accounting Standards Board or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on our financial statements upon adoption.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45905591301536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fair value of financial instruments:</span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The level of the fair value hierarchy utilized to determine the fair va</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">lue of cash and cash equivalents and marketable securities consisted of the following:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:25.615%;box-sizing:content-box;"></td>
        <td style="width:1.3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:5.9990000000000006%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:5.9990000000000006%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:5.9990000000000006%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:5.9990000000000006%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:5.9990000000000006%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:5.9990000000000006%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:5.9990000000000006%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:5.9990000000000006%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and money market fund</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">142,712</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">142,712</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">148,643</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">148,643</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Guaranteed investment certificates</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,147</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,147</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,684</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,684</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. treasuries</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">130,948</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">130,948</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">252,982</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">252,982</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">97,912</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">97,912</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">66,905</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">66,905</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">119,108</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">119,108</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">397,689</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">397,689</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">304,545</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">304,545</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">289,807</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">464,594</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">754,401</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">409,309</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">521,565</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">930,874</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair values of the Company&#8217;s U.S. government securities, commercial paper and corporate debt securities are based on prices obtained from independent pricing sources. Securities with validated quotes from pricing services are reflected within Level 2, as they are primarily based on observable pricing for similar assets or other market observable inputs. Typical inputs used by these pricing services include, but are not limited to, reported trades, benchmark yields, issuer spreads, bids, offers or estimates of cash flow, prepayment spreads and default rates.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024 and December 31, 2023, the Company does not hold any securities classified as Level 3 and there were no securities transferred between Level 1 and 2.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45905590622800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Marketable Securities</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Marketable securities:</span></div></div><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company had $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">611,689</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of available-for-sale securities (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#8211; trading securities of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,867</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and available-for-sale-securities of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">768,364</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively). </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amortized cost, unrealized gain (loss) recognized in accumulated other comprehensive loss and fair value of available-for-sale securities consisted of the following:</span></span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:34%;box-sizing:content-box;"></td>
        <td style="width:1.681%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:8.087%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.681%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:7.907%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.681%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:8.087%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.681%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:7.045999999999999%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:6.906000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.681%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:6.566%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized <br/>Cost</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized Gain (Loss)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair <br/>Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized <br/>Cost</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized <br/>Gain (Loss)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair <br/>Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Contractual maturity of 0 to 1 years:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Guaranteed investment certificates</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,122</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">975</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,147</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,549</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">135</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,684</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. treasuries</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">72,989</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">147</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">73,136</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">192,193</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">249</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">191,944</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98,092</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">180</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">97,912</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">66,808</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">97</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">66,905</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">119,041</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">67</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">119,108</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">327,448</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">557</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">328,005</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">58,824</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">58,924</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Contractual maturity of 1 to 3 years:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. treasuries</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">58,218</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">406</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57,812</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53,294</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">243</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53,537</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">69,726</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">69,684</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">238,458</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">797</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">239,255</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">612,311</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">622</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">611,689</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">767,451</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">913</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">768,364</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Allowance for credit losses or impairment on these marketable securities have not been recognized as these securities are high credit quality, investment grade securities that the Company does not intend to sell and will not be required to sell prior to their anticipated recovery, and the decline in fair value is primarily due to changes in interest rates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 940<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/940-320/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph b<br> -Publisher SEC<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/320/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/942-320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45905692880320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">6.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property, plant and equipment:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property, plant and equipment consisted of the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:68.32%;box-sizing:content-box;"></td>
        <td style="width:1.52%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.08%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.08%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="5" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,631</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,111</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Office furniture and equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,285</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,285</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,463</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,489</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,363</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,019</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: accumulated depreciation and amortization</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,464</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,251</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net book value</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,278</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,653</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45905692876656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">7.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Leases:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></div></div><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_a0537c61-71b0-4915-978f-b5bbcfc84362;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">an</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> operating lease for research laboratories and office space in Burnaby, British Columbia which expires on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 30, 2032</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">two</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> renewal options for </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-years each which were not considered in the determination of the right-of-use asset and lease liability.</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Company has an additional operating lease for office space in Needham, Massachusetts (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8220;Needham Lease&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">), which commenced in October 2022. The Needham Lease is for a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">62-month</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> term and an </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">option to terminate one year prior to the expiry date</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which was not considered in the determination of the right-of-use asset and lease liability.</span></span></span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The cost components of the operating leases were as follows for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024, 2023 and 2022:</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:59.416%;box-sizing:content-box;"></td>
        <td style="width:1.321%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.088%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.088%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.088%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="8" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease cost</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease expense</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,646</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,645</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,126</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Variable lease expense</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">826</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">787</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">774</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease term and discount rate</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average remaining lease term (years)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.4</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.3</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.1</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average discount rate</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.8</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.9</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><div class="item-list-element-wrapper" style="margin-left:11.204%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:justify;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;font-kerning:none;min-width:3.0035136717870174%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Variable lease costs are payments that vary because of changes in facts or circumstances and include common area maintenance and property taxes related to the premises. Variable lease costs are excluded from the calculation of minimum lease payments. </span></div></div></div><p style="margin-left:5.693%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</span><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Future minimum lease payments as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 were as follows:</span></span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:5.733%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.444%;box-sizing:content-box;"></td>
        <td style="width:1.8%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.757%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Year ending December 31:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,690</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,755</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,739</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,037</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2029</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,085</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2030 and thereafter</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,861</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total future minimum lease payments</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,167</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: imputed interest</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,152</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Present value of lease liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,015</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45905591328864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accounts Payable and Accrued Liabilities</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">8.</span><div id="report_of_independent" style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accounts payable a</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">nd accrued liabilities:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accounts payable and accrued liabilities consisted of the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:68.32%;box-sizing:content-box;"></td>
        <td style="width:1.52%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.08%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.08%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="5" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts payable</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,070</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,598</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued liabilities</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Employee compensation, benefits, and related accruals</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,928</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,425</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,061</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,824</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Income and other taxes</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,686</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">347</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Professional fees</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">762</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">780</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">714</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">34,221</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,974</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45905590614736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Share Capital</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">9.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Share capital:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financing:</span></div></div><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">August 2020, the Company entered into an &#8220;at-the-market&#8221; equity offering sales agreement, amended as of March 2022, with Jefferies LLC and Stifel, Nicolaus &amp; Company, Incorporated pursuant to which the Company may sell common shares from time to time (the &#8220;ATM Program&#8221;). In September 2023, pursuant to a prospectus supplement filed in March 2022 (&#8220;March 2022 Prospectus&#8221;), the Company sold an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">855,685</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> common shares for proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,508</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, net of commissions and transaction expenses. In August 2024, a new prospectus supplement was filed replacing the March 2022 Prospectus, pursuant to which the Company refreshed the ATM Program and may sell common shares having gross proceeds of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">350,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, from time to time. As of December 31, 2024, the Company has sold an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">310,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> common shares for proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,083</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, net of commissions and transaction expenses under the ATM Program.</span></p><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In January 2022, in connection with the License and Collaboration Agreement with Neurocrine Biosciences entered in December 2019 and amended in January 2021 (the &#8220;Neurocrine Collaboration Agreement&#8221;), the Company executed a Share Purchase Agreement (&#8220;SPA&#8221;) pursuant to which the Company issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">258,986</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> common shares for an aggregate purchase price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,250</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, or $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31.855</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per common share, which represents a premium of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">374</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> when compared to the fair value of common shares on the date of issuance. The SPA contain certain other customary terms and conditions, including mutual representations, warranties and covenants. For additional information regarding the Neurocrine Collaboration Agreement, refer to </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">note 10.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In June 2022, the Company completed an underwritten public offering of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,098,362</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> common shares, including </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,229,508</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares sold upon the full exercise of the underwriters&#8217; over-allotment option, at a public offering price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30.50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per common share and pre-funded warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">327,868</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> common shares at $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30.4999</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per pre-funded warrant (note 9e), with each pre-funded warrant having an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The public offering was completed in June 2022, and the Company received proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">269,890</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, net of underwriting discounts, commissions and offering expenses.</span></p><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2023, the Company completed</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> an underwritten public offering of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,846,157</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> common shares, including </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,384,615</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares sold upon the full exercise of the underwriters' over-allotment option, at a public offering price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32.50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per common share and pre-funded warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">769,230</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> common shares at $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32.4999</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per pre-funded warrant (note 9e), with each pre-funded warrant having an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The public offering was completed in December 2023, and the Company received proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">323,979</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, net of underwriting discounts, commissions and offering expenses.</span></p><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Authorized share capital:</span></div></div><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s authorized share capital consists of an unlimited number of common and preferred shares without par value.</span></p><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(c)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-based compensation:</span></div></div><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has two equity incentive plans: (i) the 2014 Equity Incentive Plan which was amended and restated in June 2020, June 2022 and June 2024 (the &#8220;Amended and Restated 2014 Plan&#8221;), and (ii) the 2019 Inducement Equity Incentive Plan (the &#8220;2019 Inducement Plan&#8221;).</span></p><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2019, the board of directors of the Company adopted the 2019 Inducement Plan and, subject to the adjustment provisions of the 2019 Inducement Plan, reserved </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">400,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Company&#8217;s common shares for issuance pursuant to equity awards granted under the 2019 Inducement Plan. The 2019 Inducement Plan was adopted without shareholder approval in accordance with the applicable Nasdaq Listing Rules. The 2019 Inducement Plan provided for the grant of equity-based awards, including share options, share appreciation rights, restricted share awards, restricted share unit awards and performance share awards, and its terms are substantially similar to the Company&#8217;s Amended and Restated 2014 Plan, including with respect to treatment of equity awards in the event of a &#8220;merger&#8221; or &#8220;change of control&#8221; as defined under the 2019 Inducement Plan, but with such other terms and conditions intended to comply with the Nasdaq inducement award exception or to comply with the Nasdaq acquisition and merger exception. The 2019 Inducement Plan was terminated in June 2020. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> further options will be granted under the 2019 Inducement Plan, and the 2019 Inducement Plan will continue to govern the options granted thereunder.</span></p><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The shareholders of the Company approved the Amended and Restated 2014 Plan amended in June 2020, June 2022 and June 2024, amending certain provisions of the Company&#8217;s 2014 Plan. The Amended and Restated 2014 Plan permits the grant of stock-based compensation awards to directors, officers, employees and consultants of the Company and the issuance of restricted shares, restricted share units, share appreciation rights and PSUs. Under the Amended and Restated 2014 Plan, options granted generally vest on a graduated basis over a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">four-year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> periods. The exercise price of the options is determined by the board of directors but must at least be equal to the fair market value of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> the common shares on the date of grant. Options may be exercised over a maximum term of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ten years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The vesting conditions, vesting period and expiry terms of the PSUs are determined by the board of directors. As of December 31, 2024, a total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,882,842</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> common shares remain available for issuance pursuant to the Amended and Restated 2014 Plan. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Of this total, the number of common shares that can be issued through restricted share awards, restricted share unit awards, or performance share awards is limited to the aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> common shares.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents the components and classification of stock-based compensation expense for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024, 2023 and 2022:</span></p><p style="margin-left:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.089%;box-sizing:content-box;"></td>
        <td style="width:1.28%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.598%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.28%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.598%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.28%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.598%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.28%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation expense by award type:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">48,384</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32,372</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,376</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">PSUs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,333</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50,717</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32,372</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,376</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation expense in operating expenses:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,088</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,067</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,766</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28,629</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,305</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,610</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50,717</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32,372</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,376</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="margin-left:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock options</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents the summary of stock option activity for the period:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:43%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.96%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.96%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:16.08%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted<br/>Average<br/>Exercise</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Options</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Price ($)</span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Intrinsic</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding, December 31, 2021</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,638,232</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.55</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">105,405</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,315,645</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30.90</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">780,725</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.47</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,651</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited, cancelled or expired</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">55,370</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24.50</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding, December 31, 2022</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,117,782</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18.75</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">147,214</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,542,473</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35.29</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">587,536</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13.58</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,526</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited, cancelled or expired</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">178,217</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31.49</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding, December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,894,502</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23.56</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">200,122</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,062,819</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42.93</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,040,136</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.43</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,416</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited, cancelled or expired</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">207,896</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38.18</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding, December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,709,289</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29.90</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">111,202</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercisable, December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,927,638</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22.30</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100,214</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div class="item-list-element-wrapper" style="margin-left:11.204%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:justify;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;font-kerning:none;min-width:3.0035136717870174%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2024, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,144</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#8211; </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,320</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and 2022 &#8211; </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">68,930</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) stock options were exercised for the same number of common shares in exchange for cash. In the same period, the Company issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">729,965</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(2023 &#8211; </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">377,114</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and 2022 &#8211; </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">510,671</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) common shares for the cashless exercise of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,034,992</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(2023 &#8211; </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">583,216</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and 2022 &#8211; </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">711,795</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) stock options.</span></div></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, stock options outstanding and exercisable had a weighted average remaining contractual life of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7.28</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years and </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6.21 </span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">years, respectively.</span></p><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value of stock options at the date of grant is estimated using the Black-Scholes option-pricing model which requires multiple subjective inputs. The risk-free interest rate of the options is based on the U.S. Treasury yield curve in effect at the date of grant for a term similar to the expected term of the option. The expected volatility is based on the historical volatility of the Company&#8217;s common shares calculated based on a period of time commensurate with the expected term assumption. Expected life assumptions are based on the Company&#8217;s historical data. The dividend yield is based on the fact that the Company has never paid cash dividends and has no present intention to pay cash dividends. Forfeitures are recognized as they occur.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The weighted average option pricing assumptions are as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.123%;box-sizing:content-box;"></td>
        <td style="width:1.281%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.584999999999999%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.281%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.584999999999999%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.281%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.584999999999999%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.281%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Average risk-free interest rate</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.05</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.93</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.39</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">66</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">69</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">70</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Average expected term (in years)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.75</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.94</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.16</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.00</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.00</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.00</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average fair value of stock options granted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26.48</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22.52</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19.78</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="margin-left:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="margin-left:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A summary of the Company&#8217;s unvested stock option activity and related information for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 is as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:48.16%;box-sizing:content-box;"></td>
        <td style="width:1.02%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:22.9%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.02%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:22.9%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of<br/>Options</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted Average <br/>Grant Date<br/>Fair Value ($)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unvested, January 1, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,105,324</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20.53</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,062,819</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26.48</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,178,816</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19.91</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited or cancelled</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">207,676</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22.04</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unvested, December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,781,651</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24.56</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="margin-left:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The aggregate fair value of options vested during the year ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43,375</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#8211; $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,233</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and 2022 &#8211; $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,752</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">).</span></p><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the unrecognized stock-based compensation expense related to the unvested stock options was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99,779</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> which is expected to be recognized over a weighted average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.64</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Performance share units	</span></p><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company granted </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">210,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> PSUs to officers and certain employees with a weighted average grant date fair value</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43.90</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per unit. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PSUs vest upon the achievement of certain predefined company-specific performance-based criteria on or before December 31, 2027, subject to continued employment to each performance objective achievement date. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> PSUs vested during the year ended December 31, 2024.</span></p><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the unrecognized stock-based compensation expense related to the unvested PSUs that is probable to be achieved was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,267</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The recognition of this expense is subject to the achievement of the performance-based criteria, which are reassessed at each reporting date. There is $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,609</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of unrecognized stock-based compensation expense related to the PSUs that is not probable to be achieved.</span></p><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(d)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exchange agreement with certain funds affiliated with BVF Partners L.P. (collectively, &#8220;BVF&#8221;):</span></div></div><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2018, the Company and BVF entered into an exchange agreement pursuant to which the Company issued to BVF </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,868,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Series 1 Preferred Shares in exchange for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,868,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> common shares which were subsequently cancelled by the Company. The Series 1 Preferred Shares were convertible into common shares on a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">one-for-one</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> basis, subject to certain restrictions.</span></p><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Series 1 Preferred Shares ranked equally to the common shares in the event of liquidation, dissolution or winding up or other distribution of the assets of the Company among its shareholders and the holders of the Series 1 Preferred Shares were entitled to vote together with the common shares on an as-converted basis and as a single class, subject to certain restrictions.</span></p><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Series 1 Preferred Shares were recorded wholly as equity under ASC 480, with no bifurcation of conversion feature from the host contract, given that the Series 1 Preferred Shares cannot be cash settled and have no redemption features.</span></p><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2018, BVF converted </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,852,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Series 1 Preferred Shares in exchange for an equal number of common shares. In March 2022, the remaining outstanding </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,016,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Series 1 Preferred Shares were exchanged for an equal number of common shares.</span></p><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(e)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pre-funded warrants:</span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:8.787%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the pre-funded warrants activity for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024, 2023, and 2022:</span></p><p style="margin-left:8.8%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.975%;box-sizing:content-box;"></td>
        <td style="width:1.25%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:30.775%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of Pre-funded</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">warrants outstanding</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding, December 31, 2021</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,775,996</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issued</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">327,868</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding, December 31, 2022</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,103,864</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issued</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">769,230</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,700,013</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding, December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,173,081</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issued</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding, December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,173,081</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><div class="item-list-element-wrapper" style="margin-left:9.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:justify;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;font-kerning:none;min-width:2.9590591368023964%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2023, the Company issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,700,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> common shares upon the exercise of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,700,013</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> pre-funded warrants pursuant to a net exercise mechanism under the warrants.</span></div></div></div><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each pre-funded warrant is exercisable for the purchase of a common share at the holder's discretion at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, subject to certain post-exercise beneficial ownership limitations as provided under the terms of the pre-funded warrant.</span></p><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company may not affect the exercise of any pre-funded warrant, and a holder will not be entitled to exercise any portion of any pre-funded warrant that, upon giving effect to such exercise, would cause: (i) the aggregate number of common shares beneficially owned by such holder, together with its affiliates, to exceed 4.99% of the total number of common shares outstanding immediately after giving effect to the exercise; or (ii) the combined voting power of the Company&#8217;s securities beneficially owned by such holder, together with its affiliates, to exceed 4.99% of the combined voting power of all of the Company&#8217;s securities immediately outstanding after giving effect to the exercise, which percentage may be changed at the holder&#8217;s election to a higher or lower percentage not in excess of 19.99% upon at least 61 days&#8217; notice to the Company.</span></span></p><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since the pre-funded warrants meet the condition for equity classification, proceeds from issuances of the pre-funded warrants for the year ended December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,477</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (2022 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8211; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,387</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">), net of underwriting discounts, commissions and offering expenses, are recorded in additional paid-in capital. Upon exercise of the pre-funded warrants, the historical costs recorded in additional paid-in capital along with the exercise price collected from the holder are recorded in common shares. Pre-funded warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,173,081</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2023 &#8211; </span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;">2,173,081</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and 2022 &#8211;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,103,864</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) common shares </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">are not included in the number of issued and outstanding common shares as of December 31, 2024.</span></p><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(f)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Warrant: </span></div></div><p style="margin-left:8.787%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In August 2018, a warrant to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2023 &#8211; </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) common shares at a price per common share of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.79</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was issued. The warrant is immediately exercisable, contains a cashless exercise provision and expires in August 2028.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45905693012784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaboration Agreements</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">10.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Collaboration agreements:</span></div></div><p style="margin-left:4.533%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Neurocrine Biosciences license and collaboration agreement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue was as follows for the years ended December 31, 2024, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2023 and 2022:</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.449%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.518%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.518%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.518%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="8" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Recognition of the transaction price</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">372</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development services</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,938</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Milestone payments</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,124</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Total revenue</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,434</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2019, the Company entered into the Neurocrine Collaboration Agreement with Neurocrine Biosciences granting the Company an exclusive license to NBI-921352 (formerly XEN901) and certain pre-clinical compounds for development (the &#8220;DTCs&#8221;). The agreement also includes a two-year research collaboration to discover, identify and develop additional novel Nav1.6 and Nav1.2/1.6 inhibitors (&#8220;Research Compounds&#8221;). The Company and Neurocrine Biosciences collaborated on the conduct of two collaboration programs: (a) a joint research collaboration to discover, identify and preclinically develop Research Compounds (the &#8220;Research Program&#8221;), which was completed in June 2022, and (b) a collaborative development program for NBI-921352 and two DTCs selected by the joint steering committee. Under the arrangement, the Company was entitled to funding for certain full-time equivalent and external costs incurred by the Company for the research and development services requested by Neurocrine Biosciences, and these services were priced at estimated fair value.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is eligible to receive pre-commercial and commercial milestone payments with respect to the licensed products totaling up to an additional $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,667,500</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, comprised of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,067,500</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in additional development and regulatory milestone payments related to NBI-921352 and other licensed Nav1.6 or Nav1.2/1.6 inhibitor products, and up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">600,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in additional sales-based milestone payments for multiple products. In addition, the Company is eligible to receive royalties on net sales in and outside the U.S., ranging from (a) for NBI-921352, a low double-digit percentage to a mid-teen percentage and a high-single digit percentage to low double-digit percentage, respectively; (b) for DTCs, a high-single digit percentage to a low double-digit percentage and a mid-single digit percentage to a high-single digit percentage, respectively; and (c) for Research Compounds, a mid-single digit percentage to a high-single digit percentage and a tiered mid-single digit percentage, respectively. Royalty rates are subject to customary reductions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has an option to co-fund </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the development costs of NBI-921352 or another product candidate in the U.S., exercisable upon achievement of certain milestones, in exchange for increased U.S. royalties. The Company has not exercised this option as of December 31, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In January 2022, based on the receipt of the U.S. Food and Drug Administration&#8217;s (&#8220;FDA&#8221;) full IND acceptance for NBI-921352, the Company received an aggregate milestone payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in the form of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,750</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in cash and a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,250</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> equity investment in the Company (note 9a). The equity investment was measured at fair value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,876</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> on the date of issuance and the resulting premium of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">374</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, with the cash payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,750</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, was recognized as revenue in the period as the Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t have any remaining performance obligations in relation to this milestone on the date it was achieved.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In February 2025, NBI-921355, a Nav1.2 and Nav1.6 sodium channel inhibitor in development for the potential treatment for certain types of epilepsy, has progressed into a Phase 1 clinical study in healthy adult participants, triggering an anticipated $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,500</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> milestone payment to the Company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45905704901088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Common Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Common Share</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">11.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net loss per common share</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">:</span></div></div><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents the calculation of basic and diluted net loss per common share for the years ended December 31, 2024, 2023 and 2022:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:46.109%;box-sizing:content-box;"></td>
        <td style="width:1.64%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:14.323%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.64%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:14.323%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.64%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:14.323%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Numerator:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">234,330</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">182,393</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">125,373</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss attributable to preferred shareholders</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">437</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss attributable to common shareholders</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">234,330</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">182,393</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">124,936</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Denominator:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common shares (weighted average)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75,721,562</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">64,739,678</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57,599,510</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Pre-funded warrants (weighted average)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,173,081</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,149,327</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,942,632</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average common shares <br/>&#160;&#160;&#160;outstanding &#8211; basic and diluted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">77,894,643</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">66,889,005</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">60,542,142</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per common share &#8211; basic and diluted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.01</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.73</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.06</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></div><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The weighted average number of common shares used in the basic and diluted net loss per common share calculations includes the weighted average pre-funded warrants outstanding during the period as they are exercisable at any time for nominal cash consideration (note 9e).</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company reported net losses for each of the years ended December 31, 2024, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and 2022, and therefore excluded all potentially dilutive outstanding securities from the computation of diluted net loss per common share as their inclusion would have had an anti-dilutive effect.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45905591307248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">12.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commitments and contingencies:</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Asset purchase agreement with 1st Order Pharmaceuticals, Inc. (&#8220;1st Order&#8221;):</span></div></div><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In April 2017, the Company acquired azetukalner from 1st Order pursuant to an asset purchase agreement. In August 2020, the Company and 1st Order amended the asset purchase agreement to amend certain definitions in the agreement and to modify the payment schedule for certain milestones. Through December 31, 2024, the Company has paid $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> based on progress against these milestones. Future potential payments to 1st Order include up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in regulatory milestones. There are </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> royalty obligations to 1st Order.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">   </span></p><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Guarantees and indemnifications:</span></div></div><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has entered into license and research agreements with third parties that include indemnification provisions that are customary in the industry. These indemnification provisions generally require the Company to compensate the other party for certain damages and costs incurred as a result of third-party claims or damages arising from these transactions.</span></p><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The maximum amount of potential future indemnification is unlimited; however, the Company currently holds commercial and product liability insurance. This insurance limits the Company&#8217;s exposure and may enable it to recover a portion of any future amounts paid. Historically, the Company has not made any indemnification payments under such agreements and the Company believes that the fair value of these indemnification obligations is minimal. Accordingly, the Company has not recognized any liabilities relating to these obligations for any period presented.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45905696798640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">13.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Income taxes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">:</span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Loss before income taxes for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024, 2023 and 2022 was as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.863%;box-sizing:content-box;"></td>
        <td style="width:1.281%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.764000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.281%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.764000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.281%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.764000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Canada</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">243,410</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">174,491</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">121,335</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">United States</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,991</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,194</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,920</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss before income taxes</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">238,419</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">182,685</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">125,255</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The income tax recovery (expense) is allocated as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.863%;box-sizing:content-box;"></td>
        <td style="width:1.281%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.764000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.281%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.764000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.281%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.764000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;Canada</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;United States</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,775</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">162</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,775</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">162</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;Canada</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;United States</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,864</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">292</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,864</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">292</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Income tax recovery (expense)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,089</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">292</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">118</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></div><p style="margin-left:4.533%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s wholly-owned subsidiary, Xenon Pharmaceuticals USA Inc., generates taxable income due to an intercompany service agreement with the Company. All current tax expense and deferred income tax recovery recognized for the years ended December 31, 2024, 2023 and 2022 were attributable to the United States. For the year ended December 31, 2024, the deferred income tax recovery recorded by Xenon Pharmaceuticals USA Inc. is related to the re-assessment of the realizability of its deferred tax assets.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reconciliation of the expected Canadian statutory income tax rate to the effective income tax rate is as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.863%;box-sizing:content-box;"></td>
        <td style="width:1.281%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.764000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.281%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.764000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.281%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.764000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax at statutory income tax rate</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27.00</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27.00</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27.00</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24.5</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development and other credits</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.3</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.6</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.5</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax attributes expired/utilized</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.1</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.8</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.2</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.4</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.2</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.6</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other non-deductible expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.4</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.3</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.2</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.3</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.1</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Effective income tax rate</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.7</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.2</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="margin-left:4.533%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deferred income tax assets and liabilities result from the temporary differences between the carrying amount of assets and liabilities recognized for financial statement and income tax purposes. The significant components of the Company&#8217;s net deferred income tax assets are as follows:</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.313%;box-sizing:content-box;"></td>
        <td style="width:1.5%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.843%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.5%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.843%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred income tax assets:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development tax credits</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42,830</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38,590</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Investment tax credits</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,818</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,695</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-capital losses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">173,352</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">119,765</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciable assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,269</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,311</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred financing fees</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,967</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,831</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,380</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,832</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liability</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,299</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,779</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,704</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">852</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Total deferred income tax assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">278,619</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">217,655</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Deferred income tax liability:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Operating lease right-of-use asset</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,097</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,411</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Less - valuation allowance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">266,856</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">214,442</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net deferred income tax assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,666</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">802</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The realization of deferred income tax assets is dependent upon the generation of sufficient taxable income during future periods in which the temporary differences are expected to reverse. The valuation allowance is reviewed on a quarterly basis and if the assessment of the &#8220;more likely than not&#8221; criteria changes, the valuation allowance is adjusted accordingly. A full valuation allowance continues to be applied against deferred income tax assets in Canada as the Company has assessed that the realization of such assets does not meet the &#8220;more likely than not&#8221; criteria. Deferred income tax assets recorded on the consolidated balance sheets as of December 31, 2024 and 2023, result from the temporary differences between the amounts of assets and liabilities recognized for financial statement and income tax purposes, net of valuation allowance, related to the operations of Xenon Pharmaceuticals USA Inc.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company has unclaimed tax deductions for scientific research and experimental development expenditures of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">158,629</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#8211; $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">142,925</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) with no expiry.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company has $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,284</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#8211; $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,074</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) of investment tax credits available to offset federal taxes payable and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,518</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2023 &#8211; $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,099</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) of provincial tax credits available to offset provincial taxes payable in the future.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company has non-capital losses, net of uncertain tax positions, carried forward for tax purposes, which are available to reduce taxable income of future years of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">642,043</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#8211; $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">422,822</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">).</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The investment tax credits and loss carry forwards expire over various years to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_d1be6160-6c62-483e-bb44-87d26b17b9bb;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2045</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the total amount of the Company&#8217;s unrecognized tax benefits of uncertain tax positions were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,850</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#8211; $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,850</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">). </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If recognized in future periods, the unrecognized tax benefits would not affect the Company&#8217;s effective tax rate. The Company recognizes potential accrued interest and penalties related to unrecognized tax benefits within the income tax provision. Interest and penalties on the unrecognized tax benefits have not been accrued at December 31, 2024 and 2023 as none would be owing due to the availability of non-capital losses to shelter any potential taxable income arising thereon. The Company does not currently expect any significant increases or decreases to these unrecognized tax benefits within 12 months of the reporting date.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company files income tax returns in Canada and the United States, the jurisdictions in which the Company believes that it is subject to tax. In jurisdictions in which the Company does not believe it is subject to tax and therefore does not file income tax returns, the Company can provide no certainty that tax authorities in those jurisdictions will not subject one or more tax years (since the inception of the Company) to examination. Further, while the statute of limitations in each jurisdiction where an income tax return has been filed generally limits the examination period, as a result of loss carry-forwards, the limitation period for examination generally does not expire until several years after the loss carry-forwards are utilized. Other than routine audits by tax authorities for tax credits and tax refunds that the Company claims, the Company is not aware of any other material income tax examination currently in progress by any taxing jurisdiction. Tax years ranging from </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_1acbb9ae-6eb8-45fa-9c42-da9b98b84dfc;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2004</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to 2023 remain subject to examinations in Canada and the United States.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45905693000656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">14.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Segment disclosure:</span></div></div><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company operates as a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_a4a2478d-a313-4066-8e4d-8e8806c474dd;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">single</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> reportable segment dedicated to discovering, developing, and delivering life-changing ion channel therapeutics for patients in need. The Company has no products approved for sale and has not generated any revenue from product sales.</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Company&#8217;s </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_d1e546bf-38de-44e9-b552-f72e3c4a430a;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Chief Executive Officer</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> acts as the CODM and manages the Company&#8217;s operations on a consolidated basis. The accounting policies of the segment are the same as those described in the summary of significant accounting policies.</span></span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The CODM</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">evaluates the Company&#8217;s performance and allocates resources to the operations of the Company on a total company basis. Managing and allocating resources on a consolidated basis enables the CEO to assess the overall level of resources available and how to best deploy these resources across functions, therapeutic areas and research and development projects that are in line with the Company&#8217;s long-term company-wide strategic goals. The CODM uses net loss to monitor budget versus actual results and to analyze cash flows in assessing performance of the segment and allocating resources. The measure of segment assets is reported on the consolidated balance sheet as total consolidated assets, with a majority of these assets located in the United States.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents information about reported segment revenues, significant segment expenses, and segment loss:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:46.279%;box-sizing:content-box;"></td>
        <td style="width:1.641%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:14.266%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.641%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:14.266%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.641%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:14.266%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,434</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Direct external research and development costs</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Azetukalner</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">106,806</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">89,303</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37,367</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">XEN 496</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,152</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,765</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Pre-clinical, discovery and other programs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,546</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,552</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,711</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Personnel-related expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">68,340</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">47,739</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36,088</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50,717</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32,372</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,376</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other research and development costs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,232</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,560</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,274</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other general and administrative costs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,657</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,376</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,996</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest income</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41,943</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,620</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,713</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other segment items</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,025</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,041</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,943</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">234,330</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">182,393</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">125,373</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><div class="item-list-element-wrapper" style="margin-left:5.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4%;text-align:justify;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;font-kerning:none;min-width:4.2253372347280465%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other segment items include foreign exchange gain (loss), unrealized fair value gain (loss) on trading securities, and income tax recovery (expense).</span></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45905594927984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Use of estimates: </span></div></div><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant areas of estimates include, but are not limited to, revenue recognition including estimated timing of completion of performance obligations and the determination of stock-based compensation. These estimates and assumptions take into account historical and forward-looking factors that the Company believes are reasonable. Estimates and assumptions are reviewed quarterly. All revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and cash equivalents</a></td>
<td class="text"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash and cash equivalents: </span></div></div><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash equivalents are highly liquid investments that are readily convertible into cash with terms to maturity of three months or less when acquired. Cash equivalents are recorded at cost plus accrued interest, which approximates the fair value.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(c)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Marketable securities: </span></div></div><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Marketable securities are debt securities with original maturities exceeding three months and accrue interest based on a fixed interest rate for the term. Effective July 1, 2022, the Company classifies its marketable securities as either trading securities or available-for-sale securities. Marketable securities are carried at fair value.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fair value gains and losses for marketable securities classified as trading securities are recorded through the consolidated statement of operations. These securities are classified as current assets as the Company has the intent and ability to convert these securities into cash without penalty within the next 12 months.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unrealized fair value gains and losses for marketable securities classified as available-for-sale are recorded through other comprehensive income (loss) in shareholders' equity. When the fair value of an available-for-sale security falls below the amortized cost basis, it is evaluated to determine if any of the decline in value is attributable to credit loss. Decreases in fair value attributable to credit loss are recorded directly to the consolidated statement of operations with a corresponding allowance for credit losses, limited to the amount that the fair value is less than the amortized cost basis. If the credit quality subsequently improves the allowance is reversed up to a maximum of the previously recorded credit losses. When the Company intends to sell an impaired available-for-sale security, or if it is more likely than not that the Company will be required to sell the security prior to recovering the amortized cost basis, the entire fair value adjustment will immediately be recognized in the consolidated statement of operations with no corresponding allowance for credit losses. Realized gains and losses and credit losses, if any, on available-for-sale securities are included in interest income, based on the specific identification method. Available-for-sale securities are also adjusted for amortization of premiums and accretion of discounts to maturity, with such amortization and accretion included within interest income. Available-for-sale securities with a remaining maturity date greater than one year are classified as non-current assets.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalCostsPolicyTextBlock', window );">Intellectual property</a></td>
<td class="text"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(d)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intellectual property:</span></div></div><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The costs incurred in establishing and maintaining patents for intellectual property developed internally are expensed in the period incurred.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, plant and equipment</a></td>
<td class="text"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(e)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property, plant and equipment: </span></div></div><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property, plant and equipment are stated at cost less accumulated depreciation and/or accumulated impairment losses, if any. Repairs and maintenance costs, which do not improve or extend the life of the respective asset, are expensed in the period incurred. Upon retirement or sale, the cost of the disposed asset and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is recognized as a component of income or loss for the period.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property, plant and equipment are amortized over their estimated useful lives using the straight-line method based on the following rates:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:49.12%;box-sizing:content-box;"></td>
          <td style="width:1.78%;box-sizing:content-box;"></td>
          <td style="width:49.1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Asset</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Rate</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research equipment</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Office furniture and equipment</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer equipment</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_47b3f612-5e00-48af-b88b-1d3d02b7448e;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Over the lesser of lease term or<br/>   estimated useful life</span></span></span></p></td>
         </tr>
        </table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of long-lived assets</a></td>
<td class="text"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(f)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Impairment of long-lived assets: </span></div></div><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company monitors its long-lived assets for indicators of impairment. If such indicators are present, the Company assesses the recoverability of affected assets by determining whether the carrying value of such assets is less than the sum of the undiscounted future cash flows of the assets. If such assets are found not to be recoverable, the Company measures the amount of such impairment by comparing the carrying value of the assets to the fair value of the assets, with the fair value generally determined based on the present value of the expected future cash flows associated with the assets. The Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t recognize any impairment charges through </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(g)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Leases:</span></div></div><p style="margin-left:9.2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company determines if an arrangement contains a lease at the inception of a contract. The lease classification is determined at lease commencement, which is the date the underlying asset is available for use by the Company. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Leases classified as operating leases are recorded as lease liabilities based on the present value of minimum lease payments over the lease term, discounted using the lessor&#8217;s rate implicit in the lease or the Company&#8217;s incremental borrowing rate, if the lessor&#8217;s implicit rate is not readily determinable. The lease term includes all periods covered by renewal and termination options where the Company is reasonably certain to exercise the renewal options or not to exercise the termination options. Corresponding right-of-use assets are recognized consisting of the lease liabilities, initial direct costs and any lease incentive payments. Lease liabilities are drawn down as lease payments are made and right-of-use assets are depreciated over the term of the lease. Operating lease expenses are recognized on a straight-line basis over the term of the lease, consisting of interest accrued on the lease liability and depreciation of the right-of-use asset, adjusted for changes in index-based variable lease payments in the period of change. Lease payments on short-term operating leases with lease terms twelve months or less are expensed on a straight-line basis over the lease term. The Company has elected to not separate non-lease elements embedded in its lease agreements.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of credit risk:</a></td>
<td class="text"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(h)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Concentration of credit risk: </span></div></div><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents and marketable securities. The Company's investments are limited to investment-grade securities with strong credit ratings with the objective to preserve capital and maintain liquidity. Cash and cash equivalents were held at major financial institutions in Canada and the United States which may at times be in excess of federally insured limits. The Company does not believe that it is subject to credit risk beyond the standard credit risk associated with commercial banking relationships.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Financial instruments and fair value</a></td>
<td class="text"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(i)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial instruments and fair value: </span></div></div><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company measures certain financial instruments and other items at fair value.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To determine the fair value, the Company uses the fair value hierarchy for inputs used to measure fair value of financial assets and liabilities. This hierarchy prioritizes the inputs to valuation techniques used to measure fair value into three levels: Level 1 (highest priority), Level 2, and Level 3 (lowest priority).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Level 1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> - Unadjusted quoted prices in active markets for identical instruments.</span></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Level 2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates, yield curves, etc.), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs). </span></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Level 3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> - Inputs are unobservable and reflect the Company&#8217;s assumptions as to what market participants would use in pricing the asset or liability. The Company develops these inputs based on the best information available. </span></div></div><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. Changes in the observability of valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy. The carrying amount of accounts receivable, accounts payable and accrued liabilities approximates fair value due to the nature and short-term of those instruments. The Company&#8217;s cash and cash equivalents and marketable securities are measured at fair value on a recurring basis and the level of fair value hierarchy utilized is described in note 4.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue recognition</a></td>
<td class="text"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(j)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue recognition: </span></div></div><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognizes the amount of revenue to which it expects to be entitled, for the transfer of promised goods or  services to customers under a five-step model: (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when or as a performance obligation is satisfied. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer.</span></p><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Collaboration agreements may require the Company to deliver various rights and/or services, including intellectual property rights or licenses and research and development services. Under such collaboration agreements, the Company is generally eligible to receive non-refundable upfront payments, funding for research and development services, milestone payments, and royalties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In contracts where the Company has more than one performance obligation to provide its customer with goods or services, each performance obligation is evaluated to determine whether it is distinct based on whether (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available and (ii) the good or service is separately identifiable from other promises in the contract. The consideration under the contract is then allocated between the distinct performance obligations based on their respective relative standalone selling prices. The estimated standalone selling price of each deliverable reflects the Company&#8217;s best estimate of what the selling price would be if the deliverable was regularly sold on a standalone basis and is determined by reference to market rates for the good or service when sold to others or by using an adjusted market assessment approach if selling price on a standalone basis is not available.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The consideration allocated to each distinct performance obligation is recognized as revenue when control is transferred to the customer for the related goods or services. The Company generally recognizes revenue from non-refundable upfront payments over the estimated term of the performance obligation or period in which the underlying benefit is transferred to the customer. If non-refundable license fees have value to the customer on a standalone basis, separate from the undelivered performance obligations, they are recognized upon delivery. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. Consideration in exchange for research and development services performed by the Company on behalf of the licensee is recognized upon performance of such activities at rates consistent with prevailing market rates. Consideration associated with at-risk substantive performance milestones, including sales-based milestones, is recognized as revenue using the most likely amount method when it is probable that a significant reversal of the cumulative revenue recognized will not occur. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such milestones, and if necessary, adjusts its estimate of the overall transaction price. Sales-based royalties received in connection with licenses of intellectual property are subject to a specific exception in the revenue standards, whereby the consideration is not included in the transaction price and recognized in revenue until the customer&#8217;s subsequent sales or usages occur.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and development costs</a></td>
<td class="text"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(k)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development costs: </span></div></div><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development costs are expensed in the period incurred.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expenses consist of costs incurred in performing research and development activities, including personnel-related expenses, consisting of salaries, benefits and stock-based compensation for employees engaged in scientific research and development, third-party expenses incurred in connection with the pre-clinical and clinical development of product candidates including under agreements with clinical research organizations, third-party expenses relating to formulation, process development and  manufacture of drug substance and drug product for use in pre-clinical testing, clinical trials and potential commercial supply, third-party acquisition, license and collaboration fees, laboratory consumables and certain indirect costs incurred in support of overall research and development activities, including facilities, depreciation and information technology costs. The amount of expenses recognized in a period related to service agreements is based on the work performed using the accrual basis of accounting. Third-party service providers generally provide estimates of proportionate performance to allow the Company to determine an appropriate accrual. When determining the adequacy of an accrual, the Company analyzes progress based on the level of services performed, progress of the studies, including the phase or completion of events, and contracted costs. Payments made to third parties under these arrangements in advance of the receipt of the related services are recorded as prepaid expenses until the services are rendered. </span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-based compensation</a></td>
<td class="text"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(l)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-based compensation: </span></div></div><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-based compensation expense is measured at the grant date, based on the estimated fair value of the award, and is recognized as an expense, net of actual forfeitures, over the requisite service period with a corresponding increase in additional paid-in capital.</span></p><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company grants stock options to employees, consultants, directors and officers pursuant to equity incentive plans described in note 9c. Stock-based compensation expense for stock options is amortized on a straight-line basis over the requisite service period for the entire award, which is generally the vesting period of the award. Any consideration received on exercise of stock options is credited to share capital.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company grants performance share units (&#8220;PSUs&#8221;) to certain employees and officers pursuant to equity incentive plans described in note 9c. PSUs vest upon the achievement of certain predefined company-specific performance-based criteria. PSUs are measured at the c</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">losing market price of the Company&#8217;s common shares on the date of grant. Stock-based compensation expense for PSUs is amortized on a straight-line basis over the requisite service period of each separately vesting tranche of the award once it is probable that the performance condition will be achieved.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign currency translation</a></td>
<td class="text"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(m)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Foreign currency translation: </span></div></div><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The functional and reporting currency of the Company and its subsidiary is the U.S. dollar. Monetary assets and liabilities denominated in a currency other than the U.S. dollar are re-measured into U.S. dollars at the exchange rate prevailing as of the balance sheet date. Non-monetary assets and liabilities acquired in a currency other than U.S. dollars are translated at historical exchange rates prevailing at each transaction date.</span></p><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue and expense transactions ar</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">e translated at the approximate exchange rate prevailing on the date of transaction. Exchange gains and losses on translation are included in the consolidated statements of operations and comprehensive income (loss) as foreign exchange gain (loss).</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income taxes</a></td>
<td class="text"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(n)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Income taxes: </span></div></div><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deferred income taxes are recognized for the future tax consequences attributable to differences between the carrying amounts of assets and liabilities and their respective tax bases, net operating loss and tax credit carryforwards. Deferred income tax assets and liabilities are measured at enacted rates expected to apply to taxable income in the years in which those temporary differences and carryforwards are expected to be recovered or settled. The effect of a change in tax rates on deferred income tax assets and liabilities is recognized in the consolidated statement of operations and comprehensive income (loss) in the period that includes the enactment date. A valuation allowance is provided when realization of deferred income tax assets does not meet the more-likely-than-not criterion for recognition.</span></p><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not to be sustained upon examination based on the technical merits of the position as well as consideration of the available facts and circumstances. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The interest accrued related to unrecognized tax benefits and penalties is recognized as income tax expense.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net income (loss) per common share</a></td>
<td class="text"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(o)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net income (loss) per common share: </span></div></div><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic net income (loss) per common share is calculated using the two-class method required for participating securities. Undistributed earnings (losses) are allocated to common shares and participating securities based on the weighted average shares of each class outstanding during the period.</span></p><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The treasury stock method is used to compute the dilutive effect of the Company&#8217;s stock options, PSUs and warrants. Under this method, the incremental number of common shares used in computing diluted net income (loss) per common share is the difference between the number of common shares assumed issued and purchased using assumed proceeds.</span></p><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The if-converted method is used to compute the dilutive effect of the Company&#8217;s convertible preferred shares. Under the if-converted method, dividends on the preferred shares, if applicable, are added back to earnings attributable to common shareholders, and the preferred shares and paid-in kind dividends are assumed to have been converted at the share price applicable at the end of the period. The if-converted method is applied only if the effect is dilutive.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment and geographic information</a></td>
<td class="text"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(p)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Segment and geographic information: </span></div></div><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker (&#8220;CODM&#8221;), in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> operating segment discovering and developing a portfolio of treatments in neurological and psychiatric disorders.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently adopted accounting pronouncements/Accounting pronouncements not yet adopted</a></td>
<td class="text"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(q)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recently adopted accounting pronouncements:</span></div></div><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which enhances the disclosures required for operating segments on an interim and annual basis. The Company adopted this ASU in the fourth quarter of 2024 retrospectively to all prior periods presented in the consolidated financial statements. While the Company continues to operate as a single reportable segment, additional disclosures have been incorporated in note 14.</span></p><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(r)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accounting pronouncements not yet adopted: </span></div></div><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accounting standards that have been issued by the Financial Accounting Standards Board or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on our financial statements upon adoption.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for legal costs incurred to protect or defend the entity's assets and rights, or to obtain assets, including monetary damages, or to obtain rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480102/450-20-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45905692968336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies  (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xene_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock', window );">Property Plant and Equipment Estimated Useful Lives</a></td>
<td class="text"><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property, plant and equipment are amortized over their estimated useful lives using the straight-line method based on the following rates:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:49.12%;box-sizing:content-box;"></td>
          <td style="width:1.78%;box-sizing:content-box;"></td>
          <td style="width:49.1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Asset</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Rate</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research equipment</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Office furniture and equipment</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer equipment</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_47b3f612-5e00-48af-b88b-1d3d02b7448e;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Over the lesser of lease term or<br/>   estimated useful life</span></span></span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xene_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of property plant and equipment estimated useful lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xene_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xene_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45905696799136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of Financial Assets Measured at Fair Value on a Recurring Basis</a></td>
<td class="text"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The level of the fair value hierarchy utilized to determine the fair va</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">lue of cash and cash equivalents and marketable securities consisted of the following:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:25.615%;box-sizing:content-box;"></td>
        <td style="width:1.3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:5.9990000000000006%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:5.9990000000000006%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:5.9990000000000006%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:5.9990000000000006%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:5.9990000000000006%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:5.9990000000000006%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:5.9990000000000006%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:5.9990000000000006%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and money market fund</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">142,712</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">142,712</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">148,643</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">148,643</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Guaranteed investment certificates</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,147</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,147</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,684</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,684</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. treasuries</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">130,948</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">130,948</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">252,982</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">252,982</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">97,912</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">97,912</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">66,905</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">66,905</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">119,108</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">119,108</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">397,689</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">397,689</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">304,545</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">304,545</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">289,807</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">464,594</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">754,401</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">409,309</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">521,565</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">930,874</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45905591323712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Summary of Amortized Cost, Unrealized Gain (Losses) Recognized in AOCI and Fair Value of Available-for-Sale Securities</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amortized cost, unrealized gain (loss) recognized in accumulated other comprehensive loss and fair value of available-for-sale securities consisted of the following:</span><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:34%;box-sizing:content-box;"></td>
        <td style="width:1.681%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:8.087%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.681%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:7.907%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.681%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:8.087%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.681%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:7.045999999999999%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:6.906000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.681%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:6.566%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized <br/>Cost</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized Gain (Loss)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair <br/>Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized <br/>Cost</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized <br/>Gain (Loss)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair <br/>Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Contractual maturity of 0 to 1 years:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Guaranteed investment certificates</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,122</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">975</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,147</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,549</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">135</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,684</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. treasuries</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">72,989</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">147</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">73,136</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">192,193</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">249</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">191,944</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98,092</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">180</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">97,912</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">66,808</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">97</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">66,905</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">119,041</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">67</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">119,108</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">327,448</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">557</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">328,005</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">58,824</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">58,924</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Contractual maturity of 1 to 3 years:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. treasuries</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">58,218</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">406</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57,812</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53,294</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">243</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53,537</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">69,726</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">69,684</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">238,458</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">797</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">239,255</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">612,311</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">622</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">611,689</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">767,451</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">913</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">768,364</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45905692996704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of Property, Plant and Equipment</a></td>
<td class="text"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property, plant and equipment consisted of the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:68.32%;box-sizing:content-box;"></td>
        <td style="width:1.52%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.08%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.08%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="5" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,631</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,111</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Office furniture and equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,285</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,285</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,463</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,489</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,363</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,019</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: accumulated depreciation and amortization</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,464</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,251</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net book value</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,278</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,653</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45905699666800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Cost Components of Operating Lease</a></td>
<td class="text"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The cost components of the operating leases were as follows for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024, 2023 and 2022:</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:59.416%;box-sizing:content-box;"></td>
        <td style="width:1.321%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.088%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.088%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.088%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="8" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease cost</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease expense</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,646</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,645</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,126</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Variable lease expense</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">826</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">787</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">774</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease term and discount rate</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average remaining lease term (years)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.4</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.3</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.1</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average discount rate</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.8</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.9</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><div class="item-list-element-wrapper" style="margin-left:11.204%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:justify;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;font-kerning:none;min-width:3.0035136717870174%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Variable lease costs are payments that vary because of changes in facts or circumstances and include common area maintenance and property taxes related to the premises. Variable lease costs are excluded from the calculation of minimum lease payments. </span></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Future Minimum Lease Payments</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Future minimum lease payments as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 were as follows:</span><p style="margin-left:5.733%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.444%;box-sizing:content-box;"></td>
        <td style="width:1.8%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.757%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Year ending December 31:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,690</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,755</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,739</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,037</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2029</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,085</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2030 and thereafter</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,861</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total future minimum lease payments</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,167</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: imputed interest</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,152</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Present value of lease liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,015</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45905692886144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Accounts Payable and Accrued Liabilities</a></td>
<td class="text"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accounts payable and accrued liabilities consisted of the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:68.32%;box-sizing:content-box;"></td>
        <td style="width:1.52%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.08%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.08%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="5" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts payable</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,070</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,598</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued liabilities</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Employee compensation, benefits, and related accruals</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,928</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,425</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,061</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,824</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Income and other taxes</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,686</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">347</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Professional fees</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">762</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">780</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">714</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">34,221</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,974</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45905698270272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Stock Based Compensation Expenses</a></td>
<td class="text"><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents the components and classification of stock-based compensation expense for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024, 2023 and 2022:</span></p><p style="margin-left:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.089%;box-sizing:content-box;"></td>
        <td style="width:1.28%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.598%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.28%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.598%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.28%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.598%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.28%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation expense by award type:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">48,384</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32,372</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,376</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">PSUs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,333</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50,717</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32,372</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,376</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation expense in operating expenses:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,088</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,067</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,766</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28,629</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,305</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,610</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50,717</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32,372</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,376</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Stock Option Activity</a></td>
<td class="text"><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents the summary of stock option activity for the period:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:43%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.96%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.96%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:16.08%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted<br/>Average<br/>Exercise</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Options</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Price ($)</span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Intrinsic</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding, December 31, 2021</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,638,232</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.55</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">105,405</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,315,645</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30.90</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">780,725</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.47</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,651</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited, cancelled or expired</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">55,370</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24.50</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding, December 31, 2022</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,117,782</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18.75</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">147,214</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,542,473</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35.29</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">587,536</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13.58</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,526</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited, cancelled or expired</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">178,217</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31.49</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding, December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,894,502</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23.56</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">200,122</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,062,819</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42.93</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,040,136</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.43</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,416</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited, cancelled or expired</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">207,896</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38.18</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding, December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,709,289</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29.90</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">111,202</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercisable, December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,927,638</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22.30</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100,214</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div class="item-list-element-wrapper" style="margin-left:11.204%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:justify;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;font-kerning:none;min-width:3.0035136717870174%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2024, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,144</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#8211; </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,320</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and 2022 &#8211; </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">68,930</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) stock options were exercised for the same number of common shares in exchange for cash. In the same period, the Company issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">729,965</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(2023 &#8211; </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">377,114</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and 2022 &#8211; </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">510,671</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) common shares for the cashless exercise of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,034,992</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(2023 &#8211; </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">583,216</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and 2022 &#8211; </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">711,795</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) stock options.</span></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Fair Value Assumptions for Stock Options</a></td>
<td class="text"><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The weighted average option pricing assumptions are as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.123%;box-sizing:content-box;"></td>
        <td style="width:1.281%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.584999999999999%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.281%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.584999999999999%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.281%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.584999999999999%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.281%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Average risk-free interest rate</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.05</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.93</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.39</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">66</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">69</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">70</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Average expected term (in years)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.75</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.94</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.16</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.00</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.00</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.00</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average fair value of stock options granted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26.48</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22.52</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19.78</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock', window );">Schedule of Unvested Stock Option Activity</a></td>
<td class="text"><p style="margin-left:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A summary of the Company&#8217;s unvested stock option activity and related information for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 is as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:48.16%;box-sizing:content-box;"></td>
        <td style="width:1.02%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:22.9%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.02%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:22.9%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of<br/>Options</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted Average <br/>Grant Date<br/>Fair Value ($)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unvested, January 1, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,105,324</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20.53</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,062,819</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26.48</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,178,816</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19.91</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited or cancelled</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">207,676</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22.04</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unvested, December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,781,651</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24.56</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xene_ScheduleOfPreFundedWarrantsActivityTableTextBlock', window );">Schedule Of Pre-Funded Warrants Activity</a></td>
<td class="text"><p style="margin-left:8.787%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the pre-funded warrants activity for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024, 2023, and 2022:</span></p><p style="margin-left:8.8%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.975%;box-sizing:content-box;"></td>
        <td style="width:1.25%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:30.775%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of Pre-funded</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">warrants outstanding</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding, December 31, 2021</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,775,996</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issued</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">327,868</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding, December 31, 2022</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,103,864</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issued</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">769,230</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,700,013</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding, December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,173,081</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issued</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding, December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,173,081</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><div class="item-list-element-wrapper" style="margin-left:9.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:justify;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;font-kerning:none;min-width:2.9590591368023964%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2023, the Company issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,700,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> common shares upon the exercise of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,700,013</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> pre-funded warrants pursuant to a net exercise mechanism under the warrants.</span></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xene_ScheduleOfPreFundedWarrantsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of pre funded warrants activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xene_ScheduleOfPreFundedWarrantsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xene_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45905693038064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Schedule Of Collaboration Revenue</a></td>
<td class="text"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue was as follows for the years ended December 31, 2024, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2023 and 2022:</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.449%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.518%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.518%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.518%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="8" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Recognition of the transaction price</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">372</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development services</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,938</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Milestone payments</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,124</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Total revenue</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,434</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45905590620080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Common Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock', window );">Schedule of Basic and Diluted Net Loss Per Common Share</a></td>
<td class="text"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents the calculation of basic and diluted net loss per common share for the years ended December 31, 2024, 2023 and 2022:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:46.109%;box-sizing:content-box;"></td>
        <td style="width:1.64%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:14.323%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.64%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:14.323%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.64%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:14.323%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Numerator:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">234,330</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">182,393</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">125,373</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss attributable to preferred shareholders</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">437</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss attributable to common shareholders</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">234,330</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">182,393</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">124,936</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Denominator:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common shares (weighted average)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75,721,562</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">64,739,678</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57,599,510</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Pre-funded warrants (weighted average)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,173,081</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,149,327</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,942,632</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average common shares <br/>&#160;&#160;&#160;outstanding &#8211; basic and diluted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">77,894,643</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">66,889,005</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">60,542,142</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per common share &#8211; basic and diluted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.01</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.73</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.06</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the effect of income (loss) on basic earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45905692956944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Loss before Income Taxes</a></td>
<td class="text"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Loss before income taxes for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024, 2023 and 2022 was as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.863%;box-sizing:content-box;"></td>
        <td style="width:1.281%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.764000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.281%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.764000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.281%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.764000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Canada</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">243,410</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">174,491</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">121,335</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">United States</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,991</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,194</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,920</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss before income taxes</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">238,419</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">182,685</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">125,255</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Income Tax Recovery (Expense)</a></td>
<td class="text"><p style="margin-left:4.533%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The income tax recovery (expense) is allocated as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.863%;box-sizing:content-box;"></td>
        <td style="width:1.281%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.764000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.281%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.764000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.281%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.764000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;Canada</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;United States</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,775</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">162</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,775</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">162</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;Canada</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;United States</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,864</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">292</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,864</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">292</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Income tax recovery (expense)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,089</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">292</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">118</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><p style="margin-left:4.533%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reconciliation of the expected Canadian statutory income tax rate to the effective income tax rate is as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.863%;box-sizing:content-box;"></td>
        <td style="width:1.281%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.764000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.281%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.764000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.281%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.764000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax at statutory income tax rate</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27.00</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27.00</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27.00</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24.5</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development and other credits</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.3</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.6</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.5</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax attributes expired/utilized</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.1</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.8</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.2</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.4</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.2</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.6</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other non-deductible expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.4</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.3</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.2</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.3</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.1</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Effective income tax rate</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.7</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.2</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Net Deferred Income Tax Assets</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.313%;box-sizing:content-box;"></td>
        <td style="width:1.5%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.843%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.5%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.843%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred income tax assets:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development tax credits</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42,830</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38,590</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Investment tax credits</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,818</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,695</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-capital losses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">173,352</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">119,765</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciable assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,269</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,311</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred financing fees</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,967</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,831</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,380</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,832</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liability</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,299</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,779</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,704</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">852</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Total deferred income tax assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">278,619</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">217,655</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Deferred income tax liability:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Operating lease right-of-use asset</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,097</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,411</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Less - valuation allowance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">266,856</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">214,442</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net deferred income tax assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,666</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">802</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45905745777536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Disclosure (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Summary of Net Loss Related To Segment Expenses</a></td>
<td class="text"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents information about reported segment revenues, significant segment expenses, and segment loss:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:46.279%;box-sizing:content-box;"></td>
        <td style="width:1.641%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:14.266%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.641%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:14.266%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.641%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:14.266%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,434</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Direct external research and development costs</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Azetukalner</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">106,806</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">89,303</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37,367</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">XEN 496</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,152</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,765</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Pre-clinical, discovery and other programs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,546</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,552</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,711</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Personnel-related expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">68,340</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">47,739</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36,088</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50,717</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32,372</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,376</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other research and development costs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,232</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,560</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,274</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other general and administrative costs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,657</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,376</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,996</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest income</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41,943</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,620</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,713</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other segment items</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,025</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,041</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,943</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">234,330</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">182,393</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">125,373</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><div class="item-list-element-wrapper" style="margin-left:5.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4%;text-align:justify;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;font-kerning:none;min-width:4.2253372347280465%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other segment items include foreign exchange gain (loss), unrealized fair value gain (loss) on trading securities, and income tax recovery (expense).</span></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45905692938224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of the business (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 899,470<span></span>
</td>
<td class="nump">$ 665,140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 234,330<span></span>
</td>
<td class="nump">$ 182,393<span></span>
</td>
<td class="nump">$ 125,373<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45905598707616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xene_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustment', window );">Prior period reclassification adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,785)<span></span>
</td>
<td class="num">$ (2,598)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_SubsidiariesMember', window );">Xenon Pharmaceuticals USA Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xene_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">Date of incorporation</a></td>
<td class="text">Dec.  02,  2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationDateOfIncorporation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when an entity was incorporated</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationDateOfIncorporation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a reclassification adjustment made to prior period financial statement amounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xene_BasisOfPresentationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Basis of presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xene_BasisOfPresentationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xene_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_SubsidiariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_SubsidiariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45905591165248">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Significant Accounting Policies - Property Plant and Equipment Estimated Useful Lives (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration', window );">Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]</a></td>
<td class="text">Leasehold Improvements [Member]<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=xene_ResearchEquipmentMember', window );">Research Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office Furniture and Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates description of term of useful life for property, plant, and equipment when not stated as numeric value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482190/360-10-35-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=xene_ResearchEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=xene_ResearchEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45905692822576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>Segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xene_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment charges recognized | $</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segment | Segment</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xene_SignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xene_SignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xene_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45905594192496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value of Financial Instruments - Schedule of Financial Assets Measured at Fair Value on a Recurring Basis (Details) - Recurring Basis [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial Assets Measured at Fair Value on a Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">$ 754,401<span></span>
</td>
<td class="nump">$ 930,874<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial Assets Measured at Fair Value on a Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">289,807<span></span>
</td>
<td class="nump">409,309<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial Assets Measured at Fair Value on a Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">464,594<span></span>
</td>
<td class="nump">521,565<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Cash and Money Market Fund [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial Assets Measured at Fair Value on a Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">142,712<span></span>
</td>
<td class="nump">148,643<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Cash and Money Market Fund [Member] | Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial Assets Measured at Fair Value on a Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">142,712<span></span>
</td>
<td class="nump">148,643<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial Assets Measured at Fair Value on a Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">66,905<span></span>
</td>
<td class="nump">119,108<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Commercial Paper [Member] | Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial Assets Measured at Fair Value on a Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">66,905<span></span>
</td>
<td class="nump">119,108<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. Treasuries [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial Assets Measured at Fair Value on a Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">130,948<span></span>
</td>
<td class="nump">252,982<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. Treasuries [Member] | Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial Assets Measured at Fair Value on a Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">130,948<span></span>
</td>
<td class="nump">252,982<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Guaranteed Investment Certificates [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial Assets Measured at Fair Value on a Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">16,147<span></span>
</td>
<td class="nump">7,684<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Guaranteed Investment Certificates [Member] | Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial Assets Measured at Fair Value on a Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">16,147<span></span>
</td>
<td class="nump">7,684<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. Government Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial Assets Measured at Fair Value on a Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97,912<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. Government Securities [Member] | Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial Assets Measured at Fair Value on a Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97,912<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial Assets Measured at Fair Value on a Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">397,689<span></span>
</td>
<td class="nump">304,545<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Corporate Debt Securities [Member] | Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial Assets Measured at Fair Value on a Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">$ 397,689<span></span>
</td>
<td class="nump">$ 304,545<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=xene_CashAndMoneyMarketFundMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=xene_CashAndMoneyMarketFundMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=xene_GuaranteedInvestmentCertificatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=xene_GuaranteedInvestmentCertificatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45905699681248">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradingSecuritiesDebt', window );">Trading marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,867<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Trading securities available-for-sale</a></td>
<td class="nump">$ 611,689<span></span>
</td>
<td class="nump">$ 768,364<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradingSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in net income (trading).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradingSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45905598292992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities - Summary of Amortized Cost, Unrealized Gain (Loss) Recognized in AOCI and Fair Value of Available-for-Sale Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 612,311<span></span>
</td>
<td class="nump">$ 767,451<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xene_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax', window );">Unrealized Gain (Loss)</a></td>
<td class="num">(622)<span></span>
</td>
<td class="nump">913<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">611,689<span></span>
</td>
<td class="nump">768,364<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=xene_GuaranteedInvestmentCertificatesMember', window );">Guaranteed Investment Certificates [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Contractual maturity of 0 to 1 years, Amortized Cost</a></td>
<td class="nump">17,122<span></span>
</td>
<td class="nump">7,549<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xene_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTaxCurrent', window );">Contractual maturity of 0 to 1 years, Unrealized Gain (Loss)</a></td>
<td class="num">(975)<span></span>
</td>
<td class="nump">135<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Contractual maturity of 0 to 1 years, Fair Value</a></td>
<td class="nump">16,147<span></span>
</td>
<td class="nump">7,684<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasuries [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Contractual maturity of 0 to 1 years, Amortized Cost</a></td>
<td class="nump">72,989<span></span>
</td>
<td class="nump">192,193<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xene_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTaxCurrent', window );">Contractual maturity of 0 to 1 years, Unrealized Gain (Loss)</a></td>
<td class="nump">147<span></span>
</td>
<td class="num">(249)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Contractual maturity of 0 to 1 years, Fair Value</a></td>
<td class="nump">73,136<span></span>
</td>
<td class="nump">191,944<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent', window );">Contractual maturity of 1 to 3 years, Amortized Cost</a></td>
<td class="nump">58,218<span></span>
</td>
<td class="nump">53,294<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xene_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTaxNoncurrent', window );">Contractual maturity of 1 to 3 years, Unrealized Gain (Loss)</a></td>
<td class="num">(406)<span></span>
</td>
<td class="nump">243<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Contractual maturity of 1 to 3 years, Fair Value</a></td>
<td class="nump">57,812<span></span>
</td>
<td class="nump">53,537<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. Government Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Contractual maturity of 0 to 1 years, Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,092<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xene_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTaxCurrent', window );">Contractual maturity of 0 to 1 years, Unrealized Gain (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(180)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Contractual maturity of 0 to 1 years, Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97,912<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Contractual maturity of 0 to 1 years, Amortized Cost</a></td>
<td class="nump">66,808<span></span>
</td>
<td class="nump">119,041<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xene_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTaxCurrent', window );">Contractual maturity of 0 to 1 years, Unrealized Gain (Loss)</a></td>
<td class="nump">97<span></span>
</td>
<td class="nump">67<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Contractual maturity of 0 to 1 years, Fair Value</a></td>
<td class="nump">66,905<span></span>
</td>
<td class="nump">119,108<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Contractual maturity of 0 to 1 years, Amortized Cost</a></td>
<td class="nump">327,448<span></span>
</td>
<td class="nump">58,824<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xene_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTaxCurrent', window );">Contractual maturity of 0 to 1 years, Unrealized Gain (Loss)</a></td>
<td class="nump">557<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Contractual maturity of 0 to 1 years, Fair Value</a></td>
<td class="nump">328,005<span></span>
</td>
<td class="nump">58,924<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent', window );">Contractual maturity of 1 to 3 years, Amortized Cost</a></td>
<td class="nump">69,726<span></span>
</td>
<td class="nump">238,458<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xene_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTaxNoncurrent', window );">Contractual maturity of 1 to 3 years, Unrealized Gain (Loss)</a></td>
<td class="num">(42)<span></span>
</td>
<td class="nump">797<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Contractual maturity of 1 to 3 years, Fair Value</a></td>
<td class="nump">$ 69,684<span></span>
</td>
<td class="nump">$ 239,255<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xene_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Available for sale debt securities accumulated gross unrealized gain (loss) before tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xene_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xene_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xene_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTaxCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt securities available for sale accumulated gross unrealized gain (loss) before tax current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xene_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTaxCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xene_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xene_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTaxNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt securities available for sale accumulated gross unrealized gain (loss) before tax noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xene_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTaxNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xene_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=xene_GuaranteedInvestmentCertificatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=xene_GuaranteedInvestmentCertificatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45905592293136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property, Plant and Equipment - Summary of Property, Plant and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">$ (13,464)<span></span>
</td>
<td class="num">$ (11,251)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net book value</a></td>
<td class="nump">10,278<span></span>
</td>
<td class="nump">9,653<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=xene_ResearchEquipmentMember', window );">Research Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment</a></td>
<td class="nump">11,631<span></span>
</td>
<td class="nump">9,111<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Office Furniture and Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment</a></td>
<td class="nump">1,285<span></span>
</td>
<td class="nump">1,285<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment</a></td>
<td class="nump">1,463<span></span>
</td>
<td class="nump">1,489<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment</a></td>
<td class="nump">$ 9,363<span></span>
</td>
<td class="nump">$ 9,019<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=xene_ResearchEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=xene_ResearchEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45905593375504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>Lease </div>
<div>Option</div>
</th>
<th class="th"><div>Oct. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=xene_BurnabyBritishColumbiaMember', window );">Burnaby, British Columbia [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xene_LesseeNumberOfOperatingLeases', window );">Number of operating leases | Lease</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xene_LesseeOperatingLeaseNumberOfRenewalOptions', window );">Operating lease, number of renewal options | Option</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Operating lease expiration date</a></td>
<td class="text">Jun. 30,  2032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescription', window );">Operating lease, description</a></td>
<td class="text">The Company has an operating lease for research laboratories and office space in Burnaby, British Columbia which expires on June 30, 2032, and two renewal options for 5-years each which were not considered in the determination of the right-of-use asset and lease liability. The Company has an additional operating lease for office space in Needham, Massachusetts (&#8220;Needham Lease&#8221;), which commenced in October 2022. The Needham Lease is for a 62-month term and an option to terminate one year prior to the expiry date, which was not considered in the determination of the right-of-use asset and lease liability.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=xene_BurnabyBritishColumbiaMember', window );">Burnaby, British Columbia [Member] | First Renewal Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease extension term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=xene_BurnabyBritishColumbiaMember', window );">Burnaby, British Columbia [Member] | Second Renewal Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease extension term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=xene_NeedhamMassachusettsMember', window );">Needham Massachusetts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">62 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescription', window );">Operating lease, description</a></td>
<td class="text"> The Company has an additional operating lease for office space in Needham, Massachusetts (&#8220;Needham Lease&#8221;), which commenced in October 2022. The Needham Lease is for a 62-month term and an option to terminate one year prior to the expiry date, which was not considered in the determination of the right-of-use asset and lease liability.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToTerminate', window );">Operating lease, option to terminate</a></td>
<td class="text">option to terminate one year prior to the expiry date<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of lessee's operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToTerminate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to terminate lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToTerminate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xene_LesseeNumberOfOperatingLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, number of operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xene_LesseeNumberOfOperatingLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xene_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xene_LesseeOperatingLeaseNumberOfRenewalOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease number of renewal options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xene_LesseeOperatingLeaseNumberOfRenewalOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xene_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=xene_BurnabyBritishColumbiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=xene_BurnabyBritishColumbiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=xene_FirstRenewalOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=xene_FirstRenewalOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=xene_SecondRenewalOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=xene_SecondRenewalOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=xene_NeedhamMassachusettsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=xene_NeedhamMassachusettsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45905780624640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Schedule of Cost Components of Operating Lease (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease expense</a></td>
<td class="nump">$ 1,646<span></span>
</td>
<td class="nump">$ 1,645<span></span>
</td>
<td class="nump">$ 1,126<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease expense</a></td>
<td class="nump">$ 826<span></span>
</td>
<td class="nump">$ 787<span></span>
</td>
<td class="nump">$ 774<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term (years)</a></td>
<td class="text">6 years 4 months 24 days<span></span>
</td>
<td class="text">7 years 3 months 18 days<span></span>
</td>
<td class="text">8 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">3.80%<span></span>
</td>
<td class="nump">3.90%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45905598856832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Future Minimum Lease Payments (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 1,690<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">1,755<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">1,739<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2028</a></td>
<td class="nump">1,037<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2029</a></td>
<td class="nump">1,085<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">2030 and thereafter</a></td>
<td class="nump">2,861<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="nump">10,167<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(1,152)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 9,015<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45905598758064">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts Payable and Accrued Liabilities - Accounts Payable and Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Accounts payable</a></td>
<td class="nump">$ 5,070<span></span>
</td>
<td class="nump">$ 8,598<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee compensation, benefits, and related accruals</a></td>
<td class="nump">9,928<span></span>
</td>
<td class="nump">7,425<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xene_AccruedResearchAndDevelopmentCurrent', window );">Research and development</a></td>
<td class="nump">12,061<span></span>
</td>
<td class="nump">8,824<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Income and other taxes</a></td>
<td class="nump">5,686<span></span>
</td>
<td class="nump">347<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">762<span></span>
</td>
<td class="nump">780<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">714<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 34,221<span></span>
</td>
<td class="nump">$ 25,974<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xene_AccruedResearchAndDevelopmentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development, current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xene_AccruedResearchAndDevelopmentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xene_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45905585363200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="9">1 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jan. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Aug. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xene_ShareCapitalLineItems', window );"><strong>Share Capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Warrants outstanding to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,173,081<span></span>
</td>
<td class="nump">3,103,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price per common share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,062,819<span></span>
</td>
<td class="nump">2,542,473<span></span>
</td>
<td class="nump">2,315,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options Outstanding Weighted Average Remaining Contractual Life in Years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 3 months 10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options Exercisable Weighted Average Remaining Contractual Life in Years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 2 months 15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Aggregate fair value of options vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,375<span></span>
</td>
<td class="nump">$ 29,233<span></span>
</td>
<td class="nump">$ 13,752<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized stock-based compensation cost not to be achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 99,779<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized stock-based compensation expected to be recognized over a period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 7 months 20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xene_NumberOfWarrantsExercised', window );">Exercise of pre-funded warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,700,013)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xene_WarrantsExerciseDescription', window );">Warrants exercise description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company may not affect the exercise of any pre-funded warrant, and a holder will not be entitled to exercise any portion of any pre-funded warrant that, upon giving effect to such exercise, would cause: (i) the aggregate number of common shares beneficially owned by such holder, together with its affiliates, to exceed 4.99% of the total number of common shares outstanding immediately after giving effect to the exercise; or (ii) the combined voting power of the Company&#8217;s securities beneficially owned by such holder, together with its affiliates, to exceed 4.99% of the combined voting power of all of the Company&#8217;s securities immediately outstanding after giving effect to the exercise, which percentage may be changed at the holder&#8217;s election to a higher or lower percentage not in excess of 19.99% upon at least 61 days&#8217; notice to the Company.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=xene_TermLoansMember', window );">Term Loans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xene_ShareCapitalLineItems', window );"><strong>Share Capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Warrants outstanding to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price per common share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.79<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=xene_TwoThousandNineteenInducementEquityIncentivePlanMember', window );">2019 Inducement Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xene_ShareCapitalLineItems', window );"><strong>Share Capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Common shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=xene_TwoThousandFourteenAmendedAndRestatedStockOptionPlanMember', window );">Amended and Restated 2014 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xene_ShareCapitalLineItems', window );"><strong>Share Capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xene_MaximumTermOfEachOptionExercised', window );">Maximum term of each option exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Common shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,882,842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of restricted share awards, restricted share unit awards or performance awards available for issue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xene_ShareCapitalLineItems', window );"><strong>Share Capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">310,000<span></span>
</td>
<td class="nump">10,701,842<span></span>
</td>
<td class="nump">9,357,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,016,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,016,000<span></span>
</td>
<td class="nump">1,852,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xene_JefferiesLLCAndStifelNicolausCompanyIncorporatedMember', window );">Jefferies and Stifel [Member] | ATM [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xene_ShareCapitalLineItems', window );"><strong>Share Capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Sale proceeds of common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,508<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xene_JefferiesLLCAndStifelNicolausCompanyIncorporatedMember', window );">Jefferies and Stifel [Member] | ATM [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xene_ShareCapitalLineItems', window );"><strong>Share Capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xene_GrossProceedsFromIssuableOfCommonStock', window );">Gross proceeds from issuable of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xene_JefferiesLLCAndStifelNicolausCompanyIncorporatedMember', window );">Jefferies and Stifel [Member] | ATM [Member] | Common Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xene_ShareCapitalLineItems', window );"><strong>Share Capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="nump">855,685<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">310,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xene_JefferiesLLCAndStifelNicolausCompanyIncorporatedMember', window );">Jefferies and Stifel [Member] | Underwritten Public Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xene_ShareCapitalLineItems', window );"><strong>Share Capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Sale proceeds from issuance of pre funded warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,477<span></span>
</td>
<td class="nump">$ 9,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xene_NeurocrineBiosciencesMember', window );">Neurocrine Biosciences [Member] | License and Collaboration Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xene_ShareCapitalLineItems', window );"><strong>Share Capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Sale proceeds of common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">258,986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Aggregate purchase price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31.855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xene_CollaborateMilestoneAgreementPremiumRelatedToEquityInvestment', window );">Premium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 374<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xene_JefferiesLLCStifelNicolausCompanyIncorporatedJPMorganSecuritiesLLCAndSVBSecuritiesLLCMember', window );">Jefferies, Stifel, J.P. Morgan Securities LLC and SVB Securities LLC [Member] | Underwritten Public Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xene_ShareCapitalLineItems', window );"><strong>Share Capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Sale proceeds of common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 269,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,098,362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Shares price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Warrants outstanding to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">327,868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xene_WarrantsIssuedPricePerPreFundedWarrant', window );">Warrants issued price per pre funded warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.4999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price per common share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xene_JefferiesLLCStifelNicolausCompanyIncorporatedJPMorganSecuritiesLLCAndSVBSecuritiesLLCMember', window );">Jefferies, Stifel, J.P. Morgan Securities LLC and SVB Securities LLC [Member] | Over Allotment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xene_ShareCapitalLineItems', window );"><strong>Share Capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,229,508<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xene_JefferiesLLCStifelNicolausCompanyIncorporatedJPMorganSecuritiesLLCBofASecuritiesIncAndRBCCapitalMarketsLLCMember', window );">J.P. Morgan, Jefferies, BofA Securities, Inc., Stifel, and RBC Capital Markets, LLC [Member] | Underwritten Public Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xene_ShareCapitalLineItems', window );"><strong>Share Capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Sale proceeds of common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 323,979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,846,157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Shares price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Warrants outstanding to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">769,230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xene_WarrantsIssuedPricePerPreFundedWarrant', window );">Warrants issued price per pre funded warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32.4999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price per common share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xene_JefferiesLLCStifelNicolausCompanyIncorporatedJPMorganSecuritiesLLCBofASecuritiesIncAndRBCCapitalMarketsLLCMember', window );">J.P. Morgan, Jefferies, BofA Securities, Inc., Stifel, and RBC Capital Markets, LLC [Member] | Over Allotment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xene_ShareCapitalLineItems', window );"><strong>Share Capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,384,615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=xene_Series1PreferredSharesMember', window );">Series1 Preferred Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xene_ShareCapitalLineItems', window );"><strong>Share Capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,016,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,852,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=xene_BVFPartnersLPMember', window );">BVF Partners L.P [Member] | Exchange Agreement [Member] | Common Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xene_ShareCapitalLineItems', window );"><strong>Share Capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xene_StockIssuedDuringPeriodCommonSharesCancelled', window );">Shares cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,868,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=xene_BVFPartnersLPMember', window );">BVF Partners L.P [Member] | Exchange Agreement [Member] | Series1 Preferred Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xene_ShareCapitalLineItems', window );"><strong>Share Capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConversionBasis', window );">Preferred shares convertible into common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one-for-one<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,868,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xene_ShareCapitalLineItems', window );"><strong>Share Capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized stock-based compensation cost to be achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized stock-based compensation cost not to be achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Shares granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">210,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Shares vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConversionBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Describe the conversion features of preferred stock if preferred stock is convertible. That is, shares of preferred stock into which another convertible security was converted, or shares of preferred stock into which another class of preferred stock was converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConversionBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xene_CollaborateMilestoneAgreementPremiumRelatedToEquityInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborate milestone agreement premium related to equity investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xene_CollaborateMilestoneAgreementPremiumRelatedToEquityInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xene_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xene_GrossProceedsFromIssuableOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross proceeds from issuable of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xene_GrossProceedsFromIssuableOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xene_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xene_MaximumTermOfEachOptionExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum term of each option exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xene_MaximumTermOfEachOptionExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xene_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xene_NumberOfWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xene_NumberOfWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xene_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xene_ShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xene_ShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xene_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xene_StockIssuedDuringPeriodCommonSharesCancelled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period common shares cancelled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xene_StockIssuedDuringPeriodCommonSharesCancelled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xene_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xene_WarrantsExerciseDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants exercise description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xene_WarrantsExerciseDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xene_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xene_WarrantsIssuedPricePerPreFundedWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants issued price per pre funded warrant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xene_WarrantsIssuedPricePerPreFundedWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xene_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=xene_TermLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=xene_TermLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=xene_TwoThousandNineteenInducementEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=xene_TwoThousandNineteenInducementEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=xene_TwoThousandFourteenAmendedAndRestatedStockOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=xene_TwoThousandFourteenAmendedAndRestatedStockOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xene_JefferiesLLCAndStifelNicolausCompanyIncorporatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xene_JefferiesLLCAndStifelNicolausCompanyIncorporatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=xene_AtMarketEquityOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=xene_AtMarketEquityOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=xene_UnderwrittenPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=xene_UnderwrittenPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xene_NeurocrineBiosciencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xene_NeurocrineBiosciencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xene_LicenseAndCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xene_LicenseAndCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xene_JefferiesLLCStifelNicolausCompanyIncorporatedJPMorganSecuritiesLLCAndSVBSecuritiesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xene_JefferiesLLCStifelNicolausCompanyIncorporatedJPMorganSecuritiesLLCAndSVBSecuritiesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xene_JefferiesLLCStifelNicolausCompanyIncorporatedJPMorganSecuritiesLLCBofASecuritiesIncAndRBCCapitalMarketsLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xene_JefferiesLLCStifelNicolausCompanyIncorporatedJPMorganSecuritiesLLCBofASecuritiesIncAndRBCCapitalMarketsLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=xene_Series1PreferredSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=xene_Series1PreferredSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=xene_BVFPartnersLPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=xene_BVFPartnersLPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=xene_ExchangeAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=xene_ExchangeAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45905594047024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital - Stock Based Compensation Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">$ 50,717<span></span>
</td>
<td class="nump">$ 32,372<span></span>
</td>
<td class="nump">$ 20,376<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">48,384<span></span>
</td>
<td class="nump">32,372<span></span>
</td>
<td class="nump">20,376<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">2,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">22,088<span></span>
</td>
<td class="nump">13,067<span></span>
</td>
<td class="nump">7,766<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">$ 28,629<span></span>
</td>
<td class="nump">$ 19,305<span></span>
</td>
<td class="nump">$ 12,610<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45905585110800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital - Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options Outstanding, Beginning balance</a></td>
<td class="nump">8,894,502<span></span>
</td>
<td class="nump">7,117,782<span></span>
</td>
<td class="nump">5,638,232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options, Granted</a></td>
<td class="nump">3,062,819<span></span>
</td>
<td class="nump">2,542,473<span></span>
</td>
<td class="nump">2,315,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Options, Exercised</a></td>
<td class="num">(1,040,136)<span></span>
</td>
<td class="num">(587,536)<span></span>
</td>
<td class="num">(780,725)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Number of Options, Forfeited, cancelled or expired</a></td>
<td class="num">(207,896)<span></span>
</td>
<td class="num">(178,217)<span></span>
</td>
<td class="num">(55,370)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options Outstanding, Ending balance</a></td>
<td class="nump">10,709,289<span></span>
</td>
<td class="nump">8,894,502<span></span>
</td>
<td class="nump">7,117,782<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options Exercisable, End of period</a></td>
<td class="nump">5,927,638<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Outstanding, Beginning balance</a></td>
<td class="nump">$ 23.56<span></span>
</td>
<td class="nump">$ 18.75<span></span>
</td>
<td class="nump">$ 12.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="nump">42.93<span></span>
</td>
<td class="nump">35.29<span></span>
</td>
<td class="nump">30.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="nump">12.43<span></span>
</td>
<td class="nump">13.58<span></span>
</td>
<td class="nump">9.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Forfeited, cancelled and expired</a></td>
<td class="nump">38.18<span></span>
</td>
<td class="nump">31.49<span></span>
</td>
<td class="nump">24.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Outstanding, Ending balance</a></td>
<td class="nump">29.9<span></span>
</td>
<td class="nump">$ 23.56<span></span>
</td>
<td class="nump">$ 18.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable Ending balance</a></td>
<td class="nump">$ 22.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding</a></td>
<td class="nump">$ 111,202<span></span>
</td>
<td class="nump">$ 200,122<span></span>
</td>
<td class="nump">$ 147,214<span></span>
</td>
<td class="nump">$ 105,405<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate Intrinsic Value, Exercised</a></td>
<td class="nump">30,416<span></span>
</td>
<td class="nump">$ 14,526<span></span>
</td>
<td class="nump">$ 19,651<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable, Ending balance</a></td>
<td class="nump">$ 100,214<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45905692893136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital - Stock Option Activity (Parenthetical) (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xene_StockOptionsExercisedForNumberOfCommonSharesForCash', window );">Stock Options exercised for Number of Common Shares for cash</a></td>
<td class="nump">5,144<span></span>
</td>
<td class="nump">4,320<span></span>
</td>
<td class="nump">68,930<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xene_CommonStockIssuedForCashlessExercise', window );">Common stock issued for cashless exercise</a></td>
<td class="nump">729,965<span></span>
</td>
<td class="nump">377,114<span></span>
</td>
<td class="nump">510,671<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xene_CashlessExerciseOfStockOptions', window );">Cashless exercise of stock options</a></td>
<td class="nump">1,034,992<span></span>
</td>
<td class="nump">583,216<span></span>
</td>
<td class="nump">711,795<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xene_CashlessExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised via net exercise (cashless) method during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xene_CashlessExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xene_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xene_CommonStockIssuedForCashlessExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common stock issued in exchange for share options (or share units) exercised via net exercise (cashless) method during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xene_CommonStockIssuedForCashlessExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xene_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xene_StockOptionsExercisedForNumberOfCommonSharesForCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised for number of common shares for cash during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xene_StockOptionsExercisedForNumberOfCommonSharesForCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xene_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45905782420592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital - Fair Value Assumptions for Stock Options (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xene_FairValueAssumptionsForStockOptionsAbstract', window );"><strong>Fair Value Assumptions For Stock Options [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Average risk-free interest rate</a></td>
<td class="nump">4.05%<span></span>
</td>
<td class="nump">3.93%<span></span>
</td>
<td class="nump">2.39%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">66.00%<span></span>
</td>
<td class="nump">69.00%<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Average expected term (in years)</a></td>
<td class="text">5 years 9 months<span></span>
</td>
<td class="text">5 years 11 months 8 days<span></span>
</td>
<td class="text">6 years 1 month 28 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average fair value of options granted</a></td>
<td class="nump">$ 26.48<span></span>
</td>
<td class="nump">$ 22.52<span></span>
</td>
<td class="nump">$ 19.78<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xene_FairValueAssumptionsForStockOptionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value assumptions for stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xene_FairValueAssumptionsForStockOptionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xene_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45905593669952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital - Summary of UnVested Stock Option Activity (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of Options, Unvested, Beginning balance</a></td>
<td class="nump">4,105,324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options, Granted</a></td>
<td class="nump">3,062,819<span></span>
</td>
<td class="nump">2,542,473<span></span>
</td>
<td class="nump">2,315,645<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of Options, Vested</a></td>
<td class="num">(2,178,816)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares', window );">Number of Options, Forfeited or cancelled</a></td>
<td class="num">(207,676)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of Options, Unvested, Ending balance</a></td>
<td class="nump">4,781,651<span></span>
</td>
<td class="nump">4,105,324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Unvested, Beginning balance</a></td>
<td class="nump">$ 20.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Granted</a></td>
<td class="nump">26.48<span></span>
</td>
<td class="nump">$ 22.52<span></span>
</td>
<td class="nump">$ 19.78<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Vested</a></td>
<td class="nump">19.91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Forfeited or cancelled</a></td>
<td class="nump">22.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Unvested, Ending balance</a></td>
<td class="nump">$ 24.56<span></span>
</td>
<td class="nump">$ 20.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45905692749552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital - Schedule of Pre-Funded Warrants (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xene_ShareCapitalLineItems', window );"><strong>Share Capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding, beginning</a></td>
<td class="nump">2,173,081<span></span>
</td>
<td class="nump">3,103,864<span></span>
</td>
<td class="nump">2,775,996<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xene_NumberOfWarrantsIssued', window );">Issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">769,230<span></span>
</td>
<td class="nump">327,868<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xene_NumberOfWarrantsExercised', window );">Exercised</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,700,013)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding, ending</a></td>
<td class="nump">2,173,081<span></span>
</td>
<td class="nump">2,173,081<span></span>
</td>
<td class="nump">3,103,864<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xene_NumberOfWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xene_NumberOfWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xene_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xene_NumberOfWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xene_NumberOfWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xene_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xene_ShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xene_ShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xene_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45905595183904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share capital - Schedule of Pre-Funded Warrants (Parenthetical) (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xene_ShareCapitalLineItems', window );"><strong>Share Capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xene_CommonStockIssuedForPreFundedWarrants', window );">Common stock issued for pre-funded warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xene_NumberOfWarrantsExercised', window );">Exercise of pre-funded warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,700,013)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xene_CommonStockIssuedForPreFundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock issued for pre-funded warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xene_CommonStockIssuedForPreFundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xene_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xene_NumberOfWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xene_NumberOfWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xene_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xene_ShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xene_ShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xene_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45905592326976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements - Schedule of Collaboration Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,434<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember', window );">Collaboration Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">9,434<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xene_NeurocrineBiosciencesMember', window );">Neurocrine Biosciences [Member] | Collaboration Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xene_RecognitionOfTransactionPrice', window );">Recognition of the transaction price</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">372<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xene_ResearchAndDevelopmentServices', window );">Research and development services</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,938<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xene_MilestonePayment', window );">Milestone payments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xene_PaciraBiosciencesMember', window );">Pacira BioSciences [Member] | Collaboration Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xene_MilestonePayment', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,124<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xene_MilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xene_MilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xene_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xene_RecognitionOfTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Recognition of transaction price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xene_RecognitionOfTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xene_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xene_ResearchAndDevelopmentServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xene_ResearchAndDevelopmentServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xene_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xene_NeurocrineBiosciencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xene_NeurocrineBiosciencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xene_PaciraBiosciencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xene_PaciraBiosciencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45905593125344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 27, 2025</div></th>
<th class="th"><div>Jan. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,434,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xene_NeurocrineBiosciencesMember', window );">Neurocrine Biosciences [Member] | License and Collaboration Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xene_PotentialMilestonePaymentsReceivable', window );">Potential milestone payments receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,667,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xene_PercentageOfOptionToFundDevelopmentCostsUponAchievementOfCertainMilestones', window );">Percentage of option to co-fund development costs upon achievement of certain milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xene_AggregateMilestonePaymentReceived', window );">Milestone Payment Received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xene_MilestonePaymentReceivedInCash', window );">Milestone Payment Received in Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xene_MilestonePaymentReceivedInEquityInvestment', window );">Milestone Payment Received in Equity Investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xene_MilestonePaymentReceivedInEquityInvestmentMeasuredAtFairValue', window );">Equity investment measure at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,876,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xene_CollaborateMilestoneAgreementPremiumRelatedToEquityInvestment', window );">Premium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">374,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xene_PerformanceObligationsRelatedToMilestone', window );">Performance obligation related to milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xene_NeurocrineBiosciencesMember', window );">Neurocrine Biosciences [Member] | License and Collaboration Agreement [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xene_MilestonePayment', window );">Milestone payments</a></td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xene_NeurocrineBiosciencesMember', window );">Neurocrine Biosciences [Member] | License and Collaboration Agreement [Member] | Regulatory Milestone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xene_PotentialMilestonePaymentsReceivable', window );">Potential milestone payments receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,067,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xene_NeurocrineBiosciencesMember', window );">Neurocrine Biosciences [Member] | License and Collaboration Agreement [Member] | Sales Based Milestone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xene_PotentialMilestonePaymentsReceivable', window );">Potential milestone payments receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xene_AggregateMilestonePaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate milestone payment received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xene_AggregateMilestonePaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xene_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xene_CollaborateMilestoneAgreementPremiumRelatedToEquityInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborate milestone agreement premium related to equity investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xene_CollaborateMilestoneAgreementPremiumRelatedToEquityInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xene_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xene_MilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xene_MilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xene_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xene_MilestonePaymentReceivedInCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payment received in cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xene_MilestonePaymentReceivedInCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xene_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xene_MilestonePaymentReceivedInEquityInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payment received in equity investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xene_MilestonePaymentReceivedInEquityInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xene_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xene_MilestonePaymentReceivedInEquityInvestmentMeasuredAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payment received in equity investment measured at fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xene_MilestonePaymentReceivedInEquityInvestmentMeasuredAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xene_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xene_PercentageOfOptionToFundDevelopmentCostsUponAchievementOfCertainMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of option to fund development costs upon achievement of certain milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xene_PercentageOfOptionToFundDevelopmentCostsUponAchievementOfCertainMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xene_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xene_PerformanceObligationsRelatedToMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Performance obligations in relation to this milestone.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xene_PerformanceObligationsRelatedToMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xene_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xene_PotentialMilestonePaymentsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential milestone payments receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xene_PotentialMilestonePaymentsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xene_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xene_NeurocrineBiosciencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xene_NeurocrineBiosciencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xene_LicenseAndCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xene_LicenseAndCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=xene_RegulatoryMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=xene_RegulatoryMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=xene_SalesBasedMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=xene_SalesBasedMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45905585318336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Common Share - Schedule of Basic and Diluted Net Loss Per Common Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (234,330)<span></span>
</td>
<td class="num">$ (182,393)<span></span>
</td>
<td class="num">$ (125,373)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xene_NetIncomeLossAvailableToPreferredStockholdersBasic', window );">Net loss attributable to preferred shareholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(437)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common shareholders</a></td>
<td class="num">$ (234,330)<span></span>
</td>
<td class="num">$ (182,393)<span></span>
</td>
<td class="num">$ (124,936)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xene_WeightedAverageNumberOfCommonShares', window );">Common shares (weighted average)</a></td>
<td class="nump">75,721,562<span></span>
</td>
<td class="nump">64,739,678<span></span>
</td>
<td class="nump">57,599,510<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xene_WeightedAverageNumberOfPrefundedWarrants', window );">Pre-funded warrants (weighted average)</a></td>
<td class="nump">2,173,081<span></span>
</td>
<td class="nump">2,149,327<span></span>
</td>
<td class="nump">2,942,632<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding - basic</a></td>
<td class="nump">77,894,643<span></span>
</td>
<td class="nump">66,889,005<span></span>
</td>
<td class="nump">60,542,142<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding - diluted</a></td>
<td class="nump">77,894,643<span></span>
</td>
<td class="nump">66,889,005<span></span>
</td>
<td class="nump">60,542,142<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share - basic</a></td>
<td class="num">$ (3.01)<span></span>
</td>
<td class="num">$ (2.73)<span></span>
</td>
<td class="num">$ (2.06)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share - diluted</a></td>
<td class="num">$ (3.01)<span></span>
</td>
<td class="num">$ (2.73)<span></span>
</td>
<td class="num">$ (2.06)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xene_NetIncomeLossAvailableToPreferredStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net income (loss) available to preferred stockholders basic.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xene_NetIncomeLossAvailableToPreferredStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xene_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xene_WeightedAverageNumberOfCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average number of common shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xene_WeightedAverageNumberOfCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xene_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xene_WeightedAverageNumberOfPrefundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average number of prefunded warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xene_WeightedAverageNumberOfPrefundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xene_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45905745795440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - Asset Purchase Agreement [Member] - 1st Order Pharmaceuticals, Inc. [Member]<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xene_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xene_MilestonePaymentsPaid', window );">Milestone payment paid</a></td>
<td class="nump">$ 2,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xene_RoyaltyObligations', window );">Royalty obligations</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=xene_AssetPurchaseAgreementMember', window );">Regulatory Milestone [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xene_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xene_FuturePotentialMilestonePayments', window );">Future potential payments</a></td>
<td class="nump">$ 6,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xene_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xene_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xene_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xene_FuturePotentialMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future potential milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xene_FuturePotentialMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xene_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xene_MilestonePaymentsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payments paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xene_MilestonePaymentsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xene_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xene_RoyaltyObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xene_RoyaltyObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xene_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xene_AssetPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xene_AssetPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xene_FirstOrderPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xene_FirstOrderPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=xene_RegulatoryMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=xene_RegulatoryMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45905595256384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Loss before Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Canada</a></td>
<td class="num">$ (243,410)<span></span>
</td>
<td class="num">$ (174,491)<span></span>
</td>
<td class="num">$ (121,335)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">United States</a></td>
<td class="nump">4,991<span></span>
</td>
<td class="num">(8,194)<span></span>
</td>
<td class="num">(3,920)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">$ (238,419)<span></span>
</td>
<td class="num">$ (182,685)<span></span>
</td>
<td class="num">$ (125,255)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45905599207424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Income Tax Recovery (Expense) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit', window );">United States</a></td>
<td class="num">$ (4,775)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (162)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Current income tax recovery (expense)</a></td>
<td class="num">(4,775)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(162)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit', window );">United States</a></td>
<td class="nump">8,864<span></span>
</td>
<td class="nump">$ 292<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income tax recovery (expense)</a></td>
<td class="nump">8,864<span></span>
</td>
<td class="nump">292<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax recovery (expense)</a></td>
<td class="nump">$ 4,089<span></span>
</td>
<td class="nump">$ 292<span></span>
</td>
<td class="num">$ (118)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal, state, and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national, regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal, state, and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national, regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45905595320800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Unclaimed Tax Deductions Related To Scientific Research And Experimental Development Expenditures</a></td>
<td class="nump">$ 158,629<span></span>
</td>
<td class="nump">$ 142,925<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Non-capital losses carried forward for tax purposes</a></td>
<td class="nump">$ 642,043<span></span>
</td>
<td class="nump">422,822<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardExpirationDate', window );">Tax Credit Carry forward, Expiration Date</a></td>
<td class="text">Dec. 31,  2045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits of uncertain tax positions</a></td>
<td class="nump">$ 10,850<span></span>
</td>
<td class="nump">10,850<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=xene_CanadaAndUnitedStatesRevenueAgencyMember', window );">Canada and United States Revenue Agency [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Tax year open for income tax examination</a></td>
<td class="text">2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_InvestmentCreditMember', window );">Investment Tax credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit available to offset taxes payable</a></td>
<td class="nump">$ 29,284<span></span>
</td>
<td class="nump">29,074<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=xene_ProvincialTaxCreditMember', window );">Provincial Tax Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit available to offset taxes payable</a></td>
<td class="nump">$ 8,518<span></span>
</td>
<td class="nump">$ 8,099<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OpenTaxYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax year that remains open to examination under enacted tax laws, in YYYY format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OpenTaxYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:gYearListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date of the tax credit carryforward, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=xene_CanadaAndUnitedStatesRevenueAgencyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=xene_CanadaAndUnitedStatesRevenueAgencyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_InvestmentCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_InvestmentCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=xene_ProvincialTaxCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=xene_ProvincialTaxCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45905593311136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Tax at statutory income tax rate</a></td>
<td class="nump">27.00%<span></span>
</td>
<td class="nump">27.00%<span></span>
</td>
<td class="nump">27.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(22.00%)<span></span>
</td>
<td class="num">(24.00%)<span></span>
</td>
<td class="num">(24.50%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Research and development and other credits</a></td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xene_EffectiveIncomeTaxRateReconciliationTaxAttributesExpiredOrUtilized', window );">Tax attributes expired/utilized</a></td>
<td class="num">(1.10%)<span></span>
</td>
<td class="num">(0.80%)<span></span>
</td>
<td class="num">(1.20%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="num">(3.40%)<span></span>
</td>
<td class="num">(3.20%)<span></span>
</td>
<td class="num">(2.60%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther', window );">Other non-deductible expenses</a></td>
<td class="num">(0.40%)<span></span>
</td>
<td class="num">(0.30%)<span></span>
</td>
<td class="num">(0.20%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent', window );">Other</a></td>
<td class="nump">0.30%<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
<td class="num">(1.10%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">1.70%<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of reported income tax benefit (expense) from difference to income tax expense (benefit) computed by applying statutory federal (national) income tax rate to pretax income (loss) from continuing operation, attributable to other reconciling items. Excludes state and local income tax expense (benefit), federal tax expense (benefit), statutory income tax expense (benefit) outside of country of domicile, tax credit, nondeductible expense, deduction, income tax settlement, income tax contingency, and cross-border tax law.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xene_EffectiveIncomeTaxRateReconciliationTaxAttributesExpiredOrUtilized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation, tax attributes expired or utilized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xene_EffectiveIncomeTaxRateReconciliationTaxAttributesExpiredOrUtilized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xene_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45905593307040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Net Deferred Income Tax Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred income tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credits</a></td>
<td class="nump">$ 42,830<span></span>
</td>
<td class="nump">$ 38,590<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xene_DeferredTaxAssetsTaxCreditCarryforwardsInvestment', window );">Investment tax credits</a></td>
<td class="nump">29,818<span></span>
</td>
<td class="nump">30,695<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Non-capital losses</a></td>
<td class="nump">173,352<span></span>
</td>
<td class="nump">119,765<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Depreciable assets</a></td>
<td class="nump">13,269<span></span>
</td>
<td class="nump">10,311<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xene_DeferredTaxAssetsDeferredFinancingFees', window );">Deferred financing fees</a></td>
<td class="nump">6,967<span></span>
</td>
<td class="nump">10,831<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock based compensation</a></td>
<td class="nump">8,380<span></span>
</td>
<td class="nump">3,832<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xene_DeferredTaxAssetsOperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="nump">2,299<span></span>
</td>
<td class="nump">2,779<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">1,704<span></span>
</td>
<td class="nump">852<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred income tax assets</a></td>
<td class="nump">278,619<span></span>
</td>
<td class="nump">217,655<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred income tax liability:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Operating lease right-of-use-asset</a></td>
<td class="num">(2,097)<span></span>
</td>
<td class="num">(2,411)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less - valuation allowance</a></td>
<td class="num">(266,856)<span></span>
</td>
<td class="num">(214,442)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred income tax assets</a></td>
<td class="nump">$ 9,666<span></span>
</td>
<td class="nump">$ 802<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xene_DeferredTaxAssetsDeferredFinancingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax asset attributable to taxable temporary differences from deferred financing costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xene_DeferredTaxAssetsDeferredFinancingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xene_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xene_DeferredTaxAssetsOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets, operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xene_DeferredTaxAssetsOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xene_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xene_DeferredTaxAssetsTaxCreditCarryforwardsInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets, tax credit carryforwards, investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xene_DeferredTaxAssetsTaxCreditCarryforwardsInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xene_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45905591194544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Disclosure - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>Segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription', window );">Segment Reporting, Expense Information Used by CODM, Description</a></td>
<td class="text"> The Company&#8217;s Chief Executive Officer acts as the CODM and manages the Company&#8217;s operations on a consolidated basis. The accounting policies of the segment are the same as those described in the summary of significant accounting policies.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration', window );">Segment Reporting, Expense Information Used by CODM, Type [Extensible Enumeration]</a></td>
<td class="text">Chief Executive Officer [Member]<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of nature of expense information used by chief operating decision maker (CODM) to manage operation when segment expense information by category is not disclosed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates type of expense information used by chief operating decision maker (CODM) to manage operation when segment expense information by category is not disclosed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45905599550336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Disclosure - Summary of Net Loss Related To Segment Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,434<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Direct external research and development costs</a></td>
<td class="nump">$ 210,394<span></span>
</td>
<td class="nump">$ 167,512<span></span>
</td>
<td class="nump">105,767<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xene_PersonnelRelatedExpenses', window );">Personnel-related expenses</a></td>
<td class="nump">68,340<span></span>
</td>
<td class="nump">47,739<span></span>
</td>
<td class="nump">36,088<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">stock-based compensation</a></td>
<td class="nump">50,717<span></span>
</td>
<td class="nump">32,372<span></span>
</td>
<td class="nump">20,376<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Other research and development costs</a></td>
<td class="nump">11,232<span></span>
</td>
<td class="nump">9,560<span></span>
</td>
<td class="nump">7,274<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherGeneralAndAdministrativeExpense', window );">Other general and administrative costs</a></td>
<td class="nump">20,657<span></span>
</td>
<td class="nump">14,376<span></span>
</td>
<td class="nump">9,996<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="num">(41,943)<span></span>
</td>
<td class="num">(27,620)<span></span>
</td>
<td class="num">(8,713)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherItemAmount', window );">Other segment items</a></td>
<td class="num">(3,025)<span></span>
</td>
<td class="num">(4,041)<span></span>
</td>
<td class="nump">4,943<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(234,330)<span></span>
</td>
<td class="num">(182,393)<span></span>
</td>
<td class="num">(125,373)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=xene_AzetukalnerMember', window );">Azetukalner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Direct external research and development costs</a></td>
<td class="nump">106,806<span></span>
</td>
<td class="nump">89,303<span></span>
</td>
<td class="nump">37,367<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=xene_XEN496Member', window );">XEN496</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Direct external research and development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,152<span></span>
</td>
<td class="nump">14,765<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=xene_Pre-ClinicalDiscoveryAndOtherProgramsMember', window );">Pre-clinical, discovery and other programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Direct external research and development costs</a></td>
<td class="nump">$ 21,546<span></span>
</td>
<td class="nump">$ 15,552<span></span>
</td>
<td class="nump">$ 12,711<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingOtherItemAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingOtherItemAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xene_PersonnelRelatedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Personnel related expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xene_PersonnelRelatedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xene_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=xene_AzetukalnerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=xene_AzetukalnerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=xene_XEN496Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=xene_XEN496Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=xene_Pre-ClinicalDiscoveryAndOtherProgramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=xene_Pre-ClinicalDiscoveryAndOtherProgramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>83
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( .F$6UH'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " #IA%M:)!2QU.\    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9)1
M2\,P$,>_BN2]O31%AZ'+BV-/"H(#Q;>0W+9@DX;DI-VWMZU;A^@'\#%W__SN
M=W"-B=)T"9]3%S&1PWPS^#9D:>*:'8FB!,CFB%[G<DR$L;GODM<T/M,!HC8?
M^H @.+\#CZ2M)@T3L(@+D:G&&FD2:NK2&6_-@H^?J9UAU@"VZ#%0AJJL@*EI
M8CP-;0-7P 0C3#Y_%] NQ+GZ)W;N #LGA^R65-_W95_/N7&'"MZ>'E_F=0L7
M,NE@</R5G:13Q#6[3'ZM'S:[+5."B]N"BT*L=J*2];WDJ_?)]8??5=AWUNW=
M/S:^"*H&?MV%^@)02P,$%     @ Z81;6IE<G",0!@  G"<  !,   !X;"]T
M:&5M92]T:&5M93$N>&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M
M3A^%$5B-;'EDD81_OT<V$,N6#>V23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R
M>&#9+]O6N[<OWN!7,B0103 9IZ_PP JE3%ZU6FD PSA]R1,2P]R"BPA+>!3+
MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,!
M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K
MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2
MBW <!.!1NY["G?1LOZ1!";2C:=!DV/;:KI&FJHU33]/W?=_KFVB<"HU;3]-K
M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M";^B00PTT0F-\D,-]]EL;%:O6R _=(^]3L?OGIC/&S@5%J[0JJ<12F$1VI5
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M7!H<&VY9X& '91/P_4)*L]W8 ]J_"NEO4$L#!!0    ( .F$6UJ[:K!12@8
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M6?5S*S@(PA( _Z\E3)[FHGQ >U2[_!]02P,$%     @ Z81;6GN//:F!"
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MA>/$GE, *$R0Q<\%H2B,87K9B5[F3PB\G9N)TD^0ABF=$+!G)9TZ!C'*W/O
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MI-=UR*M@EK>"[6A=O5:>0V!PN6%"+?142M?%UD0,2"]VZ>690\]%H3B-;'Z
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MDF_-X8;1B@D-4+^O.9>O7_0%3OLTE_\%4$L#!!0    ( .F$6UI=>F.E^PH
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M&?G^'M4OHFO3W25W$3>A]%CCZLE>#F!_[5S<+L3![C*[^A=02P,$%     @
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M*KQDZXL1<^J;JF5[:CKA]C()#J3=8!8YJB(XY<8YU<;+$-REP1ZC.-;?:9.
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M#TKC!7 _U]KM-][ X84Y_1=02P,$%     @ Z81;6G#]XK+! @  , 8  !D
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M7+">$W5I*K&2\-DC[YG<*LM! R/69RYRGR>T%^Z+2(5A,%4^,2>GO$G>3Q7
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MY:=C9BPFJQB,[JS[U4J:*K/:\X)<URMU;YY*&SI;5:]5;0<!T+/Y'*6D7!L
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M5+*N9N*"CJ33]KA@?$JDP>)>,TYECC%-CR3[_2U<-B_<5P4J6,&CMCV^@+H
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M(6&U:E'G$@FZVH?5JIQ]LEVZZ)P!;+O&W60_47!/\G=FA4BT&*?#833<0>A
M%G=$<V6Z#Q(QH\" J9$PG=P^%?U6QC9;WPB;-2L)(2 ",K[$J,]J&0I95WN'
MS&=!7_N?^Y&@7&"26U-P$=E.-Q@FT*-%:FHH.DJA$)D)$M#TM&#-$M:D1TBR
M<O,!:9,BPZ1\Y" ?(/>=?4=TU'()5N6K"RX7A(WR/OH3HM_''> 1\'=%O*?D
M6X!<TY( <K=T1O^ON@8R0FN90&^*VL;5%\_,B)6@KH(>B>K@ZMFO39*&]PZ\
MH^$0,0XT<]OE(:-9#:-3U?:0Q!Q19123H?A;.U%M9E\H@'BPD5EPB2Q#:C74
M%@GLH9%<$3?7?%2O5&&<)%K7%;_,91K2632$MH6XRR!X5O-4DE%59^^C^.*M
ME?*,9*Y38M<P8&HU4C7(D%2-H9)-V)E".2%_DF5-+@N]+&1TTZTY#2O?^H7U
M/QB3<O3N;;T0-RG>[32]6) >GO%.+M93Q,/]3=M(N=F(CX_W\$&B*H\W%+63
MGILEH:D!*5?5!8:D!;EWI]80.!3225NC2 0-;6%]&IU,>#F1+FM(]T&<1C%6
MJ>>!2;I\@406U1QO$1S"H4J<R6;DV=U//;9 ;&H;VM.Z*07M)]'IR;1U)K,#
MR]JYFHUOVAT1G"HERA:Z5*'K!OKXY!AM@_L03TYDP);-P;:(4=CP7O 'X7#=
M_-W8@VS2AA]L6@>^@C'"@SHO!(8\3E]#&(BR_-V$8)H9"C.'EPLO-YLF>9AB
MZXAL&JJ#=QJ^I\RT!S6S+=4FT3KP$RHGH2.M)].I<"8E9U JE!A=UWT**#93
MM)U"*D0+ P^:DT?"^.Y9FV1^52G. U4!<N56$6<-3V;*N?9M0XHG+"LQ$MUH
M[WR=4N!%II![&<;,%!%#-*S7B88WJ6=ZJQ>+,*D18\OPB/HR$8%Z_"YWF\&B
M"4E?['N;'FQ\),' LN!/032,UJ4/WTNZU>YKTTWXR++>'CY5?9(6[1%OMVJ.
MH\/^R:0G;/C\$VZ\J?B3R\QX%%*^A,F8-6D#GL\-?-S<D(+N&]SU?P%02P,$
M%     @ Z81;6O0$3D4:!   F@D  !D   !X;"]W;W)K<VAE971S+W-H965T
M,C N>&ULE59M;]LV$/[N7W%0AR(!%.O5DNW:!I*TPP:L1=!L*X9A'VCI; FE
M1(VDXN3?[TC:JM,Y+@(#,BG=/7R>XQV/BYV07U6%J.&QX:U:>I76W3P(5%%A
MP]18=-C2EXV0#=,TE=M =1)9:9T:'L1AF 4-JUMOM;#O[N1J(7K-ZQ;O)*B^
M:9A\ND$N=DLO\@XO/M?;2IL7P6K1L2W>H_ZCNY,T"P:4LFZP5;5H0>)FZ5U'
M\YO4V%N#/VO<J:,Q&"5K(;Z:R:_ET@L-(>18:(/ Z.\!;Y%S T0T_MUC>L.2
MQO%X?$#_V6HG+6NF\%;P+W6IJZ4W]:#$#>NY_BQVO^!>S\3@%8(K^X2=LTU"
M#XI>:='LG8E!4[?NGSWNXW#D,'W)(=X[Q):W6\BR?,\T6RVDV($TUH1F!E:J
M]29R=6LVY5Y+^EJ3GUY]HGW_32@%=RCA5C0-1>J^8A(7@29X8Q04>Z@;!Q6_
M !7%\%&TNE+PH2VQ? X0$*^!7'P@=Q.?17R/Q1B2R(<XC-,S>,D@-K%XR0MX
M'YALZW;KQ%J5\/?U6FE)N?'/*<$.+CT-9^IEKCI6X-*C@E H']!;O7T39>&[
M,V33@6QZ#OUU.W,>*HK&8."X@>L(KG!PRH9@#K]7"!O!J4 I.J#9FB-81:U6
MH.ECP7C1<V;K2&Q,&=0%L+:$LN:]QA+:%]'IW+ 03\BD C29 ;2OV*S)\K"W
M]IE81!K$\]%?9.W2Z)GQR!@[6V,W^M0W*)D6<CX:]/T$%Q GJ9\D(5S:632-
M_626'&;QQ$]RFGUS85K+>MT[X5H8[1N4DA:W&BK!2R3R5_2[@#3)S_D>BS\X
M_IA2ZL^2C&#?8RNHRIVDVR,H!1<[>\(0*?9 HK=X"?G$S^/(GV0Q9*F?)S,_
MRZ<PR?W);.9/HG!T)_%JT]LP[IB4S.SG"9S8C_+$#Z>1&:4S/XES&LW2V,^2
M>/3E._MG$A7DN3^=I7Z6)I!E_G0Z\\-P EGH3U*#%H]>SKRW;Z9Q%+T[D4\F
M*LDXC/8!BL=Y,@Q#"I1-V>^%0-O;1*$,?4ZQ5V14MS8/7Y.[1VFOR+_@?8FN
M(/ZW='<BTM0#E::53%&5O;2U1;ZT3"W(TR(]@5D('U$6M;(YQ#2Q>P)-K<\6
MCTL(3F141?2H'98FYTTI7K1"(\SP<FSC0?G2&5>)G9#'RHBT04)65"8XKRU'
MWX[(B\I"6+8V$B2!<^B(0JMK&CZYB%*3?:9<84':=6U(2-&X\X284LD<SI,?
M[X0+5BW=+M@;P4[TO(2*-H >Q(4Z//&X&CC@9D.=?WSJ) Z.^B4=(%M[*U"T
M8M]JUSJ'M\/%X]KUVV_F[M;RD<EM3=G!<4.NX3B?>"#=3<!-M.AL]UT+3;W<
M#BNZ/*$T!O1](RB ^XE98+B.K?X#4$L#!!0    ( .F$6UI12Y&$R@0  ! +
M   9    >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;)U6V6[;.!3]%4(MBA;(
M>%%69#&0I-/EH9B@G>5A, ^T="T1H4B52QSWZ^=<TE;L- DP\Q!'7.ZYY_ N
MY/G2NEO?$@5QWVGC+XHVA/YT//952YWT(]N3P<K"NDX&#%TS]KTC62>C3H_+
MR>1HW$EEBMEYFKMQLW,;@U:&;ISPL>ND6UV1MLN+8EIL)KZJI@T\,9Z=][*A
M;Q3^Z&\<1N,!I58=&:^L$8X6%\7E]/3J@/>G#7\J6OJM;\%*YM;>\N!S?5%,
MF!!IJ@(C2/R[HVO2FH% X_L:LQA<LN'V]P;]0](.+7/IZ=KJOU0=VHOBI! U
M+634X:M=?J*UGD/&JZSVZ5<L\][#LA!5],%V:V,PZ)3)_^7]^ARV#$XFSQB4
M:X,R\<Z.$LOW,LC9N;-+X7@WT/@C24W6(*<,!^5;<%A5L NS:]MU*N"4@Q?2
MU.+:FJ!,0Z92Y,_' 2YXX[A:PUUEN/(9N&DIO@"A]>)74U.]"S &MX%@N2%X
M5;Z(^)ZJD=B?[HER4AZ\@+<_"-Y/>/O_1[!XKWREK8^.Q-^7<Q\<LN:?IXXA
M.SEXV@E7TJGO9447!4K%D[NC8O;FU?1H<O:"A(-!PL%+Z/\]9B_#3<N1> Q9
M;4.>BK?RG;CT'CVBCZYJ405"-HZ(#9"PH153'\1OKB8G;EJ):JDH!E5)[??$
M9X,(OGWSZJ0L)V?#OC2>GKT[Q;JX[)W2B/#T>$^$EIA.+\T*-?L]*D>UD#\H
MQ%NI#1PLG.VV_(&1CQ(\@@5U(9^A.4I^8H.2XE2:/'($S0^0$@;(WK3C.;SD
MCO>)BEQ ]^->H(SB7N,%ALEXV,T.8-'96BU6::V7J[3"?;:.F@0Z[(#5*4VH
M?4-^)'YOG8U-*U )U,U!;U,-NQ) #YBJ%J]%N3>93%*SJ@4Z7^\L>'A$M@$V
M5,(,4K9]?(B!<[ZW 924U!MVGDD_'(PRE8XUB=CS_&MQE!PI;L]-U#)8MWI$
MG8 J\6>L<'8E=5@).]>JD?F<MM&1)/-WXF.4#M$DRHFH$(C.J 5R*5F<,N:.
M9K D3A%E *95A0N#DBD7GD38'J+@<ZZ&5KD:"EW@D@^M#(.P1^[XZ.Z4SU1Y
M'TO)71DWV";*,,*46R6]_D405!0YJ?4*[%)J[X00 BI\0H$,><7BQR6JJYW\
MJ&6'*W-3JSYPQE71I5+!+&O'M23L(HO])2-46JK."^ ,]@[$3)-K*J<%>A[\
MISLS1Y"O&]7%#NENHTF@#WFRR(GS6++R(J+1H*=0?29:NZ0[<KOYFNB:@*-H
MK:X]*^_(50S*JG!H=:P"(BKG2JO IXV^+$U%S$KYA[%(COPV.G>7Z?$9LN.^
MS^V<,3NY0KK(.8I-I0)V5-D[+G@H<HDXQ#&YM:RL.-?52'Q2"+SCKJ97/]>>
ML0$.:DKV/Z7 IIRBX3KR<3<M4W?8PIN35CBQ==+QRD(J)^ZDCI2#^E2>;1<6
MS@>O!=5)/1*7565=C3 _1YN/H3'J!V</IC='SM7A"&7-&8+3REZWO7!*LD5/
M3EF.&3:@'.O14[?<>.N5@D@WZ2W&<<<1YP?+,#L\]R[S*^=A>WXK?I&N0?B%
MI@5,)Z/CPT*X_/[*@V#[].:9VX!:39\MGJSD> /6%Q89O!ZP@^$1//L74$L#
M!!0    ( .F$6UIDYZ"-@0H  +L<   9    >&PO=V]R:W-H965T<R]S:&5E
M=#(R+GAM;+59:V_;.!;][E]!>+J#!% </?Q,VP!I.\46V)DIVND^L-@/M$3'
MG,JBAZ3B>'[]GDM2LAP_TBVP7Q))YKV\CW//O91>;93^:I9"6/:X*BOSNK^T
M=GUS?6WRI5AQ,U!K4>&7A=(K;G&K[Z_-6@M>.*%5>9W&\?AZQ675OWWEGGW4
MMZ]4;4M9B8^:F7JUXGK[1I1J\[J?])L'G^3]TM*#Z]M7:WXO/@O[9?U1X^ZZ
MU5+(E:B,5!738O&Z?Y?<O!G2>K?@[U)L3.>:D2=SI;[2S8?B=3\F@T0I<DL:
M./X]B+>B+$D1S/@CZ.RW6Y)@][K1_M[Y#E_FW(BWJOR'+.SR=7_:9X58\+JT
MG]3FKR+X,R)]N2J-^\LV?FV6]5E>&ZM601@6K&3E__/'$(>.P#0^(9 &@=39
M[3=R5K[CEM^^TFK#-*V&-KIPKCII&"<K2LIGJ_&KA)R]_5#E:B78;_Q1F%?7
M%AKI^74>I-]XZ?2$=)*RGU5EEX;]5!6BV%=P#5-:>]+&GC?I68WO1#Y@61*Q
M-$Z'9_1EK7^9TY<]ZQ][)TU>*E-KP?Y]-S=6 Q'_.>:SUS@\KI&JY,:L>2Y>
M]U$&1N@'T;_]\8=D'+\\8^^PM7=X3ONS^3@OG60#%C18TL!NV-^4,6PN4+Z"
MR>Y/>,+L4K"MX-HP0?ECB+Y8S85N,^#^9HQ7!5VD;,,-XR1;HIK-3>]?$/:Y
MWY/MD:P7);'>6U[Q@K,7[(*EPRP:)C&[='?)9!@-9TESER91EHW89>]+)2UT
M?K;<PM1A-,.:"S:-DMD0:R]8%LU2Z.B=],YME4VQU:Q1/DVC\734;C6*TA'=
M_;;LBH)H<O4@])9=B$<PGQ&73,)G^)MS,NE[O*^U%I6]V87AQQ^F:9*^/';U
MQ/4+.#^9D)W-2M@^3N'ZZ5_>B87 CD6[8;/@R?\G6TVCZ1AFSU(V'/;V;CZ<
M#<\+&!)/9_A/RUUPDVD([%NU6O-JZS:<O#1LLT3LME=J4V%?4\^-+"1Z0<3^
M*2IP],<E!]/FHK8RYZ5A7S[?$9X'$;L7E=#.3%C!YV6;LZ*&80H(Q0,K=.XW
M9%27,A>,WVLAT$0L>-4N'>"#30-V5Y:@6)<;YUOPR*&]"#$\"@VZN*_DG_CY
M^ZI( *[<6BWGM77.P /2LI>0 7O?47Y:-ZUXUEQ-PO/M,W$FJ&M1.J 'D[2X
MXL8(8UP0U2(\Y*7\D\]E*>V6'DIK=C;0YB2#:8'=N=VK'"NY:\-! \4ZIVT<
M1"729^!T;17L[?H 4QI+Q&(A7 \_6""_BY2H)W![9M]T,HAC]I>G_WMOE[RZ
M)RO8 R]K[Q81Q(970!QX)QU@V:4CN\[5"%>]3^@87.?+ +('3$5K%UFZ5W!3
MLQPQI'@F@PR;)H,Q;4W2P6(/&U0"8BBQ]AI9+!T847F#Q.\7#Z;^(AFDM.]G
MJ_*O5S2_%(QJ!$#WAH-+!T._-'-+R5C:\[+WJS,'>+E"*&N$GI :BL2X/8;-
M9EESD>X$W5/W,&E,H8O>3R?SF PFD'!*=G+OCD#;H\O%#+AR,)2"H&LPC+&%
M5BN'&"M6:Z7!+ZR0V!2%G@MJ%W8C1.56Y%SKK:SN&5^IVN/[I.Z]FE_("MF6
MO'3X$6T*.T:N:[U6ANJ8F-!(2"]0;EA("5 51$Q3#D]YLL(X?JRF&^.(/SJ(
M/P[SWNG0W9P&(BUJ( AJ3Z-I%N,"O70TB]$*'H2Q!PO3630%Z6=Q-)Z->K\
M,CE?2XOP8.(BM"23+,I&*5K#+)J,1S -PQ/B1Y *3B59E(YG+(FC+$EVMH=(
M(T<+ 47C:#:>T*)IEIQ&]33*IC&FA&F6]GY=4^<@!:7 RC:K6Y9&Z6R&OY/)
M+& VB2;QD$U'8 =%UI_)03J91F-,%TA8-!Z-C@:[W>KFP I-QX4KM;BJ38@
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M.V_E:0LVJBX+1[O<C<E''=B=A)K1>= ];>\, !*5I8JGF.2YKIU)8&ADQ&4
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M#^SC<BDK8:E<!"]YDOEX>1U4-ERC4G6+WP!%U\)J#%%M6(614;(.S% X9$>
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M]B !"IW5G PMT(2!$+"0P%(U\.JCQ@U!!B H/ %)CP;&7VL/OJLP)SX4A/,
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MU/XX4I92\7$V!B08=8#]QY>%2#G0DK9/TA(JL/.J//JS4/SPH$FS4?41T7L
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MAS].7,M2Z<92&[&'7W&^V.4Q&%7\YC)(+;4%)0^$VUY"'HE2:DFB1@6TL8:
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M(:@@UP:!XK*!&Z@J X0T?O28SG"E<=S?[]#O;.P8RY(JN!'57ZS0Y=Q)'5+
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M/R5)Y),XC-,C>$FO/&GQDO]2_O-B::S&W\RO0]H[Y/0PLNNCB:EI#C,/&\6
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MA0FTR'Z&Z6YTL[*?/JX;K9O*#I=2 *:9@/?SIM']C5E@^!9V]C=02P,$%
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M?V11"14-+3);&RR$QDK#/L98/((T ?A^*83>-LP 53GJ_P%02P,$%     @
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MO=Y\A&T^02#3PH8OV43?T3@A;&6=EELP*I!<Q3]]VM9A#S#,7@#D6T >=,=
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M:7FXI&1.>6$@?U\P)EY.BF\!]M]^C/\'4$L#!!0    ( .F$6UH]O5L_CP,
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MK45J'V-D%$NF WV?"*%7+V: \C\(PW\!4$L#!!0    ( .F$6UIR(RV3& ,
M (0)   9    >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;*U6;6^;,!#^*Q:K
MIE;:PFL@[1*D-FS:I%6KFK7],.V# Y?$*MC,=I+VW\\VA+R4L$[J%[#-/8_O
M.1]W'JX9?Q0+ (F>BIR*D;60LKRP;9$NH,"BQTJ@ZLN,\0)+->5S6Y0<<&9
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MX-I ?9\Q)C<3O4%S\8K_ E!+ P04    " #IA%M:#8]]1^\"   6"   &0
M 'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6R%EFMOFS 4AO_*$:NF5DK+)0&2
M+$'J1=4FM5K4RZ9IV@<'#L$J8&:;I/WWLX&R;'&2+\&W<Y[W-?@XLPWC+R)#
ME/!:Y*686YF4U=2V19QA0<0%J[!4,RGC!9&JRU>VJ#B2I DJ<MMSG, N""VM
M:-:,+7@T8[7,:8D+#J(N"L+?KC!GF[GE6N\##W2523U@1[.*K/ 1Y7.UX*IG
M]UD26F I*"N!8SJW+MWIE=L$-"N^4=R(K39H*TO&7G3G2S*W'*T(<XRE3D'4
M8XW7F.<ZD]+QNTMJ]4P=N-U^SW[;F%=FED3@-<N_TT1F<VML08(IJ7/YP#:?
ML3/DZWPQRT7S"YMNK6-!7 O)BBY8*2AHV3[):[<16P&>MR? ZP*\1G<+:E3>
M$$FB&6<;X'JURJ8;C=4F6HFCI7XKCY*K6:KB9'2'RI* <[BM9<T1[FE)B[J
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M07Q88_9.8]:WHA^8KT@A$(6EPCD7L3+%ZXM&/9"LK'KUG$G5^:O'3%W.@.L
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MLEM%Q/.[YH9@N^I2?S*A[6U4TU'-0#43U2Q4LU]XKZ@#232A56U4\U#-1[4
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MZL.?.T,E'7]VWHR.S@)=ST83=7QP<W8=W:R!:B:J6:AFHYJ#:BZJ>:CFHUJ
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MO\VR\NDO]08>L_R/S=-Y__]02P,$%     @ Z81;6KC29Q?N P  9!4  !D
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M%>:)]K7MR+=0NA62%0U815"0LG[CQR8/1P W>@'@-0"O"PA> /@-P'\M(&@
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MML,<.R]($X#[F1!Z.S$']+T\_@M02P,$%     @ Z81;6B'@@"C< P  -A0
M !D   !X;"]W;W)K<VAE971S+W-H965T-38N>&ULS5AM;]LV$/XKA%84+;!&
M;WZ),UM '*YH@:4(XG3[4.P#+9TMHI*HDI3= OWQ(RE%MC-9=C9^R!>+I.X>
MWCV\H\XWW3+^5:0 $GW/LT+,G%3*\LIU19Q"3L0%*Z%0;U:,YT2J*5^[HN1
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M_L+QG<<3M\EZ(\L3[FRZI6NX _EY>\/5D=M0EDD&N4A83CBL+IQ+_SP*AF6
MON.O!.[%WF=2=F7!V-?RX,/RPO'*)X(48EDBJ/JW@RM(TY*DGN-;#76:-LO
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MF#*0^S-*Q6:B'-3=L_\74$L#!!0    ( .F$6UH3H/(U@00  %@1   9
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M2[8S*AJYDSUIY$TN6,%:LE6E\;"&ERU#-7ZE\2#^[_SLK#5U$UZ%@[ EVSW
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MYOB=!-($X/NU$/JU809HOKSF_P-02P,$%     @ Z81;6@H;(L+4 P  :PT
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MO;@N,U$ N6-/H,B$K/"8K/<Y$+$A7_$0+6$#4L*:G.3()Z5 *_)^"9KQ7'U
MM6^K)7G_[@-Y1WA)[K9BKUBY5C-7(Z%9Q\T:FL\UC3] LX3L@@3T#^)[?FA1
MOWJ]>O!2W<6XM,'QV^#XE;U@T%[C/:^]U^@]J[R_M/E6&POMQDP^7JH=RV#N
M8,(ID =P%K__1F/OH\W3-S+VPN^@]3L8L[ZX18M,9EN"NX@Y<<!DWV'JZBH
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MQ:\AD$8 WV^$T,\3TV^WWU>+_P%02P,$%     @ Z81;6DX%;"7_ @  ;P<
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M9ZF7I)<QA.@44?P>$8>XEH2N7AY.+>'AR\-)CQI:#QPM^.B_#-PMK+A02;Y
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MA 'H]P^<J^<;\X'Z_P?S?P!02P,$%     @ Z81;6NM_J'5/ P  SA4   T
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MQ8&5T9R+E1WNPL"T$(7RM+D+3*@ 1JHG"P>V!S=(HY-S6:@ZMHU@?T^:Z7O
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MW&,EC'%BM/XU@LD/['X 4$L#!!0    ( .F$6UI-IL8P604  ,DK   /
M>&PO=V]R:V)O;VLN>&ULQ9K;;MLX$$!_A?!3%FC7MFYM@R1 +LUN@*0QZFQ>
M%[1$QT0DTDM23=VO[Y"*6\I1!OLRSI,M2I:/1B+/<*BC)VT>%UH_LN]-K>SQ
M:.7<^G \MN5*--S^J=="P9ZE-@UWL&D>QG9M!*_L2@C7U.-D,BG&#9=J='*T
M/=?,C.,-[43II%;0Z!ONI7BRO_?[3?9-6KF0M72;XU'X7HL1:Z22C?PAJN/1
M9,3L2C_]K8W\H97C];PTNJZ/1]-NQ[TP3I8OFN<>\HXO;&AQ?/&5 \CQJ)C
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M=@*]'?5V KT=]78"O0/U#@*] _4. KT#]0X"O0/U#@*] _4. KUC\K&20.]
MO8- [T"]@T#O0+V#0.] O8- [XQZ9P*],^J="?3.J'<FT#NCWIE [XQZ9P*]
M,^J="?3.DY]-OE/O.GX>2KWV?*WQ^M])]7@^MUPO?UE^[9S<XQ><TVU%??X+
M4$L#!!0    ( .F$6UJE?PYQ[@$  ) F   3    6T-O;G1E;G1?5'EP97-=
M+GAM;,W:RT[#,! %T%^ILD6-ZR</T6Z +;#@!TPRI5&3V+)=*'^/DP(2""I0
MD;B;1JWMN1./=%8]OWOV%"?;KNWCO%BEY,\8B]6*.AM+YZG/*TL7.IORU_#
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M;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( .F$6UK,/4)2,@L  "P^   8
M          " @0X(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M    " #IA%M:ERF?JK\%  #G%@  &               @(%V$P  >&PO=V]R
M:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ Z81;6H?EK@O$ @  -@@
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M965T-RYX;6Q02P$"% ,4    " #IA%M:]O8*W64"  "+!@  &
M    @(%^/P  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @
MZ81;6BQU:+Y# @  B@8  !@              ("!&4(  'AL+W=O<FMS:&5E
M=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( .F$6UK'FDCNU 0  -@*   9
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M970Q-"YX;6Q02P$"% ,4    " #IA%M:</WBLL$"   P!@  &0
M    @('V=   >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    (
M .F$6UIKM_$YM 0  *X*   9              " @>YW  !X;"]W;W)K<VAE
M971S+W-H965T,38N>&UL4$L! A0#%     @ Z81;6IXQU8K8 @  6@8  !D
M             ("!V7P  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"
M% ,4    " #IA%M:G3[:0>T3  " /0  &0              @('H?P  >&PO
M=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( .F$6UIN GJ)T0<
M (\3   9              " @0R4  !X;"]W;W)K<VAE971S+W-H965T,3DN
M>&UL4$L! A0#%     @ Z81;6O0$3D4:!   F@D  !D              ("!
M%)P  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    " #IA%M:
M44N1A,H$   0"P  &0              @(%EH   >&PO=V]R:W-H965T<R]S
M:&5E=#(Q+GAM;%!+ 0(4 Q0    ( .F$6UIDYZ"-@0H  +L<   9
M      " @6:E  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%
M  @ Z81;6LI, P\&!@  ' T  !D              ("!'K   'AL+W=O<FMS
M:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    " #IA%M:LZ(,VS$=  "N7P
M&0              @(%;M@  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+
M 0(4 Q0    ( .F$6UJO2#^\O (  /,%   9              " @</3  !X
M;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ Z81;6@\((N:@
M P  F @  !D              ("!MM8  'AL+W=O<FMS:&5E=',O<VAE970R
M-BYX;6Q02P$"% ,4    " #IA%M:\N+-G0 $  "&"   &0
M@(&-V@  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( .F$
M6UJ'E/,0QP(  "(&   9              " @<3>  !X;"]W;W)K<VAE971S
M+W-H965T,C@N>&UL4$L! A0#%     @ Z81;6MFWVD7C P  !PD  !D
M         ("!PN$  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4
M    " #IA%M:6Z(-P]D"   U!@  &0              @('<Y0  >&PO=V]R
M:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( .F$6UHZ_G'G(0<  !<3
M   9              " @>SH  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL
M4$L! A0#%     @ Z81;6NIZQI/( @  ,P8  !D              ("!1/
M 'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    " #IA%M:)"QB
M_GX#  "M!P  &0              @(%#\P  >&PO=V]R:W-H965T<R]S:&5E
M=#,S+GAM;%!+ 0(4 Q0    ( .F$6UI%;L%R.P4  *P-   9
M  " @?CV  !X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @
MZ81;6L=M8V(&!   )P@  !D              ("!:OP  'AL+W=O<FMS:&5E
M=',O<VAE970S-2YX;6Q02P$"% ,4    " #IA%M:0Q_S L "  "E!P  &0
M            @(&G  $ >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4
M Q0    ( .F$6UI+VY/C[ (  )H*   9              " @9X# 0!X;"]W
M;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ Z81;6HIBB"?F @
M] H  !D              ("!P08! 'AL+W=O<FMS:&5E=',O<VAE970S."YX
M;6Q02P$"% ,4    " #IA%M:$&-645@"  !/!0  &0              @('>
M"0$ >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( .F$6UK$
MVZBGVP4  )<M   9              " @6T, 0!X;"]W;W)K<VAE971S+W-H
M965T-# N>&UL4$L! A0#%     @ Z81;6B-XJVYN @  %@8  !D
M     ("!?Q(! 'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( .F$6UH-CWU'[P(  !8(   9              "
M@3,G 0!X;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @ Z81;
M6@RR]4LB P  ^@D  !D              ("!62H! 'AL+W=O<FMS:&5E=',O
M<VAE970T-RYX;6Q02P$"% ,4    " #IA%M:7QP(^W89  !6E@$ &0
M        @(&R+0$ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0
M   ( .F$6UJXTF<7[@,  &05   9              " @5]' 0!X;"]W;W)K
M<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @ Z81;6OY1E1-(!0  N!D
M !D              ("!A$L! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q0
M2P$"% ,4    " #IA%M:+\<SI_L"  ")"   &0              @($#40$
M>&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    ( .F$6UJE<:4U
M4 ,  '@*   9              " @354 0!X;"]W;W)K<VAE971S+W-H965T
M-3(N>&UL4$L! A0#%     @ Z81;6DJ?9! +!   8A$  !D
M ("!O%<! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q02P$"% ,4    " #I
MA%M:[X^BU=D"  #9"   &0              @('^6P$ >&PO=V]R:W-H965T
M<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    ( .F$6UI4>3F@J (  -<'   9
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M970U.2YX;6Q02P$"% ,4    " #IA%M:!C,QH=8"   W"   &0
M    @(%2<P$ >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+ 0(4 Q0    (
M .F$6UH%8L,I#0,  $D+   9              " @5]V 0!X;"]W;W)K<VAE
M971S+W-H965T-C$N>&UL4$L! A0#%     @ Z81;6A.@\C6!!   6!$  !D
M             ("!HWD! 'AL+W=O<FMS:&5E=',O<VAE970V,BYX;6Q02P$"
M% ,4    " #IA%M:IQF-Q+,#  "%#0  &0              @(%;?@$ >&PO
M=V]R:W-H965T<R]S:&5E=#8S+GAM;%!+ 0(4 Q0    ( .F$6UH*&R+"U ,
M &L-   9              " @46" 0!X;"]W;W)K<VAE971S+W-H965T-C0N
M>&UL4$L! A0#%     @ Z81;6DX%;"7_ @  ;P<  !D              ("!
M4(8! 'AL+W=O<FMS:&5E=',O<VAE970V-2YX;6Q02P$"% ,4    " #IA%M:
M)M7KJ@ %  !+&   &0              @(&&B0$ >&PO=V]R:W-H965T<R]S
M:&5E=#8V+GAM;%!+ 0(4 Q0    ( .F$6UKK?ZAU3P,  ,X5   -
M      "  ;V. 0!X;"]S='EL97,N>&UL4$L! A0#%     @ Z81;6I>*NQS
M    $P(   L              ( !-Y(! %]R96QS+RYR96QS4$L! A0#%
M  @ Z81;6DVFQC!9!0  R2L   \              ( !(),! 'AL+W=O<FMB
M;V]K+GAM;%!+ 0(4 Q0    ( .F$6UH>WYE>' (  #TG   :
M  "  ::8 0!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    (
M .F$6UJE?PYQ[@$  ) F   3              "  ?J: 0!;0V]N=&5N=%]4
?>7!E<UTN>&UL4$L%!@    !* $H /10  !F= 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>160</ContextCount>
  <ElementCount>348</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>61</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="xene-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="xene-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="xene-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="xene-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100040 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="xene-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100050 - Statement - Consolidated Statements of Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xenon-pharma.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity</Role>
      <ShortName>Consolidated Statements of Shareholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="xene-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100060 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="xene-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100070 - Disclosure - Cybersecurity Risk Management, Strategy, and Governance</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance</Role>
      <ShortName>Cybersecurity Risk Management, Strategy, and Governance</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="xene-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="xene-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="xene-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995455 - Disclosure - Nature of the Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureNatureOfBusiness</Role>
      <ShortName>Nature of the Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="xene-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995465 - Disclosure - Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentation</Role>
      <ShortName>Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="xene-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995475 - Disclosure - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPolicies</Role>
      <ShortName>Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="xene-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995495 - Disclosure - Fair Value of Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstruments1</Role>
      <ShortName>Fair Value of Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="xene-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995505 - Disclosure - Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureMarketableSecurities</Role>
      <ShortName>Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="xene-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995515 - Disclosure - Property, Plant and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipment</Role>
      <ShortName>Property, Plant and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="xene-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995525 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureLeases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="xene-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995535 - Disclosure - Accounts Payable and Accrued Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureAccountsPayableAndAccruedLiabilities</Role>
      <ShortName>Accounts Payable and Accrued Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="xene-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995555 - Disclosure - Share Capital</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapital</Role>
      <ShortName>Share Capital</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="xene-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995575 - Disclosure - Collaboration Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCollaborationAgreements</Role>
      <ShortName>Collaboration Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="xene-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995585 - Disclosure - Net Loss Per Common Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureNetLossPerCommonShare</Role>
      <ShortName>Net Loss Per Common Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="xene-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995595 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="xene-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995605 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="xene-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995615 - Disclosure - Segment Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureSegmentDisclosure1</Role>
      <ShortName>Segment Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="xene-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995625 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="xene-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995635 - Disclosure - Significant Accounting Policies  (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesTables</Role>
      <ShortName>Significant Accounting Policies  (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="xene-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995645 - Disclosure - Fair Value of Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsTables</Role>
      <ShortName>Fair Value of Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstruments1</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="xene-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995655 - Disclosure - Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureMarketableSecuritiesTables</Role>
      <ShortName>Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureMarketableSecurities</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="xene-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995665 - Disclosure - Property, Plant and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentTables</Role>
      <ShortName>Property, Plant and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipment</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="xene-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995675 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureLeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureLeases</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="xene-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995685 - Disclosure - Accounts Payable and Accrued Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureAccountsPayableAndAccruedLiabilitiesTables</Role>
      <ShortName>Accounts Payable and Accrued Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureAccountsPayableAndAccruedLiabilities</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="xene-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>995695 - Disclosure - Share Capital (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalTables</Role>
      <ShortName>Share Capital (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapital</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="xene-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>995705 - Disclosure - Collaboration Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCollaborationAgreementsTables</Role>
      <ShortName>Collaboration Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCollaborationAgreements</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="xene-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>995715 - Disclosure - Net Loss Per Common Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureNetLossPerCommonShareTables</Role>
      <ShortName>Net Loss Per Common Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureNetLossPerCommonShare</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="xene-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>995725 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxes</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="xene-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>995735 - Disclosure - Segment Disclosure (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureSegmentDisclosureTables</Role>
      <ShortName>Segment Disclosure (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureSegmentDisclosure1</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="xene-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>995755 - Disclosure - Nature of the business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureNatureOfBusinessDetails</Role>
      <ShortName>Nature of the business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="xene-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>995765 - Disclosure - Basis of Presentation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationDetails</Role>
      <ShortName>Basis of Presentation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentation</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="xene-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>995775 - Disclosure - Significant Accounting Policies - Property Plant and Equipment Estimated Useful Lives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPropertyPlantAndEquipmentEstimatedUsefulLivesDetails</Role>
      <ShortName>Significant Accounting Policies - Property Plant and Equipment Estimated Useful Lives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="xene-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>995785 - Disclosure - Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesDetails</Role>
      <ShortName>Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="xene-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>995805 - Disclosure - Fair Value of Financial Instruments - Schedule of Financial Assets Measured at Fair Value on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFinancialAssetsMeasuredAtFairValueOnARecurringBasisDetails</Role>
      <ShortName>Fair Value of Financial Instruments - Schedule of Financial Assets Measured at Fair Value on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="xene-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>995815 - Disclosure - Marketable Securities - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails</Role>
      <ShortName>Marketable Securities - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="xene-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>995825 - Disclosure - Marketable Securities - Summary of Amortized Cost, Unrealized Gain (Loss) Recognized in AOCI and Fair Value of Available-for-Sale Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAmortizedCostUnrealizedGainLossRecognizedInAociAndFairValueOfAvailableforsaleSecuritiesDetails</Role>
      <ShortName>Marketable Securities - Summary of Amortized Cost, Unrealized Gain (Loss) Recognized in AOCI and Fair Value of Available-for-Sale Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="xene-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>995835 - Disclosure - Property, Plant and Equipment - Summary of Property, Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails</Role>
      <ShortName>Property, Plant and Equipment - Summary of Property, Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="xene-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>995845 - Disclosure - Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureLeasesDetails</Role>
      <ShortName>Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureLeasesTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="xene-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>995855 - Disclosure - Leases - Schedule of Cost Components of Operating Lease (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureLeasesScheduleOfCostComponentsOfOperatingLeaseDetails</Role>
      <ShortName>Leases - Schedule of Cost Components of Operating Lease (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="xene-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>995865 - Disclosure - Leases - Future Minimum Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureLeasesFutureMinimumLeasePaymentsDetails</Role>
      <ShortName>Leases - Future Minimum Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="xene-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>995875 - Disclosure - Accounts Payable and Accrued Liabilities - Accounts Payable and Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureAccountsPayableAndAccruedLiabilitiesAccountsPayableAndAccruedLiabilitiesDetails</Role>
      <ShortName>Accounts Payable and Accrued Liabilities - Accounts Payable and Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="xene-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>995885 - Disclosure - Share Capital (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalDetails</Role>
      <ShortName>Share Capital (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="xene-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>995895 - Disclosure - Share Capital - Stock Based Compensation Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalStockBasedCompensationExpensesDetails</Role>
      <ShortName>Share Capital - Stock Based Compensation Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="xene-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>995905 - Disclosure - Share Capital - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalStockOptionActivityDetails</Role>
      <ShortName>Share Capital - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="xene-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>995915 - Disclosure - Share Capital - Stock Option Activity (Parenthetical) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalStockOptionActivityParentheticalDetails</Role>
      <ShortName>Share Capital - Stock Option Activity (Parenthetical) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="xene-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>995925 - Disclosure - Share Capital - Fair Value Assumptions for Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalFairValueAssumptionsForStockOptionsDetails</Role>
      <ShortName>Share Capital - Fair Value Assumptions for Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="xene-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>995935 - Disclosure - Share Capital - Summary of UnVested Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureShareCapitalSummaryOfUnvestedStockOptionActivityDetails</Role>
      <ShortName>Share Capital - Summary of UnVested Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="xene-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>995945 - Disclosure - Share Capital - Schedule of Pre-Funded Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureShareCapitalScheduleOfPrefundedWarrantsDetails</Role>
      <ShortName>Share Capital - Schedule of Pre-Funded Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="xene-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>995955 - Disclosure - Share capital - Schedule of Pre-Funded Warrants (Parenthetical) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureShareCapitalScheduleOfPrefundedWarrantsParentheticalDetails</Role>
      <ShortName>Share capital - Schedule of Pre-Funded Warrants (Parenthetical) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="xene-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>995975 - Disclosure - Collaboration Agreements - Schedule of Collaboration Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCollaborationAgreementsScheduleOfCollaborationRevenueDetails</Role>
      <ShortName>Collaboration Agreements - Schedule of Collaboration Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="xene-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>995985 - Disclosure - Collaboration Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCollaborationAgreementsDetails</Role>
      <ShortName>Collaboration Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCollaborationAgreementsTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="xene-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>995995 - Disclosure - Net Loss Per Common Share - Schedule of Basic and Diluted Net Loss Per Common Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfBasicAndDilutedNetLossPerCommonShareDetails</Role>
      <ShortName>Net Loss Per Common Share - Schedule of Basic and Diluted Net Loss Per Common Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="xene-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>996015 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="xene-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>996025 - Disclosure - Income Taxes - Schedule of Loss before Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfLossBeforeIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Schedule of Loss before Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="xene-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>996035 - Disclosure - Income Taxes - Schedule of Income Tax Recovery (Expense) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxRecoveryExpenseDetails</Role>
      <ShortName>Income Taxes - Schedule of Income Tax Recovery (Expense) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="xene-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>996045 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="xene-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>996055 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails</Role>
      <ShortName>Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="xene-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>996065 - Disclosure - Income Taxes - Schedule of Net Deferred Income Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfNetDeferredIncomeTaxAssetsDetails</Role>
      <ShortName>Income Taxes - Schedule of Net Deferred Income Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="xene-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>996075 - Disclosure - Segment Disclosure - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureSegmentDisclosureAdditionalInformationDetails</Role>
      <ShortName>Segment Disclosure - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="xene-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>996085 - Disclosure - Segment Disclosure - Summary of Net Loss Related To Segment Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureSegmentDisclosureSummaryOfNetLossRelatedToSegmentExpensesDetails</Role>
      <ShortName>Segment Disclosure - Summary of Net Loss Related To Segment Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="xene-20241231.htm">xene-20241231.htm</File>
    <File>xene-20241231.xsd</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img255015816_0.jpg</File>
    <File>img255015816_1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="679">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="12">http://xbrl.sec.gov/cyd/2024</BaseTaxonomy>
    <BaseTaxonomy items="42">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>90
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "xene-20241231.htm": {
   "nsprefix": "xene",
   "nsuri": "http://www.xenon-pharma.com/20241231",
   "dts": {
    "inline": {
     "local": [
      "xene-20241231.htm"
     ]
    },
    "schema": {
     "local": [
      "xene-20241231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2023/calculation-1.1.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    }
   },
   "keyStandard": 300,
   "keyCustom": 48,
   "axisStandard": 25,
   "axisCustom": 0,
   "memberStandard": 26,
   "memberCustom": 30,
   "hidden": {
    "total": 15,
    "http://fasb.org/us-gaap/2024": 11,
    "http://xbrl.sec.gov/dei/2024": 3,
    "http://www.xenon-pharma.com/20241231": 1
   },
   "contextCount": 160,
   "entityCount": 1,
   "segmentCount": 61,
   "elementCount": 714,
   "unitCount": 7,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 679,
    "http://xbrl.sec.gov/dei/2024": 42,
    "http://xbrl.sec.gov/cyd/2024": 12,
    "http://xbrl.sec.gov/ecd/2024": 4
   },
   "report": {
    "R1": {
     "role": "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
     "longName": "100010 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "C_3aefa32f-83d0-4641-9a89-a5c3e50f304f",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3aefa32f-83d0-4641-9a89-a5c3e50f304f",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
     "longName": "100020 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "C_3aefa32f-83d0-4641-9a89-a5c3e50f304f",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3aefa32f-83d0-4641-9a89-a5c3e50f304f",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "longName": "100040 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.xenon-pharma.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity",
     "longName": "100050 - Statement - Consolidated Statements of Shareholders' Equity",
     "shortName": "Consolidated Statements of Shareholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "C_7bc29ce6-ec8e-46b1-9da8-77d97bcac7c2",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7bc29ce6-ec8e-46b1-9da8-77d97bcac7c2",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
     "longName": "100060 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance",
     "longName": "100070 - Disclosure - Cybersecurity Risk Management, Strategy, and Governance",
     "shortName": "Cybersecurity Risk Management, Strategy, and Governance",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R9": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "C_33309322-16ac-4275-af41-8afa3963db9f",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_33309322-16ac-4275-af41-8afa3963db9f",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureNatureOfBusiness",
     "longName": "995455 - Disclosure - Nature of the Business",
     "shortName": "Nature of the Business",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentation",
     "longName": "995465 - Disclosure - Basis of Presentation",
     "shortName": "Basis of Presentation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2",
      "name": "us-gaap:BasisOfAccounting",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2",
      "name": "us-gaap:BasisOfAccounting",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPolicies",
     "longName": "995475 - Disclosure - Significant Accounting Policies",
     "shortName": "Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstruments1",
     "longName": "995495 - Disclosure - Fair Value of Financial Instruments",
     "shortName": "Fair Value of Financial Instruments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureMarketableSecurities",
     "longName": "995505 - Disclosure - Marketable Securities",
     "shortName": "Marketable Securities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipment",
     "longName": "995515 - Disclosure - Property, Plant and Equipment",
     "shortName": "Property, Plant and Equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureLeases",
     "longName": "995525 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureAccountsPayableAndAccruedLiabilities",
     "longName": "995535 - Disclosure - Accounts Payable and Accrued Liabilities",
     "shortName": "Accounts Payable and Accrued Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapital",
     "longName": "995555 - Disclosure - Share Capital",
     "shortName": "Share Capital",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCollaborationAgreements",
     "longName": "995575 - Disclosure - Collaboration Agreements",
     "shortName": "Collaboration Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureNetLossPerCommonShare",
     "longName": "995585 - Disclosure - Net Loss Per Common Share",
     "shortName": "Net Loss Per Common Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies",
     "longName": "995595 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxes",
     "longName": "995605 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureSegmentDisclosure1",
     "longName": "995615 - Disclosure - Segment Disclosure",
     "shortName": "Segment Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies",
     "longName": "995625 - Disclosure - Significant Accounting Policies (Policies)",
     "shortName": "Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "24",
     "firstAnchor": {
      "contextRef": "C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2",
      "name": "us-gaap:UseOfEstimates",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2",
      "name": "us-gaap:UseOfEstimates",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesTables",
     "longName": "995635 - Disclosure - Significant Accounting Policies  (Tables)",
     "shortName": "Significant Accounting Policies  (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2",
      "name": "xene:ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2",
      "name": "xene:ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsTables",
     "longName": "995645 - Disclosure - Fair Value of Financial Instruments (Tables)",
     "shortName": "Fair Value of Financial Instruments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureMarketableSecuritiesTables",
     "longName": "995655 - Disclosure - Marketable Securities (Tables)",
     "shortName": "Marketable Securities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentTables",
     "longName": "995665 - Disclosure - Property, Plant and Equipment (Tables)",
     "shortName": "Property, Plant and Equipment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureLeasesTables",
     "longName": "995675 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureAccountsPayableAndAccruedLiabilitiesTables",
     "longName": "995685 - Disclosure - Accounts Payable and Accrued Liabilities (Tables)",
     "shortName": "Accounts Payable and Accrued Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalTables",
     "longName": "995695 - Disclosure - Share Capital (Tables)",
     "shortName": "Share Capital (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCollaborationAgreementsTables",
     "longName": "995705 - Disclosure - Collaboration Agreements (Tables)",
     "shortName": "Collaboration Agreements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureNetLossPerCommonShareTables",
     "longName": "995715 - Disclosure - Net Loss Per Common Share (Tables)",
     "shortName": "Net Loss Per Common Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables",
     "longName": "995725 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureSegmentDisclosureTables",
     "longName": "995735 - Disclosure - Segment Disclosure (Tables)",
     "shortName": "Segment Disclosure (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureNatureOfBusinessDetails",
     "longName": "995755 - Disclosure - Nature of the business (Details)",
     "shortName": "Nature of the business (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "C_3aefa32f-83d0-4641-9a89-a5c3e50f304f",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R37": {
     "role": "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationDetails",
     "longName": "995765 - Disclosure - Basis of Presentation (Details)",
     "shortName": "Basis of Presentation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b",
      "name": "us-gaap:PriorPeriodReclassificationAdjustment",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:BasisOfAccounting",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b",
      "name": "us-gaap:PriorPeriodReclassificationAdjustment",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:BasisOfAccounting",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPropertyPlantAndEquipmentEstimatedUsefulLivesDetails",
     "longName": "995775 - Disclosure - Significant Accounting Policies - Property Plant and Equipment Estimated Useful Lives (Details)",
     "shortName": "Significant Accounting Policies - Property Plant and Equipment Estimated Useful Lives (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "C_01045051-1058-4f3f-b914-02cf2190b1d1",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "xene:ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_01045051-1058-4f3f-b914-02cf2190b1d1",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "xene:ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesDetails",
     "longName": "995785 - Disclosure - Significant Accounting Policies (Details)",
     "shortName": "Significant Accounting Policies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2",
      "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2",
      "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFinancialAssetsMeasuredAtFairValueOnARecurringBasisDetails",
     "longName": "995805 - Disclosure - Fair Value of Financial Instruments - Schedule of Financial Assets Measured at Fair Value on a Recurring Basis (Details)",
     "shortName": "Fair Value of Financial Instruments - Schedule of Financial Assets Measured at Fair Value on a Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "C_3cd561ce-d56f-4072-b50b-523fee0cd886",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3cd561ce-d56f-4072-b50b-523fee0cd886",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails",
     "longName": "995815 - Disclosure - Marketable Securities - Additional Information (Details)",
     "shortName": "Marketable Securities - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "C_f956e4c2-abe5-46ae-8429-402134a46f35",
      "name": "us-gaap:TradingSecuritiesDebt",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f956e4c2-abe5-46ae-8429-402134a46f35",
      "name": "us-gaap:TradingSecuritiesDebt",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAmortizedCostUnrealizedGainLossRecognizedInAociAndFairValueOfAvailableforsaleSecuritiesDetails",
     "longName": "995825 - Disclosure - Marketable Securities - Summary of Amortized Cost, Unrealized Gain (Loss) Recognized in AOCI and Fair Value of Available-for-Sale Securities (Details)",
     "shortName": "Marketable Securities - Summary of Amortized Cost, Unrealized Gain (Loss) Recognized in AOCI and Fair Value of Available-for-Sale Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "C_3aefa32f-83d0-4641-9a89-a5c3e50f304f",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3aefa32f-83d0-4641-9a89-a5c3e50f304f",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails",
     "longName": "995835 - Disclosure - Property, Plant and Equipment - Summary of Property, Plant and Equipment (Details)",
     "shortName": "Property, Plant and Equipment - Summary of Property, Plant and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "C_3aefa32f-83d0-4641-9a89-a5c3e50f304f",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3aefa32f-83d0-4641-9a89-a5c3e50f304f",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureLeasesDetails",
     "longName": "995845 - Disclosure - Leases (Details)",
     "shortName": "Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "C_b6853865-a835-4d1f-bb65-e80788e06f13",
      "name": "xene:LesseeOperatingLeaseNumberOfRenewalOptions",
      "unitRef": "U_Option",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "us-gaap:LesseeOperatingLeaseDescription",
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b6853865-a835-4d1f-bb65-e80788e06f13",
      "name": "xene:LesseeOperatingLeaseNumberOfRenewalOptions",
      "unitRef": "U_Option",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "us-gaap:LesseeOperatingLeaseDescription",
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureLeasesScheduleOfCostComponentsOfOperatingLeaseDetails",
     "longName": "995855 - Disclosure - Leases - Schedule of Cost Components of Operating Lease (Details)",
     "shortName": "Leases - Schedule of Cost Components of Operating Lease (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureLeasesFutureMinimumLeasePaymentsDetails",
     "longName": "995865 - Disclosure - Leases - Future Minimum Lease Payments (Details)",
     "shortName": "Leases - Future Minimum Lease Payments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "C_3aefa32f-83d0-4641-9a89-a5c3e50f304f",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3aefa32f-83d0-4641-9a89-a5c3e50f304f",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureAccountsPayableAndAccruedLiabilitiesAccountsPayableAndAccruedLiabilitiesDetails",
     "longName": "995875 - Disclosure - Accounts Payable and Accrued Liabilities - Accounts Payable and Accrued Liabilities (Details)",
     "shortName": "Accounts Payable and Accrued Liabilities - Accounts Payable and Accrued Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "C_3aefa32f-83d0-4641-9a89-a5c3e50f304f",
      "name": "us-gaap:AccountsPayableTradeCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3aefa32f-83d0-4641-9a89-a5c3e50f304f",
      "name": "us-gaap:AccountsPayableTradeCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalDetails",
     "longName": "995885 - Disclosure - Share Capital (Details)",
     "shortName": "Share Capital (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "C_f956e4c2-abe5-46ae-8429-402134a46f35",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f956e4c2-abe5-46ae-8429-402134a46f35",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalStockBasedCompensationExpensesDetails",
     "longName": "995895 - Disclosure - Share Capital - Stock Based Compensation Expenses (Details)",
     "shortName": "Share Capital - Stock Based Compensation Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalStockOptionActivityDetails",
     "longName": "995905 - Disclosure - Share Capital - Stock Option Activity (Details)",
     "shortName": "Share Capital - Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "C_f956e4c2-abe5-46ae-8429-402134a46f35",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7bc29ce6-ec8e-46b1-9da8-77d97bcac7c2",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalStockOptionActivityParentheticalDetails",
     "longName": "995915 - Disclosure - Share Capital - Stock Option Activity (Parenthetical) (Details)",
     "shortName": "Share Capital - Stock Option Activity (Parenthetical) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2",
      "name": "xene:StockOptionsExercisedForNumberOfCommonSharesForCash",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2",
      "name": "xene:StockOptionsExercisedForNumberOfCommonSharesForCash",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalFairValueAssumptionsForStockOptionsDetails",
     "longName": "995925 - Disclosure - Share Capital - Fair Value Assumptions for Stock Options (Details)",
     "shortName": "Share Capital - Fair Value Assumptions for Stock Options (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureShareCapitalSummaryOfUnvestedStockOptionActivityDetails",
     "longName": "995935 - Disclosure - Share Capital - Summary of UnVested Stock Option Activity (Details)",
     "shortName": "Share Capital - Summary of UnVested Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "C_f956e4c2-abe5-46ae-8429-402134a46f35",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureShareCapitalScheduleOfPrefundedWarrantsDetails",
     "longName": "995945 - Disclosure - Share Capital - Schedule of Pre-Funded Warrants (Details)",
     "shortName": "Share Capital - Schedule of Pre-Funded Warrants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "C_f956e4c2-abe5-46ae-8429-402134a46f35",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "xene:ScheduleOfPreFundedWarrantsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7bc29ce6-ec8e-46b1-9da8-77d97bcac7c2",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "xene:ScheduleOfPreFundedWarrantsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureShareCapitalScheduleOfPrefundedWarrantsParentheticalDetails",
     "longName": "995955 - Disclosure - Share capital - Schedule of Pre-Funded Warrants (Parenthetical) (Details)",
     "shortName": "Share capital - Schedule of Pre-Funded Warrants (Parenthetical) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b",
      "name": "xene:CommonStockIssuedForPreFundedWarrants",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "div",
       "xene:ScheduleOfPreFundedWarrantsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b",
      "name": "xene:CommonStockIssuedForPreFundedWarrants",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "div",
       "xene:ScheduleOfPreFundedWarrantsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCollaborationAgreementsScheduleOfCollaborationRevenueDetails",
     "longName": "995975 - Disclosure - Collaboration Agreements - Schedule of Collaboration Revenue (Details)",
     "shortName": "Collaboration Agreements - Schedule of Collaboration Revenue (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_779d7deb-a421-4227-83c3-8ac2dfc35f90",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
       "div",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCollaborationAgreementsDetails",
     "longName": "995985 - Disclosure - Collaboration Agreements (Details)",
     "shortName": "Collaboration Agreements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_494ce105-0b9f-4d43-a7ae-9d4280f4ce87",
      "name": "xene:PotentialMilestonePaymentsReceivable",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfBasicAndDilutedNetLossPerCommonShareDetails",
     "longName": "995995 - Disclosure - Net Loss Per Common Share - Schedule of Basic and Diluted Net Loss Per Common Share (Details)",
     "shortName": "Net Loss Per Common Share - Schedule of Basic and Diluted Net Loss Per Common Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2",
      "name": "xene:WeightedAverageNumberOfCommonShares",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetails",
     "longName": "996015 - Disclosure - Commitments and Contingencies (Details)",
     "shortName": "Commitments and Contingencies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "C_0451fb9b-54f6-4a4b-8ade-92b89ad35f70",
      "name": "xene:MilestonePaymentsPaid",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0451fb9b-54f6-4a4b-8ade-92b89ad35f70",
      "name": "xene:MilestonePaymentsPaid",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfLossBeforeIncomeTaxesDetails",
     "longName": "996025 - Disclosure - Income Taxes - Schedule of Loss before Income Taxes (Details)",
     "shortName": "Income Taxes - Schedule of Loss before Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxRecoveryExpenseDetails",
     "longName": "996035 - Disclosure - Income Taxes - Schedule of Income Tax Recovery (Expense) (Details)",
     "shortName": "Income Taxes - Schedule of Income Tax Recovery (Expense) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2",
      "name": "us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2",
      "name": "us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails",
     "longName": "996045 - Disclosure - Income Taxes (Details)",
     "shortName": "Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2",
      "name": "us-gaap:IncomeTaxReconciliationTaxCreditsResearch",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2",
      "name": "us-gaap:IncomeTaxReconciliationTaxCreditsResearch",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails",
     "longName": "996055 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)",
     "shortName": "Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfNetDeferredIncomeTaxAssetsDetails",
     "longName": "996065 - Disclosure - Income Taxes - Schedule of Net Deferred Income Tax Assets (Details)",
     "shortName": "Income Taxes - Schedule of Net Deferred Income Tax Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "C_3aefa32f-83d0-4641-9a89-a5c3e50f304f",
      "name": "us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3aefa32f-83d0-4641-9a89-a5c3e50f304f",
      "name": "us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureSegmentDisclosureAdditionalInformationDetails",
     "longName": "996075 - Disclosure - Segment Disclosure - Additional Information (Details)",
     "shortName": "Segment Disclosure - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2",
      "name": "us-gaap:SegmentReportingExpenseInformationUsedByCodmDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2",
      "name": "us-gaap:SegmentReportingExpenseInformationUsedByCodmDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureSegmentDisclosureSummaryOfNetLossRelatedToSegmentExpensesDetails",
     "longName": "996085 - Disclosure - Segment Disclosure - Summary of Net Loss Related To Segment Expenses (Details)",
     "shortName": "Segment Disclosure - Summary of Net Loss Related To Segment Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2",
      "name": "xene:PersonnelRelatedExpenses",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xene-20241231.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingChangesAndErrorCorrectionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingChangesAndErrorCorrectionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Changes and Error Corrections [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureAccountsPayableAndAccruedLiabilitiesAccountsPayableAndAccruedLiabilitiesDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "totalLabel": "Total",
        "terseLabel": "Accounts payable and accrued liabilities (note 8)",
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r57"
     ]
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureAccountsPayableAndAccruedLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accounts Payable and Accrued Liabilities",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r57",
      "r60",
      "r1127"
     ]
    },
    "us-gaap_AccountsPayableTradeCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableTradeCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureAccountsPayableAndAccruedLiabilitiesAccountsPayableAndAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Trade, Current",
        "terseLabel": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r55"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable",
        "totalLabel": "Accounts Receivable, after Allowance for Credit Loss, Current, Total",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r1060"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureAccountsPayableAndAccruedLiabilitiesAccountsPayableAndAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Current [Abstract]",
        "terseLabel": "Accrued Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureAccountsPayableAndAccruedLiabilitiesAccountsPayableAndAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Professional fees",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "xene_AccruedResearchAndDevelopmentCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "AccruedResearchAndDevelopmentCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureAccountsPayableAndAccruedLiabilitiesAccountsPayableAndAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Research and Development, Current",
        "documentation": "Accrued research and development, current.",
        "terseLabel": "Research and development"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: accumulated depreciation and amortization",
        "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total",
        "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance",
        "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r137",
      "r677"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss",
        "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r18",
      "r70",
      "r143",
      "r672",
      "r705",
      "r708"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r8",
      "r18",
      "r489",
      "r492",
      "r580",
      "r701",
      "r702",
      "r1037",
      "r1038",
      "r1039",
      "r1047",
      "r1048",
      "r1049",
      "r1050"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r956"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r723",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1141",
      "r1205"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r969"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r969"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r969"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r969"
     ]
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "crdr": "credit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense (note 9c)",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "xene_AggregateMilestonePaymentReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "AggregateMilestonePaymentReceived",
     "crdr": "credit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate milestone payment received.",
        "label": "Aggregate Milestone Payment Received",
        "terseLabel": "Milestone Payment Received"
       }
      }
     },
     "auth_ref": []
    },
    "xene_AggregatePriceOfTransactionAllocatedToPerformanceObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "AggregatePriceOfTransactionAllocatedToPerformanceObligations",
     "crdr": "credit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate price of transaction allocated to performance obligations",
        "label": "Aggregate Price Of Transaction Allocated To Performance Obligations",
        "verboseLabel": "Transaction price allocated to performance obligations"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r1014"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r927",
      "r938",
      "r948",
      "r981"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r930",
      "r941",
      "r951",
      "r984"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r1015"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r969"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r976"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r931",
      "r942",
      "r952",
      "r976",
      "r985",
      "r989",
      "r997"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r995"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalStockBasedCompensationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r408",
      "r414"
     ]
    },
    "xene_AmendedAndRestatedStockOptionPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "AmendedAndRestatedStockOptionPlanMember",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended and restated stock option plan.",
        "label": "Amended And Restated Stock Option Plan [Member]",
        "terseLabel": "Amended and Restated Stock Option Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of EPS",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r205"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCollaborationAgreementsDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r475"
     ]
    },
    "xene_AssetPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "AssetPurchaseAgreementMember",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset purchase agreement.",
        "label": "Asset Purchase Agreement [Member]",
        "terseLabel": "Asset Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r108",
      "r138",
      "r167",
      "r210",
      "r218",
      "r234",
      "r237",
      "r282",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r477",
      "r481",
      "r534",
      "r668",
      "r760",
      "r844",
      "r845",
      "r878",
      "r905",
      "r1091",
      "r1092",
      "r1160"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "Total current assets",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r144",
      "r167",
      "r282",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r477",
      "r481",
      "r534",
      "r878",
      "r1091",
      "r1092",
      "r1160"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFinancialAssetsMeasuredAtFairValueOnARecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Assets, Fair Value Disclosure, Total",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Financial assets",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r508",
      "r509",
      "r866"
     ]
    },
    "xene_AtMarketEquityOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "AtMarketEquityOfferingMember",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At -the -market equity offering.",
        "label": "At Market Equity Offering [Member]",
        "terseLabel": "At-The-Market Equity Offering [Member]",
        "verboseLabel": "ATM [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r910",
      "r911",
      "r934"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r910",
      "r911",
      "r934"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r910",
      "r911",
      "r934"
     ]
    },
    "dei_AuditorOpinionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorOpinionTextBlock",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Opinion [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1018"
     ]
    },
    "xene_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax",
     "crdr": "credit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAmortizedCostUnrealizedGainLossRecognizedInAociAndFairValueOfAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized Gain (Loss)",
        "label": "Available For Sale Debt Securities Accumulated Gross Unrealized Gain (Loss) Before Tax",
        "documentation": "Available for sale debt securities accumulated gross unrealized gain (loss) before tax."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAmortizedCostUnrealizedGainLossRecognizedInAociAndFairValueOfAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Unrealized Gain (Loss)",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Unrealized Loss",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r257"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAmortizedCostUnrealizedGainLossRecognizedInAociAndFairValueOfAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "verboseLabel": "Amortized Cost",
        "totalLabel": "Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r253",
      "r299",
      "r667"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAmortizedCostUnrealizedGainLossRecognizedInAociAndFairValueOfAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Debt Securities, Available-for-Sale, Total",
        "label": "Debt Securities, Available-for-Sale",
        "verboseLabel": "Fair Value",
        "terseLabel": "Trading securities available-for-sale",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r254",
      "r299",
      "r508",
      "r660",
      "r866",
      "r870",
      "r1061",
      "r1145",
      "r1146",
      "r1147"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAmortizedCostUnrealizedGainLossRecognizedInAociAndFairValueOfAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Current",
        "verboseLabel": "Contractual maturity of 0 to 1 years, Fair Value",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current."
       }
      }
     },
     "auth_ref": [
      "r250",
      "r299"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAmortizedCostUnrealizedGainLossRecognizedInAociAndFairValueOfAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Noncurrent",
        "verboseLabel": "Contractual maturity of 1 to 3 years, Fair Value",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r250",
      "r299"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r992"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r993"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r988"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r988"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r988"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r988"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r988"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r988"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalStockBasedCompensationExpensesDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r379",
      "r380",
      "r381",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r991"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r990"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r989"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r989"
     ]
    },
    "xene_AzetukalnerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "AzetukalnerMember",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureSegmentDisclosureSummaryOfNetLossRelatedToSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Azetukalner",
        "label": "Azetukalner [Member]",
        "documentation": "Azetukalner."
       }
      }
     },
     "auth_ref": []
    },
    "xene_BVFPartnersLPMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "BVFPartnersLPMember",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BVF Partners L P.",
        "label": "B V F Partners L P [Member]",
        "terseLabel": "BVF Partners L.P [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfAccounting": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccounting",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Accounting [Text Block]",
        "terseLabel": "Basis of Presentation",
        "documentation": "The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "xene_BasisOfPresentationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "BasisOfPresentationLineItems",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Basis of presentation.",
        "label": "Basis Of Presentation [Line Items]",
        "terseLabel": "Basis of Presentation [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "xene_BasisOfPresentationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "BasisOfPresentationTable",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Basis of presentation.",
        "label": "Basis Of Presentation [Table]",
        "terseLabel": "Basis Of Presentation [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "xene_BurnabyBritishColumbiaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "BurnabyBritishColumbiaMember",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Burnaby, British Columbia.",
        "label": "Burnaby British Columbia [Member]",
        "terseLabel": "Burnaby, British Columbia [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "xene_CanadaAndUnitedStatesRevenueAgencyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "CanadaAndUnitedStatesRevenueAgencyMember",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Canada and United States revenue agency.",
        "label": "Canada And United States Revenue Agency [Member]",
        "terseLabel": "Canada and United States Revenue Agency [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r134",
      "r829"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFinancialAssetsMeasuredAtFairValueOnARecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "verboseLabel": "Cash and cash equivalents",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1143",
      "r1144"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and cash equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "xene_CashAndMoneyMarketFundMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "CashAndMoneyMarketFundMember",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFinancialAssetsMeasuredAtFairValueOnARecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and money market fund.",
        "label": "Cash and Money Market Fund [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureConcentrationsOfMarketRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "terseLabel": "Cash and cash equivalents and marketable securities",
        "totalLabel": "Cash, Cash Equivalents, and Short-Term Investments, Total",
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable."
       }
      }
     },
     "auth_ref": [
      "r1036"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "periodEndLabel": "Cash and cash equivalents, end of year",
        "periodStartLabel": "Cash and cash equivalents, beginning of year",
        "totalLabel": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r76",
      "r163"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Increase (decrease) in cash and cash equivalents",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r76"
     ]
    },
    "xene_CashReceivedForLeaseIncentives": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "CashReceivedForLeaseIncentives",
     "crdr": "debit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash received for lease incentives",
        "label": "Cash received for lease incentives",
        "documentation": "Cash received for lease incentives."
       }
      }
     },
     "auth_ref": []
    },
    "xene_CashlessExerciseOfStockOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "CashlessExerciseOfStockOptions",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalStockOptionActivityParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised via net exercise (cashless) method during the current period.",
        "label": "Cashless Exercise Of Stock Options",
        "terseLabel": "Cashless exercise of stock options"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureChangesInSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Accounting Principle, Accounting Standards Update, Adoption Date",
        "terseLabel": "Change in accounting principle, adoption date",
        "documentation": "Date accounting standards update was adopted, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r122",
      "r130",
      "r246",
      "r283",
      "r284",
      "r285",
      "r290",
      "r291",
      "r292",
      "r303",
      "r312",
      "r448",
      "r457",
      "r458",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r483",
      "r484",
      "r485",
      "r486",
      "r497",
      "r498",
      "r499",
      "r501",
      "r532",
      "r533",
      "r554",
      "r576",
      "r578",
      "r623",
      "r624",
      "r699",
      "r700",
      "r1023"
     ]
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureChangesInSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Accounting Principle, Accounting Standards Update, Early Adoption [true false]",
        "terseLabel": "Change in accounting principle, early adoption",
        "documentation": "Indicates (true false) whether accounting standards update was early adopted."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r176",
      "r246",
      "r283",
      "r286",
      "r292",
      "r303",
      "r312",
      "r449",
      "r459",
      "r469",
      "r471",
      "r486",
      "r499",
      "r501",
      "r532",
      "r533",
      "r625",
      "r699",
      "r700"
     ]
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureChangesInSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]",
        "terseLabel": "Change in accounting principle, material impact",
        "documentation": "Indicates (true false) whether effect from applying amendment to accounting standards is immaterial."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r191",
      "r288"
     ]
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateTransitionOptionElectedExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateTransitionOptionElectedExtensibleList",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureChangesInSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Accounting Principle, Accounting Standards Update, Transition Option Elected [Extensible Enumeration]",
        "terseLabel": "Change in Accounting Principle, Accounting Standards Update, Transition Option Elected [Extensible Enumeration]",
        "documentation": "Indicates transition method applied for adoption of amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r293",
      "r450",
      "r462",
      "r464",
      "r470",
      "r471",
      "r472",
      "r488",
      "r500",
      "r503",
      "r551",
      "r552",
      "r553",
      "r555",
      "r556",
      "r557",
      "r579",
      "r701",
      "r709"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r967"
     ]
    },
    "srt_ChiefExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ChiefExecutiveOfficerMember",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureSegmentDisclosureAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Executive Officer [Member]"
       }
      }
     },
     "auth_ref": [
      "r1059"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r964"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r962"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r140",
      "r141",
      "r142",
      "r167",
      "r198",
      "r199",
      "r202",
      "r204",
      "r212",
      "r213",
      "r282",
      "r323",
      "r325",
      "r326",
      "r327",
      "r330",
      "r331",
      "r348",
      "r349",
      "r352",
      "r355",
      "r362",
      "r534",
      "r716",
      "r717",
      "r718",
      "r719",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r748",
      "r770",
      "r789",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r1020",
      "r1043",
      "r1052"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Warrants exercise price per common share",
        "verboseLabel": "Exercise Price",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r363"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right",
        "terseLabel": "Warrants outstanding to purchase common stock",
        "verboseLabel": "Pre-Funded Warrants to Purchase Common Shares",
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureShareCapitalScheduleOfPrefundedWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Outstanding, ending",
        "periodStartLabel": "Outstanding, beginning",
        "label": "Class of Warrant or Right, Outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "xene_ClinicalDevelopementAndOtherMilestoneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "ClinicalDevelopementAndOtherMilestoneMember",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical developement and other milestone.",
        "label": "Clinical Developement And Other Milestone [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "xene_ClinicalDevelopmentMilestonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "ClinicalDevelopmentMilestonesMember",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical development milestones.",
        "label": "Clinical Development Milestones [Member]",
        "terseLabel": "Clinical Development Milestones [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r968"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r968"
     ]
    },
    "xene_CollaborateAgreementPremiumRelatedToEquityInvestment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "CollaborateAgreementPremiumRelatedToEquityInvestment",
     "crdr": "credit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborate agreement premium related to equity investment.",
        "label": "Collaborate Agreement Premium Related To Equity Investment",
        "terseLabel": "Collaborate agreement premium related to equity investment"
       }
      }
     },
     "auth_ref": []
    },
    "xene_CollaborateMilestoneAgreementPremiumRelatedToEquityInvestment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "CollaborateMilestoneAgreementPremiumRelatedToEquityInvestment",
     "crdr": "credit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCollaborationAgreementsDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborate milestone agreement premium related to equity investment.",
        "label": "Collaborate Milestone Agreement Premium Related To Equity Investment",
        "terseLabel": "Premium"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCollaborationAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaboration Agreements",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r112",
      "r126"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCollaborationAgreementsDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCollaborationAgreementsScheduleOfCollaborationRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r475"
     ]
    },
    "us-gaap_CommercialPaperMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommercialPaperMember",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFinancialAssetsMeasuredAtFairValueOnARecurringBasisDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAmortizedCostUnrealizedGainLossRecognizedInAociAndFairValueOfAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commercial Paper [Member]",
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r322",
      "r899",
      "r900",
      "r901",
      "r902"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies (note 12)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r100",
      "r670",
      "r747"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r314",
      "r315",
      "r812",
      "r1082",
      "r1087"
     ]
    },
    "xene_CommitmentsAndContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "CommitmentsAndContingenciesLineItems",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and contingencies.",
        "label": "Commitments And Contingencies [Line Items]",
        "terseLabel": "Commitments And Contingencies [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "xene_CommitmentsAndContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "CommitmentsAndContingenciesTable",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and contingencies.",
        "label": "Commitments And Contingencies [Table]",
        "terseLabel": "Commitments And Contingencies [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "xene_CommonStockIssuedForCashlessExercise": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "CommonStockIssuedForCashlessExercise",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalStockOptionActivityParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common stock issued in exchange for share options (or share units) exercised via net exercise (cashless) method during the current period.",
        "label": "Common Stock Issued For Cashless Exercise",
        "terseLabel": "Common stock issued for cashless exercise"
       }
      }
     },
     "auth_ref": []
    },
    "xene_CommonStockIssuedForPreFundedWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "CommonStockIssuedForPreFundedWarrants",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureShareCapitalScheduleOfPrefundedWarrantsParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock issued for pre-funded warrants",
        "label": "Common Stock Issued For Pre Funded Warrants",
        "documentation": "Common stock issued for pre-funded warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureShareCapitalScheduleOfPrefundedWarrantsParentheticalDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common Shares [Member]",
        "verboseLabel": "Common Shares [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r895",
      "r896",
      "r897",
      "r899",
      "r900",
      "r901",
      "r902",
      "r1047",
      "r1048",
      "r1050",
      "r1141",
      "r1202",
      "r1205"
     ]
    },
    "us-gaap_CommonStockNoParValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockNoParValue",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, No Par Value",
        "terseLabel": "Common shares, without par value",
        "documentation": "Face amount per share of no-par value common stock."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "us-gaap_CommonStockSharesAuthorizedUnlimited": {
     "xbrltype": "authorizedUnlimitedItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorizedUnlimited",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized, Unlimited [Fixed List]",
        "terseLabel": "Common shares, shares authorized",
        "documentation": "Indicates whether number of common shares permitted to be issued is unlimited. Acceptable value is \"Unlimited\"."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common shares, Outstanding",
        "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance",
        "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r64",
      "r748",
      "r766",
      "r1205",
      "r1206"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common shares, without par value; unlimited shares authorized; issued and outstanding: 76,416,086 (December 31, 2023 - 75,370,977) (note 9)",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r671",
      "r878"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r973"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r972"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r974"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r971"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r150",
      "r152",
      "r158",
      "r662",
      "r684",
      "r685"
     ]
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPropertyPlantAndEquipmentEstimatedUsefulLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer Equipment [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r28",
      "r49",
      "r50",
      "r245",
      "r811"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r28",
      "r49",
      "r50",
      "r245",
      "r711",
      "r811"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r28",
      "r49",
      "r50",
      "r245",
      "r811",
      "r1022"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of credit risk:",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r114"
     ]
    },
    "us-gaap_ConcentrationRiskDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskDisclosureTextBlock",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureConcentrationsOfMarketRisk"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Disclosure [Text Block]",
        "terseLabel": "Concentration of Market Risk",
        "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskLineItems",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureConcentrationsOfMarketRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Concentration Risk [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r811"
     ]
    },
    "us-gaap_ConcentrationRiskTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskTable",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureConcentrationsOfMarketRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk [Table]",
        "terseLabel": "Concentration Risk [Table]",
        "documentation": "Disclosure of information about concentration risk. Includes, but is not limited to, percentage of concentration risk and benchmark serving as denominator in calculation of percentage of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r28",
      "r29",
      "r49",
      "r98",
      "r811"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r28",
      "r49",
      "r50",
      "r245",
      "r811"
     ]
    },
    "srt_ConsolidatedEntitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ConsolidatedEntitiesAxis",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Axis]",
        "terseLabel": "Consolidated Entities"
       }
      }
     },
     "auth_ref": [
      "r172",
      "r477",
      "r478",
      "r481",
      "r482",
      "r586",
      "r817",
      "r1090",
      "r1093",
      "r1094"
     ]
    },
    "srt_ConsolidatedEntitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ConsolidatedEntitiesDomain",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Domain]",
        "terseLabel": "Consolidated Entities"
       }
      }
     },
     "auth_ref": [
      "r172",
      "r477",
      "r478",
      "r481",
      "r482",
      "r586",
      "r817",
      "r1090",
      "r1093",
      "r1094"
     ]
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CorporateDebtSecuritiesMember",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFinancialAssetsMeasuredAtFairValueOnARecurringBasisDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAmortizedCostUnrealizedGainLossRecognizedInAociAndFairValueOfAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Corporate Debt Securities [Member]",
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment."
       }
      }
     },
     "auth_ref": [
      "r857",
      "r859",
      "r866",
      "r879",
      "r893",
      "r1199"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCollaborationAgreementsDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCollaborationAgreementsScheduleOfCollaborationRevenueDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "auth_ref": [
      "r170",
      "r171",
      "r333",
      "r350",
      "r585",
      "r604",
      "r666",
      "r831",
      "r833"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentFederalStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxRecoveryExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Federal, State and Local, Tax Expense (Benefit)",
        "totalLabel": "Current Federal, State and Local, Tax Expense (Benefit), Total",
        "negatedLabel": "United States",
        "documentation": "Amount of current federal, state, and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national, regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1026"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentForeignTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxRecoveryExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Canada",
        "label": "Current Foreign Tax Expense (Benefit)",
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1026",
      "r1045"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxRecoveryExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit)",
        "negatedTotalLabel": "Current income tax recovery (expense)",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r445",
      "r1045"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxRecoveryExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Current:"
       }
      }
     },
     "auth_ref": []
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r919",
      "r1008"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r919",
      "r1008"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r921",
      "r1010"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r921",
      "r1010"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r923",
      "r1012"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r921",
      "r1010"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r914",
      "r1003"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r915",
      "r1004"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r915",
      "r1004"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r913",
      "r1002"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r913",
      "r1002"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]"
       }
      }
     },
     "auth_ref": [
      "r913",
      "r1002"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r916",
      "r1005"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r918",
      "r1007"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r918",
      "r1007"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r919",
      "r1008"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r922",
      "r1011"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r920",
      "r1009"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r917",
      "r1006"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureTermLoan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Term Loan",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r165",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r321",
      "r322",
      "r332",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r341",
      "r343",
      "r344",
      "r346",
      "r550"
     ]
    },
    "xene_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTaxCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTaxCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAmortizedCostUnrealizedGainLossRecognizedInAociAndFairValueOfAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contractual maturity of 0 to 1 years, Unrealized Gain (Loss)",
        "label": "Debt Securities Available For Sale Accumulated Gross Unrealized Gain (Loss) Before Tax Current",
        "documentation": "Debt securities available for sale accumulated gross unrealized gain (loss) before tax current"
       }
      }
     },
     "auth_ref": []
    },
    "xene_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTaxNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTaxNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAmortizedCostUnrealizedGainLossRecognizedInAociAndFairValueOfAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contractual maturity of 1 to 3 years, Unrealized Gain (Loss)",
        "label": "Debt Securities Available For Sale Accumulated Gross Unrealized Gain (Loss) Before Tax Noncurrent",
        "documentation": "Debt securities available for sale accumulated gross unrealized gain (loss) before tax noncurrent."
       }
      }
     },
     "auth_ref": []
    },
    "xene_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAmortizedCostUnrealizedGainLossRecognizedInAociAndFairValueOfAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Contractual maturity of 0 to 1 years, Unrealized Gain (Loss)",
        "verboseLabel": "Contractual maturity of 0 to 1 years, Unrealized Gain (Loss)",
        "documentation": "Debt securities, available-for-sale, accumulated gross unrealized loss, before tax, current.",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax, Current"
       }
      }
     },
     "auth_ref": []
    },
    "xene_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAmortizedCostUnrealizedGainLossRecognizedInAociAndFairValueOfAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Contractual maturity of 1 to 3 years, Unrealized Gain (Loss)",
        "verboseLabel": "Contractual maturity of 1 to 3 years, Unrealized Gain (Loss)",
        "documentation": "Debt securities, available-for-sale, accumulated gross unrealized loss, before tax, noncurrent",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax, Noncurrent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAmortizedCostUnrealizedGainLossRecognizedInAociAndFairValueOfAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Current",
        "verboseLabel": "Contractual maturity of 0 to 1 years, Amortized Cost",
        "totalLabel": "Contractual maturity of 0 to 1 years, Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current."
       }
      }
     },
     "auth_ref": [
      "r299",
      "r1064"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAmortizedCostUnrealizedGainLossRecognizedInAociAndFairValueOfAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Noncurrent",
        "verboseLabel": "Contractual maturity of 1 to 3 years, Amortized Cost",
        "totalLabel": "Contractual maturity of 1 to 3 years, Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r299",
      "r1064"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAmortizedCostUnrealizedGainLossRecognizedInAociAndFairValueOfAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Table]",
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureMarketableSecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Summary of Amortized Cost, Unrealized Gain (Losses) Recognized in AOCI and Fair Value of Available-for-Sale Securities",
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1075"
     ]
    },
    "us-gaap_DebtSecuritiesTradingUnrealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesTradingUnrealizedGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized fair value gain (loss) on trading securities",
        "negatedLabel": "Unrealized fair value (gain) loss on trading securities",
        "totalLabel": "Debt Securities, Trading, Unrealized Gain (Loss), Total",
        "label": "Debt Securities, Trading, Unrealized Gain (Loss)",
        "documentation": "Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in net income (trading)."
       }
      }
     },
     "auth_ref": [
      "r1063",
      "r1076"
     ]
    },
    "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredFederalStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxRecoveryExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Federal, State and Local, Tax Expense (Benefit)",
        "totalLabel": "Deferred Federal, State and Local, Tax Expense (Benefit), Total",
        "negatedLabel": "United States",
        "documentation": "Amount of deferred federal, state, and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national, regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1130"
     ]
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxRecoveryExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "negatedLabel": "Canada",
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1045",
      "r1139"
     ]
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxAssetsNet",
     "crdr": "debit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets (note 13)",
        "label": "Deferred Income Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r423",
      "r424"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxRecoveryExpenseDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit)",
        "negatedTotalLabel": "Deferred income tax recovery (expense)",
        "terseLabel": "Deferred income tax recovery",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r120",
      "r1045"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxRecoveryExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred:",
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "xene_DeferredTaxAssetsDeferredFinancingFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "DeferredTaxAssetsDeferredFinancingFees",
     "crdr": "debit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfNetDeferredIncomeTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax asset attributable to taxable temporary differences from deferred financing costs.",
        "label": "Deferred Tax Assets Deferred Financing Fees",
        "terseLabel": "Deferred financing fees"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfNetDeferredIncomeTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred income tax assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r439"
     ]
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGrossAbstract",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfNetDeferredIncomeTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross [Abstract]",
        "terseLabel": "Deferred income tax assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfNetDeferredIncomeTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Net deferred income tax assets",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1135"
     ]
    },
    "xene_DeferredTaxAssetsOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "DeferredTaxAssetsOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfNetDeferredIncomeTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liability",
        "label": "Deferred Tax Assets, Operating Lease Liability",
        "documentation": "Deferred tax assets, operating lease liability."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfNetDeferredIncomeTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Non-capital losses",
        "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1137"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfNetDeferredIncomeTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r1137"
     ]
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfNetDeferredIncomeTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Property, Plant and Equipment",
        "terseLabel": "Depreciable assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r1137"
     ]
    },
    "xene_DeferredTaxAssetsTaxCreditCarryforwardsInvestment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsInvestment",
     "crdr": "debit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfNetDeferredIncomeTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment tax credits",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Investment",
        "documentation": "Deferred tax assets, tax credit carryforwards, investment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfNetDeferredIncomeTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development tax credits",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1137"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfNetDeferredIncomeTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "terseLabel": "Stock based compensation",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r1137"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfNetDeferredIncomeTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Less - valuation allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r440"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesAbstract",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfNetDeferredIncomeTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross [Abstract]",
        "terseLabel": "Deferred income tax liability:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "crdr": "credit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfNetDeferredIncomeTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "negatedLabel": "Operating lease right-of-use-asset",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements."
       }
      }
     },
     "auth_ref": [
      "r1137"
     ]
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "totalLabel": "Depreciation, Depletion and Amortization, Nonproduction, Total",
        "terseLabel": "Depreciation of property, plant and equipment",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r37"
     ]
    },
    "us-gaap_DescriptionOfInterestRateRiskExposure": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DescriptionOfInterestRateRiskExposure",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureConcentrationsOfMarketRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of Interest Rate Risk Exposure",
        "terseLabel": "Interest rate risk, description",
        "documentation": "Description of the sources of interest rate risk exposure faced by the entity."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r43",
      "r44",
      "r45",
      "r46",
      "r48"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r910",
      "r911",
      "r934"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r910",
      "r911",
      "r934",
      "r977"
     ]
    },
    "dei_DocumentFinStmtRestatementRecoveryAnalysisFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtRestatementRecoveryAnalysisFlag",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Restatement Recovery Analysis [Flag]",
        "documentation": "Indicates whether any of the financial statement periods include restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to \u00a7240.10D-1(b)."
       }
      }
     },
     "auth_ref": [
      "r910",
      "r911",
      "r934",
      "r977"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r955"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r908"
     ]
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r966"
     ]
    },
    "us-gaap_EarliestTaxYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarliestTaxYearMember",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earliest Tax Year [Member]",
        "terseLabel": "Earliest Tax Year [Member]",
        "documentation": "Earliest identified tax year."
       }
      }
     },
     "auth_ref": [
      "r1134"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Net loss per common share (note 11):"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfBasicAndDilutedNetLossPerCommonShareDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Earnings Per Share, Basic, Total",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic",
        "verboseLabel": "Net loss per common share - basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r195",
      "r198",
      "r202",
      "r203",
      "r204",
      "r209",
      "r465",
      "r474",
      "r505",
      "r506",
      "r663",
      "r686",
      "r836"
     ]
    },
    "us-gaap_EarningsPerShareBasicLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasicLineItems",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfBasicAndDilutedNetLossPerCommonShareDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureNetLossPerCommonShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r199",
      "r202"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfBasicAndDilutedNetLossPerCommonShareDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Earnings Per Share, Diluted, Total",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted",
        "verboseLabel": "Net loss per common share - diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r198",
      "r202",
      "r203",
      "r204",
      "r209",
      "r465",
      "r474",
      "r505",
      "r506",
      "r663",
      "r686",
      "r836"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net income (loss) per common share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r24",
      "r206"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureNetLossPerCommonShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Common Share",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r194",
      "r205",
      "r207",
      "r208"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r540"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Effective income tax rate",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r427",
      "r863"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Canadian federal and provincial tax rates",
        "verboseLabel": "Tax at statutory income tax rate",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r427",
      "r451",
      "r863"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r430",
      "r863",
      "r1046",
      "r1131"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent",
        "terseLabel": "Other non-deductible expenses",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r863",
      "r1046",
      "r1131",
      "r1133"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r863",
      "r1046",
      "r1131",
      "r1133"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent",
        "terseLabel": "Other",
        "documentation": "Percentage of reported income tax benefit (expense) from difference to income tax expense (benefit) computed by applying statutory federal (national) income tax rate to pretax income (loss) from continuing operation, attributable to other reconciling items. Excludes state and local income tax expense (benefit), federal tax expense (benefit), statutory income tax expense (benefit) outside of country of domicile, tax credit, nondeductible expense, deduction, income tax settlement, income tax contingency, and cross-border tax law."
       }
      }
     },
     "auth_ref": [
      "r1132"
     ]
    },
    "xene_EffectiveIncomeTaxRateReconciliationTaxAttributesExpiredOrUtilized": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxAttributesExpiredOrUtilized",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Tax attributes expired/utilized",
        "label": "Effective Income Tax Rate Reconciliation, Tax Attributes Expired Or Utilized",
        "documentation": "Effective income tax rate reconciliation, tax attributes expired or utilized.",
        "terseLabel": "Tax attributes expired/utilized"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent",
        "totalLabel": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent, Total",
        "terseLabel": "Research and development and other credits",
        "negatedLabel": "Research and development and other credits",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits."
       }
      }
     },
     "auth_ref": [
      "r429",
      "r431",
      "r1046",
      "r1131"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureAccountsPayableAndAccruedLiabilitiesAccountsPayableAndAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Employee compensation, benefits, and related accruals",
        "totalLabel": "Employee-related Liabilities, Current, Total",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "totalLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total",
        "terseLabel": "Unrecognized stock-based compensation cost not to be achieved",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r409"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized stock-based compensation expected to be recognized over a period",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r409"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized stock-based compensation cost to be achieved",
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r1126"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalStockBasedCompensationExpensesDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "terseLabel": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r907"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "verboseLabel": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r907"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r907"
     ]
    },
    "dei_EntityIncorporationDateOfIncorporation": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationDateOfIncorporation",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, Date of Incorporation",
        "terseLabel": "Date of incorporation",
        "documentation": "Date when an entity was incorporated"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r1017"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r907"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r907"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r907"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r907"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r1019"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r960"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r1013"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r1013"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r1013"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureShareCapitalScheduleOfPrefundedWarrantsDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureShareCapitalScheduleOfPrefundedWarrantsParentheticalDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r129",
      "r154",
      "r155",
      "r156",
      "r173",
      "r174",
      "r175",
      "r179",
      "r186",
      "r188",
      "r190",
      "r211",
      "r287",
      "r293",
      "r304",
      "r364",
      "r446",
      "r447",
      "r460",
      "r461",
      "r462",
      "r466",
      "r473",
      "r474",
      "r487",
      "r489",
      "r490",
      "r491",
      "r492",
      "r494",
      "r504",
      "r541",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r554",
      "r559",
      "r580",
      "r682",
      "r701",
      "r702",
      "r703",
      "r723",
      "r789"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r970"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r927",
      "r938",
      "r948",
      "r981"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r924",
      "r935",
      "r945",
      "r978"
     ]
    },
    "xene_ExchangeAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "ExchangeAgreementMember",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exchange agreement.",
        "label": "Exchange Agreement [Member]",
        "terseLabel": "Exchange Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r976"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFinancialAssetsMeasuredAtFairValueOnARecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Assets Measured at Fair Value on a Recurring Basis [Line Items]",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r508",
      "r509",
      "r522",
      "r866"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFinancialAssetsMeasuredAtFairValueOnARecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r508",
      "r509",
      "r522",
      "r866"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "verboseLabel": "Schedule of Financial Assets Measured at Fair Value on a Recurring Basis",
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r1143",
      "r1144"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFinancialAssetsMeasuredAtFairValueOnARecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Domain]",
        "documentation": "Class of asset."
       }
      }
     },
     "auth_ref": [
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r523",
      "r868"
     ]
    },
    "xene_FairValueAssumptionsForStockOptionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "FairValueAssumptionsForStockOptionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value assumptions for stock options.",
        "label": "Fair Value Assumptions For Stock Options [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByAssetClassAxis",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFinancialAssetsMeasuredAtFairValueOnARecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Axis]",
        "documentation": "Information by class of asset."
       }
      }
     },
     "auth_ref": [
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r523",
      "r868"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFinancialAssetsMeasuredAtFairValueOnARecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r340",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r507",
      "r509",
      "r510",
      "r511",
      "r512",
      "r521",
      "r522",
      "r524",
      "r591",
      "r592",
      "r593",
      "r852",
      "r853",
      "r857",
      "r858",
      "r859",
      "r866",
      "r870"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFinancialAssetsMeasuredAtFairValueOnARecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r508",
      "r509",
      "r510",
      "r512",
      "r866",
      "r1146",
      "r1149"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstruments1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Text Block]",
        "verboseLabel": "Fair Value of Financial Instruments",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r517",
      "r519",
      "r520",
      "r521",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r659",
      "r866",
      "r871"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFinancialAssetsMeasuredAtFairValueOnARecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "verboseLabel": "Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r340",
      "r368",
      "r373",
      "r509",
      "r522",
      "r591",
      "r857",
      "r858",
      "r859",
      "r866"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFinancialAssetsMeasuredAtFairValueOnARecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "verboseLabel": "Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r340",
      "r368",
      "r373",
      "r509",
      "r510",
      "r522",
      "r592",
      "r852",
      "r853",
      "r857",
      "r858",
      "r859",
      "r866"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFinancialAssetsMeasuredAtFairValueOnARecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "verboseLabel": "Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r340",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r509",
      "r510",
      "r511",
      "r512",
      "r522",
      "r593",
      "r852",
      "r853",
      "r857",
      "r858",
      "r859",
      "r866",
      "r870"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFinancialAssetsMeasuredAtFairValueOnARecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r508",
      "r509",
      "r510",
      "r512",
      "r866",
      "r1146",
      "r1149"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFinancialAssetsMeasuredAtFairValueOnARecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r340",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r507",
      "r509",
      "r510",
      "r511",
      "r512",
      "r521",
      "r522",
      "r524",
      "r591",
      "r592",
      "r593",
      "r852",
      "r853",
      "r857",
      "r858",
      "r859",
      "r866",
      "r870"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFinancialAssetsMeasuredAtFairValueOnARecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring [Member]",
        "verboseLabel": "Recurring Basis [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r866",
      "r1143",
      "r1144",
      "r1145",
      "r1146",
      "r1147",
      "r1149"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Financial instruments and fair value",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "xene_FairValueOfPreFundedWarrantsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "FairValueOfPreFundedWarrantsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of pre-funded warrants exercised",
        "label": "Fair value of pre-funded warrants exercised",
        "documentation": "Fair Value Of Pre-funded Warrants Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "xene_FairValueOfStockOptionsExercisedOnCashlessBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "FairValueOfStockOptionsExercisedOnCashlessBasis",
     "crdr": "credit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate grant-date fair value of stock options exercised via net exercise (cashless) during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Fair Value Of Stock Options Exercised On Cashless Basis",
        "terseLabel": "Fair value of stock options exercised on a cashless basis"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAmortizedCostUnrealizedGainLossRecognizedInAociAndFairValueOfAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r300",
      "r301",
      "r302",
      "r345",
      "r360",
      "r495",
      "r529",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r683",
      "r851",
      "r866",
      "r868",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r879",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1075",
      "r1077",
      "r1078",
      "r1079",
      "r1142",
      "r1145",
      "r1146",
      "r1147",
      "r1148",
      "r1149"
     ]
    },
    "xene_FirstOrderPharmaceuticalsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "FirstOrderPharmaceuticalsIncMember",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1st Order Pharmaceuticals, Inc.",
        "label": "First Order Pharmaceuticals Inc [Member]",
        "terseLabel": "1st Order Pharmaceuticals, Inc. [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "xene_FirstRenewalOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "FirstRenewalOptionMember",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "First Renewal Option [Member]",
        "documentation": "First renewal option."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyExchangeRateTranslation1": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyExchangeRateTranslation1",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalStockOptionActivityParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Currency Exchange Rate, Translation",
        "terseLabel": "Foreign exchange rate translation",
        "documentation": "Foreign exchange rate used to translate amounts denominated in functional currency to reporting currency."
       }
      }
     },
     "auth_ref": [
      "r548",
      "r549"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "crdr": "credit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Foreign exchange gain (loss)",
        "label": "Gain (Loss), Foreign Currency Transaction, before Tax",
        "totalLabel": "Foreign Currency Transaction Gain (Loss), before Tax, Total",
        "terseLabel": "Foreign exchange (loss) gain",
        "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r536",
      "r537",
      "r538",
      "r539",
      "r786"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionGainLossUnrealized",
     "crdr": "credit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Unrealized foreign exchange (gain) loss",
        "label": "Unrealized Gain (Loss), Foreign Currency Transaction, before Tax",
        "documentation": "Amount, before tax, of unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r768",
      "r903",
      "r1151",
      "r1152",
      "r1204"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign currency translation",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r535"
     ]
    },
    "us-gaap_ForeignExchangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignExchangeMember",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureConcentrationsOfMarketRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Exchange [Member]",
        "terseLabel": "Foreign Currency Exchange Risk [Member]",
        "documentation": "Trading of derivative or nonderivative instruments whose primary underlying risk is tied to foreign exchange rates."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r931",
      "r942",
      "r952",
      "r985"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r931",
      "r942",
      "r952",
      "r985"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r931",
      "r942",
      "r952",
      "r985"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r931",
      "r942",
      "r952",
      "r985"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r931",
      "r942",
      "r952",
      "r985"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r965"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Office Furniture and Equipment [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "xene_FuturePotentialMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "FuturePotentialMilestonePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future potential milestone payments.",
        "label": "Future Potential Milestone Payments",
        "terseLabel": "Future potential payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative",
        "totalLabel": "General and Administrative Expense, Total",
        "verboseLabel": "External general and administrative costs",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r772"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalStockBasedCompensationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "xene_GrossProceedsFromIssuableOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "GrossProceedsFromIssuableOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Gross proceeds from issuable of common stock",
        "label": "Gross Proceeds From Issuable Of Common Stock",
        "documentation": "Gross proceeds from issuable of common stock."
       }
      }
     },
     "auth_ref": []
    },
    "xene_GuaranteedInvestmentCertificatesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "GuaranteedInvestmentCertificatesMember",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFinancialAssetsMeasuredAtFairValueOnARecurringBasisDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAmortizedCostUnrealizedGainLossRecognizedInAociAndFairValueOfAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Guaranteed investment certificates.",
        "label": "Guaranteed Investment Certificates [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "xene_IanMortimerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "IanMortimerMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ian Mortimer [Member]",
        "documentation": "Ian Mortimer."
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r910",
      "r911",
      "r934"
     ]
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "crdr": "debit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "terseLabel": "Impairment of Long-Lived Assets",
        "totalLabel": "Impairment, Long-Lived Asset, Held-for-Use, Total",
        "verboseLabel": "Impairment charges recognized",
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale)."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r36",
      "r85",
      "r867"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of long-lived assets",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r86"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "crdr": "credit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfLossBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "Canada",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r426"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfLossBeforeIncomeTaxesDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income taxes",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r102",
      "r107",
      "r664",
      "r679",
      "r838",
      "r844",
      "r1053",
      "r1055",
      "r1056",
      "r1057",
      "r1058"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "crdr": "credit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfLossBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "United States",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r426"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalStockBasedCompensationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "terseLabel": "Income Statement Location",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r305",
      "r311",
      "r313",
      "r514",
      "r518",
      "r523",
      "r696",
      "r698",
      "r773",
      "r825",
      "r869",
      "r1172"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalStockBasedCompensationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Domain]",
        "terseLabel": "Income Statement Location",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r311",
      "r313",
      "r514",
      "r518",
      "r523",
      "r696",
      "r698",
      "r773",
      "r825",
      "r869",
      "r1172"
     ]
    },
    "us-gaap_IncomeTaxAuthorityNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityNameAxis",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority, Name [Axis]",
        "terseLabel": "Income Tax Authority, Name",
        "documentation": "Information by name of taxing authority."
       }
      }
     },
     "auth_ref": [
      "r435",
      "r1136"
     ]
    },
    "us-gaap_IncomeTaxAuthorityNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityNameDomain",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority, Name [Domain]",
        "terseLabel": "Income Tax Authority, Name",
        "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": [
      "r435",
      "r1136"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r419",
      "r427",
      "r432",
      "r433",
      "r434",
      "r437",
      "r442",
      "r452",
      "r454",
      "r455",
      "r456",
      "r721",
      "r863"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxRecoveryExpenseDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Income tax recovery (expense) (note 13)",
        "label": "Income Tax Expense (Benefit)",
        "totalLabel": "Income tax expense (recovery)",
        "negatedTotalLabel": "Income tax recovery (expense)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r124",
      "r189",
      "r190",
      "r210",
      "r222",
      "r237",
      "r425",
      "r427",
      "r453",
      "r687",
      "r863"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r421",
      "r422",
      "r437",
      "r438",
      "r441",
      "r444",
      "r715"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "crdr": "credit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount",
        "terseLabel": "Unclaimed Tax Deductions Related To Scientific Research And Experimental Development Expenditures",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r863",
      "r1131",
      "r1133"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "totalLabel": "Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total",
        "terseLabel": "Accounts payable and accrued liabilities",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "xene_IncreaseDecreaseInFairValueOfMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "IncreaseDecreaseInFairValueOfMarketableSecurities",
     "crdr": "credit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureConcentrationsOfMarketRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) in fair value of marketable securities.",
        "label": "Increase Decrease In Fair Value Of Marketable Securities",
        "negatedLabel": "Decrease in the fair value of marketable securities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r1025",
      "r1041"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r931",
      "r942",
      "r952",
      "r976",
      "r985",
      "r989",
      "r997"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r995"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r912",
      "r1001"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r912",
      "r1001"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r912",
      "r1001"
     ]
    },
    "us-gaap_InterestRateRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestRateRiskMember",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureConcentrationsOfMarketRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Rate Risk [Member]",
        "terseLabel": "Interest Rate Risk [Member]",
        "documentation": "The risk associated with changes in interest rates that effect the value of an interest-bearing asset or liability, and a servicing asset or liability."
       }
      }
     },
     "auth_ref": []
    },
    "xene_InterestReceivableAndAccretionOfDiscountsOnMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "InterestReceivableAndAccretionOfDiscountsOnMarketableSecurities",
     "crdr": "credit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Receivable and Accretion Of Discounts On Marketable Securities",
        "documentation": "Interest Receivable and Accretion Of Discounts On Marketable Securities",
        "terseLabel": "Interest receivable and accretion of discounts on marketable securities",
        "negatedLabel": "Interest receivable and accretion of discounts on marketable securities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentCreditMember",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Tax Credit Carryforward [Member]",
        "terseLabel": "Investment Tax credit [Member]",
        "documentation": "Investment tax credit carryforwards arising from certain qualifying capital expenditures including, but not limited to, rehabilitation, energy, advanced coal project and gasification project."
       }
      }
     },
     "auth_ref": [
      "r1136"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureSegmentDisclosureSummaryOfNetLossRelatedToSegmentExpensesDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income",
        "negatedLabel": "Interest income",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r221",
      "r237",
      "r844",
      "r1040"
     ]
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureMarketableSecurities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "verboseLabel": "Marketable Securities",
        "documentation": "The entire disclosure for investments in certain debt and equity securities."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r128",
      "r249",
      "r251",
      "r530",
      "r531",
      "r1169"
     ]
    },
    "xene_JefferiesLLCAndStifelNicolausCompanyIncorporatedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "JefferiesLLCAndStifelNicolausCompanyIncorporatedMember",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Jefferies LLC and Stifel, Nicolaus &amp; Company, Incorporated member.",
        "label": "Jefferies L L C And Stifel Nicolaus Company Incorporated [Member]",
        "terseLabel": "Jefferies and Stifel [Member]",
        "verboseLabel": "Jefferies and Stifel [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "xene_JefferiesLLCSVBLeerinkLLCAndStifelNicolausCompanyIncorporatedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "JefferiesLLCSVBLeerinkLLCAndStifelNicolausCompanyIncorporatedMember",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Jefferies LLC SVB leerink LLC and stifel nicolaus company incorporated.",
        "label": "Jefferies L L C S V B Leerink L L C And Stifel Nicolaus Company Incorporated [Member]",
        "terseLabel": "Jefferies LLC SVB Leerink LLC and Stifel Nicolaus Company Incorporated [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "xene_JefferiesLLCStifelNicolausCompanyIncorporatedAndGuggenheimSecuritiesLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "JefferiesLLCStifelNicolausCompanyIncorporatedAndGuggenheimSecuritiesLLCMember",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Jefferies LLC, Stifel, Nicolaus &amp; Company, Incorporated and Guggenheim Securities, LLC.",
        "label": "Jefferies L L C Stifel Nicolaus Company Incorporated And Guggenheim Securities L L C [Member]",
        "terseLabel": "Jefferies, Stifel and Guggenheim Securities, LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "xene_JefferiesLLCStifelNicolausCompanyIncorporatedJPMorganSecuritiesLLCAndSVBSecuritiesLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "JefferiesLLCStifelNicolausCompanyIncorporatedJPMorganSecuritiesLLCAndSVBSecuritiesLLCMember",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Jefferies, Stifel, J.P. Morgan Securities LLC and SVB Securities LLC [Member]",
        "label": "Jefferies L L C Stifel Nicolaus Company Incorporated J P Morgan Securities L L C And S V B Securities L L C [Member]",
        "documentation": "Jefferies L L C, Stifel Nicolaus Company Incorporated, J.P.Morgan Securities LLC and SVB Securities LLC."
       }
      }
     },
     "auth_ref": []
    },
    "xene_JefferiesLLCStifelNicolausCompanyIncorporatedJPMorganSecuritiesLLCBofASecuritiesIncAndRBCCapitalMarketsLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "JefferiesLLCStifelNicolausCompanyIncorporatedJPMorganSecuritiesLLCBofASecuritiesIncAndRBCCapitalMarketsLLCMember",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "J.P. Morgan, Jefferies, BofA Securities, Inc., Stifel, and RBC Capital Markets, LLC [Member]",
        "label": "Jefferies L L C Stifel Nicolaus Company Incorporated J P Morgan Securities L L C Bof A Securities Inc And R B C Capital Markets L L C [Member]",
        "documentation": "Jefferies LLC Stifel Nicolaus Company Incorporated J P Morgan Securities LLC BofA Securities Inc and RBC Capital Markets LLC."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LatestTaxYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LatestTaxYearMember",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Latest Tax Year [Member]",
        "terseLabel": "Latest Tax Year [Member]",
        "documentation": "Latest identified tax year."
       }
      }
     },
     "auth_ref": [
      "r1134"
     ]
    },
    "us-gaap_LeaseContractualTermAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseContractualTermAxis",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Contractual Term [Axis]",
        "documentation": "Information by contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r575",
      "r1024"
     ]
    },
    "us-gaap_LeaseContractualTermDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseContractualTermDomain",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Contractual Term [Domain]",
        "documentation": "Contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r575",
      "r1024"
     ]
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of Cost Components of Operating Lease",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r1154"
     ]
    },
    "us-gaap_LeaseExpirationDate1": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseExpirationDate1",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Expiration Date",
        "terseLabel": "Operating lease expiration date",
        "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPropertyPlantAndEquipmentEstimatedUsefulLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r574"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LegalCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LegalCostsPolicyTextBlock",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Costs, Policy [Policy Text Block]",
        "terseLabel": "Intellectual property",
        "documentation": "Disclosure of accounting policy for legal costs incurred to protect or defend the entity's assets and rights, or to obtain assets, including monetary damages, or to obtain rights."
       }
      }
     },
     "auth_ref": [
      "r320"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee Lease Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r564",
      "r575"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee Lease Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r564",
      "r575"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r563"
     ]
    },
    "xene_LesseeNumberOfOperatingLeases": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "LesseeNumberOfOperatingLeases",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, number of operating leases.",
        "label": "Lessee Number Of Operating Leases",
        "terseLabel": "Number of operating leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseDescription",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Description",
        "terseLabel": "Operating lease, description",
        "documentation": "Description of lessee's operating lease."
       }
      }
     },
     "auth_ref": [
      "r565"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "terseLabel": "Future Minimum Lease Payments",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1155"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total future minimum lease payments",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r573"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "2030 and thereafter",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r573"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r573"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2029",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r573"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2028",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r573"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r573"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r573"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: imputed interest",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r573"
     ]
    },
    "xene_LesseeOperatingLeaseNumberOfRenewalOptions": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "LesseeOperatingLeaseNumberOfRenewalOptions",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease, number of renewal options",
        "label": "Lessee Operating Lease Number of Renewal Options",
        "documentation": "Lessee operating lease number of renewal options."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseOptionToTerminate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseOptionToTerminate",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Option to Terminate",
        "verboseLabel": "Operating lease, option to terminate",
        "documentation": "Description of terms and conditions of option to terminate lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability."
       }
      }
     },
     "auth_ref": [
      "r566"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Operating lease extension term",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1153"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Operating lease term",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1153"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureLeases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r558"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r56",
      "r57",
      "r58",
      "r59",
      "r60",
      "r61",
      "r62",
      "r167",
      "r282",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r478",
      "r481",
      "r482",
      "r534",
      "r746",
      "r837",
      "r905",
      "r1091",
      "r1160",
      "r1161"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and shareholders\u2019 equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r101",
      "r674",
      "r878",
      "r1044",
      "r1080",
      "r1150"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and shareholders\u2019 equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r133",
      "r167",
      "r282",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r478",
      "r481",
      "r482",
      "r534",
      "r878",
      "r1091",
      "r1160",
      "r1161"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "xene_LicenseAndCollaborationAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "LicenseAndCollaborationAgreementMember",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCollaborationAgreementsDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License and Collaboration Agreement.",
        "label": "License And Collaboration Agreement [Member]",
        "terseLabel": "License and Collaboration Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LicenseAndServiceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LicenseAndServiceMember",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCollaborationAgreementsScheduleOfCollaborationRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License and Service [Member]",
        "terseLabel": "Collaboration Revenue [Member]",
        "documentation": "Right to use intangible asset and performance of related service. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark."
       }
      }
     },
     "auth_ref": [
      "r1098"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Category of Item Purchased [Axis]",
        "terseLabel": "Category of Item Purchased",
        "documentation": "Information by category of items purchased under a long-term purchase commitment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Purchase Commitment, Category of Item Purchased [Domain]",
        "terseLabel": "Long-term Purchase Commitment, Category of Item Purchased",
        "documentation": "General description of the goods or services to be purchased from the counterparty to the long-term purchase commitment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r1083",
      "r1084",
      "r1085"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r39",
      "r1083",
      "r1084",
      "r1085"
     ]
    },
    "us-gaap_ManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureConcentrationsOfMarketRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Servicing Assets and Servicing Liabilities Risk [Axis]",
        "terseLabel": "Servicing Assets and Servicing Liabilities Risk",
        "documentation": "Information by type of risks inherent in servicing assets and servicing liabilities."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities, Current",
        "terseLabel": "Marketable securities (note 5)",
        "documentation": "Amount of investment in marketable security, classified as current."
       }
      }
     },
     "auth_ref": [
      "r1035"
     ]
    },
    "us-gaap_MarketableSecuritiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities, Noncurrent",
        "terseLabel": "Marketable securities, long-term (note 5)",
        "documentation": "Amount of investment in marketable security, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r1035"
     ]
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesPolicy",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Marketable Securities",
        "documentation": "Disclosure of accounting policy for investment classified as marketable security."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum [Member]",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r316",
      "r317",
      "r318",
      "r319",
      "r375",
      "r415",
      "r512",
      "r621",
      "r695",
      "r697",
      "r710",
      "r738",
      "r739",
      "r795",
      "r797",
      "r799",
      "r800",
      "r802",
      "r823",
      "r824",
      "r850",
      "r854",
      "r860",
      "r870",
      "r871",
      "r875",
      "r876",
      "r889",
      "r1095",
      "r1162",
      "r1163",
      "r1164",
      "r1165",
      "r1166",
      "r1167"
     ]
    },
    "xene_MaximumTermOfEachOptionExercised": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "MaximumTermOfEachOptionExercised",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum term of each option exercised.",
        "label": "Maximum Term Of Each Option Exercised",
        "terseLabel": "Maximum term of each option exercised"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r968"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r968"
     ]
    },
    "xene_MedpaceClinicalDevelopmentServiceAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "MedpaceClinicalDevelopmentServiceAgreementMember",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medpace clinical development service agreement.",
        "label": "Medpace Clinical Development Service Agreement [Member]",
        "terseLabel": "Priority Access Agreement with Medpace Inc. [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "xene_MilestonePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "MilestonePayment",
     "crdr": "credit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCollaborationAgreementsDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCollaborationAgreementsScheduleOfCollaborationRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payment.",
        "label": "Milestone Payment",
        "terseLabel": "Milestone payments"
       }
      }
     },
     "auth_ref": []
    },
    "xene_MilestonePaymentDueOnInitiationOfPhase1bClinicalTrial": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "MilestonePaymentDueOnInitiationOfPhase1bClinicalTrial",
     "crdr": "debit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payment due on initiation of Phase 1b clinical trial.",
        "label": "Milestone Payment Due On Initiation Of Phase1b Clinical Trial",
        "terseLabel": "Milestone payment due on initiation of Phase 1b clinical trial"
       }
      }
     },
     "auth_ref": []
    },
    "xene_MilestonePaymentReceivedInCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "MilestonePaymentReceivedInCash",
     "crdr": "credit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payment received in cash.",
        "label": "Milestone Payment Received In Cash",
        "terseLabel": "Milestone Payment Received in Cash"
       }
      }
     },
     "auth_ref": []
    },
    "xene_MilestonePaymentReceivedInEquityInvestment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "MilestonePaymentReceivedInEquityInvestment",
     "crdr": "credit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payment received in equity investment.",
        "label": "Milestone Payment Received In Equity Investment",
        "terseLabel": "Milestone Payment Received in Equity Investment"
       }
      }
     },
     "auth_ref": []
    },
    "xene_MilestonePaymentReceivedInEquityInvestmentMeasuredAtFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "MilestonePaymentReceivedInEquityInvestmentMeasuredAtFairValue",
     "crdr": "credit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payment received in equity investment measured at fair value.",
        "label": "Milestone Payment Received In Equity Investment Measured At Fair Value",
        "terseLabel": "Equity investment measure at fair value"
       }
      }
     },
     "auth_ref": []
    },
    "xene_MilestonePaymentsPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "MilestonePaymentsPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payments paid.",
        "label": "Milestone Payments Paid",
        "terseLabel": "Milestone payment paid"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r316",
      "r317",
      "r318",
      "r319",
      "r375",
      "r415",
      "r512",
      "r621",
      "r695",
      "r697",
      "r710",
      "r738",
      "r739",
      "r795",
      "r797",
      "r799",
      "r800",
      "r802",
      "r823",
      "r824",
      "r850",
      "r854",
      "r860",
      "r870",
      "r871",
      "r875",
      "r889",
      "r1095",
      "r1162",
      "r1163",
      "r1164",
      "r1165",
      "r1166",
      "r1167"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r988"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r996"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r969"
     ]
    },
    "xene_NeedhamMassachusettsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "NeedhamMassachusettsMember",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Needham Massachusetts.",
        "label": "Needham Massachusetts [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r162"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r162"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r77",
      "r78"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfBasicAndDilutedNetLossPerCommonShareDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureSegmentDisclosureSummaryOfNetLossRelatedToSegmentExpensesDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureNatureOfBusinessDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "verboseLabel": "Net loss for the year",
        "negatedLabel": "Net loss",
        "totalLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r78",
      "r103",
      "r131",
      "r148",
      "r151",
      "r156",
      "r167",
      "r178",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r189",
      "r190",
      "r200",
      "r282",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r465",
      "r474",
      "r506",
      "r534",
      "r681",
      "r769",
      "r787",
      "r788",
      "r903",
      "r1091"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfBasicAndDilutedNetLossPerCommonShareDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "totalLabel": "Net loss attributable to common shareholders",
        "terseLabel": "Net loss per common share - basic",
        "verboseLabel": "Net loss attributable to common shareholders",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r182",
      "r183",
      "r184",
      "r185",
      "r195",
      "r196",
      "r201",
      "r204",
      "r474"
     ]
    },
    "xene_NetIncomeLossAvailableToPreferredStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "NetIncomeLossAvailableToPreferredStockholdersBasic",
     "crdr": "credit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfBasicAndDilutedNetLossPerCommonShareDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net income (loss) available to preferred stockholders basic.",
        "label": "Net Income Loss Available To Preferred Stockholders Basic",
        "negatedLabel": "Net loss attributable to preferred shareholders",
        "totalLabel": "Net Income Loss Available To Preferred Stockholders Basic, Total"
       }
      }
     },
     "auth_ref": []
    },
    "xene_NeurocrineBiosciencesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "NeurocrineBiosciencesMember",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCollaborationAgreementsDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCollaborationAgreementsScheduleOfCollaborationRevenueDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Neurocrine biosciences.",
        "label": "Neurocrine Biosciences [Member]",
        "terseLabel": "Neurocrine Biosciences [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update and Change in Accounting Principle [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureChangesInSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]",
        "terseLabel": "Changes in Significant Accounting Policies",
        "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r130",
      "r176",
      "r177",
      "r180",
      "r181",
      "r192",
      "r193",
      "r247",
      "r288",
      "r289",
      "r463",
      "r464",
      "r466",
      "r474",
      "r493",
      "r502",
      "r577",
      "r581",
      "r582",
      "r626",
      "r627",
      "r628",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently adopted accounting pronouncements/Accounting pronouncements not yet adopted",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r968"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r931",
      "r942",
      "r952",
      "r976",
      "r985"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r959"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r958"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r976"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r996"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r996"
     ]
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Supplemental disclosures of non-cash transactions:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense)",
        "totalLabel": "Other income (expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segment",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r845",
      "r1054"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureSegmentDisclosureAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r839",
      "r849",
      "r1054"
     ]
    },
    "xene_NumberOfWarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "NumberOfWarrantsExercised",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureShareCapitalScheduleOfPrefundedWarrantsDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureShareCapitalScheduleOfPrefundedWarrantsParentheticalDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Exercised",
        "documentation": "Number of warrants exercised.",
        "label": "Number Of Warrants Exercised",
        "terseLabel": "Exercise of pre-funded warrants"
       }
      }
     },
     "auth_ref": []
    },
    "xene_NumberOfWarrantsIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "NumberOfWarrantsIssued",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureShareCapitalScheduleOfPrefundedWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issued",
        "label": "Number Of Warrants Issued",
        "documentation": "Number of warrants issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OfficeEquipmentMember",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPropertyPlantAndEquipmentEstimatedUsefulLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Office Equipment [Member]",
        "terseLabel": "Office Furniture and Equipment [Member]",
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OpenTaxYear": {
     "xbrltype": "gYearListItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OpenTaxYear",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Open Tax Year",
        "terseLabel": "Tax year open for income tax examination",
        "documentation": "Tax year that remains open to examination under enacted tax laws, in YYYY format."
       }
      }
     },
     "auth_ref": [
      "r435"
     ]
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r838",
      "r1053",
      "r1055",
      "r1056",
      "r1057",
      "r1058"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureLeasesScheduleOfCostComponentsOfOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease expense",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r567",
      "r877"
     ]
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability",
        "terseLabel": "Present value of lease liabilities",
        "totalLabel": "Operating Lease, Liability, Total",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r561"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liability (note 7)",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r561"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liability, long-term (note 7)",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r561"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid for operating lease",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r562",
      "r569"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use asset, net (note 7)",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r560"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction",
        "terseLabel": "Non-cash operating lease expense",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r1042"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureLeasesScheduleOfCostComponentsOfOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Discount rate",
        "verboseLabel": "Weighted average discount rate",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r572",
      "r877"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureLeasesScheduleOfCostComponentsOfOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Remaining lease term (years)",
        "verboseLabel": "Weighted average remaining lease term (years)",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r571",
      "r877"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Non-capital losses carried forward for tax purposes",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r443"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureNatureOfBusiness"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Nature of the business",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r96",
      "r712",
      "r713"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureAccountsPayableAndAccruedLiabilitiesAccountsPayableAndAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax, Total",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "terseLabel": "Unrealized gain (loss) on available-for-sale securities (note 5)",
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r146",
      "r147",
      "r682"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive loss (note 6)",
        "totalLabel": "Other Comprehensive Income (Loss), Net of Tax, Total",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "verboseLabel": "Other comprehensive (loss) income",
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r14",
      "r149",
      "r152",
      "r157",
      "r186",
      "r541",
      "r542",
      "r547",
      "r661",
      "r682",
      "r1037",
      "r1038"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive income (loss):",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureSegmentDisclosureSummaryOfNetLossRelatedToSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other General and Administrative Expense",
        "terseLabel": "Other general and administrative costs",
        "documentation": "Amount of general and administrative expense classified as other."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r1203"
     ]
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherIncomeAndExpensesAbstract",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income and Expenses [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "auth_ref": []
    },
    "xene_OtherMilestonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "OtherMilestonesMember",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other milestones.",
        "label": "Other Milestones [Member]",
        "terseLabel": "Other Milestones [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r968"
     ]
    },
    "us-gaap_OtherResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherResearchAndDevelopmentExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureSegmentDisclosureSummaryOfNetLossRelatedToSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Research and Development Expense",
        "terseLabel": "Other research and development costs",
        "documentation": "Amount of other research and development expense."
       }
      }
     },
     "auth_ref": [
      "r1128"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r929",
      "r940",
      "r950",
      "r983"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r932",
      "r943",
      "r953",
      "r986"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r932",
      "r943",
      "r953",
      "r986"
     ]
    },
    "us-gaap_OverAllotmentOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OverAllotmentOptionMember",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Over Allotment [Member]",
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment."
       }
      }
     },
     "auth_ref": []
    },
    "xene_PaciraBiosciencesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "PaciraBiosciencesMember",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCollaborationAgreementsDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCollaborationAgreementsScheduleOfCollaborationRevenueDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pacira biosciences.",
        "label": "Pacira Biosciences [Member]",
        "terseLabel": "Pacira BioSciences [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r957"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireMarketableSecurities",
     "crdr": "credit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchase of marketable securities",
        "documentation": "Amount of cash outflow for purchase of marketable security."
       }
      }
     },
     "auth_ref": [
      "r1062"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property, plant and equipment",
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r967"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r967"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r959"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r976"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r969"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r958"
     ]
    },
    "xene_PercentageOfOptionToFundDevelopmentCostsUponAchievementOfCertainMilestones": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "PercentageOfOptionToFundDevelopmentCostsUponAchievementOfCertainMilestones",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of option to fund development costs upon achievement of certain milestones.",
        "label": "Percentage Of Option To Fund Development Costs Upon Achievement Of Certain Milestones",
        "terseLabel": "Percentage of option to co-fund development costs upon achievement of certain milestones"
       }
      }
     },
     "auth_ref": []
    },
    "xene_PerformanceObligationsRelatedToMilestone": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "PerformanceObligationsRelatedToMilestone",
     "crdr": "credit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance obligation related to milestone",
        "label": "Performance Obligations Related To Milestone",
        "documentation": "Performance obligations in relation to this milestone."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PerformanceSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PerformanceSharesMember",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalStockBasedCompensationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Performance Shares [Member]",
        "terseLabel": "PSUs",
        "documentation": "Share-based payment arrangement awarded for meeting performance target."
       }
      }
     },
     "auth_ref": []
    },
    "xene_PersonnelRelatedExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "PersonnelRelatedExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureSegmentDisclosureSummaryOfNetLossRelatedToSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Personnel Related Expenses",
        "documentation": "Personnel related expenses.",
        "terseLabel": "Personnel-related expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PhantomShareUnitsPSUsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PhantomShareUnitsPSUsMember",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalStockBasedCompensationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PSUs",
        "label": "Phantom Share Units (PSUs) [Member]",
        "documentation": "Share-based payment arrangement awarded as phantom share or unit."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1116",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124",
      "r1125"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1116",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124",
      "r1125"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r960"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r1016"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r959"
     ]
    },
    "xene_PotentialMilestonePaymentsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "PotentialMilestonePaymentsReceivable",
     "crdr": "debit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential milestone payments receivable.",
        "label": "Potential Milestone Payments Receivable",
        "terseLabel": "Potential milestone payments receivable"
       }
      }
     },
     "auth_ref": []
    },
    "xene_Pre-ClinicalDiscoveryAndOtherProgramsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "Pre-ClinicalDiscoveryAndOtherProgramsMember",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureSegmentDisclosureSummaryOfNetLossRelatedToSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-clinical Discovery And Other Programs [Member]",
        "documentation": "Pre-clinical discovery and other programs.",
        "terseLabel": "Pre-clinical, discovery and other programs"
       }
      }
     },
     "auth_ref": []
    },
    "xene_PreFundedWarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "PreFundedWarrantsExercised",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureShareCapitalScheduleOfPrefundedWarrantsParentheticalDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-funded warrants exercised",
        "label": "Pre-funded Warrants Exercised",
        "documentation": "Pre-funded warrants exercised."
       }
      }
     },
     "auth_ref": []
    },
    "xene_PreFundsWarrantsOutstandingDateIssuanceDecemberTwoThousandTwentyThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "PreFundsWarrantsOutstandingDateIssuanceDecemberTwoThousandTwentyThreeMember",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureShareCapitalScheduleOfPrefundedWarrantsDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "December 2023",
        "label": "Pre Funds Warrants Outstanding Date Issuance December Two Thousand Twenty Three [Member]",
        "documentation": "Pre funds warrants outstanding date issuance december two thousand twenty three."
       }
      }
     },
     "auth_ref": []
    },
    "xene_PreFundsWarrantsOutstandingDateIssuanceJuneTwoThousandTwentyTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "PreFundsWarrantsOutstandingDateIssuanceJuneTwoThousandTwentyTwoMember",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureShareCapitalScheduleOfPrefundedWarrantsDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "June 2022",
        "label": "Pre Funds Warrants Outstanding Date Issuance June Two Thousand Twenty Two [Member]",
        "documentation": "Pre funds warrants outstanding date issuance june two thousand twenty two."
       }
      }
     },
     "auth_ref": []
    },
    "xene_PreFundsWarrantsOutstandingDateIssuanceMarchTwoThousandTwentyOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "PreFundsWarrantsOutstandingDateIssuanceMarchTwoThousandTwentyOneMember",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureShareCapitalScheduleOfPrefundedWarrantsDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "March 2021",
        "label": "Pre Funds Warrants Outstanding Date Issuance March Two Thousand Twenty One [Member]",
        "documentation": "Pre funds warrants outstanding date issuance march two thousand twenty one."
       }
      }
     },
     "auth_ref": []
    },
    "xene_PreFundsWarrantsOutstandingDateIssuanceOctoberTwoThousandTwentyOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "PreFundsWarrantsOutstandingDateIssuanceOctoberTwoThousandTwentyOneMember",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureShareCapitalScheduleOfPrefundedWarrantsDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "October 2021",
        "label": "Pre Funds Warrants Outstanding Date Issuance October Two Thousand Twenty One [Member]",
        "documentation": "Pre funds warrants outstanding date issuance october two thousand twenty one."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockConversionBasis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockConversionBasis",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Conversion Basis",
        "terseLabel": "Preferred shares convertible into common shares",
        "documentation": "Describe the conversion features of preferred stock if preferred stock is convertible. That is, shares of preferred stock into which another convertible security was converted, or shares of preferred stock into which another class of preferred stock was converted."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r63"
     ]
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock [Member]",
        "terseLabel": "Convertible Preferred Shares [Member]",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r895",
      "r896",
      "r899",
      "r900",
      "r901",
      "r902",
      "r1202",
      "r1205"
     ]
    },
    "us-gaap_PreferredStockNoParValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockNoParValue",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, No Par Value",
        "terseLabel": "Preferred shares, without par value",
        "documentation": "Face amount per share of no-par value preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r1096"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorizedUnlimited": {
     "xbrltype": "authorizedUnlimitedItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorizedUnlimited",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Authorized, Unlimited [Fixed List]",
        "terseLabel": "Preferred shares, shares authorized",
        "documentation": "Indicates whether number of nonredeemable preferred shares, or preferred stock redeemable solely at option of issuer, permitted to be issued is unlimited. Acceptable value is \"Unlimited\"."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred shares, issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r348"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred shares, outstanding",
        "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance",
        "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r748",
      "r766",
      "r1205",
      "r1206"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1036"
     ]
    },
    "us-gaap_PrepaidExpenseNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Prepaid Expense, Noncurrent, Total",
        "label": "Prepaid Expense, Noncurrent",
        "terseLabel": "Prepaid expenses, long-term",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1034"
     ]
    },
    "us-gaap_PriorPeriodReclassificationAdjustment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PriorPeriodReclassificationAdjustment",
     "crdr": "credit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Period Reclassification Adjustment",
        "terseLabel": "Prior period reclassification adjustment",
        "documentation": "The amount of a reclassification adjustment made to prior period financial statement amounts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "crdr": "debit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from public offerings, net",
        "label": "Proceeds from Issuance Initial Public Offering",
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Common Stock",
        "verboseLabel": "Amount offered for issuance of common stock",
        "terseLabel": "Sale proceeds of common shares",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Warrants",
        "terseLabel": "Sale proceeds from issuance of pre funded warrants",
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "crdr": "debit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Proceeds from marketable securities",
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from exercise of stock options",
        "label": "Proceeds from Stock Options Exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r13"
     ]
    },
    "xene_ProceedsFromUpfrontFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "ProceedsFromUpfrontFee",
     "crdr": "debit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from upfront fee.",
        "label": "Proceeds From Upfront Fee",
        "terseLabel": "Proceeds from upfront fee"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProductConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProductConcentrationRiskMember",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product Concentration Risk [Member]",
        "terseLabel": "Product Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCollaborationAgreementsScheduleOfCollaborationRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "auth_ref": [
      "r241",
      "r622",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r827",
      "r855",
      "r888",
      "r889",
      "r890",
      "r892",
      "r894",
      "r1088",
      "r1089",
      "r1097",
      "r1171",
      "r1173",
      "r1174",
      "r1175",
      "r1176",
      "r1177",
      "r1178",
      "r1179",
      "r1180",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1185",
      "r1186",
      "r1187",
      "r1188",
      "r1189",
      "r1190",
      "r1191",
      "r1192",
      "r1193",
      "r1194",
      "r1195",
      "r1196",
      "r1197",
      "r1198",
      "r1200",
      "r1201"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCollaborationAgreementsScheduleOfCollaborationRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "auth_ref": [
      "r241",
      "r622",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r827",
      "r855",
      "r888",
      "r889",
      "r890",
      "r892",
      "r894",
      "r1088",
      "r1089",
      "r1097",
      "r1171",
      "r1173",
      "r1174",
      "r1175",
      "r1176",
      "r1177",
      "r1178",
      "r1179",
      "r1180",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1185",
      "r1186",
      "r1187",
      "r1188",
      "r1189",
      "r1190",
      "r1191",
      "r1192",
      "r1193",
      "r1194",
      "r1195",
      "r1196",
      "r1197",
      "r1198",
      "r1200",
      "r1201"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r148",
      "r151",
      "r161",
      "r167",
      "r178",
      "r186",
      "r189",
      "r190",
      "r282",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r465",
      "r474",
      "r476",
      "r479",
      "r480",
      "r506",
      "r534",
      "r664",
      "r680",
      "r722",
      "r769",
      "r787",
      "r788",
      "r864",
      "r865",
      "r904",
      "r1039",
      "r1091"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPropertyPlantAndEquipmentEstimatedUsefulLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r574"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property, Plant and Equipment",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r115",
      "r118",
      "r119"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property, plant and equipment",
        "totalLabel": "Property, Plant and Equipment, Gross, Total",
        "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance",
        "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r136",
      "r678"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPropertyPlantAndEquipmentEstimatedUsefulLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property Plant And Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r574"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net",
        "totalLabel": "Net book value",
        "terseLabel": "Property, plant and equipment, net (note 6)",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r574",
      "r665",
      "r678",
      "r878"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property, plant and equipment",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r115",
      "r118",
      "r676"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Summary of Property, Plant and Equipment",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPropertyPlantAndEquipmentEstimatedUsefulLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r574"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPropertyPlantAndEquipmentEstimatedUsefulLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPropertyPlantAndEquipmentEstimatedUsefulLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]",
        "documentation": "Indicates description of term of useful life for property, plant, and equipment when not stated as numeric value."
       }
      }
     },
     "auth_ref": [
      "r1081"
     ]
    },
    "xene_ProvincialTaxCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "ProvincialTaxCreditMember",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Provincial tax credit.",
        "label": "Provincial Tax Credit [Member]",
        "terseLabel": "Provincial Tax Credit [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "xene_PurchasesOfPropertyPlantAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "PurchasesOfPropertyPlantAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchases Of Property, Plant And Equipment Included In Accounts Payable And Accrued Liabilities",
        "documentation": "Purchases of property, plant and equipment included in accounts payable and accrued liabilities.",
        "terseLabel": "Purchases of property, plant and equipment included in accounts payable and accrued liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r957"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r957"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "auth_ref": [
      "r316",
      "r317",
      "r318",
      "r319",
      "r367",
      "r375",
      "r404",
      "r405",
      "r406",
      "r415",
      "r512",
      "r594",
      "r603",
      "r621",
      "r695",
      "r697",
      "r710",
      "r738",
      "r739",
      "r795",
      "r797",
      "r799",
      "r800",
      "r802",
      "r823",
      "r824",
      "r850",
      "r854",
      "r860",
      "r870",
      "r871",
      "r875",
      "r876",
      "r889",
      "r897",
      "r1086",
      "r1095",
      "r1146",
      "r1163",
      "r1164",
      "r1165",
      "r1166",
      "r1167"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "auth_ref": [
      "r316",
      "r317",
      "r318",
      "r319",
      "r367",
      "r375",
      "r404",
      "r405",
      "r406",
      "r415",
      "r512",
      "r594",
      "r603",
      "r621",
      "r695",
      "r697",
      "r710",
      "r738",
      "r739",
      "r795",
      "r797",
      "r799",
      "r800",
      "r802",
      "r823",
      "r824",
      "r850",
      "r854",
      "r860",
      "r870",
      "r871",
      "r875",
      "r876",
      "r889",
      "r897",
      "r1086",
      "r1095",
      "r1146",
      "r1163",
      "r1164",
      "r1165",
      "r1166",
      "r1167"
     ]
    },
    "xene_RecognitionOfTransactionPrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "RecognitionOfTransactionPrice",
     "crdr": "credit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCollaborationAgreementsScheduleOfCollaborationRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recognition of transaction price.",
        "label": "Recognition Of Transaction Price",
        "terseLabel": "Recognition of the transaction price"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r924",
      "r935",
      "r945",
      "r978"
     ]
    },
    "xene_RegulatoryMilestoneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "RegulatoryMilestoneMember",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCollaborationAgreementsDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regulatory milestone.",
        "label": "Regulatory Milestone [Member]",
        "terseLabel": "Regulatory Milestone [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Domain]",
        "terseLabel": "Related Party",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r248",
      "r374",
      "r583",
      "r584",
      "r669",
      "r675",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r765",
      "r767",
      "r794"
     ]
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r583",
      "r584",
      "r1159"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction",
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "terseLabel": "Related Party",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r248",
      "r374",
      "r583",
      "r584",
      "r669",
      "r675",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r765",
      "r767",
      "r794",
      "r1159"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCollaborationAgreementsDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCollaborationAgreementsScheduleOfCollaborationRevenueDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "auth_ref": [
      "r170",
      "r171",
      "r333",
      "r350",
      "r585",
      "r604",
      "r666",
      "r832",
      "r833"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureSegmentDisclosureSummaryOfNetLossRelatedToSegmentExpensesDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCollaborationAgreementsDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type",
        "documentation": "Information by form of arrangement related to research and development."
       }
      }
     },
     "auth_ref": [
      "r418",
      "r1129"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureSegmentDisclosureSummaryOfNetLossRelatedToSegmentExpensesDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCollaborationAgreementsDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type",
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others."
       }
      }
     },
     "auth_ref": [
      "r418",
      "r1129"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureSegmentDisclosureSummaryOfNetLossRelatedToSegmentExpensesDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "totalLabel": "Research and Development Expense, Total",
        "verboseLabel": "Direct external research and development costs",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r417",
      "r825",
      "r844",
      "r1168"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalStockBasedCompensationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and development costs",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r416"
     ]
    },
    "xene_ResearchAndDevelopmentServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "ResearchAndDevelopmentServices",
     "crdr": "credit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCollaborationAgreementsDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCollaborationAgreementsScheduleOfCollaborationRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development services.",
        "label": "Research And Development Services",
        "terseLabel": "Research and development services"
       }
      }
     },
     "auth_ref": []
    },
    "xene_ResearchEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "ResearchEquipmentMember",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPropertyPlantAndEquipmentEstimatedUsefulLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research equipment.",
        "label": "Research Equipment [Member]",
        "terseLabel": "Research Equipment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r925",
      "r936",
      "r946",
      "r979"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r926",
      "r937",
      "r947",
      "r980"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r933",
      "r944",
      "r954",
      "r987"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureNatureOfBusinessDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit",
        "negatedLabel": "Accumulated deficit",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r91",
      "r673",
      "r704",
      "r708",
      "r720",
      "r749",
      "r878"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r173",
      "r174",
      "r175",
      "r179",
      "r186",
      "r188",
      "r190",
      "r287",
      "r293",
      "r304",
      "r446",
      "r447",
      "r460",
      "r461",
      "r462",
      "r466",
      "r473",
      "r474",
      "r487",
      "r490",
      "r491",
      "r494",
      "r504",
      "r554",
      "r559",
      "r701",
      "r703",
      "r723",
      "r1205"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "crdr": "credit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureSegmentDisclosureSummaryOfNetLossRelatedToSegmentExpensesDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCollaborationAgreementsDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCollaborationAgreementsScheduleOfCollaborationRevenueDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "verboseLabel": "Revenue",
        "totalLabel": "Total revenue",
        "terseLabel": "Revenue (note 10)",
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r106",
      "r210",
      "r219",
      "r220",
      "r233",
      "r237",
      "r241",
      "r243",
      "r245",
      "r365",
      "r366",
      "r622"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerMember",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer Benchmark [Member]",
        "terseLabel": "Total Revenues [Member]",
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r245",
      "r1021"
     ]
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue recognition",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r771",
      "r826",
      "r834"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use asset obtained in exchange for new operating lease liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r570",
      "r877"
     ]
    },
    "us-gaap_RisksAndUncertaintiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RisksAndUncertaintiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Risks and Uncertainties [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RisksInherentInServicingAssetsAndServicingLiabilitiesTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RisksInherentInServicingAssetsAndServicingLiabilitiesTypeDomain",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureConcentrationsOfMarketRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risks Inherent in Servicing Assets and Servicing Liabilities, Type [Domain]",
        "terseLabel": "Risks Inherent in Servicing Assets and Servicing Liabilities, Type",
        "documentation": "The nature of risks inherent in servicing assets and servicing liabilities."
       }
      }
     },
     "auth_ref": [
      "r605"
     ]
    },
    "xene_RoyaltyObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "RoyaltyObligations",
     "crdr": "credit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty obligations.",
        "label": "Royalty Obligations",
        "terseLabel": "Royalty obligations"
       }
      }
     },
     "auth_ref": []
    },
    "xene_Rule10B51TradingPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "Rule10B51TradingPlanMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule10B 51Trading Plan [Member]",
        "documentation": "Rule10B 51Trading Plan [Member]",
        "terseLabel": "Rule10B 5-1 Trading Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "xene_Rule10B51TradingPlanOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "Rule10B51TradingPlanOneMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule10B 51Trading Plan One [Member]",
        "documentation": "Rule10B 51Trading Plan One [Member]",
        "terseLabel": "Rule10B 5-1 Trading Plan One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r996"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r996"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Shares price",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "xene_SalesBasedMilestoneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "SalesBasedMilestoneMember",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales-based milestone.",
        "label": "Sales Based Milestone [Member]",
        "terseLabel": "Sales Based Milestone [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureAccountsPayableAndAccruedLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "terseLabel": "Accounts Payable and Accrued Liabilities",
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureNetLossPerCommonShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Diluted Net Loss Per Share",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAmortizedCostUnrealizedGainLossRecognizedInAociAndFairValueOfAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "terseLabel": "Schedule Of Available For Sale Securities [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263"
     ]
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCollaborationAgreementsDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCollaborationAgreementsScheduleOfCollaborationRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r475"
     ]
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCollaborationAgreementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]",
        "terseLabel": "Schedule Of Collaboration Revenue",
        "documentation": "Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r1140"
     ]
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of Income Tax Recovery (Expense)",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r1138"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Net Deferred Income Tax Assets",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1135"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTextBlock",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureNetLossPerCommonShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table Text Block]",
        "terseLabel": "Schedule of Basic and Diluted Net Loss Per Common Share",
        "documentation": "Tabular disclosure of the effect of income (loss) on basic earnings per share."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r25",
      "r1051"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r428",
      "r863",
      "r1131"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Stock Based Compensation Expenses",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Schedule of Loss before Income Taxes",
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions."
       }
      }
     },
     "auth_ref": [
      "r1045"
     ]
    },
    "us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfNonvestedShareActivityTableTextBlock",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Nonvested Share Activity [Table Text Block]",
        "terseLabel": "Schedule of Unvested Stock Option Activity",
        "documentation": "Tabular disclosure of the changes in outstanding nonvested shares."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "xene_ScheduleOfPreFundedWarrantsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "ScheduleOfPreFundedWarrantsActivityTableTextBlock",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Pre-Funded Warrants Activity",
        "label": "Schedule Of Pre Funded Warrants Activity [Table Text Block]",
        "documentation": "Schedule of pre funded warrants activity."
       }
      }
     },
     "auth_ref": []
    },
    "xene_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of property plant and equipment estimated useful lives.",
        "label": "Schedule Of Property Plant And Equipment Estimated Useful Lives Table [Text Block]",
        "terseLabel": "Property Plant and Equipment Estimated Useful Lives"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPropertyPlantAndEquipmentEstimatedUsefulLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Schedule Of Property Plant And Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r574"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureSegmentDisclosureAdditionalInformationDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureSegmentDisclosureSummaryOfNetLossRelatedToSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r34",
      "r35"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureSegmentDisclosureTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Summary of Net Loss Related To Segment Expenses",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r34",
      "r35"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalStockBasedCompensationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Stock Option Activity",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r12",
      "r92"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Fair Value Assumptions for Stock Options",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "xene_SecondRenewalOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "SecondRenewalOptionMember",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Second Renewal Option [Member]",
        "documentation": "Second renewal option."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r906"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r909"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical"
       }
      }
     },
     "auth_ref": [
      "r243",
      "r244",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r735",
      "r736",
      "r737",
      "r796",
      "r798",
      "r801",
      "r803",
      "r810",
      "r813",
      "r814",
      "r815",
      "r816",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r828",
      "r856",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r891",
      "r897",
      "r1097",
      "r1171",
      "r1173",
      "r1174",
      "r1176",
      "r1177",
      "r1178",
      "r1179",
      "r1180",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1185",
      "r1186",
      "r1187",
      "r1188",
      "r1189",
      "r1190",
      "r1191",
      "r1192",
      "r1193",
      "r1194",
      "r1195",
      "r1196",
      "r1197",
      "r1198",
      "r1200",
      "r1201"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureSegmentDisclosure1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment",
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r210",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r223",
      "r224",
      "r225",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r241",
      "r242",
      "r245",
      "r839",
      "r842",
      "r843",
      "r844",
      "r846",
      "r848",
      "r849"
     ]
    },
    "us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingExpenseInformationUsedByCodmDescription",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureSegmentDisclosureAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting, Expense Information Used by CODM, Description",
        "label": "Segment Reporting, Expense Information Used by CODM, Description",
        "documentation": "Description of nature of expense information used by chief operating decision maker (CODM) to manage operation when segment expense information by category is not disclosed."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r225",
      "r237"
     ]
    },
    "us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureSegmentDisclosureAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Expense Information Used by CODM, Type [Extensible Enumeration]",
        "documentation": "Indicates type of expense information used by chief operating decision maker (CODM) to manage operation when segment expense information by category is not disclosed."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r225",
      "r237"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureSegmentDisclosureAdditionalInformationDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureSegmentDisclosureSummaryOfNetLossRelatedToSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingOtherItemAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingOtherItemAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureSegmentDisclosureSummaryOfNetLossRelatedToSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Other Segment Item, Amount",
        "terseLabel": "Other segment items",
        "documentation": "Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss)."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r224",
      "r225",
      "r237",
      "r844"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment and geographic information",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r240",
      "r243",
      "r840",
      "r841",
      "r847"
     ]
    },
    "xene_Series1PreferredSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "Series1PreferredSharesMember",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series 1 preferred shares.",
        "label": "Series1 Preferred Shares [Member]",
        "terseLabel": "Series1 Preferred Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureSegmentDisclosureSummaryOfNetLossRelatedToSegmentExpensesDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation",
        "totalLabel": "Share-Based Payment Arrangement, Noncash Expense, Total",
        "verboseLabel": "stock-based compensation",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r861"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r394"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average grant date fair value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r394"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "terseLabel": "Shares vested",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r395"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalFairValueAssumptionsForStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r405"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalFairValueAssumptionsForStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r404"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalFairValueAssumptionsForStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Average risk-free interest rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r406"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalStockBasedCompensationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common shares reserved for issuance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of restricted share awards, restricted share unit awards or performance awards available for issue",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Number of Options Exercisable",
        "verboseLabel": "Number of Options Exercisable, End of period",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r385"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Options exercisable, Weighted Average Exercise Price",
        "verboseLabel": "Weighted Average Exercise Price, Exercisable Ending balance",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r385"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Exercised",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r398"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedLabel": "Number of Options, Forfeited, cancelled or expired",
        "totalLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Total",
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired."
       }
      }
     },
     "auth_ref": [
      "r1106"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Forfeited, cancelled and expired",
        "documentation": "Weighted average price of options that were either forfeited or expired."
       }
      }
     },
     "auth_ref": [
      "r1106"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureShareCapitalSummaryOfUnvestedStockOptionActivityDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Number of Options, Granted",
        "verboseLabel": "Options granted",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r387"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureShareCapitalSummaryOfUnvestedStockOptionActivityDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalFairValueAssumptionsForStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value, Granted",
        "verboseLabel": "Weighted average fair value of options granted",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r397"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Outstanding",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Number of Options Outstanding, Ending balance",
        "periodStartLabel": "Number of Options Outstanding, Beginning balance",
        "terseLabel": "Number of Options Outstanding",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r383",
      "r384"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Exercise Price Outstanding, Ending balance",
        "periodStartLabel": "Weighted Average Exercise Price Outstanding, Beginning balance",
        "terseLabel": "Options Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r383",
      "r384"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalStockBasedCompensationExpensesDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r379",
      "r380",
      "r381",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Exercised",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r388"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r387"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-based compensation",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r376",
      "r382",
      "r401",
      "r402",
      "r403",
      "r404",
      "r407",
      "r410",
      "r411",
      "r412",
      "r413"
     ]
    },
    "xene_ShareCapitalLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "ShareCapitalLineItems",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureShareCapitalScheduleOfPrefundedWarrantsDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureShareCapitalScheduleOfPrefundedWarrantsParentheticalDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share capital.",
        "label": "Share Capital [Line Items]",
        "terseLabel": "Share Capital [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "xene_ShareCapitalTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "ShareCapitalTable",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureShareCapitalScheduleOfPrefundedWarrantsDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureShareCapitalScheduleOfPrefundedWarrantsParentheticalDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Capital [Table]",
        "documentation": "Share capital.",
        "label": "Share Capital [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalFairValueAssumptionsForStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Average expected term (in years)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r403"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Exercisable, Ending balance",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options Exercisable Weighted Average Remaining Contractual Life in Years",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureShareCapitalSummaryOfUnvestedStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares",
        "periodStartLabel": "Number of Options, Unvested, Beginning balance",
        "periodEndLabel": "Number of Options, Unvested, Ending balance",
        "documentation": "Number of non-vested options outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureShareCapitalSummaryOfUnvestedStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Number of Shares",
        "negatedLabel": "Number of Options, Forfeited or cancelled",
        "documentation": "Number of non-vested options forfeited."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureShareCapitalSummaryOfUnvestedStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value, Forfeited or cancelled",
        "documentation": "Weighted average grant-date fair value of non-vested options forfeited."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureShareCapitalSummaryOfUnvestedStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Grant Date Fair Value, Unvested, Ending balance",
        "periodStartLabel": "Weighted Average Grant Date Fair Value, Unvested, Beginning balance",
        "documentation": "Weighted average grant-date fair value of non-vested options outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options Outstanding Weighted Average Remaining Contractual Life in Years",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "crdr": "credit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Aggregate fair value of options vested",
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock."
       }
      }
     },
     "auth_ref": [
      "r398"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureShareCapitalSummaryOfUnvestedStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares",
        "negatedLabel": "Number of Options, Vested",
        "documentation": "Number of options vested."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureShareCapitalSummaryOfUnvestedStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value, Vested",
        "documentation": "Weighted average grant-date fair value of options vested."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Aggregate purchase price per share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance (in Shares)",
        "periodStartLabel": "Balance (in Shares)",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "xene_SignificantAccountingPoliciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "SignificantAccountingPoliciesLineItems",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Significant accounting policies.",
        "label": "Significant Accounting Policies [Line Items]",
        "terseLabel": "Significant Accounting Policies [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "xene_SignificantAccountingPoliciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "SignificantAccountingPoliciesTable",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Significant accounting policies.",
        "label": "Significant Accounting Policies [Table]",
        "terseLabel": "Significant Accounting Policies [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Significant accounting policies",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r164"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r140",
      "r141",
      "r142",
      "r167",
      "r198",
      "r199",
      "r202",
      "r204",
      "r212",
      "r213",
      "r282",
      "r323",
      "r325",
      "r326",
      "r327",
      "r330",
      "r331",
      "r348",
      "r349",
      "r352",
      "r355",
      "r362",
      "r534",
      "r716",
      "r717",
      "r718",
      "r719",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r748",
      "r770",
      "r789",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r1020",
      "r1043",
      "r1052"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureShareCapitalScheduleOfPrefundedWarrantsDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureShareCapitalScheduleOfPrefundedWarrantsParentheticalDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r64",
      "r67",
      "r68",
      "r129",
      "r154",
      "r155",
      "r156",
      "r173",
      "r174",
      "r175",
      "r179",
      "r186",
      "r188",
      "r190",
      "r211",
      "r287",
      "r293",
      "r304",
      "r364",
      "r446",
      "r447",
      "r460",
      "r461",
      "r462",
      "r466",
      "r473",
      "r474",
      "r487",
      "r489",
      "r490",
      "r491",
      "r492",
      "r494",
      "r504",
      "r541",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r554",
      "r559",
      "r580",
      "r682",
      "r701",
      "r702",
      "r703",
      "r723",
      "r789"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical"
       }
      }
     },
     "auth_ref": [
      "r243",
      "r244",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r735",
      "r736",
      "r737",
      "r796",
      "r798",
      "r801",
      "r803",
      "r810",
      "r813",
      "r814",
      "r815",
      "r816",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r828",
      "r856",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r891",
      "r897",
      "r1097",
      "r1171",
      "r1173",
      "r1174",
      "r1176",
      "r1177",
      "r1178",
      "r1179",
      "r1180",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1185",
      "r1186",
      "r1187",
      "r1188",
      "r1189",
      "r1190",
      "r1191",
      "r1192",
      "r1193",
      "r1194",
      "r1195",
      "r1196",
      "r1197",
      "r1198",
      "r1200",
      "r1201"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r173",
      "r174",
      "r175",
      "r211",
      "r559",
      "r622",
      "r714",
      "r734",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r748",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r767",
      "r771",
      "r772",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r789",
      "r898"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r173",
      "r174",
      "r175",
      "r211",
      "r248",
      "r559",
      "r622",
      "r714",
      "r734",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r748",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r767",
      "r771",
      "r772",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r789",
      "r898"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r928",
      "r939",
      "r949",
      "r982"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "xene_StockIssuedDuringPeriodCommonSharesCancelled": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "StockIssuedDuringPeriodCommonSharesCancelled",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period Common Shares Cancelled",
        "documentation": "Stock issued during period common shares cancelled.",
        "terseLabel": "Shares cancelled"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "verboseLabel": "Conversion of shares",
        "terseLabel": "Conversion of preferred shares (note 9d) (in shares)",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r40",
      "r64",
      "r67",
      "r91",
      "r342"
     ]
    },
    "xene_StockIssuedDuringPeriodSharesConversionOfPreFundedWarrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesConversionOfPreFundedWarrant",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period Shares Conversion Of Pre Funded Warrant",
        "documentation": "Stock issued during period shares conversion of pre funded warrant.",
        "terseLabel": "Conversion of pre-funded warrants (note 9e) (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "xene_StockIssuedDuringPeriodSharesConversionOfPreFundedWarrantsToCommonShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesConversionOfPreFundedWarrantsToCommonShares",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureShareCapitalScheduleOfPrefundedWarrantsParentheticalDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock issued upon conversion of pre-funded warrants",
        "label": "Stock Issued During Period Shares Conversion Of Pre-funded Warrants To Common Shares",
        "documentation": "Stock issued during period shares conversion of pre-funded warrants to common shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, New Issues",
        "verboseLabel": "Shares issued",
        "terseLabel": "Issuance of common shares and pre-funded warrants, net (note 9a and note 9e) (in shares)",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r63",
      "r64",
      "r91",
      "r716",
      "r789",
      "r805"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalStockOptionActivityDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Number of Options, Exercised",
        "terseLabel": "Exercise of stock options (in Shares)",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r63",
      "r64",
      "r91",
      "r388"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Conversion of preferred shares (note 9d)",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r64",
      "r67",
      "r68",
      "r91"
     ]
    },
    "xene_StockIssuedDuringPeriodValueConversionOfPreFundedWarrant": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "StockIssuedDuringPeriodValueConversionOfPreFundedWarrant",
     "crdr": "credit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period Value Conversion Of Pre Funded Warrant",
        "documentation": "Stock issued during period value conversion of pre funded warrant.",
        "terseLabel": "Conversion of pre-funded warrants (note 9e)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, New Issues",
        "verboseLabel": "Amount offered for issuance of common stock",
        "terseLabel": "Issuance of common shares and pre-funded warrants, net (note 9a and note 9e)",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r63",
      "r64",
      "r91",
      "r723",
      "r789",
      "r805",
      "r904"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of stock options",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r64",
      "r67",
      "r68",
      "r91"
     ]
    },
    "xene_StockOptionActivityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "StockOptionActivityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock option activity.",
        "label": "Stock Option Activity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "xene_StockOptionsExercisedForNumberOfCommonSharesForCash": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "StockOptionsExercisedForNumberOfCommonSharesForCash",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalStockOptionActivityParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised for number of common shares for cash during the period.",
        "label": "Stock Options Exercised For Number Of Common Shares For Cash",
        "terseLabel": "Stock Options exercised for Number of Common Shares for cash"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total shareholders' equity",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r67",
      "r68",
      "r82",
      "r750",
      "r766",
      "r790",
      "r791",
      "r878",
      "r905",
      "r1044",
      "r1080",
      "r1150",
      "r1205"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent [Abstract]",
        "terseLabel": "Shareholders\u2019 equity:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapital"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Text Block]",
        "terseLabel": "Share Capital",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r166",
      "r347",
      "r349",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r361",
      "r364",
      "r496",
      "r792",
      "r793",
      "r809"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCollaborationAgreementsDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r548",
      "r587"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCollaborationAgreementsDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r548",
      "r587"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCollaborationAgreementsDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r548",
      "r587"
     ]
    },
    "srt_SubsidiariesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "SubsidiariesMember",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiaries [Member]",
        "terseLabel": "Xenon Pharmaceuticals USA Inc. [Member]"
       }
      }
     },
     "auth_ref": [
      "r1099",
      "r1156",
      "r1157",
      "r1159"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosures:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r975"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit available to offset taxes payable",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r443"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardAxis",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward",
        "documentation": "Information by specific tax credit related to an unused tax credit."
       }
      }
     },
     "auth_ref": [
      "r443"
     ]
    },
    "us-gaap_TaxCreditCarryforwardExpirationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardExpirationDate",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Expiration Date",
        "terseLabel": "Tax Credit Carry forward, Expiration Date",
        "documentation": "Expiration date of the tax credit carryforward, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r443"
     ]
    },
    "us-gaap_TaxCreditCarryforwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardLineItems",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward [Line Items]",
        "terseLabel": "Tax Credit Carryforward [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r443"
     ]
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardNameDomain",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name",
        "documentation": "The name of the tax credit carryforward."
       }
      }
     },
     "auth_ref": [
      "r443"
     ]
    },
    "us-gaap_TaxCreditCarryforwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardTable",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward [Table]",
        "terseLabel": "Tax Credit Carryforward [Table]",
        "documentation": "Disclosure of information about tax credit carryforward available to reduce future taxable income. Includes, but is not limited to, description, amount, expiration date, limitation on use, and related deferred tax asset and valuation allowance."
       }
      }
     },
     "auth_ref": [
      "r443"
     ]
    },
    "us-gaap_TaxPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxPeriodAxis",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Period [Axis]",
        "terseLabel": "Tax Period",
        "documentation": "Information by period subject to enacted tax law."
       }
      }
     },
     "auth_ref": [
      "r1134"
     ]
    },
    "us-gaap_TaxPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxPeriodDomain",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Period [Domain]",
        "terseLabel": "Tax Period",
        "documentation": "Identified tax period."
       }
      }
     },
     "auth_ref": [
      "r1134"
     ]
    },
    "us-gaap_TaxesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxesPayableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureAccountsPayableAndAccruedLiabilitiesAccountsPayableAndAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Taxes Payable, Current",
        "totalLabel": "Taxes Payable, Current, Total",
        "terseLabel": "Income and other taxes",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r57"
     ]
    },
    "xene_TermLoansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "TermLoansMember",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term loans.",
        "label": "Term Loans [Member]",
        "terseLabel": "Term Loan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureSegmentDisclosureAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1059",
      "r1158"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureSegmentDisclosureAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r967"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r974"
     ]
    },
    "us-gaap_TradingActivityByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TradingActivityByTypeAxis",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureConcentrationsOfMarketRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Activity [Axis]",
        "terseLabel": "Trading Activity",
        "documentation": "Information by type of trading activity."
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "us-gaap_TradingActivityByTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TradingActivityByTypeDomain",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureConcentrationsOfMarketRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Activity, by Type [Domain]",
        "terseLabel": "Trading Activity, by Type",
        "documentation": "Gains and losses on trading activities (including both derivative and nonderivative instruments) recognized in the statement of financial performance, separately by major types of items (such as fixed income/interest rates, foreign exchange, equity, commodity, and credit)."
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r995"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r997"
     ]
    },
    "us-gaap_TradingSecuritiesDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TradingSecuritiesDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Trading",
        "verboseLabel": "Trading marketable securities",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in net income (trading)."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r508",
      "r830",
      "r1061",
      "r1145",
      "r1146",
      "r1147"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAmortizedCostUnrealizedGainLossRecognizedInAociAndFairValueOfAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r345",
      "r360",
      "r495",
      "r529",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r683",
      "r866",
      "r868",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r879",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1075",
      "r1077",
      "r1078",
      "r1079",
      "r1142",
      "r1145",
      "r1146",
      "r1147",
      "r1148",
      "r1149"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r998"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r999"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r999"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r997"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r997"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r1000"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r998"
     ]
    },
    "xene_TwoThousandFourteenAmendedAndRestatedStockOptionPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "TwoThousandFourteenAmendedAndRestatedStockOptionPlanMember",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2014 Amended and restated stock option plan.",
        "label": "Two Thousand Fourteen Amended And Restated Stock Option Plan [Member]",
        "terseLabel": "Amended and Restated 2014 Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "xene_TwoThousandNineteenInducementEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "TwoThousandNineteenInducementEquityIncentivePlanMember",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand nineteen inducement equity incentive plan.",
        "label": "Two Thousand Nineteen Inducement Equity Incentive Plan [Member]",
        "terseLabel": "2019 Inducement Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCollaborationAgreementsDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r475"
     ]
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFinancialAssetsMeasuredAtFairValueOnARecurringBasisDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAmortizedCostUnrealizedGainLossRecognizedInAociAndFairValueOfAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "US Government Agencies Debt Securities [Member]",
        "verboseLabel": "U.S. Government Securities [Member]",
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB)."
       }
      }
     },
     "auth_ref": [
      "r835",
      "r857",
      "r1170"
     ]
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "USTreasurySecuritiesMember",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFinancialAssetsMeasuredAtFairValueOnARecurringBasisDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAmortizedCostUnrealizedGainLossRecognizedInAociAndFairValueOfAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "US Treasury Securities [Member]",
        "verboseLabel": "U.S. Treasuries [Member]",
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)."
       }
      }
     },
     "auth_ref": [
      "r835",
      "r857",
      "r859",
      "r866",
      "r1170"
     ]
    },
    "xene_UnderwrittenPublicOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "UnderwrittenPublicOfferingMember",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Underwritten public offering.",
        "label": "Underwritten Public Offering [Member]",
        "terseLabel": "Underwritten Public Offering [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r994"
     ]
    },
    "xene_UnfavorableChangeInInterestRatesOfMarketableSecurities": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "UnfavorableChangeInInterestRatesOfMarketableSecurities",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureConcentrationsOfMarketRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unfavorable change in interest rates of marketable securities.",
        "label": "Unfavorable Change In Interest Rates Of Marketable Securities",
        "terseLabel": "Unfavorable change in interest rates of marketable securities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Unrecognized tax benefits of uncertain tax positions",
        "periodStartLabel": "Unrecognized Tax Benefits, Beginning Balance",
        "periodEndLabel": "Unrecognized Tax Benefits, Ending Balance",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r420",
      "r436",
      "r862"
     ]
    },
    "xene_UpfrontPaymentInCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "UpfrontPaymentInCash",
     "crdr": "credit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront payment in cash.",
        "label": "Upfront Payment In Cash",
        "terseLabel": "Upfront payment received in cash"
       }
      }
     },
     "auth_ref": []
    },
    "xene_UpfrontPaymentReceivedInEquityInvestment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "UpfrontPaymentReceivedInEquityInvestment",
     "crdr": "credit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront payment received in equity investment.",
        "label": "Upfront Payment Received In Equity Investment",
        "terseLabel": "Upfront payment received in equity investment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31",
      "r32",
      "r111",
      "r113",
      "r116",
      "r117"
     ]
    },
    "xene_VariableConsiderationAllocatedToPerformanceObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "VariableConsiderationAllocatedToPerformanceObligation",
     "crdr": "credit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureCollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Variable consideration allocated to performance obligation.",
        "label": "Variable Consideration Allocated To Performance Obligation",
        "terseLabel": "Variable consideration allocated to performance obligation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureLeasesScheduleOfCostComponentsOfOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease expense",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r568",
      "r877"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r963"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantMember",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "terseLabel": "Warrants",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r895",
      "r896",
      "r899",
      "r900",
      "r901",
      "r902"
     ]
    },
    "xene_WarrantsExerciseDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "WarrantsExerciseDescription",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants exercise description.",
        "label": "Warrants Exercise Description",
        "terseLabel": "Warrants exercise description"
       }
      }
     },
     "auth_ref": []
    },
    "xene_WarrantsIssuedPricePerPreFundedWarrant": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "WarrantsIssuedPricePerPreFundedWarrant",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_DisclosureShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants issued price per pre funded warrant.",
        "terseLabel": "Warrants issued price per pre funded warrant",
        "verboseLabel": "Warrants issued price per pre funded warrant",
        "label": "Price per Pre-Funded Warrant"
       }
      }
     },
     "auth_ref": []
    },
    "xene_WeightedAverageNumberOfCommonShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "WeightedAverageNumberOfCommonShares",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfBasicAndDilutedNetLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number Of Common Shares",
        "documentation": "Weighted average number of common shares.",
        "terseLabel": "Common shares (weighted average)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfBasicAndDilutedNetLossPerCommonShareDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted",
        "verboseLabel": "Weighted average common shares outstanding - diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r197",
      "r204"
     ]
    },
    "xene_WeightedAverageNumberOfPrefundedWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "WeightedAverageNumberOfPrefundedWarrants",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfBasicAndDilutedNetLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number Of Prefunded Warrants",
        "documentation": "Weighted average number of prefunded warrants.",
        "terseLabel": "Pre-funded warrants (weighted average)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfBasicAndDilutedNetLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfBasicAndDilutedNetLossPerCommonShareDetails",
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic",
        "verboseLabel": "Weighted average common shares outstanding - basic",
        "totalLabel": "Weighted average common shares outstanding - basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r195",
      "r204"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average common shares outstanding (note 4):",
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "xene_XEN496Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xenon-pharma.com/20241231",
     "localname": "XEN496Member",
     "presentation": [
      "http://www.xenon-pharma.com/20241231/taxonomy/role/DisclosureSegmentDisclosureSummaryOfNetLossRelatedToSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "XEN496 [Member]",
        "documentation": "XEN496.",
        "terseLabel": "XEN496"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r961"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-16"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-21"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1B"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4F",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-5"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "860",
   "SubTopic": "50",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-2"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "320",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-5"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-12A"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/942-320/tableOfContent"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "326",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-3"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "326",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-3"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "326",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-3"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/250/tableOfContent"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/808/tableOfContent"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1403",
   "Paragraph": "b",
   "Publisher": "SEC"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-7"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-3"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-6"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/320/tableOfContent"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-2"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-10"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-2"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477123/405-50-65-1"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-2"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-4"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10A"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-5"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/830/tableOfContent"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-17"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482014/830-20-35-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479424/830-30-S99-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-5"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-5"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-5"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481435/852-10-45-14"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-2"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-6"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-17"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r949": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r950": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r951": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r952": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r953": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r954": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r955": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r956": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r957": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r958": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r959": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r960": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r961": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r962": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r963": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r964": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r965": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r966": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r967": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r968": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r969": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r970": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r971": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r972": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r973": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r974": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r975": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r976": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r977": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r978": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r979": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r980": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r981": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r982": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r983": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r984": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r985": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r986": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r987": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r988": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r989": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r990": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r991": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r992": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r993": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r994": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r995": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r996": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r997": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r998": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r999": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-X",
   "Number": "210",
   "Section": "2",
   "Subsection": "2"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-14"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482190/360-10-35-3"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1124": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1125": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1126": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1127": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r1128": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r1129": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r1130": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r1131": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1132": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1133": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r1134": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r1135": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1136": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r1137": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r1138": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1139": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1140": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r1141": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1142": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r1143": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1144": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1145": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1146": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1147": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1148": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r1149": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1150": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1151": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1"
  },
  "r1152": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1"
  },
  "r1153": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1154": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1155": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r1156": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r1157": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r1158": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r1159": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r1160": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1161": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1162": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1163": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1164": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1165": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1166": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1167": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1168": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1169": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "940",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/940-320/tableOfContent"
  },
  "r1170": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r1171": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1172": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1173": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1174": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1175": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1176": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1177": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1178": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1179": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1180": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1181": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1182": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1183": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1184": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1185": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1186": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1187": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1188": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1189": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1190": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1191": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1192": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1193": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1194": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1195": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1196": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1197": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1198": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1199": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-1"
  },
  "r1200": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1201": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1202": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1203": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1204": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1205": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1206": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>91
<FILENAME>0000950170-25-029149-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-25-029149-xbrl.zip
M4$L#!!0    ( .F$6UK I1NLU<@* &3>$  2    :6UG,C4U,#$U.#$V7S N
M:G!G[+P).)1OWS=^"=E"=MFF+"E+RIIU:+&DDDJVF$IE"R$9ZR6*[*$HRE@C
M8LA6MLDZ)!$BE&5&"6'&,H:9N>9_=3_O>]^_^WGN^SWNX_\\[W'?S_/F.+ZY
M+M=YG'-^SO/[_7Z^G^L\)^9GYA2P\X2IA2G LHV%M82U! "8X\!1@.4_^?.K
MD_]L'RS,MX  )[>@R"8KBRRP38"%58"%V0X@ ("%_=\: /_KAV4;*QO[=@Y.
M+FX>N$'-3@#&PKJ-C96=G8T-?AH&/P?8!-@%]QPRV2YD?9E#UE=8_4Y*+J?<
MD<H6D;,?2?(:5_PBN;A%Q<1W22CL5=RW7TE32UOGL*[>T6/'3<W,+4Z<.V]S
MP=;.WL'EZK7KKF[N'OZW FX'HH."H^[>BXZY'QN7FO;P47K&XR>9>?D%A<^+
MBE^4O*JJKJFM>_VFOK6MO:,3W]7];F!PZ-/PR.?1L6D"<>;;]]D?<_/DE=6U
M=<H&=7/K%RX6@/7/T/\F+@$8US8V-E8VCE^X6+8%_FH@P,:^Y]!V01-KCLN^
M0K+J=SB%CZ3D5K9PR6F<)8E<\?O(+2JO.:U _@7M3\C^,6"1_[^0_1G87W"-
M 3M86>#%8Q4 D  $[<N+ W[;;_NO-*7HPEN4VZE6XNP9.89Z0LMSM@L:ML#G
M=YQ=Q$T)8#5D4GK^POLC1[F #9XE\'5(R/K+9:K=&)9.BEE!0;+%[OWX@)=]
MPO/R)@=9K'*M4[:80+;G2%I;O>[QO>]4B ,1!FV0J'8I$S#80\]@ O?S_^H.
M:\T$[@::,@&,.$[.C"Y7KT.G=L ?N_+'STC^PW63&23P51(*O4)/1)"2?DRN
M$L5FW%A[<-,N'KC55D0W2(U#_N%Z'4$UN^6S28Y?T01;]?/!O@142@[_ 29P
M+[&$"?1Q@@I,@+#OKV^5A\!IZ8^XV4ZUKH],@',ID0D8'0HWC3!H^ WD-Y#?
M0'X#^0WD-Y#?0'X#^0WDOP>0!B__HP.Y52G$JEB['=LXD+<PL\Z!TPWZGHDG
MONOFV0LHG"GY>L>&N)[#,TFJK$%M3O//X.C'$7^X#HX@+248(R_'/]"70/T9
M)LNWO]L^^<_#0OYO@/T<&6!KYR=P]BXRE0F0A?]X(S*/_/,,_P&<L8P3$^"1
MM(%KZIV0)1-HM_[K6]MB)O"_ISK_SXL%! 725;QL(?31334F(&#VQQOG_#],
M<_)O)+^1_$;R&\EO)/]SD7@JV_97%]^80?\D7CAST-AP91]KU/^1DY5X93N'
MG4Z8S]RS9\LU-LKR3SKD7&Z@GW\)S#W>?QL>)!/X/=^_D?Q&\AO);R2_D?P_
MCZ12B\%O&665;5XF9W:^Z_+3*,SJ)C=  /^.3.XE]18V?<@A]PIV190+K\TB
MIYU;FZ4_UF*W=J!NW:;D\!_\%U#,_V.D_V\@OX'\!O(;R&\@_[V :-TK=PN^
MN-,[;D!3WVIW6!!C'VO\_UFU^O"Z#P?J-1S7Y"3?5727NNI*9P]&_9[KWT!^
M _D-Y#>0WT!^ \')78R)7PO3&^Z5F!@^_#DMW;I/O .PFL:).L]O"'08^)94
M[;Q--/0=-<-MSOT(F EG2S1X.VXZO0?80!S"7LS9%K?OM_VV_UJK"O"ADC-(
MD&EUJ<X%)I"\"^2'XZ:SVF>3KX\).(TP 1.'#7.(P%!N7?L/?]O'LF9]'!#^
M'V;^T)X_340?26*%"7 S@:X+RU"#&A19,R_S=YY4LRPN](=QK!06.$?]0#Y2
M_:=C^&4BB>4@/@%GP@2J+O2Z>&+(1+5^\.<0RW<)1?J]:TR@O U>2*SKGT:,
M[HQE GOLP84*)M#O.3J2L\7_S9CGN/ 9EG\5N\@$8I$SN_R9 'Q57![YA@D(
M@EWJLQ!\86TL8S.MMLG5O6ZUX/P=XPM^1<THMQG 27N/KM$+AN>7P24U6BG]
M'J#WSPZW/]J;R9U, %]'9V,">\OC_GB7PR?7"JY(@AO\JQ[KF2L^7+"G>3&!
M+\C>TF$W("]NW[^,E<MU,@$R$3'$!$XL+MPGX^AH_#IR($)W<EO8,LUC<FL7
MUAZ[EZ0XP01JRYA ;N9ZYC_]R/UO^Y]GRG\F+\\3?Z:T" -/N/!Z\),)K'\%
MUT2PMY*7U 8:U?[CWR(0_^SL]G_!.) $!#P/="; @E4C8>GWO)G PBLF\$/9
M.??O/3&6F6CBZ >5'([_,(K:/-O_S\;P)[,;FZ6C>]80-*T;P]IPMI=19W!
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MV)Q3*^[\DL)X3[OINS@8/H#A4J5+A0:IW=>FNA])"WF%("1T'::=GGRML;%
M?03/3,QD7R$]:#A T@L*R+B?3CB(05=[M[M,]H\4AO=MV2[NHCF,CM*1_:%F
M!)"/ZD%V.>HO<8SB=IXSZ*M(R[= 1#TZAW^NDP9Q#]($W,<*ZK4FVYG  6A7
M;T/'C/NL8''W12;@$;45+JU!X6^U2I[<T:PS=WNLKZW)GW:E=5Y#1>A&;&".
MR9[#<4$Q7R\%,X%#&&(6I10>F!G]& -#U^!/1N!UG%7?9+?4.!;$<39VR?=$
MI@I<8^%=\>^>23([L3))52Q:M":+3:NU]_"*V9%EBK;']5YVE<DPB)4ZI+EJ
MP7K9F#=UUWDZ?NG..@"1M93'#8T&+$M7\L:0Z_<>V0<+=?D)D_@=Z!1J/"T(
M:C-B)<M/(,@?7DP_KOGAW=RK=)'JWU:GSLA):TDG!#S(;DS!M(\,:1NIUY+K
M6DO#G$<'K/1/#,ZD?*R[;G%CHU+QN47W82WZ"6@"MX):Q]#$\:L> #0*[0CU
MH.J0/<UCSE-M_(OZGI_\'/ORAHK*@U2-5GO]'&+_]Z8! GHQ+^B[5V6G.CZ)
M@V"VBNU 4N6?C).J3OAO'(MKIZF8(:TZRV *!V\022%M8A+\T356<C9#MS:O
M6'CM;:\XF>UR2V5[^&FTW&8_QU>$*!/PQHZV326VUT[NI+LRDE74@\ZJ97B,
MHVZ_#Z=L;0OWUK.-&@5;4,C+84?(*E[A^S<SU 5+LDV?=;-M._RI>][,9P[5
M9=6&8Z/[,NK"=W<7>DA0<(8UQ/%W/GO-O\4>>Z6K+O2MN_5.8VI1T>F:K8!2
ML 6@>TU/\AXG]"()#4X>")?:>D?Q2S%]O+[ LWP$607U1)+S-!-P]C5&?-)I
M0\5#[-2:0I,RM)P--#2XM$=,X%2MUE>!3DF!WGVS<F_*EL70RVWA'(/?/AD<
M#Z'H'SZZ2[ZU=ML+EXUG'*Q#<5 P<@J#@>6'6U^4C!(9<:_1TI^0U2O8DE]=
MD?E=_.QH'A?+7M7BN^6!+DEO2A!UN#LX#S 6(^3=J#OU[%RGA&O,@4MW@VK/
MM Y[#*AWTJN]_:M3_?@'(I"GZ?9PV6G'B#<0*;8LI,804)^7=S^:3D7N?;N8
M<OCRJD=Q"&*:8^P%.A#B_D@3@(5(U(F/X8IASRD$MYPX-3DKR8(GK:9&3O;)
M[]OYGE"P[5\Y($XYLB3AVEVXA%7KM/#"+E]Q?)';%"F@;KF/_2'1TO=U8 O2
M@=['@"N82\GW$97A%2.B#NN4^MKZNV<Z7HP?B;N7&F#SR,ZQ98.+=R-X-FF(
MA4%"'^T,A_WTD6C-= ^NUGU5_JR9MO"UO4?(F)0OH>\TVB0V<10\G$DL"<DT
MX"L3^!% WX*Y9@_.$Y2V*IN3X2#?;BKV^'C1@WV;LWF#2YQDFF"[S6W2B]W.
M,??F#Z%PDS5-A$GZ+C(O 1;@_$[UQ.<Z*7"M18U ;:KA-@2BF,!I6=QKW.=9
MR,(VA@G\Y'%A CEQD+089+G,:+_$! ;O8Y?4*+KP$&RFF0!MVV=X#+(11O5Y
M<?NV)5(RGGND;#JD/[M<W!%IT+!@&?*:%)R8(=#U6E=7O,//%L?7C A+_<$$
M6KFFOL0'=2%)"6Y/^A[2X9HO&16\-%^S3 ^"08U4,X&M_3]8J6-PQFAR"][[
MB*A_=5 S3/FTU=ZIQ8K!1941?7Y]K^D$5U)Y#,0)C]#- 1NO<.K<\8$ !9H\
M4A5ZYHK&!31</+J;H91!%Y6#S!Q]MHB^<$,)^,.GDA K.G#:=7X CYT7]MIO
M&6V8&-S5&B0I$JVS=VR;%5U.8J__MR)=&I]GCY$2U ^R(EUY]GF'>H%%U-,?
M"-IN'=&8RQZ)4M=:WLG7QD=<N<%G)EWANZ::00\: T>J$5O[E4EB$,]A?KJL
MWE'6@=;9!:B61G=C75><3E[LH.G1G6MTLMG)R90"'K8Z]L8&&\:0=77Y9$/S
MXYOWK5!XJ9%L:CS$?8TFBW9LMYAV<B4@1FM>** OC'>_TDW5J(EV/&LZ1=[P
MI-Z@^M/,T./32YF:".Z+'MH;.UXYE(X>Y",$'+P+U)&]Y7(6.KRI+E/+B\ID
M_0YM:"\3N"O9Z9!G=7.#YP7/X1F[X>L[),/)+1RZ+<0U6":8\.H0K=J00FA-
M]/#(V3A:F^!H3Q#E24Y=BL2P)K^<^)AM0F*!(,^#,$_"5S.(>Q>-Y3,ZL9IG
MT;&US<G^:F)*XZ'IVHSW22A5_..1;2=C#W_0-1B)@?K"^<D94;AK%BIT%YE<
M'W]$U/KAWC+Z9?G8WASQ/68<N\G9G^A8]#)DN8AGW W@9QPN!, <Q3:<%%H9
M'ZQ:CIV*52T<\/9*#;E=6U=7E_"VG;W5L4HV@0A(!=M,BM.-2?B(M<T *\')
ML+@/ G(&KX_>D5@"<?(N=_H<J.,4)0WLVZ^J975!Q+8+WU4Q(8%C0N(;"Z@4
ML [1Q@3&Z@B8#E546[C@I\9KA50/PO=]A,P!<8GN*Z_KT3.[J_T$17?S;-/S
M[]-DV<HG)%.5X* X-[5HZJ3F3'U"L>RZFJJ8W%5Q&/UA>)>7#3^;P.!"G$\T
M<NHELA*9H*4?)G>$FD5I6'B17Q>M)OO6._W<752&C7\W18OZ)!]L88%VTX]5
MQJ#(8IU!NW$-L0>NQBV)'^O:X/FN5_M5-7H*SY%M%:Z\0J.4,F+"]T"=#G0_
M>\^ZK:ZZ(39?CPO]><6'=+==N\R&#-PU%S5GC)B,N6?@E$L=/!'O0&*,C*UM
M/I+0K<B7/3[1J/SZ6Q!M\L2F%>4+'+GZ!#AR67J80+XH;@=R*@51@TL,D+8U
M)5G%!_0P'+0SV)S-"X\49-M=/#"X$KF=\X=>)J.#456>OC&5$;LT(NE*HJ<>
MT+O4I1=^GH5N^@.Q@H)3045Z,A,HTL$NU5%@-DAUR@4_RUG M<TQ[+2E,?P'
M)L /%S\@0[<)#,"]"J2G+O) +1)64*H"$'84M0."XUYH,1Q!WS6\=&\D[5;>
M>=8]OO4<K$]G7W1UT5?C:$D6@N(3]N)*LNG7#0".LV&EFR5P=OA #XXZ/1"0
MS#&GEVFID7-96) ^JK0SL?%JPM16("$"N2U4NM 3(PZZHS^W^JAZ-SH>(+P?
MV&^67+'O;53V,_V9%4]:,2.M67J4;D35RG&WMF_S\O5A>T>[9#ZY?8R]Y5+)
MUV0'Z!2<,]*8 -=R:"!9'2DP+ZIN<#OS2R#[=^.WI4&[:TU/\RWEX6JR>/5X
ME4_11.J5C@O[>9V?-NM.GF$'0'4DR1%!I;Z&9^@@/!WFI:L8B$NWP-VAJ$/Y
M\;JAAM60BU@M.FGKW=CB]F/VFP=D4X*6.\(3P)8;()% A-["/FHAB^T#J?*!
M]$>.F"T&7*?V7\GA7Z 1 G_"JH!(X(CX_O$:"8SV,NC5?)W9TU9_4F.[:.CE
MZ=I8_&$#;?\%5.O&XC3I2M]41D<(5?-3YB>U@)"ZNK=N-W-T9>PN;(9/OW4V
M>L2@4?/;@WVB#>3V%I9,F+C<R'1D-5@Z>S"\\S3/CE54RS)=N ZOATH.5_O:
MG/;"Y(5J.C;X<5W85.@KEV)B^I:?[K(QXM4DZ3@8GUG648.)QBY?RYP8-_-1
MW?LZ]:*&@[E&[5DS$A\C[*T6 ^$YH?*Q4>.Y=NG++XS,@<,#%O*MSW('T;3W
M43F&': &AG3<*KK^:5RHB7H/FX:;D('C$."DXGI)>"K5[[R+7)KS\J\S8"0F
ML'B(R"]\%/:]Z(UFU8J/WP?:SW87=O",Q[I$3AQ\[X1(M4S!(PX:/639XB=B
MJ$J*/_U)L]99)\BH=K#"N65_M'ECEE#L=C^CL-,:,(WQ^F7:TD4F*1+#V"L5
M@]#^H!$-/3.)( ETCWG+>=]2H9Z=>K8$GWO@5#1"Q$AC+GU"@9S<R5/*>P3:
M$Z#:7+A#UFWFBLF%SL=,0$?7 (/5(F4LPG3*UDT>^7D[0Z(#CASZF?2S!\8;
M[,[LOW;MTE$>1[!AI&Y0F(7QCHZD9DWSQXZ=#)Z,6D<L2AO9N3S;.Q;_>(86
MPZ42]72+.%'?ZVA;^5'%6TO:%+5W>)C+>V\:\#-.6$W.[_S-G.R<X!14YS)=
ML(U21XV97I9T#]]!%KNOI;^@7'9:V=K37_9NG/S^^Y1B9T!\&1^NO-5/O5."
M+PO5&EX7CSB/.?:).\(/2>SMNXA!.0";(S:_CM=!W?4Z\6(M#C'M_(KM!P9E
M1S>US5398H6C%*UY5QJ*:<]HM@7H$<I[*CN\$&VU<*V&C ]ORYN_\'U^8+:G
MUNBJTH?"BHV4XN_:4KI2?I[4$$8YW<IW"M;5&7J]M:L*-1_*(F)X>W^>#$E>
M(F*I(T^I480Z/"99+SQK&L<_1LUWJAYTT9YS<4MY7RJ9<5F<_4[+JL;03'8U
M"Z,+S0%Q*]"4Z987?#BIJ[1C*G[FD_55%^5/V/=U%UM\/(]IQ2F!4\\1=3X_
M9XD(=L]L0=)RHL.L8VJKI5;M^5IC;P$G>PO+[]Y<K$NN8[B#N$M]HTCB(A.(
MVSVHA>.CYK<,!XHF)/J&N4OYJCU]M;];UCFWJNM',*')B@*WBKSHP03XJGDP
M]VV-#)/6B:^\3CAJ2'"HRE8)R]LKRHG3VA8Z@/#34-^DD,'^J<DX;><]Y.T%
MP_4W')(P!AF(_;*'7;\LKKZ+NI/6$Z[%B OE@+M\'MY95W\@=MK.2'YYN+GE
M,O]H@C8R7-*-D.*G=612^6G8&+3?2"Q4-(M@E5#6J"A:7*OF&^CI18EDX:$\
M8;O\)G$K@(:[!QY#54W2=V(<!WW6K&0P\6?JPS+'ID8WK6?%]HMTPIG_>I*M
M9#@3H/9SK#7I=&#9'*E&2.F>$B_2EW2.<Y9?*U>O2^&_N_1R;=P17T5*;+K\
M.O>2"G5GPE.3U1+LVLZ/;.>V.564=E4W2$)KQN/DE_J4#:.'DXE&W&G3?3]'
M0Z;W>]];=9L0R&S_4@X\+&LS8@+U3Z6IM/PY5#LBR<"UE(H@.N>6NGT':S7S
M]C7W)4[W#N6IJYN&7Q??D.KGV&@BJU$JJ(JD-/.Z$0,? OBS26^^5RTWZUJ#
M=VV*3C[!\G6,<M^$W*3(JG<\G -<&+&-)B4F^7,8H5 :[4E^W9_J],)'M3E=
MG^Q6PI('<-FHN\A718M[:(&?[7D#\<URI ^Q;(?L33/OWM1Z4[/;]"[BU1>$
MBII<]K-H3R)F;('"18VA27F\"/$BP!ID)Z?/\.%U2;2UC8/NS;T[5'-H3W6^
M$I-/ -!ZHR31AQ^]81Y_D?1I=OS67+IVTHU]78]TBCA7^&PQ34Y>H **9+X\
M+M11B<8<(XDE-%H&%;>H?MAA6[7/QKQ(X.Z>VZ1<2I+&'=00F& 0<GD:Q^+A
M?"B%>'!L+K'8]%Z2O/7ND_O99/R"NN;P%=MGXPW<X33'[OYJ?F)/ TWZH;)<
M]P'A:1>GI9L?HNYM;&O>07:EB_A0E$FG"P^D$1"QH$M3M(5L*E*V?9J@?_%:
MS3$#A ?D@YS*1=0Q 5C*QR%VKJ, *K_U\"U'Q89$.1I;R4=UJUO]#UG&3D;;
MX+]^X-]>A7-%4.5=X<9C56:@*#H-GS&!R+:U..JQ\WB]]4V_JSM4KK,)?/#O
M7ULT1@RB(F".+&("E;/MSTX;RK6B!,!JM<(463C%"F0\F-Y^[MR#E;#2)8;0
MQ<%&$Q?1_,+>V;'W]^?V N^Z<H>F-/C.S[[ 3L=3GL .=SO4CA&;/8GJ-[C\
M8H$[PXRAWBF>8GT97']#4Y':<=67:OLCABZ802&0K^<2>.7>&NF3>9>P<A?%
MQTX=N;9Y87_H@WMG<C9-\*</ZG8 X)EL!;)1\K3JWE7'D0/A/46?C4?$-"Y;
M90@^**QX'_6"-5V$'%9'%TZCG&H@7VSFCL+3&DVX$BQ<9T9#G]O+:,YX*+RY
M>GE#/]# %AO>/_)Q'F0//0=R;5?&\ELHB>BRGWS'PO&:@(M")#KK-9/X\:<"
M[2M60TFRYP])J;^Z>/&AG#P?S]60B'VLM!)J!LT;ZD-P:?X(L))"M]$.?" ,
MZ/\H6%ET#&BL?%G,!!J;[H9VO26U^X](?8)[K$V&Z9U,L8V9SHC'U<XDLB4T
M.[VZ;+>-?PFKN"Y"ET 7=6*J$8N[*;?'C!X1<$+VX^.%<6-C'5(_; 1D[=ZJ
M\+/X)AD:^M-,8!+*H8J0ZUJ<#V3/MD_(D!6CRSCK&%\9KXXEE)2^4>?)_DQD
M K#Z]"C=;G/Y8\3E-3FYM<(2RIWT@4\74WM\@"O!Z0+%\K2TS,I_UMFMG5_
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MIZPXFS<%3^$,8^689N2NF&RA[CO%*(NR9)F>N0?1EMYW;[=O6U1H[YIZ!A\
MR8^YP.)E#>+L*(HCYX\9@:+!2>=N:$[)FPN\RKAO*,%X$:WN%U6[,UFH1U5^
M]ZM-K_;QL#*F)0$#63*JAQB%5H):L3EP/8("Z[<LX#GB#7!MM_).+O!1$QF_
M5_+$!V/_Z0P )D$NBE#]2]K\G"M+8/AP,T@2JQBO362FT%TI7*#!ZDB84R/)
M\9KJ)M/4,P,GH%^:$XL56B_N?)O]BD_A F[%;FQ=EG;679!8$&RL\)B/?/UR
M(T^7;\$2%=.625UA762?8<;0"8ZTXFCB>Z^AZZ0,NIGHZ]E\<$;F4_W%L^:
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M/R-A(1)ME:'%#,\/9IVDUTS%XDLSW).//OG-3[!(>WAIXO*67"4SV67\T%=
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M-XGX-['3+V!LG9[$%]>6/9:T&Q/9>&=$['4%N3Z=-)D$RU=L,'AM]+":K5Z
MP0(HS=VE8&(/<^3*5[X-L=P+: )FFOGSQD(@FP-9\]?$GM#ZA*/-9?NMN^Z5
M)PV='?Q0W%RHH%C@L9K*\!!3JR)Q.)0.5!:.-[(\FH;3#Q]YZ#^ R<AA"><6
M&KKPG"5!)XEUT7<-,5"^)$4#Q"&7:$#AS06Z^1+$=P73@)V;C/3=AT=C"6EA
M2LC]IF]U?-R\$VU]7G,=;>D:L=16>_KY 'POX_5]01[H;KB0OV2WAB=6@"+\
MWLA-)$,S>DBA!:7<D5C.TQSIY4"M D#&P?^R8V"=# RO&S_\P;L:Y($M=?'0
M=V"K0SGM.:6@0_FE"CC0-C%%06$1[^"<H-"O28X2=CC4,:E3)B.CQ+Q0<6O"
M_O$-]^?BJBJS/S4V%1E^[;18Y[5: S66,0LC2.J!C3OIO\3U=7J^)U#Y]R-U
MM&%M#A2^8VP1L3)/8NM7[ZN><-N$!J;4TC7X 0U(K$)LKT?0 .V[5 (U!S/U
M<G(/QNG+T$J-"S)_Q.B0"S^9L0(;S)245C:V=H4&W*$;RV.##?'#:1==C!K4
M,LL]%<X5<OG?DBK=P["ULJS:L'Z 89OGOTS.0D\.)>@><I,=C^5BZ3D@267V
M3R2?#VR#[<,X+:E-&A-JB7E.G"67SH4W=U1\"+_D7C0_F7#[/H@Z#X ZR/\Z
M&PLC!T*0#>(@$-A5)VG*2S*R)/!V;A\Y;-2DG/;8X<9FJ6H; 86EJJ#[\X4,
M%J67/KP6;W'F>"!Z/]?>+"O35$6DA&&M?$F?KB%-S0@B<S]F7<<"_P*'WI*E
M.\"ALS1ZP&+"AO@EBL- G +AW6A%82M#^Y+:LO0!\PCU9O=W>F+[(E3@$["+
MB!3!<@H7@NC\G6(%GJH8]#>IBNZ4;CG0]6,Y_88"\NLUCOL0DIJ?F[9(!UG9
MZ3(IFGBMJL?%NP*#MS'3;8"K5CU>7]GTAJRA9W2(6-)Q'#H<<:C4Y1'Y0O^M
MHM*ZTJ<V;?8J875=2/&\>Z_.>P"9[NWH%2C6HA$.]3^*_Y$7[B$@4?FIN,1(
M4?EZL:+!:/C4JE%R9J7$@AV<? 9L@^W%.-;*!RBT\KUSE/!*7+YW[[IU3)T"
MN3]I0B?FEC_5, LZ"R'NI)MT^FN2./%4"FPZGF-A._/U$U>.AR-M[J4:0?-7
M'I<F]P,*VX--DV4K2QT$%B*J)G6S*=WTR6+-R4$9M_MI5@%TK4]M^7+ZJ'?V
MV5-Z!JURG8$T -D4 K^%\U/:)-* :(V.-TEW3"<7.<7X#D.77C(DUP/[7N[=
M3OT"LMTF:PZ1CL$AK6G0&\)/4\\N+8HJAZL"S%_?_.JHL3_\W+"+8,:R1C_-
M3'E)AEJG?ID>/W9V\=:W,_ON6SPZ\\M]<!*M1+T:.(!8=?5MHT8MT8!L8Q_9
M>E>2^&P]?)C<PN6-;E3#1)Z4?95NF*1>K/Q4T+!F^M3(TR:&.& XQBW&#>'K
M?X:D@UV)K(-6X.\4:GZU<ND,[IM)8IQP?6K]Z#>^0O;9;#O 0&'Z??Y8'O%*
MRF'2U=>&8LRZO8HOB_?3]>:<7<Y@8QD*KXL8?M_5LH"3W.CBR=!U*'NI=P$T
M7W#Z^@L^(ZW'GHQ*SBL(6,)I*NB1N/"NEVU/_$04.?&9X_6E9R*&F;B/<%^(
MITBRS6PN#$&VWNWD U$\JFL&V\(\R.6)+IZ&,IDJT0:GN@[7[S5E6?^ )(D-
M+LZ#)PF/$G&Q9[_Z:-F'].F7S'SN=9!6Z!!80F0@2_6;_5#1J!);XHN?,OV7
M2)G\W?<G$\5.J[2JKZIVH!?$0+9H_/W)^DF6DHPS2^<.ZAD@M*ZQ0+D"*UA>
M;K31"?9;7^,0IW273!0_NW .^][@;N8NTV\?C<'WB.V?-&";[=UQ_CWFEWN"
M67[I<=+M,^;WW0 G039A&G#4?!;$W*,!Z_SYVZ^I><CKKF&P4IUBTLK%[TOL
MH^R7B1"),:X//ENR+I6-\00TC)J)G'H*8X [< 90=*;&[9L/6L1+N_/6*MP;
MY^O.YGQG(K<:CVTK!0)1='/;EH*B^H[2S>[3_*N'+D:^CCM*+M1+_.B+/2#9
M-77B/-!$D,E)FX -%!R!U]"C"5:>&$J?57OTQDR<^B!^Y[6%-C53PP^+BCZH
M==A%#5PPY9H8$Y@J?(Z]FH%]KF,0_%2X\A *JP%!C%L"(:Q,7"'0PZ']7&."
M6V2<Z^(DGHS[&.'SBE34.GZD-D;_Z%<^OI6'[_>WK7YYEB/ \E)E!DJW:R:8
M&ZZD$YNA\-NUC+BF3'D\6/FN/?6XPUZK-@\.DSJ+B:OE"<&KY3<:>%L"QY#X
M2W!>L'] >6!R7PF,=VY"I/+FW*'TP%?24GUN3AQ<>>.PP2AJP7?X5 B\*#P_
M?]R9QWGB1)SSNYK9*#FUYH*@4^^54@"W;DET#F6GFM4[^O08L*:D<R58+Q^'
M,EVR\5+,I3$*X=F3M:/5STDL8IL9CI"MP]1@AYH*TCCVG>MF=-G FDKB^8H$
MW(/;KL_V^X:VHY>/S((&*2O4H U7ZA$EPL&F>)(89G$!_Z4-@<_\9=46^>(R
MV!-@?/WI^;(%A83S[VG 7;43' ^8KE]?1_>5X[52P8-IC;D_R$QE:7PQE*U,
MVV8]"3A2/4B5!8G3AM5++,72M>3;&ECGB:">C,,4P$A'TRA) ;)@_2.ZFAWP
M_$HQV+E3'-@YR>-_52):J=:]N><N=VUS3(( I6;L?%'=Z?G". $]+5-?*C.)
MDZSAK4,,Q%-$A/$IG3\Z,VK?6XE-W)^P/YO#4^7S+1"Q8L:"&9P=I!Q@Q[K,
M-LL^UI+@,U-JGLM5=#KD]ES<OK"5E^5K6V*W&VGPE\RE?D6R[?D!:Z.*F^D"
M:<XYA>+O]5]9,!L0#^]\OZ7:_+T4.CR+8Y]8J#+)=N5+>S?\%5N0%^I=7B']
M.3=;5?SD'H99_C;D'(2XDQHQ2CG2?[A' P#9"<*M[P?*'BVHZ7JW&Y=<'"T$
M+/>?N</D/\YBM[$)6Z*3-J9GU$RX8Z<=SI)@_"TOUV9LC#U"4/=3L!?+R0-"
M?F33-(D^//H4R9;^EWK49W4'2._;6JI$2J>M7Y YMB[:L=GQ?6D3'8.9IYC*
M!6]"#S!L3"Y!ILFN,+#+*B]*>NE-<=EWBI32HIF-E'1DK-;X!X&KQ2G+V7.=
M2![!",I+^MP^Y::!+P4Q=;7(J<GPFC-3S"0?=W&"8T=NAKB&41FB^+G@!>PM
MTQ?2R'@"[Q9*F<)E371^T3*)?U96/8U<@FFI$N\@9?TO"Z2!-X=:<:&KR# @
M()E\$-DAV4T#%J%OZ$?V%8(?V6")G'F:U[M" VZA^[O"D1SKIF$CS.@(#U6'
MU&^](T*.(SCUS]JOS%YV2*C )N"7[9S(VN#70#;JZQ(N[ J_[:2U9?#A\=L8
MY(H<JMJ- 7?(?[(W"!X9/Z0,FBC0([U/L;/@RTN8,CB?OU+HM&N]>@ S3C]S
MI9$&W ZJZ^5-QSZ#O1CU"MP@(!OI!A6Y.(N/:'W@/=HT,OG$H7_I9Y)'W,RW
MF^/2C8^^+9E?#&J"S,R-8*XI&A\9U>F5]G"^:3?2..XR+<^1JBO=].!HY1>1
MGT'P4.0HA'B'](ZLYF_1[SG.UW0IJ??;,IM8Q:>^V51IG4==B>*J-@RA"28J
M2IL.BZ_H-BB_#]Q+<M)0)R ,"'RU[HZBY4'ZG-,^%ZTI=9:,$_=N/,AQZ\O+
MVX 2G*=D@^KD'/M^34CT+OI7!TOZ/>TK$*^DSB])=(J*B]L?3IM:E4.D!$K0
MM6T_^#GS>/]'3_5:UV;BZKBI](IPT9=#=WL+;_)>MM %>.KW HO,@#]U&DY2
M@4TM5[X9&R+9UV>>B+B2*7"D+/%(7<*';SEZ#>8MAH>)G;KD8R"=1)>8+C$3
M'(SE#*<#U!N578]=[U?LU),\6]JXY9?[XHNV1I&^5'O'=%T$/H^R/X)X%9^:
M[YION1 H49D^X3U[;=G<4NQ.S#)#JK&=KF@\(HU_*A3Q;I(-!+PA4V"*:R[)
MP:AP^%[AXXH M5[U^/&/W?[=(MJFE]<VMLU8CA.6/KZ8<H@<V8@>1W%VS!8R
M\25_$Q#G-KW@*3Z(CR!X@2;"F$797.3<]P4J&\5UJE:AS4ZXOT;I74FBY=U'
M!4X*9Q(6A$[9?V*Y<"BNV2W3>=6]&8'7A0WG-6?*:2G6#/J;I2=6E%?*O4)]
MGG15K3A# T1O P<E5$PR2QC6-RD\:Z#!SPP:8"?H"CY1VBSP46Z$/181(2EC
M*_P5L!T?'0I#^$7-*\=K/K"7&HY+YXE[;OW!@HP0% %*\?X"(H,&TT@6X-ER
MY,8P<IT7;?9W'V=!77]K:B%SY+?&<G]W!$:A^)U[Q,HTH-L8*0K'V]& Z@(:
M,)A./W,EZ(6Y?K4BD1A6N XB U6:1^%!3+4M!1-?$:!7!A;#^F^JPHMC:B3-
M:NYA2M>[!H+@B5V_;P='0K?3@.$(D'6)K![X&11%<)%XK A'QZ?'<Z>LU^1T
MI&\ Y.W<]K9VA=7!A3" E[F+XO<%Q+Z;2SJ<* #58X*UK69!9R @^R!8;$4#
M/AZG 5EM"$4:T+"/!LSXTH"*EG)PU&(#0K9$-B@%LH.#K3.4L]^5JL4\7MT"
MO\GC 3.Y(G"0G+WQ48)H35=U8PJ$^E3I<CZ)_1J!\T=#I5%&57":H\=P\-J\
MA1CL,)T>#@)48W0*W!D>W$UQ(2&F81R1KYSS27R2([8Y'+K2 4(04MMEQ-5>
M^7P.^7"1& 988GL6=.T.]2W< 15# XH0K53]YA&M%Q_8I8P#[LLLWU.LKCQR
MKES<E;LI941N,[@EL!SLF,0_4 [7VD<2:6I"\)= #WC'7RN63#(]8-&N49'\
MA3V^J*LO?GI>+F8=S 55P2\P=E#+L?A7W<E>Z2-QTP(W_/(#3G1\=#OI!4]G
MDG<5P-;4!RRL2M&U]'[:HONT^M8&.VH_J8Y-PD?\5I!))$><31"/M38@ 0'<
MM&&GO?O ?3HD^'2&X-H%O.Q.12]K9PLY_@\_HB8OIJ3:=X<9,4M -!CAYY>0
MU]&C"L0,:@XH;3MV5UGD1%^-D-('9;ZRD8]I;T<; ?*%N-?6H8+<%\T.26JJ
M#=;Y:]& 4'_D+=F(]/',RC<+@<=K,S^[J>D$'"H^NZBN9O3A:VY %%?F=S(;
M'C5E&E0'=1Q(5PXKB5637-K?FB9VH3CDQ]/7;P2O?<]186^UV5!D6$CW>3ID
M*?!M+C:W\'ED@],%R5OBC[[,X$JMLX ]0/TA0(UACA[S?O5N:_I$RF^J2@U[
M$$5 --Z\?<_E\/9LC(6I+H#<#\-?G20=4XZM4<49>TV7ARIVR-KWRU*:0R\4
M.7]Y;.07GN8N4V=S<OBA/#"53J%0$VB JRN=9A1Z/2F@:QJ/1)2TQG%['^FT
M$9OT1]GW>DLL#JDM"S,*R*URK?ENT  ]8_<FM8.1BS^+!A0+E,W"'6=BPY;"
M"H88=4\T2Q-4ONU[>,I[ 9&**;&@<.&(=ZC9*WD8@FIMS]%,97W;O8U2ND+U
MS$&EM<5"%=_<7KZD>P45#4T:P"(;V%66+ASVI@!/;DGSS3%CJJPX5]=<?"NI
M2=#/-WY:4RU]JQAG2CFHT 83DITJI&;6:.(RF#^NN)A+1%_X_O&ICC@AGZ/-
ME45(88S#SV*B$-E0ABE\>HF-Y0GEKH%J@[+*-K+=;]M7D(P@>M,/QGDZ92I^
M22P7X3?*N+UT>@LYZNMQT'+D(9NRLM<ME#MJ($B#W8"PTHR,I*_,8)QG5Q3W
M9&>^(7;49THMI818O.?I[3JCD&N9-0Y',''\\)FY"&J,+QQ\:87IA4ZSU-,G
M1-'&&\\&N]X0O)/H=Z?L$MVMCK;=G;@4P\@]GL44_P@W@)%( UD5R"?0\7#L
M]?C]I&(R8JELL\[NO@;J](B]/'2+ R<43UFC< (!U60I9$?=-?IIC:/'6F]F
MT=-YX-X\.C4<IS,&QQ?T,*L+,8D(JN/V1F(W'Q_!WTE4^IKN<='Z7)%Q=>>H
M,UN8VA?1CDON:Z@?B.<($1HP%8TH=EABF2Z>7CGHG'FLK)]S#;%8K!!)^6E^
M2<O6BB%&#H0VI0-;=$M&UPSQ8KK-1UO0(Q<=A"JRP0,Y(T@#B'N3:8"N4B 1
M_$)?(8LFT^'+9TKP-"!HI52]VLA@1&74;(T]H6?+1WUYV8<=[)DE?)0E[H1N
M/OZBU +14_1-N#1PK[O>A09,V]TFQ^0:;LD6^#3@$K5A'1@*ESIXWA^UT=I'
M [25J#UP2G09D@@MID.X@OYJ.AP-LO&2M< O@@O.(-. O[Z7QQ?!)8S"/<93
MVN3MC/9?R&K$^V.?Q1R$4PVB5.S#3 ,*6\7LJ \T?;M9\ QT6O&2'J$W.="
M&^3?;O=^@N'/H+?X%./)3*8T(,<4\1I9@J9P51/=J6\U]&%/_-T^>J?V$J4J
M97GO<6 U.OAT#R]^=R$UQU*T7EKTH(J0BRQX%%&GL.P3*>#M_&:AM75ID?"Y
MCJ1XKLC9@*5!==.'CA \&F3/WVG61 .&CIE2]SNOT0"0-8V^AZ=QX#A\G0<Q
M %VZ2B>MRZ0S9.MS/?^V/M\+.@OI=AV:\+$QT&C!SFTN'FVU*DOW,&P'Z?/_
M/();F*#/7]?KT?0I"S.% ]2A>KA6WD.%E;(@==/1%>*U/HPC)D0M/%8F1MG"
M0LWSD]G\1Y-1QNP?AY-#8[SFXMY@0N#"I(/3>8LO"'5$&F#2XSDNW]4$BB49
M.3];KVY^W,;!#SWT_GU,9=?7/)813-^2RV&^GA$-)VFYYH2P%#Y=*4$F 0L.
MMOI9570$#7!$DR0V&Z CYX>G")Z/K=P-DL3&G-)M<RX7)A2>[-4]6ESLWY;4
MC%?-@LZV$>EQ;VBDUB&*$@F12S*=M@C3N#P-Y;/2/6%S=W]+0)F^L_?KF* R
M]X=']5SK?./O%K[926\$)<$>#&^))@R[#X43YM'%I!MDJBHN7;H6?"?FY,_5
M5W;R;HE=$DK$=0S^ONFBJ]+F:'PDY:;X6,$G]B"4U H$-OJL04,$;B*UC!ZN
M!MD"R'#PZR;1-SZT%W>YLNBI,<]\F=SYT= ]K7,?/SYCU.Y"6 &@'V;J([RX
MO,4U$LGBSX:+?N&B<^E[;D42#;@B-[?V187M^,/;9RK[XE<":YU7UT V'-GG
M&MB$W*](7CGTJVJ\)>ZY>+[2XU,V+0KR71VLHHEDY(,-]/IIP@[59O/7Z3[I
MK_YQ[A'W-9M18^>2.6)1Y*4;X7)B65=N]!\8"5@@O)B.H B1R4<HEPF*H.3W
M#13/W*;7'CU'Q5\Y(6,"B*\J!IZ1/*%],X<>  <8MJ3(ML@&=_JA<D1![+RM
MIP8?USB\L;5SBK_ML6#_SD;J\W*+$5-)-.3GA5N9J%BD)A*Z@>1U1O KYD\*
MY,[X4JJ^1=U/VF9S6?;N?QI+N."%_GIK83*N$KV\.86A[*<?>W/2<<4U1PO?
MUO=]5>U-%B4'#_,.UY/U<MT;AN0!@8X/*+IM:-B+N8T0I%RL(.5[OB=%FPS<
M/^ER/S8N@WWTFAXQ[9*M'K>DTK4C9G9G]XG")"%,@"1D/GXH&33>_@(V6)F"
M21:K;/1#&D0_I%\\:8 ]?=B>)(M-8WS3%":\CM=;2W:/H\*X<9ZNJ^O](AN'
MSN,NL-2,VPFKM8'(YL%9Q)+ 3L4!*OV,.R&X.Z:1@LZ!1TOKDC:7<J4O8#7&
MDN/3K@;92Y Q88#_T;_MO#8M.VQ!Y"99DX\Z/1HQ#5+BM%J=^+[YJM^_LWFM
M8=+'O4TK+S>@^N]?;;1W1A%PLMW(Q>_%UT9FZ1QU'496 GS"G] ILR5RX1.=
M)#H/#^XT/+:3>XUL-T=L+\+7!8F>.W4<S!A[_D!CE\N(965R 256+2$F1/,,
M+&/G)07>%KTEH;5366LG6>XT>O8RR':9;E=&=>F/0+IS*!K<M"6;!S9BV)'.
M 7QKYTC!R/?#(Q.C[$Y")FN0QUS\1:?MK)(>H5:@!?XN>"C(&D"6"^P*E"HE
M>#WV7#DP-L]7_L!.W"O<72")XQ[+([1*VR%*Q"]'"%&?/D+":;H?N/X%2CT:
M53+/?HU[8&1B0/Z\]9D#K*:7$EH+WVGZ-,:LWO4%HOZ+##[,!P>S^79?^2)4
M-B-T#=U% T;HAW,8CR16A7AK'9ZWZDRRL0YX3@.*:\8><T6NGD:,NI= 3=P[
M :3D)/Z<Z=;Q@S1@8V+'692CE^VOT'>4KC>+_,CUA,&?^HL[7_G'4E&8VYIW
M;=WK?;LBT2??>(^GT>WEUQN,P9C+E?Q;>P*MJ,:9K5+1"K=F(F/V,.K;AL-E
M-;B^30:6,("!.PE&6S)J%E3D)/*X,]$99#5BMR').U\A;XIP]XO:P:.,3WJ*
M9 QYH;M-1Q @:P]9!>S7.A;:(J(R0#%R"G"5+CYR3:#Y=BZ'D+J2M1M%G^0;
M]%NG*<R0 M9B$>DDG-?4J6->%Z=^NICEDCRWO6.,.&4SS6;)?MM]XK<X0V9R
ML8G #8UEPWTQ/@W2@//%O0Y.(KV-/MT"]D6)5SKXK^\[<J,O"7K!@I,^V9WJ
MAA])%D0)8Z_SA.5@]-V0Y1%U@Z6"FU4605GEGZN.UGS-VSRWRH+H(L>1NO"0
M>L0A?]4 +.:@TT"\:V"P>*5@P(=!R=>GX]G$'B<\F%5)\! )A<7NQ,ZAGDA[
M] 'OT(L$SLE(#82K^]LQH2<WRGG:&.4 WG/&]Q79V[2C--]"",K$33J(6N\T
M8BE^' S#6S39R?>6D%-/YE,SWHWI%:8PGC4H?QQ0/ZP!J,XATF"%N@.O?,CG
MO,UQU[@Y]0)\<FIXLL5?/_R"\85_+7@YHZRZ@!AS;4"1Q+P66_ 6)B[*.LY4
MJV/EF4,=^==TW8\-3WL_+[=!V K7JY[PNG5HOQZS3UL8?.HQ7?DQH2#]F#=V
M]99B#APKIN:?_" 3E*ZNFWZ'HSVRJE)76[N>"U"7S()F^WOBX((D(>+%O@T,
MQ,AK3[Y3]GP:Z\"#+XK54\51!OB$A.9E 4#$U,07!/R!G2NRWOE3*2 F&^P9
M@<=0##V=IFVOBGI]ZE^J[UO:$"IYPO*<B<*JD<6J4L]R:'"C,Y>BB >?3[77
M[!<[Z'O%O,\JOO1<LER<XV/3E)0<@1%XC?/J(&Z2PJ5/M"'1@ \VSG9BE=]+
MHJ,399^E:[X>/79'- /34RJD;2WV<>*A7Y(C9)6%F$O?DN Z7O][))\";X5Z
M+4Z"7LJ[!4'CUHQ#22V^G^^D;!YO&\KNXL=IX 26$%%TIC9;[TK_IT2_35CY
M6IKA -/#2<M)I8UOSSUD1L0QRLS^PWN^+EZF6 JP\%(O.=(C+(M%MZQY\ZH,
M3&3-#<6R8NFY0XW8[#MFVN;F@X>XOCTX<\@#/0 -@A5.-KH.3UXHZ=. O;&R
M85=B%_[^,\V)^)J12>B-O49&\6:7A"*#T262@/.TZW"U <E+J09Y%\GF5.79
M]NP 1-R<+'08=X@0@A1YC0E#C@X2=4CE9"5_EP$-9RQ5]C+J0K1EB-]QQ4[Y
M:8_0Q4WI:1UQAK2[^&8\BQTS,IO_W%56KK,,0<':9BS:!S@ 30"]GU1+AOMK
MDKI>C3L&GNA9GPV?%\#Z!><.=SYDFK_Z_):GQ41EN\M4:'<4 .K ;\:39#GS
M%NF\N$)#BE!N0( _<?TP^P2BR[S*5%;&?>Z(6'M%PY6A9UU"OA:C=F+T-7^J
MM<<Y_?9X1%B=,*E5QFJ:A_=%V[Y78M*+#UFO]O4GQ^"A6M_7TZ)W6F3(#I%;
MU3(&\OS0WD4#UN_RGN-*#+-CK7PX8GCM![(9SH@#!ZY[M)S9*9NB[$[4P#\J
M=/@P[ S*5&5^QMX7BUHZEG3L-O_>A6/E1U(T&RZO9T%3D+?@H[/$3&I>H-IB
MGU#+"#SXOFBXX_7^D@P3H0<:<QGUZ:XG-)XUQCU?YU>B&I!\/J)T>M.WHB>4
M8BLK'_'+R,6XTJ/*.S5&4^6+??C!J?NQ3MDD(_T^XHCDN>KD\\5Q2T':*,7/
MXD_Q"E\CD@*<?VDS!KT'@.L  .P+8JB'=)LQ]O($F69)K.;FB!V.-].?U88E
M3Y:S4'@CL/J+\+>.:LC8&JD"YTO.JX;"U4X+#\[=4:JTQWPN?8$>?E%!;II#
MA,'*]"D'O:8LECCQJRN-6B)X>.0ZN;*SAWM<IEO;X0F7>]UGN0:;C17$3GLO
M"G?UE.E2 ?+U71CWADM@H^U>0_%20<LTCEZ9SQF@7;93ZTG$6TT6+#Z1OC'W
MX/;<AC3@<7;K&'D<N0H&P:,1X32 ;SV>Q=\* ;.S,E6*_+Z\\I5K>4VC<IGI
M?05K9X5DFTDIU3&P$X%_X$57 BQF#TD6F]$5Y&]\+._NX;[T'WQKG^7/7^0M
MDMX[Q45=:;:HH0'-2CNE2*B<(J<IRY@MI/5.KF"H.YVL8#CO#EBUH)[XW]D\
MK2QG>^[0V)(L^QXS]X_E H?P=)]I3PP@S;T"N[68RPD#P?;N-^S5S^4S=[L=
MEA=3:??0J;?Q0'N@#Y(.XG6:8 #E(#1$X[B;I_L;[9XB0Y_JSJ^.[97CBFW9
MARA4YY$_=K?MK[N_69RQH0%/X#,"=*3TG]YF04_\/ON2%YO)3??J+U%7P-)E
MI\V#U._@V2#A/Y)\83F"IGB/T6-4-LRZM7FLCAOCV#F"UMFJ(FXU[--W;6*%
M6= IYW_<TPU1A"A%4+A6B%[4@@VR['ZZ+;0B"*?\B"DRXIYK=0G+L>0-'GYO
M[49N!7E&\1NN0SB0#8U'$$]\AUTE.;UW]NKKN+[M8WOALT6']YT@U 1B?*WH
MSM+@H6Z67P5TDL9OMY.=>OH5#;!+@V\?7:#0_=34I\E5ZR4Z8Y *H %978A?
M#GY.PALE T5)W(X3I\4^#A]XMS[+$N>\"B'2P^$0&; 358*)XFD)5!K4,'4.
M3.,>8RI4V+K]8Q^_?U5I1=LWMU5<W%.&U7C*_E#0L"YTY[83<CW8F=A$I'.8
M)&LTL@*S?>QG#8YXB1H)"@2VC\B\B<!OT^.)FM+B4N=KHQ?E7>5*[ QEZI9G
MDDL<DGQ6$"8D7(.O0]RZ$ 8ZCY9^E!;$)LCM%<0[&*,FHH.:SH*N'24U*Y#M
M2<]\2=-R]/FE8BKA0Y.-@W72U,C#O=+79)K+TEYYCR=M7]P+M'=(0(2W+9*\
MDT%6 ;(DZ<6T\6;SZ.1^4JE2-?6BI]/-F#%6YL:W-AS.YT]/(;M.*8R^@5L'
MLOISX3'U*$8K$J1Q=<QVCN_Q ;]N*QURH0B_1O$,+T3,AX[B ?6CUAZ*'ND@
M8:TE4^R[1X;%XF;F\?X-UI.#)I4&ER02/KE+7JJ8FEH6Z R< -MH -YN)1S&
MJ,7\"\;N?QD+YY[?'DC,L['2]W02QNG=OUT:Q6][ULI@GWB,,B<)QTL]#O9-
M?I)H0(R@C%\8$VI?SS7Z>97[9<B:E,?-[F.5_=FB].'%%ESY^<M-]-<7LJ33
M.V5^"FM#B'!N4N=,>;IJ"FR)F?T<N?[P0L[UQ)!3^F\5&2BMR 9M&G#?- I5
M6E?K.<TI:T2X&M]47IHTLJQ.5;AH??7DVR-0MQ/B1I'9:4)![1W"4O,(TA$>
M'L+9M;?PD4<^PM#M:KM2JAX"V7"8!MR)7@E-+V]XSCVG:&S[RJGT2M\KP0]Z
MK/=O($[,V+&'C95+6[M\GGF?G,1P '-[I_'E["*!?,([',E%@M+5?/Q'2[,7
M1]I/5VD-9^ZW#!M&B3'G%,*$?5@J6.*1#=;TL&XRC@8 6@<;IDT?IZ5_+VVI
MR[U91 -N6]K9M@\\.9I_H:+L^I"<P!X?B*;4VB;=J5 .W9Z"04AWNPQ)Q5-=
M_/-U1T(&6.\OBTR:/:[MO^[36;B8*^;&$CMFL;Y ,)J:#05/>M]'<'B_;QWY
MV7CEEKW,TX/2RGIB8TP56T$"EZL/DW]+Q]S)<IJ$#[-/GRYU+YBW&HR2=JBL
M2,6^+HPSN&&>4KX_GZ^0,4PXR(PE*PO:($N2[*+P]AE12VJ4;F!EP[1$",>>
M=@3:&;PIKTGSE__")1=V&O^RZ+@=2Z"ZQ2MD Q1Y:Q*&\/?&HUJZ]CL=) K*
M9%!>_Y0BLRUEC#B3WDP(WKY<^EC:/83UWNP@<1*;1MD/(>J1;A0T?'2R:GM2
MRC:5*I J?/;XL;!TOK%7J2YVGH<SLQTTUQ"%*(Y +F]EK%[$G@AL@)1I6<BX
MZ)5T&;7>$=>Q-RTN/<>6ONZ[MMRA06=6V)V[D1&+KS&P0.C=JL ,)IFW3H*<
M_;Z!&_JW4G(3T*DY(6T\(@S""R3M@(.XR451PFOK?'5;/],THZJ@L;N?G"S>
M.<M\\+I_*^S8!?W4^ ?U[DV,#.CUA53^/+THQ]YK8RZW$GE[(K*E&'/\]NOZ
MZY*- NOIO!WCM'0R0*'5UT/0=41<7G,B)7=$US.Y!/<MW,C2@-G]:T8G$,BQ
M<RTT-#Z0BZ3<L&T>08^?]I#RKPU\\" ;62Y?4I\2=+1GE[)?O!3P$S;QKDX"
MV= <R$X*SC'*I1S%2\1^\*S,3I*\$])UN?)6ZIG(N*'%BQ7PI7WC^?,!^B!G
M'3562>CY_5L$V1B<CVV.%&SD;$AS$B X'Z2*BR+"0^'XLZ[#.E,?*_FJ7\T+
M$O/=#B0:?)H?:/W)?5,5*&A]][!"8N7V/K^?0:JFI*.H)1:R@;_?M1ICPNE-
MA+&(K;FGM::#26UQ\F*7^_''R%RM!Z)7!8:[6'(#"8-<4_$1$_SX/<E[$K'C
M4B:%92$JB<9O4,Z.ID]?0&"B!W^*)3TT,;4K'>UF0)P"!V#\%E/EC; #I+Y[
M/TJBSZBL0N@!H(68VR<>BF8E16INGA ?!V?R5R#,UE?1_?A5S>]UR04-1+_G
M,@JS)Y8\/R^E\KQ4!7<R<#LMB%AJGO]M GEZ\XDGI_.5RJKN?;G$:':!YN L
MH?&J:I$:)./: N(FLD&9;B4FAUV)NA5]%'T"!/LF'^W]K?%AS]V!(V?-(:(!
M0;HWY+Z=]4@N1>JG;U*$DLG"WJ&7*[^?I!CCSF7^V*QZ53D"+5/Z/K?^P944
MCB'2S?2K[-;)C$$:(/L+\NTZ?5>?T>V'NJ-]""R\3N;::[/(:MF*B]W(]M.U
MY5-IE$,0/#O.-;I X^AK;VASF877PY'F9)NC/^OOWSGU3GW1_A!7<A=I)]][
M_R#8"E]7]!Y=JZ(!/ZB^FPV3I,.HQ3R\=<OI.BG\8*2_M2;U0UEO:YH>[HN,
MR_$4A6K+9]<+9V<HOR#$T3/?7P^6V$I9!0NJ>%JS6Y,2BRO%JL*.Z=X+>LA;
MKPK)_%Y@Z7LL94]8]ERZ4KZ"M=.CTP/[%6;=H@:.ALL/2WOQGGE9.%M[]Q^S
MA1VQ68E$XD9!1F2RA>Y??C9CX<+"MS@QY(BM4M].'^6_S@I5_$/M;R\CEE%-
M6U&>H@+\FK\@I'?TI8V XV8;D42!G68.-A;I-* !@UA]('B0ZJ,,QMP%7\#O
MT54VKQXSJF>L9?I$K:SVIL=":M5CI_"+:3=GPH??CCPPRFR;NX8LDJ!P(Z:@
MBZ[39%,!?]4!#1V_MR-Z-V.5Q.0BW[F,;:5G#"V #5G0_E_@-/7X>A SG3/?
M3 T2_;L)E!:;_O/"YS/#,<>1=U=(XHA%,MGV;O<\?0L]45R68PT>@W<5<:?[
MQ%S;U974[;3<AZB2D%48R+E%]_"!$> B:IM]<(.'X R><_$":X6V!MM113 *
M#VIJ9=&%\P-\GZ?FW2T7!JZ,"Y\-VP_/!FP,OFM#M-8M$/:%.4UKGE@QK'6P
M]JOX>DD^8"HO\]25V5^-0?"O.' O)PV0J,7!R% GS+9[)7JQ#V2#YG06!+;[
MIJ(@3$DN1J8CG3$<NN_WS2#]!HJT9)$->^@>R#4&<T!)-FI"C "-OC%8JEXA
M*Q$U-!;PTI!I12UL]$/S*2L=U'A\WEVJ,O4YY@Z2.?!+)C,2( G.;Z\8)GD[
MR"-6Y%<>7SC N7E0 H9QQ2W" >@:D<ZV4L!O,.XZOL">3%5"P;?$]S9SVY@H
MB=K2JO*^CX+\N&LA/N&WS(TK8XL>LE2@>V1)$FT4OA6Z 5_,Q3M?(-W&83B]
M(ZSJ/LG#Y#M/4C!R6?O?,%I]5;FNPO(R4(EZ+[ '6;C9&#]BH?-"A_ QP]7U
MT,!J_>8C7Y=WU<VY7PQGI:P[:ES%O)ZC?"D)J-\LY$G9P)&)HX1TS,L[0Q@G
MMNI RG7G+'L->WZQ4@"I@<&;K9".0YM1H[SIL_6^RM$E-("QR55<+<=+\$X.
ML4XGGXG;I$=74'),]?H93:E.NB--P*;AQNY.Y;/'*IS08Z7.9,2+43;1B_&-
M"+R!ZTZE479_??S'SI/W/5#<UD=+![(]\W2.Y3*^:G?VF:E)\K"/X4YC#5@(
M(NV4[#.D/D<Z( 658RG"'TF9N$L.P5\M I%)'!Q?GW'FFV3=KFR^&:2&)!WO
M:H7%('=V3<:B!<'BJF0$YQYR%-2Q-*8'[^,F'SPL$A;CQE-&-R-?0@89,; Z
M)OJ!:=S6;X)#+7_1@$,U,CAAYV;S@7?,2\UEZ3',R]^#O8:/YC0+9\7<AS]!
MS_>UPC@IRCCD7F2CZ,>1,SZY+ZS]S*VCK]WWTG=A&>Y[>($?EOQ6@K""B$,=
M1$Z%T"E_*^<CG-V )X++*>V@LLQ#_-P#I1J&X?,I5T+-R\RR-8 L/S.6:<32
MSE54Y@I\VM(-_&=7P%\2W_7$PT5O&M_Q'%N;P)_#]<KXS<BAU+V?554[=RHZ
M,J504[3$*0;4'(H80?]23ZF1C(01@=T6H02^< ->&BDZ^';(T\^VR8,S"^U'
M,*]7=EHNU- U(KCTF6<^IU>+5W(]H:K%.]F(3:[B@<"M@=S+R0V?7\9)$6%3
MDXM4/'DJ[LF^)U@9"5.#5U&2J3-SJ0_&$O<SV+1'K1Y4^5&>%. (:44ZQP^7
M#>),&V*M&PAG($;VV?/(&]SW1$^*C&W=>U65\5F%7Q7"CUY;(#7A37&SBW!"
MZYI%;X%2OM^",_7\]J!M42^:,Z.V)HU._N).9THWLYKK@)\<;N#ZJ&J65_NS
MWU=]$DT)NGW=-R1G_YEEUA;_5^1S@6UP5AK@!(,BO)&M5L8I'[P6RHP6A$]\
M11Q>'5$HPE[@X0CO:,X69W2$;%507\"GIN$1-("CAOFWT@-AE,O3G*X7^HX4
M9_Y403]5:C2P'8,6F<:$Z$^LS WV4SQI (L(19+P*-'MC;\&"8E3=WEX[8>U
MCVA9O\-MG_TYQD7JS!+W7L8AI06W3>F<-?0AW#[@/M%YF**+8[V5J2,F?@1K
MQBT7=-!&FZ5[[Y+63M5[S&21;./*?IUI80E+PNE7[FQ/4CGUCDL$/7M9\=GX
M@TF$FPI<XCQ F"0=<UVZ338!>P-/50UJW/"<]H/O/5FK$O7%LG=#R'B VR9Q
M;[ZM/&,^_Z'%T;@03,[>U<EP)*L&+SY?K[S'7S9[KBS!NHGCR#7%+^J6-F>K
M=:IU1*9GW]ULGGVG-'\%L.A"EO(5XCA9IN*;-:WKB\>LO3._-!5WYABY\'2J
MV;%'GBUQ:[TZ'L*'-=!<"W+^=3[DY\C$JH#,\JNH:;:G.8FF@D8\[\"#<;JW
M;G?=83)C(83BFT!V+O(9L"M3*K6)&-&GX3=M)"39:"Q+/%G()$L/^O<O\39N
M['5[.16,<-*G+ZQ\X#<NZS:.R7T:-B?M8R^9RTU"?I[ /F$QP4FK>?*2(60]
M9(,&R 3VFEOP!4KU+I4$NXNUK_T:T<TH&7[()G*[>D1+'EZC]O(F1F$9,S4:
M/_1M?MXOCZ <RYOW_.=MTY(PYJ'"O7MJ (@*/V1.&]8%I1R0 /?:XTQ';ZYJ
M*M3[(I^\QL_;E:1:V5^;O+# $??UYL4?;RR+]C ZC%0C2.)=%)Z^:>461+0O
M2RSEZFN$DQULS3!UU++/H>A.\M)><I/M"?\\I\-+,UR(/OU&4Y+HY&(^/N+2
MI_YUOTZ'RZF-CG?B-"]UV^@ML3'K?-A.:;_^0"%%=051, $E!6!-(7/$;:^(
M$DT)T[@1E==Q1IHG/W^[<"Z80<9U[^GI/71R+I$.%$\A.-OH@0VK-[*)B_G:
MNJV:U($KK=V%J2HV;O$O2CV?_L$Z%&XB=$(7SP_F;5NXVNC3@QI<*_P=^)3A
M&XEG!3EJ3@.Z.W?81[#6)K74E<HQ^ =+4.S*KOPS8EE53O'^0D**65U]D8]L
MB\%$K"HRX*R4*1$.-.#C @W(*O#+0;H%IF!]_^;94V#[CU1*^S\AE)H=*J;<
M7(T)RQ3M]8=D+ZC5;*KY/@T]'ROND+RXR@$L5JH_B[F#,9M7%8VZ^.1FG+;W
MD7,63+XW@K.@6'>B)346/.T]B'.I*\0A([2.]KK@!A8_VFU>+H[1:S"0;DDU
M5!'&9PNK[P4' P]X\TUB-T/7Q_>,';Y6X,+.)*3M6:Y[7>_[S"%0%7W&2$KE
MVZ\EF<3:2ZQ/P;M!W],!R==1_^TR2]'YM]L;J"FE'R OG8$73%(?(:C,SOT:
M_\EO'"&CO[WL-3+XMWK]_R,X_Y%("=GL]/,+#*7'F@7I?RF*^Q;R5=%T:^\7
M&F ; 8;:??L-,B'V;XOC!O']JYL3_K54T@!N9+O\[$X+N8NV_Z'V8)!&?B-B
ME2=Y'C50VZDU30.J,.T6X=Y&X-F' 9>W!ROSQA";%EM[ <\_6KGH?T+^.ZLC
M_4_)7[QIRN@@%PY)(L3/(W,!]SHF\B3Q.V9=P:[8SGC*M)8&N-#9H8[2'XSJ
M=V57_ADQOU^P8Y=!6/M RIWY20).%DN)!;P'Z,HI.DP#%JI^:[,R!QM#Y'K;
M_9V'@-:_VKC]-\@^9#.<OA);(,0.@45L[=UI7WC[MUH6.O_)+X(T:WVA6>"5
MDNB=.NBY__(9_"9_*> ^_,'%'=2XO0VEI@=I-/U-W78T?P]\1DJ6^@BVS>FG
MMI,9\);!\4_@AO_=':,($I30D\@%U 9OMP5\VG1K#]T_#\+G)2&?:X[2E5)5
MZQW5>:QO69:<3PGS=OB;^KE9+/_J<_;78J$^#2,1:4 0:N9[SU_]IY^AV=L4
MU'$%L:#+CO7_JR]X_[U1\)]!>)N])T$-^VW4G&WM7P)$,Q;UOW97=.?[%T_V
MKZ<,N_+_GOR[OW+ZBQ?K9HEUG%P51H'5:#"D=#F1VK)M$?;K=T_,(+_^!%9M
M-_C:#;YV@Z__:X(O&WBS:63=?M)5K*U.:YWJ]U<]&LJY0:ZE H0?C7L-<(\L
M]:5X,C%-"#$:T/29!MB[;DN-P&=A- "6!:V11-.U&?L#65A.Y5V"K<73%ZV'
M!D"EJ+&87VA'&O 220D,TL*_KH/2@(@4L'5RW:($^0T.PO4I&F@B?4U?UV:#
M;C2 L V0&Z-(<%#$@BR$[+&C?X@*#2!18?A5S- H&$6,WVJC 6V_("M[I78N
M2_H@%EUH@*Z?/@5'G_ Z<A?9+K)=9+O(=I'M(MM%MHML%]DNLEUDN\AVD>TB
MVT6VBVP7V2ZR762[R':1_=F022F;[[P504)GG*=AO_O[#9U+.\WV MOD1PR>
M$/STI7TY\C1@VRXKVK!S?_,V[$=<"@U@YJ(FB7[_F6D:-7*^N6\/QWF/O0SP
MA5IOM)TIZ3AB\=X!*,EZ6^ZP>RA]=!'ZZ+_^M.ORY]VQ762[R':1[2+;1;:+
M[/]69-U_O[CP<T\,Z;CLHJ>;@[B;OVW/<+SV7H?EQ!%[NP!L%TDR;3'>^>W8
M%WA+@"C7#XZ<I[\8X[>6EEJ P%S9G>L9J77[8/A+=-@0\"08W^VU,W3O[DOS
M762[R':1[2+#_^6N=IWD[R!:6F$H!UX0U=)[#7"DZNSBA%-9;[R[J*<W^;.@
M>1Y_<SF.4M.+G'J-+%)4B_XBT1(KRI7+)'>\SY7Z"'WY/UA@4U!3&^;=@V#Y
M&RN<_?O9 P%877_8[U''_W[V#)MAO'CD[Q<4_A\GW\TR<<"B@0;\;D%_-V<Z
MLHN[R':1[2+;1?:G1\;;14H&SZ3!-[JVHTB8WP]V<P&#OV0ZM#S=Z/UJQWP7
M79<\GN1.-]EO(7,(-F2[B>E[I-6F(CD:G*<!HHA4.T$:$!(9V,%7OB)- WC7
M([N7#B=E%-, XZHUNRK,C@D?.Q%/LAZ!CPOW]8'59BP35_ZT2_/GW;1=9+O(
M=I'M(OMW9'^5U8#@_YL/_J#I"NXU) N/G2F3C:Y2%\Z+R</0*3CHP;"!^@\9
M$%OQ6 Q)$K/XQ#E?<8UBV<LM_YCQO)<,W7QC"GS_+-'&GS<.VD6VBVP7V2ZR
M?P[91[%6^N@X6#\-.+\E]/OAKSO#\6:3PU+-Q4XCIV,)%H8U_9[L%1^69!+>
M;-T_*7X-&XOT]_&ZGKW0&Z15AI>8H %E!33@5?I&^BH-8+0R<2EP+8,5V^GS
MCM=$Y"382*8?9RENG6^B8NU>:</2,7CSKBVYKJC)C599JNAW*9(H>L4/W#M,
M XZI$JS!BA8:D*.6BV12_)>GH._*KNS*KOS_)!9Y_KPT(*D2/PJVF4*1<Y\G
M:EIKU:?0E)2N\$FBFK<?#3 Q7V< $T$(#4B$-:"()[R]Z&2=S_/[X/$I^!87
M18 &W,R+0*[W.-C: H%W:4"#-7RF34L*.<B/68^X@IX*Q]2ND*0<*,]F6URW
M<0?!A/D4ROX_5^KSKNS*KNS*_^MBEX&W ,_/-KF2A7=:Y^9)^:X)KJ^$8%8M
MM(200W/8%:JJ=3?+MCX)"IY#[D$.O<-.4A4M!RUL\H)HP(P^WH$:E2E, _IT
M,SP]&+;R:0#S/1J0?(A$#P=L;M* 7N%+F!!!<!,S58!:M4?Q8A9B$-LZ[RWP
M.O\-53<NX^(,;<0-OLV^?ML!UY9D>&K^.-T\E]LGZ=I8CO<WXI-&W*#*A^W_
MI*#*4T8#@-NP'O).$7AJ'C4G^$+B69FR'GPE\AGZPD9;GM*9GL0HM93;*K=O
MA$!?";]E*/EG*T)=3A$8.G'\C@8S1)S*_,@7V10O,M]]]-L+K+#O]L299S_+
M^CX>C6UC.='^F*M]-A=PNV)Q,9\DT3+"F#9 4?W@Y)@M/3APV?HM_S?#1.U6
MU:[<A^O_<JKP-V)RU>%Z9.ZS=3-YT^ZK:SEW;\(5AVQ9\29K[$OU\^XQ-X,4
MWN;>/F%P_<RA_7JLE.-_K.G4/Y0/9YS=/=Q<F8H/X;A>V:,:<U"FM64"%:69
M7 OB][(W#C"8_+<7L#G14EK0.=/AZL14SM/><$DRH;I:)/C*K>3UK+WK%@$L
MC9C(S8ML!12>:<-7AS\E:9[\D1#<H1YB#SQT3O_NK_[QE^N/!4%CXHO#3(LU
MY4E[ZF=>JK#4 O;_\OW<E5WY_UC^/*&0K6RXOT2!=QDHK*Q;YOSB>>ZUBU=M
M8A?E&88*XN 9[E>IIL@&/AIPJXNC+&,:Q4>B 8UE5NM6!3D'JQ3F/RG(%+9$
M+9?+E2#'TI*LWV5!&U0P-U?BW(]TP"(>?F!@.2C,VDX#4GD[O,N)-TF%4]6&
MLIZ=7%GE3S3:KA>_/*F0>0.R@5Y71H0BV7O.HD-*=,U. >$V@ IL=:!B4ACL
MG&33N(TE4X_@&@3WUO;;67TCKB;SS]RZ>7F(!GATLVS5=C&EKI;(O[/0"6$]
M'%\_U:^T*4LY ,%"*)+4U_X^V4-S=[Z<+<5P7>LXX"?S3,#!1@_:&7?PK<CK
M.L%_8'<S1R:L*['E80(SZ0:XJW8YU6'\2Y,$]'?9" 3>*/Y)G2:^-67ZVJL!
MEZ4-:TGT]5%7'C'QRM:^F3)]%A:-Z2#X\;?H?MEH#/["Y!,XN[_\Q)%TX9O+
MBFO1V=:M[]_MS5?G^:$?Q%L4>#]4DX!XKDQ\.+=9;G[YN*7+_6/EGO?Y->05
M[[%N<.1IOF7,^!T;8?5FVH8@JN@HH$,'L5Y+^E@G?P=<:S]3JN\7)QKPZT4-
M1G9)V5%>@Q3^:%3V_CZ?GQAVZU?;L!^(@7C*?E/0( Y- ^PO(^?L\K5A%J1R
MD'6%+(\)EQTX_;UIU%+U\8?K<O=B;D77^VTL;*!_0(E#)&$L)@@IL!'/2++\
M*&14=):@].W"XZUO+W\:0L?-M @0 GI=@B!+B=[.H_I@UJQ ;AHP]1ZU^ENA
MM8\2-.#\T2SHU_2_5Z^=2B=X(2[@ET H]5V=^(*6,"&QBL]*X\&8:(FTT'*:
M*KNT/X=]4L#"6A3F(7(J#+-JY>]* ^RXZ--,RX*.14-)8JC%-I%8X5<N-N$A
MI^_(Q8Y2LDP[B46^*+OOE#GZH;B L5^)0!6S/%%4\>?8+. K=8>_/+FV>?5D
M^PC'*N[9@9=<@Q.8RFA7TEH\6"$!1EF!!G3TE9A5!9(06#U&'ZA6+PB>,?]/
M5:+/T1HWA8QE!@4J,BPCBN.;_%!1D_P:8E-#UYVFOZ_H5K_?([Y:X[:Q(8!>
M5B:Z4:,"8=Y"V-;@W+LCPMF(4>O%%TN" 26=&8G!:<\MNPYO4#2=\1"0M8"L
MK(^C/IR=/OT.*'_1N-WN?$/#+UUW+45'[(0*!%(M:Q)1OC'^;EP_RU$MC #Y
MTG?O_OUG'LS7G[R<?;/GX&C\MR#X"R1):B4(Y/86:JSJ#$>YNCA,*UQ/LM9A
MSLBMD"*:N3^+^J2>*=>8B4&M8E3W.+G%5M<AWD@1#X)[%P@CR"B$D(W3INF^
M#)<\TQLR.:95!Y,@S@QWF"J_V2.G#R6WW2#-+)Y5X&FW2:;0@':*).1LDVE5
M?Q[?0*)B4=FI]Q_&3?8\"HWS(Z*-0J?*XY:/&+[NS3E^)/SRC\Z><'U*,7IT
MDB06OXB=0HDL"'I%^]]X[50G6E)9*+:H]EA6W/E(F]A*X[T9/AO_V<1>3-XH
M<A@UI6C6&HW'-$Z=.!$DD]<*M/F%SFG#9M-HP%Z=-AJPSI8,4CMI0.M;&A F
MBJ,!VTP=-"#P)PW 707IQ[@3R0C_E49"T "&.__VSD.)PDH#7M_ (BG,+^CF
M61)"P2JY[KN[K;CBZN>@^%"OA=_GTO53 LLAA0*6AAP?<CPY6,7F6='K5PEI
MBQ9D=>]\XYJ2>*SKXP\?/[YR',!;V1R,[6#Y"L,$:O.W]FK6(O?2 )=XDEBS
M[YV4MZ1)[,]7Q.<"/]VRYLQS^+,C>/A$7-)C>&]"5YXT$I89*'47;=OB* S3
M\(CM\9_1TYSR*Z:9(S^]#]B>D#(0?5@=9"Z6H##Z2RKB=X9+:@+N@ G6$J=;
M:AP;10([:MWQ\7"9]1OG<Y9"7V[(B8=SUN\O,]'TQ05!65YC;BTAIQ(F>6;C
M)!P&DK_J^@>D:RD#R-FA]2[3P;A #OJ'D.6]BZ=.9PWX;I2NZLZ6R'6Z"QY.
M"-&SN(L^)#*\H@V3[=%?QZW^L:-QM"S<*+_:2"7-8S#-S*H1,Y$Z?25<KBV_
M@I=\FZR,;!#3.D8QP;=@(BF&61=2R[M'QX=K9-S61FV 7Y.>JI)GIA('DQ&Q
M@9R5(8,M=4))/WBGP8F>.AIPA@;PL/MGLLZB?ZRCUS6I"1N:4F8DU:FF/ T.
MGB8K^?9/RRK(HK8$+_<$WVZ6U14"&62EXE8B,ODJ"2P1'E)/Q#Z55U37.*7/
MLC&Q5P[=L'F0A7?K4D4W=;H;5G:7&M7*$S2JHZV?3'G.1H28/VE3T9"?"M1/
MIP&&J#C#W Y\?IOSNRUU:+C2@_![4[ BC)A(!"_H#2\Y6H=B:2[POF9T(!%Y
M=[YM4SLX&7F\[; (P]S21)#&/U>Y6RH/GQ9:HXMSN<0IT61E/%'@J;C $-=Y
M<=RV5;NI*N9E_,6N&8:O08;U3,G=@"$E0FDNDYVDCT.(U'5!G9)LRJ9JVDX)
M2 B;GUXA62RC%NEVF2E^@&*KE8)#/>$>F]O??L3)@]-NB)?!( UU<N3,&J2<
MZE6Q@.A%!B%OH8,S]_1*>Y!-(^P$G*.=O6^F+LGD6:0;U'\M>&Z1*@;W#'S*
M0-'XA<2;K(Q8-Y_N\'I#NGHKK+\HF9CP*/AE@DRL>YT,-0SI"&,^N[:0*;A?
M7W#YX>N9J>N91%SY&GJ=LXCD.16K)L>;%EXRZMCOPG;H/B!\2D%TZ8JG:1AL
MGV?NK>_^HMF38ASR71PQK',C9[1A/W,+' 4S0_TTP[-=I)7Y5OES]J@"^_88
M=%RL[_)ML0]JJV "SV+J7$?T0;9!O,,T)GQ#O%OC.':%8S[60=*ZVLB2LG7L
MYH.I1)4Q"$/?2WM>RMU .J<H-NY:_$Z0LL+?VUP)(.Z?,9@K%LU-.G5ZZ]1Z
MVZ;^F4X@X"I]W9JI<?[,Y"MV$^.D8?0YWT?O75B&%>)EOPVW\YQ3B+=[CO[U
M>A-DG2/+GPS5_*16=K/LQ8W5UNE'AQ@#AS.SA0,65N-!UE/N+M,Z"]-[X!DM
M2$ME&K"ZKXKN+;F18MJP!F7* 3@1@;=8'"6<0.SS5D(+MH\8/M3ZGD#&>(S_
M2(Z?X-YC>E]JS<=$6XD<2@.8L^BV:H &$-F05,81#/3R<GS;5OK_?M%2<:0F
M\?D]$[ZUB\4E2-NT@W+GFOV"?J:^@%+"*' :<*-3E@88%;R%;!=1(S%33R<9
M05$2BS'!X<D+<[+G>$H&EI5=SPH+*5/PR#ZT:1-X=1E1XD7A5B"Z]]2P?%A(
M=Y[_XO5F+JV\\,9IV>=,NMW"Y0XQ<5/Q]J/+KB0)%"71=!\-&((:T8!>3[0W
M]0T-F'E*9RLMU,OT8S<2!/^&FT9$N&@<G:8:Z11*NQ2XRMXX^[_8>\^@IJ+V
M7W0C(%5ITDN0(BH@2I4:4&DB(BJ]1 5%0$!Z)Q2E%T$!Z2@@G= [A-Z;M-!)
M*"(]H09(N?&\]\S<.6?NF;EWSH<[<_\?UI?,3M;::SW/K^SU[)6SQ4JZY B?
MKS,^QWOVH3 S["$1$)8S(P+EL<5$(&_?4OO_O+M/@9)>EUJ2D?!V$"?.'J.>
M'(:3R]F2,SS]D+,[[=RS%3;T$NP=L>H,=JTS!3#K,<M[@O"+(K,S<LL&)#1H
MF5'ENI@N:OB&3OSM4-W?0Y+4?1<5<D[KW5#2V"KR<<QT'9GT$VZC+%[G6X-=
MDDN=E#NI3XOMUMJT#>P]9NT9"<Q/A90#C@/ZL;XG[[#LJ'"K*"VL+2I-D*.C
MFFWB%CD'\,ZU[?P9%;KT)TG"*!(!6PN?Y5T%Z&=#K5!YL!VOCUNM2F@# TM
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MC0:6N MR=Q=MVHW1G#B8N$M'M%HLI:QRW.]M"=CS8\8\XA/#6B%;+&]]&K?
M>CZI_QY\52B)\MV&_#;!.YMAXR&!+@C-:.NCDH$A?UHY/%)5LE>?=/^T26#A
MAB<U26,?*P48X-H4OGEHH.)3M#:#<T/:3UD)P<MU^^W& 7?]>*90"?.[5[(W
M37_EA@PN/7Q(\YTOC*<WG0@H$,B;;7+-WV>*(-PNPJ/%'4KL/M[.5#%VRH_V
MX/WVC.J>IN4WHW%X);S=%QR;Q2*NQ.OO+%/3(%M9_<5Q.2PEQ'\\-[!P0IKL
M\'M5\^O$FH97WA1JMRA\UH0E9IR@&R/;I/A8)P(KHA<2:"<<DR>RNS?4S:P0
MI^Z_8;XY7?68BX;F*D;T;G^:"&</]&GB!!'H3%*A@8YU>A.!P ,H9@L@W [H
M]"4"*IX0+ -)TS%I?8!=8YY.YK^J??<QP)?[K0VV"R'P5*!U"*'<HSBJKT0@
MSL!L&2L ;1<=--G5BY#(8;FNNTGQ(UF()UBD3^D9%>:E&A4%HS]U.RY&.. 3
M89D(5'I\OKCC9X9A"/&3+["P,[5,$\AE-U(\;76\$;[A6S'"Z*(]$I"".X^\
M)>+,8]\P__-4FHQ7C[5T$M?NH-0Y?=.:U*GJ"T@>O%(.QQ*U MVE+#!9LC>]
MG)>/?7[\P\O=S%66;Q'S1TM6 #]$!+P01S3H0P(U% WID)7-](R44=R,?"CV
M<^N6M:C@[:9?UM_71)E;T]UV54$]@^_G&LO^C-<(F]NX&B]2]I8],>YMM0OI
M%K(NB6_^H!"F\4#E1Z ,?L8.A'ZL%UPW9SSQY'</A8I>9M)UZZVG.V$CWL>P
MB  I4AS2J7 -YMMQ[7]NUBU9M/O%G7*]/,*133;A_IS6-\IO02TC"Y2]3ZO)
M<%_U(48!8UF5X&Z]0(7%XZQ()3G/_$WT\,=I!$N*E/!/^;L#GCWP /%21(O?
M/G+XBI+NROY5K(>&=9S)E$,)+T)QZIU#;AFU/$X=L/-3KDK=Z)K3-_/.B]N=
MSI)\M-? ?N^45I-<AA"15;GV.(M,A?U6]"T^EG*.M^T\_9-,J3@K_#<H,AY,
M!U-BR/6*>HF $99V;3TKM=:AS5'W.26#@?N\RMNG$^V6K-5HH\]'>G0S?=8U
MO\4$RH-F7E4[L_''?XUMK28[V-^%L^V'I)9KG<K-N/M1/LG"'AR1>H6V@BM:
MB,"GT6Z.JL9>G!!7SSVG._=.SL[]$@GQ6<P!?)MP9C]E9Q3^J6'DDE>9P#O]
M!,JN +./=[UXCF$#I2\(U!-HR,M)F/NMFHONI).]E3U5_J]D>\*VQC;#.^:'
MTX'@"/98K9%9IM\MO"9Z:VU<KRC0E_6R83/[V%NC.Z(H\*S6>X7\T!K%IC6$
MDZ6LR;3ZHV>'-^<X9Z"#]Z*O@K/ZH.60G=4<PF06G_1^*-?Z\4C66V>'D^1,
MA&<J;7]U4,7D:JQW[S& G3&Q9.0P-4\4Y \7YH][]L"*E3RGI]M:0X/78+*8
MH> 5-:[XXLDX2>E&0BA?3XCS?^WR'-J\E".E=OU-9W3"N[7,7+P]1I% :W)!
MYB5U8E;%)XP>J?(-<))1KV0<$6(J2@O/$3;(?9W^Q+7WM2HH^N7S3!J^3P@S
M-"D]Q[!-O2ILZ)JAF"NM3<5FFP<#*4L1LCN)[12@Y +^,:J[276297]+-^*A
MS5_ZML^*XL\GK$/??[P1:ASQ5RAF JS;9H.&;<.05#BF.B2A GE%@7#1E;RO
MW/5QH$<KST6I3[^O/TW9+'9&9@522P1PS ]1T$Z)SZW7L6$_L%'ZOO KM@[N
MK/7:SV\9.W)\\<[3&I6?\^X&H!(.8WB& ]BV)H%:A @(:1J1Z*<0?@0S@*T-
MN!W,3HR!UNS/ATE$0"*#?J8I(K!CYX07G7I/?L[UOWX^#-N;Z((?2&QE'?\A
M L/V6)+I"RZ"]O][EZ\^"W\S*1 L::>%2K4*_YGT7"%\U480_<R^!NN*M+!:
MD8MRRZ)Y[U%IL<5537C$V)NQMP%0MHG(JR3B50,&X6AU,+E=P.7?./W5%AN#
M";^'!?.@.ML$H7W>IO"Q0'*M$.&44-G8;V2X?.6\23M3'?M/^E.9G*R:DY6!
M8 489&:T&XH5M&G3%6DWC5G*6=G&*TPK>2=KTT?V'VCY1$P&!3YUG?$7/9/'
M3B 7N5%$H"N+#:OWH,47+_IP*K>RJNFKXI_/ C%=,4E6">8A"7J\)*(1R\]U
MT?+HY>[K_?FSZBOVYHU6.#X5:I45":G6*'SGIXP:'!R^_+<K8-'1FLI>UCPF
MOF[QJ0\1N$T(;J6%MM.U\D6)7K'O;A6<+JF1B;SUMN*;N72 %6!!;?N2,3_:
M 5= ?J9AP6[RD5,Z0W?RZ&UYXZN 3X_4?K7&%S^B^:HS:45>Z"OZC7S+]'HD
M8?L(BA4.:W>XT4''.[9 K:'4+V:0 5]Z,[LC"NJ"H[5AP:T"=0GD;F)=(=S9
M5=2=P0K%(?L(4@I^SB>EH)#FPXFK)?DJWU_=2L2K!TQDH1\M,CS\O2<3%SH7
M"BM=SFNN UD;9# ^IKO]B[R^G5MO<<O'$[8AL7+:(<'FQX-Q./VD9/%+-V^K
MENIT>L)Q*<0WN__MB_0?'+U.0^0#]J<B!&J2<Q?.[R$"QR@0(<(')PM;R,)>
M=\(E97$3 <0GZ+GP7_(+:5($Q]TG MO!T+]YL+4X ET:$1 $!\&W6T8)49/V
MYPO_ZPO>DY\M%>;4UG][=_/&MZN_[F?T_BE2U_UE1K<+T9B80<GPFCTM=U$H
M6K+H=.SR#;HNN&!T['EQAP3W?"K7L#FHO?@57JLNA; Y=W]%O<G'S2ZMG9Y
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M%)F^;E3?^QA8JZWR*\K['GRI0.AK;"!]0D#B10WISJ4JDL!S+*8)9K8O5+A
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MWA$NR4#6)R^ZX*)ICMBEVH'_<^AH_\P4JQ40[Y9I1B9,R:1AHNRY[9N(*7*
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MA2M48@*#1DS@[@ 3N'"<G@\;KAO.2VF]#%<Z,;&?//$,?O"/N9!).L)[)!_
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MI?$Q@8-!C/?T>Q]#4=CO8VD%W@8)+ODML)IRK<D)4)&_U^8CHS+291&#JP?
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M1<YVPQ%7!ZM;ISBJ5;8$V@=P5;F\ \ECA02-9)(U025^.Z'V=,&@I]I\1$\
M\$]<QS3?(IHBR?C4<.Q/J"PE>X;[@ ][:?9#%L-;\W8"E8CFM6W<MNN@^^R@
M^\?REX>3G!L/.O%M+]"W4$TC].,XXP1CQCL]]Y?OWA5_# =@?I;^F<K2[K6
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M9QLH(;.<KJ?,0B<.,P _V[]Y4B^^STK\QFTQ&%5Z,DR ?:.-^_[7BS+GI@R
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M-O:[DL[L54K(^[$_G\UL^@=?_KB>O!U(D?^3:-N-_2]!AHNL=":P 8Z84YB
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M((0XS0_\M9^I7QT!V?5KT@7/DQ><G9$"6O=OTC-B+IX%Y^66#!$5*.(=2X%
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MT4O>;7C_8_Q/V#S1FX40QP03D)9OAAJ*\=GEF)A0,9+$YQD<$(B^,RQ'N\R
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M]3#)YZ%QI8V O >R2G\%WM;=%:)V)GF"WV@(^[0=FN">@O<-4PB]3054 ZD
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M:T<("K_'NN@R!UD_3](A0X?=7.6,Z:8M.T_N-(\_];UV6TQ^_G,"%4BU@7X
M^Z@ K\^&%DE9 S\UL1HO'<D@=?UN6DG;Z9_LCS74D)&(#R=1L^@H!-M/XT_C
MS@VXW!?]7\MR7B??8]&!2EMEI).DR6SXO:W]BIS9<J7^#?M;E/?J#'I&!H[N
MID[T"W"BJ%0[JV"P(I%QMEFAVP-N^0SOO"'85S,Y=/<W>@QW[]95IBWZ?KH>
M,OB;2 7F;@=?PP^9CSJRO]VH3+W*"!WNGXSHQH>:5W3M=*HQX:TC)!9K"E>X
M:GO6N197;S_0K-!CC%D"$-?)[+1,<-QW2Y,L440TL"::S^8:G;M[8%J]8SLB
M6XJNUKH0ZW;OO73MP$2%DE#.\9;<DME\JW$LM'J_Z(-66(L8(;;&C(M.R+Y%
MP_#MTD$(V@0>Z(\"F3D) D0N" ?QO/9(3>.A.N)B31=&ZH?^F1=?61*,I^8%
ML'\57I)A*FA^%<&YC;NSZ:RQ%]'?\LP2OR4]D%S7[[['W$-V(?V@)(-*Q/-=
M,V>J'ZA=_YV]^BA-OEKA-^]^CO]P^*MTC/"13S[KW/E.*E"YU(UB^.G;L!6^
M638X,F75J/>"+<7K+?>0W._@TY2W:BK^T7-B$15-MW#-6KTUA)/I7D$2A4,=
M#\>5OTT_]!(POWCQ^=)**GQZLP8/QT&23)WE#.F-1@;G)<0W8:SHEA>A^\^@
MYX)/$K5FKS%.O\0E0O5\Z ]B-,.XBZ_H&N],AW'/BD7[T*Y0':C>L,+L_ZDN
MOR9ZOK&Q+-:6[T<A^M>+0X$#02;.;07R!60W%\A)5*QX].N21*E_Z*K(SHD,
MS#LJX)VG>U0U=.C0,DHP[D1&AYZJ3'.U[;00RJM=2;Z^"%[5NZ^5L*GRF*Y[
M&[50!Y[.)(58DJU'Y_&PB$V1I)\:]=^&-MU<%W=<MYY>QK47,%TW.UA5LUE%
M *SMB:9//.9S.9Z0;:X,?A.$+ERC VO </27)7(J_-2QKJ6 "JQ<QQZNF/<,
M^D>T?_TQ\=8_0L_!]@_":8)+;(!NF.)"84 \07,L,\UV1PKS-;_TQN^G5'SP
MGBR3N,^FXW\1K^NV2[<R\V]"F;5@6@!*W8%3@2\M)52@F/EX'A<HVS("7Z+R
M$%ISXRLH-/)&-Z_^J>L[0'$A31N!=.R4-U?Q02FQ_1BO_:3%HG$2-&6=4SRZ
MQ[3J2&:?Z!YWCU 36<UV>^\O<65T+\>_?.!=0/?/JN<LNN1ML??]IU ;Z']R
M)9_/OV'Y^P2+AUA0 3E$!(3=!QHYPQ%\9>XG?^S3FD$YIRW4Q9@4QSMQ#R92
M- 2^YJDJ.R(WO?:OTE@H/:$;MQGKX5'NW."&4@DJJFQJUFY4OQ@;1<R-9]%B
MF5SPB% 78"5?\-H7@X];:M1C9;])2@9K/?D8;\EOX(.8@8@YR$1'O(;C5 -A
M.R]Q"*((8N-2B7^_JY057JC$%M?F<\%DIM1J\V9E.YI-:@JR$;0T1$JH&G[N
M<XH\P?]-LN#V)=R+-8R1;KGCLSPQ/!@OD+;:T)P8?J<HM\)1[_O+X=R.%\H#
M3(L*Z^*TD+B#]UN?>+]RX,?U?<<J<M AYU[MCAO;%\GE*V^K(EE>G QH18W<
M_J!GJU?PX(Y&S0-U@&X N,U)7"(]IWG\/TWL^&@,WB]22F+/T+PP-M-L<$OE
M[SUS]O2#YR>UH,)ITG $B(%P>\_$(,Z1;\T9]#V<V>#+2V9<B)>=_P5+[;GT
M4G&J6_60-Y^USYTH@2'G?,RB K8,Z"/E?U!S.1:DAFB*7R85T-&'CT/(7.TV
MOU%0QSZE4:Q951[.Y]#\?9*]\X6 !O<K&CTT)@-*R>71K$5@,< CR8O4>Y6>
M])D6F8[KBC?[\X.M)E1@O>8(2K %[_3!P&8W]&ZV!;F+=L4]_V3-B%FF<->/
M(V6V>:HLTB+&2K%L."->KQ0/>"&$*UC[/2OC:N%JK3J_90IS+I/HN,G:&HT0
MKI%L:',_)V H"74T*G8"^TL&49I^+/$8, R1(UD97J#A]B9W$<FO!?YIQ-+W
MDX47K-ATF>1V;B!7%ZB !WKWO#ID!$;FWZ$"(LF=D'WY2<1*NPEJA?[_+0D:
M1;31U92+&1'-YBR#*)JC@WX$N_54X^L%7W,HZN$7MG6%=U#+:YUYEP>H (YO
M-(?T\">]\;OT)4F@=6V%E@J9_E.Q4#(58-09OE'#FGC4E &[-R66-N\M*>@I
M*F#G-XO]VTZ#,=#-9-H4 P@R.Q-XU_Z \I()C&E"K4W/@*JS5*!"&K%\!MZ-
M)K-+P0;70\7@$G_W:JH03U_&VMU7W):ZO41>B@.;)(*U/L@UMTR9]BSR5,:^
M7KI:34=./SZSCUBPCP:_TYC7A@48%%1'HF7#]WQ@&&*VDJ\V*VC.?W#P:!PW
M9/9.J?-RI1EI,]\;M40J@6XI@*^<@ ]Q5^D_XN'Q-1# /Z^[LT$#.L[G?YF-
MIWC:Z0^Y742@2YR42UM9=W#8AI_8BZ_3&(0]C)NW^EWM9#N\,9*:QSOVYLLO
MGLJY!ZM,)O"V,2"!/15N"?Z$U[@G(ARHP(7VSRM\1>N!=G4I/S^93[A!G,+E
MU)\^O]FJ9A%$F/G"="364/:IIU5&+Z'L5(_]"PT&H?R(<%83^%M$;30-4M'8
M_P9OL=6S7K<&MQKWYVNGG6OCSUO]6&VM3CPC?.M=FCY#^EX%?/]X S"++$_<
M*%BI;>@<*8[V8;95WRBU.24R6?FRYTWLX5N!D$#82DLN@;XML,SCYY,YZ\LK
M=O=^/&Y*4M?R[J+A/%[(>1IJ2D8+R$IHZC5QXU0M']6<9S 7K C0_#,)]1%S
MBU!%WYAA0+1=;%%]=E347!?;)/AYI58&49%KL73M!Q[JG5N5ISLT1/(,7YQ>
M8<C8T96Y^:/Z.0_[NK9&4,G*D2>O%.IB=:*. >:B-CWO M+-B9YPZU\B3VBP
M%-$H8QRL]_$J6?4[P]G7%U7J=G"S4\95B\TR5M 71X=C,DOM"STNDO<TF!6W
MQ1 <3%#+Q%'DNPVKPV79VVU=.,NTSO_(8N;X'*Z^E& ;!S:"$N P_#3(M:QP
M5+X5M\N?M2%A]\Z\HH M3T<K6>+>S2M)K#0F#EY%S!;"JVT227>"[0G<<;(&
M7HQ%<RD1 1ZO\Q[VV.:]1V>B+D(*H'@-!'&7 *%$8\#7I\&OJ..CQSXT)Q !
M==!IQL1+\JBBE1?$<$%-<'Q0%]M[)^]!XKN0?$\ZE3CP"ZI)^[V@TG+BPYZ7
M[M=$C)IO&J.*  0_%<!;L!Y*N%.!QYG'V[RE^#VUX]JWJ DX\49%@2V"\%&W
MJB'J+_3K.[?(]H17M3P]!ZB.0E(! 70(@VI 9]^BMSUIB<W&%W$DOXINAI]
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M!!U"K?(6MHV7U"%C2V0.R'[4 -D:W]@>RM4R?-GZ*<;0,6^84[*HW,S-:#;
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MQUM N7GZ6L 1U\W$;PB<Y=IHW/1<]#E>M<Y7\B:GS%WS_/B+NJM3*H(;^FG
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MOGMB0I(&?/,%B5M@]A-V.JHW#<#5(\OB*&P>G."4*H+L'T>\(3W:0GU6$87
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M!1Q&:4"1QS8ZJW"IK@Q*.9-KH*9-_Q]^]?6?F[D->@N9;OVQ EQ"*P/MQ33
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MY(C?2CC'&IL',A?0,11S;"JPTV6^6[1^&.?,$IOB>" FO5J?F9.P^%D\._J
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MN">@R%/SVX#$FZE9^^/-5R*R#?:9"Q*)?Y<1( RK0+4?RC:3.:8H6WMS[]$
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MWP$6@@E=<5^37@5RC(,#L(/;R1P_I%_)^ 0@HL:"U9-^95F(.WWY%9%$Q+R
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M@FNN 3EW[)_OCPTQT=+H]'>?\:+Y5P<]K&O&?=]O5\'Z41UC?W9IXJ2X6.)
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MZ$Q'^@'82MF^VR>G6W8GO]U8F58X0PSA%<Z5;,.X8?#QF"I'FCM%.\"M",X
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MR$'9D&'?_W*X-V:.E7AT+NI04 M1D^2GWK(NC6M+BO'^TV Z%*C5*J@L$BX
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M^7;8,8,M3X":5@V4'X9JCG!?5!SSD&+_DDL?IN6?#5E8_>_S'L9^YY-%66G
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MRMC@48<BJ*9K#>>13<*WX:QUM^:",5+?JI-=0ZW=FD0<A]RMWVGZ2 MVB"]
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MU#:4<)T#H6-N+ZK.<WZ:C@PK\'C5.62G8>4B[^TMP5#X':;Z_.%3"Z;Q(S'
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M52YC.]5AI4%-H1P5@C@'\ZQ52H*S(+1<GSZ&$",KWY3VILW*:R2<8-._$'R
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MQ62ZX/ 6TZ%T_5,^"0!@T@.@E]H4__^_3FO0+%7;Y0"]XECO)PXB29(@-?_
M@DGKWV=IJ"W._%L"AYXX9+YOG[D%M-V.+1,B.SWUT@74[@^;)%(9]?+#HR0-
M<G)]A!X->&F&ICSFI2OY]]X 5T $4N*QKIL3)C/R\+@LMNC6;RT/S^;:"1]O
M;1IIH1)'4?.W=+1LAG<LF'YWD#5JB2"@?%!S!P'2"[MO9_1?[L _'[4<1#6)
MPNZH^K]"LD\P)8ST[U?>5G[9'33TE),]M (/)R)(=H>PY>UE.&N=#C1ZIR>S
M(:!&U4O$N9L&%$9Q-1$QGA_"8.S_.7NB&TV2:"XD=0^?Z]25'F::"S"-'_M;
M119@I5XU?$4#X *H ]Z ?1L:P,!/ UX-CE';S?1IP/4T7CJ*,.+HHR\_9!=*
MI,)ZE"J-4*\:4Q.24U?4ZO)B?C>2DK&7:I6E+TY9?8D/)'-G$$_BQ0O%*W#H
M2/Y*X>?7XE\KI#Z/$/$UK\W/P56OPG-9^T.9MO*R.1ZWZ/(.:$OFZ^>Y70C_
MV3US"A<K<8E55.\,).7F0Z8\?W]+/:@<^3$E%N:*FE"Q\#:?[PMW)H@M&$HI
M=_:?/O_90F"OLBSKV*G5B7KY.1K0J!1) X[Y5PXT").0.DSF;E93S5'*VA]/
M=6-KP6$QT-%,^J23'@M@ CW9UXMZ,[N#4_<>FGEK0A=B@R9."V!GC)S[=U?@
M;!ZS>#/,N(@#X3T2-HP4GNR;CRF6K3'3Z_(2-'LX;PQG;*WZ,0?%DM(/&V*!
M)?)Y7()(TX%:UK/LB3@=Y6;8F8DISBON':)G$J??V%PRX*5K#-K$I44TR*R4
MN>N>'1RS*OG^O$E!P8+Q1:()>> [@/9Z:M-TL$GF5B+R$F1S+Q06DJ4JJNO1
M%*]/IK",5)V=/SJV>YOP/- REJ!1J+DW\!+H<UF['>AS8N6C7!]K;GO1"X^S
M5'<WX;Y! CAT!%74O?+ _'EYVY"7]X<MYT@3SE?Q"*R"FQ;'R*RE'F^%TCX3
M'+3KE#%J3#*VKX_8!]*LF4'8VE/00P:4QPX8/>!;'%@0A.0Q%*Z3*#1Z'4T#
MY.H_HG[M/05M]7XV9$V?Z$4RGH/'0TN7(NK4%Z8E Q(DXL*]WV<+I0YVW8/5
M)5IN,\!QZSL=? &@.051PI7.YM=])VFY[0GP&&L7WR_=_Y@R/HU=%#97:-WM
MT_%<AOP*I)HM-6$WNFC Q\J4W5T T8&/)L)([/CS#"CV.BC_\R]?PJ0O_[H%
MT!W6NM5X0U-"+WSANYQX+ P@TA]+C05Z1OV]8? AG_),*RX_EZ"LVP11Q/)U
MOT[GR?ZQ9BPG;.XM#2@9:SW<KU 20IRO'#F[Y"=3JIJ:^SA* =+G+'G8H6.,
MP7[.AO3"0$'=!&H\9Q2;QT./ _5F+0>'P[O75)@5MCZF^.*&WNS>TCZW @\)
MDL:-/:>*K:0>P")51X:^*CISZK.D2$HS22 ^1V 0+!NGLH\UF%"JM&]DD^!$
M7U)*:+$9TSANP'&Q,G@AT2Y-[KGAR8Q\K9L$N/V_GKNS#4[,\6E*+N096<5]
M3H3=X(.X[,#]*%MK%W$BUX]6;^O])%XZ\CJR#W["F?(%Z_D.B^,M'\]WMV]/
M^!IL]?FUUX6]K=L-S%QS:W'%%[7'#GC(DO@ 3#B"&=?+/\$%&=]1Y!?2:V?[
MYM[?ND2?_X-Y(W@5WAU(YA0A/DZ=;!>8Y5,SU9"I'%,])ID>X/[JHZEIM)5V
M_\US[M%GZ+H$,:M;,K;SB6K &<.8; !@R>9@HG_6;\&0DOEEQ=I^)*4=_?F*
M;$5UE*UL_,*?Q'MNBTZ7_GXU,O^LEFL ((.GP%$%*??=0XP0+,F59.=%E4L^
M<#3 D'O,VC>>S,J\O7"\M+=OMJ\^M <'95K691I0(&OA:L^[Y-D6]WC>/W/%
M,U*P^PM'K!;+RO*_)B!"WNA>0+9!R[#KK#+*Y)OX:[I206<-I@R-GCWY*1*$
MFK'O_8E#PT-VS,-!Q%QJ[ANG 2T=S;/_#)LWSJ'72LJ]M >P[(??G>'[;K,M
M,_7%_Y*G*I(15#R7.A$PR]LYT-GPN85-H\_R!AB.!!!V8"1$47NP(KXGL:0X
M/)7]T=_[\C*)Q!;)$C365>DVQ\>Q&! 7F\1HP)VG\F^+UZD<]B=;(0WJVUZE
M1>$J-$!BX-?!V-_CO'1S:!;L@Z0(<,K7<16DI[BW.[;>0STO+#]HW?"90KPT
M(&O[8T* 4RR, $"W=MHM^U@U1(0DT +GW-$@:\P7\@W[9[S?'_UQD['[#2Q8
M-'14>B.K8FQ #YJ>)0'VT8C:3)4;]@DP<\7QY8VL3_5J;[U3V-J"':\>>KM$
MZ*L/,6K&DN2,UM!X%RLS!]Q>2T8H_X&:@;'E^HMCRFU&&VL?M'UT5C<T3QVK
M+_IZP1H_,5G<>2=!*@%5\^KS+3$FO?.#.</EJV;VS9O7&I)^EM5'KF](:?O&
M7HIRNK2ZHQ82"Y#)I&>@]S=1$JAR?\L\G91)<.\O'CRIRC^V[(]-3CY^2.06
M=\@R_I)U'.RM/;)MED/M5( O,T*A<L@W^ZTY;\_)''D)@''?BY.X2_;<T8P%
M]F_,H]<<#G40]_'32<\;)(+.B+GJ#Q6G$@<'LHYS34FW2#4XC=[J] Q*8H'T
MC-8JA4/+;)JAX[-7,EIF61 JT&C_PKBD"E-?D2M-GZ:E-WY87-;=*49NANRE
MGZ)7LA]8T[[T<7:YYJ/4PO7AHJS1+?JPD^'7?*^];'D?R-@@507VTI/:F=H
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M^,E>U)"TI]@B,?M7SNXT4U&,@))8.N< .*&64'@1WLD"[@D5LH#+?>U,F?@
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M_M7M_VO7_@W462I%%_S$[5HLH.@,U_V_PW(7AF )I&L;VYE>Z-4-Q%M_">"
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M.4,,)12&/,H@0]D&%53VR3;)1J=L@YF#!P\W.$H?:.V+?7!Z/TJI$VY"E[*
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MGE%YLW:#Q645]Q"V &.TO,\^?#WFE8!SO$RM\3K9ILGQ^L[E?>,ZLJC%@=0
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MO*G0_/QMFTD\B%N(/D^WOTIWSE[_[KT4V7?^Q[&'31JZ,U_.<'U',XY;TAW
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MOO)%=7YSV^1N2N5;A<<"\<<$J]@51@M'<HA((A;"S[R'&;\#;64!;(K@BG(
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MH#O@:+HQ"[A<"3(%G; Y(.7XW(JT%YK&\0HQ7)H[&_W\"'I%H,J(!5R%2UA
MUKL7+$"C/0H[[R]BRXRJZ($3&['C,O]''DWT-\PT@05('ZIE 30^+#.Q)J2Z
MNN333&9E58JHW4Y]KWCO<P)L H7K1_>E#DHL+;3_.^Z?L*(,_B2,Y@!MB5M*
M0_V<ED9O'B\T'&TOG/G^H8=#(L.=8<=>!SJA(+GE^KF@Y>2R0#]!MQ>8*"=I
MPNG@O'??FER&U\,F)64WKA3SLX^I4[&A*F3*16-HSUR4FNYSU#H'GV\UT0)\
MKL!K9&"'<;4&VF_C1(G$GS4!.-UB^!V(C*U2M(./:5^A.J*?&12<XW!09XBP
M.2LOT4M>_G/F\,G2#H%'VV:N8>R=-TC=Z3>C!0^AOX8.Q@8??NT^KB&*4S8+
M/UG28.>)OQEALG=CTT&#'1*'8HP'V1@^# E$-C+<DR+0$P<?(T^U/[/X9I"4
MSXS,[Y-Y$&\C:1@GB4HPEI$B21&7M.BB<!^!'^,0RWT1B_,]PV4B).N&*S,[
M()>18-J<6*_"M7'_AO8?ZW&Q,W3Z!C\9*)>BWTA!L+ U^F/)(Z=UEN_2)X1H
M/:*,\*Z*MSR<&T]SJ\6[DI-AQ-]= 2,J6,#T?;H9F:%8U5/"9JL2?IC))U\P
M.SK?<6U/\#D55;17JKC;C"::S)S.%TSH[R"DR%J&GXF=DU:8U)(8E)!=48;:
MD"%SDOF\BH^.M</PR?O9.-H/.A*V]]N;E<X_#FO^8A-BNN&:8V:XYKZJ5R/J
MU9@7T;+G(\TH=U6HJG'.A[?]D#OVR'UHY]+L-S?LV"/D7OM*N^<P]DZF/0W1
MMY*[8-D:([7>2OU;,@=:M,)[$FY>&SW#M=A&-P+KKOIMI637GX= K8JN$E28
M,MDN>*SS>!*EN"!'L/!"<<B-':?$GAC</KJ93#GVADRQ($)[WO?F+]:(=ZGI
M2,3WF*%L20TI4JHE]A?[ EM-P!=]7S:.O21VL !H-YJQ)0^::[ 6A]JI]R]\
M1I"06<@1!?>GM]I!YU=];Y( P2</5@9&[ ?=)1*8.\SA5A+;C+NC_PZ& N54
MBE$Q8KIV3NO>M X<UU;_'N4M-^I\9*[],!OC%;Z51+E$#C\#W3?\B/#(VYY]
MG;PZ.]"13E>?R8G1;QJ1[ \_R2]ZK+#G2"-H1N+04(%T1K*#;OI=&9)-2*S_
MOO.,".[[O18JUQ$>@:4/N*E54() ,7>!9&(B*8H6I5#NH*(R&CKA<<3EVJNB
MX/S\Q>_161?H1PLVKUNY'/AZ^VK/%Y"BY1+;^R$M;1Q)#Y2,](;G=5-.''*[
M=3UI@[6:WYMXS@,Q7R;WL*]Z0G%4+FWHRN",2U.-Y /]S''3:"]/CK#X;5T!
MGK-<Y? $\3N)5H[8\0@4K6:8 [G0O*J[=4>W!@=?*:ZIX8G=>US:_'@HL%<Z
MGHLKF6F%,);@8M\D&T_/C-@5V[B*5\%B23.'=';&OOM>/AB#$V0,@W6;J_@H
M7DU8D25+<MCR*KXLQ^A9NO@QBS+#4<M8R97T':<,-G;&?>#:X6^W[@7X<VXK
MB[9O=38M=W)^/*Q)9R,>365[V+C;>H? R:_UZ[@W>#-BIWNFY1&;<B*,6#_V
M'\*(*U2IX1+M[3G*$E6ZX_C.:6TV[7-S%D6\/TD-_3B"^:H8XJ6<]%?NW4QI
MKW/KK2X6U;$SU157R_S2>.K:[6RUL7C'T4I$W:CZ:,5A'3_MCWREP8<<<G*>
M8DX5"972X[3#2AM+/"_?.A !,+B9)"2E>(XN'9L>H2/)6+UP*E0CBM[HW:TX
M^E Q0&A9N#!]W92[5'O\&XG]LJM&S"B2'0K"8KFKE(:/S>C),IV->(T)9G&[
MS-JF6]6&S=P.7H_5D^X97&8(^]),2B/K14*;VC0X';]DEQ4;Q258:8V^]!]1
MHZ:,J1\ID((WH.EZ _*QX56H8?&3>J_OFT0T-?'F1$7EB+T,B O![&&7 OB/
MI**F;M>(_&RG7>[<UV::+S4T]C#O4B&5,[ZP.N,QI37?WOO 3L&$]K8M[NK5
MC?Z-/_;H[%2]P%&X"%R#"6-*C!RP#H^QBTOOF\1RYQ&UC&RU#1/#K_4VQK<*
M8G;?ON5<K=H&W$*_Q#($RFA?F-FPLH.(6(I"X$+=JG6E"]_G\A#J0_LY@8WO
M7G\3X"BN]K3IRP?/$S;[F2-=!4R*3!X0[EXU^E9?D;M%0?*E?4+8=M4MP"V-
MU)Z%:A; L9L9/U/%FSJ%W:*T9S396'BB>_4NYX^#DU'KGWB'O1QA:DW$#D\]
M,5M\.DS<V(O+UJ[Z.-MBH"@WZ[2]\&FD*[OF1=094:G^,UQ4%2*2%-J#-Y%,
M/KZK:C,JZ@'NY+M&GY"G-,SNY3;E6T:O5&N%C]T69L;6DXBQ7XV'G0NICH/-
M=QE.!2<_.1RM+DST%K]D'A8C]-TJ4:Q<ZL@(M7U4.1UI(2>D\IQA11BN(FQ2
M\J@F6%1T8XVY74>W*V!]]?28C[5&LH[US)#KT2%'7>HQ'/82W)W9CI'RDHK[
MME\4E.-Y-L_O6L__@&WR7S?<!<4Q%.O8%1X[ NV0#@O(M,=F@13MV!7E) 3B
M3K* <9]@_%6PSG^7\O)1I_KY*]2-M]EZ=CD_N(-% FLAB2%D,VP[[3O(24&%
M,/@R'!-#%JW]L^9:R*\/-[M\N#NRW$8N <#4)4&&&0MX8\@"Q,#Q!Y 7"]@%
M0M]\N6K)D*KCB$PC6GQB0) $V:996 Y<NEC[29]VJ;7,3))3:O/8=RZI9 "N
MDOV!Z36FI4/>=!7<Z9$WUON[)-GR9T4VY,\.;LTK9 _H@*EU[5>?52OJ0H%)
M6+Y%@MADX#$MWV=?'+QXFY.V7NK+>Y^>6BNG/X2M7V8(<M&2J(0F%M!K>08R
MS)Q2F4HOBY@I?G>\N"KN;.?L]WO/HT^(16UTNV?'/A7;ZPCS%E%#+;J5>+%?
MF\]UVT2HI&R3$A))&-DN>:\Y02A\N]0^USMM?EZ.B$_(0EQ2XJ[^@Y<<K'?0
M16INL( (ES=!R[AFCM*.]B-2E#;\=\0N#I &'^#74U"AAUW"\!J%D1:?KPLM
M@U^3O]^KBK";[9FQ?&BUUW22\R2STWN)65K#?*C!/C#A-D&FO*CBVYR\53@E
M!5W(7Q7T&BV[@]HE]I%K?HA^&*SS9F"S</'-1LPT)?FKN +KWHY4NOQ27KB;
MJTQ\WI2;0*;9>W?IE]MX;CNN)D";J?0Z4((A8S\<N^%2!JW(TO+DR,SFDY.?
ML@;S-NW=R'][ X=-EN.*'R(/,I+KY/V.#5;O8P$CH0W7$H_1OYUX,%[A45Y:
M7!S!/?+DW18]Y9UG;_4'J$;[KW?%4G04>[.M*#<J5>K +9-NW_H=!J22!Z2[
M%$3LKUQ4O!:ECW[HM8_X4 #8#XBYIZ*F2QZ=-?^6L%E+[KWVBSM=15L ]G*9
M=20YC%,[M)=<QP*^:LU5*>4.6+T;-G#JM2,8/]VM]4"4<V?$^:?OJYP'QR+H
MO+0$*,>6,C+$%;FT7&X@(R'6E?7J:IUY5HQ4<4[+CE'7V'R08]5/0P81)@C?
M0Z:$3B479-,<*]]]J8OY<<(XB3-K)[#O?E,C^[945#XLB\CK0G**=GPC7(;>
M4"*.PWD79#IJ5DA4ND::HBM69NK31J,V<;V<L0[ZN?JYSA5TD.=]8^I"U[R$
MBS#B,9=/N^U^R?FS7_.]C+O5[V\7['_;%P.3.\>FL^GL#$%(BS)W_).'XGK(
MY8U7O+TRM5V#F&YI]>&5U+J+52UMKX/KD'L^!AU 2,:V3C'6FKWFX[2:+()+
MN0=Z&_S][=V>V0O1RK9\D^/=5;5S4/?FX9<O8K7'R#LDRNDR^!XTBN1 X- ?
MCN4T4NB[7EI699DCW*9R,R]^B$>//"6%WV_LXA9)OX'O1:- &_(&BRF\2N39
M1'_/O<\Z.5,*9A5,*G9>OG?*^'UH !NQG0CM5IP.I1ZB77W\IE>HC/-EA1HL
MU^4L+S)O?E(]K,NY]]MGJULAPN> $0[/'S4KS$+P:BP/_HNRQ*9"JFF16Z;.
MD.'GJNB=9M<KWL0?B;EPCNT\:9N:ZZ<L /-(,1:# +I>?:N*2O0ZXPBG_.0;
MAF;WM7IL-57ND0YOJL^.DDC/Q,GW, 3+8![P622?SOG/2^%R"F=O7(MM&-BI
M(+6#HIGP$F\]R4T3ZUE:H+C11*"ME/2&EW9&@R /%)RVC^S4Y6YHGGTU-RHQ
M87NYVI.4DAD54M%8G>'4C9*DH=# ]]<]]QP5C-N@+N#MAQ=@8S3"362*%6GK
M-VC@4P.AV#0]]Z1B=.;=,V^=?*]1R=;'+(]W[NH_W?K,*^II[2V4$O,<)-PL
MHAA;A<G&A1Y_NKNH2RYO3DI6[O:]I%O2X]O2:IT*#F[@.C)H1MV.N(7[S$?N
MF" 6(.)<(P7I]:KS=XXU6IQKL,VJE9NYLFGJP.OY^!TO]N]FO\.0)*6B("E,
MX[&Y,)#M1M*9+IGJI--519\^MLD:U,G#/1O.7'P"2+*+V<2>!)A&T R";GR'
M99B1(J%P8 EC(\X1-G[  GH^@1,=N?2Q?_C[<W;Z""2,,)3586D  M0^&OG,
M> O7DE9VU? @WG]]$ASHV&,'$.-9@!-*E!0(KV/HED>X[+97V_O\L+[GI]<'
M _2/R,0$,1RG3C)>(H,K9ZIT5;]VQGD[4>1K 4,='Y86MG!Z1555+39I,14U
MW$QSIPB02Y)F')FAPQQPIY9?63!6AJF7+1W H+_">![#"\(A!"3)N4*A#R7=
M5</8."=.7$G]8B%X09<%G'N(=D>U/^FA9"-1\'*,*+$OP#LL/J?X->9HT'U:
MY3.4>C/ZE-DJ,!XA?.)3?0!0&@5P B.= 4H_7Q)!EC0F=&"H/0(+,'Q]\[[D
M?VX/9<C[JT=>.1C/+<QQW3QVM7OHEC=#%CK)C&68^U(PM$++2J[XCR5=RKZ:
M'CO19Q/EG+:IA2[2B(NJS+2.:] NZEYQ'2G<5<K!ERU2?E:;<)*D#U--9CG(
M2.VMLRTNB]9Q%.+]_B+X[-/+"W>:P9, "] E!%ET);. !L*&R?A";T5W<8WO
M#\?NRVF%CR%=@FW+9@@$P3QF]--P.T%LF (VS GJ9.'\<$7&G[(BM%P;'_0,
M;S=Y4!ZM/QLN?N"3)"G-Y:L/<P[>B%MG>R8#,C-0W3;G7)/ L ?KG,YYXX_@
M D6-R#>3WAS8E56OLS*#JU>_>UO4=9M46B. K\05P;S&0\10-*]-I]J)Y^1)
M@L"<^Q3OE.53Z;<>&\SS[L;G&%Q]?1]\>MA<PDXJA8D15?M98EF(]'* ]91/
M</L=188.?\"R'$V4H3XLM*[K.6^247AT[3U-=H(/31':E<38P@),F*F2GS3V
M,2R[E!YVMRXY27V:Z_6M-)<7,=L?3[S;G. BP:DQ(94)7AS8SHRIX<"!]4*P
M,(9?31QWY:40UH6@7>08TC"W8%A\O8SV]@@R2HOP[[ 4:\5("^7RS ER<4KA
M"ROF"U_'$\\,U;6[M=3?Y&Z02Y(]<(%_ZLGS;5PI2TQ'!@KJ&8J-3N'O9%P8
MJKRC5#T3G-EWPV[4@Z[-R58?8++0<GG#XB*,I#Z#Q>#+]J":S=A)M%"5K)C/
M3:<7VO>^F%LRDSMWATP>T=(])1GWXY;K%]=&?])?\K"E7(@TM!SN+GY[WORQ
M\6>;E\7F/PYN%CA4[" LLV__450M#4!_0H=YO$/SC5>DE#]O*?PZX6DFW,-1
MD7; LNG:K<S*H=.JF),PDC<XD2#YA-# I6K]>LQZ1:4KQ+JQ!AY+73<?/TCT
MK=^N)SM;%BHN+XLE,Q\RRSWRW0P@J>&O[KH)*<;\CK*RQ[]O-YO^P'MM(^50
MWWR3(_1S)'K@?(?(,9B;]"/PWLF/WRH=?5HU'N5F]^UPA_NP5?%/,X!U47=Z
MQ,YPE9$8@@28QQ&4[NU^G#OY+C6-KOVFERML8U9?,$]Z&T?IR%<47AT\#5XF
M0'*$<#^O85$4!\,3N_G=,%>,P&OOXF\G/R@>O?TQ;??L5VJXV1,2Z,-<H836
M$NZ\PCF>LD2'6O-5OHIO.W[[*7]+>'K_EQO,KQ^,T<%^GT?:(1GANG8AW K#
M.^/BQ(! I>-CQSM.Z?8=O7JD&Z]5>-);> #IF1VNL0X ?:RA]SLQK#B2S_K]
M_C)2<>#L#A;@^RY%R>.#YI&ZQ27B8Q;@@.IM'RJ;KAO2HZ*B74S"APC35(O^
MAK&,PD!.J+YU).716>L1 4\TO]].Y_A^,,VN5)F6Y7TLL\I21]GX5OG4%+;!
MEB'0,+(<A;'#]-YV":JPSO9S5X1..1UN=+0LX[EG?>G@,3F[TP"VH2P?\->A
M&X)U[OB#N,CS-:&TFQ74=1:Y;SGX*TSS<8$F_D_4GQQ0.(@"(E9N+\ \"\C
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MXQ:66[6\BO><*"UI)E^^GSXF4/+D^LF7>[COW?<QV(N!,SAIS10_$K9UH3:
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MB:3^.#5>L7$.D!:8-U"DO[2\'>=W!@=O,8(>W5:<5# =2DR^-N ]>5E+0C'
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M459.D"QYZDUK62'LPL#HEBOBRM<R^X2;KER/9J<J^-L,+;UEOMXU)86PE09
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MM7N&L,>8(G9F\POX<DJ3%D;GQ QP&P_]&CR]Z7)W<YQ#(OS245G7S>$5;0?
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M+K^!S.P:L\".X[W0MVA@]-\[/FXV!N+?3![KM4>3\2GP*%+*G804*JIIE-N
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MWG);D>S[^>$:VI*1VG8EV\*M-!J3B1UZC50CIL-LI4+)0!%]^*KR64R&AHN
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M\3^O&-\<TB<#(>6!?3>WGQH(+.!']%LE6N['[6S_J$H@ [0QQ-PZZJ\]WF3
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M5?C:P58YG'XR'^W,7XZ7I$$U4"&Q,8#W?2X, %D"W7,VA!0*P189P/_M'Y?
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M2+LH5:B ?O60QOXVTZ"_,@,(^BG[H_N@$1P!-E\&%^;>,P"T11]-W W..L8
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M@]^:VD9+(\]/?RTBE[;LUN$^-^S65D2Y>7]V+%+ZJ&K?:BO+\^*P^*;.6'
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MAAD4E4:%K\<5X[R^D$_=0LKYGK7O-*1T>0>"7HB'DS0IP[RB!W:[\\M,SYP
MU 6^U@6W1]2KUO-\^*<R/[_+R6J91<A]=6??-:29TV^CN6CX.RYRX752[O99
M>8_YCSTLEDW,.OV.PO?;15N*;.U<OLEX1%#CDKG]+_#,PA)R;O19 3BP-V4J
M.LKM>8[:(&9@E-&VHIYYOO6-4:P_05;KI-K/.*/;?]1TA[84(-^$8$KHAP46
M4&;Y,FW*6Q0YX41K49#V#7KL)_LM/X.H9V01V=9)NT?JT)'E\<^!C;" 6"3_
MLJ$ #7:+\C7G[KKZFZ;X4OXCH4E:<@J$MB5D$V(%2[_->,;\8J@S@=:EF6.G
M-7HGFU1O3F!OC^=$CW3.MKH]<7O\[30GFSG!I1>?N[>/,+L9&@Y>Q@&*86+A
MF+[/8I6ZG;R@ZM7O]F:D.<?376^'$AX.K1=!K24Q"PWY&(=H7=-=0@R37ARN
MH":=ZZK%4]5D1?>:9*I%Z#..L+\VG$N<OZ!JI236FH+EVUOP?*#"@YX'::^:
M94<PA6*MI!6^+W_,G0PB?EL9LH"']$&1E;V)BOW91+D7$(B1#&"?KBOR_>1.
M??1 F)K^Q%L\0?[;E:-*A3F<'/ :[25D8066[+@V?+^S=V+"0,QYWZGC"?N>
MG=$T*1J]!-'/K4&M&/S4#^SW#R7$6@?KZNZM'<]5S]A'37+HJE1.=EWS^835
M;D[B&D, 1QVEE=-U&2CX0<R)L26M5%&TK:9J1['C>]NL=8L,Z?!; CRBZC+R
M.L?Q%3@@X"OL*,W-?##GE.VV54G5CI7IKF6517RA?LD:4X%!PJ.0(R+U6$&L
M1P92#"W^K:YG1<-:A.;=;O%J_9*TI)3I[5'/%;$WLS*KA\!-[!TEEZN#A@<#
M[@=;G5<DG>M^.?T%,5M_ME%@8=>&<QW"?OLAN)BTEH_].PX'XU+Q6.Q44O;Z
M^4WKW<7L7:FA*1&&\%G0HBX1PD]/L+N:]DSF?ZB7M,%Z$$N?L?_"C.#^F#YX
M:7GE"M]4G$/]D'V?>]OGFP8QCKE)+G:RJ;^B';? %:RA[CQ#S)AHZ6;W<\"!
M%#YFZ3NHRO-7O(0%Y%S9VC)0V"W\8LV'>FHHV>-GZ0S.<;NK,PVI6^G/\D+.
ME%4D/;WN<=0U\C*@]LA4D(UQ>\_JSUF_1)3Z-UKZMU1%$'"(J[VYYK=[O_+[
M>?2\3W?<*,@AK/8'4[:;,=<Q#8A].+0_W734(TL\/=BJJZ%.[KM_=:73;\IG
M&>^'.=K,*0E.(O(#GGPC8131A"S#-2>3442GV:GHW<&ERZD(Y:"/SG.$9:K5
M<$R;Y0>31P>L.1X%#BW+_8?HR XQ(2R+IP^40J6+FT_C^#R^.2V*/+\;55"%
M/.W_74T]9"76I],:33&"?\_F9NAHA8.BS05C!_@OYKT:;3EL9ST2K!?VUXX"
M@X9!G@4D?R*O,2/6L)LBN#65*S;I-]95QBT-%TQ[/-_!NNW('O_G4CFPQ3Z0
MZQ.4ND3J\5LS+&#7DA>3/#1'8 A< \U4PK!+4,K;3!=ERN7 9K-!;FCHCF>_
MQ"YE3H(1P0YPLK<_([&#':S;.P_*\R8+("/7=@099UF XRITG][B7Q80%H2?
MB7>';U$08,P# 'R.]<#O',_2A/#KX[W#@@RR8Q$B?K#0R3+ON*WBXSTX/U[G
MZ]_+XHXJ)G:N.Q($3&YU>\.D%-KJV6726< Y[Q%OT*PP#K\L/CF(?]Z.9Z.A
MIE56DC\M&,J7@-TE%13A5Y0+EWB_>,_H[/0:#Y@:Z=IP]DR6>B\[4.C@(>D@
MU\_H\Q2MF!H5(OWM_D343V'4O0HWOE]&\=S)I6VQ:O$8Y_&BK>PI-\:1XXU3
M<G%E<-$%K(CWEKGGUBD_[IB+\1<Y6CZ<B;7*/#KO/N]?>(G9QDPU/!J@1YQL
M=#K<WE#E_5=ITK+W_KVQ"#6Q$[*,Q!;=:LG,I<5#P(X<2:Y9#S:<-M716?EI
MS!0Q7.Q5W&N1JO!6IO30"_%"O4B9[B&*+P7"#2O'Z(\908:'R >*IG_HGW[\
M%>F15FE_<42CH$HQ5V/BQ>\F]%]VE/\T_BEVJG)26,- ANA52'17EC63J7MZ
MBGU%OD561NIY*R>%($3;FT<H9GZKXP0[1;LB_>"2[KOAG>]]<>T!R0ZM-O?&
M..^:_G7;G.<U@A>P@$.(J0F4-?^_Q("T%A8@["<RL.7PE'[QZWO!) N.<(#'
MK"^R51$;N0XK1S/IUZ&TRXLVINL$*-C2HLCMTZF5'Q=U;T[NSWJ#$_BIVJ9Z
M"&D=A]F\\^Q.&^ZOZG_(YJ;FLHF8#GW#;TY8+^2S@' ?^-YBM K\=^^H&FEL
MP:(S?&BUV(U#7T$OB=#NHPVV/HQ5E=#KYIR#,?@;J2 M9@H;:9]6OQ:5_.!:
M^8<B;R+]='E,BMNCXV5OH^5;"^74]FG.?S6>QG]%"#*,*OKJX \P)TTL\\S[
M3\2%^<Z9NLA&7I]Y_.,3IV%$?#GXI!)[;#-!!!P&^2GPAJ6@6A7S04-I0@#E
M\G<S\/PMJ^CB"@6T^.?Y4P<X+X$[H.2_M&P^A)NQ!^;"]C4/T4BQ%K6U@OV.
M"OR/?U#ZYR="$'&PD3"25@MBI(B:&T8T3)[VYO.H.IGW]4'@]>\C3J=?JD?[
M'DK*N*?-%@5(-V,^,DY!GH%1APG2#!L=*9!IO-6PO/3WK>68FGZ/F5$CO_HZ
M][ZF6(&$3KPDUMT;QK!A)B$>_,5($SXL*>0,!X1=[Y\/4I*Q\5.M;4TQ2Q=*
MU#U=7]_E-<4"3!$E=@QAARE<TSC\(OE^I61AX=(@Q51H8 +G,R@\=^M<R.-G
MK@>!(^9_"L>B 9J* Q2,#=!.S#?Z6!2.(4=+FZ[%M'1<*'+[H!HM<C])QX?]
M;^/O=7S0T""^ #^<U=@<Z-98O(_0C/<$^RIZ[T03<6_4.]1:+404ZCT+D^,5
M!ABJ%+%Z9Y6RRJINQA7BROD5ON;CY]V^>J0E35\_+%A0VUY!K.;P;(68?O7M
M\\#UEYSO.8Y@7OBXL[GO;2<D68^6W@J&38E$XO)J4,+&QW<61\TZRL;NL0_6
MM>,ZK&GR?EL=A<L_IU.?4X^LQ.MB\RX;7 2P<.3WA)<SM#2ZR]BBI<]N2)^A
ME'J<] Z48O-:U#!7ZC>"B^@;--2'.(4&^^!73KD&8RX25U69"C35O9.S.V0A
M3$.(GCC_,Z/E<]-NLE!6,(J^0AYBA'JR #ASOSM[(/[U&DTYFQ&F[KW+ C)8
M@$D[<B .>QI/=L*FG>_+Q.PZ==KU'UE_9;0T% UL(6E2>$82$P$V/&8!_]J6
M=J_5UI;W%=^OK7VKM%+<7?/]9T-N_+P0>!]>6KCRGN[*X.GM3",CKE!.5*3Q
MCN$.+6#@0WZGMM<P"86_(ZWE<J;K"O?6A6=#/G>5<8W[GU;54'SZZ!7)"[\G
M#E$"KA:^4PV*RPF&<"  E6H%1Q&PLK67=G 8 S%MH+GA^)*Z..'@?N*.S\5V
MAU\AH48[T=J$D@Z,$52="(8OH+ %+]A'2*N2Z+,G3->:7/$_KB 5'VQ[2_!E
MF]ZE#R9!,.>Z:V0LR-5!MP-'G=7Z&&ZDHG]&-;7?^E5:*C\X_K60%=Y6\%=S
MN5(7%U:&N6U3_U/J=I8"78H9BW?!'L2T@QPEW65,Y8G1:^L//_Q,'9Y2K1VY
M<'F5XY*/J-W]8W=] M,! K-<W]N?/#1UN!+E_?">%D8,_SS$L\"0W,GEG(%M
MP4<BA^6,L3'P2L6K#P;WK?\VO_]8?%$VP:?_[7<3ZSOQ-4-4:$SVJT:;8[@?
M3&N/4W*1\W?/WL9L))>)8S083[#UNFAKUWS,B.V@R(,%E;<Z[:Y 9YX4>(*
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MM/2TDDJ39B+ISX\^Y?U-%EEO;Q\X:P2/A9,=57:D14V9>SN>_UT9FD4RCCB
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M*;7UF3+N5S?GZ0PL "1!AN= K[E7'D;_5G>,CIG;A"07$[A5=95B-73[MJI
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M(V?8!A"?\8Q<\1.<EZSU1E58+HMBR:SC;=&>T(,#"_VIX)#B'F.+)[A*<97
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M$:2%-TZ%D:BC=OA7*5[9JLK)??5H992H)%:7WJHE<CIO],HI(\D(0@]Y3PP
M2(8+EEYE7T=HU%ZG?_U[\">J+#[F?K^ND'.Y=W*L/0]+L9B>]_OSN2O4[YKS
MD/]N581?C-<!1^%.D.\OF0DTNYH^L]WJ52P*KO]AV1EGZGUWW2/&<"Q^"I.G
M=G6?9L3'#WU/][LW_F$]MY*0;W.>[X)BYTMR*UK8DS"=-8FB']2D%E.$EPWN
M4W2;C'K3FDZYVKQ:_-&I_&;ZSXB1K*-HV\ELTN:$ > S5F^V;P'> V$FXGE<
M\SXO^-U_'3;#/W,AME:KV]ZN[)DC%G13+.J[ULF3]VU>UE7ZQ<)->C''W&4;
M1"EPH!\J0S*HAMT:QC:D:/K1G-O*,>KL&0PIU4^MRC/?9_ZY\G'?Z%1&.D1H
M6D0TA>/RU@3?(;M1B$7$V0V5XEZR,)2QY^_5)X5:F*J.;TR "YX[_HYO4L9P
MMP9:P)]1I;[EE3K9[0[!BYE"5>4?LKZSL31\O?56Z?'J)F%X;* 0YA0G3XTK
ME ><H/#X55+<!]R5AEPK'>.7K[DU[+-^NRG9UMM/=,][Q]/Q^B#)J+(B7O>6
MV,-?Q\!JR4)I.$J>3F,";AW&R&IU.W>V:^+"!70<UL+@\"GYZ>^/0QIF^\00
M5>UF"NN3F,#FC"<3>"]+6%]GE"!\8:LTGB:U"F[\@[@I1@%"6U"Z4G0?B/T]
MW1 "[_KA#VZ&5;JF1-UP8QG<F_W)[=2W6/B+<_6C<XMKZ[OUW03 !KU8QJ2U
M;/@5VLW)W[96OU6H=^6W1:4"3L^XT4%$9SB@/JW2T[I#P!&$E9JXR2\N / U
MT#X>.J(^&[;)0+6@I$K#_6V-*LO[#COE.+]:F6C0=7[3?C=Q[)G6UCRF#QU4
MPY<)L>N7_%23-RYZN'PW3,UX,NZP3E[_*>-8<X] K5;_Q9+W@;J'&5_0]U:!
M@-]UHLDH07UOI<_V]_IWKI5[2/7?Z>A@MV#G'4.4^2;Q-2$*1;Z(&FIKTI6I
MJ82D4V0NKPO:*O87Y@5*\^IO'WQ"?!27\=:2FF\ @#Q4--F ;WBJ5>IX[XJN
MM&%GEH%(V,R=WYZZUW YF(1<CBO-[EG;I-6V)17$Z-.@VS1U#KIIWOP-E/#M
M[!L+!_\\_[IGY8C(7BD+;XG#L\%F%S"E@E?9KC:^N/BB-?.ZVLVK@,1QKC,2
M3P]1+)>7R00]*(&FC;M8_CO3^BC<[//^B< ,^V%Z9XSGYB'J[X K8(,ET6D1
M?(YFT;D_$9IXI@S%/W?0/_'RA)Q%4_F][? SMS:6-^K9R2F/R>ZVX)"R"5DC
MTMTQN+?EK.!U:5:E(TDWK,:T-0&-5E^T<A'X/F7I&CFJ=T*N@<@W+T1]/[P\
M="44E'[.\<^7^4;',Y(=5\QTZQ"E"S:(P/M'<3Z,')S^)"AD=6[YHXU_>:Z;
MAU_&D]+^CF>//N8F?54]PDXZQ!ATJL*=M7N5:Z57D#!D-61[,J^>&XN5N 1L
ML !2?2SY=MX4H\8DGXZ&G;I(=VXS[]RQ!@ZV8H>,?N,L4;9'M\/\:UO\C@JR
MT/]9'"-?5!X:OL;(\N23,GCO/-N84G>B3_VT2B)6>RFIH^KT6_+CU6W29AE-
M$:?\.X"?+DDF!&U&-'L/G:N,<N"QVF,?>C;1Y"_ZQ@[IU\O_2@_8UQ&^N-=\
MUX?A0$;^:ND@+.)<;NGL5M3R3&Y(3)\6^M6:&U=+#7Z,<04;%(GW\9%C7U8;
MO,B.S1W&BNHA!=SODF>B?/5&)&9V*Z5U8 K4_MWW+>]F1:G59EUVBD7XG4R"
MY^V#\/??MEF7=1020I:LHI80T)B6 !ND01<*[5H3Y0(-A="2Y_>5L ZJ*RD_
MAC4R!>?;S#9=S/S@PKJ#/MAKY)0F)L#M YJ;FS*43<)Z9BQ7(J^]?7&Z^SRZ
M&W,)X67;)&HA E)\47@V'&8<S]V<Y&I3^RFN1XN3XX?,&U^9C.):^;F"XZS;
MBHQ7X'@2O@S=V#TD;@F%3OK+F(7K5?\N4II,U$CQC1+J2.03)2RL7RA-[KCT
MJ>PUBX*0UZ=O['H4O81/LR.77:_].^K8?&Q@<7)VV7JB$W4%NGW?S?NQ8ZXI
M]OA7)2 ![@'$P<4"4C+8( ?>1<6AOL3F/,<(EM),C4+^>>8HM#2[5>1"L?_+
M!)SBF<#M ,HO/8XLKG>; "O$!1&H?R#E*50LGKL,RPVI<N3VK6RD=1@GWF[X
MIV3? *=DI2BA#!F\F328$X$?MJ^,#\0'8_%D']KDL:2[;IE&ZL.E+]1"*>K#
MWU_O)TT?QOO!V0I33FYW(N$UPT-U6>H/H@ *)MZ.JQ_G2U['D.&PR&.98-:B
MT".9V7VNG;JV/OIM]U9.8SI02VE(]\&,CW6" 8,[9JU8P;F=A[I\912IRKP.
M-;<3+VW'7/E']0RO_'E],VE8FOC)Y3BKS,62Q&Z3TI*OU_X:"+5=9Y$T:6!'
M)Q#:"=!Q=OK!V8F496M&SI236F4.%.0A;B!NF"\A;NY]9/M2.:Y>.\!\9WO7
MO]B$TP^<IFZ1DTORY)H&+MIHW]8J,>K;%&SY*M,A?MTM"[!G#60_M(&N7X6.
MD-JP!UQ=\^"?[<\4?.+N)0^ETS\S,C71.Y6YP\'0-YD<\%[?57;*".TJXL5Y
M U3M<%?(U'RR\ODR+(_UW*<&/]+]YW@W8P5SXN^W$NT2V[*)/HN=X&7\%U3C
MJ@!.&I(?!_="Q<<G^M4N'Y27[XM)+U3]]D.O^TS#H4U%01:*YO(\^48K1DJ7
M P/)U9,-'A>9J75+/$GD#P^]^J2&,8&)P)/-\-!1TK(*#8VS[=.QG1HYV3AV
MZ2M%H2I11_$(MN2_L/<=8$UMV[H+08,"!@2D$Q04%1 +B-("(DTVQ8(H"%$1
MZ2 @TED4 :4K"@I"D(Z42 =% M*4+E5Z0I$.H85 VEOL>\\^^YR][WOWWG?N
M\7SOZ?<-398S<ZTYYYCC'_^:8XZI&%I-&;($^M:/J@-&)1$I09?>1Y9 [B"
M^0QY@1LU"#:*)C5Q??<2[LK#.)>VN\K&B&%UKL I.^&<+G%,)Q8UMPD1V8!)
MWZ[Q3]C=LHC@^)MSN_*$4U=E3NTL/WHT6"AMU[26Z-.A#4AC=(A:)"ED.-(6
M9'&_U_MU\4&6XB47<^7N4R):DU>!=ZSH5X@V[-=,G+C? DW8^VR'MYPC<["2
M,B-_LD'YIBAO]<R&[>8VOK%2=@B?KEK6K(OBM/;'S"MJ],6Z\3@YQMB5L:R*
M^JDPL1)G4-]>GTCCR+7:\7:-,1-/,F J_O=7TX8?"\NZI3*+WS\Y%.R>=)3[
MZTVN^VJL)T0FA$.BC"D-U&P0%X<"H(D19D*FHC2B;8V89]%W@YFO+EUY]M#N
MG"1/TL=-V:T02$_VC?(A<8&(8OND,B_(MWC8=ETFJOBSE!MJY%,#&_; 03X_
M<K6O[.K6=AH.+"[EL-;J]TW?.XYM13E@SI#<>CEMT6?+:*,+JDD(S83$!2#9
M97?GP1I9%+[@)0.F[->[)XYKS'NLRMGA$#;4#6HT$I< ,H)W8^,,"<?1KKL*
M?!S>F954:USFWA$NU.)Y=VUN!*MY)'G7VR!#%65#@V0O!C_D 92 ;R^B /4)
M'"A3BVQNC+\=__U3KY:=\< 1PZ(#,8<2)N]HO=K\@BF<3H:/2Q##H+YE\[;L
M6G\U2G0O>5_6=;!"L_"&+$NSMT:1 Y^)1T!4-"O.O,QFA1G$18&$RV&#5[_*
MRH9;[PWCJI<U-= IV/4U<,I2P5E^8ZX=,90.@48"K15!.(_9IY;_;18M9&3D
ME-F^LUOX6J;'L2?FQQH/F@2<?+T<3L3,A. R:Y![O-D)+S(?48X5Y06]KU,I
MMV__*,KLK'W'"Q=#9?-2XF+X]<#M*Q#?DO+MIO%V%;<'G[G6YW9FP*ZTDR6@
MVB/R.,#HZ#@BY1Y%V1=#W$V:(A_3O(OEDB'KJ.UZV=M.?.A"KG44 ^O<!5ZZ
M84:/'6'(8KX RS*$S0+<XPA$)5^N.QF_O1GYC4:AC6=[R%(Q6<8[Z'1;N8I3
MV^ZY2-N!;<10(.I"G:1!ZQG=30=L)DDY8XD(O9!/8R:9JZD>O[R,W9PR@R/N
M1S5@<]MW6Y?QZ_FG?S,%Q$N*(OE4IH5<7AOIJ />"V1U6BMR+QVPUH>5/?+V
MN75<,G7U^Z-:5@USA;?VS>]@2QJ)J[W85^! #(WY]%A/%;:<FBCI*/7HN\?X
MJ)>3@^*F=C1ZS<,/47EO VE,JX2>"Q^U?2RL$EBC,R\E^O6%.:WE*-%C=X^K
M_NDOXJ\1"N<H(/_6%1R2PAXWEDC[8"G=J/I6^66AIFQUH"$6')$(04J6\8J*
M=F+?A1YAG&SOSR$:$\3G1_'N,@CF0P,2)JI"C0-IQP?':G!QYMVLKVD5C>%@
MC3IHV2Y,^XI@3B%$U9*M'%P-G\V$_G+]R+['YZDCH%_?M"&D $V0]I]&XE[1
M@6)P_NLRFZ+:,D*GH*2KKXX_,MEX5W394Z?L9E>^S0^;>A"3RY"X/B#A/NY8
MF1,X;U//Q7!YJVGT4M'[@O<1=P,61[RL#5]<]W"I^ZK,N.-T22LHCRI#43CT
M/V&Y2H2NU(_"BG.B2!=+>,JQSS3!0^K4AANA,GJY/$Y")TFKJ*]0;12IZ]#3
M\&)QJ?(L$0J:$3S:8N=K2DQ_.>'?UG_R24%BHA)\'/70MPU)4$.RG[_56W76
M!#4T]^2L):KLYI#:Y(>BSV>&VJK'=W=S?,',?H<8[+G*[;PP)M1T902M*U;X
M;,<#'68*+(/4)*0WH&FMB,_0="P38\W'39!]W3%SF!I^]9$G^#DAY?7S0ZJL
M5K@'30VAGN1 4U=(L[>)W$UJ6-5)WQ[/"]?0+//V#I.ZTO.YQ_E"EKQ37@KH
MYR/E)[&X6,2[O@9LOTW#$>7#WXP'Y*T#OFWN;%]B4CBYZA7U"?O *IF9B):P
M!*4=Q\NX*>G;X3"$B^B!D'%4XX)TXPA;YX/--0D4UY>W.F)Y1YQL.FZ*B I:
MNF11;+?*(6]=@1KN"R>5X?H^*;%\,I,./BMKPD%>>UQP*<P]%8<F1J]C7M !
M7 8=* 3KT0/FG^3BY6JU#I:7HW\AG]"^^]2@>>)Y#;.*XM,!K G$LW"']4DB
MF0M+;/-]9^35([+!\;+W'_P'A?,XLY%/<D#"& 3*T3.0#X*;N@9QGE#:%F2%
M\%ZX1@J'')%& .NQ#.XY-U?!@F(E9XEA3?FJK/'Y&=;I4=&;W(ZO^H)YD4'@
M/>QN"BS+"MPK13DZEG79>J1WK'/A[@['X2'CO \O5MT$<:5P\U!BTQ%& HH(
MT<B $Q0Q4MGAG#$TTXR;]=A@;-)WF,9U]IM#L<_.\_-<8_0]&>YCNRP\1V-.
M@(8,66<</@K_&OQ"=*S'LJ=$DGG9?^7)9R&8*C2]W^\YPD@*^8K$A8)EXF&R
M6@Y58A[-' ,Q+*:H*Y<F%PV&!(*87B"B/*E?J*$@[AG(1@<L^XJ6CQ?LS_6^
M',$VT2K;7:1)[/G&^UW[52G>B6I+K H%\G;F&IA07\$6B86XU>A:F'(%]Z8;
MV6T[]1^-C];[T(B_A_B\T_WM2//\>P]_T<A3BLF/JCIS]2Z=$YG8X-Y*@*"$
M.4EYVXC[#L0JBW;'X%N3RPB$EQ&*QU-!1@^E0,E3;VF,JV-5_M1XJ-L#00%'
M5UL$R2I+VK*S\^HS_(%N3 9"S#_XFE= IO^0EW )-7$[R;WTPG:4=."R7+CW
M;AR&E=;.SYW:G#IM>SM+H,X0/+>S;2\I>,QY>:)4F^)'W0/=_J9O,XH3:['D
M;\9!D*MKUO$R==$JB9<HQTE>,IU?P/,.MX]&Y*R?_]UKV-@WC$/&7[A CV#8
MA,T"-%5]?'M1!"WD0/-8XX+&=EQ&JG67^UWW)B7+UJ?I^WPB+M78[3T=BYFQ
M)/Y",AR+>D0'6-?0;.X9O/CNO'V'7HB*94GL.-#@LP=-^^AS0QTX.:Y]->WQ
M,]'[GV>%M-:.50>20BFOJ44@+A:Y$[+#@3GND5-:STD9&^T5U\HBCZ3RJ)U2
MT?CT""X3TW@0>R-K6R_''"GL;L2ZHK[\*_B@RF@K,_L:?[W,K L//=#E8WS=
MEI9=V(\&V^DHF Y22QU<LT1)08*=5GGW _!&U[K36BL09P?%)O655'F71K ?
M(.U9-B&*;T,)18R:Z&BG>#MKAE,N[$V0^<NA7#?V\./S_D>=]8@.3O'4I(+"
MLJZ\6T4E$0<#1@Z%RJA?96"_Q7J$,=TDQ0^I#.+>8(LVHD K5-!NO#XP6.OR
MEJGR<LQ^%O*D"MHM*0?U#$O019$.6RX<()_QU@JL0W,\^"!@JJSD0%N/A^QO
MC'+R!K.OPRGS6V";Q-;]%+]CW^HZC%4YJ=,=$C[.MK &8].V OQ'<[TBAGQI
MF=;S ^R>?,<EOP>?\"DK;W6%^-OR:C98(X*U54!#QN87TD?AB ST[D'W!(/N
MB9?%55:EY>4W1,_./$O!YN@_$M[?33F BT"H];RX3&P3BCF6Q&BGZD_*QER&
MFL($J60N^IUEH_1 S5+4IV'ESOF;UQL=T%;'E5V#99!NI9 +G63;B\6]! O:
MZT?[HVK=WCO6)4C8FKR"E$J5\9S N.V=VN_M5H,KF'X(W7EW[=3Z?$L5]H;I
M5N Z]^8'LCU8(T_CH/7&ZS:DC[$=U_;6M[]G7SQN+WCI38O%;N</VN(L;?+?
ML5K;9BAA+)/";DDL+5AFV_(^7&1K#^B&<5#?^#!ZG$.ZJY["_')W;Z)2CCFN
MC,+N1<S[N"ST',4W_CZF-J'FP_424XTK_@?7;CB<0<>XW8S46D(-L7$Q$.3F
M@\B[O:6I<95*3,*"74E2U[[W<F0IS@C$*-H]BIYR$3ZH^LSEF^!>WTU@KQ\\
MD^N2RLYM<:$=)O2^&&OE)U_H64@I+^H^<$*O4%TPY+8(SA$F&+K]1JL:,PBG
M,6<2O,::;<PD",I1SHJWO3LK!@MYU23X1$0NS&J(N;4S%G"33"&;>P"QT./X
M]F;FHY1G4D=T3Y1=RK'1)D=/J#T5JD;<E^[$5D(TBF1%@MP<)C%J@8,LB7/L
MV<W21PZBG(]+[+6_#;[VP$K&'=+WA:>#JLA".<H^49SF_/I;ZRI9?HN)I./%
MD;+W*@==]L_#G+U[G?5?Q<30N,E"ZH 'O![#9$H*P\L]\>;#?Q;E<1O0+G@7
M9G5AN.)B  ^OH/ +2BG)G+:;CVQDC2Y>?+-\9DJS*R1XT5'F2^ISF:I[S;:;
MBX<^SWS2PD:5@&:0WC$0^FHW:/R$V+"TV6,YKA;I,[U%Q];V#1JKL_IYP=1,
M:.+;W;8 O]PA&V:5+^FJHRVYN%\K]>FCR]2%JCNO$1D2R9#2)>H/BM.88P@;
M8Z=GS0Z1C-*&,D,=C*\]*6,V;RZ(R3V>N90TVH;E6A\E'9!>V-S_QCE^AU:\
M<\M8-V@[:_WX[+<]N;B]"GN#L1\]H5[+WM[@S<1+378L,4&1S&+[>/AM%.&G
M,E*]D ?\HX/*7V,<9UU073SS@628]R'J<\JY78EXH2/U;M]KW63B3GQ:84D1
MU@[]K*8\>D:C@7GZE,32Q2,,P/:?!\ M>#(W91.L,01Q:*PP:!-AL[B*#TZT
M=&,MN[;RIMP29J/+6;#IPZT+JD*$<\*1PJD/L:T<\AEW^7%-4H2EHZW;P6KN
M6Y+5S^]*;40E8_J.08H3AG2 3!#M)&F!P%A?!1 N<.CGSS8%])Y[PEQG/'S!
MV2B)_RJE/=V7%ZPY"\W.6'3QU/S4<DB#F30I*.V;B;5\6P'W9&IU9^R)M#./
MM8<;7#C7YI7FME)2_$ZF%;XJULD1@24>3W1R2"U[=:BH 4M:O8-]$3703-NM
M0[Y$,:(F/\ @2"9:7=\[[%UUFK/O/DT;.?@R,80Q_/5J'S?U%H0]AWT_HW=3
MKA"B\*A@BM18N7G(U2Y[?HE'X<_>A#OE[_*8S<2D^QBZ6>]<@SNZ[-/AI$X\
MY>XF: [?TO0=R_VJ@O!'E"$I'&A\6<.'"/T&)'SM27OX.D\237/SSF-4U9II
MU16)G?W%=UE7?$,(@=M''G#01ME1E;Z()V^Z FD+1H;=J0QR')WG>C2_A-^"
M-V$_0I-CDYD: ^(@Q.&0<AU&&E)3[!T=E+\X\P9AWU>@))RG))Q.,ZY$$3"S
M$CAT-6:7-YQ0FHB/VGTCS$M)&7Y0:KE!K+_$Z/LQI?T?2_]]<6=UBMA/#:J$
MD8VM+S>/2=B^6G>7#$I\Y4\$JE!Q7X8RD\V2UK?8('3G1/-MXS:JV#7CS5F2
M@J,+=U3\!>5[F3X<*X5.=5?&,TXHT4JV7Z@%;*^W/&D0:UA4[75UN.)&]79M
MW(1E;O1#E8A"_MLHA1UU4_=\\Q7J&[OC4Q5%L4<-&EUEYC[L02"MGA.E25M&
M:S4$ :(SR8>L3+JB3\CT7ULO>]<5G28E=N+)PY>=BCR&;2<"P^F _-:.4, V
M12M=B+M[W<B@R?>M*B+=5\?W&YIP<31@M-BONU+5*5UOY'#%:=,+!$DGZ<&]
MXWQ-I]X!2</OC>9,(:17)FW0F.W)=]UMZV/,*"*AU]?2I(D6"5>[#<Q;FBPN
M^V#=A':=1-L$]]&8OT).\N[E"\1W[M^X"_T>UY3VE,@Z'IDZ1]T*<&[$_N*&
M63P(>>4N=, <)!W,#%86L#DC+$%""[\;.?3D]C-GQT7QJ/8RZKSE1AFK_I*.
MI2)-E@IS1]4:@T$R84H(75:IW(6\!?,1YQ'32MM]=R<F@GC;;"%=1KYL)QW)
MI'!*$)]24Y2/SM".DL#T;T,SL301W?.:K])8I6H_UU$R^6KACI[4.U0_K"4:
M06$DF6>0+!NO=0S.7NN4T(J.E?#G4XL86I?=$E4'?)W!FO-(2\?'$"V"U2ZH
MU8["\9&V@XG'=0RUQ1Y<$>6I/L#\><*+]H(2:S-*4'4<;#-UGKKT[FLQB:E\
MQW4'AY1H'/9:1,_C*=&D=>H&-$^J7T)CS@4YBA>N BDJ,(#-W!!@J 98PA_D
MIU:#!#6H 1HAXW0 -C<0DD!-3+,]TQ=7T2M[A?RXF0<WQ.X9R7RN%71_;@!K
M01>.UH+<E-,D^S222WTR1'*-&_>TOA+6N[Q38S/M4!5!25^VB=:++I3SPUIC
M8+/\ED]DH%;,(F_;VHH*.KG:16K76K)Z(M10=Z#Y5TL'&I9((M@%I.-8WD7'
M0'FP?TTCVB><6KHXW.(U*/+XT"6_1^8K>6@_!$&U?> :V:0X9+S%+>J-3,OQ
M.O[\U ,KE=4\.TPB,C<LRF=(ELA!)4AC9GQ[$ 0M:PR-U1U5,[JC6"NCST[&
MV@XS0+U:]MJB_"YU;/++P-<5_3FS[<0&"=10W].^3<*,73*(T(?[2]UZBW[I
ME"IP?F.J==-A"@O22GP'OJH(7UDN^O0^,\*7WSVAUOB49'QD^KW;I9IXG=<$
MIW7,9-%VUF5M^$!A+?%5=]6A]M29VMHX^5*TF^"']-%)DV%MR4>1K[Y5]ZUW
M04BW5(N VPCS$9)>I,UJ9;O:9LX05]Z^]C_T\:VZB'"-/^8\-.=SMA>^;)VL
M7?AUV.I.U1Q\+Q'QK.%KZ3:QC? ]NCU]-)<"1P43+BT?#TF_&<7==#AI>*Q_
MCT^&7:Q"RMW;7W"1ML012-GY79=(!\47ON*E.5$WO4]&=&F?8K JFGT?O>.$
M2;C8I.I@Y.MK56BH&VY2/WJ;^K"BV;WK_8Z$ZA?.#L13PDHT8$F5\T*>EK)4
M+#1:@6"!(X5CM!K)E"])T1^;+G$9<S<3:#QEIJ]X9T4I5'_)\HY&#\7+$]'7
M_@3-I"BZK%#=21(PB[26P1X'CYJ+(%^)'3SY1?2]M"]<=@&"Z)7;Y,M@S5Z*
MA\>8P((73E+^D4N[;'W3;E>!SP:M$CSD=VV[6(1K5\:J#E5!ZBL#UFC+WK;,
M0!VC Q;JQT+Z<VS\6R0U"-IH=-SV#GLZ\#X>LKZ/J.%(7,@UY3U],EA>;\>N
M_'Q%=:O9NU**<9>X5YG"X0-WO2F?/VK^LB8$ID7M("'4"7O],]U!-?];A5UY
MESNYF1][I]UIVEL-NT(RLOSWZ->@,=U34BC-JJ)7W)TZU@V]!K6'Q1D#G_8-
ME%GG?^AYOF9A@7PLNM4!VR3XCO@"/31>WWX:__+5^SZQP]YN+CZ"_JPV!B:F
M@#8@S2M+?;&=/)IV^,LR#.<6E#^9>-C#W.T0KW!L:>N@XEYL7]]R#HTED'QZ
MX5VG-X@GFQ\:0=NZ9+<0ORX\B.%Y$GNG'/9=,/+<@BD/A7V0&%;<[<V(QX9L
M?<_*R?TV$R5&C-NW/Y&E_QAK>%(>HZ]HQST_9$8\!0%U7PKM$R@ 35<6*7E$
M<+Q/>M<@I)4!#YT>63X-/K-1NU=BP_GH_NOC+_9>NV!T69Z]FATT?N:'W _B
M7H %8(-T/ZIF?SRB;D[ 1.<;YFYB[/#KB/#.=TBYHCW4C+\$(<#JE 4Z*?J9
MNADVI1U#)GKY^85J@JE[T_7W'>6KD?T(V;4COCW01-$$_;%\>>M*CAI?\WGJ
MNB2+3%Y>/FLN=^JNX*:%WHG&> I\.Y<CDR#UG=VZSG.2HZ.DO($3\38U,^O\
M>0>[</6SC).#?LHOJ.V03M;LA?J3"5*)@,#$\P>R/49O?UD],R>?OY@36<8[
MDX3MX]XZ1(!<N/UECM9R#51EHK5!0]<IT]:3PPVT>\]C>D+FXFE%D*L3!5HL
M?:O%(^<Q^#DI&'[R.9%@#!@M[$G8X!JH/::]Z#6NE#,/^41,MU_<DH]6H:B#
MBFB"$98DCFD<'5A<&7-\M.6:.*:=FA>?$!N-.&M<P\%K-ICJN-H*JD%F<PQ+
MX62$<+.>?-+]FI+$F&%$7E[G-U6'"SL_K[+7H#\.<B2MD_7.,DX?M4K>49DS
MAJE9@GFC.HXK*HTU\^9++AY(VJ]\0?IP?T<.NZE+DO->E_AU8TC7/:GY2-PC
M9;X^!U<I%YS&"S?A$F2B(IMDWIXG4X<M:X)55%;U&;LZL4?6$:0#2 H7OT)%
MUR\W]K><8V?(M0E[U"C($I'Z>FTFZ54KZ"T#4357LA)8LXNF.#(;F[-,5.A_
M4#-9\JDF>[1Y=9=">?RXHXI\I!<1,SWXZTO.!]X<U%C) R#,.N9XZH'0[]]U
MON%?U'<HO,XI>(B0J_*96U,.!2CNU'+()8DS Z@9 V2SR*8%BIJ+9)Q*K?AS
MM-60F:*=JXB#XCC3PW7,5,Z8)84]D%A7VI.A'UR@+QSW7E_<-R>KP:E\TX-C
MR!X/5CNAAB8A^PZWWDY>'T4ZHC9J?#Q%S);S"-F ]JUG]TG<%$,^<]M#LBL1
MT]O>CZ Q&^'1K$/622*DP0S3UC%F5DZ]3Y;E^O([#D51O7/UESRGMMWM/"Z&
M*?1>R+#;XF/]+?%T@*V_T='2TGYG\2TU_C.?V0].I(2_WNNLW_N>:D.8V=)+
M]=S+EI?6-;$F;+Q_:2WO(@$^H#FF$4,8Q[N%R0KIK0B<E@Y91Q95YAJ=8N8]
MWJGPW0\9B25)CM:9M(>B^*8(*2W'+YNX1C4]W@SWKI ::^@><A?TFNA;NP+I
M<0K)W *'#9!GFG-8UO7"-XL[SY1)36G.GD;')-&H.9M>)"-\A LQ@UJ>6Q(<
M,&Y,F!HH8?$0>AS?]\ S[2*#X-I5$89OPCW4)LI^@FE(@+(PR5RKJ#BT8V#F
MQ.#GIX=;[-W.BO*M;=TR@.7^@&,"#6W;BUD\E)NCD(C#GI8CVPYX2PB%"T/D
MHE9L'\W(_1$=(+DVB(:=R2_<^<PV*&9>^N2IB:,L:&D"$9.WO?!"T$MT(UXD
M4-.23G?BROK&J\@W<]\*.CS3MHC9N7%&KISF^X+LJ@Z( *P ( 3P,A*X]2\7
MA1F\JRR*EWEZ/,]!JNE],&\2SV-"=62$T?8BI0MM#_3(3)ZDHN6B!LL&D$G&
M]EIWP,V+A5K&B+57U?>^[TNS:'"'T(7F#]:<1-[##,00'Q)*HD)\3ZA9<YWQ
M=!Y(J9=<8:<99],!8[U3FF9.(U@KJ^1=^0LY'Y;L!; CC<@\^= C.\ZY;5[>
M!.<4R_J3$HB)4&O][V"3EDC'-N:5R%=IO3JR<;4*"@()?#)=UD_27NGA=]2E
M,JLL;#[$3%^#)I$!--VNTZIIYZBQ% E[>-W"J8'!F[06+0=^A@]R>QXKKU*&
M5>?:QU$E36\,KSXPX/(!JM-3_/8$S'(XV3LYU$HH<IZO[=81.("(N;IF %O5
MAOSDJ]M5>IM2TTMNE$0%>BHEUH]_4[06(T=3W^##Y4Z^'O=,<DE:)SI2]K43
M]4DSY!/NA_L@)X=KP3YO*O!B9)?=*2V<%M,M_TJ(+7B:]V78$N5#@=#KYDF'
M0^_>X.C.D7C[[L#S;%R /"<J'E&"IG B<>""]&TW#XSUOC.E!=I$C9)0WI"$
MPS@=[B/#0A]B.K&ZV[$W$N/Z%'8CXHLNU^;/M-W&NHYO<OUN!'<[WG*4\+)\
M?.]2XLOQ68E&&23I@#Z%:V?)V5V%A^4=]%_SW.AQ,W<>YRNG+2XU8#^&0K:Q
MF!J['3\&]SYW.&H,$7Y-_CGM8)>Q0)O#W?*HA:?C64GW#CF;E%5@I@7P4[72
M;-XG""UFO(2/:0^)9Y;M'C.G:C;53X8_%PY,\NQ+@12U/8K"#:/MWEB>(J(_
M%"7@\Q,M'[P;;!;8G!__[AH-?^]STZ@+0=!!]R/&L/,?<6P"4&?MFU_(<YQ?
MZRM]9=_,O4_ XC'#!W2EQ/H !)5XY* 7\9=.I#4FI&\+033]V/8VWJ*%WV/E
M(&QAW^G"6)\WV,E4EV?W/3VIVYR,#U'41]G'2!PD[5S^CN0BF>@5EA#N7CX0
M)2=W<5!]\(-W*!G9PQ%*JU3>_XV4^0O!-R23]$ZD!YI,MEY^08]74PW$)BL4
M-Q3[4K^J,'O IFT)"-J>)3*CMRLU_\&PWB!> VWI<:CW96E!6*S3*_7"!M7!
MP?NB2G,;WR'M.P6IBHEO+9H?:S&\UQ;Q)'9_:<S'],J+(I:BWKX:^%6P[PP=
M4 )=N&ZKK &^YV-_?-CNK]X(H@ZYLJ,7.2_@00?25J[5FY-":"K&C=1 1^1:
MTD6 =@2+2T>NW+\$]J5/T<*+,/[S8"^V:VL/>9RV![+%XCMYJ)YFX'2S/$FX
MD6I+128GLPW\Z-C>OT@PN*Y+\[&Q^;=_K1B%^Z@NX$?J3L=K;)BM[W3 :VO/
MR#_L;+-_B+P=I@-O*;,]AA_H@.%FQR[3J*T9Y#"BJ2QG5R/U 7HQ:M*D^S^%
M1_\L,=3!EOL&;O6\SW;;@'> QD!K%[87GDEK-2D)R@1S$?K4^#*K?T0</4-3
M[L2Q\)@!;#*2= @QG[<_Q^>M>U?]EM=83]ZZT+XK"*:@DILT@KE@\X9+.S[J
M,[*_"->6LYPPIA&!-U&P'E$@BGS9MUC#J29\,@",ZMCR0D!<2KPVXC0>4ZN_
MQVK_^P?[W4KE?WG85]B(B)-L*]3JC^MY=_6!($,]X"5C59"BD;Q3W1!@905@
M^I_0_X".,^(8!TG+4;-@^L/U.O=1FJ+Y%GI&17#)7WF#6N)(9>W+[8MQYUP"
M!Z_1@8Y6SU; '1F&G!"'4UT07R2^R< WF?KI0-]),^18^^9NR(K>;%RY2&1C
MI*F> ==;#';5_^7%]]\)XC66<,FQ7[010IM:6P2SN^CEKN(YLK6E6]PEJ]A3
M8D>,A.U;WXW#D$@Z@!H;)1V.HW#"QN'S'F/,KBBAN8&]F:R>)3W+IK(+_945
MF$/EE\AYYZ<G)%9KIMYA1IJ. (P 7#7T?S,G)8;KN@9,5=)VQ8]8/4_R3XN(
MYEQX=AK5 EM@@!P,4VJR\E':U_W(_3(H+O<[HQ=*EZ4:WA'[]AG[)-=(.H0F
MG\GA=&B&;UHF51JMP]4!=Z/Y&4*[$4F'4*1"N%:AR,,?',NK*U5QA=,AF)EV
M^=G%C^;F&^TV&\9_.\V8['#C^7N5R\?7,;6.I&-R%,Y:8A"U:)T-1N-N#),1
M$K_8-3_22QR]:F68SOKLR.#WV8>!P#MQYF$D/[4IQ0]Y (F+1Q'TV4"B3,<"
M$B^%OOAQ&4&TO8$RF\$X?#EZ@C>8R8B'%RA"KX?OLEV?9P64=OV#3=O!UUI?
MM0X<L)!8.3DM4.9$F=NLW3[C *P1IP/6C@,;XSNGPB@2XPBV?O?+WV=[;]_.
M4GK?ME^B0 8]YVKK$AMN3M4W&XY:"X3(IJ]OS6C!0N/\&]Q.0ENRW=UNR[(2
MGJ(;,E*"92=O?:8#[Y^I!O0K?O#1]?7_^I_;!OM3_ER\!\EZWCLZJY2]SRPC
M@L1+@W6-##K3"KLLRZUZCUAX,#J IQD%=%Q=%]IM*">H44A<-%@<,C](5IE%
MLD\LNP5K!CA(+BSD/1@T*K%]V>*,XOD<9>02$,?!0/;?T#<+W+J=XG?$^MJJ
ML77L_C)682\O!?=[3E_3(P]IWOZ">R?F;$/];VX]03'XCHP66=8M#>C@UX0Y
M22YYUEOJ7W4>YZ,-3N8Z:\KQ"EL,9Y'3IKXC]7HV%K@82$'05)Z"]/&V>RKQ
MRBM7U.,^8^6\_..9+N['BZ=*;D_JNTB205?7ARZK^;Z^J1F>OD/U^]3XU7D_
MB0RD=EQ]_I]_LM]V61L;_F7KM0S#^'MI2K #.(<'U[@P#H'4RW0 ?7%9B(>F
M)H=<)V"W]AB5J=*RP?9T0/=';^KY1\MUVG:BB/T%=.#68#M5_%FIA-R- )U$
M\<ME06XZ2A'=ES ;B7C72Z/9(@:PY7,0OSE*!V("PF@?I9%K%HG><'-:"0W=
M8;0PM=!/9O;MQ.ZK.H$)]1;%6<L*\4DM7LH/'/+C&_F6]>G&Y\K'HZ0/1O4#
M* HG2"PJKWAVMDKH8ENFM;#%Z$WXUGTZ,$<V@#7(&(VB"?/801CM2>[HQLH2
M'7BQ!M86T@$[Q-;A(G"T&4LSZH!5/_A9[&>QG\5^%OO_NY@K*QV83:!L]4WS
M4!2DMR/M4FSEJ!2("D[Z7(/^#K"D]7U5::,#;!F&0BUEOG1@#:^"2.S]RP;;
MJI8N.H![C2AYO>&LCJC-OM%#T'SEUB>$'*_=,KI-!_8V4]^!T_&M= !TH .;
M._R4&5.J*'0@Q(+V#;FF>X\.8.- "B:5)A1'OD4'OLHFT&BF=&"EZF?!GP5_
M%OQ9\&?!?V+!MV7@+%:>NNL/I=_RAU XU8@? X;38O#%;]_N%FMV@PP_@&SW
M!"AKD.]O*DY.W;RV[I.0#M:<1=HJA,5I50DUM:CPKAZGTH&9VH'WVQ$=$!AH
M?2;9GH&+;FS7F@SWF\9@D?A^L!1.Y;R!79H<I0,2TW^X^\]R/\O]+/>SW,]R
M_[!R_Y[2Q78-\0<<*"J1)AV.6_"P9]&6J_6X='XB1FH4X*0#>L)K#)M+?UE@
ML9VG<M)V8\G&9NV%H_CN_&K.J%-+?;1*-E?LW],.!H(0]\;4'^@%XF>YG^7^
M2>5N=LU/=DO;V[UA:G91--#8$7MH\G[HCDAML35,Y=_/E[D190"L.5&EC!"<
M,<)R*/*YIEM[^KXQ=R],'3Y5]O3$BYY:X^IT7]5H;=R*$H!4P^)>@(7M%%%E
M1!$I)O_;6]MK1M.]1<V\H9>8.G5.+=PX?4#@SN. O2>C+D4-S8Y1&/%LR!HS
M_LXU4^41B0=E7?,'7AQ\<E#8;G]!0WT 0^R0@-B*?N;%A7],(K!\T08ZL#R.
MZ*8#%Q?F?DM%Y'=N=(?/$MEF=(L/<P-SF" ^0@=*\^C F_CU>(  [@<_ZR&V
MOB.?&;VS0JSL+J(#^7<JP3]+2Y3,]K];>/LI/^6_+*T]V/$&5.TF?V?NL E-
MT8*"?)H,%_JSS+5&CZ>Q*WS;"?J"Z$#'Y8_OX>LZ-)\C.VQ^=!/^!^0<'6"G
M XWAV"D2FT=4$'9"'.H-TY"5BVM+?WX=(/9,*P=N7NZ45EU#-,7^\ ;\*@U]
M2&ALD^E ?\Z]@I)VTG+<-))H ZR </#SG2G:AR@JDU'YKP]<B:P=7>&%QC9_
M^]AO[D66#A_82O+.'YU8\6]LJU<==H453:VEVK[YZV<KQA;%HW3@P%$D#MEB
M5"8^A-HPVMRSC-@#?KZH3X*O<B]\V>"A]M#.^PG]Z)6[W\O-LE Z,"$D1W4&
M)WJZ^Z3&L)LP73IP$[TI"WALU"Z1Z !B$;N.L<%PDWR@S^/4/EK)PM4?'@OT
M+Q#>\E-^RG]+?HO9MOYK)'<'+/+/0$VB[@%JDW4(4L]/=&#ZJ-DP;"N=#B@_
M9Y#]T8WX'Q!!.O 8A'!BE;*KLO'3Z KG-@S4;A[R=/O3RX"7S:_)&*UYDK?@
MDSH__/%_%7-;-#2V'>!\3]'U@2F*>_,:@@Q94F0(=N+D-D(WT@(DAGY]8#,$
M?FF3]28TM$Z0;Q.ZL7,;M@UV_&<W ?Q3#*O2&&ISESX-3ROIZ/OM<S'#=V$N
M.A#]'$U ?)<8C%F4)N=0@MRC@I 3A\0IL,U0XL2_5%+DWW#;I!Y<V9M JT"N
MV,S:QBZC*($9D";I4^+]%,GX#0H8M8':ZBLQ"J4HTX&H9=H<'3 FOOWA4=,_
M+*GL3_DI_[=2Y.H(.?L$FD9QCASD?47Q@? )*\;&/P6U%V/R?Q),!\3_Z#;\
M#\A>L X)P<0FC=','.^XN7N[+VY3GGU4^-/+?DHEOYZM5!RV38;2?_C3_RI_
MI7']N?8N$%_?@E,A0XK^$_J&@1,V*,''P;GM PO4O0*V43N+X5\EH?RO=C5I
M69H2*$X'[D,V?]KV]]^ 5?@?*%REYB?TRKX8&B.EWLO9IYX.N(+1R; ?C=9_
M@]R_)W*NLLWN&)IJ%]@G3M-5$?8AD&G(1C*&:CN04^^+ !LACN=*!_*\#']X
MU/+?''#T&Y4S_>@D+ <9#UY:YI8!3 &G_Y$.V)O0 379.=F)$2;R*+$'NW;:
MK$A%&/YG#,XHBE1$.W]_F^)!4RQ0!7)==-%4%RZ&@A]-OG_*_UOR,T3\#P)#
MCB$@G*#0 0;,24(9Y=$B./>.IFV6^*>7580'/L(ZP&/&ZK^^P^SXT4__J_R5
MQ]GUGJG8YNM4&*U515C_3_B;40C)BZ;&@UP? J</?JSY%;:!XA]L2?_&JK:[
MQ]%48^A .9CW0/9W7P"/D#\2.#-1O/[F;FUHE&AW/E;\^SDX!HQ9_P*0_1MT
M_Y[(O8^?K#2"V,P,=@YJU>%DN/+O7EH:CF'AV'$*^)X.]'Y\^^-?BO]>_DKF
M\D?*HP2VW^R#5ZA'&!/_9HENQ?&OJW?)<-B?DCB)1LH-:.3.@G,OH6E6DPQ^
M/MQ.JP@%OJ7\"U#PG_+_CORV2I=W[+>E.V!Y^(^XYA[Y9XDI_ [_Z ;\#P@C
M>AD.804-].M[23*AG7=#KG\#Q3!Z?W8U&6[_ZTFZ4@?_[4B9'_WL_S:HOU&Y
M4EN!F]N$W3>0#MQ+AHO_D<+EU%*4H($-0V\M(M<XS'"_(C=@_*--Z>]EJE('
M,HM?Z, 0LO<]_^^_^2G6_I'#83@(F91':73 CPZ<-!M".X'#J(DC#-W_ KC]
M&W[_CLJ9ZCJ/2$!LYL'H.M2H& ,8VOOW;RZ742&CRS3D,#AGUO/C7XS_7OY*
MYXP<;VI&T('Q!F0V[3E#&^EWJW0><G]=O^N !?XIA^,>ITE"'U\CUUN@:7:K
M SG!:0FQOWK [D<3\'^.'#B@H0WL38N&?;=BL,JUKM3$SWE4M3OE3W?<O"O]
M]$RV.=?@DVK4T2FC+XH,96($">-SYB_4Z@]>?+1#6,[H,O/G \^C504#X ?]
M$/^Q _Q%+/*0M$2:57*L!]^EJWO3BM@!H2]GN8 MB8,(=BLY3I]X-D>M^''T
MD%KV#6TY&&Q#^S02%KBR/E;BS[2#661-9 +QANN_Z ,;.F!R<Z^T?JPL*8HZ
MNWH\_V#9+UN.+[ZZD#IVOCT6E)&3@0JP<Q5@Z<AD&C S&0)\X#&B.#(_]L=K
M]K^:_%QJ_!.YTGV\JM;<P]W(O:0T?MQRHS*KG[@N]' \*^?%WQ^7N1Q&3*(#
M <762$:*@_=.9&V%J]&SH^GD.Y]Q\"-U+ZL_AKM,62X2,2]ED"2IX">6'C*-
M>+N%BMKQUIBOX.Q!)8E5K_\H=0U\Q@^L>5!\ J #0;I(Q%JO/NW&)3H [^J
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M$+,",>@/ \"8 #A5R7B5 \]W24GY*K5\T=D<+(/)FR\^@\7;N8[&N\+?0'G
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M@%NE9<?KHQ6?. 98&Z5WSGX\'F\]_; @^./*[AHKAUU"M5P*A*8X"U>2C)/
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MPYJ*(HMT[.W$EPRN^0X;QTUZWW3MOGX,(1X$$%>--_(AF2A<OCRL=MYE@&Y
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M[J-NTF2H$"L6M_"1A'5H)64[Y,5"$B/T?88:AJ8[/U^H/=I9+YEP6_8RQS3
MENJP@<8FMHSI<C)* G0.M,+.B$.EIIJ+/UL#YXM$K?RV>I';+-OSP-Q?-BCC
MG"PZ\Q2&)&O"RP6Z/]V<=6[[XA9-V=A8NGJ_WJBUY#&24WL<GTT7K.!@U!(L
MS[[#ZWSA)"@!J#MS)(O4W>-:$(9_#<M[GBLKZPGHC6/4>+ !NYNPRPERD9F
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MD36Z:>)SVZ5SW]8V77&!"5"/0=IO[Y7./;[ZU>G<%4.;F8VDUHGF[VM-Z&0
M=4MZ@6UY'WWIWLEK?UQ\UPW%Z -'_YLTO_[O<OR_;;"NH?Q4BK>"W/]XN_$
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MUU^J]Z7^VR;HQ0?&&?ZH1@:'[W]]7= _'S8^3& 4&7COTPP3^$3_PW:FBQ&
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M5"3T4T_6$@-0[LJ/FV1'MA:B(Q_JJ!-M+PQIO?L^:]TDF'Y6RY^AN M0S9@
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M%3Z.,BZ*:B:,ODH LUEYZ^V4^<SBZLJ'*?O681/!X,N?MJ>RGIR;JV0">1P
MB@_*J:L4(J[/J+;K0A]AW]&*S$X)%)\T?381N\@IFJ4I&"!+3EV$C]?&HG"?
MT9]WXK80YF>ZMP\>JW7Z]&$@GXU;Z\0'MJ+\?HF <H(!KK:Y\0@!0[R*%%^9
MV@*E,IS(D<2GWZ(J<I3G -/["X<@US/@0TVOF,"!7_2+F*J$):0FM8"+4U_I
MMQ;$%SFR;V>0%4PC8/=I[IJ^]_K+O&F$[2\=J--HTHWUJ7"<1^>Z5$AX.^;
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ML5?./CDD7^P<-9&:' ''34,\5^D*A=SJ :9 \[X+5/S !#P-%4=W0;=<0[#
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M]'?\D%4TVT":6-^X?8?TB=.'DO7(2?)F9G^+8O<5RD0<RH7A=P%038.195S
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MAE<?9ETLFGED,*W%QGQK2<TB:6F&K#',*?<>$N':C+,?B^XD1M5,.K\8:/(
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MK@[27KA.\5GBH9[QB27LWS"<S]%U*ZU8O'+ITRYP_;[\TGO,<U>]7I.TK30
MK;HW)ZAW6R05ZKS HJ]EG76KH!R"D0H70(^V$W;L AR9K%3JQ4P,-PH?E)5U
M@#^=.B2YW#P\L'I_\07]66WE\^H5+U=$H)*QREZKDEGX-[@TXCYBWZ(DH@/'
ME\2]LWA3]U*G)*GZC+<Z/&BUM+3W=X QUYP(&_U)F*?,9G['AUPM.T$MZX(\
MVT-R3$]P;\+' M1K]QC>86R#-SB?K6#_0*>[U?])YN&3%5=2IIYQ<QVW-FG\
MBIS0#O=AI3968G3AZ1U'$G,J23A>]X.?@G-6SO0=;Z//[A.[9/2W_P]09< ;
M9@6@,3U/J&?)!+R-& ,!WB3+>*_>'/#ZDW)VL*3ADZ.AIXO%Q8[()4!JXLO,
MR-8$BUY\8V(V5EG>!:!D/NX"KFH?WWOYJ%ZI:HXYT#-\0F>9\^M"6)C*-KCW
MMI>8M#>X/R5Y./PDF$(\=3?O+Z0HGB[\I3[-\<?QPD#AFYVO]<-+FA^/T(Q)
M86(RG.95@W>?';YPZNFY&\W=A:1K@(%S/N!_6X6Q@R/FX]90QUC/)#NQ_1WY
M5P6)[UUFX0B.>B9V3[:^BRK5(KM/,N,9/NG.KZ35-X^YRL[0/[0'"BE38=/X
M1@!M^K_4CZ#8C*Z3T E-XBCU 90AF0Y;8EX9DQ,^FV%XT;2P3?U%:C2'O^@&
M-G'C34 OGT?FK>..#O5^DD=[+)0+1-@@%*%R\V=CP3(^U'BH?Z(-GH#26U7M
M^=I95+=XZM0I >#2086WP$E/NCLSRT07!2\#;Y+<U"&EX"/C;@SC7/D.W=B-
M;S/FM]7WN[AX1IP]QG%"7BY1$G)$^*!!A9CE;*KK='5\PUW*]^:3'@8RS*$K
MHU,E.T^OG+#,B@M2.7U7CC>O_PG_!6,N[/.]'R#U66M_N73Z1BYE*^%PTO7K
M5^ BP9^U+KWG%KTR=@TX  " G@@;<Y"%K"L*6HQY;&J:?.)RN.H$SJV]SJ,J
MI?>TA +5>Z.R]+&MA(E5B =!U#CHEHEOP\5<=KP5G#8<G&$[X/IRY:#\&[ZF
M#D__XY9"%]JSN8@CY.IG.&(2@7(E8:)?/%XKY5";T\#Q<IAH<.DN$.A;'Q-W
MP&#3A!'(U&!FX8B1%*1'9G@I=1 22O!\/7[,=?WSIM2/+JFX$U:_)\\EM3TW
MM^F,0,CN O<P8V@R9CF??L:><69XH_$*P10I;!F"JJO*,CH6P-?&UGBOAKO>
MXL$*6\PFM(%P)3PU0+;@8NJ4GVI-N)6^&SSB]LMIX@N[M'MG'R<%G7,\IGD7
M&,.2>IM38&-_300'EH95'-SNB,,*[,T>3=F>6#T>)UV+5[WU=<5&>^,HX ^$
ML:B)%+BY"RB,V.\"$;O WZQXB#T@E*ZF2]MP*#VSP*/BUJ1T6J%\LOMYAR2/
M;T:(]+/K,EW:4!1"B&'H2\9P+4AJETDHU4Y4GG_T\.6GSCX;JAU58V_T"JOD
M>R-E&"[4H 0C=LJ.^T8Q\Y'E3Q.:5+;U07OY0]?3'/F,X[_HMY@OM\Q&(+"]
M3Y'2$-]$L/+%>'0<="#:K+JZVX)LI78#_;Y=_\"<_',S_ZGCS +H8+"S5<T0
MDFP>N6K+M?7:BV'^T2AIY-FU[#@C?V!GA-*'H9C[@,?/710R9N_HSR4>#R[H
MB,WE![BKB+S\!G:>Q%50WHXAXGFI_D*#<WYP)X]2JI @&2.*6%DS*.Z,H([F
M(.P!YB66IT6C6UP91W?.?Z6TD;P^?AS_KCB<[8?^V##RT-$\D)=-_L1YT;*\
MB/&?(P47&;&L\X.A#H00PB,E^;%K!TQ\/H@&269=;]35&>_$:-=;TAK-E/AE
MB1K=5W3UQT_S\H>([JS3]]1$.8WT?8I&P:CITU0%@[3REL#OOL;,A<:?M4+'
M+WBORD_EX_6OZ.L?P+&R[%,,>P,?Q<^TL@^EDG^C97]%X$*J.L;31^=.XI&O
M;D-5TT/9,ZDY%K,1VDU"*,07T)>8 @.=.CDBC96M+;5O4"OV!ST <GG]'+--
M@8<'.'.+1LJVQ8+\-M:\O!5["S*$<=!W4_B/.88X@:S+D'\L+2ETD4#5[+,X
M7LI*1>8*<YR%O>#C9 V(RY*R*3]PAQHT1JLJ>%^L]<S:X0&PN<A 7F8T:;$L
M,<FX4@>F49W/4 I?.&I7UWQ1D4*-)I^(0.7Z?5M!YX<O[&V4-A$=!0UIP13M
MG?.+OK[OT\(6"=^>/K)0SEO=9OG#/;*44U*8_.GMHR([G #LXO^W_;G_TX]_
M5]\H/?[ODAP ];<X=%87L4G![7#;59^&/J%[\X.3_ZN-:!%*_^>7E0:/\/C(
MVQ>&1&R+;"BO(;HC$ @$,1=9R?^";H(Z]LMG:M-L*N_C@D[_AU-/CEO^>76[
MN_9N%Q'^&-)&N.+8@R=HZ\S"9:/+8:HC4S)A9R]5!*O?#;I:??4<,N?,8]5S
M_"8Y+/R%H5R#C<G3=ICY1E=VS-L(^SY^(@X6'Q,_&%2HPHRV*%=Y&O//BT?R
M2PKLQO217VC*102HC(Q'N'CMZUDGPV(FK*E"R*Q:,;*^XN'\])OYVRORYSNW
MFK=-._663>$ENT YOC5;@X1H2^$+#F\=-G3W\H_U\M;9+_5&X?Y? '\:_P4;
MQZK6'W%EV)@F7<:1H;DH,\OLD'!"\!8;1_*Y2PK?TT9M>!,?;QK9+406%7+G
M'D\&+@'L?6S-)4P'FZAK@]@2[\/QP2NEZE[=EI(7$6B>]H>?N7JD!K78H&#D
M5VRGFB?M.#,_CY)>H:'J3\>*+%R5QBLVJ(@$M;PZA7D%E Z-;+50X.2F%*IK
MLST\SG]B(O3CD-JY)?ELEX<G"E39E!.W]N'>^(#'?!A"*M.L]"$#DT:Q4U"9
M.>\2_ Q>-_WRV/^#?BMB.' =TZ#YUK5)90,#'?2DG*65@U(D&40;1LI(EYDJ
MFO.ZJENAMC'[:9:(8$+QT0LMG'F]X6[LM-9XCSF/%?K$^=7/^DSW(<!.F,H#
MF=TV9_;O KF-@;^^@WCKNE_^/!,J6NOJBI<$]6=(,7=L?/O@^0!Z'^)_M;7+
M;CV,?A7=HKX+>!)B"15)!2DH#>+A4-*WAMON1<9C+S><!O3?_!_LO0=84]NV
M-KP0I$OH'8*"HM($Z2T@(DT!"UV(BDJ3)E5:$&F"@*" @@*""-*"]![I(B)5
MD!H2D%X2:B#MC_O<<\X^9^_[_?_WW/W=O;_[P_.,YUE9&5F\<ZXYQQCO+&-.
M8E)8&JB)A,"1K46\I#]36R9+"/=BB!!6-_-[I9&C*[NEW+Q3S(0H<>L"J@9?
M0;45GOCV4_\G)=$G9S3:8<HPC!7\>\(E+"+\'>Y9SD*75T&<526W_S$.8\2-
MC#&L9<%[ST?/!JNA)@ND&O!CX<,#32(XZ+4^'QO_-=&:4D2D6!)GNMR$=8-1
MZ/1TRAB5X/[]PP L%=EF\F1*SI;)&B-<ZQDHU%BTL=CEZBGXX9: Z/&RDRP!
MAX%#M*JL@1;;1RE1V"FUBM20GCR;Q*UQ%HE9\'@YB3X9KX_K[=P=FV^& $WO
M\R8O!=ZWC*TQ[?8\]@FP"509X9-*</N&__GC3&(T23:D)T/8LDD"YU.AH;78
M?Q[K5GOCA.X3+EH7?Q:Y/!RL& A9>=%6U2$ZH,_LL(!=A;R!_T"2F*3PM";H
M1E5W,,Y([ZPSMV*JTMI.RMR#BU]/7'_(OR8^)^AS")'_3<#,HE^+$"F1@=6+
M\(;Q./&D*98[N/JX!+)%FFB."81QOL(<-R>4G:3&R5*,LQ>L64=A_?MR6Y4F
M/2[.J9@8,ZSFJM25PI1^[?&:DC6WZZ=F+36OQ(ZI&OA*YG3J:C5&#ST?*;G=
MCH5';)U(8K+=V<]HO.FNN7>KF_U9MX#'9Z].H?T80@.Q##+].)-)4WIJR4X&
MXVU=$2+6D/P.KYB19*T%%WAY:W3'*'<\]99R@C)U?!B"M0%&J1IK8F.%Q.AJ
M$_^BIO2S2Q>>VJQ@P8^+API>G??]&)]SFDZGPU,+/)89#7."A@70IGOE*[4A
M:&R9'.WLF36/#XSIC1-.%WH8B&=\(\S!FHTATT5-O+5]"NZ12)#PTOKE%+UX
MB=?2?@V/P[.T-])]FK]Z[=8*!O 3BC#K!+96$J.]7_YX*UI#H(-ML?=T<2NL
MQ0Q=W2:^_DK^)*BOM">D-*0'AM%V!S5V9,()]U+;95UD*ZZ8<+5/O0D47OAN
M$(FW70DLFZGSPFU0[3V@%.8[\;&Z%UXGR"X!G?FD8CFU\E$;W96'VP*GCFJ:
MM>J%P94N1ZH_BB=L0B=E6F&T-OYT+:KND5*B^M.#0P5B_M_E\AOL$Z97KYLT
M0T/M#N.$4.-0D+^)296^5/'-*@Z%Y(:K9:U/SJI&W6][F'0];9<?D)B%C8NC
M?.!M\$<DJ>J:AW==+AU:[V:F4I%Y=;+#0*UW'GK=7"FZXH7/),?5_C7:!1\F
M*ZE9WJ[3N%ZA?5.ZO3HCK+@U,1[FU.AB&N<V/9A55?OP1G6\KHI+;(2R1-_-
M*+? D3?^$I8C"+>$,3745'D>\<V]K6#]\4D]'X$/P=.GFH,;@B;/!%@LBQ,X
M1T@,A[&[Z-Z$;1@'@0ECY/+83V1C,F+H9N*[J<Y=[E0MH:*I/ S\_,^,/A3G
M+T'2)/5FG(BRP[5.E^<8L;Q+-;2\_DG1_4KG[DXI<$9YIGH@%)*-'/5#55:W
MFH1G\&'V/WZPM;)Y,7L'.*1>DQI*!_9[YU*+ZYXYCP$]5#!A5V]A<WC2M%KS
MY7[U]82U #(@K:$X-J:F?X4^V5R>U[2 $_310P*-'(<U0[E)QX+ 6'"$)H^3
MT?NE$2Q\%"UG)'"6R6F0ZDWURPYA+64ZN#I6"]R6NJJ&7O7;22>65KR6&U@R
M6K8%HX%X_8].9I=7<^_Y*(,1?"0K^.KXC@#.P0FS/)T05=%;%BV-UN]FK?=7
M[$NH?[B^U5L,4R0#'W@([%$[Q1CW538T)!K*2Z C9N9,XK*%S#__&-OQZ'O+
MG?]5L]^>\5&MV%>!:KM+,.@8;:QKUF+*F$]V> SOC.F;<],%IS/HA/*IG0LG
MM:K-!\>5/YMPM'W<M;CR-N1"T64M<&<>@0<^K3YFORQ\MJ\HQL@][]")F&.S
M9YL%XSY3#;W9GA]K'"'1!^,MOR,=.7#45],N-)565 RT-$08=J>KG.&J%=0,
M-B"X;(^0&(7PDL[("FC+:Y@>YFN2 I1ULNW#N):]5 /3@ZN1YQ-QQ^D8'VA^
M^VE+:'YFVKA-&J4XX-Y.&"ON63N)-EBFQ<+N1-C&UYE5_OB1#_%3/49[[C<%
M_4$"<6^J7OGT +!K4($0F048G3H'#%U\)[4K?@#3P1PF=SS^^Z=P8>/[W0]7
M1Q0(4B'(S&H9"L=V68^-0L4_0AO(%_,O+6T:I+CL&8Y>2#P3<3')$-M6^*AC
M)KYFVF)[A P<IL6!L48S[LV/"6<QFR8I>+OD/#)P(<8ENDR8-_E!]>/QP\E1
M$Z+;\)G4*Q3<1V'-Y]]A3]06-&,ZW+>*KZS-#?]PJ[QY)M[J96**]COW*]<2
MZK[O9H&0)KCC42L1> T" R8R;L9=.$@+YQH(7^)F*X<0Q-(D+60G.OE='XCB
M=6I:V3V^$^I"MG2Q(]//9?6889P$V@^M_+K\9*#E4F[0>_[PRV0 K/&<"MK"
M#,'H07"GI1I<CB"B@JQH#%K:03'J%IS.&ESLH]="*&$:9AZ..^U ! CV9" "
M&HO8$PZ%-)S45 WBKTU3"X3%"-.F/4B_9]J)MI6:3:Q5NWRXZZXRS33+MT5%
M_HCX]_=2TWPF&[>+,N^CAZ^E\4R#4\Y+YH6!Z!IA- AF2BR4F(FYV@-"0\(5
MBNW/8^\O\OL6"_7@#=!PKH9;5(*?_42;/T1:71!(&$!4PD8MFNVD,'3-2!#.
MO:._EQOAD%EYO&W0Y"2QO8XP<)WJZ%[B?L*\%EBO_[\[^0(D&C9[N CV77&3
M#!C,%L=T8D&$T,H$/.T4;%'].17A,JS9$#8[3:%.<*->(I\#E/H[&2B&Y6UQ
M[782./-(QHPR^UL-9* _Q0>CD; _L@_3UA*H^&\^[.4_/02&\IZ6T@G[0]_^
MXZ*/5@.^/T<& O<9IXH$_KZ9[L\_S>778E9/!LSVOA7\LI4NB[G^[QOGS(\D
M["]")L&?J_/_=/;T:RE(A7D0Z;8+?:ZLKX&S2!54Z7FP(K ),:W:A>D?F^GZ
M_I@=>US?_,5;_>RDL<:QJ''E+]6JE1M6K?SSTFM%'ST8%O*RYM, _"Z) 8E7
M[,6FHY,3=C)>#2RRZ1Y>\9HX9S[119-D?.CSS$WWR1) I>.,!)X.DQFU2I!%
MK8KK5.GJ;XTS!9[A$=!Z> B0[5!&-_$20R$.EJ0CA.-]'?"\XKSHOA!<A<3<
MGBO-C;L.AZ[(F="$U,+[TO[+^SPE_G$82GT 6MV=# C+$DVVLEC\_KEOSJ6K
MX9\;ZD+5P;]W  H<C'4@A*/(0(G]WO% VH=D0"0=LC]WDOK6_\?M?+0&QW0%
MND5IXL6<Q'Q1E]F,SG(L%#!HMC3Y8?-6[?$:_HP&KNI&6&B+M7$.V\T=B>ZN
MI%M=NY'<A^1 =C##W4GC4;C\Y(6>D.UO<9-E9*!1HR$1]"T"=A**,07A1*&K
MLE@\VAF7APJ>>^GZ3LVV2W7RNERY^@]+UL-;U/D:C1H+U)L<)$8'O.X"&:@0
M7Q6EBR#(/' O<I+U_SR@)K!\RMHF,#D%57IK:K3Y$XD*.@PEL,-10V2 A0PX
M'%$RK*]T<7J7-KS P.'")L:NK*%"HSR/<":X$6,1TX]"3F(@3R2##/!:WYW&
M<A8M%*OW T>[.,ILQTM][FZ>J!&CH]D1'T:\I_A '$0?<R'BSIN%/GHI*:GB
MZ?-4%_II)-@3GI^<9JG)8JGZW]TDB4AUQRD+D-2WUO$ F'A"@7A^!!U%X++?
M8<4A\-!F!W"KTJ#9FX&>=&+-P\=!2:_GHYZ0@?T%ZED$3@1)B$E![!P"[Q]U
MV;]E]V@!DARB\$L"])OKL9 RMPC:3*S0UGR&QAEKI>_1G2]_'%Y5;[AML9(U
M3;5P&)#ZLRW9_TI@,A#,=3(P&IX7M05YS'\$D9DO9'C)<'JL_:7]QG&_25%.
M@"J#7CW$AZACT9-9008^!DO,C+3&>;7L5KWW"I9^%NR>N_>0\?C$I_,7QSNI
M/></FW@X4F,0)'HH_OSX$J55N*K3E2Q%*[1_FXMSE;[3WA7/D!<53E-"UXW,
M'$:\HY_0CUG29J:B\3Z&2 5]+R<Q&.'-0WHH+:\'GN#F+J^O*=SJ%7C6YMQ>
M)@=R#XNI?NOP^2O,YQ4VHW/_X<#1FNI!R:QZD8GV0T7M 3PTL_$FFUE'^/]W
M=DIOP)\T:0YH"N% =L/;L?E2(JK&A9SWKZOH;H:T*GZD)TE]J=D]UFC>1/=S
M*0N!!5>.79]>:6+$F?DXN19U^XG6VZ:PO3AN:98J(0]I*='<G0X,A0E;"R?#
M290N46WW6L6HV+W57%/^FZLT2[]"6NM.Y7ESB#_S;2ID9@!I/H0F2'-04RA(
MHZ\!DF?5ZB 4AT@Y]MBP("S_#)4*-35">0O>"<:=Z"1P,'5"R^T*X?ZQZ#9^
MGZ_5P25&!=:]=R^7'G_UR>"$T[AR)Y8EN!:./)FM;V_9=_/:#48@Z0_:+?T_
M1LI]W''85 SI0D6ADCD92."#@68=J3N]H7O,$V1@I(4,+)RRFZ3;SR4#FLEH
M51E"I!ML&07;XH2[/2)2 NU,0R#MSR[#'RW_=AS?O7\+1+- Z%@2XU4R('Z8
MAQA@!UOH5L4)=Q)=B) L>!-D.A>RX7$9-I([3WI2#G^X AM&#.XS I/9?X%P
MZ*?D.Y"!:\CYX7=_OPB5786-*.&1?>;;-\8H'MI]%Y'U5SOLKABY#_]:;&:#
MV(:^!NY0HOR29\1^0F% Z3W8B %I@63V%XN3_^-0/IO_B#^SF"?5B#?V82O?
MZBVM_?:;MRC.I=#W#\EJ 9S]"!^%XHXC5RIEVN#<D[AJFRK%*A)_0_70O;0E
MR>)/UZKINH\*QM]U,X#6XRQ^=+9 HP*JVWIY%Z=X!FXXE;B7E]*/#J'U!U_9
MU\>3@5\(H?CTNT>8!)1#I.B',KSTA\"<<W7UKF;(,T]GIT^*_HC79#@1JOFF
MO"+L\Y2$B__PR9GS6K&O<YPC9B"&E7_$<8-L,S <-F$)ENN[W>:/)*G;[V<N
M:@FN/]3<)5:Z$YE'BD:>^7.LP\8IYJJO)Z '\(?$0F;%040O<)?$=WG0'LTH
MQ7#)VD'0O7L,K63@>N>&X<X1:I*V(FS[BREM^Y_=-@[D?Y;\(R^DTS^S1?;1
MQ2\@-OAJR0 \@M)*KS36@;:-2,$2;;_K5Y]3*?S9A?BCQ1X71=*R[B0^<H=L
M91A^+WH=;+5UR8J3^^Y@R;=KS$D== "@FN1_*!02 _I/<ATAC'Z>+T8&CFB*
M.%-JU;YQ@"" UCC79SWYR,LIU[:7Q6CLQH/$#@MQFH<96B>:V$MQ1EB%=QY-
MU-BK;,W4%QK%E8433>D4= ,@/_?6Q\"V3!IL*.&JVCKIK-YO[F@)>QXH'B@>
M*!XH'BC^%Q5->TGO$;W% >Z_^=+T>I ([NVQ6R%@7"GH:C:4"ED;&:H>^?<3
MP2T,'##I:)?K<O!0PK6>^JQ^=X,%M0=F_62@)1.71P;.X]L1.-$F,C C3S7/
M:9'S._=A!YH'F@>:!YH'FG]I3:Y?DG#:4=098>A,(L<Z-R78C\>3@2??C'K#
M(9SFQVP^"DL"MY.\C5 $5!;H^ <R8"N.S]DSW_9.@[5 'Q>K16# ,2]6!8_P
M;V4.G%X@ R@3PE4RD!V,1A+8D#!L&K 9(]'_V]N0 [T#O0.] [T#O?]C>N_]
M=D%],.MM&1SE&TXRL)#I_S/IJQ^2</?]%.$H+OM#TA2 O?7$1_4X9C'3,I^Z
M:VM]^]'/-'?FJ]YC4(IY'S"*)AQ&YRFK2\<%F$ ="]^0@0@(UH3T>#<6AM$+
M)@,=CM1?3\+U?GO[0/% \4]2/&UY- GMF/78J$NBX%A\[HM0.K2Q1!_BWSO(
MKGLHN&RW#2&,V]6M:,"\J\\=LUY*"]J5R7>R.-,N)N%1?,PMF5.P('&QUU,+
M7)"),82,NJZYRR-BZG9>/WL'?9'"AT9R=.P>.99$/T9EXZ$7$NA'BD=%2O@G
M\8KJ9S]QU>\[; ;5I0[5*/P40D<X.]#$C1,PZO,NM%QE6_%>+&%7OUER.'NO
MR(.6P>_^!=6TG=-_R!S=7V6ET($<R/\G.5CY\%MY&JI-<XB^F>8VVX+V=(SU
M2>IPK$ED@XJ?B^1("+A?^AW?(9>XTRU.'M>2U+M$'):HEL<:REM([)CW0VO:
MF-ZH3YM1M@*7-%*'QQKKVR#8&9D]$K6=/<I]C^%GC=XD)(5JG/2'M"B#L4;^
M7EEDX,6)EV3@4P4"$^6O1XIP9X%-)UPD [/6"ZE9^Z ?1EJ"\X2C4VQDX(U-
M:R9.=!"RQYV TVD0)0/GJJ,@&+UWL TI;V]3.A4R0.\7#ELPQ\R3Z+=Z2;HY
M)-9U>C+05XSJ); M9A)B;84XJ;["6H10X'VN!HIZF,99,I!(L>+A:BV0+0E_
M+TIX$N! !HZ-Z.D"7IG_C@>"8L$D$!FG!,E L_!/R)7]_0?@#L =@#L ]V>"
M*PIV;R:Q<\O-M)"$!%G23KS0@"T.U]=UC$!F.J 4^SJ:3]U,T$!!&%_;S8*9
M<4$/E0$A >./ GI <%IC99 02A"$RVU0Z8-] 5W<(@-PZTT9$.S3K7E2?0*1
MQJ)&1GL+_#E4!?GO6,"_L=<+62Q>_UY1>O]>ICK5D]2O?EM/_?]>JI+X&&#^
M-_54\9LZ=\G)#E7I/0!W .X W &X_RG@*GMQSRA&G?_>K#^T-6M%/8[C(AW"
MT\4NZOKN8]@L'P0?M=]'%^UOT6+'I?HD%.?0.AO40#'JHOG;57 7$SJ<GC,9
M:)="]=9!YAC>!8#V?>#RF#Q"^-M?\K_(VDUD>L(FH;,GJ3/^9U;? ;@#< ?@
M#L#]Y<!=1\0$'44I#,Z-HV L"9-*ES@N"27D5@;8WI^2( -/O9';763@F2E=
M@C\UQ;0'DH'T5DVP>W+33MR[3*B-O5WOOX.&*^."R0!XACA"JER]]I?A)']I
MPG0 [O\P..=V1&2#BB/I3E[4EI$5G5[U0-'1$!6PO(>$QX-E&V_30\#?_F@!
MZE! $*#3-OJ#D@4<[!HYD/^;Y&#7R.\+Q5A%PV8ZH)L$VH;.%N0&!Z4V2EKW
MC@?X_>YM(-!Y"ZQ->._$\[<9@S\;_B]B[Y))>;=]L)5OY99C\P3_[BTP7@%X
M (E"S,I2;+9M)RE,8N(7P'9@U/H>\W7*J_4D UDQNX<7-!_MF1[Z[\ZT\K\T
MK!IHZ!ZM"0E%JNP;^<=U!=6<,"<E;'F>B0'/28P_6Y/!%Q(B_!,B(+/'Q0ET
M>S$[L_A8TA(9.*K%DOT7V/7Z=RFQ:8=ML*23:B$;SDLN*5@HX=$[2DLR(:2%
MJN-1NP18PBYT?Z32(H:@2082L*1E,F"]4_"G;X ]F&@_D/]KY6"B_7>%!?:[
M4^2-:O_)S'EE "B+=*TBMB^8;B/W3T?_BWRH[*6\V07(CO-HD:L72?W./HA(
M,:29K<@-WI\.>H8,:'.M,?U$# =A=@F1TK#E&DIDHQL8]M-KYU,Y_@7LZ3_L
M:@96AO!(G QX4&S^@LNO/P&;($;8)T,3'&B3:[5KEX?XC72N0:\E<X/]&8F:
MT!YX/[B=#/C GF;1_=G>^E\\MQ0:L4=WB<)E,O<4?!2Z_>$D[4'8B#CIDI9P
M, 9/@G3BX427L<+V$#"L$T<I !DH#C3[TQ.C_4N2M']0.=M&3V$EBO'@)>7M
MF]*I39LTD@%7&S*@H["L,#M%@T?N?$-LG;4KUQ(&_1Z#LTC E9/.>?RD>)0N
M]DB+$KI<RB1Z<5)]^$-R?QW(@?R'6-554R)^'$S4VBR]$-;Y!!&U(4\U4_<[
M7@TK]-N,WL"E/QO__P&A@Z#!%#]!( -4<%E,-2%\#;9<2C*P>_V[M[6$QQKI
M^F"GK75_DJ$K?7\V^E_DGSSNWK!B[4^^3J0C]6@)F_P.?[.(P@62='@@VQ.P
MA6.-S;^X;>"ODG;R%ZO:ZY]*TGY&!FI@Q=X*O_H /(CZ+8&S$T69[#$84-X2
MZ59CK2::#-0A/IE2Y_\%7/8_7/>OB5Q=VH\&"PJ;640L4TIU(@ND^:MQ<C,T
M H28(<#JR,!P8\$?DH'G#Y-_DKF2J9H$ 3+0^01VE7B2^C5&?(H,5!63@3=I
MVVD;[H>"U_'.R'T^N%46B.YW29Q$)\&*\N:48<LO*-VL.0OVZ40OJ38&^)[]
M%Z#@!_(_1_[ DRK^ITCDW$U7=X760^=EU=^RO#V6(KJ5Q0QE_=F9$?.X(P\2
M(A"SXC\' :,V#/<0,SRK>2@XL'P)E=YX:&W.3P^FH-Z3<[==-![R(ZM3H[#-
M&SS>VY*26GYQ2K#QZ"SH2=<@TT+3$-7^\-]<)&$2C+EL0@?0$8[M$JC(@,8I
M& J=P4*Q%'9D@ P<,Z5;/,*U1PF509P8/R+C+AG88T_ ^><]0BQ8(,C I^=4
M^SJZ(>ZPUG9U(3)PCJ)(.I]#$CXUO;[/M4X&-HX#(4_[H>E(#-:$#M8'AY&!
MQ)-D("K&7XT4$4@&"(^UP&_E+>9V">I7FY%;$D@R,&L(.4!P@.  P?^U"/X9
MZH90'OIK+$6K)B1&/A13NI4HE!EZ2N1&IA)R?"I4L_FW0SN%&WKZQ(:&4R[Y
M/6K^][<??1:@_K)%/= H#VO651<$P)A8)(:.L)4%&C@ML1GXZS*"?UTZZJW(
M&,+4OY11[]>E XA'LQ%*B'\IX^5_*5TH1-\1WK/^ZS+^2_U2$/ ?(#A <(#@
M_S<(_F5HE_!3YU>/L^(?(7#*M/#XWF]IXFVZLJ0EWD/Y?0" %_WM<"^\2X-N
M9P.3^WKY,R4\NQGJH?[UC-?BBL0@#XE1?'HZ"\R$Q%">GO(Z:H#R;_/_](+_
M^55_@."_ 4&3-LX";^MO@?;!6]HLKK_KF9-TE!9Z_ND+9]R;C^+KOO./VH,#
MBGAI:5BUU+V&[H9R_U>F@&K=N2B%4'7?GR4#787O?SV_#FRN1R&Q),@D;-GN
MFYW$/V<<\O\"-.V?4B+:00:P,^ A,F"XNOR/R?50%>0_!UK@)_YE# ; P+AA
MGXS!^W.0)(M21_ &0SD9*+G5 /N]B?:L(S'_,M(#/XG=[90)1S+E&#2)^,_K
M8BK<Q9\GO.^2HWWZM)XNE3E*+5I(-0W8#I"8FV3:^4A,"[J4KY/K".%5/_Y^
MB8>.=<SFNJU\V8U0W\A*4P]+ZMZ _6,=^X-7*L/V.[QK*VJUQ3@Z# Q8M^Z(
M4<>#G('*7T8PN>8U57'5&"0JMZBZ20WKFXQ*M[3P+E^Z8A@=6^UKDLH9)?!@
M<2!4@S]F+]606(:X>\3+M'*@(O/)%&O3D/M=5FMK;4_O.QEW::+[!'0/1U_Q
MT%^$ZHU"1Y?,%WWL/85Z&D(Y4^0,2T78GH0&L :8'J[[=8DEOJA?Q>:@W,/R
MN*=.8=\E9'\=>&#$-5M6R,?0,2%YZ:M_268+21Y3'2=Y(0_EZMQK77IW3/K>
MZ)C<Q*L[_2#[\0]9/Y>0_"=-4.*3>B!V=WJ]99,11R'9^SP1/:V<X<[WOV38
M'QDUVT ]RTQ&B*YJ"2-T@]Z3@2/->(K=[_?$6)!H)BF=2^@DL9H,W-[PT%3&
MG7Q&!DR48(0H+;#993MQE,F8TG14_''+('$LN'5LI8CJVH<TOUL";P2FC8\$
MJI]M]>3OIHD5<WN3//+&G._*V7CZ65.:_](HKYF0T=72_I6\(1^U%RLKQ:E!
MNV?911]#&MH.:1$D/M]#.)H\XH]_ZQTK$VU]N.,MW[4Q/?D.VZ_MUVZTT%H]
MI,ZHH%IY?LVTEZOM<@]U4:+A8S&WVK&%)3[>VRQ\^J+?ARK^%W.%'DV*N)?3
MD"C5H#IX'.'2.YR7<>A=ET;M6?T<7JE-WIFGQ#X38"N+92EFSPSA2@9&M0W,
M<:CI+#T:@?0FR(;Q,Y+ HQT3,I ],PTG,-13#)$JL%\2LS?32@8J$U86T84O
M5@@:6)>6NN(OQ57*KF[25J-EM(#+';XN:KCU;K":V>"V(_NR<5W,&@/M;,HQ
MP])MFH>=QT+E?QG@A<M@+3H2(IKH&UQ 7+A!O7X9MF'%ZH8DLT3;]!M7V,7Y
M9#:VEVTAD4&N*"CO6#J2V<77NB=?A&]E=$R]RD-N(>J5\!#5T/_[FBJO#,DT
M2WF!O9N^\;JQIY<\].R>4U6-^!:,\\]-VKP;3CLSJD$[\'%SZWTSL]Q;MB5Z
MT4TN B1DE Q4(#HS64)&XU"3('1"C'</!XDCF'$<KSB\QEFU<?P;H?;8V(V[
M8XL;F>G*Z]#O%BN+!<[\G:TR+%-+?O>G)GNR%Y*,U-OXA&8'L_WNBE"EW++$
M#O71-?QG0*^P<]Y^"BP9 "%W4YK4B>4DQ44R0*O)Z3(6]S57^.4#6(XSF]-@
M^8M9'DTKRR]BG@U*DY]$-?*IE]OK*GV_5Y\Y2XE=[CZI)F[P9@[DP6?/DACZ
M9Q!C$C,FJ[*NZ/3UZ R9H2"FG=5SM&4I:#[YP;CS>S<>TJZ)GN.97TPCU51$
MYT9=*H_Q<SJN;W;;%__EXZMG'^=''FKQRUN\PBVCD:VP2-\P?&>&]$#06<?;
M&PU$0X/+ZE_RQU^@G\Y+Y^1YVIF]"QF%E9$^! N_?!?D@ G^0?ABKF;I)OTD
M_F.H%FW?(6W11B!82??.(O]4,MRJ-=^)IQ0Y>ET:YR8B:9\8?"WY:D(^U_N_
MK;/C:L-UHI7"-,&C1OFX[K8 OZB5&Z:;UY'U;SW?''XDJS\QXR@>ZD_;<&5\
M9Y"8 I?)&G0-4?!7#,2_-*>72II;Z)*$O\[/&J-Z%J_2#@3KZ-YQXI][!A_3
M@^4@M?.M#:GUU&DJ[O&Z76$ IM_3>/8-AV^VNW+TJ,<*ZLNMC8[E#$WS RDQ
M>\OMD$J_E=7IUX;!X'88M[K4FR7?-LD=O_*)HGYV*ZT;*5_IOA2I;M/69N+<
M0*,04FQ"& )SFN+:GRY0+]5)_(@F ZZ(46,'2S0..5WM=]3,?&Y=+",4ENVC
ML#S%CFO&#'8:"&:P82,32]XB/(MN)[?ZS009: D_TSU6>H-/__0%;2'ZG^M!
MX%X^[@Y,UVT-GY[+#- 3._DU8)KC^P[\=>7ZV.Z.,Z;IC6>N"QG@(8CG+G&7
MO7"3DBZ13K',%7SN455$U;Q-JJ#:BN/:R",HT:UDD@'=SF8HCLN/XMI]Y,%5
MG2N%7L=:Z3J0M$:BKTY+]4P9;/%5' K5S,VND6$DF&! <2BC!$;_G(O#J$2_
MMRE7]#]W/YEUCP,9!U@$T(NP?1(5V7^D=5AV-OYHG0&[PK;?-7 ZZZGM/4H=
M'.;I)XE"":QUZ:BFZL*%_9[&METIQ?B%:N&+LNVG:+H$0FLN] Z1 '"6D[P<
M&2A(.Z46E"2ZN;CQ[,K(Q@P9H/E(+%-W=Y\I]D-UMIMP.0>4O%=ZO'9/D@Q4
M2[/E,1WI.B?*%L[;+,BV"!T22I[P&^Z?:/O<_TDN]P%-X-U0J7Y=#V%17!X&
MWV*1DB(LAC5_^=8.:O##6MMWH[#WA.#*I0^EXO2=2:K\P+I5/ZWM-[K",Y?W
MD@Y?2&75UX_WORT:QG[^%NC-6$<3';%1W:EH+(@FTPX'*[G>K*:!2C =F)!(
MUC_J&>FMSIQ$Z?F)4(P!(A;&2_!#([CU9D!\_E%MW,--,DU5ND,.,>=CQ)J2
M:73N.9X+90SU^M@.P(R]+5XZ0WE( HX\_8O\(T_D7T.N/HBH&YTP./GB2Z=S
M9\3C2/0$<T:C2]^JC*L[RBA6)<E?S,P[D>'TYR4^_4]"UQYI<?^59NG^M-G!
M?ZPZ<S'\QUJT4'4_74H7[.DE!LF0PI)7^V %T,U%.]%L2I._.T]JXB$#VH8[
M"Y!O,GM;60Q_;#46V"*M+?7FIJ[KN?/2K#]]>D8U@VI1BWNAR!;29BU=,.Y-
MO#"U6,TUSL'N1QVF<AD9,_8[@<_IB)WW>8N)+]W7LJNTE+B?/I7M5:=>U.)9
M*'JM9CN@X'/D';+9E_Z3++>ZSUI.M4+Q?\_29]-OL%D!"E.Q2P7OGRH@_LO'
M?.J]%6()9#8/3O3\.518O#QG]+=<_TWIOW\_5,GQ+]!^?LII/C+P36EO^WW!
M?UQD,0?^_8A&2T7$<CIQ?4$BX,^?0_ZU_')(8Z'9+ZE6M?A\(<MOR8 W[/14
MD<#?CVW\8U=Y9 4I8:]-<6(UD]_KG6VKVOWP!7>?BO'M_;-AJCX[:$06^!&4
M-0OW$"4A=/UBF=$9(&+\B:1S /6:5^=B#TR9L9WWS%+>,<0Y,F"?^<0UQ\5W
M2GBHY**O$6/XYJL'(?:16H<>O9XXN;BXK@4N\S8+- JOKPI;.L:O@C:XG/K&
M@H\FT.R_8"(.%A#\[R\@@,^VDIAR@P/]);<&Q=>BHG,L1\2!RED1AU?"R%2H
MR;(F(@F!DZ8C1'BOX_FER,!6$R- "@F2>#"#"%?MR8SS5I&66KMG:L"UY7%=
M7I9.]@NUX1-6P2SE*=#G@)F$=342 PJO\SW(&2>%4C.O<WGMKH<A4)LEOIVL
M\Y)58;SP WU-L#S89:^DKXG:"C=.8MB=0?"/.Y7V%HTZ<P]CC$6NGKGJ5'1;
M<MQ(YHQX-?5 HP6)OA=O  W2P(X\;@*[#$;';:]6/7/B:DO_=$*-I\T9=SKD
M@GH@_BD5,?SRY3:T?LY3P:@X03;2P".BLR&0\Q[9FKNX6Q?7>CCL\YC+2X,;
M-?&<TIWB#T-5=^ SXR3&1?RY901_TUFE%IE#SA>">4P'9N/1 XHNN2XON(<G
M$]9L+8Z^]:"Z<D%_06+?G%@1(N\$IFMB]4_:O-)D=$K!E<FBK-SAJ-%U@WO8
MK'.6K.,3@!XL%W8"BC'I#1_+7 7AK[3/0%@KA]]0>K'KLL?>+LNN;/2XY1?[
M^>-:;)VA<F=H53BI]MHQ[JW[O6$AFD&*86N7JF7]W]%\9,Z]KNWYS8A=68A!
MJ)#(!+L[CG^MAPJ)]?(FW8;S_Z@E QEG,F;W1S"M6 N=:@QRM=[^S5AHU;Y[
M6Z([*[4C8Y6<XJ'X5Q_0B%J9T4"2P84H,G!]D R<U]8"ZU[6%KGO,M\;C:CD
M:7:/D%$/4<:Z-L4/MX>W7 9W5:N5U]U>?*0%UNZ'ONZE!'N7B8]%?>-(,HO-
MWV+8JI"15RL2<(05?[@91F9U$"\?I(^H&%0_BF7LO=;0E'RS*D8AFD_LAN7)
M<8_YK%X=+;"=J=>C^,8"Y5R#IP9\$W%]^QC0]ON3U+A5,A#V80DFX!IRVNY$
MG%/1E%,<G"HO]HCXU3I+,A" DQQ&C;CK]#&#C4U69 ALWPB!2BM8=_%XT?I8
M4](0N+ZAHK;B^7G=#N3D1.;9A]5B3[Q[G??)P$Q"9^\H&)6\(DNXG=F2LEL^
M27_3U49_<&W6):D-X/_Q<+*^9JXQ83JS#1H.9FLX4]?;O.?]OD%U(-Q\H%AJ
M5623925D;>+Y5Z[:Y44MX1%=KD=H,/L"B;LTV,2FSL9(>5CO@0TO$_NZ5Y<0
M#X6]-^H&B:/AN%/@E8CI'NTM!"OA2NF'QK@II8AA=IT+OC5SBR8T]KD."V0
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M,.<5E-* \]5-Z3 0-"0<626S(A6TJVI+R+91LK0.EKDT),UVWL%M=2?U"E#
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MI/IQBE43)B8&><*$7Z(0,=S\$;-ET?:/N9DKGB@=1B_6=FI(K/10MUF;/*[
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MVH97D .Y"&U!K+Y$QYF@H:NU0L\-YL?$VXZ<O4_[^;3"H ,C+=!Y&;F1!5H
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M=N]"8LGP<<65!"KM:8L4TO<0E@J,TJK*FX441W8!&0$;K0).$4#^!6\O-1F
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M?W1B.# _:0S,%62/R4$U?FV<GM3!JUV._[IA]B)*V3_U9(B!J#H8UH%(NN1
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MXB[L<[U<G -[?@&O[_^9',\@!)KD::+WI1:273:);?QF4=N8<VM 6:=PMOG
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MS9/3J^-%YP;<?J,$<NY@IS+J71T6/;+3(^B $?+?5Y*((?SH -,RD@]]MRF
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MW**F^J$T?:5:$X[79H;7_O.?$_M_PNM_\5.(_Q;H*>Y3,ROH (5M%7:HBN:
MXIZ#DK4D9(IJLV[YY>QIE[7#)LT'T4.(VL!_0A;(U0@(9A\!<C'BH#P#TX*M
M_U(^T0$ARS4G0)-6VU%4^8O%U%W'SX<1 ^P_D;7O4A]1-,!14&KT88I%9>5Y
MY#&]?94C D*7<\*,E=M]NFZY1<>(T'P8)BQ$,#@5I3*P^\7+4?ZK2R8Z^)8A
M]\.>!87#HKH#"4;@"*<5U?;^8C<F@9D^A')?T0;)MT,<I'J;H#NS7Q^T)[%Q
M;C(<BR645ARPBV+W@7..;EKOQ5>5Z+;U<;),/SFFSE[IW6!C!< WR?L=]:
ML:ODXTQWIHG'X\G9-H##O>?P-&IA<V'N6R5\&%T7Z2-ZHS?ZG<_<V6IDK^W2
MY4]2L;]H./;?F[!O2.(-Z)24)?DFT;^CT:/AW=R:[5 6'JAD%CFK>Z0Y8?&L
M#F0(?1J->TX'F%$MLE%&8P9*KM/G1S^BA"\0K<_ZGOM='/#]B^R#8(P^C0/X
M>UQ B1SVCJI#YC@TJ:H,W8Z.N_*B'D"K#R\HWV._?LUZ:=E_68TLAZ"FY#70
M(J<1R[U76O]NXICL(8[X:>%8':H"Y*8 X%%H=R$[I>X;0P>!=" SV.YOX6 0
M3<+W$@0%K3/#1"OA8.V%QAVYP<<+JS;G$\X_EZ^X.,TD!/ ^D,\TERF1]C^0
M'-,+HYC_!=B@ C8\J-U-<:P6Q?NKTD_266+>5T54>R.UV:1PXN-L\8*>0)'2
MSB8#2I"$.IS@12W2M2^KGA?)U=>?J;F8E2LVEE']?6&C('*\BG&UXW#NY<8+
ML1^CS.^^\>]--5&[6F,L=>'5??F:KT=;\UD*B*:1"\),)%5&VF4Y2HY[[^-;
MOFJ@/_1VY,_CPKG+#8('7W %'X.+(HCAJ'CP+-@/J\VE"O5VR%T?;'9^[^;;
M&)79D%\ZG<T/.^_RD4PLX;+>06TTGWE<>R8>7 ;XNN_#\A'$Z[#X0TB* >O:
M>(/HO9Y0[LSCL:=NU\\9&3QH2I1;>[S3S5[$F*DV]*X(&8M[JEQ'L"1<'(U/
MK?N&F3I%(WU5D:&6J!^O)LNAX.=<(501,]!<FZ'?BGX:6Q^:!8W+BIBK>DL-
M(=4_.97A9(Q?\,N4\)@2,'G]W87 /"VN[[^/!KG>0/%M[W>;& LT$ !MWRWF
MZT&23RQ1GUU$T]*<D&!A8,5A.>HW#.3X2@?D>%$,1)I3Q@ ;SA_ #XK,!W^7
M?((.=#>4(\8[((?"(3.(5FG$XHT1Z&P]XXJ$BL3_!X%RYC44^<Q+9MS#!S*9
M+F[F9N4F]7?8QT6H152 O$]ZH *S)R.(>2H1?0LVX[N"#8V>S=D=V2=WV]3O
ME$FE_+389T=:KW&#7)7GB(IJWGDTOL&L2>MM5%<_64ZL/9W'C=QD,_IQ??YK
M8WI71/WP_2#A=IY*UZQSLNX3?&TQZ@\WR7+V!&:*T01$FMR+O\H=5G$YA#G@
MO;&@BYG<+1'/^X6SX3K@31*L(ST6*8G&Y2/X"1L$JF58=-FDRU2;\[44@>JL
M/^=O2>H=#;@K\]U^/RG -\";RS#HJ$U'G-_;^V_]V-^-,)GAU&']2*JH=_M%
MU_&XS1!.V70"LTU#^]/L,#X!B-8YD %?WB"KE[J:TM,1' &JYR4\(FL'U\?<
M[V$BS:>-!7GOP0,?T91PC*#H317"6I!:"C^225AKP=JPW(D,A5?YGKZ4CQ%%
M.GW1:_8@)RO*K0='L.M\NG5'BZ380TDFW7)ON%:HWJ6T4[+'8!195@SKGU"P
M9Z DXTN0SMSU=HK\5)0;N4$L3L;9 1_@;/OI9ZM>L],JQ/.8P+"T]BYJN00'
MI0HJF)#]JWR+3B<O6'BG_9'JGU5VWA;'>!XCC>^LP7+0Q&N;!SKAT'7O<<3.
MGC^%;P"ZR.?.P+9FVYI,UFV-7.1@\X9A_O?\9]1ZAW]?:HZ\[WI2V(8ULMM@
MU/]^X#T68H^8OD&($LW_ ,:PF![XKQ:M!#IPG30>5TM9>T]X.#9I4.BW7=.<
MT7EJX!]OW9)%[W*,".T?>[&%="9R))XM,:28'-LU]:=O\XCQR=IS!D=J[GE<
MC]#9O 3I6:(*C8-<>4CV-Y_)0:1S5T?R?*[S'/<>.5J_XM?>&QHV\UT1."O[
M+'@--HQL0T_9SWMWZI\:MQFD.A=+I91>5W8?N?UH_ &;Q*6.[8)H?U+V'L,3
M8E7)"IVIY>3<^9,Y)72 \R0I;^.R6=;<R2;=%UK117?^"> (MS$D3*'Y]4R(
MXWOMM)BZW=$@_->&S\,;)U*?[$\5##[-NMWT^X7KN>K#X)UBODTOB?DO)ED2
M@@XS;/9&$H[61ARK2EN,C-;Z-Z-!]]6@&2A>QKCW&/'@"@'4<W0.=^Z2?&[6
MP=_#6WC,=OV/PX3I:F?L!99]%J+_-!W 5:2=)"NQ]/RXZ!:@'[R/Z+!A7^*C
M"D!!*!+L<C6C ]?";M($HR)86P3)R[R'1Q<8Y*(=UH?]#T1.PADB:5-'E_Z*
M7(*T[:>#Y\B)\PB"5%4ZQQ3LU\<K%3ZH,M.MJ^_\\U]FUK_N&^@OH$"<*!6M
MZ&HDP9KR8,)Y;4Z)M+N77L918JZ\VW1;@*)9?(9UN^;*AUL>H:WX9NYY:.Q.
MD! XTUBV5WDBA--;M4? PZJWW.W";!3*1J?+GV)']B_VC5"(B])E*_0.N!MG
M]@GRM2'A&.&QJ75.2E:T#S.YF5:,P.7 Q!'N^;I0B*^;1AIM?8GB@IX<-.VO
M'XP+_OT8PY*^J+3;#W**4&Z1D?B67'<<'1!UG>N/%J$X;#8KEWD6U#C1QA3B
MJMU'F,CP''"V\60"BICH[-PMEV%6LGJUJ<14]NG+)65>G2/H0BSY)&%GBAWS
MY>':T9,->V/O.LU^<(*C]P=-=?, \$.+YII37RIQLV,<#K%\=?Z?H;=9G57\
M/6?ZY*U*11XI!&ZVGZ?V^<%JE@B)E%M15T?N[FY"_"4A3]Z9?&7@=96H<C%!
M*_FDQNL/'&W%MI9Y$#<OAO9^4QW]>%WG<O7ID!<B ['61\7YS4;L5%&5X?9M
MH4-^8L97/EVV5R66%@BRFB@'U\JY2]!\F ^Z1_ZV=+ /*'8)(+&EA;R7L[OP
M^+:REZ>!^X*WG3LRZ-KH@>?[6:K?WTY/5-_A*'UH2I#:PTB4@*.O!4\>X:F1
MY]:$EY;$C0:L#-5^MQ\%SL* 9IV(0W@IGN=S5]^S#WL_7V>\N/VSI60*G=M/
M/KW4N?D$+=(B'WYGNRWL5_"]*/L =5DCZ&]<1IA<=A_\B20 5J ]L,D$4MB\
MURN\[UNO0OSG5.K8*:.N:>5K%OK_[*_!7B&(CH@#?@)T70BZW8AZA\"]?+:$
M\\KC5H=I87V4S:=DLV4FNR[:_\3^:[EBOG.,+W$<T9U:S APIV"T$R(T?OMM
M!F-F,6) #RE#.E!]%7UX6>E0]G\/*B[W0V_Q,(9'6:;3A$?A_^;M"!-U#SX.
MV;HQ#GZ902S;[6Z?3#\</T08PJS _^C/EZ3^3WG(M<A1.K":3ST<&?WOOPRP
MZ:,._]"!R$.NN4JI_U%#\Y]?[/VO7S>;Z,#-@]$/_U)!4WRTZ7_4R]CQI!^N
M0&<A/QK^E]=_,!M;CJAJ]DX$$MZJ6PAYG%W570PFP!K0-=Z=34$B9#],^[Y0
MW*/;OHUFF0?!G^YCKF:5I4=0-5!OT-[]2;E%+*2;%68Z:5)-*>$G9Y9DG+7&
MNAZP\PQCMP$P_G%W]_(C8?L+\S#^R?!LL]H198]M.?_(Z'4.:+///]6XHH./
M6?_?*HS^37/NC^_^32%-.7-_"P2!(=.!$#I0%7DS'-6^R7@#V4#OHOS^\SGH
MOW[]WPVZE1K^=2D-L!3%N8\F5""6O;YY->=_1T:"4PU@@O^8#W/K?]B4F\3(
M$/]!44V,UK]I<'Z@Q @\6(:F[*_1@4]O&.G7$H=:N_ZW1;<*'?CO/;K1?UMT
MT_Z>_#F#Z&ET0TP$\M&XP)9A6F,+SPHC8K*'3Q,DHRY,Y;R:K^@:OEFB=K;@
MQ]M'"L5WY -;P#J2-U7@!F@UM VVWT,LV^]2E#ZN?/*7-'W][NIK_+<&'U=K
MHTK#UK652Y#6_G4%DI0S+1?JNUU&_K"Q=+GA>D[L&*G#Y^AX=INVM2O.73]F
M*8_V%\5\!,?M\NQ;K2ZTYKF.A"E@X/QUC4+&JAP:4[6OVC6R][\<7$,X4>,8
MDE^I$B,MDN#@%!U(WJDPJQN>S^,,*-N"_'!^BI+YQ^ !P<CXKK8XM#3*;![[
M%"9,!_R03V%\S3P+5B:[W<KS*:9#"_PS&H:^7/*V79U_7MT37G@3EU98SKR/
M!#F2*&K?$LK"2,Z.WDTI'9)&S9S!,K;2L@\DQ&4/'C^7<=@SV*49S79]\MVZ
M7,R:QI/,#K!:E3 O*RU")\)P>_G$=)QUG*9B94LOPOO.;61,"<U%*?6UH;34
M>VAI-*(<@2F@ [N_Z,".T"7(=P1F\P Z20?6WT-H%^H0@;":?6I6*A_XM0Q\
M&HM^^C\MH@'",811RC_.X"\T-]6PLOUHF%/=M\2I@ "]7]E7HAJBCFN8ZO+A
MI<W.4PO(%[JP=>R$-9*S0[H1R3Y54X477#TM\^,'GKWN4_VKI(SXR7M&9^JM
M?V*X!\8W%*BB%6T1]54X%6/'SPGVM9\&M7[V',UBR@]=_<&59GAL_#L=(!IC
M4[!\>A<6]!$68UZ)EB-LN<?4#%X_8GUN+6?TG>6"DKBV["(GY\HEF=D21"L+
MU02?PG'>U7\O=BQ@LRSYM$?:PSNK0\69(R\&7WHZO-#6-W,ZT-W[2]_TH.O;
MN)1^$2M2PG9'5_^UG-V =Z; >JA5P<J]>_<0*=\0,#2Q6N]H3L7#N;/$1I/?
MG!ISLD.7N#^'L^17GTO'3.O9;\?3 58_6C-<>O50!=..YCD_NCM9WS@4I'I7
M@1+P.OM<3W-/ +.ID-0C#9'E"S;L/5BB4><TZ9W)6BH?Y+G8*"W5$'RGMB]V
M8$_J961KY0 Z("E_F^HDBM!6JZ!(QM&NPC;4MHKY%BU!;F\&#;W&L$AW>=CA
M]='#=H:\#QW(OEO+R.XO&8Q256DK\O^%E"(S(\+%]CJXN5+/)SN'RSC@!@./
M?BR^S;:69B$?D=Z'5D7CGA0I#)60&X+?BA=?^!0>K-J!/,<V;7.,.B&G&.U_
MR,WX?&S4\6]D)%&MJ]WJJ66D[_SD&"OG'_,^3]LGS_C[[AVTQ4:,D[(I"E08
M26S=F'*I]WUX@K1IZV\*6VYP_=#JS,$#EYGI;JD'GVSK0]G#F/46V&*@ ^].
M\1R[J\TJG/[ZR%M4%L(;/34\']2%8%W)&\U-THS6NORIQO+Y:,BWBV-V7\+-
M7K:JRC?<XSZ]RJN;1X K@4.0HP:B9'<;DNAK/))O5<#)L3]D<64*S-5;/\[R
MXI^$1S.?,,!QA>IBOG8^LNI-VDNB79V'M^'#4 '.OJVC?DPK:='=J(MT( Z^
M0YG01"=E_0J2O]\3R2QW5ERIY;NWSDHKJ@\RO;F'8H33NW3@V39#K3SSHV5$
M0D>2[YY675-C:([N2YR7C(OMD2=*_*$"#069OQ!7L$1+]&3$$LZZK3?:^GI=
M,C=*>,4N]^.'E&./>]O,7VBX.N_K2_%\+^:"$1W4#BY8PB@<KG1 29+JPM R
M(X;V7$%0I$(@M(LN]@1VJB@[:#4W#:(WZ$ .$I;"< X3],%I:\9R!S+(6)EE
M,@"V#6^D8P[R0LX;+%,1K\K^KWI6&":=*IH"FF$9:S?Q"%TXBK@]2@U'M/IT
MPV3"73X!/(^2Y&. 7^/R1:P G&&)K1#$XJ0FY/"0#DR'H,:3J9Z,V9B0V]N<
MO-='7QN^#R]KSXO"K[T,JONF,61+B3^&N1\BE1;^.V)\[22F YFX1VS^M8#@
MT"CNX<:[BF?O=,Y#2X'0M_&L+V, ^>P!II'Q;08A9_U,IKSU0?/I&1,_*DT8
MS%;Z9LZ:B0?_*:Q7+N,R%_\UM"0WU+)&*V/@^'<09A#P<?K@)V95L2HT[3KI
MT))4;OBH9G?!IVKQQ!#WFYM>GNZQVNQ_I/T/Q,F3"]AD"-$&D2Z:L3S@-QX4
M%52EN39==<XF:XC;NM;9.$CX\Q?SQPXYLL$G/.3NG;W'M(^B\B_A.O>3J<$+
MU@)^6EOMO,C[ 8\"E%->/.=8OZ1HU&"T>'2AS E\1@>": 9X1,S%^+I*JW,8
MZ?X?<845/C'(JT<E%Z"X0FQ-*FJ=0,281:9HWQJO<Y4\.5KZ[,3!YXIB!;^-
M6Z$=S><N&&;#_*.<B5;(=#VQRN7<C,KEP]!B6REQC?-ODPOX@[>9IF*@_2GS
MUJW<06G0VB=%0"-)@-@Y5H?/[]5LDGJ6D:W(.L*AL!BXD;B21]NO_FNQ'X,"
MW+_"IB#7;67[CACH(D9$T=+PTV1G-UH&'?!O"GHJ.9JZ>-$5F5PG?4THR/?B
MV0:-3:./HE<+U&R^'-Y!5ZM-;.[]) >0^N?[XMZKHM^M-#2(MCRLJ/07U7JP
MU)L:^W)C;N[2["46CR(> &Y!!SH,Q! []R\B:41&DG];R<!"N-F \ZC7S<WD
MI?NA[L_-UY0%I<DLMQB2+[WU(A[N=B(L?BVDLYYXE+[ Q_TV.@S]5//%-=-'
M7DW _7ZW%SBD$-0?^01Y%*79JV+F.K3K6.=X]2R/FM/PQI4OVP;$!O^X_N>S
M]T<B!MBLUY,HR@[@#X;O/40EUE\<&'L]S'EBQ:;XP1WS0TU^@3;O#=YW?YM+
MX)J@I,TRQ 0#JJ_H(XPA?,V($JH9D=;P=,<DI(8! >SD W[M&X=,%-PZM-\>
M9QCC"-?@RN-&Q&VD]<'^?C%O(LB1R>#]G0VTQ^B]V/$=AV_L X@SH" :ET<'
M&KI**)KAK9IT0,KB@]6\)2GHW4KF5/O#S Y/&5NOW-XBE9B:+*-RP%LV&#:I
MUL8WE3@/ZT3R./D?!B75JES4N=,PRUN&\LW9WLR273JM-T9H9=>Q3:,.L)=$
MN3<GM,\C4H-41=RDHD5]Y<THE6\<#'FZ<4MCZ"?6S_)*T<F(NQ:!._G_." =
M!KO3F+9BSB?J4# -;@@^ZY5\D(NQ/JSLY$AB_GQ? ^Z;@ET:'; GN64&ESG]
M>NO'#S,^!OI_\;5Z^<J(4*]7FS(2O$:=9SC\!5#*'UL+(VA/)3ZM7>M=,PP*
M*#^YGI.=8NKCW?A%2O6D:?Q+X1OQ&471R\R40%H1/DLMWH#3D?\U'7CB;8;;
MI0/IVA4'?QL1,]RUIU^-EE8//708I;T)5S.U8F^7E,E*%KBKV:MK8ON,B>5,
MS'V,U'V,"/5O!> -.K"XE MBG"$T93\ S$'C\I%;1@^Q565@4@1-"-773SZU
M1,THO+#F2P?>N*$O+S-OTP&0Z[QG2"3QQ):N@YLWC"#F>550V+G-PN [,R.7
MGB.JX?0;,'1@2CE*_PM)G?AM[A/>ZLJLFC!$BZ<!=/2<YNDR("LLZC?:'[)'
M^1!5D!U\3/Y3*C,G[CU,=7Q]HR&IJ,M6HIT966C_N/\;@JM%;3"D?V)\K[F.
MM/'-_1%;H3N>!V9K_7G*Q73N<NY@OX0=IRSTQ"YW&EDZ!NJ^#L5A*_*G'3[:
M[R6.O/"4BN%@.,CP249 ?QJE2@>6\2%0RMY?QT&-HR:E]MK(_J2F^;G'[\WP
MTFK7FO(ZO5Z<#_!J&W+)* O*?;BWV5246%1@/Y&^@&0U+?(H4B,VGCKWC6KX
M]@,=P%J%LJ]=@OPJ@!(#6U[M+0<%&6C/N#UZ\"@MJ_7XMK8L P<(WM)!S: F
MH7M>-;27< D?&&]EW>-*PS<E;V99/02#8CD>"+>SJ2_&[;,[9>/-")'$]/GZ
MTG>^$0E?W_DU2)8\C_%U^A4_)L[)]U/E%X:ZK><A8Q()?0*>6&Y1(P:'CULY
M0FO&^C;V_:7[[M364_Z)D4[I27^\M;ONPYQ-[B7*?8=)/I3ZI=#IQ/:BW-6E
MXW@:N,>68VXC=VKTC+6X7&K91C(8A?!!D4\<S1$[1*>U2(=O_>DC3%E2K.0L
MXC/:Y1]MX=/A19?D=WJ1[K :D)_68G"4W-2Y':ZETY==;ESNZMNO6H5@+3 (
MJ&IMR/P<S/IEPL%#FHS1D<L[',-BYCB^QGNG=\F(JE?/9N)YY&/T+<3",>/"
M3%2EV?#IO2Y:2G.0]&92'03B%NY\-</T5DO1I'*A^W/6.\67)]11H>SL#4&K
M["#G+TKH!#A2)/ ESB:!1_?&0'%#W7.]%H]QH< DAY93+P-IF^6$'50: E<+
MUR5;OX\Z/K8S'6UL.=ILNJW:4TNP:]N]\G(O1G3B9\?&]^^(P+?VW3"BD1K'
MZKA8B^Y(3M?&V*_S#J6I'P.\DCS2?]:T)BW^PUNF,Y.?*,Q$NQG>^QT4)^VE
M&Z3@4V4PCC5Y$D/:024:9L+9IC=^VDB8>^HZH\]HGR?;4ZXC6H6I)TD7_FDB
M(>*B;@3-GQZX>L-JB/#6=5.=USE?HLO0>C/->0A]I3F$$ARE0 XFB>[/ESV]
MOCIM7UTTQQGXKC" P#US;6_5N#>@&B!]4OBEYYXYUO)J %0DL\.J&]"?26$)
M>DU/;[^R;39\FVNKP7[3DV)S/$9;-L80%Q->S(<7PZ-:H=-R>P8DE@LRQ\9!
MV5DR['*SH&;]T'2G]WW/H,+.!F,A\6EFO=.H203YE#55^ <%#WY^%Z5$*GW?
M,'KY5F\T0CLR:_#/"2F/S8)&1#!IT7[9FT B"<TK(]BB;(.J_*=XWP=?2-Q<
M^)3<ZSKT)T<GS6@C3<<[*KO@J-H8^CD=()]B3PQDA*/I$[J%8M9-DL'1[[/6
MUH?UZPUFU9G['<;DMG#$.9I.,=_Z\%[IE[3-O4C2;H>RC,Y#TX>>RS=?WDKW
M \_^NP(/U'KN7F)]UO">!^F)8#29JOVA_1V'WCBICJ+!B'7S?MC=W7>(E8!1
M /%0AI4.9-ZXQ #;J@R8_9;?/@8^@> .,#@9)4+J;*XGS<PYA?M1UM5K@C)^
M.EYY2I:[/W._(-H?^^_+/ZH8-J-RXUKS\!_70=>V@>XRB$:]ALY"05@Q'RY]
MSV*\#CN)W/NBOH9?LC1Y^5WVJY+@8Q5J^1>NR WQI:(7-!=P#%WKFAA+!SSU
MS1S2_LB5^\WQUZ,_'[&J4<_D]N2\I6'F,KY=Q\@4P63;:&+[7G(+J2N5J6ZX
MZN/=/ZJ96>HBJU=QYB]=7O2=Y7-Y["9 ,0?GRA8:8O2XB<-M6:L"_>_(?N-&
M(^Y?+!,</\HF9?[\;^R]!U13W[8WNA$5$3" ]!84$!4101"I 94F(E@0J5$1
M$1!0$ 3$;(KT)A94E**(" @1Z0A$NJA(E= #H9= 0@F!)#MO<[YS[SGG?\]X
M[]WOGO?][WT#QUA#LYQ[9Z^YYIKS]\N>:R[''S'CS1PAHUC=("DXF&YM("OB
M24CZ.;]7#=4'.J6(^#EJQ;/*TNA])Q7+OY1=.I%9?:7FMG=-S2JJ[T;H^Y/O
MIC4?Q.[(EBQ^]H[MXA6V;95W@FG;ODJ&823@ "$)WIC6YB2WZM'"[KM)!(27
M9JH>-2D^;]B0D_#29 B%EZI:2EVA5V0 "#V.,64]9/T"0PAI6H&.>L3,ER\M
MJ>B>W'*/W<6^%'ED]FM3UK@]QYP1_(2/8ZCI-,M,O\6F49W6")DNV8.J=">O
M1*)L8 +MV2]4#,>DSK:-S!(WW U)HX9JR;9 JY$XG7</=!5>D4Q&@[.TU8AC
M:WKN].GF?=67X+"'@OJKQ6C6VY^040T=@Y=;KI:_G$_YF'=2=TJ70=D1T2(J
MO_IR2Y#.*K2'_(4%9$3!-&(A@@6,RUVJ@"&</\^,_SUTD2!C2J-?]JP1]-(
M-$Q6JF_=XA;P((^9%<,XTCY0(U%C%*GZWF>7"GNPSZ.Z,FF)R>A<(B(&B0C4
MNNH#WH.A586-_J'%4ZE[.[0["@YXO=G6>8S(!KC+I@*J;+1V^CZP1D@5W9M
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MGG0&(>8(Q,D84K4LU%(17_KN5KF[D7&G)_=MR7Z;F4:3TU[FT@7G0KSCL_)
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M&[=\U*'0P6S8O(H%N-O"1%EM5I5M&#H$#_LU:N4G*(N]TH8:V^W, NP:_%A
M#&I,'L'T1C8K]*@BUK;"= &OK"?^#U;%(,*^Z3)X72D!)>DC?J!:S$]EM)ZO
M"5OC2]I]6GG+D,$>\/&0PY9LW=05IN0Y/>0S%D ^O1#, OAU=P3REY,)]7';
MS3BL'EPZT-U]?CS6%?^PM%7 Z%TD9E[W:@OF _P5F!/@1D:88YXM-8IFZ8T,
MN:M$,A<TQ=QHJ#3P$.6M_?'2T>A1OF59H]8JMAE'DS=G[%8?M:I+BTE&Q^CN
M]Q,;-2YJ5WO_N,\T[/&IQSW&P?:5/;Q>.>9@'FB[;+'-5/SX(<6,XM*XO='*
M8<9=>['M5L'+$J"F#U$UJ7,O=Z$,H/,]N=   ,5!&*\.I^**T9'@+?_J/2[H
M78?G P]BI%,NN^KG'Q-'%H@PAK=E'%9_I OIS*Z7TMA&JM"UN%U%*3*VQ<>>
M4Z?>7K[\^&+D6X<1<TN=W/Z;Z0A^VAH958=&ZDK.L@!$I?'68\FDTM[QRGCI
M5=Y\O%W]<$9H^%2^YC7<4Z4^),2)H+2.H*/G%W#.]]$",X]B&GKO.(,?>E4_
M91SC4MUN%U(5A8H#G2Y:<% XWT&-2/+YN <9;6J#B"8;CV?[NAY3E?C<KETT
M6 .X/[UA=Y%E]!"KOZ+(1BAAI5IPM^OZPR$Y/..^_YM7,:8\EV;6*7#@_/D)
M^_2SG8G"%D=N$\[4  G\RCU8#\HPYT/T?*&&T3@I9\W<B)[!\X&H]^!U9HJ'
MW%'>ZXM8X9M+BF\EKSLP><"SY[84&+Z[$@8D!%Y(Z59UD0QYJZ!5<'QG#M?1
MW3T IWR;U2/:JU%"+9)3]%HWM,?/UOQ+@G3?X,P=@V-6X>((#8X/LWK('YX;
M--8PA0-J-,8M9^:N1$ [VEG OEX7&+\HLX!T.ZNE51C,':"1WC'<F.E[R/G!
M]X2R'#V)LS=)'NY.2Z1):_E;(B_X/VI(!*,[T0Q^%O#U@M]NZOW.97JN;XB+
M<VDY6^?5O<:RMV\;W5[[=50/^<[*-PG?O=AG7R?84#G[^?*-.*=H@V]:]A*"
M5YM.[, V>/9[0IP:Y(71H=R/M%G#^WGJ#E4J=D99TT(DMYUF7-KD@UPNYPRG
MT1Z7E&/9YE"WX,D>L6U,(YNA^@DUR0V-+\FC9RC]4P4M*B?E\JOR;!4:Q$EA
M):=BMUM<]V["JJG#RV/X55KI:HR/\3(A\I(#JK0]\]G>E/<4H7)-?T3"42_C
MG'>.!<?5F.WM>LAP\--&;6GT5\)6M0?J3=7[W*J,T*662ZK,:\*5085\,D>Y
M7DJ:<HS*:>%)4%I6WW32;6OK&L&JJDHW@7,GQ9K$]BY;&@#[18?9XE=\HP'&
MQIN[YPPD9;41'?+(SWN$&K.O-#=O_&><F^CM&@EK$DK62RJPE-2'4\0-)Z45
MI)$XR$9-9CF!1F2#7Z$W HWN^T]\[T0N^_MP9AJMD48E,K;/=E:!9@(6[!>O
M&H*MJC-_C0VXEP2: GK.C#(ZZIO[AL X2/8A1-KHG##)/V.FLG:Z<72KR/"K
MURKK/@RW]6MO@U#!.@H09R<\T3)M>6&I,2-H<9=+T5XEZY@O'_M.(#[$B_ 9
MC2E@FJ@;&:<O6WVXK9*=ZR^6^-;G!Y[#OE;JO +Y,"=@=349U7K29"8;L9%6
MW2='%?&QI+SZ3R;*E5TKIE]W7&E-5(W4C&4!*TOH-L\Y& EO7:&9T8^Z^+J\
MZ[>=M9IJ&Q1O.5NKD4]\&BJ;^+&SJ&/;KC&)(\WGFMB1;RY:;+6H$ZQTX^9[
M=TZZ+[$Q)S*C[6 00&47W,,6? G(W;)#1CKDB+YDC02?*>S6W*$^'-G</ )5
M;/^6,./?4:RE8!B.G.N_NOMG@_6]+[449<?7C[W,'32PDTCB H._E5I.L\Y3
MPWZ=8MSY,'WLG@D57>AFT_#.;"=.YOH^RYT7N8.[Q"#\_G0$41!W':0=**ER
M39;*',&*]_0:1TD\?T2+L+%^NG=NJ\K76/4MET>"6QY$T8^!-7*8P[0,=*<:
M+D[W("WXO6ZB#T\7[\!L0,O/\[SI*I^2)Y1+5Q\[']2?"J P;<_I25F2P1&/
M-')"3;<N7Z>GAR=I+JA?I_/HZ:8?I]9>#O;3O'](%=,XX'GJ.1YJ)E,"<^N2
M%>9^_-)&:2$X@B0\T(*^P@'&9(J=B.SQIO*3421'<C67^S7JK&G7<I70?;IH
MT=C=LE2*-']MW"&54Y,J!V-?,[6LGC(N;U05@P:&ME-4U\UK;VJ#'_S<N1M%
MARG;2SW>*03S<HH\ BS&KE8@&G&7P.$HY.(A6[!'G 7<5 0-8MH><"S"R[!S
M!'8 "=0RVDML?W_@K?9*6\_W7)DG[]W/GGD>)W$HO3+:^52?U\_CMQ;].=28
MAE #JH C&'1*V.9B<_:9NV1WEC-?O)GA?#L/(_KJJ;J!;PXW@'EIH>-R7RAH
ML%UO![#QYPI;VT[H CC\!OD)3Y*GH$>)M*ROT);R;E5]8J[IZ#WQ,\)S[0,O
MQ<XH%L9NFUQP',+E:NYG)WKVN(W@8JI%&7L+VK0=W^L^SSGE'M-??LWJ^EEQ
MN43$UN".ZMZWT8"AI8_3%='+@DXR>Y[&\AK=UI=..,WXQ2Q!#:>@-DXA_=!_
M&>?<X6/K=M1]ITO2T 73%[7"-X*)U\8^R#XRS_YEPE2!%U-4:S2!;-K:CQCQ
MK:*"(;=ID^?:Y^:_E@BM#Q6X[=:+-9:R<W -D[X[!MIEHZZC:0>R(DE/#'X'
MJH\^T&TI41C2)TJZR+'IG9F_S%?AO9I+]X/O^0SL?0YQ*E!LZVV@5T1DG-2&
M.0VXJ)]KW2IL,U3H(_YZF]-5M9]NI;LF1700HTQYAB;MW'N&-BT A_BXD.]Y
MR"!N/*H\)>6]\I -E]&U7_,-(7%?YV?.:N(_PNOV%P<)9FI;WU,.9^?-2!VA
MH8A(8=/<@>*6F?[IBOC,&R$ST[&_TOL'U$TXV;D6XE\PJIY3-3=<P4T%_XQI
M!RE*"RG8L#1Z LWGYBZ?5+>PY:KO8">'[X-U_"H['-9$T>S@\!-D441#WJ4.
M5-].<W&7)*7;A79,K-5O+.\U^YY^K5/OKEQA;SPZ&PV]90$W$+WW:G"%":$D
M5<0N?;XG<Q;ZWEJVLA>^4U12%LL._9J\TGS-7)+.A%TK1@TSA".;T3WC5P.R
M$@*/8OW"\0V:#UMO=_=9M@R62!W@J=_C,.2C_6WNN(,R^F%%PMS&@3F[:6"N
MF?-PBT)30/=SB4Y_E0&_"%OIQL=\.]@RG@(7*;^VPW07ZI^"E[O65P+9#->?
M0,R*2B4026GQ17F[YL?Y'ZQ3BU5-/*711_DJZE]L33T:KX5?=J?O@@&;=B4G
M_=#-BD!JN"G3@Q<K-_2&[?&"=[;SA3M'F_>P]5!2S3MP9^%;\S'?:A_-]<,.
M$^*T-=)MQ*LN6'3T<6E=_*9BDA@FPFTTYK;F3N.A U 71ICYW@<I.HO>-9^G
MC5)K"#4*;-'MV%M1EMAZ+*=2@7WU"Y[*9@!X8_@*RSZ1Y^-<[H9KD);S-#DM
M6 #WHSX#B9A?NK/9D@KO8 O?.)LYY .F21/?M!!V;Q6SI0-I37FZZF]KG/@P
M7)IW\F><??DM2NE:,G1;=\?& 50X-W?4J'K8/.,"N7JQLY;L^I!@7U[F8WK[
MMD2NS<'7D[%EDF[TZK=!VB@J2+N;QETM<=-!2(@X6#05+4*]U?^"Z!"TZPN8
M%K"Z<W_Z+B01&717*1(2[ Y4S.^S-7?/[?EQK=/,4Z+#]MW'S.2]HP<'0$Z.
M)RW@,4*Q.H,OVEZ%?H[B6?/@9/V%V<>5>0*:=U=++F^+C1;,FP@$?M[>0B7B
M/HCM9Z>YM\$@%DD[D!9R6.E64<(NOTF+S\*[2A;N$!5=<%YYBR2>K2^V[JKW
M&<V\5RT *\ /,XCC52L;IZS1PM[T$LSX'61U9?&!9<1$7,")A -WBA,DG*5H
M6-(E6&%IS(B-7QC[G.>(R1B</S&!;R:YGE_NYR-7_+U2T23#H]\S\P\['>>7
MK(R/F$7G?GO#9W'W7+3/_R*S5F,<#,&3U#NT!,J/D1NXK$#--F>\SZO(1,6\
MO2J((S'W'+(E</47'W1V+4^CL<L6'&0$O!)KU'##;R")U.E*C6%0<"K[*(/0
M&U"2[3@!",01A_IT>FI'-1JW*T=/65&WP:-)2;+HLZJWR'RJK+N?PK'3>"L+
MR%W&+CA$ ]!!74GX=@=!-Z24N:<SQ;+RGKNC!I</-<73NMPB AAWVH_82FF2
M=%M%4D_!=S)C'*#QEU3+=$FYN]DD'>]S>^"*)UT;NEP[\FC0Y !/JI> =VL>
MYMLY/=&*2XE94]V)UB[=)=1'!F*&!?VUC][+6(2.ZW'HVUR$R<C/!(:@%E69
M^497G6%5A<=(^.T==>ATPL\=?DS<]X*=V^;%2\)8R:/  D93ZK/U)[#[F:/I
MC"X\!+F?&U"Z8_8E?" 529U\+C]FQ?.C"7DFEH)^5V3!T8PK3IAK>HOI2.6&
MZG_[B)-TW36'[GUV$TJ4]7]UY]R+L;C@YN$0\TQ0&2D,#K_$%>/K4+SVK>0;
MHTT5@R&F"C6\^.(/5V]]N\P3V2D]/"HR34+WF@FP,=0=H 88UK>*$5R2?:M&
M6(!$C\O-6JZ7>RF[BM1/G'1ZMT6 VU]B=Z?@>AV=;Z.JTZU 4:Q-H#$MR_NC
M/2W5[XW;*\6; S.< MW][^/J[+]CP&.&8](:%EYWT.UA FP);VZ6).]ZZ9S9
M:YA8X^SFZ29R:L<QV\8">:ZO:Q?OK"?36 "UA!D-24!=#N)BOE7NVU_=<Q%H
MD?P=]]3-^XY"DG3SH1L:(HSZZX7(T_1K\+PJZ6Z<1R>#NND9+O9[F,;N2209
MMC@8E2;_.-\U%W5H+$@[]/!V'<3([%+F<\;N56@GVOO^MCSJ2PK?K>L/"I4I
MQZKU$JJM;BAW2HU&0TL?TA'CJ(VLL) CLY@]W:HX 8;[%XIB?C8WM725CS"
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MR+8ZG_?LBOXWM;55NB%8HP'MPK0?N,,LYA8[A.<K<K^3==E (/WS<#7-1FC
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M-K=NMY%+7H$X=<A::/*W[/PY%!_M3:]U316_[K&>T'=FSZ^";0-'4414%#8
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M>1MN*>8OW;(Z_6LMM(@%Q);/@TVA(VN^] L,WDH:#T7(D1STS$E7U*VE)3G
MZ:/!XS-;\77I+;QSNNL:;&N'#D3,LR^JF_\O%)F_]M?^VG]Z"PEN1F\IXG@(
MOVZ3-Z'GI4N?O 8;=[. +B>:-PMP+8@AK'_SU4<N(/_=S$A ]K^;/^E#?,<S
M!,JA<X%SU4S_>!9@&G06XO2B3\/P5@5V)87!E.:M*KBPMPC=S/,/"(V(L,H'
MS5!DTYG1B=G--G]DO&[X+/-DVQV[K*O9T\-4-=O#ME.3VD<0GS\\FG]^'8O^
M7'P;9<@HINO 'ZW.Q@)V%[?^8$>-\7R!3R2?6=%'OB9C.PGE>7PF_&&J?1>E
MI:\:LX"6'%Y2D2/U-//%$P'?: >N\\<,$LDFS$WT63LB;ED,)O^78XCXMG"[
MENH3Z4:^KQ=[W:2/I)V6#7V(\-R0S&T L$^=H19T6?9+]<DK#$GRI\%W4A_)
M'ZW"0&31Y[!E2B#$%43>WS$>WEX=I2LRN\+C9,9G^CU.;J?P_;4 \: ?+QE>
M\RR #6SVT4-,S3@Z8C(O-4J[QZFD7N15,^94.WM[LI6\BW"MD9L11$9U\NPX
M!397]_A[]!L=G%(Z1SS+9GU:DO<4YV< E,95V3'X73O!G8]7VK'"=1\HR@\&
M/G:TFE>:"*9T8#W%]G6<]CY97A/!IO>51BC^.?XX)E0SNL#]U(M/:EUB1B=N
M^;D&)*:F1W)^)PPZMF$E!\/,\VZ*&N=[\;0W,/.H:5S22:?Y,=W'!Q9'M77Y
MDKQH+7 WUT!=5!; I:?HM#3-_XZ.BAYO<>PILSYZU$<W/KJC^1UW14TOZBS
M./\JZ=$?<?;-)/"!K>O/-Y>A")@#%XF*I/AXY%^2,#=NXFV+.'+BOU+@@B,G
MR6\^A0N80?J#6?_@H;#CQ/^(.QY>$$_>Y)N1N*-X'"7EZ2"2XO8JU:38N E[
M?3>0]%1^TC=?[U^. '@#)!L2MHXG(B "3'J,1)E%E!^,N-IJIA_TBB! (,:
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MJN&T&&%6$ N@#2H ^)$9FBPO(\/;#FHYCML^.DR0*M[8A+C88=WJ^&?B-;$
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M:9KKW;!&@40/%5;IJ2F=WKG&4U]7<^5#[QA]8P&-)QR M&DRLWHXZLJ^Q?$
M<;VKWL;C(@:6;VR>O),?%*'BD[UA:E* 9'^KZ9\7<RFE3O[Y^(/32L4/OI#V
M3EZ__V(450I@KX:=AD=^%^;:M%B#B1$MIM"IM_)UTH#"-Z#*3T:DBEV";+6
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MQGI3.7(+[U/[C(O] H9JF%"G1XZ@&"R0O=.3EMN*7SGPA[3>R'C"LO[OQO#
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M*74+FR&Y#XGD-.)VO^W%(40A-ZETW;BBO8=J)Q=^?I$(8AGP S3,$+*%$9.
MXW/?]?[MX:ZC3$.3<>MG3\O(]SK:.L=]7[UZ-9@'#>\*_H,OQC8;[*E<91D=
M\&N;L64$L(BIP;F-FM%54HTH9/,$>T?G>'OG7L%/H_MMZP5*?!RDMAYC*PM,
MFK'#8?SJ[@E'=TY-&L<=T=Q)FB>+[%:\P0&(BLM=V-5(S(7_U)B.L)W^&[9:
MB&L<(!"<F_<<)Y)?H58"B4+HA7=XADWN!01C6Z !9,)&0Q6$51UZ$@QW^1P@
M61[^9_ /G%&EA%$0 7XCYL+K$M!MHAB:7 JNG"H%&6P,6[*$BW6G@P.@Q.$C
M@(ZTAY*H5#23 TR=?;V-B ')3]$K5TLQ3-X1<.ZK'2OB7P:/A*/+"__[SG*#
M:YHY8&M\.?MNS-; %- (17% T=>ZB8LP73$.V@'0F1OAO_Y(EMT0\_[[IDQZ
MX46FLW0KLY^="-9+03SN"B)T@X.5_FZY5X[]"#C49<BGW)YB$:+W_<B+)!N#
M\USU=:W'U>@T2A,.C*O6P(Z HNX7\$SWD&T<P Z"3<D-)+]F%"0X?W<?]Y*(
MNXVAH&";V_*<OD$7& PP3[7L8A,?5FL4!D9/I!F$*;18MLF'C^3%O4Y&?H\K
MQZG1M\CF%6X(VD//I5I>_QEJ4'C=;((RW4*36K7[W7/_DJZ]]NL),VK6.OLA
MU%LNY$[AGBQM%]N%XG.L2AK<8XYN(79^G?0FZ'Z>9%_Z<]MIR=<GLU4U]C&:
M,<2& >W@^&XJ]V??H@79MD[JA_%H1)\>/HDNQQQ<L&&)R]):J& C\O'3N6/O
M";X![_]<NN9^]V .:#0R\SL.M<?AA83]C(.7?J=6!\YX\$VH8K]W"?X)'GFK
M)'52.Y!XXIJNG/?EO..'0'2K83>"<8GN>N589TS.'U6><7>:#?J@%I3D)3=,
M1BZSU:@< .+?H.2>H>8V9@@Y6IJG>2'/5%78//DE\>)AN;.V]I(J&ZM2/$*\
M9,Q/DC\U,1AU^\8IL,$HFSMKEGF0I$I5'(0CJ)P4 Z?J P7]RLRW-I\IS6-)
MRW^LLH@!D5V=8?NX6>R)A_;T\A,/_3"B\\=QNS(K.  ZW8,#G$(.?87,RR.(
MB[:P0%U+56/1_O:Z)OBY(!0#T\_6<X"*TAHP6_5?QG^LI<=7V^<&:C:^+"-^
M.*L8>>Y398WK#5X!K*RYA>#Q.OY@*J9U@[73'N*WG[1Z!.WMKY:!1:\-BI+X
MP,=3YV_F_0$;K3'[3^4NUL6RT;(_VE;-%'WZ!M>1S.L=RAA$M8.STSMZ@ U"
MOK[,!S.;2Y5.F;(2$;L'EI7BK-C@>3=NL!$O ^T.]&RN<HW-IF(?NU3T8ILW
MDC0?Z5A'6/.VE5T)23,[]559^U#7T34(SMGG'*!$]RWU.UDJRO\7SFW4]JOI
MX8_H%W6EY3ZK$J;ZZL/MS$&*C0_TWFH#S",LRD*\B4?PE'?5JI*KOV,#N$+
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M,D07S1%5,_H&9?4D5:)P^O"O\2&-'PN\CQ15$?$/!6\D-&X.]FR)GZ=[<SB
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M/Y1>0P":_$H&SM#"GR<6Y7 VCS$DV,B1-L7_F4#@&SJC&R%/;9Q"1N,$ @_
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M(]HZ15,@N?AT9\%+@M3E"\TPFES.''EA=?/#?>E&I@"7@!NJBPA)56G2L)C
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M=&P_*B_VNF!?\-4=3D?I&9&.^V<4YA.66;K#+B$Y"?3KV)NA '(")\A_<>1
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M"+DX?F,$O3K+L^&RIBL>->;_8O56Z/8Z_(LA* D2769^\WJBR=H.3.#7IT,
M?8E5$V\SQJ#[L0CU:#LC?4HL1^*A&H?"(*\ZV7",*FY%:*,=&%RSH1B&+& O
ME!)+&=P76?*D)X()W*3 M@S/82U@"#@.T8ZN!CN\PSI=Y$:WJ(;F'CMB#H8Q
MWS'"N)C.^][7O<FK',F]1IN8*0.2L;00%61,NXC1T\+9PMZ:O'4T(5P_G"E<
MW[!Q4&?U\G[9OERW&Y U*@$K![N)IAP+7FVB7@]WKQI1:=:?[4/']&(L;Y<L
M'5";?+;R\&UJU<IPU*-C5O9913;PQUAA(]EPE@B,RD -;2JF0.+L.K+&Q]+
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MT/2_+."OM3:*!MEEN?F(UM6+'8XX>\"@,&BY7LH4M8?!4I#$ZWTI43 QS4'
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MN*(,$ 64]3.UXS7V:0CERO ZBRO6]][.1!C9= B@DT*45AWG9@Z$:U)D"4Q
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ME]=^;TO,T\9Q6>6L&;],NI4>A<2-]Y,>X\RPL%#DT4$UDU7 #E6?5CL2W+:
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M8?G7Z0%\0_6/>#;'-2K.3W%_OB/%KXT>A//Y4N<\ @&_))&O]UBU';R=/7E
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M],IBY&)-[&10DPH:X_V@*NY8+Z-O1%8\VGB67%"3^N(B2IP!.R5P6XSZU(7
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M46Y%*0O>,=)-ZO9^*]#S<-B3&)BY-=S=O*4FK,]GDNZ.I;[D_95^&K>;4ZI
MV]+>-#5^G)S1(@8//&Y/C^^0YM\85L>7UD[(-C]:8Y.IJ2Z$F).&U*ZI@_ V
M=)2:NS-9=F7B4$53KZ^?DYS_P<[L]C=_C^<??$UQ@Y0228.5)LDL8JRE._A>
M6"J$3KPY*:U!3,"^L"5W6Y^!D!.H,NEWZ:@866@$ %:5&>73'>_*#M_EX7,O
MZ\@L9?^JCZ+>A U.DKCDEU-ROKY*#;Q&M*J=C"ZQX.]LT#JO+'W\,61,\-/V
MYA#U,3U>B9#'U3$8&GBY.6Y);V*&+IM_[T+X#?JC=5+244&@(**-W]_7DR7L
MV%=B4O?-:^<RC,AMU;4.9]85T8.!P.6A__8>K?\?%YU- 5"" I/I4/&+A!M(
MTD==):#=\ RT(6],#G+\']F2?HH>"J#?+\C_OWU'_U>M#?__7I[9M#CCP6"2
MMGV%9<\PGY<!CW;/M8>O24UG(!;PZB3^+I$Z<$AND0L0M##3#D2J!A58_C1T
M^"BW(NI_I8'V_0'1?A/662JU'/\&<8,L31E&8.!P8T1[O.#FC.S\]JS#3'8)
M#8?+IZ\^]]CB^]XPT-V:#"%06+*FNGL@!TXN XVY/&LY4G%Y[?<ZV:HDMCS,
MJ.O\3BL@._*_%F&SF742O/\03)1]/?'OUN9J@OK+>R?,5F>@R;=GH-RH8]H-
MU9 3TXC_E\?Y4U#U_Z&P_N]<G(/P5.!>TAFH'E'N(?L?7H!\(L*@JU<A)/J3
M*/PJ,1K8.@,)VXC\%P[G!M3%_]W&U_^Q.78*#D8**3P#5>B3TAO3_Y.Y>2Z+
MZM].=. 5\B10@S%&H_Y#)^;_=I/A_W2AE5TIB76+K']8L?#OQN9BU%G_R<)Q
MW_7?W1US6>AQ]J10"N6LL#VYZD<71!EV!O1T3;S[OS0Y!TW]1U,NY$H\P#1+
M^9JN#-#5#R/??0";^O-?V#:>\@'GAXG7"9KX+'(8R6A9Q4BW.L-XK*84_KFI
MD='DCEG-IS?>UT'/1UL4D&U9+MMH%(EC%)\[+CHJ/'$'RF0&[_#9Y,P?FMV:
M,+#,%7<5FODN_*J5UCTQ](TOXNG?[L"N)W)*>T26=LKXMF2'$6UF9Z!GUA!\
M#,%'.NJ.RF6Y"1*DT'J+ >]5V3HRYY,4)M,+,OV(7N$)Z"ZR>D-U%+]#3WQ!
ML,1_(ZCG$BKZUL2=+7"<HB.[4E1C7/UUL6D+7*K/#+W=-)'/8;G&@,_BMVZ,
M$8X#ST;8<UK6YYX3D-$+-KNSXO3V3B$G47TN)8WUU^>;;_IN7P+[ GA59I+!
M,"!.X&H'KH_L)JYN6>AF'>[$A-+7Q]SEUGCMIL]O._).E>DOJ))H0E;L6W_T
MK%99%F(QX45?B\7XOUAV0)@5%.[&BRS*DDK/0&W"+;+6_F+DBNIXZD7]J]D)
MEYM+\S_T/7Z"^+*MS=HK*K:<@3U$HYK D=D"M3A8<)-^KE77=\VO&^FQ0;2<
MOZ7*LT6J!2/H8]QAK6!,,G8 ]4_\+/NBT5"*I4(!,;!L1+M%667^J&!::!67
MIG>7_R(M".$-Y6P1V5P0((B@]?EJ5F]JLH3_&<MU%[-NU4OXPR>4[3YZR@MP
M'0GP&9 ;4*X"&KJJB-J'=18NGW]K9H=)>EIFA(-6@_8[? ;!L8'=P.QB;45.
M/M )9?(H=7ZN?@:*"Q1H;N[+;_=[='R:UMKN\ELR%5DTTO+W,#-#X* 1C*11
M1^@NF1E0J2TJT&:?FZ-/TXG<?<%]>_4%3]OV)D4!? ^DA5^>; 5?4!;)N\>H
M?C4UXK#?'!_S4DLR@?OP"+R>B[\1Q9W";?L>Q,1[0XP:1,M-+5"Y:3A$+?HL
M<E?O7.DMJ)K^(7(%!C"U$0U@\/@.50XL5VA-GG!M?>.HK*62=M.:;95ATHO(
M,L;,:GL:+SI4L?XL]<KO+**2/_<D<,61Z\E,9U'IPQ<!GV@Q:PBT G"1=&J*
MO;Y,9&$%IA"U438:HXZ-=$@<<^]U![LTVYKT7P>\_L.?=T7"9NY"2E:I3__V
MD&$!>DQ4!;'T$:HJBYLX]:_;OG[3?2-=[.O1]X0D&/>Z7'[++(JD QD)]V]\
MQEZBI9YB-AT$5]&WQ2HM:?X,8%H&TN@3G MB/M^F>=[((+)ZSD]S>_,0_/#?
MV :,^:]O.'0US EZM%*.V#PW.3>.'21=H@:T3"BBT$9Q$O@@"4* 8/1G(+MY
M/WP1.>\(%N%+AW3.M]G.EIS +#<V3/_I,C6"[\_V</>'$#R04[,(@ES&2BBN
M6XQ0LKR$# G!Z\-.MV$W*'>21*V>>"P2!647R<J2B$ +5Y+//6#OZ X5Z3LP
MF(-U=9Y\=Y2A-!C%NQY!LK1ENIX^%9"QSKB$JT8]W]S&P(866\'3B&7H#B:W
M(AF[]Q/ORYPJA^LN4:F8L^H+TSNHN>3YL+MPYE0N"D3Z10E=H6/J#&R'Z'[U
M(X:ZI[',I7_LB^5L"?@^]^2^,T6@?<#&QOT@.KSRQ<RVX>N5K<O?O;!C%YB9
M>Y%,G]07/X+Z!B.((8(&XU1I'?$Z?#VORV1+?[+R!W%&]2?%M?<--B/8*6K4
M-<H$Q8!R"1 AOER=WJ@-E)KL'(NYG[Q_U',:?D-17-#,@/Y4T@%;WIQ_ZQKC
MYZ5GJ\9]Z!8P'*F#RPF[$\_JP,7TUJYX]OS2A]N5+R"@K+)V:/Q1Q7#:$YU;
M5&JBB6J@B[[IH+\=.X*''"YS+=(>]?_X=%D;TZ0B?G_]*W__:,C>"5D<FP1<
MV)NH 1,<H!Q3Y+R6 7"XJM;)S[79I_3\IU0S*%/$$H575(/#E2%+/?Z73D,1
MSKB+T;)-;\4U=F"O,3%T/404\)4  2X<$VY]M?1_,@8(ZSA=,7-LX7L1[L8O
MSF8?.-]J]*M_Z'A#Z1W"*N?2>550,Z0DF#VP<.&^$^G GQ+-ZV(10-] !!#E
M> 9ZH!_E5-?J&TQU_$_LV\-PRM-/( \Z<.1?)@BLH6BV^W<%0'Q:B2,HS"Q.
M7Y02'V%_\3-0@C1ES7\+B <2U6UB;8RP]D^KQOW/?[8R[Q&-G#(K?J;YQ.&R
M+\<9:&NMV5+H4&B(/ICD1<YM8L/R_:P+A.!LBHK:.&N:QWI=W_KPLS_&X_98
MN[C_9/WF5.N54#N'RD#&Y6"M_5 "\UO9?(1;2_I<6??%HTOY_+*NS>QCE6N_
M-S<D0J_>95?<-52,,4VDY"H<$(/7/9FPQ2K"K"T<3(!K=>$B#MXJ/^K3 >YI
M6-_UCT+/2OY1C+<X%0$8DHGL)+D)0$"^$\QN3D;9?)^8[+7L$6X.&_'9>_G/
M&<C!>TZ[3J]XNG<O\UW@ZRTP]HD^04P%LW.L&!B"LQ'7MFH24U8I92V&<ZN<
M@O4G4*H(Q\$9<7PNH?97#E<YR=:YL->30]D7R/!^&7SO!G]EYI)@)K\7=?H9
M2"L:&F%#\ZTF:@9*3S#K9L0P ^ 1]Z"<)MV\HR/DGQ" :0 2<H<L8C!\F"6C
M_FV,PRBH=O,T(*R$:?VG@MRP"-4'/]N3(7H*4VY#?3H#A=FM4,\M/,@AD@40
M#\%L)+8B?S5L.&HY@R#RR;%1%\AA2^432=R=7[[H=NN=&<>.^,GB&2@$ 5U-
MA_<#J.=GH.'AR<-O^U?<=B-9[N]P0=,N49&4 F=RL(]9XJ!5X'C9OSY##*Y2
M+W_4YAB,.7_&DA,:&R[X06=_?IW-^I/\\9SB;O>W8NC+,Q!!'(KA(RKHI< $
M[R $MBVL,S0%FKC2/<G?RY[L2'VU?/,GY?[;W^>W)U#U?,W26N,&Y4!6X=:3
MA'#+'SJ6'2+<;1R:0B+\[C,H980CD@"1;UV<86D_S9R92.(,SZ,M&WQUIUQU
M9MS"7K*=S^O="KN<@D)K+@N4_ &Q5+I(AW*,+#.<4$*<MY[ORK=T//Y\/B29
MVS )X_QK48R[5YGE$?GQB]$:LNP#[CT)Z7],:;GON'6MW.AK%PJ^>(\'3"$W
M"J@9S>7L&B);X+C.,OB<(V]6>6QX97XWOW. )_M.P+.']QXF3]+"E<$X@"*>
M*!DBZ"0H1Q!?&GA@:2<#":^.Z3%+["P?=9>Y:97H([IZFGU(1:"FJ%DE"A#H
MPML[;.0F517\%1KJZEJR3XZB_9S$#/TZ_>[RPL>N/.]G;[VX>MR#I"!@$*I.
M'Y-&%-O&.BRR8IH0?LL7>+WKTH</HPG.JU$C,*G;8(79/\*,:LJ"XL35=":F
MU5MS#QQ\>+AO#?#+,]S;>=)>P3*:?N*W@MSQP_JM+,3Z?($7W1_=66ZZ_UVG
M<-.$];&JQN.(]T+/M.[^7AY4>45]0(W_ZURSX"]"6/>Q6Q:PO-^ [2IW%C7A
MDO>=[Y\]7\$OD@;*%%M^L4Y#'LU.)J8MHSA>+8B/"HT?JMP?-:RLYXE#_WZ1
M??G$^)OH_:>9-Q4&'\#:P"1."/[Z"/2?> &X4P?B0H6GCMA1^2._:JAC]MSM
MKM2>(C:]=L Z-2X$_ B(.0,M18%YE*UQ3'@'[ M5X:P*[=BY 8D1_>M7?B^&
M)ZI9[2O5P<:H*5J#H""^NWD&PE,4'^:K:1ZBC1ZU:A !M#J=@?+[;?S^9_UR
M]?XGW6Z=R%0NT)41Q.EQZAE(O0:1XTJZ=!^X ,:W?1N7CE9WL%OI+RERNQ5Z
M.?6&%H2Z1$ 7A+"'?F,A94R&(N9<R:+5R'JG@U'@?-6*)!/E&:KL0V0O\&[:
MUR6#G_>E*%15J7!F\+-%D<_;/^3Q-A8L:]-<T\IE644 %[G/0!^X0A$[-\]
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M,MC9!M_4<S=;Q-KD1-E(U [OD;CL_=XZ%$HA64UK&K(7C-;FVM@,_Q%[E&S
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M$^*2OT^.'O/*JZNMK4UTKGG&B7QUY%9=W,7<VQ+,)9Z?@36@)1LZ%T/GC#\
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M$1TXH?X"IW7@NYL_WLC[NGS1NXQIT,+,R^T9?,WHJ6EX5YCF<X&!)V6^50?
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M[OV %*%;G1O]=41(1C]//(%9U3;7WDJ@?A]X&M$M\SXBV0\1 R<9^_P>:3\
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M2X&_ED6R%@T2>CJ/55Q,3IW*&L^&3G@+F50,^:]Z<;)9<R*S7[!ZM3!)WY(
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MXXM-@/?AF6JK_TVS_F]V8O9JB67H[@2<P0%090E)^W^XB-TFT"4/@)>=@[1
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M1$@3.CL*:<- C_$1 GJ=/?=T)%G)D#XVDON"<*<[-<_XA%.[2OOY^:]H:#!
M-Z2SH%O;)G9:#P"69?J19E!;([9L/5/.M\C<3S@EUC#""%Z+%S^_7(4M15]!
MDRR@DQJ=B!I<]/8LOU<S:Q/IN66?>'J*@\ZCRDZY+J9+&6-H1>$L$[7%2#I;
MP.'&K)!9T ' T43=_O"()2@S<*_35PJ^R34X([**^(@Y2F<*U0!Y<[ QS1++
ML'$[IT[QDWQ.<)DK#R%]<5*^$9.;V=!6)5!1:<V+J!2KQUY)QK7WPRS)IRM.
M5_LHR5<7\?Y5./'LSXRSZMLKGL?//NUY*G-V#B<!OP\'SV9TX'[S=*&CL[3
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MTJDL021)<A!A!<-%/1<L=.#(:QKF5=S\-U0I.UNG((2>2NRV.G+3::&&[0U
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MKIN!,F,J!LJ(RV]TE:6*$7B=V*2HKR>0UX]?%.MYX6FS.+=RIPT:SE\Y3=8
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M=?4+2@2^+_%8WRC\TIN&AKIH>X]1R0C1/3GO"]Q>7-S%GQN6$\6A$(I8& T
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MJH:EJ++2IN"F9*W2=53('^.&+]7.GW3R!GX_3_Y80AI",X,=)$VR/+A6V%M
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MPX_0(-35XU+B3B"L.ZK6WFHVI;C&\:+X&Y6=5H<)JY[;3PU1T0'KUO :.%F
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MLHN:,@+3VH+N;%AD_QG]V, $>Q&N)T"\06F $3_7U& J@;A1.1\\&=S^])0
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M"$17K,\BZ"A\@G\C1<9?L9SL3D T)!HW?"W9YHY]FU?BWUXQ ^R=QU)EYQ>
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M .(M;MXNCV0 ,^(7:$_ F7Z66>Q?)-!JBZE-*AB["=L>*OU[J,7_>]S6C68
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MM*]KJ<HS #B"ZO"_'W!>X<SS\^$.S6K&-[(%8\XGFDL!?+[OT]B9<1P$)=R
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M?,G)N*1.1??7HUNV;^(BO7C$-H079%B7/LNP'^8;LU]#_D239ID5( ?>"[+
MU1TG6 F>I'<'P[.(#RZ9U7UC]RY^]NK\]0:6AA@/)M%DYB!GD6@8P0K"ZJ]"
M?E!F12_J(AKF3[W7?IBK5#LBEU!Y^*'4]T:R!^QE[<[>UAMT#';T GZR*7K=
MK:3UD8WAV75$L?W,L<3NV-:T?A;:D FL57KI S/KK1 #EDL_SL-*KN<D%BU<
M.)#((I?N\**JZO7=EV<2I4[N*Y*YR/HR30$V8-00&YDF1D9.!4";:L4K#YHG
M)3ZS8&G,%!NO*P:>"82TL4EXSVM(9&D?.:+Y\(CIOC@]@/>&$1#@O!9.:F1>
MTDOJ(5KBD7Y%)/^BW!Z4LVB"GL2A@^[7=!2^E6,//VW#_P#@L3VP9O9F-_+I
M(;S!%S)R";K[ZMC\S?&KB5WNV>-?SZS]%._!%*VA_3VPD5,[$U)W=].^5:M-
MN]L3#\E-]4XF0TI*K#SGFBYKS>[O<F+?FYW+.A@(K?"573U(XF=>P0>J(BWG
MT9>G?M%WRR,+/L4,-\MJ\V_E_."NP_P4C?AZR8]8AQRZ]3!F6C'QN(7NH1L?
M]^OH+:B_8:&Z[>R9@IKY!&, 0[1P>B(:ELM,43J\6U)]X%!^++T#E@CY#_0D
M0:*@A%LK6T?@IQC UT,,H,<-%@DC:+IMG:H]R3QB"MT^[DO+W]G*&VSC(MK3
M KOH4;[4&\P#7&";'=&"%LQ\<#WGNME)*3N#,@C@D#!J?7?NYVIIER_7+D4]
MA;ZY.[3:0;D/UILS $=8,+;$/)RPUGAP^X&Z2#71>?["Y<?US<FC8VV;+^TT
MQT56]9A\96("ZX(V=9'EY(/@XE3E.Y<8@&6<4:0[AWJ/T.>/I"T'8^V2H\5K
M9UX]I2>0&W%,8H/A*VAYOA/\>@A]RA7L Q_%CJ64 '2[5/X'6%5,^!J;,?NF
MBS8H"2MBIMWLILJ6FH\.L)(#.8E#OED_\E_JNW&\B,H+XPMLN)5Y\D+:<QZ:
M!G+!:RJV"<7K;TP82(I057MR^M%R/MZ.YY!HRHLKF<O\E^RWUN=8?M![L*M:
M="EPN.H"/;8<.5E5!UGU3XZE^<_#MCUJD"NZ_WO7%JN-Z. I?RC%T=FJ($LF
MK'?@BZO4$U/X,O?E;<LSMX)>18)B]KV!4!0B&+MJI"K' .Z*RS( ?4GD+>0O
M+QR:>L"Z'L%9*S(/AY"U<V^/D<N&&@</$#Z$X/EH15S:^NS+_%I!A]$%N^'Z
MS(SH![H.;[R]+5?I@'4T4L)>K[UF';+V/D5C#WL EJG"UICU&$IBZMW@7F\W
MG-L+101 -1@\[]U"L55TR!54\=J+/:Y]6=W+)!AZ6G9;I$<I1<W/L&3@U&U]
M%Q_.+JY=/'/#KW@TT<IJRNF\KU$NB!%S"*9J*I# /V$]WY?_?9/+\S&+\6K^
MMYMKLB_S-'BO4O-I+\')B.WPI1_$2]CI/:4XN0LPOSOW%XW+8Q1?ZHO='(\8
M/#:ZR]8I]/:L*H_L^@IIFXS'&8TP:7>>F!24%29GW5EMV!=\<W^SZWRWQ.H%
MIYV-9H.]P'H3T)$7<VXZWML"/93\J/(N48B44C9^Z\+(),KYJ5A+]9)$#=,E
MN_0M#3;TBIK6W4IR0%^S+P4EF9(%MB4BSP#&RQE ]S1R\5.+?=K@"5BB'1O"
MGY7FO'7@?W71Y4"NE$O/29P$*"GTO3LKW4^LT:M=H.MV^:#F #46K%=E6HS8
M4%BQ='V^.>R@D]&>W/.Q+J<18G("!SSC=FE>-A!X[@K@M_PIQ$TZ5Q?E&C*J
M] KYI"$Z3"OVJ^JVRVBAD=):8N1(/WW%<9(!7 / 1T\MB!""+)UK@W)EF)QM
M!)5PG2HB#"=$;R8YJI[S4;^//RE=?HV:$N.]P"M$,X=W0,L.-KIA[!M\GY5/
MB9NY_OI6;/TN4?\>[YK+PN?1H*UP-J]TWOP-4>4-+M&\BX)GQZR[V-784P1T
MX]?'D^EN4 <4^8A-+A&!X_37[?-WRYHWE_]RV\G+UP_-X3AXM]'6M=RV15-9
MK;:4)FGSO7ODSIB.SER^_3M>DXHC7C?76X6H.?!!*,$<A@&GY/'L65150LUR
MDD2(5\'8\-6X/)^T*_JR,FPZ.D^" Z$?P!$+DG<(R8-LET[F5'EQ&J$;FG&N
M3E!R.4SX&XNI^\^T0$_D,V+I>'-LN)NKRP.'3R^Y"VITVS?6D$OY1(]F\( Z
MU[RZ(O'4:_U\F^$[1I)7U+5.F;M??<O&<Z$")T1V9[*Q/ T%?604+'$2<9GL
MP9WG[?+E9^)]4M)9U-M<OMO"DZ] T<WU=-[O"&;]+#?"&WR CYE+[.VM/>5,
M2CL(OB!A/.856C/&OV N'-^ED/H\J,7/@O2!('^KW[,K?%N-GOMDT^L)!J,:
MK_=DN<M9H%#]9X02_?[$&7(/D;<9*XRO/;[H%(5SV""7OABX_]IX0>:0Z:,'
M%BT<K1@C?XLE9"!J,A]",(GFU2CL\X>ZW7\Z;+XW0_Z>K_5]G<)<*:O7J8%>
M]:HXL6[V33=M.),$ZA5 )P: N4D*[RG-ZXHV&46KI7YW=)NI5X5)JMZ=_1%Q
MKE[MVVPORLY3[6J??F%EO[Q=C*B?BD^!G;VGT7A#M.1D(:N*Z72@? \L%%J&
MHAZ 3(%UL_W^YR9I+BG-A;K2(YD2ICTKH<_T$?(^#,"J;9L("ZX]L>/9X6,W
M%C;SI\S"7 Y_-XP''TY4.#P^HV]PN<:C>WO5@952EX$*8P#AJ!WQWXY9'JF5
MU.?.?Q$'+4$-G\YH\D._"TL<V?/,7GR/\_816@2S*N>BV)F)8%'TSEENQQGB
M\7NE%9$Z86?<GN2=S"C<IX,;]EN+!&AN&1G!#LN2EK9'7E>P[=>DZNY!<8"3
M7\!R9,O*R GYV(;1%.%](D[CTIB$E,U/$Q<O-EP0?8MH7-2 5*U;K+D39NE<
M$/</_@>CFK '-U(\B:Z%4U->&5D1.MPY/O6/%W2H0C&NNV:S)1 )$#[F-=6
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M01QAT8#V@J*Z^()QE="X6Z,0L^"O=[AOS2/@4*6P(;59\^73ZS.3.V\+91J
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MVZ!:@@T\"]1F Z2WEBSU@%/P.3%<$ASVBMD&UM?AYA#A4QR(7HL]!FSG@+
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M.A2MB;@^<4B@&:S -XO2\+'KA=>N["];O-1%"4KQ.JA_Y%.[:&P3)'7;,3%
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M"SKZ($F4AK;KK=$BJ^Z;?U)*&3'K+2555K^>W'BHG/SYOG 6^<N<D2U\!18
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MI*O-#$)@[ICAS>(TQL_YTJ>AB()@+0CUC_N6JOCU8??'.14OC^'OQ%19[[C
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MG]OGLMP^?PMCKVG!MFE,"B!?Z*X11W1*J/;[B':['BYAQZ9Q,WD]'/[FM,R
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MB2'2.T #"@*M_O0R9W]7\JP1-DG5=MS-7+#[>E]"G0;$"5%S=BW8M+#F7VF
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MD'FH&>YJ!!#">E[?W]5=[H?VRLY+(7RFS>Z;HPZ/!#0<8F4LPXRZ+?4V.;,
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M4+][P":Y\U'3[L.\QJ9+^1$/A+YC5QT'5-=ZI6K6Z6C"G_(:?2<N EI2'E9
MEL;S3DP''1E96XG/KF+QTBA13$Q@/<6($/YD3GA(B:GA0;0%! V\PDU\_S$Q
ML8I'99/.US??23 V9C&>>9B/%-FE:]2/@4Y>N;:FKCZ\)MSX$L]/4=B//D(W
M#1 !<#H6#W&@MD-+%"@=V3,Q(E@[.T:90'9L\+IWG>EC!/^N''UJJ\),J.SW
M24)$]>ME YOM<C8)JSU>NH>\CYL((5X<7ZV-NVN]*-L ?2S!1;1^,^)B+]"S
M4E @W_7.E&#[,(6%__1#/4S8JOEE^[<&@*&,R7&A(7A.X4PVPI=83.6((:D3
M,=,6Q)Q\U\%UV NWA?PG3(>B[24/&;%\$=)-VE4P &X2O1LJD>$J+2KIJA=L
M1M_=;\X1YA(YKFBF>10E3-RB R]MRIN'HIG[B;M<+TM('Z^6)'D,R:E<9,?(
M[*<L_;QPE&D6/3Q*4"'JDY2';!<F]\NO>F#+RM7PKV+"JC]G0 \;4T4(G4\R
MN;2/X:$-ZC7\>+M4.]?R[Q\UE,ZO\U^!U7)C9^:\)S_)]=!I1S.$G_X6N9$.
M:X*+VZD=V=E+>3Z!2AFWO#0-)0B V/'*8 TQAZ\8K""9MXIPBY+N$ZF*9G+9
M]@KT?.WH87#K"\!HU+$^^\S,>VD7D=2MQZ=0L+SYZB@V3*J\K.R)H]Z'^ ]O
MHAEJ.5F0QZ"X:YDCH5?PY4\WT8^H$M6!X:5XNYBP-H&V=1Z6U=?<W*#$Q)(/
MZC(SH4/6FUXD<V(H1@14C^2_ >,Z6S$(UTOU=^?2.LN\WKYQRR+9 N3Y=@G:
ML;:<1SI(MB-^)1FXH_EK3L,@5CV27P/MSG/IN*EF"'EZ3 0&2X_<8)WXKFR;
MR\>P:T5?00649'DZ694O[<LI7/?:XOIH=[,Z/F;GZ_75X<\-]\9ZY_E)7#>V
MPS:YP/M^EHE8A55?Q8T,CYSY+#-4$<+\5(-N>0?U__/"RK_D;R(<\"]%^:T)
M+/^/[0$ PD'QS";X>W+\7U.&_B?%:MF"S;,!E0@'WI/7AX(!Y@PSS?V!A!_H
M !J 3<G\7#%0JH:O>7W3N-<YU#)L-BZ4^D8[>":S)N >J !ABFBG 1Q;BE$9
MD)Z25JW3GF]>!A\2O->2K*I],W'L(6I%D.!)O/R>?)+HGW5]Q-; RT<MB=.>
M.<XQQ?H;:!%A0#G*]//*N9BS;S[D+G_@"W@HQ+?X;TQO^BOX_ROX_S\I^/]+
M?LDO^1>%U3Z;FH<&4UC1<9/$XRCR<U,M:L,E&O!3W8KRR VZ^(I.5+K<B10Z
M:OY  [Z=ZT4OJRI20WWTP"_^FFC[G7WH3TB2PG^.JG#XWN-.&C71X)D-?!HY
M-2J2[)4>$LMW<)*\]:$QC#DCI*:#$H-@<\_D0T@M5*G,>.>,3@Z;RP4WLI][
ME%YX($0I,:36@FT91>:=)]C9R9KV(B07DX_'L=3'331+OXBXDR@)Z8Q+U(%(
MNF]_.)H@U'.TN>],J6&6^,>.&@$XI <A 3,W[7Z8VR]-$D]LC4Q6/BS0(G;/
M''_*NRG ]-_>B9A/2$PT^@P-*+[:_K?$VWT,LU0)NL9JZJ3X@7?94??^,HPP
MY#]FX-;C^B>8)G^3&]M/D+/"$%+$[J#^;Y^[V%[ +E//7D+6(E^@/,V_H%=1
MZ_S3NO^8?QO0_,]*R_X?D0HO.K5IT?3:G:5/[8]YOT^]#6RL14SBJ9!QY))]
MO[W<;Z8U]T_/$/YWV<*EFVD ?@;<1P,NK"S]+>]V\.E)QJ UDMODKC#J.NH(
M3G:"!I05T(#7J5NI  XI@&PQ ^_^@"18%[J USF*Z;#.H1KY1SFXL_9%_25O
MZ2_Y);_D7Q.ETI?GU#H/"3.5DUG1!_;RK,KN1Y$LB&4*5UN;G_TT<<TMK8OI
M%BIT2IS;*<BF 1EOT5[U:$]M?1H@H4P#,K&J/W0%Z#HSO9/B"_YVE GW"(D-
MHQZNI0%//[IW(5N/?H4L-:=0Q:#3T-WC9>CM147J&=2"PE])+ -YF 8T/"73
M^:_!U4$JQ8"NVE20_]<-5<H12SUP>R99 ]V(WK3R0*[U0<FAAG]_">UQXOOU
MM%]/^__C::$TH(X+?G$,6=]?BKD_A]G[RZX[21Q1?Q59#'EY(N>##2QD:N4J
MP_$L;G%K%WB^Y4/MP9_]?$#4:RNK\_QZ%CJ $!..,?G?8;5_<ZR4N8O>H#-@
M802]%7>R0++_Z%#YV$#6H0&'GF;NKD(V>>RQ7]FZD,<!FW\";?<WF:^F#ZOD
M-QHP!AFH%/G]5;!VPS]Z5% \N!SRXW<T()@&*-F/9=Y'CD-GCS+T_1/X)OZ&
MV7_G6+$S?3 A1U?*#R>WZ)U*M&#+A/^^\@H>^AM._-,=HG\GOSE7K+UN&,;0
M@)EF2![U.4,'\> :<O0J?8JU![3[JS_2W::4>E&X!_.[V$+_T*/"/[-W.O59
M&F2K#2F#NMD%F3WH3 -N- %W_VQWV"_Y)?]-A*&3&$%7^C0 4NO>!E>@JW2M
MS-UE.@7+@?WA?0NV,M1_08SBWR=7U2KVH"J%C=INJ_J;7\."+9$82-47A&R-
M(7]*?:W;:['5U!_X-P"%/ULI_EZ\)P[36WB;!JR"E^SV_?Y*3^+6E/D.AS$-
M8* Z?*W0G:8!E>@6ZTCB_^WDX ,6_VSK^WN9J[:FV]X%]%(B#3CRZ?W?^3=R
MF3IK?A\4@*$:UN@7X%7T%LKMS_?%_%Z^Q(GN)15%7J;(E?_>PP',PW^K&E;]
MZK=R8BY,=7LI9@]I()=>4(WMZ[*0+4<ZJ151>!KP1[Z.8+4_.S#U2W[)?Q>9
M)_^Q?T*NM_I?<ER,6O_E;+W17\B*S9_>@SV1^QW1*DAM'H3,-$.S:,!P+M.W
M/R!8.!H 0K8XS%.KXBC,UE_^LEL@6.#/UHM_Y[M>XZ7K=F7D-FCK4_CO+K)
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M#^WEO/RF?)TCZ&3<>^9(Y%RR%D$?[/F_2U/^=VG*_P+97O]S2E,42&L,<D?
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M X,K$3>HN0CW_3$D=C#!,C;3*,,1?>AI^S,U\1%HQN&AGW*)?4E>QJ'M/^J
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M4"?X,=J@'(UEF*H8J:,#BL_T0(IYV=DTU=JM?O'RG-<X'A08."TJ(M8#@U2
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M6#AHU[7L0D]>W;;"Z\4$E=HI%ZC$O:H*L[Z:^;3KQ[QOD*['((,EO<+L/ O
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MD7<ZI.#:\H]Y@!5[N?XXS#$UU&"."6Y?2&>JP^[#@3R[4$I>#OO+L>$8E4>
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M7M/R'6U^(6<(CE&SOFH"1RY)58V,=C7&525O#LV\A<\T(4_+(:+!#>>_1=I
M(@B] <B,6[#QV9+=)V'B(:1SG],AV*#LU/T#=)'C&F*/:I\<?5R]+7WB\Z(@
M%11D&ORMV\NTZ,]E56Y\,VCI^2SQ\/9@B.B9)L@QF/-S:IVM@13GL84U#&D0
M2?6K;NZL' ZD%;6):5Y3JB[EHS@UY+#20$HL* 0[S=A[R-UWT?*+3A,OKV=+
M&!1D_V)1<!E!RSP #$G"GJVB;I"ESN_O_#P5\?6^98HOI-1K+(\-F 97TL/S
ML*^&RTMO;?KM6I7J*VY]73+V26"L]%CMWI7>R2SV-ME[2:F7[$66'\J7L Y
M&%IUO!9<@-6X.:8Y^8^QO#N;K(UAG80!]M8UAA[.B-KU$"^+O=EA\BYIA.OE
M_%<P9/>MLL<N/R^&K>H3 P=+\_NT_<P^_W ]HN$1^QJ(D*U6E-HLEYWB8\;B
M81+V=E?R#E!P=+# =0?HJ-P!-K^1TP&0 _963I-<R8+XWC2=@L#&B.GV<_L$
M0V0A9Y2*4=#24OR_ZBMGCO337U(1S;O'/G^\2OW^-&[PP;'-'4"0[4FFP"SF
M]YU!Y&8/#'6M-9:V;6').\"<4X!*9B5D!6SD(CJ387;7KF'-%CW(E)3O+",E
MU>NU%\:L3BP.N]R^]SLE9]()2F +\#$\V-^1[\%'.CJT?A)E8):FW+9HU6 O
MI+S)_&[JZR/E\:DH>HL8^G=7P8+D0DAH&%5KN(MHEN<_>GYV?^RVFA<1=(+R
MV0+9L+(U4A$K+RD?3[>&Q;0F8EI")+;':D-)O3EW3YWMGU4B''HP9ICL5@![
MO!PRU6EM^/!14<]^3B(@8./^N[(-Z[6"@(TJF)6$W\?4[]?6N&!DMZ@6>R3C
M1$MKQ[?P>V<,AZME8U>&Y@JQ1.;IA]0N=D((3!C6-F&^(W[Q&QSDQG&:']!'
M A+=#J6C/OR>2&<F7(=9+G*X9#K+DG$7>VE]:JDS8(KEVR&I9Y6$5)DX76LT
MRNV;TG%%X2DL5].5D_3[IRGM[X/OA)Q7C2:ESN6@Z4$Y?XR6:&B*.7,WUQ2R
M"1$K(YF\C%>\.4*B1X5I7HM>.")ED#REW 5L$,=6W$\GM)"%Z\T+6O:G&@3L
M\N5PF5-E*_].V@%6N_G^_&$/3(CU&(8PW%JF7/$J!$ORAX'$5BL3C6J;2C=*
M4JI>P!)F1),IMD8Q;UF+QO :(@.G_([Y>=9WYZZ/IQ[X:G>*XTM[T0G3050A
M*(>L1#()NS)W -?-+I:^@_V6  /&Z9_W4#59#_)V@!\5-GS]#E)<7%RYV_9S
M <R]D5/B.T!KU_!6QT6??Z37;,V\*6?M[FF0VCD/C?U5QT&6V)O, 8FP],HJ
M>WKWA-,YW<Z DP('4N[+R^Y+=C=!SE4SY-B].<JL1\:&OB#UK4:PFI$P*Z=1
M:H/QX7?=JWCTBZE@PZ, ?6.#W8;RA"/B(=7&@!$#=*\[]5=IE=XE\X!;<W9D
M$HDS^&S2*=QFI- O-;EM^^=XV!%8H2/)E;/V]@@Z6M"M,M55H+)$5)BXSZ#?
M^A2'X>.PH![R\^212+; ,88I_EL>&S:,@%A<</'"P)OU@NU@ULJ;TB(M'M?\
MI)"9M,?W%DR08^))A7DW8]\/N?F$-$53Z-42F8;W#%Z&,-<G2$M0*"N"3"F:
ME#(69%KWX'<Q+R<MAJZ2$@(0G;HU8?[^B@&'E+V^%N@R]\]>G=$GKI@WNAVM
MH)%C2C<[I=TSU)[^B#3OU9"I66A<,I$OVWO1A+\#()B@9]7^P!@_8@Y:G'&F
M53>C$4Y6N+8^K\H6+_]S89V,>S"#=T1OR;(&V&;D)#*DOL;,(#R:I!^#\4S!
MR$< /P V*6L+C8O1 ZB/)+.%X\N=O3X65ANAR> <INS*G[^FU0X3>CR5R H*
M8*E4$WOY@A.M:YJ37CU /2%"&G-MC!6, ]7^X9ZENX%0Q437Y^\7ALN;*0_"
M%-*W8=/E?D;EIX*-#*6CH>>-QB3-?W9L#_U,,Z[/[.HA R E?R2]HY4\>KBK
MV72X;(,<ZV3/W]9@UZ":/B=OL F?4H:":5;5!#]D^]*'^D#/9]NEXV?3V( %
M^AIK9MN&KP]FS0HD^QZ\#)0WI9*T9X2WMJ[ TP:<=CS1J&ZBFO.,Z$7\C('4
M4!T,Q*-)#B]K^;/N YI'B'>'-=+IQJ-/5\H:E>28[79[.9@+[%:G&\3IY%&?
MS=CX3C^?F?'[RAX\#[Z_-8@P^73I^"=V,$L";++&^4_PL'+294"E2>_MJ)H_
M]-4QZ?MF^ =L<>COXL<9R+$8.]/JI@HEEHU^EGL'#=K4/ASS1\A_+PK<YS>T
M^@8!#0[!+M@%E!]"Q+#YJ6Z$8N[ZACZEWBPIAY(TP^^Y<G*S&\P/N8BY?+H:
MQ$%3H[^"7L 0KQY<0.X*(#D/^U\;/7@C>V558$]HA/%% DK3F#FX.4DEL 6N
M,'0A+S-J_Z^BJ3A9UUZ-_5[9NM_8J74MNDX21@B77PT6L**HL+ML(+XIY?+J
M-SZ?1I[45F8*!07R^S!K)D*CE:[525TU-WZ>Q8XP$01L 'E@_B#7NA!]%/H\
MM3;411'%\(^K9/FW%^8[-U<49<DLCDQ\X["@-HK=YAN7IV&^=RP;, ["^+DZ
MH$UH!X@CB/O=Z+\KA!%;O/TV\VMBUH"?%5I=<T2(T[#8[&C!?;4!,J4&*:[I
MWZ#LQ#1VO00>0,AY^]"/'?L=,>8[\$_%GZLSPN]6%#\H/+=?Y6.*24[E$&#.
M%GG2LZWA!4]IYD"8Z_IGN<.)BM\XGM3MYK665$<KS7T$W*%)ML!^QL$E/%>V
MY0?J<[)/;^6?J 0UIV)+JM6[ V-WE384%WW_"+'*P>NLXU/@RC')%H1 XP]'
M]6[7#O\;>XHOWM\MS=\41'K7NT'<0$)I9<Y8L)&MVN]_8W>'>X&KR_N<^'?E
MEH:/[P>U@1(*^VGX3-HD6_"8\,G@D<6+]U^DS1JTSY.X+QU+13U*"EWJ*N;;
M%&?(,/5!!/L;6Z;;_X#-H/&>MP\?(+'1W!''N\:Y<OJ9]?B^VK/5+<G00?.X
M(VM[6_Q0L89& :*8S#F_>RM'T:=VT: 0XG(+936^5K-E4MCAS[4S3D:5GH$/
MH[HN,LE6L&53WBE(?*!FKASRFTGP'K:_2-N*OG8#>7A%0;FZR^CD!;3;$PZ6
M#XZO(<8&"IIZ1M$WZ[YK]SUHJQ)"&&\R63#*\D7YJ,E?0@K@U*C]7XOL^C1_
M_CB29W9$Z/O6"3N'=I/V$P%SF!("A['V0HX(*[.4>?^UZYF,,)6HW [#]W+M
M9:R,UFBEF63ENJ2<7^3,I^4ZJ-'3])$!_[M-*F7YD'N';G63>X#6WLBKU^\!
M)IA)C^VY2!-D)8IJ01BF@Y$@MQ_3=MK[&NEC\DI(P]V75Z?*?M9@LB[M"MU<
M&DW#/(,U"K$B0).EUT"L0IPD->G5H(S2R?[!F&"I*Z\\?L\X APS*3: ZP6T
M.*.?<>4\LK%K6.M&[Z<?(VJ>U9I^C&CAD3LOI2_5K_K?7X*8L%'YSH 1#=H0
M$?9LNQKDB*WA3VCG!W(K7!\]RTO),CQ<&3OK#^P:#^_FVS1G2,+2T< C<"I4
M?'HIEG!JW?"*1LG9XK&Z1MK;W6_FMN+V2VFJ6 :M#9"-491*PONU1H005LQE
MH++3^SK-,R-MSY"L<\FQ [GO9OFG+N[?UR%A853K5?AWP;*83+UHY'PA^U0O
MZ!EK9WDU@_OH4_&^+NG'6M,*_$9&_ O?<._]&(KL84*U>2L+90/]F4+LQ:&H
M/Q>RA#YD+/IH[!'PC'(/DLE[S:E\_>15,1/D&R35G"SJ.[+5;(#9=3,ZY,=U
M*E-W8.FP]5?U[G<<A)_^EK.!HSFD1K#)G2V DZ=6-Y6LB9E>%6M-6_3E^N0F
M,NIYC.OWHSUW7+8ZKG5AA@*& ^C^U!U@F49EF%++TRM"M5DZZC]KL%7G#]E]
MW[JNA>8B%H*&&*K+&G+"%9N$ 9Q=OP25+'SULS,3%%^[>NI49%+.^(F]'%]A
M&2J!U[JB,**5R6*^"EK=(\N6Q>H#*U7JH9<LGNJGJG1)S][&\I(+NJ+ "O.F
MR<C:1UF$B WTV_%.J;BQ4JZ#7 >1=7$(,Z.E60RD/-F<@.;%2?]8ZTO1?9V_
M,'@GHD!^53P[K6\VF-@?!IRUB7]3?[C8QHCS,:+[BC5#2D=-+5LH?3P@6.SL
M8=H772W]&9)+W@-41C)T>(XIYM5>"SLKG8#'DT++N8DS+_RO7BV<$_$Y6F=;
M)6E^PLC8!<0DH-S)D%I(.W*8[)@P-;?"$URB&Y4_(7)D;W3+Q:BSB6G\?7S/
M5$X_XN8\8;3$L.^OO'_<Y7UJQY5W5612BJN3;'&&]_?-PY9FW'=UH'<PT-P%
M.^*;S"-0(G6R#:_7O<$0D77KO>61,2&OU;0O]%<P[AVV#S?<]#D7T8,<[J3G
M0T$,"^SI<S3[B$W^$1&KL3%SGK8QW@7;ZQ\F)3\?>'YTZA^Y2,Q!L,G)4)XO
M%O3HDOORHZ1&](&%B_NR_8>YYQNLL WB+WNV ('F/.W5F#R"<8,\@\$WXSXR
MX<,.I[U"0O9'B*<7QL6?86H*:@'+:MOO6=7:"^S][,]A*Z\&]DPZ#%F=\5*]
MF^79HN<?"A;-F2#C"-0S70IZ3&6":+WN^FM7K=\3/2=:."^'.CFOM*.WNDR9
M2]MN$'GFOD$CGG-0YX75W>H$AJ+MF9 4=X6K;Y\4"\\BZANOAL6S#6%#^&?P
M9&8DRH>04'LHU",I0/+T+3MSQ:L26:=O(QCU,]N#BYE,B7!Z9245TY)&[;#H
MEQC$9%^)_FZ1^_1L4,6VL_.Y/5*Z NHHA>?=?#-%+9H"2SL ";U2[3/]5'!R
M?D*>EE/BI2;W1>(8]EVQR(?RH_6!D0N?B?-U])]],Y 1X\CH_(\/E>CE^Q=Z
MO??SRHB?$Q8=37JZA-D-*ZTTRA,FE@+>61VMB-VG@P*#B#=+B*8Z%!]9S^7V
MF8.KQR-D'P<3K>#II.!.]_KAQ2'?%KOJ)9'Q7_D:CU+.G'J[_LN"UH[6WW??
MN)*#.8C_0A!HT&+WHD3+<8BIN!2FR)NEVC37]B5=)_?75H_/E!PVTU+*E%;8
M9-G_*Y?K#/N[@A@4>(AF'NV9Z=)7&76R]97U#<<C]:UCC?47S$6+[(S3?\_!
M-)]RX\44,<9OVF#4856'CR:\)1 4N#LT AT4>I33;):KQF)V@TZ<EYS&YVIC
M8AH.]]F*)L@?MC25X^%TB*$8WP38LNP33.ENLE?R:/;E;K:@R8C'O=KH%/Y3
M4P^J_=Q^Z4E%=DH?6YV36EO!C&"6UXH75:<PT9HZ"]U6VB*'"E.&#D3[7E:W
MMAC#*]G_EO<*ANEZ)%M0<]IAB%5\V&=0ZCN-\='Z(FX+V33()"P2I[^MXTZR
M,C4W3WCZZO76&Q0]5+_E[J%VXT^3_+'JI1Z8.$U"A[M60F<0L3O GEMX;LC@
M4JKW%$WII,[846E/S('?E'S.JWZY?HL73*2[+F*NLYL)5$O"H]M8F<[6'4 ,
M9[B5L^\CEJC@TGHG,W90I/6SFD>F/%I^?8 LA_)PD)P!5VIF2L9M=@ _C9QJ
M]U!IF-):\G_Y.C5XC[(KE$UB-4!ZEI%F5'JF%[>EH/DUCSK14P^K1G3F3[#X
MG !V$$C)0U(MNX:7FB=%F&=GNCB]]RR,)*47C-VTWU-)IZT^M?@D^"A)"^LY
MD_/<_J<74S2!HK'%U#;JB#MWRMKG+E;0HK5&Y5@Q:D(IL@7FZ!AQEABL:Z[L
MPPY8(4K[NX)QM[+*K+F8\@-Q0GY:HNJ)'<8IR,9P^T:0>AK#V_$&"CI%RVI7
MDJQU/ICM?UJ\4G.K;NY;UTV ]0?Z4[H#-"M2U>S[0OY@AK<]W_A_<KE5]4]P
M%\.X89,I#BVB8LDRY)MD,>\<SN<66=5Q&BLZN<V6(2,7AFX+^[^\4W"G-6DN
MGMT/4@H4C'IQTHPC$%TVH;6J3N;N#65589.JFOD[B,#>4;(X\S<\Y/UL+KT$
M8WUL[[1"F7= F8YD=</[C$64#H?#C$&^.C^?4<?II38 7X3_0J9:(B,&<CAZ
M_?'*T#WK;_[!5759)MUO-=0/W-@!G.42M[('1[,8O6T-\I ]0Q:G0KM GK)V
M+S0O6.#]I5Y_&(KK/M(=6_@NJ:6:=+_DFI]XX8O*W;"H[E%S+W.8#,L44VZ?
MM*=T,26VIJL^4L 8NVW>I HM;.3IG$/I2L,Y_LXIW3M B5Q(+J)#X]3ZM"9S
M;P<]?4 [*%AY*^(<72;OK&K.PUS):GM)P.!DNV4TCY3@[?N^V[+0,1C39[">
MUB.F7IQ4(PI^&7E<E1'D6B?K)7*WN^1"RUWUVYXW%%6+^'2HJLS=+116 1G!
MU*<A+E4Y;)Y'6Z?JC^=_C?&,_] Y0\BZUPX6$Q?N:(NVIQ#/7+FX80.P+W,P
M'\!B_%OB*X<@P.9TQ 9,A[2X*IS7O.P\U_<K^VN<:7BHRN' /6?,CM8';Q ;
MR!38(N3KS6FJ4[LRW<O==#I;PNC#*J=_FRC%F7__UKU/WF+UJ,AEV'4L0CEC
M3'UJQJ.D1".&R\@!4#14Z3E@,!?_"Z1$@2(D30&F\KL^S9<9RB<3OQ;A TE9
M/GPV?*?3%OYT\_40J Z86*YFD)_DIU_T._-BMR=/R,K8\4,+DZL$HA7;';R&
M'EZ?P:R<G_9%[>HX<)[Z6[RJ+EK%,26Q1GUKG]4-AZ&G!TP E[E!G;^U#GGZ
M:?W1=4%32%Z?[6B5ON4;[U-/$$3JE7MWG\H)V]71TU#]KS5/B5Y#(:IBT\CS
MJHNZ^4=>J%\:Z]R]GLWB!?0L[%77<@1R=]4B("7B\G@N3K6FUQ^GM0.,9-X;
M2!O_K#B:KN?GOW:GL5*)\G7UM@-MJ0\\,"FYL2:._T:H;"=3$!&:*CEL%=HI
M[^S=EEH<!X"7#5\_B8-W]96XEC"3Y)6+,QC(GL"#0T\_N *^3^%7O\VW>L0A
M*"5Y$XP"%5 5A(>C]">L"IS/M/REIB.4'D-7OV+GNG:5*ZU'7[3LFV%=8VYW
M\RT.+MO"VE(# Z;6-9$%< _H(W*,E"P^T8$<48DVV=VF=.H*CZJ>R/-J?27[
M-B35$1P:I1 :C33/]C7(S__VJ7Y=:#@_^E+DE_J=?X;BM557D[^0R]$\\[H3
M4M3^'(+?GM/B'Y^K7C]H8E@7+,]WNH,$:A*HSH2]18_Q^[%\38$6TL&RH;?&
M+R?]</':%[2Q]CP>8'"Q^0/+%\.2&S7Y=@!OJ^6X_*]__OG )7'TG5*-$?_L
M-OL*'U-\C?YID"T[OTUHQG O=DJ\+UVP# V0TY(V^UEYCOGVZ*V8.I?'D7TR
M6P1();G% B_)[I0);G5,LD8++JY]*!^PE4@MT+UP[+$7=?-ON>85Z,4,6A+?
MGY&5''WK%PW_LJC\M2=OLG:TM]?O\N6\H8LMAP2[W]S9I1<69()\/4E%HR$5
MNV3:)0OV,9Q/;[9MW<" B/^7L_]XG#OC[=@3M'_FUHL8C!/K%(M(]M@!AKLL
M(+77CC>W_0H_DD@?>\T2C1[MB;M>^07YC$OA\KU9MO@?#FHX6]":$<H\276+
MF4KDHKM4YGS__EE#X\;EZM.'>=5E>>76_["ER[EF4(_)E/P=H.I)B^D@7F!I
M0I!*?QDHD+5N5>N=>F(V1>)BE50,I['%=_[O![EB_JYRWGR/59S9 >+O(KAE
MT[N5:-]FS^5_S4$I'['UZI)<;:8:?3P^RCC8Y^2[)G"SP4OK6^'$RT^KW2>D
M^:I1Z7ASL$F?3,G>QBQ/YNO%DA@E)6NB2XA=)=BL5,.TT0F+3J5W,?]X[8\6
MD#>?PKS=_G+8>R0K+^JB>] #7K[M5[F(Z4AZ1\^FI@!^PDVV06/O!77-0GN;
MO3SA'P^U6R@^#V?0OX$NDQ6_"HWSJ3%-=[[M2\D^$YLJ&\*L2BLRGBP#83Q!
MO?2TO(A547FB-#([H^?(O5"/Z!W L7!#D8#^0GY-''HE-&0LB%4.X(*_?H3G
M6'_^/(Z &GA@W/;?O>W]_P<'E^;_OO<2NY'TO^_:E(OX^N^\EIY_[=C,^'^O
M?X[OXQ+$S6!C?H751:$3[1XUH :P:,G] '488!V%K>,.SH:F&8E7'![QN83^
M::@[,'O@_('E])^/68TFLNA>^1(&-W6S+[-6(B5$%S?ZPG@@5(O?8#;*L0)A
MA,;[_MF&+^&$[TP4=O)*VBPSS [//OKNLZ%!VE<+)].(SD$M8?<&$? 4O5NY
MK%Z7]F /?ZH2<)7GK"# E0O8<&_\WT@?$O^?+9GLOOV/')<^CMG_HA43%OS/
MR2[_[ESP_Y7#92L.G)5&,6*V!T__S\_=?$^Q_]<N3.+3QO\YU04X^=_=QN@_
M'O]+*Z:2U_\QRP587XN9I+%1X^"26[^;&I7!1G4PB"S?D>+_;HO]7Q-S_D,C
MII6E_Y'B\D!_DO/^&N/FY+8TT9&H0E6=@,--V0[P,FLS"Z""_U7[I7KPOTIW
MR16)_X^FR#X!0\:/Y-][>U'+MT@[0.\3'5:2_;HO#+9\60]![[61 )MWV5/F
M49+.2<C=IKAEM]GKXYH'GF5OZ;Z_>]:(8<-7"_L1 ?+LT!IY&<7'CBD>7"W#
MVX)-AU WNN+!]_:-HT0^W.4?T8GEEB5M=ZLH7TVCG#8ROG8WCPG80H%=;L]8
MCKF(+@QTT'Z9F(OO0?*2[N^9.Q_QBSUAL'+&\$VI8]G*HR][Q?7]NA\'/<\Y
MAFGL2F">GR$,=UR"DJFO;2_V:-]'NY!)NCW.UMQZHJ8&RQ[?NS^9?KK*;YBU
M US(+O$N7YFK>B8^G7-H?["GL.Z7QXDMG AAWS\IL)<H@8>NC/.CS;32C0]#
MTE,!*T:F?K\R%MRCK>_ZUMAD"&L<>(+J&GNMM#[OS45+8_,W80-@])-X<^']
MLSU?UP<+BK8'MS;S'\]GW=[L]>.;\Q'_5W"T(D+*(2NF#".F4S\338ML(@QE
M7:ZB"CGV6%=-JONJ<I_W :24S?F,\\AE=?S&W]Q]_,V$=:NH;XW?M<::LPWB
M ?9>%.4]>W=_O2CM?<N$2G_I$8_> $/+(.R#YOF*YOWD2^)O3WO^\X\95J&?
M,05#Q8>L(F.$&_ZK&Z);E;8K<JIS/N3XR&(6J:QT(<'ZVOK9X^V=7T2_&[7=
MO\8(^UL>ND$&/]P@46VL'+^H$=YRSU:>1WO^E&Q"47@$]]K>[F-__'_.EKX
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M'=!<OE*&TZ<F1='"6P<T/%\O2ISW59?,V %N?'09]>_LV+>'HY:RR?5A*8M
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M<9P;M<);=*DV;\SGI0PE[OH>QW?[SOL!<F=86B>VN_G6)A/)L^=H(:P$F1V
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M:#Z048W J\^[GQE<.>)F66;Z=,56RB9(^VBU:C]XD@7^.X>_"X:&!Y'+WW8
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M9DNUWJEQ%YW5O9>TRY=QF14%2^S_8.^]XYK:MK7AA2 (",&"=$(5E"ZB@$#
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M@25HVR"E\S/I8-UA1F9IPM7 (G^Q!'.2MMJ*I0%GMN&@D05<1\178#3_&TN
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M6",#_JL./)=:$YP7Y1'&VW$]]VZ@8Z_6VSTMZEO2X_N/B6C/HMAO9_.!%YD
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MZ2TD 7Y)#_UBZ;\>UVJ@!>=KP#'4;C-^VS/NJC:?%GTD7BK<TIFZC7H))]O
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M*]_!29G:^E]6V(::50C6&Y5^9;>P1!WU,F "Y[)E#_9>DVDXR:MX*L G_$@
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MM3;I/&D]T!+ I]NNK5\O0 LB4/K)8\T'J)K-Y:+=VS^1@M%K^^H;3U9.R+Y
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MDK-LWY1Z<0QIA]\CUN$<L2!#7.QJLZK-A/"@OY_G0IK_XR0ZX6=AE[6V)R]
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MH_ZD=#J7L);"R1"WRM=NC &U\PXH! N=K11^6, GE 9R-/=5/GFJ+]@"(99
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MOSE7"E8H\/SL$))4L%<G Z!-*._,%@?A6DR[$O&K@NI"2/M"'/%EXMDIYQ
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MKB8)MDX5J+D\XY2W/DMTIIZD(-@'%X[I(-$LZ=^#R?-S5OKU&\D1^MQ,>T&
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MC=W(D^=*2;=9^);YAV*Z'7KD)@.)/I ,"/G'0G9/P,0+W:C<K=ZKQ>H7'(A
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M5OXL..3PN,AE^FOW5Q]5.J$#:H*Q><X%"OW_=_OO]M_M_Z>MT3V*XB[5N,B
MO6@R&<@OM[CVGXK6BJCQ4A@D(9:?EPS\9$HD P7XH*52\&4RT%N^.H('MLC
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MUO FZMI^2$<<8H3@1(TI606#69H$(3LW4.<R]TAUL'_G5V0>D8<,Z+9!>\E
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M8_TPM^8E,I XH@UMA/[<[S1EQYVV6_BWW&AV'8A\<D_9D&-?+D+O#%RDW*M
M=;(9"]^PP(*(X=5@HG Z*L5]3I6DCS8BH11EB>**Q%>X6I(N_"H%C7G,*"QN
MZ'HF2LQ%;< F4;N'#RA_2-7D]\4DDNX5AJ'V_MU9_NT/<H]NM8<0JP0^[H80
MV=,(\! A"M@5K\CB0?/PK?H2/!7.DT+20]%$3\IHU<T'0OKP[JH4C&&]\9QJ
M(D%S"_88^3OBE 01(<"/A*"3^V@4&1!._?=,;B;(.?7,05<P&0"GD"#GS#F7
MC^+_7>G(SXF+4->[07TT0J*G_*;(9]0>)_R(YSLI18 ,/.3 QQ)*SBHH0\'A
MGS?K#W63FYP#A83&MRR.,NG./Z$6H+\UP9$HS$/P\>/E8Q+\R!<FD8 DX>$J
MQ$;*-9G.'V_^LK1MJ$V3/IN;YZ1^K[62#;*3Q%[UA9_.GXW2>).![_ <TO-_
M+8-H-"'9E!%>1_$CQN[0(0(9V$%L03XAMZE)]%\I-_&P _H70OI_V'O/J*:Z
M=EUX(2@B0J1W@@\H" BB%$$@H ]-I @BG:B(B$@'Z01!Z1WI741 2D3I+=)!
ME-X[H?>$&B!9.>%Y]W?&V>_>8W_CC'&^[WG/.?RXQT@6Y%ISK3GG?5_7+/>,
M->ZA7.$/0<Q3>8)+NQ+X%' H8]L ;T@$X$N'=0A#[FND#GQEZSBC9WC;[M@(
MT6&.M20@,A9WR7:4?'(1#6*H>=A)ZK%=^+$E/%[B*.W?^CQXLD*S%[&1!B"4
M>KT;<(C+\+?3F,?00R@>1@2>6)!JR].#@ W=A#0=7L#3DI[M*XGA$8%9(G!,
M+@K&CO=0=F5@- DRX]JXX'R.A$?;?!4O#\@[&C$W8,761P[]=#H_1_4S_2[)
M^TD D>;PGP?K<LAB?RSKF6/Y47>;2_,7EUZV\:=&%B,R]B2R?E[M%Y[GW"JK
M>+W7]4PW8\CWAJRARTRH$X"UZG_[Q"NR0H@S,N5]&YX:.51IMP%["]9SD5B;
M'9P:T: JL<7V4A+DJL74;BLR/HY1<URYV"?PH^KX-T>FV9L]^?1*9/,+0I;\
MM2Q!EPDZL!F%]_&%?1'[XD6G&S7%3>%*5UD</XR6:DH1T*'6\-3P8VT=B+BY
M&B('C,,[D'AQJ1;1(PAB+H8(8(]@LUGUUQ ]I!;%F4#J,J2P8GYLC-?#J.)T
M\]JLD083$[>^7A*21%]\[@JX;EH?^F+KYEVKA[X[T)V]6AVO)-3CIW)_C20?
M7-OD!4H]KUL^.M:H2?UF$T5J%6?BVA9IW+W[F4,>VZJ9Q&ZU  AUV#^OFZ'$
MFC/UBOQ,Y70A KYU/EZ(AMNH^5 W?;".CU1=!D*['"VH;?*:(\1ZI *T [&A
MK(:K0?=I.A5(PTC:KRMN5W_C9/VB:PMJGQE!.&N]9 0$./ZI]38=UKW4CT4N
MIX!4-3EC;3,:S(?/M>2MF:<RN9H(7!ZIKAW+3L-<2H@[3A>;9SP0#^%U<(P&
ME#YXMT"#XU>G\4I+N67N)@<;5_U6?V2C+^R%_LE:8#.-@E4H%6]=FDM #SC&
M]X>#?<3SG=M=6S[60RQQNF [J(<?!(=1=/57<2IHRR"E]*SK16'5A7[CSBP7
M:B3W[<3TJBBC*'<R(5.1&S _[G]4^./K+EO^DKI76G):_2EZ4S]%9Q=<VSN'
MBH/A7MJ%P'>YB4#;%2(PMXMHNN=%<CB9!Z"T**G_9T+65+VT,1?"('0K,Y#]
M%.@1C8\4B62HU%_&61K6IK>I#6R()FM(*[Q,"NZ.9N6-NE-A0A>-&UY8(63Y
M7+ND..QXOFTB 46HU4_#);1Z$(%06Y_A8E/"%_L:J=FVGPJLAVD$2@_@N :D
MZLU51,P5O3!4_26%8=V^Z;0P[KS6P_!C#=ZW%_.N/%A%H8!4K+?P7U \PX%1
MI IV8>#!K/QHW@]?6W)8C7\8=^["W J\ORL5K:YJP+EP"3RKW^<+HT/,%+#H
M7UJ;X@R1<@G?[:^E#3R0PVT,XX6P3&H\#!W2H N!$M%P'^2>Q,4,C<,#R/F,
M7B2[WK@[0NCE4B'_3+:'7)IR"V.0?9!S_PU/V!LP8^GK60[4'APC3OJEJD\3
M=%NC%'Y,H4@2S]:'?J5]=BY)<R5?*Y+1[EQO/MWHN,5Y@U/X26P'EXS^GMHQ
M&TY7MT>>_26-3X!D@LJ[=\XO)QVNS<9%*,YE 7.IVI2#/O]O:6WB"#ZX-E#I
MMR788)0!1FO VUG:((<"4_RDGRSF$($<>FW*Z%XE1K)AKSND<. _"SV^( J&
MQ*.*(*/=H-I^-+B&6$XL.!3%N9+:,V4C;)\13F"ZCC""?L_ QV[P$H9(JE%,
MF[+J57)QQL=1];Q55[$QPQ^WA+=CZ,Y1=?S@+]DP$\L#^Z$4XD/I0AE!1HRN
ME_RK6>*UQP,Q) _=BF!/V \GW5@%G7%T #VB*,.GX+5(SU2C3Q*LG?@Q7]AG
M"#TXGD$M'NIN\17+'8GX@YY>/'I[I$MFHU53)N,7.ZYB3@O/6,33_[E?5NI3
MD_V!?2G<NNS#.=^%((?J!?<9VC#I%?A[9VW*(J_[N+8Y2+#'NP./UJ(\-9M;
ME,Q.OY#L-YZ-^[(U'*.:/7Q\[FNJ\>?/]Y)$6ARIT=Y$S&?A$E8@X%LNA-H;
MDE]:SMAK0>P:#>]8G2RV)14[$ W_!#NB<"%<&2=UB(^(89(+Z;56@/J3V(MN
MQ9M!65EJ>LF?TK#U"2+PWN=6[B0T<D?B^#H1."M#B@S(0"(P2?)OBM7(U@_'
MV5CPA2\7W.LD[?3NN.D]-/,G6T/&!B=R95:&V/);;WW=UPZ'?PSNVZW?*Z9A
M00MPO^@NFS96&69K?[ 3G:Z/%R _RNZ;,RBTZ3W/<^_27.YY5/>R$+8 O) O
MCNV<?1\DIESB/2+K&!N6L0 O2::8\DFPNJHX2<$?>8\^&IZ(PNA @55Y_M[7
M>YZJ!TTY*YM]T1SR\H8J#_NWSL#8 =#Y4DQF>BXI=N[E#XICRFJ[J?W89/S$
MUD#H4G+Q1ID:$5CKH5P-Q-.W[B]"V=P:Z*62N+(>M]X(T1GFS]M=@?<^.<SD
M"+C%PK/;H(5!-B)Q)/?15*>K,N!UK[B;X4I]/J-.<ZND29ZQ0Y0:0)AR "6.
M\\5&K84L.:Y/+/6_?KZTFPEI0.*N$<I2/;J"GKSLE"A]W^B?-F62U,W*ES&O
M(CO\"_I5OR442>YU-V8R4^K&1,O9C]DWQM+MDKAGJ$5ADEH^<M;]J)F/Z5=-
MU5N8L<%]]UY9AKVW;[$OOF&O*8-MJV#J1S3(R0,K/OP#,]C'5<\J)/O&51QL
M[3.#GRG'&0L7I8KI]K@NB9,=$S)786/5IFFC"NDN1:4YWK(C>EB<9<42_#S>
MF^ O*X7]1MAC&GK:4_PIZ7.\P<=GVW=LV9Y=7^@@0]T_)F_U^>,KSFHF:2^6
MHK7_0<#YVCRF9(U\\@W@#[$9E2[F>L8R$@.(\[I6,23J'*ZB.13OJ58;;[EC
MKC.B&UW?QKITW-;G*^3%3OHG6S?]V3<EYPKRK'O<HNXR!MEF.5(+,3\FQ<N7
M 8HG61"RA\J/X.]W@^:N<@AQL-+?G&$*ISL';-J+M?BXK65@=+O]C,1BI,7K
M7NE?L']JQ?D\@E97RR>0Y/X%<;"Y SRCG0$VI_;(M:GFF""J614<XV8;,Y/
M?]E]_+58#Z&?I%.42 V9EJ3,<W&?W;U8<G_3-,M8K%P3MU7U:I=N>#U'1P2<
MGZ&XQ7;N(+Q'45N?^<>'*FJ5T!KZ+3)A1Y]+'/93:@(FA=_15<ZGOT_<XZ_:
M73$0)SLB!7V*VA,7T)*Q=TSJ>^;PWFEU<R)@8DSJ*1)X-*)!%#9O2^)>/B1)
MEFDPO$OR3")%__B[@C@9CHI4*(DW=@Q6;Q-3C50I"<?(-AR()@CM'8,7+(D
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M$NRF_N80?)FURY-;KBH3,O:REAJC>>Y1:),/1U@6AY[-A(U<R<X3_4_+'HC
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M%,5D\5C@491J*ZWU]ED2[9&7#3$<VU)!18SR?0B6,G%\FV)UG/TE;$^"P-"
M1M*:6JX?_7XWPG:'__&//8E.7%-;/7UO:4H2TF5#$LB;";;5\\@^.?*#&WI)
M5DS4'W^O$.?C\CSV08VG/JWF3#M=D/32R2$F$H23W#S_+FL)_AKA([+(12N$
M6Z+V6_*=(!&)_/D0U11'F=*'OC]5M#65K?<[0:H:-!&@69D^7RN7"U^39$Z(
M5F[96$S3T3LW1?<S/36+D>PH&IUQ>,:,"%01:!!7B4!9+CX>QHP8/@3MX ,D
MQ82WFV7L09KB[^5\65^UU>>B00A.EREM?,["NK;H,TO1F2I>P5X3%N9BM3BD
M<.'>)=N)^\^6()R<>3*!/1>9A?,W8B_/LGZZ!%=:('Q^R(VG?G9_2?HX=QOF
M2[D;R3(!#=QFPI$"\]FGI&9/!)J(P/XY.(&_ CD1Y&4S>S74 ^?_0/"<&HN@
M DF#_#ACC?$$+R2@N2"FV,UW1_+YEGF?C!34V(?T/O &\9PUB'AW29%[@.PP
M"Y/;RH"[U5K//3!W^8F&3I]Q@KEO">]"9-:/-AU8',(0"H!75V#T>+K<5T>F
M ZYBPI)#Z[T;/Z)Y+C3Y*3OFRF&$<+LZG:7Y8YU^N95/;L/>DQ3@,;_/2')@
M UOA;MI#VS*N*Q9GB_R90H5G; \-/<[A@4S(LN><:*,-!QH9X$+#JZM@YJE<
M$:(4))X?W_5PFTV+/TH%1P1@,%82Q<N89JJ50W/L8;0"15U,N27/4"<9>54'
M>C>#JP_34K2FNI>ZMRB;8&,JLUO---S##\')/N>5SQ41C\N3L7_F_1YD,XB-
M7HG=0S[18L*IZ^IR&DVE.'YRCI@U]A\F.0X%Z$\YU+HK]FAUQJAAIF-J-C%/
MH]][QEZ%N2T+^0;#CV?H1D\5.5S Y3;I5SM?[%B4M7.(TSU +7SPOD.WMBQT
M)!,A2CFFMM\<W\I/:9_P>UFM"R$&2C!G85E^C#UZ/5S/W[OA=^V.1<V??YV[
M4D7X2 3,QV%^1WQCJ;IFWQM9_GCS(>S#Q:;%-_,,*Y'W\0<U9#HNT,;SH-ZQ
M*:FF*7%SLUKT1JO<G+UVPGM_3-^N*DV]'PB<(:.D6,H][$:'3__Z'D5K+.MS
MUQ>6D_'/N4+\W2I !5>$%B%Z;4<7I!J=@UP<\>+%#&5X%JWL5T2-P9+LQ%=C
M<H_$>1=U-R&Y]PEGL('A^#^2:<910<YE)I97%QQ^2D-S (3@R9EO^+AI9B(P
M8GBR>!N99KT,'7NV/T0$T*B08N&EB$7*0=,8@Q3'FW%FBEQ*7@2%\TWV/ ?(
MGNX1ACE39%-WD,[HFC[=V,CDO;/A!>WZ$.&IUXK*Z!OJ-R-HW?>1W?=[^LHX
MTO@??ANXSB>F;N5RMMWB>#1 *<I\>F%F+Q.RX:0\\'30>?S."*NL*W/YCA#M
M^Q?O^4S,PYX&P#I@5. 0_)M(+#94/09LE$:4;3R+=^,M"\M*GTEH;.^]9, U
M[YCK>WOWD($DH5"%3P,U,):AV=$+B*M\ T@^L18*[6=,.JXS-(65[6V=Z30^
ME<MP9CQ9\:CQY#@N6_G7,K33N$RXJIO"I1L*?@' 9WBMXTMXCY[-18-:#L>A
M5^OTC]T[>!W(BZI6;W@,TK#L7R-D[@4K5&#TFJ,"QGD#,A:ZN8I0R#WD:H"I
M5J/1 $(^*W=*65/1T!_R(W+G\"$IY+PK_=.<:^]]LM2OT42RO:7TZ7# A^R$
MOM:ABY2[/"/9K(XB/F"-.D1XK8C $-_K'\Y!YCSDXRO3:$0DZOQ3G I:-^O'
M3B6=;%)JB5U")[@C!LJ[0V<)VFZ=<]"FW]3* _,9+1Z7XX2+57VG>-X\97@J
MUM#)35F$N(4JFV[VOH6&1N;6]Y]QI[O^N])MVJ-\./P>>?KQ33FGB%*R>=@9
M+SN7F8P@D+GJW9=QK8+QLO&2'P:-DEI9#7JK"H23B2*].2$(&TZG2:\DS3+$
M8(YLF)7OSW=O_3QC-S;@K6'T'3;"NHTM5]\%A"@V/ 9\5181,H17A&#4ZT',
MVWX\!.T:/?-67ZKBY@=_8=E:2WM6#J?^M64%F#THA)?I]^%S4]'#[.&?A.)D
M,\25V1^Q\L[;LG)[TL$#,^@1,ZGI J$FE8B+5M7O-S[%^A8;.00=/(ENBJ#<
M:7M%^(4Y:-$B=_/[.;3:WUQ]KZY9K'/A2M_W:_;R.C+SW#3.3KB:)LG>PPKV
MJ8R+7O@MF2_8X8Q7 +Z D'#B>([L_,LX8(QNU=1Q)%W1.&K:NO.CW41:)*9\
M>L8LS\U\4V@OX7Y?X:ZGD">'P+, #K?FER7*)7G:3KY? '+9N3*O<6SL?@[.
M&]/45%%=:M2:5#AA3!XJ9/QUIVKD]WL]03<>\FZ*MT/U!H18A#4CK@@]S2E?
M45B<84ZS79YBXWU;R6!4N+7]@+F+&M6?.D<*1VIST$,6B8SCLZ\01TH2"!XX
M)VP^FT0JFI(3P ]J\"%2YW6=/2][JZ V_7+?@'Q2WA^+"^Z6I7$*W+E\9%OP
M#I56ST11>1Y<C*<[_<L,HP'#YW?9#(W<S_.$89Q: '<]QH<*7*[_=;805 R2
M[#=7143M=:=;A?9-^4(=O*E_B,8)='(WHKX@1DDA'(( 5DB,J?%>3F&6IKF4
M4 WA@6E]%3Z/O)Z0C9B/QN6"=6W@V^LG\92DX.=M!TD:X-O)NMI5Q'XX%O4.
M,?O(+7D:I.<2[8J9>!VZ(517KR9#2[ ^-,+%.M"TA>P9\D1;A"]RF-+JE=1D
M94)@).I]0K_)=Y$@52P1N )I1JDB=L^O':F32%?DGR>;B8G QR%44C>._US=
MIV7X)9>#0>1&(;W3A=8#G?.#70.L.AZID4U%")4W4Q*8E-%LT2#Q5NZ[J:%Q
MK;(E"M @%$87>7@!AR",GJR+Q%MI5<.@B]8G,]6Z:"X&_<'2*_T2=^[,7?J@
M>GV!GO&.K=MK9]G(+A2/_F9DVV$RX.(AVAC)JC6#Y'1#Z$2>F711MQ))BZ2B
MIV<]XKSHTL9%\%H-^[J@.<29OWLR1^?O189+^>2EBGF<]F4E0<TQ0. /X;?V
M7)=-?]CP/;F$Z):8P-_'<*=@*1NKD8%E%*;)[[\;'_K=Z./AEU9N%_2T5X'[
M(%(1H[S[#34XT>L1@057?N\GQH@L^W]K2;#)B>!R(_O>GRF-G,X(A):J-&UQ
M6S$GK"%7)'4U[#C#;:Z,!=-E?(ER=)03(,?RS]F=A+\K 2A/45]QH<EGOW.:
M;][1S(K]];3FC+3[F.+6$?N\/$D;ROH(6U</EB$C:J6\LU=B5#OEFFVD!;(&
MSL!<6# Q'A%IUD?WRK&N 794QJ9V6FF^'71=A0YKCQ>&=PUX;_[.'U-A)RQ9
M*3R<CMVEZ*&,QE_"26?CKV+*4[(-KIJ-]3YQY^;Y5D[K8\E7(NLJO;%EA."0
MYS/$BV%(PBQ(]$H$W_:2KWC-F\V7FO(';'<JB0#[8KT V&M&AG//GH1+5N7
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MZUO%ZU?5-D2N^JF.FK!:Q/QQ/]7W_HWV[H=F41FLLJ^"@JK3N@;T'H)Q,"4
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M(_V8&+6.^>3[_VA.Q6V-4])8RG<B<S5]HI;!:._5CVB+!_/<>L:L^#O#7$J
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MUE*SJGO28@])]]'WNLG4Y&2-W.]?.]_IU>*MKLC&>-2(;>FI=I\+$2#O]>+
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MZTXL7/()4FB<0M5,"&TZ@(GV\"4P]7H,0]=P"!I/.74.T:@(7:AYA")I]C*
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M4>W;#W 1LKF8M[T32#K;^_G>B!D!#2@+&7[C?)_;09' ]].IYDBYC:SS;/I
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M0Q?DY*FL^_&D!4H"_3<#D-+G^E?[^Z^CQ+85L<7UAOX#NO7HMWL&$4Z-RF<
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MT;S%G>R@@YS;:_82<,<M>GBN^RH;;/18/HEVC1%X..9]2?;,"A>"C6Y>+\P
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M6V4)1J-5>%MN3HD"(Z>WM6B?\RH,G"*\&EP?4QN<=.(!"J8=5;ZYODOHV:9
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M*>SQ@[4XMO!=OMN*R'VH95<80GUICA0V,.6[;;B$W5GUA"7)D25&Q/^NR@H
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M]OC^A <FQ\M,!R,9^"GT%UQ7[S":]HSU+-P[N"1<KIYJRRJ>R],>+YY:NO+
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M4%_-T4=)H#9(N4*,<.6N[--&BWLZ.#UX]K%+,21#6_ZZ19>RJL3]-J-M<@>
MH3,%Z5TD?*(QHG\3QX/N"O,)I"L_-Y<YWR612N*RNA7$_Z69P]*0CTZ$^"+A
MW5/#+[U_PP;>DI?6V0#$NT15N5K;M^F]:WHM+,%+I[KB:?G>5Z)D:G+V]9S!
M'0X8YB;P.H@1-P?L809^L,%!A\.<"TX::018DY82X'PRT#.((6,F,5J##4A*
M+!IK<\!P5):VWIB:Z--U%)&[,2_K1<F$>/%L0*&D& Z$$MA-%+SZQ"K]VZ=K
MK->?XNMT1=X309.%'B3.K&)A8;K8\Z\GX,Z!L7WAMUAOIJGN3Z<8+F2CKZ(O
MC <D1\(4.!F3>@<"JJO[\:4X 4^=.O7H]YY#J>9<#ZK23A7NMQ;_FI?XQ%YE
M^^^C:K8AW\Y15CL]M(I/72E>,1YX\.!L!YI[[;8,9_),%H37JG]2-U"THG P
MW4/H5[(IEY]E)>"'%PT_F!]2WY+%2B[P\O5+R%LL>NL5\K[ME;Z?2:K??1Z%
M[&E\O(8<_1$DBAES$CBI]>QJ4:938VL;'-7WT.?+GBG)'P13HA*O8R]X,3#4
M?%;5ZREO3-C+"XK7I"]>=R')5@7(_/VDD'@!+8X9EY/+M#X?]+O[4TL59T.&
M#<O(;N8%:EZ+@W6:CFO)PL%N:L3.]O&0OCK.I^&@7P1W:KG5FO&)9DWA1_YT
MQS68<O");& ?_@8J&?Z'UX)44 [62V7/H:9+P5=RR%O5.^9O9A6$C7V,S,&;
MR/)-+/.J+]>(JUE+7X;^FU2W*(7T(I5.E(?=<,*4>)?1T34#/+]'QL[$Z!?\
M:+FYPIGZ3/[>'PVZWS%G@#7T" 'B\V+HA]\J[=-* *7,E./5<Q]++M^(Z3FO
M825WRR2?I,=%PBP'=/* _6K&T-C%RN2U'N87)4E+DON;9:L5 \*:$,,&;#G:
MI(SI0<-)6@@C';*RT>71OYCJ[$$Y;?QCCY*;P)"5Q3C'ZZ[DN:9X>/^N8R8@
MPV<=9E-@^\/*:^[V V3YF*M!^L"SGAQ]><>CZ0<$I Q9DXT?.,FK=!5<^Z.
M5B0W\[SW^V.\]Z:?O>23);IEY\1/#,^,56+"8/.,$5B #E%1<8;>'\?VK/HH
M5?_2M16&.3[#ZX6G9F1D^JE$R)"5 L,^.7[^(EVC9-)YK+[X1XJ[WRZ!".4!
M5Y.&G!8JW3$2;)$,#WO77$=+4:58!E;1:',Z]Q6)53])R2\[ /#,S].I'3+^
M;]]^.AI]F:^&C\<<N/RP8N+DOVC^XA=\T%SE8T>D1<A(+.GNJ,RGM)\?%*C
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M6_:MI0")5^C&>48<8M>Q7 SZ*6ZJ<*:ZZ]!/T-,Y1?A:]][E4&1"B8])TUB
M\-'V-FGWJ_L1V<R:+OU5]!B1+.[M'T09N!(_JIQU48!^6M(-2E&^"ZDV(*8T
M!._B*WMH+ZG\-E6O[!JIXZ6/7ET2*.T5BK:V%XVQ_&I78IJ+Z$OA_'M3+K/5
M5;JLKXC8]MG2.]M2MO+)W1-I!7Q5S8$N_@M_FXQ"_/<FU2@E>7EG(;GLB<.[
M=*L_^UD0+AP;*BA9F<;[,3D9^S!?1O$Q]WPS2<2H5:Y:UDZ;GQDS+:<II%<
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M2.+ &>BLI3KYVR,[-*9R"^Q QHX&MQ-YB?2+EXZJ:5S*5'_5&5YMNL8&FGL
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M5S5\U]@LPL62"VO&0-(%K;RLWG&=1).@\HFW7\;W7#VS^+B_8U!B9!+%?8Q
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M=8.\%29F]$GMR++MFUBYB82/YM3:#696C W#CCUA # 74D%CY][?(9;<A.D
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M_E;/"1L="3OY!]D96=!)L8<7>-XQ@*.?B /HNM'Z[R\B5$]F'VP^6U+YPV_
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M_W1$NKRH_,I;1W;H$ E#3.4>,]LU(RG&E6-S(/2>G(#7"%8KI>T$XL":L0+
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MR NJ.OEQ8<$ESZ7W?MR49[:92P8G+_\2OZ?.D5/.,GW%>OD+19H^@"Z')S$
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MA %5A[*#P_# ] =TL:8Y,03*I\ :J:5Z)\]C:_?+^::&)MMS#,-AW6@_LM0
M3--&"\%5QILR$:2=)HX7?'*]A?-S9697!B&]%IN+':G_ VS_QX66@P1 * K
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MX@P] 9R!R9L0LQI)L,1UBOK"_ ?]RE-@<[5GU*X*%GAL]"VV*\=@OU(^[1/
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M/_)H*9$AANR!\2".IM(4K'PJG)DGJ7P3>WWBSQWHAH]:6R$N1#I0I5X%/_I
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MJY19);[_/9__BUQ[]S*8Q_  Z28I3#$@#EQ/[M^S(+JFNX?QRN9@6#2JJT\
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M]PA+T"X]GZ_AV,N<@%E0$2M?"36(-0RGU4&"=I*A#?P:Z]CF!G*0@(VWRJ>
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MV,YQ; &[--?;P3O)>JS7QU7)'BODZA3YD25PGN->BG5L\ 812>4WPPEM_2-
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M!DP&WWL+:S--<!RK$A+,Z\RM6(U<.OOL\=MD=IEO2#4T\1YJ%MB#9 ^"JY)
M^*E,KS?(WJ5C4X?0EXZ02Y?EGL<Z7IT'Z!L@TACXK]"AXPOA,^1VJ*T*4>[K
MM>?V*ZSDF4F^(MW5!>8N_1Y>QJ4Z-T<F4ZJ/=>"F1*$4JJ)@4:A5>*30W=QU
MU9<YE1'*SY6#+EQ)C?H\@+Y!6I)D=/EPWT6_,UP0(32I7(N0UT();">8<#I]
M"#YEU/CQ^_P/3S9U'C:9#/LA1J =*2J!U""<F+ZI]]^_+)LL.<M1=5E[OUTK
M+A^ [D"O,3I3@[C9G/:E<XPB9*G&GR>HM\,^WO\<;>"XL+#\0C\TQ^."UM-
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MBUQ^^'W0^TN;D,:#A608(E?&>>W7^WOFE]I1#UYB5TI(:@_[[ABA"=A(O^R
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M^)_C_^<A0I]D <T!V@AQ%H")06WI66/S;C ]0:GY?]0\V'^-6(X%S TC%%F
M;2\S]?(#%.D^9E?37!(U(HC=LAE>H O!F&;.+=CM"1:P)"L2M>\?64":#QG/
M")5@ =<: ,074.A>9V<**MI!_W*BMK*P'^1I"<QEE RL%TX7E&!>4S2GL:$9
M<B(,;N@$?,=F5QQ@ZH)=^8K:\)KF9@$KSS-8@*';&X8<L_4?9 82);SE.(9,
M\ "@/=AL<ZH"FO[.OP5%.P'V](]X/LH$7;I.3X;QH6JA6SE3(= 3T)DJ*'MA
M71 T9L_L\T-=K4\9[B&OWOB%"/F?.S2OAL_9WC*G'P7E4O40U,EJ0$7C(,T_
M G'T\]1/C.H7/K[HM/G[.M\O>DT/9-'2*$RJE4 ;=G0!]_*%3?'.@.O4W>-)
M/NA_?X_?9Y<A+6W]Q! 7"%#<I#/%>[CQ-$*ML38=OZHM\C<*SE&NFB;775]Z
M\*[LX[3$Z0)5MJV=<!^0X,>O4I8'*K6&*OD4N'WYM*;N/KTY[N9'"OT+[0PY
M>:EW.1Z_+4E.:L$CCS)2ZFT)P4I*:DOZ'$&*ONPGK75JWO*>E63/>>].+F(>
M^D)Z:C,I!8O=>_])8F#6="'1]4C9QAI\;4UX-_[2\7N7%B]M81:]9U6BK-KM
M.,F0*)Y4#5N-U8N?>_Q-)!X+4 5 *]Z\OC)*&J?$DJ=7E3$N6"[?29UKY#'7
M*:?NO_D_3KK?WHL\PA[D,KI[FMBM9R2I2%&%C PP>7[U=72255J"Q(0Q>P,;
M*2D_R:+Y"$FR0)N^-.,5UA,E2$W789.*.UDZD/_CQTF9!Q#+QEAGML'XXCOE
MCP5'O&#]Z\T@69SQ7QDBHKE=\);T*P-C=-?A*TP.0<BIE99&'Z.CZ)J9Q/""
M_<>_QQ'>8#R102GR@6[8/_>GWIS,WN*?KMI&JH=!)Y+MH[IGN4XDP5NP5Z S
M6=.EZ';LJ-6UR*Y9C;\9WMZ44<^"BP?]T!<?.CIL3$Z\\-_+VBOJF"99)HW"
MFBD9!S9G[[^7^C!?.S9>$[53S?XJ*3MI5M='/J7])7QEEV;HBI:L%_0G*@NY
M!Q6=*:R)/?MX1'#X@MKUYS\@JAT"\EB" >0\<V*:9 [A8 [N/;)RS;/IFK75
MGKJ3/WFK3^&:SU^+$^OWX'6*"T)G%S"GL7RZIB0!"A6\E)=+?GOK8;HF#EP1
MRD]M7%;5NVRZNEZ'J8G?.O[PG^>5M[+L7M%GQDR(EQCA)'^ZB'G3>;H5.:,5
M&S/V[0TA[:/[AJOXG2<"JJL.#XZ7(_Y<7-%]M>%=G62Y9=2.'5>C&&4WU?[.
M423[A0>Y^N:[)3],N#(\_%<M4"X^AG\HZS9[IF,<!V]X_(N#  +TPQS["2$*
MDN)>=F>T0F*MM/.GDS0.#SA[*/UYU'S$Y?3&Z8F,"\8C2HNHX=!MS"@\OER)
M!>IL?X7@85)'@1%C3^H-'<7\-7858<"HKU<DJD3Z??&=688+_NO6&PJ+5G[C
M.%@RIHL[?O97$5'61X,1C# IK4//L(!XI=NJ.R^H[I8Q#CVFQN09 3OSJN#/
M[+NRH$B>E[F(7?L'V_/!K!3=9 %)A\WW9K'#V)CU4*1J&96-AC3"( PRU4TO
M1:PM.0-?B[.2GR,]PI,OS^&WW6>FQW4H*'Q4Y%80[,2H2=%R"DXRX6OTCIDB
MIP[7>GG3;?"Z?5"5<'HJ5!@UP@YC 0./ANA#J.:3V+EJ:A3SEV8,=%NZ ;,$
MI>37Q"Z#/8TI"&WM&./$1DJR@%FK"\R/V&P!JJPF/9T%'&$!H]?)\LP\T0HV
MFM=_5I#OY".,J"I?;-V$'AJ="__X3]0/ZUY3_2I3N$Y Z>9RPW<<VXN7>U:S
M>+I0!H5 RFC6<6$*!'S!W#ZC83J*[#O<;M_>]N?;.?%CX2S@E,\2K !*>F"K
M.7N_D+30*D@]?7AAX, C 4%S9]WDZ&<WTP*3SL0?^2?J*IW2?'P5%C,-Z!]C
MMKUD 2VM!?3;U'GO&:C8Q0^*$UTN=HJ+B;#?EEZ26T*/35)ZD2[L.S*4Z?UT
M?'394JK,+(K75?71/^OIV(K3MLH^H\-;>:_2#QBO/GX3V@)Y_4::6(@*1\TD
M8 _0S:!M":;$IQ@'C8;"&!\UX:=_AVT"=Y0KB2%,O^$>3WS"IW?$K!G]$P@A
ML/$7+E)R_>MK6+<&6#O&_3F&$UT\81[$/H/ZNK&F87+'F:9C;I>#[L.L$(@J
M(1E24OO[:%O,[MQH#!L6^F/BX'ZP3OVZ!E?T^VB)HRDYF:L&4J-DF5G^&%)1
M<\;4>3*W4__69Z+HP0<R I,ZS]L?\)_RG)Y!94'C4"3+Z3$;(J9=SXB 7\'.
MFFRU50USOM>JK6ZL";FF,/^"].AAQU?V I-GCWW7H.X@]WS*$HBN-Z.=#6 !
M-TC%=WJ+)G""E8F3HW+V%!WRQO<#1K^[QD'JI,^BFF41OJ0=@GS'=$R6<X=I
MD234Y@<V;*K=]Y)##7H5>0]]:%/$%Y5":LWA X)#?6EG4<TV&C3G(<_&TP'W
M7E&Z%0^4<VY,R<@<D&A[R.4*3<+".GN/T76H\^"E4TJH#L[DN@>E0]N9OE\X
MA$86GM069?0LUY7WG4"TEJ <F5!&"9*=KDLJF2J?51%[Z)H.>9)Y*J7-_F;"
MLZG;CW]]^JN4RSO'WH]-$4B 0K94DB!5SB';$/Y)FZFE6GC,M_2Q6: F_8"D
M94__R\AM_<8*-D8R<G^CFBE=#_2>O<R86.P[$)O/L0!Z FC2G_P#65[D/>HZ
MI!Q+3P5]$0JOQ@(^/L$L8)F'RPD>G@NWT6W/'Y8OW<\Z8*31JV/9_::LN4DF
M#SY=MFX ^0XAW<+N7C2/0%,40,3/%[(:8\K[);5F;1;XGTOX\@;W*$[LYU*O
M)2P!2S*'C1O-(.-($LU3$#)7O-+*.;H>X>?C^NCH'</ELT_Y:$-:$C@+-=P-
MQD,2O!UR@&Y/RI_Z,N/Q5-G==%!I7?E)39PGWE5Y[HJ^E1?=KH*-_BC VWIP
M&T(]RQ6)M_3^/CW+7W1"9RB9XVAHLW?8^4NKL'%\!$]5U-.[D0<#%"YSS=L1
M8YF76  <'F&GR,C ND[S(6P&MOPODMVJLXA=9T:EY":EY17#^+47!O]B?5&.
M<.I95!,4@KA(HMN=)7>\+Z!6V, '*]HW8D+K:WY"EN]N\^HO+AE 2OA_?34]
M\HDKU4!2SPQU%%(IEK5 V2*%+7V73<.T;?T])3O2TK.0,6(B&<1\V(XR@E98
MT873*/Y4_YE)DPHTQ'5'2N[!L*D.YT;H&W%YCZ;,F']_DFJ]:ZPV<31IA";9
M:-6*9D6-FXU]. %S%3=/L!\FU-QW/6G,5U(1U 1$/.H)UB:#-/H9*X[[?(T&
MA9TN(*Q%1GQ>?WS^ B/5Z(4YW)KI"9W)#(&,P3H> BR@O7U8.VDO&K^U2^YI
M<V4!AS3B[AT7=,E*)1YOMKW0S+Q';T$UJT'GYNE.+,!)] $(GPD ZO%YU%?8
MYM*=N__U:<'V"!^GJY)/Q5YK_./KPD&I]JN^OQ(%/S7+%=&X43JGZ66KC/"F
MN2+[,[#E JU! I+6UF,3)1UE?!&XL:I K_&*X3@E=/UMU;*>[@YMWT47=C*&
MD@PBBG9  \(;VF8^NB:I>'G(K+LG=\"V7J=Q]/G?^\_+)L8TSZGAT=:[FD:,
M*JR'R@BQX[[=06KGK&)1+Z^K>$)#7 +4?+"-#TA[UBRO:661?,^8*#.,13+Y
M0.%K!'7&Q%B?\-=D:@[8#QIZ*<\7N_.?^B&S4S9CEO2F69*KSQN6 2'=@X]!
M*(^I;PAZ*JV-'$/U>E^H@Y.=O$MP![>,$MWO!Z-U?ZZ>?/)22&VWCVL5NE)(
MNQU@1'E/#?0@"AR.^W!LI.2<_J#Y6\^VFZ<O73 T4+W.2/J!69AF'@:%K]ST
MC!4C:IX%]'MX-NXK'J4 M7;D<2JW]C+%VSJF<CDN^E5\FT2@4T/JZ4>?V6ZH
M'M'VP_1@J<H%1?X?$.94HZ(1PVK1*O&\S7&#:;^''-JU$;I2AY[^T^[CVI*A
M\;* SH,DS!\6L)4UU?A+]DRG--M@*D#O1FG!0 5#/8L/\\'P+K( ?N2Y?]:P
M5X6EU1._#/5=WA,$OYYXFYT1K3*(7X)V8*EGX"L[,[W OZS&#&+=X01+C]M!
MBB^>'' *&&V&8#T/C8]LYPK,=U'Z.,VI9Y20%JH.LW:OS3,VB8PS<^]_X!#X
M+3D:RDT[,8W&V>U;F'EL[H&KPL6B].8_'2]$.;'<R(,!BK:,,N@SZ!&$P<"*
M'<VTG*R<6"W9)A;09HE]"YN_#30OO^/7MMH^2S-%"&7/6JVL0UL7E;-<4>4E
MH1'"Z9/PPN/130MAYX->6G 1H/0C8:MKOJ#<N&.KO;OISK->'_%DO*(Q--%[
M#[]M"6NS6BDB#]P!-8<+1B3 O?T^V=5.'(^PE]7<P3L9C:[*&)_X^=&@09P-
M_<Y?A&%)-:7L,3(15I^,BI:F!97.*6?)O_X9IG2(&'\#%Q?>]"A'[X*!* HN
M]B2)XDPFIQOW!6<&I@P9T8- _Q40R_3%SB25+JLRP9MPS'%@[L!(-W=*:;L4
M5($WXG&S^?'M$YNP>ZCF6]"9C^C#]>ZDZ38TK[YPP+=>6.W0"KV0IM.1)O?;
MPD2B(U\V)5(V.>SR/R[)HC(P4#21/2\77JG7]<9H3[XB08ZYIDS(]D?!-:JN
M8X-#>A7QLEZX&BXK4)Y\(\Z(D#QM5JNT]&DRO=LL8!G_ =4L#7J^+%L4/J&0
M&77P.81D<Z%ZYGJ>GH;$Y5V%V'60'I/1&V;G]NN/#;" JV$A4"<-]"[[/RR%
MKQ$,UH?NU!Y&%=C$KJXH"[##8_?43#$KN(<L(%F_B 4\'E]GR*5CX]?'X4SS
MM&;4]FHP"_BD7@LPOT&?%@6L,7D"M*?L:\]6^)IP?4U_EN@]C-7$>F*I<CFA
M-$.WC"DUTM,,9SA1ZY9]8ZV[KV5IC*CT6TB4A?=?-NHF+)"N0%;/X6%DK-0_
MY%$J=]$7RKYM/"TAF2L=\2SL_-43"QH;T"8X52&I)4G2MO,C_2J9_PUATD^G
M*-JNXP(GX82:KGVBE%I/GT#7OV!5-BIV-A,[DPLAF6L5KT+:2-CPV'47GVSE
M*PM.KZ7?6*7B+=\+,]>+I.="CF&=43,Y6)+E>R[*N])*DE_YZ0_0)*5G?%,E
M&OU=XN?/J\7+_N&Z4ROV\N>D48&B.:6-\0WKZ&$%JLG8BFZ;MBDI+%Y#\B3>
MV*9.T:3PJ9;,KT YI4* ,8%N%:'N@*(\GE10'0QB1U>'N&0:JD7R\Z*;^O)G
MU?3>:%]5O^N?'K=T0JZ\C 6&P9N_Z_[R'4QP:U6?TZMP(N#^65FV1U^4[0N2
M_=DK(.^CD-NT0+"]?A_X:#;A+6\$+E)Z0CBL=:=D\( QW9V@0E7"K>"+$5=)
MQPK)1V^69OTC&O>5/ L_5<86^>[#Z^1"KHLC=($;N^M,[@0P?D1(1JW=LG0E
M:GO) ^H]A)XK_YO\W0(9N=_AOUX<<HX/3T^;GJ>#;'.#^0(Z\V.CS:=;2B-=
M1:/BZ5CVP&^'>=,=*YV8I8%2S'"W-V6+D:ENQN/AN3,K%W\_C)OW16D<G\IK
M6]',IMT8R'O4!6C5]"H'M@JWRC:#X49 :VWAQC:C6Y.46P>ZCEC=54I)YZ@B
M-$-C9D.@[M"9E/2]0=1W;/@4B)M]MR)\YSKNA;-3CGN]_QUL]%@_$BOSGZ2/
M&TCF8190*M++3/CCOJ?(B&\4>D0_R<BAZQ!LQITKZP8JZM[.10Q&/AIK>S?'
M3I>') VR &THR>(H>GRZ.9,%Y$KBF?%_SK#O)3&RH7-) 1!F4PIJ$8>Q)Q]R
MR'4/U=_]LWT>O2YQEL*LP4C][U- X@+/@3=$K5ZT\EO(HU2#MF%ZY#V4X@8P
M>9%Z5/?9Q#J:X_@B4WA0&0QDU&RW&0+J[R/V.#1^6M'8.B#&XM#<C?#$H;VR
M7"8.1;I7UW!N+!@Z:_6JO3CN+6Z=GY/+:_8DO6$9%%DS^2" ^_:.CE.22>;M
M):+FKA^_U]0,_0UD>]!ZHX[YY-=UU09RCSN%G:(/ADX&G9.,;44)C%'+._;\
MLF<K*B<_+Q7-'PO][96L>OI.6'.4@K8%UT+/#QHOJOD^XFI!=[X;2I NKP&*
MQ&49QH*NB!["T.AD])+=)QH7R*$74"[H$-21[5YQNNG@EF)GY?O;RE<(*S<\
MGSXH<7 (13U'S4<ADB_ BNU.,4#H<,+RC.M-59-/M_0(6[1/7 OA6>/*#AW[
M@NR%5&F&L0"7A*"V83ON(:5M#[5K-7?#_DT899YTK'+R&^E^ETG&TP&NS?VL
MU2GE9%Y8A7674CCM1$#<E;NVQ8#3L#V7<IT]P#;B(S\ &9!?<5=211PE&20^
M>)=T>+&YOOIZ,TWAN5]:>$X'5A0[4P4]I!'YQZ@MVT-OC TS^NN<P27HT_K*
M&EKS2Z!I6Q+Y8PV42+!J?$N="AN:!V%(#JY**7*=';]57O%F*+-_8M<9^!F5
M*]EPAGV']O\JWL@89WS"SN3#V.A\!+,K RU,M0$-,^1>_[_^L8[+ NOG'*\D
M=Z@IOJL[PBG,4-S-!-4NZBC=GE'M(R!,+;H195+G\\/&^/'X=QLME94Q,>2]
MRYL=955>TPT RAW[WS-$%?U&"H"TKT?",L+LP?ZD6A5:L,':_%>Q!+ZC.$@5
MI9JP7U,A^[VF!;DAX<UO@\^3'#LWOZO\_J9Z-V5 :HA1@R>[TT#BZ*1/HT:O
M](/:H>PS.Z6.@*4+XBDG\;K*>6XOHUI'G>IJ2DMKWM#'E<1.5R5:7;K(L3&7
MT["\:@Z:V-*D%3))VVD_ZVG$K4P%[9JG%TLV3U]$IP[K9QLU!.%:!'8%*R T
MCB74WC61EQ& ZJ5^N4.Q(D8& /M *7LETFP_WP9V;I2. KD$E"=;Z;/8A\L;
M#DP>D%-/]Q)9 (W+B 7D50NS;:C0!:.8!B]8P(@"E,$&;;+:TM2D!W6!U@:T
M^08:] U4\W'4')<*(^PC"!/'L!]^8(E3L+U9%K#'EBLP)\'D >>XO"@)RVPM
M1RTF7,%^%!A!_M.!C"ZWXLM17\HKZFHSWB'7IEJFG)M7-SY@%E#_UR]RX:/\
M9YT9Z4+'V=2Z"9@CUP[=B53M_, 1?T"+XX?%(= 6O8=5:]*%60",A(MC 80'
M=.XAN!+"UI^WS%J[I/VWN[_G%^%,4[@L"_B6? )^PEF_DI!SG+K_3IT+=?K#
M$E.IBII"6'RV?29BLMXJ>;)=E9TQGP&+:5Z[;(DO%-FM'?:'\F#A)5RVU(Y(
M7.ORM^6,VZ9?P0%JIIAHF+H^\4B+L"V0,O@).%IM$_=-9Q)5U)FT:39<K&M2
M..Y2ZOIWKHO#TDC( !T85AQR4.J=0$\(-!4]GC&CLHH&SS>B^>- ^>)2._5&
MDI&;H\A'&]DM<Y"H-&UN8@&.Q"QF-&HF/43@5>USNW"3[Y!$!Q8 9;RD@Q(L
MK)(YBN5#JMA.!J@1UAJ<, \U5LM$!0/MZ6U9ZHZ[CM[-?#E!P>X432;WTQ]4
MH\>X+_U*2<MBC&M L"+-%OG3CHM16"]Q.G164D%G^>W8[-^AO/,1-BV?^[0V
MCS!&':[+2Y-W47HYR@P0%)YA1IHU8%+TX\-;)6H&_>OGX#(55;'NV<6F2M6"
M!Q-[+1-B>/).7&V6R4=B$1;[;_.X0+BP+@)'Z,KDK3W/&,*J@DV LN_95_K/
M!LR\O#D[)LMJVZ7T'79J7S)$430X\U<6.I+_RZR ^.*.M=IXJUS_U&6X7J-C
M=.-PHDGL>:!4;,7+ )* VG_3*:-CF*F91,"N<J.^3B]K6E7M78LYAJ_Z4S+W
M0<O>IUI,3 #][@5R1V0/G*('%894ZLUH"E/_I,1?I#XR63A[\MWN"VM%$-4'
M=DP6-C +$.*M3P1H/+9R)U(#'OIG])^U;77;89VB&)^W,E77*MF83TKA'(C.
M9@U0K8X3S/!MD-%UIJ#9];,<1)/-^GI1C\X"7K_>>SC0%*9 1](( JLPLDQ;
MCBXL!'FF7_VL1^6HPQ!GWD-K4_3%DS]$:3=^,V:Q4S.^F"$XU0%*532"41\B
MC^IMQI@S5WQ)5BOSY+\TBCPC#V%*6!>^>NP-P1;>49T0]-E61,KLNXE$8,@E
MV!HJ0. .;- H' I/&OW4GJ4DGI_4IL/]*46LZTP<V[VK1T.U9MB9PFS4LV13
M)G<2. AGJ9T%O7D!ZSBIHX/%YQP$S2#=OSA&N-8UEHQXS"V97)1L"A\CO3Z(
MIA5P;L" G-\>CW_N6C9VH5SASN_;F;KFYYO&@G:@\2Q "#M3 "WG"M]:?NLS
M'5WKA(]^[5DU,'$U$^"KV=1:'.>\R )$W?860%W6U@6+M3O:7V_I2#9Q__HP
M?T+U6D)B<?N+NH!_T*NA!E(5G(!4^/YBBHSJQPR_>_<XRB_P?.6237T.L'^1
M/X"%[+^W R-9>,A3 DG,+S-PSFES^3:;H@N!!>8%QOBRCX<1WRO\;JP],M&5
M_OSFP9'K;!CS?0[TA DPNYE<#97]*L5KNB8HD;^9<GD=&@&RF8:"W]6.*1#>
M5R6S\7)J81:.4CQL)2B9U&E7\E5B4O2Y9SXC&HHTO^JZ-VLKW7FU8;J&.)EB
MQT,>@V<Z -GG9]C_P49T*(ID\U51LC:-6-T1=_*K[EB%OES??!9GV(-W[7#^
M!5$SF;1-L[ZS<^+,(@3TPVA T,WJ :531\:;HK^&GSAXS> 2\%RTOU&="J==
M9G9A^1&:!2[:FG'JV0]6/(3&?8X-D\HCGHQZ? ][F=@X]6:E493Q6?]P .Z.
M.#2*#G,/1OXZ;A"J%F8L*><P*#7(ML4GPM?09F4I2RH-F+-8;/UP7XPK?OO+
M9_90:@8+.)7^@;D$HK(4%HR T0&F>=PLA/'Z%0L8"$Y /88(@=1V>Q Z"=UC
MQX,:CZ8%DA*);L@"OB>C]^!EN0(K:0:@XW#",KR3]DOKTJ/ 25V/ZA0BPQBA
M.&9T*M9.76"7TX8%X"^!)'(0\Q-%5<314U1$0+8X@5J,.<,^ET0]M4-_"7(E
MZ&,,\=T0DJV>\]VDV=@EEQ[UG0'EAQWX\3JG OUG*XO&S2);U71!%%,/)-NS
M+.!CNS^*]#!IM/P!N3=\&Q5=>PNM/$CQ*VTI#BW;L(FD-0D.2[VOZ^-:-*(?
M??,)6KX>0OE^E 4<RD^_4BH+T:NY))LX8;6HASJ/(MV<II[I#4,<SIN@JU&;
MBT>HUK:<$L$2IB8WKYN&2]C\]$Z/#F/_%<@5L849%Q!$3J'+SX7G3KA;H025
M3E6=?Q2<<UW0_N\#T^OO>KA^_P['H&X ^\P9MM E6!&KGJZB57&RDKWPK9=;
M@ZA<DF6?U! %0A?*XGL"':UKY7L)RH8$0M6&1=$!@=<YQ4:%\$5%L@2EE[K)
M O@::(8!L):I [6V[C=>/W(-&;TTLBP6)JR4(LI1NL<"%)A9*(?>"%$H#_(
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M\#D3Y;;C2:[,DP.?7*S_#;O(_?:R-8G<##N:I!>@H)W262S 3C_RGQ4<ILR
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M.?B8=A\-0@JCX-<_WI>[?;H!='\++K(,<?(^"[!@8'5/5Z_Y79U-,#OR4\S
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MT-@ESV!=5C"SUZ+,W$"'_5H< RV?#Q8'BLGXU1X'EE&:M+-?1K7#<F-ZZDT
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M6^SX^DMC]V[C7^R4TA% N@-YZ/L:0FL^5%-1_<;(FV.VMET[IQ*>WOTL'O+
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MZS?H-O1D9F^?]M@.)#OCHFM#;7DL'GN6DVY^]#QZ4]88>AZN93XNEYB^?5>
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M<[BC@.ZP IC[\3--Q1QI3ZOMVU6&(B>YY5T\N4&:VX(C0__;)66WW80((40
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M.S^3\W R'_RL$WJX]]K2(8S>H\*T30\P@9YQF18W;X:)U?$>(??P>Y$_#03
MYV8!\,H2F*;\J_V31@N&%#>Q@<2[.TQ:">D5,@3RD[:)1"3_VX2<*0""R;_3
M!,#".6'H:D?O^I^.8_$NO@DN!'("U5KV0(N3!FVF,KA]X-]*[2A>%2O'3<Y2
MLVRTTJ__UXA6S;>*DO>E/^R+4>G#$63E*Q]>;,Q[U ^F,>!<%6^& $A$, K@
MU1UYDPC:,S/RZ 57$!%K;0'"'=GG(:(=%(5("KVV*.$-D;PK+3OB+L!N&X2%
M#+?W=9=B[TP-T1X5E00ZEHT9>N_/^T$?FW!>P[43 +&]^&[X>@& ]G[ES@GM
M;Y0L=&1&P]HLXU 4&>H@SJ$0^Q%MF'+^>FZ'3!1&$7>JM]IT [H.9O3LF>?4
MC1,/GAW-.D>HY$] /7QIWJH\]R#8F*LP+  "D#$*4V2T7D5UKCJ$81(E9RU#
ME7 ]O$06<NWTBMJ=ZB/7VU+TTTH]J^^I?'X)?)(:RL+G^95Y>,PTN"[E%A?.
M7+].NYW]#+6\<V(D1%7M16%WSE+*UZHN3$10!,;HZMC99MW[/;*)1B>F9CH-
MVRE&(/TFUYAEJHGM]'P)+M[BZN6'X+>R]=\\<_PR$KRBGQ*T-^_9C,45X,,+
M+\]FH[Y0]P>Q82G:[Y\]8YA*0!%,<DRC.OB]135UFJ\$2MWB6C%(,B-.$5<)
MYAD).,.GHU->Q@7#PZG=D9'&M=E^8;(9$5<=KUZ:"LSUU(NX"A4* ,E#4#)+
M - (D^XM"$BON&G>B]7O#F5$%V)G.9ELF\?,X28!(/TK<\O0?'6*W:.[#L;C
M.52N7EU6V-CH.X*1C5AO?BH+OM%:5FQ%;74/H?F@T(=PF@!HXV\#(YK@B18V
MN]CP6V:=P^%AEHO-^/U@%1R6<GC8T>G*1X(R%&%?6U^5OL(9$KNH[^2VU?+
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M1:.]BY78HE:'6NC:!K D]F='[6V7+>_DL6ZH\P"W2@#$E5(O5D0Q,UH$0+P
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M?J:<'@JEH;^\9QL1@N]T62/N(K2%WWR(!$]11U],=+,Q'&MHM!!E&9DQ3S$
MZ^))K* XX].;/+K#)YUONT#4EMH7#6O8[\++6G1=H^NW,0G#:Y*$^:)4GY<U
M@0I;V)(JS7C S)5^D)^EGG\^U<[HHLIDJH6;O?W)MTUEP"&56:JP+ M&$@E
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MN1)?BX6QG%O)23>4;;9!%R87)7%'P,&.GJUMON+L$PDLWGK"+HG$+S-\.'7
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M4_MO)_H'L:?>LC/O%&K$!3+&6 6'";M!T^P'J<5#.C8,L7Y]G(]^K?%ES49
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M]'AT(ESWR/U'(][>3@EKG',CWDCI&%/^"WQN_VG.I<QO$6@0^]$7<[D=\_6
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MU")TGVKSK/.%[GN_W:EN73\8Y3=:DJYL_4=16-GW<CSN7U,7^2]9>T+FK4>
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M\$1Z*!K>!HCQ4A&_8TFZ+'\HC5->7=G>=C64V^6M UI0E8M,-\G\\B2<@7X
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M\(JY^;@UQ \D&:$/B#BUM^AZ1<DSIBGY-L%BS;<[N31SL/89GZ@*U/R)L8Q
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M_LEL0.@H05MLF,] *$XM54T%L2GQ0<#B3;WQET$.J$1NJ_?M<ULW$3.)']!
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MW=;)"C(N>ZKO^!L._;?Z,5=+?N5) .T0(GY\V&[%*+&K(/)!\U[<-2CCNF*
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M,C4)LD9 0)#*KO)Y,H:U;[H#O[^_(--^VD8EN=AO^&6KVHE/;3N.6FSB72?
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M4^G)FU45GUJXJ[9Y[!K0%'K]Q*A7-?QS>Z6F]1KU/TX2;L!LP&S ;,!LP&S
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M,](=$9[#P5$A"_T\NQ85"NH[+R)B9 G#D27Q).:Y-7Q8H/0+:+TKX@JE6D2
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MY,C&0<F K@.<04RL[$ SBFO#'G7LS\E@27:'Q9T]=,AJ7T9'$GV\.RMVV7/
M^:WXIC4?^I(\MOL*9,A [89(;U==X.W*EHR".&:O+.X$J7[=?#%I2H,BYC*G
MV'N/WG"U_OMBS4*@3?96C1AG\CM/Y\WO&B6@QUL%"[B%R2TLHS"N??,X"NU=
MEX-<V [-(*UU2=:O;D1%YP1J3K> )3O).0Z5E5,_P_?+.M0-+>&T?EMV^S
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MY;.P'T2T[+-GZB0V2T;[ZH</NP26(.+U3B:N..L2X=HEQ1I\6(A$4>BWU[:
M@<I!*'F*#U-J1#[$!3 I.P)OJV<0T6L%Q9N/[,UX3R(WI&^[NDW%Q4Q1#;M)
M[C3L]M--ZTG,7NB00DO ;AN%F!\ZNZ#6+V'AE[62<^Z]ZDYMS"J[L%!KU;;[
MAH&2U!M-(5CA5X0\T'+>1-W_C!-9F8[:AG4YI"],N%H_R+$O.EVX6'-9]9LB
MD G?7]B_N$]5]?W'G3@)!@T&C714=2G$<C3*YS9?VMSK4S!A_$2HKY#B._R>
M>GR@I[X^T>A18]5;Q"O<_G5ICC=+]>Q:_LA=G%S @9T]3(S2M_[W^V:MJL'/
MS7L:G*W^M J\41< .;O([1\42A1,D,_Z6>B#K4H)ZW)[>NCW0(=:\'/=I.S=
MLY]WBH)#S1E&GY[]5 [T_OW]@]*> U][[WK0:/Z.QSQF]3,B8O[J"AX)(\FZ
MN[VG33X)G[2^:3+_U\ALQ@,*/1N_Y6&'?@KO%-5CLV5V(71.&6%[6,1>OK+4
M7['H$>DZ=7?D[??-V+6P5E05?/X9PVPW,=_/Y" Y22F0X\K\.F1VHRCM?/1:
MUYF,VRTFWD_;;VR_:K-Y$Z3DYQ,&!$ED)Y=U+$RT_?S-A6JJU?-A*3K43/CP
M\I^0\(+YC;L7CFA,"B9" _\I1^^HL@+#,?%:M)L<F;6EU&-']=&5X_N[$@KZ
M+_E&?[E'^IYY/B!&[4X1\&))TIFC >*VCK0Z3,+ CLJ+R2)QN>!BLNS!/3'8
M'U_J''=M2J'?:;L]G3D#_./INXM4).\7&(<#$/'USGP6\)"LS-#P4<4Y"-FS
M+(JW\;38Q9*I!96\;TDNOWW^DO:0:\C0@0YTM2SLZ=)/,K*=TMGI=D!_O,,X
M-4[W.:6IF?I^<NGJ);N)Y97VMVI27>(4'-!JQR"N[0Q&<I2<@&5S!)@&H7FQ
MRG ^;.LP@O/XM(HU S&61(??^V#'X,-B/&04CEQKBRIU0LCZ2Y_DP](K:- 3
M6Y=%4;L][X3[ZH9O"N_5\/@B+.72IMQ4<]1UO#7ZY+5HW=B=C_&SECO\B^(-
M#Q<)593^-YZ2]]_XB=!/'Y:1+!7*:#\Q<J0;$Q10[O_)S?28[F53(_U5Z6[Q
MRGK'%*>_'*REW]X,.?Q6RMQSY,=8"23&CF))YH64HGEBD'ZY_VK_+F*(+:JM
M672P5NE=JG,@D7AK^DW]H]7P_%#C'F\^K+68^QSXEH43%?QK*!@?'Z91)/0S
M/Y>23X2N(JMUN+*8>TC($H?DP[Z$(,#7@#=J[0!M,P"F0  ?]GX6QO-#K\5"
M1\6':2+-LN.?S=44Y/DP"9R8./@^>7=%C^#4ODH_=..W76K)0X_[[GI=NWIW
M3^+7 -Y.7D]=F-2$"\X80J!# @[;8H(P#.0FT]O"?178K[&^I?)6^<EO;S[>
MY;YSZZ5M6YO.8[/:]L",3%_"8# )1SO8IK<PL8<P$9CDTTV-YIZ"SO^?%U'I
MJ0/BOUT\V/-AHLA8RC?/3WP8&"  >;=CTYL-L'\&F!]UTIG6KJT96$;<H_GG
M@=H<C?@DXJ2]FO8WYSOZVO,/E[? G/]G%.W_7G\KZBCJ.*\/]5U=\*.%#ZLW
M@,TT_S>_4;+^_^9<6O2W:-P3W<Y]*QI-CG8#M>XG>'R8:4-LEUM557-M0V,?
M,?!66:U&I+$#5?1FUH6&^@&BYA*#1+;R3G\_2YW5]55/M. (AAC=AG]/J-9/
M1=ZD)2.4R$$,S';(D4ELZ]W^C@G?AK,?6-#41>Z8Q:N2<B;'SX"QM<7C'3N:
M#U6PS.=9V(AQFV&3R>$,Q2?N,P?>L_7^"/?A[$#S1,=R9U+7S_)H!)%?%7N3
M@>J1CC(%1AUE:DEN'%)P)]?U<=PCZ7#AG343ASN7S(<XAYAVDG;,@S]<);07
MI]<!IX&RQ4 7]HB9<#<:&8W_DP:>MPUBCT+JH"'[+K<&B4ZEZDQAXG"N!>K)
M-4OW%6E)Y-.3B/YKX4O!XX9^1J9E$*$]HU3/5<S0<,+L(O@UBZ'EX%3N5><Z
M5/\QEX[()8 6!#EHJ1,!7J#=74M-#<34BC49&P4P*)+^$7]\=T.AL#IM)J=8
MDG&,IX^_7IP+R!L=%:SYJ?P]VDEYWQK"+;WV-5_FOD&B^; $0BVA0]F,)]JR
M+NRA7<Q<" C\T2OH77+R7X^QC@SB_1?9FKBKC#G;T'=>A_LTI\ZS8LNN]_=.
MN\$W0W@ML_;,_%D_9+7!=&O ;IST"'X;SN"-@.U>S?V,.SJ,WP4=OPB6%2?P
M$,Z3T/6YMH@#Q2^H'2$WOTZWV>@U<1/%YOSRZVL>ULY?:G2#M]C%TD!36@IR
M:YIC*D.$LV.:26I]RA*BVA#5VS"QS3K@,?0=)[&8BC1'E!BO7]%I,.=/]XDD
MRR99O8J&>JFGLM;U0NPTMADWC;<+WPD(<PS!&XQGU3T!UUROLAP3,0&,.#?6
MR$,=SVCC&QTN8P\:2E=1/M$#%RJ<O>,L^TI_+.R;]+M>Y?R*<U&PJP9HQ);>
M<0V>*&7=%NU018GF*$S-[67:C.ZHC!YYBY A2T_9S.ECM(:5DB;@5X9>#21,
M]M<^FWKE,]_3.*,3"X VF''9MQ1IG,B4>QAO^_BZ-31W%LQXB--GVOJT& S%
MM2<$IRK,&&A7^A3-FNP<''#BYI%-\[,D(CY.!FC/$']H71_:VQ"694LV/V*]
M9K;NRGO'AVVGW*+=CZ"T$)).D+KSW3VH<SDJ+,ED-2EL4LODX8'<-_=M60=B
MC <5'')GE=#C"R:+U$5JI*W9N4&=>?5D\]8>*9%^A]7TC-!'**J[ZX33A&M'
M>$ DQNBRBYN+K4R/Q*#"T6HS+?*GJNX=K$9SM?-5JCOV$*8O\T2C2%.I'#D1
MWO9#ZY>A@+(59%QHU1Q"W,B0:1-FK:G7,<RYG=N<%)77*X6.'$=3X#CUU"OI
MV)LZ<N5E^>07$N9BP9D 1T:)W3^ VT,06D#2"U%297R83TVEXG;(9;P5OS?N
M2FJK6I*?D;J?*)2PS]F7,G9.]\? GA&+!W6+;,HHX9I/3=I*&]N"^\1$%M_!
MAXG\$$ABFJB6SKBMZWIR9'N.VLA^TAN6^D.<?=26LMI%2OEGZKB+R\\%M)>7
MIY>/#QKC4SA3YY#^Z*SS_IS?X.U$2/5$M1\8QYX4+'8R_L/D_JL#.&=@Z@W9
MFC'N_)>5^>)S<+R+#Y/2C;HXEB"OWZ30$-8.ET K8A]LC3ILF/4EX86,$3*/
M CJA$M80OYY8*%UMKU%4ZJR'2;]N:FS.SLH<IR=3SL,X]W(_]DAZJ/2YMY_=
MG+'^<"ETM9KIJY0V*W*]_?H?([+KOD#+X1HD57]*)7G] DX6ZF42QY+8C_NO
M5R9^[YJ4J7I#J68AV-XYP9%*ZW-1^F[@Q^H"-,LWT@AI4EDXIX,NPN)WUI1=
M-F]^N O=SM$7*%_A4!++D0E_8!2TCL./XD]QBW51FR:ZHAA+L:(%D[X>4ND,
M;^?R?4/E.K5EYDKG!SE)3K59M@IG/JUH.4P*US:.N(S)'(:M!_%$_<!N)\AR
M'8;_@)<8F?](*+6FVQ!W>3C7>^6,XFQ8)A262K_8GQ.7K# O*EGNI?IU_45/
M^K^>"D#]CEZBIAS,)24>W)-X\EJL;N+.Z^:"W\EG+'?8O[B2<K+OS+X]VU]O
M+H)MNO1W)UB/H-><0Z!#;='$;$-L]FVMA1\%D0FR%YL2/,YL?J*:XG5VIWUK
MD<K0M\&+(D\%K"P=BN+#3C<2.8K^ N%GR3F$B:/]$&L0R+T"@4[V3FYV@VZ#
M;H-N@VZ#;H-N@^[_';HASJ];D9:S )VI,TIA'^2-@_ V+0LX-6]J(8YZB]""
MDJCM-H>B&%J7="9^ E(FA\PD"_-<>@..9!H2X-@S(QTY^^K(M6D71K2,]*<M
M<2\052;[H" PK%51OHQ)D)]PPJ+:#+;$?"PIAY+:/0X&R)[I"VX\247WV#@,
MK1BN!R!M*VIC7%RSNKOC ^C)SE\>7Y%%O5_B[+#C2>[E/N*)\F$8G"XWEJP$
M7U!F'?OL-O,=YS)2:PM<@.",+'J,25]N?NV7N 2\AIW?;T2E\F?Z,>3]OR5O
MX3V;THH8_U #?"&P60*=M0Q/18#VRG?"38QPY^NKH"#YEVP^#,Z1!.'C1CI@
M4EOOCAROIX5M?E%A(<QLA_;%$SG[6,WY3'?\IQXC!X/D[%<4+]0CDZWX7IH2
MTH\0[V+72KB+%#>ZP?)A2M:\'8/0+9G&G24A$A5/3DX/Z:&?BA5^,Y![_ QQ
MB;7U35BA;Z:;VF=_@YC2[?TPR0QV"O<U'^8+I_9V]F-7IU;;>Z4@/LS9\HVB
M[3-N*Q5"M[(S+HFJ#>#V,R+EZC[A] N?5/ZLF'&07\*RRCZ^U)I@/&%PQ=@&
MW+M\&!HQWMW9U8*JUF_5D<+^)3!2QB%"9U"GKEV<RC:;NVK.G!M39>=-7_@N
MZU6D+XY8K5_MBJ_%7LL.-E:Z4O_P+5!*A-1].(I$1L\V7Z0LA9[;K)7:$5&5
M%6"!&&MDI-2&H!E)QTZ\U\2K<6P';M8,A<Q4\&QY,2#;5LFNMH$$#YCJE1IU
M,Y+C1N&.0<[@.)T4K:L32]G&$64@8YMA8$]1]2<C!#U;Y (X'5=3O^DS'^8]
MH-L8B?8T;H\I)#<$1Y;,%>]O(&=&/K_Y["TR"P.I3W.41->U\;T.:Y:I 'K!
M99R=#S5N-PTU.ERW&N'X%MB.*I:\7@6N])N6<BS216@*[(SDX5[3IIAGXV_E
M]6_O[P'.#B,WF^R<27>(",QB\&'S7$.[6E)E144EN;&FJK*J)F%/;75U;;03
MO:ZV+OHD@T3ZI7$_5DV6D[L2N67'IB](,+\9 7S2GN/#MF;^U\70=E?&*G?S
M(@7T*P*6S2-J-\@VR#;(-L@VR#;(-L@VR#;(-LC^KV3AJTDFFIRCX.%N/DPT
MKAV^#7O'*2RP9@AG6N#J+_[^V#O)S%4DIOZI)*Y(ZU7:+L,C$C OX/]JQ7VG
M)"'I+RC5I#CA=_G^.6JLLO;(QS= 6ESYM7OYNV&!')L#]X3.*,7EC'Y.?HZ]
M!#QS_9LKR865XK.56"6&=\9U"\86/BQ);[SIRBF>?(9UWT)-D HR0=8E(\QT
MW\H+>#\&ND2#4[XIA/!A]VW-^+ GAVNG6W5B(Z+^!WOO'=3TM_6-!@$1Z460
MKH(4:8H4!22"TD1$1>D8%:0*T1\M0"#T7A0$%*3W&JE!"$0(144$Z3TD"-))
M*.$K).'&<YZ9>Y_SO#/GWF?FON=Y9\X?^Y_,RG=V6VM]UMI[?U8#*H-<TC/$
MK'QM= GEY^%QDA.IL&,O=:]L\_O7:VLDP>Y<E."&)*%6X4:O'#[KJI_3<&>
M3E81_VS/N9&YN2V[9!<I.7M+<)?QX]/P48*$(%#?C9)P)UG&:=\@N%<OF37
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M;9%FI+!>7=K\KMUJP:$[F(KHT +/S^"F)<E]M$X@DI0YM$6^#[ $>R!3NW3
M@YL2A-P$[U*?5[F,%.66C#LCZQO0ZD_J.=*DKCG1H4=CF^-6@U446S>DVQ%H
M5F9=D>Y)FZF)X/F<1V*V7),[>)_WP1JM'VPE>"E.I$)=0FY\S@6],M2E.5@-
M88QYL*&U*4E.2?OR_#07!\S&.#]NU?34%N-,,\OV)?J'-NF6PX:F#K?UX")
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M9?_!0E_O%']^MLI30RKCHF3Y=Z%'#RU83FN'&3))W *MPR5(6@1E[.]T*!.
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M/".9X$M0)9Y#&YZ[$':@M6/_X.$$3JPG">?</I0Y9] U-I[I'E)786?[K:[
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M''K4X,XFVN 0+D#_,K>=8WU]6"*WA63/ZEOP8D"+LSJ >ZF*F: 0A>G89JT
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M;\$+2A>!A0BTI3=-G=]==SA"W1"^925LV3#HA7$)W6U]*=RY*2,^.PN<A5]
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MF=;6<([J%I5_6:RZ3W5KG=>C3UO2PN4)_B$?U.:P;DIA<MBW.7-.2JLO1@*
MQC(0L%$"E P61N4%[DC!P(L.V24N!A;I1:KYMZZ:=2DDE2FX\]:?/-#\5P'
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M:;V7QT(0P;(J-O30:O\WAF4^&YU*2V[W:W7S@]1"Z18AP8,F@_9$8^71R=:
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MR;,#Q+/V;GJF7P2CLD\?H*L] LEI:KV]BW-?6*=V55-Q2>#RR9:;AJH!_)P
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M\&R#)J='YO>N,[; .&_ -106/CG9P]0EGIDS7PBW3^KO 1N<VRVMM0/Y50F
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ME@-F[W_3,RDWB]\WZB&-:$FJQ9#;6;%51JI[>3\H'3;D$>/<?P[&YP#04VT
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M27\31KNV YDHLDAX4VB<1%WFW3!;;VSUI<]2GU96'"W(C;$=^]X!Y_YG.?9
M<:+VG<%;@3#:'?@D#U5C>8(&!Q4MP?6)0[&WJQS,6U :N@>X8%,K5.![F?;W
M_02!>M&3L'8TN&Y\851[@ \!O]J2+>XKA'59#!5N?>_=$-2^9YMIC#;0"V,=
MYJ/8XFB,<4<@CLZ<#2UFWG#UMO;9)G4DP41^+#X2P+6+^!\IBO#7O?,]OT.Z
M)?JMZWO'CI 0:L&%=H>L^H^?'=G2WAG?AD$^%*7%&4%+(^W>H;[#JC$KRE10
MZHLA;=DY+&.#W!(@T[XY_]9X/53@=Q[C#1FT<J_MPMK0MAV(4US;C,*PGZ/I
M&+9]<[S1*GZE\FVC;Z1!MQ?7IDLBQ[=%@\2R 9L'"4NK8<L)5+>>2@>H",ZS
M4_$>7J?4#(YWD"\:_^FWZIR1'_9(NT3?ES)5+C:=6OG>%='C[$C(T]?[&59X
M9)"E32FP<FT8J@II*E,/$=1AU^')!8]P+!'H%W%T@]6R"CV'NAE[JN4(D$8P
MIZNVH53&_[!]KXVP+E8LCFW+QA9KZ5U/>NVP].B*PWSQ6^\\D!CJ6Y0NV>IF
M2S<W/I?0@S,<"<%[V)8W7(28IUG^']C%8*3$QT"/U"W=J1"ANCX)MA(B>3]K
M,M^?6=4+9\"%O;YW#9FM$XJ!V,F;PPK9IF<M9(NZY>T\;JS^WZ]4;]>.;B"M
M<,VBGQB(T<)8\D:6#6-(YW*?[/7%[927CQ*&*^I\?<^_L;AP8F!";G'=%Y 8
M:$J=/^Y/*1#_T:]O)TX*L)L+8XEQ<2[!>/#+&K,:; 7:7P@2%(L"&TQ+]/?9
M$C0%2DGCV-YVQ$]V,C"?TNX;P&H^^$%GB C-5KB*LMFYEN\:][IX+[%G3J\\
M,[N,AX*1S,4>-8VO%WNWF]NP\E<Q2M<%T/B27A@XP+)HUBZM,CEDX(3LE&=]
MQ/]/W=A]!:/FBMVR*=,&:0D,4T$D(32H1XC7WVN1^'$)==,N Q:X(?@]WTC'
M:T.K:J<4/AR>L(*?7$RWY$NZLWH4H627=S]+'#KDPPG&NPNFZ4DL;\ZBA1%-
MSH/:_BAUN]9Q%[G:ZJ'[M;&&X0;U13X6ZGV;&5^K'0\$=Q=[)EY(0'8K[A5N
MRD7E[>:8S'X=1P6C^ !O2HJ ^0F!SOB__E;M&3'?](?WORR43%!VW\K6R:">
M>_G4XY/QA2^P^XLR2?'J=S.HBPC_2HK-^D"@@A&_F5YS1E=/?'&3)N2B[]9/
MNND*CFD.O.I*H?,Z[QTR/JG&TBCY+7T\+?2AV\C1FDP'@62(X\W(?,-D50F/
MK?%V%TUZ7-(;$0#;@5*BZU/ZHN"'E_(*:^4?'CB%?3?M5%/-G1QUZ)">-<^?
M<"J&>),,!K*Y\18UQ*D3E>LJM<,AB&;#=VV$]^9O :1/SF\5M'IE-#D:QRVR
M$9>()A>C]P;?5'*!?J!CDST@6S?O>#&V3?)^>LK=WU[Y&ULLJ7_8SNPY>7V/
M)+:-.,LRIO-]00D)@.+!-)FE0=ETXBS8C0=/RL0J9E0[.CF]:<>F;7F*7E^H
M^<ZSA$F$D4L-3G\25HDV +VP";-7MC,AI,"B_9JIX=&&X:.T'E"*=,RQWX;<
M; V'*+$H5,QD-".3;IH/9:G@::E$BR:V2!O1(+,D' P'A0YI$Z>TZ[Z0T>W?
MT\<O?,+VP(10$_@]6H+:ZBR+=T &5?AV)>O":Q_-U;N%"LTCLT-UW7%'].T&
MI+H(?SNC@30.K\2;K_?3VEP%_O)],!1R0:0YXH9[Y+Y:ZEZK'V&U#I]LK'#I
MOP0M,U"D#Z0@[VH44$D2 *9]?74*VB[-**LX^S);!EUWJDH'8GY28@\ZAG>N
MG)[?#L/I=@JX/?*V 5S;T@M:94R_9Z^33_QN<3T\Y6M=F[;VINZJN9+\K)P
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MFYW.V/+LQ_ZYOGM,UQ5T4*]A==I$$Z0G\QY2\KO2Z6]#V%@#*##;T97#%]A
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MP\BDH/OEU@V:D<?[<5*0/=\DI:IT)F;2#+-T2C)'Q&2KHO.PIJ2V8E5/ =-
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MN6BS$^1>UN<)'T:F%#S;BH8WR?HNC]52H/V42 +CZX/Z4I8%;:%S\KR6@44
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MO*2JI+"#VB/0#PY'+OHG@$QSB]YFPK;8W1P;8G%<D"!:'XPF;4]_Q%S_U$C
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M"NN854%,BL^ZDK+$?6W/6QK4ZPITYSX_-G@O(?DD?2]Z'/\_-^'2GYDY,(N
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MP!Z[J<PR4R\NB%W>2A#D9I!NDQZ#Q6$U>:[#,_6Q8LA*FKIMH/T9*EJU3'O
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MJGGJT,#0X+A,^8E&4S# ^T3N]+JEJ!55K"XSC",Y!F^V7+&!6_"[YN^.K)X
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M96"19Z^>$DT;4&(4U@$I=$-UQD+U'%A$-!.UMD('AD\IR #+ER,Y,DP>4(^
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M/7"#>S(;^3!U)<$D0^984N/ >\V/JS"0CK^5>\L=5(,(K54(1B=-90R. N2
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M!;-I_S[-WZFR)+GGR%3*AE7(Q?Y[E"VJG:3VDP1-H# 0])62@M%;P4C93?"
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MF;DLG\A*ZVSX#K!<^]A8&-!0_Q3,"0&&Y_3;7TWS3Y>9E9?:Y24^L8R8EHW
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MD]'%.EMB9=H&:_Z-5L?YU2KDX67BH&!9;4"72(K]-6H.N*WV=._@I"B$W*H
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M^-EO87W/2N,*7$XWO(9Q8U:>C#\$0N(JX^:R?D^05^QIV>:Z__V%[Z,/#U@
M5"3X'S5_!C5,\3;AH!'@*VL:K+(TB<^1^IZ66F?\7^R]>5"3V=<N&AL5$3$*
M" I"5!"T&:(R*4/2BHB(&)6644@K(D,,:62*$!(4F84TH*#0$)%)08A( (5
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M*H^+>>KOQW/; Y%X2IM,D<%D#5)'>!MT#@E9PR5/ZH"M08#' ,& 333MJ9H
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M1A\V73R=->PVC#50BZK"V)8/.P64S5D?=HM_RG-3:Z#!#6ZC$TGU."8T31&
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MS%?_48+S\X::2E$=+?'[#6E>PPH7W4791.MS%S4 **:"[,DANRB>G+VC]G;
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M*?8;/;UQ]/]XT6='%RR-HM:3Z<QT%RIW* D.)RXYMBNS8J$2HXKQ1>-?Q;\
MU'$YI.DL;"QA'O'[BR^R3K7)E7KRD998R(%:&R<P Q!WM>WCT/?R>7J@#5J(
M2WJ4VR73'B2@GH2V[0.FRWC7HS@T5]VY-0>]O*G475&JF)OUL ,)<HA9]*__
M@WU+?'>)V/E'([#Z" 5YG^9T9-IT:<7TE4\&^Z2P8$IC"]8%!:X?$441%9<Q
M=9,=A'K9IYK]M\VUT!,/F<)?]/N= H(1!L"W=-K:*/TP-7C28*C8>Z\;ZOBH
M:52FPTR&_@V3N,K^\!M#K->$O[J2AG__L-'I%GI)0_R+Y)@TG[@=I$SC6!FM
M'KWM;>KY)Q(]7PU&/ENK<0L4:C$J\)BSOEC;B1R7;_,%#05GQ@>OW'UCL=MH
MDW+CX&4X$YK:I@.V M/ME!WVNZPF>NZV&>"=F9/6P A'E..%=BT!"UT;V)9-
M])?W:7GYI]XMPQ 3C^X=67;K:PI??OH_7SN=7MDCA^@1524_"Y43Z0>%< $U
MP7Z# )WJR1MK4QZ@^PIJ=(^/$B[%BZKM8/6ST3X/)NC?EG$-JJI[?COE?NL6
M)G1GO_V%INKSZYPT_[L1ZOBH<=TIRCTY)!29BJP3I3P%[Z 5[[9(S& 9$O>
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MJD*_-Y9:-20758[Y]AA^B\G/9>)PF^US_DHMRXK@,UBP%-A.NDG(-"7)_QA
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M]#P[\SUO=M?4X$DLHNX(W-W9=K2QA IZ^@R6LV\TS-6:6_(KB I?[L &9I%
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MYI]BW"_S/';VO8V\)3+P[%LJ/EM4>E(3.R( \NE)#K?XZ%3#?:/$$/ [4W8
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M?@*" (,9@@[?5A!?1K3O'.Y6J:#CN=EHWG(Z?P1I$)9+:&M.C]:<L';$>3>
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M=YCJ87FQED:)LN5>F?E(,T*-6>EVU*)U[&R^2"W*N3I .=&HGK$.@XS@2_M
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M$:6QC#_N.[;$^8^::,A1Q<.ZUDO)O,3FMTG(MT,BDZ9[A7?OP(VSYU<P[2C
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M&.:N06*UR(6/U)SWD12LA3SMX:5Y>@K<LC-X8T.ZKJ\(AA%1N[+;II#/?Z)
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M99X6LO^2<'WB:_]*^:WT*.];.<B&3*:-\K,6@3T/VK:<5K!?1Q%LYD(5",[
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M'VFBUYB9(]D[8>K0+""Q%2;.Z39(F!M7/E%/V"M^"+KWA)B";VZ=5-YR HY
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MD7P(S=^$E&MT^4CNBVQY'"CH9,\2F?+<%!V!KL05ZZ-F$ZK,29T!HP8_J--
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M7Y T3$*BA/"%DKZ*1.>@3-=E89^\_AR"F<=A+,"0I)8")@>;D@B5"")#XUN
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MDITMB=#M:D6K7"23BC@-)=$4,T[P2*0D21D>HB6I!FZF:>>\2UTVXU:X-$'
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MS%^= 36("CL"O:R;-#SX?0237)CCYD#WTGKU6)U<F_4-#\?0S* ; TAD6#B
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MC84;ZG)X>T*Y .]F=QZ)OFW610"*MBT\E?NV^A ;;0?:4ATSY6&JIBX,?#T
M%O;V-[SFZ()M5UZ#!M.2)8<P)Y,>3>N6.&67U^8,U+2Y0\F936_OYL5 R*<G
M:AT6&Z0&7FS#=&K/U7VQS=K,%MAPBK^8+?HQ2=V#%9B&LT^BYR]??+TTR(:K
M%8,E:N;K;\Q.UX97#T&208OX]DDT158A C!-Q-&9:>I]C,3ON!A>"1#FN.D8
M)EP-M:MC@IG@IUE]O20(-IB[%;\LEC*;$+#I[=\ZV1O3 C;7ZL_ )%S]:5Q?
M_>7O!IAK;JG;"TBW.R6@M^)B<K4R2/4P,O>0=W B8!F4"Q?$2*G]0FTVX ^&
M!@Q79SH3U<6F]ZW(76H"XKPSG B@6\P:P^G7Z'*OINEK5RBV+=K3AJK Q6^%
M(W97*JIN'ZYG#^#XX<4AD,S$;;8Q2VM.ODQIQ6MK*\TN_*0XT5P%'8LQS0W^
MGN'*<@B8V%7Q:00<Z&5SBJ<VMW)V03&>2\8?#Z\P\1SKCNM+9O,:!K*W,X$3
M%6 XN+HBE\-KA.AL6_@)6L#B1W59N$:A5UGC;W1WSTJ):X^WX5,3H>L"G"X3
MWR=!4C/#;FLMH:26IBVYY'+2@&>P-A&N"O3W1$!G6Y,#WBM0E#=%4K("W4L7
M;=9]*TR +ES4(S#0L'3EBIP6NIS(Z8+<7"&I*2B%<MW)T*DBW&B-N%-3-]E'
MF!(-$ _>8IK!X$I!;UVY+7QRV%#"?,FCGB]G8<K-==I:Y5X[ AI5 @QD4;4
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MH._:+*8S+!AH2ZR1UY;]*EWB!W+W2+@<_ D$/S:%F1Q:B(97@9)& "!WYME
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M.H+/L FURLE;N2-KML)BN[^[T13;OFB-_XW6QX6[17\YC?%7@'79>##Q_6)
MJ'N^<ENXICG!PGB#$@,WG*<,]WTGGB]X\2E,A';[6]=?-@!Z=U5(W(DK8N14
M[[%9Z#B;5BYVNU:3RG8#K#HT;%P)K6W6>C;:C9?IQO/L9J\M\>5PJQG!@+-_
MCRN7GU=Y>U^.VKBZ*G/UP=']736Q(& D0J>(RO&?^<<.?ONZ@P]BX? \QW_=
M3MK"W;.9;@S$/YTSN]D,/S73F]Q+/WWXT/1%9L,2S_^XW#5WU]\??'C1!SFL
M7:3N3D(.#MK @!]UMAXH2?<<EWQQ7'+4DGLO4N>FZ !C;[UPMGBM=RUA&60;
MR!7OI[^3KU\^[@:.IYO/X<]S1=M;^;G1V-RN2GM6U5BD<.C<4.Z(2SRJ!O//
M%AQG5AN,9_-.1&Y1-@9^P#>]#P:KP&,QM[RLT2?L#!9W?]/[0+:]N9)5O3%S
M3[CXEB:XS\G@QNK#*@2%+@=-[!ST4^9@)\$S\ VL>F5DZ68/*RYBT?MVA@PH
MB?%E]=)I(Y/JJ1MM2=5&'H[*'&1R>Q TC)-R;^!R58/FPURQ8IA46+S)*2UE
MY722FU];EDV\H/[G_V7OW9_;1I)TT7\%L6=ZKW4#XHAZVSY[(]2RN]L[8[>.
MY=[9.+^!9%%"&P2X "B9\]??_#*S7B HR6Y[6K81L3LM2W@4JBJS\O'EEZM2
MCCQ_M(#P"KQ8'RREW<'QGJ>(Y/NQIDM3\T>LN8>/.S4<ZRLYC,LJQ_/TF#2S
MG'8M%TB@PRDC647;7YPSV'!!LX/S6,^79(XVUJ:<:BL[&Y%S.28\=;Q/ZL&\
MC^8;[\BK&3_[Q8\7:7=:&$NBW;%U94;);T@%Q^25>#[=;[>8W0[X> ?ITF5,
M$QK:%0?VW4PAXB_<2?39V$ \6WR6KY;2?*8V)EF;K[U=V)^@GR]TM_T<V"CO
MV$8Y%QME4-I;RRV\6CL[_]N[6&>OG5)N^OAA!<7.:3'&3[05]S<&-MEET$)^
MO68U6>1LM@F/7AEV/' R%.062.K8H!S9T7''FC^F9==_4,?>KUH_0:>.-W2J
M?O>#="EIS%!A\JT?I2ZAUCZ/5M1UXHF^5PO"@]HML@GY/T@-E<Z@)_68?HQ^
M',+N0]C]L8;=#X>P^[<8=A\LL7[(C>\F%P39$M<^XJVVJ*;CP@8EOE=;]R/<
MZO$S!XUX#"I-!^6<5M\5-D<Y.;K<KFW?0S3:N;HR#=?K,,XJV!:W9"!I7!&^
M*"*&8FX%KOP,9+)D']"@2V[)K.V;M2( [;L!RY5Z@<)8"Y1;U%:H*)IE.1K\
M5(Q"::;79K8J3&BDE6*R62H;[LG%(=:\K;5R7L#"]-G)Q)@R6;6Y.!DPY&C0
M&C[@1UE[VO&QA=V..6[!]EBF%XXGZ&1:-E/Z'YC+B^Q*OH<LBH62J;%-].[U
MI;6).A!F&M7,AC80.T$]<Q/.LVM;;LU8CNO"0B?K$'R-$GP&$58M]17FPQ2U
M%W*U?5W0YV4&CH/\1C@,)!9- F;:Y/S-)<U;TZP,O^3:%$M'?L!+:</JEBD+
MR1X;?(E#*J/'M.6304O=JQ!\^,RI^W=8R,>EO$@>?YVVU834S_[>_EAJZ,JR
M0B?6F0LPUGI.L:P^)$+8(XO,Y_$Q_FD:NK8JZW"[Q5\UGQ01W"-O-:4OY?\\
M*#*(0D:O-WO]5Z\\H0!G:!\3>Z^25K(NO;BQ\CV:C.(&XA5Z$=)0#FA0?I[D
M._ N>.SV%+&!76DHM:R6JAOYZH/]@XTK2:GE\YR5#U:>Y&]7JKR">VTBS7G6
M69D5:]!!))?V<=?9C",57%M"6T7JPP[W1J>D&,<G)\^3\<'H0/Q268/3T=,?
M4EQQ_ -/^1&9UC]87]D-DRM/7-V]1%GHN[/W#)8LT23D5MJIB^/;:"U<-GU_
M5:-@)3F[?+W!PZ:.MV]A7>C& '4,S[H&7FDXQ]RT)T=#8G[4LL[QMLJ&26A;
MZM+I/2Z&L!F2S:9UU31^" G&N&Q8(#JACH/1D<L9<MB8XQ:CY%>9H/W3HV"2
MKGW7E)F: SV1W:?'F&$6&[T,(MH5'73YWD4[2R<QH;2DMDN9S!OS_G2Z_7WE
MT<,_UQU0O?G2BEK@"6@,Z8^<$E_\B'OVF,XP%DJ=4#Y_$A2<LU6\-58HI>"!
MTO?FG%2Y@QZ"S@ %*X0-D[E0G6RW74]73W*V4BLNBBX&8<@G,S//]1S</R73
M=]WLZ,&PJ3^8C;LGYI@\H<=5C#<0\Q&:#7"%Y\GRWXOV^=YH;V^\,TIL!H Y
M,3CYAW\M3-:PFK%&:I@^1#(W.(V665[?@DA+1I$W$M\$_Y88N^**A&/C%M0Z
MHAF'-'%ZY(W/6J(\"C:U/,N?D:36Z+FYN>%7'^W] #U_Q6=>'<QM,)O;)BZ:
M_E'D=,?V^AWK^X#%W/9Z)@+9F+@FG"4<LG"2Y!B+=F#%1^V[S73@1TT!SIBC
M_='I#W:9PW>(O<.G$9W)QZ/#_JOV@JO8HC@8[?=>.?971OMU?!K<8#^=+R-;
MPL]\,.]3(Z>CW0=VGGB7Z?'9)Q&\N?9)IV#?+G=QPBGIA1,(?I9\^0U-L-Z9
M;ERQMW$%>X;_09<<'/$EX^XEM,5@-L"\$//*2YM3-=;484/@5LS@#2%)71]!
M^XD;\B(/<,: M0DW-%E'G,A?/=T[>@ZING\?-0F8 \@$<M_'*1?9AVKL1>;(
MI[^(]^DA+)5[]^G!:/RP?;I_.CKXN'UZ2-;IM[1/3Z)]ZI>QPZ;25?^I*W.B
MU=VU=K]8Y8KGD_C."S,U"^LM\NYH3'R/Q=?=I?!YR[9)00<2>"9.CAZR9;;F
M\%"C<O5QIPR*<OI?>>^9XDPVZQ0#ZM*P96>#8(S0J5!!R5E5>"K/>9.X=<<]
M=C/H0:'YURV'J_7-(F6S[#WF[1?XS[.JJ'E<9EO'@1"/KJ=N[?B'YW$*$[$@
M7+Q;9&MR]20')*\X?3K:<Y=SP=*R,<\:0S-,VI+>2F^B5[E,TTW>Y.+Q/+-7
MZT5TU2P&J1^<C$X.?PA30/HQD@/ZZY;;QB>C_<=_&WGE]][VO__:UMT)U'S9
M_M'H*>V,H*).TG'X1?^>VIQE735-S2W;I*F*?/8\2MGEI5W<VN;IW(7Z!]XS
M?0_0/^R=(+7'_(&D7=23I(=O9+?]NWR^>^.A=ACRU, WY3]\Z<R@IMH?GAS\
MU(Q?._OLR_6095GDLQDIS\^[,C9J\'BS[AO^^\?B^,6,^#H@!I_VL4_*_QB/
M]W>&3?J5K=M9UW[_QC?IT7C8HU_;LIUU/<=O?(\>'@][]&M;M@MQ#+_QG3D>
M'_9NS3L\D8/#T='1'W5%_B4^Q^?;[W\"_O"A2_^@E7XM\>Y/C[S?I[X&/?7'
MA?A!*\F9AZ]#*3U,!P5YM6&3/9)%X<35L,F&3?8E%X5SGM_4)I-$YK##'LN*
M<))\L&Z_>>OV(LI[?E9<UX/>'V1:C_9^^"/O_XCLP:?G<P?]]$CT$Z,SOJD3
M<#"S'MVB,+AGV&3#)ON2B\*XL&]JDPG8:]AACV5%&$@XV/*#+?^OL^5/C@9;
M?M!/#ST!GW9L^6$U_MS5.!Q6X[&LQNGH9%B,Q[(8QQUW<+"C!COJ"]A17 #R
MQ<VGP7#Z!O31P7 X/);%..F 2X;%^#.-V"W9RV$Q_HSXTQ;)L&83_1<5<P]M
MI_*M4!4.=*@#'>ICID,]&NA0OWH=\T?I4/_$-DR?OR6V(S#OX1$P-7@/I40^
MY@*8Y?,Y75*V'O,]O<[J;$J;ERD8FN0*+%3"F:E4/P%;#>[/IZLBY#63%T3<
M:&"C$Q*>R5K(+5?,90": &;[4EHP\'^EH"&;5HN\!2<,,X)59:*$8MQ]ITO_
M-5F1 )3"F*'L9 9-E*M5B^O ^X%)$1(*-S7H570'VXNGRZ!Y4FH!H8CPA!-I
MTEPKU0"F!S0.2E(1\=K0?-',-"9X;/RN>$T*4'[1<<>W-(9L,>;*]$OTK'/.
M;JW?/QJ='(P?2PW_P>A@_^/+XW';)U35/^BV.R);+)I?H*8^L:KAH?:YNV%+
M]&OC@=:./_WCI?8;SW:V_.DW$ A+[G.A/O<*_LM7Z*MRMCY3Y7WROR?U7S^U
MK*EY>%W3L#D>_^;HJ=1\0%)C?#@Z_%?E- ;M_J6T^Z\WS.8.41>K]7,%S :)
M_=P@E_!_A3_Q@10CPY+]64LF+).?5B8^Z-=O0;]>=-WVY-^OVN?)\2"SCT]F
M#P]46@\_7PWBL#Z?%<*LZ]./*Q^4Z7>G3#\1(,.#GIEI)0V#GJU =2RQ4D[*
M?L0Y7[3/_T4@Y^',>(0ZZ8@)G4DG'7^^6I=A?3XC!H2;N6Q?G^',^,;/C/-N
MDNP_DH-!4!^?H!Z-59$>]7O*P_K\Z8KT4-:GGXMQ4*3?FR+]GFSO_4$E/3Z5
M=/1T="(JZ70X,A[A^D#OW[4^PY'QC1\9/W80:!K\/AT=^4:2@^ ^/L$]VM/L
MXNG!H%@?X?JXM.+ID%4<%"LKUN_)&!_.CT>NGT[02QOZ:?_I<'X\PO6A\T/.
M]X.].\^/WIJ\+UDZ\MFTZ.>N&PFZ4Z;<7MZV#D:[T8U2!>VN;O_0K";M>DEO
M1A5$V-3]D]KGTAM/C]$4%/)UL(-;_OU_G>Z/CY_C)<DA_^/D>1>QRY47A<FX
MY^>5*0'[XW:0W*QY=UIPSV9W^99*#K23;6D64<9B;@PWF]:9X!]00B"].^DB
MO*GFALSXC4,5]W_@M%K1TV8KUV>RIW-\,(%9_=YL=+FF@\P5D. 1J,:(5VBZ
MJFO#+5)] VN\,&S%ZIM:?NT=Y#^W%$@S59U[MVF;N P(M3U9TU33W'?_W=[+
M.E\LZ^K&++BLAYY3*1X5=ZR:%"51]#!#_\<U4<MKVFOT9'KIJK$[Y9RV"#?!
M_;FH)O2?5PLT(6VTO^KY=59>F10=N\]_?K5[KL51KE$Q#;V8[]:&6[+2$_US
ME0+DWL=>R&,;&H*7G*W-@J6-,O=DI=U<NE[GOB#K(^J6CH]//J9N:?_+U2T=
MHMK^H^N/]D])DWV1N_Z$HJ4'5S,,C4"_O4:@GW]9'K^Q.70!O?=C'U$7T&&'
M_H&"J&_M$S^Q)N$/GYQ?TQ'YM4<)V=Q-GES L!6CU170+U9D@ZKM/8,-2S.X
MCG_[KZ7N_AZ5T\>W$OO7%'E_Y3/VIS4X&/;P-NQ8M^?B<-1\8T?-Q7#4?/UB
M>KC?:1'QE7^/-"$93H%'LAS[XWLZD SIIB#0OBV S+Q9=\332XER<Y#[PL>[
M-T+2>Q_Q1'T.?7]A[GQ2]/;NA>/@PCF= [0(U]W!V@Q/N5J8FF/Z48( V0&;
MG$DFJU:R#675;A__GY'#^6S[:L.W_XB-QJ]ZEK<TBNE';+W+U8(^AM.,2F-W
MF<U-NT[>FF95M"Z_\>+'B\]*BOZY1>C9'QG=YQY,$L8\(6Z:@*6M>FN*(FFK
MPM2<+O.S*YFSLY?AQ?3$AG8YDE+\UPI4>HS&%U:_O)SF,\YOTO(QS2#D9I>D
MI[[B9.V,!*@Q":=N&TY>O7M)KTAY4->T)/0XFY"RMXO((@^G"5-.&O,U5A1M
M:@MC.MY'(4]H >H#.Q<?GP =W'/=%IU!=YP"5G+/'?OA'= KIT>C\?UW!0K6
M?$"VF6:1$\.VG1$M+\^53#3/FN34605=8;*0.[ZFS4:S:OYGE6%9DZ,?\#ID
M-/U\9O7"YDG;MLY)C\F,TD!NJA7IXC4M\0+4AFPS-,^39;.>7N<973P-?ZT;
M(_H5C;6N<MIXI S+^&]F;<)_8G+R<FXTB<NX@?%S643,SR+[O6)*1293]8L.
M4P%OC8>;)B0C;-\OJAEO9DD+"RVC+$4U1?X=TVJRFK;SQDZ3-/\H.1, !:8M
M7"6/0V@8_3 >[Z0RU(I6B#;G@GP/61J>WEG^SW^"V)*O/MI/D_U#VD%T3U,M
M2A(Y" I0, =I,CZ2O\QIDURMC( KZ-=[9+/LR.BO33;+IM?RMS'_;>^''=D/
M[)W.D,X%W$ 2RXXZU Y"82'A5PA%*&;$2D?.@C:OBJ*Z;9XEI_YI3T[POBW2
M=!!<=SPZ\M=%$C0.+]L_"J_;D)N#X^#:@S&F)T:%*"#D(7JGP;K25NG1/Y=.
M_30Y[:"LMO(RKU:UB J>>8T$^&JVECG=WZ((.I-RN$43;=4P!\#5?*R"V3:8
MC]<O/3-WJ1H'A*GXGP.4,X=[K/_+D8SONVSKEX\/4$MSSQT;GTY2<WK_7<&W
ML\:\SF; 4)V]9#P2HRVJ0 F0BL+)F9<KQJ32Y]]6*M7T)@"$8)_4!L<@@@T\
M+X+?\ =H-@7]\\8AEO(\TV,$A0%055X+0R^DTF%:%"0""]5]6FT6&7/STCMG
M]>I*MF)9Z2D\94!(@ST-]5O?R/#<ZM$.IVO-C1>4S4\!1FJ6K);TX\+0%%G:
MX:EQVF/C6+9*M")+3UX^R^DE.'_(O/'B<R86=9G\5I,5=,7&]9GB=/#NR_5B
M2<9K\@KLVIU13[-ZEE<W63-=04)A7N-E<Z8@)@-(!TY/N8'!R1<T0B99\T%T
MA9'1 EU7;*A/$YQ/= :U?F?3:QJQ-.7Q3?A\?I2 ?^0K2[/2SR!YRA9ZG'4>
MM^4Y+\]_IHV@+RNR":\9+P8CV4;)/]@X=2O*S\.IUJC9Q6OSY/+%CE_T>;(W
MVD_>7Y%:'1UN4])[HV.]Y&"+?G87[/<I9I&YT5.]YFFO0AZ:"PS-!;Z2Y@(Q
MH\W07.![;"[P_416SF:N]\ %_)5?JFERN9KLG@5,^QIR>9&U&2O[5Q#7?)'\
MNC1E\O=L8HKDY0=Z'J-0G]"E.WSMXPIV?,T1MW]5PPDURG2]9UCO9G5U!1/#
M]DA(:% YC*K&M+C>H(5$ACY\9*YDG8!2#^):X,P9(/JXU[!%S/XR/=BL8(7!
MZ U-O>R..'!<I" %#)O5"=H% E;VK3'O9:SDS>%-0?R(QVA1]LG;+1]*/W>_
MLS$D"!QUH8>/->24=0L![B(TEY'C?GQ@7WG%P5-$C!R,@-Y2_L?A\0[YDV,F
MD^*TTB%^>[2WPV)Z=,25[AYX@#^.QWNQE9>*+:=>HS?9R!@E*WDI"U2LTRC,
M9DW()_MD8/X@SSW<&0T"_T@%_IT-1Y'I;#A](AJ<19QW(_9#55Y5D,Z3W;4A
MATK5 /U_BATCSND2$CS-Z9O8^9R:G!/HM,<1JMM[^KS@\R"4$ B[>+*TC<5Q
M@.-#+\\+#9W,JVJ6:K\;VG6P!]EI?D$OX%XS^WO[AZ/D)_AK.D@,S08W4E>^
M\_KBO%,#\M.OEX$@U?",9O+)QR1/M)=/]W^P%3[\E&2,W^+Q$MN17^X?LH"(
MUT4>=RM>-WW;*4D?_:=[P\'Q*/'M6J\K&Q' C.%=_)9]>FB;[UJ!AQJ8LN,K
M82CIJ!,TC_%A&GJW1L8?^NFQTND=<?*$&[QNU(Y!P(]/=M).J%V"$_:##H2
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M@MA4D+4H9I]B4DAA"T,=^XP+A$'+7G0:-OSX^'2+>8!CQYL'L5%0<:46;%)
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MN,F*$?#'=\K()VOVT1;,)D4VE<88Z,2=&U/0L2MG;,K_I*'P87NURHM6:I7
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M"6Z3INMM<BL \L?I*E8<S)\D^T1) )AKE3F4%M:H15E%4=G0Q<*TU]6LL2$
MTK0T=0@HM-8O735&\HE/]G>2FTPBE/8V&I!6Y_B*G6[MA[0+0HTN,PM4DB,M
MV-=N3#Q3F1(IV2H/^CEG;A>:M,,]A?0>/.VREC*[#E83E#7*4=PH8P5S;YAZ
M(502F= TS$Q+N@]1:Z:.6MI4+2@.[ML$=K7XXF6^E#H?+MBND/4%>],LGR'B
MG((TEMO;[.\]YRXW^\][Y9LO&3\'E4)UNU5#?K;JA4>1=7H8>1I.U-W+%E0G
M%SK7S^A)'UKE2N*5>T7_?WZ-RJ0B>4V+4"".-O <W,ESP"8:=K#;V#"L88YE
M5W9WJS"1%L4L3W6&V59I<Q%F3JC<<%T9I(GDL5K2,ULRXW($X.BW337#C_;V
M@ 6Z27T %:PYD*)YSD5@CI3&!P_%'(/YP8I/^1D\D>JK-R_D![16$=,X57U[
M-,)?=TT)-@;HOJI^'](8J#*T[_S;S8G]%K:_0HD6JSZ@/4%I'9\\]$7LB3#M
MV:2NLIDPT7K>&Z&^5J-1"5QM%R9/AK5TJ9'M%!.D6=#&-FO8\L:U/UZ\ .M?
M4/?U@"_.N \.V;HWX]&63Q[9O\)A"^EF,,Q=UZ"+Q,#0=#OF"Z6ZN%[1/N64
M*KZ<%@7/Y-'Q68JYJXVR 3.CSJW$,)F72$/H8E+"Q1:>P47>ZNQ!8R_S*I\)
M10\;M7)\V"]SG^'HP6E;\P>-767L+?DS6AP935G )8$MA,F&D$8\')8Z75U"
MF0;<K.\0'AR2!Z0T]: 4KANFC,)B%&M<SW2((BX!=.)%31NK32[7Y:RN%F8X
M&3IUSEG=EEPC?.'6DG8U,]_0L4['\H]YQ6PKTX&3M%/Y%;!NCY]RY1>+ )NH
M;*05* _7/1DDO6 67M5&ZI/NF&X^'/0\Z+!?>3Y,I%O\TUA^';@AT[P5TY1;
MPJG.2((#*+4<R>OH* K*'\0G9<$\YFOXQ_V_XI]Y>9U/<E@-3L-GOD*5S?;_
M7)5HB;2_SYR#H#\6Q9XW+HT7#2Y-WOSX:O?I_OC@Z(C4>?BVSHGH7DYN-RL9
MVLN2JM*ED#S@6#U_A*M9K4J.C>MMG(8)H@:8ZBF=U,BG@:V4-8J=^Q11#U)=
MBL^-2FW_<C(Z<AR1]%_2;V!_769K8;*KDO\V)2(Q#["H.:]H7"\]'"(/V3U]
MEO-Y.+MTQ7FU6)@:435>S;_K?CVSSV\&JWJ+^'_T3'[-NO-/0,;]/5"=T5S[
M*;U[\[\JIU]U1>67/Z^@]1:& [;0S5FY0L*>0RN8]9_,I+:_V?_$TXU]"4:D
M]B]A>M_QY]C?."@5/H,-OX!QE\GTV= E4]2>8ZD_]<(3;=OAT:2!-_'?+]\\
M12^8FJS9A7!=NM-H7YP+>S1$-FWHZ2";]>Y<:3B" Y@\ !I_H\/?\OG\)4(J
M#K3$!QH8.Y(UH[^0K%G5G.MP!S4OA-5#M']TDOP!(E<H&3CZ\? 1QT1Q=RW3
M($A=4LC-U8+9@>R/72;:.-4Z*]KU[H16G9X*?W,B,L.@/"L^8$O5?71G^(R7
MW849 _[0T.?L;H&0^Z\QP<Z#E,*C+6;TC09.9]YLHIA2L,O0IV@&)H=K+5SY
M_%@.=6JK5.$.7JN[2B:E@<$%'D1'?HC*7Y/Z#8C1_A7YOJS(9NO4XJ+"&:'I
M-,N/W*S.C[T"/ZY$0;<L&KG+5;D;K!G^^677C4P[8RPCMU\/_-EV*)FJ%L7X
M+@T>",N73C154\D3^M/,S+FS#EMF@@+N;@TA;)<A!BL/G7&+V!/Y^3"2P1ST
M03T&QU"Q56'K.U[:.\[M@Q]U5ZL!V34@NQXKLNOI@.SZ[I%=WXAM]$**E:W!
M::,7VP\3ME];LL.W'"H>4,0G%O("C,CA;*U+? 31D3M>5FH_F%MTSZG96-&#
MVZ="T0PE+W*N=4$F=0EJZ%:-"#D(4"XJS13T7QN66 J>_=4\(T.@9A,H-LHS
M=QASQ)L=L;SU75$<Y"/DKY_DF(U6.%#486F2FZI 7F_WBH-.L5O3:+C,Q^F.
M->7A7E^;N:D5:[W5VAB,_RB9JKT=&9C?5(61#0!L46X;=:"":EHAH\'3K9>7
MW)E%>B-PDAL+J.AZ.*[>5^L:],Z>8SIPF.#533XS=OO8MA5+M9V]E[K]2?Z]
MZ3;;N#;Y8D)#QM":*!(Z7Q7%+K>A,XME4:V-43E=M:BP6%93-#A %JEL./G#
M%)4,"UNI+]P=LWUT-& _-[7'[M@KQ:_>,G8DQ19HU<"1B-GN:LF=2?2#.![W
MJ,W5[UO&V.=SWDRP#39<P'"[J'!LV1&]TLHT-!!#_(E%UL*9L'-3W_^X(T9>
MO0>=E:;1F873I8,@LN 6A4!Q:]0F. TB!UA.LMV?Z/?<Q56R 9N.'WN[<:3(
MQ8=$F;/&V9VO%* 5?@N.O]*X@47\H#[%KGEF8UI&Y\(E-S-N@^:X@"R0=LJD
M=J:YKHJ9-,Y23/<K][14%1VKQN[Z*1>AY?!%9B2?[7)+&G11N,I;G,@PWS,N
M7.*&-6P6B-..3<+]?[02JD2O*1I8PT6E63%=*;:+U, J*]U,/\R H.]X@U0R
M'LC]OD2]R^QM-@WK7<)1\FK.L=0/, @:TW]5NAG2;*X9V?4_*TF!TV_P[57)
M,0D.;E;3%<8)?FD^?(*MK+GU;;(A1Q-'"<AR4$(Y:UQU-DSXS:ZB5_M\,-;$
M+[0$;[:.!M_C9-+I]_M>.>?&L%<"4%IK=QO@7E8MFBFY)4@LFE&PP3+;,TTV
M+FV A9[NX]S2-/5H.!D>Z\FP9?\NLQP@2X1?5\MY73&R9FUWSU^.]CSBWO5W
M]"GROQP$?W<W0ABRYMJV8;8M^Z"Y5$UT7L5Q3<_%[<0']91KWTMWJW()!3Y*
MM#! GX7_8D6F6Q9F%?LB@:%N<T@KA<X*EJR8V0Z<K%2:.P*D? (BH4-OY.+3
MI1T#>2M3QF7]93^8O\%9B%-N059M/[5-?H2=/IS5380 )G9\%&Q,>SA7XE;3
MOCT>G1QMV[=*Q?F7T]&^OP:@/O9$  >47>? 9DYM_E1I6^T70 B>*299]NO_
MHTU?7YPQGN#D.:SY*90\^^,\+.#"*YIQR2U:M$. $-=.TG$'TPZ',2/-S4PA
M>S&7\.7YF].SW1<O7S)6+\Q2'O7C10('>&OF+^GX'M;X_ 10R-WXDZC-$@,=
MK[D09BT%0E%/\#\&,%D-+LZCU0SOMI\$DKI2%U\4L-^$7F-L>O;.)-K8#4H\
MOCW+ON(M+%TL_G*P'ZH=Z3T6A!2L'<:%#7+'_F&X&1F>AC")!/=L*$\O)HL^
M^Y O5@O?$".^KAF)@;TKJLE]3#C$<7BD^Q>Z5['!/#%B&-S_[1P=$%>3*8"M
M K9"[HQ^!:>ZII[1Q\P12?PZLF'?M>SU;P4]T))J4BA0GG?'$NAJYUIVHU99
M) W<7+I>*QA:RF[<UH)_PUU@GB5/\AU%=- E47,^+H?U-3N,]98*)QP43[*=
MT$JT(_Z=:4:U3,<FFP5'Z*/Q;VW@[QV'Y>O8>P=IDE2;(JC'1$><,\*%3R8[
M4N00O8#..'__W?EX+B!@^9QFC0D*P"*_[CE-"^;%E%S_&O1*D'"$#Z&S0V]G
M+'!$-;3-:Z#E5GG>.]6!KK2I?]A%T"-=[S9\J'/JWPI @.=RY/[EE"W[M3Z2
MXXDL\3PW:<S+LI"ZLPAW%(\UGG88*F0M<86)"?32S&@D9+*&+65A23Y4(LNI
M!7KR><[T8K8VF%GR^U'R6XGB;J;&S'&7ML<$4<X#,SLB ZY<AL$F^OC=R7JW
M1VKP:RM  D:AG_-BBZ"$*W#ON@VJ^.M2Q1R]=YONSFU&*XWP+:RC&K2)5;UU
MKW$:KG^K::"WY/O+2@-K*=-KLAW&]K>EZGRZE\RRM5._MS7R@R7"3.00=Y(S
ML@]7I:-7"EO-LHP@.C4)FU[C=-@\9WH,,)&/.]!HW*$;T^-U)X?:7-207EK5
M;>/;?*- GQYD.;,Z/MDV4U!5]^:@7[P[_Y>-=MP_VF (X9G0'>O'[+$O\R4D
MJM<!3B_N"3=*7DKJ6E*)'R4?K$!OC&4B!X<$SP^@(1P( TEA822GS2^(\A#!
M@>5PHQS#WIYGP4RUA49S'S1,I9"$F;%"# UV?SQ.-B+H-%KQ''DANC,#Z/(?
M? 0;#IJCUIO9+EI_8$N7C_O]A,F:NZ8]ZO-D +H-0+?'"G0;[PU(MP'I]FV8
MKK]9QSZTZ.YQBJR5:>U+G$>*)@^ ;M;7NQ^]SG@:Y' *;UAN6*!Y=%X&.(BN
M#01;2LFW?$[;6<V,%*+AJ6NU8<<B!8P^"L4ZS*F+V]C_..V_&PVN]'AU,NJV
MHSFXV(*A/7@;SQ2FPDUF@!/:FO/NP^K+C#7>6%LGI9F"H:D.&:*D75@KJ?B5
M$J+>D4'KY+33+H D1@A&>ZEG%E,Q:3J@PY[JGVVKD)?=/P6+<HGEM34.-I!J
M2R+FB-=N&/KENN<U_.&2?\RV>126Z-H7"2_K'/-5!02Q<(J8?J!K^<70T.Y0
MM7J#^2.<>9>!K&XKGH2=%K!V;;UB9I9&<!J5;?^6"3M%![+0046X@$=[_X?]
M*<UXO^92T6W)\:^ZY/:+YZ*[$*CM%9H;A9_;)EP( 2_.[J[J?! ^8?_H-'UZ
M>FP!V@^%*W M9G[#0 40E7G"A#L1#%&6_,E?#L:CTZ,C:5Z/-^XH47=\HR-=
M813)^.@'H. 6R"ZK*WNPMSLC+_0&OI11P<"U&KV5I^2+!>>Y#=-1!LIOR45G
M-",EZ>9I![,ZJ(8'TLHV@(SVX&9X@XZ;-OF5Z5$O(J3F4#W>IS[.:'L6*!T_
MZ=$))7/#MUY&LH^::M8<[IJT7T=DT_]9Y7@E@Q_%2-ZP10+6O"= I8)KCT3K
M?5G=,N!O_.O%_OCI*6N:_W[Y9CS>&Y-X^^$%][CWV7O8A/BOK# 86><[DK^O
M/IC%A.3^*KD<9:-Z5(R8#M86BG#D*2=1EW8_/V:KACY+6% Y;9R52#'*;+35
ME9%:%7S?ME>^@F/*9!.+G+,ST4/%0*)E6:%ZW96J^OQFF'3R$ ./'F!802>Y
M]:AC7]^[A%Z:9>L('DY92M'WV(+-(H&,]Q])SF2U!H:6A6N^XLJE'B")WQ,.
M:DWWQ@^[0R;#+6?A)D]'QR'(S>]$SQ(6NDXA]A?60C]61.!O (^WU2Y,^F2;
M26]W>%5V<\QL3I@/VB5#\@GT<*E\"7%ZQSWXQ\>P)0;YZ)Q@JZL5*7JR?_?Z
MC[ 0L<@>W+8S#=?CXJ!N:<X$T4)(*#=[1)<4-2RJ&:BU!,(ANX>DQLQ66C9F
MG^6W,>S.NEK1[G74+0=C!JD?\@<POIU!3G_9#P!1#M1I88@T%M2:M)I="E_P
M#XMLWJAB4R7@Y='G2QP0ZS@&J/:!T*3+32WM?Y!<M?(6 VW<"3R03-U#9#T(
M=6C?.Q8Y>%P3]/W!?K>,U7(&MC5"+0%GM2*'R* U+>PQ^N5UR4T3;&U*0$Z:
M";F^4G:J;V??%-E0,%H%JHO\9<X%7OP'P?#HVT566B%>:I4,62!6&^S'MO%<
M7H=\T9;FDJY';-*$W--!Y3$7%G,#QJRQ71%*96L)2G"V?ALK!Z[*DJ+5/NK;
M_C"J8:87[A(E5+0Z R'?K%93VSD(R;7C3TW#;H2^V5W2<'J7(X$ Q2N:O.DI
MT//S--7> 0'9BB4]P==8$L)NC=SVM;%*4D.KGGNF-AP.I[%G,^Z'53-N%/-5
M@TD1#LGN=76;!IMORL#WLKH)OL2=(HTM*<GKF2L4\021J=MQ=FOP3M?@R=*T
M.<<;[2R/$I!_!HT_)B:ZCJ.I$NUTH<[5%+/H2 BMC U^<JR0P#G;>UJ3!PHG
M;5KM\D_8A!IGGR7[8ZF^T#B8DKFGR<EIYU<X9FF[T\E3)K_3]FZ4C*E)GGB&
M,!K"2] >HX^VBEYIR9\]@7"SHS%TZ)\##GA);+M'6H=%#IG Q<&Y0GN]KG^3
MW;<!DI/^E3XX^)(K[1=Z?'+W0G.HLSNXH-T!%S;;$39RX%FL;F,ZE.);FA%,
M3'MK#'-"GVI'@L.CY,G6'@3(CNP,KM57(@\X<_1P!NV](U?$2GKJ8!"_27W6
M0X1FO-<O-8=?5&H"_?AT[Q%)S<&)E9K#>Z4&T6\72Q5S($STW,FANB7+HGU1
M&VM'DW6S$D.,;1!3NEXJ8G4NT(^Z5A:/H)>6M8M=^P3'D>=VC^Z78!-QJ3NL
MS5[J:0]=A,_95E@$$-]?73M_.?,$"1SP&>@M8\W6(\T138/0Q$>>CY9%A67\
MZ/\02UQP3))@*;F_*\T\>8@6..Q3 EY&3[V,2LLUX41D7? (A/;XXX^Z =0Y
M@#H?.ZAS/( ZOT50YW<8;CVW 9"J'"R"N%A]DE<N3K76CJX1N17-R:IA""&?
MA-I@-0PI<32K-INM:&G@^8S;^MR0X<CV1!B/E52>-D,R"WIOP_U"H@AN$("[
MS@L3QF\YT DKQG] S)GM&X>F"=NXS,',$;K"S*Z470EL&+91BM(.95)S"+ M
MT*?2CU"3./PQ2# V;+_,T34Q2&WZG99H1Z7@V>5L,]P8CU@+B-@86<"(0.]:
M4ZN%PR/3F6OHV9T"T\[*X:IX>:<6C0!VCVQF%MQQ2UJXNL#D%09;8CC,2T#3
M9Q?+(9=F#HSE> ?#QXR2LW+=%UBM:H]5U6B\=/:-O)=*6W@A* E&PO4=2%@M
M1\6D*W[5?. >D5?^3=(M[+;S:M0130S=2MO@)LL+);F2RF0._@[>0]B66EE5
M+2&>@%IL^M%#>6H7;A;\\\85F'>[8-%TBQ,'7 ,SI3/9TA6']>MDGL/UA(#1
MAI.-[WC'I-V>Y#DW.D+TH++3N*L#JO?YM\K>R;V*XBH]VJ,3F_+I82BSF8GZ
MO7RU_#[$93,/[O:]/JM&R6M#GI9ZP8Q/:N*D\[VR'>AIZ1R'1M ,=+@A+X7!
M_W[N)D9:,I4P.6MV[;(%U##IXT56%#3EY8J=-8_39+U&XQTEEWH)TW.@!Z6
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ML3YAJ_!%H!TN1!<,QGZ,,K JTFGRX/S5$S$3A+7'KS!02,Y)WV*(9YUCI!S
M%'/---H9L2B8R?_9]J <??1BMR"1WC4"&^$/7YKZWSKA#\P@+]')#W$<KK-
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MP6Z?@G.43C.;!!##2*TV'XGI:2H=89U"A*@/[?2:A"Y[%]$::*%H&N#3&_
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M_35Z(W-)\-<%?%,2C.30@YX.EF/MI(]C3;_!\<4A,(0<XDRK8,_"CGX^Z;"
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MZ!?7'I?@X(71@XH1C>3F^&\==&<5##O88PE#XF0 &H_(_Z^RG$(^ A/GHNK
MVQRUY!@>K4[?F3\8QS2L#3 A5Z;W/\CSY%X9"=$7F_*Z:15 ,'QI<9FV7"8)
MXX7!#1((9XOOZ^[0M.(]%NE>VS+$/I>>B]H8F8293A\JK,GP<0\?C!4L28$)
M^SV7C8ALBA9%YEY#XZ%]/VHB'V -_/L4*KV"$=W-)>[WZ#3-MN2D9(-Q0S**
M%>7 Q;ZGZ0Y;VN=QY=R+!66G(X*[N)!:;;,&@TB2N A,<BX>-*H %19;G^]=
ML65B:,),%#67A'(RCK8&D7 IC!T:/_+A-Q5T>B7I+N>1)O(XQ*ZJ7LL1"R8
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M_$7F0J9@W+>X#(IGG<=/V'L,KM^J#>- %+P?9W0R]"%LA\@5,[&$E(X-%WT
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M&@-/59'+6962584\/(@\DQU9FF$67P:HT*1$'^8I8;=2$ZC1-2HGHIX X:V
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M#=]R->V&7"'#)B/.7,P:J+@I&$YU8/(D*&;&0H=$0-R? F=R_)"P7TNCWQ[
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MKD],-['0XK#MWXB<TS$'>[)GML8IRN ;6ZQ$?(2(%6UUTHV?J$UU,<6J,\T
M_'@N11.7&<B)P18XH;!4U&(UX0&J"4>3#WOO7+,/98N\4$DB!9V*F0T6M(1-
MC)IV<G#)RA'':/0)(A/4KN5M*@*[R1HV#$2<@-:I-Z!4 ?#VH!H%I_"Z(ZF^
M3';B4'4'A3:Q0,KFL;NH!SH"WY2;2,2^G@/K[<[=XD757AA.A,7BKHX)!N[H
MMYU]SGO(G5<"G>APIKE;5M+LN$<&O&7 5.[@(@1?88>NH-8AU#7JI#5H(/'W
MHWZD8;R_/2()?>&7A71V!#\W0L*7>9CK+E<X7#+]X(EZY@"<@]-0M.ZX!HS!
MB6P@.H39D-Q70_)#G_4$Y&T*DLYEH155U367&) 5FMD;+<9;/*BX^P0P!>^Y
M<F*).'';0C:&R]_0"&VJ&UG>!'5VR&-A_:[MDYV<Z/QN/)V)".1!CR])6K$6
M5.'><\/FW,<F'++X8?!@W#].\7.L=F@IORE.694NK9V*IY@ C2'4(OD;9-]%
M(;C(<NPN&AZ,-*.0C<&&Y:X,BZ.!\$"E1U!V*38?JM,,,2QR;F@U7EPS"8Y\
MXTAX3\NC")7"I,8)F_V-]\=,(.DJ"L=<M\G1CE$K0L7P*H.WZH_:F\JS4.HV
M6 !5<C QJ>JJWE97G>#;DOZ0;,OPZ:.N>(<LRR,Q;64)?WO05?4_V&);Q2X?
MGO+G/[Z0?^ ARCV_(9GDVQ_JUSR'A,OK"JV]M#0A+F?9E3=^\>S9;_& >GD<
MVJ-G?#:$B83;L17: 37\\TX^Z.2C+>NK!F6/[(F^?OE,(A$5R/026I,3YJ_(
M+__+TP%CWV\Y&R9>%1;2ZK()?_+S,[<#__JT+D_>?:,'@>SI\7+!M.LG#XMC
M=8@B7B?$XY;5,?CUBY>7")H?CSU[2_>^1LWFP'05?%$6FDHH0G>G($AC<=8A
M6V+NCV#)RB&:)7&P&%#;8QUO3O*^QT<6^W.5(29AI_>(@JKK&IV+#%<ED9.+
M1I>Z0#\9+% 5S962EO/S,A(15]OEN)\A1WM^=;55:T3C^5>XCTWK2NHHENSJ
MKK-/Y.VD3O0N2P]G>V]=A:"QTP!R!)-VZUJ?XPK1_)KF5<#(DUN6*"7;L<6M
MBO<IL)>V62L "2"3O[&]R?;K<)&8,!L3/7:K4MK[-=S4OEGO-F+_-ZC@*,1[
M65V66]7^R;>[A!R,U_,9S'1JS9@(6[!)*#C1<_C(;\#S5\5;6DE3>YM&N,A\
MYB>#HJRO_*?3M^!I;B?T0)/3W2;GY,D>T*>[9[D\C_J<^<3^H'QBX<FQF2_:
M2A+@]"%W./>O (9W=DSK3^0?\#*X68*R.P3C3ND8Q9YOV*"<#-G,2CLOZ7>\
MI./Y@-3/Y)D]D@1*9$ED!]$<\?C\N<OJG:'Z,U3_7D'U/WDX0_7_0%#]^:"<
M#\K?9I'%8%5]M<ER,8JR<!'_%D[*;BV]O(D#R2(H-GE*T6.BJC4[??-:?L=K
M>=G79"E;)S$EKN&K=D(TP_)%7@G2P^J&(GN3DI*&H)CE).>%_F]9Z*D=)$("
MK)!="O O)MWP<6";_-^O)/5H\/*\.M"9_N1=%33F53VOZG]A54L'OI#O7)D@
M3.=T7ESGFQ*>*:?6J$AV$O1VFR;R3))_ M<062A2;IP];BL6A!1'<[BL@/)E
M:RR4HUUF72FY%4%S&@!5)N*=23;787U&JN#6 Q=6A-4Q3L*)K9_E_8/1S+7W
MJ26)I94ORE,M3\/5-N#DG.1NR>N#3JQMZ9OT0F!$,C[:K<C>ES:"@;_0*8D0
M:RZ9O\?6T K*\, .H"B>8N"OK^B.$-.'V0F'M4-0>)M6U0*,1,<!U@\ZHMJ]
MH,8%&FYL-2QI"M)8J+D4KEZ;$"9_OH4OV[=>G2V^;K0S/-XQ]4AYQ4'N :)*
MK(KJ3&M"?8]'DJ%DC9W6=SM*5S,;IG)6\LL^O!)/2!X.\[)=;[6+Q<@&T0NM
MD\N#0[FH9T;;]V<S31%<I7=ZJV(]2./Y%8I;G"KP3-!4_7LV7&01&/A"FGVS
M"QBI6!WER0&_:=81]J4M64/N0=^I@+8+8RY+&RNBFJ7O:<"\]^M:]^_#TIE]
MIG_*9S)?N3P<T*JK*">N02&5ID GG!F@"JV]!YV&82%V(!;9>G:YM&TGFT1/
M=1J&:X4])AO0TV/VX;4-^XVX9@V9T,6FI[RP*V'?K^=8>T_>W7QH#-IQK*E5
M D+6)X!V,S08/EP'.[K."$UER1>VWIG ;0[2,'T9WFE8N'_OP_-NZLI+HQ0Y
MTJ4CPS:%,N*6D%X8[6<#58H'3J*='9<7EA<T)/;M'HZ6"FT9Z6"\FG0&HGR\
M.(8C*3AKKZJK+3$$4QLT-HM@EU8A'F^.50HZ$CQ8$M9A*LK7%>EIWAP03*_U
MB.'(PDM!%S9IF+5U<JS_ GV0ZWK=:V&H\8^NG)OA*B$:7\/%W"RZU_5VZ[H?
M!4Z:$U/27A22GISJ#B+Y]<E^*6]\[M<I->_<,7V:[K6$Q>ROFE/'CR=;>(%^
ME/ 4+T# M6.+1?C.R^"9T&?D GD:0O'-XIMXG1_D.D(1OFTD@NBJ]KI>24)H
MHKME8H])HFD'6)!T6XAX$=#)Z%6]HM]V\/WVR$8,X*?OX"R:HY-W&9T,&H4R
ME/!EW68TO,EZEYV*7D36G\GHQ'%RI>9O7W3T)<6,#DW*D>$WF[8,1K<7,#E]
M, ;=9I'C_CI)UDMT]T14,N$=IN=CRCR)&)+*^*+&-K!.^TCEP@;M<'!4+7H)
M[DZ&PJ#.'S,\5KIP$J'%BN=)V,08_T^D<'>G?#@X6^J)M7&[<U>Z+8]D@=OC
M^<')Z0A14;6N)K5<+4PL[A!KIA3@^[?)Y] I]SBC8^4599K6,]ZG+9+3!>Z0
M6-.@Q7RUL,+(G)^12J<]'H;S0&HK+,\*?T!U$=MKHH.$;-JZ;->=_B$UV>2]
MT.+2^31!N+3N&E4GDSXUC<K:ZJH_W%TG]$,Y$M2#"<:]Z9+>,TA@81^"/>[7
MZ1V[][X\BF=Q8A$5BV ^UXVX.]>@][BPAI\N/!K>\F8C_)G!DR\U#DXZ>M)4
M/+D6SQ8OLF$<+AM0J@L?_D!%@G1<<E]$2:O7IA %AI]]=1%>AQPG<3$C9QS,
M;"_.4[\O^W!]H?]R!QSI[*5Y];IN *[N_CQ853.(8 81_#9;E!M2#*3H2H@#
M$,DHTAX9L5%D)E@VRK:\L>J%$6J)N#J3OR"C[:LB=O1J.5"$+^&@-<'A,5T_
M:9B3#3+#Q.:]\/L :EQ_2_05YI4WK[QWO/)JD2XD63?6'NSHD\6\[N9U]V[7
MW;H\E,*""HY*_0DYAEC[5!K^XVP$Y\7XCA?CIH)ZJY:-#J(54&X/ERO$D!(L
MTF%<]N9INNC>4RG^?/;CF7ZT;<JUP+'G+M1_+I\P=Z'^&[M0'\U=J',7ZGQ4
MSD?E8)'Q]&.&T*"BHU1+PK+YQ J2D/#R+.NR/9Z=/!D_Z-3U\[VC+2ZLI=%Q
M0*,<%V'MGKU8G1#GNT2XQT -C9 2$CN>\&84<7)H8LF<;E#A<N7%XG6]>KTL
M5Z\[:@]O'JS1UZ$C5&)##)2$\,@RKX!G/H^E6)6!'@RM%'8Q18PB[U<LQOZ9
M#Q^R:($/=+;XMLETE-U"Q%BK!7?@PR<0]EE\JW3\^-VCQT\68_&XZKK97N/)
M+K;-,EQN<M+DZ$'NL;D]L/&[PH:=B\/(QNJ[I D]5)_1>A,[KHJHU@#0(%/\
MK"NLJII\E?I+:KP;U>U6$4#,=4X^CDA):94I:Z-($F5GG,9'3]Z[HNF'8DO^
M=]F2'?#D&S;);U5%OJR7-9HE;D!(+41U9.FK5[6*/:^:?B^D]KE%"E\&1H_[
MBZ@'E+V, G 5C%"S0S65K/ J$4%:-V<L)HV::*&X"IV3KJ[WV)=1K$WJM$3$
ML:;7DE\V7"32#6;G$0'=HNDG> C(2E!Y8@!6!6X=?*]X5%K!GAR'W-H*JYMD
MU6I&N-=3M->^3ASV=92@MVIP)6_1 \9=W3=R)Y;KYHI\^^$&:WD4G31G5&%B
MD[R(*W0F))<$ERRS@$?L8$LG3>=U7@7/ZIW+_@"ZT[HC6$4<?*#:NWK4.$ \
MS2&KP"9!D'"W\/BJR%D)&I(01-A2XS+CT>16A\/(I#9KD5H\M,V6QU._?[UO
M;NB1]'O!=:Y5'U3!*/+R!.Y_4(F6,/\#N1&>*ZX([!">Y2K^(KC=-=@+UU6X
MU5KHC;$=^QIXR. :[V1=A4N7[''M@:)L\9*J"V>^!X9;FCBG]O7;C]A8"A?&
M>JU!4P\\::G8/L,HY)@X634O!%Q7;P"'".MN17G"-4FI(YNR38FX)2)VA+6J
M(AY]$M(\T2Y8;;33."J)%]K1)V"KI,K>58>#]MK;:*E/CO8H]5*Q@ZAZ7FC]
MT(8GCZT:BM/RB?Y S N1-$/6OX'M5U_7VV#^6LH,;+6E(TGKP Y6X0^"*EF7
M.W2_0CA@+]3$&]R#9O>B:0WD#.?L@JX.7E:'I[#]:3YX0NH7:>=5;\) 88]E
ML8F/";IJI8AY08YIZ&C*O^JU+\&J!^9\2Z\QOR<,#2LW/D0R4/A:L%QX#C[Z
MI1 P;VHU+-I 8_J>RGC:M\$^;STDT_D=@R6>UH8MI]&R"^\01@$.$[X!7.H#
MFJV=G6#>]?(O/N]Y2]BAV/=&<%M+#8*T$^*NFU[#)\?I-+862S8U';(]DGEC
MOV6_Z@Q>^_?SE L<C2Y6U::. %6JY5%EUNNB;6X.E][\A*VYYE<+0_"7T5YZ
M6>'?#(,_]]?\^_MKQHS-ZA1WKK=F ("%%UJU.>ER[==%,061!1I_"P=BBN?Y
M.;P'EI$SPN?#99U&-H9F"SE.TQ^$/EM=8)?RR*2U )H&Z?1E[ F* <@ 89V6
M/]>^?\Z,0ZIIX]%E3E7=KB/F[B B4[4 C*%^F1%0223O[ROX3+)>&]4 9F#\
MX.8!%XI.YZ5PJI/\*O7O$:.][TJE1TT]0\@DF"2> +M%R5KI5L*<;#/)0=B)
MC?B'\"N,5XA@:%DE'%:D*%+"(DILX<[B)2.&*9(IT1,QG8_=$?XL3N=N:'3D
M=10*N*<?JDI%V<0HL8S+W$3Y\,OZ2N'EUQK4)@J'D0XFPIT<9YF]VO?OH/Q0
M;-JWX@O*Z29K@RYU[I*%]4$"Q.XJ+(PZ[>=P1E9H?NL&'7NYCS[>A=J+4$0V
MNB(U'.:;TZW,N!O#>M]V3>$V2E1]CUS\80^V,'-(ZK<-'?5FSPON<&0S.0%W
M^*# WD5Y ]%X:WY?E\?PEA^L(7XWZD=I#HQ57(8P792-@K:Q$OF/SJ]G5)IN
M,(E!]/9HFQ-3R.W<Z;F0;_5IF>N;JGR-<ZJ*G8@I@D)/"N)1Z;-WUJ5J6^YG
MZP^)AUW&69'^GNRCQ$.B\Z;G%1[T*)TN'8H7.U5==*^1[0.T3N%K.D66JAG'
M!>$T@/\B7%=A581UV\5 0E_XE+BDO%2C(_B;:+Y)#-!-B2%$<5Z)'F_A6F#
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MD</L+H--W?:[95VJ(%\9#Y;K?HMF(CWXQBO2TG)^ 3O7W"MT^+1;B"7*T=7
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M\\PH!SO*4Y:U'YTPMJ*1L]RVTBA*:XJ2F:M_LJZ##YC"^WXFO=KH:J./S=_
M>39%LMR_R8*)1[0*6&M,"8I@XF.C",LY7<)JS*LQ_V@!H4DG"ZE$*L.1:TZ@
M9FU!O"6,=*LEKY;\Z &AL5T#$S!V+"46*8A,ZR%!K22DFU>K7:WVL0,_0K56
MMXXQ:&<.^&+0!7_!W_R!V>&5R& E,GA:1 :_78D,?D)$!NNYMYY[/]"Y1R(S
M(;D9>(@  " >N9%Q+MZ@!FC%^S5J&0J)EVYUSE8C?5QL2LDM_:;A[,"$$&U
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MRY;H>:'TW//-JUA!\@;$("#5HNV<-J+=H^)IUY]\X@$2X*B^$H7:;$EJH%A
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MOFVFT8K2-\1SIK5$=-]W!@W:0/8VFKPJPQ]Q;.M]AEYI CI0$%%A"76D&5,
M#J:[TW9]%G:F+6=4J0)L'(Z/A*8K"9=16*!I4ANPV1&Z84P8@-EP%_Y2E[MW
M]*3JE!Z\ZTBG31O*QIDW,3FS94G"AVQW('D3VY(GQ_'CQP:/L.I3J'@?7U6:
MI(B)&3W]A819CO)^^7QB@GC_:;]A[#D/273]@<A^/0N>[%GP,AS^]24Q;V''
M0G_-TLZB:4#:@[ 3LBWBUX(%5_ZL>[#@!LDMC3@R#H96\.:8."HM]4CYM960
M8UTJQRD<D)%ZSZ^GE!O\0'\-HG.EC0:>)X^C96_:+V3__ E&@S>#FPL[5J&_
M@AZ$/J"<ZNW!SZ3.2Z\4/ G]NM\L2:C>,O1,Z=+L?GG#$GETD?@(20*)J.6&
M(ZKJS/9#OZ'S-(8/RC+/9)[*[)9GZGF^^1,G4(KHT$T>.0VJJ?<]YDR3!].-
M 5,>@?YT]);$_98$.9QQ$V;\2(<?(]G[AKYN+D]T<_GB<(7]+4MSR/&9>=O%
MG&6JR)'YX:")PBDYVDBYM!#6!1J@*S*KVH%8=B?)H(#SMVKWRM47$N^Q[X5B
M1HG]-AUQY,[X+<T(>R$T1,Z>-Y5!'#+>T4 U!&IE[Y'L"]7/>"^^OWOE&?1/
M(M.@R-7X!Z(GWLI;<ON)*X)WL413F9<*"ED-?H1>3A*TDV[V[5VS$ P_2-T"
M+\(0UQ+%C+9_WT-51F#R>U%ZG+8*82^=>!VFN!<C\#M>2H&<X3FF>T4#3.BA
M)M-[,J4$B1;DQ*.<-CQ*><8R$FD&4_?C4HABNH?FTJ44]BU,GM^V9)7E%$'^
M58K?E>[YX?SU"UW>; [83/JJ8TJ:"<4-2U9QTKQKB;W>7:<69<*_S LO1(EE
MOJ4>0+C.T%5);1%#O%.ZA9PL3V!]]P_:>S^*5Q,3,$Q=HS" ZB!(^W^Q@/-C
M,$6O/H*9C6^73#;"3:_R02="0F,_0>G9W -%$@(?+:*U'\MZ*F8MC103*:F2
M-:&T8 ^+)=-6JKYPQ>N;929U0I%VIZIGUS)03\K57>W8S,;7L5"9\WS4F&X=
M7(W(:I&RB"%*U,8V[,* _'/U9+J;6U9_[W1 ]Z&C6D3O(SF+2KDC#8PYOQD&
M^7_/OOGJ+Y_3W?[OV5^_^M^7<X<-_#GL*J*@Z.=HS^)H>W8>L97+H,E![IPR
M9#;MYF;T _/SX_B4N7/L_[5;R( @T::4VT-;^\N)VVI/$8,FD"&WS4V+0V$!
M7,!$5YJ+'-&5-9<%^9+B!\E7R1'(%3T\H_>W[QRY9R?(NUC]6LQKV=454+Q0
M.PFU+"H2HT'*K]]1:GRS SE]:\D+93T1/G9!\A*P#(D[JL$1;O&T=H)5SVQ%
M/G\LR.=?KLCGGQ#R^9/V.;XX3/P'>Z:@]A-*-).3Y)JTRO=V3HM0TQ6^2597
MPRTE58U8$:E@%[2%\U5? ^/!R6H*ONQ&2<U9PU!;>,Y#:L1#MT.24MDIEHO#
MZ(*SQCF4?7!?[KOOY';?:Q;EY@PJ8F7:'67+,IZ.?Y!9%B87(@789(?DN^"3
M"+RT%P$4*-(I]^$SYP/Z&YJCF8^"U[$' _E>D93=>/-,%>1L'D$HH=7BI@3K
MAN1.E+;U-W2?5%$[HP=C$)R1I'<0F$Q6#"Y)JW'V+GD^6]S E)Z[BO-@L(.;
MQB_=O32]^ZT^U#V(,1+60X05U%!<'@Z0A4D*8$.'EGO]3%2.X^KRPFO3;F:0
M S"*S0Q8_>1E*60*+\Z4;;SD=;FN!M:8L0B=[ 02S&3?-!]2IZ$)4;S4N1T$
M,Y\&+/=$[S'(I@0J]'X4DQ7,3FOJI$"W-.2KR5D)@I:TZMXW4?N4/?!/^EC\
MTF^PJ.EFA+ 6[3 Y9RCH*X'20T"X=P>D&7V@.R287A+Z9.5*0"+W+*PX4*R*
M77NZ ;W2].: 4KL_/ZH>K+-]1<)Z(C>6S<S+/NTDK5J2; 1[AK=A/UA@%>#H
MMM_<8*-2NDXL56!HL!>EEZ',JM\7N%A;^V\T*O!(P&$DT028NYAM?EHKXT%+
M8ZTRQ!E[%4$@)^^XM8)DOP>)Q=T9)T%!"< TI$X-Q%0U*,E-^.AR]^L^:[!#
M&4Q8+RXBA1O8$T6!,2%=@?A'.3A)HLV]NSM&M*ACF]45U1T4?]">O%L?\T!<
MKTPK^S;XD3:MR(^?6K$:/ G41G-&=P-<D)J]C[)NQ=^Y$^7"!GL?T;^TF_8,
M$,L_0P&]+[1$+:5WQ;,+=!_N(7<,1$V@<WO66POJ5"%1H5(;5Q>XTQH.H6@:
MLNMNAC"8.$MZ?5M.6?9+11X[CKCFI#4<:,*'[UV$!A*EE?O.GS1(QVI^%V?L
ML:KW_MLZ$Q()6,\Q3@FWUF!4G#^6-I%P%[O[T*-S.KZ33@5%IY[BO'Z;Y-!U
MSQ.8AZI_\[F*EM#I]J;PJK1+:=:%-X5=YK/2QOD(CZ7FIM1;)!M>]4F8=;6L
M7P2,O_0]T)LD]&FPBVU7[<E]SPR8'RU(DBO&IN-"6*X;L,N$JA'C$1M5_#_^
M[MHS$*?_= \)8>7;YDL_.!!& # K*N$]ST1NTYL7.N.F-VT03QI3>U.PD<R(
M[6Q).O ('^AP[WX\:;]JU1QU"QH;/QOX(GQ2$DM?QI_ALE'56FC[<L^A\76^
M%3N(I7,_=@)RM/&EHLF$[$^*38PM>UH.\^KB/-BVX8#@#&FXU4O3--1L: GD
MQ+JB22G&[KT;*,):2=<(L/^NKBFCHW9:];'#/8#CB!GOXLH.,M32AYU[0 7]
MW5 %=\\7,XM+X')(A_:<90K2QIFF%CJDH^%3]JX+I]8PF63;<?,RS'B.B2*D
M6H?+F8=4GM"UQ &+\3@38DSJ=X@"JZ#^2]X.X:FXZUZ GGQ\CJB@Y\/LT"21
M)?Q+Q"!9_C%Y?<\W,65QS[!+DGT"Y+P?>R3^*]G <&U.T'EGX8P>_LC5P<V)
M*OCMI&^8,9X9+D14P*7^S?BKX*YFNZ.3EF-M;=VCF(#Y@4<X 0+\D(8OB%)Y
MYL09*P%?V.Q;X12!RZ*>2N+TA_2U/C]8[=IF/B\!DAN6]M9AU%P:(,[X:PGX
MT'X;\ =E$R!XE$?:NAH-Q'M!WF4N)(XI!HO>4UYJ%;6C/US:GNZ%;<_?IL8N
MALQ.LE'EY+X/Z:C@C+:"=QX8+5C.G&'NDHTC,58#NS#/<%&DZ0]E&-SVQ]W^
MM&:39U+A]^(AOJ>>W(F*JZ"A:0>Z"UAQN^G3P;!/H([&[_:SY&]' FJQ%T+K
M#T':!B4 %-9B,Z"YA,PF,#CQ06,&_OXG\QX2'1,43Z:IR,:@Z=UW52_:GK.Y
MT<H2?U)BFYP*/-8ID$)7/*TB;$UW+LR>.37H6)4 FN?.'WKN'3,;(YK7%;:Z
M4T_4G5H ,//&JOEE[L#/^UT'+CA=(O=+ZF0$U/#OG[(-K'1M*UW;#V-9W^O$
M)/$S(?*(V2;4<FZH:3U0HH5"\7OP8*F&\\K-NYK^(\M-+65VQ!>+R1W;WB]N
M9G ]30QJ%Y(NH786(=N. L(FY!KC>\(7<;C%,@JWE*'>5*0CW8(QPN)OUO6R
MKI</<%28T&R),.WD)(RND<"@U@-#<Q2#F9T-@[\G&X@-BQ^R E8P^0HF?UI@
M\E^M8/*?$)A\/6S7P_;'=4X7',IY>8&H(.B,%;:J'GJ_5/TE'U/@[41VO#J7
MJ[U_''F(^_,,:7F+)/10%J.":K8 TLX@M>MR6)?#!U@.9)<P8D:8D84^'(]N
MJD&I"*35F<O)Q1G5+/OG[AZ0B]%*H#;GNG=W@-6LBV5=+$_U[-""D9(H#\<,
M/2A#T IE?:8#P7] A4HI]5?Y%X FLHM5<^V$XUI)OI8Y<_V%P6!WL$=-BEEF
MT53(:J_+:5U.C[^<< >SM2O++YG[_[E&B,7B0C'U&Z*YG\"0K&$#>UTQD!8H
M;UD! EW>7JZMU] XY+H.N$^L)SF@^B"J8]#K>58^/A4C-L7M281O75CKPGK\
MA55.X8B&;TH7V/<^SU* D2 0F7B*M9Y884HZAA]:D+TN0?5\:=U\TCB5SP,.
M:>G4GR%Z,:?2B3Z"TT@VKN+:"R=P;;P&-[13YWV;[4-!(X6WC+/_SS/S+= 6
MG(372<$P.0H$:EH17RDFF<C)*87*C';A?>M8"T.)EZD<A+_SE<OJU!O\+#5U
M:!^H:G2D[+WSUG-A/*(AK'BMI[H.IIP)[[VOR784MTN1*B"/9#/ODK;8:T(N
M1[1CY-M/-ES)I[H&%&A[)C\#JPC63#&%EM?09=J59[=1S&]F".)Y?/XM(=%H
M+W:D];1G,G#_AR#F] U_Y>LP(%IHK[[Y6E&==Y!0V;=GZ2I_>>Y\S/+B%Y_]
M2H",9U?6#/C-7?<UUR_16[!U.W2Y&5IVOY#^VSMQ6(*__*SP%WWQ@@<XQ^_@
M\GY0#/245=VK_D+NLY-Q?&'8T]]>>N_5R'-^\;:0[K@IN3LHV(54UQ] 6U8Q
M*B.;\ FZ>\3?J>5CF!51".M&B[L%>-+G(TA+_9)XA?V.LQK:;^%G[DM'FAIO
M!\:U8AH,1[R9 MW3T$,$-@F8TZ@T&N+)$II0FE&Y?[4=![E38;])9RO1<P0.
M]@G37LW0V4("PO!-RT<OF[TL&]DC474?B81C]L$ !3:]I/X)78DVT4GK7=EU
M%?%E#,:NXSOP$\%J[>C?5-0Q3Q_9BPS)3\]TCAFI26;O1Z1=)K'Q=M8IP!/8
MJ.8AP0NF&'+_>B?WV5 6"H!@-%8F0.@(.YZMX)[9I)$;P-HC0TV0;?T<V*,M
MH-F!"@WY[LCW$6D1X-B#3H[MW*3[];10M'-14A%%9L"ZAPFDG '=_EU.IB+P
M?TM#I7Q+NRYE=\*Z\F.^J?K:J)66G'ZXLMU]VY!NZO]X8]VWO+R__9\"4TE_
M_1\_E+W?PAM9*?\U^I-D\ZTW])]--HN?F]VP][O2+WZE>^'@W9T>R*?^WOV.
M*33\0$"PN//[]AT_G1\'I*^L:"N13OE_W72TH7_M>E=V_FXO(\H_[%D\CA(8
MX9[X)YN;VME^ &$U8C4#WIK\&<TO-4X WL-_^8U[.((E)'*Y?QVMZ25$'+@G
MFO3P>$Q3'BPU-FI@!KS]N;_&1&&C]<OSIDS:NVL#9#-=O4MO]G_\5]@LT&:.
ME0Y'P]JK?Q6*#7B^><E[#ST&3M)N/$GNN3RIG-[W-P8Z$;T+&9IGSF#4+$_B
M];[V1RZ9_&<OZ$C[%5L][5A^VL0P_!=W%!J!CO."S_WGAI 2?K(_>_'LY!V8
MX_1H$^I^VA/V'=I>!!'%KZ9W:$,)A58B;F*GGCJ'G$9/!:1!7'FJZ>CB';\4
M_C6SFQPZ_T@^8GZ7I@4C%XP?'/5KT3LP[>=+8BO^3[$7/FUU >/J,M=&H#I.
M=(DM)8+?6#E H!Y])ZQC2ACC7X[T47-C!K5\87<E/E.M8M,DT/82'R7TC4SU
MJ.BTP\8L+@?\A^EG@L?(?E\^IAF[W)/$*.C!DK2ZEY(6R=J0^W0CDE2O"$ZQ
M2/MVH0<K$,\/RF@GW6#8/I02I.IQ9C(13=43](D_E6AZH+W(DLX;L<\K72K%
M5/[(0CPLGW#P,>48R/5-!?H2II%S]%&LTOPC:&M=VX#*>(9!+D@HW8YMZX2;
M4)O6TEZOI#WMA.;A:N =$;L1<AW#M0;Y>]IY2"I-*.9\&'G:HL46;VQ*PK""
M0%<0Z),%@?YZ!8'^A$"@*]_+@Y/C(0M._ :<SWD0;PJ!8=!A;!U9<VR:/N$'
MTK!D6L!#"HZZ2X6R=^RD$7S3$HYF;#@=;U(W>7[0E:GN(_8:WQ+;DV2+@G\8
M71SEO-3$F) 1:XR]%)/%T"1#F!!TN,;&^WG.T%O'A9-U'D4_4_-=\$$IU/&6
M>>LBH]FD()5SKZXISTW6SU_]6CAN7OK/>L^TT*0 TRO9D%+3_>&QGL<DSHS)
M#.NRT2FX+,E'WL?K$&<PX8U*P6OV/J%^Y1IBG+.?HZRAN>PE**0$/>! 4H;+
MTGM:4*'*/1_SP49-*R5G;::&-*<2DN>="KAD(7JQXVKY:=]K:MO9YCF5,,63
M7BGV7)GV3'O8@P=F&8 P4?L1*JM+1#J<96<!&J$,X_@GY6BJ&JKGS-5L)[K-
M(FK*F2/+18CSBR\5Z#;J2T*Q6TB49EZ:34Q88L:'H9:?;_3<O<)@K%M;?CM0
M&GC]LL3+V$WV77G71"W7I9>35+CMS!/A^;ZEUT]+P*A[/F09$:P[I-QY-^WO
M(7!3^!]1#EWN%4$W-%S670E-C#H<R2L)):<X"WHP^ ^..\G[T5D2*0;]RZ<]
MEF@HQEJ?PA"R+*-]]?(?*QW<ZAXGHASZAF/JM"[O^K$:>)5NJ:0X;$K0CO4#
M,?R(Z^MWB+%+2&_T&I7F5$5UFDR)G-KHR=A<+?9@PHWL2-Y:ZND9FB)VC+,@
M#5IT1*$ODJM^\T@I?E:W^&-VB_]&FK)$*Z\DFM0Q9OF^HTD!R:!U!E4C"V>4
M"*%=T981MY:V.KTK\3WIL4EWYK@R]5KMF67)JU*=NY#_[4>XGO>H6R2'<7.Q
MZB9*7<URQEO5##8TPOB?\DQDA/[@=S=N7XL"*]:H/Q<)%%7U40UN*]*K=Q6)
MPF$OH,K)/N#4:7PRC3-T;@POD,<N:Y$AIBKQ_$4)0DOV$T([T# C1''OF%V9
MJ-Z2.YF_,"%,83QC_R!W92==5\V-(^Y6L9L4KUO  _;V[@B%PX*9UI2H+(KD
M%M1^#K@JH' 23M#HF1.* "N(%_K>==CI6"Z[)V@ 5]5OJR#:T8."THIHE[O@
M12@78<)6B*?EDUR"*]V2ER;U@1MUV[WG+ILS;_+W#(Z.!NO-YTXD4YC9V=++
M1043WNNA5". *2%,HRIZYP+I&ZTYJ3]4W9[=.RX[3)0ML#6>&J"W^<WP!(3Y
M0>'ZINSVM9Q.U(L!74B:# +#0&VB'0=4<8N\M88BYLK>M2+*/P%$^=X)= <5
M0I$<6 H1)';C)6(+=&M+T6JGCVRGXM,@@AZ1NSF/P\I:M9K>!R'2D.04IT^F
M(&,5_FO6;7"UQ4>W18;=$I[GH$!([2. XW^S;HJK(7X(0RPW?K0^^I8 ,@9Z
M ;X:J++YP);H;S7-U30?V31M1N0$B0&JU+&@&P$8I^<V97%$47.US]4^']D^
M-;+NG'<C4>N+#B:9HK:Y3G*N4$-IHW(#Y3.13%TM=K781[;8NN6,JLC3K1:W
M6MP'(+JHFJEZXCT@LI6$9;7-#Q/Z.&2! K)*439=M0N"1:()W!_+#B6OE>$D
M6_H79 >5KKON<A5$PB0AI*W'W=T**N&>_B!=%E%H_H5P5P\W&6CR6.$D(9,G
M@LQ^_SBV=XXD\!0&+E!1Z3 ,B*T<M&4@: (D@>CCR-10";ZQ[(DZ?N@7<XT8
MK8Y:\L4YZR=S/SJNUX;"YA<'QBX<76.@NQG$[Z'-(PWNJ&O5-:H*IG%YYD&&
M0,\@?<&U$+\$)KE8]IG.UX !;C.BIM=>;-N8B]<7.XF#ZTZ]S&+HTI(Y?+[Y
MJMFTNUW9$W"?&HLW?Q_W-PRW$S4[*#LC]!,P!0Z C4AN!$#4ENI?_C=0B:;;
MG=!;3#G>T+XG$GDH_R.V1.B(I%O@6F"Q:&I=CO7RA1H^02A<)^1_4GV>0[(2
M(>P';32<&>3-R;]B0I7'*0%PRRV]]T+A#KD.!$%<65F]L^N,O.,/TJ+P :OF
M:P??VL'WM#KX_G/MX/NI=_!]*H[=&\FE2I.0$/-,VMZ+I&F\$+ [M^-<:2]@
MX>&R]B:]I_:8'@Z(,G7=XDB#BFYYPV>KW(W^S!X!J%3>->T=8_#'AO]M(6R8
MG-"#/FVPJ*N#>S8<"2_*C!!MPWT4_NQ_G9-J#CY$$9+,/!2%*Y9]E&>6W\EY
M"\<1A"()GY.%C>[]I8\%>7VB1AE)3+<)P]@2PN\M\)M"%,4.@#:>,06'\/W%
MVF(18'_\@3,X"DS&W7CH2+Y?V)_\^P@0HCZ_\($4H4<)ZL'$>T%(/?%-8W?D
MQ3;Q$XM@Z)S(=IR)G\3M+SEWF.;+/D4_]J3U"HC3UG\052UQKE*PI/?S_*!"
M*PSZ4795MQM/3/>6=-A),XK&)8SO;=+7"1AD_C7UW )7-;= Y/+D,_4,V9>]
MJ;QN5-R>,095<L;>4EH8"_J."'?93RZH$%U_-'3CF9V]GCH5Y4$M=<M#6L=B
MVU0A;%>ET(0Q_#0HI5,Z<7:]?FGM9]Z^][5G</#>1>WW<LG]CB*_&20N.I=X
M(4@?W0G(<++LQ-7?B(FHYUL8Z&O8$]C0,D[SD_:3U_Z:^_MKA(4H!KI^3?E_
M5OV1]RZ<*5A'MHA#3(1H[:NV(UG'KCPG@&WR2'F-$^HY$L>P:9_'CKC+IOD)
M$W%2<F+OL)E)8L5L8=IIL#;0_'2<K4G38RG;=]L9PZN:0U>"18U4!3@S0*TT
M1+N#KG/Z;M/.;9:=M&BRL:GR^092VDPI='/1AM;>;XA5'9BOL Y,YF@R$&HM
MKYD6:&*J;FJDE+X15])<4?HT]="5)L;0;,O\G$"BA'.1FW;T4J8!/S;C1+JN
M0KD3P2H)!S%S;UJ-SA]>E)VR>3(?G35$Z@2N"1H%3F_BV/NB83*H76G7,Y$]
MD:]#@R-T%Y87.UJ=IITF;J+E'TM%'TR+AVW4Z:7'23T3^IN\0+K*G::".$%G
M.2C092M]+-O(NJDYV,A>8'<DGGLPB,H&1#?,S-2Q.L-T*6\5OH03^>[H1$\&
M3V$_/;_CQW>V?BI[U3=M8!*3;NM:=YQDD^%H2+>@Y)1,FMG5X&CWHC@#KFT2
MS)EPY/[6I"(0M)GM)&4I(]),=+M6W,\-:_8/>*B4(%>\_"M]?\%DM56>UI3N
MP'QET[MN-^JTXD08$<K/SSP+?_-MU9[1S.U?ZSAHG8-7OY 6=\*D:*:+Q/IT
M*Z"4>=C.PZ31#W;UMMU-V<A6P[MKQLE(F>WV?C?=TSL3?OD'>$N'L5$)$6V6
M*[A3$YL5]W-NFI&H.Z%%%?D-Z*G,#K_V=JV%ZD^@4#T(%[/_4>4;0EY+*%!#
MU,+DM\R#2DI1/B9'0^R-!"'"TQMEJNKVAA2Y^RC#0TNV=XA^ ;GT3_BN1(?N
MBA=:3?VIFOJ.M _DD"+?XZK5I^)LL;Y] &?/T1!ZQ6Y^ T6HPZ+@/DN<>>OB
M6!?'HP.66-8'I!3,>D9)*]%G]M9YJ$@V!YST&J'-L26KH:Z&^LB&.J.SVG5C
MI2(CS)NE("#V\RFN\[^H??R"NA^EOM+HT1M?WS:-JYE4CZ//LA:NKULG7P)G
MO/_0ZJNL5OY!1/S$RM,D 9<BW8Z2M+Q1PYEA9?'CI:]\N U>Q&,B_*$:F+&Z
M:CV6<WE1UYP)41C9AO"=2ZLQ[ZGBF'P&3-<:,3*%07!A?&V:6A?-AULTM?>=
M!8JJLBH1,]PKQQ419!*,A'?V< !8&8'SR,#;07)K_JR@P\ _/&6] 2!)@,.<
M@ OR<2S( L4HJC+$0G.SMKBNJ^'15\,(13;7 ]W,C "1818.4-^WNXH@)8S
M @(IIG 9/2&;O"D69]TGF]M=^VM6X_[P40!OSRY+?K@VUF0A 4=%1%+#B$E
MA4(S5=TQN^-04;4=W^X U>)-@-3-IF6Y4,]N)T3(VARAT=3#02^HH/40I(Q<
M]3EZPD[I__*XEJ6&0.5=M+B:?'HOL Z^5T5*A.A[E5Y6XDE1=1.6-.F:U3PD
MY5L&-7"&!AP)!<@?PTLA_<BZ>H>,(;LU=7LGM-Y2NT<K2M_6>QV@,$*'\9$L
M810XCC4SPAY$2=UK2"*:-P:0/&SJ_!UJ'5 Q&<\55CG!+T8PU=Y?JB7&>FH
M"KG40WG;=OJAD<$(,DVQ$.SG=:C%HEL?]M\J;B 9;A'HA -R,'T<#$KYO??N
MMAVX!R>*3H>R,5]I()!PVSQH'K0';:%6&L2RZLN31C.L'35K1\V3[:CYS=I1
M\U/OJ%E!R5E-K&MZAS,NA7LXRA-07Y D:IN;=J*E846"16E<:DZ)(@;D3&PF
M)JK&)K"M"-Z1L)9/4?0BK'CECSDX>7D5&F=!8H5Z1[:2+Y[21(?EJI85J,2]
M 9>]0.<,V;RVK\#0_0;LYTN7B:C@%(:-B?H_AJH/;6&&D DMY;<<TE!AWX!M
M"U$)TM#5?[W/RGS%-6558PY2_B(9(*.Y1!W\4P%YHY6C[3X3!6=N[/=W/55]
MKUS\4@F.EZ2Y2/#CK>(;>31G[@WJ(/(^=/$O=49NN4C'P.<;VN3:*?,_5?*&
MB[KN\1?>PY1V==Y9O//<G]%D0[IG">S#[WTMF-YHNVAW8WX(X(G75KTI<+(G
M.0<.!=-Z!U\;21G"D?\M\AN&\#D%B-!;5@$!\ZI''SEN#DY"!Q9WJG;HRC^+
M;,![O&F:R+:I!@K+_=BKR)<QS&U *T'"K7!(M"V"_4M8R MK$C(NK%W>S?GD
MZ7='MQ\1A2$ZH%V=3P863\#]7_%+!OSF+?</(I1ZR3KRG_WN-[_8_ PKB2]$
M..#LI?K*;TAEMZEABK6D#,:A![Q46DX!%OZYA?0N*)7CM7^GVA#IV<0'CQA!
MY%Y3Q2=Z;1F#%B3=[N@G$8(#.]0+\(?JA!7T'U [[X998N%)QWR?].FE3E;L
M+82,19 \TR5+!Q>O6?]'_]XI9Y&3K"OT7$(CB"1"6 L^]DOZ.0Y&'P](J]8M
M"13-!,4>75NB@E!Y=,^@HH*C2'4!0PE+SCO;(SMOIS%MINFYR1!Y>]KPTDWU
M&:$QT+BN'7N6_S!@_'B2VI:<K_&IS[G'1L^:+T-/\N8M=R%IU^G7GW_YMDC$
M"LO>-&K3IF?\X:.KSZH8&(30MZYQAVH(2B+@AL'&0OXCSUA052-\^7.Z+4G_
MZ3'+Q78:X<WH-Z2^T+J[_!8"F_Q.TY+^P='A3$IP5-JI9?/F?"GUAD-8W9\C
M],"??_/R[;?/^3]V!*RUKH+L*M4UM 7W,]$+D5J0]$2%_56HA%R_\[M2[ 0[
MZPX6_\U"[[P;APXMTY[<Q[O),<7NE)Q#([?)"Y9 70KU8.S9)6G6,,W:F1NY
M:M+7(FW@XJN9I*MYI4]KJUWW6C,;VD@R%<LMK@@R)AT[LJ1C(#KUCN+N*%MS
MV!VON(N+ 42,%!CDRQX 6:C4,M)Z2C%A F"OFK_EGX8XF4S,4<2 8^Z,:I.P
MSM&_[OT;:<P%Y]\$5LM3K(GNF[;=SZ8.>_U.]NS=G[]\4_#'TJ)3\JD_OW[#
M.T=R7</DEE[RU9LB2(Y.SR!I65RRI+)+U;-$4CB=G'7W>+*[QYO$B+U)$='9
MA74%?33M?0\ZM9C_Q7_,>V@G<>A-*<_JY5H6%EPG98(C(AHZ77QH!\MQS>["
MUL6K*KF%C:%43GNYT8!J9 O;#FX7Q?$>H$1;I+&-Y"? 5IAD*)(X1YQ$ZQR:
M'D1#8%U0WRY6)BE+D<NC"^_8UOM9HF6JD6MO6T2.[ .0585ZK3[:&P8"/8):
MIM%/>X?$>U'D!;KOB/:$7&:46 _.NR<80^)G$>TC-NGJGR3J+,W>>R>UO#Y-
MWM"CT8O5HI_8!#,*@I)PQQL3YR)B=9%DJSF]LT NTDRY!*<$(QI\7B$36=?]
M__O_DDR%^*]G.DF8W5%")3Y+B?;1+Q<]/8.K84,NI EV.&N3M$K\+"T*=E:#
MOG@\3$L(4))RO-(<N(;0%;*@[A)->;JAO^[1^]R#>ASQW,=K/QR>T1WA.&L5
M._0'TZ%F53^9:>H$!(CKZHMY;GN=J%L:4E0V&V^82/]+&3]-:NP$*B>.MJHN
M090IVE@Y*,,;(7'T&W;=;_WN1?%QTBJ</F>8WBCQ+C/F)%KS#UJU4Y!R&-3N
MV IGIJ'T1&PTY-_:3&6^!R9!]Z9T=_[W-*@+FZ5.YO2ER9901=@W/]WGWV8&
M,-&61RI1S6/#%72_>)\%X5&;HS8!'"V 9V3J]$JPH3QHUU@+; E[ ?41(F@8
MN(E=NDDFG!LYSC%>F;@8<>%UY%_BM0&\[_::\D8VM _9T(+!(7*Z;R\ !HFW
M^NKKK_R?7WWY56^,1K/0;==/?8'<];.[#WL',Q;8"&D*RM_A8)IPP1)A[)P+
M:_65G^R9^3<5%,ZPRBS:\D,,F-2= 8,[UR[=R@JND4GRD^D\7I5-N2]C9NCS
M;PN;M4>RO%?"OB1QGS'M!=^74&U0?#9I63LN(";]<Q%F\ 8] +&J2,V3N=QD
M"-;-J4#NLRN[W;&8!IZ:_"\4M,W_-FYFO,U$8)RK,3DD]Q29%LMR?:Z2H5XI
MCT1R$VF$,25^"G33F<G.<75*"85V2]X3;+"$'#(U2] I-0W- 6$8G]B&L>X7
M<3)>9==ZK-:EO^=,BJXA*6R^_OREK06^?<D^$'ZMG^WI (,CBY:&S5LM*7Y1
M;+Z@_\?__"]N^[_F=L\W;Y98;]1AA\F-O4L*!.( HWZ-A6YO-[D7A[OV[_9A
MS8Y('/^.8F'<YN@=%K 3Q?PT9::VY!$BYF2G66K<X?+VV3AD\!YX/\3F)"J@
M(-BD*_$^0GNKF9,GM9)6$.D*(OUH0*2_74&D/W40Z:=R:K^-4!HD.#O_.?$0
MS9E<DN>O^1OO]Q$"29.U.&:,WT?EV,",B3+16(>F'?-!G.U5;[$\R0 "&&[Y
MQAH2^%\&@5D4P'S0W>RE-L7JGL=4_$<]$@LYK>"]>)\ "5AVAP.M=G)# D;%
M(K\SXY?\.SDM'1%B8OQ-:Y!J 4F ::4G/)7O<,O8Q)),R*[JB3_OK3WN)<Y:
M=$86PBZYLR:]:X1R'-<C@:2PCJ7W$:!5 V8PGR0PQ3]%8&G**C^DY-O5P01@
M+&^DSED$OA4)G5]:-3!X2R8KY,QZ[L89I&4<BS%]&](9-Y3FPV(69YA'@]H#
MRZ3W6FJ)$:=H, T49V27(6699JS)RO:H3"0!(L+"L<._T(9>A 21#=&4!%VC
M;,T9T>V0-BH20:L,;A!.^6;/P>"$8?8_V@PU/E,*A[=:T*(P2+M_C4C]_N+'
M4]ABU[126HKQYVZU'_V+I!B+]A-M#A"5@!Q64XICV*H":=M"ABF[.V%71J8H
MOW/9Q(T?S[/\KD'?I?V7%4=0*T#509,L%5+I5=>A^JJ[;'E7"(OSN>R8[BW@
M8)<:5%]1CA:CH76WKXB^HAD6=U&+Y-UU$&:-WTF+!8(#ZT@ A7MK^T$WB4G.
M=BFWII6?ZJD'D6OUXN'M0=?E Y<:@;@2B7R&%+?S"[)*X:3A"HQI=>6>+8Q/
M@//H%_=.0!/\ ]#P8#["IA^!5Y.>V;1?UBZHC\](/YG38+'I)[BYQD6[SXF,
MU)J:T3.$U.C<+QYJ9$0HM%"[N'$-;>T!Q)/_)$,ZYF)&"D"-5%YMMPFUVG0,
M2P>$U&:(WEH!O.6^Y>^!)I]RYU3MQN.IPA2+D\#W%;=U .K<'V&(!$(-/*E*
M]@M+^OD&/5OSV9S2S/A[<3E0)VNBC6DH$9C13,8J =U&$J&GJI<B.9U3L<,C
ML'XD) >0"Y-7HPQ-U^5[5&AJZG7ZR2<_?G5 ?S);SI_XF)@@]^1-4G5.U"DR
M:SIL2IK#7SK8U-XDM-9XYX8DXKK-#6"'#9&5U6;_0C0(*(G_1 #5S=JT;/(A
ME#.E%4F&,[C0&FDTM):WDY<D(L!.H7_>7>>#4)(PP"-(;;";NXU\S5!^S#46
M+_L.3VN%K([C^SF.+TU[X$*GKGJ4P1:XFK:#F(;M>FP,?XO!ND8-;5J9U6D+
MKAHZGPR@VV2<((!LS)#CNIC?FX%7]NZ$2T\[<WM[S0GKE#Y1,Y$2]QM*HZ0]
M41S;; P?7W?Z>F28V?AJ[/(= >*E%!-JL@F10K"L1%F04I"<W":@),R^4)B@
MX,G\Y=B"KZP&HP1GI5R"?F2$-@:)F0"N))N-A]$"$%JRA5\2;E-(Q/B':E](
M)U5URZC+*<=L_+I^AN_!8N/T >[S@Z0Y;EL3F6V$KUFN07]4_3D.UG8[7Q^$
M*LOP7#+DUU]<W@'$2KD?9&\$^]))IF0Y";G[NYP I_'S2FE>DZ"*D^?7Q]C#
MN:YZ3K"(-XUK77V&S-C991T&=SH/H>N$2*SX#-Y*5R@GNXV94.F"E(ZX!7YJ
M-*P=-L*+CCV)4RVOV/]XQ00SAB7]-7I&W--7,UTS+%*?W@0]M7I]3CQP!6/Z
M;).^]"O#IK(/._[4^1<.A"+2LC% N$@>)J8OTO.NHU@I/IB<%WTFJ4+EC2M#
MT^[,.*."#I5H[UJ[FV%N4U:T9.-9W*"R#Y9)"/DWP4_F]A^?%_>IG%E<@T2!
MU6#VQT9Z<8>+%1B>[3K73)-%4NIY"R:VC@J-0@:]>>4ZMR6E^ND(\@]BB/9T
M$*2D1J? \\U7369C#U7?M'),&"MB0(_W3\@8C:&'S@'IH.;L/O=F\?X;Z3JR
M%\V&?XD*<2$!DWPI'6N02NZEIC!II.>Z".2VGV_^)"AN&9BBRAC R1=E!WBZ
MDVPIKF,@JW*E&JZ"WV]^5OV<]JY;9LGF+G<I^*+=7<YL',Y_\!_VGT9_:!$I
M"1G:R8T=WC0"ZI0^C8L;?UEG+6 $).>#S][^G)[V6;@PTPO_S/^^<16-G57P
M)'9N*"XUVM786O\66E=LKZ:^O7Z'F]&-:7(59@I:#O!NZ/!,OLFRB1-0>+Y@
M8GE'H(#SLG^R%@*/_L))BI(IE[= A.J(W32<*"XX'H>J(YI42<JMN_$3W8W]
M=J 50=)#(Q!%=+Q[^"&U+-A8:#,>Y=2+](NM[!D$$&N7^CO8*7/#SGK=-$QF
MD<2,FY>*S5<'0V2BQAGVB4OPN4T27=Q^ D$<]+-%1+XL&+RN!^$K4NY]0_ <
M*&WC>?-R%[!*UZ<7OS6;6!_X_LUL[]N[YJ[$&>0GC28$^_,4-\Q)AGB]\'9"
MMF$I\7]/#)=L-,F\XR]"!%R$9IKK9-BSN>*(@.1SVO$\2>'1]27WR8QZ =GQ
MI+>4%22\@H2?+$CX=RM(> 4)_T2\EW!(PKUMW,")$<[W)QWT_J@?=^P:()DB
MQ2GP;(R!RF%+I8+@FON/7L] <B,,+I?Z'$;$:GNQC.DPX>\"Y#B"MJ1H5U]B
MSS;WNM$IR,]!X6@$HG'G'^4*M1N^15EO"/Y5)77!)LD%?H%VWCW'L*%J$+OS
MK.)B+M'((0+E;"15IQ5\N!%G LW0YT)!$I6YEJGRF0FG]Q;E [# Y:]RZ"2%
ME'\E].QH=M+'$HF%X)JR;V$K-NH/G=I])&%<3"&^;]8PANF2/_QA$X5K@&)+
M'(RXC*F;1>$-AER01TQY"\'# -@8RWJ112NI=7-"51+8MDM=4#$IG!R,A*!Q
M\*'PK1/60ZI!P^3<R?OF?47,"K/HR,?T0T7G&!7%/Q]!=:'-Q$ESO*[T8RD4
MB+!*I:ZBO,$X)!&!YH4U#!A[^/33>;$0ZZP&":!V7&/G 10F'U]?9/8#'O80
M>I^5/4,O*DMU@I2Z]4N?6Q+,?/OO0M&RZD]4Y,3]*)M7)N'FIK_T4$ZB,7)A
MR0Y2GMR'-RW-<" \3=ZSK6L <CJ@RT$35IR5]J:Z(1?&Y.6$*3:?,?^FC93.
M24*RB^\C\I/YC?J4C/QZPGR;)_8J)VW(FLGQ$5TGK9=IOHK!3@M0"]I_&045
M]KP 8*+YEK543%^O]%Y0!R>_'GWCR/P,S'=HY6#,6?35Q-)+2/H:9)0?U*'Z
M3MA'F/<J'.XA? 346?F$E<B=:U#,,<-<B@C)8T"MO1^311]Q<T=(Q] "G1?O
M)8P.)[6I9CV I$T+'_X6G21J%\$O1./C;UXS80V;7L2@ISOB/7'[Q T20]G'
M_@DF'I4^^*VC,NC!GYR5E'O9  :[]9*_$DYW502*!)8?(93F4SE5WV(/BJ#%
MF;'^N]\8O7T.@>CTW)Y#?U&P$/_5,Q:UOX+?BE+NWUA??_OJK[]]^>SUYY\;
M[U-RV8*0#,[BWJ$H)+4?X ,V_<G;F>NRXV"MJ<0>;ZOH7(6$XCWY+5%;TL&
MCU.O35WP'8$?RMC#OL7I3AU)8-H:(]0A:'[>(G/C)DN8*[&SJ>:RJ)" 1I?V
M(:/O Y%P\%"GM2^9VYTXU:'$H=,ZI9^%H:D067:T#-75;2S"$F@B>VG/NK^>
MH!O4%?!*@-!K=^-4=TK5R*; !'G&>.ZS/00<,CDM[127PE)RNHO%]&^*SJ)T
M,[*IS"$V=E3))T1ECH3()$-E@C%/ '&E(UCIK=X3!_9?,1RWB@/HZNVE;=:
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MOX//B*+TT.?6S85VCZ4AR\Q3!U6'C%! #-T[HV;JFOVT*\CN]7R]QI]RU(<
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M#ZD@"[.I@G!1"%+5,,6Q9K97XE;U.],-NX<3\E<J[S85-X]Q-9%@V7ZZ_']
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MNC!O+(TH>9*]3,]H/T,6V=IX##":90'-T])%)3"6=TCS'!5N%Y"?L==Z/1O
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MH22Q=_[=ZC:2;U/*J>TG=*$L^:?8Q^P!(W*$0B3O*40JDBN37=<R/1#,]EN
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M@QIG)_K=5J]"AU$4@IK&OBVTC")\ )V#&;J5@2KT?$RF'JAID-0&&G@/N(%
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M2-\\J/%7?L<E!K#GC*)X2RB*+U6<OC]_\,;\ZQ?R![] ^O7=K7$S8+$O:3B
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M35MKF:NQS1!$]E"TTG#@U5B$03_L>O&/R3==)GE#%0Y1/SEA,&DD$+^(GH?
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M$E4B',0%[&A'T^T:3)GL>%&2KV[M:@YNL1KS(35+G,\D>\2X88B3L!V_8?
MG'3L?U^:%&D]@M5RT,R+'=.%/8W-G"[X&E4*$24MZ8,:XC";BFZK%M/$W:)C
M1PK3]EVM"4)$J)NFU;SWW_9V=VF4,R&O,>_44Z1[9S9:7U.Q^,,?\A_7\T$Q
M_!G^[E7<?\XKC\[N!;J!W#\$7PR_>4[4SK"U_"T.U-U3VH0^;P/G.'P#QE:$
M\M\"D:?6N(R3 E@&2#&CPE!\$"3BEKDT=FANU1"/F%8$_//?2T2B4N7ER5K
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MS_D;"9OL!@V>M!BVA_)T'M825T6*AM-=0XJ4\DVK?@M*MZQ*55(KVFXU 1S
MF:21F,VVHY!\<'*-= )O$JPQ1E5A,:FQ*)>UZWC+X[0IO_QZ/=C$SAI?3'._
M>G*[?B&^&6O0CO)]4S-/BIF^?'D3IB?0M"W!1LX0$!P"AU3_2B6(0+%H=N'T
MHA+$S?'U=/]I^F60I)U@?<056BY#V;0!6="]@7C:1G"#P3<V'5#6_?12*G@[
M!/I>2?X5WE,[AY=)AY@E&U[[E'N>*8,89*+PDG6#TUEF(K?,D7-I^F_S+R,U
M(<+5(?B9^H[I4!*(B:4*']W\NS-T[5# 8LX33 +QY,41M(]RGPP95A@7O3!_
M3\BN;A)1W[CC?VN?/AWMA%FOR/[M1&^]/7?AL"0Q!IFR1,R:C2A'.I=>I2R)
MO,YT3.R+_/L9<%8,=48E SCZTY4Z7OZ98;/L(QCQ2VM/)6?1OBU".HK$@"P6
M@6*RI1+OA9$@1D1IQ!TN]):_>!)RN^OA&ZDS"<0W)B-OO56;\Y)++)"NAK.2
MJK<8,6D+3%31XNX8UZNB"H?44H65][Z!T+9*A+PD18JJT$0A7U):=X(^UJ;4
M$4Y\1S@Q;R(S:5I_CM\@I4=O;I241B)V"J[M?]5:K&A/5:\$#":7R.NR:4"B
MM$ZYWN 8L,.%<&4,4J]9@^?_:J3OU2]GUX@DFA&L!4EIUH7S&/@MF7X9?T,[
MFA3@_:'9UZ^IEY!D<!Z2E ULJ5\F<TR5\;^\3F4_5H\*W'VRPVO>6.Q^(D=0
M=L_W;.B\S;%>RR!KKP$:#9/FHS7/H%+@]98ODDP./>PO\3F[M#77,9.Z1F_2
M-K_:1E2M48!)7[;N/]E5#=K ASK-;5W:F<[>;[A5G0E2O.JS;54O,]UI[VU3
MI(#6G& !^+>:&XE=^=5&! G[%ST*H-$*#VF5MQMZ;T;[>XM-^MB*(*F33/Y8
MK@9@(K6UQ5EH4S?V2LFY&TUF:#(O:HS6:->B2K>X<AUEW*+6%1AU(KW8_\_>
MUS:W;23K_A64U]G850"-]Q=Y]U0YLK/']R9V;NR<L_LI-0 &$C8@P 5 6<JO
MO]T#@ 1%ZH422 [(WCHGMB42F.EY^NF>GI[N]GY)U;]@ N0V+ZLY:YPB<2$-
MEJ;&(@9X.B0VJQGL*7"7N[XBW794$.5R!]I+*FYVGB("T7>>5CZ#MF1E$LLG
M_9 Q@,27Z+(0NQ#Q>ZU+,YX6,5BBQI0O\I4$QKIZ'3WPW39!S?4ECNDTR7)S
M.%ND?2U^?U7@WK?;BS9&#0:+]_QZGDH;-<9;Q\T0EH]K;(-8+#0-7_LO[ST\
MO65G>^9C=0A- M=T"I^K+AG.>2'9?NV1+H*#@TZG[;U=<9NHYLLZSXN1B-#9
M4EZWQMD%UO#=JVL%EKRQ6[VP]AP'^V=7IF(1.NY/290Q:6M)+.-_X$8D/,5T
M@JJMS7+3A17019RB0_3G-OC!:VAX9J?AF6 7!ED$#J^::KQ]22U7C=CFEH..
ME]X:RNE[HP*"X!"EP.S?,&JAO!(U'_6WOWSYK1)_-=Z^%D3?*N7RQNN3> AQ
MV0PC%K'2%1S@.V^?L?25*LJ*JA? 6YP2K>G4_7S7!5/6(\W+W-&T6H1LFEXC
M3;SM5CRK@>K:4=3BL*C#_.),J8_GYH1F 6?!@55:\^5N8P'L)@[7!IC!M>R@
MCP&CZ')!@&())\J/?3TL>6?],2=%-&+I7=/H*REI3"^I>WD[IJV)T&Y->OX0
M)F'VW/U> NTJJEO%:DW(PK]J@[L=_=WC.?5 ^ZA%<B?N_9N&8TE7H$2A,28*
M.90H-'K-VY H=()7?WY=WA/XO+A<,DA8YT!F] !7\-%18V5:-3'$?W&\K/8A
MQQWI>Q[Q:0C>D66HBJF;MOBO)0PH_,4D?V4U>Z2Y8R#<0N&K@J>"I7#^Y-7M
M2RV]&AWHR'09'S="^/Q1P@<__Z))/Q.;T=YMXK:XGKA'\:KY][R"KU6O[XS<
M[8DO9<ES:I>G&=2JOX*3P-]JX(44\];B+6KM3_3ONO:J(JE[5O&S;E< [Q&M
M1^N%!;V"W41S#'_6?;K]4+_Y:]M P)M8W_4M6SOZQK2]N>-;QL1\PI>V_XHW
M\>R]O(@F1!-JOV).K#W-2)[!=7V+^RS2.L/HPH4L^N.BA%UKK+54FHC_]7N-
M-!XX_F SP:X3T.WNTX]N-+W9X_8/XG#OL!OWR<H#,(:_^?L+0W_Q;.&L=B6'
MK=VL5L0EZDT]R;NY[E"<S]N3K_GICY(W.M?/R?]>>VL[[>_/84YAF7ZO@I]7
M:14OT^0I[M'^)"$V&"0*?&7GZ),T\)6PV]D9/X^#@N2V<??(L/%%=.MX[:#Y
M?#,H \)VJ\'-R<W?PO+-?V'80KFJ)B)RL3-(RB!2 J"L +0Z )H$P*< <%Q;
MTH=-_+$9)Y+8(=ET'"[E;OD6K3SY[*3BI.+'K.*[\]_'(6!2<5+Q(U?QW>V0
MQB%@4G%2\6-6\8]M@YTWK][SYF^O2>,)OX3?T<K[$%$_D9>W'O:+DD1/HCO"
M?@]'^#;.Y)F9%U+D,FY34GA;-(].: ?QL/HOS0OI9;0*K,<+Y^5^T;.1FW8I
MJQ+99Z=:*.HWF<>.KWVJVUAA13Q%/$4\13PE.ZR(IXBGY.6I0+6MK4^&1X8N
M8BEB*6*I,;,4>5.D;J1N>U.W5Z?@%3P57AO/,[:/Q=^;@DNQ^"=6U.[*UU*4
MG@P(^?W[MANFH:M6<.R&@V!%VTG"T0CIR7 ]U3&VSJ D6!T=K(B>"$?RT9/N
MJ)[K$:Q.'E9$3X0CZ>C)-E7?)^>)E(R4;'=*YAJJ9SN$*DI^ERO@_H^FDU_3
MW2W&'GO8ID/T+*&0.QD,,A@',QB^&N@4<2=4$3L1CJ1C)]M5'9OVC(0J8B?"
MD73L9)FJ;^B$JI-'%;$3X4@Z=C)-U7+)=R(E(R7;X9F[I7H6*=DNXNT2MCT:
M3[S],W8-/-L6ES*+9SQEO.2@.;D+'9*,2$:D=X0IDA'IW1CD13(B&9'>$:9D
ME!%ABC UYK+ 8J9I'L/ FC<,E]G7"A7C"<VC^^]JUV-DD9V/B#A>U4J:1\64
MR@E3V)_"_OO/2S+4P-ZZ6Q*AZNA01>Q$.)*.G4Q/=4W*2R)4$3L1CJ1C)U_U
M#'*="%1$3H0CZ<C)L%5K^S:XA"H2!RG9XY4,[YQ2G:*])TU2*'Y8'/^6@VPS
M&'.L)"PME2N6S;ERP=)<>9455?5:*7*E+AF*1:EX-"_3.J5"!V1TR.CLW^A0
M"PB"%=$3X4A2>K)4QZ&0/8&*R(EP)!TYO3+5@/KYW"&<C?U\]KZ?,PZRGVN?
M__TY?#DLT^_5BN655O$R38BTB+0.2UJGX%(=A+1&(!?2MGW7D51M_]@]!,JN
MS]^&\%9>+GXR<6:U4A59&BL=D(X\Z/]C4<)RY0J_CBY9?K$2[]\OBVRW%!3[
M'Y$4Y39?#XOL" W<*T/5W;U:."F1.9)=\E@@2G1)="D+%H?-\0D"@B7!DBB2
ML'A$6!S:H_0#X^2121XET:5TH"2ZE)$N37>O5S.D1.8H3GRDE!SIM'0Z;:IZ
ML-<CVJ,%YMZOB@R)=G-BXD+$Q3S,N#SD^DQP_U14E1+RI"AY6ZQ)J=GUON]_
M2"KID;NITLCQJ>[ 2_E0>(3V[95I^:IM'# 4.GJ@'G2;+S-0B4&)0:4$YL"[
M?M]477^O+>V/#*C$H,2@4@*3&'0_#&HZJND0@QX5@](U(((I\>E!^-1Q5&^_
MMR&/#*<'/(H:O>Q(Q_>CXYYJ6P<\F1H]3C?J>'=(!7\RF)?XZ\:[0C!]U_ON
MGOM!A@__/L#!SW(P][V\^2@^^2RMX:71%H+[E5_Q?-[OZ[$BI?X%*GOB6-9]
M4G*E%]*C1/*_7(G36,F+6BEY5%SD\'R%Y3?P+R$K)<V5^I(K-YR5E<)!.+'R
MGD=\&O)2L0Q5,773AB_$^!=+55BE1,5TQDKX7%TLGE(DRLM@8BLPVBPM<B4I
M2OR".5':-5F^/<97XN^4;_"PDF>L;IZ%P_C$YV41E6G.E?,BRQAH-JOA@2J>
M F9S40WNI=Y[$;P8OU< 5[ LPXIQ><4B_(HR*].(J\I+8Q(L/@ZO+GD%<XTN
MQ:1B&%U6S*8@+ 5\[BOX1J6*WS#EI3<Q%E^$/WE5@Z0G=Z%K.QTTI8?7DW6P
M)][W/?%^N)[QO%HYPCUY[?P*T$T Y\4W!+8@=J6:3V'T\*+J;JCR5I9"SQY4
M7_%?JU-B$W3M@F./:^5;6E\JS57,JB&"H@)&J/FT4EXU_Y[#=C2N7I\-LFI[
MVE(/O4IKFVN40+M8S5A:!P0'@T^#L>-OM8S=%//ZC,WKXFWS8$/7)_IWG<,2
M(<7-*GY6<6!4X,$V=Z27AW*55FF89FE]<]9]>D."2?-PRYM8^.QKE ".HYT"
MB/3Z[8LW=WS+F)A/^-+V7_$FGKV7%]&$:$+M5\R)M:<9R3.X>[+9_.V3V3:R
M[ ,9;A/=2+?H"=G]2&Q-NV]OWJ[Y1Y5517*ZIR&KH6_NR+JET!Y.6MTHU@TR
MV*&8EZ&?ISBEWQKE#HLLWF(=_@4>8[<*@[QUF(,,9= Q/>J5']!K)E'@*[NM
M TE#U)4UU%WR^8BI27I;>8]L&W='MT[,GM[1X'P('T0&1.Z6"<Y%C.1O8?GF
MOT0\]*J:B)C*WMT]&41-@!T;8*T.L"8!=DC CFZK_427X]B,(DE24K8>L4N\
M6SY'KT-".,L@>*(*HHIQ(7;G5+'3?<F(!4]4050Q+L3NG"IVNB,<L>")*H@J
MQH78W5+%QSPJ.:OXFU?O>?.W[6XBG,XZ$-X)[Z>T#H>(KCZEW8M<F4SC*<7U
M/BUYA"G'L/8YRX"!JKHZDR31:<1UMO9\T'52M2)(=B0[TM]QR)%D1[(C_1VO
M'$EV)#O2W_'*D61'&#RT'$EV(RA<WQ/I<#V1'XSU],LJ'$D;Y'=_\GK^!\OR
MY46;+31BQ_(^BMC:XZ2W;9DA662WG_I7.T.;'*0\;,=.W55]W3U1/.Y9;8\*
MAL2#Q(/'PX-^H%KZ4[)/CP&.1(-$@T2#(P7@H#1H>:KE>B<*1Z)!HD&BP9$"
M<-A=L:<ZY V2UI+6CDEK'4,-+ IE29.W3*<R^SF5^>>'3W;P7-S3@0RQ!FUY
M#F:[_OH7WS1,@B'!D';>A+LQX&Y8UUTUG*=<Z"<0GC8(B?P(=Z,G/\-6/7>[
M3KV$0D(AL1_A[@C8[]4I^W[[::9[//(BK95%:P/5-4[UA'0G[7'I*LRH#EU^
M@:]$69JC@)HNEVD583/7&V56%A<EFU9RD ^=R(Q*=F3A)+%PIJ$Z-F43$ II
M5TZX&P/NAHU).JISLKMR0B&Q'^%N7+@;EOU,U3,,0B&AD-B/<#<"W V<C!,$
M3^G912 D,9&N[CE*I?HV.2K27'FA4OU/@_''/&Z*]5.-?JKO. Z7FV1'LB/]
ME5V.)#N2'>GO>.5(LB/9D?Z.5XXD.\+@H>5(LJ,:_2>4F,S+JLASGFDESUC-
M8^55FD?9' 4!+RRB/[205?#COX7EF_^*BNF,YQ6KTR)_[J422EBF*#P=!1WL
M*,C35=_0"86$0ED\",(=X6Y?[&=[:F!3$05"(;$?X6X,N!NV;K^EN@[Y?H1"
M8C_"W1AP-VP2I*GZ5$"+E%4B,9&RWE/MS@Q(6:5)63[$N4P(+^;EXB<39U8K
M59&EL=*![!1/;C[7E[Q4YCG+LB(2)S?\&@]G^/XKR0RP0'1T<P32E=YJ/E&4
MQVA7#=6T]EVQ@9!,2"86)NR.&;N#LG"@.NZ^X[ $9 (RD3!A=\S8'3832C6]
M?1>P(" 3D(F$";MCQNZP\0C5]2@<(0F029#$" =G!%,U_7T7U#XM(!_BRM:0
MVF%.3%R@N)B'&9=NA095AE]YQ5D973:](_@5SXK9%'XERYF?W$LQ?B];;OD^
MM</-R_&@]A@-K*&KUMY+=XX)UR/S%D<'9^)EXN6C /*PH1#74QWCL,$0N7%-
MO$R\/&;\$B^/DI=U1_5<CW!-O$R\?)3X)5X>(R_;INK[Y"Y+0\O'+$IBB#$R
MA&NHWMZKO8P)UD.>)L*?#.8H_KJ81_^ZG3UQ+.N[?=VYNQLZRW??][IGB.;I
M$C ?&-2.CB*'ELB#IY9*FD<E%_4EPQOEI6U. @7>F:5%KB1%J=277+F!1R@<
M!!<K[WG$IR$O%<M0%5,W;855"M:D9"7\MB[P9]9$>=\TAP&9P"!9UG2)4;KZ
MEO Q]B>OYW^P+(='K8[ \";.8@2S,@5!@PB4>,[Q>\6\5(K\HH")*[]<PI<4
M2^&S-..SZD:)LC1'8E#J,F59)>:,XX>?UJFHF*D4B7A$DI95O7C S^_?W_JN
MJH"8YPF+ZGF)KX*_I%?P$) 7#**:SV9%62O1O"Q1EOB>9 X?Y>M#J)1O/,OP
M3WSOK,!U@=\HG]Z_@^>$T[2J8%RJ @+$G\-,BR2I>(VR8+!BC6A@"JT,<4WP
M2<W8S0UC5P!=L."X*!E'<<-W4>[MTGP%@?0?&S^T5/_\\,D.7)3<2V=B+I8F
MK?IK D],*_'C7/F9W8AWX>_R0LE@O6"59_.RPL]?]H34!R0\OWG31/D%5&+Q
M&0'<M(H*H/T; $1Q4;)I.\I5Y+@3?3&Z=FCX-A9?L1Q0V[YD.L_J%"336XNX
MG%\H$;PHC6'2L,2@V[S&=?^_5YZJ?&)7QL03 Q%_-6"$:S5;-PW(["M37*97
M/!?+FB\^A^*ZY"R.BCF,K@<M?*A6U>R"KP@)QW#KZ_T*L?WBL)V&=Z*X]364
M3#X7JHPZ,<.O5 K(-L?9,'B5<@DF$7Z=L+14KE@VYY..665@-N46S<?I%0"+
M516Z$1=<:XT_#@6>!72,'VC'_*<P ]=GFO4VR?BUUN@ 2. ,9C.?YF\!<+.,
MW9SA;]<\BXD#+@(.J\W4:7[P[WE5I\E--T+Q50U(\^VLJ%+Q; $5  'X)=<H
M#ISBPD6Y?J3383S#,"V=21D6T%M-+8/E:?^+JWFY2(=JYY/F0 A")<KZC,WK
MXNWJ+T#2S8^;Q1<Y42R!Z9ZQ[!N[J=Z^>+. R49O$]>PAXNU]1UV&8_%P5JN
MV-/<+/<TW2P7#<H6;I:UP<TRG^5F.4;/-JV[6:V+!9!?<9]P>C/XJYA:7A99
M)F8)]F3ID]SMD*DK%F@H#PM-XCV.5<\#$[Y'XQ;U?,&[/:GG.4O!Q-V+L_0H
M5\2P)Q:Y(GMR13;6O#$GINO=1X7/L>Q[XD+QY+.TAI=&6\CG'QSXIW7EW\7P
MJ;2J2V%#E0_KR;,G;TR0=!*@UN(;$J,(Y8 R3I&A_X1'7O2DR5:EN; V?9-2
MW;5U[RP+/ ?-"6@F['I0S;ZE->P?+QE04=4H:(&:6O-IA;TI\-_S"KY6O3Z[
M:]TDR_#>M<:WB]0,:G7G@9/ WVJPGRCFK>_:/-/0]8G^71>FA+ED;%;QLXJ#
MF0?2;=/Y>U<#KL!LA&F6UC=GW:<WY/PW#[>\B?5=WT=M1]\XJ6_N^)8Q,9_P
MI>V_XDT\>R\OH@G1A-JOF!-K3S.29W#W7##RM[]?])1NZ>D67;LV[YW]H[J7
M<LKR6#3(,_3-'?*V$<[#-P4WS'6'XGQ>=.U;HY1AD<5;R/M?X-\]9R>T]M9V
MVM^?PYS",OU>!3^OTBI>ILE3W*/]2>(#^K@D"GQEY^B3-$2G!4/=&3^/@X+D
MMG'WR+#Q173K>.W@'8UBMY&?# C;K0:?BTB$Z'XI,@ZNJHF(7.P,DC*(E  H
M*P"M#H#;);R.3:2':%,LX9;T81-_;,:))'9(-AV'2[E;OD4K3SX[J3BI^#&K
M^.[\]W$(F%2<5/S(57QW.Z1Q")A4G%3\F%7\8YO%]^;5^S9)\C5I/.&7\#M:
M>1\BZK>#)IC/OKM]\(OMSUR(]:SP5VD>9?-89/7W\K1%5+N?K+VU!HQ.T ?Q
MRIYSC_W@8'R\<+:KLO!L]!QAI03;5TU[NQ)7XX/7/K5MK*@BFB*:DI>F+%,U
MW.V:0XP/7D131%-$4V.F*=-4?6/KP^21P8MHBFB*:&K,-&6XJNX;1PXOTC;2
M-BFT+5 M9^NCZ9&AZS Q^^=TIQMC*'G8F'U9)%Q4K6FK.\"O*JQ6EU\H"=^R
MP=P8I4D^FEQ&E(P%NF:V:I@4CR=4$3L1CJ1C)U_U7)U =?*@(G(B'$E'3HYJ
M^ &!ZN1!1>1$.)*0G*PM.PD2J$@<I&-;)0FICD>G6D>7'/_4BV/C"<5_QCK(
M^U5_*84Z.L]-2BG*;7>VNIAT+);)51UKKW$S N;1 I-(DK H"Q8'WB*[QEY3
M_ F81PM,(DG"HBQ8'/:^INKK>XTC$C"/%IA$DH1%6; X;,;U?N]@G3PL26"D
MQSM)-]/WFL]QM+ <V<V*U74P)R8N1%S,L>GAL1SY_./AMIJ')!AIA#YR'U4:
M.8[D^M]CI'>$AL[UU4 _H,\J#4S'Y(3)C$ZB3:)-*8$Y;##451U[KU>K)84I
MT2;1IDQX)-J4F38MK%)UP'0D:6!*M$FT*1,>B39EIDW35"V7O,TQ'2U)(S+2
M;)DUV[!4SR+-'O:P"?YD,!WQU\4\Q/O3/(:'G-D3Q[*^>WOP@X3EN^][W3-$
M\W0)F \,:D<G6$-+Y!&'74K:-L>)E?!&>6F:$UN!MV9ID2M)42KU)5=N."L5
M#J*+E?<\XM.0EXIEJ(IHT\XJ!?N*L!)^6Q>B8_M$6>]+$A55??MEACLQ%B^;
ME2E(%>:KQ'..3[H$^H$777(61\4\K_%GU7PV*\I:*>8ES@#F!3)02E[!"*-+
M,<^87_&LF$U! @J+8*YIG<(T\5?)O)Z77)D5*)X4Y (#G_(R@K^F?XJN*#B;
M;SS+\$]8OFZX\!>EWTVEWTBEDV0W[%M?0_GE<R&R(E&*&7ZE4BY*EJ-4&(RQ
MFVC"TE*Y8MF<@_P>J!%W2Y!.;]&6<F155<#<\#W?TOI2R?@%/*WBY54:B4<L
MQ9D(B1;Y18%O".=5FL/K8;B\9,V(<1 (UJ7(>M*=#*)T[JDJG6%-O&V4SMJ@
M=.9CE2[8B)7=Z-PHE<F:N/M0)GCN'[SNR?%A;6H5 ,&.KHOKW:=-AOPV3#SY
M+*WAI=&VMW:5CSD AQ/Q+.7R%;0C*;*L^(:X$TX@@'** /X3'BE *427"M&M
M,$UUEWWO" <0BRP#2GG!Q4.$%D27++]HX%]?%JBD-9]6V(0,_SVOX&O5Z[.[
M%DFR_*&AUT.Y->]V19I!M1L1' <^"":!O]4R=E/,ZS,VKXNWS3,-79_HWW4;
M%YA+QF85/ZLXL#_049L4UDLPNTJK-$RSM+XYZSZ](7.L>;CE32Q\]C5.'L?1
MCAYD>_WVQ9L[OF5,S"=\:?NO>!//WLN+:$(TH?8KYL3:TXSD&=P]::K^]EFJ
M&PGVX=359Q9_&6^W:I+''=V/#9W:'P_1_OA?X-]UTA[DK>VTOS^'.85E^KT*
M?EZEP5XH39[B'NU/$A_0QR51X"L[1Y^D(3(S#)4Z@DMLX^Z18>.+Z-;QVD'S
M^690!H3M5H//121"M#D7QQ)7U41$+G8&21E$2@"4%8!6!\"M3[=')=*= 7!<
M6]*G7F =KW$BB1V23<?A4NZ6;]'*D\].*DXJ?LPJOCO_?1P")A4G%3]R%=_=
M#FD< B85)Q4_9A7_V&;7O7GUGC=_>TT:3_@E_(Y6WH>(^LG8(.?@]]F>N1 ?
M<7%Y5;<)H=1X7K9+E0<'V..%L^<+DT=X&=(VU,#>.MXQ,GCM4]O&BBJB*:(I
M>6G*]%37I%[T1%-$4T13\M*4KWH&.5/$4L12Q%+RLI1AJ];V9]PC@Q=I&VF;
M'-J&U=[WVL1MI-HVLKXE!U?B9^+RMQQDE<&8XU[=$N6"I;GR*BNJZK52Y$I=
M,E%XI>+1O!1U0BA>3]:$]@#[-B)__8MO&B;!BF!%]$0XDHZ>+-5Q*#I/H")R
M(AQ)1TZO3#6P]MIN[>!;P\<+9^NLPF. %]$4T91\-'4*3M1!:&H$<B%MVW</
M5M7VC]TG.,'D>"F;N@\*W!^+$L2/-<N;,LC]B/TAV\=((NO1N7922E%N<[35
M?:5C,5BO#%5W#]@T7!)DCF2?.Q:($ET27<J"Q6&S;H* 8$FP)(HD+!X1%H?V
M*/W .'EDDD=)="D=*(DN9:1+T]WKK0DID3F*$QPI)4<Z+9U.FZH>[/7(]6B!
M.;++&Y)V9!\4W)][;3</R2722'?DKJDT<AS)7<+'2.\(;9JMJ[YWP."G-# =
MD[\E,SJ)-HDVI03FL%=8#-5RB3:)-HDVY<(CT:;4M*GZOD\H)=8DUI0*C\2:
M,K-FH#K& >/.TJ"4%)L4^Z@4V_14VS]@3HTT,!WR3 G^9# =\5=YS@R6[[[O
M=<^0P\ITQ3#3/(;/GMD3Q[*^NSV*G@3,!P:UHU.IH272/\#"/T0;G%@);Y27
MP<11X.E96N1*4I0*?%*YX:Q4.(@H5M[SB$]#^+)EJ(KHS,XJ!1XS8R7\MBY$
MD_:)<JL5R:UW&/;$6KPD+M,KGN//F7()- +/9J"C[((K(<M8'G&E2!00[!]<
M@+57,4UA>7S[.\T'E9N49W&%A=;2_ H&,H6)5Q/E*\QF?G=YMHUUV928]P=O
M3=SEV.&+,&>44<*B&O[":N4;5^(T5O*B5BZ++(9!WMPQ_"AC594F*3P9I-B]
M&<:!@IT, ECWZ %K>MLAUMJ 6/-!Q/J3X#[$/@JI+%\\%1=Y!TA=';3;$TR+
MU.9F8[7Q]>O/4Q404IVR++N!F245?%Q,.BN^K<YY_:NWT1NG5PW<T49?<*TU
MKH@=^"*@##_0@NQ/@>[K,\UZFV3\6HO3DD<US.(,X#>?YF_CM)IE[.8,?[MF
MN2<.V&[$49LDT?S@W_.J3I.;#E+BJQH Y.VLJ%+Q[))GK(:%!;M_C?A%3"Y<
M@.M'6GKC&0;B><W0AM8X;[6P*BQ/^U]<S<M%)DH[GS3/TAP&5@->SMB\+MZN
M_@(DW?RX67R1CL(2F.X9R[ZQF^KMBS<+F&QRY<0:]G"QMK[#+N.Q.#K+%7L,
M=OW#V(JU-GY#B^6G]#_S-$[K&\'"YVR6UBQ3?N55,2^CE;JK*Y)JIXM30^_?
M]>ZSL\]1_$,)3[SJ#(611EN(\TLC-N3]A63)5UG*YVNAQ*SF*CJ"E^"6*DF:
MHZ&,%1"<4LS 3T6FJI19F<*4X&7@LI3%_.)2N"X5RX1-Y2!:@&S?&B?S7)A9
M,(<<* Z\@K*88H/0C '%B:<*B,-Z\AR<#'91<B[\"57\/.9AW8X&'C-1OJ3"
M?L_1LTK1SBLSV-VF$1I[7N*;NH&MN?W+V94L18>#7<#++F#>2@YN0L2J2YA?
M$7$>"Z1,BY*C>YR#+S6QE;!U2Y8B$%/!^:=5->_\BC493)1WXG%WC2=NWHR3
M%7_!!X#7A"(0/]SLG,$#7WJ.#>-JW:4.SD^'DS$8G";/'\QPV,:0 6EZ)XT/
MUQ&?U6+3@9N\ G3GHM5M@!3JU5(WB[)"!WS*_N"(,G#TX<G@7]\(_017'SP4
M\96ETBK?TEIPPE2@.RZ:/24J';X.MBG3M*Y!]T Z,%Q0WVI)S5%CYB;*;WF=
MPF_F$3P*9HJ['WA8!-*[X#ER$:C"/ 3/+6\8H"SB.6QE2PY[G#FP6 IJ"'MK
M,01^/>.XS2TZ3FLFB9J6"TWO^(+AZ$+XC. D',XJ22WGB%K9JCF(<96A*KFP
M3]!?"N-_ 0QBQQR#[0 \P(BPDK:IOV6U!I#5&J85/S/>+E:XLRMHY*HE#' _
M^FY^ 7LT)',=K-6TV;PS@>6?60GHQ7VZVNC$_^'B0?"(GWXZ%Q#Z KL[GJG*
MIQ0DPN:5\E<VG;U5SG&?G]^HL+V/BG*&^..QJK11@G=??U9^*8N+DDT; \D
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MN]LW&D\.R/9I,#W7$,Q4CH=Y5VE]0TSR>"?DJ<Z&Y]C+1(2)\GE>KKKJ_?5
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MY&S8Y&R,$7_D;)"SL6MGXSE*NCMW85F8]/<B^;U-+ 7#+8WCT,O6 (_A\V*
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MT'=1! M25\J,W8@^UQCT9%%4SGG<]TS;6G(^E9*3@'*.H=3)>)(0)0;@/J[
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M/K,\S3=T6X/=(NP4$S?2S(@9H6<GKANLG>T\)03XGH?UEX4O];7QKI:>V#_
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M(_ZY'"\N>T)8+VXJYKLKG2R2^N[ZFNM__1=-B7I>O6RN?>?F[(>MOG_Y*?]
M76=+C:?9XY@MZSRVC:U^/WEWDIWV9IM6%3_YF'WXMD^T/9\MLT%_V+/-OF(E
ML5U'MO'@[ZMD:M3MME=3[J6\'65?9;9<O:7])8)SZ//7]?M],?=%'9_5,7N!
M&;EKF[114O.Y[^[6C7T8UV,WGF00/UM__IZ"L/;G*#O1^J\W)7%UFZTF_NTS
M'R,[^8@\D70WUW;"^4Y^2)QPB6_\WV[LN*O1XK*OU_:8V^GKA<&]]//"'O$1
M?6(.Z7;D"=F&EGRA-EI_>VGT _>RK@1X%6,65Z>XD!O9RF_>ZGH[%?JEKWY
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MHH>=H"5&1,"I)_=C^^$@ZDE_))"FX4/PL*7I.-+Z ,1C!R)0(" /*!" >,1
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MY&84XCY:)[&7DFP>4)-U2%%C4-(N?\9$@C16&HE@/<T"1Z5F.TM?*DI&W$#
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MRS$&(\TI)(>.8D*"% #R0 HZD0*1)(F.6B2B,.4 &U,.L(D(,X>3Q-)$OG&
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M!3 #F,$%!O0">H&* <Q#MB7P+D 5>!=X%\"\=S #%0-ZMXC>@ZN[9(8'$[5
MU/J$N(X,::$3BICZZ#PCUN*[=9?$R""2D$@Y3Q"/.B(M@T;Y2:V3)LXE>[?N
MLJD$>W&S$.Q54P?VRZRN7\?%F_2;_=11J24=&<KV76T)<WHP<QH4"= [7/0>
MG"))2C01SJ$4N$/<8(Z<Y1))[:FEV/#$>1<[ 4"1#GI.][1G?7[[UP>'GM R
M.F&V=)-XT!L$?K03._6QLG5I:_]3]/'<Q7G%R*BBN,R9O9+UD\<!]@EL&>>]
MIZ%^HK4GKO'!91X!T,<-:*#DGK:7^@M >9C<O,/- SV'/I WD#<@>-@(/KAD
MG;7":A4\8D8GQ"W%R$D5D,&.&$V3E&*CRZ>721+/,0K<1,2UPT@33Y&/3@G-
M<(@N;K3M: X,>+-<U L[+?9_\G$"2HR8PB.C5+\2<S"'>SZ'086&C6 ((0Y7
MC@S6B5E!$ W1(BXH1UH*CQ25QL; (W:J$SDJG:+.9I,\//7+/Y?CQ65'*T7E
MB!N9A6GOQ]P,:DJ#*($H#1O!($J'*TK86T<PX2@9SQ&73"!C$D&"6TZ=(2ZQ
MC=:&B3K*I39(8"40#TDB2X/-0N:U9LHP&?SN1$G(D9(@22!)($G'@V"0I!U)
MTE$<!R1)Y,0'AJ1T#/%$&#(4)V04LU9Y)J+>B,R(XBI_2B&G!48<<X5L, HI
M'CF7B7FF.A7!AYWW(Z48$;[W$W^.@DMV?RH0R"+((L@BR.*.9)%BFDB@"4FB
M ^*>261$8D@8[!T.4824-F)#CY4.-"LB33;_D[71*6E03/FA#X'C*'8OB[".
M!HH(B@A0!D4\J-REX9%**I"C..L3H0QI'B(*$FNCJ)<I;NJ3$3)R3Y%U42 N
M;<R?H:8<1DX8MR5RZU2?OBA+AJJ1H02TJ>_;K_9]0,LA[JYZ'1?59%;798I4
MB[-8748[[\=!5[!?ZO@.;>KO<6K'44L/0#QV( (% O*.F@*WNIT(D'H(2 6.
M!.0=-4<"$'L6%4/SXMX:;Y@P [X#( (0@0(!>?M&'E @ +$70 0*!.1!F=^V
MRB@\UBHH*I'VI6.ZC029TF\]1J^H22DD9NZ646B%0\A7@50P&G%A-;(D!D2C
M4(DEK$W<Z&G[.BZNF]AV7>%'&1\QMO?"]][,^N&4\('P'"@$#UMXP/<&(!X#
M$($" 7G@>V_-]Q8BQ< 44M8:Q+W-OG<( D6LL_,=N(N1WO6]E8N>R2102"E_
MIFPZM<1*1$S('KRD404*OO>A^-X]/2KBN&J57]7ULCD*8I;R9#P_S_.W;>LX
MJJ9Q47T_G2UB96Q/@B<H7QX67QRVEP"!$@#Q&( (% C(.VH*A/)E0"IP)""O
MC\FD/:1V8M)6&Q+*P0,4<<HB<C'_J5FP1EN%L?1W4SN6*2VC#HA9IA%/(B%#
MA$<V4&TL9<H)?._N]!*@QO#3<IXO]FV<CV>A/90@6ZQYJ7[RD02,X%&V%21Y
MCF(V@@X \D 'NM&!R(CB1B,A@D7<"(,,"PEQCSGS/DDOPA9UX+_L9!GOEX$G
M-%VF(ZSW?F@TS$C0 M "0-[ \R8 Q&,'(E @( \H$(!XQ$ $"@3D 04"$(\8
MB$"!@+QC28HRB0V-6"/F;42<$H<,%PIA1[VS*CAG<1=USY 4'?2,A$;-/2A^
M;N80<K:.H10_7\1I;9NI'#^5QW%=_NRA_!FD&Z0;HA< XA$"$2@0D'?4% CE
MSX!4X$A 7B^1UQ..!"#V+"J&[LV]-=XP809\!T $( (% O*.;U$O&4,UIA%)
M:B3BS"MD C7YCCR+I<%1,.3NHEXP# MG. HN)L2)I,@%KY$@3%**@_=<W5W4
M.PW_NZP7Y_E2ZM]FIWD$RC78R5L[#J^F+^S%>&$GS?:W'\N:Q8L;2Q;-4L:;
MB_*P_C7^N1S7V0SOXOS#V,=V9?#7Z&?OI\TW=K0L*/!(D;V?/PYS&M0$U 20
M!PXU ''00 0*!.0!!0(0CQB(0(& O&/)*804L#&6(N:T*$6_'&FF!+(N_PPU
MR:5N"H4AIW#D<QKZ+/>@U/CEISCWX[KILUR7>57-VHG5#Q:&RN+CXX7^:CV$
M.P#$8P B4" @[Z@I$"J+ :G D8 \2 FU>\>=$20FC8R4 O&4'SF#+2*<.6N"
M$LSHK3=6OIGU64>MX<E-EA43(X(-)'8&/3.AU'I@QALFS(Y6 &CBSDI-$=4\
MD[DC%AE&,/(Z)1<B4R1ML[-^TSSDZ_S_^.R^'C$%&G <DQ/B D#>(<K"49S>
M*Q573 6+HA &<8L=LMI09**EG!A#'=]8G'Y,P?L6A>AA)_QF16(4%.E>;#\<
M1#WICP32-'P('K8T'4=:'X!X[$ $"@3D 04"$(\8B$"!@+QCR5MCR;'22B'E
MF$=<:HD<EA$Q'I3+L;\RB6V[Z?4V\]8<*M+W6I&^[^;7JSJE]3/W%"H=8LWZ
MF\59G#>-L>?Q+$[K\8=836;U[DO6.S4_%+5O%=R])Y\^(K4G+NL!Q$X 9@ S
M4#&@=^CH[0D5;[5 '] .: >N!O0.';T]X6H \Z#!#+7U!V?>0X4J\"Z &< ,
M+C"@%] +5 Q@'K(M@7<!JL"[P+L YKV#&:@8T+M%],*VT"?7>6HIB=,L(9>T
M1UPXB[0.! 4;J/%&4BOEW3I/K7GB01%D==2(\QB1ICY_,":E<4C6$G:WSK.I
M/'MQL_#LU=3/SN,OL[I^'1=OTF_V4]<[0<E(,+'O,L\!T<EP]HJ"*H(J@BJ"
M*FY+%:.C-'ACD3&1(*ZSPIDL:XA;A8G4QGFFNMC] *K8?SKI5!5[VKD_O_WK
MHT1/:!FF,%NZ23SH;1(_VHF=^EC9NC3W_RGZ>.[BO&)D5%%,^9X%X\GC /LE
MMHQS<&\>9<V>N.<'EX$%0!\WH(&2>^HB_@6@/$QNWN$FBIY#'\@;R!L0/&P$
M'USS$AVDL80(E+SBB(=4EJJX*1U,O/,&2VK"W?0=L2PD;B**4BC$H\/("LD0
M]L1IB47BUFXT+VF.37BS7-0+.RWV?_JA"G+$B1QA+?N5H8,YW/,Y#"HT; 1#
M"'' <L0PM<E2%+C"B'.KD$U8(R.D%5;9P-S&&1"/DJ/2+^ML-LG#4[_\<SE>
M7';4+(N,N) CS4"40)1 E(X'P2!*ARM*1%GC*"8H")X%AA&/#%4>*48)9]Q&
MS^)=4>(N!U566B2E9HA;HI#CA"$3M7-&.V6QVYTH&3,B?.]G#PUJ0H,D@20-
M&\$@25#GUYT(6BF%I)P@0IQ W(LB:%8@F@3FECN/F=N(S**QRC"' J$YFDL<
M(ZT-1RH$1T)D@AC2I0@^\-2CK(8YN@0U/()Z=Y!%@#+((LCBUF21>A^)5PD1
M4TK929&XH/*CF(61R1"D)!OE[];1&+!"(J28XTEJD8N2Y'^<YUX+H[S8O2R2
MD21[/PSP*)@$1!%$\4"@#*+8__0ECTI[X2V2R@;$L4C(::81Q9+I)'/P)LQ=
MB6(V)LMH0IJ%'+G)'/<9JPVRPK,H<&*8IYVE+Y7@(X,9:-..TY?K'5CYOS;?
M9//P 1.&KAVY;>^2N?[U+_W<$RRQGQO^)K_Y8;???/.S\2+_J/\&@_QV%BOK
MRQDX=GJ9WUU-9XO\Y7:>G\[LDM_V?FXGU86=+\KNK\59K&,ADJ; URYBJ-)X
M:J=^G-]4+_(3Y_E[ZY,[%@[C#Y6?V+HN,_9]1*MY5FZYU(G]1_.&E6W^B<;3
M$#\]0^QYFL1/*(SGL2&#9]EJR_/I\S"N+R;V\EEY=6,2GX@\&\O-KO81MD_\
M[[)>C-/E^KZ;CZ(X#<\O9O6X^>YYG-C%^$/,%/"IF+T8[HH-/CU01\@38'(M
M6%L&RH-@42KN;K!%'I[5OV4TSZXV:Z[N9SR=C*?YPA89)<_L<C%[?ON%;.GV
MZ7;PFRV;-N7;?68G'^UE_?R[OUW!Y%YB+V-X Q<;X]OM,.YH!V#[VU^#S)-8
M?CUBN[[IA\+V8SN(+GL4V\'Q_[Q\_>9U]?;_GO[Z]],7+W__[=6+TU_>5:]>
MO[C+4-NW4..JW63.?USSY3^\K<_^D2:SCW5/".#%38I_UUSH?>F8?5U>,5K1
MHQ?9;M7/Q6X['\]^&.+[EY_R#]1U'J7Q-,OS;%G;:6AL\_O)NY/LO$XF=E[_
M\#GSW-%/LKZP#BSVV:X&3Z1,L7=O<'_(Z>[>JSNWW?C_=W2]7&XKW+<=MG)3
MY>THNV&SY>HM[8\0G".BOZ[?[POZ+NKXK([9@\PDLC9.&SPUG_ON;@>(#^-Z
M[,:3'%P^6W_^GMX.[<\)=8*U^>M-N5_=8JOW?_O,Y\@)U8_XU",^DG%O=O13
M<$\'<T_=GB![+ZD\J%W*PSJC]*3KR;Y2R#LZSGVXV?>,T?+*OW]'\'==V/'I
M+</6\-FBG9\6T&]$1@\:A_\OVGGU,H?)X5:?GFUB>L!CT7N^&,RQW%NSY+!T
M$,:K/ZQR\%I*04JW*:6/;&UW#(8']@#V&#R(M\X>K-\(!_8 ]@#VZ"U[T'XC
M'-@#V*.;,+Y96_O&3M\]RF?W8FGP<2SSYB+.[:+4?)5BRP_CQ3C6SWJ;_MYN
MS>Z@=/-H[0BV ]O!_!VN'<%V8#N8O\.U(]@.;-?[R/&+*\ /"A*;FRV;#::K
M'WG"H5%?#25OEEHV/W;SUW%GQ;B[/##J=5Q4DUE=/V(N/&WCZ#%.D"WNANQG
M&N3A1MO]SN4> [#3&7YO:XY=G$3)<=3<\=)RD916]@(9:B(*/&+!J&5>;)S/
M_)B3*-_.9_ERRKF37;?@H(R/&-M[9ZJA3^W=]]?H\=0&;0%M 6UYJK9P*X.0
MD2).:$#<6(:LI0HI;(A.1&;-T!LM@)G7T:> LOI@Q%W1(Q$-(D[%J&@2][0
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M4)X> !"4Y\B51\JD%-8<1>IRQ*,(1A;[_*?!U&+I*;/^*15-/5(>.A)&@_*
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M(W52:(:$% YQYQ(RE'K$?9**6*]L$%L\>/9) O/ 4P!).>L<&D1!G1M(3A\
M"))SY))#7:3649+#&9%C&I$H<M@0%#3%S#,3 ]%;/'AV!Y)##1MQ#)(#DC,
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MV\%LF;KH//_L6?D>%.PE*A$BBM.>H/0*<[1 CLBK&7S7Y>H/$H%E'B$4J]Z
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ML1V!TQ%ECWN\GS*EV>(Y-EM4I=EB:;;8ZYKXJ&:+Y-C-%AV&3COB03(KDG'
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MLS_#M7=?M_0=D:9ZU=NHOZ&?L@MFF=?7YG]?)E;R]X@=HR99HUF1K2& 31+
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MTS4C1Q&9;&#HRI;KK5V6CRIW@-!IK[EAOOLT%SMJ/5/@0A,FHY=*!8_^JH?
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M7T'_PG^7P'\E%%+8<4#L6."P\%^!P\*.A1T+'!;^>W;^.T5DV'#J.7- *QH
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M!Y\9HW]*Y(9I'1=XGKC++SYXW[$ZRB?BC87;BXL1//^<\7'CRRXE@ABM*17
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M((+N9A\\QH=XID A&2'"BTHH(EE40N&_2^"_4R2D*8Z<"@8(&BR@D$F@N&4
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M=?P<PC@E*2_CL8OEW&_F2Q0(+1[($!'DI?+?"52XQQP1*'3*9<. 6AR PH8
M+#&C5$>=;NBV"D=62J2"!URG?D(X_F2LA\#+0%@@T%@CG\?Q&&$YB#;T+U@
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MJDN:X-W\(]"GHICB0=L\_OO)&0SKHFK]C!BJ>CR;5##.?_\W32E^:V<(KD)
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MBDA/(P.-1H5)B$>BD<-4(&)!J6%'?1+AA7"-"CTPMY0BZH)([<"U#7OH?,6
MYU,0JIY G4F16P)01U3"X&ABC32W&!DG+!;62YW</OCH4%"G!U1TVSP:5, X
M/> ,Z5CPRG.$O<@&C51(AVS0Y+[7"AO&^%9ULXA9BDIX1).4B"=)D7:*H(2]
M4TZ&0+W:TC"M."U4S*]9<D##M-]M<@1\C.'W&0A:\SZ]:[=N[0\9,*;-\NHE
MO^!U?KG3;R-#+3H> #L'2%U7/8,E;DTCO+B!BYHV6AO/ZOE93[2.YPH3D<#
M]IE/+/CQUMD$$":\<$GH&+9.*3Q$Z[0!@"MS(OZE'L5F!N.\M U^7=!KV>#C
MPV2Q%__S^!-<=[;'Q,);TF0ZP5R?3^.X;1)GLQ67PP)@#25;3ZM/=C2/*XO\
M"O;@4[XD+", ]5*7#ZL/\"T86NVJV6QMQFG[]Z)&J@?S&,8&%B#8BV<+TQZN
M#'4F29/-4S^:YS2=ZFP^F]O1%7?;Y16?[11<@9S,M+SY4QS#OYMA]5-&XK!X
M%-Q9CQ=+DMDM0_,TK&)T=]N:@QR2RZ[%I%,;6^,)4)O@89?&5%7%W]KTM^;
M5PMG:]VER,(UBJVG,EXXKI^G]0QN X/1C6I_M=/8BX!:P)H0JP/*S>$0#]HC
M$[5#/@0.MJ266.THZ$$2Z'N-HI8&G!4,9@$G 6EJP8H0T7G\4@$U,\!&#]@M
M)8BZP%V;.GA=6W:?82*1W'IN\M:GSYXJ0^"X)D2",UC2A+79\C"2P=%I8I#0
MB<"-DH-CJQD2(3)+"7?>;:7!'HAAR(#V8 -LA=9MU'Y^O@3M-!^-<N!DZNNF
M1>_\Y:5*BM-VLYZHMQ5@ZS2G^4Q:6ZB:G"_:Q]I9MC2O::T^>;O",<M-"$@(
M4%G<.;! (V@P;AWA+'FBW9;RBN *.Z(<LL2 A^S@<DVESAQAE(\D*(NW>-'F
M;::6(Y_DTFPRYK<,#SONW&XY*ZVMEM^9YFTH<&G%-=G"N@R8=)]Q(O%$"FJ1
M%X2!,QQR)5WBD1121L6L5BSM@W&^SRF+[]/_+*CT?OI;SNK\99[#JL!/T8-B
M:]/Y039C^.[B1^M/-Z]]^@X350/0M=WFLDV7!-12#W0/SUXM\0JQP.4BGF*)
MD@B;B)52FG&*G\)"K<^[9(9KX11P=G]JQ6_Y\]/5$#?&=)M%LB+:UCO5UZTK
M9>(WRVR]"!*TZ[IEDH4=7^%EGX#.)V4#%AXEPP'HM!?(^.!0PM'(E"R-\OGT
MU8]+BK7L=_ECL_RU(?L([/$WW^(AD._F0YM=X,)%5.2ZQ913B*Z\PGK#<VRW
M/#<RA'RL/^6\T'YMH6N2>&)$(VML0MQPC<">IR@IH8CT*B:WHU/OP]W$@R6]
M23/0IMO&U^4>^J5)G[DMU,WB?.!@:V_]DB,O4^%*2&<CI/,+.$)K"=([PSI=
MXH#C"#%I%:4(U".C',Z[ QA93",2F)H(/Q@OZ'7=095)(AF#+,UU9BU)R!EM
MD8E&)S"PG,SG]UXHQ*2Y'!!Q<R>+3K!.CT-,/J2H",>(1)$3]AA!UB>',. ,
MYMAZIK>2(; @/,C,)EIGC\XQI%4P2$6JM&-6:KKMUA\JQ,0T'TC2\7W)QX68
M_GBTP:5$(L'<)90<&-&<.X&TP!$1;UP,-&FCQ!876IUP K;#/@G$1>9"IS0X
MA9)C$Y0''GVNX-(NLYK>&1TH$:B7.GJD@R!@#9.<^LXEB<@*+7.V#B/&),>M
MV@=WO7P$2H&I35G'N:R/$2C/)4N"<@2@F(,"P DV6 JN/B6:*T_$=M;%0UCH
M&2-0NT, =^JJ$J;J-D<JF_?YP..WPMO<09,C:U5$!KZ7C ;/W%X@\P7#5+?S
MZ/'$L-:RO[.K?"QQ+,J#$MQZY!,G +L.8#?'I(QT3 4"/\NM'4-J1% 1#,'H
M'6A7+8%#L1#(B\ H)]PQNE7S[E!Q+ :+8U2WE>*>XUA]+07RLG64GJT.B.ME
M'9!W\]GI9 H/#4NOXGHEG%(69*TJ\97B7V:4@)S>0,"L.QN0R!80VO#EJ#[+
M6%N-6Z=C+0-UZ<B!K$]73VE:\V@RGU7G=IFR6F2_N[+O>RG[+?ZBO(ZAM7D
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MW)&)8RR0"98AJ3W3WCO+\-8!2"P,!=\)(QP409R)",X3$RC%%"+@<Q)B^TA
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MD91R+",##) >((%SAHRT"C'J3/(V2AKYBT("HP.F;CX2_PI%LD!"@80""4?
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M28AK!OY%9!S!]]1)E1R@1^=BLT_&"]6)5JE=$=."%WW BY)#VYW8["J'=K/
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M#9Y!3?0GX+AFA[4C"I8.Y57JT?5(;8<8-Y.L&79J2$_'Z:>$@)\(U%M]6!Y
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MPTO_/?QU6'T-$Q@M'*31Q:#-^Z#X+5S7?B)OOSFYY-ZKY.=7;Z;^/*[^8J<
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M'4$F6(V4"@9^LU[YK4W$[_.6S?NT#$2_G_Z6Y[NF>O:0BZJ4&!C3B78)QR:
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M6P3E!$#?9;:_WGM_UNIP(7G>)]5<;(DCI'"Q)8[ EM >2R,M18+R7/^'@%W
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M1_Q_Y,T#/9&;W(XV96E_?L?2R=F?9?EYD1GF)J.P+[Y>CG$OS@?!PT,X'\]
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M%C)KCSA.FNG9K*G,O#L0/)N$@]FECZT XP'KBTD-U#M,.'6K.=')*1XTA0]
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MJ/M'P1XEJ1Z_+AD4"O9#ER1@["LS)V!\GL!(A%968HVP*BCBV FDN*?(A].
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M;\E&.Z3UTV(X&]["@];B?\&.R]YN)(;OFK<'O!X[9?YA:O6MELY[]GI_QW5
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M527PW9*Z>][44DZ4UDB/&#4$\5QX)+VAJ/#4AM1YG-MMM_Y9'L:K?!L.Y\'
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MRKNK:]\5IK(KTU-J;0<Y\;=E V\-X;DW$;ZLH T79.E(,?[FM?UF%5YI48S
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MM+)E)F7B!JW?&PP5J 3!"80RE5 0G$"E-5'I R?'D#D#I38-H#8US"_;$3!
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MNLF$*G=@U/J5G6Z#P0*94.8.J7GD#[0+SAJ'&BB$==N !_  'L #> "/N?!
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M$@IJ%;BTMA5)RL=2+I9C-5>HZNRF8[8C8(!"H)!&\_^ZP&FH>00\@ ?P ![
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M03,I&X?3?L$ER$X@E):$PFF_X-+:3_NU+>A.C73.=@0,4 @4TL@&&)J] SR
M!_  'L #>,R"![I3O;J3 ]U)__A%0]W)'EINI]/KW>I.]D5GX^?].O1<=AKY
MN:<T)W;R5QYD<_I$SEK4:'86TI.EK*3*Z0N?C>-D*@O:IA.>"!87!6YY)5HM
M*TT;:_2&"FGMR@C;U10?=E"!2I"R0"@="24]QP9C!2YMD4OG8I8M:UGV$%I6
MPYRS'0$#% *%-#("AF8$ 0_@ 3R !_  'K/@@995KY;E4M>XG</B3R3=M0]E
M])2U.IUAWUZ6M7J;5K7>!S11I:+8#B4/#![)\^ZD4/5@=Q5/U>F,PBLR)DZ1
M,'FPR>H/00]D9Q.>3*E-N>JV5,ID;7791Y$GL9<$D6"_!''J!?) O71/78#-
M5SI90I,2>1"L0"4(5B"4CH2"8 4NK8M+][TOR%4-<\UV! Q0"!32R 08FO0#
M/( '\  >P -XS(('<E6]<M6&SB#8E32[F8S:A$3E7+CNIC6J<[5_ZBRG)O)4
M0)@R<<3L:L(.PA2H!&$*A-*14.0(.@W&"ER", 55 :J"?I%=XU #A9#> SR
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MCP&]&\]3]E]\.CNLE"VUP2I.9K+LH/"A8FEE(4U*[F&G%:@$$0N$TI%0-BH
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M!EF<EY<4S[,M"G%_KJ[WY"&ZLU0<I&+&*5 3%31%-*SN>W4_+33BWM?+)*8
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M[#K()HO[;YM4/0N<U\5N(2L)?( /\ $^P ?X8.\1,OO([(-"H)"&4[VA*3;
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M/?=?@S ,Z/>/>437PG7?QKP'A_T9IK9TS6$\3&!;\UP]^.,&=-+VC-=N3!4
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M)]L@C-U_8><LB.)'/\26!W]]L5P?M+%D(P;D'B'?7/DG@>T2658YCTZ>R6P
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M2L[]2R]X:=I_M56,OK7H P^'.RMDT%\5<2VEQ:9[896FT6H,_6^L-A-'P1L
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MO4(.!F?8:%/JHUY?8U(%$5PKX,R[J\ ]K2][>.Y\6;./ZNG[I21J<O3F#F\
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M3@28Y$*  G "F0&KFJF&>K-@B;[&?>>K%=-870"I:F]6ZDQG.M$RH,\LEJ@
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M^1ZDRGSYC>+^QUQJERNH7./NH[>-V?B&-+PM*XO/!SH.=!'\.VXES[CX^(X
MTRQ7S]1D@1^EJ6DAGG-.2O6>,M45)E18@>,']=:A;XV&X)32PM._1!2@K]N
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MO,(IL#P$C</GV&T#4CF0Z&$FR&M"P]5"V] -<DUH>+<;<NA46HX*16:20*&
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MEGRC1S"[?N ?T1&)E;-R]&M,.&A<8H=<HAY%  )<J<"V//+ O'@%OSA\2O;
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M@\JV04;S&3A3$?@R" 64&L^$3/4YY&L-0)$IDAI#2>,2,GH7A IN6O0^32Y
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M,C3*@,4D/[1GOX/!+$\4EAT8 YZNTP]$]H 6IMKUN/PS8"ORPX8P%BU7MV%
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M(WD,QN8O@S208Y(JP7@K_^M__NGS\1__-P]],Y'MX%; BX#[X-",#3R[P04
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ML? !-_L71?ZJ;(/P_Z+:CY>D'H*Q9RC\XPS#%&+M[-MSILI\0VW\GQ(BK*"
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M:!/##.:EK'S,:Z4"\>LV)1B3HKHB>>M<P6&:E!\ZH080Z0K&"#Z_>?!=B]I
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M$P?AS<672JRS3'(U]Y,7>D+?>]^%W+8U_54!:=I@#DW1%I(:7Y$"GI?!6PK
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MR;J"-^%N[Z\F!_&"YP4"&)_C%4K!GCI"2!7ID\@P4J]S^3@;(C/O1ZIJZ69
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MQDL24@GZO>:]-?C,OJSUT?\:[@X[&CISXZ^VU,S!4YN#FI35]H%]DOZ"".8
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MEK>:.84CG/ A>TIHVDOQ=Y!</B7Y_R*XF!)\ _\+<XXP 6]+]A.T4^J2\\[
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M9M?,K7@" 8J;XX193.,KRKZ G"!2#W'DH ;(CYOC6Q"= '@&\;OO G+^R46
MIX&K!!:94']"<@!D_)Q&<>&B^GL&0$BF 9=)SA-WD@LW]=]%S5(% QL%2L'U
M%]^<V&O.'46U\]5.DNR8_VTP0",^8@!8CQ&.$0(O+^XWC%N$!IGPI!?<9DC
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M(N#$BW("ER $.U\LFVW,B ; <+/; 10/JA?O"3IJ*/0/W;; Q[M3$H<!0QH
MQ'4A=^%T\WLQD'F')[S(C6:&FI1\=62T9%F%G388U 'R:16G0H,!'2+I5G'
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M0!@OO*,?^DB,H5*+(FL@UM?<5T='7$&7U==#/J7_?>A:SS'Y@-Y>WX.HM+(
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MM"A8Q3((F;CM8TRR*E\%6N)VC&+V7O01@YSM,\KQ62>.5"YE(;[H(YL!+#?
M-UU);4HYGT70YUW;F\5740 =_"@'\6(? YS4D=2IV:T&3^ =A!DPY^ KB=-&
MP /^5QWL@/_QQS:.O,Q--W&N[DA'1=1F:J,S8A.M-3-(B-%I=EMM :5[.(DP
M ?6,F)%I6NM9$;^*,B0$H)A)3X_.D<8:Q&:S3O0)O&4Q]-0@8.7V[$Z*RBKB
M?57GX8(LCJ"\#<&E'R6N#Z"H3NCE)5C-]17C)\G =] HZ8:VX"/40I2?H5L>
M)M"?07D#K%/V"3ZD#;1-O'="_T^L!*""3J+ ]W+=$GK;AH+8[&[]T E=WPFJ
M5$+>&8>:L36>_(]>W)Z%T\L54/@)Q2+A";C1/O3S!6I\<1M##4 2"NP.JJ]?
M.*X?.T+"BM94.5X)0+5%X-)=0[,KB-[04I4:GPP8LX?B^3WX ;2@HQ 4"=2D
M&?7:Z#M3S2W76^A!0-&!)<'O?GJXRN#TCB"&7E:0>46 !/X_[\7YH)VT#AA)
MK\/$LX21F\0Q0A<=9A,RP)N^)-7<73Q,+*NY9",)@W7Q>$D;[W56,\N"7C1N
MT]O?):>2N7D5X"JUTUL7@R98M56LR!3N025-.,;WH@$>)X>ICL$JSG2FE\%D
MPW05X$Z\X]GNXRH0GI9]IUG'E1R 3LCZ_<C$&=,1F(X*H4QRGAJARXY6G:>:
M<V(J$3/K\Y!#9AOF:9_L*(K#E'6LAKPT]#BO8,_SJ:5]IY;CSP:SUP3\)X,S
MNWE';,R^ADIK;=+TF9?AZ.WUW>C#J8H-X<*Z!DQL:PKZ3.E);GL^K2<<\)#\
MG<::ES;+2[0%\2Z*C[=1O$D/T(KCW]E5,K;R\\%]%J#6I\K>I2\9O?$YO>*<
M7G%.K[ _O6(+13( 7H+<LR]OT#,,TUM S*N@M+11<G,+@*@9>_&Y)L\.5 KX
M 6@!74)OK/J:><Z<113G+D173DD3(K:;="Y/P 5PCWMW85[^KK[QRI\?HZ]J
M/HM2."H4T]V 6)+/@59Y5ZB?ZKF"&"7S.WNHIO,7<5\B5(FJL6MQW<8O;U ?
MN0<?_AG]#>KT_/Y8-55B9I3"T967URUU1NWL0F5[]+-C4:[R)1+AL4'C**;E
M8@^_C*Z)X%/%UCGC18 '0K,HY"Q^4N8U\/=Y72T23:/&4TS;;T[LXVM?<&S?
M T4HB#,+$E'#!IIJI;H[O!1.S.6@=IHXP["6G#1-P.DQV_Q$=JQ$;VWS?@ .
M"FI[%VGC$?DQI) &G$ZB5O-2)5H'#*A>3Q*D7?7Y:H(4+2C6]YRE>T[@5IS
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M-0$S,VJR+N:T^B)+#WC9N,\U,;NH+D7AA([G0&7])?31VW9(=2=/X!V$&;A
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M9"/W:WNQ:1/N-=2/<#X19/U%(6)>1G8,NX^^AS[:LV%FL9#;VCOU/Z"X<[)
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MG?6P[K^R$/1X"_YA--]R!E9>=B.#8AN""R[]*'%] &? K+M!;VY"+'4;^RZ
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M0@JN3@6*':<4 Q[8DC90J0!:<+3++CLPT("J;IJS#!-+81DMDH=:.I8';>?
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M^$^E.7^-RO0%9E3:ND=740 %[FK"&?$R)[/OE] KO$RT5UW8M'Q<VIZ*!F/
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MA\LLXNZE%683\Z(UG;H7[;!T\]2*U<J\S8SR8N\C)^SLX-Z?C=RV]]"1"1.
MPV)E!@AB)_(U,-'61I)*J-K=BJ?1?S<XK#:XSDKR$I$NGZ@;S[R-"IV &-G
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M.;0I<;*:>?+7_1+W ([.__?_ U!+ P04    " #IA%M:: ,SJN4M  #=0@$
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MO(XDF(? 1>0U3$,3QVH8KJ3>,0]%SC8&/I=2L#M&OF?8*O$J9[4BRPO&P,6
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MKF 2!N.*'@M\G).!= :[@ (TZ1J/DY,2'^ ^VPV=B763?<1O<YU%R/;. R2
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M*NZ+4#=U@&\I-(5V"PR!LUICPK<7UIN-OM+W^5T)-/OMI<CIX-$GU?>[]S3
M-\ZG9D_2BRRJV#V/4N)W.HBO3?+,-ED8W#'&5-+W,[P8]X,LH)AW)!BWT[C\
M'*E-64'A1@]%'9@"1FG0VLYIR*)L C_;D+_I'P;_H5,D,)P:K?W)!(UVZU*@
M;_&9'#:)V>!5J97C)#3L2GU_"_M*5_DD,L/WH/0@XCY!<5=@E9I8!SN\IEQ)
ME\JU&U*W%L:-[VPL0T^8Z[Q"/CX#=6M!6?(ZFY3\$Z9.E!1P6BCTK&I0H^!Y
M,XF1&6G0=)%,DBI!#-P,WKM&,/R4[I%E--@-W1)LN8G(1,3LYU<2WD%B@%^U
M,6^^WL..,W&=!J9,6T*P(#3,QZ2SF>0";K^ =,1>,IA(!AH"T4YB/EF1I:!1
MN-P\>V#"&Z)?(#:UYQ<SJ'S49(!J,L&?S&=6#VQEXIFW[CGV5USN-:["HO0X
M",U-#+VN4:N%#[I$,2ZC;F-D#I4?>4283BTI6RIQ'X'H(Q#;&8'8<K7AZ>#1
M5FL-KYUMBF/@:7D#7!P&ZCR;V[356&MPS3DG$_01Q8V$PRHGH;F &T!JI#+8
M.1CN!I%(P.P4!8.$RZR)@4$\H<UX-B)\ Y;O7Z:0#:7WL8RVF6O.:V&\$Z%M
M[M:=Q$Z<#6'HE(278R7N*C55IV+@85DCP.&L>#9?(UOSP?%8'\$>VMYP&&\0
M16G2Y7!I!I,#E$^ES?]3<+J02S?)M@?4:O/)NL$LIY,ZJ#EW[D64$G9OXG9-
M,']L!^RUJL.HE-&AB!EW"RZDH^&3MYU2H_N<!SF!-1<^['V-0'WLS-:Z&:-+
M=35Z(/=LQEZV<KL8<&^YM4DRW-]R'@P<-S,Y%\R.MVE#,9O%:EP%3//]FJ)0
M*[G>F%N>!CLG;7;;S$[! \R9(=@\:\W8P#A&*3_>4,FQ!-2#^)%S+*0!<D!7
M8_;*A0U4)1SZMS,L(;$,?HLNDDR_1X9\R3V[@/'^"88+V,92DTD2!K]40"7T
M_((&%ADUF^RV&IG^LN[]1G29H^V*/7NL[PD7N+(6AUM_1TJH6Y*=/Z,F"1@:
MRP2F5K!4^939A\'AD^/]X&>5S#&^^I> FY\#PQ5C_.$B#/X\_CDX^NN4D9![
M8,]B.'0GP#^[M'3S$6;N(%=<@LD)UH IA(A?<K0TTR5"1N%*\X;6[0+$ZMW8
M+PW>^[O.O59[VL>2>GRQG#95$GW',Z8@)T;?=Z0V.V;&C6>!@<<#DDQX68+Y
M1+@K782^?1N5/WR+7>)BI.-;4,GQ7W@PUKY,,+5)X0!&9''!35N"<9L.=A_7
M?;AQW2=]7+>/ZSY(90RE/0LJ4M+3-5RV9O',HCU.GL+:/#4">2V[;$WZUFVX
M\R>I[/>N#_8:?%N#'VZY!O^;TNCS%JG,JBUKL]RI0MGT&^L]J7-MV,/8+#Q.
MM;'1 C!)?C9D'C+N#G] A_L,8_!Q8!I75CF<9IM$://+\3FFN!OLO%F=A&BL
M:EMBSHNQ*.V<"&NTQ ZOB*F%FW4T^[7A'<SL1Z<N?$,)2(E7D]OE3JW7/A'#
M"#13)86P4?O%M/0I17:R-%D&-E>VW4F:#10;S&E )P@&P:$,SIT:FU 582[\
MI);UE73H56 ]]!Q], 67EQ*N!#RC-Q+DM@PM:;[I':8./X\+>*T4!.KPUQ?L
MDZ=UUW/M!HCL#H([BZ-^D>8,[S(7S\.B55UH$*_0LZLKWP;J<)WY!LY#!"7Y
M[F $H-B275,>#KC&CZ[?WLYU59>%WRI^U(NVEF@[&#QZE7&2V]J2^XUB_<)]
MW"B3CLY4#D!&9H?9W@VX%69JK/!$YP7%FMHE3BBVJ6LDS<YP%U,333=(#*PJ
MW,S-KN1>6PF>&>)ZFIW7[:Z=(FNCNIYP/1;+PWF9ZS"A<YS%1DN#(7SH%=@E
MLXS:=^]\IFU,(Y\IF*B*/BA3:[I5?N PN+S\_2(,?KL8O0B#5[^^>0[:\"5\
M\.+W?X;!Q4_OX$?L\(C5"*:%S;P4:? R)7X#O_S,X<O=$&O:(,B PB(HYQ&2
M9S9:@ND+=1$!8D^=;QNS@P]WO<)][)>3=!KI9U/_5?M9S%P9T,0_0RS?7]AK
MVVPN&%-^=$E2DTM>,F3?. Q;6[ZN!5SO,1^CW[$(=$C="@JXDCX. IE;<F"X
M&EX9EJWC; 77LP25'+[/=V\ULA,0X'%ENGYCA8TK%6,]7% &9(D9"R8QP='&
MN\;E0;"B$]N#21U;4(&)86"@BE\YE$BWHQ$[PBI=>A.?^A!&4[=509;1:)M
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MTM/!HXV0MKI^?CO_UFO*IPVL"DZU+*4'J=A8-0 _X,J'ND*$EJ3'4"D=E7G
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M@Y5'P_W/+I">/<9BW#_^Q[/'LW*>_/C_4$L#!!0    ( .F$6UKF(G5921T
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MY%0]'6TH'=$1LE08J>$M<*I:$-U$%!91E:F262M) 1'F? 'Z 3S/C2KX.%O
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M<AYB#&NW?@Z[C7XT,P <2R70/:P"-MF**8@">#H3X%LP$]B3'G<$8AV<?U'
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M*E2@DV\=[*Y 58M$R'EIK8.PKP&KB@S=8K$-3SJ^$:"7H1I\J4D#[YE %YE
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ML)0:I#WPJH_^;U;P7(0/1B1:E%$H9X">!3Y@+E4%1^8"EH2A0?BN5( WSHM
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M.-&T(_8ZH>Y4E?@$'&CA4WTQ D+LI[01%% CD'=)DCFD=YA2J91(.>2YN.&
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MK[,WO[\)WO[M]-UOIR_//GYX]?+T]7N\[K"UT'C$HU24Y?_^%YC5^B!-RNI
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M!];=><D2?)[/<X:!Y*GE1&,:-.7 $%%!12YU$?P!SG@9)]%.%PW)"TRLCSV
M[?!38 /2^%30$>-_UMVFJ2S8823WP'$54_;@2MCWO+$+WKW*L].9-CRXE&3I
M=[ELD*['N2/)["SMB]8.]4"/L0$]5I,,O$TBD_OR[/<QIG$=1_[E*I'+X.PS
MG&GTGH+?D7JJ$\;QV*UI'>EIQM*G<:3!OASYF>ZW0\DPAF-]].SI$[=Z]S"
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MCR7")1D'8.HRKF-J^/C"5+R.]23W^52\CM&6PV.]D_$W+DC1E1+)0_2'-N+
MF&\PV]CI&$:5$W9)9$)5MQ&?--*K.@50S6? ("Z2HB)\G?=+)J0=)RDS&C4G
MQH=.] 'H%NWI)BWNGO5.R>0VZS1WJW4\+*LTRUOX5UU(SP)Y7^I33GQ]BJ]/
M\9K ._5#6XS+34#X*X<BU54/YQ(L&BR9A0EF%N;89[!X_H!)[=2+"6]4K$6
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MW$?"S?&'R3*1<1OSXC)?TX6RTCX[$PNE\H).EC'7)(9T,O+#R6MWGN0!AE,
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M.871&),:24FS<I=F1H%XM%^3E"P^ XZC51VR!46?.?@IR2@X6+*Q9NPX$X1
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M7C:BG*"U#?FJ$]ML)A%! %N %*9L=+5J59<K*WG(.!\82H/HWN($*&T?*GQ
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M4W&Y@,4)WH(?'6T9BD7<*?2WYK&AUN]*KZ ?Q*#'+IYT9IJ]UQ$"1G$'@9J
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M9V].P9()3M_\$KP[>_ON[#T8-J<?7OW^QELW([-N'MT3Z\;MFT)TC<B&FH/
M%%G5KM3P/8JGT:-X=C2?8I/B#XZ-J'B(([,3R9Q*E&V).[:X8!X:PMYSB%!]
MK.JETC0G>\4--#9M)ZJ((ZJ;-A^CR@'VL7VSP17E:T7R2%&/#F#$,BNVB7G]
MV1GWV3F>_-DQ;$Q]\3O$T@:+/!/!$E&KC"^7L@W'S0MFFC/Q\VWG"K;/&Q73
M0[O<DSSMP7MQ>/Q@+V6L7Z4/AN\ H"C]X1P%7,NF.GG^)3:UE\7>CAG8B!UY
MF]VRF'WAC8F);.!I&A/]L#RL0$VP=Y/.TYGP*387T!0*?F].96^>3'YODG"]
M%!Q>9CN7N#<&HNJ&D[]--M(-W>M@/X%%75)^BAC;$C-UT3"1,?B#RP39/#!*
M3/"2NK1\]PUZ?TVR'<SX2PJ9B^8UU(F&:R8R9HA]?_#4AO0;K,@8B=9CP24X
MTW3[5"934EF!:BBPU<'P&!^5+.J>8FU5A]OI8[!P?D4%>6;MU.(@&&8WTW-B
MV_>M^6%-)AGE;V/YBK@02<HE%:U7T=*;,#+>"P[SMG'WNP4JO3T@8/W=@E8J
MB7T1> $W$0'W:)("[H:T%?N25MR@O%UG:*.[(E;JKT#GSE[(;Y^*9,W1.L7H
M!L_>07)3W1*WT=4'W:/>/>K]VTWDR;B'YU'OMW=Z1H%Z]Q;.[5DX"!AAB/;S
M51+',KL=FV>*!H^G$+S*YAF@ [P&Z2":9&(MSJ6+NV:N(A^PF8H_\_A>^#,J
MCO!:GL-F=1->%[*=X1KH?KSO[?KIKNBL&48Y(HC;J$9:<%CYJ#C4$[V=OBR>
M\XK>D2%S@VQ[>4'Z0B&M2R;4B_&*SHLM04=-PT)8@C1U6H9I6=W77Y9=IW3+
MC,7Z+X,3;8:^],L%00J+\D^9*8*7)*;8V3+4BB'2"@2CVYDLRE6RL6L@D9@5
M+B)6.N:-,:M";=P<G >]0KQS9S3F89+"=S2XHE:.*KP,A)+ I%6/N@:\M#DK
MU9Q:_Z82GW4?T'-1Q*G2BZ0#<]BAL-EW-V!K;T"U=1L/?8'OS:N(B:B()Y-4
M$4W#KU5YIB58G$LF7"(#2@1QS7RHV+3QG,ZBB.$!*((*FYI23=;Y.#<LJ4V1
MGQ=B73+].0PXXY@[&&%PE[6I*.TFPK"235=8ZN#Z/B$LF!K2LU9[6:[A@-UJ
M#5JX2U+HHE76GDNP]0HC*Y&L+B],[EF9?JH(M3V' AP27;_:C/K;Q_6L17=A
MK\0 W8'//')@M\:[>[B[NRJ_O7K_\NSUZ],W9[]_;,/;/6!L#]*+PZ,'NMCD
MT<-GIQX/UE.49HMVD'B4JM$XP.\F==U5M)&%F,E+^^KOT5 WRF:HPDHPV2E6
M'K7KM/$!8!O+\YPLXP191U51%.D.5^^QNFL4];=+IY<B2;'#IY.:,1\I0C_5
M\Q.N6,A,PD+U,_&I[@/*80GY>G>MV+QM-YX?6L"1-/M\.JE3??S@#05M? />
MMAK-MDX\RU@>ZSK35(:&L@-=4,MAR2 %TY6ZOR]+8D\YYE5E[/Q"D_+#0;TL
MN'20O-F5S#0_,07?X"K[HQD[=+%NLJR<9,Q^@H_T.:3_1/EF:V?#GS@S0L)E
M3/?.]5$7%2Z&@W<P?0$N5R#)>#!&U"D3>E. QYALP',T\5,X:T5?'!7)\/DK
M2U9BOF2OFH:A?HZV)R?2%"\U1GO:%"<.=S]/4__:<'+2''!]V)A7+4V<ZDRZ
M8&%>O_,>['KW"F&'305.UDCDT<3,C),'K]"0A.<R+OU%<*J47[&3B/E[EE-_
MUHA/P+BB<JRXDRQ'?-S%[*$$UJ*H2QO8PT8.<N@'"\WJXT(6R'TL%E10#Q-)
MELB^+HLB+U3##/T<8:%.+ BCM.;:;Y!UBX1-%Q7N='F6W--^"WQ!MTSG.JHF
M-V>)@O;UOLO=[Y&X_6V( U>>X@N-U]=/\:PBR,CC3+SZ:B?V#*%+'*0)?Y:R
MV/&[*[<A!>-M9+LMB3VHQH-J1C&1'\<]/ ^JN6>@&F^"[F."/GJ@&N,$IV59
M%]0=QIN=+=L"&7(<KQ##^@SQ()L.&7/ 5EB3,;?M.%>Z<97\+*-:]>TQ65ED
MI49+<:E>@BY54/!]BHO9O^.\^POPCW6BA"@T56;>>GZJ!=U"8ER,(EF&T8>'
MI"LYC#_=-9RY6@#,"R;O1#L7._T@3CK#;&@D"OQ=S?;0.9JVU-E-M7U0U@U:
M4R5A:F(2766HXGAL<DF1&=SQ7ET2_,'><; ?/W@OX6VJR*8_TLWU>:6BMYI@
MJF?/)Z7K)W*HZR)/P.5+,!3,@+ ZDQF<JTARY0P'7<Q-W= 7![CY-J7N,TEA
M<'Y-ANRBZU^8K&<"KF'"1_<"EA5.T38,:"P8O,:,I!X,A[-5C+I%Q+6C5PZS
MC\;,NM;G/.LR 361EN_:$HX@BG0!DGWX2H"4E!(E9@K+&_O3?9/3_>3!FQPU
M-@S5;9;NC[=RFJ0.!S2V<-;H)&M:%=$R(L&?[LFD MT1>%OG'/^\7.6,8$LR
MVN4]/<Q5'R-JIUE0WW'S>NR=[6V5^Z]8=OJ/HQHG'*54;$K)3((,>$-; RD2
M$=4&_T;!9!0[!J=AZ?S)NLG)^O'!SS4X3VP2_<PI/7^\]F(EU=I P3Z5XI(9
MIDN5":ASI*V:4DLJKQIT*<PFG: >'!!%7C&CXC0"<QBQ^S"K_C3<Y#0\?8"_
M]ON_M?^1B$SO>LV-6Y9$C=J)\_J-=Y.-]^S!&?N.($K.3,FMWXA#=DXO04-H
M+![#T-"A9+@29T_[G%SZE@C>-OJ%8=J-/"4%&V=P)#5S5(7578:>H5[:*FJP
MTAW)]OPE@5:34ME77&X0)1L,QK;&;IN/,H2<'VBGU"Z7<,K I:MHG&)PYY[^
MQ-\(<_?PP5^Q'3$%@5Z+2]+Z_Z<NDC).(I\-O](*TT4N:T2R%!9X;&E#M,8Z
MIV7FY#>3M_W_[7UI<]M(ENUGO5^!F'D]+470:FU>9/7K"%EF5:G#)7LDN5P3
M%14=()"4, 8!%A;)[%__[I(K%HI2B1)HHKZ4)9% (I%Y\R[GGJ/2$RV$YG8/
M ]$C2$OR#J$B.3:4Q.5D%/E$;*Y;+' [()BD0&=:#W,DBEL,_ZU\P<!)'M H
M\W*$XL%2+#SBSJ&RL/#4F&R$(7!(!D^02#"*@:?4)%K$-U5W_U]K6:D'"](R
M8]!=[;'Z_?R0_;R[,8SAI61I$@7>>Y5<Q@5W3$K,N,;Z/=W.-CKQN0F+VXYB
M86G;#[Q0!,@R2FT:IL/+E ^LC@0^Q9C0*;10>J:18URB(#Q_P-57:/D.& YA
MWBUF[G/N Y.U@<:.!J4] 4,RC&?"X3MKN*[553?0A"FD,R#)1N [V!0GT;\3
M=!A][U:,<GAG'J8SI5]2Y::"&4,[D86R5L*/J!I^C?&SOE!<9VEY)=42)@+&
M$N;4,A?XA?)\'-??<R75-/=R(DED4P_%IM$B,5Y(OSYW(D)[\Z@VGO995,-D
MEL,7Y/]@<MA<,)_E!4P5MLV-8C!U$GI]C]G2>,+J1Q<RENNTI4]=YQ77:EY]
MW?::'2#6E).#",H<5]KW<66\@!=%Y0<+^JE+=$*U7'$E,&D7R>VA0CU4J),/
M\J;;P^NA0CU4:!T=^KV-TP2"PVF:.<20EPCKL 69>@]@;J#>P(M'K6B1GEP1
MJLB7,3..I%JE.$AI/_B""?/U]2MJ6K5+@7LZ9!H#<!7$-ZR6Y/',2(<IU3"5
MT;MAB@=)[Y",P6I6XODY6E]ZW+5A#%H>E)^#DQ6]J]*[*IU\D,-N#Z]W5;Y7
M5V4M3L[3,^_+Z>79\.+"^_+3\'SX\0<W5RR!9G1\2GQM6#MW]*F"5'AX"LV$
MGWGC*,L+;JY46>HE"TD^8K/T8\_SK\.SCV?>IY^.SW\^/AE^OCP].?YPX9V>
MG6S_?93]XXE,W,.VQO.\J"=NM9O_U$[4<K"]BXZU$[4<=#%B>>R5\6[VUO.\
M?\W[#Q?S953 0>J=*%<;NYBQ=ITMA)&&V7V]_X3L"9U:9^OYU/WK7Y=3<*[M
M4/;CSQR&2T_2_/8#>35G_D1X'_R\^!?^Z_<^=NYCYRX^R.Y.M\?7!\]]\'R/
MHZSCK( 7P;4(RUAXQP-E+X8*\HF"5SV%HC59'S]=GD)$//QU>'YR>C'T?OAX
M_C.>_O!_C_]VX7T^>S\\]RY_&GI[.WLO(5I^__ED^//P[-(;_O?GT\O_P?@9
M?CK]9>A]^G!\]H#YW=YY>:]3;*$%V06?LF":;AZ0ZW^@+<&_O@"O(BVE%=5$
MN]L[?SF2GX>U0EU1;U4W)1M/N+BVRI86A/JT_!!\*G19?%]OOSKXBVTPY2,H
MB_FW(FSYYN'>]OZK1;X*_\BJ0U3F&U^]Q53,1P/^HGD7U)_".2CP,+ 3 #!O
MK_'LN!&(&/)CN4#@LS6?S?HJ&7+]W05/C?NNV9W'B@86*\5]?.N<# TOM2L3
MV=DY_%7 G[U/X'A.X HES4/NG28!)0OW7[W<\7Z,X@FR#7SQ[:S*8NMG[[[K
M1_[,DWSP<GM_?_\O3SHA[\HL\4>S@??N9.#]\O)'[^#+FWL_]F-OFS_Y3 U>
M5,6*P?_13C_58;8FZ9&.%V00SDHH VZ95HC6*,O$31H000BV"N623W* [=#8
M>:1!".PJ)6$9<* Z_*-$I@*P'O 3 F$9DSSVVJV,MXD78EQQ<-3I?(P$6G:K
M@(+S%AYM:1&7'+-%!#9G @IL;L2W1=U1!".93EEZ@MOBX>/,@4H,-8KC975>
MB@U1ZM0;T1"9G)(ZJ1195DF=S7S+0=M4F2+M?0FO5FG&8)AW#6YPX1VK>NGJ
MO*OF]!;,1"=?X$ W U=Z*?E5X@M<G:G_J,;<R:G6N#=YKMB+OWKF.+"YUA5%
MGV@XSZQ^"RE.I63@<NZ@-7LMLO<:7.;6QR[5M]T/?O</MP\6"F'K7WVUL_UR
MH<!Y+:+?YZJE/RS!_=O)=9K">MX,KD7P%65NMN"\T%9K#,LFO86K_/X=QLR/
M.?T+FZZ7_NZ1!T,JS GQ\7Q>D-5OEL7?UM(BWC68NR4;&K/V_XPSL5C(Y>?7
M>G<]9O[BR5;K6J?A]P\?Z(;L]C[(2IJ&WS",129(U^6HL-JOJP>R]"SNX^X$
M6"OPQ^3__<?>?[2]&!M.M_\*[K34-R5GW.[=LP>PTT%<[&)YV!3VF7$BIQD2
M+(DDB--<9F61O^"M]W\=^-JRSU[OV5W93JTNV4"ZTDNL\+_!H!J7T9J9XB4%
M@\/JINTCPNZ?GFLP=TM:[N]%6 :D8(^UI@3&@!*:P34R!ZW-LM_KE_V:+?O3
ML26;Z;+P,*O5=1H3=S)MBVF6!D*$U+CH>[D?4TJV4G4(I"+G'02>GI]E?G)5
MIW3:E%^S*B>&JVLDKOUX7*FDH!IG65RG6?1O7W/M(1V7TB*1Q%9;'4F[=!P[
M05*BF=:,T[+$R@_ HM4D+6'@ O'^FL:AR?4?2YY7=XV,!"XI5;8*O6E<YL3>
MP-?-P?XBW;:?D<XI"LOEDFX*5>SM99F.8$:E#EX#WR)K/,C[/()2X>--NM?#
M=:PEQ^T[N;/>X,TC.S#G7UAWT#L75UJ$U+LH_(+!.E+P)Y)"V^YBDRPA":))
MI 5R5KM4/L'+:"(Z$O9MJ. J^6V5#5*49U+?]FVG5EAUB3E953M$/#C8?JGS
MIG?G60\.EY=FW=W9>6B^],D]KDD4AK%H<AQT3XMJ-YL6R)09A7_*I=B_%TQQ
MOP-)O"6>J7\"9_HDK?]],V/?S-B)!]G=[?;X^F;&Q]L^J]+,>$^[T7%G]G-2
M1+&K9K&)Q'52A5('N/X4XF<(BY#< [Z)PI3LFH[2]&O>("9!4798(M9/AK?H
M@BK%+EC<256"8LN0QELN,,IM&$V,F[003(K-#,_PWG"@8:[U*YBW%S]/($*?
M+X,AER+K%]_ #><0"ZX_M<C\7-^[PO2GH9LXH@*_#IN8M9G:$P7P<<E77;EV
M:G(-2D&  H;0<?GSU.:$9EXE'[^-*8@<PE0_*+B6*W7*YHWB#.X9XO)S]*4F
M?LB1KJ\GDUZ?F4?Z*ZS(X%K*&:*6@1<203:.(4JUU#K]$B5$Y%I"@5;%A:@9
M$.$!+V2<N[NSO;_I;SG\B7UL:<5L_&]<9Y)"OAK4(:5\7HYI3X7@X^><9J"D
MT1\E;F&Y#6#5E;'><AIURX(NZEQHW(%R =MWS90*6,NHX-(T!+@C+?"">=/5
MR.#7?B(C9B>2!M\DQ^>(<EK3C2(4]QN\A"@WC#&B?AKD])]%1FU36;"QM"<X
M9!Q0T"Y LR8+,U+]1[TH2E441<[+LA11'F>!O6E97UX4,A_3;D>6VOOCR^%[
MFBLNC1/%(,R772X?/%7@<@^.H^=Y?=V8@95@-'P8,O/-P?(RA@>OMA>"6-:_
M^69[9^]AWSQXN?WF39^G7/D\Y3/,K/>?8_IO9[^?XW[U=A JNY17U:D7\JA0
MB@O*+*!*&;A77Z(B$7G^M-N@4W.[@F:D4_.WO+7Y28FR.6K%O:?2[>7_73Q$
M[VY]UW.\)C/;NUL=.-+.)(I+>EK>YI_*F#RL8CV-A<\ 1W.4+NV!&S&K:[)R
M5M!(=FK^EK+S+#]R37??$Z#;OA^.P5?W6M2/(\) 5PBQQDY X;=44".U:?97
MEI(N/Q<0:25V@X/#8CWP_#A-KKCBM>GTD&]YL[3,O !M#,'-N.MHX(W\Y*L7
M9OZXP,K9!.Z.L! 2/$^KY$U=96Y]=$6H=I+7]9R0*J_MP#.TK]LGZ]3ST-E7
M=.(G?NA[#12\/5*X1PIWYD$,"K>;X^N1PNN'%+X7_&O']1X?3\KC61S*98EW
MK.^,SE$3[:?Q'I'.\.+R_/0$$687,)=#[_/9Z:5W_.7X_+UW_./YD);KLXOU
MK4A\_&RL:(\-;OWI],*\?8;$@POTFT(;_NXR3+^7*/<?D2U9DR>O[_0=__SQ
M[,?6F-YNUMW=9R&1Q_(4')42=?%'FJ6E<X'?G0WHPLL=>#XBZ@D4'R6!4OB5
MK0D.:)M#Q84$E7=?;N^_>5E15'[<U='E';.QX1@4V730FY)_')^]?P9#8G,'
MK:8ML31J!R12*_])PMR_=\F>(%+<6?QTB@KQ3(N_8SCZ+S\-SX?'%TM.D'=\
M$HZW-S:PXTRN#.S4\KU$W,8S3TRF<3J#TT?^0S1UGC+9?E10"V<>A9&?4;O/
M=>IM1EO>K<^=7_ 0-U%:YMBBFLR[(/VOX8+4-,GD+FDVP!\W([@^##>C>@JU
MAJ;RRK+I4O8YF38S1<;B>Z,T\5^,(_ ]I^"_IR'>$^;IQ;SOMX_N3^F@K%CR
MO./K^9U<S^JE81=<Q"Q5JC&1A%=4 YE:]]1"?2[R(HN(W8_SLY\35$*Y]3-%
M_P.+-S+:7Q-PSK+(,%LYYA59R"A^QQ47)7<LSCE+OZ5]S](@^Q#!.X"[G)>Q
M.,+FO[5> B>T!, RS'N=\&<EP%-5V^$V:LS+(Z>8U=%.??DW\+IU>_68&A7U
M>Z KYI:WWO*.UKN]]>SC%Q0=/A_^\/%\Z%7R 5].+\^&%Q?#"_C#\:7L J4=
M[-N=G9.R*.E%B$F4R\YC23" S:!!>B,2>A?4/ZO**SFUS?(U"S]*1.@VJ4IU
M,?5M\V5LZ^;C(W_*>GK'-::/SR]/3SX,O=-^2M24G)Y=#L\_G0\OCU%B^YG+
MV%W(;%I%:QC,Y 4*C;T0K,9( P+_2U/M.T5I9U8:J\]4KCNBYW^!%\_?COQ<
M8%:[,>;4P[:9SCL9;\H!6D#AKT),8:RQKMO+PB3-U)S)^8]_[&[OZN/&JD]:
M+'KN)3LT#956=3&.$JJ3FKXIMZS;F/Z2<[D6)^MIPAP)&D\P %\D1O@S,LQ0
M<)>G$P&?(9>4I3HEM0,33* ?2M?[5E &$H[>'"_.%T#?<^#ALI1<'R*;@+NC
MR-^CA&D>KOT;)N.<"!\'#7<5Q&P#GBM_#FE.E+-%E_>]P)]2H9^HB^"Z.%C[
MRG@_C"2)+.<6T7(A+@@\PL&I S>MX<;H'^1!%HV<%"HRWU1/\7N9J0;5A&>S
M7,^^ DDC8F__\/7AZ[TW!X>'CV2V-G=?;CV%V7I\,@3.M!V/QU&,#%XJUT8\
M/?;:]-7*+*3;:5:HQ(&]*_.(FA=.9"6 V(N/@\)2+994.D0&A==)QT=>BWGL
MUWCGUOBKE5[C'\05Q&#GBI^*H$MZN>,RS[F>1:SQS"!%''73:1I1Y U'3IH1
M6'GL)F,RK4.<%[( [/P]D8F<M'3(NJPD)AQ>_A1!TP/D0X(7E7/P.+V>Y5C\
M(Z T#CJ&CXXC9+:?D?HQ3(5_10Q+$64=D9K-'X_]*#-IOGYC=7UCO5[IC84>
M2F4CX?)FH)=)*0W_*&'58A4;?L*T!^E$NSEUDJ$C/P_;<I#!C@0:"A@CY;OP
M_TAK7DZGO& %41+"AQ-,<*'7I0^;!=9_#TQ>06!R2YYTQ4#)W1X>;LO#'I+\
MW4"2^S._<V?^FY4^\R\DR9VQNZV1(P>*BM=W;_O5YIZD];5S/X_BK:[J,NU\
M4G;O^TC*GF(U!NY94'+BKKQL@QU<B[SL#U+<:EIF<+"*O+Y9;?)ND^%4=>8^
M6]GYP^=PI0\?=S'60L\[L!0F4H#5&Q5_,LH<T(_,@0\W1IYR8<%OJK=L0<=@
M*-SG:U9E^^SMK.3VP9I3)L8B8^[_J%I^PU6K"P+(AA*+7&VN@6<\/W+D]%]H
M_;,F1%Z.4"@BI\0_[CJE_6"$*M1U!\HAS-N^OQP/L=\?3[$_=E=R?^!2Y6JQ
M6NM<S*WO 2Y=-?^>PIV&S<%7AE6=1S!./_.BR33-"MZ16O#5.9Q\!";'0A>3
MI9X!X;^"$J\AMY/>34:?Q=I+_<99F8VSM[(;YUKX(8$GT.Z/&9=Q(Y)(D$Q'
M$K/*1YC20H:_3V!UXT*NVWG&,<)5\)-8>2.G"V535?0VD& *7.UQA!H=5#((
MTBG)"A%$@Z"N_*_:#21ZF>(5W""J%-WODU79)_LKNT]0-X9,-T+X446(P$-)
M$)?@)7'8'9>9'W-<@>I"'FHW^0S]+5F_RWPQ9[%JKE-+XBUU3ER1X#5>9P '
M"2*JS&<&U%428L>!;-OD&^#[T<=9:LXQ*8ED!&Q8/*GR!7X.>,+J]VB78C(0
MQD''$VQ!_#U,%W]T]TA_!$*AJQ(K.)LD<^V;XUCIG]-'*86C[P/74Y\:E86Y
M)UD.^U,MQ_"6!G!)]3?I)BNX2V\;5L8V'*RD;> -2EKPF'[ $S1,"7B%&0,X
M,F$V".$AODTC5"]#G3_6/Z(-55SC!PT(ZSU2IC5<CO<4@K)R/BI#H_^=((X2
M+ZG3&>X%^TVP,IM@->&(>&I9IC=%C4XP]&4A.SV=OTGM477HJ0_2P<0'8";P
MJ.4L S%WF-XI"6+D5)X\?#$_0CD^;KZA;[@?Q'T$-Z]G"\EEA3NJ09 .J;HY
M([Y464PA(<=6?A$W9HHQVQ1E&D.]3QLOY[;,]3NQXSMQ-4&31C"WBG1GATZB
MV17<'7TN]2N)U"=T5PO0W6>,/?IRUJ>W[RK(+0&RT?$&+=VSMN2FM6I%LN/3
M<OG3T#N_^'S1=V]U"RBPM[W[7> $")G=MVVUR"^YXN<ZB]90LM%9 C3O P6$
M=TC2K&8K$C$?.#P#>+R,9JI3O4*",)\!07:#D6LU]G[[K__</3@\^AW;KM57
MJ%G>*Q.D,'!X9\"TZ/+6UL"[BFXB*>6N;LURO4E(J$,_-BKT4GU>/RN?F%+@
MF#]NZ9U;S6+6.3@@GI(3UJKFYZI*T@L?O$,8)F52J77,2:7B! QLE7I+W=WF
M#[#%UFVE=1R-NAO^&IXZ]V6Y+@V",B.6"-:5K_3S2$EPG$)NK[N!"1]XT=CS
M24IYT%8"YYDRJP&&]4",[+.P1PZ_74<C7'R=(E?AZ*53K'%>*^.+0P-'_GB%
M!6ZI5K9CQW*%-'=[;^,,?L*-""&PSRK"N#=QHRTRH>MT0I$!FL^F0N54/9LQ
MA=C@."), 7^",\<V]P;M)KYA^Q@20X$O29UB807@"K9TS[:EW=I\_=Y[P-[;
MWSC-\<P,R&VAY=3ON88]I[PVTU:?I%XZ@N'ZBJ H@HET?9O<*Z?264)70:7"
M1%'$LEK+>XD\"L,/X+U+<2O#'Q7-6DZ$ 7"GG"0+=)ME9+T[RJJY=Z\XE33V
M$6YY,8$MCZF^+F_@OIFM;V9[]H=8 8&-OIGM^VEF6R_^.4;M7D5@)WP%\9/"
M/ '_(A-_E&#*N6J%Z!"K*"8@6(^(+8ZHN FK+D^XJ@-;J:=E9:R9ZDP9#2_/
M \)?I=G,@XUPG<I[P%G*I6,[AQ/E*A,Q\#1 1%;+TN K.M?7?G(E#'8QS:[\
MA H.\*:^"J(-<:YK'=^MZ'U,_C)N'S94(=D/80[Q[MWRR7NG_"%.^<$&+K X
M,EFD#[#">[>\[I8W>,K-NZ;POPI5>!93M?G)N/"OPS0H)\R= CN0+V#[S@P;
M28@4-IU&"7X*@VT1@-?N9\0;B\T F8*IB20O,T$J O:;I$J\,45HNF1>L>59
M_#A/%WB@Q@$2U+1UA"I?S#G*>OX%[9AKD?R 9BQ4*6 WE,'/4R@3)5KT4DT#
MC=3,A6TN"3F0A/"\YDI>+!#B1T@@Y YFH<T <[&98KG![]YG>#K24NRRC%:@
M8*HA>,*YQU3*"*,KQ&9@VADV/4]C#,X+WDFF3XC)U'W150Q'PW%5.7TDV91L
M441O&5UGI-W)6WEJ>SLZQXZ^W'C/+VJFDQO>B5E*O45M+W_I%J:][7U:JW J
MN?4K]+6(TR9/<9=BZ0?K*+S:3?W$3E'4#0KLF^9-.I#I%$+6\TM$"BO+#J29
M_6/NVH6Z,Y7+!$W8;Z6';*57&[_(#-:)+O8=P6;*<\T&/=2DZO 'Z?:.\>-%
MEL:/U3>]N_-D2*ZZ&,JS;]?][=<[^_9_KQZM;7K94*YGJ5S6UVR7HJ-M;ZB+
M+[IN#A:QPB>")M#^U?X6^"1Q>CLP'@UCT3#'K%P?R_-0I7\U&>]M+DS4-2?G
M1_5<6%"WOD;])P>U=;12<ZC68)>F<,#^>9+6%KHK%N% <ZQ2BHK?$**,5XV2
MDL5O,C$AW0'P*BY$1LU(G_CY,Q/]N7">XCI+RZN:9V_OJS:<9W_>=>R\6WHW
MZK/LX!9_K$L;VC[T+,2!J^/2T-6*T"KO-L.L;F+K]U!!E?>O;SA\*&+W8H%,
MZ@-/)F&EW AXH_ 5""@H++&_))5_*%'K&^H(,$ #&&&49BIUX-B% 1F7D<!Q
M(;28#D]B22EN\9<.KD^"!BMB0UIE2!/P5CZ@2:RK?Y>-A.8A?.]N'K,M JW9
MXPJ$GW.2&[E=&BRB' ?3]]K9F[#DG!1FW!.]]JP7)/$F"RJ+F3_I1\X]U1QY
MXE.3:(9)-'$E& A99"5+S<"6G4"(QXS"<E@W:5PF!<ZK/4 7 C.@G!Q<'XQ#
M0L]$1XT2)5(5!&=!4J$!ZV03GQ1,90]X-)F($,<,/\-$!KC"8*B\K).TJJ"3
M6'DH>@+Y@K5#)@<\D-D]/OU&PJ7B83'2G-O;G,5&5X6A@,G\FBL8YDAUO=7H
M:>_[6C;57L4G5=V[=[R;@0%5.I6/.]YHE.M/P$,3_H+!FB+<&D@2"=E2E&;P
M++3/X?E+7@T!IP)B_Q93>KBR,4^@TP[\@/:O2'MH,A6)-*?PF'$D2OURY%7X
MA:130?L,LYW4=N@B/JS,XQ1?4^Y'H7Z#UJH,>_]A=?R'I7?I/X__T):VZ8;G
MX)VE!9X%VE##MF4)%7DN\[;/9DZC5EJUW@/U9W "5+VA]N2RPQC625$K(+ C
MD<B8G++]7$"H7L18;-_&?_>Q]2.LAKZ'I9WB\@J7K> $.42Y**@P=IDO[VQH
M:3ZF;<?;]2#A4NHPDTP3CL=F1^O&*<LD>QINH]ZYF>?<P 24F020^OKQJ$3*
M=16IGFND=;FJC6.1WS3C<=0YN*]GBB^40B#I!H5.R\]]7"L<FQT-\ POX$XM
M5)E9JZU<9AB+ZC7@G'VTL+BM#/\\;MKVU5U_=Q^;&Q=:^KEFX[L[W0WO'K#1
MK([_+LQYCT+N4<B=>XC];@^O1R'W*.35/65E9I?[2<F_(=\K*>(9_Y8"/'0'
MK>P>_<&@7'0>%;PAIB">(S%__T-2:T>1*XK(M)'L)G=Z>]!-I$QN>R+7GY.=
M,M?@.-9G7J*\C OMJ5'(W#MJ#W346IJ[".99T#L'#R& =4C@S2 0L<PL-K^Q
M@:F;Z):PALN'@OTUD5M@1WUU"63UIW MV J^Y)E2 1666HF=E, %;O%!Q4=1
M%I03?-Y PNHC\A*I*L&<\G[P-4EO(:JXLL;*.KAN'YW,B3<\!65711:@' /'
M-F:J$JP"4?S8\N614&A?BFODM,ER1DYNLKXXI>J3%^;G<?5^K>M_":=$QW%A
MKSW]WX4#Y)O7O/U$T]0%U?7EF\:=#MM%NW.6]F<K8+3>*(M96:0!T<3CQ,05
MX6:7B=O8+Q0[Y,]^!CMT]^4#_>0;!)(&?BQGD<CJK!EYM?WZ$8ER.Q7M2HL^
M$WYFY8[TKR(GC64P+_AB\$W!$=3(WT(&$S_$!TZJ/JRZ#(@&9G-WRZ6"J?0K
M;Z99/57?F)T(A8]ZZ(JV1V0YMV3?7A.0YP[5%"S?3R'"YVP&>4$R;4)(?;AI
M*/) Y4I";%>+8"W"0;#5K6ZKWMZN\U'\QAS%/Z396$1%F8DC6/E!JEH@3JPD
M;+]8^L.Y+1AAX,H S7H0$<<Z&/EKV?QD5-%8H( 87'4GV1VV%IFRD.$=6]BB
M6@6)91'NZIE;F)9MVWLWHT!G*IM"Y@_.C:@-.,T*7CB\H<!&!E.6.#DE='(;
M,#3W9CS2U-#>FZYE=4P*4Z>;>RFWF4XSMLUIX%MLD%2YR]( PKC<H&(QBRU3
M:!S&8>7(IR8_AS[O5P'KS_L$UYS :B[)P\J]$SA41S"EWJ<47BC+8I.[,*6?
M97:C69&LH0]R4_,3EP$V.J9$P*\8\/F:6]HUD H:CEB !:_?W=E^Z9#%;5:Z
MNO4]]!K<VD94 H$0I*LRQ:H9$QTC'C#1.*&14!5 ?*[<* ?@MZY$ M&X7N<*
M2*=&]G)[=Z^^VI\[$.V4$5^_$_]0G??O(TQG)&%^Y'TD].HYF:)^=:S]$7^'
M?6?#)-N<M0B10E_D17IK(G.#89ZA,@LVB9O$(%C=6S!@^74T57:P%<+L0*GK
M: GU/=GVF5>.L,V(3LNM2K2X33WT%5_"QC+<I(5H.!%'"M2L[#[A?G6B]8[Y
MP\1CY'::-. G< K0^,/!&RET# TE5/L6'C: \TJ>=U-_QL1]26W \R9/GE#7
MDOV5FKE4GWHEM-9)%7?:*ISFTJ&A5 Q=$UU "M[1*Y*-].C .%/*C*C)3+;N
MX% 8+A+/K $MYH#T!]Q:'W"[._* N_2_M;?KK]N\;/1G7"6,O2-FT\4QE5P&
M(_NW=B9&'229U#,&)5=HR;.(JZM:M\N_,DJR=@"D(F:D9/(6&&,UKFS,<TJ#
MK,?5&OFI@\<]Z]P$KYUIQ^@SS53003,Q-W2M!WO,3ND'ZAI4C,-=ZQ3>1AS1
M7XLXK"6.[[CK-OR;VCI-_D$7-JLP-.???*CQ^&;51/;\(38 O1=?1I1+UHO
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MFB?7!:.Z3S46(;&AR>\4_C>.PV A^%D8RU"4PLZTS )8XH)591O8 XF=H+(
MY<)U;GID2]'T45G7H[*E*S@O/>=?;</3Q%>I8/HJREGX7E@6E/(-22V-MEB(
M7 RYPI(KF<-(41.XR8MIEEYE_B1G#648;\+I]X(9'33-0JU,AFU]BG= I=D7
MR&+!@_E1DA<+I8H&+8DBDT&"JT29.G(X7!U' 1@P92F1M10)_&5=6N9:)"]#
M]1$R\"]L-@Z5/3<WJ\]#?4[O1 8MP?_M. )< >-[7+P]*S^?7IP,/WPX/AM^
M_%S%P?<PL@4B^>W=#=65<K!S>-S#Q.[)\$@:CP5WI''NWZ[WVE-KDONAU/[)
MP=,N7F!1 <X>["OS8Z=XG(2-3#;HW.L#JJVQRV=9&6QXJO:YXR# GQ97*7G3
MMN0#G3CV6<E'I,./4VT^'_M17&9.14?_2E)?^3,E!#X2B8 9;E9]EZK@,L@9
M2%I':S[9)98<0]R$9G5552=YH6[WY=N#-RME#O8VSJBVTLH&N*Z6X!@6LBD[
M:9=E4B:*3EIS7V'8:KC&4Y=NK''EJU9*W.58CA6A]0UJ<8S&)!:218J4#*(\
M"$:E$E2=_W.3@T#Y"TW[C453B*N^#>A_03J=F:?AWUA/A 2G6"767+!^@9-A
M 28PUIUI)1 >C#:'TNV>9A!E1E.P;;K,"7LM:RIW(K$I_\FP?ND_&EI6]77T
M6*-QA+=B_2^LR52XPOA;E ;@IU1?UK3H] @X/:%42]8M'[(GE#XPTF_?>@T.
MB5S=!ENT9+"Q.F*.5LP]V=\X5;3)M":/O&-Y]F6.S$8GA__T1&LK8$3_*!%U
M@>E1&2LJIF.+(=M"937:R3HS98/2AF1N5$9$Q^L$8"N8:AO)-D?$"@ /$HV1
M:QO\,!1&8DTZ82-.+"L=Q"7WPX,A'D7L5Z4N+W<EFM_VAI$$YC6.=OY(2<+0
M9"7PVI04< :8-Q\NG/1%N0L2$)1SW3"$.N^18BQ"2:GV[]TYT90U-\GHU2-#
M[,URQ2P?;$A-3N\XS\N,I"E[8^?.TA"Y*BQ'"?-C#$XB2X+<%;!_)V1"9C6'
M0^GE0O@3E%(T5!<WD' 7[=-8O@0%_I606 H5S<]A6O\&N(PJX4CTK+*L9;PA
MP=9J)#!4I.!.<VOPD,B$FT'-&LPU(W!ARS,Q+%I75+ C4GXL*@1^AM\KV481
M 332HBDU&FEQT,)1_0O,+)FY@0QMV0P*/['E!.X6;^DW]IR-_7+C0L#;E,%^
MOZ7=^3F5"0W%ZM*PYJ/<]DXX^KM)(U21PNP(0QG+1"2PKP+!:'0.1/1%[6B0
M<SY\F5S ]E0"PCF_)MUB7C_S=?D@ H<DXJU[ ],*NPC"*1H+YG,PM:\&PQD>
MF;:I4.+,$0-C2L.0*8N:7#8%N94/4O&8*L813)$"]9N;7_M@)85 BQFC@DIU
M=_>XN!X7]^P/\:K;P^MQ<=\7+J[W:!;Q:%YMG*48I<!0T9+T+DV%!5FHM(1S
M;"?IG1PU6DJ2YE:$1GY:)L$#^,(5)T=OKU/&P<&_\;BO=>\HF<EIF:%2"BDV
MJ%=FZUJKJ\K4A*3X:79+YHT=_(S8G^:""0^E8ABZ&%Z"$0C^&[TV'?5@,AOF
MN \J'K(%7V^\*\%<<[SXCDN _3Y<B.U4N<H24"J]>I&41L]=U50K3:Q&S46*
MJDI<*&VK.MB(<J%8@+&T6RT*\B8P;+\9'K(9WFS@M_OE7UG^2(VF%KWBW,US
M(G"MY:7[A?>0A7>X,>2\&EB2H6[L[1=BFS_D<$3<)1&N_"7-$E&CA5B<)T V
M%% ^U#71,R-!1YR&A4]9)HE<9X0F7Y?;N^L40HUH4'"_9,95<54O^DW"S4:Y
M],FXSR&(IA@=ND,WNO0,8N?[F2>J]$A:K>C"/H:LAG3KDKT]>!#R;V?CQ_2&
M/^M]\&_))?AGF45Y& 5V;;TW#8TNFNJRF2 L)C/89X/@4^?9%4TS%ZN96DXE
M=EM(V>TF"J)HD!;E'0)/<NQHB<O)*/*)G%WW>.!V0&A*@9ZV'N9(%+>8.+4R
MK0,G[4JCS,O1!*R9S_B_B!N6RL*"=&.9!H; ,5Q=,;%)+T=\4W7R_[66E7JP
M("TS1O#5'JO?SP_9S[L;PQA>2I8F4>"]5V4Y7'#' 7;OX!KK]W0[$>K$YRXP
M[GN*B>PB@$.6Z#Y"$2 #*O6)F!8S4WBUFB)8Y1;] @OO9]I(QF6!T1M]0+:G
MJ$Q*\W? :@CS8K'@F7,7FBRI-O54*+$+&(YA8],R#6V7M5KZ!IJPA702).G)
M:$8=>1)&/"$)=>]6C')X7QX6@:1'4N7(0GU4L!%9*"O,_(2*X,,8/NL+Q766
MEE=2[6$B8"QA3OUZ@5\HG\<)"CQ'XU2S1">2VM:H]C*T1[\Y=QY">]^H%J+V
M252C9/[%%^3X8$7-7#"?Y07,%+;LC6*P<A+"?8_)TL#$ZD>?7L^KX[OYU/5:
M<:GFU==M+]D!8E8YDXCHSK%+UH,+XP6\)RK96A!2#6L0JMN+T1-)NV)R?Z(]
MZ$3;VSA-P#N:IIG#TW:)B!!;0*7?!W,]U0:2*FKLB/3DBE"Y?@RW<92,=#X=
MSS6*B1WQ=GWUBO9-[4)@H8?<1@S[Q>BT:_4?)?RCPMD;*RZ&9QO'X#^Z[NP<
MN1X]ZMHP!BV/R<_!OGH/+^CA!9U[B-?='EX/+U@#>,$ZG:*G9]Z7T\NSX<6%
M]^6GX?GPXP]NXD3BU>@HE3#=L'8*Z3,&J2#Q3)H)'V+ *(/(C=J65,IFR2)P
MC]B&^-CS_.OP[..9]^FGX_.?CT^&GR]/3XX_7'BG9R?;?Q]E_^A2L\!3" @O
M\*+N>N#=R@/_]02N-<JBOPYR"/)?Y"*+QH_VU$X$<["]B^;!B6 .NAB]//;*
M>#=[ZWG>O^;]AXOY,BK@:(6H4+K=V""(99QL(:@US.[K_2?L2^[4.EO/I^Y?
M_[J<@G-MA[(?G6YW_>T'\FK._(GP/OAY\2_\U^_/_D*?V3WH4P=]ZN#9'^)-
MMX?7IPZ^T]3!4HS\XW&2T45#$<CZPEM*:%,-+T_C:$G'Y/#;=31"$_)8DH+[
MV_O[^\LCP<39-\\B;]:EK,W^]L'!Z\/=P]V#E[L[K_8/'TO'>U>G9)9$@?DL
MR^]'D2#W:Y?2*K)T;S22$"*I>$%NX3.S%V,LW,,&P+WO;>Z]_,N6*S"5>,)J
MM^?TVC@M,V_S8,OSDP1K^KD43^'/.#*)WB9]G8J\"I^)BB@#S_<85!$<_2)_
MCU_DWX5'6X-JU4L+[J34\IJ6.76_8[F?R$[JTCL*0D#41H:QV;X=3-!C,^?V
M1F,Y1F/ONS0:ETA<K7#*:L?YWHFD^D:L<U)D:<>L2I7YT$]F1'>AP4/Z*&;N
ML/OK9?D+*V9I.-6)TK]R\,X*[)RWH)V1 /W'- V]<U:UVQPA'%,RP]E7BG+#
MRH;CEI0!%C83 6<X2T@BC/3'8@RF28U?&3OK7I:M@WF3\'CBO\='DL5Z,-,Q
M6&CDC?8F</%K--91BLSM<9S>LNFK+9>!08I*0@^IE(=Q%DR6]>80%8>6&:%?
MDXD($7Y.X('(HGAK?1F28\&^)"/M(X(72,0]1@P3^'9 9'IT",'C$24)H??G
MW^-.TN(&XO*E^,<MMK7/@_1YD'7/@QQV>WA]'J3/@\PK@.Y\5XF0O9V]E][I
MV?O/)\.?AV>7WO"_/Y]>_@\6_N&GTU^&WJ</QV=+IKO_OF9T#I*BG\;%I_'3
M\/R'CS"%L!"]"YC,H7?\Y?C\O7?\X_F0EFKG:UHK6)KM,KKC\J?3"_/VO8D?
MDE;N;ZHT^[NWB5&,"IZ<U)(.G]9W^HY__GCVX]NVY[?#HEV9*7HL+T'^G+'+
M4D]#=;H!XE<!?_8^@;,]@;N7%)?FWFD2=(I %U.D@1*'LQL*:HIFWHF?^*&_
M$)!L]^7V_IN7%239XZZ.+N^8C0W'H,@<4F]*_G%\]OX9# GKP*VR+;&P.0,"
MY\A_$B#Q]R[9$X0Y.8O?Z6U]\L7_[(4*=W8(B'Y\T;H'UF(2CK<W-B[=G+?O
M)>(VGBF5NE#+U34PF:2):)+*0Y(Z;S/:\FY]U@>$A[B)N(#G)_,NV**]QYV\
MBB>?>$\V([A^A-WB1<G$&TB(;=+\M49H.WT^2A/_Q1B[T&5N'>X)\_1BWO?;
M1W?4I4W?RL*_%NOYG5S/ZJ4I&2!+O)*IB"HU9NR-]#Z);)R"AX@4(9R8U0R'
M6+I*L&>^##A'.P''+(M09LRYD*$-H+B=*V1W+,PYR[Z%U.34C.-#Q+7M\S(6
MKB[L.K[^$WK]8!7:7F5DVFZG988$4S;%BIA2+0IK8/B=:_ AL"5]BMVQ?FS:
M:\>L=ZS> 5TQM[STEO>S[-11M]_-V<<OWB6>N3]\/!]ZE3R [ X;7L ?CB\E
M+P[M7*==?5*B/!<>)Y,(B\HLR*+U5H/T1B2^$FO0Q#VY[(=6M5HB6*UWGZEO
MFR\C<(:/C7S);L(JZJ>>]E-B^ALOA^>?SH>7QY>G'Y><:-]9A8SFO<!4SZ8Y
MWK$X4P[PD1"72\=</LW6>J]!-?E=J)"U[:ZN$C@-P!>)49H1 484U.4I\CYI
MP)9A&&'*/6(#Q^M]*RCS"$=O7C#$"2[ &K*X+"79,1%^E+DF&F',#W5OTRG-
M0D(YDG(R*[C\'*)37922%_A3JNW_6_!U<;#VE?%^&$$27] M'/J,LL(C7!,.
M56^,_D$>9-&H1@!6/<4?C/F4R^O9+->SKT B6-K;/WQ]^'KOS<'AX2.9K<V]
MUUM/8;8>'Z?%&3;-YZIR;+ X<V=M^FIE%M+M-"N4D_K>.R7N>F+XFF!S!P2A
M$YIXF)D0"N9G2\='+=:Q7^*=6^)O5GJ)-_'7Z]7.E(I4QI)ZF\AD7&+>;SI-
M(PJ\X<1)LT3,JDS%:6;HR@M9]W7^GLC\30I;QDKH6+E+.+O\*3/NCV:270XO
M,[V>Y5CSPWO@PH=_1<DX0F5IU$,>(_N<?T64LP8S[(_'?I3E_<9:F8UUN-(;
M"QV4RD;"Y<W8+I-1&OY1HK3<:8(Q,68]F VU(@ N3YT<.\B1$Y6E[5 : --=
M^'^BF9M.><&RS Q\F/7&2?I2GC4+K/\>A;R"*.2V%.F*X9!WNSV\'H?\?>&0
M^U._:Z?^_LY*G_KUOK+6T)$CQ0NI%K"W_6IS;ZM.U_HH_NJJ+M/.9V67WM3Z
M1 4/+,=,D6_-D3=YZG:]CB=F?Y"]J23%F(L&;N6!+#L3NZ5.<:I"<Y^N[/SA
ML[O2AX^[&&O!YQP@A</+&A5_,L9DU5)X_N":9=\5N3KC;JJW;('%8"#<9VM6
M9NOLK>36P8)3)L8B0T'%O"Z>@JM65P-0Z206N=I8 \]X?>3$Z;_0^F=-C+P<
MP7Q(,G[?B)-:VB7JN@/E#.9MWU^.=]COCZ?8'_LKN3]PJ7*I6*UUKN36]P#7
MK9I_3Z%.P^;@*\.JSB,8IY]YT01%KGE'\DZIDH;[4C);59*EO!O+$)5X#;F=
M]&ZB2D1U+_4;9V4VSL'*;IQKX8>$G$"[/V90QHU((A+O)8X:7,5A2@L9_3)8
MW20"WRS:@E?!3V+=C9PN6/N1BMP&$DF!JYV$R;A@$*13,5#X#,*Y%B)INH&$
M+6OEF+X.O6K[Y.7*[A.4T233+36-&#E$@GN"<V;3N,S\F.,*XILBUCK&_1)K
ME/W%W!-_E,149+'&R7/B2E#6C43=;PE.9>NZ8RM)B&T&LE>3;X#O1Q]GJ3G'
M(NZ&,6*>2EG)^8(6#JQ^CW8I)@)A''0\P1;$WR>*66KW2'\$0J&K$JLWFT2U
MY)OCN"Y&J.\#UU.?0E(L?4^R'/:G6H[A+8W>HIA,N\D*Z]+;AI6Q#:]6TC;P
M!B46-4P_X D:ILQZYJ$ZYAAF@_ =XMLT0BEQXMY#/9E42I7C!PT"ZSWJF#9<
MCO<4(K)R/BKEX8H?31!$B9?4Z0SW@OTF6)E-L)I81)*"-Z87R0L13U46LKW3
M^5N%*E5]D XF/@ S@4<M9QF(KL,T3DD$(Z?RY.&+^1'*\7'G#7W#_2#N([AY
M/5M(+BO<40V"E'G5S1GOI4IB"@8YMO*+N#%)7A0V"IQ!>I\V7L[ME>MW8L=W
MXFI")JFM4Y)\NC!W=N@DE%UAW='G4K^RE9%;4.X^ ^S1E[,^?2=WYA+@&AWO
MSM(-:TON6*M6(SL^+9<_#;U/%Y\O^M:M;H$$]K9WOPN, .&R^YZMYLFY<+GN
M%])?9LEE"8-W2?=-IQ4I80X<@@$\7D8SU:9>83YHISV0;6#D5HV]W_[K/W</
M#H]^1\8,]?$7N'NI UOQV5+?O%<FR&3@4,^ H='%KJV!=Q7=$&6'3=Q]353_
M(>$/_=@C#"".-A.!B/"9Y)/S^8F3HC^>5Z6OE:MI3QM-R 0NP@\I4Q34/$[<
M(2A; ,.DO"IUD<G$JGP=.">.1H$?XIJB-V1S":@BPN[.]KZCB@W#4;?#7\-C
MY[ZLWJ5!4&;$%D%0SFIOCU1UD*(-_I5NC2A2;&5(RLE(4"X,9YD=9:S'C\!/
M]C/T)B2!NIIJ:M<C$7.FX&9_HUI2?R"PMAM*,%W8XY)8H%,<<UXK/XQ#&D>.
M?(4S;JGFN6/G>85>=WMOXPQ^PBT+L;,_BF)LP9 ;;I$)7:>C#4W5'/X5JL'J
MF8PI+@=O$[$-^%/%5!EXG/B&'6=((35%HU488D3+XN[9%K=;&Z_?=P_8=_L;
MISF>K $=>;22^OW6L-^,-(K*%"2IEXY@N+ZB-(I@(ET7*&<M#MPN2JD)\V>B
M*&*A%&IH+Z%781@%O'<I;F7XHR)DRXEB .Z4CR/J;):=F9'U[B@5Y]Z]XHDJ
MKT1\$Q/8\I@?[/(&[OO?^OZW#CS&7K>'U_>_?5_];^O%6<=@WZLH+Q0/7>8A
M4B0:1P'_(A-_E&#,N=B%H!*KEB8@J(^(88YHNPGB+L^XJ@M;*<-E9:S9[4SU
M#2_/ \)?I=D,9;:N4WD/.$VYXFRG?J)<92P&GL:5R");&GQ%]UHJB2G(8YI=
M^0G5*>!-?15$->)<USK 6T'_F#-FN#]LJ$(R)L(<XMV[Y97W;OE#W/*##5Q@
M<62211]@A?>.>=TQ;_"5FW=-X7\5JEXMIFKSDW'A7X=I4$Z8< 5V(%_ ]IX9
M;9(0B6PZC1+\%(;;(@"_W<^(9Q9["#*%;A-)7F:"% ?L-TD%?&.*T'3)_&/+
ML_AQGB[P0(T#)(1JZPA58IESG?7L"]HQUR+Y <U8J'+%;C"#GZ=@)D)+'C)B
M7$X#C=3,A6TN"7"0A/"\YDI>+! 92  BY!D66<&' AAO18V#W[W/\'2LI1AI
M&>1 X51#^(1SC\F4$<97".G ]#1L>I[&&'5ZD;V;$RC$?NJ^Z"KTH^&XJIP^
MDJ!*=C6B:AU*V"%73][*;=O;T3EV].7&>WY1,YW>\$[,4NHM:GO53'<^[6WO
MTUJ%4\DM>Z&O140X>8J[%&M$6&_AU6[J+':2HFY08-\T;]*!3*@0()]?(O)>
M678 X?O6NW3M0MV9RF6*)NRWTD.VTJL-)?-]HJN"1["9\EPS2 \U"?M1N][R
MGVVUWMUY,@!8)[7 7^_LV_^]>BP(V-*;>IZE;EE?LUV*CK:]H2Z_Z ([6,0*
M!0F:0/M7^UO@D\3I[<!X- QA(QUHZ?I8GH?""*C)>&_S9VZB 5=JT=P<KA%R
M?87Z3PX*7A0A./!\#*XC<>,<<]8K^CF*X>4@AJ)_'\M\'T<K-8?*)G1I"@<<
M+R5IS?"X@A\.PLHJ;JEX&I'F>-4H*5FX*!,3THX +^]"9-13]HF?/S/1N(O*
M*JZSM+RJ15JVG6N#Z_;^1\?\CZ4W2S[+#F[QC[NTH6TGQ,* N%H\#<W)B&CS
M;C/,LB>V_A*5N'G_^H:&B3(H7BR0#7_@R:2XE(R!Z "^ @$>A8GVEZ1R$R7.
M?<,  @9H ".,TDRE<AR[,"#C,A(X+D2(T^%)9#?%+?[2@6=*[&=%+$JK1&D6
MY<H'-!%Y]>^R']0\A._=346W!=&N2\8<"#_GH@-2]#181#D.YF"VLVEAR3E"
M0A[JM6>]((D 6E 5SOQ)/W+NJ1[7$Y]Z?3-,:HHKP9C6(BM9+@BV[ 1";J:%
MEL.Z2>,R*7!>[0&ZH*0!Y4CA^F <$GHF.FJ4L)2JZ#@+D@H_6+><^*0^*UOY
MH\E$A#CFF.": :XP&"HOZR2MJB E5EZ0GD"^8.V0R0$/9+:53S]">EJ,2BPD
MFW.7HK/8Z*HP%#"97W.%GQVIYL4:Q_!]7\NFVJOXI*H)^XYW,S!@6*<2=<<;
MC7+]"7AH0L0PR%:$6P/)!2([P](,GH7V.3Q_R:LAX-1,[-]BBA57-N9M=!J(
M']#^%>E'3:8BD>84'C..1*E?CKP*OY!T*FB?8?:9ND==#(Z5"9[B:\K]*-1O
MT%J58>\_K([_L/2&ZN?Q']K2:-WP'+RSM,"S0!MJV+8L@R//9=[VV<SIMTNK
MUGN@_@Q.@*K_U)Y<-HK#.BEJ!1UV)!*9(Z'J"Q=TJA<Q%MNWY7/ZV/H15D/?
MBM3.4GJ%RU9PP0*B7%3%&+ODI7?V)34?T[;C[7J0<"EUF$G"$,=CLZ-UXY1E
MD@0/MU'OW,QS;F "RDQ">GW]>%2RYCJ75#XVLLB,,L"QR&^:\3@2*]R0-<47
M2B&0=(-"IU?K/JX5CLV.!GB&%W"GJI6R'I+;0W([\!C[W1Y>#\G]3B&Y:^O
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MC3(O1Q/P'WV&7T;<*U86%IH>TY0P!([=ZJ)I31)!XIN"*?ROM:S4@P5IF3&
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M0,MCGA?*.A&8-PK0E\" P,H8ID13(Z(TF2[F[E539=!:(4/"WJ/$I"I@ST
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M5<>D7%#ER@863M:K4<@>0K'DVCQ@S!V396+OVWVQ @%)(2Q8:HQ3K<.!T#9
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MI<];P.QOI(UEP(3!\]+1!Y$HTF'8C-!8+>DO;RT/'P&J3"U)P@/IJ%VW;?V
MQ1X!7@EF5QD*[M3/;J3U768E? /4K\X:X/!N?8;=)GWY.RS^3^KH'1&@JK<0
MS/^Y>OO]Q=GUS^_.Q4]GWY^+-Y<__'#Y_NI_-W< W_F=.[_S8?S.S_W2O6&Z
MMQ?B_=OKB_.K*_'^7^?OSB_?#'IEG#12U:@W++B"+(C7-=XUB"-NJ 0<4,20
M,^2:(;/-^D$)JD)RKVF'CQRU9$_?>..1#UO@QMIV+DTYBW/'7X<@/<$Q9-'E
MO8L1^!?V>CR^62X*-2[(K2X5"S)XN)>0&+9DS3MV5]N+X*JXZ;H\IR=[T65?
MP,FN@S+^I/O@#].>G96BQR]&SV&U T^-931^T<T0ZZ_0D-@HE>UG.LT#%NU;
M%.(WF(Z-9&+)(M5QG"A_J:.<X&ZR6?WM 471#YM$^M$#D>U#5[?\OG0"F%UF
M)<XJ4)T->=ZQ_Y]YT1T;/^::=QMRFQ?Y#VK'QWR%+FE'/S/("OS_<87Q(3RY
M_O1QB>D_"GX6/V&P#QY9$1T4XNW%Z\ZV)U]HDN)S;<QGHJW?(7%/CD=??YS$
M[9!]7T(:/$6)^\_56!P4!Z)ODO>IKO5#P77I76(5Y8SA'U.0%!U.C#GICYD5
M[OY;F8D?<X,UZN8CN?GC[:<=-S\:A:$_-!;'WP[?J,D0^YOL6/EQ%AJ[;8X[
MV>;SS4'L.'5[">@<4;CCGA#-;D,_?6&O\3":L7A]?KECR\?<Q4?S6/Y_+%\/
M[ _'"_ O1AI[&8!]Q.3$+M>UW;DN'WW]"'IZT9-<UU-.,Y]=7Y^]_M>/YQ?7
MXNSCTSM/>66NKL^NSVEA+M^(]Y?O_NLS+\\?/'%\:V5PVP0@N?;'!?,7D7)_
M<,^.'UO0/;9V>GDPR>/5JS^]/)B7:?+J_P!02P,$%     @ Z81;6J>&<&#3
M4   0B8#  T   !X96YE+65X,3DN:'1M[7UK<QNWENUGSZ_H>T_EE'2+8BR_
MDMBY4T5+=,P[LJ0CR9GD(]@-BHB;W3S]D,3Y]7<_ #3Z09&4I9BR<*9J8DG]
M0&\ &_NQ]MJ_3HM9_)__$?PZE2*"_P:_%JJ(Y7\._]C;_^77'_D'^/./^N^_
MCM-H$>3%(I;_]W_/112IY/+MS_.;=S.17:KDK2B+]'^IV3S-"I$4[_XW/3)2
M5^:6_]E3221OWNZ]?#=3R=Y4JLMI\79?)>_F::X*E29O,QF+0EU)N/G7'^%6
M>L3</&"2)L5>KOY'OMU_/B_T:_>*=/[V^3OZVT3,5+QX>Z%F,@^.Y75PELY$
M8BX<IT61SN#:0MX4>R)6E_!"' .^#>\W[PG3.,W>_N,Y_>_=]505<B^?BU"^
MG6=R[SH3<W[=-7_!.(VC=XVQW38<^ML7F24HOR1-)(GC6D7%].U$%7LA_%V2
M (<W4S5618#3@7>!4.;KBF3_Q8IAW"*5$%XOLWL6R_Z]B>6/X?')<7#Z<7#V
M:7 P_'PQ.A@<G0>CXX/^,C'1M^'J2XJW;_IOWOST0W/"[DERL9RTEM-R2=WW
M>OGG/_;?/'_GUXHCDM'Q^>AP>!9<G T.1\>_!:<G1Z.#/[V('!&))/+R<.3Q
M6ZDB&:L$;K]6Q30XD_E<AD50I)N+Z<X'TY;+Z$#"(:^2X"(322Y"/+SS 'X^
MEV&9P5DN\WM1Q6^>FB:^Y_6RZH/O;T'<_L%/^?Q%"SB,19ZCT7PI8=A9)#,:
M#SP0QMIM(D]B>;,7J4S2YGH+.[^<)>\BE<]CL7B+?WVG;7 KB/Z;UV!,-VSK
MO\J\4).%&27=N2>3J,/H'J<W*!+\3#U(^ U*\R$7[I;-&+L=E?,QS<R@]#>H
M!(^&O;P064$NS[OZ'T"T_&N>[$R*+WMB GOSK8BOQ2)O^T5F&DF,?9S"33RE
M1S-I#ZAK-O(5OV/+Y6+P_F@8G'P(#DZ.+X;'%^=_@UVG?R9'^NVK_C[J]L<C
ML6=&0E\[.OKD2(9I)FA_EK"!,U0(09[&ZH%&?PHJIC'%A1C'TGQ(_:C!I8Q_
MW8,#)"VU\N+'_O*B__R'=_IR^/Q8S'/Y-I=S 9\C667!LZTNO%*Y&JM8%8NW
MYFI]$5P568U S]Z'9__\@ZNG] <81?5C$2VY]>=7_==O[G;KR_[+M>Z$?V3-
MKS/Z%B=J+,(OEUD*T[FGE\6$_M>]+*Y!@JSSW[+FQU]T2*:F\D&MN_;12S1Z
MK\"^5J&(]2Z"ZUJG/=SF:GGW$7L_]?=?O?S!WH+JNL/NVO\:8QNO7G$BK+N/
MUG/D^S6%WS'Q3:%N+L,ME$U+ ZX9];@X.SG\?' Q.CG^2K'Q)W5)KE/+/[0L
MORI@NY;L]KL$MGUJXO6K.ZD)+5Q7(]0TQ\O^3\]?-30'Z-*7+V_3'/=J1][=
M-L#[WZH"'AUN,-^#;ZI8'K7H3F668^#G( 61R"@8+X)BJO+@%$R><+%UBN?;
M9(F\TO%*IS7?[[W2N:OHCN2EB(/3+*7<* 6>TR08);D"YP4#TB@3KWN\[O&Z
M9TGNQNN>NXKN4!8<CP]$$J$.RF58TL_IQ*L@KX*\"EIS'WD5='>?*Q$Q)MB#
M29H%OZLT%DL44' DKG-25-XINY-6>N&UTI/22D.OE>YL4Z:S>:Q$$LK@9#)1
MH<R\HEE?>B^]HGE2BN:#5S1W%=V9Q/H"M&ZLZ9-[5>-5C5<U2\#,7M5\779+
MQ 0 !S6C$2]>VWQWVL9#;KI1)!YSLPGX\FQP?#X@R,UY<'#R^_!L>!B\_S.X
M^#@Z;Y<=;8?JV'(HSB-1']Y8\5"<;RVZB\4<AIM.ZA59'ICC59!701Z8\S>%
M9APW"1-49_)29)2)*J8R.$Z3>3F&1P:C9))F,YNV.H&_9@%&D$52+QSUVLEK
M)Z^=/'3G7FS+^1QN$!S#0;7C&$3!  LT@S_3,@L.L>BI*#/I]=#ZPGWE]="3
MTD,>OW-GT1VGP? FE'-VT-Z+'-PSL(-LL/E 96$YRPO,I7M;Z/O303[6O"36
M[(/-&XCKT^!B>#8:' 7')\>GG]\?C0Z"T?&'DS/XO2_Y_%Y5AS=??)SY6XON
MG_^X>?%\/WSW2<#N5R+FGZ-W;E!GZ]2/MUJ\ZMF2_>/CRU^M>FP@V>N>K],]
MKQ^'[O$>4[?']+MWF-:7%@%P1L/SX&SXV^",J("]#W6?R_'-XU FWI#Q/M2W
M%MU!FDP4KAOPGW0RJC,YOG4J:(MM&:]^GI;Z\7[4UV2@3(5XF@0FD.-5D%=!
M7@5Y,,[?I8(.51[&:8Y:Z'851#P7""!\+Q,)C[&009\=]\K)*R>/T+EOT9V
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M"'%, Q7'Z=9-^D*0-7XAV0P:3,_?E-XZA3SL9;.FP3@U !:>;*X/U+!E[RN
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M[C -2[]ENPR3 I;:E!.MGJ'^_E$R(I/=JN'VU@%W:$3]-8LR) ;C;5F3_R>
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MI]'B/__CUQ^GQ2S^S_\/4$L#!!0    ( .F$6UJ;T)BB6 4  !\:   /
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M@M4$&\W7S7! TT-HZMV#)F"YU.@O<OW*/RV$$HICL5TKESK'"1Z2 ?P_4[7
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MY-+3_!\K=295A,JC%A(SR&L)L13&DJ#?:>>FTJN4%[B^F&4\7?E3GJ&&0US
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MENFZ5'.]@\"MFBM_^TN:C[^0B25;&W]9&QZZ1Z+/OQD>^N>E_P=02P,$%
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M<5(V59*6BP6,8&$MVHZ2HDR6JDHN5=[H9 E3T(/Q@SZM"X#K3!>Z4GD"T%\
M!(LL65;EI;$ ?3JE'B@3^+_$-@O8)BPG2R8Z+U?CY&)NK/R\3K(2WBO*.EDV
M%2H%25W">SC.,M>UIFGH]<FO<-#P=$0__=8 F*8&!C5%8FJ;P#)-I>MU,EDG
M^@J 81%7IH H1:KI,T2-_H(5B/(TU_1O4Z0E+H+D.DTS6>_G:@4XH54ZQU<
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MV&<<$FI\=HPD'<:,SBG- XVD)*D.;VBT0:?9"&R^S"G'2[ERZ71-EK=UGRW
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MH.L'T[\Q?PO;1M$@K*72@J)H2:0>NH1V "9G.<D":'.."9D"5R$.0\E5]%W
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M\WJ1?_]O4$L! A0#%     @ Z81;6L"E&ZS5R H 9-X0 !(
M ( !     &EM9S(U-3 Q-3@Q-E\P+FIP9U!+ 0(4 Q0    ( .F$6UID"6$"
M6-H" &" !  2              "  07)"@!I;6<R-34P,34X,39?,2YJ<&=0
M2P$"% ,4    " #IA%M:.UQCWB0F!  7R3@ $0              @ &-HPT
M>&5N92TR,#(T,3(S,2YH=&U02P$"% ,4    " #IA%M:"W['Q$]N 0 "&14
M$0              @ '@R1$ >&5N92TR,#(T,3(S,2YX<V102P$"% ,4
M" #IA%M:: ,SJN4M  #=0@$ $               @ %>.!, >&5N92UE>#$P
M7S,P+FAT;5!+ 0(4 Q0    ( .F$6UKF(G5921T  /+G   0
M  "  7%F$P!X96YE+65X,3!?,S$N:'1M4$L! A0#%     @ Z81;6I\^U!<Q
MQ@  W\\' !               ( !Z(,3 'AE;F4M97@Q,%\S,BYH=&U02P$"
M% ,4    " #IA%M:K^N;,\P?   7X   $               @ %'2A0 >&5N
M92UE>#$P7S,S+FAT;5!+ 0(4 Q0    ( .F$6UJGAG!@TU   $(F P -
M          "  4%J% !X96YE+65X,3DN:'1M4$L! A0#%     @ Z81;6IO0
MF*)8!0  'QH   \              ( !/[L4 'AE;F4M97@R,U\Q+FAT;5!+
M 0(4 Q0    ( .F$6UJD10PPKP@  'PW   /              "  <3 % !X
M96YE+65X,S%?,2YH=&U02P$"% ,4    " #IA%M:;!TO+)D(   B-@  #P
M            @ &@R10 >&5N92UE>#,Q7S(N:'1M4$L! A0#%     @ Z81;
M6D L$?3'!@  J"L   \              ( !9M(4 'AE;F4M97@S,E\Q+FAT
M;5!+ 0(4 Q0    ( .F$6UKY3.?NN08  &4J   /              "  5K9
M% !X96YE+65X,S)?,BYH=&U02P$"% ,4    " #IA%M:Z=8[=, @   6O
M#@              @ % X!0 >&5N92UE>#1?,RYH=&U02P4&      \ #P">
) P  + $5

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>xene-20241231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xene="http://www.xenon-pharma.com/20241231"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="xene-20241231.xsd" xlink:type="simple"/>
    <context id="C_809415c5-c3f1-437a-ba07-2d600eeb3db7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_855c2687-033c-4d5b-9d65-93762e253c78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_870ddace-7d98-45a8-a1ed-2e57f3f089eb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_878cde20-56e4-4ebb-9add-30ed0cd3a427">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_884f4d71-a8e8-44ee-82ca-8ef780dfaa13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_88dd1245-4241-4674-abff-66b46ec29d01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_8a94fa8c-ce7f-4a9e-a9e7-bc7ebbe394c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">xene:XEN496Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_8af453ba-33f4-44f7-9e63-cd2ff108e084">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_8cda2242-cdda-436c-b1a1-5d38d90e788c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xene:FirstOrderPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">xene:RegulatoryMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xene:AssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_8f08380d-a06a-4f90-aa7a-aeae88ce9ee1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">xene:Pre-ClinicalDiscoveryAndOtherProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_8f26e8bc-db97-43e5-8f12-99b79372a387">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_8f915973-7e56-4b21-9f25-8542155d2101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_8fa80a4b-d219-444e-a4d3-dce7bd9ccd8b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_91296a7e-80ef-40a4-84c1-540e6b53ed31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xene:JefferiesLLCAndStifelNicolausCompanyIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">xene:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_959e7299-f8b2-49e1-8078-5dac2b5e2683">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_95fad8c0-4f7c-4bda-85cb-111b56b2cfba">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xene:NeurocrineBiosciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_9887e0d2-0944-45f8-8ebe-b8362c753b06">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_9a4e5db1-ae6b-4123-9a4b-819384e01155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_9a7e217e-4eb8-4d7c-b2ca-de82b025bdab">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">xene:GuaranteedInvestmentCertificatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_9dc51c40-1728-4dc4-81a5-109cda1ab80c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_9e565a8f-9b0e-4173-a3a3-09356a71706a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_9eb01a35-61ba-4b6e-af95-b573e9492a46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:InvestmentCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_9ee56ce4-a340-480e-9aec-44adf7965a2c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_9fcee154-e6d6-49cc-9847-f1ad966fc19f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xene:Series1PreferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_9fde0c8e-4519-4f2d-bac4-a130605b9e35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_a3786e8d-3a38-4f5f-915c-ad289a237b50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_a4e5a889-56d8-4a0f-bc5c-ed4272cae01a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_a52ed6c9-11b1-42c8-b685-959088b4d45d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_a581601f-604c-40e0-a538-b4058e27858a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_a9775569-4b1a-42fc-b962-e5d75b4877a4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_aae837d9-73f6-4e0d-b04b-74e170785875">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">xene:AzetukalnerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_ab08f408-103c-4988-a8d5-e291b741e1ed">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xene:FirstOrderPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xene:AssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_ae6f53cc-56cf-4ba7-a7f9-cfdd12d99cbe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">xene:ExchangeAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">xene:BVFPartnersLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="C_aec75604-252f-46ec-a913-19116503fa3a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xene:TwoThousandNineteenInducementEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="C_b0bfec10-59dd-4234-9f58-271c37fde21d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xene:NeurocrineBiosciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">xene:SalesBasedMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xene:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_b156f885-8692-4ecf-bf11-f2e6c2c97795">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_b17712b6-e1df-4014-af5c-fd1016d8f5cd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_b273b0da-ce99-4209-9b93-ffb50f246430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_b54bd813-bcee-4527-8ce0-2c924fa24d1d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_b676a389-6e42-455f-9fad-4ecafdc8c411">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_b6853865-a835-4d1f-bb65-e80788e06f13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">xene:BurnabyBritishColumbiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_b73046f7-b8e0-4dca-8c99-1daba94d7875">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xene:TwoThousandFourteenAmendedAndRestatedStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_bc5911cd-b1ff-4b0f-a581-4c001670e9a5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
        </entity>
        <period>
            <instant>2025-02-24</instant>
        </period>
    </context>
    <context id="C_c0de2a82-98b0-4310-ad4c-fc4a77de4ddf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_c36523e7-e5b9-4c2d-b6c3-bb9552e83dbd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_c6f61c40-d49e-48b0-81c2-ceb75830debe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_c9472f62-0148-495c-b52e-860ba1e4f49e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_ccebda2c-e532-4b8e-ac5b-a03dd5ef7b48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">xene:NeedhamMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_cdaa9dc0-7dd9-4606-9431-1abf2c692823">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">xene:CashAndMoneyMarketFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_ce952f40-3105-427e-bbaa-fffd07f2063c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">xene:BurnabyBritishColumbiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">xene:FirstRenewalOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_d2815981-23d1-4abc-9bb7-2d642884bbe6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_d9195ae5-00f1-40d7-86d7-25551a0a0739">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_d9305b94-dbef-4162-bdc8-5136220dcc47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_dcfeb94e-b8c0-4a04-9c3a-f7a9d496157a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_dd36de89-61c3-47d3-b597-7a827f1ad7ff">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">xene:ResearchEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_de04a46d-af61-488e-a31d-4bcee768b536">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">xene:CashAndMoneyMarketFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_e03fe75c-2f66-4f62-8b71-f0cb7b6dd2c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xene:NeurocrineBiosciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xene:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-31</instant>
        </period>
    </context>
    <context id="C_e0854642-1362-4d48-aab9-14c1634c7adf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xene:TwoThousandFourteenAmendedAndRestatedStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_e1049099-ba3b-4285-9482-cc2e1b4be2e0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_e41e64f7-0a7c-4d69-9147-98202c4d2812">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xene:JefferiesLLCAndStifelNicolausCompanyIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">xene:AtMarketEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_e51a83d7-051a-440a-9383-caa0acb0c6a7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_e5737a61-1f16-4af6-ac8a-b3e0f4d46fae">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xene:JefferiesLLCAndStifelNicolausCompanyIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">xene:AtMarketEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="C_e9b5b17b-a190-4b8c-8268-dec97ce1d7a0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xene:JefferiesLLCStifelNicolausCompanyIncorporatedJPMorganSecuritiesLLCAndSVBSecuritiesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">xene:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_ea541069-c8a0-41f5-a186-def6edd37f4a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_ebe1e93e-63c9-48fd-b7f8-764857c13f18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_ecdb23a3-e394-4b57-b4f0-5e84d7ca4b27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_f2b24689-5075-4df6-a2da-72c8837936dc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_f7541451-edb6-4acb-8f0a-790bab15be88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_f75f1b7d-970c-44d9-af0e-c5a826dcce23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">xene:CashAndMoneyMarketFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_f76418ce-447a-47fa-abce-3e02aca037d2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">xene:BurnabyBritishColumbiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_f8c4b477-a573-4a64-a72d-9223363b6d20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_f90eb819-58f1-4a64-8683-5de3a214bcb5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xene:JefferiesLLCStifelNicolausCompanyIncorporatedJPMorganSecuritiesLLCAndSVBSecuritiesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_f91f0158-e869-4802-841d-82a3345ebc02">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xene:JefferiesLLCStifelNicolausCompanyIncorporatedJPMorganSecuritiesLLCAndSVBSecuritiesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">xene:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_f956e4c2-abe5-46ae-8429-402134a46f35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_fa095704-4846-4a02-9bc0-f78ed31e8f79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_fb8162b3-a597-4e6d-b07d-93335801c609">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">xene:AzetukalnerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_fc078d20-42fa-4250-b769-ef250cdd40e5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_0031901f-461f-45c7-b720-6eb40956e950">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_01045051-1058-4f3f-b914-02cf2190b1d1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">xene:ResearchEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_01a82667-15d7-4024-a57e-2657379f179f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_0451fb9b-54f6-4a4b-8ade-92b89ad35f70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xene:FirstOrderPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xene:AssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_0514d61f-b883-40b3-87d9-7e278b3a6820">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xene:JefferiesLLCStifelNicolausCompanyIncorporatedJPMorganSecuritiesLLCBofASecuritiesIncAndRBCCapitalMarketsLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="C_0592fb80-0d71-435e-a735-fefde780f550">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xene:TwoThousandFourteenAmendedAndRestatedStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_0a8f0fd9-0cf5-45b3-8b78-096409d7c4d6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xene:JefferiesLLCStifelNicolausCompanyIncorporatedJPMorganSecuritiesLLCBofASecuritiesIncAndRBCCapitalMarketsLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">xene:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="C_0cc08d87-8298-44c1-a950-93f5421805de">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xene:NeurocrineBiosciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_0cd8e1e9-eb16-4592-8338-e8cd60e3e9b2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0dedc115-eabd-4f39-a7bf-4c55dd4adc43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">xene:GuaranteedInvestmentCertificatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_0e65ad73-e8f3-456e-8770-603f8bf6e43d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_0ee5ccd7-b9d5-48bc-900e-21a7360e15ff">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_0f230ef8-cad8-4ce7-bee0-026b0567d14a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">xene:BurnabyBritishColumbiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">xene:SecondRenewalOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_13ef935b-4e96-4f11-925b-9ffc59e4e262">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_144eba44-d44f-40ad-8b2c-6acd462b2319">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">xene:Pre-ClinicalDiscoveryAndOtherProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_1687d09a-5433-43c2-90f1-f650513a2fa1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xene:JefferiesLLCAndStifelNicolausCompanyIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">xene:AtMarketEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_16c2e333-259f-4e18-b025-1a7840b2cf5d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xene:NeurocrineBiosciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xene:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="C_1747e417-b850-4047-ad97-74e446f3c37c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_18ce0587-947d-4000-ad21-226659cdded6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">xene:GuaranteedInvestmentCertificatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_196d5f56-7bc1-4e8e-86d8-d5f88f81bbfa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_1a3df49e-e657-4eb0-a563-0c1b8605f4aa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_1aa8c882-c640-42ab-9434-c87e60af198d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_1c604906-e061-40ec-b25c-b0b029e35f62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_1c8819fe-6ad0-42fe-bce0-e8f35f30bcb8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_1e9a793b-d120-4f40-8894-7ddb1de35191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_22406e30-26c0-4443-96a7-32b9fcae62e4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_2298e5e3-65b4-4e1c-93f1-f5027b90c559">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">xene:GuaranteedInvestmentCertificatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_279f5f99-a2c7-4a1f-b98a-9e98fe07b653">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xene:JefferiesLLCStifelNicolausCompanyIncorporatedJPMorganSecuritiesLLCBofASecuritiesIncAndRBCCapitalMarketsLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">xene:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="C_27ad495b-a0bb-495a-8e89-83c9f5fe8b65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_283501b6-a859-4835-8637-5667f1ffb39b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">xene:Pre-ClinicalDiscoveryAndOtherProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_286fc5c3-6fd1-4b6d-bd7e-b335add2e3e5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_28f99d5a-d64c-4e7b-8a46-afb927c32234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_295d7ebf-ecb2-4863-8055-c5d32414b32f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xene:JefferiesLLCStifelNicolausCompanyIncorporatedJPMorganSecuritiesLLCBofASecuritiesIncAndRBCCapitalMarketsLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">xene:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_30871dbf-c703-4cc7-943f-7794f870694c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_31a54459-014b-4693-8a7e-9d5cd1d9fedb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_31d21974-f2b1-4354-9468-ccf01410882d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">xene:XEN496Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_32311f37-d351-4094-8188-e5c4e217f4c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">xene:ExchangeAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">xene:BVFPartnersLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xene:Series1PreferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="C_33309322-16ac-4275-af41-8afa3963db9f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_38463dbb-8c79-451f-b24c-b502ace3c611">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xene:PaciraBiosciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_3a167406-79b6-4756-b860-23ced3e7666d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_3c658b98-b12a-46a6-99c1-797a10c45fb8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_3c7df611-38a7-4085-9e60-23c55dba93c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xene:JefferiesLLCAndStifelNicolausCompanyIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">xene:AtMarketEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_3cd561ce-d56f-4072-b50b-523fee0cd886">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_3e2186d8-8a70-4a7a-821a-ef78292cca8c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xene:NeurocrineBiosciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xene:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-01</startDate>
            <endDate>2025-02-27</endDate>
        </period>
    </context>
    <context id="C_40c485fd-1ab2-4c3b-9ab4-26de3dc49364">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">xene:ProvincialTaxCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_44cf67e5-b119-4290-96d0-c01203738404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_4936f148-6a25-41e1-bce8-c9880d5a5e27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xene:JefferiesLLCAndStifelNicolausCompanyIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">xene:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_494ce105-0b9f-4d43-a7ae-9d4280f4ce87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xene:NeurocrineBiosciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xene:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_4984049b-32ea-46b9-98fa-440cbfdf680d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">xene:TermLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_4b115a6a-6683-4a17-b413-9e8bb98b7a0b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_4b92f893-c873-482f-8d2a-12d3073fc31f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_4d6ff41e-1e70-42b9-bd5c-6e5b839ec13f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_4dbe77ca-9a85-4dcf-8f71-e478f9594e17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">xene:AzetukalnerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_4e096b75-1c3e-4f4b-a2d5-46dab7c31772">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_50bacaa3-fec8-476a-a9ec-7fcc62c9f5b7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_53032a5e-ec82-4a52-98b9-c114209ab7e7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">xene:GuaranteedInvestmentCertificatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_577a2a65-5c5b-4519-baed-db30c894bf0f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_580473ec-137a-44c3-af0d-b97a202a4a2e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xene:JefferiesLLCAndStifelNicolausCompanyIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">xene:AtMarketEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_5a1c869a-3031-45a1-b8b8-07258801ac33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">xene:TermLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-08-31</instant>
        </period>
    </context>
    <context id="C_5a4cf558-ec87-4536-9f7e-a17702358f73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_5cf39887-6843-4791-adcb-c66041161085">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">xene:CanadaAndUnitedStatesRevenueAgencyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_5edde648-d952-4a12-a2fc-5d27c42f48db">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">xene:GuaranteedInvestmentCertificatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_620b04e6-7aa7-4a6e-b3fe-1655d998a981">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xene:NeurocrineBiosciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_63ad59ce-e171-4295-bb49-279aaf68cd61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_664789f3-25f8-4a48-9938-65726d2fa13a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">xene:ProvincialTaxCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_678bf7e6-b4a8-4a8d-a08d-fd80c5153186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_6c905a81-8dbd-4c7f-94d4-609f8be01e6a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_6cf3e3b1-576f-40f1-acd3-00e00c79c90c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_6f467048-a278-4893-a073-167e3300ed14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:InvestmentCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_71cbb8cb-9965-4745-9068-1c329cd37142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xene:Series1PreferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_75650c11-6320-415c-9740-299a3731566d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_779d7deb-a421-4227-83c3-8ac2dfc35f90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_7a64b01e-5173-4d9f-837a-bbb2c4168382">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">xene:NeedhamMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="C_7ab2ed07-5dfe-432a-be61-bebc4c8597c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_7bc29ce6-ec8e-46b1-9da8-77d97bcac7c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_7c1e5b7a-577b-4134-b465-b0ccd0cdbae9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xene:NeurocrineBiosciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">xene:RegulatoryMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xene:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_7e416cfe-b299-48b2-a9f3-089ca9635d44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xene:NeurocrineBiosciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xene:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_7e56dc4c-bf82-4de2-abd8-51bda8f0b0a0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_7f8727e8-25d3-49ce-a4eb-f560f9d67b08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001582313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">xene:CashAndMoneyMarketFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_Lease">
        <measure>xene:Lease</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_Segment">
        <measure>xene:Segment</measure>
    </unit>
    <unit id="U_UnitedStatesOfAmericaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_Option">
        <measure>xene:Option</measure>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_ee040fe6-5ff9-4b8b-b421-2951ce6d6d91">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_50016ee7-5920-4be7-8a65-1501db419c63">0001582313</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_0359f0fc-03f6-4a5e-8245-5e7df891b1e1">false</dei:AmendmentFlag>
    <us-gaap:CommonStockNoParValue
      contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f"
      id="F_39c5f094-0153-4965-ad86-c59ffc0f4633"
      unitRef="U_UnitedStatesOfAmericaDollarsShare"
      xsi:nil="true"/>
    <us-gaap:CommonStockNoParValue
      contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35"
      id="F_26650381-9407-4b93-8775-249a9131e1c0"
      unitRef="U_UnitedStatesOfAmericaDollarsShare"
      xsi:nil="true"/>
    <us-gaap:CommonStockSharesAuthorizedUnlimited
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_1d3d9cda-8981-47f6-bb6f-8de466ce6eb3">Unlimited</us-gaap:CommonStockSharesAuthorizedUnlimited>
    <us-gaap:CommonStockSharesAuthorizedUnlimited
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      id="F_00c5c9bd-d79a-4de3-b0a2-1106d3ce3eca">Unlimited</us-gaap:CommonStockSharesAuthorizedUnlimited>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f"
      id="F_a8ea127d-d3e2-44fe-898c-1a5dafe7f461"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35"
      id="F_c639d4bb-46d7-4e69-bffd-36f05365c504"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration
      contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f"
      id="F_47b3f612-5e00-48af-b88b-1d3d02b7448e">http://fasb.org/us-gaap/2024#LeaseholdImprovementsMember</us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration>
    <xene:LesseeNumberOfOperatingLeases
      contextRef="C_f76418ce-447a-47fa-abce-3e02aca037d2"
      decimals="INF"
      id="F_a0537c61-71b0-4915-978f-b5bbcfc84362"
      unitRef="U_Lease">1</xene:LesseeNumberOfOperatingLeases>
    <us-gaap:TaxCreditCarryforwardExpirationDate
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_d1be6160-6c62-483e-bb44-87d26b17b9bb">2045-12-31</us-gaap:TaxCreditCarryforwardExpirationDate>
    <us-gaap:OpenTaxYear
      contextRef="C_5cf39887-6843-4791-adcb-c66041161085"
      id="F_1acbb9ae-6eb8-45fa-9c42-da9b98b84dfc">2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023</us-gaap:OpenTaxYear>
    <us-gaap:NumberOfReportableSegments
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="0"
      id="F_a4a2478d-a313-4066-8e4d-8e8806c474dd"
      unitRef="U_Segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_d1e546bf-38de-44e9-b552-f72e3c4a430a">http://fasb.org/srt/2024#ChiefExecutiveOfficerMember</us-gaap:SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration>
    <dei:DocumentType
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_74c10fcc-5185-4106-8536-c14609b50866">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_03bf3640-9f1d-4ffa-bb95-a7bc5f8d5eb1">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_74e1769b-2de2-43bc-bc7f-15a96c7a7d25">2024-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_cd636dd0-d655-4d3f-a4af-a07b889030b8">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_f219e2a4-faf9-472c-ae3f-f1c57fa08fc1">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_2d000b7e-2fdc-4452-9b5c-fc7c5f912115">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_8670ace6-2fd2-426d-abd3-90e67b768e47">001-36687</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_7e5042d8-196c-46b3-828c-6d89ec5841cc">XENON PHARMACEUTICALS INC.</dei:EntityRegistrantName>
    <dei:EntityAddressCountry
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_e1f5bd45-2079-47f5-aaa4-78aa7f51a5ed">CA</dei:EntityAddressCountry>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_97661067-8b59-46b2-9af9-ebe811cd7f20">Z4</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_a2f4b0da-bce2-4f5d-847d-25c254a2f1a7">98-0661854</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_17c7a2c1-2772-49ee-8814-7eca1b6ab380">200-3650 Gilmore Way</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_5e0df37e-6b2c-4157-b7e3-520f417cad57">Burnaby</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_2a6d07f8-f81b-44b3-87e3-7763fe6842cf">BC</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_87c7665e-81a3-4ca5-8aff-26b74c83997c">V5G 4W8</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_e314dadd-0c14-4f8c-b1bf-3a59bd851778">604</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_0e876845-2f49-4d21-80c5-ec35f796dff2">484-3300</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_95416a47-40d4-4ada-ab79-8caf4cefe5ea">Common Shares, without par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_83b09a56-6899-4ebd-864c-6ea382337f93">XENE</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_33d88abe-c966-4e07-91a5-f18189789294">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_3ca7fa25-674c-495c-81f3-bb7d3e351a50">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_2d4b2c6a-24d8-4def-85aa-dae5d9ea37fc">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_bed2fda5-e147-43ee-9dc4-744834f9e5e1">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_8bea4781-37e6-4650-907d-cc7e64909a46">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_9307ed67-2525-454e-b194-f9cf431e0fa0">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_ce6b4e56-9bc1-4f4b-bc9d-b9ada0738468">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_acf2b768-839c-45c0-a0a4-3a986b71bdc8">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_550af773-d0b9-469a-a376-3cd5b5b19e4f">true</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_a88f4685-3073-444a-a240-9ff526ccdd29">true</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:DocumentFinStmtRestatementRecoveryAnalysisFlag
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_7e8881be-741d-4f8e-b7a8-25e142099168">false</dei:DocumentFinStmtRestatementRecoveryAnalysisFlag>
    <dei:EntityShellCompany
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_9ac0cabd-b1b9-4c1e-a76f-5d0afd5dfb9d">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_f8c4b477-a573-4a64-a72d-9223363b6d20"
      decimals="-5"
      id="F_6e2f0da3-86ca-4e86-93d2-c54ba5ae626a"
      unitRef="U_USD">2946200000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_bc5911cd-b1ff-4b0f-a581-4c001670e9a5"
      decimals="INF"
      id="F_fa70130d-93be-49b6-9798-b48076e7bae5"
      unitRef="U_shares">76542811</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_2a97915a-bd1d-4dc6-b239-d45a6dee0ead">&lt;p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Portions of the Registrant&#x2019;s Definitive Proxy Statement relating to the 2024 Annual Meeting of Shareholders, which will be filed with the Securities and Exchange Commission subsequent to the date hereof, are incorporated by reference into Part III of this Report. Such Proxy Statement will be filed with the Securities and Exchange Commission not later than 120 days following the end of the Registrant&#x2019;s fiscal year ended December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_919e3f4b-d556-4860-b9ed-0c8731417db5">85</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_33485b29-5e99-4fbd-a1fa-62a77acc7429">KPMG LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_b825c2a0-2c70-4cc5-bfaf-12fd5afd5e1a">Vancouver, BC, Canada</dei:AuditorLocation>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_cc934457-1a83-43cf-9428-e626356b09b5">&lt;p id="item_1c_cybersecurity" style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Item 1C. Cybers&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ecurity&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We rely on both internal information technology systems and networks, and those of third-party vendors and contractors, to acquire, transmit, store and otherwise process information in connection with our business activities. Our ability to effectively manage our business depends on the security, reliability and adequacy of our and our third-party contractors&#x2019; and vendors&#x2019; technology systems. As such, we have implemented an information security program designed to identify, assess, and manage risks from cybersecurity threats.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We perform risk assessments relating to cybersecurity and technology risks at least annually. Our cybersecurity risk management program has been developed based on industry standards, including those published by the National Institute of Standards and Technology (&#x201c;NIST&#x201d;). Highlights of the program include:&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Corporate policies and procedures that guide our use of information systems, confidentiality and security strategy;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Identifying critical assets and high-risk threats, and implementing technical prevention and detection controls and response and recovery practices;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A third-party risk management process to assist in making risk-informed technology product and services decisions on third parties&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; who provide, manage, store or have access to material data or information, including the completion of security questionnaires and independent assessments of controls, audits and/or contract terms;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Defined data loss &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;prevention standards in place to detect and prevent data loss, including requiring third-party service providers with access to personal, confidential or proprietary information to implement and maintain comprehensive cybersecurity practices consistent with applicable legal standards and industry best practices&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Security awareness training for employees to identify cybersecurity concerns and take appropriate actions; and&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Evaluating our program&#x2019;s effectiveness by performing regular internal and third-party assessments of our controls, including external penetration testing and consultation on security enhancements.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Risks identified through our cybersecurity program are assessed to determine the potential impact and likelihood of occurrence and mitigation plans are developed and implemented accordingly.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Audit Committee of our Board of Directors bears the primary responsibility for oversight of cybersecurity risks. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Audit Committee is composed of board members with diverse expertise, including risk management, technology and finance, equipping them to oversee cybersecurity risks effectively.&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Management&#x2019;s oversight is performed through an IT Strategy Committee, a subset of executive management including our Chief Financial Officer, or CFO, and Chief Legal Officer, and relevant functional expertise, including our Senior Vice President, Information Systems, or SVP, IS. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our SVP, IS, is the primary member of the IT Steering Committee charged with responsibility for assessing, monitoring and managing our cybersecurity risks&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;With over 20 years of experience in information technology strategy and operations, his background includes extensive experience as an IT executive at various companies.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;At least annually, the SVP, IS, and the CFO provide a comprehensive report to the Audit Committee regarding cybersecurity risk assessments, planned enhancements to our cyber security program&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, and incident reports and remediation, if any&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The SVP, IS, oversees processes for the regular monitoring of our information systems, including potential vulnerabilities. In the event of a cybersecurity incident, the IT organization and designated members of executive management follow an established Cybersecurity Incident Response Plan. This plan includes immediate actions to contain the threat, mitigate the impact and assess materiality, and requires retrospective review and identification of corrective actions to reduce future risk.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;During the fiscal year ended December 31, 2024, we &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;did not experience any material impact&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; to our business, financial position or operations resulting from previously identified cyberattacks or other information security incidents, but we cannot provide assurance that they will not be materially affected in the future by such risks or any future material breaches. For a discussion of these risks, see &#x201c;Item 1A&#x2014;Risk Factors&#x2014;Risk Related to Our Business and Industry&#x2014;Our business and operations could suffer in the event of an actual or perceived information security incident such as a cybersecurity breach, system failure, or other compromise of our systems and/or information, including information held by a third-party contractor or vendor.&#x201d;&lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_6c9306dd-c4bb-4323-899d-270f3db50624">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_ea5608ee-c75f-4ebb-bb69-847f12eb41f6">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_6c2076fd-9b1a-4971-87bc-5e26dfc9d77e">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Audit Committee of our Board of Directors bears the primary responsibility for oversight of cybersecurity risks. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Audit Committee is composed of board members with diverse expertise, including risk management, technology and finance, equipping them to oversee cybersecurity risks effectively.&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Management&#x2019;s oversight is performed through an IT Strategy Committee, a subset of executive management including our Chief Financial Officer, or CFO, and Chief Legal Officer, and relevant functional expertise, including our Senior Vice President, Information Systems, or SVP, IS. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our SVP, IS, is the primary member of the IT Steering Committee charged with responsibility for assessing, monitoring and managing our cybersecurity risks&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;With over 20 years of experience in information technology strategy and operations, his background includes extensive experience as an IT executive at various companies.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;At least annually, the SVP, IS, and the CFO provide a comprehensive report to the Audit Committee regarding cybersecurity risk assessments, planned enhancements to our cyber security program&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, and incident reports and remediation, if any&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_f7174961-8f59-4616-bd1e-dc23e4e32335">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Audit Committee is composed of board members with diverse expertise, including risk management, technology and finance, equipping them to oversee cybersecurity risks effectively.&lt;/span&gt;</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_eff38539-a678-47f4-ba43-88d88d782e7b">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Management&#x2019;s oversight is performed through an IT Strategy Committee, a subset of executive management including our Chief Financial Officer, or CFO, and Chief Legal Officer, and relevant functional expertise, including our Senior Vice President, Information Systems, or SVP, IS. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our SVP, IS, is the primary member of the IT Steering Committee charged with responsibility for assessing, monitoring and managing our cybersecurity risks&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/span&gt;</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskRoleOfManagementTextBlock
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_ab575f10-394b-4e64-8f77-0da4c2e6307a">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Management&#x2019;s oversight is performed through an IT Strategy Committee, a subset of executive management including our Chief Financial Officer, or CFO, and Chief Legal Officer, and relevant functional expertise, including our Senior Vice President, Information Systems, or SVP, IS. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our SVP, IS, is the primary member of the IT Steering Committee charged with responsibility for assessing, monitoring and managing our cybersecurity risks&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;With over 20 years of experience in information technology strategy and operations, his background includes extensive experience as an IT executive at various companies.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;At least annually, the SVP, IS, and the CFO provide a comprehensive report to the Audit Committee regarding cybersecurity risk assessments, planned enhancements to our cyber security program&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, and incident reports and remediation, if any&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;</cyd:CybersecurityRiskRoleOfManagementTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_5f668af9-9a08-483a-835b-9bb496ea8c87">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag>
    <cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_2bda5c05-cbe8-4815-9e1a-7005413013d8">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;With over 20 years of experience in information technology strategy and operations, his background includes extensive experience as an IT executive at various companies.&lt;/span&gt;</cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock>
    <cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_cdc90510-c29d-4ceb-9f36-d4128908d53e">&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;At least annually, the SVP, IS, and the CFO provide a comprehensive report to the Audit Committee regarding cybersecurity risk assessments, planned enhancements to our cyber security program&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, and incident reports and remediation, if any&lt;/span&gt;</cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_faeafed5-4a62-4fb3-b543-44dc06d346fb">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_8b3a7573-839f-4af8-8188-283332f373e4">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <dei:AuditorOpinionTextBlock
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_ca0385dc-63d2-40fc-9ea3-2a230c4deaeb">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Opinion on the Consolidated Financial Statements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We have audited the accompanying consolidated balance sheets of Xenon Pharmaceuticals Inc. (the Company) as of December 31, 2024 and 2023, the related consolidated statements of operations and comprehensive loss, shareholders&#x2019; equity, and cash flows for each of the years in the three-year period ended December 31, 2024 and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the years in the three-year period ended December 31, 2024, in conformity with U.S. generally accepted accounting principles.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company&#x2019;s internal control over financial reporting as of December 31, 2024, based on criteria established in &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Internal Control &#x2013; Integrated Framework (2013)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; issued by the Committee of Sponsoring Organizations of the Treadway Commission, and our report dated February 27, 2025 expressed an unqualified opinion on the effectiveness of the Company&#x2019;s internal control over financial reporting.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</dei:AuditorOpinionTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f"
      decimals="-3"
      id="F_6dc39787-7119-4c1b-8849-b2511c38b97d"
      unitRef="U_USD">142712000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35"
      decimals="-3"
      id="F_2eeceed8-6ac3-4f4c-a59e-9a050aabb107"
      unitRef="U_USD">148643000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f"
      decimals="-3"
      id="F_acd9d3a0-222d-4d0d-ae84-25d00c5ac69a"
      unitRef="U_USD">484193000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35"
      decimals="-3"
      id="F_5c848739-67f8-4716-a1ae-1038bcfffd2f"
      unitRef="U_USD">489439000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f"
      decimals="-3"
      id="F_13d86e32-9138-42d4-94f3-cef415f1e138"
      unitRef="U_USD">1469000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35"
      decimals="-3"
      id="F_4850a452-bf2e-4dea-844a-7ef7549eaadf"
      unitRef="U_USD">874000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f"
      decimals="-3"
      id="F_9a15be7a-bfba-45b2-ba25-52336e6fa9b4"
      unitRef="U_USD">6890000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35"
      decimals="-3"
      id="F_f6e1fb00-cc45-43d8-9bae-b5261e70f4c9"
      unitRef="U_USD">6006000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f"
      decimals="-3"
      id="F_7d554c63-57b9-45bc-b32d-b6bd78b54edd"
      unitRef="U_USD">635264000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35"
      decimals="-3"
      id="F_6057e138-69aa-4d28-8b69-5a9a793b0a3b"
      unitRef="U_USD">644962000</us-gaap:AssetsCurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f"
      decimals="-3"
      id="F_7715a948-882b-4e3b-8e22-9f7c2128638e"
      unitRef="U_USD">127496000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35"
      decimals="-3"
      id="F_cac65d7d-f527-4d9f-9c56-945f974a56b4"
      unitRef="U_USD">292792000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f"
      decimals="-3"
      id="F_2a3f25d2-1604-43d5-927d-8036c4c699fa"
      unitRef="U_USD">7939000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35"
      decimals="-3"
      id="F_b5a9fd1b-c0c4-439d-a15e-5396e3c2baed"
      unitRef="U_USD">9193000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f"
      decimals="-3"
      id="F_fad3bebc-47f1-4978-a771-a91aa792cdca"
      unitRef="U_USD">10278000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35"
      decimals="-3"
      id="F_da28435d-1cfa-4731-b463-7eec094fdb8d"
      unitRef="U_USD">9653000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f"
      decimals="-3"
      id="F_9909017d-a6a9-4796-a382-2831e9f0721e"
      unitRef="U_USD">9666000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35"
      decimals="-3"
      id="F_472e70d0-959d-4b08-9d23-8934d3ae1fda"
      unitRef="U_USD">802000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:PrepaidExpenseNoncurrent
      contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f"
      decimals="-3"
      id="F_b611f19c-8d7f-4125-87bc-483311402689"
      unitRef="U_USD">7496000</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:PrepaidExpenseNoncurrent
      contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35"
      decimals="-3"
      id="F_501d86e1-d1ea-467c-8fdb-d00b47881337"
      unitRef="U_USD">7396000</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:Assets
      contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f"
      decimals="-3"
      id="F_d07904b0-a91d-4fdc-9edf-2dc84fa1334e"
      unitRef="U_USD">798139000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35"
      decimals="-3"
      id="F_1547721e-f5a6-40e2-9542-9927e2a4f3b3"
      unitRef="U_USD">964798000</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f"
      decimals="-3"
      id="F_b13924f3-670e-4b60-9a09-0e0620f619be"
      unitRef="U_USD">34221000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35"
      decimals="-3"
      id="F_2595d4cb-9e26-49df-929c-75d9ad58b5c9"
      unitRef="U_USD">25974000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f"
      decimals="-3"
      id="F_e98f47d9-2136-41e3-92ec-6c5e2f91312f"
      unitRef="U_USD">1369000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35"
      decimals="-3"
      id="F_5f80e307-1937-4716-a562-f7facfeb9e04"
      unitRef="U_USD">1299000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f"
      decimals="-3"
      id="F_10961cbe-8588-48fc-941d-d88ca42c41ba"
      unitRef="U_USD">35590000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35"
      decimals="-3"
      id="F_73c988fd-fa80-4796-922c-541681a0ac61"
      unitRef="U_USD">27273000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f"
      decimals="-3"
      id="F_69675a05-1880-42f0-bc7c-28f2d56e376b"
      unitRef="U_USD">7646000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35"
      decimals="-3"
      id="F_2612ac4a-6943-43fb-abd7-0af76fee12cb"
      unitRef="U_USD">9604000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f"
      decimals="-3"
      id="F_2f066d07-9eb7-4f32-96f4-5539b105968c"
      unitRef="U_USD">43236000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35"
      decimals="-3"
      id="F_9a3f768d-3450-4800-bdd3-cfe662b26bdc"
      unitRef="U_USD">36877000</us-gaap:Liabilities>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f"
      decimals="INF"
      id="F_385dd1e2-fbba-4c8d-8780-59529df01316"
      unitRef="U_shares">76416086</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f"
      decimals="INF"
      id="F_55558247-ace0-4409-a269-b246de2be885"
      unitRef="U_shares">76416086</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35"
      decimals="INF"
      id="F_b696a4ac-c742-4b5a-880d-0b59c201ffaf"
      unitRef="U_shares">75370977</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35"
      decimals="INF"
      id="F_52d162be-b94e-4876-a874-ea391dacfe35"
      unitRef="U_shares">75370977</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f"
      decimals="-3"
      id="F_a1a545e7-ae7b-46b1-bc7c-6cb3d00a5f9f"
      unitRef="U_USD">1456836000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35"
      decimals="-3"
      id="F_fae97182-1420-46d5-9da3-fa5f1b08ef6e"
      unitRef="U_USD">1436374000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f"
      decimals="-3"
      id="F_c396720c-9803-44a7-9054-c8f1908b54a9"
      unitRef="U_USD">199149000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35"
      decimals="-3"
      id="F_0288a900-9516-4361-b55e-25c5ceb73436"
      unitRef="U_USD">156764000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f"
      decimals="-3"
      id="F_486287c4-ea82-4928-9f66-89cd8cd6d2be"
      unitRef="U_USD">-899470000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35"
      decimals="-3"
      id="F_274ddab6-698d-484c-8ae1-8317d59f47d3"
      unitRef="U_USD">-665140000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f"
      decimals="-3"
      id="F_867527ff-8595-43d5-8d1e-eef739a2c324"
      unitRef="U_USD">-1612000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35"
      decimals="-3"
      id="F_484e5f92-8b80-447b-b6dd-f99ee7462376"
      unitRef="U_USD">-77000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f"
      decimals="-3"
      id="F_48d7464d-bebf-40d7-ac43-619a11fddf38"
      unitRef="U_USD">754903000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35"
      decimals="-3"
      id="F_92f91707-55d0-4f96-a3c3-8fc5596e7373"
      unitRef="U_USD">927921000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f"
      decimals="-3"
      id="F_835ea991-7ed5-44cb-9336-8104afba589a"
      unitRef="U_USD">798139000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35"
      decimals="-3"
      id="F_b3bb91d3-875c-4df2-9e31-c48f68a7f50f"
      unitRef="U_USD">964798000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="-3"
      id="F_447fc576-8309-411e-bc94-bc8bbf27fd11"
      unitRef="U_USD">9434000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="-3"
      id="F_e5c8384a-c78a-4a2e-bc5d-547c5b8cad53"
      unitRef="U_USD">210394000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="-3"
      id="F_7a38c236-f556-415f-9e46-5528b3e39735"
      unitRef="U_USD">167512000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="-3"
      id="F_85bcf776-c4dd-4235-9e76-e46ab8ac6e43"
      unitRef="U_USD">105767000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="-3"
      id="F_46438c6a-9e87-49e0-8929-e5c58d99686b"
      unitRef="U_USD">68904000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="-3"
      id="F_40115b69-e8b6-4f5f-b72e-a775b4be7c7c"
      unitRef="U_USD">46542000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="-3"
      id="F_da2e7173-36b6-47b0-ad26-2ff006bceafe"
      unitRef="U_USD">32810000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="-3"
      id="F_c209dec3-166d-4257-a830-32adf9ecf15a"
      unitRef="U_USD">279298000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="-3"
      id="F_75a2e4a7-a01d-4d54-9f77-7c96c7eaa230"
      unitRef="U_USD">214054000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="-3"
      id="F_f695f82f-d796-44e1-a7b0-d597843469d5"
      unitRef="U_USD">138577000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="-3"
      id="F_78b07f53-1579-4777-bbc8-c559555cb56c"
      unitRef="U_USD">-279298000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="-3"
      id="F_93c3d00b-f953-448d-83e7-77634fb74ebd"
      unitRef="U_USD">-214054000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="-3"
      id="F_b1273147-6de5-43cf-a696-1f98d61a1abb"
      unitRef="U_USD">-129143000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="-3"
      id="F_62280b6a-692f-4d51-aba9-f77e2988b43b"
      unitRef="U_USD">41943000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="-3"
      id="F_8fe97750-3a79-48e6-aed0-db7f6400c766"
      unitRef="U_USD">27620000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="-3"
      id="F_1fd4a085-544c-4e49-8bb7-f703ac2d4a2d"
      unitRef="U_USD">8713000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:DebtSecuritiesTradingUnrealizedGainLoss
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="-3"
      id="F_b1268a37-8104-44c9-8f6c-2ca1b74f669b"
      unitRef="U_USD">3550000</us-gaap:DebtSecuritiesTradingUnrealizedGainLoss>
    <us-gaap:DebtSecuritiesTradingUnrealizedGainLoss
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="-3"
      id="F_da4a3182-fdec-4ef2-b85f-cef4ef8c6651"
      unitRef="U_USD">-2934000</us-gaap:DebtSecuritiesTradingUnrealizedGainLoss>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="-3"
      id="F_279fa379-edeb-438f-adc1-7c9bed1e61f4"
      unitRef="U_USD">-1064000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="-3"
      id="F_cfbd39e6-51d3-4a9d-b7ef-6fb4c6ae96ee"
      unitRef="U_USD">199000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="-3"
      id="F_c80b2901-cfad-48b3-b155-7d890e247e37"
      unitRef="U_USD">-1891000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="-3"
      id="F_9c58b7d1-fafe-4cb3-ad5c-6a4213187cb5"
      unitRef="U_USD">40879000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="-3"
      id="F_66839f2a-d7f3-4b3d-a6d7-9960d976d8b4"
      unitRef="U_USD">31369000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="-3"
      id="F_e30b69d4-e1a3-4c2b-80ef-2587d16627c5"
      unitRef="U_USD">3888000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="-3"
      id="F_52fc254e-982c-4f33-b015-87b866eb88f6"
      unitRef="U_USD">-238419000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="-3"
      id="F_b6f70fe5-f9c9-4768-b162-2fbe2a9340b4"
      unitRef="U_USD">-182685000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="-3"
      id="F_28c85c2d-b1e2-45a4-9864-b43d4358a3a5"
      unitRef="U_USD">-125255000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="-3"
      id="F_eb45b234-0131-4d1a-a9eb-f548c0b228ef"
      unitRef="U_USD">-4089000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="-3"
      id="F_1e138eed-5ee7-498c-a491-7507fa01e9e1"
      unitRef="U_USD">-292000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="-3"
      id="F_6d7819fc-e6bb-42e0-bb56-385f910ffc90"
      unitRef="U_USD">118000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="-3"
      id="F_bc79b445-3b03-4399-aa35-58fa3b665726"
      unitRef="U_USD">-234330000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="-3"
      id="F_72a498d1-eca6-48f2-a851-b2da900c44ef"
      unitRef="U_USD">-182393000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="-3"
      id="F_4631a160-7e6f-44e6-b9f8-71e4f979ade2"
      unitRef="U_USD">-125373000</us-gaap:NetIncomeLoss>
    <xene:NetIncomeLossAvailableToPreferredStockholdersBasic
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="-3"
      id="F_b4e6f264-4f4f-49a5-beca-0e18dde4c948"
      unitRef="U_USD">437000</xene:NetIncomeLossAvailableToPreferredStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="-3"
      id="F_5149dd99-68e3-475c-8e8c-417aad9e2cdc"
      unitRef="U_USD">-234330000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="-3"
      id="F_19d9d7ed-c593-478b-a9cd-b764823a5349"
      unitRef="U_USD">-182393000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="-3"
      id="F_64368606-c249-4e8c-a802-aff11e4649c0"
      unitRef="U_USD">-124936000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="-3"
      id="F_26bb6b0b-606d-4376-a702-b274bfca57de"
      unitRef="U_USD">-1535000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="-3"
      id="F_1b432161-bcaf-4c5b-be5f-fdad3e2b5351"
      unitRef="U_USD">2923000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="-3"
      id="F_a73f2f29-75a1-4079-8fe5-8738296373e5"
      unitRef="U_USD">-2010000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="-3"
      id="F_6b2bedad-0e88-4d40-870f-b0e946109ece"
      unitRef="U_USD">-235865000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="-3"
      id="F_3b4b66e6-85c0-4002-8de9-d082c8279c4c"
      unitRef="U_USD">-179470000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="-3"
      id="F_88c7167e-391c-4bb5-8fe8-29a9af457af3"
      unitRef="U_USD">-127383000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="2"
      id="F_50950cc1-f474-439d-8a87-8ccaaef085a0"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-3.01</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="2"
      id="F_b99f121c-5216-412b-b3e9-6541c3345ddf"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-3.01</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="2"
      id="F_08153874-c4d7-4f03-9e1b-b0bf7f632bf6"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.73</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="2"
      id="F_45a793b9-8030-4fab-b6b0-e30d0de4997a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.73</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="2"
      id="F_0dd87bab-b074-4242-a8e9-fe14c68875d2"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.06</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="2"
      id="F_358ef9c6-eae6-43e5-81d3-d38ccd8b3a0c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.06</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="INF"
      id="F_32b7928e-0220-4b0e-9957-ba5371524862"
      unitRef="U_shares">77894643</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="INF"
      id="F_2a7a383d-32ee-4f8f-a468-2cecc1004c4f"
      unitRef="U_shares">77894643</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="INF"
      id="F_de236e4e-8ead-4f06-84de-0f78fe95b0ef"
      unitRef="U_shares">66889005</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="INF"
      id="F_8a8a6e1e-f940-4034-abcb-38a7312382ef"
      unitRef="U_shares">66889005</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="INF"
      id="F_88133d6e-d7fe-4125-8ca9-27294dcdb1cb"
      unitRef="U_shares">60542142</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="INF"
      id="F_06672432-87a1-41cf-9ce1-45319b57b381"
      unitRef="U_shares">60542142</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding
      contextRef="C_c36523e7-e5b9-4c2d-b6c3-bb9552e83dbd"
      decimals="INF"
      id="F_d8aa7f8d-1a7e-4649-bc01-ad3546d75285"
      unitRef="U_shares">1016000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_c36523e7-e5b9-4c2d-b6c3-bb9552e83dbd"
      decimals="-3"
      id="F_0389c95b-9053-4a53-ab15-36026fbc56d8"
      unitRef="U_USD">7732000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="C_0cd8e1e9-eb16-4592-8338-e8cd60e3e9b2"
      decimals="INF"
      id="F_a1c10987-d136-49e9-89aa-4b13a412531f"
      unitRef="U_shares">51634752</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0cd8e1e9-eb16-4592-8338-e8cd60e3e9b2"
      decimals="-3"
      id="F_f5415eab-6f29-43b8-9237-fd6eedd0682f"
      unitRef="U_USD">783170000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_286fc5c3-6fd1-4b6d-bd7e-b335add2e3e5"
      decimals="-3"
      id="F_d222a03d-1d2f-4afd-82ca-91039bc3f86a"
      unitRef="U_USD">117495000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_8fa80a4b-d219-444e-a4d3-dce7bd9ccd8b"
      decimals="-3"
      id="F_71bd3815-9f16-4cd7-a027-d1533faa05d6"
      unitRef="U_USD">-357374000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_8f26e8bc-db97-43e5-8f12-99b79372a387"
      decimals="-3"
      id="F_e99f6e07-b014-4f6a-bb72-b07c91935d0a"
      unitRef="U_USD">-990000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_7bc29ce6-ec8e-46b1-9da8-77d97bcac7c2"
      decimals="-3"
      id="F_a9123e52-2ef9-407f-9281-17ef3888293b"
      unitRef="U_USD">550033000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="C_d2815981-23d1-4abc-9bb7-2d642884bbe6"
      decimals="-3"
      id="F_c1aab079-c492-4b5b-bb14-aa9984f25fba"
      unitRef="U_USD">-125373000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="-3"
      id="F_fe47ff74-51f6-43c2-bf2a-d82ba3527c80"
      unitRef="U_USD">-125373000</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_6cf3e3b1-576f-40f1-acd3-00e00c79c90c"
      decimals="INF"
      id="F_144d5004-b099-45a0-9028-04ff810c7d50"
      unitRef="U_shares">9357348</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_6cf3e3b1-576f-40f1-acd3-00e00c79c90c"
      decimals="-3"
      id="F_865b0f4b-0f51-4675-8001-9c990f00f103"
      unitRef="U_USD">268379000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_9dc51c40-1728-4dc4-81a5-109cda1ab80c"
      decimals="-3"
      id="F_ed991982-9fba-4db1-bdcf-f504ebd4a97f"
      unitRef="U_USD">9387000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="-3"
      id="F_7bde4560-4c9f-4ff7-a8fd-0243e0ceaa56"
      unitRef="U_USD">277766000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_9887e0d2-0944-45f8-8ebe-b8362c753b06"
      decimals="INF"
      id="F_3f11fb99-4527-4f24-842c-0350ca7ab545"
      unitRef="U_shares">-1016000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="C_9887e0d2-0944-45f8-8ebe-b8362c753b06"
      decimals="-3"
      id="F_9159e801-48b9-4400-8bb3-f78bc1336ec0"
      unitRef="U_USD">-7732000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_6cf3e3b1-576f-40f1-acd3-00e00c79c90c"
      decimals="INF"
      id="F_4e3a9af1-8806-429f-a489-6e27d6af4a50"
      unitRef="U_shares">1016000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="C_6cf3e3b1-576f-40f1-acd3-00e00c79c90c"
      decimals="-3"
      id="F_0252277c-3612-42fd-9054-933e2fad4f15"
      unitRef="U_USD">7732000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="C_9dc51c40-1728-4dc4-81a5-109cda1ab80c"
      decimals="-3"
      id="F_294d37ce-a3ac-4c90-a307-d56509671652"
      unitRef="U_USD">20376000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="-3"
      id="F_bffa6b73-2cb4-4adc-af54-31a510e23031"
      unitRef="U_USD">20376000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_6cf3e3b1-576f-40f1-acd3-00e00c79c90c"
      decimals="INF"
      id="F_fe9e7f7e-8184-4a99-aebf-490ebb3645b2"
      unitRef="U_shares">579601</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_6cf3e3b1-576f-40f1-acd3-00e00c79c90c"
      decimals="-3"
      id="F_85cb7d2a-553b-4878-9cd8-d16fa015b599"
      unitRef="U_USD">5855000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_9dc51c40-1728-4dc4-81a5-109cda1ab80c"
      decimals="-3"
      id="F_5e078531-a325-4177-be4f-4ad61ed8d3bb"
      unitRef="U_USD">-5150000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="-3"
      id="F_2dd5c129-3c4e-4a92-bb5c-b06a53ee0d75"
      unitRef="U_USD">705000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_809415c5-c3f1-437a-ba07-2d600eeb3db7"
      decimals="-3"
      id="F_1d7afd8a-1310-4f67-8535-2cc6096aa834"
      unitRef="U_USD">-2010000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="-3"
      id="F_f2bfc3d8-8605-4025-babf-e93f261f156f"
      unitRef="U_USD">-2010000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="C_3c658b98-b12a-46a6-99c1-797a10c45fb8"
      decimals="INF"
      id="F_e2b903a9-7e87-434b-bed5-c59a67503a98"
      unitRef="U_shares">62587701</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_3c658b98-b12a-46a6-99c1-797a10c45fb8"
      decimals="-3"
      id="F_ca1b9283-04bb-4fff-9afa-168d5b230e92"
      unitRef="U_USD">1065136000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_a9775569-4b1a-42fc-b962-e5d75b4877a4"
      decimals="-3"
      id="F_c9d3bce3-5f14-4771-97d9-f6b16fd717be"
      unitRef="U_USD">142108000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_44cf67e5-b119-4290-96d0-c01203738404"
      decimals="-3"
      id="F_aa7f04a2-94da-4d34-8d83-13cda5adb3f6"
      unitRef="U_USD">-482747000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_13ef935b-4e96-4f11-925b-9ffc59e4e262"
      decimals="-3"
      id="F_ce6d890e-0539-48d4-b5ec-779afd6b91ba"
      unitRef="U_USD">-3000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_959e7299-f8b2-49e1-8078-5dac2b5e2683"
      decimals="-3"
      id="F_30fa6019-eb62-4628-8d97-4ceab60c6615"
      unitRef="U_USD">721497000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="C_4d6ff41e-1e70-42b9-bd5c-6e5b839ec13f"
      decimals="-3"
      id="F_46400233-3975-4337-9106-ec1613aa5467"
      unitRef="U_USD">-182393000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="-3"
      id="F_d76fc319-87fc-443f-bd6a-616f0f555684"
      unitRef="U_USD">-182393000</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_b676a389-6e42-455f-9fad-4ecafdc8c411"
      decimals="INF"
      id="F_fc153deb-431d-4fc1-b3b5-af8a2ce9fada"
      unitRef="U_shares">10701842</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_b676a389-6e42-455f-9fad-4ecafdc8c411"
      decimals="-3"
      id="F_5f61eb2a-5e59-4349-bede-03b0f6069e48"
      unitRef="U_USD">330010000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_3a167406-79b6-4756-b860-23ced3e7666d"
      decimals="-3"
      id="F_b78cb211-7f1f-4f17-89ed-cf3ebc750a8f"
      unitRef="U_USD">23477000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="-3"
      id="F_3281de95-3365-4d72-b955-b2c66059539e"
      unitRef="U_USD">353487000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <xene:StockIssuedDuringPeriodSharesConversionOfPreFundedWarrant
      contextRef="C_b676a389-6e42-455f-9fad-4ecafdc8c411"
      decimals="INF"
      id="F_f7ce2daf-cdd2-404b-aa29-b9764bc6fffa"
      unitRef="U_shares">1700000</xene:StockIssuedDuringPeriodSharesConversionOfPreFundedWarrant>
    <xene:StockIssuedDuringPeriodValueConversionOfPreFundedWarrant
      contextRef="C_b676a389-6e42-455f-9fad-4ecafdc8c411"
      decimals="-3"
      id="F_33b3cb41-e41e-470c-9a37-4b6baa284c60"
      unitRef="U_USD">35913000</xene:StockIssuedDuringPeriodValueConversionOfPreFundedWarrant>
    <xene:StockIssuedDuringPeriodValueConversionOfPreFundedWarrant
      contextRef="C_3a167406-79b6-4756-b860-23ced3e7666d"
      decimals="-3"
      id="F_fc2a4f14-c610-458d-bb10-f72cd0e4a10c"
      unitRef="U_USD">-35913000</xene:StockIssuedDuringPeriodValueConversionOfPreFundedWarrant>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="C_3a167406-79b6-4756-b860-23ced3e7666d"
      decimals="-3"
      id="F_4528a618-75aa-4279-94f6-14966a1e8d9b"
      unitRef="U_USD">32372000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="-3"
      id="F_f1d5e415-7c3b-417f-a682-1e816b979f02"
      unitRef="U_USD">32372000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_b676a389-6e42-455f-9fad-4ecafdc8c411"
      decimals="INF"
      id="F_39a578fc-7313-43ea-8d1d-ec592ea406f1"
      unitRef="U_shares">381434</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_b676a389-6e42-455f-9fad-4ecafdc8c411"
      decimals="-3"
      id="F_5a7780ed-87b8-402d-b96e-77f2a7852448"
      unitRef="U_USD">5315000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_3a167406-79b6-4756-b860-23ced3e7666d"
      decimals="-3"
      id="F_38512282-4f68-471f-ab8e-3195a3a8ffb6"
      unitRef="U_USD">-5280000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="-3"
      id="F_cfa4ef8a-acf0-4d79-9b08-4bdc5043fbab"
      unitRef="U_USD">35000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_196d5f56-7bc1-4e8e-86d8-d5f88f81bbfa"
      decimals="-3"
      id="F_394d9e85-2acf-48e3-858f-e02cebc31aa0"
      unitRef="U_USD">2923000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="-3"
      id="F_621815bb-fd4b-4904-ba46-68c2a2094f44"
      unitRef="U_USD">2923000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="C_c6f61c40-d49e-48b0-81c2-ceb75830debe"
      decimals="INF"
      id="F_aa5a87dc-398f-4a20-b67d-90b1982f6656"
      unitRef="U_shares">75370977</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_c6f61c40-d49e-48b0-81c2-ceb75830debe"
      decimals="-3"
      id="F_908f3a51-2dea-4524-865c-7269aed4e0b7"
      unitRef="U_USD">1436374000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_f2b24689-5075-4df6-a2da-72c8837936dc"
      decimals="-3"
      id="F_0cab1014-f9c4-4635-99f1-54a42b91bf3b"
      unitRef="U_USD">156764000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_1747e417-b850-4047-ad97-74e446f3c37c"
      decimals="-3"
      id="F_61e41cd3-66b3-4f13-920f-973aa7c35e87"
      unitRef="U_USD">-665140000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_fc078d20-42fa-4250-b769-ef250cdd40e5"
      decimals="-3"
      id="F_202f1d2f-618d-4c36-95f3-590cb0de5dff"
      unitRef="U_USD">-77000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35"
      decimals="-3"
      id="F_094e2625-b20d-4123-84de-d608972c6fef"
      unitRef="U_USD">927921000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="C_870ddace-7d98-45a8-a1ed-2e57f3f089eb"
      decimals="-3"
      id="F_c087d726-8cc1-4ae1-9acf-eec729ffdf39"
      unitRef="U_USD">-234330000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="-3"
      id="F_c55fed37-7aa9-4ca1-9dd5-e08c72d4bee2"
      unitRef="U_USD">-234330000</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_a3786e8d-3a38-4f5f-915c-ad289a237b50"
      decimals="INF"
      id="F_ef8a891d-4a22-423e-be1d-83da98a7006c"
      unitRef="U_shares">310000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_a3786e8d-3a38-4f5f-915c-ad289a237b50"
      decimals="-3"
      id="F_ee317498-55da-4959-93df-4c043ccf6c5d"
      unitRef="U_USD">12083000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="-3"
      id="F_36092e08-3cae-421b-9457-0b2cba7dbba0"
      unitRef="U_USD">12083000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="C_d9305b94-dbef-4162-bdc8-5136220dcc47"
      decimals="-3"
      id="F_f992802e-6296-43c7-9d29-fac3e7aa9d91"
      unitRef="U_USD">50717000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="-3"
      id="F_dfd099a2-3b85-4d94-8375-abace29fbfa0"
      unitRef="U_USD">50717000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_a3786e8d-3a38-4f5f-915c-ad289a237b50"
      decimals="INF"
      id="F_3b951ef8-9665-4ff8-b90a-143ba9d75398"
      unitRef="U_shares">735109</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_a3786e8d-3a38-4f5f-915c-ad289a237b50"
      decimals="-3"
      id="F_2f4ba682-2848-4b1a-9310-c8ffbde371fc"
      unitRef="U_USD">8379000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_d9305b94-dbef-4162-bdc8-5136220dcc47"
      decimals="-3"
      id="F_674737da-e559-4a0b-a892-9ea241992b40"
      unitRef="U_USD">-8332000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="-3"
      id="F_06407877-7b3c-4686-b06e-34d7b22079f3"
      unitRef="U_USD">47000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_884f4d71-a8e8-44ee-82ca-8ef780dfaa13"
      decimals="-3"
      id="F_8661b83f-bf8c-45ba-88d1-dad29c962a66"
      unitRef="U_USD">-1535000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="-3"
      id="F_eb22dc9a-99e1-48ee-9faa-4a701689bc37"
      unitRef="U_USD">-1535000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="C_1a3df49e-e657-4eb0-a563-0c1b8605f4aa"
      decimals="INF"
      id="F_8d69a115-fc74-4df1-a849-b06cbc90629d"
      unitRef="U_shares">76416086</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_1a3df49e-e657-4eb0-a563-0c1b8605f4aa"
      decimals="-3"
      id="F_8302afa2-d470-44a7-af08-956a5a7ad3bc"
      unitRef="U_USD">1456836000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_4b115a6a-6683-4a17-b413-9e8bb98b7a0b"
      decimals="-3"
      id="F_17a9b201-d547-431c-927c-7321434aec3e"
      unitRef="U_USD">199149000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_1e9a793b-d120-4f40-8894-7ddb1de35191"
      decimals="-3"
      id="F_a6656241-11b5-4c57-b4a5-2f504a4bc03b"
      unitRef="U_USD">-899470000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_7ab2ed07-5dfe-432a-be61-bebc4c8597c5"
      decimals="-3"
      id="F_2cce1c7f-19f9-4140-8d79-4e2f536dd661"
      unitRef="U_USD">-1612000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f"
      decimals="-3"
      id="F_4e78c5ca-67ad-405f-b838-20638f64a459"
      unitRef="U_USD">754903000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="-3"
      id="F_e40e84b4-6681-4df5-929e-d4e0532a3c56"
      unitRef="U_USD">-234330000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="-3"
      id="F_4a6d56e2-412d-49a3-aa27-70918f161a68"
      unitRef="U_USD">-182393000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="-3"
      id="F_453a8117-ab6f-40d7-8bd2-23ebd73f6c03"
      unitRef="U_USD">-125373000</us-gaap:ProfitLoss>
    <xene:InterestReceivableAndAccretionOfDiscountsOnMarketableSecurities
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="-3"
      id="F_d83ea07a-39ae-4621-b9f3-1303fd6437ed"
      unitRef="U_USD">-816000</xene:InterestReceivableAndAccretionOfDiscountsOnMarketableSecurities>
    <xene:InterestReceivableAndAccretionOfDiscountsOnMarketableSecurities
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="-3"
      id="F_ddb8ab76-2150-45e0-b698-aa57af5070e3"
      unitRef="U_USD">5785000</xene:InterestReceivableAndAccretionOfDiscountsOnMarketableSecurities>
    <xene:InterestReceivableAndAccretionOfDiscountsOnMarketableSecurities
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="-3"
      id="F_66f77084-e2be-4710-a0c4-e902a06c23ac"
      unitRef="U_USD">2598000</xene:InterestReceivableAndAccretionOfDiscountsOnMarketableSecurities>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="-3"
      id="F_94141482-b19a-43eb-bf64-763fab10bb1e"
      unitRef="U_USD">2560000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="-3"
      id="F_866686ca-e387-44e5-bd20-e488a8ce6887"
      unitRef="U_USD">2061000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="-3"
      id="F_4f8dcad2-c816-4446-a183-515d4d460383"
      unitRef="U_USD">1405000</us-gaap:DepreciationAndAmortization>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="-3"
      id="F_48ab69c6-4d2e-4761-b7e9-47e6bf68da3f"
      unitRef="U_USD">1254000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="-3"
      id="F_47bfa0f2-60cb-47df-ba07-caa3d3853075"
      unitRef="U_USD">1213000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="-3"
      id="F_467745a6-8d55-4ba8-939d-a62fbeb7dc75"
      unitRef="U_USD">819000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="-3"
      id="F_7288b4ea-523b-4271-8385-60235e0a980d"
      unitRef="U_USD">-8864000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="-3"
      id="F_301af402-34d9-4774-a882-bd1e4b3d3987"
      unitRef="U_USD">-292000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="-3"
      id="F_83330ba2-c12b-42fd-9a3b-a7eaf6c4d9a3"
      unitRef="U_USD">-44000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:ShareBasedCompensation
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="-3"
      id="F_ce6bdf12-ff53-4966-ad74-14c0074a0f62"
      unitRef="U_USD">50717000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="-3"
      id="F_ac449ca6-904a-4080-a4ef-61c8e673ce69"
      unitRef="U_USD">32372000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="-3"
      id="F_d23d30ec-9a8d-4ec9-8648-50e798e7071e"
      unitRef="U_USD">20376000</us-gaap:ShareBasedCompensation>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="-3"
      id="F_639635c8-0ac8-4431-bd18-03cec099e2e8"
      unitRef="U_USD">-745000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="-3"
      id="F_11c381fb-5325-4da7-a15e-dfacc761e063"
      unitRef="U_USD">640000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="-3"
      id="F_a9bb7456-5417-4ba5-b438-9b8de388443a"
      unitRef="U_USD">-2729000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:DebtSecuritiesTradingUnrealizedGainLoss
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="-3"
      id="F_09e1d623-6e84-4658-821b-8297afee3fae"
      unitRef="U_USD">3550000</us-gaap:DebtSecuritiesTradingUnrealizedGainLoss>
    <us-gaap:DebtSecuritiesTradingUnrealizedGainLoss
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="-3"
      id="F_185b8f53-830d-4e8d-967e-5a0606840f5e"
      unitRef="U_USD">-2934000</us-gaap:DebtSecuritiesTradingUnrealizedGainLoss>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="-3"
      id="F_e3220857-4754-403d-8339-3b411cee0c67"
      unitRef="U_USD">614000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="-3"
      id="F_a51391e5-a6e9-49d0-8c74-94c6eda71eb4"
      unitRef="U_USD">-130000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="-3"
      id="F_dff3f36b-b5d4-4e20-9460-735c32c30294"
      unitRef="U_USD">-1757000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="-3"
      id="F_18c2fe85-e07b-4040-962a-b615dae2852e"
      unitRef="U_USD">984000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="-3"
      id="F_4ff1905b-24f0-4769-a6e0-9d618d780be3"
      unitRef="U_USD">-1574000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="-3"
      id="F_4cf4bc99-bbd0-4230-b733-615d89c6babf"
      unitRef="U_USD">10495000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="-3"
      id="F_ad428d46-feee-448f-9a39-f290fd6658a4"
      unitRef="U_USD">8531000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="-3"
      id="F_375fcfdb-312a-4408-9f32-fb8022029b35"
      unitRef="U_USD">3931000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="-3"
      id="F_a7d10099-a45d-4cfd-a578-802d26c6e5c1"
      unitRef="U_USD">8062000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="-3"
      id="F_2d67988f-b07d-48e1-8d0f-d4d5976d6669"
      unitRef="U_USD">-1220000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="-3"
      id="F_30247b71-2b4b-46a7-bd67-544fd6652939"
      unitRef="U_USD">267000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="-3"
      id="F_b4923755-cdb8-4fc7-9503-5ee34d2d6cd0"
      unitRef="U_USD">-600000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="-3"
      id="F_efd9307f-a3ac-4582-b3b0-28f494750a14"
      unitRef="U_USD">-181389000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="-3"
      id="F_1ba5df0a-bc2b-413d-bf6b-c2736cbe6ddc"
      unitRef="U_USD">-151112000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="-3"
      id="F_ee805c93-a8da-4408-aaae-9ce209b1e85a"
      unitRef="U_USD">-101028000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="-3"
      id="F_72be9a5f-bfaa-4007-8c59-02d2287ce9d4"
      unitRef="U_USD">3075000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="-3"
      id="F_2b75c44c-0b38-4e02-94b1-632668585a3d"
      unitRef="U_USD">5617000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="-3"
      id="F_0b6595c5-9bbc-4ba9-923c-b07efaafc402"
      unitRef="U_USD">2894000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="-3"
      id="F_86c7ef54-87b5-4255-9b93-b856589d7369"
      unitRef="U_USD">532268000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="-3"
      id="F_bc0238aa-1ff1-472b-b6fc-b8d61dddea91"
      unitRef="U_USD">793907000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="-3"
      id="F_5edbd239-b506-41f6-a678-98511c3176ef"
      unitRef="U_USD">551137000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="-3"
      id="F_b9a73644-02df-42d6-9102-be668b1221eb"
      unitRef="U_USD">700343000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="-3"
      id="F_59e0729a-e04a-4468-81c7-03b2d3c7b67a"
      unitRef="U_USD">688139000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="-3"
      id="F_e7a64e96-d080-41bd-aa98-318506a187e6"
      unitRef="U_USD">260626000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="-3"
      id="F_6599f4b4-9334-4a65-a562-a8875ef7eb90"
      unitRef="U_USD">165000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="-3"
      id="F_1e2b6583-565b-4bbf-922c-4cf671ac7ad5"
      unitRef="U_USD">-111385000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="-3"
      id="F_2be2ab21-4a54-45f2-b091-d8203c39ed18"
      unitRef="U_USD">-293405000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="-3"
      id="F_954f2858-3870-4edf-b9ba-43e5168373db"
      unitRef="U_USD">12083000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="-3"
      id="F_8133d723-44a2-40b3-8ea7-69767b8ce1f0"
      unitRef="U_USD">353487000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="-3"
      id="F_cafc83a8-bb3c-468b-a9c0-b2cf3b2a8c4e"
      unitRef="U_USD">277766000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="-3"
      id="F_257803d3-b705-489f-ab03-c615e530c570"
      unitRef="U_USD">47000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="-3"
      id="F_4ffde8b0-0451-4df5-8932-7c90979dae48"
      unitRef="U_USD">35000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="-3"
      id="F_bdff1d77-f378-4f90-9923-a40076318f1d"
      unitRef="U_USD">705000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="-3"
      id="F_53345580-9e6f-426a-bf8e-f5bcef31f147"
      unitRef="U_USD">12130000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="-3"
      id="F_8a4c0835-7376-4774-973d-c758b2a94dde"
      unitRef="U_USD">353522000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="-3"
      id="F_031d1f1d-3a20-45d3-87ad-b751bb52478d"
      unitRef="U_USD">278471000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="-3"
      id="F_0e82ab7e-6aa6-447c-a3a8-64c6790fcb8b"
      unitRef="U_USD">-1672000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="-3"
      id="F_b176baad-ca75-4d1e-9301-ceecc9e0a9e6"
      unitRef="U_USD">376000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="-3"
      id="F_9649d0f2-ed00-49c3-bae6-aacbd60385c9"
      unitRef="U_USD">-2484000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="-3"
      id="F_f4379bb2-4d49-4d2d-b524-a01d41bd53d5"
      unitRef="U_USD">-5931000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="-3"
      id="F_8ca89132-5030-46ff-9bac-5cee5c2ea9e3"
      unitRef="U_USD">91401000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="-3"
      id="F_768bd748-cad1-4b49-9501-9e8504420bad"
      unitRef="U_USD">-118446000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35"
      decimals="-3"
      id="F_8c8b2226-a3f2-4582-b94b-0a877aec5f12"
      unitRef="U_USD">148643000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_959e7299-f8b2-49e1-8078-5dac2b5e2683"
      decimals="-3"
      id="F_5b4f2d10-8d03-4304-80ec-fd08258a787d"
      unitRef="U_USD">57242000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_7bc29ce6-ec8e-46b1-9da8-77d97bcac7c2"
      decimals="-3"
      id="F_44b9adbf-4d80-43c8-8237-0c29623c2233"
      unitRef="U_USD">175688000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f"
      decimals="-3"
      id="F_de392aa8-ac3f-46cd-8fdd-cc7a3052fe34"
      unitRef="U_USD">142712000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35"
      decimals="-3"
      id="F_1c4bc058-1456-4dcf-b374-7a0f349d6be8"
      unitRef="U_USD">148643000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_959e7299-f8b2-49e1-8078-5dac2b5e2683"
      decimals="-3"
      id="F_f2475e74-5672-4add-a7a9-d4c636090f69"
      unitRef="U_USD">57242000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:OperatingLeasePayments
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="-3"
      id="F_2d5f0ca1-9aa8-4812-9e69-ceaabbba57cc"
      unitRef="U_USD">1672000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="-3"
      id="F_5b7e2872-11ce-44cf-91b7-644890bc18fe"
      unitRef="U_USD">1624000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="-3"
      id="F_3faecadf-0540-4269-9ffb-0c719c0375ef"
      unitRef="U_USD">919000</us-gaap:OperatingLeasePayments>
    <xene:CashReceivedForLeaseIncentives
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="-3"
      id="F_409c220b-adb9-4d50-a0b2-c59e4ddbfe7b"
      unitRef="U_USD">1489000</xene:CashReceivedForLeaseIncentives>
    <xene:FairValueOfStockOptionsExercisedOnCashlessBasis
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="-3"
      id="F_ecba1115-f0c6-45bf-86c9-6d237b3a43fb"
      unitRef="U_USD">8305000</xene:FairValueOfStockOptionsExercisedOnCashlessBasis>
    <xene:FairValueOfStockOptionsExercisedOnCashlessBasis
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="-3"
      id="F_c63746f7-07b6-4f00-a3dd-bddc84508d3d"
      unitRef="U_USD">5250000</xene:FairValueOfStockOptionsExercisedOnCashlessBasis>
    <xene:FairValueOfStockOptionsExercisedOnCashlessBasis
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="-3"
      id="F_7df17ace-2832-4763-b053-7e593c29d34e"
      unitRef="U_USD">4491000</xene:FairValueOfStockOptionsExercisedOnCashlessBasis>
    <xene:FairValueOfPreFundedWarrantsExercised
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="-3"
      id="F_e1dcc252-47db-42f6-b405-616575b38869"
      unitRef="U_USD">35913000</xene:FairValueOfPreFundedWarrantsExercised>
    <xene:PurchasesOfPropertyPlantAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="-3"
      id="F_1ee14c35-0b74-48fb-ba08-f18d53a073d4"
      unitRef="U_USD">391000</xene:PurchasesOfPropertyPlantAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="-3"
      id="F_d5896ef3-35e0-4bf2-987b-546d98b5f56f"
      unitRef="U_USD">3019000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_d08a4738-8de9-4baf-8cd4-f6fde5267b8c">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;1.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Nature of the business:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Xenon Pharmaceuticals Inc. (the &#x201c;Company&#x201d;), incorporated in 1996 under the predecessor to the Business Corporations Act (British Columbia) and continued federally in 2000 under the Canada Business Corporations Act, is a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing ion channel therapeutics for patients in need.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has incurred significant operating losses since inception. As of December 31, 2024, the Company had an accumulated deficit of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;899,470&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and a net loss of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;234,330&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for the year ended December 31, 2024. Management expects to continue to incur significant expenses in excess of revenue and to incur operating losses for the foreseeable future. To date, the Company has financed its operations primarily through the sale of equity securities, funding received from collaboration and license agreements, and debt financings.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Until such time as the Company can generate substantial product revenue, if ever, management expects to finance the Company&#x2019;s cash needs through a combination of collaboration agreements, equity and debt financings. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The continuation of research and development activities and the future commercialization of its products are dependent on the Company&#x2019;s ability to successfully raise additional funds when needed. It is not possible to predict either the outcome of future research and development programs or the Company&#x2019;s ability to continue to fund these programs in the future.&lt;/span&gt;&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f"
      decimals="-3"
      id="F_b058bb96-cc64-4ded-b96f-6e4e8a509f40"
      unitRef="U_USD">-899470000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:NetIncomeLoss
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="-3"
      id="F_9dc9a77b-c6e7-42eb-a0cf-90aee2767fa5"
      unitRef="U_USD">-234330000</us-gaap:NetIncomeLoss>
    <us-gaap:BasisOfAccounting
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_574be053-639d-4e8f-8935-1ee0635a9d11">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;2.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basis of presentation:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;These consolidated financial statements are presented in U.S. dollars and have been prepared in accordance with generally accepted accounting principles in the United States ("GAAP").&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has one wholly-owned subsidiary as of December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, Xenon Pharmaceuticals USA Inc., which was incorporated in Delaware on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 2, 2016&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;These consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All intercompany transactions and balances have been eliminated on consolidation. Certain information has been reclassified to conform with the financial presentation adopted for the current year.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Correction of prior period error&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;During the year ended December 31, 2024, the Company identified a presentation error related to the accretion of discounts on marketable securities, which was incorrectly presented within proceeds from marketable securities as part of net cash provided by (used in) investing activities in the consolidated statements of cash flows. As a result, a correction was made to the prior periods to reclassify the amount of accretion of discounts on marketable securities within net cash used in operating activities, resulting in an increase in net cash used in operating activities and a corresponding decrease in net cash used in investing activities for the years ended December 31, 2023 and 2022 of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,785&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,598&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, respectively, from the previously reported amounts. The Company evaluated the materiality of the presentation error, both quantitatively and qualitatively, and concluded it was not material to the consolidated financial statements for any prior period. These presentation changes had no effect on the previously reported consolidated balance sheets, consolidated statements of operations and comprehensive loss, or consolidated statements of shareholders&#x2019; equity.&lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfAccounting>
    <dei:EntityIncorporationDateOfIncorporation
      contextRef="C_b273b0da-ce99-4209-9b93-ffb50f246430"
      id="F_0ddfc50f-30f4-4f66-8085-88c8399645e3">2016-12-02</dei:EntityIncorporationDateOfIncorporation>
    <us-gaap:PriorPeriodReclassificationAdjustment
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="-3"
      id="F_c33c4fa4-8946-42f0-ad00-dc235f02f888"
      unitRef="U_USD">-5785000</us-gaap:PriorPeriodReclassificationAdjustment>
    <us-gaap:PriorPeriodReclassificationAdjustment
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="-3"
      id="F_c7c44499-b706-4a46-b48f-d1921e93680c"
      unitRef="U_USD">-2598000</us-gaap:PriorPeriodReclassificationAdjustment>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_846cbfe8-ebdc-46be-ab72-849c1ab163fe">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;3.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Significant accounting policies:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(a)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Use of estimates: &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant areas of estimates include, but are not limited to, revenue recognition including estimated timing of completion of performance obligations and the determination of stock-based compensation. These estimates and assumptions take into account historical and forward-looking factors that the Company believes are reasonable. Estimates and assumptions are reviewed quarterly. All revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(b)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cash and cash equivalents: &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents are highly liquid investments that are readily convertible into cash with terms to maturity of three months or less when acquired. Cash equivalents are recorded at cost plus accrued interest, which approximates the fair value.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(c)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Marketable securities: &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Marketable securities are debt securities with original maturities exceeding three months and accrue interest based on a fixed interest rate for the term. Effective July 1, 2022, the Company classifies its marketable securities as either trading securities or available-for-sale securities. Marketable securities are carried at fair value.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Fair value gains and losses for marketable securities classified as trading securities are recorded through the consolidated statement of operations. These securities are classified as current assets as the Company has the intent and ability to convert these securities into cash without penalty within the next 12 months.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Unrealized fair value gains and losses for marketable securities classified as available-for-sale are recorded through other comprehensive income (loss) in shareholders' equity. When the fair value of an available-for-sale security falls below the amortized cost basis, it is evaluated to determine if any of the decline in value is attributable to credit loss. Decreases in fair value attributable to credit loss are recorded directly to the consolidated statement of operations with a corresponding allowance for credit losses, limited to the amount that the fair value is less than the amortized cost basis. If the credit quality subsequently improves the allowance is reversed up to a maximum of the previously recorded credit losses. When the Company intends to sell an impaired available-for-sale security, or if it is more likely than not that the Company will be required to sell the security prior to recovering the amortized cost basis, the entire fair value adjustment will immediately be recognized in the consolidated statement of operations with no corresponding allowance for credit losses. Realized gains and losses and credit losses, if any, on available-for-sale securities are included in interest income, based on the specific identification method. Available-for-sale securities are also adjusted for amortization of premiums and accretion of discounts to maturity, with such amortization and accretion included within interest income. Available-for-sale securities with a remaining maturity date greater than one year are classified as non-current assets.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(d)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Intellectual property:&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The costs incurred in establishing and maintaining patents for intellectual property developed internally are expensed in the period incurred.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(e)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property, plant and equipment: &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property, plant and equipment are stated at cost less accumulated depreciation and/or accumulated impairment losses, if any. Repairs and maintenance costs, which do not improve or extend the life of the respective asset, are expensed in the period incurred. Upon retirement or sale, the cost of the disposed asset and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is recognized as a component of income or loss for the period.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property, plant and equipment are amortized over their estimated useful lives using the straight-line method based on the following rates:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:49.12%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.78%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:49.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Office furniture and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_47b3f612-5e00-48af-b88b-1d3d02b7448e;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Over the lesser of lease term or&lt;br/&gt;   estimated useful life&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(f)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Impairment of long-lived assets: &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company monitors its long-lived assets for indicators of impairment. If such indicators are present, the Company assesses the recoverability of affected assets by determining whether the carrying value of such assets is less than the sum of the undiscounted future cash flows of the assets. If such assets are found not to be recoverable, the Company measures the amount of such impairment by comparing the carrying value of the assets to the fair value of the assets, with the fair value generally determined based on the present value of the expected future cash flows associated with the assets. The Company did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t recognize any impairment charges through &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(g)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Leases:&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:9.2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company determines if an arrangement contains a lease at the inception of a contract. The lease classification is determined at lease commencement, which is the date the underlying asset is available for use by the Company. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Leases classified as operating leases are recorded as lease liabilities based on the present value of minimum lease payments over the lease term, discounted using the lessor&#x2019;s rate implicit in the lease or the Company&#x2019;s incremental borrowing rate, if the lessor&#x2019;s implicit rate is not readily determinable. The lease term includes all periods covered by renewal and termination options where the Company is reasonably certain to exercise the renewal options or not to exercise the termination options. Corresponding right-of-use assets are recognized consisting of the lease liabilities, initial direct costs and any lease incentive payments. Lease liabilities are drawn down as lease payments are made and right-of-use assets are depreciated over the term of the lease. Operating lease expenses are recognized on a straight-line basis over the term of the lease, consisting of interest accrued on the lease liability and depreciation of the right-of-use asset, adjusted for changes in index-based variable lease payments in the period of change. Lease payments on short-term operating leases with lease terms twelve months or less are expensed on a straight-line basis over the lease term. The Company has elected to not separate non-lease elements embedded in its lease agreements.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(h)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Concentration of credit risk: &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents and marketable securities. The Company's investments are limited to investment-grade securities with strong credit ratings with the objective to preserve capital and maintain liquidity. Cash and cash equivalents were held at major financial institutions in Canada and the United States which may at times be in excess of federally insured limits. The Company does not believe that it is subject to credit risk beyond the standard credit risk associated with commercial banking relationships.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(i)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Financial instruments and fair value: &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company measures certain financial instruments and other items at fair value.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;To determine the fair value, the Company uses the fair value hierarchy for inputs used to measure fair value of financial assets and liabilities. This hierarchy prioritizes the inputs to valuation techniques used to measure fair value into three levels: Level 1 (highest priority), Level 2, and Level 3 (lowest priority).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; - Unadjusted quoted prices in active markets for identical instruments.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates, yield curves, etc.), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs). &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; - Inputs are unobservable and reflect the Company&#x2019;s assumptions as to what market participants would use in pricing the asset or liability. The Company develops these inputs based on the best information available. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. Changes in the observability of valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy. The carrying amount of accounts receivable, accounts payable and accrued liabilities approximates fair value due to the nature and short-term of those instruments. The Company&#x2019;s cash and cash equivalents and marketable securities are measured at fair value on a recurring basis and the level of fair value hierarchy utilized is described in note 4.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(j)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Revenue recognition: &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company recognizes the amount of revenue to which it expects to be entitled, for the transfer of promised goods or  services to customers under a five-step model: (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when or as a performance obligation is satisfied. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Collaboration agreements may require the Company to deliver various rights and/or services, including intellectual property rights or licenses and research and development services. Under such collaboration agreements, the Company is generally eligible to receive non-refundable upfront payments, funding for research and development services, milestone payments, and royalties.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In contracts where the Company has more than one performance obligation to provide its customer with goods or services, each performance obligation is evaluated to determine whether it is distinct based on whether (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available and (ii) the good or service is separately identifiable from other promises in the contract. The consideration under the contract is then allocated between the distinct performance obligations based on their respective relative standalone selling prices. The estimated standalone selling price of each deliverable reflects the Company&#x2019;s best estimate of what the selling price would be if the deliverable was regularly sold on a standalone basis and is determined by reference to market rates for the good or service when sold to others or by using an adjusted market assessment approach if selling price on a standalone basis is not available.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The consideration allocated to each distinct performance obligation is recognized as revenue when control is transferred to the customer for the related goods or services. The Company generally recognizes revenue from non-refundable upfront payments over the estimated term of the performance obligation or period in which the underlying benefit is transferred to the customer. If non-refundable license fees have value to the customer on a standalone basis, separate from the undelivered performance obligations, they are recognized upon delivery. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. Consideration in exchange for research and development services performed by the Company on behalf of the licensee is recognized upon performance of such activities at rates consistent with prevailing market rates. Consideration associated with at-risk substantive performance milestones, including sales-based milestones, is recognized as revenue using the most likely amount method when it is probable that a significant reversal of the cumulative revenue recognized will not occur. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such milestones, and if necessary, adjusts its estimate of the overall transaction price. Sales-based royalties received in connection with licenses of intellectual property are subject to a specific exception in the revenue standards, whereby the consideration is not included in the transaction price and recognized in revenue until the customer&#x2019;s subsequent sales or usages occur.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(k)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Research and development costs: &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Research and development costs are expensed in the period incurred.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Research and development expenses consist of costs incurred in performing research and development activities, including personnel-related expenses, consisting of salaries, benefits and stock-based compensation for employees engaged in scientific research and development, third-party expenses incurred in connection with the pre-clinical and clinical development of product candidates including under agreements with clinical research organizations, third-party expenses relating to formulation, process development and  manufacture of drug substance and drug product for use in pre-clinical testing, clinical trials and potential commercial supply, third-party acquisition, license and collaboration fees, laboratory consumables and certain indirect costs incurred in support of overall research and development activities, including facilities, depreciation and information technology costs. The amount of expenses recognized in a period related to service agreements is based on the work performed using the accrual basis of accounting. Third-party service providers generally provide estimates of proportionate performance to allow the Company to determine an appropriate accrual. When determining the adequacy of an accrual, the Company analyzes progress based on the level of services performed, progress of the studies, including the phase or completion of events, and contracted costs. Payments made to third parties under these arrangements in advance of the receipt of the related services are recorded as prepaid expenses until the services are rendered. &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Prepaid expenses are classified as current or non-current assets based on the expected timing of services.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(l)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation: &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation expense is measured at the grant date, based on the estimated fair value of the award, and is recognized as an expense, net of actual forfeitures, over the requisite service period with a corresponding increase in additional paid-in capital.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company grants stock options to employees, consultants, directors and officers pursuant to equity incentive plans described in note 9c. Stock-based compensation expense for stock options is amortized on a straight-line basis over the requisite service period for the entire award, which is generally the vesting period of the award. Any consideration received on exercise of stock options is credited to share capital.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company grants performance share units (&#x201c;PSUs&#x201d;) to certain employees and officers pursuant to equity incentive plans described in note 9c. PSUs vest upon the achievement of certain predefined company-specific performance-based criteria. PSUs are measured at the c&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;losing market price of the Company&#x2019;s common shares on the date of grant. Stock-based compensation expense for PSUs is amortized on a straight-line basis over the requisite service period of each separately vesting tranche of the award once it is probable that the performance condition will be achieved.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(m)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Foreign currency translation: &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The functional and reporting currency of the Company and its subsidiary is the U.S. dollar. Monetary assets and liabilities denominated in a currency other than the U.S. dollar are re-measured into U.S. dollars at the exchange rate prevailing as of the balance sheet date. Non-monetary assets and liabilities acquired in a currency other than U.S. dollars are translated at historical exchange rates prevailing at each transaction date.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Revenue and expense transactions ar&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;e translated at the approximate exchange rate prevailing on the date of transaction. Exchange gains and losses on translation are included in the consolidated statements of operations and comprehensive income (loss) as foreign exchange gain (loss).&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(n)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Income taxes: &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Deferred income taxes are recognized for the future tax consequences attributable to differences between the carrying amounts of assets and liabilities and their respective tax bases, net operating loss and tax credit carryforwards. Deferred income tax assets and liabilities are measured at enacted rates expected to apply to taxable income in the years in which those temporary differences and carryforwards are expected to be recovered or settled. The effect of a change in tax rates on deferred income tax assets and liabilities is recognized in the consolidated statement of operations and comprehensive income (loss) in the period that includes the enactment date. A valuation allowance is provided when realization of deferred income tax assets does not meet the more-likely-than-not criterion for recognition.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not to be sustained upon examination based on the technical merits of the position as well as consideration of the available facts and circumstances. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The interest accrued related to unrecognized tax benefits and penalties is recognized as income tax expense.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(o)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Net income (loss) per common share: &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basic net income (loss) per common share is calculated using the two-class method required for participating securities. Undistributed earnings (losses) are allocated to common shares and participating securities based on the weighted average shares of each class outstanding during the period.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The treasury stock method is used to compute the dilutive effect of the Company&#x2019;s stock options, PSUs and warrants. Under this method, the incremental number of common shares used in computing diluted net income (loss) per common share is the difference between the number of common shares assumed issued and purchased using assumed proceeds.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The if-converted method is used to compute the dilutive effect of the Company&#x2019;s convertible preferred shares. Under the if-converted method, dividends on the preferred shares, if applicable, are added back to earnings attributable to common shareholders, and the preferred shares and paid-in kind dividends are assumed to have been converted at the share price applicable at the end of the period. The if-converted method is applied only if the effect is dilutive.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(p)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Segment and geographic information: &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker (&#x201c;CODM&#x201d;), in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; operating segment discovering and developing a portfolio of treatments in neurological and psychiatric disorders.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(q)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Recently adopted accounting pronouncements:&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2023, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which enhances the disclosures required for operating segments on an interim and annual basis. The Company adopted this ASU in the fourth quarter of 2024 retrospectively to all prior periods presented in the consolidated financial statements. While the Company continues to operate as a single reportable segment, additional disclosures have been incorporated in note 14.&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(r)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accounting pronouncements not yet adopted: &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accounting standards that have been issued by the Financial Accounting Standards Board or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on our financial statements upon adoption.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_98dce005-8f8c-4c64-b13a-5474ea23b780">&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(a)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Use of estimates: &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant areas of estimates include, but are not limited to, revenue recognition including estimated timing of completion of performance obligations and the determination of stock-based compensation. These estimates and assumptions take into account historical and forward-looking factors that the Company believes are reasonable. Estimates and assumptions are reviewed quarterly. All revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_ecf100e2-7193-4969-8e77-b971815534d5">&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(b)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cash and cash equivalents: &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents are highly liquid investments that are readily convertible into cash with terms to maturity of three months or less when acquired. Cash equivalents are recorded at cost plus accrued interest, which approximates the fair value.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_7e615fd3-3e3f-46ae-8e6f-48616e48e3ad">&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(c)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Marketable securities: &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Marketable securities are debt securities with original maturities exceeding three months and accrue interest based on a fixed interest rate for the term. Effective July 1, 2022, the Company classifies its marketable securities as either trading securities or available-for-sale securities. Marketable securities are carried at fair value.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Fair value gains and losses for marketable securities classified as trading securities are recorded through the consolidated statement of operations. These securities are classified as current assets as the Company has the intent and ability to convert these securities into cash without penalty within the next 12 months.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Unrealized fair value gains and losses for marketable securities classified as available-for-sale are recorded through other comprehensive income (loss) in shareholders' equity. When the fair value of an available-for-sale security falls below the amortized cost basis, it is evaluated to determine if any of the decline in value is attributable to credit loss. Decreases in fair value attributable to credit loss are recorded directly to the consolidated statement of operations with a corresponding allowance for credit losses, limited to the amount that the fair value is less than the amortized cost basis. If the credit quality subsequently improves the allowance is reversed up to a maximum of the previously recorded credit losses. When the Company intends to sell an impaired available-for-sale security, or if it is more likely than not that the Company will be required to sell the security prior to recovering the amortized cost basis, the entire fair value adjustment will immediately be recognized in the consolidated statement of operations with no corresponding allowance for credit losses. Realized gains and losses and credit losses, if any, on available-for-sale securities are included in interest income, based on the specific identification method. Available-for-sale securities are also adjusted for amortization of premiums and accretion of discounts to maturity, with such amortization and accretion included within interest income. Available-for-sale securities with a remaining maturity date greater than one year are classified as non-current assets.&lt;/span&gt;&lt;/p&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:LegalCostsPolicyTextBlock
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_734a97ce-c5d4-4fa5-b394-7b9368f8d1c6">&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(d)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Intellectual property:&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The costs incurred in establishing and maintaining patents for intellectual property developed internally are expensed in the period incurred.&lt;/span&gt;&lt;/p&gt;</us-gaap:LegalCostsPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_03e4637c-1767-4d30-8df1-6527f61d5c6a">&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(e)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property, plant and equipment: &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property, plant and equipment are stated at cost less accumulated depreciation and/or accumulated impairment losses, if any. Repairs and maintenance costs, which do not improve or extend the life of the respective asset, are expensed in the period incurred. Upon retirement or sale, the cost of the disposed asset and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is recognized as a component of income or loss for the period.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property, plant and equipment are amortized over their estimated useful lives using the straight-line method based on the following rates:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:49.12%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.78%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:49.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Office furniture and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_47b3f612-5e00-48af-b88b-1d3d02b7448e;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Over the lesser of lease term or&lt;br/&gt;   estimated useful life&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <xene:ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_b6a3be30-8b06-40cb-9f66-6c500e2c1624">&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property, plant and equipment are amortized over their estimated useful lives using the straight-line method based on the following rates:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:49.12%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.78%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:49.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Office furniture and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_47b3f612-5e00-48af-b88b-1d3d02b7448e;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Over the lesser of lease term or&lt;br/&gt;   estimated useful life&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</xene:ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_01045051-1058-4f3f-b914-02cf2190b1d1"
      id="F_5b9f790a-11bf-47a4-8b6b-0d8b12c700c4">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_9e565a8f-9b0e-4173-a3a3-09356a71706a"
      id="F_e882a652-287d-4b6e-a262-5a439063ba03">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_31a54459-014b-4693-8a7e-9d5cd1d9fedb"
      id="F_55edf1a0-44de-4cb6-be88-8787b272dce4">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_0e7997c7-8d93-4cb1-8e4b-580f7890f6aa">&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(f)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Impairment of long-lived assets: &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company monitors its long-lived assets for indicators of impairment. If such indicators are present, the Company assesses the recoverability of affected assets by determining whether the carrying value of such assets is less than the sum of the undiscounted future cash flows of the assets. If such assets are found not to be recoverable, the Company measures the amount of such impairment by comparing the carrying value of the assets to the fair value of the assets, with the fair value generally determined based on the present value of the expected future cash flows associated with the assets. The Company did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t recognize any impairment charges through &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="INF"
      id="F_ce964814-00f1-4e91-86c5-21d6315a6231"
      unitRef="U_USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_d20dad3e-6481-4d96-878f-caa139b68dbb">&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(g)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Leases:&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:9.2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company determines if an arrangement contains a lease at the inception of a contract. The lease classification is determined at lease commencement, which is the date the underlying asset is available for use by the Company. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Leases classified as operating leases are recorded as lease liabilities based on the present value of minimum lease payments over the lease term, discounted using the lessor&#x2019;s rate implicit in the lease or the Company&#x2019;s incremental borrowing rate, if the lessor&#x2019;s implicit rate is not readily determinable. The lease term includes all periods covered by renewal and termination options where the Company is reasonably certain to exercise the renewal options or not to exercise the termination options. Corresponding right-of-use assets are recognized consisting of the lease liabilities, initial direct costs and any lease incentive payments. Lease liabilities are drawn down as lease payments are made and right-of-use assets are depreciated over the term of the lease. Operating lease expenses are recognized on a straight-line basis over the term of the lease, consisting of interest accrued on the lease liability and depreciation of the right-of-use asset, adjusted for changes in index-based variable lease payments in the period of change. Lease payments on short-term operating leases with lease terms twelve months or less are expensed on a straight-line basis over the lease term. The Company has elected to not separate non-lease elements embedded in its lease agreements.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_38a412cb-fdb7-4ae7-a3a2-cf2baead9a41">&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(h)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Concentration of credit risk: &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents and marketable securities. The Company's investments are limited to investment-grade securities with strong credit ratings with the objective to preserve capital and maintain liquidity. Cash and cash equivalents were held at major financial institutions in Canada and the United States which may at times be in excess of federally insured limits. The Company does not believe that it is subject to credit risk beyond the standard credit risk associated with commercial banking relationships.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_4142c5d0-78b3-4218-820a-3a405b81c821">&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(i)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Financial instruments and fair value: &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company measures certain financial instruments and other items at fair value.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;To determine the fair value, the Company uses the fair value hierarchy for inputs used to measure fair value of financial assets and liabilities. This hierarchy prioritizes the inputs to valuation techniques used to measure fair value into three levels: Level 1 (highest priority), Level 2, and Level 3 (lowest priority).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; - Unadjusted quoted prices in active markets for identical instruments.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates, yield curves, etc.), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs). &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; - Inputs are unobservable and reflect the Company&#x2019;s assumptions as to what market participants would use in pricing the asset or liability. The Company develops these inputs based on the best information available. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. Changes in the observability of valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy. The carrying amount of accounts receivable, accounts payable and accrued liabilities approximates fair value due to the nature and short-term of those instruments. The Company&#x2019;s cash and cash equivalents and marketable securities are measured at fair value on a recurring basis and the level of fair value hierarchy utilized is described in note 4.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_0d2dc80f-7197-4c62-a692-232c6c1ac643">&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(j)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Revenue recognition: &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company recognizes the amount of revenue to which it expects to be entitled, for the transfer of promised goods or  services to customers under a five-step model: (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when or as a performance obligation is satisfied. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Collaboration agreements may require the Company to deliver various rights and/or services, including intellectual property rights or licenses and research and development services. Under such collaboration agreements, the Company is generally eligible to receive non-refundable upfront payments, funding for research and development services, milestone payments, and royalties.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In contracts where the Company has more than one performance obligation to provide its customer with goods or services, each performance obligation is evaluated to determine whether it is distinct based on whether (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available and (ii) the good or service is separately identifiable from other promises in the contract. The consideration under the contract is then allocated between the distinct performance obligations based on their respective relative standalone selling prices. The estimated standalone selling price of each deliverable reflects the Company&#x2019;s best estimate of what the selling price would be if the deliverable was regularly sold on a standalone basis and is determined by reference to market rates for the good or service when sold to others or by using an adjusted market assessment approach if selling price on a standalone basis is not available.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The consideration allocated to each distinct performance obligation is recognized as revenue when control is transferred to the customer for the related goods or services. The Company generally recognizes revenue from non-refundable upfront payments over the estimated term of the performance obligation or period in which the underlying benefit is transferred to the customer. If non-refundable license fees have value to the customer on a standalone basis, separate from the undelivered performance obligations, they are recognized upon delivery. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. Consideration in exchange for research and development services performed by the Company on behalf of the licensee is recognized upon performance of such activities at rates consistent with prevailing market rates. Consideration associated with at-risk substantive performance milestones, including sales-based milestones, is recognized as revenue using the most likely amount method when it is probable that a significant reversal of the cumulative revenue recognized will not occur. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such milestones, and if necessary, adjusts its estimate of the overall transaction price. Sales-based royalties received in connection with licenses of intellectual property are subject to a specific exception in the revenue standards, whereby the consideration is not included in the transaction price and recognized in revenue until the customer&#x2019;s subsequent sales or usages occur.&lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_f67a358e-a476-46e0-b703-4e9f69687bf3">&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(k)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Research and development costs: &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Research and development costs are expensed in the period incurred.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Research and development expenses consist of costs incurred in performing research and development activities, including personnel-related expenses, consisting of salaries, benefits and stock-based compensation for employees engaged in scientific research and development, third-party expenses incurred in connection with the pre-clinical and clinical development of product candidates including under agreements with clinical research organizations, third-party expenses relating to formulation, process development and  manufacture of drug substance and drug product for use in pre-clinical testing, clinical trials and potential commercial supply, third-party acquisition, license and collaboration fees, laboratory consumables and certain indirect costs incurred in support of overall research and development activities, including facilities, depreciation and information technology costs. The amount of expenses recognized in a period related to service agreements is based on the work performed using the accrual basis of accounting. Third-party service providers generally provide estimates of proportionate performance to allow the Company to determine an appropriate accrual. When determining the adequacy of an accrual, the Company analyzes progress based on the level of services performed, progress of the studies, including the phase or completion of events, and contracted costs. Payments made to third parties under these arrangements in advance of the receipt of the related services are recorded as prepaid expenses until the services are rendered. &lt;/span&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_2694b3a8-575e-443c-a9c2-d1e48da7b6d7">&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(l)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation: &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation expense is measured at the grant date, based on the estimated fair value of the award, and is recognized as an expense, net of actual forfeitures, over the requisite service period with a corresponding increase in additional paid-in capital.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company grants stock options to employees, consultants, directors and officers pursuant to equity incentive plans described in note 9c. Stock-based compensation expense for stock options is amortized on a straight-line basis over the requisite service period for the entire award, which is generally the vesting period of the award. Any consideration received on exercise of stock options is credited to share capital.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company grants performance share units (&#x201c;PSUs&#x201d;) to certain employees and officers pursuant to equity incentive plans described in note 9c. PSUs vest upon the achievement of certain predefined company-specific performance-based criteria. PSUs are measured at the c&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;losing market price of the Company&#x2019;s common shares on the date of grant. Stock-based compensation expense for PSUs is amortized on a straight-line basis over the requisite service period of each separately vesting tranche of the award once it is probable that the performance condition will be achieved.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_7a558da2-e4f6-49f6-a361-4f030d6e0bc0">&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(m)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Foreign currency translation: &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The functional and reporting currency of the Company and its subsidiary is the U.S. dollar. Monetary assets and liabilities denominated in a currency other than the U.S. dollar are re-measured into U.S. dollars at the exchange rate prevailing as of the balance sheet date. Non-monetary assets and liabilities acquired in a currency other than U.S. dollars are translated at historical exchange rates prevailing at each transaction date.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Revenue and expense transactions ar&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;e translated at the approximate exchange rate prevailing on the date of transaction. Exchange gains and losses on translation are included in the consolidated statements of operations and comprehensive income (loss) as foreign exchange gain (loss).&lt;/span&gt;&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_6bf1da4a-63d9-4cb5-a326-4f5674c4e167">&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(n)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Income taxes: &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Deferred income taxes are recognized for the future tax consequences attributable to differences between the carrying amounts of assets and liabilities and their respective tax bases, net operating loss and tax credit carryforwards. Deferred income tax assets and liabilities are measured at enacted rates expected to apply to taxable income in the years in which those temporary differences and carryforwards are expected to be recovered or settled. The effect of a change in tax rates on deferred income tax assets and liabilities is recognized in the consolidated statement of operations and comprehensive income (loss) in the period that includes the enactment date. A valuation allowance is provided when realization of deferred income tax assets does not meet the more-likely-than-not criterion for recognition.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not to be sustained upon examination based on the technical merits of the position as well as consideration of the available facts and circumstances. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The interest accrued related to unrecognized tax benefits and penalties is recognized as income tax expense.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_2134ddd7-6f25-4eff-801c-379587bbee87">&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(o)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Net income (loss) per common share: &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basic net income (loss) per common share is calculated using the two-class method required for participating securities. Undistributed earnings (losses) are allocated to common shares and participating securities based on the weighted average shares of each class outstanding during the period.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The treasury stock method is used to compute the dilutive effect of the Company&#x2019;s stock options, PSUs and warrants. Under this method, the incremental number of common shares used in computing diluted net income (loss) per common share is the difference between the number of common shares assumed issued and purchased using assumed proceeds.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The if-converted method is used to compute the dilutive effect of the Company&#x2019;s convertible preferred shares. Under the if-converted method, dividends on the preferred shares, if applicable, are added back to earnings attributable to common shareholders, and the preferred shares and paid-in kind dividends are assumed to have been converted at the share price applicable at the end of the period. The if-converted method is applied only if the effect is dilutive.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_c4ae5410-02ca-48c9-93e8-a2a5c6816249">&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(p)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Segment and geographic information: &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker (&#x201c;CODM&#x201d;), in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; operating segment discovering and developing a portfolio of treatments in neurological and psychiatric disorders.&lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="INF"
      id="F_b70877bb-397a-426f-8c96-e744995b9eec"
      unitRef="U_Segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_c0bdf5e4-2f86-4c8b-9437-2e963ab96c43">&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(q)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Recently adopted accounting pronouncements:&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2023, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which enhances the disclosures required for operating segments on an interim and annual basis. The Company adopted this ASU in the fourth quarter of 2024 retrospectively to all prior periods presented in the consolidated financial statements. While the Company continues to operate as a single reportable segment, additional disclosures have been incorporated in note 14.&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(r)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accounting pronouncements not yet adopted: &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accounting standards that have been issued by the Financial Accounting Standards Board or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on our financial statements upon adoption.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_e82e0947-a3ee-4dd4-a283-c9e084e5167c">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;4.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Fair value of financial instruments:&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The level of the fair value hierarchy utilized to determine the fair va&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;lue of cash and cash equivalents and marketable securities consisted of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:25.615%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:5.9990000000000006%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:5.9990000000000006%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:5.9990000000000006%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:5.9990000000000006%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:5.9990000000000006%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:5.9990000000000006%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:5.9990000000000006%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:5.9990000000000006%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash and money market fund&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;142,712&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;142,712&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;148,643&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;148,643&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Guaranteed investment certificates&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,147&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,147&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,684&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,684&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. treasuries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;130,948&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;130,948&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;252,982&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;252,982&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;97,912&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;97,912&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;66,905&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;66,905&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;119,108&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;119,108&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;397,689&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;397,689&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;304,545&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;304,545&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;289,807&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;464,594&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;754,401&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;409,309&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;521,565&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;930,874&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The fair values of the Company&#x2019;s U.S. government securities, commercial paper and corporate debt securities are based on prices obtained from independent pricing sources. Securities with validated quotes from pricing services are reflected within Level 2, as they are primarily based on observable pricing for similar assets or other market observable inputs. Typical inputs used by these pricing services include, but are not limited to, reported trades, benchmark yields, issuer spreads, bids, offers or estimates of cash flow, prepayment spreads and default rates.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024 and December 31, 2023, the Company does not hold any securities classified as Level 3 and there were no securities transferred between Level 1 and 2.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_fbe52223-41c1-4f40-86b3-e774935a73c4">&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The level of the fair value hierarchy utilized to determine the fair va&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;lue of cash and cash equivalents and marketable securities consisted of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:25.615%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:5.9990000000000006%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:5.9990000000000006%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:5.9990000000000006%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:5.9990000000000006%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:5.9990000000000006%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:5.9990000000000006%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:5.9990000000000006%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:5.9990000000000006%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash and money market fund&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;142,712&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;142,712&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;148,643&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;148,643&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Guaranteed investment certificates&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,147&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,147&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,684&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,684&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. treasuries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;130,948&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;130,948&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;252,982&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;252,982&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;97,912&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;97,912&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;66,905&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;66,905&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;119,108&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;119,108&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;397,689&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;397,689&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;304,545&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;304,545&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;289,807&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;464,594&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;754,401&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;409,309&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;521,565&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;930,874&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_7f8727e8-25d3-49ce-a4eb-f560f9d67b08"
      decimals="-3"
      id="F_1873a220-9e8d-43a1-84b1-4380bba7877e"
      unitRef="U_USD">142712000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_cdaa9dc0-7dd9-4606-9431-1abf2c692823"
      decimals="-3"
      id="F_8f878dad-69de-4522-bf78-e0db15b46f12"
      unitRef="U_USD">142712000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_de04a46d-af61-488e-a31d-4bcee768b536"
      decimals="-3"
      id="F_79ba99bb-eb33-4625-8603-bdfdde742c29"
      unitRef="U_USD">148643000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_f75f1b7d-970c-44d9-af0e-c5a826dcce23"
      decimals="-3"
      id="F_d0600fac-ca24-485e-ab54-f823d1751644"
      unitRef="U_USD">148643000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_53032a5e-ec82-4a52-98b9-c114209ab7e7"
      decimals="-3"
      id="F_ffbefff4-eb13-4596-a7d5-9c34cce196d6"
      unitRef="U_USD">16147000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_18ce0587-947d-4000-ad21-226659cdded6"
      decimals="-3"
      id="F_2fb7b596-6636-42be-9e4a-06a5718a5067"
      unitRef="U_USD">16147000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_2298e5e3-65b4-4e1c-93f1-f5027b90c559"
      decimals="-3"
      id="F_853dd7ae-d6c3-4fb2-9df0-d276b9fc16b6"
      unitRef="U_USD">7684000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_9a7e217e-4eb8-4d7c-b2ca-de82b025bdab"
      decimals="-3"
      id="F_27a588ee-8822-4d0c-bcee-d79cd9fed845"
      unitRef="U_USD">7684000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_01a82667-15d7-4024-a57e-2657379f179f"
      decimals="-3"
      id="F_cc6a8160-47f1-443a-939c-be0260a903f2"
      unitRef="U_USD">130948000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_a4e5a889-56d8-4a0f-bc5c-ed4272cae01a"
      decimals="-3"
      id="F_919a26b5-829f-4369-b6fb-1c0ede4d53dd"
      unitRef="U_USD">130948000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_ecdb23a3-e394-4b57-b4f0-5e84d7ca4b27"
      decimals="-3"
      id="F_3a8332ed-2f80-4aa4-9116-2132689746ca"
      unitRef="U_USD">252982000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_d9195ae5-00f1-40d7-86d7-25551a0a0739"
      decimals="-3"
      id="F_9b64e65d-a94f-493b-a1e1-06da602191fa"
      unitRef="U_USD">252982000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_e51a83d7-051a-440a-9383-caa0acb0c6a7"
      decimals="-3"
      id="F_41f0e4b4-ed11-4038-ab46-d1822acb4a4e"
      unitRef="U_USD">97912000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_a581601f-604c-40e0-a538-b4058e27858a"
      decimals="-3"
      id="F_6765ab86-f3ae-4248-ae1d-4055e1e6e62f"
      unitRef="U_USD">97912000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_1aa8c882-c640-42ab-9434-c87e60af198d"
      decimals="-3"
      id="F_253c5e5e-cdce-4818-8446-4f55dcf5ea67"
      unitRef="U_USD">66905000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_1c604906-e061-40ec-b25c-b0b029e35f62"
      decimals="-3"
      id="F_ad456444-12d4-4671-80e0-56fdd9fd53f5"
      unitRef="U_USD">66905000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_9ee56ce4-a340-480e-9aec-44adf7965a2c"
      decimals="-3"
      id="F_59df8415-7a02-4ca8-b6c6-511f34f8fba9"
      unitRef="U_USD">119108000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_63ad59ce-e171-4295-bb49-279aaf68cd61"
      decimals="-3"
      id="F_b72df64b-5c55-411f-836e-447567d7b93f"
      unitRef="U_USD">119108000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_7e56dc4c-bf82-4de2-abd8-51bda8f0b0a0"
      decimals="-3"
      id="F_c05ff53d-d9eb-47cd-96a4-2d6371c56db9"
      unitRef="U_USD">397689000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_c9472f62-0148-495c-b52e-860ba1e4f49e"
      decimals="-3"
      id="F_e79dbb8c-994b-4ddc-96fa-73a0bbf555bd"
      unitRef="U_USD">397689000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_88dd1245-4241-4674-abff-66b46ec29d01"
      decimals="-3"
      id="F_ac1287ed-5a38-4669-b73b-415921fa663e"
      unitRef="U_USD">304545000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_27ad495b-a0bb-495a-8e89-83c9f5fe8b65"
      decimals="-3"
      id="F_af959500-8a85-46e5-a611-7301245bc555"
      unitRef="U_USD">304545000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_6c905a81-8dbd-4c7f-94d4-609f8be01e6a"
      decimals="-3"
      id="F_460b4144-6a87-4eef-91de-1eef203a4b0f"
      unitRef="U_USD">289807000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0ee5ccd7-b9d5-48bc-900e-21a7360e15ff"
      decimals="-3"
      id="F_e915c404-151c-45bd-a9cc-888ef01dae6e"
      unitRef="U_USD">464594000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_3cd561ce-d56f-4072-b50b-523fee0cd886"
      decimals="-3"
      id="F_ee817083-85b0-4db1-bb66-ad8520983277"
      unitRef="U_USD">754401000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_30871dbf-c703-4cc7-943f-7794f870694c"
      decimals="-3"
      id="F_97334216-1bb3-4ec0-9832-54fd04453dc6"
      unitRef="U_USD">409309000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_e1049099-ba3b-4285-9482-cc2e1b4be2e0"
      decimals="-3"
      id="F_863cb05e-6bc0-479f-88f9-470029d47918"
      unitRef="U_USD">521565000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_9fde0c8e-4519-4f2d-bac4-a130605b9e35"
      decimals="-3"
      id="F_c2cba7ec-0536-420e-87f8-4d0739f6bf73"
      unitRef="U_USD">930874000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_e3baa447-e1a4-4814-b8ec-583cc764bd70">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;5.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Marketable securities:&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company had $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;611,689&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; of available-for-sale securities (&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &#x2013; trading securities of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,867&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and available-for-sale-securities of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;768,364&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, respectively). &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Amortized cost, unrealized gain (loss) recognized in accumulated other comprehensive loss and fair value of available-for-sale securities consisted of the following:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:34%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.681%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:8.087%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.681%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:7.907%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.681%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:8.087%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.681%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:7.045999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:6.906000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.681%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:6.566%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized &lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized Gain (Loss)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair &lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized &lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized &lt;br/&gt;Gain (Loss)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair &lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Contractual maturity of 0 to 1 years:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Guaranteed investment certificates&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,122&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;975&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,147&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,549&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;135&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,684&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. treasuries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;72,989&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;147&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;73,136&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;192,193&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;249&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;191,944&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;98,092&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;180&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;97,912&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;66,808&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;97&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;66,905&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;119,041&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;67&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;119,108&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;327,448&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;557&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;328,005&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;58,824&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;58,924&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Contractual maturity of 1 to 3 years:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. treasuries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;58,218&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;406&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;57,812&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;53,294&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;243&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;53,537&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;69,726&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;42&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;69,684&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;238,458&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;797&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;239,255&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;612,311&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;622&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;611,689&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;767,451&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;913&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;768,364&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Allowance for credit losses or impairment on these marketable securities have not been recognized as these securities are high credit quality, investment grade securities that the Company does not intend to sell and will not be required to sell prior to their anticipated recovery, and the decline in fair value is primarily due to changes in interest rates.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f"
      decimals="-3"
      id="F_a8105c7e-2371-4270-862a-43588e9fc4c4"
      unitRef="U_USD">611689000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:TradingSecuritiesDebt
      contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35"
      decimals="-3"
      id="F_af98c0ee-551f-430b-b977-8266b764cc0e"
      unitRef="U_USD">13867000</us-gaap:TradingSecuritiesDebt>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35"
      decimals="-3"
      id="F_8a87fea6-c516-4ccc-bec8-a0d024a7084f"
      unitRef="U_USD">768364000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_1382048e-073d-459c-b781-1efbe2223c27">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Amortized cost, unrealized gain (loss) recognized in accumulated other comprehensive loss and fair value of available-for-sale securities consisted of the following:&lt;/span&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:34%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.681%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:8.087%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.681%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:7.907%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.681%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:8.087%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.681%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:7.045999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:6.906000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.681%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:6.566%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized &lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized Gain (Loss)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair &lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized &lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized &lt;br/&gt;Gain (Loss)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair &lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Contractual maturity of 0 to 1 years:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Guaranteed investment certificates&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,122&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;975&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,147&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,549&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;135&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,684&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. treasuries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;72,989&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;147&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;73,136&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;192,193&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;249&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;191,944&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;98,092&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;180&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;97,912&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;66,808&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;97&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;66,905&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;119,041&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;67&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;119,108&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;327,448&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;557&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;328,005&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;58,824&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;58,924&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Contractual maturity of 1 to 3 years:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. treasuries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;58,218&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;406&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;57,812&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;53,294&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;243&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;53,537&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;69,726&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;42&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;69,684&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;238,458&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;797&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;239,255&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;612,311&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;622&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;611,689&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;767,451&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;913&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;768,364&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="C_0dedc115-eabd-4f39-a7bf-4c55dd4adc43"
      decimals="-3"
      id="F_4b635088-d69e-4d29-aa8d-4009d227fa11"
      unitRef="U_USD">17122000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <xene:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTaxCurrent
      contextRef="C_0dedc115-eabd-4f39-a7bf-4c55dd4adc43"
      decimals="-3"
      id="F_c6fd3ba9-6142-4956-91f7-bbce28eaa7fc"
      unitRef="U_USD">-975000</xene:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTaxCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_0dedc115-eabd-4f39-a7bf-4c55dd4adc43"
      decimals="-3"
      id="F_737161c5-f003-46a6-b3fc-973709831a8e"
      unitRef="U_USD">16147000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="C_5edde648-d952-4a12-a2fc-5d27c42f48db"
      decimals="-3"
      id="F_7eb38472-2736-4739-8ce3-fb5b62277a74"
      unitRef="U_USD">7549000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <xene:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTaxCurrent
      contextRef="C_5edde648-d952-4a12-a2fc-5d27c42f48db"
      decimals="-3"
      id="F_39f0851e-d9bc-4566-a1e3-6f4cbb7c4501"
      unitRef="U_USD">135000</xene:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTaxCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_5edde648-d952-4a12-a2fc-5d27c42f48db"
      decimals="-3"
      id="F_55984f49-2171-49e1-b80b-16958714fa94"
      unitRef="U_USD">7684000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="C_ebe1e93e-63c9-48fd-b7f8-764857c13f18"
      decimals="-3"
      id="F_ad2e0ef7-1cbd-431e-b021-a9cd1fa35cf6"
      unitRef="U_USD">72989000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <xene:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTaxCurrent
      contextRef="C_ebe1e93e-63c9-48fd-b7f8-764857c13f18"
      decimals="-3"
      id="F_e2bbed75-adb6-437e-ac60-fe67c7181f58"
      unitRef="U_USD">147000</xene:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTaxCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_ebe1e93e-63c9-48fd-b7f8-764857c13f18"
      decimals="-3"
      id="F_56375395-02e2-4cd0-8296-e3b9b1737474"
      unitRef="U_USD">73136000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="C_577a2a65-5c5b-4519-baed-db30c894bf0f"
      decimals="-3"
      id="F_7961d9fb-74fc-4058-96c5-2405a96c47e5"
      unitRef="U_USD">192193000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <xene:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTaxCurrent
      contextRef="C_577a2a65-5c5b-4519-baed-db30c894bf0f"
      decimals="-3"
      id="F_2afd2ddd-325c-4cd8-98bb-08098f688097"
      unitRef="U_USD">-249000</xene:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTaxCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_577a2a65-5c5b-4519-baed-db30c894bf0f"
      decimals="-3"
      id="F_6b3e065f-8e8c-41ac-9fb8-4defc7d78788"
      unitRef="U_USD">191944000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="C_c0de2a82-98b0-4310-ad4c-fc4a77de4ddf"
      decimals="-3"
      id="F_75c9353b-f2fe-4ed9-bafa-43b27de4f38b"
      unitRef="U_USD">98092000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <xene:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTaxCurrent
      contextRef="C_c0de2a82-98b0-4310-ad4c-fc4a77de4ddf"
      decimals="-3"
      id="F_2abdb6f0-bf5c-4e1b-a396-e37e5da926ea"
      unitRef="U_USD">-180000</xene:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTaxCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_c0de2a82-98b0-4310-ad4c-fc4a77de4ddf"
      decimals="-3"
      id="F_1ee7f7b6-59cd-4c7e-9980-1b91b8d0815e"
      unitRef="U_USD">97912000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="C_50bacaa3-fec8-476a-a9ec-7fcc62c9f5b7"
      decimals="-3"
      id="F_428884af-89f3-4f9e-8fb4-d5ce43a4296e"
      unitRef="U_USD">66808000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <xene:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTaxCurrent
      contextRef="C_50bacaa3-fec8-476a-a9ec-7fcc62c9f5b7"
      decimals="-3"
      id="F_33c849b1-0bcd-4ea7-92d8-7bc531d993a5"
      unitRef="U_USD">97000</xene:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTaxCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_50bacaa3-fec8-476a-a9ec-7fcc62c9f5b7"
      decimals="-3"
      id="F_1c2713d0-85e6-4f4e-a4d4-c8d16c45f72a"
      unitRef="U_USD">66905000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="C_4b92f893-c873-482f-8d2a-12d3073fc31f"
      decimals="-3"
      id="F_b74f9354-b05f-46d5-8556-8eb4ab883154"
      unitRef="U_USD">119041000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <xene:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTaxCurrent
      contextRef="C_4b92f893-c873-482f-8d2a-12d3073fc31f"
      decimals="-3"
      id="F_f1fa8e03-5ace-49a2-8c9f-7775e291a149"
      unitRef="U_USD">67000</xene:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTaxCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_4b92f893-c873-482f-8d2a-12d3073fc31f"
      decimals="-3"
      id="F_c3a60fe6-1772-47a9-8b90-a8335c49c676"
      unitRef="U_USD">119108000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="C_9a4e5db1-ae6b-4123-9a4b-819384e01155"
      decimals="-3"
      id="F_54171d5c-d2a2-49ad-8b93-dda6159a2522"
      unitRef="U_USD">327448000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <xene:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTaxCurrent
      contextRef="C_9a4e5db1-ae6b-4123-9a4b-819384e01155"
      decimals="-3"
      id="F_1ab8a106-a566-4c2a-862f-ed63e062ba34"
      unitRef="U_USD">557000</xene:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTaxCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_9a4e5db1-ae6b-4123-9a4b-819384e01155"
      decimals="-3"
      id="F_f30fc5ec-208f-46a8-92be-67e560ad08c0"
      unitRef="U_USD">328005000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="C_678bf7e6-b4a8-4a8d-a08d-fd80c5153186"
      decimals="-3"
      id="F_92bc0a48-67c7-451b-8424-96e98220c1c1"
      unitRef="U_USD">58824000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <xene:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTaxCurrent
      contextRef="C_678bf7e6-b4a8-4a8d-a08d-fd80c5153186"
      decimals="-3"
      id="F_7075478c-53fd-4985-b6a1-ece67459cbba"
      unitRef="U_USD">100000</xene:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTaxCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_678bf7e6-b4a8-4a8d-a08d-fd80c5153186"
      decimals="-3"
      id="F_997392ed-fedb-45bd-bfd5-79da039e3412"
      unitRef="U_USD">58924000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent
      contextRef="C_ebe1e93e-63c9-48fd-b7f8-764857c13f18"
      decimals="-3"
      id="F_7992a3dc-622e-4ec0-9a42-e3f7b8c267e1"
      unitRef="U_USD">58218000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent>
    <xene:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTaxNoncurrent
      contextRef="C_ebe1e93e-63c9-48fd-b7f8-764857c13f18"
      decimals="-3"
      id="F_521bf13a-21b9-4da4-8abd-4baf7396df0b"
      unitRef="U_USD">-406000</xene:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTaxNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="C_ebe1e93e-63c9-48fd-b7f8-764857c13f18"
      decimals="-3"
      id="F_841bdef9-fa45-4b51-8560-e6315410421d"
      unitRef="U_USD">57812000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent
      contextRef="C_577a2a65-5c5b-4519-baed-db30c894bf0f"
      decimals="-3"
      id="F_84bbbbf6-7a1b-4f02-b17b-7773ae5dbca3"
      unitRef="U_USD">53294000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent>
    <xene:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTaxNoncurrent
      contextRef="C_577a2a65-5c5b-4519-baed-db30c894bf0f"
      decimals="-3"
      id="F_6763b608-20c1-4174-a3f3-2be47c969383"
      unitRef="U_USD">243000</xene:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTaxNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="C_577a2a65-5c5b-4519-baed-db30c894bf0f"
      decimals="-3"
      id="F_a1c107aa-b5b5-4ee8-ac34-e448a2820edc"
      unitRef="U_USD">53537000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent
      contextRef="C_9a4e5db1-ae6b-4123-9a4b-819384e01155"
      decimals="-3"
      id="F_d32a1006-ff6d-4409-a251-7addf532d12f"
      unitRef="U_USD">69726000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent>
    <xene:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTaxNoncurrent
      contextRef="C_9a4e5db1-ae6b-4123-9a4b-819384e01155"
      decimals="-3"
      id="F_3c99d0c6-14f0-4fef-b719-34e0a03ed290"
      unitRef="U_USD">-42000</xene:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTaxNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="C_9a4e5db1-ae6b-4123-9a4b-819384e01155"
      decimals="-3"
      id="F_66983ec4-64b5-456e-ab7b-c449f3623b5f"
      unitRef="U_USD">69684000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent
      contextRef="C_678bf7e6-b4a8-4a8d-a08d-fd80c5153186"
      decimals="-3"
      id="F_51da9246-7872-43ea-9494-318a56951c57"
      unitRef="U_USD">238458000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent>
    <xene:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTaxNoncurrent
      contextRef="C_678bf7e6-b4a8-4a8d-a08d-fd80c5153186"
      decimals="-3"
      id="F_110e550d-3448-4b8a-8eaf-2704f33edb11"
      unitRef="U_USD">797000</xene:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTaxNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="C_678bf7e6-b4a8-4a8d-a08d-fd80c5153186"
      decimals="-3"
      id="F_941a3b9d-4754-46fb-8410-2502c6b14cad"
      unitRef="U_USD">239255000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f"
      decimals="-3"
      id="F_abc294fa-43bd-4835-b39a-2b9ec22fd6af"
      unitRef="U_USD">612311000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <xene:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax
      contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f"
      decimals="-3"
      id="F_f0858a3a-e6bb-4468-8de7-4fe1d0952f28"
      unitRef="U_USD">-622000</xene:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f"
      decimals="-3"
      id="F_0f55ef37-c6aa-44a6-8c2d-2ef4e8a16813"
      unitRef="U_USD">611689000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35"
      decimals="-3"
      id="F_2c0d70ab-4ebd-4c8d-bd84-b404c2ddd48e"
      unitRef="U_USD">767451000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <xene:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax
      contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35"
      decimals="-3"
      id="F_2ef28550-4294-4495-872a-413cd42fcc5d"
      unitRef="U_USD">913000</xene:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35"
      decimals="-3"
      id="F_87edfef7-3260-4dd0-ad2a-1a3d93892cc1"
      unitRef="U_USD">768364000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_e2403ccd-a53c-4a3a-8e18-1f8a97952062">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;6.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property, plant and equipment:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property, plant and equipment consisted of the following:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:68.32%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.52%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="5" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,631&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,111&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Office furniture and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,285&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,285&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,463&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,489&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,363&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,464&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,251&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net book value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,278&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,653&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_15f52cb1-4da6-4be7-aff7-05e79949b88b">&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property, plant and equipment consisted of the following:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:68.32%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.52%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="5" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,631&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,111&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Office furniture and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,285&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,285&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,463&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,489&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,363&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,464&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,251&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net book value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,278&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,653&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_01045051-1058-4f3f-b914-02cf2190b1d1"
      decimals="-3"
      id="F_0bf52cbb-dacd-4ea8-bd94-e13bf0c18f28"
      unitRef="U_USD">11631000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_dd36de89-61c3-47d3-b597-7a827f1ad7ff"
      decimals="-3"
      id="F_3a5d5539-0c33-4774-878c-84a0daa74d79"
      unitRef="U_USD">9111000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_1c8819fe-6ad0-42fe-bce0-e8f35f30bcb8"
      decimals="-3"
      id="F_e261307a-19d2-4c2f-92b3-282544a477b4"
      unitRef="U_USD">1285000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_ea541069-c8a0-41f5-a186-def6edd37f4a"
      decimals="-3"
      id="F_4a72f11d-3989-4c97-a1fe-137e1f33fe3b"
      unitRef="U_USD">1285000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_31a54459-014b-4693-8a7e-9d5cd1d9fedb"
      decimals="-3"
      id="F_ba9ffe49-62ca-4ae1-a7d2-ea390e3ff803"
      unitRef="U_USD">1463000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_855c2687-033c-4d5b-9d65-93762e253c78"
      decimals="-3"
      id="F_72d336b6-77e8-42f4-8b91-b81ab6693b3c"
      unitRef="U_USD">1489000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_4e096b75-1c3e-4f4b-a2d5-46dab7c31772"
      decimals="-3"
      id="F_c27210f2-8073-45e6-8ba9-696f3c381c85"
      unitRef="U_USD">9363000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_8af453ba-33f4-44f7-9e63-cd2ff108e084"
      decimals="-3"
      id="F_d035a59d-ba73-41cb-a6bb-c2bdcaad1e84"
      unitRef="U_USD">9019000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f"
      decimals="-3"
      id="F_f6db06e3-67b8-4880-a55a-155f59b50c27"
      unitRef="U_USD">13464000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35"
      decimals="-3"
      id="F_7460bfc4-6f29-4de8-aca4-19068e6ca198"
      unitRef="U_USD">11251000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f"
      decimals="-3"
      id="F_2ce4c6c9-c7e6-4867-bffa-a2615fac31ca"
      unitRef="U_USD">10278000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35"
      decimals="-3"
      id="F_1e939bc1-2481-476c-8532-d038fd68ac2e"
      unitRef="U_USD">9653000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_d8dfaacf-e0ea-4c4f-b8aa-8cf1a974dda7">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;7.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Leases:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_a0537c61-71b0-4915-978f-b5bbcfc84362;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;an&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; operating lease for research laboratories and office space in Burnaby, British Columbia which expires on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;June 30, 2032&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;two&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; renewal options for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;-years each which were not considered in the determination of the right-of-use asset and lease liability.&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The Company has an additional operating lease for office space in Needham, Massachusetts (&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x201c;Needham Lease&#x201d;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;), which commenced in October 2022. The Needham Lease is for a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;62-month&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; term and an &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;option to terminate one year prior to the expiry date&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, which was not considered in the determination of the right-of-use asset and lease liability.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11pt;font-family:'Calibri',sans-serif;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The cost components of the operating leases were as follows for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024, 2023 and 2022:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:59.416%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.321%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.088%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.088%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.088%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="8" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating lease expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,646&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,645&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,126&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Variable lease expense&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;826&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;787&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;774&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Lease term and discount rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted average remaining lease term (years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.4&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.3&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted average discount rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;div class="item-list-element-wrapper" style="margin-left:11.204%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:justify;"&gt;&lt;span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;font-kerning:none;min-width:3.0035136717870174%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(1)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Variable lease costs are payments that vary because of changes in facts or circumstances and include common area maintenance and property taxes related to the premises. Variable lease costs are excluded from the calculation of minimum lease payments. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:5.693%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;	&lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Future minimum lease payments as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 were as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:5.733%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.444%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.8%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.757%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Year ending December 31:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,690&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,755&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,739&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,037&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,085&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2030 and thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,861&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,167&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,152&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,015&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseDescription
      contextRef="C_f76418ce-447a-47fa-abce-3e02aca037d2"
      id="F_bd2c8b08-a7f9-4062-a13d-0d215f79f77f">The Company has an operating lease for research laboratories and office space in Burnaby, British Columbia which expires on June 30, 2032, and two renewal options for 5-years each which were not considered in the determination of the right-of-use asset and lease liability. The Company has an additional operating lease for office space in Needham, Massachusetts (&#x201c;Needham Lease&#x201d;), which commenced in October 2022. The Needham Lease is for a 62-month term and an option to terminate one year prior to the expiry date, which was not considered in the determination of the right-of-use asset and lease liability.</us-gaap:LesseeOperatingLeaseDescription>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_f76418ce-447a-47fa-abce-3e02aca037d2"
      id="F_494c9559-2c82-419d-8464-7a39b6002323">2032-06-30</us-gaap:LeaseExpirationDate1>
    <xene:LesseeOperatingLeaseNumberOfRenewalOptions
      contextRef="C_b6853865-a835-4d1f-bb65-e80788e06f13"
      decimals="INF"
      id="F_4dceec58-d5b8-4bab-a87b-45c55c39e15c"
      unitRef="U_Option">2</xene:LesseeOperatingLeaseNumberOfRenewalOptions>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_ce952f40-3105-427e-bbaa-fffd07f2063c"
      id="F_15085fc3-0b53-47a9-8229-a45b641f68bf">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_0f230ef8-cad8-4ce7-bee0-026b0567d14a"
      id="F_9db72306-09d9-4e52-8e6a-874e690b8b74">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseDescription
      contextRef="C_ccebda2c-e532-4b8e-ac5b-a03dd5ef7b48"
      id="F_99738259-862a-4d92-8d8f-a2d5d88bcaf5"> The Company has an additional operating lease for office space in Needham, Massachusetts (&#x201c;Needham Lease&#x201d;), which commenced in October 2022. The Needham Lease is for a 62-month term and an option to terminate one year prior to the expiry date, which was not considered in the determination of the right-of-use asset and lease liability.</us-gaap:LesseeOperatingLeaseDescription>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_7a64b01e-5173-4d9f-837a-bbb2c4168382"
      id="F_8aa44486-9685-4d30-a857-31054e4918a2">P62M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseOptionToTerminate
      contextRef="C_ccebda2c-e532-4b8e-ac5b-a03dd5ef7b48"
      id="F_a273dfc0-4152-432d-b4da-df8771cc8e7e">option to terminate one year prior to the expiry date</us-gaap:LesseeOperatingLeaseOptionToTerminate>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_e75bbeca-765f-411b-b794-0cfcc7c138d0">&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The cost components of the operating leases were as follows for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024, 2023 and 2022:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:59.416%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.321%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.088%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.088%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.088%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="8" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating lease expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,646&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,645&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,126&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Variable lease expense&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;826&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;787&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;774&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Lease term and discount rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted average remaining lease term (years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.4&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.3&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted average discount rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;div class="item-list-element-wrapper" style="margin-left:11.204%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:justify;"&gt;&lt;span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;font-kerning:none;min-width:3.0035136717870174%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(1)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Variable lease costs are payments that vary because of changes in facts or circumstances and include common area maintenance and property taxes related to the premises. Variable lease costs are excluded from the calculation of minimum lease payments. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="-3"
      id="F_04a8b348-cfc2-4f65-b1a7-2db878541763"
      unitRef="U_USD">1646000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="-3"
      id="F_16a57ba8-72aa-475e-9535-c54f6cd12c91"
      unitRef="U_USD">1645000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="-3"
      id="F_c01fb1b8-0633-4814-a500-f2a48c63df54"
      unitRef="U_USD">1126000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="-3"
      id="F_c1a45d73-bd9d-4966-a361-d6a7331b7229"
      unitRef="U_USD">826000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="-3"
      id="F_cbfebd64-0a27-4991-9ad5-212be654e613"
      unitRef="U_USD">787000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="-3"
      id="F_64a56835-5cfe-48be-95ec-d5d10f7f7ac6"
      unitRef="U_USD">774000</us-gaap:VariableLeaseCost>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f"
      id="F_bbb78354-2948-49bc-a8f1-4516f261140e">P6Y4M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35"
      id="F_1c95cfa4-4a4e-423d-b9d0-ac26fe379363">P7Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_959e7299-f8b2-49e1-8078-5dac2b5e2683"
      id="F_cc60d7af-cb74-4aef-8f54-6ed7c440b23f">P8Y1M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f"
      decimals="3"
      id="F_23befde7-785b-4c1a-a6b3-d7f220bf8108"
      unitRef="U_pure">0.038</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35"
      decimals="3"
      id="F_8a9a6a9a-6a0b-4c4e-91fb-86c8654b59cf"
      unitRef="U_pure">0.039</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_959e7299-f8b2-49e1-8078-5dac2b5e2683"
      decimals="3"
      id="F_fa06d0bd-5a2e-41ed-8a74-d76018158e5c"
      unitRef="U_pure">0.04</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_86166d56-eca2-4db3-87d4-7f1bb7fc996f">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Future minimum lease payments as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 were as follows:&lt;/span&gt;&lt;p style="margin-left:5.733%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.444%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.8%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.757%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Year ending December 31:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,690&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,755&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,739&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,037&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,085&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2030 and thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,861&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,167&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,152&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,015&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f"
      decimals="-3"
      id="F_cc0a4245-4d2f-4ee6-a8af-9274caf0d316"
      unitRef="U_USD">1690000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f"
      decimals="-3"
      id="F_08e001cb-d23c-41d1-83eb-542c3229b9b4"
      unitRef="U_USD">1755000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f"
      decimals="-3"
      id="F_a3fce00d-4e3f-4e5e-ad9a-aee728ff3ca5"
      unitRef="U_USD">1739000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f"
      decimals="-3"
      id="F_6eddb810-f9e2-4e70-85b3-2dca3c31fe6e"
      unitRef="U_USD">1037000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f"
      decimals="-3"
      id="F_bc53ea66-e1ac-4c83-9b84-6da11a24e368"
      unitRef="U_USD">1085000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f"
      decimals="-3"
      id="F_135b220c-b02d-4a54-9881-b27c3f47b369"
      unitRef="U_USD">2861000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f"
      decimals="-3"
      id="F_330a75c8-5127-4d5e-93a9-e701584d7945"
      unitRef="U_USD">10167000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f"
      decimals="-3"
      id="F_945dac85-8524-4cdf-af47-527b2c7ccc65"
      unitRef="U_USD">1152000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f"
      decimals="-3"
      id="F_01be45e2-f65a-4821-8ef2-9f42daaea636"
      unitRef="U_USD">9015000</us-gaap:OperatingLeaseLiability>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_95d069cc-e952-4d3f-ae5c-f5706702f8c0">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;8.&lt;/span&gt;&lt;div id="report_of_independent" style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accounts payable a&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;nd accrued liabilities:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accounts payable and accrued liabilities consisted of the following:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:68.32%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.52%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="5" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accounts payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,070&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,598&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Employee compensation, benefits, and related accruals&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,928&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,425&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,061&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,824&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Income and other taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,686&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;347&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Professional fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;762&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;780&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;714&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;34,221&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25,974&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_475ac2e3-61b3-4fe4-8355-046687f72364">&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accounts payable and accrued liabilities consisted of the following:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:68.32%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.52%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="5" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accounts payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,070&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,598&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Employee compensation, benefits, and related accruals&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,928&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,425&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,061&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,824&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Income and other taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,686&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;347&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Professional fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;762&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;780&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;714&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;34,221&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25,974&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f"
      decimals="-3"
      id="F_33377877-0364-4cdc-9127-e14d1e6b599f"
      unitRef="U_USD">5070000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35"
      decimals="-3"
      id="F_cfb85ae6-844d-4354-bf9d-aa3d9f8d30e7"
      unitRef="U_USD">8598000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f"
      decimals="-3"
      id="F_29cccb7f-2add-4f1b-ae2b-a381aa23974a"
      unitRef="U_USD">9928000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35"
      decimals="-3"
      id="F_0f2e61f8-5e9c-4d90-9f92-f48bb7f87b0e"
      unitRef="U_USD">7425000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <xene:AccruedResearchAndDevelopmentCurrent
      contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f"
      decimals="-3"
      id="F_bda0b8aa-054f-4b14-947e-587be3b0e20c"
      unitRef="U_USD">12061000</xene:AccruedResearchAndDevelopmentCurrent>
    <xene:AccruedResearchAndDevelopmentCurrent
      contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35"
      decimals="-3"
      id="F_2cc3b2c1-fc3b-4cb4-9856-642dbcb31196"
      unitRef="U_USD">8824000</xene:AccruedResearchAndDevelopmentCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f"
      decimals="-3"
      id="F_0d677319-6273-4f91-b4f6-8fddee5f79b1"
      unitRef="U_USD">5686000</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35"
      decimals="-3"
      id="F_90921a49-00b7-42a7-b083-207d97145cfd"
      unitRef="U_USD">347000</us-gaap:TaxesPayableCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f"
      decimals="-3"
      id="F_3544fb0d-7b85-44dd-9a6d-d5364b9d4b69"
      unitRef="U_USD">762000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35"
      decimals="-3"
      id="F_b1c12e0a-80c7-47e9-bdda-8d1002f0299d"
      unitRef="U_USD">780000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f"
      decimals="-3"
      id="F_7e67297c-051c-4e30-9849-fa2d586fddc9"
      unitRef="U_USD">714000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35"
      decimals="-3"
      id="F_afb96153-08e2-4dd8-9c44-d66c05024519"
      unitRef="U_USD">0</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f"
      decimals="-3"
      id="F_2415dfa3-8bff-41fe-9175-29e68c6c427e"
      unitRef="U_USD">34221000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35"
      decimals="-3"
      id="F_896fea06-6ea5-499f-ac59-c091090081a6"
      unitRef="U_USD">25974000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_14b2c51d-f208-4596-a88f-3b2b67be6153">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;9.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Share capital:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(a)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Financing:&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;August 2020, the Company entered into an &#x201c;at-the-market&#x201d; equity offering sales agreement, amended as of March 2022, with Jefferies LLC and Stifel, Nicolaus &amp;amp; Company, Incorporated pursuant to which the Company may sell common shares from time to time (the &#x201c;ATM Program&#x201d;). In September 2023, pursuant to a prospectus supplement filed in March 2022 (&#x201c;March 2022 Prospectus&#x201d;), the Company sold an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;855,685&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; common shares for proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,508&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, net of commissions and transaction expenses. In August 2024, a new prospectus supplement was filed replacing the March 2022 Prospectus, pursuant to which the Company refreshed the ATM Program and may sell common shares having gross proceeds of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;350,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, from time to time. As of December 31, 2024, the Company has sold an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;310,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; common shares for proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,083&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, net of commissions and transaction expenses under the ATM Program.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In January 2022, in connection with the License and Collaboration Agreement with Neurocrine Biosciences entered in December 2019 and amended in January 2021 (the &#x201c;Neurocrine Collaboration Agreement&#x201d;), the Company executed a Share Purchase Agreement (&#x201c;SPA&#x201d;) pursuant to which the Company issued &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;258,986&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; common shares for an aggregate purchase price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,250&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, or $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31.855&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per common share, which represents a premium of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;374&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; when compared to the fair value of common shares on the date of issuance. The SPA contain certain other customary terms and conditions, including mutual representations, warranties and covenants. For additional information regarding the Neurocrine Collaboration Agreement, refer to &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;note 10.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In June 2022, the Company completed an underwritten public offering of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,098,362&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; common shares, including &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,229,508&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares sold upon the full exercise of the underwriters&#x2019; over-allotment option, at a public offering price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30.50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per common share and pre-funded warrants to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;327,868&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; common shares at $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30.4999&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per pre-funded warrant (note 9e), with each pre-funded warrant having an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The public offering was completed in June 2022, and the Company received proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;269,890&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, net of underwriting discounts, commissions and offering expenses.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2023, the Company completed&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; an underwritten public offering of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,846,157&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; common shares, including &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,384,615&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares sold upon the full exercise of the underwriters' over-allotment option, at a public offering price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;32.50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per common share and pre-funded warrants to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;769,230&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; common shares at $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;32.4999&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per pre-funded warrant (note 9e), with each pre-funded warrant having an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The public offering was completed in December 2023, and the Company received proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;323,979&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, net of underwriting discounts, commissions and offering expenses.&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(b)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Authorized share capital:&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s authorized share capital consists of an unlimited number of common and preferred shares without par value.&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(c)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation:&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has two equity incentive plans: (i) the 2014 Equity Incentive Plan which was amended and restated in June 2020, June 2022 and June 2024 (the &#x201c;Amended and Restated 2014 Plan&#x201d;), and (ii) the 2019 Inducement Equity Incentive Plan (the &#x201c;2019 Inducement Plan&#x201d;).&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In September 2019, the board of directors of the Company adopted the 2019 Inducement Plan and, subject to the adjustment provisions of the 2019 Inducement Plan, reserved &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;400,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; of the Company&#x2019;s common shares for issuance pursuant to equity awards granted under the 2019 Inducement Plan. The 2019 Inducement Plan was adopted without shareholder approval in accordance with the applicable Nasdaq Listing Rules. The 2019 Inducement Plan provided for the grant of equity-based awards, including share options, share appreciation rights, restricted share awards, restricted share unit awards and performance share awards, and its terms are substantially similar to the Company&#x2019;s Amended and Restated 2014 Plan, including with respect to treatment of equity awards in the event of a &#x201c;merger&#x201d; or &#x201c;change of control&#x201d; as defined under the 2019 Inducement Plan, but with such other terms and conditions intended to comply with the Nasdaq inducement award exception or to comply with the Nasdaq acquisition and merger exception. The 2019 Inducement Plan was terminated in June 2020. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; further options will be granted under the 2019 Inducement Plan, and the 2019 Inducement Plan will continue to govern the options granted thereunder.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The shareholders of the Company approved the Amended and Restated 2014 Plan amended in June 2020, June 2022 and June 2024, amending certain provisions of the Company&#x2019;s 2014 Plan. The Amended and Restated 2014 Plan permits the grant of stock-based compensation awards to directors, officers, employees and consultants of the Company and the issuance of restricted shares, restricted share units, share appreciation rights and PSUs. Under the Amended and Restated 2014 Plan, options granted generally vest on a graduated basis over a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;four-year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; periods. The exercise price of the options is determined by the board of directors but must at least be equal to the fair market value of&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; the common shares on the date of grant. Options may be exercised over a maximum term of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ten years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The vesting conditions, vesting period and expiry terms of the PSUs are determined by the board of directors. As of December 31, 2024, a total of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,882,842&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; common shares remain available for issuance pursuant to the Amended and Restated 2014 Plan. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Of this total, the number of common shares that can be issued through restricted share awards, restricted share unit awards, or performance share awards is limited to the aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; common shares.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table presents the components and classification of stock-based compensation expense for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024, 2023 and 2022:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.089%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.28%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.598%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.28%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.598%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.28%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.598%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.28%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation expense by award type:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;48,384&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;32,372&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,376&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;PSUs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,333&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50,717&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;32,372&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,376&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation expense in operating expenses:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,088&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,067&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,766&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;28,629&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,305&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,610&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50,717&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;32,372&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,376&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Stock options&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table presents the summary of stock option activity for the period:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:43%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.96%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.96%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:16.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Price ($)&lt;/span&gt;&lt;span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Intrinsic&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding, December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,638,232&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.55&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;105,405&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,315,645&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30.90&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;780,725&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.47&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,651&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeited, cancelled or expired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;55,370&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24.50&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding, December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,117,782&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18.75&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;147,214&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,542,473&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35.29&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;587,536&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13.58&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,526&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeited, cancelled or expired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;178,217&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31.49&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding, December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,894,502&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23.56&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;200,122&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,062,819&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;42.93&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,040,136&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.43&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,416&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeited, cancelled or expired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;207,896&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;38.18&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding, December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,709,289&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29.90&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;111,202&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercisable, December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,927,638&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22.30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100,214&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:11.204%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:justify;"&gt;&lt;span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;font-kerning:none;min-width:3.0035136717870174%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(1)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;During the year ended December 31, 2024, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,144&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &#x2013; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,320&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and 2022 &#x2013; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;68,930&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;) stock options were exercised for the same number of common shares in exchange for cash. In the same period, the Company issued &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;729,965&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(2023 &#x2013; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;377,114&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and 2022 &#x2013; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;510,671&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;) common shares for the cashless exercise of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,034,992&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(2023 &#x2013; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;583,216&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and 2022 &#x2013; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;711,795&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;) stock options.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;At December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, stock options outstanding and exercisable had a weighted average remaining contractual life of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;7.28&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;6.21 &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;years, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The fair value of stock options at the date of grant is estimated using the Black-Scholes option-pricing model which requires multiple subjective inputs. The risk-free interest rate of the options is based on the U.S. Treasury yield curve in effect at the date of grant for a term similar to the expected term of the option. The expected volatility is based on the historical volatility of the Company&#x2019;s common shares calculated based on a period of time commensurate with the expected term assumption. Expected life assumptions are based on the Company&#x2019;s historical data. The dividend yield is based on the fact that the Company has never paid cash dividends and has no present intention to pay cash dividends. Forfeitures are recognized as they occur.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The weighted average option pricing assumptions are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.123%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.584999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.584999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.584999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Average risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.05&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.93&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.39&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;66&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;69&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Average expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.75&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.94&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.16&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted average fair value of stock options granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26.48&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22.52&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19.78&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A summary of the Company&#x2019;s unvested stock option activity and related information for the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:48.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:22.9%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:22.9%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of&lt;br/&gt;Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted Average &lt;br/&gt;Grant Date&lt;br/&gt;Fair Value ($)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Unvested, January 1, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,105,324&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20.53&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,062,819&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26.48&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,178,816&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19.91&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeited or cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;207,676&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22.04&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Unvested, December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,781,651&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24.56&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The aggregate fair value of options vested during the year ended December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;43,375&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &#x2013; $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,233&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and 2022 &#x2013; $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,752&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;).&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the unrecognized stock-based compensation expense related to the unvested stock options was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;99,779&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; which is expected to be recognized over a weighted average period of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2.64&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Performance share units	&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;During the year ended December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company granted &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;210,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; PSUs to officers and certain employees with a weighted average grant date fair value&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;43.90&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per unit. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;PSUs vest upon the achievement of certain predefined company-specific performance-based criteria on or before December 31, 2027, subject to continued employment to each performance objective achievement date. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; PSUs vested during the year ended December 31, 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the unrecognized stock-based compensation expense related to the unvested PSUs that is probable to be achieved was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,267&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The recognition of this expense is subject to the achievement of the performance-based criteria, which are reassessed at each reporting date. There is $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,609&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; of unrecognized stock-based compensation expense related to the PSUs that is not probable to be achieved.&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(d)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Exchange agreement with certain funds affiliated with BVF Partners L.P. (collectively, &#x201c;BVF&#x201d;):&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In March 2018, the Company and BVF entered into an exchange agreement pursuant to which the Company issued to BVF &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,868,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Series 1 Preferred Shares in exchange for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,868,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; common shares which were subsequently cancelled by the Company. The Series 1 Preferred Shares were convertible into common shares on a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;one-for-one&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; basis, subject to certain restrictions.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Series 1 Preferred Shares ranked equally to the common shares in the event of liquidation, dissolution or winding up or other distribution of the assets of the Company among its shareholders and the holders of the Series 1 Preferred Shares were entitled to vote together with the common shares on an as-converted basis and as a single class, subject to certain restrictions.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Series 1 Preferred Shares were recorded wholly as equity under ASC 480, with no bifurcation of conversion feature from the host contract, given that the Series 1 Preferred Shares cannot be cash settled and have no redemption features.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;During the year ended December 31, 2018, BVF converted &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,852,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Series 1 Preferred Shares in exchange for an equal number of common shares. In March 2022, the remaining outstanding &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,016,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Series 1 Preferred Shares were exchanged for an equal number of common shares.&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(e)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Pre-funded warrants:&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:8.787%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the pre-funded warrants activity for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024, 2023, and 2022:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:8.8%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.975%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.25%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:30.775%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of Pre-funded&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;warrants outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding, December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,775,996&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Issued&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;327,868&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding, December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,103,864&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Issued&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;769,230&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,700,013&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding, December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,173,081&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Issued&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding, December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,173,081&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;div class="item-list-element-wrapper" style="margin-left:9.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:justify;"&gt;&lt;span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;font-kerning:none;min-width:2.9590591368023964%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(1)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;During the year ended December 31, 2023, the Company issued &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,700,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; common shares upon the exercise of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,700,013&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; pre-funded warrants pursuant to a net exercise mechanism under the warrants.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Each pre-funded warrant is exercisable for the purchase of a common share at the holder's discretion at an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, subject to certain post-exercise beneficial ownership limitations as provided under the terms of the pre-funded warrant.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company may not affect the exercise of any pre-funded warrant, and a holder will not be entitled to exercise any portion of any pre-funded warrant that, upon giving effect to such exercise, would cause: (i) the aggregate number of common shares beneficially owned by such holder, together with its affiliates, to exceed 4.99% of the total number of common shares outstanding immediately after giving effect to the exercise; or (ii) the combined voting power of the Company&#x2019;s securities beneficially owned by such holder, together with its affiliates, to exceed 4.99% of the combined voting power of all of the Company&#x2019;s securities immediately outstanding after giving effect to the exercise, which percentage may be changed at the holder&#x2019;s election to a higher or lower percentage not in excess of 19.99% upon at least 61 days&#x2019; notice to the Company.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Since the pre-funded warrants meet the condition for equity classification, proceeds from issuances of the pre-funded warrants for the year ended December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,477&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (2022 &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2013; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,387&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;), net of underwriting discounts, commissions and offering expenses, are recorded in additional paid-in capital. Upon exercise of the pre-funded warrants, the historical costs recorded in additional paid-in capital along with the exercise price collected from the holder are recorded in common shares. Pre-funded warrants to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,173,081&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2023 &#x2013; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"&gt;2,173,081&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and 2022 &#x2013;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,103,864&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;) common shares &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;are not included in the number of issued and outstanding common shares as of December 31, 2024.&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(f)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Warrant: &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:8.787%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In August 2018, a warrant to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2023 &#x2013; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;) common shares at a price per common share of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.79&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; was issued. The warrant is immediately exercisable, contains a cashless exercise provision and expires in August 2028.&lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_e5737a61-1f16-4af6-ac8a-b3e0f4d46fae"
      decimals="INF"
      id="F_88647751-5795-4bb6-9e1e-c08b7d4ccbd8"
      unitRef="U_shares">855685</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_1687d09a-5433-43c2-90f1-f650513a2fa1"
      decimals="-3"
      id="F_ea0c2f79-5177-402a-97f8-14f9ca7037a6"
      unitRef="U_USD">29508000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <xene:GrossProceedsFromIssuableOfCommonStock
      contextRef="C_580473ec-137a-44c3-af0d-b97a202a4a2e"
      decimals="-3"
      id="F_5202d596-7e8e-476e-beaa-bf74b92b366e"
      unitRef="U_USD">350000000</xene:GrossProceedsFromIssuableOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_e41e64f7-0a7c-4d69-9147-98202c4d2812"
      decimals="INF"
      id="F_b30acf93-c69e-42e9-aac3-dab8c6bb21c3"
      unitRef="U_shares">310000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_3c7df611-38a7-4085-9e60-23c55dba93c2"
      decimals="-3"
      id="F_f1ddd5a5-a433-42d8-a2d1-e01b784306f3"
      unitRef="U_USD">12083000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_16c2e333-259f-4e18-b025-1a7840b2cf5d"
      decimals="INF"
      id="F_133e979c-6efd-48b1-aa1c-867d8188dc33"
      unitRef="U_shares">258986</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_16c2e333-259f-4e18-b025-1a7840b2cf5d"
      decimals="-3"
      id="F_9fe4a1a5-17f0-4308-84a0-9b5a05ac68fb"
      unitRef="U_USD">8250000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_e03fe75c-2f66-4f62-8b71-f0cb7b6dd2c7"
      decimals="3"
      id="F_6b3dc7c4-0c57-4067-8d60-278777093341"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">31.855</us-gaap:SharesIssuedPricePerShare>
    <xene:CollaborateMilestoneAgreementPremiumRelatedToEquityInvestment
      contextRef="C_16c2e333-259f-4e18-b025-1a7840b2cf5d"
      decimals="-3"
      id="F_c47015f5-ac66-4a0d-abaf-aa5c5bf58ed9"
      unitRef="U_USD">374000</xene:CollaborateMilestoneAgreementPremiumRelatedToEquityInvestment>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_f91f0158-e869-4802-841d-82a3345ebc02"
      decimals="INF"
      id="F_d0811a8d-2397-4d8c-9e8b-cdd4fe48607d"
      unitRef="U_shares">9098362</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_f90eb819-58f1-4a64-8683-5de3a214bcb5"
      decimals="INF"
      id="F_e164ac49-4afc-48b3-979f-1db9062f089b"
      unitRef="U_shares">1229508</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_e9b5b17b-a190-4b8c-8268-dec97ce1d7a0"
      decimals="INF"
      id="F_5b3a49dd-558b-4bb5-ae8c-4ab143fc18bd"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">30.50</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="C_e9b5b17b-a190-4b8c-8268-dec97ce1d7a0"
      decimals="INF"
      id="F_e1c1652a-c513-40d7-b01c-6566e73a873f"
      unitRef="U_shares">327868</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <xene:WarrantsIssuedPricePerPreFundedWarrant
      contextRef="C_e9b5b17b-a190-4b8c-8268-dec97ce1d7a0"
      decimals="INF"
      id="F_458ed1c7-3d46-4067-a176-09e077783420"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">30.4999</xene:WarrantsIssuedPricePerPreFundedWarrant>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_e9b5b17b-a190-4b8c-8268-dec97ce1d7a0"
      decimals="4"
      id="F_cf7ad05c-f94b-48c5-9cdb-f0e96ffa2e6f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_f91f0158-e869-4802-841d-82a3345ebc02"
      decimals="-3"
      id="F_81f4f318-a9af-4948-8192-f75716c7efbe"
      unitRef="U_USD">269890000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_279f5f99-a2c7-4a1f-b98a-9e98fe07b653"
      decimals="INF"
      id="F_87e65d2c-97b0-4a00-a02e-5029e5d29c52"
      unitRef="U_shares">9846157</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0514d61f-b883-40b3-87d9-7e278b3a6820"
      decimals="INF"
      id="F_cdfe7140-1e5c-4d31-acfb-0c7e040ac383"
      unitRef="U_shares">1384615</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_0a8f0fd9-0cf5-45b3-8b78-096409d7c4d6"
      decimals="2"
      id="F_f1e104bf-fb7b-44b5-850e-1c9bed2f8975"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">32.5</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="C_0a8f0fd9-0cf5-45b3-8b78-096409d7c4d6"
      decimals="INF"
      id="F_888d511d-14c3-461e-a586-84a3199fb4a7"
      unitRef="U_shares">769230</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <xene:WarrantsIssuedPricePerPreFundedWarrant
      contextRef="C_0a8f0fd9-0cf5-45b3-8b78-096409d7c4d6"
      decimals="4"
      id="F_c463f524-e04b-4878-ada2-4b21847c15d9"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">32.4999</xene:WarrantsIssuedPricePerPreFundedWarrant>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_0a8f0fd9-0cf5-45b3-8b78-096409d7c4d6"
      decimals="4"
      id="F_7a0eb858-a5ca-4f94-aa7e-9a0e632dc3b5"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_295d7ebf-ecb2-4863-8055-c5d32414b32f"
      decimals="-3"
      id="F_24d754ac-cf41-46be-a41d-96b37d124d6d"
      unitRef="U_USD">323979000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="C_aec75604-252f-46ec-a913-19116503fa3a"
      decimals="INF"
      id="F_f277630d-f51b-4d4e-97d2-621ed6cfc2ea"
      unitRef="U_shares">400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_aec75604-252f-46ec-a913-19116503fa3a"
      decimals="INF"
      id="F_b237afb8-783a-4968-a79c-a4677773980e"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_b73046f7-b8e0-4dca-8c99-1daba94d7875"
      id="F_68e83bff-ef16-4780-bb59-fdd011d9152d">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <xene:MaximumTermOfEachOptionExercised
      contextRef="C_b73046f7-b8e0-4dca-8c99-1daba94d7875"
      id="F_913d81e5-e7eb-4974-bb6a-314e0edc1df7">P10Y</xene:MaximumTermOfEachOptionExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="C_0592fb80-0d71-435e-a735-fefde780f550"
      decimals="INF"
      id="F_2124fb5a-11a6-4005-9da3-68c38ccba30f"
      unitRef="U_shares">5882842</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_e0854642-1362-4d48-aab9-14c1634c7adf"
      decimals="INF"
      id="F_9da3cd7b-f3db-49c8-864f-d6cca2ceaced"
      unitRef="U_shares">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_2093aba0-bef7-4b93-92c9-16f8c7f4f4d9">&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table presents the components and classification of stock-based compensation expense for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024, 2023 and 2022:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.089%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.28%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.598%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.28%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.598%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.28%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.598%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.28%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation expense by award type:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;48,384&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;32,372&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,376&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;PSUs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,333&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50,717&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;32,372&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,376&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation expense in operating expenses:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,088&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,067&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,766&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;28,629&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,305&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,610&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50,717&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;32,372&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,376&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_75650c11-6320-415c-9740-299a3731566d"
      decimals="-3"
      id="F_dc46e45f-7899-4900-9ef4-2319619f65e0"
      unitRef="U_USD">48384000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_22406e30-26c0-4443-96a7-32b9fcae62e4"
      decimals="-3"
      id="F_35577cc5-24f3-4682-b7df-20649b534daa"
      unitRef="U_USD">32372000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_5a4cf558-ec87-4536-9f7e-a17702358f73"
      decimals="-3"
      id="F_8bfaa4af-2033-440b-a8bb-37e62d2977d7"
      unitRef="U_USD">20376000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_b54bd813-bcee-4527-8ce0-2c924fa24d1d"
      decimals="-3"
      id="F_1033fc69-d539-4bee-8c1a-2899afbce424"
      unitRef="U_USD">2333000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="-3"
      id="F_1151f825-8ae4-4f07-8518-e09db91eeded"
      unitRef="U_USD">50717000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="-3"
      id="F_61b18987-77d4-44b7-ac11-cce363fa90cb"
      unitRef="U_USD">32372000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="-3"
      id="F_f5faefd1-8719-4bdb-a48b-d68cf2793099"
      unitRef="U_USD">20376000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_dcfeb94e-b8c0-4a04-9c3a-f7a9d496157a"
      decimals="-3"
      id="F_1c40afd3-04a2-45c3-93e3-d50e5cfd47e3"
      unitRef="U_USD">22088000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0e65ad73-e8f3-456e-8770-603f8bf6e43d"
      decimals="-3"
      id="F_437dbe81-c6c6-4562-b388-f45a9f416060"
      unitRef="U_USD">13067000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_b156f885-8692-4ecf-bf11-f2e6c2c97795"
      decimals="-3"
      id="F_01010394-25cf-49c6-8a28-1b4ee597987c"
      unitRef="U_USD">7766000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_8f915973-7e56-4b21-9f25-8542155d2101"
      decimals="-3"
      id="F_ef56af89-209f-4c0d-a692-a987e7a537ac"
      unitRef="U_USD">28629000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_28f99d5a-d64c-4e7b-8a46-afb927c32234"
      decimals="-3"
      id="F_f37ca0a4-8bba-477c-95cc-cc6bab6a48d6"
      unitRef="U_USD">19305000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_b17712b6-e1df-4014-af5c-fd1016d8f5cd"
      decimals="-3"
      id="F_3a19049f-9141-4e12-a41c-57ca397bf03a"
      unitRef="U_USD">12610000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="-3"
      id="F_fb0ca2e8-859a-4e6b-ae45-cf020abdf021"
      unitRef="U_USD">50717000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="-3"
      id="F_e15affb4-d693-4255-8d26-ea7efd109a2f"
      unitRef="U_USD">32372000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="-3"
      id="F_ed53ceaf-4db0-4f03-91b0-ef3be7051eef"
      unitRef="U_USD">20376000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_e8f22f47-0c1a-40b3-b280-9fb794e483ac">&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table presents the summary of stock option activity for the period:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:43%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.96%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.96%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:16.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Price ($)&lt;/span&gt;&lt;span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Intrinsic&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding, December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,638,232&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.55&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;105,405&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,315,645&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30.90&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;780,725&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.47&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,651&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeited, cancelled or expired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;55,370&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24.50&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding, December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,117,782&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18.75&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;147,214&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,542,473&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35.29&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;587,536&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13.58&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,526&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeited, cancelled or expired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;178,217&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31.49&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding, December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,894,502&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23.56&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;200,122&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,062,819&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;42.93&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,040,136&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.43&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,416&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeited, cancelled or expired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;207,896&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;38.18&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding, December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,709,289&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29.90&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;111,202&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercisable, December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,927,638&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22.30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100,214&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:11.204%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:justify;"&gt;&lt;span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;font-kerning:none;min-width:3.0035136717870174%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(1)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;During the year ended December 31, 2024, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,144&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &#x2013; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,320&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and 2022 &#x2013; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;68,930&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;) stock options were exercised for the same number of common shares in exchange for cash. In the same period, the Company issued &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;729,965&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(2023 &#x2013; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;377,114&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and 2022 &#x2013; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;510,671&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;) common shares for the cashless exercise of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,034,992&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(2023 &#x2013; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;583,216&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and 2022 &#x2013; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;711,795&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;) stock options.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_7bc29ce6-ec8e-46b1-9da8-77d97bcac7c2"
      decimals="INF"
      id="F_dc4ef384-3f1d-46da-bff6-4bfb89aaca90"
      unitRef="U_shares">5638232</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_7bc29ce6-ec8e-46b1-9da8-77d97bcac7c2"
      decimals="2"
      id="F_e24e7583-a360-4a4e-91d0-fa1acdf62d1b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">12.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_7bc29ce6-ec8e-46b1-9da8-77d97bcac7c2"
      decimals="-3"
      id="F_93f681b5-4c1b-4eff-978b-7124be99ef2b"
      unitRef="U_USD">105405000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="INF"
      id="F_32c25da7-510a-4bfd-8101-06b09e666169"
      unitRef="U_shares">2315645</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="2"
      id="F_40f1f344-f0b8-456d-bd3d-62cd4252aa97"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">30.90</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="INF"
      id="F_a60e40d6-f0a7-4664-9557-159b0c1dda9e"
      unitRef="U_shares">780725</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="2"
      id="F_d722f20f-3a0c-4259-9816-37268b701b21"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">9.47</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="-3"
      id="F_fed44b0c-52cd-4eae-88c2-338d4f129cc3"
      unitRef="U_USD">19651000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="INF"
      id="F_be2afc5e-184a-40e4-be2c-3cecc1688843"
      unitRef="U_shares">55370</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="2"
      id="F_197ac13f-1201-439a-a3ac-76f583dca89b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">24.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_959e7299-f8b2-49e1-8078-5dac2b5e2683"
      decimals="INF"
      id="F_53a9a176-0cf2-4169-acf5-6366779c73d8"
      unitRef="U_shares">7117782</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_959e7299-f8b2-49e1-8078-5dac2b5e2683"
      decimals="2"
      id="F_101724e2-7f06-49ac-9a56-8ec269444a35"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">18.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_959e7299-f8b2-49e1-8078-5dac2b5e2683"
      decimals="-3"
      id="F_f57fae6d-4851-4262-a7f7-d1fc2c85d37c"
      unitRef="U_USD">147214000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="INF"
      id="F_a44b554c-4c93-4ed4-b2ee-6040f6e014ae"
      unitRef="U_shares">2542473</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="2"
      id="F_d6670b95-d8d9-420a-b328-d56f43822bc4"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">35.29</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="INF"
      id="F_87ca79e6-4ead-485a-ba2d-df4c28b5870e"
      unitRef="U_shares">587536</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="2"
      id="F_72bcee06-f3a0-4c9d-bb5b-bdc295aad69a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">13.58</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="-3"
      id="F_ae78d418-87e0-4786-9766-7313bf824e90"
      unitRef="U_USD">14526000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="INF"
      id="F_21c2d6b7-a4e4-4122-92de-1cd0810762a4"
      unitRef="U_shares">178217</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="2"
      id="F_1603deb6-c5bf-4acc-8e57-a36310b2d60d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">31.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35"
      decimals="INF"
      id="F_fb079c1f-48a4-409e-bd7f-e4b84cfd5a92"
      unitRef="U_shares">8894502</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35"
      decimals="2"
      id="F_d851e488-ab29-482c-8f44-1f7e5b343812"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">23.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35"
      decimals="-3"
      id="F_dc4b1eb4-a4fc-40b4-ae1b-3cbaa989d939"
      unitRef="U_USD">200122000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="INF"
      id="F_6254e2fc-a080-4789-a3af-7cf9cc6b0420"
      unitRef="U_shares">3062819</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="2"
      id="F_0d0d5a61-c3a5-48e8-a44a-dade357b5ed6"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">42.93</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="INF"
      id="F_97da7800-5198-4176-93f5-1e6f81beb772"
      unitRef="U_shares">1040136</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="2"
      id="F_0a679030-822f-43e3-a105-321729435498"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">12.43</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="-3"
      id="F_62b6908a-ac54-4e4c-9876-eba3774dd7e3"
      unitRef="U_USD">30416000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="INF"
      id="F_8c4e4f80-6ff5-4b9b-b276-13c6dcaed42c"
      unitRef="U_shares">207896</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="2"
      id="F_1f8196c2-dd02-4b1c-8d90-2842af03b570"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">38.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f"
      decimals="INF"
      id="F_14c58473-386f-4866-a56a-2afd727fd910"
      unitRef="U_shares">10709289</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f"
      decimals="2"
      id="F_dad7bcd7-a990-434d-9ff3-40b997440293"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">29.9</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f"
      decimals="-3"
      id="F_4876a36d-3077-4faf-8610-62c2dde799cd"
      unitRef="U_USD">111202000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f"
      decimals="0"
      id="F_6c98e2f3-d166-40f2-9bc4-45cda3ee7bd4"
      unitRef="U_shares">5927638</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f"
      decimals="2"
      id="F_63f7f217-7308-4e74-91e9-c78c0b8a8b49"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">22.3</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f"
      decimals="-3"
      id="F_0c7c9b2a-5a1c-4de1-aa0c-eb7157ee3188"
      unitRef="U_USD">100214000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <xene:StockOptionsExercisedForNumberOfCommonSharesForCash
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="INF"
      id="F_652d3bf9-3a2d-43d3-80ad-544a1cc650dd"
      unitRef="U_shares">5144</xene:StockOptionsExercisedForNumberOfCommonSharesForCash>
    <xene:StockOptionsExercisedForNumberOfCommonSharesForCash
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="INF"
      id="F_8e7de686-ad5b-468e-a3e3-d8ac5f044f40"
      unitRef="U_shares">4320</xene:StockOptionsExercisedForNumberOfCommonSharesForCash>
    <xene:StockOptionsExercisedForNumberOfCommonSharesForCash
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="INF"
      id="F_334ac0f4-fe81-4f01-b449-ef688383ef60"
      unitRef="U_shares">68930</xene:StockOptionsExercisedForNumberOfCommonSharesForCash>
    <xene:CommonStockIssuedForCashlessExercise
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="INF"
      id="F_12b2c0af-47a7-4a01-9807-40b9f3adb057"
      unitRef="U_shares">729965</xene:CommonStockIssuedForCashlessExercise>
    <xene:CommonStockIssuedForCashlessExercise
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="INF"
      id="F_164abfc9-44a2-4138-95d1-ff75080cab6b"
      unitRef="U_shares">377114</xene:CommonStockIssuedForCashlessExercise>
    <xene:CommonStockIssuedForCashlessExercise
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="INF"
      id="F_c049626c-b7b9-4407-b89d-22cafc75e7d0"
      unitRef="U_shares">510671</xene:CommonStockIssuedForCashlessExercise>
    <xene:CashlessExerciseOfStockOptions
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="INF"
      id="F_daaeaa7e-5994-4b30-822a-d829f5a3c63d"
      unitRef="U_shares">1034992</xene:CashlessExerciseOfStockOptions>
    <xene:CashlessExerciseOfStockOptions
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="INF"
      id="F_1348c32d-91c3-444f-bb31-4560365b877c"
      unitRef="U_shares">583216</xene:CashlessExerciseOfStockOptions>
    <xene:CashlessExerciseOfStockOptions
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="INF"
      id="F_4f9aa6bf-bf38-4755-947e-edf8b764639e"
      unitRef="U_shares">711795</xene:CashlessExerciseOfStockOptions>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_a9c07741-091d-4803-80fb-c124327b0f4c">P7Y3M10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_fe248b17-436e-4ef2-8d1f-834dc21b0f37">P6Y2M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_c57bc58b-ada1-4182-93a4-3b89c3cc313c">&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The weighted average option pricing assumptions are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.123%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.584999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.584999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.584999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Average risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.05&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.93&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.39&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;66&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;69&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Average expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.75&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.94&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.16&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted average fair value of stock options granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26.48&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22.52&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19.78&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="4"
      id="F_fe858673-4fa5-4bf1-b3c5-9d569017044e"
      unitRef="U_pure">0.0405</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="4"
      id="F_4eecaad9-3785-4695-95f7-69b8f714e782"
      unitRef="U_pure">0.0393</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="4"
      id="F_ef63ad90-0443-45a0-bc57-04ec4725e858"
      unitRef="U_pure">0.0239</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="2"
      id="F_cf19897b-a51d-4727-98e6-d708891125ee"
      unitRef="U_pure">0.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="2"
      id="F_e9d3125c-7f4e-47e7-ae97-2f4feee2ae19"
      unitRef="U_pure">0.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="2"
      id="F_382e33c9-149f-4837-9e34-3822b67fbae9"
      unitRef="U_pure">0.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_561bb163-6d55-4c24-966e-e843fcb0411c">P5Y9M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      id="F_4a5774d5-68b6-4d66-a1a9-373c7d49e24d">P5Y11M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      id="F_bdddbfc8-18c8-4623-9d69-0e67eafcaf13">P6Y1M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="4"
      id="F_32fa4a20-fca9-4a1f-982a-2213bbe25552"
      unitRef="U_pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="4"
      id="F_47831a46-f015-4ce1-b7e2-33423eb0d249"
      unitRef="U_pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="4"
      id="F_0ff06690-f899-4f6c-8f9c-79be82e5c7b3"
      unitRef="U_pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="2"
      id="F_6cf79fef-fc4e-4123-9ebb-9a4f74bbf097"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">26.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="2"
      id="F_018ce381-81dc-4cf3-b0b9-3dd8f5d17caa"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">22.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="2"
      id="F_d9bbbed1-cd96-46a5-a777-7fd4807d65c2"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">19.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_2164335e-365c-4871-86cc-143a221b9e23">&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A summary of the Company&#x2019;s unvested stock option activity and related information for the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:48.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:22.9%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:22.9%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of&lt;br/&gt;Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted Average &lt;br/&gt;Grant Date&lt;br/&gt;Fair Value ($)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Unvested, January 1, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,105,324&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20.53&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,062,819&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26.48&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,178,816&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19.91&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeited or cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;207,676&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22.04&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Unvested, December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,781,651&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24.56&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35"
      decimals="0"
      id="F_d0b2e9f2-3f72-4f01-81db-ba3c2946c0a4"
      unitRef="U_shares">4105324</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35"
      decimals="2"
      id="F_4a42eb4b-d751-49ac-841a-969e945f2027"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">20.53</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="0"
      id="F_aa9ac6f2-1256-453d-857c-f7d568049b28"
      unitRef="U_shares">3062819</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="2"
      id="F_539847e3-d436-45fd-8185-e34646fbe5f9"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">26.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="0"
      id="F_57833d76-a93b-4cae-ba2e-02365046deb7"
      unitRef="U_shares">2178816</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="2"
      id="F_1c7be198-4f95-48ca-81dc-41897786a6e8"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">19.91</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="0"
      id="F_8478a086-44cf-4b14-83d3-ab568e0cbf05"
      unitRef="U_shares">207676</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="2"
      id="F_d54633d9-333e-464e-b033-0272a802a06c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">22.04</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f"
      decimals="0"
      id="F_769d1a2b-8786-45d4-9f53-814c05e93d92"
      unitRef="U_shares">4781651</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f"
      decimals="2"
      id="F_58f4bce3-6b5f-445f-ab5f-55998bd05c99"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">24.56</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="-3"
      id="F_abee601f-00c2-46a4-bddd-a0e828d0fff8"
      unitRef="U_USD">43375000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="-3"
      id="F_370af6ef-e47a-4371-8717-2f300d76afdc"
      unitRef="U_USD">29233000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="-3"
      id="F_01cb5fc1-bf3b-431d-8973-68e37cf5913f"
      unitRef="U_USD">13752000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f"
      decimals="-3"
      id="F_0dd293f8-5ffb-478b-a7e8-b0a9bf94d74d"
      unitRef="U_USD">99779000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_206f1235-ad11-4446-bfb6-eabd29eb5143">P2Y7M20D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_b54bd813-bcee-4527-8ce0-2c924fa24d1d"
      decimals="INF"
      id="F_059acf71-67f3-4379-be44-60d22f462cef"
      unitRef="U_shares">210000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_b54bd813-bcee-4527-8ce0-2c924fa24d1d"
      decimals="2"
      id="F_65103e7c-f7a0-4559-880c-6fc9d9c5b40f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">43.9</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_b54bd813-bcee-4527-8ce0-2c924fa24d1d"
      decimals="INF"
      id="F_ce46828c-cc05-4d38-aa0f-6021dc208e74"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="C_878cde20-56e4-4ebb-9add-30ed0cd3a427"
      decimals="-3"
      id="F_097f0f22-553e-4c5c-a85b-3ee8f4aac96a"
      unitRef="U_USD">2267000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_878cde20-56e4-4ebb-9add-30ed0cd3a427"
      decimals="-3"
      id="F_eeb2c88b-28f8-4605-b5ec-80e34e38590b"
      unitRef="U_USD">4609000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_32311f37-d351-4094-8188-e5c4e217f4c9"
      decimals="INF"
      id="F_0e007c5d-4852-48cb-8f82-b5feca4ca03a"
      unitRef="U_shares">2868000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <xene:StockIssuedDuringPeriodCommonSharesCancelled
      contextRef="C_ae6f53cc-56cf-4ba7-a7f9-cfdd12d99cbe"
      decimals="INF"
      id="F_a14df433-abc3-4830-9cb2-cf561311a8ec"
      unitRef="U_shares">2868000</xene:StockIssuedDuringPeriodCommonSharesCancelled>
    <us-gaap:PreferredStockConversionBasis
      contextRef="C_32311f37-d351-4094-8188-e5c4e217f4c9"
      id="F_4c2104fe-7a00-4192-b598-12e031ab9a59">one-for-one</us-gaap:PreferredStockConversionBasis>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_9fcee154-e6d6-49cc-9847-f1ad966fc19f"
      decimals="INF"
      id="F_90b59748-f0fc-4e77-bd01-1fb89f053ef2"
      unitRef="U_shares">1852000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_0031901f-461f-45c7-b720-6eb40956e950"
      decimals="INF"
      id="F_5a0ec61d-9a3e-4185-998a-ab5c1b2e3eea"
      unitRef="U_shares">1852000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_71cbb8cb-9965-4745-9068-1c329cd37142"
      decimals="INF"
      id="F_f306e76d-8e43-4320-ae26-533bda67a6cb"
      unitRef="U_shares">1016000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_f7541451-edb6-4acb-8f0a-790bab15be88"
      decimals="INF"
      id="F_2ecb89a8-640f-45de-907a-731d2de14285"
      unitRef="U_shares">1016000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <xene:ScheduleOfPreFundedWarrantsActivityTableTextBlock
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_18c1f253-541a-4afd-8fb8-2035d55aee82">&lt;p style="margin-left:8.787%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the pre-funded warrants activity for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024, 2023, and 2022:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:8.8%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.975%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.25%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:30.775%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of Pre-funded&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;warrants outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding, December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,775,996&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Issued&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;327,868&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding, December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,103,864&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Issued&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;769,230&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,700,013&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding, December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,173,081&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Issued&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding, December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,173,081&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;div class="item-list-element-wrapper" style="margin-left:9.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:justify;"&gt;&lt;span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;font-kerning:none;min-width:2.9590591368023964%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(1)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;During the year ended December 31, 2023, the Company issued &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,700,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; common shares upon the exercise of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,700,013&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; pre-funded warrants pursuant to a net exercise mechanism under the warrants.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;</xene:ScheduleOfPreFundedWarrantsActivityTableTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_7bc29ce6-ec8e-46b1-9da8-77d97bcac7c2"
      decimals="INF"
      id="F_bafc9c82-7b56-4460-82a3-7e8074d2a0c0"
      unitRef="U_shares">2775996</us-gaap:ClassOfWarrantOrRightOutstanding>
    <xene:NumberOfWarrantsIssued
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="INF"
      id="F_60d748a7-6aa5-433d-9dbb-527acc4fb312"
      unitRef="U_shares">327868</xene:NumberOfWarrantsIssued>
    <xene:NumberOfWarrantsExercised
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="INF"
      id="F_7cd5a51a-4e0c-47e4-8a7d-ad9854bb0035"
      unitRef="U_shares">0</xene:NumberOfWarrantsExercised>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_959e7299-f8b2-49e1-8078-5dac2b5e2683"
      decimals="INF"
      id="F_a7aa28f1-87c8-4284-85f7-cdbc3a504fa7"
      unitRef="U_shares">3103864</us-gaap:ClassOfWarrantOrRightOutstanding>
    <xene:NumberOfWarrantsIssued
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="INF"
      id="F_6d31be29-5169-47e2-ab2a-e88f0d72ed00"
      unitRef="U_shares">769230</xene:NumberOfWarrantsIssued>
    <xene:NumberOfWarrantsExercised
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="INF"
      id="F_7f6fa339-355f-44de-ac2f-34f86d01096d"
      unitRef="U_shares">-1700013</xene:NumberOfWarrantsExercised>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35"
      decimals="INF"
      id="F_5e4aa73c-153b-4f66-a41e-17cd4a0d5ff4"
      unitRef="U_shares">2173081</us-gaap:ClassOfWarrantOrRightOutstanding>
    <xene:NumberOfWarrantsIssued
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="INF"
      id="F_ad8620fd-02e6-4340-88c0-be4670c649df"
      unitRef="U_shares">0</xene:NumberOfWarrantsIssued>
    <xene:NumberOfWarrantsExercised
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="INF"
      id="F_270ea92d-15db-4b6e-9615-ce337efa0071"
      unitRef="U_shares">0</xene:NumberOfWarrantsExercised>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f"
      decimals="INF"
      id="F_8c0696a2-5246-4417-a4fb-36bbcda1dac4"
      unitRef="U_shares">2173081</us-gaap:ClassOfWarrantOrRightOutstanding>
    <xene:CommonStockIssuedForPreFundedWarrants
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="INF"
      id="F_cc492a75-6d9b-43f2-85cd-f9b717d0bbd7"
      unitRef="U_shares">1700000</xene:CommonStockIssuedForPreFundedWarrants>
    <xene:NumberOfWarrantsExercised
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="INF"
      id="F_8bdb4b60-573b-4775-8578-cd254ac9842a"
      unitRef="U_shares">-1700013</xene:NumberOfWarrantsExercised>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f"
      decimals="4"
      id="F_6a76bf5a-08a4-41a6-a142-03fdc3e0da1a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <xene:WarrantsExerciseDescription
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      id="F_0bb91995-fdc5-4d7c-8d40-053d16ef2eb8">The Company may not affect the exercise of any pre-funded warrant, and a holder will not be entitled to exercise any portion of any pre-funded warrant that, upon giving effect to such exercise, would cause: (i) the aggregate number of common shares beneficially owned by such holder, together with its affiliates, to exceed 4.99% of the total number of common shares outstanding immediately after giving effect to the exercise; or (ii) the combined voting power of the Company&#x2019;s securities beneficially owned by such holder, together with its affiliates, to exceed 4.99% of the combined voting power of all of the Company&#x2019;s securities immediately outstanding after giving effect to the exercise, which percentage may be changed at the holder&#x2019;s election to a higher or lower percentage not in excess of 19.99% upon at least 61 days&#x2019; notice to the Company.</xene:WarrantsExerciseDescription>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="C_4936f148-6a25-41e1-bce8-c9880d5a5e27"
      decimals="-3"
      id="F_427a4222-1f8a-448a-8c40-c7a49c14d959"
      unitRef="U_USD">23477000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="C_91296a7e-80ef-40a4-84c1-540e6b53ed31"
      decimals="-3"
      id="F_bfd421be-70e0-4290-bcff-81283405e262"
      unitRef="U_USD">9387000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35"
      decimals="INF"
      id="F_8fcb6ae7-54e7-467b-bbd3-38d63aafab6f"
      unitRef="U_shares">2173081</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35"
      decimals="INF"
      id="F_cc90abb1-1756-43f4-b4df-844700596685"
      unitRef="U_shares">2173081</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="C_959e7299-f8b2-49e1-8078-5dac2b5e2683"
      decimals="INF"
      id="F_d8bf3838-07a9-4793-9414-6943eaff3e05"
      unitRef="U_shares">3103864</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="C_5a1c869a-3031-45a1-b8b8-07258801ac33"
      decimals="INF"
      id="F_22c31423-39cd-49da-a2f2-cece31b494ad"
      unitRef="U_shares">40000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="C_4984049b-32ea-46b9-98fa-440cbfdf680d"
      decimals="INF"
      id="F_14f1bae3-6b63-4aeb-a055-39a90ae6cf24"
      unitRef="U_shares">40000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_5a1c869a-3031-45a1-b8b8-07258801ac33"
      decimals="2"
      id="F_3d6f1ab0-0c23-4999-86c7-5bae3516d4c1"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">9.79</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_3e3f34a4-6006-4bab-80cd-64b6307ccc2d">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;10.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Collaboration agreements:&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Neurocrine Biosciences license and collaboration agreement&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11pt;font-family:'Calibri',sans-serif;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Revenue was as follows for the years ended December 31, 2024, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2023 and 2022:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:56.449%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.518%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.518%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.518%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="8" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Recognition of the transaction price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;372&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development services&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,938&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Milestone payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,124&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;Total revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,434&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In December 2019, the Company entered into the Neurocrine Collaboration Agreement with Neurocrine Biosciences granting the Company an exclusive license to NBI-921352 (formerly XEN901) and certain pre-clinical compounds for development (the &#x201c;DTCs&#x201d;). The agreement also includes a two-year research collaboration to discover, identify and develop additional novel Nav1.6 and Nav1.2/1.6 inhibitors (&#x201c;Research Compounds&#x201d;). The Company and Neurocrine Biosciences collaborated on the conduct of two collaboration programs: (a) a joint research collaboration to discover, identify and preclinically develop Research Compounds (the &#x201c;Research Program&#x201d;), which was completed in June 2022, and (b) a collaborative development program for NBI-921352 and two DTCs selected by the joint steering committee. Under the arrangement, the Company was entitled to funding for certain full-time equivalent and external costs incurred by the Company for the research and development services requested by Neurocrine Biosciences, and these services were priced at estimated fair value.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is eligible to receive pre-commercial and commercial milestone payments with respect to the licensed products totaling up to an additional $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,667,500&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, comprised of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,067,500&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; in additional development and regulatory milestone payments related to NBI-921352 and other licensed Nav1.6 or Nav1.2/1.6 inhibitor products, and up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;600,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; in additional sales-based milestone payments for multiple products. In addition, the Company is eligible to receive royalties on net sales in and outside the U.S., ranging from (a) for NBI-921352, a low double-digit percentage to a mid-teen percentage and a high-single digit percentage to low double-digit percentage, respectively; (b) for DTCs, a high-single digit percentage to a low double-digit percentage and a mid-single digit percentage to a high-single digit percentage, respectively; and (c) for Research Compounds, a mid-single digit percentage to a high-single digit percentage and a tiered mid-single digit percentage, respectively. Royalty rates are subject to customary reductions.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has an option to co-fund &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the development costs of NBI-921352 or another product candidate in the U.S., exercisable upon achievement of certain milestones, in exchange for increased U.S. royalties. The Company has not exercised this option as of December 31, 2024.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In January 2022, based on the receipt of the U.S. Food and Drug Administration&#x2019;s (&#x201c;FDA&#x201d;) full IND acceptance for NBI-921352, the Company received an aggregate milestone payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; in the form of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,750&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; in cash and a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,250&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; equity investment in the Company (note 9a). The equity investment was measured at fair value of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,876&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; on the date of issuance and the resulting premium of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;374&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, with the cash payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,750&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, was recognized as revenue in the period as the Company did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t have any remaining performance obligations in relation to this milestone on the date it was achieved.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In February 2025, NBI-921355, a Nav1.2 and Nav1.6 sodium channel inhibitor in development for the potential treatment for certain types of epilepsy, has progressed into a Phase 1 clinical study in healthy adult participants, triggering an anticipated $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,500&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; milestone payment to the Company.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_10f842c9-6e11-406a-a0fc-186aaccfeb5f">&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Revenue was as follows for the years ended December 31, 2024, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2023 and 2022:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:56.449%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.518%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.518%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.518%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="8" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Recognition of the transaction price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;372&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development services&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,938&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Milestone payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,124&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;Total revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,434&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <xene:RecognitionOfTransactionPrice
      contextRef="C_0cc08d87-8298-44c1-a950-93f5421805de"
      decimals="-3"
      id="F_92a1ec74-9826-4c7f-9eff-8e85944924d1"
      unitRef="U_USD">0</xene:RecognitionOfTransactionPrice>
    <xene:RecognitionOfTransactionPrice
      contextRef="C_95fad8c0-4f7c-4bda-85cb-111b56b2cfba"
      decimals="-3"
      id="F_3a329517-0994-470a-8917-a43cbe296956"
      unitRef="U_USD">0</xene:RecognitionOfTransactionPrice>
    <xene:RecognitionOfTransactionPrice
      contextRef="C_620b04e6-7aa7-4a6e-b3fe-1655d998a981"
      decimals="-3"
      id="F_e408482a-a14f-472d-bc1e-e93d9101e93c"
      unitRef="U_USD">372000</xene:RecognitionOfTransactionPrice>
    <xene:ResearchAndDevelopmentServices
      contextRef="C_0cc08d87-8298-44c1-a950-93f5421805de"
      decimals="-3"
      id="F_d00c3aab-63e0-4e99-9bc3-2a8eb8514d70"
      unitRef="U_USD">0</xene:ResearchAndDevelopmentServices>
    <xene:ResearchAndDevelopmentServices
      contextRef="C_95fad8c0-4f7c-4bda-85cb-111b56b2cfba"
      decimals="-3"
      id="F_974dcb87-4200-4f27-bc8a-ad3731200a4e"
      unitRef="U_USD">0</xene:ResearchAndDevelopmentServices>
    <xene:ResearchAndDevelopmentServices
      contextRef="C_620b04e6-7aa7-4a6e-b3fe-1655d998a981"
      decimals="-3"
      id="F_2a3d7196-d173-4bf8-bd7a-217c641acaa8"
      unitRef="U_USD">1938000</xene:ResearchAndDevelopmentServices>
    <xene:MilestonePayment
      contextRef="C_0cc08d87-8298-44c1-a950-93f5421805de"
      decimals="-3"
      id="F_01e888f3-8e9f-4797-ab78-7e11cdf4f33e"
      unitRef="U_USD">0</xene:MilestonePayment>
    <xene:MilestonePayment
      contextRef="C_95fad8c0-4f7c-4bda-85cb-111b56b2cfba"
      decimals="-3"
      id="F_5d46d81f-0cb5-47b0-8305-370dc8264b28"
      unitRef="U_USD">0</xene:MilestonePayment>
    <xene:MilestonePayment
      contextRef="C_38463dbb-8c79-451f-b24c-b502ace3c611"
      decimals="-3"
      id="F_39b921b5-b2eb-4c84-bc26-91e389a52c3a"
      unitRef="U_USD">7124000</xene:MilestonePayment>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_779d7deb-a421-4227-83c3-8ac2dfc35f90"
      decimals="-3"
      id="F_6dd6f495-7fc4-45b0-ad8a-e6c64b689918"
      unitRef="U_USD">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_a52ed6c9-11b1-42c8-b685-959088b4d45d"
      decimals="-3"
      id="F_481a29a7-3199-4d18-bcc1-db0ab5a96533"
      unitRef="U_USD">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_fa095704-4846-4a02-9bc0-f78ed31e8f79"
      decimals="-3"
      id="F_f7461ae4-54c6-437d-b96e-a6683be02197"
      unitRef="U_USD">9434000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <xene:PotentialMilestonePaymentsReceivable
      contextRef="C_494ce105-0b9f-4d43-a7ae-9d4280f4ce87"
      decimals="-3"
      id="F_a693516d-fd1f-43b5-bdca-c96d9352c581"
      unitRef="U_USD">1667500000</xene:PotentialMilestonePaymentsReceivable>
    <xene:PotentialMilestonePaymentsReceivable
      contextRef="C_7c1e5b7a-577b-4134-b465-b0ccd0cdbae9"
      decimals="-3"
      id="F_67f47cd2-1a50-491c-9b7d-4ad5add40fb2"
      unitRef="U_USD">1067500000</xene:PotentialMilestonePaymentsReceivable>
    <xene:PotentialMilestonePaymentsReceivable
      contextRef="C_b0bfec10-59dd-4234-9f58-271c37fde21d"
      decimals="-3"
      id="F_50974bf3-fa5e-4c3c-ac16-d7c9f556453c"
      unitRef="U_USD">600000000</xene:PotentialMilestonePaymentsReceivable>
    <xene:PercentageOfOptionToFundDevelopmentCostsUponAchievementOfCertainMilestones
      contextRef="C_7e416cfe-b299-48b2-a9f3-089ca9635d44"
      decimals="2"
      id="F_d2874ab3-9bc6-4ded-adf0-d7d5754167a2"
      unitRef="U_pure">0.50</xene:PercentageOfOptionToFundDevelopmentCostsUponAchievementOfCertainMilestones>
    <xene:AggregateMilestonePaymentReceived
      contextRef="C_16c2e333-259f-4e18-b025-1a7840b2cf5d"
      decimals="-3"
      id="F_0d5e9640-5588-4dcc-b485-afbd2a93c18f"
      unitRef="U_USD">15000000</xene:AggregateMilestonePaymentReceived>
    <xene:MilestonePaymentReceivedInCash
      contextRef="C_16c2e333-259f-4e18-b025-1a7840b2cf5d"
      decimals="-3"
      id="F_682a2743-dd1a-43d2-ad86-54c41dc3c98a"
      unitRef="U_USD">6750000</xene:MilestonePaymentReceivedInCash>
    <xene:MilestonePaymentReceivedInEquityInvestment
      contextRef="C_16c2e333-259f-4e18-b025-1a7840b2cf5d"
      decimals="-3"
      id="F_8a91c7d8-91f1-4295-90ca-7b27ddf67b65"
      unitRef="U_USD">8250000</xene:MilestonePaymentReceivedInEquityInvestment>
    <xene:MilestonePaymentReceivedInEquityInvestmentMeasuredAtFairValue
      contextRef="C_16c2e333-259f-4e18-b025-1a7840b2cf5d"
      decimals="-3"
      id="F_4659953d-fed0-4515-acd4-7dd0d23bd12d"
      unitRef="U_USD">7876000</xene:MilestonePaymentReceivedInEquityInvestmentMeasuredAtFairValue>
    <xene:CollaborateMilestoneAgreementPremiumRelatedToEquityInvestment
      contextRef="C_16c2e333-259f-4e18-b025-1a7840b2cf5d"
      decimals="-3"
      id="F_35fb5846-db35-4b0c-969e-95e3447bde37"
      unitRef="U_USD">374000</xene:CollaborateMilestoneAgreementPremiumRelatedToEquityInvestment>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_16c2e333-259f-4e18-b025-1a7840b2cf5d"
      decimals="-3"
      id="F_09d1ca16-e46d-4b97-828f-d8ef1f7ec4fd"
      unitRef="U_USD">6750000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <xene:PerformanceObligationsRelatedToMilestone
      contextRef="C_16c2e333-259f-4e18-b025-1a7840b2cf5d"
      decimals="INF"
      id="F_8f821d61-33bb-40c9-a62b-b8a8b328f1e7"
      unitRef="U_USD">0</xene:PerformanceObligationsRelatedToMilestone>
    <xene:MilestonePayment
      contextRef="C_3e2186d8-8a70-4a7a-821a-ef78292cca8c"
      decimals="-3"
      id="F_6554e041-2f03-4e5f-baf6-0e8fd392b5c7"
      unitRef="U_USD">7500000</xene:MilestonePayment>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_62569122-e5c8-4aea-8f4b-6ab610f363b4">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;11.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Net loss per common share&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:11pt;font-family:'Calibri',sans-serif;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table presents the calculation of basic and diluted net loss per common share for the years ended December 31, 2024, 2023 and 2022:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:46.109%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.64%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.323%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.64%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.323%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.64%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.323%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Numerator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;234,330&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;182,393&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;125,373&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss attributable to preferred shareholders&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;437&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss attributable to common shareholders&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;234,330&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;182,393&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;124,936&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Denominator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Common shares (weighted average)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;75,721,562&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;64,739,678&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;57,599,510&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Pre-funded warrants (weighted average)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,173,081&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,149,327&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,942,632&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted average common shares &lt;br/&gt;&#160;&#160;&#160;outstanding &#x2013; basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;77,894,643&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;66,889,005&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;60,542,142&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss per common share &#x2013; basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.01&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.73&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.06&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The weighted average number of common shares used in the basic and diluted net loss per common share calculations includes the weighted average pre-funded warrants outstanding during the period as they are exercisable at any time for nominal cash consideration (note 9e).&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company reported net losses for each of the years ended December 31, 2024, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and 2022, and therefore excluded all potentially dilutive outstanding securities from the computation of diluted net loss per common share as their inclusion would have had an anti-dilutive effect.&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_cf7c349b-13b8-436c-8cde-9a4d099acb79">&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table presents the calculation of basic and diluted net loss per common share for the years ended December 31, 2024, 2023 and 2022:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:46.109%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.64%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.323%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.64%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.323%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.64%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.323%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Numerator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;234,330&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;182,393&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;125,373&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss attributable to preferred shareholders&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;437&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss attributable to common shareholders&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;234,330&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;182,393&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;124,936&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Denominator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Common shares (weighted average)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;75,721,562&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;64,739,678&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;57,599,510&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Pre-funded warrants (weighted average)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,173,081&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,149,327&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,942,632&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted average common shares &lt;br/&gt;&#160;&#160;&#160;outstanding &#x2013; basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;77,894,643&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;66,889,005&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;60,542,142&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss per common share &#x2013; basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.01&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.73&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.06&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="-3"
      id="F_76ba4724-0de0-44b9-bbbc-3e18635877d8"
      unitRef="U_USD">-234330000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="-3"
      id="F_7f4f17a3-2892-49fc-a08c-97955407f729"
      unitRef="U_USD">-182393000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="-3"
      id="F_65fc303a-4d9e-4435-affa-e9e4ec214e78"
      unitRef="U_USD">-125373000</us-gaap:NetIncomeLoss>
    <xene:NetIncomeLossAvailableToPreferredStockholdersBasic
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="-3"
      id="F_37db3456-00c7-434c-99f0-c9862cb958f6"
      unitRef="U_USD">437000</xene:NetIncomeLossAvailableToPreferredStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="-3"
      id="F_f6571758-3911-4ca8-b85e-9d4d9ec72e77"
      unitRef="U_USD">-234330000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="-3"
      id="F_c25535cb-581d-4990-834e-78b107811b0b"
      unitRef="U_USD">-182393000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="-3"
      id="F_17a9c80a-0962-40d7-94e2-ea4721a2876f"
      unitRef="U_USD">-124936000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <xene:WeightedAverageNumberOfCommonShares
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="0"
      id="F_58c41eb5-61b5-4939-9ae0-da18743b0be8"
      unitRef="U_shares">75721562</xene:WeightedAverageNumberOfCommonShares>
    <xene:WeightedAverageNumberOfCommonShares
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="0"
      id="F_416ffaf5-1541-4a81-b987-ffadf8bd4929"
      unitRef="U_shares">64739678</xene:WeightedAverageNumberOfCommonShares>
    <xene:WeightedAverageNumberOfCommonShares
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="0"
      id="F_3187ec8d-a797-4ac9-8724-e956721a4c74"
      unitRef="U_shares">57599510</xene:WeightedAverageNumberOfCommonShares>
    <xene:WeightedAverageNumberOfPrefundedWarrants
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="0"
      id="F_a04abdac-2dc3-483a-af3e-cf3c63f29c1c"
      unitRef="U_shares">2173081</xene:WeightedAverageNumberOfPrefundedWarrants>
    <xene:WeightedAverageNumberOfPrefundedWarrants
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="0"
      id="F_a527cc88-8abb-424b-9eee-ee398ea424eb"
      unitRef="U_shares">2149327</xene:WeightedAverageNumberOfPrefundedWarrants>
    <xene:WeightedAverageNumberOfPrefundedWarrants
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="0"
      id="F_94676e46-caa0-4ad9-91b3-7eb471be39ba"
      unitRef="U_shares">2942632</xene:WeightedAverageNumberOfPrefundedWarrants>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="0"
      id="F_4efe65eb-881c-477c-bd74-48a55ddd3e41"
      unitRef="U_shares">77894643</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="0"
      id="F_3986ce2f-7811-4a05-89ac-6873183d86c4"
      unitRef="U_shares">77894643</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="0"
      id="F_07a04cec-7181-4225-a2ee-c2d615d3a784"
      unitRef="U_shares">66889005</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="0"
      id="F_e5d46b26-4672-4a8b-8eb6-76e76d30f9a2"
      unitRef="U_shares">66889005</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="0"
      id="F_45bcff97-782b-4ba4-91ed-9df58ee3b742"
      unitRef="U_shares">60542142</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="0"
      id="F_c1a5679a-e2cb-46c6-8281-1e088e90bbd5"
      unitRef="U_shares">60542142</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="2"
      id="F_eb32766b-c46e-44bb-843e-215f69812f15"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-3.01</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="2"
      id="F_4975cb16-e1d3-4c9d-9e3a-fd1b60b9d3d0"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-3.01</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="2"
      id="F_a7f7cf19-fcc6-4997-9f70-64068ec64afc"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.73</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="2"
      id="F_30f96318-a024-4bcd-8bbb-73f4f471d1ee"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.73</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="2"
      id="F_fc6ab22b-dd8d-4299-8118-d1f0648a2d8c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.06</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="2"
      id="F_a8c21b6f-e9aa-430c-939a-36f79a411362"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.06</us-gaap:EarningsPerShareDiluted>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_2cc1c0a4-16cd-4455-a5c5-31af6b769f6f">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;12.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Commitments and contingencies:&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(a)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Asset purchase agreement with 1st Order Pharmaceuticals, Inc. (&#x201c;1st Order&#x201d;):&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In April 2017, the Company acquired azetukalner from 1st Order pursuant to an asset purchase agreement. In August 2020, the Company and 1st Order amended the asset purchase agreement to amend certain definitions in the agreement and to modify the payment schedule for certain milestones. Through December 31, 2024, the Company has paid $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; based on progress against these milestones. Future potential payments to 1st Order include up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; in regulatory milestones. There are &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; royalty obligations to 1st Order.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;   &lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(b)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Guarantees and indemnifications:&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has entered into license and research agreements with third parties that include indemnification provisions that are customary in the industry. These indemnification provisions generally require the Company to compensate the other party for certain damages and costs incurred as a result of third-party claims or damages arising from these transactions.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The maximum amount of potential future indemnification is unlimited; however, the Company currently holds commercial and product liability insurance. This insurance limits the Company&#x2019;s exposure and may enable it to recover a portion of any future amounts paid. Historically, the Company has not made any indemnification payments under such agreements and the Company believes that the fair value of these indemnification obligations is minimal. Accordingly, the Company has not recognized any liabilities relating to these obligations for any period presented.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <xene:MilestonePaymentsPaid
      contextRef="C_0451fb9b-54f6-4a4b-8ade-92b89ad35f70"
      decimals="-3"
      id="F_ff99ad22-70da-4817-9d4e-8d8253bce875"
      unitRef="U_USD">2000000</xene:MilestonePaymentsPaid>
    <xene:FuturePotentialMilestonePayments
      contextRef="C_8cda2242-cdda-436c-b1a1-5d38d90e788c"
      decimals="-3"
      id="F_8f9c5237-590c-4288-9974-f7a3ea4ac295"
      unitRef="U_USD">6000000</xene:FuturePotentialMilestonePayments>
    <xene:RoyaltyObligations
      contextRef="C_ab08f408-103c-4988-a8d5-e291b741e1ed"
      decimals="-3"
      id="F_e1a4bd5f-ca81-402d-bed6-7e512519941b"
      unitRef="U_USD">0</xene:RoyaltyObligations>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_d959a4c1-cb17-4bf4-8492-b18cc87941df">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;13.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Income taxes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Loss before income taxes for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024, 2023 and 2022 was as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.863%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.764000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.764000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.764000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Canada&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;243,410&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;174,491&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;121,335&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;United States&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,991&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,194&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,920&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Loss before income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;238,419&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;182,685&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;125,255&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The income tax recovery (expense) is allocated as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.863%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.764000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.764000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.764000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Current:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;Canada&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;United States&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,775&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;162&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,775&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;162&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;Canada&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;United States&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,864&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;292&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;44&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,864&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;292&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;44&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Income tax recovery (expense)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,089&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;292&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;118&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s wholly-owned subsidiary, Xenon Pharmaceuticals USA Inc., generates taxable income due to an intercompany service agreement with the Company. All current tax expense and deferred income tax recovery recognized for the years ended December 31, 2024, 2023 and 2022 were attributable to the United States. For the year ended December 31, 2024, the deferred income tax recovery recorded by Xenon Pharmaceuticals USA Inc. is related to the re-assessment of the realizability of its deferred tax assets.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;reconciliation of the expected Canadian statutory income tax rate to the effective income tax rate is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.863%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.764000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.764000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.764000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Tax at statutory income tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development and other credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Tax attributes expired/utilized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other non-deductible expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Effective income tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Deferred income tax assets and liabilities result from the temporary differences between the carrying amount of assets and liabilities recognized for financial statement and income tax purposes. The significant components of the Company&#x2019;s net deferred income tax assets are as follows:&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.313%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.843%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.843%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred income tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;42,830&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;38,590&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Investment tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,818&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,695&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Non-capital losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;173,352&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;119,765&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Depreciable assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,269&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,311&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred financing fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,967&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,831&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,380&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,832&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,299&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,779&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,704&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;852&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;Total deferred income tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;278,619&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;217,655&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;Deferred income tax liability:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;Operating lease right-of-use asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,097&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,411&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;Less - valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;266,856&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;214,442&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net deferred income tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,666&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;802&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The realization of deferred income tax assets is dependent upon the generation of sufficient taxable income during future periods in which the temporary differences are expected to reverse. The valuation allowance is reviewed on a quarterly basis and if the assessment of the &#x201c;more likely than not&#x201d; criteria changes, the valuation allowance is adjusted accordingly. A full valuation allowance continues to be applied against deferred income tax assets in Canada as the Company has assessed that the realization of such assets does not meet the &#x201c;more likely than not&#x201d; criteria. Deferred income tax assets recorded on the consolidated balance sheets as of December 31, 2024 and 2023, result from the temporary differences between the amounts of assets and liabilities recognized for financial statement and income tax purposes, net of valuation allowance, related to the operations of Xenon Pharmaceuticals USA Inc.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;At December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company has unclaimed tax deductions for scientific research and experimental development expenditures of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;158,629&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &#x2013; $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;142,925&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;) with no expiry.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;At December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company has $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,284&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &#x2013; $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,074&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;) of investment tax credits available to offset federal taxes payable and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,518&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2023 &#x2013; $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,099&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;) of provincial tax credits available to offset provincial taxes payable in the future.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;At December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company has non-capital losses, net of uncertain tax positions, carried forward for tax purposes, which are available to reduce taxable income of future years of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;642,043&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &#x2013; $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;422,822&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;).&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The investment tax credits and loss carry forwards expire over various years to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_d1be6160-6c62-483e-bb44-87d26b17b9bb;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2045&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;At December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the total amount of the Company&#x2019;s unrecognized tax benefits of uncertain tax positions were $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,850&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &#x2013; $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,850&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;). &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;If recognized in future periods, the unrecognized tax benefits would not affect the Company&#x2019;s effective tax rate. The Company recognizes potential accrued interest and penalties related to unrecognized tax benefits within the income tax provision. Interest and penalties on the unrecognized tax benefits have not been accrued at December 31, 2024 and 2023 as none would be owing due to the availability of non-capital losses to shelter any potential taxable income arising thereon. The Company does not currently expect any significant increases or decreases to these unrecognized tax benefits within 12 months of the reporting date.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company files income tax returns in Canada and the United States, the jurisdictions in which the Company believes that it is subject to tax. In jurisdictions in which the Company does not believe it is subject to tax and therefore does not file income tax returns, the Company can provide no certainty that tax authorities in those jurisdictions will not subject one or more tax years (since the inception of the Company) to examination. Further, while the statute of limitations in each jurisdiction where an income tax return has been filed generally limits the examination period, as a result of loss carry-forwards, the limitation period for examination generally does not expire until several years after the loss carry-forwards are utilized. Other than routine audits by tax authorities for tax credits and tax refunds that the Company claims, the Company is not aware of any other material income tax examination currently in progress by any taxing jurisdiction. Tax years ranging from &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_1acbb9ae-6eb8-45fa-9c42-da9b98b84dfc;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2004&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; to 2023 remain subject to examinations in Canada and the United States.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_53978bbb-2bde-4fbb-bf1d-a78a8b82a631">&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Loss before income taxes for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024, 2023 and 2022 was as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.863%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.764000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.764000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.764000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Canada&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;243,410&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;174,491&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;121,335&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;United States&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,991&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,194&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,920&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Loss before income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;238,419&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;182,685&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;125,255&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="-3"
      id="F_d9ebd8c6-2b11-4a44-a639-21677727c2a5"
      unitRef="U_USD">-243410000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="-3"
      id="F_9273da94-acd8-4faf-b2f4-419026120296"
      unitRef="U_USD">-174491000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="-3"
      id="F_9dc73a93-4e66-4c8e-a210-bd9e9d9563a1"
      unitRef="U_USD">-121335000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="-3"
      id="F_9411ff31-0bd3-4c2a-a7d7-01bb9a3918ca"
      unitRef="U_USD">4991000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="-3"
      id="F_35f08f4a-0ce7-4395-8c9d-c12e8a99b60c"
      unitRef="U_USD">-8194000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="-3"
      id="F_c07b7c46-f687-4657-adf5-25f2b8b0d9a0"
      unitRef="U_USD">-3920000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="-3"
      id="F_60e60843-dd53-49a9-98ff-b04ffaa07dc7"
      unitRef="U_USD">-238419000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="-3"
      id="F_91a15758-e3f2-493d-b92b-d96c874c8854"
      unitRef="U_USD">-182685000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="-3"
      id="F_38102a4e-831b-4e9a-b706-9fb8c249e0a9"
      unitRef="U_USD">-125255000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_15a400b3-e97f-47f6-aa2f-1043510b4e2c">&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The income tax recovery (expense) is allocated as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.863%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.764000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.764000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.764000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Current:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;Canada&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;United States&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,775&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;162&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,775&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;162&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;Canada&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;United States&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,864&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;292&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;44&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,864&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;292&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;44&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Income tax recovery (expense)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,089&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;292&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;118&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="-3"
      id="F_3d92ba24-e23e-45d9-89e2-333e58d6e01d"
      unitRef="U_USD">4775000</us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="-3"
      id="F_fe847218-5064-4177-af01-1265d2a85de3"
      unitRef="U_USD">162000</us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="-3"
      id="F_54d7785e-2342-49c8-b647-9c12eba706dd"
      unitRef="U_USD">4775000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="-3"
      id="F_d864d70e-0846-4002-8de6-33057a94ae56"
      unitRef="U_USD">162000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="-3"
      id="F_958476f6-63a6-4462-8de0-a080f564ae0d"
      unitRef="U_USD">-8864000</us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="-3"
      id="F_9a6e7cfc-ef1b-4d94-a27a-a21704cb9766"
      unitRef="U_USD">-292000</us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="-3"
      id="F_0f6daea5-8fd1-4109-afde-41a6c42d9173"
      unitRef="U_USD">-44000</us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="-3"
      id="F_296ee654-43dd-48a5-bb14-66c164232c75"
      unitRef="U_USD">-8864000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="-3"
      id="F_0c91d3e7-50e6-4359-a2fa-ced1b2aa4bc7"
      unitRef="U_USD">-292000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="-3"
      id="F_676628dd-0777-434d-9cca-de4da72ed907"
      unitRef="U_USD">-44000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="-3"
      id="F_6658734b-c168-4eff-83ba-02a771a1b687"
      unitRef="U_USD">-4089000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="-3"
      id="F_7cca6afc-dbf3-42a6-b5bb-bdea9debfa4c"
      unitRef="U_USD">-292000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="-3"
      id="F_fe0c2baf-9dfe-4e45-ae29-97efe827772a"
      unitRef="U_USD">118000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_d2f310f0-b34a-45b3-8655-6551b7fd4eb0">&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;reconciliation of the expected Canadian statutory income tax rate to the effective income tax rate is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.863%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.764000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.764000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.764000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Tax at statutory income tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development and other credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Tax attributes expired/utilized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other non-deductible expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Effective income tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="4"
      id="F_7168bb54-a342-48ce-b507-5e49f47b21b8"
      unitRef="U_pure">0.27</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="4"
      id="F_89a90e52-21a2-4271-827e-508dc2a14acb"
      unitRef="U_pure">0.27</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="4"
      id="F_9c9924b1-d7f6-44dc-885d-e9b997dc719d"
      unitRef="U_pure">0.27</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="3"
      id="F_40846eb3-be33-4797-863f-1d27d2cc996a"
      unitRef="U_pure">-0.22</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="3"
      id="F_4ae25bf2-abea-4da0-a92c-2b15369bb869"
      unitRef="U_pure">-0.24</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="3"
      id="F_5eaa3007-58fd-4c58-b63a-c06cf96d10f9"
      unitRef="U_pure">-0.245</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="3"
      id="F_0f41eb86-c24d-48d9-a2e5-8c8872f98689"
      unitRef="U_pure">-0.013</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="3"
      id="F_1cbc4e31-3191-482c-a47d-5a773bb0cf17"
      unitRef="U_pure">-0.016</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="3"
      id="F_f0800070-2710-4d20-a8ef-77e4b1f9a6f8"
      unitRef="U_pure">-0.025</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <xene:EffectiveIncomeTaxRateReconciliationTaxAttributesExpiredOrUtilized
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="3"
      id="F_00ec383e-0c4d-4cd9-bed8-8956ffdeca4f"
      unitRef="U_pure">-0.011</xene:EffectiveIncomeTaxRateReconciliationTaxAttributesExpiredOrUtilized>
    <xene:EffectiveIncomeTaxRateReconciliationTaxAttributesExpiredOrUtilized
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="3"
      id="F_e0cd4226-0a95-4a72-b74e-f03adf2217b1"
      unitRef="U_pure">-0.008</xene:EffectiveIncomeTaxRateReconciliationTaxAttributesExpiredOrUtilized>
    <xene:EffectiveIncomeTaxRateReconciliationTaxAttributesExpiredOrUtilized
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="3"
      id="F_6de54c00-056a-41ef-978f-d1b957f710bd"
      unitRef="U_pure">-0.012</xene:EffectiveIncomeTaxRateReconciliationTaxAttributesExpiredOrUtilized>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="3"
      id="F_c5e46c8f-4a0f-415b-a788-e4b595059a1a"
      unitRef="U_pure">-0.034</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="3"
      id="F_50e53e26-4cf0-4878-98fb-c9ab720f4972"
      unitRef="U_pure">-0.032</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="3"
      id="F_f083026d-9734-4fa9-a249-5d905dedb45a"
      unitRef="U_pure">-0.026</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="3"
      id="F_697f3c16-76d2-4246-a149-abd98c8d93d0"
      unitRef="U_pure">-0.004</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="3"
      id="F_7a070717-5125-470e-8817-4a1868a437d7"
      unitRef="U_pure">-0.003</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="3"
      id="F_2cdfd69a-dd84-451d-9ca6-0b59a886b7a7"
      unitRef="U_pure">-0.002</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="3"
      id="F_3c743e50-1780-43ec-97a2-d06636c99734"
      unitRef="U_pure">0.003</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="3"
      id="F_33e8bf15-7de3-4cbd-ab62-ce24906ba49c"
      unitRef="U_pure">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="3"
      id="F_bfcc40fb-3d99-444a-9edd-d77e1bd25573"
      unitRef="U_pure">-0.011</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="3"
      id="F_5d935373-2e9e-454b-bee8-c5aaf4a40699"
      unitRef="U_pure">0.017</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="3"
      id="F_b6e5e65b-8c0d-45b8-ae21-ca03d83e060a"
      unitRef="U_pure">0.002</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="3"
      id="F_a9b2fc99-1d1d-4913-a231-132131d6c573"
      unitRef="U_pure">-0.001</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_9571d943-1345-4326-ac25-1ec92c183c22">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.313%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.843%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.843%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred income tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;42,830&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;38,590&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Investment tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,818&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,695&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Non-capital losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;173,352&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;119,765&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Depreciable assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,269&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,311&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred financing fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,967&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,831&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,380&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,832&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,299&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,779&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,704&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;852&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;Total deferred income tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;278,619&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;217,655&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;Deferred income tax liability:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;Operating lease right-of-use asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,097&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,411&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;Less - valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;266,856&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;214,442&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net deferred income tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,666&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;802&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f"
      decimals="-3"
      id="F_4d88ecc3-06b8-4e21-b361-3f792ddc9a41"
      unitRef="U_USD">42830000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35"
      decimals="-3"
      id="F_617faa72-fd5d-4090-b6f7-8dcdf09d1903"
      unitRef="U_USD">38590000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <xene:DeferredTaxAssetsTaxCreditCarryforwardsInvestment
      contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f"
      decimals="-3"
      id="F_14e474a2-aeeb-4905-961d-a3bfe0adcca4"
      unitRef="U_USD">29818000</xene:DeferredTaxAssetsTaxCreditCarryforwardsInvestment>
    <xene:DeferredTaxAssetsTaxCreditCarryforwardsInvestment
      contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35"
      decimals="-3"
      id="F_d967c22f-5f19-4b42-b6f6-31b22c90a401"
      unitRef="U_USD">30695000</xene:DeferredTaxAssetsTaxCreditCarryforwardsInvestment>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f"
      decimals="-3"
      id="F_f62017ac-796d-479b-9bec-130cde174253"
      unitRef="U_USD">173352000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35"
      decimals="-3"
      id="F_1fea6199-34e2-48e1-ad64-744f59b80345"
      unitRef="U_USD">119765000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f"
      decimals="-3"
      id="F_b3149074-ce00-472b-a1e3-5571dbfd7c51"
      unitRef="U_USD">13269000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35"
      decimals="-3"
      id="F_8af31f4d-7213-4407-aee7-f7122a4808ce"
      unitRef="U_USD">10311000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <xene:DeferredTaxAssetsDeferredFinancingFees
      contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f"
      decimals="-3"
      id="F_8a0268db-77b7-4107-88c3-8d714249687b"
      unitRef="U_USD">6967000</xene:DeferredTaxAssetsDeferredFinancingFees>
    <xene:DeferredTaxAssetsDeferredFinancingFees
      contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35"
      decimals="-3"
      id="F_a3ce8411-d870-4935-956a-1785cc2ac23d"
      unitRef="U_USD">10831000</xene:DeferredTaxAssetsDeferredFinancingFees>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f"
      decimals="-3"
      id="F_876b648d-9a00-464e-8052-22dfb87f3093"
      unitRef="U_USD">8380000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35"
      decimals="-3"
      id="F_907cf4d9-9d74-4d9d-aaeb-43c06eef0336"
      unitRef="U_USD">3832000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <xene:DeferredTaxAssetsOperatingLeaseLiability
      contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f"
      decimals="-3"
      id="F_02fe8754-33ed-49d4-b7b2-5d21299d260d"
      unitRef="U_USD">2299000</xene:DeferredTaxAssetsOperatingLeaseLiability>
    <xene:DeferredTaxAssetsOperatingLeaseLiability
      contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35"
      decimals="-3"
      id="F_b6dd677f-1a51-4f73-a7c9-ba776c561b79"
      unitRef="U_USD">2779000</xene:DeferredTaxAssetsOperatingLeaseLiability>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f"
      decimals="-3"
      id="F_32b00fd4-b6a2-4010-8066-445873bdefee"
      unitRef="U_USD">1704000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35"
      decimals="-3"
      id="F_6023991e-4cfc-416c-9a17-9186a925dd25"
      unitRef="U_USD">852000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f"
      decimals="-3"
      id="F_0d51d9ca-04cc-4ea3-b469-058e8d116ba2"
      unitRef="U_USD">278619000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35"
      decimals="-3"
      id="F_49df3668-40e8-42b0-a8f5-d0b516b41197"
      unitRef="U_USD">217655000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f"
      decimals="-3"
      id="F_9d7fcb8e-32b1-457e-8eb2-6e2c445805c1"
      unitRef="U_USD">2097000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35"
      decimals="-3"
      id="F_f3cc9f9e-5637-4203-9d40-2ddb7651a649"
      unitRef="U_USD">2411000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f"
      decimals="-3"
      id="F_8924f50e-2b84-44a8-87c5-baa108830690"
      unitRef="U_USD">266856000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35"
      decimals="-3"
      id="F_1e7db189-46d9-420c-91bf-e0408abca428"
      unitRef="U_USD">214442000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f"
      decimals="-3"
      id="F_1ddf5284-5efc-430d-99ee-ecb32a3cc609"
      unitRef="U_USD">9666000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35"
      decimals="-3"
      id="F_225666ee-d7f1-4449-8794-a0d3fa76b4db"
      unitRef="U_USD">802000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="-3"
      id="F_eca83ebb-1e2f-41c6-aac3-be986c5a0b5d"
      unitRef="U_USD">158629000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="-3"
      id="F_a5b3e91e-95e2-4180-af4a-aeeba8aae2e5"
      unitRef="U_USD">142925000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_9eb01a35-61ba-4b6e-af95-b573e9492a46"
      decimals="-3"
      id="F_eecf5914-1b1b-47ef-9081-ddd556a244da"
      unitRef="U_USD">29284000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_6f467048-a278-4893-a073-167e3300ed14"
      decimals="-3"
      id="F_e3797ee0-b360-4c9e-a767-4bf30c32794f"
      unitRef="U_USD">29074000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_40c485fd-1ab2-4c3b-9ab4-26de3dc49364"
      decimals="-3"
      id="F_8ebe65bb-1ad5-434e-b6a7-ab026f7f98e0"
      unitRef="U_USD">8518000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_664789f3-25f8-4a48-9938-65726d2fa13a"
      decimals="-3"
      id="F_9860d241-57e9-42d0-8108-b9576e13ab11"
      unitRef="U_USD">8099000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f"
      decimals="-3"
      id="F_4491e9b9-45db-4983-b0cd-7dbbaad0e60e"
      unitRef="U_USD">642043000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35"
      decimals="-3"
      id="F_9a0862a1-0469-4e72-b93f-409ff31eae08"
      unitRef="U_USD">422822000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_3aefa32f-83d0-4641-9a89-a5c3e50f304f"
      decimals="-3"
      id="F_9a48eae5-3c9e-4e10-9d80-189be209ddba"
      unitRef="U_USD">10850000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_f956e4c2-abe5-46ae-8429-402134a46f35"
      decimals="-3"
      id="F_5893a50c-86e4-4770-88c9-d1e496f691fa"
      unitRef="U_USD">10850000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_84fe8b2b-a491-4be6-a239-a235d5df6844">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;14.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Segment disclosure:&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company operates as a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_a4a2478d-a313-4066-8e4d-8e8806c474dd;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;single&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; reportable segment dedicated to discovering, developing, and delivering life-changing ion channel therapeutics for patients in need. The Company has no products approved for sale and has not generated any revenue from product sales.&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The Company&#x2019;s &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_d1e546bf-38de-44e9-b552-f72e3c4a430a;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Chief Executive Officer&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; acts as the CODM and manages the Company&#x2019;s operations on a consolidated basis. The accounting policies of the segment are the same as those described in the summary of significant accounting policies.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The CODM&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;evaluates the Company&#x2019;s performance and allocates resources to the operations of the Company on a total company basis. Managing and allocating resources on a consolidated basis enables the CEO to assess the overall level of resources available and how to best deploy these resources across functions, therapeutic areas and research and development projects that are in line with the Company&#x2019;s long-term company-wide strategic goals. The CODM uses net loss to monitor budget versus actual results and to analyze cash flows in assessing performance of the segment and allocating resources. The measure of segment assets is reported on the consolidated balance sheet as total consolidated assets, with a majority of these assets located in the United States.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table presents information about reported segment revenues, significant segment expenses, and segment loss:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:46.279%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.641%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.266%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.641%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.266%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.641%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.266%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,434&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Direct external research and development costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Azetukalner&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;106,806&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;89,303&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;37,367&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;XEN 496&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,152&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,765&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Pre-clinical, discovery and other programs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,546&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,552&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,711&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Personnel-related expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;68,340&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;47,739&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;36,088&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50,717&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;32,372&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,376&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other research and development costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,232&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,560&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,274&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other general and administrative costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,657&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,376&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,996&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Interest income&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;41,943&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27,620&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,713&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other segment items&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,041&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,943&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;234,330&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;182,393&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;125,373&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;div class="item-list-element-wrapper" style="margin-left:5.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4%;text-align:justify;"&gt;&lt;span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;font-kerning:none;min-width:4.2253372347280465%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(1)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Other segment items include foreign exchange gain (loss), unrealized fair value gain (loss) on trading securities, and income tax recovery (expense).&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:SegmentReportingExpenseInformationUsedByCodmDescription
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_0d7190cd-9b62-4b7c-83e4-1680b6c8cb1d"> The Company&#x2019;s Chief Executive Officer acts as the CODM and manages the Company&#x2019;s operations on a consolidated basis. The accounting policies of the segment are the same as those described in the summary of significant accounting policies.</us-gaap:SegmentReportingExpenseInformationUsedByCodmDescription>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      id="F_9c96442b-2ac0-4505-8554-17f3c790ab1a">&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table presents information about reported segment revenues, significant segment expenses, and segment loss:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:46.279%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.641%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.266%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.641%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.266%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.641%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.266%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,434&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Direct external research and development costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Azetukalner&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;106,806&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;89,303&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;37,367&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;XEN 496&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,152&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,765&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Pre-clinical, discovery and other programs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,546&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,552&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,711&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Personnel-related expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;68,340&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;47,739&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;36,088&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50,717&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;32,372&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,376&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other research and development costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,232&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,560&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,274&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other general and administrative costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,657&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,376&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,996&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Interest income&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;41,943&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27,620&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,713&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other segment items&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,041&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,943&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;234,330&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;182,393&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;125,373&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;div class="item-list-element-wrapper" style="margin-left:5.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4%;text-align:justify;"&gt;&lt;span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;font-kerning:none;min-width:4.2253372347280465%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(1)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Other segment items include foreign exchange gain (loss), unrealized fair value gain (loss) on trading securities, and income tax recovery (expense).&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="-3"
      id="F_75929e18-d32f-4042-b23b-e50dc08cb3fe"
      unitRef="U_USD">9434000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_fb8162b3-a597-4e6d-b07d-93335801c609"
      decimals="-3"
      id="F_3bedc1f2-5287-42c4-9b43-eacc998a088a"
      unitRef="U_USD">106806000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_4dbe77ca-9a85-4dcf-8f71-e478f9594e17"
      decimals="-3"
      id="F_710ee2a5-f316-4fad-8e07-bf9b742db976"
      unitRef="U_USD">89303000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_aae837d9-73f6-4e0d-b04b-74e170785875"
      decimals="-3"
      id="F_765ad926-bc29-421e-a965-c1536e7ce58d"
      unitRef="U_USD">37367000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_31d21974-f2b1-4354-9468-ccf01410882d"
      decimals="-3"
      id="F_93e2317e-8d52-4500-bacc-b1dca504452f"
      unitRef="U_USD">5152000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_8a94fa8c-ce7f-4a9e-a9e7-bc7ebbe394c7"
      decimals="-3"
      id="F_4bc80e0d-ac13-474a-9830-e982a4e1b6c8"
      unitRef="U_USD">14765000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_283501b6-a859-4835-8637-5667f1ffb39b"
      decimals="-3"
      id="F_f11b68ee-806a-40a8-a2f3-461646141751"
      unitRef="U_USD">21546000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_144eba44-d44f-40ad-8b2c-6acd462b2319"
      decimals="-3"
      id="F_473610f3-eac1-4ad2-9df7-746cecde6f30"
      unitRef="U_USD">15552000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_8f08380d-a06a-4f90-aa7a-aeae88ce9ee1"
      decimals="-3"
      id="F_1d547eb3-3b06-4b72-a528-6aa330aa9807"
      unitRef="U_USD">12711000</us-gaap:ResearchAndDevelopmentExpense>
    <xene:PersonnelRelatedExpenses
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="-3"
      id="F_45791c5e-b58e-49b8-89ec-42487a63fab1"
      unitRef="U_USD">68340000</xene:PersonnelRelatedExpenses>
    <xene:PersonnelRelatedExpenses
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="-3"
      id="F_77947f60-c839-4f18-bc7f-2745bad711ce"
      unitRef="U_USD">47739000</xene:PersonnelRelatedExpenses>
    <xene:PersonnelRelatedExpenses
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="-3"
      id="F_d0cd9b8e-fa8c-483e-8f1b-3ee49f7f5d76"
      unitRef="U_USD">36088000</xene:PersonnelRelatedExpenses>
    <us-gaap:ShareBasedCompensation
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="-3"
      id="F_7fdf6abb-969d-4ab7-8fd4-acc44882c4ef"
      unitRef="U_USD">50717000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="-3"
      id="F_9d32c96c-b822-4ca9-8726-d6da29c13179"
      unitRef="U_USD">32372000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="-3"
      id="F_5168ff61-a058-4749-8865-8c9beeb3c461"
      unitRef="U_USD">20376000</us-gaap:ShareBasedCompensation>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="-3"
      id="F_7800a468-ef7a-46b4-8c36-ed859776057e"
      unitRef="U_USD">11232000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="-3"
      id="F_9be5baac-d6a1-462e-8e1f-9db14b3294b8"
      unitRef="U_USD">9560000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="-3"
      id="F_344c347c-8ce3-4aab-a339-408a679755b4"
      unitRef="U_USD">7274000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="-3"
      id="F_2da5f1af-341f-4913-915d-5807fceaace0"
      unitRef="U_USD">20657000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="-3"
      id="F_b0a672db-2c45-41f4-a525-4865571507cb"
      unitRef="U_USD">14376000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="-3"
      id="F_80ebba54-cf8e-4797-a600-623e5717ad12"
      unitRef="U_USD">9996000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="-3"
      id="F_0b177868-7bf2-4a92-bbd6-ebbe9d81bdc0"
      unitRef="U_USD">41943000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="-3"
      id="F_070a630d-a79d-47ab-9671-099a4b06b13f"
      unitRef="U_USD">27620000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="-3"
      id="F_8bc0ea80-bdbb-4166-87a6-bc7391b42c30"
      unitRef="U_USD">8713000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="-3"
      id="F_1187bada-7afa-4026-8860-e6f676a3a347"
      unitRef="U_USD">-3025000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="-3"
      id="F_85f1d84d-13ae-45ce-abf7-31d2d4bb9b7c"
      unitRef="U_USD">-4041000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="-3"
      id="F_a6c728af-6aeb-4ae8-8787-f4809276fb6e"
      unitRef="U_USD">4943000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:NetIncomeLoss
      contextRef="C_7bec36f5-dff9-4d97-a1a6-19d8cc62e7d2"
      decimals="-3"
      id="F_2452d3c2-b6b3-4456-b258-2a36ccc0ec27"
      unitRef="U_USD">-234330000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_43c8ecfd-0530-4bf5-95e9-1b7ee72f5a0b"
      decimals="-3"
      id="F_5fcaf90c-3133-4b82-ac96-3d0771b3edc9"
      unitRef="U_USD">-182393000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_9014ed90-7c7d-49f9-b75e-4dafbe44da3b"
      decimals="-3"
      id="F_380ba679-c75e-4d27-ac51-73c08e259c6f"
      unitRef="U_USD">-125373000</us-gaap:NetIncomeLoss>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="C_33309322-16ac-4275-af41-8afa3963db9f"
      id="F_5a72996a-0739-4f36-856a-cce1541c0888">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="C_33309322-16ac-4275-af41-8afa3963db9f"
      id="F_04d9e0bc-6019-411c-b7c6-0d780c8a679d">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="C_33309322-16ac-4275-af41-8afa3963db9f"
      id="F_a60d50a0-f3de-41f4-9241-c449a3280b19">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="C_33309322-16ac-4275-af41-8afa3963db9f"
      id="F_7f072e32-50c7-4151-a9c1-e628fc9a9006">false</ecd:NonRule10b51ArrTrmntdFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
